<SEC-DOCUMENT>0001104659-21-065999.txt : 20210709
<SEC-HEADER>0001104659-21-065999.hdr.sgml : 20210709
<ACCEPTANCE-DATETIME>20210513165710
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-21-065999
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		56
FILED AS OF DATE:		20210513
<PUBLIC-REL-DATE>20210709
DATE AS OF CHANGE:		20210514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Immuneering Corp
		CENTRAL INDEX KEY:			0001790340
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-04858
		FILM NUMBER:		21920510

	BUSINESS ADDRESS:	
		STREET 1:		245 MAIN STREET, SECOND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-500-8080

	MAIL ADDRESS:	
		STREET 1:		245 MAIN STREET, SECOND FLOOR
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<html>
  <head>
    <title>tm2115679-1_drs - none - 25.343884s</title>
  </head>
  <body style="margin-left:auto;margin-right:auto;width:775.71pt;">
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="text-align:center; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">As confidentially submitted to the Securities and Exchange Commission on May&#160;13, 2021. </font>
        </div>
        <div style="margin-top:2pt; text-align:right; width:541.31pt; line-height:10pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Registration No. 333-&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font>&#8203;</div>
        <div style="margin-top:4.5pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 4.5pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.9pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.9pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.9pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">UNITED STATES </font>
          <br >
          <font style="letter-spacing:-0.28pt;">SECURITIES AND EXCHANGE COMMISSION</font>
          <br >
          <font style="font-size:8pt;letter-spacing:-0.16pt;">WASHINGTON, D.C. 20549</font><font style="font-weight:normal;letter-spacing:0.28pt;"> </font>
        </div>
        <div style="margin-top:3.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 3.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.89pt; text-align:center; width:541.31pt; line-height:16pt;font-weight:bold;font-size:14pt;">
          <font style="letter-spacing:-0.28pt;">FORM S-1</font>
        </div>
        <div style="margin-top:-1pt; text-align:center; width:541.31pt; line-height:8pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">REGISTRATION STATEMENT </font>
          <br >
          <font style="letter-spacing:-0.16pt;">UNDER </font>
          <br >
          <font style="letter-spacing:-0.16pt;">THE SECURITIES ACT OF 1933</font><font style="font-weight:normal;font-size:14pt;">&#8203;<font style="letter-spacing:0.28pt;"> </font></font>
        </div>
        <div style="margin-top:3.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 3.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.9pt; text-align:center; width:541.31pt; line-height:8pt;font-size:14pt;">
          <font style="font-weight:bold;letter-spacing:-0.28pt;">IMMUNEERING CORPORATION</font>
          <br >
          <font style="font-size:7.5pt;letter-spacing:0.15pt;">(Exact name of registrant as specified in its charter)</font><font style="letter-spacing:0.28pt;"> </font>
        </div>
        <table style="width:541.31pt;margin-top:5.5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9.6pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;font-weight:bold;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">Delaware</font>
              </div>
              <div style="margin-top:1.6pt; text-align:center; line-height:7.5pt;">
                <font style="letter-spacing:0.15pt;">(State or other jurisdiction of</font>
                <br >
                <font style="letter-spacing:0.15pt;">incorporation or organization)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.44pt;">
              <div style="text-align:center;font-weight:bold;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">2834</font>
              </div>
              <div style="margin-top:1.6pt; text-align:center; line-height:7.5pt;">
                <font style="letter-spacing:0.15pt;">(Primary Standard Industrial</font>
                <br >
                <font style="letter-spacing:0.15pt;">Classification Code Number)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:172.43pt;">
              <div style="text-align:center;font-weight:bold;font-size:8pt;">
                <font style="letter-spacing:-0.16pt;">26-1976972</font>
              </div>
              <div style="margin-top:1.6pt; text-align:center; line-height:7.5pt;">
                <font style="letter-spacing:0.15pt;">(I.R.S. Employer</font>
                <br >
                <font style="letter-spacing:0.15pt;">Identification No.)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.71pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">245 Main Street, Second Floor</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Cambridge, Massachusetts 02142</font>
          <br >
          <font style="letter-spacing:-0.16pt;">Telephone: (617) 500-8080 </font>
        </div>
        <div style="margin-top:1.7pt; text-align:center; width:541.31pt; line-height:9.5pt;font-size:7.5pt;">
          <font style="letter-spacing:0.15pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</font><font style="font-size:8pt;">&#8203;<font style="letter-spacing:0.16pt;"> </font></font>
        </div>
        <div style="margin-top:4.2pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 4.20000000000002pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.6pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Benjamin J. Zeskind, Ph.D. </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Chief Executive Officer </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Immuneering Corporation </font>
          <br >
          <font style="letter-spacing:-0.16pt;">245 Main Street, Second Floor </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Cambridge, Massachusetts 02142 </font>
          <br >
          <font style="letter-spacing:-0.16pt;">Telephone: (617) 500-8080 </font>
        </div>
        <div style="margin-top:1.7pt; text-align:center; width:541.31pt; line-height:9.5pt;font-size:7.5pt;">
          <font style="letter-spacing:0.15pt;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</font><font style="font-size:8pt;">&#8203;<font style="letter-spacing:0.16pt;"> </font></font>
        </div>
        <div style="margin-top:4.2pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 4.19999999999999pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3.6pt; text-align:center; width:541.31pt; line-height:8.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Copies to:</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <table style="width:541.31pt;margin-top:2.89999999999998pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9.58pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:264.66pt;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.16pt;">John Chory</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Nathan Ajiashvili</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Evan Smith</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Latham &amp; Watkins LLP</font> <br ><font style="letter-spacing:-0.16pt;">1271 Avenue of the Americas</font><br ><font style="letter-spacing:-0.16pt;">New York, New York 10020</font><br ><font style="letter-spacing:-0.16pt;">(212) 906-1200</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:264.65pt;">
              <div style="text-align:center; line-height:9.59pt;">
                <font style="letter-spacing:-0.16pt;">Frank F. Rahmani</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Samir A. Gandhi</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Sidley Austin LLP</font>
                <br >
                <font style="letter-spacing:-0.16pt;">555 California Street, Suite 2000</font>
                <br >
                <font style="letter-spacing:-0.16pt;">San Francisco, California 94104</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(415) 772-1200</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:4.81pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.6pt; text-align:center; width:541.31pt; line-height:9.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">Approximate date of commencement of proposed sale to the public: </font>
          <br >
          <font style="letter-spacing:-0.16pt;">As soon as practicable after this Registration Statement is declared effective.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:2pt; text-align:justify; width:541.31pt; line-height:8.5pt;">
          <font style="letter-spacing:0.16pt;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act of 1933, check the following box.&nbsp;&nbsp;&nbsp;&#9744; </font>
        </div>
        <div style="margin-top:3pt; text-align:justify; width:541.31pt; line-height:8.5pt;">
          <font style="letter-spacing:0.16pt;">If this Form is filed to register additional securities for an offering pursuant to Rule&#160;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&#9744; </font>
        </div>
        <div style="margin-top:3pt; text-align:justify; width:541.31pt; line-height:8.5pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&#9744; </font>
        </div>
        <div style="margin-top:3pt; text-align:justify; width:541.31pt; line-height:8.5pt;">
          <font style="letter-spacing:0.16pt;">If this Form is a post-effective amendment filed pursuant to Rule&#160;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&nbsp;&#9744; </font>
        </div>
        <div style="margin-top:3pt; text-align:justify; width:541.31pt; line-height:8.5pt;">
          <font style="letter-spacing:0.16pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </font>
        </div>
        <table style="width:541.31pt;height:29.17pt;margin-top:3.89999999999998pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96.66pt;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.16pt;">Large accelerated filer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">
              <font style="letter-spacing:0.16pt;">&#9744; </font>
            </td>
            <td style="padding:0pt; width:150pt;">&#8203;</td>
            <td style="padding:0pt; width:150pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96.65pt;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.16pt;">Accelerated filer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">
              <font style="letter-spacing:0.16pt;">&#9744; </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 0.597pt 0pt; width:96.66pt;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.16pt;">Non-accelerated filer</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 0.597pt 0pt; width:12pt;">
              <font style="letter-spacing:0.16pt;">&#9746; </font>
            </td>
            <td style="padding:0pt; width:150pt;">&#8203;</td>
            <td style="padding:0pt; width:150pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 0.597pt 0pt; width:96.65pt;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.16pt;">Smaller reporting company</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.013pt 0pt 0.597pt 0pt; width:12pt;">
              <font style="letter-spacing:0.16pt;">&#9746; </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:7.98000000000002pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:96.66pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:150pt;">&#8203;</td>
            <td style="padding:0pt; width:150pt;">&#8203;</td>
            <td style="padding:2.003pt 0pt 0.597pt 0pt; width:96.65pt;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.16pt;">Emerging growth company</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.003pt 0pt 0.597pt 0pt; width:12pt;">
              <font style="letter-spacing:0.16pt;">&#9746;</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:4.71pt; text-align:justify; width:541.31pt; line-height:8.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.16pt;">If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided to Section&#160;7(a)(2)(B) of the Securities Act.</font><font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; &#9744; </font>
        </div>
        <div style="margin-top:4.1pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 4.10000000000002pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541.31pt;height:56.59pt;margin-top:3.39999999999998pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:3pt double #000000; width:0pt;">&#8203;</td>
            <td style="border-bottom:3pt double #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="9">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">CALCULATION OF REGISTRATION FEE </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:3pt double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.917pt 0pt 0.833pt 0pt; width:277.56pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title of Each Class of Securities To Be Registered </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.917pt 0pt 0.833pt 0pt; width:120.5pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Proposed</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Maximum</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Offering Price</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)(2)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.917pt 0pt 0.833pt 0pt; width:120.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Registration Fee</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 0.833pt 0pt; width:277.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.16pt;">Class&#160;A Common Stock, $0.001 par value per share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 0.833pt 0pt; width:120.5pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">$&#8199;&#8199;&#8199;&#8199;&#8199; </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:5.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 0.833pt 0pt; width:120.25pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.16pt;">$&#8199;&#8199;&#8199;&#8199;&#8199;</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #000000; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:4.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:4.2pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.16pt;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule&#160;457(o) under the Securities Act of 1933, as amended. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:1.7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.16pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:1.7pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.16pt;">Includes the aggregate offering price of additional shares that the underwriters have the option to purchase. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:1.71pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.16pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:1.71pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.16pt;">Calculated pursuant to Rule&#160;457(o) based on an estimate of the proposed maximum aggregate offering price. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:3.2pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 3.20000000000005pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4.6pt; text-align:justify; width:541.31pt; line-height:8.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.16pt;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&#160;8(a), may determine.</font><font style="font-weight:normal;letter-spacing:0.16pt;"> </font>
        </div>
        <div style="margin-top:3.09pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 3.09000000000003pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:1.6pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 541.31pt; margin-top: 1.60000000000002pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;min-height:706pt;margin-bottom:21.86pt;margin-left:27pt;width:541.31pt;">
        <div style="width:541.31pt; line-height:12pt;font-style:normal;color:#FF665E;font-family:Times New Roman, Times, serif ;">
          <font style="letter-spacing:-0.2pt;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</font><font style="font-weight:normal;color:#000000;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:541.31pt; line-height:12pt;color:#FF665E;font-family:Georgia, Times, Times New Roman, serif;font-size:12pt;">SUBJECT TO COMPLETION,  <br >DATED&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021<font style="font-style:normal;font-weight:normal;color:#000000;font-family:Times New Roman, Times, serif ;font-size:11pt;">&#8203;<font style="letter-spacing:0.22pt;"> </font></font></div>
        <div style="margin-top:5pt; text-align:center; width:541.31pt; line-height:16pt;font-family:Georgia, Times, Times New Roman, serif;font-size:14pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;Shares<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font></div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:541.31pt;">
          <img src="lg_immuneering-4clr.jpg" alt="[MISSING IMAGE: lg_immuneering-4clr.jpg]" height="48" width="281" >
        </div>
        <div style="margin-top:10pt; text-align:center; width:541.31pt; line-height:20pt;font-family:Georgia, Times, Times New Roman, serif;font-size:18pt;">Immuneering Corporation<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.36pt;"> </font></div>
        <div style="margin-top:5pt; text-align:center; width:541.31pt; line-height:14pt;font-family:Georgia, Times, Times New Roman, serif;font-size:12pt;">Class&#160;A Common Stock<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.24pt;"> </font></div>
        <div style="margin-top:7.833pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7pt; text-align:justify; width:541.31pt; line-height:12pt;">We are offering&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class&#160;A common stock. This is our initial public offering and no public market currently exists for our Class&#160;A common stock. We anticipate that the initial public offering price will be between $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. We intend to apply to list our Class&#160;A common stock on the Nasdaq Global Market under the symbol &#8220;IMRX.&#8221;<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:6pt; text-align:justify; width:541.31pt; line-height:12pt;">Following this offering, we will have two classes of common stock: Class&#160;A common stock and Class&#160;B common stock. The rights of the holders of Class&#160;A common stock and Class&#160;B common stock will be identical, except with respect to voting and conversion rights. Each share of Class&#160;A common stock will be entitled to one vote and will not be convertible into any other class of our capital stock. The shares of Class&#160;B common stock do not have associated voting rights (except as may be required by law) and each share of Class&#160;B common stock is convertible at any time at the election of the holder into one share of Class&#160;A common stock, subject to certain limitations. See &#8220;Description of Capital Stock&#8212;Common Stock&#8221; for more information on the rights of the holders of our Class&#160;A common stock and Class&#160;B common stock.<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:10.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9pt; text-align:justify; width:541.31pt; line-height:12pt;">We are an &#8220;emerging growth company&#8221; as defined under the U.S. federal securities laws and, as such, may elect to comply with reduced public company reporting requirements for this and future filings. See &#8220;Prospectus Summary&#8212;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#8221;<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.2pt;"> </font></div>
        <div style="margin-top:10.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:9pt; text-align:justify; width:541.31pt; line-height:14pt;font-size:12pt;">Investing in our Class&#160;A common stock involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRIFA">13</a> of this prospectus.<font style="font-style:normal;font-weight:normal;"> </font></div>
        <div style="margin-top:10.833pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:10pt; text-align:justify; width:541.31pt; line-height:12pt;font-weight:normal;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.<font style="font-style:normal;font-family:Times New Roman, Times, serif;"> </font></div>
        <div style="margin-top:10.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541.31pt;height:51.35pt;margin-top:4.5pt;border-collapse: collapse;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:459.01pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Per share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:9pt;">
            <td style="padding:3.27pt 0pt 1.79pt 0pt; width:459.01pt;text-align:left;">
              <div style="white-space:nowrap;">Initial public offering price </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.27pt 0pt 1.79pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:9pt;">
            <td style="padding:3.53pt 0pt 1.78pt 0pt; width:459.01pt;text-align:left;">
              <div style="white-space:nowrap;">Underwriting discounts and commissions<font style=" position:relative; bottom:3.75pt;font-size:7pt;">(1)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8.97000000000003pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:9pt;">
            <td style="padding:3.53pt 0pt 1.78pt 0pt; width:459.01pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds, before expenses, to us </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.53pt 0pt 1.78pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.81pt; width:541.31pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:3pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-weight:normal;font-size:8pt;">(1)<br ></div>
        <div style=" margin-top:3pt; margin-bottom:0pt; line-height:10pt; text-align:justify; margin-left:20pt;font-weight:normal;font-size:8pt;">See &#8220;Underwriting&#8221; for a description of all compensation payable to the underwriters. We have agreed to reimburse the underwriters for certain FINRA-related expenses.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:5pt; text-align:justify; width:541.31pt; line-height:10pt;font-weight:normal;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">We have granted the underwriters an option for a period of 30&#160;days to purchase up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;additional shares of Class&#160;A common stock.<font style="font-style:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.16pt;"> </font></div>
        <div style="margin-top:5pt; text-align:justify; width:541.31pt; line-height:10pt;font-weight:normal;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">The underwriters expect to deliver the shares of Class&#160;A common stock against payment in New York, New York on or about&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021.<font style="font-style:normal;font-family:Times New Roman, Times, serif;"> </font></div>
        <div style="margin-top:7.5pt; text-align:center; width:541.31pt;">
          <div style="margin-left: 41.132%; margin-right: 41.132%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541.31pt;margin-top:6.5pt;border-collapse: collapse;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:11pt;">
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:11pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:120pt;text-align:left;">MORGAN STANLEY</td>
            <td style="padding:0pt; width:18.22pt;">&#8203;</td>
            <td style="padding:0pt; width:18.22pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:72pt;">
              <div style="text-align:center;">JEFFERIES</div>
            </td>
            <td style="padding:0pt; width:18.22pt;">&#8203;</td>
            <td style="padding:0pt; width:18.22pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:60pt;">
              <div style="text-align:center;">COWEN</div>
            </td>
            <td style="padding:0pt; width:18.22pt;">&#8203;</td>
            <td style="padding:0pt; width:18.22pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 1pt 0pt; width:180pt;text-align:right;">
              <div style="text-align:right;">GUGGENHEIM SECURITIES</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5pt; text-align:justify; width:541.31pt; line-height:12pt;font-weight:normal;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">Prospectus dated&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021.</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:48.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TABLE OF CONTENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:350.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tPRSU"><font style="letter-spacing:0.2pt;">PROSPECTUS SUMMARY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tPRSU">1</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tSCFD"><font style="letter-spacing:0.2pt;">SUMMARY CONSOLIDATED FINANCIAL DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tSCFD">11</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tRIFA"><font style="letter-spacing:0.2pt;">RISK FACTORS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tRIFA">13</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tCNRF"><font style="letter-spacing:0.2pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tCNRF">73</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tUOP"><font style="letter-spacing:0.2pt;">USE OF PROCEEDS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tUOP">75</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tDIPO"><font style="letter-spacing:0.2pt;">DIVIDEND POLICY </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tDIPO">76</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tCAP"><font style="letter-spacing:0.2pt;">CAPITALIZATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tCAP">77</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tDIL"><font style="letter-spacing:0.2pt;">DILUTION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tDIL">79</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tSCFD1"><font style="letter-spacing:0.2pt;">SELECTED CONSOLIDATED FINANCIAL DATA </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tSCFD1">81</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <a href="#tMDAA"><font style="letter-spacing:0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:16.67pt;white-space:nowrap;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tMDAA">82</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tBUS"><font style="letter-spacing:0.2pt;">BUSINESS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tBUS">94</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tMAN"><font style="letter-spacing:0.2pt;">MANAGEMENT </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tMAN">136</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tEADC"><font style="letter-spacing:0.2pt;">EXECUTIVE AND DIRECTOR COMPENSATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tEADC">142</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tCRAR"><font style="letter-spacing:0.2pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tCRAR">150</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tPRST"><font style="letter-spacing:0.2pt;">PRINCIPAL STOCKHOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tPRST">153</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tDOCS"><font style="letter-spacing:0.2pt;">DESCRIPTION OF CAPITAL STOCK </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tDOCS">155</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tSEFF"><font style="letter-spacing:0.2pt;">SHARES ELIGIBLE FOR FUTURE SALE </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tSEFF">161</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tMUFI"><font style="letter-spacing:0.2pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tMUFI">163</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tUND"><font style="letter-spacing:0.2pt;">UNDERWRITING </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tUND">167</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tLEMA"><font style="letter-spacing:0.2pt;">LEGAL MATTERS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tLEMA">174</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tEXP"><font style="letter-spacing:0.2pt;">EXPERTS </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tEXP">174</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;">
              <div style="white-space:nowrap;">
                <a href="#tWYCF"><font style="letter-spacing:0.2pt;">WHERE YOU CAN FIND MORE INFORMATION </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:16.67pt;text-align:center;">
              <div style="text-align:center;letter-spacing:0.2pt;">
                <a href="#tWYCF">174</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20.5pt; text-align:center; width:456pt;">
          <div style="margin-left: 39.474%; margin-right: 39.474%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of Class&#160;A common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our Class&#160;A common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For investors outside the United States: Neither we nor the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of Class&#160;A common stock and the distribution of this prospectus outside the United States. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">i</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:204pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BASIS OF PRESENTATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except where the context otherwise requires or where otherwise indicated, the terms &#8220;Immuneering,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;our company,&#8221; &#8220;Company&#8221; and &#8220;our business&#8221; refer to Immuneering Corporation. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements include the accounts of Immuneering Corporation and its subsidiary. Our financial statements have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. Our fiscal year ends on December&#160;31 of each year. References to 2020 refer to the year ended December&#160;31, 2020. Our most recent fiscal year ended on December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain monetary amounts, percentages and other figures included in this prospectus have been subject to rounding adjustments. Percentage amounts included in this prospectus have not in all cases been calculated on the basis of such rounded figures, but on the basis of such amounts prior to rounding. For this reason, percentage amounts in this prospectus may vary from those obtained by performing the same calculations using the figures in our consolidated financial statements included elsewhere in this prospectus. Certain other amounts that appear in this prospectus may not sum due to rounding. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">TRADEMARKS AND TRADENAMES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Solely for convenience, trademarks, service marks and tradenames referred to in this prospectus may appear without the</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">&#8203;<font style="letter-spacing:0.15pt;"> </font></font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#174;</font><font style="letter-spacing:0.2pt;">, TM or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, service marks and tradenames. This prospectus may also contain trademarks, service marks, tradenames and copyrights of other companies, which are the property of their respective owners. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDUSTRY AND OTHER DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains industry, market and competitive position data from our own internal estimates and research as well as industry and general publications and research surveys and studies conducted by third parties. Industry publications, studies and surveys generally state that they have been obtained from sources believe to be reliable, although they do not guarantee the accuracy or completeness of such information. Our internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which we operate and our management&#8217;s understanding of industry conditions. While we believe that each of these studies and publications is reliable, we have not independently verified market and industry data from third-party sources. While we believe our internal company research is reliable and the market definitions are appropriate, neither such research nor definitions have been verified by an independent source.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">ii</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRSU">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">PROSPECTUS SUMMARY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;font-style:italic;">
            <font style="letter-spacing:0.2pt;">This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information that you should consider before deciding to invest in our Class&#160;A common stock. You should read the entire prospectus carefully, including &#8220;Risk Factors,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Some of the statements in this prospectus constitute forward-looking statements. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. With more than a decade of leadership in translational bioinformatics, we have established a track record of generating insights into drug mechanisms of action and patient treatment responses. Building on these insights, we developed a disease-agnostic platform that enables us to utilize human data, novel biology and chemistry, and translational planning to create and advance our wholly owned pipeline. Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and other oncologic signaling pathways. Our lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We plan to submit an IND for IMM-1-104 to the FDA by &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. In addition, we anticipate filing at least two additional INDs for our other oncology programs, one in each of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Our platform is enabled by our ability to efficiently analyze high-throughput molecular-level biochemical assays, including transcriptomics, genomics and/or proteomics, collectively referred to as Omics data. These different types of biochemical assays each provide us with unique information about the molecular mechanisms of disease biology and drug response. Since our inception, we have partnered with industry-leading pharmaceutical and biotechnology companies to perform a variety of analyses that utilize our expertise in translational bioinformatics. Examples publicly disclosed by our partners include our analyses of ibrutinib, ipilimumab, daratumumab, glatiramer acetate and pridopidine. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">In early 2018, we began applying our proprietary platform and approach to internally develop our wholly owned pipeline of orally administered small molecule drug programs. Our approach played a critical role in determining the most important characteristics for and creation of IMM-1-104. Specifically, our platform enables us to: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.49pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.49pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">leverage insights from human data to identify disease transcriptional profiles we aim to counteract; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">identify novel biology, specifically evaluating new ways to drug an existing target by utilizing our proprietary Disease Cancelling Technology, or DCT, and analyze mechanisms of existing drugs; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">generate novel chemistry that overcomes MAPK-feedback loops to achieve optimal signaling dynamics; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6.5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">profile IMM-1-104 in a large number of 3D models using our own translational planning to identify the types of cancer most likely to be sensitive to the product candidate. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Our current oncology programs target mutations of the RAS/RAF/MEK/ERK, or MAPK, and the PI3K/AKT/mTOR, or mTOR, pathways. The MAPK and mTOR signaling pathways run parallel to each other, and in over half of all cancers, one or both of these pathways are inappropriately activated (as depicted below). Existing drugs targeting these pathways are limited by toxicity, resistance and/or are narrowly focused on subpopulations with specific mutations. The MAPK and mTOR pathways function to drive cell proliferation, differentiation, survival and a variety of other cellular functions that are critical for the formation of tumors. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Fundamental Cancer Signaling Cellular Pathways: MAPK and mTOR</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
            <img src="tm2115679d1-tbl_cancer4c.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_cancer4c.jpg]" height="347" width="608" >
          </div>
          <div style="margin-top:10.91pt; text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Each of the programs in our oncology pipeline are designed to cause cyclical disruption of abnormal activation of the MAPK and mTOR signaling pathways while limiting drug-related toxicity. Traditional drug approaches have been designed to sustain pathway inhibition, which can cause on-target drug-related toxicity and limit clinical durability as a result of drug holidays or treatment discontinuation. Based on insights derived from our translational bioinformatics platform, our differentiated approach is to design drugs with short half-lives that provide enhanced mechanistic control of the target of interest and break tumor addiction, which is the tumor&#8217;s ability to indefinitely self-replicate, metastasize and evade the host&#8217;s immune system, among others capabilities, through deep cyclic disruption of these pathways (i.e., signaling dynamics). By cyclically disrupting these core oncogenic signaling pathways in cancer cells, we believe we can create novel therapeutics that maximize therapeutic activity in broad patient populations while providing an improved tolerability profile (as depicted below). We believe we are pioneers in this unique approach of leveraging signaling dynamics against tumor addiction. </font>
          </div>
          <div style="margin-top:11.81pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Signaling Dynamics: Traditional Sustained Inhibition Versus Our Cyclic Approach</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
            <img src="tm2115679d1-lc_tradtion4c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_tradtion4c.jpg]" height="209" width="578" >
          </div>
          <div style="margin-top:14.21pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Wholly Owned Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our oncology programs target clinically validated pathways, but we seek to improve patient outcomes across a wide range of addressable solid tumor types through our differentiated programs. In addition to our </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="text-align:justify; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">oncology pipeline, we are also leveraging our platform to build a neuroscience pipeline initially focusing on Alzheimer&#8217;s disease, or AD. Our current pipeline of product candidates and discovery programs is depicted below. </font>
          </div>
          <div style="position:relative;margin-top:10.6pt; text-align:center; width:456pt;">
            <img src="tm2115679d1-fc_discovery4c.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_discovery4c.jpg]" height="290" width="578" >
          </div>
          <div style="margin-top:18.19pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Dual-MEK Program</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
            <font style="letter-spacing:0.2pt;">Our dual mitogen-activated protein kinase kinase, or MEK, product candidate, IMM-1-104, is designed to be a highly selective inhibitor of mitogen-activated protein kinase kinase kinase, or ERK, activation (i.e.,&#160;phosphorylation), prevent MAPK pathway reactivation and have a short plasma half-life that reduces sustained pathway inhibition (as depicted below). Unlike MEK inhibitors approved by the U.S. Food and Drug Administration, or the FDA, IMM-1-104 is designed to prevent RAF-mediated activation of MEK by engagement of the RAF activation loop on MEK, such as CRAF-bypass, and further disrupt the kinase suppressor of RAS 1 and 2, or KSR. Additionally, with a short plasma half-life, IMM-1-104 can achieve deep cyclic inhibition of the MAPK pathway. We believe this innovative method of pathway inhibition normalizes cancer cell signaling dynamics and prevents further damage to normal healthy cells. Collectively, we believe these qualities differentiate IMM-1-104 from known MEK inhibitors by potentially enabling IMM-1-104 to avoid drug resistance while improving tolerability. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Dual-MEK Inhibition Prevents Activation of MEK and Downstream Activation of ERK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="position:relative;margin-top:10.5pt; text-align:center; width:456pt;">
            <img src="tm2115679d1-tbl_phospho4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_phospho4clr.jpg]" height="248" width="546" >
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In preclinical studies, we observed that IMM-1-104 inhibits MEK and ERK across a wide range of human and murine solid tumor models, including those with activating mutations in KRAS, NRAS, HRAS and BRAF. In addition, we evaluated IMM-1-104 in murine-based KRAS and BRAF mutant solid tumor models representing lung, colon, pancreas and skin cancer, and observed therapeutic activity with improved tolerability when compared to current FDA-approved MEK and BRAF inhibitors. We are also currently evaluating IMM-1-104 in a murine-based NRAS melanoma tumor model. Given the activity and tolerability observed in these preclinical studies, we believe that IMM-1-104 will deliver clinical benefit as monotherapy and, in the future, may potentially be administered in select drug combinations for patients with RAS and/or RAF mutant solid tumors who currently have limited treatment options. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">IMM-1-104 is currently undergoing Investigational New Drug, or IND, enabling studies. We plan to submit an IND for IMM-1-104 to the FDA by &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. We intend to initiate our first-in-human Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, if our IND for IMM-1-104 is accepted. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">MEK-Immuno-Oncology and Other Oncology Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our MEK-immuno-oncology, or MEK-io, program is focused on developing innovative allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of &#8220;cold&#8221; solid tumors, which are immunologically inaccessible. We believe our investigational MEK-io program inhibitors target MEK in a way that disrupts the MAPK pathway at ERK and also reduces baseline MEK activation. We are designing these inhibitors with unique pharmacokinetic, or PK, and pharmacodynamic, or PD, profiles that enhance cycle inhibition time of MEK and ERK to optimize the patient&#8217;s immune response and promote maximal antitumor responses when administered in combination with select immune modulators. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We observed an initial </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> proof-of-concept for our MEK-io program in a widely utilized syngeneic murine model where we observed synergistic antitumor activity in combination with a checkpoint inhibitor. Our MEK-io program is currently in the lead optimization stage of development and we are screening multiple advanced drug analogues for optimal PK and PD profiles that maximally modulate antitumor responses through cyclic inhibition of MEK and ERK. Top candidates will further be evaluated </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> for drug-like properties that demonstrate synergistic therapeutic activity when combined with select immune modulators in preclinical immunologically cold solid tumor models. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are leveraging our platform to continue expanding our oncology pipeline by targeting the MAPK and mTOR pathways in novel ways. We have five additional programs in various stages of drug discovery focused on targeting these pathways through novel pharmacological approaches. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">In addition to the expected IND filing of IMM-1-104, we anticipate filing at least two additional INDs for our other oncology programs, one in each of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Neuroscience Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">AD is the most common form of dementia and one in three adults over the age of 65 succumb to AD-related dementia or another form of dementia. We believe there are specific subgroups of AD that can be stratified through gene expression and brain pathology. To identify AD subgroups, we have leveraged our platform to employ a patient-centric, data-driven approach. AD is a neurodegenerative disorder of uncertain cause and pathogenesis characterized by memory impairment and further cognitive decline that can ultimately affect the patient&#8217;s behavior, speech, visuospatial orientation and motor system. AD is a complex multifactorial disease driven by genetic and environmental causes that affects older adults and is one of the leading sources of morbidity and mortality in the aging population. The estimated total healthcare costs for the treatment of AD was approximately $305&#160;billion in 2020, with the cost expected to increase to more than $1 trillion by 2050. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Our neuroscience programs are in the early stages of drug discovery, and we are evaluating undisclosed targets to pursue a unique approach to treating AD. We believe we can slow the progression of AD by developing targeted therapies for distinct biological mechanisms that we have identified in specific AD subgroups. Our platform and expertise in neurology and neuroscience have allowed us to determine biological differences in </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">AD patients to help develop novel therapies that may potentially address the significant unmet needs of this underserved patient population. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Team</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We were founded in 2008 by our Chief Executive Officer, Benjamin J. Zeskind, Ph.D., and a member of our board of directors, Robert J. Carpenter, with the goal of leveraging translational bioinformatics to generate insights into the mechanisms that cause certain patients to respond to specific medicines across multiple therapeutic areas. Our multi-disciplinary team brings together experts across translational bioinformatics, preclinical and clinical development in both oncology and neuroscience and includes individuals with extensive experience at some of the leading pharmaceutical companies, including Johnson &amp; Johnson, AstraZeneca and Incyte. We are supported by a high-quality group of investors, including entities affiliated with Cormorant Asset Management, Surveyor Capital (a Citadel company), Rock Springs Capital, T. Rowe Price Associates, Inc., Perceptive Advisors and LYFE Capital. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our History</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our company is built on more than a decade of leadership in translational bioinformatics. Since our founding in 2008, we have established a track record of generating insights into the mechanisms that cause certain patients to respond to specific medicines across therapeutic areas by analyzing Omics data. Our computational biology services business has helped us to better understand how translational bioinformatics can contribute to each stage of drug development, from early drug discovery to clinical development and through commercialization. However, we recognized the limitations of applying translational bioinformatics in isolation to specific stages of the drug development process and realized that bioinformatics could be even more helpful if applied continuously throughout the drug development process. Over time, we have developed a proprietary technology platform to facilitate that process and, in early 2018, we began applying the extensive insights from and capabilities of our platform and approach to create a wholly owned pipeline of drug programs, initially focusing on oncology. </font>
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases. Our platform allows us to leverage human biological data in new and creative ways, which provides counterintuitive insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views. We are developing novel therapies that aim to optimize both safety and efficacy for diseases with suboptimal treatment options. To achieve our mission, we are executing a near-term strategy with the following key elements: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rapidly Advance IMM-1-104 into Clinical Development</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Progress Our Pipeline of Additional MAPK and mTOR Pathway Programs to IND-Enabling Studies</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Utilize Our Platform to Advance Our Neuroscience Programs.</font><font style="letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Continue to Grow and Advance Our Platform</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;"> </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Summary Risk Factors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Investing in our Class&#160;A common stock involves substantial risk. Our ability to execute our strategy is also subject to certain risks. The risks described under the heading &#8220;Risk Factors&#8221; included elsewhere in this prospectus may cause us not to realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the most significant challenges and risks include the following: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have a limited operating history, have not completed any clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have incurred significant net losses for the past several&#160;years and we expect to continue to incur significant net losses for the foreseeable future and may never maintain profitability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Even if this offering is successful, we will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, or to obtain regulatory approval to treat the indications we seek to treat with our product candidates, we will be unable to generate product revenue or the level of planned product revenue and our business will be substantially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We are early in our development efforts. Our business is substantially dependent on the successful development of our current and future product candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval to treat the indications we seek to treat with our product candidates, and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems. Any failure of these or other elements of our platform will materially harm our business. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">Our long-term prospects depend in part upon discovering, developing and commercializing product candidates, which may fail in development or suffer delays that adversely affect their commercial viability. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The COVID-19 pandemic and potential future pandemics could continue to adversely impact our business, including our anticipated clinical trials, supply chain and business development activities. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations, or CROs, to conduct certain aspects of our preclinical studies, and in the future, our clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">We contract with third parties for the manufacture of our product candidates for preclinical studies, and expect to continue to do so for clinical trials and ultimately, for commercialization of any approved product candidate. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-left:12pt;width:456pt;">
          <div style="margin-left:30pt; text-align:justify; width:426pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented. </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">If we are unable to obtain and maintain patent and other intellectual property protection for our product candidates and technologies or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be impaired, and we may not be able to compete effectively in our market. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Corporate Information</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">Our corporate headquarters are located at 245 Main Street, Second Floor, Cambridge, Massachusetts 02142. Our telephone number is (617) 500-8080. Our principal website address is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.immuneering.com</font><font style="letter-spacing:0.2pt;">. The information on or accessed through our website is not incorporated in this prospectus or the registration statement of which this prospectus forms a part. </font>
          </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">Implications of Being an Emerging Growth Company and a Smaller Reporting Company</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
            <font style="letter-spacing:0.2pt;">We qualify as an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended, or JOBS Act. As an &#8220;emerging growth company&#8221; we may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not limited to: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the option to present only two&#160;years of audited financial statements and only two&#160;years of related &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this prospectus; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">not being required to comply with any requirements that may be adopted by the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on financial statements; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the completion of this offering. However, if any of the following events occur prior to the end of such five-year period, (i)&#160;our annual gross revenue exceeds $1.07&#160;billion, (ii)&#160;we issue more than $1.0&#160;billion of non-convertible debt in any three-year period, or (iii)&#160;we become a &#8220;large accelerated filer,&#8221; &#8203;(as defined in Rule&#160;12b-2 under the Securities Exchange Act of 1934, as amended, or the Exchange Act), we will cease to be an emerging growth company prior to the end of such five-year period. We will be deemed to be a &#8220;large accelerated filer&#8221; at such time that we (a)&#160;have an aggregate worldwide market value of common equity securities held by non-affiliates of $700.0&#160;million or more as of the last business day of our most recently completed second fiscal quarter, (b)&#160;have been required to file annual and quarterly reports under the Exchange Act, for a period of at least 12&#160;months, and (c)&#160;have filed at least one annual report pursuant to the Exchange Act. Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements including reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have elected to take advantage of certain of the reduced disclosure obligations in the registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might receive from other public reporting companies. In particular, we have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:440pt; margin-left:12pt;width:456pt;">
          <div style="text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company, or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. If we were to subsequently elect instead to comply with these public company effective dates, such election would be irrevocable pursuant to the JOBS Act. </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We are also a &#8220;smaller reporting company,&#8221; meaning that the market value of our shares held by non-affiliates plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700&#160;million and our annual revenue was less than $100&#160;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (i)&#160;the market value of our shares held by non-affiliates is less than $250&#160;million or (ii)&#160;our annual revenue was less than $100&#160;million during the most recently completed fiscal year and the market value of our shares held by non-affiliates is less than $700&#160;million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal&#160;years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:2pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">The Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Class&#160;A common stock offered by us </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares (or &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares if the underwriters exercise their option to purchase additional shares in full). </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Option to purchase additional shares </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We have granted the underwriters an option for a period of 30&#160;days to purchase up to &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; additional shares of Class&#160;A common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Class&#160;A common stock to be outstanding immediately after this offering </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares (or &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares if the underwriters exercise their option to purchase additional shares in full). </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Class&#160;B common stock to be outstanding immediately after this offering </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;B common stock outstanding. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Use of proceeds </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We estimate that the net proceeds from this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; million (or approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; million if the underwriters exercise their option to purchase additional shares in full), based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.</font>
          </div>
          <div style="margin-left:204pt; margin-top:8pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We anticipate that we will use the net proceeds of this offering to advance and expand our clinical and preclinical development programs and for working capital and other general corporate purposes. For a more complete description of our intended use of the proceeds from this offering, see &#8220;Use of Proceeds.&#8221; </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Voting rights </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Following the closing of this offering, we will have two classes of common stock, Class&#160;A common stock and Class&#160;B common stock. Holders of our Class&#160;A common stock will be entitled to one vote per share and the Class&#160;A common stock will not be convertible into any other class of our capital stock. The Class&#160;B common stock will not confer upon their holders any voting rights (except as may be required by law) and each Class&#160;B common stock will be convertible at any time following the closing of this offering, at the election of the holder, into one Class&#160;A common stock, subject to certain beneficial ownership limitations. The Class&#160;B common stock, once converted to Class&#160;A common stock, may not be converted back to Class&#160;B common stock. See &#8220;Description of Capital Stock&#8212;Common Stock&#8221; for more information on the rights of the holders of our Class&#160;A common stock and Class&#160;B common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Risk factors </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">You should read the section titled &#8220;Risk Factors&#8221; beginning on page&#160;13 and the other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our Class&#160;A common stock. </font>
          </div>
          <div style="width:180pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Dividend policy </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">We do not currently pay dividends and we do not anticipate declaring or paying any dividends for the foreseeable future. </font>
          </div>
          <div style="width:180pt;">
            <div style="white-space:nowrap; margin-left:10pt; text-indent:-10pt; margin-top:6pt; line-height:12pt;">
              <font style="letter-spacing:0.2pt;">Proposed Nasdaq Global Market </font>
              <br >
              <font style="letter-spacing:0.2pt;">symbol </font>
            </div>
          </div>
          <div style="margin-left:204pt; margin-top:-12pt; text-align:justify; width:252pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">&#8220;IMRX.&#8221;</font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:152pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The number of shares of Class&#160;A common stock to be outstanding after this offering is based on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;A common stock outstanding as of December&#160;31, 2020, and includes an additional&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class&#160;A common stock issuable upon the conversion of all outstanding shares of our preferred stock on a one-for-one basis immediately prior to the closing of this offering into &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#160;shares of Class&#160;A common stock, subject to certain beneficial ownership limitations, and excludes: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock issuable upon exercise of outstanding stock options granted under the Immuneering Corporation Long Term Incentive Plan, or the 2015 Plan, as of December&#160;31, 2020, at a weighted average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock available for future issuance under the 2015 Plan, as of December&#160;31, 2020, which such shares will cease to be available for issuance at the time our 2021 Plan (as defined below) becomes effective; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;A common stock that will become available for future issuance under the 2021 Incentive Award Plan, or the 2021 Plan, which will become effective in connection with the completion of this offering; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of Class&#160;A common stock that will become available for future issuance under the employee stock purchase plan, or the ESPP, which will become effective in connection with this offering, and shares of our Class&#160;A common stock that become available pursuant to provisions in the ESPP that automatically increase the share reserve under the ESPP; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares of our Class&#160;A common stock issuable upon the exercise of outstanding warrants as of December&#160;31, 2020 at a weighted average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Unless we indicate otherwise or the context otherwise requires, all information in this prospectus assumes or gives effect to: </font>
          </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, each of which will occur immediately prior to the closing of this offering; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">the conversion of all outstanding shares of our Series&#160;A convertible preferred stock, or Series&#160;A Preferred Stock, and Series&#160;B convertible preferred stock, or Series&#160;B Preferred Stock, into shares of our Class&#160;A common stock immediately prior to the closing of this offering; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">a&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;for&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;split of our common stock, effected on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">no exercise of the outstanding stock options, restricted stock units, or RSUs, or warrants described above after December&#160;31, 2020; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">no issuances of Class&#160;B common stock upon the closing of this offering; </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">no exercise by the underwriters of their option to purchase up to &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;additional shares of Class&#160;A common stock; and </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
            <font style="letter-spacing:0.2pt;">&#8226;</font>
            <br >
          </div>
          <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
            <font style="letter-spacing:0.2pt;">an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of Class&#160;A common stock, which is the midpoint of the price range set forth on the cover page of this prospectus. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSCFD">&#8203;</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:93pt; margin-left:12pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
            <font style="letter-spacing:-0.2pt;">SUMMARY CONSOLIDATED FINANCIAL DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
          </div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The following tables set forth our summary consolidated financial data for the periods indicated. We have derived the consolidated statements of operations data for the&#160;years ended December&#160;31, 2020 and 2019, and the consolidated balance sheet data as of December&#160;31, 2020, from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that should be expected for any future period. You should read the following summary consolidated financial data together with the more detailed information contained in &#8220;Selected Consolidated Financial Data,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our consolidated financial statements and the related notes included elsewhere in this prospectus. </font>
          </div>
          <table style="width:456pt;height:359pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:9pt;height:18.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:341.17pt;" rowspan="3">&#8203;</td>
              <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="10">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Year Ended</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">2019 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:31.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:2.583pt 0pt 2.167pt 0pt; width:0pt;" colspan="10">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in thousands, except</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">share and per share</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">amounts) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <font style="letter-spacing:-0.2pt;">Consolidated Statements of Operations Data:</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Revenue </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,311</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,920</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Cost of revenue </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,280</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,223</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Gross profit </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,031</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">697</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <font style="letter-spacing:0.2pt;">Operating expenses </font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Research and development </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">15,004</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,279</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">General and administrative </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,110</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,709</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Total operating expenses </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">18,114</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,988</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Loss from operations </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(17,083<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(6,291<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Interest income (expense), net </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">43</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(293<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Loss on conversion of convertible notes </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,125<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:341.17pt;text-align:left;">
                <div style="margin-left:20pt;">
                  <font style="letter-spacing:0.2pt;">Net loss </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(17,040<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,709<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 3.25pt 0pt; width:341.17pt;text-align:left;">
                <div style="white-space:nowrap;">
                  <font style="letter-spacing:0.2pt;">Net loss per share attributable to common stockholders, basic and diluted </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(4.82<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(2.18<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:1.417pt 0pt 1.833pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding used to compute net loss per share, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,535,811</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,535,811</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:1.917pt 0pt 0.833pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Pro Forma net loss per share attributable to common shareholders, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(2)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2.78<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:2.167pt 0pt 2.583pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">
                  <font style="letter-spacing:0.2pt;">Pro Forma weighted average shares outstanding used to compute net loss per share, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(2)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,127,858</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:6.5pt; width:456pt;">
            <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:7pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">See Note 8 to our consolidated financial statements for the years ended December&#160;31, 2020 and 2019 appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per share attributable to common stockholders. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:9pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">The unaudited pro&#160;forma net loss per share for the year ended December&#160;31, 2020 was computed using the weighted-average number of shares of common stock outstanding, including the pro&#160;forma effect of the conversion of all outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of common stock, as if such conversion had occurred at the beginning of the period, or their issuance dates, if later. The information presented in this table does not give effect to the sale and issuance of our Series&#160;B Preferred Stock that occurred in April and May&#160;2021. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="border:1pt #000 solid;margin-top:3.85pt;min-height:694pt;margin-left:57.66pt;width:480pt;">
        <div style="margin-top:10pt;margin-bottom:213.5pt; margin-left:12pt;width:456pt;">
          <table style="width:456pt;height:164.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:308.04pt;" rowspan="3">&#8203;</td>
              <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2020 </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Actual </font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Pro</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Forma</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
                <div style="text-align:center;">
                  <font style="letter-spacing:-0.16pt;">Pro Forma As</font>
                  <br >
                  <font style="letter-spacing:-0.16pt;">Adjusted</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(2)</font>
                </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">
                  <font style="letter-spacing:-0.16pt;">(in thousands) </font>
                </div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.25pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <font style="letter-spacing:-0.2pt;">Consolidated Balance Sheet Data:</font>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">37,090</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Working capital</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">35,475</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Total assets </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,423</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Total liabilities </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,801</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Convertible preferred stock </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">58,104</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,738<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
              <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.04pt;text-align:left;">
                <div style="margin-left:10pt;">
                  <font style="letter-spacing:0.2pt;">Total stockholders&#8217; equity (deficit) </font>
                </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(22,481<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:1.975pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:8.485pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:10.5pt; width:456pt;">
            <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:7pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(1)</font>
            <br >
          </div>
          <div style=" margin-top:7pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">Gives effect to (i)&#160;the receipt of approximately $24.8&#160;million in aggregate net proceeds from the issuance and sale of our Series&#160;B Preferred Stock that occurred in April and May&#160;2021, and (ii)&#160;the conversion of all of the outstanding shares of our Series A Preferred Stock and Series B Preferred Stock into an aggregate of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class A common stock (and no shares of Class B common stock) upon the closing of this offering, as if such conversion had occurred on December&#160;31, 2020. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:9pt; margin-top:4pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(2)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">Gives further effect to the sale of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share (which is the midpoint of the price range set forth on the cover page of this prospectus), after deducting underwriting fees and commissions and estimated offering expenses payable by us. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:9pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">(3)</font>
            <br >
          </div>
          <div style=" margin-top:4pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">We define working capital as current assets less current liabilities. </font>
          </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">The pro&#160;forma as adjusted balance sheet data give further effect to our issuance and sale of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class&#160;A common stock in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share (which is the midpoint of the price range set forth on the cover page of this prospectus) after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share (which is the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#8217; equity by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&#160;million shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#8217; equity by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming no change in the assumed initial public offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
          </div>
        </div>
        <div style="margin-top:2pt;margin-left:12pt;width:456pt;">
          <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
            <font style="letter-spacing:0.16pt;">&#160;</font>
            <br >
          </div>
        </div>
      </div>
      <div style="margin-top:2.1316282072803E-14pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRIFA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RISK FACTORS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">You should carefully consider the risks and uncertainties described below and the other information in this prospectus, including our consolidated financial statements and related notes appearing elsewhere in this prospectus and in the section titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our Class&#160;A common stock. Our business, financial condition, results of operations or prospects could be materially and adversely affected if any of these risks occurs, and as a result, the market price of our Class&#160;A common stock could decline and you could lose all or part of your investment. This prospectus also contains forward-looking statements that involve risks and uncertainties. See &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221; Our actual results could differ materially and adversely from those anticipated in these forward-looking statements as a result of certain factors, including those set forth below.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Financial Condition and Capital Requirements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have a limited operating history in developing pharmaceutical products, have not completed any clinical trials and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a biopharmaceutical company with a limited operating history in developing pharmaceutical products which makes it difficult to evaluate our business and prospects in future product development. We have no products approved for commercial sale and have not generated any revenue from product sales. To date, we have devoted substantially all of our resources and efforts to providing computational biology services to pharmaceutical and biotechnology companies, organizing and staffing our company, business planning, executing partnerships, raising capital, discovering, identifying and developing potential product candidates, securing related intellectual property rights and undertaking research and preclinical studies of our product candidates, including the anticipated Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We have not yet demonstrated our ability to successfully initiate any clinical trials, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability to develop new pharmaceutical products than it could be if we had a longer operating history. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by biopharmaceutical companies developing products in rapidly evolving fields. We also may need to transition from a company with a research focus to a company capable of supporting commercial activities. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have incurred significant net losses for the past several&#160;years and we expect to continue to incur significant net losses for the foreseeable future and may never maintain profitability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have incurred net losses in each reporting period for the past several&#160;years, have not generated any revenue from product sales to date and have financed our operations principally through our computational biology services to pharmaceutical and biotechnology companies, the issuance of convertible debt and the sale of our convertible preferred stock and Class&#160;A common stock. We have incurred net losses of approximately $17.0&#160;million and $7.7&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of approximately $25.7&#160;million. Our losses have resulted principally from expenses incurred in research and development of our product candidates, from management and administrative costs and other expenses that we have incurred while building our business infrastructure. Our lead product candidate, IMM-1-104, is undergoing IND-enabling studies and we expect to submit an IND to the FDA by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. We intend to initiate a Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors if our IND for IMM-1-104 is accepted. Our other product candidates are in much earlier stages of drug development. As a result, we expect that it will be several&#160;years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">candidates, we expect that we will continue to incur substantial research and development and other expenses as we discover, develop and market additional potential product candidates. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase substantially if and as we: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">advance the development of our lead product candidate, IMM-1-04, and our other product candidates through preclinical and clinical development, and, if approved by the FDA or other comparable foreign regulatory authorities, commercialization; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">incur manufacturing costs for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">seek regulatory approvals for any of our product candidates that successfully complete clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">increase our research and development activities to identify and develop new product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">hire additional personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expand our operational, financial and management systems; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">invest in measures to protect and expand our intellectual property; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish a sales, marketing, medical affairs and distribution infrastructure to commercialize any product candidates for which we may obtain marketing approval and intend to commercialize; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expand our manufacturing and develop our commercialization efforts; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">operate as a public company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The net losses we incur may fluctuate significantly from quarter to quarter such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital and our ability to achieve and maintain profitability. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if this offering is successful, we will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is a very time-consuming, expensive and uncertain process that takes&#160;years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses to increase in connection with our ongoing activities, particularly as we initiate and conduct clinical trials of, and seek marketing approval for our current and any future product candidates. Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or other comparable foreign regulatory authorities to perform clinical trials or preclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of our anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any product candidate we develop. Following this offering, we also expect to incur additional costs associated with operating as a public company. Accordingly, it is likely that we will need to obtain substantial additional funding in order to maintain our continuing operations in the future. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, we had approximately $37.1&#160;million in cash and cash equivalents. Based on our current business plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to fund our operating expenses and capital expenditures requirements through&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. Our estimate as to how long we expect the net proceeds from this offering, together with our existing cash and cash equivalents, to be able to continue to fund our operating expenses and capital expenditures requirements is based on assumptions that may prove to be wrong, and we could use our available </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">capital resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our future funding requirements will depend on many factors, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the initiation, progress, timeline, cost and results of our clinical trials for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the initiation, progress, timeline, cost and results of additional research and preclinical studies related to pipeline development and other research programs we initiate in the future; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost and timing of manufacturing activities as we advance our product candidates through preclinical and clinical development, and commercialization; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential expansion of our current development programs to seek new indications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the continued negative impact of the COVID-19 pandemic or future pandemics on our business; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the outcome, timing and cost of meeting regulatory requirements established by the FDA and other comparable foreign regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights, in-licensed or otherwise; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effect of competing technological and market developments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the payment of licensing fees, potential royalty payments and potential milestone payments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of general operating expenses; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost and timing of completion of commercial-scale manufacturing activities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of establishing sales, marketing, and distribution capabilities for any product candidates for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of operating as a public company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to use the net proceeds from this offering to advance IMM-1-104 into clinical development, including to fund our anticipated Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, and additional clinical trials; advance our other preclinical drug programs and the design and development of new product candidates, in oncology and neuroscience, and to advance these programs into IND-enabling studies that would support an IND filing for one or more product candidates; and for working capital and other general corporate purposes, including the continued advancement of our platform and hiring of additional staff as we expand our operations. Advancing the development of our product candidates will require a significant amount of capital. The net proceeds from this offering and our existing cash and cash equivalents will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources, which may dilute our stockholders or restrict our operating activities. We do not have any committed external source of funds. Adequate additional financing may not be available to us on acceptable terms, or at all. Additionally, the impact of the COVID-19 pandemic on the capital markets may affect the availability, amount and type of financing available to us in the future. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our product candidates on unfavorable terms to us.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may seek additional capital through a variety of means, including through public or private equity offering, debt financings or other sources, including up-front payments and milestone payments from strategic </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">collaborations. To the extent that we raise additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through up-front payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to our product candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our ability to use our net operating losses and other tax attributes may be limited.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, we had approximately $22.0&#160;million of federal and $14.3&#160;million of state net operating loss carryforwards, or NOLs, available to offset future taxable income. Under Sections&#160;382 and 383 of the U.S. Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50% change by value in its equity ownership over a three-year period is subject to limitations on its ability to utilize its pre-change NOLs and other tax attributes such as research tax credits to offset future taxable income. We have not performed an analysis to determine whether our past issuances of stock and other changes in our stock ownership may have resulted other ownership changes. If it is determined that we have in the past experienced other ownership changes, or if we undergo one or more ownership changes as a result of this offering or future transactions in our stock, which may be outside our control, then our ability to utilize NOLs and other pre-change tax attributes could be further limited by Sections&#160;382 and 383 of the Code, and certain of our NOLs and other pre-change tax attributes may expire unused. As a result, if or when we earn net taxable income, our ability to use our pre-change NOLs or other tax attributes to offset such taxable income or otherwise reduce any liability for income taxes may be subject to limitations, which could adversely affect our future cash flows. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Development, Regulatory Approval and Commercialization</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval for our product candidates, or to obtain regulatory approval to treat the indications we seek to treat with our product candidates, we will be unable to generate product revenue or the level of planned product revenue and our business will be substantially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are not permitted to commercialize, market, promote or sell any product candidate in the United States without obtaining marketing approval from the FDA. Foreign regulatory authorities impose similar requirements. The time required to obtain approval by the FDA and other comparable foreign regulatory authorities is unpredictable, typically takes many&#160;years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. For example, a U.S. federal government shutdown or budget sequestration, such as ones that occurred during 2013, 2018 and 2019, may result in significant reductions to the FDA&#8217;s budget, employees and operations, which may lead to slower response times and longer review periods, potentially affecting our ability to progress development of our product candidates or obtain regulatory approval for our product candidates. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be unable to demonstrate to the FDA or other comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the approval policies or regulations of the FDA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, even if we obtain approval of our product candidates, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may impose significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy, or REMS. Regulatory authorities may not approve the price we intend to charge for products we may develop, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could seriously harm our business. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be able to file INDs or IND amendments or comparable documents in foreign jurisdictions to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While we plan to submit INDs or comparable documents for our potential product candidates, we may not be able to file such INDs or comparable documents on the timeline we expect. For example, we may experience manufacturing delays or other delays with IND-enabling studies. Moreover, we cannot be sure that submission of an IND or comparable document will result in the FDA or other comparable foreign regulatory authorities allowing further clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that such regulatory authorities will not change their requirements in the future. These considerations also apply to new clinical trials we may submit as </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">amendments to existing INDs or to a new IND. Any failure to file INDs on the timelines we expect or to obtain regulatory approvals for our trials may prevent us from completing our clinical trials or commercializing our products on a timely basis, if at all. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our company has limited experience in designing clinical trials and may experience delays or unexpected difficulties in obtaining regulatory approval for our current and future product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any future clinical trials will be successful. It is possible that the FDA may refuse to accept any or all of our planned NDAs for substantive review or may conclude after review of our data that our application is insufficient to obtain regulatory approval for any product candidates. If the FDA does not approve any of our planned NDAs, it may require that we conduct additional costly clinical trials, preclinical studies or manufacturing validation studies before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA or other application that we submit may be significantly delayed, possibly for several&#160;years, or may require us to expend more resources than we have available. Any failure or delay in obtaining regulatory approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve any NDA or other application that we submit. If any of these outcomes occur, we may be forced to abandon the development of our product candidates, which would materially adversely affect our business and could potentially cause us to cease operations. We face similar risks for our applications in foreign jurisdictions. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may encounter substantial delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before obtaining marketing approval from the FDA or other comparable foreign regulatory authorities for the sale of our product candidates, we must complete preclinical development and extensive clinical trials to demonstrate the safety and efficacy of our product candidates. Clinical testing is expensive, difficult to design and implement, can take many&#160;years to complete and its ultimate outcome is uncertain. A failure of one or more clinical trials can occur at any stage of the process. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their drugs. The outcome of preclinical studies and early-stage clinical trials may not be predictive of the success of later clinical trials. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, we are substantially dependent on preclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions for our product candidates. While we have or will have agreements governing these third parties&#8217; services, we have limited influence over their actual performance. If these third parties do not make data available to us, or, if applicable, make regulatory submissions in a timely manner, in each case pursuant to our agreements with them, our development programs may be significantly delayed, and we may need to conduct additional studies or collect additional data independently. In either case, our development costs would increase, perhaps substantially. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not know whether our future clinical trials will begin on time or enroll patients on time, or whether our future clinical trials will be completed on schedule or at all. Clinical trials can be delayed for a variety of reasons, including delays related to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial design; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining approval from one or more institutional review boards, or IRBs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional subjects, or withdrawing their approval of the trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in enrollment due to travel or quarantine policies, or other factors related to COVID-19, other pandemics or other events outside our control; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes to clinical trial protocol; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical sites deviating from trial protocol or dropping out of a trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">manufacturing sufficient quantities of product candidates or obtaining sufficient quantities of combination therapies for use in clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment follow-up; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subjects choosing an alternative treatment for the indication for which we are developing our product candidates, or participating in competing clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">lack of adequate funding to continue the clinical trial; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subjects experiencing severe or unexpected drug-related adverse effects; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">occurrence of serious adverse events in trials of the same class of agents conducted by other companies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">selection of clinical end points that require prolonged periods of clinical observation or analysis of the resulting data; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a facility manufacturing our product candidates or any of their components being ordered by the FDA or comparable foreign regulatory authorities to temporarily or permanently shut down due to violations of current good manufacturing practice, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any changes to our manufacturing process that may be necessary or desired; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For instance, the ongoing COVID-19 pandemic and the measures taken by the governmental authorities could disrupt the supply chain and the manufacture or shipment of drug substances and finished drug products for our product candidates for use in our research and clinical trials, delay, limit or prevent our employees and CROs from continuing research and development activities, impede the ability of patients to enroll or continue in clinical trials, or impede testing, monitoring, data collection and analysis or other related activities, any of which could delay our clinical trials and increase our development costs, and have a material adverse effect on our business, financial condition and results of operations. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, conducting clinical trials in foreign countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be delayed in obtaining marketing approval, if at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain approval for indications or patient populations that are not as broad as intended or desired; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be subject to additional post-marketing testing requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">have regulatory authorities withdraw, or suspend, their approval of the drug or impose restrictions on its distribution in the form of a modified REMS; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be subject to the addition of labeling statements, such as warnings or contraindications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">be sued; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">experience damage to our reputation. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all. Any delay in, or termination of, our clinical trials will delay the submission of an NDA to the FDA or similar applications with comparable foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates, if approved, and generate product revenue. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our claims for differentiation or the effectiveness or safety of our product candidate. The FDA has substantial discretion in the review and approval process and may disagree that our data support the claims we propose. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If we experience delays in the completion of, or termination of, any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize our product candidates and our competitors may be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">able to bring products to market before we do, and the commercial viability of our product candidates could be significantly reduced. Any of these occurrences may harm our business, financial condition and prospects significantly. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The outcome of preclinical studies and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA or other comparable foreign regulatory authorities.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Before obtaining regulatory approvals for the commercial sale of any of our product candidates, we will be required to demonstrate with substantial evidence through well-controlled clinical trials that our product candidates are safe and effective for their intended uses. Clinical testing is expensive and can take many&#160;years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. We do not know whether any of our product candidates will perform in current or future clinical trials as they have performed in preclinical studies. Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA or other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidate. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates. Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have limited experience in designing clinical trials and may be unable to design and execute a clinical trial to support marketing approval. We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could seriously harm our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We cannot guarantee that the FDA or comparable foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit applications seeking approval of our product candidates. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for any of our product candidates, the terms of such approval may limit the scope and use of our product candidate, which may also limit its commercial potential. Furthermore, the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying approval of our product candidates. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interim, &#8220;top-line&#8221; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may publicly disclose preliminary or top-line data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line and preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data are available. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the trading price of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the interim, top-line, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. Moreover, such disclosure could adversely affect the trading price of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our current or future product candidates may cause adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with the use of our product candidates. Results of our preclinical studies and clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with approved or other investigational products we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patients in our clinical trials may in the future suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. Some of our product candidates may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory agencies. In addition, if our product candidates are used in combination with other therapies, our product candidates may exacerbate adverse events associated with the therapy. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">side effects or adverse events that are unrelated to our product candidate, but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If significant adverse events or other side effects are observed in any of our future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, if any of our product candidates receives regulatory approval, and we or others later identify undesirable side effects caused by such product, a number of potentially significant negative consequences could result. For example, the FDA could require us to adopt a REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and costlier than what is typical for the industry. We or our collaborators may also be required to adopt a REMS or engage in similar actions, such as patient education, certification of health care professionals or specific monitoring, if we or others later identify undesirable side effects caused by any product that we develop alone or with collaborators. Other potentially significant negative consequences include that: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be forced to suspend marketing of that product, or be forced to or decide to remove the product form the marketplace; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may withdraw or change their approvals of that product in one or more countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory authorities may require additional warnings on the label or limit access of that product to selective specialized centers with additional safety reporting and with requirements that patients be geographically close to these centers for all or part of their treatment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be required to create a medication guide outlining the risks of the product for patients, or to conduct post-marketing studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may be required to change the way the product is administered; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we could be subject to fines, injunctions, or the imposition of criminal or civil penalties, or to sued and held liable for harm caused to subjects or patients; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the product may become less competitive, and our reputation may suffer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any of these events could diminish the usage or otherwise limit the commercial success of our product candidates and prevent us from achieving or maintaining market acceptance of the affected product candidate, if approved by applicable regulatory authorities. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patient enrollment is a significant factor in the timing of clinical trials, and the timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials to such trial&#8217;s conclusion as required by the FDA or other comparable foreign regulatory authorities. Additionally, our clinical trials will compete with other clinical trials for product candidates that focusing on the same therapeutic targets (e.g., evaluating patients harboring RAS mutant tumors) as our current and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">potential future product candidates, which may further limit enrollment of eligible patients or may result in slower enrollment than we anticipate. The eligibility criteria of our clinical trials, once established, may further limit the pool of available trial participants. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Patient enrollment may also be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment for any of our clinical trials may be affected by other factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">size and nature of the patient population; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">severity of the disease under investigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">availability and efficacy of approved drugs for the disease under investigation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patient eligibility criteria for the trial in question as defined in the protocol; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">perceived risks and benefits of the product candidate under study; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">efforts to facilitate timely enrollment in clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patient referral practices of physicians; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to monitor patients adequately during and after treatment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">proximity and availability of clinical trial sites for prospective patients; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">continued enrollment of prospective patients by clinical trial sites; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays or difficulties in enrollment and completion of studies due to the COVID-19 pandemic or any future pandemic. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, even if we are able to enroll a sufficient number of patients for our clinical trials, we may have difficulty maintaining enrollment of such patients in our clinical trials. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if our product candidates receive regulatory approval, they may not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our approved product candidates will depend on a number of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing of market introduction of the product candidate as well as competitive products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the clinical indications for which the product candidate is approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on the use of our product candidates, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the potential and perceived advantages of product candidates over alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the cost of treatment in relation to alternative treatments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">24</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of coverage and adequate reimbursement, as well as pricing, by third-party payors, including government authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the availability of the approved product candidate for use as a combination therapy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">relative convenience and ease of administration; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the effectiveness of sales and marketing efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">unfavorable publicity relating to our products or product candidates or similar approved products or product candidates in development by third parties; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the approval of other new therapies for the same indications. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of our product candidates is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors and patients, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be unable to obtain U.S. or foreign regulatory approvals and, as a result, may be unable to commercialize our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be marketed. Satisfaction of these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. We cannot provide any assurance that any product candidate we may develop will progress through required clinical testing and obtain the regulatory approvals necessary for us to begin selling them. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have not conducted, managed or completed large-scale or pivotal clinical trials nor managed the regulatory approval process with the FDA or any other regulatory authority. The time required to obtain approvals from the FDA and other regulatory authorities is unpredictable, and requires successful completion of extensive clinical trials which typically takes many&#160;years, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when evaluating clinical trial data can and often changes during drug development, which makes it difficult to predict with any certainty how they will be applied. We may also encounter unexpected delays or increased costs due to new government regulations, including future legislation or administrative action, or changes in FDA policy during the period of drug development, clinical trials and FDA regulatory review. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any delay or failure in seeking or obtaining required approvals would have a material and adverse effect on our ability to generate revenue from the particular product candidate for which we are developing and seeking approval. Furthermore, any regulatory approval to market a drug may be subject to significant limitations on the approved uses or indications for which we may market the drug or the labeling or other restrictions. In addition, the FDA has the authority to require a REMS as part of approving a NDA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug. These requirements or restrictions might include limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry. These limitations and restrictions may significantly limit the size of the market for the drug and affect reimbursement by third-party payors. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are also subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries, and generally includes all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">25</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our approach to the discovery and development of product candidates is unproven, and we may not be successful in our efforts to use and expand our DCT platform to build a pipeline of product candidates with commercial value.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">A key element of our strategy is to use and expand our DCT platform to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of various cancers. Although our research and development efforts to date have resulted in our discovery and preclinical development of IMM-1-104, it and other product candidates may not be safe or effective for the indications for which we study them in clinical trials, and we may not be able to develop any other product candidates. Our DCT platform is evolving and may not reach a state at which building a pipeline of product candidates is possible. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have not commenced clinical trials for any product candidates developed with our DCT platform. The scientific research that forms the basis of our efforts to develop product candidates with our platforms is still ongoing. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our DCT platform is both preliminary and limited. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates. For example, we have not tested any of the product candidates being developed using our DCT platform in humans, and our current data is limited to animal models and preclinical cell lines, the results of which may not translate into humans. As a result, it is possible that safety events or concerns could negatively affect the development of our product candidates, including adversely affecting patient enrollment among the patient populations that we intend to treat. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Given the novelty of our technologies, we intend to work closely with the FDA and comparable foreign regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates; however, due to a lack of comparable experiences, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates developed using our platforms, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted or approved by the FDA and comparable foreign regulatory authorities. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Additionally, a key element of our strategy is to use and expand our platforms to build a pipeline of product candidates and progress those product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have been focused on identifying a pipeline of product candidates directed at various disease types, we may not be able to develop product candidates that are safe and effective. Even if we are successful in building our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be approvable or marketable products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop, get approval for and begin to commercialize any product candidates, we will face difficulty in obtaining product revenue in future periods, which could result in significant harm to our financial position and adversely affect our share price. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Even if we are successful in building our pipeline of product candidates, the potential product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable toxicity or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future, which likely would result in significant harm to our financial position and adversely affect our stock price. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">26</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may develop our current and future product candidates in combination with other therapies, which exposes us to additional risks.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may also develop certain product candidates as biologic/drug combination products. Additional time may be required to obtain regulatory approval for our product candidates if they are combination products. Our product candidates that may be biologic/drug combination products will require coordination within the FDA and other comparable foreign regulatory authorities for review of their biologic and drug components. Although the FDA and other comparable foreign regulatory authorities have systems in place for the review and approval of combination products, we may experience delays in the development and commercialization of our product candidates that may be combination products due to regulatory timing constraints and uncertainties in the product development and approval process. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or comparable foreign regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product or that safety, efficacy, manufacturing or supply issues could arise with any of those existing therapies. If the therapies we use in combination with our product candidates are replaced as the standard of care for the indications we choose for any of our product candidates, the FDA or comparable foreign regulatory authorities may require us to conduct additional clinical trials. The occurrence of any of these risks could result in our own products, if approved, being removed from the market or being less successful commercially. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also may choose to evaluate our current product candidates or any other future product candidates in combination with one or more cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell our product candidates we develop in combination with an unapproved cancer therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved cancer therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the FDA or comparable foreign regulatory authorities do not approve these other drugs or revoke their approval of, or if safety, efficacy, quality, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with our product candidate we develop, we may be unable to obtain approval of or market such combination therapy. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we successfully develop our product candidates, we may seek approval from the FDA through the use of accelerated approval pathways. If we are unable to obtain such approval, we may be required to conduct additional preclinical studies or clinical trials beyond those that we initially contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if we receive accelerated approval from the FDA, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA may seek to withdraw accelerated approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may in the future seek an accelerated approval for one or more of our product candidates. Under the accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful in the context of a given disease, such as irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. If granted, accelerated approval is usually contingent on the sponsor&#8217;s agreement to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">27</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug&#8217;s clinical benefit. If such post-approval studies fail to confirm the drug&#8217;s clinical benefit, the FDA may withdraw its approval of the drug. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to seeking accelerated approval for any of our product candidates, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other factors we will decide to pursue or submit an NDA for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation (e.g., breakthrough therapy designation) for our product candidates, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or other comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development, review or approval for our product candidate would result in a longer time period to commercialization of such product candidate, could increase the cost of development of such product candidate and could harm our competitive position in the marketplace. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because we have limited financial and managerial resources, we focus on research programs, therapeutic platforms and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other therapeutic platforms or product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success than our product candidates. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs, therapeutic platforms and product candidates for specific indications may not yield any commercially viable products. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are early in our development efforts. Our business is substantially dependent on the successful development of our current and future product candidates. If we are unable to advance our current or future product candidates through clinical trials, obtain marketing approval to treat the indications we seek to treat with our product candidates, and ultimately commercialize any product candidates we develop, or experience significant delays in doing so, our business will be materially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are early in our development efforts and we have not yet completed our IND-enabling studies for our lead product candidate, IMM-1-104. Our other product candidates are in much earlier stages of drug development. We have invested substantially all of our efforts and financial resources in the identification of targets and preclinical development of small molecules targeting the MAPK and mTOR pathways in cancer therapy and small molecules targeting central nervous system disorders, including AD. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The success of our business, including our ability to finance our company and generate revenue from products in the future, which we do not expect will occur for several&#160;years, if ever, will depend heavily on the successful development and eventual commercialization of the product candidates we develop, which may never occur. Our current product candidates, and any future product candidates we develop, will require additional preclinical and clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other markets, demonstrating effectiveness to pricing and reimbursement authorities, obtaining sufficient manufacturing supply for both clinical development and commercial production, building of a commercial organization, and substantial investment and significant marketing efforts before we generate any revenues from product sales. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">28</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The success of our current and future product candidates will depend on several factors, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the successful and timely completion of additional preclinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the successful initiation, patient enrollment and completion of our anticipated clinical trials on a timely basis, including any delays arising out of the COVID-19 pandemic or any future pandemic; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintaining and establishing relationships with CROs and clinical sites for clinical development, both in the United States and internationally; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the frequency and severity of adverse events in the clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the efficacy, safety and tolerability profiles that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timely receipt of marketing approvals from applicable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent of any required post-marketing approval commitments to applicable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the maintenance of existing, or the establishment of new, scaled production arrangements with third-party manufacturers to obtain finished products that are appropriate for commercial sale of our product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the protection of our rights in our intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the successful launch of commercial sales following any marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a continued acceptable safety profile following any marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">commercial acceptance by patients, the medical community and third-party payors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to compete with other therapies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any future collaborator. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize the product candidates we develop, which would materially harm our business. If we do not receive marketing approvals for IMM-1-104, or any other product candidate we develop, we may not be able to continue our operations. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems. Any failure of these or other elements of our platform will materially harm our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are substantially dependent on our platform, including our proprietary technologies such as DCT and Fluency, which are supported by our information technology systems, for significant elements of our drug discovery process, bioinformatics and computational biology software systems, database of information relating to our product candidates and their role in the targeted disease process, amongst others. Although we invest substantially in the backup/restore, high-availability architecture, monitoring and reporting, documentation and preventive security controls of our systems and proprietary technologies, these elements of our platform are still vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious or inadvertent human acts, and natural disasters. Our information technology systems and proprietary technologies are potentially also vulnerable to physical or electronic break-ins, employee errors, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology systems and proprietary technologies, failures or significant downtime of these systems could prevent us from conducting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">29</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">research and development activities for our current and future product candidates, and ultimately delay our drug discovery process. Any failure of our information technology systems and proprietary technologies will materially harm our business. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our long-term prospects depend in part upon discovering, developing and commercializing product candidates, which may fail in development or suffer delays that adversely affect their commercial viability.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our future results of operations are dependent on our ability to successfully discover, develop, obtain regulatory approval for and commercialize product candidates beyond those we currently have in preclinical studies and early stage development. A product candidate can unexpectedly fail at any stage of preclinical and clinical development. The historical failure rate for product candidates is high due to risks relating to safety, efficacy, clinical execution, changing standards of medical care and other unpredictable variables. The results from preclinical studies or early clinical trials of a product candidate may not be predictive of the results that will be obtained in later stage clinical trials of the product candidate. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The success of the product candidates we have or may develop will depend on many factors, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success of our research methodology in identifying potential indications or product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">generating sufficient data to support the initiation or continuation of clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtaining regulatory permission to initiate clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">contracting with the necessary parties to conduct clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successful enrollment of patients in, and the completion of, clinical trials on a timely basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">adverse events in the clinical trials; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">any potential interruptions or delays resulting from factors related to the COVID-19 pandemic or any future pandemic. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if we successfully advance any other product candidates into clinical development, their success will be subject to all of the clinical, regulatory and commercial risks described elsewhere in this &#8220;Risk Factors&#8221; section. Accordingly, we cannot assure you that we will ever be able to discover, develop, obtain regulatory approval of, commercialize or generate significant revenue from our other product candidates. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. We will have to develop our own sales, marketing and supply organization or outsource these activities to a third party to commercialize our products. If we decide to license our product candidate to others, we may need to rely on the marketing assistance and guidance of those collaborators. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Factors that may affect our ability to commercialize our product candidates on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of physicians to prescribe our product candidates and other unforeseen costs associated with creating an independent sales and marketing organization. Developing a sales and marketing organization will be expensive and time-consuming and could delay the launch of our product candidates. We may not be able to build an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our product candidates, we may not generate revenues from them or be able to reach or sustain profitability. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">30</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may attempt to develop product candidates. In addition, our products may need to compete with off-label drugs used by physicians to treat the indications for which we seek approval. This may make it difficult for us to replace existing therapies with our products. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational biopharmaceutical companies, established biotechnology companies, specialty biopharmaceutical companies, emerging and start-up companies, universities and other research institutions. For example, our product candidates and programs for oncology and neuroscience will compete with products or programs being advanced by certain pharmaceutical and biotechnology companies. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying and in-licensing new product candidates. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have chosen to initially address well-validated biochemical targets, and therefore expect to face competition from existing products and products in development for each of our product candidates. There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Many of these current and potential competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources and commercial expertise than we do. Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities and experience than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our commercial opportunities could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors also may obtain marketing approval from the FDA or other comparable foreign regulatory authorities for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. Even if the product candidates we develop achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If the market opportunity for any product candidate that we develop is smaller than we believe, our revenue may be adversely affected and our business may suffer.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to initially focus our product candidate development on treatments for various oncology indications. Our projections of addressable patient populations that may benefit from treatment with our product candidates are based on our estimates. These estimates, which have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations and market research, may prove to be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">31</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may not ultimately be amenable to treatment with our product candidates. Our market opportunity may also be limited by future competitor treatments that enter the market. If any of our estimates prove to be inaccurate, the market opportunity for any product candidate that we develop could be significantly diminished and have an adverse material impact on our business. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any product candidate.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our applications are insufficient to obtain marketing approval of our product candidates. We believe our approach of treating conditions or diseases through neuroregeneration is novel and, as a result, the process for, and the outcome of, FDA approval is especially uncertain. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical, or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues, and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The COVID-19 pandemic and potential future pandemics could continue to adversely impact our business, including our anticipated clinical trials, supply chain and business development activities.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, SARS-CoV-2, a novel strain of coronavirus, was first reported in Wuhan, China and has since become a global pandemic. The President of the United States declared the COVID-19 pandemic a national emergency and many states and municipalities in the United States have announced aggressive actions to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing &#8220;shelter-in-place&#8221; orders which direct individuals to shelter at their places of residence (subject to limited exceptions). We may experience limitations on employee resources in the future, including because of sickness of employees or their families. The effects of government actions and our own policies and those of third parties to reduce the spread of COVID-19 may negatively impact productivity and slow down or delay our future clinical trials, preclinical studies and research and development activities, and may cause disruptions to our supply chain and impair our ability to execute our business development strategy. In the event that government authorities were to enhance current restrictions, our employees who currently are not telecommuting may no longer be able to access our facilities, and our operations may be further limited or curtailed. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As COVID-19 continues to spread, we may experience ongoing disruptions that could severely impact our business, preclinical studies and clinical trials, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption or delays in our operations, which may impact our ability to conduct and produce preclinical results required for submission of an IND; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in receiving approval from local regulatory authorities to initiate our planned clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays or difficulties in enrolling patients in our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and clinical site staff; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in clinical sites receiving the supplies and materials needed to conduct our clinical trials, including interruption in global shipping that may affect the transport of clinical trial materials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">32</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in local regulations as part of a response to the COVID-19 outbreak which may require us to change the ways in which our clinical trials are conducted, which may result in unexpected costs, or to discontinue the clinical trials altogether; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel imposed or recommended by federal or state governments, employers and others, or interruption of clinical trial subject visits and study procedures, the occurrence of which could affect the integrity of clinical trial data; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval timelines; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">risk that participants enrolled in our clinical trials will acquire COVID-19 while the clinical trial is ongoing, which could impact the results of the clinical trial, including by increasing the number of observed adverse events; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal of the FDA to accept data from clinical trials in affected geographies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">These and other disruptions in our operations and the global economy could negatively impact our business, results of operations and financial condition. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our future clinical trials may be affected by the COVID-19 pandemic or any future pandemic. For example, some clinical trial sites have slowed down or stopped further enrollment of new patients in clinical trials, denied access to site monitors and otherwise curtailed certain operations. Similarly, our ability to recruit and retain principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, may be adversely impacted. Our planned clinical trials may also be impacted by interruptions or delays in the operations of the FDA and comparable foreign regulatory agencies. We and our CROs will act in accordance with the guidance issued by the FDA in our future clinical trials to ensure the monitoring and safety of patients and minimize risks to trial integrity during the COVID-19 pandemic. This may have unforeseen effects on the enrollment, progress and completion of these trials and the findings. These events could delay our clinical trials, increase the cost of completing our clinical trials and negatively impact the integrity, reliability or robustness of the data from our clinical trials. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities upon which we may rely in the future, or the availability or cost of materials, which could disrupt the supply chain for our product candidates. To the extent our future suppliers and service providers are unable to comply with their obligations under our future agreements with them or they are otherwise unable to deliver or are delayed in delivering goods and services to us due to the COVID-19 pandemic, our future ability to continue meeting clinical supply demand for our product candidates or otherwise advancing development of our product candidates may become impaired. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The spread of COVID-19 and actions taken to reduce its spread may also materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, there could be a significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity and financial position. In addition, the trading prices for other biopharmaceutical companies have been highly volatile as a result of the COVID-19 pandemic. As a result, we may face difficulties raising capital through sales of our Class&#160;A common stock or such sales may be on unfavorable terms. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">COVID-19 and actions taken to reduce its spread continue to rapidly evolve. The extent to which COVID-19 may impede the development of our product candidates, reduce the productivity of our employees, disrupt our supply chains, delay our clinical trials, reduce our access to capital or limit our business development activities, will depend on future developments, which are highly uncertain and cannot be predicted with confidence. To the extent the COVID-19 pandemic adversely affects our business and financial results, it may </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">33</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section, such as those relating to the timing and results of our clinical trials and our financing needs. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may fail to adequately meet the requirements under our computational biology service contracts to pharmaceutical and biotechnology companies, which may harm our reputation, growth opportunities and prospects, possibly resulting in related losses.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Over a decade ago, we began to offer computational biology services to pharmaceutical and biotechnology companies. We have deprioritized this business and plan to gradually wind down our computational biology services to pharmaceutical and biotechnology companies in the future. However, we are currently servicing several companies and in doing so, we must: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">accurately assess and meet the customer&#8217;s needs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">ensure our computational biology services meet industry standards and practices for performance of similar services; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">retain the proper personnel to fulfill these service contracts; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">compete effectively with other computational biology service providers performing similar services. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we fail to adequately meet the requirements under our computational biology service contracts to our typical high standards, our reputation, growth opportunities and prospects could be adversely affected, possibly resulting in related losses. In addition, as is typical for contracts of this nature, there are inherent legal risks and potential liabilities associated with our work under each of our past, present and future contracts. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Relating to Our Dependence on Third Parties</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our preclinical studies, and in the future, our clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We substantially rely, and expect to continue to rely, on third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and to monitor and manage data for our ongoing preclinical programs. We rely on these parties for execution of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We, our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, there is no guarantee that any such CROs, investigators or other third parties on which we rely will devote adequate time and resources to our development activities or perform as contractually required. These risks are heightened as a result of the efforts of government agencies and the CROs themselves to limit the spread of COVID-19, including quarantines and shelter-in-place orders. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">34</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the capacity to absorb higher workloads or take on additional capacity to support our needs. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We rely on, and in the future may rely on, third-party datasets and collaborations with third parties to inform patient selection, drug target identification and other bioinformatic and computational biology analyses for our existing product candidates and any future product candidates and for the supply of biomarker companion diagnostics.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are using bioinformatics, including data analytics, biostatistics and computational biology, throughout our drug discovery and development process, including to identify new target and biomarker opportunities. As part of this approach, we interrogate public and proprietary datasets, including, but not limited to, human tumor genetic information and specific cancer-target dependency networks. We rely on these datasets and data analytics for multiple analyses, including identifying or validating some of our biomarker-target relationships and access to these databases may not continue to be available publicly or through a proprietary subscription on acceptable terms. Our past, present and future use of such datasets could also create potential liabilities for us if the data provided to us contains inherent errors, inaccuracies or artifacts, or if we improperly analyze, handle, store or utilize the data. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of our product candidates also rely on the availability and use of commercially available tumor diagnostics panels or data on the prevalence of our target patient population to inform the patient selection and drug target identification for our product candidates. In cases where such biomarker diagnostic is not already commercially available, we expect to establish strategic collaborations for the clinical supply and development of companion diagnostics. If these diagnostics are not able to be developed, or if commercial tumor profiling panels are not able to be updated to include additional tumor-associated genes, or if clinical oncologists do not incorporate molecular or genetic sequencing into their clinical practice, we may not be successful in developing our existing product candidates or any future product candidates. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we decide to establish new collaborations in the future, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our drug development programs and the potential commercialization of our product candidates will require substantial additional cash to fund expenses. We may seek to selectively form collaborations to expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">35</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may face significant competition in seeking appropriate collaborators and the related negotiation process is time-consuming and complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the one with us for our product candidate. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If and when we seek to enter into collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may enter into collaborations in the future with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may seek third-party collaborators in the future for the development and commercialization of one or more of our product candidates. Our likely collaborators for any future collaboration arrangements include large and mid-size pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product candidates could pose numerous risks to us, including the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations and may not perform their obligations as expected; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#8217; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available funding or external factors such as an acquisition that diverts resources or creates competing priorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.31pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.31pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.3pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.3pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">36</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-left:30pt; text-align:justify; width:426pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the marketing and distribution of our product relative to other products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to potential litigation or other intellectual property related proceedings; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug development or commercialization program could be delayed, diminished or terminated. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse and compliance laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, submission of false claims, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting/rebating, marketing and promotion, consulting, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Manufacturing</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">37</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We contract with third parties for the manufacture of our product candidates for preclinical studies, and expect to continue to do so for clinical trials and ultimately, for commercialization of any approved product candidate. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or drugs or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. We do not have long-term supply agreements. Furthermore, the raw materials for our product candidates may be sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the breach by the third-party contractors of our agreements with them; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the failure of third-party contractors to comply with applicable regulatory requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the failure of the third party to manufacture our product candidates according to our specifications; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">38</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the misappropriation of our proprietary information, including our trade secrets and know-how. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not have complete control over all aspects of the manufacturing process of, and are dependent on, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event that any of our manufacturers fails to comply with such requirements or to perform its obligations to us in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, including due to the impact of the COVID-19 pandemic, we may be forced to manufacture the materials ourselves, for which we currently do not have the capabilities or resources, or enter into an agreement with another third-party, which we may not be able to do on commercially reasonable terms, if at all. In particular, any replacement of our manufacturers could require significant effort and expertise because there may be a limited number of qualified replacements. In some cases, the technical skills or technology required to manufacture our product candidates may be unique or proprietary to the original manufacturer and we may have difficulty transferring such skills or technology to another third-party and a feasible alternative may not exist. In addition, certain of our product candidates and our own proprietary methods have never been produced or implemented outside of our company, and we may therefore experience delays to our development programs if and when we attempt to establish new third-party manufacturing arrangements for these product candidates or methods. These factors would increase our reliance on such manufacturer or require us to obtain a license from such manufacturer in order to have another third-party manufacture our product candidates. If we are required to or voluntarily change manufacturers for any reason, we will be required to verify that the new manufacturer maintains facilities and procedures that comply with quality standards and with all applicable regulations and guidelines and that the product produced is equivalent to that produced in a prior facility. The delays associated with the verification of a new manufacturer and equivalent product could negatively affect our ability to develop product candidates in a timely manner or within budget. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our or a third-party&#8217;s failure to execute on our manufacturing requirements, do so on commercially reasonable terms and timelines and comply with cGMP requirements could adversely affect our business in a number of ways, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">inability to meet our product specifications and quality requirements consistently; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">inability to initiate or continue clinical trials of our product candidates under development; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in submitting regulatory applications, or receiving marketing approvals, for our product candidates, if at all; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">inability to commercialize any product candidates that receive marketing approval on a timely basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">loss of the cooperation of future collaborators; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">requirements to cease development or to recall batches of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">39</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">in the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for our product or any other future product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our future profit margins. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Legal and Regulatory Compliance Matters</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our products for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include, among others, the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties laws, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant per claim penalties per false claim or statement. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Criminal Statute on False Statements Relating to Healthcare Matters, which makes it a crime to knowingly and willfully falsify, conceal, or cover up a material fact, make any materially false, fictitious, or fraudulent statements or representations, or make or use any materially false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items, or services; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">40</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Civil Monetary Penalties Law, which authorizes the imposition of substantial civil monetary penalties against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1)&#160;knowingly presenting, or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2)&#160;arranging for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or services reimbursable by a federal healthcare program; (3)&#160;violations of the federal Anti-Kickback Statute; or (4)&#160;failing to report and return a known overpayment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the Centers for Medicare and Medicaid Services, or CMS, information regarding payments and other transfers of value to physicians (as defined by statute), certain other healthcare providers starting in 2022 and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. The information reported is publicly available on a searchable website, with disclosure required annually; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">some state laws require biotechnology companies to report information to state agencies and/or commercial purchasers on the pricing of certain drug products that exceed a certain level as identified in the relevant statute. Some of these laws and regulations contain ambiguous requirements that government officials have not yet clarified. Given the lack of clarity in the laws and their implementation, our reporting actions could be subject to the penalty provisions of the pertinent federal and state laws and regulations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For instance, the collection and use of health data in the European Union is governed by the General Data Protection Regulation, or the GDPR, which extends the geographical scope of European Union data protection law to non-European Union entities under certain conditions, tightens existing European Union data protection principles, creates new obligations for companies and new rights for individuals. Failure to comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation to personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR This may be onerous and if our efforts to comply with GDPR or other applicable European Union laws and regulations are not successful, it could adversely affect our business in the European Union. Moreover, the United Kingdom leaving the EU could also lead to further legislative and regulatory changes. It remains unclear how the United Kingdom data protection laws or regulations will develop in the medium to longer term and how data transfer to the United Kingdom from the EU will be regulated, especially following the United Kingdom&#8217;s departure from the EU on January&#160;31, 2020 without a deal. However, the United Kingdom has transposed the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">41</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">GDPR into domestic law with the Data Protection Act 2018, which remains in force following the United Kingdom&#8217;s departure from the EU. In addition, on June&#160;28, 2018, the State of California enacted the California Consumer Privacy Act, or CCPA, which went into effect on January&#160;1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. The CCPA may increase our compliance costs and potential liability, and similar laws have been proposed at the federal level and in other states. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve on-going substantial costs. It is possible that governmental authorities will conclude that our business practices, including our arrangements with physicians, some of whom have ownership interests in us, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage such inability could have an adverse effect on our business and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources and substantial monetary awards to trial participants or patients. We currently have insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have an adverse effect on our business and financial condition. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of our product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">42</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to realize an adequate return on our investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors and coverage and reimbursement levels for products can differ significantly from payor to payor. The Medicare and Medicaid programs increasingly are used as models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive pharmacoeconomic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are unable to establish or sustain coverage and adequate reimbursement for any future product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We face potential liability related to the privacy of health information we obtain from clinical trials sponsored by us.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations promulgated under HIPAA, as amended by the HITECH. We are not currently classified as a covered entity or business associate under HIPAA and thus are not directly subject to its requirements or penalties. However, any person may be prosecuted under HIPAA&#8217;s criminal provisions either directly or under aiding-and-abetting or conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive individually </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">43</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA&#8217;s requirements for disclosure of individually identifiable health information. In addition, we may maintain sensitive personally identifiable information, including health information, that we receive throughout the clinical trial process, in the course of our research collaborations, and directly from individuals (or their healthcare providers) who enroll in our patient assistance programs. As such, we may be subject to state laws requiring notification of affected individuals and state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, certain health privacy laws, data breach notification laws, consumer protection laws and genetic testing laws may apply directly to our operations and/or those of our collaborators and may impose restrictions on our collection, use and dissemination of individuals&#8217; health information. Patients about whom we or our collaborators obtain health information, as well as the providers who share this information with us, may have statutory or contractual rights that limit our ability to use and disclose the information. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws. Claims that we have violated individuals&#8217; privacy rights or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse publicity that could harm our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we or third-party contract manufacturing organizations, or CMOs, CROs or other contractors or consultants fail to comply with applicable federal, state or local regulatory requirements, we could be subject to a range of regulatory actions that could affect our or our contractors&#8217; ability to develop and commercialize our product candidates and could harm or prevent sales of any affected products that we are able to commercialize, or could substantially increase the costs and expenses of developing, commercializing and marketing our products. Any threatened or actual government enforcement action could also generate adverse publicity and require that we devote substantial resources that could otherwise be used in other aspects of our business. Increasing use of social media could give rise to liability, breaches of data security or reputational damage. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations in the future may involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations in the future may also produce hazardous waste products. In the future, we may generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we will maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the potential use of hazardous materials in the future, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of hazardous and flammable materials, including chemicals and biological materials. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The FDA or other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may choose to conduct international clinical trials in the future. The acceptance of study data by the FDA or other comparable foreign regulatory authority from clinical trials conducted outside of their respective jurisdictions may be subject to certain conditions. In cases where data from foreign clinical trials are intended </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">44</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (1)&#160;the data are applicable to the United States population and United States medical practice; (2)&#160;the trials are performed by clinical investigators of recognized competence; and (3)&#160;the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any other comparable foreign regulatory authority will accept data from trials conducted outside of its applicable jurisdiction. If the FDA or any other comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval for commercialization in the applicable jurisdiction. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and reimbursement of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any regulatory approvals that we may receive for our product candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the product candidate, may contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve our product candidates, which could entail requirements for a medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or foreign regulatory authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as on-going compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic, unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">45</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory authority requirements may subject our company to administrative or judicially imposed sanctions, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">delays in or the rejection of product approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on the products, manufacturers or manufacturing process; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">warning or untitled letters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">civil and criminal penalties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injunctions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">suspension or withdrawal of regulatory approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product seizures, detentions or import bans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">voluntary or mandatory product recalls and publicity requirements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">total or partial suspension of production; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">imposition of restrictions on operations, including costly new manufacturing requirements. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. We currently have a limited set of compliance policies and personnel, and intend to develop our compliance infrastructure in the future, as our clinical development programs progress. Developing a compliance infrastructure is costly and time-consuming, and even a well-designed and implemented compliance program cannot necessarily prevent all violations of relevant laws. Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our product candidates, if approved. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we may become subject to significant liability. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#8217;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">46</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Disruptions at the FDA, the SEC and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent&#160;years as a result. In addition, government funding of the Securities and Exchange Commission, or the SEC, and other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, in recent&#160;years, including in 2018 and 2019, the U.S. government shut down several times and certain regulatory agencies, such as the FDA and the SEC, had to furlough critical employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Separately, in response to the COVID-19 pandemic, on March&#160;10, 2020 the FDA announced its intention to postpone most inspections of foreign manufacturing facilities, and on March&#160;18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. On July&#160;10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Additionally, on April&#160;15, 2021, the FDA issued a guidance document in which the FDA described its plans to conduct voluntary remote interactive evaluations of certain drug manufacturing facilities and clinical research sites. According to the guidance, the FDA intends to request such remote interactive evaluations in situations where an in-person inspection would not be prioritized, deemed mission-critical, or where direct inspection is otherwise limited by travel restrictions, but where the FDA determines that remote evaluation would still be appropriate. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may face difficulties from changes to current regulations and future legislation.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively referred to as the ACA, was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. The ACA, among other things, subjected biologic products to potential competition by lower-cost biosimilars; increased the minimum level of Medicaid rebates payable by manufacturers of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">47</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">brand name drugs from 15.1% to 23.1% of the average manufacturer price; required collection of rebates for drugs paid by Medicaid managed care organizations; imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell certain &#8220;branded prescription drugs&#8221; to specified federal government programs; implemented a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; required reporting of certain financial arrangements between manufacturers of biologics, physicians and teaching hospitals under the federal Physician Payments Sunshine Act; expanded the types of entities eligible for the 340B Drug Pricing Program; created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare &amp; Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. By way of example, the Tax Cuts and Jobs Act, or the Tax Act, was signed into law, which included a provision repealing, effective January&#160;1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. On December&#160;14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was eliminated by Congress as part of the Tax Act. Additionally, on December&#160;18, 2019, the U.S. Court of Appeals for the 5</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">th</font><font style="letter-spacing:0.2pt;"> Circuit affirmed the District Court&#8217;s ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the mandate could be severed from the ACA (i.e., whether the remaining provisions of the ACA are unconstitutional as well). The U.S. Supreme Court is currently reviewing this case. The case is expected to be decided in 2021, although it is unclear how the Supreme Court will rule. It is also unclear how other efforts, if any, to challenge, repeal or replace the ACA will impact the ACA or our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, effective April&#160;1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2030, with the exception of a temporary suspension from May&#160;1, 2020 through December&#160;31, 2021 due to the coronavirus pandemic, unless additional congressional action is taken. In January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five&#160;years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. The likelihood of success of these and other measures initiated by the former Trump administration is uncertain, particularly in light of the new Biden administration. Since the Presidential inauguration, the Biden administration has taken several recent executive actions that signal changes in policy from the prior administration. For example, on January&#160;20, 2021, the Biden administration directed all federal departments and agencies to consider taking steps to withdraw or delay certain regulations and guidance issued by the Trump administration that had not become effective as of January&#160;20, 2021 to permit the Biden administration to review such actions for questions of fact, law, and policy. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, on May&#160;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Beilina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">48</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">a federal framework for certain patients to access certain investigational new product candidates that have completed a Phase&#160;1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its products available to eligible patients as a result of the Right to Try Act. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect that other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. Further, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Our Intellectual Property</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to obtain and maintain patent and other intellectual property protection for our product candidates and technologies or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our products and technology may be impaired, and we may not be able to compete effectively in our market.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our products and technologies and to prevent third parties from copying and surpassing our achievements, thus eroding our competitive position in our market. Our commercial success depends in part on our ability to obtain and maintain patent, trade secret or other intellectual property protection for our product candidates, proprietary technologies and their uses as well as our ability to operate without infringing the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or our product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and, in some cases, abroad related to our product candidates, technology platforms and their uses that are important to our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, we own pending patent applications, in the United States only, related to our platform technologies, as well as pending patent applications related to our product candidates. We currently do not have any issued patents related to our product candidates or platform technologies. Further, patent prosecution with respect to our pending patent applications related to our product candidates is in the early stages and, as such, no patent examiner has yet scrutinized the merits of such pending patent applications. Our patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such applications, and then only to the extent the issued claims cover the technology and such third parties practice the technology in countries where such patents have issued. With respect to our patent applications related to our platform technology, we filed those applications only in the U.S., so it is possible that a competitor may practice outside the U.S. the aspects of our platform technology disclosed in those patent applications. We maintain other aspects of our platform technology as trade secrets, which were not disclosed in those patent applications. There can be no assurance that any of our current and future patent applications, if any, owned by us or our future in-licensed patent applications will result in patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around, invalidated or rendered unenforceable by third parties, or effectively prevent others </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">49</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">from commercializing competitive products or technologies. Composition of matter patents for biological and pharmaceutical product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications related to composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office, or USPTO, or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the subject of much litigation in recent&#160;years. As a result, the existence, issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Although we may obtain licenses to issued patents in the United States and foreign countries in the future, we cannot be certain that the claims in future in-licensed U.S. pending patent applications, corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the USPTO, courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in future in-licensed issued patents will not be found invalid or unenforceable if challenged. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or our licensors or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patent applications may not result in any patents being issued; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors, many of whom have substantially greater resources than we or our licensors do and many of whom have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">countries other than the United States may have patent laws less favorable to patentees than the patent law typically applied by U.S. courts, allowing foreign competitors a better opportunity to create, develop and market competing products. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The patent prosecution process is also expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product or technology. For example, certain jurisdictions do not allow for patent protection with respect to method of treatment. Moreover, the scope of claims in a patent application can be significantly reduced before any claims in a patent is issued, and claim scope can be reinterpreted after issuance. Even if our current or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">50</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">from competing with us, or otherwise provide us with any competitive advantage. Consequently, we do not know whether our product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a non-infringing manner, which could materially adversely affect our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is also possible that we may not identify patentable aspects of our research and development output before it is too late to obtain patent protection. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18&#160;months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. In addition, the USPTO might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license, including those from our licensors and from third parties. We also may require the cooperation of our potential future licensors in order to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by our potential future licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that we may in-license, and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may be unable to prevent competitors from making, using and selling competing products. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Even if our current or future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned or potential future in-licensed patents by developing similar or alternative technologies or products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and any future in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party pre-issuance submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity of our patents, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found. There is also no assurance that there is no prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim in our patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize our product candidates and compete directly with us, without payment to us. Such loss of patent rights, loss of exclusivity or our patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our product candidates. Such proceedings also may result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable or trade secret aspects of our technology platforms and research and development output, such as our employees, outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, licensors, and other third parties, any of these parties may breach such agreements and disclose such aspects </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">51</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">or output before a patent application is filed, thereby jeopardizing our ability to seek patent protection or maintain the trade secret status of our technology platforms or research and development output. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As referenced above, we have filed patent applications directed to our platform technologies that involve certain of our proprietary software modules. Moreover, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, rely on the above-referenced patent applications for protection of certain modules and trade secret protection for other of our software modules. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our software may be limited. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to comply with our obligations in future agreements under which we may license intellectual property rights from licensors and third parties or otherwise experience disruptions to our business relationships with future licensors, we could lose license rights that may in the future be important to our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the future, we may enter into license agreements under which we are granted rights to intellectual property that may be important to our business. We expect that any future license agreements where we in-license intellectual property would impose on us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements (including as a result of COVID-19 impacting our operations), or we use the licensed intellectual property in an unauthorized manner or are subject to bankruptcy-related proceedings, the licensors may have the right to materially modify the terms of the licenses, such as by rendering currently exclusive licenses non-exclusive, or terminate the licenses, in which event we would not be able to market products covered by the licenses. We may also in the future enter into license agreements with third parties under which we are a sublicensee. If our sublicensor fails to comply with its obligations under its upstream license agreement with its licensor, the licensor may have the right to terminate the upstream license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize our product candidates incorporating the relevant intellectual property. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates or platform, and we cannot provide any assurances that third-party patents do not exist that might be enforced against our product candidates or platform in the absence of such a license. For example, our programs may involve additional product candidates that may require the use of additional proprietary rights held by third parties. Our product candidates may also require specific formulations to work effectively and efficiently. These formulations may be covered by intellectual property rights held by others. We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive for commercializing our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, disputes may arise between us and future licensors regarding intellectual property subject to a license agreement, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope of rights granted and obligations imposed under the license agreement and other interpretation-related issues; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">52</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our right to sublicense patents and other rights to third parties; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amounts, if any, we owe to a licensor in respect of sublicense fees or income or in respect of backup product; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our right to transfer or assign the license; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and its affiliates and sublicensees and by us and our partners and sublicensees. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our future licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The patent protection and patent prosecution for some of our product candidates may be dependent on our future licensors and third parties.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We or our future potential licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our potential future in-licensed patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our future potential licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our future potential licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our future potential in-licensed patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As a future potential licensee of third parties, we would rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property under some of our future license agreements. We would not have primary control over these activities for certain of our patents or patent applications and other intellectual property rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other intellectual property rights. Future potential licensors may have the right to control enforcement of our future potential licensed patents or defense of any claims asserting the invalidity of these patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our future licensors. We cannot be certain that our future licensors will allocate sufficient resources or prioritize their or our enforcement of such patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual property that we may need to operate our business. If any of our future potential licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">53</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, even where we have the right to control patent prosecution of patents and patent applications we have acquired or licensed from third parties in the future, we may still be adversely affected or prejudiced by actions or inactions of our licensors and their counsel that took place prior to us assuming control over patent prosecution. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Technology we may acquire or license from various third parties in the future may be subject to retained rights. Our future licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for use in fields other than the fields licensed to us or for use in noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It may be difficult to monitor whether our future licensors may limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe or misappropriate their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our commercial success depends in part on avoiding infringement or misappropriation of the patents and other proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Because the intellectual property landscape in the industry in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on third party rights. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S. and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates, as well as related to our platform. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates or platform may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of any of our product candidates, and we cannot be certain that others have not filed patent applications for a product candidate or technology covered by our pending patent applications, or that we were the first to file a patent application related to a product candidate or technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. Moreover, because patent applications can take many&#160;years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, identification of third-party patent rights that may be relevant to our product candidates or platform is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict whether a third-party&#8217;s pending application will issue with claims of relevant </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">54</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Further, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims of patent infringement asserted by third parties would be time consuming and could: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">result in costly litigation that may cause negative publicity; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">divert the time and attention of our technical personnel and management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">cause development delays; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or unenforceable or not infringed in a court of law; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require us to develop non-infringing technology, which may not be possible on a cost-effective basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">subject us to significant liability to third parties; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Although no third party has asserted a claim of patent infringement against us as of the date of this prospectus, others may hold proprietary rights that could prevent our product candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to our product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of management and employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the rights may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign our product candidates or processes to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing our product candidates, which could harm our business, financial condition and results of operations. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Parties making claims against us may be able to sustain the costs of complex patent or trade secret litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11pt;">
          <font style="letter-spacing:0.2pt;">Moreover, if our product candidates or platform are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be involved in lawsuits to protect or enforce our patents or the patents of our future licensors, which could be expensive, time-consuming and unsuccessful. Further, our future in-licensed issued patents could be found invalid or unenforceable if challenged in court.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Competitors may infringe or otherwise violate our, or our future licensors&#8217;, patents, trademarks or other intellectual property. To prevent infringement or other violations, we and/or our future licensors may be </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">55</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">required to file claims, which can be expensive and time-consuming. Further, our future licensors may need to file such claims, but elect not to file them. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable and/or is not infringed. If we or any of our future licensors or potential future collaborators were to initiate legal proceedings against a third party to enforce a patent directed at one of our product candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty or written description, non-patentable subject matter (laws of nature, natural phenomena, or abstract idea), obviousness or non-enablement. Grounds for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent intentionally withheld material information from the USPTO or the applicable foreign counterpart, or made a misleading statement, during prosecution. A litigant or the USPTO itself could challenge our patents on this basis even if we believe that we have conducted our patent prosecution in accordance with the duty of candor and in good faith. The outcome following such a challenge is unpredictable. With respect to challenges to the validity of our patents, there might be invalidating prior art, of which we and the patent examiner were unaware during prosecution. </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent applications or those of our licensors is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business. Even if a defendant does not prevail on a legal assertion of invalidity and/or unenforceability, our patent claims may be construed in a manner that would limit our ability to enforce such claims against the defendant and others. </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights, particularly those in a foreign jurisdiction, may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Enforcing our intellectual property rights against third parties may also cause such third parties to file other counterclaims against us, which could be costly to defend, particularly in a foreign jurisdiction, and could require us to pay substantial damages, cease the sale of certain products or enter into a license agreement and pay royalties (which may not be possible on commercially reasonable terms or at all). We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </font>
        </div>
        <div style="margin-top:9.63pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our Class&#160;A common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business. </font>
        </div>
        <div style="margin-top:9.63pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Derivation or interference proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Derivation or interference proceedings provoked by third parties or brought by us or our future licensors, or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">56</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">priority of inventions with respect to our or our licensors&#8217; patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our or our licensors&#8217; defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring our product candidates to market. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March&#160;2013 to a &#8220;first inventor to file&#8221; system in which, assuming that other requirements of patentability are met, the first inventor to file a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March&#160;2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This requires us to be cognizant of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we were the first to either (1)&#160;file any patent application related to our product candidates or (2)&#160;invent any of the inventions claimed in our patents or patent applications. Even where we have a valid and enforceable patent, we may not be able to exclude others from practicing the claimed invention where the other party can show that they used the invention in commerce before our filing date or the other party benefits from a compulsory license. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Leahy-Smith Act also includes a number of significant changes that (i)&#160;affect the way patent applications are prosecuted, (ii)&#160;redefine prior art and provide more efficient, and (iii)&#160;cost-effective avenues for competitors to challenge the validity of patents. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would have been insufficient to invalidate the claim if presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus, the Leahy-Smith Act and its implementation increase the uncertainties and costs surrounding the prosecution of our or licensors&#8217; patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time-consuming and inherently uncertain. Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">57</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">intellectual property and may increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Further, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. We cannot predict the breadth of claims that may be allowed or enforced in our patents or in third-party patents. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, Congress or other foreign legislative bodies may pass patent reform legislation that is unfavorable to us. For example, the U.S. Supreme Court has ruled on several patent cases in recent&#160;years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our or our licensors&#8217; ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing patents could change in unpredictable ways that would weaken our or our licensors&#8217; ability to obtain new patents or to enforce our existing patents and patents we might obtain in the future. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We or our future licensors may be subject to claims challenging the inventorship or ownership of our or our in-licensed patents and other intellectual property.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may also be subject to claims that former employees or other third parties have an ownership interest in our patents or other intellectual property. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we or our licensors are successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our future licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20&#160;years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the term of a patent, and the protection it affords, is limited. Even if patents directed to our product candidates are obtained, once the patent term has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of product candidates, patents directed to our product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">58</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review process. A maximum of one patent may be extended per FDA-approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14&#160;years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain foreign countries upon regulatory approval of our product candidates. However, we or our licensors may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we or our licensors are unable to obtain patent term extension or restoration or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may not be able to protect our intellectual property rights throughout the world.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Although we have pending patent applications in the United States and we seek to file patent applications in certain other countries, filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we or our licensors have patent protection but enforcement is not as strong as that in the United States. These products may compete with our product candidates, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our or our licensors&#8217; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our or our potential future licensors&#8217; patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our or our potential future licensors&#8217; patents at risk of being invalidated or interpreted narrowly and our or our potential future licensors&#8217; patent applications at risk of not issuing and could provoke third parties to assert claims against us. We or our licensors may not prevail in any lawsuits that we or our potential future licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our or our potential future licensors&#8217; efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">59</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. While an inadvertent lapse, including due to the effect of the COVID-19 pandemic on us, our patent maintenance vendors or law firms, can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely affected. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition to seeking patent protection for some of our technology and product candidates, we rely on the protection of our trade secrets, including unpatented know-how, technology and other proprietary information to maintain our competitive position, especially with respect to our technology platform. Any disclosure, either intentional or unintentional, by our employees or third-party consultants and vendors that we engage to perform research, clinical trials or manufacturing activities, or misappropriation by third parties (such as through a cybersecurity breach) of our trade secrets or proprietary information could enable competitors to duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Because we expect to rely on third parties in the development and manufacture of our product candidates, we must, at times, share trade secrets with them. Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Although we have taken steps to protect our trade secrets and unpatented know-how, including entering into non-disclosure and confidentiality agreements with third parties who are given access to them, such as our corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. With our consultants, contractors and outside scientific collaborators, these agreements typically include invention assignment obligations. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology and processes. Further, we cannot provide any assurances that all such agreements have been duly executed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. In addition, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">60</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of this information may be greatly reduced and our competitive position would be harmed. If we or our licensors do not apply for patent protection prior to such publication or if we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information or alleged trade secrets of third parties or competitors or are in breach of non-competition or non-solicitation agreements with our competitors or their former employers.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As is common in the pharmaceutical and biotechnology industries, we employ individuals and engage the services of consultants who previously worked for other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information, trade secrets or other proprietary information of their former employers, or that our consultants have used or disclosed trade secrets or other proprietary information of their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.11pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We use and will continue to use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Moreover, any name we have proposed to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We use third-party open source software, which could negatively affect our ability to offer our solutions and subject us to litigation or other actions.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We use open source software licensed to us by third-party authors under &#8220;open source&#8221; licenses in our platform and solutions and expect to continue to use such open source software in the future. Use and distribution of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">61</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">open source software may entail greater risks than use of third-party commercial software, as open source licensors generally do not provide support, warranties, indemnification or other contractual protections regarding infringement claims or the quality of the code. To the extent that our platform depends upon the successful operation of open source software, any undetected errors or defects in this open source software could prevent the deployment or impair the functionality of our platform, delay introductions of new solutions, result in a failure of our platform, and injure our reputation. For example, undetected errors or defects in open source software could render it vulnerable to breaches or security attacks, and, in conjunction, make our systems more vulnerable to data breaches. In addition, the public availability of such software may make it easier for others to compromise our platform. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Further, there are uncertainties regarding the proper interpretation of and compliance with open source licenses, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to use such open source software, and consequently to provide or distribute our platform and solutions. Some open source licenses contain express requirements that we make available source code for modifications or derivative works we create based upon the type of open source software we use, or grant other licenses to our intellectual property. If we combine our proprietary software with open source software in a certain manner, we could, under certain open source licenses, be required to release the source code of our proprietary software to the public. This would allow our competitors to create similar offerings with lower development effort and time and ultimately could result in a loss of our competitive advantages. Alternatively, to avoid the public release of the affected portions of our source code, we could be required to expend substantial time and resources to re-engineer some or all of our software. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Despite our efforts to monitor our use of open source software to avoid subjecting our platform to conditions we do not intend, there is a risk that open source licenses could be construed in a way that could impose unanticipated conditions or restrictions on our ability to provide or distribute our platform. Additionally, we may from time to time face claims from third parties claiming ownership of, or seeking to enforce the terms of, an open source license, including by demanding release of source code for the open source software, derivative works or our proprietary source code that was developed using, or that is distributed with, such open source software. These claims could also result in litigation and could require us to make our proprietary software source code freely available, devote additional research and development resources to re-engineer our platform, seek costly licenses from third parties, pay monetary damages to the owner of the copyright in the relevant open source software or otherwise incur additional costs and expenses, any of which could result in reputational harm and would have a negative effect on our business and results of operations. In addition, if the license terms for the open source software we utilize change, we may be forced to re-engineer our platform, incur additional costs to comply with the changed license terms or replace the affected open source software. Although we have implemented policies to regulate the use and incorporation of open source software into our platform and solutions, we cannot be certain that that such policies will be effective and that we have not incorporated open source software in our platform and solutions in a manner that is inconsistent with such policies. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Intellectual property rights do not necessarily address all potential threats to our competitive advantage.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may be able to develop products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we or our potential future licensors might not have been the first to make the inventions covered by the issued patents or patent application that we own or license; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we or our potential future licensors might not have been the first to file patent applications covering certain of our inventions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">it is possible that our future licensors&#8217; pending patent applications will not lead to issued patents; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">62</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">future issued patents that we own or license may be held invalid or unenforceable, as a result of legal challenges by our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">we may not develop additional proprietary technologies that are patentable; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the patents of others may have an adverse effect on our business. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Should any of these events occur, it could significantly harm our business, results of operations and prospects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to Employee Matters and Managing our Growth</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently do not have and have never had a marketing or sales team. In order to commercialize any product candidates, if approved, we must build marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services for each of the territories in which we may have approval to sell or market our product candidates. We may not be successful in accomplishing these required tasks. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on a territory-by-territory basis, with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and scientific and medical staff. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could adversely affect our ability to execute our business plan and harm our results of operations. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary, including bioinformatics and computational biologist specialists, for the future success of our business. We could in the future have difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">63</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, we had 26 full-time employees, including 23 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, and as we transition into operating as a public company, we expect to need additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identifying, recruiting, integrating, maintaining and motivating additional employees; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory agencies&#8217; review process of IMM-1-104 and any other product candidate we develop, while complying with any contractual obligations to contractors and other third parties we may have; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">improving our operational, financial and management controls, reporting systems and procedures. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our future financial performance and our ability to successfully develop and, if approved, commercialize IMM-1-104 and any other product candidate will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to successfully implement the tasks necessary to further develop and commercialize IMM-1-104 and any other current or future product candidates and, accordingly, may not achieve our research, development and commercialization goals. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Risks Related to This Offering and Ownership of Our Class&#160;A common stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">There has been no prior public market for our Class&#160;A common stock. We do not know whether an active, liquid and orderly trading market will develop for our Class&#160;A common stock or what the market price of our Class&#160;A common stock will be and as a result it may be difficult for you to sell your shares of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering, no public market for shares of our Class&#160;A common stock existed and an active trading market for our Class&#160;A common stock may never develop or be sustained following this offering. We will determine the initial public offering price for our Class&#160;A common stock through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of our Class&#160;A common stock after this offering. The market value of our Class&#160;A common stock may decrease from the initial public offering price. As a result of these and other factors, you may be unable to resell your shares of our Class&#160;A common stock at or above the initial public offering price. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our Class&#160;A common stock and may impair our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">64</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of Class&#160;A common stock as consideration. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The price of our stock may be volatile, and you could lose all or part of your investment.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The trading price of our Class&#160;A common stock following this offering is likely to be highly volatile and subject to wide fluctuations in response to various factors, some of which we cannot control. The stock market in general, and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. The trading prices for Class&#160;A common stock of other pharmaceutical and biotechnology companies have also been highly volatile as a result of the COVID-19 pandemic. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Broad market and industry factors may negatively affect the market price of our Class&#160;A common stock, regardless of our actual operating performance. In addition to the factors discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this prospectus, these factors include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing and results of preclinical studies and clinical trials of our product candidates or those of our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the success of competitive products or announcements by potential competitors of their product development efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory actions with respect to our products or our competitors&#8217; products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">actual or anticipated changes in our growth rate relative to our competitors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">regulatory or legal developments in the United States and other countries; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developments or disputes concerning patent applications, issued patents or other proprietary rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the recruitment or departure of key personnel; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.51pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.51pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.5pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.5pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fluctuations in the valuation of companies perceived by investors to be comparable to us; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">market conditions in the pharmaceutical and biotechnology sector; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">changes in the structure of healthcare payment systems; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">announcement or expectation of additional financing efforts; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">sales of our Class&#160;A common stock by us, our insiders or our other stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expiration of market stand-off or lock-up agreements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ongoing and future impact of the COVID-19 pandemic, or any future pandemics, and actions taken to slow their spread; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.4pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">general economic, industry and market conditions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and adverse impact on the market price of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our management team has broad discretion to use the net proceeds from this offering and its investment of these proceeds may not yield a favorable return. They may invest the net proceeds from this offering in ways with which investors disagree.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We plan to use the net proceeds from this offering to advance IMM-1-104 into clinical development, including to fund our anticipated Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">65</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">patients harboring RAS mutant tumors, and additional clinical trials; advance our other preclinical drug programs and the design and development of new product candidates, in oncology and neuroscience, and to advance these programs into IND-enabling studies that would support an IND filing for one or more product candidates; and for working capital and other general corporate purposes, including the continued advancement of our platform and hiring of additional staff as we expand our operations. See &#8220;Use of Proceeds.&#8221; However, within the scope of our plan, and in light of the various risks to our business, including those discussed in this &#8220;Risk Factors&#8221; section and elsewhere in this prospectus, our management will have broad discretion over the use of net proceeds from this offering, and could spend the net proceeds in ways our stockholders may not agree with or that do not yield a favorable return, if at all. If we do not invest or apply the net proceeds from this offering in ways that improve our results of operations, we may fail to achieve expected financial results, which could cause our stock price to decline. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or our market, our stock price and trading volume could decline.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The trading market for our Class&#160;A common stock will be influenced by the research and reports that securities or industry analysts publish about us, our business or our market. We do not currently have and may never obtain research coverage by securities or industry analysts. If no or few securities or industry analysts commence coverage of us, the stock price would be negatively impacted. In the event we obtain securities or industry analyst coverage, if any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our results of operations fail to meet the expectations of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our principal stockholders and management own a significant&#160;percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately&#8199;&#8199;&#8199;&#8199;% of our voting stock and, upon the closing of this offering, that same group will beneficially own approximately&#8199;&#8199;&#8199;&#8199;% of our outstanding voting stock (based on the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and assuming no exercise of the underwriters&#8217; option to purchase additional shares). Therefore, even after this offering these stockholders will be able to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our Class&#160;A common stock that you may feel are in your best interest as one of our stockholders. The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their Class&#160;A common stock, and might affect the prevailing market price for our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If you purchase shares of our Class&#160;A common stock in our initial public offering, you will experience substantial and immediate dilution.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share is substantially higher than the net tangible book value per share of our outstanding Class&#160;A common stock immediately following the completion of this offering. If you purchase shares of Class&#160;A common stock in this offering, you will experience substantial and immediate dilution in the pro&#160;forma net tangible book value per share of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share as of December&#160;31, 2020. That is because the price that you pay will be substantially greater than the pro&#160;forma net tangible book value per share of the Class&#160;A common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the initial public offering price when they purchased their shares of our capital stock. You will experience additional dilution when those holding stock options or warrants exercise their right to purchase Class&#160;A common stock under our equity incentive plans or when we otherwise issue additional shares of Class&#160;A common stock. See &#8220;Dilution.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">66</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sales of a substantial number of shares of our Class&#160;A common stock in the public market could cause our stock price to fall.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Class&#160;A common stock price could decline as a result of sales of a large number of shares of Class&#160;A and/or Class&#160;B common stock (collectively, including Class A common stock shares issuable upon conversion of the Class&#160;B common stock, the &#8220;common stock&#8221;) after this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering,&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of common stock will be outstanding (</font><font style="font-weight:bold;letter-spacing:-0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;</font><font style="letter-spacing:0.2pt;">shares if the underwriters exercise their option to purchase additional shares from us in full), based on the number of shares outstanding as of December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All shares of Class&#160;A common stock expected to be sold in this offering will be freely tradable without restriction or further registration under the Securities Act of 1933, as amended, or the Securities Act, unless held by our &#8220;affiliates&#8221; as defined in Rule&#160;144 under the Securities Act. The resale of the remaining&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares, or&#8199;&#8199;&#8199;&#8199;% of our outstanding shares of common stock following this offering, is currently prohibited or otherwise restricted as a result of securities law provisions, market standoff agreements entered into by certain of our stockholders with us or lock-up agreements entered into by our stockholders with the underwriters in connection with this offering. However, subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning 181&#160;days after the date of this prospectus. Shares issued upon the exercise of stock options and warrants outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted by the provisions of applicable vesting schedules, market stand-off agreements and/or lock-up agreements, as well as Rules 144 and 701 under the Securities Act. For more information, see &#8220;Shares Eligible for&#160;Future&#160;Sale.&#8221; </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the completion of this offering, the holders of approximately&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares, or&#8199;&#8199;&#8199;&#8199;% of our outstanding shares following this offering, of our common stock will have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We also intend to register the offer and sale of all shares of Class&#160;A common stock that we may issue under our equity compensation plans. Once we register the offer and sale of shares for the holders of registration rights and shares that may be issued under our equity incentive plans, these shares will be able to be sold in the public market upon issuance, subject to the lock-up agreements described under &#8220;Underwriting.&#8221; </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, in the future, we may issue additional shares of Class&#160;A common stock, or other equity or debt securities convertible into Class&#160;A common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our Class&#160;A common stock to decline. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We do not currently intend to pay dividends on our Class&#160;A common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our Class&#160;A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have never declared or paid any cash dividends on our equity securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to any appreciation in the value of our Class&#160;A common stock, which is not certain. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Provisions in our certificate of incorporation and bylaws and Delaware law might discourage, delay or prevent a change in control of our company or changes in our management and, therefore, depress the market price of our Class&#160;A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation and bylaws, as we expect they will be in effect upon closing of the offering, will contain provisions that could depress the market price of our Class&#160;A common stock by acting to discourage, delay or prevent a change in control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish a classified board of directors so that not all members of our board are elected at one time; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">67</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">permit only the board of directors to establish the number of directors and fill vacancies on the board; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">provide that directors may only be removed &#8220;for cause&#8221; and only with the approval of two-thirds of our stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">authorize the issuance of &#8220;blank check&#8221; preferred stock that our board could use to implement a stockholder rights plan (also known as a &#8220;poison pill&#8221;); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">eliminate the ability of our stockholders to call special meetings of stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prohibit stockholder action by written consent, which requires all stockholder actions to be taken at a meeting of our stockholders; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">prohibit cumulative voting; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">authorize our board of directors to amend the bylaws; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establish advance notice requirements for nominations for election to our board or for proposing matters that can be acted upon by stockholders at annual stockholder meetings; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">require a super-majority vote of stockholders to amend some provisions described above. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, Section&#160;203 of the General Corporation Law of the State of Delaware, or the DGCL, prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together with its affiliates owns, or within the last three&#160;years has owned, 15% of our voting stock, for a period of three&#160;years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any provision of our certificate of incorporation, bylaws or Delaware law that has the effect of delaying or preventing a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our capital stock and could also affect the price that some investors are willing to pay for our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws will provide for an exclusive forum in the Court of Chancery of the State of Delaware for certain disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the Court of Chancery of the State of Delaware (or, in the event that the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware or other state courts of the State of Delaware) is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause or causes of action against any defendant arising under the Securities Act. Such provision is intended to benefit and may be enforced by us, our officers and directors, employees and agents, including the underwriters and any other professional or entity who has prepared or certified any part of this prospectus. Nothing in our amended and restated certificate of incorporation or amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe these provisions may benefit us by providing increased consistency in the application of Delaware law and federal securities laws by chancellors and judges, as applicable, particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">68</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">and protection against the burdens of multi-forum litigation. This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive-forum provisions, and there can be no assurance that such provisions will be enforced by a court in those other jurisdictions. If a court were to find the choice of forum provision that will be contained in our amended and restated certificate of incorporation and amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General Risks</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, collaborators or potential future collaborators, may fail or suffer security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Despite the implementation of security measures, our internal computer systems and those of our current and any future CROs and other contractors, consultants, collaborators and third-party service providers, are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failure. If such an event were to occur and cause interruptions in our operations or result in the unauthorized acquisition of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as HIPAA, HITECH and GDPR), it could result in a material disruption of our drug discovery and development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Notifications and follow-up actions related to a security breach could impact our reputation, cause us to incur significant costs, including legal expenses and remediation costs. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the lost data. We also rely on third parties to manufacture our product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal and/or international privacy and security laws. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption, failure or security breach. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our operations are vulnerable to interruption by fire, severe weather conditions, power loss, telecommunications failure, terrorist activity, future pandemics and other events beyond our control, which could harm our business.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our facilities are located in regions which experience severe weather from time to time. We have not undertaken a systematic analysis of the potential consequences to our business and financial results from a major tornado, flood, fire, earthquake, power loss, terrorist activity, future pandemics or other disasters and do not have a </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">69</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">recovery plan for such disasters. In addition, we do not carry sufficient insurance to compensate us for actual losses from interruption of our business that may occur, and any losses or damages incurred by us could harm our business. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We are an &#8220;emerging growth company,&#8221; and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our Class&#160;A common stock less attractive to investors.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we intend to take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">being permitted to provide only two&#160;years of audited financial statements, in addition to any required unaudited interim financial statements, with correspondingly reduced &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; disclosure in this prospectus; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding the communication of critical audit matters in the auditor&#8217;s report on financial statements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We cannot predict if investors will find our Class&#160;A common stock less attractive because we may rely on these exemptions. If some investors find our Class&#160;A common stock less attractive as a result, there may be a less active trading market for our Class&#160;A common stock and our stock price may be more volatile. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will remain an emerging growth company until the earliest to occur of: (1)&#160;the last day of the fiscal year in which we have more than $1.07&#160;billion in annual revenue; (2)&#160;the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700&#160;million of equity securities held by non-affiliates; (3)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period; and (4)&#160;the last day of the fiscal year ending after the fifth anniversary of our initial public offering. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The requirements of being a public company may strain our resources, result in more litigation and divert management&#8217;s attention.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As a public company, we will be subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of Nasdaq and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and results of operations. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">70</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">business and results of operations. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors, particularly to serve on our audit committee and compensation committee, and qualified executive officers. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By disclosing information in this prospectus and in future filings required of a public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our Class&#160;A common stock.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&#160;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We will be required to disclose changes made in our internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are a smaller reporting company, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&#160;404. An independent assessment of the effectiveness of our internal controls over financial reporting could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the expense of remediation. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">We may be subject to securities litigation, which is expensive and could divert management attention.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The market price of our Class&#160;A common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">71</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:476pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. </font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">New tax legislation may impact our results of operations and financial condition.</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The U.S. government may enact significant changes to the taxation of business entities including, among others, an increase in the corporate income tax rate, an increase in the tax rate applicable to the global intangible low-taxed income and elimination of certain exemptions, and the imposition of minimum taxes or surtaxes on certain types of income. No specific United States tax legislation has been proposed at this time and the likelihood of these changes being enacted or implemented is unclear. We are currently unable to predict whether such changes will occur. If such changes are enacted or implemented, we are currently unable to predict the ultimate impact on our business.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">72</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCNRF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus contains forward-looking statements that can involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, future revenue, timing and likelihood of success, plans and objectives of management for future operations, future results of anticipated products and prospects, plans and objectives of management are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In some cases, you can identify forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; or &#8220;would&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.71pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.71pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, progress and results of clinical trials and preclinical studies for our programs and product candidates, including statements regarding the timing of initiation and completion of trials or studies and related preparatory work, the period during which the results of the trials will become available and our research and development programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the potential clinical efficacy and safety of our programs and product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the timing, scope or likelihood of regulatory submissions, filings and approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to discover, develop and advance product candidates into, and successfully complete, clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the potential market size and size of the patient populations for our product candidates, if approved for commercial use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the implementation of our business model and our strategic plans for our business, commercial product, product candidates, platform and technology; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our commercialization, marketing and manufacturing capabilities and strategy; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the pricing and reimbursement of our commercial product and product candidates, if approved; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the rate and degree of market acceptance and clinical utility of our commercial product and product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish or maintain collaborations or strategic relationships or obtain additional funding; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our competitive position and the competitive position of our programs, product candidates and platform; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope of protection we and/or our licensors are able to establish and maintain for intellectual property rights covering our commercial product and product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developments and projections relating to our competitors and our industry; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations related to the use of proceeds from this offering; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of laws and regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our expectations regarding the time during which we will be an emerging growth company under the JOBS Act; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impact of the COVID-19 pandemic and potential future pandemics. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">73</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:252pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events or otherwise. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, statements that &#8220;we believe&#8221; and similar statements such as such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; and &#8220;continue&#8221; reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus also contains estimates, projections and other information concerning our industry, our business and the markets for our programs and product candidates. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. Unless otherwise expressly stated, we obtained this industry, business, market, and other data from our own internal estimates and research as well as from reports, research surveys, studies, and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section titled &#8220;Risk Factors&#8221; and elsewhere in this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">74</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">USE OF PROCEEDS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We estimate that the net proceeds to us from in this offering will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming an initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. If the underwriters&#8217; option to purchase additional shares from us is exercised in full, we estimate that our net proceeds will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share would increase (decrease) the net proceeds to us from this offering by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&#160;million in the number of shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the assumed initial public offering price stays the same. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million to advance IMM-1-104 into clinical development, including to fund our anticipated Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, and additional clinical trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million to advance our other preclinical drug programs and the design and development of new product candidates, in oncology and neuroscience, and to advance these programs into IND-enabling studies that would support an IND filing for one or more product candidates; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the remainder for working capital and other general corporate purposes, including the continued advancement of our platform and hiring of additional staff as we expand our operations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve. We may also use a portion of the net proceeds to in-license, acquire or invest in additional businesses, technologies, products or assets, although currently we have no specific agreements, commitments or understandings in this regard. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend on the uses set forth above. Predicting the cost necessary to develop product candidates can be difficult and we anticipate that we will need additional funds to complete the development of any product candidates we identify. The amounts and timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of our development efforts, the status of and results from pre-clinical studies and any ongoing clinical trials or clinical trials we may commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates and any unforeseen cash needs. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect. We may satisfy our future cash needs through the sale of equity securities, debt financings, working capital lines of credit, corporate collaborations or license agreements, grant funding, interest income earned on invested cash balances or a combination of one or more of these sources. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">75</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIPO">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:444pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DIVIDEND POLICY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We currently intend to retain all available funds and any future earnings to fund the development, commercialization and growth of our business, and therefore we do not anticipate declaring or paying any cash dividends on any class of our common stock in the foreseeable future. Any future determination as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to compliance with contractual restrictions and covenants in the agreements governing our current and future indebtedness. Any such determination will also depend upon our business prospects, results of operations, financial condition, cash requirements and availability and other factors that our board of directors may deem relevant. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, you may need to sell your shares of our Class&#160;A common stock to realize a return on your investment, and you may not be able to sell your shares at or above the price you paid for them. See &#8220;Risk Factors&#8212;Risks Related to This Offering and Ownership of Our Class&#160;A Common Stock&#8212;We do not currently intend to pay dividends on our Class&#160;A common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation of the value of our Class&#160;A common stock.&#8221; </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">76</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CAPITALIZATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth our cash and cash equivalents and capitalization as of December&#160;31, 2020, as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">on an actual basis; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">on a pro&#160;forma basis to give effect to (i)&#160;the receipt of approximately $24.8&#160;million in aggregate net proceeds from the issuance and sale of Series&#160;B Preferred Stock that occurred in April and May&#160;2021, (ii)&#160;the conversion of all outstanding shares of our Series A Preferred Stock and Series B Preferred Stock into an aggregate of&#160;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our common stock, as if such conversion had occurred on December&#160;31, 2020, and (iii)&#160;the filing and effectiveness of our amended and restated certificate of incorporation upon the closing of this offering; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">on a pro&#160;forma as adjusted basis to give further effect to our issuance and sale of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share (which is the midpoint of the price range set forth on the cover of this prospectus), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The pro&#160;forma as adjusted information below is illustrative only, and our capitalization following the closing of this offering will be adjusted based on the actual initial public offering price and other terms of this offering determined at pricing. You should read this information in conjunction with our consolidated financial statements and the related notes included elsewhere in this prospectus and the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; sections and other financial information contained in this prospectus. </font>
        </div>
        <table style="width:456pt;margin-bottom:7pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:8.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.03pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:21.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Actual </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Forma </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.083pt 0pt 1.667pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Pro Forma As</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Adjusted</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:21.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.083pt 0pt 0.5pt 0pt; width:0pt;" colspan="16">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except share and per</font>
                <br >
                <font style="letter-spacing:-0.16pt;">share amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:315.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">37,090</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.03pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Convertible preferred stock, par value $0.001 per share: 8,528,116 shares authorized, 8,081,268 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro&#160;forma and pro&#160;forma as </font>
                <br >
                <font style="letter-spacing:0.2pt;">adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">58,104</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:315.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Stockholders&#8217; (deficit) equity </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.03pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class&#160;A common stock, $0.001 par value per share: 15,733,000 shares authorized, 3,535,811 shares issued and outstanding, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; actual; &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; outstanding, pro&#160;forma; &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and outstanding, pro&#160;forma as adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.03pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class&#160;B common stock, $0.001 par value per share: 6,032,183 shares authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and outstanding, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; actual; shares authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; outstanding, pro&#160;forma; &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares authorized, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; shares issued and outstanding, pro&#160;forma as adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8211;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:315.03pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Preferred stock, $0.001 par value per share: shares authorized, issued </font>
                <br >
                <font style="letter-spacing:0.2pt;">and outstanding, actual; shares authorized, pro&#160;forma and pro&#160;forma </font>
                <br >
                <font style="letter-spacing:0.2pt;">as adjusted; no shares issued and outstanding, pro&#160;forma and </font>
                <br >
                <font style="letter-spacing:0.2pt;">pro&#160;forma as adjusted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8211;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:315.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">3,253</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:315.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,738<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:315.03pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; equity (deficit) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(22,481<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:315.03pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total capitalization </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">38,423</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:15.985pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">77</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:301pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, total equity and total capitalization by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&#160;million shares in the number of shares offered by us at the assumed initial public offering price per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro&#160;forma as adjusted amount of each of cash and cash equivalents, total equity and total capitalization by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares of our Class&#160;A common stock on a pro&#160;forma and pro&#160;forma as adjusted basis set forth in the table above is based on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class&#160;A common stock outstanding as of December&#160;31, 2020, and excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;additional shares of Class&#160;A common stock reserved for future issuance under the 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our Class&#160;A common stock reserved for future issuance under the 2021 Plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock that will become available for future issuance under the ESPP, which will become effective in connection with this offering, and shares of our common stock that become available pursuant to provisions in the ESPP that automatically increase the share reserve under the ESPP; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock issuable upon exercise of outstanding stock options granted under the 2015 Plan, as of December&#160;31, 2020, at a weighted average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock available for future issuance under the 2015 Plan as of December&#160;31, 2020; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock that will become available for future issuance under our 2021 Plan, which will become effective in connection with this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">78</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DILUTION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If you invest in our Class&#160;A common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the pro&#160;forma as adjusted net tangible book value per share of our Class&#160;A common stock after this offering. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our historical net tangible book value (deficit) as of December&#160;31, 2020 was &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of our Class&#160;A common stock. Our historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and preferred stock, which is not included within stockholders&#8217; equity (deficit). Historical net tangible book value (deficit) per share represents historical net tangible book value (deficit) divided by the&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class&#160;A common stock outstanding as of December&#160;31, 2020. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our pro&#160;forma net tangible book value (deficit) as of December&#160;31, 2020 was $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of our Class&#160;A common stock. Pro&#160;forma net tangible book value per share is determined by subtracting our total liabilities from the total book value of our tangible assets and dividing the difference by the number of shares of Class&#160;A common stock deemed to be outstanding, after giving effect to (i)&#160;the receipt of approximately $24.8&#160;million in net proceeds from the issuance and sale of Series&#160;B Preferred Stock that occurred in April and May&#160;2021, and (ii)&#160;the conversion of all outstanding shares of our preferred stock into an aggregate of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of Class&#160;A common stock as if such conversion had occurred on December&#160;31, 2020, subject to certain beneficial ownership limitations. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After giving further effect to our issuance and sale of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;shares of our Class&#160;A common stock in this offering at an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share (which is the midpoint of the price range set forth on the cover page of this prospectus) and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us, our pro&#160;forma as adjusted net tangible book value as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, would have been $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, or $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share of Class&#160;A common stock. This amount represents an immediate increase in pro&#160;forma as adjusted net tangible book value of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to our existing stockholders and an immediate dilution in pro&#160;forma as adjusted net tangible book value of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share to new investors purchasing shares of Class&#160;A common stock in this offering. We determine dilution by subtracting the pro&#160;forma as adjusted net tangible book value per share after this offering from the amount of cash that a new investor paid for a share of Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table illustrates this dilution: </font>
        </div>
        <table style="width:456pt;height:124.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:382pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Assumed initial public offering price per share of Class&#160;A common stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:382pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Historical net tangible book value (deficit) per share as of December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:382pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Increase per share attributable to the conversion of outstanding preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:382pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma net tangible book value per share as of December&#160;31, 2020 before this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;"> </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:382pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Increase in pro&#160;forma as adjusted net tangible book value per share attributable to investors in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:382pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma as adjusted net tangible book value per share after this offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:382pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Dilution per share to new Class&#160;A common stock investors in this offering </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share (which is the midpoint of the price range listed on the cover page of this prospectus) would increase (decrease) the pro&#160;forma as adjusted net tangible book value per share after this offering by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, and dilution in pro&#160;forma as adjusted net tangible book value per share to new investors by approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the underwriters exercise their option to purchase additional shares of our Class&#160;A common stock in full, the pro&#160;forma as adjusted net tangible book value after the offering would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, the increase in pro&#160;forma as adjusted net tangible book value per share to existing stockholders would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share and the dilution in pro&#160;forma as adjusted net tangible book value to new investors would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">79</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:37pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">in each case assuming an initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range listed on the cover page of this prospectus. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes, as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, after giving effect to this offering, the number of shares of our Class&#160;A common stock purchased from us, the total consideration paid, or to be paid, to us and the average price per share paid, or to be paid, by existing stockholders and by the new investors. The calculation below is based on an assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share, which is the midpoint of the price range listed on the cover page of this prospectus, before deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </font>
        </div>
        <table style="width:456pt;height:68pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:245.62pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares Purchased </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total Consideration </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Average price </font>
                <br >
                <font style="letter-spacing:-0.16pt;">per share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:245.62pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percent </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:245.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Existing stockholders </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font>
            </td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:245.62pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">New investors </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:245.62pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Total</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.46pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.035pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:18pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:5.565pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share would increase (decrease) the total consideration paid by new investors and the total consideration paid by all stockholders by $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;million, assuming the number of shares offered by us remains the same and after deducting estimated underwriting discounts and commissions but before estimated offering expenses. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Except as otherwise indicated, the discussion and the tables above assume no exercise of the underwriters&#8217; option to purchase additional shares of our Class&#160;A common stock and excludes: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;additional shares of our Class&#160;A common stock reserved for future issuance under the 2021 Plan, which will become effective in connection with this offering, as well as any automatic increases in the number of shares of our Class&#160;A common stock reserved for future issuance under the 2021 Plan; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock that will become available for future issuance under the ESPP, which will become effective in connection with this offering, and shares of our Class&#160;A common stock that become available pursuant to provisions in the ESPP that automatically increase the share reserve under the ESPP; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock issuable upon exercise of outstanding stock options granted under the 2015 Plan as of December&#160;31, 2020, at a weighted average exercise price of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock available for future issuance under the 2015 Plan as of December&#160;31, 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent any of these outstanding options are exercised, there will be further dilution to new investors. To the extent all of such outstanding options had been exercised as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, the pro&#160;forma as adjusted net tangible book value per share after this offering would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, and total dilution per share to new investors would be $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If the underwriters exercise their option to purchase additional shares of our common stock in full: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the&#160;percentage of shares of our Class&#160;A common stock held by the existing stockholders will decrease to approximately&#8199;&#8199;&#8199;&#8199;% of the total number of shares of our Class&#160;A common stock outstanding after this offering; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the number of shares of our Class&#160;A common stock held by new investors will increase to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, or approximately&#8199;&#8199;&#8199;&#8199;% of the total number of shares of our Class&#160;A common stock outstanding after this offering. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">80</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSCFD1">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SELECTED CONSOLIDATED FINANCIAL DATA</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following tables set forth our selected financial data for the periods indicated. We have derived the consolidated statements of operations data for the&#160;years ended December&#160;31, 2020 and 2019, and the consolidated balance sheet data as of December&#160;31, 2020 and 2019, from our audited consolidated financial statements included elsewhere in this prospectus. Our historical results are not necessarily indicative of the results that should be expected for any future period. You should read the following selected consolidated financial data together with our consolidated financial statements and the related notes included elsewhere in this prospectus and the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; section of this prospectus. </font>
        </div>
        <table style="width:456pt;height:303.5pt;margin-top:6pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:16.75pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:341.17pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 0.667pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended</font>
                <br >
                <font style="letter-spacing:-0.16pt;">December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:10.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:28.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.083pt 0pt 0.667pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except</font>
                <br >
                <font style="letter-spacing:-0.16pt;">share and per share</font>
                <br >
                <font style="letter-spacing:-0.16pt;">amounts) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Consolidated Statements of Operations Data:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,311</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,920</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 1pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,280</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,223</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.75pt 0pt 1pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Gross profit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,031</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">697</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">15,004</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,279</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 1pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,110</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">2,709</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">18,114</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">6,988</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2pt 0pt 1pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(17,083<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(6,291<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(293<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 1pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loss on conversion of convertible notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1,125<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 1.75pt 0pt; width:341.17pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(17,040<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,709<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.25pt 0pt 1.667pt 0pt; width:341.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common stockholders, basic and diluted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(4.82<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 1pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(2.18<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0pt 0.5pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding used to compute net loss per share, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.333pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.417pt 0pt 0.5pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pro Forma net loss per share attributable to common shareholders, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.417pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:0.417pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(2.78<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0.667pt 0pt 1.583pt 0pt; width:341.17pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pro Forma weighted average shares outstanding used to compute net loss per share, basic and diluted</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.667pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.667pt 0pt 0.333pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">6,127,858</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">See Note 8 to our consolidated financial statements for the&#160;years ended December&#160;31, 2020 and 2019 appearing at the end of this prospectus for further details on the calculation of basic and diluted net loss per share attributable to common stockholders. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:3.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">The unaudited pro&#160;forma net loss per share for the year ended December&#160;31, 2020 was computed using the weighted-average number of shares of common stock outstanding, including the pro&#160;forma effect of the conversion of all outstanding shares of Series A Preferred Stock and Series B Preferred Stock into shares of common stock, as if such conversion had occurred at the beginning of the period, or their issuance dates, if later. The information presented in this table does not give effect to the sale and issuance of our Series&#160;B Preferred Stock that occurred in April and May&#160;2021. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;height:125.5pt;margin-top:5pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:363.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:363.26pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.75pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Consolidated Balance Sheet Data:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">37,090</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">13,782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Working capital</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">35,475</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">13,558 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total assets </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,423</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">14,099</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total liabilities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">4,015</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Convertible preferred stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">58,104</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">16,612</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(25,738<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(8,698<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:363.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; equity (deficit) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(22,481<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(6,528<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.4pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:6.9pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">We define working capital as current assets less current liabilities.</font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">81</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDAA">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF</font>
          <br >
          <font style="letter-spacing:-0.2pt;">FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled &#8220;Selected Consolidated Financial Data&#8221; and our consolidated financial statements and related notes appearing at the end of this prospectus. Some of the information contained in this discussion and analysis or set forth at the end of this prospectus, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section entitled &#8220;Risk Factors,&#8221; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. You should carefully read the section entitled &#8220;Risk Factors&#8221; to gain an understanding of the important factors that could cause actual results to differ materially from our forward- looking statements. Please also see the section entitled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. With more than a decade of leadership in translational bioinformatics, we have established a track record of generating insights into drug mechanisms of action and patient treatment responses. Building on these insights, we developed a disease-agnostic platform that enables us to utilize human data, novel biology and chemistry, and translational planning to create and advance our wholly owned pipeline. Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the RAS/RAF/MEK/ERK pathway and other oncologic signaling pathways. Our lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts the kinase suppressor of RAS 1 and 2 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We plan to submit an Investigational New Drug, or IND, for IMM-1-104 to the U.S. Food and Drug Administration, or the FDA, by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;.&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;In addition, we anticipate filing at least two additional INDs for our other oncology programs, one in each of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the period from inception through 2017, we devoted substantially all of our efforts to business planning, service revenue generation, developing tools to aid in drug discovery, and recruiting management and technical staff. Since 2018, we have focused significant effort on our own internal research and development programs. We have financed our operations through service revenues, the issuance of convertible debt and the sale of convertible preferred stock and common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our operations have been financed primarily by aggregate net proceeds of approximately $56.7&#160;million from the issuance of convertible notes payable, convertible preferred stock, common stock and the exercise of stock options. Since inception, we have had significant annual operating losses. Our net loss was approximately $17.0&#160;million and $7.7&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively. As of December&#160;31, 2020, we had an accumulated deficit of approximately $25.8&#160;million and $37.1&#160;million in cash and cash equivalents. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our internally developed product candidates, as well as hire additional personnel, pay fees to outside consultants, lawyers and accountants, and incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">82</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based upon our current business plans, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents will be sufficient to fund our development activities and other operations through&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have not had any internally developed products approved for sale. We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our internally developed product candidates. If we obtain regulatory approval for any of our internally developed product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through service revenue, equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2020, the World Health Organization declared the COVID-19 outbreak a pandemic. In particular, the ongoing COVID-19 pandemic has resulted in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, access restrictions, restrictions on public gatherings, and stay at home orders. The effect of these orders, government imposed quarantines and measures we have taken, such as implementing work-at-home policies, may negatively impact productivity, disrupt our business and/or could adversely affect our development plans and results. We cannot presently predict the scope and severity of any potential business shutdowns or disruptions, but if we or any of the third parties with whom we engage, including personnel at third-party manufacturing facilities and other third parties with whom we conduct business, were to experience shutdowns or other business disruptions, our ability to conduct our business in the manner and on the timeline presently planned could be materially and adversely impacted. It is unknown how long these conditions will last and what the complete effect will be on us. While to date we have been able to continue to execute our overall business plan, some of our business activities have been slowed and taken longer to complete, particularly with respect to our process for recruiting new employees, and we continue to adjust to the challenges of operating in a largely remote setting with our employees. Overall, we recognize the challenges of launching in a pandemic, will continue to closely monitor events as they develop and plan for alternative and mitigating measures that we can implement if needed. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Components of Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.63pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our revenue is generated by providing computational biology professional services to pharmaceutical and biotechnology companies. We charge an agreed upon rate per hour based on the aggregate level of personnel assigned to work on the project or a fixed fee for a defined scope of work. Our contracts specify the period of time over which these professional services will be provided. We recognize revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. We use input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We expect revenue to remain similar to prior&#160;years in the near-term as we continue to provide services to our existing customers and these revenues could decrease as we deprioritize new services work in order to focus on developing our wholly owned pipeline. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our cost of revenue expenses consists primarily of costs related to providing professional services to our customers. These costs include salaries, benefits, and equity-based compensation expense, depreciation, facilities, and other outside services. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">83</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses account for a significant portion of our operating expenses. Our research and development costs consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">personnel costs, which include salaries, benefits and equity-based compensation expense; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expenses incurred under agreements with consultants and contract organizations that conduct research and development activities on our behalf; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">costs related to production of preclinical materials, including fees paid to contract manufacturers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">laboratory and vendor expenses related to the execution of preclinical studies; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">facility costs, depreciation, and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance, and other supplies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our direct research and development expenses are not currently tracked on a program-by-program basis, but we anticipate tracking costs on a program-by-program basis at the time IMM-1-104 enters clinical trials, which we expect to occur in&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. Substantially all our research and development costs in the&#160;years ended December&#160;31, 2020 and 2019 was incurred on the development of IMM-1-104 and our other preclinical pipeline candidates. In the&#160;years ended December&#160;31, 2020 and 2019, we advanced several programs from discovery into preclinical development. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with product development and the current stage of development of our product candidates and programs, we cannot reasonably estimate or know the nature, timing and estimated costs necessary to complete the remainder of the development of our product candidates or programs. We are also unable to predict if, when, or to what extent we will obtain approval and generate revenues from the commercialization and sale of any of our product candidates. The duration, costs and timing of preclinical studies and clinical trials and development of our product candidates will depend on a variety of factors, including: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successful completion of preclinical studies and initiation of clinical trials for future product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successful enrollment and completion of clinical trials for our current product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">data from our clinical programs that support an acceptable risk-benefit profile of our product candidates in the intended patient populations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acceptance by the FDA or other applicable regulatory agencies of IND applications, clinical trial applications and/or other regulatory filings for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expansion and maintenance of a workforce of experienced scientists and others to continue to develop our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">successful application for and receipt of marketing approvals from applicable regulatory authorities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtainment and maintenance of intellectual property protection and regulatory exclusivity for our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">making of arrangements with contract manufacturing organizations for, or establishment of, commercial manufacturing capabilities; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">establishment of sales, marketing and distribution capabilities and successful launch of commercial sales of our product candidates, if and when approved, whether alone or in collaboration with others; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">acceptance of our product candidates, if and when approved, by patients, the medical community and third-party payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">effective competition with other therapies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">obtainment and maintenance of coverage, adequate pricing and adequate reimbursement from third-party payors, including government payors; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">84</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:33.85pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintenance, enforcement, defense and protection of our rights in our intellectual property portfolio; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">avoidance of infringement, misappropriation or other violations with respect to others&#8217; intellectual property or proprietary rights; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">maintenance of a continued acceptable safety profile of our products following receipt of any marketing approvals. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We may never succeed in achieving regulatory approval for any of our product candidates. We may obtain unexpected results from our preclinical studies and clinical trials. We may elect to discontinue, delay or modify clinical trials of some product candidates or focus on others. A change in the outcome of any of these factors could mean a significant change in the costs and timing associated with the development of our current and future preclinical and clinical product candidates. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development, or if we experience significant delays in execution of or enrollment in any of our preclinical studies or clinical trials, we could be required to expend significant additional financial resources and time on the completion of preclinical and clinical development. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We expect our research and development expenses to increase for the foreseeable future as we continue to implement our business strategy, which includes advancing our product candidates through clinical development, expanding our research and development efforts, including hiring additional personnel to support our research and development efforts, and seeking regulatory approvals for our product candidates that successfully complete clinical trials. In addition, product candidates in later stages of clinical development generally incur higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. As a result, we expect our research and development expenses to increase as our product candidates advance into later stages of clinical development. However, we do not believe that it is possible at this time to accurately project total program-specific expenses through commercialization. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our general and administrative expenses consist primarily of personnel costs, including equity-based compensation, and other expenses for outside professional services, including legal, recruiting, audit and accounting services and facility-related fees not otherwise included in research and development expenses. Personnel costs consist of salaries, benefits and equity-based compensation expense, for our personnel in executive and other administrative functions. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We expect our general and administrative expenses to increase over the next several&#160;years to support our continued research and development activities, increased costs of expanding our operations and operating as a public company. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with Nasdaq listing rules and Securities and Exchange Commission requirements, director and officer insurance costs and investor relations costs associated with being a public company. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Income (Expense)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Other income (expense), net consists primarily of interest income earned on our cash equivalents, interest expense related to the conversion of notes payable and a loss on the extinguishment of the convertible notes. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">85</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Results of Operations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Comparison of the Years Ended December&#160;31, 2020 and 2019</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our results of operations for the periods indicated: </font>
        </div>
        <table style="width:456pt;height:217.5pt;margin-top:9.99999999999999pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:271.9pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,311</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,920</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">20.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,280</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,223</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:19.5pt; text-align:right; white-space:nowrap;">4.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Gross profit </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,031</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">697</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">334</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">47.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271.9pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Operating expenses: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">15,004</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,279</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">10,725</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">250.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">3,110</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">2,709</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:19.5pt; text-align:right; white-space:nowrap;">14.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">18,114</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">6,988</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">11,126</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:19.5pt; text-align:right; white-space:nowrap;">159.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss from operations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,083<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,291<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,792<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">171.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271.9pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Other income (expense): </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Interest income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(293<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">336</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(114.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:271.9pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Loss on conversion of convertible notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,125<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">1,125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:19.5pt; text-align:right; white-space:nowrap;">(100.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:271.9pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(17,040<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,709<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.735pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,331<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:19.5pt; text-align:right; white-space:nowrap;">121.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.5pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the revenue recognized for the periods indicated: </font>
        </div>
        <table style="width:456pt;height:49pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:296.26pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:296.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,311</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,920</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">391</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">20.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.49pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Revenue increased by approximately $0.4&#160;million, or 20.4%, to approximately $2.3&#160;million for the year ended December&#160;31, 2020 compared to approximately $1.9&#160;million for the year ended December&#160;31, 2019. The increase in revenue was due to an increase by approximately $0.1&#160;million, or 7%, growth from existing customers, approximately $1.2&#160;million from new customers during 2020 partially offset by approximately $1.0&#160;million decrease due to customer agreements that were completed in 2019. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cost of Revenue</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the components of cost of revenue expenses for the periods indicated: </font>
        </div>
        <table style="width:456pt;height:126pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:292.93pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:292.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Employee related costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,087</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">906</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">181</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">20.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:292.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Equity-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">108</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">167</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(59<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(35.3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:292.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outside contract research services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(14<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(70.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:292.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and other allocated expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">74</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">124</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">(50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(40.3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:292.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:15.75pt; text-align:right; white-space:nowrap;">(16.7<font style="position:absolute;">)% </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:292.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total cost of revenue </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,280</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,223</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">57</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:15.75pt; text-align:right; white-space:nowrap;">4.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">86</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cost of revenue increased by approximately $0.1&#160;million, or 4.7%, to approximately $1.3&#160;million for the year ended December&#160;31, 2020 compared to approximately $1.2&#160;million for the year ended December&#160;31, 2019. The increase was primarily due to increased employee related costs of approximately $0.2&#160;million, offset by decreases in equity-based compensation, facilities, depreciation, and outside contract research services. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the components of research and development expenses for the periods indicated: </font>
        </div>
        <table style="width:456pt;height:126pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:278.56pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:278.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Employee related costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,505</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,801</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,704</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">205.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Equity-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">503</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">306</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">197</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">64.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outside contract research services </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,646</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,938</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6,708</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">346.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:278.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and other allocated expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">330</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">222</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">108</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">48.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:278.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Depreciation </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">66.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:278.56pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total research and development</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">15,004</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,279</td>
            <td style="padding:0pt;padding-left:3.4pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">10,725</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">250.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.9pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Research and development expenses increased by $10.7&#160;million, or 250.6%, to approximately $15.0&#160;million for the year ended December&#160;31, 2020 as compared to approximately $4.3&#160;million for the year ended December&#160;31, 2019. The increase of approximately $10.7&#160;million was primarily due to approximately $6.7&#160;million of outside contract research services for our preclinical candidates due to an increased number of discovery programs and increased spending on later stage preclinical efforts. The increase also includes approximately $3.7&#160;million of additional employee related costs, primarily due to higher headcount and increased equity-based compensation of $0.2&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General and Administrative</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the components of general and administrative expenses for the periods indicated: </font>
        </div>
        <table style="width:456pt;height:156pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:282.93pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:282.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Employee related costs </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,426</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,102</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">324</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">29.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Equity-based compensation expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">476</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">863</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(387<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(44.8<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Professional fees </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">836</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">470</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">366</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">77.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Public relations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">289</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">19</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">270</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1421.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outside consultants </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">18</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">201</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(183<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(91.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:282.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Facilities and other allocated expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">34</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:282.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">27</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:21pt; text-align:right; white-space:nowrap;">35.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:282.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total general and administrative </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,110</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,709</td>
            <td style="padding:0pt;padding-left:4.65pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">401</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:21pt; text-align:right; white-space:nowrap;">14.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.9pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">General and administrative expenses increased by approximately $0.4&#160;million, or 14.8%, to $3.1&#160;million for the year ended December&#160;31, 2020 compared to approximately $2.7&#160;million for the year ended December&#160;31, 2019. The increase of approximately $0.4&#160;million was primarily due to increased employee related costs of approximately $0.3&#160;million, increased professional fees incurred for accounting, auditing, legal, and tax services of approximately $0.4&#160;million, increased public relation costs of approximately $0.3&#160;million, partially offset by a decrease of approximately $0.4&#160;million for equity-based compensation expense due to the fair value of warrants issued to several advisors in 2019 and a decrease of approximately $0.2&#160;million for outside consultants. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">87</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Income (Expense)</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the components of other income (expense) for the periods indicated: </font>
        </div>
        <table style="width:456pt;height:96pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:283.56pt;text-align:left;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Change </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">$ </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands, except&#160;percentages) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest income </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">58</td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(15<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(25.9<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Interest expense </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(351<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">351</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Loss on conversion of convertible notes </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,125<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,125</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:17.25pt; text-align:right; white-space:nowrap;">100.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:283.56pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other income (expense), net </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:7.245pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,418<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.745pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,461</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:17.25pt; text-align:right; white-space:nowrap;">103.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.81pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Other income (expense) increased by $1.5&#160;million, or 103.0%, with other income of approximately $43,000 for the year ended December&#160;31, 2020 compared to other expense of approximately $1.4&#160;million for the year ended December&#160;31, 2019. The increase was primarily due to approximately $1.1&#160;million loss on the conversion of convertible notes and approximately $0.4&#160;million non-cash interest expense related to the convertible notes in 2019, partially offset by a decrease in interest income earned from our cash equivalents balances. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Liquidity and Capital Resources</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have financed our operations through service revenues, the issuance of convertible notes payable, convertible preferred stock, common stock and the exercise of stock options. Cash and cash equivalents totaled approximately $37.1&#160;million as of December&#160;31, 2020 and $13.8&#160;million as of December&#160;31, 2019. Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cash Flows</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our sources and uses of cash for the periods indicated: </font>
        </div>
        <table style="width:456pt;height:96pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:357.97pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt; width:6pt;" rowspan="3">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">(in thousands) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,621<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(4,442<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(53<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(21<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:357.97pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">37,982</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">17,171</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:357.97pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net increase in cash and cash equivalents </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">23,308</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">12,708</td>
            <td style="padding:0pt;padding-left:1.32pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Cash Used in Operating Activities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2020, operating activities used approximately $14.6&#160;million of cash, primarily resulting from our net loss of approximately $17.0&#160;million, partially offset by equity-based compensation expense of approximately $1.1&#160;million and cash provided by changes in our operating assets and liabilities of approximately $1.3&#160;million. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2019, operating activities used approximately $4.4&#160;million of cash, primarily resulting from our net loss of approximately $7.7&#160;million, partially offset by equity-based compensation expense of approximately $0.6&#160;million, non-cash warrant expense of approximately $0.7&#160;million, non-cash interest expense on the convertible notes payable of approximately $0.4&#160;million, and loss of approximately $1.1&#160;million on the conversion of convertible notes payable and cash provided by changes in our operating assets and liabilities of approximately $0.4&#160;million. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Cash Used in Investing Activities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2020 and 2019, investing activities used approximately $53,000 and $21,000, respectively, for the purchase of property and equipment. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">88</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Net Cash Provided by Financing Activities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2020, net cash provided by financing activities was approximately $38.0&#160;million, consisting primarily of approximately $37.0&#160;million in net proceeds received from the issuance of Series&#160;B preferred stock and approximately $1.0&#160;million in net proceeds from the issuance of Series&#160;A preferred stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the year ended December&#160;31, 2019, net cash provided by financing activities was approximately $17.2&#160;million, consisting primarily of approximately $13.4&#160;million in net proceeds received from the issuance of Series&#160;A preferred stock and approximately $3.8&#160;million in proceeds, net of debt issuance costs, received from the issuance of convertible notes payable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Funding Requirements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any product candidates we may develop may never achieve commercialization, and we anticipate that we will continue to incur losses for the foreseeable future. We expect that our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. As a result, until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through a combination of service revenue, equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. Our primary uses of capital are, and we expect will continue to be, costs related to clinical research, manufacturing and development services; compensation and related expenses; costs relating to our headquarters and other offices and or laboratories; license payments or milestone obligations that may arise; laboratory expenses and costs for related supplies; manufacturing costs; legal and other regulatory expenses and general overhead costs. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Based upon our current operating plan, we believe that the net proceeds from this offering, together with our existing cash and cash equivalents of approximately $37.1&#160;million as of December&#160;31, 2020 and approximately $24.8&#160;million from the sale and issuance of shares in the second tranche of our Series&#160;B Preferred Stock in April and May&#160;2021 will be sufficient to continue funding our development activities through&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. To finance our operations beyond that point, we will need to raise additional capital, which cannot be assured. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We will continue to require additional financing to advance our current product candidates through clinical development, to develop, acquire or in-license other potential product candidates and to fund operations for the foreseeable future. We will continue to seek funds through equity offerings, debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed on favorable terms or at all. If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders, including investors in this offering, will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Because of the numerous risks and uncertainties associated with research, development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.91pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.91pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the impacts of the COVID-19 pandemic and potential future pandemics; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and results of our potential future clinical trials for our other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the scope, progress, results and costs of discovery research, preclinical development, laboratory testing and clinical trials for our other product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs, timing and outcome of regulatory review of our product candidates; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to enter into contract manufacturing arrangements for supply of active pharmaceutical ingredient, or API, and manufacture of our product candidates and the terms of such arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">89</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the payment or receipt of milestones and receipt of other collaboration-based revenues, if any; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of any future commercialization activities, including product manufacturing, sales, marketing and distribution, for any of our product candidates for which we may receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the amount and timing of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property and proprietary rights and defending any intellectual property-related claims; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the extent to which we acquire or in-license other products, product candidates, technologies or data referencing rights; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such arrangements; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our ability to access the private and public capital markets or to obtain financing at commercially reasonable rate; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the ability to receive additional non-dilutive funding, including grants from organizations and foundations; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the costs of operating as a public company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Further, our operating plans may change, and we may need additional funds to meet operational needs and capital requirements for clinical trials and other research and development activities. Because of the numerous risks and uncertainties associated with the development and commercialization of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated product development programs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Contractual Obligations and Commitments</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes our contractual obligations as of December&#160;31, 2020: </font>
        </div>
        <table style="width:456pt;height:61.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:210.18pt;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0.333333333333333pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Grant Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Payments due by period </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:22.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Less than </font>
                <br >
                <font style="letter-spacing:-0.16pt;">one year </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">One to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">three&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Four to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">five&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">More than </font>
                <br >
                <font style="letter-spacing:-0.16pt;">five&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:210.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Leases </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">775,663 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">144,943 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">244,740</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">328,648</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">57,332</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:210.18pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total contractual obligations </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">775,663 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27.75pt; text-align:right; white-space:nowrap;">144,943 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">244,740</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">328,648</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:21pt; text-align:right; white-space:nowrap;">57,332</td>
            <td style="padding:0pt;padding-left:1.14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We enter into contracts in the normal course of business with third-party service providers for clinical trials, preclinical research studies and testing, manufacturing and other services and products for operating purposes. We have not included our payment obligations under these contracts in the table as these contracts generally provide for termination upon notice, and therefore, we believe that our non-cancelable obligations under these agreements are not material and we cannot reasonably estimate the timing of if and when they will occur. We could also enter into additional research, manufacturing, supplier and other agreements in the future, which may require up-front payments and even long-term commitments of cash. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Critical Accounting Policies and Use of Significant Judgments and Estimates</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our management&#8217;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the&#160;basis&#160;for making judgments about the carrying value of assets and liabilities that are not readily apparent </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">90</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Research and Development Costs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We will incur substantial expenses associated with manufacturing and clinical trials. Accounting for clinical trials relating to activities performed by contract research organizations, or CROs, and other external vendors requires management to exercise significant estimates in regard to the timing and accounting for these expenses. We estimate costs of research and development activities conducted by service providers, which include the conduct of sponsored research, preclinical studies and contract manufacturing activities. The diverse nature of services being provided under CROs and other arrangements, the different compensation arrangements that exist for each type of service and the lack of timely information related to certain clinical activities complicates the estimation of accruals for services rendered by CROs and other vendors in connection with clinical trials. Because payments of research and development activities do not always line up with the provision of such services, the balance sheet may reflect either an accrued or prepaid position. In estimating the duration of a clinical study, we evaluate the start-up, treatment and wrap-up periods, compensation arrangements and services rendered attributable to each clinical trial and fluctuations are regularly tested against payment plans and trial completion assumptions. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We estimate these costs based on factors such as estimates of the work completed and budget provided and in accordance with agreements established with our collaboration partners and third-party service providers. We make significant judgments and estimates in determining the accrued liabilities and prepaid expense balances in each reporting period. As actual costs become known, we adjust our accrued liabilities or prepaid expenses. We have not experienced any material differences between accrued costs and actual costs incurred since our inception. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our expenses related to clinical trials will be based on estimates of patient enrollment and related expenses at clinical investigator sites as well as estimates for the services received and efforts expended pursuant to contracts with multiple research institutions and CROs that may be used to conduct and manage clinical trials on our behalf. We will accrue expenses related to clinical trials based on contracted amounts applied to the level of patient enrollment and activity. If timelines or contracts are modified based upon changes in the clinical trial protocol or scope of work to be performed, we will modify our estimates of accrued expenses accordingly on a prospective basis. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity-based Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering, we issued equity-based compensation awards through the granting of options, which generally vest over four&#160;years. We account for equity-based compensation in accordance with Accounting Standards Codification, or ASC, 718, </font><font style="font-style:italic;letter-spacing:0.2pt;">Compensation&#8212;Stock Compensation</font><font style="letter-spacing:0.2pt;">, or ASC 718. In accordance with ASC 718, compensation cost is measured at estimated fair value at grant date and is included as compensation expense over the vesting period during which service is provided in exchange for the award. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We use the Black-Scholes option pricing model, or Black-Scholes, to determine fair value of our options. Black-Scholes includes various assumptions, including the fair value of common shares, expected life of incentive shares, the expected volatility and the expected risk-free interest rate. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally outside our control. As a result, if other assumptions had been used, equity-based compensation cost could have been materially impacted. Furthermore, if we use different assumptions for future grants, equity-based compensation cost could be materially impacted in future periods. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We granted stock options to purchase 245,122 shares of common stock during the year ended December&#160;31, 2020. The fair value of our awards in the year ended December&#160;31, 2020 has been estimated using Black-Scholes based on the following assumptions: term of 5.92 to 10&#160;years; volatility of 67.3% to 80.85%; risk-free rate of 0.36% to 1.45%; and no expectation of dividends. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We granted stock options to purchase 714,496 shares of common stock in the year ended December&#160;31, 2019. The fair value of our awards in the year ended December&#160;31, 2019 has been estimated using Black-Scholes </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">91</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">based on the following assumptions: term of 6.08&#160;years; volatility of 66.99% to 70.44%; risk-free rate of 1.77% to 2.20%; and no expectation of dividends. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We will continue to use judgment in evaluating the assumptions utilized for our equity-based compensation expense calculations on a prospective basis. In addition to the assumptions used in the Black-Scholes model, the amount of equity-based compensation expense we recognize in our consolidated financial statements includes incentive share forfeitures as they occurred. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">As there has been no public market for our common shares to date, our board of directors, with input from management, has determined the estimated fair value of our common shares as of the date of each incentive share grant considering our then-most recently available third-party valuation of common shares. Valuations are updated when facts and circumstances indicate that the most recent valuation is no longer valid, such as changes in the stage of our development efforts, various exit strategies and their timing, and other scientific developments that could be related to the valuation of our company, or, at a minimum, annually. Third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, </font><font style="font-style:italic;letter-spacing:0.2pt;">Valuation of Privately-Held-Company Equity Securities Issued as Compensation</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The estimates of fair value of our common stock are highly complex and subjective. There are significant judgments and estimates inherent in the determination of the fair value of our common shares. These judgments and estimates include assumptions regarding our future operating performance, the time to completing an initial public offering, or IPO, or other liquidity event, the related valuations associated with these events, and the determinations of the appropriate valuation methods at each valuation date. The assumptions underlying these valuations represent our best estimates, which involve inherent uncertainties and the application of management judgment. If we had made different assumptions, our equity-based compensation expense, net loss and net loss per share applicable to common shareholders could have been materially different. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the completion of this offering, we intend to determine the fair value of our common stock based on the closing price of our common stock as reported by Nasdaq on the date of grant. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table details equity-based awards that we granted and awarded in the&#160;years ended December&#160;31, 2020 and 2019: </font>
        </div>
        <table style="width:456pt;height:233.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Grant Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Subject to </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Awards </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:4pt;padding-right:4pt;letter-spacing:-0.16pt;">Granted </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Per Share </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:8pt;padding-right:8pt;letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Estimate of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Share Fair </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value Per </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Share on </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Grant Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Black-</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Scholes </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value Per </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Share on </font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Grant Date </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">May&#160;15, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.72</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.72</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">3.02</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">December&#160;16, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">150,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.45</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">December&#160;16, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">554,496</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.63 </td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">February 25, 2020 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">65,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.39 </td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">February&#160;25, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">139,100</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.55</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">July&#160;3, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.62</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">July&#160;3, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">15,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.61</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">July&#160;3, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.63</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">July&#160;3, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,674</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">3.41</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">September&#160;25, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,000</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">2.62</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">September&#160;25, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,674</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.35</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">3.40 </td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">October 5, 2020</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(1)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">4,674</td>
            <td style="padding:0pt;padding-left:1.435pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.77</td>
            <td style="padding:0pt;padding-left:5.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.77</td>
            <td style="padding:0pt;padding-left:7.765pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">4.69</td>
            <td style="padding:0pt;padding-left:7.68pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.7pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Represents an equity-based award for services rendered in 2020. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">92</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recently Adopted Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Refer to Note 2, &#8220;Summary of Significant Accounting Policies,&#8221; in the accompanying notes to our consolidated financial statements for the&#160;years ended December&#160;31, 2020 and 2019 appearing elsewhere in this prospectus for a discussion of recent accounting pronouncements. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Off-balance Sheet Arrangements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under SEC rules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Quantitative and Qualitative Disclosures about Market Risk</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Interest Rate Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, our cash consists of cash held as deposits at a major financial banking institution and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. As of December&#160;31, 2020, we had no variable-rate debt outstanding and are therefore not exposed to interest rate risk with respect to debt. We believe a hypothetical 100 basis point increase or decrease in interest rates during the period presented would not have had a material impact on our financial results. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Foreign Currency Risk</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All of our employees and our operations are currently located in the United States and our expenses are generally denominated in U.S. dollars. We believe a hypothetical 100 basis point increase or decrease in exchange rates during the period presented would not have had a material impact on our financial results. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Effects of Inflation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We do not believe that inflation and changing prices had a significant impact on our results of operations for the period presented herein. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Emerging Growth Company Status</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As an emerging growth company, or EGC, under the Jumpstart Our Business Startups Act of 2012, or JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for EGCs include presentation of only two&#160;years of audited consolidated financial statements in a registration statement for an IPO, an exemption from the requirement to provide an auditor&#8217;s report on internal controls over financial reporting pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board, and less extensive disclosure about our executive compensation arrangements. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an EGC to delay the adoption of some accounting standards until those standards would otherwise apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i)&#160;are no longer an emerging growth company or (ii)&#160;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We may remain classified as an EGC until the end of the fiscal year following the fifth anniversary of this offering, although if the market value of our common stock that is held by non-affiliates exceeds $700&#160;million as of June&#160;30 of any year before that time, or if we have annual gross revenues of $1.07&#160;billion or more in any fiscal year, we would cease to be an EGC as of December&#160;31 of the applicable year. We also would cease to be an EGC if we issue more than $1.0&#160;billion of non-convertible debt over a three-year period.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">93</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:91.84pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">BUSINESS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. With more than a decade of leadership in translational bioinformatics, we have established a track record of generating insights into drug mechanisms of action and patient treatment responses. Building on these insights, we developed a disease-agnostic platform that enables us to utilize human data, novel biology and chemistry, and translational planning to create and advance our wholly owned pipeline. Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK pathway and other oncologic signaling pathways. Our lead oncology product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. We plan to submit an IND for IMM-1-104 to the FDA by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. In addition, we anticipate filing at least two additional INDs for our other oncology programs, one in each of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our platform is enabled by our ability to efficiently analyze high-throughput molecular-level biochemical assays, including transcriptomics, genomics and/or proteomics, collectively referred to as Omics data. These different types of biochemical assays each provide us with unique information about the molecular mechanisms of disease biology and drug response. Since our inception, we have partnered with industry-leading pharmaceutical and biotechnology companies to perform a variety of analyses that utilize our expertise in translational bioinformatics. Examples publicly disclosed by our partners include our analyses of ibrutinib, ipilimumab, daratumumab, glatiramer acetate and pridopidine. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In early 2018, we began applying our proprietary platform and approach to internally develop our wholly owned pipeline of orally administered small molecule drug programs. Our approach played a critical role in determining the most important characteristics for and creation of IMM-1-104. Specifically, our platform enables us to: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">leverage insights from human data to identify disease transcriptional profiles we aim to counteract; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identify novel biology, specifically evaluating new ways to drug an existing target by utilizing our proprietary Disease Cancelling Technology, or DCT, and analyze mechanisms of existing drugs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">generate novel chemistry that overcomes MAPK-feedback loops to achieve optimal signaling dynamics; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">profile IMM-1-104 in a large number of 3D models using our own translational planning to identify the types of cancer most likely to be sensitive to the product candidate. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our current oncology programs target mutations of the RAS/RAF/MEK/ERK, or MAPK, and the PI3K/AKT/mTOR, or mTOR, pathways. The MAPK and mTOR signaling pathways run parallel to each other, and in over half of all cancers, one or both of these pathways are inappropriately activated (as depicted below). Existing drugs targeting these pathways are limited by toxicity, resistance and/or are narrowly focused </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">94</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">on subpopulations with specific mutations. The MAPK and mTOR pathways function to drive cell proliferation, differentiation, survival and a variety of other cellular functions that are critical for the formation of tumors. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fundamental Cancer Signaling Cellular Pathways: MAPK and mTOR</font>
        </div>
        <div style="position:relative;margin-top:7.41pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-tbl_cancer4c.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_cancer4c.jpg]" height="277" width="486" >
        </div>
        <div style="margin-top:12.01pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each of the programs in our oncology pipeline are designed to cause cyclical disruption of abnormal activation of the MAPK and mTOR signaling pathways while limiting drug-related toxicity. Traditional drug approaches have been designed to sustain pathway inhibition, which can cause on-target drug-related toxicity and limit clinical durability as a result of drug holidays or treatment discontinuation. Based on insights derived from our translational bioinformatics platform, our differentiated approach is to design drugs with short half-lives that provide enhanced mechanistic control of the target of interest and break tumor addiction, which is the tumor&#8217;s ability to indefinitely self-replicate, metastasize and evade the host&#8217;s immune system, among others capabilities, through deep cyclic disruption of these pathways (i.e., signaling dynamics). By cyclically disrupting these core oncogenic signaling pathways in cancer cells, we believe we can create novel therapeutics that maximize therapeutic activity in broad patient populations while providing an improved tolerability profile (as depicted below). We believe we are pioneers in this unique approach of leveraging signaling dynamics against tumor addiction. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Signaling Dynamics: Traditional Sustained Inhibition Versus Our Cyclic Approach</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.42pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_tradtion4c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_tradtion4c.jpg]" height="209" width="578" >
        </div>
        <div style="margin-top:16pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Wholly Owned Pipeline</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.42pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our oncology programs target clinically validated pathways, but we seek to improve patient outcomes across a wide range of addressable solid tumor types through our differentiated programs. In addition to our </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">95</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">oncology pipeline, we are also leveraging our platform to build a neuroscience pipeline initially focusing on Alzheimer&#8217;s disease, or AD. Our current pipeline of product candidates and discovery programs is depicted below. </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-fc_discovery4c.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_discovery4c.jpg]" height="290" width="578" >
        </div>
        <div style="margin-top:16pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dual-MEK Program</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our dual mitogen-activated protein kinase kinase, or MEK, product candidate, IMM-1-104, is designed to be a highly selective inhibitor of mitogen-activated protein kinase kinase kinase, or ERK, activation (i.e., phosphorylation), prevent MAPK pathway reactivation and have a short plasma half-life that reduces sustained pathway inhibition (as depicted below). Unlike MEK inhibitors approved by the U.S. Food and Drug Administration, or the FDA, IMM-1-104 is designed to prevent RAF-mediated activation of MEK by engagement of the RAF activation loop on MEK, such as CRAF-bypass, and further disrupt the kinase suppressor of RAS 1 and 2, or KSR. Additionally, with a short plasma half-life, IMM-1-104 can achieve deep cyclic inhibition of the MAPK pathway. We believe this innovative method of pathway inhibition normalizes cancer cell signaling dynamics and prevents further damage to normal healthy cells. Collectively, we believe these qualities differentiate IMM-1-104 from known MEK inhibitors by potentially enabling IMM-1-104 to avoid drug resistance while improving tolerability. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dual-MEK Inhibition Prevents Activation of MEK and Downstream Activation of ERK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.5pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-tbl_phospho4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_phospho4clr.jpg]" height="276" width="607" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">96</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In preclinical studies, we observed that IMM-1-104 inhibits MEK and ERK across a wide range of human and murine solid tumor models, including those with activating mutations in KRAS, NRAS, HRAS and BRAF. In addition, we evaluated IMM-1-104 in murine-based KRAS and BRAF mutant solid tumor models representing lung, colon, pancreas and skin cancer, and observed therapeutic activity with improved tolerability when compared to current FDA-approved MEK and BRAF inhibitors. We are also currently evaluating IMM-1-104 in a murine-based NRAS melanoma tumor model. Given the activity and tolerability observed in these preclinical studies, we believe that IMM-1-104 will deliver clinical benefit as monotherapy and, in the future, may potentially be administered in select drug combinations for patients with RAS and/or RAF mutant solid tumors who currently have limited treatment options. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">IMM-1-104 is currently undergoing Investigational New Drug, or IND, enabling studies. We plan to submit an IND for IMM-1-104 to the FDA by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. We intend to initiate our first-in-human Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors, if our IND for IMM-1-104 is accepted. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MEK-Immuno-Oncology and Other Oncology Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our MEK-immuno-oncology, or MEK-io, program is focused on developing innovative allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of &#8220;cold&#8221; solid tumors, which are immunologically inaccessible. We believe our investigational MEK-io program inhibitors target MEK in a way that disrupts the MAPK pathway at ERK and also reduces baseline MEK activation. We are designing these inhibitors with unique pharmacokinetic, or PK, and pharmacodynamic, or PD, profiles that enhance cycle inhibition time of MEK and ERK to optimize the patient&#8217;s immune response and promote maximal antitumor responses when administered in combination with select immune modulators. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We observed an initial </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> proof-of-concept for our MEK-io program in a widely utilized syngeneic murine model where we observed synergistic antitumor activity in combination with a checkpoint inhibitor. Our MEK-io program is currently in the lead optimization stage of development and we are screening multiple advanced drug analogues for optimal PK and PD profiles that maximally modulate antitumor responses through cyclic inhibition of MEK and ERK. Top candidates will further be evaluated </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> for drug-like properties that demonstrate synergistic therapeutic activity when combined with select immune modulators in preclinical immunologically cold solid tumor models. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are leveraging our platform to continue expanding our oncology pipeline by targeting the MAPK and mTOR pathways in novel ways. We have five additional programs in various stages of drug discovery focused on targeting these pathways through novel pharmacological approaches. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to the expected IND filing of IMM-1-104, we anticipate filing at least two additional INDs for our other oncology programs, one in each of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Neuroscience Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">AD is the most common form of dementia and one in three adults over the age of 65 succumb to AD-related dementia or another form of dementia. We believe there are specific subgroups of AD that can be stratified through gene expression and brain pathology. To identify AD subgroups, we have leveraged our platform to employ a patient-centric, data-driven approach. AD is a neurodegenerative disorder of uncertain cause and pathogenesis characterized by memory impairment and further cognitive decline that can ultimately affect the patient&#8217;s behavior, speech, visuospatial orientation and motor system. AD is a complex multifactorial disease driven by genetic and environmental causes that affects older adults and is one of the leading sources of morbidity and mortality in the aging population. The estimated total healthcare costs for the treatment of AD was approximately $305&#160;billion in 2020, with the cost expected to increase to more than $1 trillion by 2050. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our neuroscience programs are in the early stages of drug discovery, and we are evaluating undisclosed targets to pursue a unique approach to treating AD. We believe we can slow the progression of AD by developing targeted therapies for distinct biological mechanisms that we have identified in specific AD subgroups. Our platform and expertise in neurology and neuroscience have allowed us to determine biological differences in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">97</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">AD patients to help develop novel therapies that may potentially address the significant unmet needs of this underserved patient population. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Team</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We were founded in 2008 by our Chief Executive Officer, Benjamin J. Zeskind, Ph.D., and a member of our board of directors, Robert J. Carpenter, with the goal of leveraging translational bioinformatics to generate insights into the mechanisms that cause certain patients to respond to specific medicines across multiple therapeutic areas. Our multi-disciplinary team brings together experts across translational bioinformatics, preclinical and clinical development in both oncology and neuroscience and includes individuals with extensive experience at some of the leading pharmaceutical companies, including Johnson &amp; Johnson, AstraZeneca and Incyte. We are supported by a high-quality group of investors, including entities affiliated with Cormorant Asset Management, Surveyor Capital (a Citadel company), Rock Springs Capital, T. Rowe Price Associates, Inc., Perceptive Advisors and LYFE Capital. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our History</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our company is built on more than a decade of leadership in translational bioinformatics. Since our founding in 2008, we have established a track record of generating insights into the mechanisms that cause certain patients to respond to specific medicines across therapeutic areas by analyzing Omics data. Our computational biology services business has helped us to better understand how translational bioinformatics can contribute to each stage of drug development, from early drug discovery to clinical development and through commercialization. However, we recognized the limitations of applying translational bioinformatics in isolation to specific stages of the drug development process and realized that bioinformatics could be even more helpful if applied continuously throughout the drug development process. Over time, we have developed a proprietary technology platform to facilitate that process and, in early 2018, we began applying the extensive insights from and capabilities of our platform and approach to create a wholly owned pipeline of drug programs, initially focusing on oncology. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Strategy</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our mission is to develop novel therapies by utilizing our disease-agnostic platform to address areas of high unmet medical need, initially in cancer and neurologic diseases. Our platform allows us to leverage human biological data in new and creative ways, which provides counterintuitive insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views. We are developing novel therapies that aim to optimize both safety and efficacy for diseases with suboptimal treatment options. To achieve our mission, we are executing a near-term strategy with the following key elements: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Rapidly Advance IMM-1-104 into Clinical Development</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We believe that IMM-1-104 has the potential to treat broad populations of solid tumor patients, specifically those with inappropriate activation of the MAPK pathway. IMM-1-104 has been specifically designed to overcome MAPK-feedback loops and, combined with its intentionally short half-life, could have the potential to provide broader therapeutic activity and an improved tolerability profile relative to known MEK inhibitors. We believe IMM-1-104 has the potential to target patients with a broad spectrum of mutations in KRAS and NRAS, as well as other mutations that activate the MAPK pathway. IMM-1-104 is currently in IND-enabling studies, and we expect to submit an IND by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Progress Our Pipeline of Additional MAPK and mTOR Pathway Programs to IND-Enabling Studies</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;"> Other key programs in our oncology pipeline also leverage our knowledge of the MAPK and mTOR pathways, translational bioinformatics and signaling dynamics. For example, we are advancing programs which modulate MEK to potentially enhance patient immune response to cancer as well as programs which modulate the formation of RAS dimers to kill RAS-driven tumors while sparing healthy cells. We are also applying our platform to other relevant pathways and have initiated a program targeting PI3K&alpha; in the mTOR pathway. We intend to develop other programs for the mTOR pathway, as well as other oncogenic pathways. In addition to the expected IND filing of IMM-1-104, we anticipate filing at least two additional INDs for our other oncology programs, one in each of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">98</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Utilize Our Platform to Advance Our Neuroscience Programs.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In addition to our extensive oncology pipeline, we have built a neuroscience pipeline initially focused on AD, which leverages key components of our platform. We have identified subgroups of AD with distinct molecular drivers and have identified unique undisclosed targets for these specific subgroups. Currently, we are developing small molecules to inhibit these undisclosed targets, which we intend to continue advancing towards IND-enabling studies. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Continue to Grow and Advance Our Platform</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We have built a biopharmaceutical company that fully integrates bioinformatics across all aspects of drug discovery and development. We currently utilize our bioinformatics platform for our drug discovery efforts in oncology and neuroscience, and as we advance our product candidates into and through the clinic, we plan to utilize data and insights from our bioinformatics platform to not only guide future clinical development but to also provide key learnings back to our earlier stage programs. Lastly, we continue to iterate on our existing technology and processes, and develop new technologies for our platform, all aimed at creating the most efficient process for the development of product candidates that we believe have the potential to optimize both safety and efficacy in broad patient populations with high unmet medical needs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Bioinformatics Approach</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Leveraging our history in translational bioinformatics, we have built a biopharmaceutical company that incorporates our expertise into every step of our process to discover and develop novel product candidates. Our goal is to meaningfully improve patient outcomes as compared to drugs developed through traditional drug discovery approaches. Our integrated approach has already yielded programs that have exhibited preclinical activity against a broad range of clinically challenging solid tumors, which are advancing towards the clinic. We have expanded our team of experts, including drug discovery and clinical development experts, to develop a pipeline of product candidates by leveraging our translational bioinformatics expertise (as depicted below). </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Bioinformatics Expertise Leveraged Through All Stages of Drug Discovery and Development</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-fc_prop4c.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_prop4c.jpg]" height="319" width="547" >
        </div>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Cancer Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Cancer is the second most common cause of death worldwide with approximately 10&#160;million deaths annually and an incidence of approximately 19.3&#160;million new cases in 2020. Cancer is defined as a collection of diseases in which abnormal cells divide uncontrollably and can invade nearby tissues. The uncontrollable division of abnormal cells typically results in a malignant tumor (i.e., cancerous) or benign tumor (i.e., non-cancerous). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">99</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:161.01pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">There are two main categories of cancer: hematologic (i.e., blood) cancers and solid tumor cancers. Hematologic cancers are cancers of the blood cells, and include leukemia, lymphoma and multiple myeloma. Solid tumor cancers are cancers of any of the body&#8217;s other organs or tissue, including the pancreas, skin, lung and colon. Core tumor capabilities seen in cancer patients include the ability to indefinitely self-replicate, develop new blood vessels (i.e., angiogenesis), evade cell death (i.e., apoptosis), sustain self-sufficient growth, invade other tissues (i.e., metastasis), alter signaling pathways, evade immune system responses and modify metabolism. Tumor survival is dependent on certain of these capabilities (i.e., tumor addiction). </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MAPK and mTOR Pathways</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In all cells, signaling pathways govern how cells regulate themselves as well as direct activities in relation to other cells in the body. Two of the most commonly altered signaling pathways in cancer are the MAPK and mTOR pathways. MAPK and mTOR are both oncogenic signaling pathways that run parallel to each other. RAS is a family of related oncogenes found upstream in each pathway that codes for four highly related protein isoforms, HRAS, NRAS, KRAS4A and KRAS4B. In over half of all cancers, one or both of these pathways are inappropriately activated, often through mutations in the key members of the pathway, including RAS, RAF and PI3K&alpha;. When RAS is switched &#8220;on&#8221; through the activation of the membrane-bound receptor tyrosine kinase, or RTK, the MAPK and mTOR pathways function to drive cell proliferation, differentiation, survival and a variety of other cellular functions that are critical for the formation of tumors. In addition, the membrane-bound RTKs can separately activate the mTOR pathway without the assistance of RAS. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Through widespread adaptation of molecular profiling, we now recognize that up to one in two cancer patients harbor tumors which are inappropriately activated through the MAPK pathway, and an additional one in three display alterations that impact the mTOR pathway. Many of these patients display tumors with activation mutations in RAS or RAF, which lie upstream of MEK and ERK. Because inappropriate activation of the MAPK and/or mTOR pathways supports many of the core tumor capabilities described above, efforts to create new therapeutics to target these pathways has been a high priority in cancer drug research. However, therapeutics that target the MAPK and mTOR pathways have not lived up to the expectations of effectively disrupting these pathways with high patient tolerability. Nearly all targeted therapeutics against the MAPK and mTOR pathways have been designed for sustained pathway suppression, which has resulted in on-target drug-related toxicity that limits clinical durability and potential drug-drug combinations. Developing novel therapeutics to effectively and safely target these pathways may provide clinical benefit in large patient populations with significant unmet needs. In addition, although these two pathways represent two of the most active areas in cancer drug discovery and development, targeted therapeutics that more effectively and safely normalize, but not ablate, ERK and mTOR signaling may uncouple drug activity and tolerability, while optimizing both. Our oncology pipeline is designed to non-chronically disrupt molecular pathways that enable tumor addiction while limiting drug-related toxicity of normal healthy cells that also rely, to a lesser degree, on these pathways. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">100</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:50.09pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Programs Target Aggressive Solid Tumors That Display High RAS/RAF Mutations</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-tbl_target4c.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_target4c.jpg]" height="295" width="608" >
        </div>
        <div style="margin-top:18.69pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Differentiated Approach to Tackling Some the Most Challenging Cancers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are leveraging our platform to target the MAPK and/or mTOR pathway. Our differentiated approach is to design drugs with short half-lives that provide enhanced mechanistic control of the target of interest and break tumor addiction through deep cyclic disruption of these pathways (i.e., signaling dynamics). We believe we are pioneers in this approach of leveraging signaling dynamics against tumor addiction, and our insights derived from our translational bioinformatics platform have substantiated our belief that this will result in better drugs targeting this pathway. Traditional drug approaches have been designed to sustain pathway inhibition, which leads to on-target drug-related toxicity and becomes limiting for clinical durability as a result of drug holidays or treatment discontinuation . The mutational activation and/or overexpression of the signaling components that activate the MAPK pathway are well-known, and MEK has been previously validated as a therapeutic target. We believe our programs, as compared to FDA-approved treatments targeting the MAPK pathway, have the potential to be differentiated by their unique engagement and PK and PD profiles. For example, our lead product candidate, IMM-1-104, is designed to inhibit ERK, prevent MAPK-pathway reactivation and have a short plasma half-life that reduces sustained pathway inhibition compared to other drugs targeting the same mechanistic pathway. By cyclically disrupting these core oncogenic signaling pathways in cancer cells, we believe we can create novel therapeutics in oncology that maximize therapeutic activity in broad patient populations while providing an improved tolerability profile as compared to other FDA-approved treatments for cancers caused by MAPK pathway activation. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Oncology Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our current development programs in oncology are focused on providing treatments for patients with solid tumors caused by mutations of the MAPK and mTOR pathways. Our Dual-MEK product candidate, IMM-1-104, is currently being evaluated in IND-enabling studies and is complemented by multiple earlier-stage programs that also target these pathways. The following table summarizes our oncology pipeline: </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">101</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-tbl_pipeline4c.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_pipeline4c.jpg]" height="261" width="607" >
        </div>
        <div style="margin-top:12.13pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Overview of Our Lead Program: Dual-MEK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:9.62pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Background of MEK Inhibitors</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Activating mutations of RAS and/or RAS in the MAPK pathway is observed in approximately 30% of all cancer patients, and inappropriate activation of this pathway is observed in up to 50% of all tumors and represents one of the most highly utilized signaling pathways in oncologic drug discovery. In aggressive solid tumors of the pancreas, skin, lungs and colon, mutations in RAS and/or RAF are even more common. For example, approximately 40% of lung cancers and approximately 90% of pancreatic cancers are due to RAS and/or RAF mutations. To date, FDA-approved MEK inhibitors have been ineffective at treating RAS mutant tumors when compared to BRAF mutant tumors because of a well-known mechanism of resistance, CRAF-mediated MEK activation, or the CRAF-bypass. In addition, a well-known limitation of current FDA-approved MEK inhibitors are their high rates of serious drug-related adverse events, most often in over 50% of treated patients, which results in drug intolerability. The longer half-life of these drugs (e.g., up to 2 to 4&#160;days), or moderate half-life (e.g., 3 to 6 hours) with increased dosing frequency, contributes to high rates of adverse events because these drugs systemically circulate for an extended period of time destroying healthy normal cells, which also rely on the pathway for survival. Our goal in developing IMM-1-104 is to address these shortcomings to potentially provide patients with better outcomes, improved tolerability, durability and expand drug-drug combination opportunities (as depicted below). </font>
        </div>
        <div style="margin-top:9.62pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IMM-1-104: Designed to be a Highly Differentiated Dual-MEK Inhibitor</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.12pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-fc_highly4c.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_highly4c.jpg]" height="228" width="548" >
        </div>
        <div style="margin-top:12.13pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Solution: IMM-1-104</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.11pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have leveraged our platform to develop our lead product candidate, IMM-1-104, which is designed to be a highly selective dual-MEK inhibitor that promotes additional scaffold-related disruption of KSR. We are </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">102</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">developing IMM-1-104 to treat patients with cancer, including pancreatic, melanoma, colorectal and non-small cell lung cancer, or NSCLC, caused by mutations of RAS and/or RAF. In order to overcome MAPK-feedback and CRAF-mediated MEK activation, a well-known limitation of current FDA-approved MEK inhibitors, we developed IMM-1-104 to allosterically inhibit MEK by targeting the site lying adjacent to the binding pocket of adenosine triphosphate, or ATP, which results in downstream inhibition of ERK. In addition, unlike FDA-approved MEK inhibitors, IMM-1-104 is designed to prevent RAF-mediated activation of MEK by unique engagement of MEK that further disrupts KSR. We believe the bypass of these drug resistance mechanisms will provide for better patient outcomes by enhancing therapeutic activity throughout the course of treatment. By reducing steady state drug trough levels, we also designed IMM-1-104 to limit or reduce high rates of serious drug-related adverse events (e.g., ranging from 45% to 69%) that are observed in current FDA-approved MEK inhibitors, most often given in combination with a RAF inhibitor, which contribute to discontinuation rates of up to 10% to 15%. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">With a goal of improving the tolerability profile of our MEK inhibitor, we designed IMM-1-104 to have a short plasma half-life of less than 2 hours, resulting in a near-zero steady state drug trough concentration that enables deep cyclic inhibition of the MAPK pathway. We believe this method of drug cadence-driven pathway inhibition has the potential to normalize cancer cell signaling dynamics and prevent further damage to normal healthy cells. Collectively, we believe these qualities may differentiate IMM-1-104 from known MEK inhibitors by potentially allowing IMM-1-104 to avoid drug resistance while improving tolerability due to its dual allosteric inhibition of MEK, KSR disruption and short plasma half-life. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preclinical Studies Overview: IMM-1-104</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In multiple preclinical studies, we observed that IMM-1-104 inhibited activated MEK (i.e., pMEK) and activated ERK (i.e., pERK) across a wide range of murine and humanized 3D solid tumor models, including those with activating mutations in KRAS, NRAS, HRAS and BRAF. In addition, we evaluated IMM-1-104 in murine-based KRAS and BRAF mutant solid tumor models representing lung (i.e., A549), colon (i.e., Colon-26), pancreas (i.e., MIA PaCa-2) and skin cancer (i.e., A375), and observed therapeutic activity with improved tolerability when compared to current FDA-approved MEK inhibitors. We are also currently evaluating IMM-1-104 in a murine-based NRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">Q61R</font><font style="letter-spacing:0.2pt;"> melanoma tumor model (i.e., SK-MEL-2). Given the activity and tolerability observed in our previously conducted preclinical studies, we believe that IMM-1-104 has the potential to deliver clinical benefit as monotherapy and, in the future, may potentially be administered in select drug combinations for patients with RAS and/or RAF mutant solid tumors who currently have limited treatment options. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Preclinical Studies: Maximum Tolerated Dose and Therapeutic Effect</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In our early maximum tolerated dose, or MTD, studies, we observed that oral administration of IMM-1-104 twice a day of up to 150 mg/kg/dose was well-tolerated in mice. In other preclinical studies, we observed that the maximum therapeutic effect of IMM-1-104 was reached when administered orally twice a day between 100 and 150 mg/kg/dose. These dosing studies provided the basis of IMM-1-104&#8217;s dosing schedule in subsequent preclinical studies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Preclinical Studies: Pharmacogenomics</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In a pharmacogenomics study utilizing a colorectal KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12D</font><font style="letter-spacing:0.2pt;"> tumor model in BALB/c mice, we evaluated downstream ERK inhibition of the MAPK pathway after IMM-1-104 treatment. We orally administered vehicle, selumetinib and IMM-1-104 twice a day at 100 mg/kg/dose, then harvested the tumors after 18&#160;days of chronic treatment at 2 and 12 hours following the last drug dose to evaluate RNAseq changes. The tumors were collected across distinct BALB/c mice and RNAseq changes were evaluated using statistical analysis software. Consistent with IMM-1-104&#8217;s designed short plasma half-life, we observed deep, cyclic inhibition of most of the top genes in the ERK transcriptome, as noted by the differences of the dark and light blue bars, which we believe may improve tolerability by allowing healthy normal cells to regenerate before the next dose is administered. For example, </font><font style="font-style:italic;letter-spacing:0.2pt;">Erg1</font><font style="letter-spacing:0.2pt;"> and </font><font style="font-style:italic;letter-spacing:0.2pt;">Spry4</font><font style="letter-spacing:0.2pt;"> were both downregulated over 16-fold at 2 hours after receiving the first dose on day 18 of the study, and at 12 hours after the first dose, which was prior to the second dose, both genes were approaching their baseline state when compared to vehicle treated tumors (as depicted below). In contrast to IMM-1-104, we did not observe deep cyclic inhibition of selumetinib, but rather observed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">103</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">sustained MAPK pathway suppression versus vehicle groups between the two timepoints on day 18 (as depicted below). The top 20 genes were a subset of a 52-gene signature for ERK signaling. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Head-to-Head Comparison of IMM-1-104 Against Selumetinib Using a Colon-26 Xenograft Tumor Model: Deep Cyclic Inhibition of the ERK Transcriptome</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-bc_tumor4c.jpg" alt="[MISSING IMAGE: tm2115679d1-bc_tumor4c.jpg]" height="251" width="578" >
        </div>
        <div style="margin-top:12.8pt; text-align:center; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">* Adjusted p-value &lt; 0.05, for each treatment versus vehicle (n = 3-4 independent tumors per group)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Preclinical Studies: Resistance to CRAF-bypass</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We evaluated IMM-1-104 head-to-head against four FDA-approved MEK inhibitors for CRAF-bypass resistance in a KRAS mutant NSCLC tumor model. We exposed the tumor cells with 100 nM of each drug for 2 hours and evaluated MEK and ERK activation levels. We observed that IMM-1-104 was able to reduce overall activity of the MAPK pathway at ERK and pathway reactivation at MEK through a decrease in MEK and ERK activation, resulting in CRAF-bypass resistance. In contrast, we observed that all four FDA-approved MEK inhibitors displayed an increase in activated MEK, resulting in CRAF-bypass (as depicted below). </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Head-to-Head Comparison of IMM-1-104 against Four FDA-Approved MEK Inhibitors Using a A549 Xenograft Tumor Model: Prevented Downstream Activation of ERK (&#8595; pERK) and Inhibited Activation of MEK (&#8595; pMEK)</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.9pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-bc_comparisn4c.jpg" alt="[MISSING IMAGE: tm2115679d1-bc_comparisn4c.jpg]" height="279" width="608" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">104</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:27.59pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Preclinical Studies: Activity and Tolerability</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We evaluated antitumor activity and tolerability of IMM-1-104 head-to-head against binimetinib and selumetinib in an aggressive murine colorectal tumor model (i.e., Colon-26), which expresses mutant KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12D</font><font style="letter-spacing:0.2pt;">. We observed that IMM-1-104 demonstrated greater tumor growth inhibition, where notably 5 of 8 mice experienced tumor regression during the first 10&#160;days of dosing, as well as greater tolerability, evidenced by changes in body weight loss, or BWL. In addition, we observed that IMM-1-104 had overall better durability of antitumor response as compared to the two FDA-approved MEK inhibitors, as demonstrated by significantly lower tumor volume, or TV, progression. This study demonstrated that IMM-1-104 as compared to binimetinib and selumetinib provided greater tumor inhibition, lower BWL and lower TV progression (as depicted below). </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Head-to-Head Comparison of IMM-1-104 Against Binimetinib and Selumetinib Using a Colon-26 Xenograft Tumor Model: Body Weight Loss and Tumor Volume</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_selumet4c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_selumet4c.jpg]" height="313" width="608" >
        </div>
        <div style="margin-top:14.69pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">After observing the results of the Colon-26 tumor study, we completed two follow-up </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> studies, where we evaluated IMM-1-104 head-to-head against binimetinib or encorafenib, a BRAF inhibitor, as monotherapy plus the combination of binimetinib with encorafenib in BALB/c mice tumor models with RAS and RAF mutations. It should be noted that when encorafenib is used to treat KRAS mutant tumors that are wild type for BRAF, it can paradoxically activate the MAPK pathway and antagonize the effects of binimetinib. In addition, the drug doses and schedules used for binimetinib and encorafenib in these studies were consistent with what was provided in their NDAs to the FDA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We evaluated IMM-1-104 head-to-head against binimetinib monotherapy and in combination with encorafenib in the KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12S</font><font style="letter-spacing:0.2pt;"> human NSCLC tumor model (i.e., A549). When comparing IMM-1-104 to binimetinib monotherapy, we observed that IMM-1-104 had greater tumor growth inhibition (as depicted below). The observations of IMM-1-104 head-to-head against binimetinib alone and in combination with encorafenib, which was not considered relevant for a KRAS mutant, RAF wild-type tumor model, has been included in the figure below for comparison purposes. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">105</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:202.14pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib Using a A549 Xenograft Tumor Model: Tumor Volume</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_immbini4c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_immbini4c.jpg]" height="337" width="607" >
        </div>
        <div style="margin-top:14.69pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We also evaluated IMM-1-104 head-to-head against binimetinib and encorafenib monotherapy and the combination of binimetinib with encorafenib in a BRAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">V600E</font><font style="letter-spacing:0.2pt;"> human melanoma tumor model. It should be noted that the administered combination of binimetinib and encorafenib for BRAF mutant melanoma, such as BRAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">V600E/K</font><font style="letter-spacing:0.2pt;">, is an FDA-approved combination. As expected, when comparing IMM-1-104 alone to binimetinib in combination with encorafenib, we observed that the combination therapy had greater tumor growth inhibition (as depicted below). However, when we compared IMM-1-104 to binimetinib monotherapy, we observed that IMM-1-104 had greater tumor growth inhibition (as depicted below). We believe the greater single agent MEK inhibitor activity provides an opportunity to expand IMM-1-104 into drug-drug combinations with other MAPK pathway inhibitors, such as encorafenib, to treat RAF mutant cancers, such as BRAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">V600E/K</font><font style="letter-spacing:0.2pt;">, among other MAPK pathway mutations. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">106</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:27.79pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Head-to-Head Comparison of IMM-1-104 Against Binimetinib +/- Encorafenib Using a A375 Xenograft Tumor Model: Tumor Volume</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_imm1bin4c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_imm1bin4c.jpg]" height="341" width="608" >
        </div>
        <div style="margin-top:18.69pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Preclinical Studies: 3D Tumor Growth Models</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">3D tumor growth models mimic the tumor microenvironment, or TME, more closely than 2D models, and we believe the 3D model more accurately reflects human tumor biology and complexity when evaluating pharmacological data of MAPK pathway inhibition </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;">. We established several dozen humanized 3D&#160;tumor models that display mutations in the RAS isoforms, amongst other mutated MAPK pathway targets, including BRAF, CRAF and ERK, to evaluate their sensitivities to IMM-1-104. In general, we observed that tumor models with KRAS or NRAS mutations and certain molecular profiles were most sensitive to IMM-1-104, followed closely by tumor models with BRAF mutations. For example, the IC</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:0.15pt;">50</font><font style="letter-spacing:0.2pt;"> of IMM-1-104 ranged from 68.7 nM in NRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">Q61K</font><font style="letter-spacing:0.2pt;"> to 214.7 nM in NRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12D</font><font style="letter-spacing:0.2pt;">, whereas the IC</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:0.15pt;">50</font><font style="letter-spacing:0.2pt;"> of IMM-1-104 ranged from 814.7&#160;nM to greater than 10,000 nM in BRAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">V600E</font><font style="letter-spacing:0.2pt;"> and certain RAS mutants, respectively. More specifically, our 3D tumor modeling data suggested that KRAS mutant pancreatic cancer and NRAS mutant melanoma may be particularly sensitive to IMM-1-104. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">To further examine the translational opportunity in KRAS mutant pancreatic cancer and NRAS mutant melanoma, we evaluated several of these cancer mutations utilizing real-world data through a pan-cancer registry, the Genomics Evidence Neoplasia Information Exchange, or GENIE. The total number of patients in the analysis are depicted below in blue and the&#160;percentage of patients with a known mutation in KRAS or NRAS are shown as a&#160;percentage of the total patients (depicted below in black). Biomarker sensitive profiles (depicted below in green) and biomarker resistant profiles (depicted below in red) are projected subsets of patients with mutated KRAS or NRAS that may be sensitive or resistant to IMM-1-104. We observed that the overwhelming majority of pancreatic cancers associated with KRAS mutations (i.e., 92%) and melanoma associated with NRAS mutations (i.e., 73%) are found to harbor a biomarker profile that may be sensitive to IMM-1-104 (as depicted below). </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">107</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:84.65pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Translational Profiling for KRAS Mutant Pancreatic Cancer and NRAS Mutant Melanoma Utilizing a Pan-Cancer Registry, GENIE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_kras4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_kras4clr.jpg]" height="264" width="547" >
        </div>
        <div style="position:relative;margin-top:11.19pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_nras4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_nras4clr.jpg]" height="260" width="548" >
        </div>
        <div style="margin-top:14.69pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In a further </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> study based on humanized 3D tumor model data, we evaluated the activity and tolerability of IMM-1-104 head-to-head against AMG-510 and gemcitabine alone, and IMM-1-104 in combination with AMG-510, for 21&#160;days in the KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12C</font><font style="letter-spacing:0.2pt;"> mutant tumor model (i.e., MIA PaCa-2). In a previous study conducted by a third-party, AMG-510 demonstrated sensitivity to this pancreatic tumor model. Comparing IMM-1-104 alone, against AMG-510 and in combination with AMG-510, we observed tumor regressions with insignificant BWL (i.e., within 3% of baseline), which we believe indicates activity, durability and tolerability of IMM-1-104 against a KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12C</font><font style="letter-spacing:0.2pt;"> mutant pancreatic cancer model (as depicted below). </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">108</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:4.39999999999998pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Head-to-Head Comparison of IMM-1-104 +/- AMG-510 and Gemcitabine Using a MIA PaCa-2 Xenograft Tumor Model: Tumor Volume</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_amgimm4c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_amgimm4c.jpg]" height="352" width="547" >
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_imm1044c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_imm1044c.jpg]" height="397" width="547" >
        </div>
        <div style="margin-top:5pt; text-align:justify; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">109</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Clinical Development Overview: IMM-1-104</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">IMM-1-104 is currently undergoing IND-enabling studies. We plan to submit an IND for IMM-1-104 to the FDA by&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. We continue to expand our preclinical pharmacology models, including research to further understand sensitivity and resistance biomarkers related to IMM-1-104. We also plan to conduct 28-day good laboratory practices, or GLP, orally dosed safety and toxicology studies in rats and dogs, and also plan to perform PK studies in non-human primates prior to initiating our Phase&#160;1 clinical trial of IMM-1-104. We intend to initiate our first-in-human Phase&#160;1 clinical trial of IMM-1-104 for the treatment of advanced solid tumors in patients harboring RAS mutant tumors if our IND for IMM-1-104 is accepted. The Phase&#160;1 clinical trial of IMM-1-104 is being designed to primarily evaluate its safety and tolerability, and to also identify dose-limiting toxicities. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our clinical development plan for IMM-1-104 will initially focus on indications selected by our translational data. Additional indications will be based on future preclinical studies and clinical trial outcomes. Our goal is to further expand the development of IMM-1-104 in indications, including a broad range of RAS and/or RAF mutant tumors. In addition, we plan to evaluate IMM-1-104 in combination with FDA-approved MAPK pathway inhibitors to treat certain cancers in the future. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MEK-io Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are developing innovative allosteric MEK inhibitors to be administered in combination with select immune modulators (e.g., checkpoint inhibitors) for the treatment of &#8220;cold&#8221; solid tumors. We believe our investigational MEK-io program inhibitors target MEK in a way that disrupts the MAPK pathway at ERK and also reduces baseline MEK activation. We are designing these inhibitors with unique PK and PD profiles that enhance cycle inhibition time of MEK and ERK to optimize the patient&#8217;s immune response and promote maximal antitumor responses when administered in combination with select immune modulators. KRAS mutant tumors impact approximately 15% of patients globally and include cold or &#8220;non-inflamed&#8221; tumors. Cold tumors are immunologically inaccessible, meaning the patient&#8217;s immune system cannot provide an appropriate antitumor response because the lack of T-cell infiltration in the tumor, which is required for the immune system (i.e., T-cells) to find, target and attack the tumor. Checkpoint inhibitors work by helping to reactivate and enhance the patient&#8217;s immune system by allowing T-cells to better provide an appropriate antitumor response. If a cold tumor were to become &#8220;hot&#8221; or &#8220;inflamed,&#8221; this would create an inflammatory process enabling T-cells to infiltrate the tumor and allow them to recognize and attack the tumor (i.e., an antitumor response). We believe our investigational MEK-io program inhibitors have the potential to turn a cold tumor hot, and when administered in combination with a checkpoint inhibitor, could provide an innovative approach to treat patients with cold solid tumors by providing MEK/ERK inhibition and optimizing antitumor response, which would not typically be seen in these patients. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We observed an initial </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> proof-of-concept for our MEK-io program in a widely utilized syngeneic murine model where we observed synergistic antitumor activity in combination with a checkpoint inhibitor. Our MEK-io program is currently in the lead optimization stage of development and we are screening multiple advanced drug analogues for optimal PK and PD profiles that maximally modulate antitumor responses through cyclic inhibition of MEK and ERK. Top candidates will be further evaluated </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> for drug-like properties that demonstrate synergistic therapeutic activity when combined with select immune modulators in preclinical cold solid tumor models. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Trifecta-MEK Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are developing potentially first-in-class therapies that are designed to uniquely engage MEK and inhibit the upstream activation events of MEK and the downstream activation events of ERK in MEK itself, for the treatment of solid tumors. We believe the inhibition of upstream and downstream activation events of MEK and ERK bypass MAPK pathway reactivation events (i.e., drug resistance). Our investigational Trifecta-MEK program inhibitors are designed to be differentiated from IMM-1-104 due to their potential novel allosteric inhibition of MEK and KSR disruption, along with their unique PK approach. The potential dosing intervals of our investigational Trifecta-MEK program inhibitors may broaden the application of these inhibitors to metabolically diverse RAS and RAF mutant tumors. We are designing our investigational Trifecta-MEK program inhibitors to be administered as monotherapy to provide potentially better alternatives to combination therapies inhibiting MEK and RAF in BRAF mutant tumors. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">110</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have evaluated one of our investigational Trifecta-MEK program inhibitors head-to-head against binimetinib and encorafenib in a cell-based potency study to observe comparisons in the reduction of activated MEK and ERK in KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12S</font><font style="letter-spacing:0.2pt;"> and BRAF</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">V600E</font><font style="letter-spacing:0.2pt;"> mutant tumor models. In the KRAS mutant tumor model, our investigational Trifecta-MEK program inhibitor provided greater inhibition of activated MEK and ERK as compared to binimetinib and encorafenib (as depicted below). In the BRAF mutant tumor model, our investigational Trifecta-MEK program inhibitor displayed greater inhibition of activated MEK and ERK as compared to binimetinib, and greater activated ERK inhibition as compared to encorafenib (as depicted below). Our Trifecta-MEK program is currently in the drug discovery stage of development. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Head-to-Head Comparison of One of Our Investigational Trifecta-MEK Program Inhibitors Against Encorafenib and Binimetinib Using A549 and A375 Xenograft Tumor Models</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:13.7pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-tbl_a549tum4c.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_a549tum4c.jpg]" height="180" width="559" >
        </div>
        <div style="position:relative;margin-top:13.7pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-tbl_a375tum4c.jpg" alt="[MISSING IMAGE: tm2115679d1-tbl_a375tum4c.jpg]" height="234" width="547" >
        </div>
        <div style="margin-top:16.4pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">KRAS4B Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are developing mutation agnostic KRAS4B inhibitors that are designed to bind to a unique, undisclosed site on KRAS4B for the treatment of solid tumors. We believe our investigational KRAS4B inhibitors have the potential to disrupt RAS nanocluster biology and prevent MAPK signaling in patients with KRAS mutant tumors, which represent approximately 15% of all cancer patients. Although drugs in this class have begun targeting RAS mutations, such as KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12C</font><font style="letter-spacing:0.2pt;">, we believe a majority of KRAS mutations, which we are designing our KRAS4B inhibitors to target, will remain unaddressed. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> tumor model, we observed a half maximal tumor inhibitor concentration, or IC</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:0.15pt;">50</font><font style="letter-spacing:0.2pt;">, of 1&#160;&#956;M for one of our investigational KRAS4B inhibitors. A low IC</font><font style=" position:relative; bottom:-2.25pt;font-size:7.5pt;letter-spacing:0.15pt;">50</font><font style="letter-spacing:0.2pt;"> value means that a drug is effective at low concentrations and may provide lower systemic toxicity when administered to the patient because of the low concentration required to generate therapeutic activity. Based on this tumor model, we believe our investigational KRAS inhibitors may achieve KRAS4B inhibition when administered at low concentrations, providing a potentially improved tolerability profile as compared to other FDA-approved MAPK pathway inhibitors. Our KRAS4B program is currently in the drug discovery stage of development. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">111</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">RAS Induction Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are developing RAS inducers that are designed to hyperactivate the MAPK pathway to potentially induce tumor cell death. Our RAS inducers are designed to be agnostic to known activating mutations of any oncogene of the MAPK pathway, providing the potential clinical opportunity to effectively treat any patient with an activated MAPK pathway, which represents over 50% of all cancer patients globally. A recent study validated this novel pharmacological approach by demonstrating that the hyperactivation of the MAPK pathway in tumor cells that express mutant RAS or RAF are intolerant to further increases in activity at the level of ERK and induce tumor cell death. This approach was further validated by clinical observations of secondary tumor reductions in some patients when targeted agents that inhibit the MAPK pathway were discontinued. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> KRAS mutant tumor model, we observed cell-based induction of the MAPK pathway at activated ERK of 844% when administering 30 &#956;M of one of our RAS inducers. Additional </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> modeling is required to validate this pharmacologic strategy, but we believe that, if successful, short pulsatile target induction will be critical. Our RAS induction, or RASi, program is currently in the drug discovery stage of development. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Covalent-MEK Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are developing irreversible allosteric inhibitors of MEK by attacking one of three critical amino acids lying adjacent to the binding pocket. We believe the covalent, or irreversible inhibition, fully disrupts MEK enzymatic activity completely avoiding any potential drug resistance from MAPK pathway reactivation events. Covalent-MEK&#8217;s novel pharmacological approach provides scaled attenuation of the MAPK pathway disruption that is anchored to the half-life of MEK itself, which has been reported to be approximately 12 to 14 hours. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our Covalent-MEK program is in the drug discovery stage of development and builds on our dynamic portfolio of novel and mechanistically distinct MEK inhibitors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PI3K-alpha Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We are developing allosteric PI3K&alpha; inhibitors designed to target PI3K&alpha; agnostically in common mutations and further disrupt upstream activation events of the mTOR pathway. Similar to IMM-1-104, we intend to design our PI3K&alpha; inhibitors with a short plasma half-life to potentially normalize tumor signaling dynamics while retaining healthy normal cells. While still in the early drug discovery stage of development, we envision our PI3K-alpha program will be able to address significant unmet clinical needs in certain subsets of cancer, as well as reaching a broader patient population in combination with one or more of our MEK or RAS drug programs, where the mTOR pathway may synergistically work in tandem with MAPK pathway inhibition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Neuroscience Programs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition to our extensive oncology pipeline, we are also leveraging our platform to build a neuroscience pipeline initially focusing on AD. Our neuroscience programs are in the early stages of drug discovery, and we are evaluating undisclosed targets to pursue a unique approach to treating AD. We believe by treating AD-related neuroinflammation, rather than treating amyloid beta protein, or &beta;-amyloid, and hyperphosphorylated tau deposition in the brain, we may be able to slow the progression of AD. We believe our platform and expertise in neurology and neuroscience has allowed us to determine biological differences in AD patients to help develop novel product candidates that have the potential to address the significant unmet needs of this underserved patient population. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Alzheimer&#8217;s Disease Overview</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">AD is a neurodegenerative disorder of uncertain cause and pathogenesis and is the most common form of dementia. AD is characterized by memory impairment and further cognitive decline that can ultimately affect the patient&#8217;s behavior, speech, visuospatial orientation and motor system. AD is a complex multifactorial disease driven by genetic and environmental causes that affects older adults and is one of the leading sources of morbidity and mortality in the aging population. Established risk factors for AD include age, family history </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">112</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of dementia, rare dominantly inherited mutations in genes that impact &beta;-amyloid in the brain (as described below) and apolipoprotein E epsilon 4 allele (as described below). The disease is most often categorized into three different groups: early-onset AD, late-onset AD and familial AD. Late-onset AD, also referred to as sporadic AD, is the most common form of the disease representing approximately 90% of the patients, and is classified in patients who present with symptoms at older ages (i.e., &ge; 65&#160;years), while early-onset AD is classified in patients who present with symptoms at younger ages (i.e., &lt; 65&#160;years). Familial AD is an inherited form of AD (i.e., genetic) and patients with early-onset AD most often have some inherited form of the disease. In contrast, sporadic AD most often involves common and rare genetic risk factors, as well as environmental factors. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Available data supports a worldwide prevalence of AD of approximately 35&#160;million people, or approximately 6&#160;million people in the United States. The prevalence of AD is known to increase exponentially with age, essentially doubling every 5&#160;years after the age of 65. Diagnosis of AD is typically only considered after symptoms manifest and while the diagnosis of AD can be based on clinical criteria or detection of certain biomarkers, such as &beta;-amyloid and tau, a postmortem histopathologic examination is required to confirm the diagnosis. Recent emerging evidence supports that neurological changes may occur&#160;years before patients start to experience early clinical manifestations of AD, which is most often memory impairment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations of Current Targeted Therapies for Alzheimer&#8217;s Disease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since 2003, no new treatments for AD have been approved by the FDA, representing a significant unmet medical need. Despite clinical trials of numerous agents over a wide range of mechanisms, including small molecule inhibitors and monoclonal antibodies developed to treat tau and &beta;-amyloid deposition, respectively, no disease-modifying treatments have been successfully developed. There are currently only five FDA-approved treatments for AD, and these treatments are widely considered to only briefly and modestly improve AD symptoms, ultimately failing to prevent or slow disease progression. Without a disease-modifying treatment, many AD patients require daily supportive care from their families or other caregivers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pathogenesis of Alzheimer&#8217;s Disease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">While the pathogenesis of AD remains unclear, the genetic basis for early-onset and familial AD is understood most clearly. Most AD patients appear to have an overproduction and/or decreased clearance of &beta;-amyloid, which is neurotoxic. This explanation of AD is otherwise known as the &#8220;amyloid hypothesis.&#8221; &beta;-amyloid is produced by the cleavage of a protein translated from the amyloid precursor protein gene, or </font><font style="font-style:italic;letter-spacing:0.2pt;">APP</font><font style="letter-spacing:0.2pt;">, and cleaved by &alpha;-secretase, &beta;-secretase, and &#947;-secretase. Presenilin is a sub-component of &#947;-secretase and is partially responsible for cleaving </font><font style="font-style:italic;letter-spacing:0.2pt;">APP</font><font style="letter-spacing:0.2pt;">. Mutations in presenilin 1 gene, or </font><font style="font-style:italic;letter-spacing:0.2pt;">PSEN1</font><font style="letter-spacing:0.2pt;">, or presenilin 2, or </font><font style="font-style:italic;letter-spacing:0.2pt;">PSEN2</font><font style="letter-spacing:0.2pt;">, and </font><font style="font-style:italic;letter-spacing:0.2pt;">APP</font><font style="letter-spacing:0.2pt;"> result in overproduction of &beta;-amyloid and are known to cause familial AD in greater than 95% of patients. In addition, the pathogenesis of AD is believed to involve a second protein, tau. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Tau plays a role in stabilizing the biological mechanisms required for facilitating neuronal activity and communication. In patients suffering from AD, observations have shown that tau accumulates and causes neurotoxicity as a result of its hyperphosphorylation. In addition, transmission of pathologic forms of tau between neurons has been proposed to account for the spread of AD in the brain. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are several other important and potentially overlapping pathways that are considered to be involved in AD. For example, the strongest association of sporadic AD involves human apolipoprotein E gene, or </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE</font><font style="letter-spacing:0.2pt;">. </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE</font><font style="letter-spacing:0.2pt;"> is involved in multiple cellular processes, including cholesterol transport and immune regulation, amongst others. </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE</font><font style="letter-spacing:0.2pt;"> is known to have three alleles, including epsilon 4, or </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE4</font><font style="letter-spacing:0.2pt;">. Carriers of one </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE4</font><font style="letter-spacing:0.2pt;"> are two to three times more likely to develop AD as compared to noncarriers, and those with two </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE4</font><font style="letter-spacing:0.2pt;"> are at approximately 8 to 12 times more likely to develop AD. Despite </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE4</font><font style="letter-spacing:0.2pt;">&#8217;s strong link to sporadic AD, some carriers of </font><font style="font-style:italic;letter-spacing:0.2pt;">APOE4</font><font style="letter-spacing:0.2pt;"> never develop any cognitive decline. Unlike familial and early-onset AD, the genetic basis for sporadic AD is complex and poorly understood, and often involves environmental factors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pathology of Alzheimer&#8217;s Disease</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The hallmark neuropathologic changes of AD are diffuse and neuritic plaques, marked by extracellular &beta;-amyloid deposition and neurofibrillary tangles, comprised of the intracellular accumulation of hyperphosphorylated tau (as depicted below). The pathology of AD is characterized by the widespread death </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">113</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">of neurons in the brain and follows a destructive trajectory starting at the hippocampus, which is responsible for learning and memory. As AD progresses, the pathology gradually spreads to other important regions of the brain further causing cognitive decline. Among AD patients, the levels of brain atrophy vary and the underlying cause of this is unknown. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthy Brain Compared to an AD Patient&#8217;s Brain with &beta;-Amyloid and Tau Deposition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-fc_brain4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_brain4clr.jpg]" height="229" width="546" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Heterogeneity Among Alzheimer&#8217;s Disease Patients</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A growing body of evidence suggests that AD is a heterogeneous group of diseases, which may partially explain the lack of consistent clinical data, including clinical trials. The cardinal symptoms of AD are cognitive impairment, including memory impairment, loss of executive function, impaired judgement and problem solving, behavioral and psychological problems, and visuospatial impairment. While nearly all AD patients struggle with cognitive decline, there is no prescribed pattern or progression of symptoms. For example, some AD patients have significant &beta;-amyloid and hyperphosphorylated tau deposition, but experience little or no cognitive impairment. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The pattern of memory impairment in patients suffering from AD is distinctive. Memory of events occurring at particular time and place is often profoundly affected in these patients. These memory deficits develop insidiously and progress slowly over time, evolving to include deficits of semantic memory (i.e., general knowledge accumulated throughout life) and immediate recall. Impairments of procedural memory (i.e., how to perform certain actions and skills) appear only in the late stages of AD. In addition, behavioral and psychologic symptoms become more common in the middle to late course of the disease. These can begin with relatively subtle symptoms including apathy, social disengagement and irritability. However, emergence of behavioral disturbances such as agitation, aggression, wandering and psychosis are seen as well. Approximately&#160;11% of AD patients suffer from some form of psychosis and at least 75% of AD patients deal with agitation, aggression and wandering. Although the signs and symptoms of AD are understood, the underlying cause of the disease, including progression of certain aspects of the disease, still remain unknown and provide an opportunity for the development of disease-modifying treatments that would address significant unmet needs in the underserved AD patient population. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Approach to Alzheimer&#8217;s Disease</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe there are specific subgroups of AD that can be stratified through gene expression and brain pathology. To identify AD subgroups, we have leveraged our platform to employ a patient-centric, data-driven approach through: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Patient Data</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Categorizing and quality controlling postmortem patient data available from multiple public repositories. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Patient Stratification</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Using a combination of different types of data, such as brain pathology and gene expression, to stratify patients into certain groups. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">114</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:32.3pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Our Expertise</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Leveraging our computational biology expertise to develop machine learning algorithms to detect patterns across biological data and find subgroups based on distinct patterns. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our approach to stratify AD patients based off specific subgroups and discover therapies that may benefit these patients is depicted in the image below. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">AD Patient Subgroup Stratification and Application of Our Drug Discovery Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:10pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-fc_recursi4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_recursi4clr.jpg]" height="172" width="546" >
        </div>
        <div style="margin-top:13pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe our platform and expertise in neurology and neuroscience has allowed us to determine biological differences in AD patients to help develop novel product candidates that have the potential to address the significant unmet needs of this underserved patient population. Through postmortem patient data, we have determined multiple subgroups of AD with varying degrees of neuropathology and cognitive deficiencies, differences in brain gene expression irrespective of &beta;-amyloid or tau deposition, and inclusion or lack of high-levels of gene expression resulting in neuroinflammation of the brain. We categorize the subgroup of patients with high-levels of gene expression resulting in neuroinflammation of the brain as &#8220;Type I AD.&#8221; </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Through our next-generation approach for AD drug discovery (as depicted above), we have been able to develop a streamlined strategy for identifying novel product candidates by utilizing the following elements of our platform: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Novel Biology</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Leveraging DCT to identify robust novel targets using gene expression signatures from each AD subgroup. Characterizing mechanisms of action in central nervous system, or CNS, cell types for target assessment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Novel Chemistry</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Employing our Fluency technology to accelerate the identification of small molecules that selectively bind to a target of interest. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proprietary Translational Planning.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Utilizing the AD subgroup data that we have generated to select ideal preclinical models to improve clinical translation, including AD subgroup-specific induced pluripotent stem cell, or iPSC, lines, and defined existing and novel biomarkers specific to these patients. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">By leveraging our data-driven discoveries, we believe we have a unique advantage to develop a targeted strategy for patient selection and to increase response rates by treating the underlying biology of the AD subgroups. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Neuroscience Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our current neuroscience programs are dedicated to providing treatments for patients classified in a specific AD subgroup for which there are significant unmet needs and underserved patient populations. Our neuroscience programs are currently in the early stages of drug discovery and we are focused on advancing these programs into lead optimization. The following table summarizes our neuroscience pipeline: </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">115</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="position:relative;margin-top:8pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-fc_neurosc4c.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_neurosc4c.jpg]" height="160" width="601" >
        </div>
        <div style="margin-top:16.8pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Neuroscience Programs&#8212;Rationale for Treating Neuroinflammation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe treating neuroinflammation in Type I AD patients will slow the progression of the disease. Previous academic studies have shown that neuroinflammation is a possible cause of AD pathology. In addition, other studies have determined that neuroinflammation is an early AD event that precedes &beta;-amyloid and/or tau deposition in AD patients, and is necessary for AD patients to progress from mild cognitive symptoms to more severe cognitive impairment leading to diagnosis of AD. In a meta-analysis review of peripheral inflammatory markers in AD, an academic group reviewed 175 studies that enrolled over 26,000 patients and observed that AD patients have elevated inflammatory markers, including IL-1&beta; and IL-6. In another study, IL-1&beta; was associated with a faster rate of decline on executive functioning in older adults and IL-6 was associated with a faster decline of verbal memory. These observations are in agreement with our studies that identified subgroups of AD patients with elevated levels of neuroinflammatory gene expression. Collectively, through our own research and publicly available literature, we believe that treating neuroinflammation earlier in Type&#160;I AD patients may be able to slow the progression of the disease in these patients. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Solution: IMM-ALL-01</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are developing small molecule inhibitors against an undisclosed target, or AO.01, for our IMM-ALL-01 program, which is currently in early stages of discovery. We believe that inhibition of AO.01 will decrease AD-related neuroinflammation by reducing the activation of microglia. Microglia are innate immune cells that have been observed to significantly increase AD-related neuroinflammation. Our preclinical studies in cultured microglia have demonstrated that 50 &#181;M treatment with our AO.01 inhibitors decrease the release of IL-6 (as depicted in figure B below), an inflammatory marker that drives AD-related neuroinflammation, while promoting anti-inflammatory IL-10 expression (as depicted in figure A below). </font>
        </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">In Vitro</font><font style="letter-spacing:0.2pt;"> </font><font style="font-weight:bold;letter-spacing:-0.2pt;">Observation of AO.01 Inhibitors Decreasing the Release of IL-6 and Promoting IL-10 Expression</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:14pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-bc_vitro4c.jpg" alt="[MISSING IMAGE: tm2115679d1-bc_vitro4c.jpg]" height="241" width="546" >
        </div>
        <div style="margin-top:13pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">DCT revealed AO.01 as a target involved in AD-related neuroinflammatory mechanisms dysregulated in the brains of Type I AD patients. Through our bioinformatics analysis of independent study data, we observed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">116</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">that gene expression of AO.01 is significantly increased in activated microglia. In our </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> studies, knockdown of AO.01 gene expression suppressed the neuroinflammatory behavior of primary microglia. Our RNAseq analysis of our internal microglia experiment confirmed reduced expression of neuroinflammatory pathway genes after AO.01 knockdown. Based on these studies, we observed that knockdown of AO.01 directly correlates with a decrease in neuroinflammatory markers. We further observed that knockdown of AO.01 gene expression decreased neuronal hyperphosphorylated tau deposition in a tau cell model. We believe this suggests that AO.01 inhibition may block multiple independent AD-related neuroinflammatory pathways by inhibiting and/or suppressing the release of neuroinflammatory markers, including IL-6, and decreasing tau deposition. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We plan to improve the </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> potency of our AO.01 inhibitors by focusing on a resolved catalytic pocket of AO.01 to further reduce the proinflammatory activity of microglia. While our preliminary studies demonstrate high cell permeability for our current AO.01 inhibitors, we plan to focus on optimizing blood brain barrier penetrance during lead optimization to provide desirable activity in the brain. Our goal is to increase translatability by exploring the effect of our AO.01 inhibitors on inflammation in human microglia derived from acquired iPSC lines of Type I AD patients. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Solution: IMM-ALL-03</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are developing small molecule inhibitors against an undisclosed target, or AO.03, for our IMM-ALL-03 program, which is currently in the early stages of discovery. We leveraged Fluency to identify and rank initial hits against the AO.03 protein and screened a subset of hits with drug-like properties through a cell-free assay. The screening assays confirmed several Fluency hits from different chemical classes to AO.03, and subsequent modification of our AO.03 hits significantly improved inhibition of AO.03&#8217;s activity (as depicted in figure A below). Our preclinical studies in activated microglia have demonstrated that 10 and 50 &#181;M treatment with our AO.03 inhibitors decrease the release of IL-6 (as depicted in figure B below). In addition, in our preliminary studies, we have observed high cell permeability for our current AO.03 inhibitors. We plan to optimize blood brain barrier penetrance during lead optimization to provide desirable activity in the brain. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fluency Platform Identifies Small Molecules Designed to Inhibit AO.03 and In Vitro Observation of AO.03 Inhibitors Decreasing the Release of IL-6</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:14pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-bc_fluency4c.jpg" alt="[MISSING IMAGE: tm2115679d1-bc_fluency4c.jpg]" height="239" width="546" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Biological Relevance of AO.03</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Through our platform, we have discovered that AO.03 is a target that is involved in aberrant inflammatory pathways in Type I AD pathogenesis, and that reduced AO.03 gene expression corrects the expression of genes related to Type I AD biology. In our </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> studies, we observed that stimulation of microglia into a proinflammatory state triggered significant increases in AO.03 gene expression, whereas reduction of AO.03 gene expression had a causative effect in converting microglial behavior from a proinflammatory state to an anti-inflammatory state. Similar to AO.01, we also observed that lower AO.03 gene expression blocked </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">117</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">neuronal tau deposition in a tau cell model, including phosphorylation of tau at a protein site called Threonine&#160;181, or p181 (as depicted below). Based upon literature, there is strong evidence that p181 phosphorylation occurs early in AD progression and is positively correlated to the age of onset, suggesting early prevention of p181 phosphorylation may significantly delay AD symptoms. While </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> analysis of stimulated microglia after AO.03 and AO.01 knockdown revealed non-identical, overlapping changes in cytokine release, RNAseq analyses have revealed that the targeted pathways of AO.03 and AO.01 are different. Concretely, reduction of AO.01 gene expression reduced expression of signaling genes for oxidation phosphorylation and the pentose phosphate pathway, whereas reduction of AO.03 gene caused a reduction of genes widely known to be involved in neuroinflammatory pathways in AD, including the IL-6 and toll-like receptor signaling pathways (as depicted below). We believe this represents unique opportunities for regulating several neuroinflammatory pathways in Type I AD patients. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">The Biological Effect of Reducing AO.03 Gene Expression on Inflammation and Tau Deposition, and Pathway Analysis of AO.01 versus AO.03</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:14pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-bc_micro4c.jpg" alt="[MISSING IMAGE: tm2115679d1-bc_micro4c.jpg]" height="265" width="546" >
        </div>
        <div style="margin-top:17pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Platform</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Consistent with our approach of weaving bioinformatics and computational biology into every stage of the drug development process, we have developed a proprietary disease-agnostic platform that allows us to leverage human biological data in new and creative ways providing counterintuitive insights that are not constrained by the inherent limitations of conventional approaches or prevailing scientific views. We are developing novel therapies that aim to optimize both safety and efficacy for diseases with high unmet medical needs and suboptimal treatment options. Key elements of our platform include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Insights from Human Data.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Compare distinct groups of individuals who differ in a certain aspect of disease or response to a particular therapy, or identify new patient subsets. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Novel Biology.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Identify novel targets and new ways to drug existing targets using DCT and/or our insights into mechanisms of response. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Novel Chemistry.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Rapidly identify small molecules that selectively bind to a target of interest using our proprietary Fluency technology, and/or engineer PK to achieve optimal signaling dynamics. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Proprietary Translational Planning.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Use humanized preclinical models and bioinformatics to prioritize indications and identify sensitive subpopulations. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Underlying each of these elements is our rigorous quality control and ability to analyze complex biological datasets. We are one of the few biopharmaceutical companies that has been involved in defining best practices for robustly analyzing bioinformatics data, as evidenced by co-authorship on journal articles together with regulators as well as writing invited reviews to educate the scientific community on this topic. This attention to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">118</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">rigorous quality control pervades all of our analyses, and we believe this enables us to extract meaningful information from a variety of databases of human data, including GENIE and The Cancer Genome Atlas Program, or TCGA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our platform is not limited to a single aspect or pathology; rather, it is disease-agnostic, which we believe enables us to identify, develop and evaluate product candidates across multiple disease areas simultaneously, with our initial focus in oncology and neuroscience. While we currently have an emphasis on transcriptomic data, our platform is not limited to a single data type and thus we believe it will be able to evolve as new datasets emerge. Our platform enabled the initiation, discovery and development of our lead product candidate, IMM-1-104, and has led us to identify additional product candidates with novel compositions of matter by leveraging our platform and drug discovery process. Moreover, our platform has been applied extensively in successful partnerships with large pharmaceutical and biotechnology companies, and through our internal drug discovery and development. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Insights from Human Data</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our analyses often begin by comparing existing transcriptomic data from two groups of patients (e.g. from those whose tumors have metastasized versus those whose tumors have not) to help elucidate the biological mechanisms underlying a particular aspect of disease which we seek to counteract. As another example, we may analyze existing data from patients with differences in response to an existing therapy, in order to better understand what is happening in responders versus non-responders. We may also analyze existing data from patients with a disease to identify novel subsets of patients. Our platform has enabled us to conduct multiple projects that involve stratifying patients into novel subsets. We associate transcriptomic profiles with each subset, which can then be directly inputted into DCT to identify novel targets specific to a given patient subset. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Novel Biology</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Disease Cancelling Technology</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have developed DCT to identify targets that reverse a disease signal across multiple relevant genes with the potential to yield product candidates with differentiated mechanisms that are less likely to be discovered by traditional drug discovery methods. Additional biologic context is derived from quantifying the extent to which different time points, concentrations and perturbations (e.g., inhibition and overexpression) may cancel a disease signal more effectively than existing drug targets. DCT ranks target perturbations by the extent to which they generate signals that counteract disease-associated gene expression changes observed in patient data. Thus, we believe DCT enables hypothesis-free, data-driven identification of novel targets and new ways to drug existing targets. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">DCT leverages gene expression data derived from human patient samples to identify targets that may rescue abnormal gene expression and restore pathway homeostasis. In addition, DCT identifies biology relevant to attenuating a disease by quantifying the similarity of genome-wide signatures of specific aspects of the disease to signatures of target induced gene expression changes using a mathematical similarity metric. Uniquely, DCT quantifies the per-gene contribution to overall disease amplification or cancellation. An example of a typical analysis begins by running DCT to identify an unwanted, disease-specific gene expression pattern. The ideal input to DCT is focused on a specific aspect of a disease, such as tumors that have metastasized versus those that have not, rather than comparing diseased versus healthy states. DCT identifies target candidates by screening a disease differential expression signature and comparing it to thousands of target gene expression signatures. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">DCT is able to rapidly compare disease state signatures against vast numbers of target signatures. DCT ranks signatures resulting from the modulation of specific targets by the extent to which they oppose disease signatures (as depicted below). Unlike some algorithms or artificial intelligence, or AI, approaches, the results originating from DCT are designed to be interpretable from a computational and biological perspective. This platform uses gene expression from patient datasets and does not rely on literature. Together with the target, DCT provides a specific list of testable genes associated with the target of interest, relevant drug concentrations and temporal dynamic information driving the result. Thus, we believe DCT can identify new targets and readily detect dynamic relevant biology relating to modulating a target in a better way. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">119</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A summary workflow for DCT&#8217;s novel target identification can be described as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Carefully curated and quality controlled human transcriptomic data representing a specific aspect of disease, or Input 1, is input and vectorized for processing (as depicted below). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">A carefully curated and quality controlled library of gene expression signals associated with perturbing specific targets at specific time points and concentrations, or Input 2, is input and vectorized for processing (as depicted below). This library can potentially include clustered regularly interspaced short palindromic repeats, or CRISPR, RNA interference, tool compounds, screening library compounds and existing drugs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">The strength of disease signal cancellation is measured between Input 1 and every target signature in Input 2. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Disease Cancelling Technology Summary Workflow for Target Identification</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:14pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_gene4c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_gene4c.jpg]" height="543" width="525" >
        </div>
        <div style="margin-top:12.99pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A second filtration step selects target candidates for which multiple biological pathways are restored in the proper direction compared to the disease signal. DCT includes a method to compute a per pathway contribution to disease canceling in terms of&#160;percent contribution to overall disease reversal for cases when a specific pathway is particularly relevant. DCT is designed to have many capabilities in addition to identifying novel targets or novel ways to drug existing targets. To enable rapid translation to experimental validation, DCT can suggest ideal concentrations, temporal dynamics and marker genes to monitor. DCT is also capable </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">120</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">of predicting target combinations for a given disease or an ideal target for combination with an existing therapy. For expanded utility, DCT has a graphical user interface that enables our biologists to interact with, sort, modify, query and run results along with producing visualizations of results. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We believe DCT has several advantages over other target identification technologies. The platform uses patient data as a starting point, rather than artificial 2D </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> models. For example, our neuroscience program uses gene expression data from AD patient subsets as an input to DCT. We have presented data at American Association for Cancer Research and other conferences demonstrating how cell lines fail to capture the heterogeneity of patient tumors, and our discovery team&#8217;s experience in the 3D tumor modeling field has also highlighted the limitations of 2D </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> data. Moreover, working closely with several FDA-approved drugs, we have found that transcriptomic data was most frequently and dynamically linked to drug activity. Thus, our core insights are derived from transcriptomic data (RNA), while some of our competitor&#8217;s platforms may focus on sequencing data (DNA), imaging data from phenotypic screens and/or literature. DCT is focused on identifying novel targets or novel ways to modulate existing targets, with the goal of generating novel therapeutics with improved clinical activity. We have not in-licensed external drugs and we do not focus on &#8220;drug repurposing&#8221; activities. Our pipeline is composed of programs with potentially novel pharmacological effects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Biological Mechanisms of Response</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We also identify novel biology by applying translational bioinformatics to analyze the biological mechanisms of response of existing therapies. This may include comparing the transcriptional profiles induced by a drug at different timepoints in order to highlight biological feedback loops that we then seek to counteract. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Novel Chemistry</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Fluency</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We developed Fluency, an easy-to-use AI-based tool, to allow for the rapid screening of large compound libraries for potential binders to a protein target of interest. Fluency can be run with any compound library, including libraries containing millions of compounds. It identifies the most attractive drug candidates within a library by making ranked predictions of binding affinity for all compounds. It also makes predictions about the target binding location for all compounds, which allows us to filter the library for drug candidates that are the most likely to affect a specific region of interest on the desired target. Fluency accelerates our drug development process by allowing us to go from millions of potential compounds down to what Fluency selects as the best hundred drug candidates within a single work day. This allows us to quickly advance only those select candidates to medicinal chemistry and experimental validation (as depicted below), increasing our capital efficiency. Knowledge of the 3D structure of the protein target of interest is not required, which expands the applicability of Fluency to include targets with poorly defined or non-existent 3D structures. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fluency Accelerates Our Drug Discovery</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:13.8pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-fc_compou4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-fc_compou4clr.jpg]" height="234" width="509" >
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">121</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To illustrate both the ease of use, as well as the power of Fluency to identify promising drug candidates, we constructed a test screen of Tukysa&#174; (tucatinib), a recently FDA-approved drug for the treatment of advanced breast cancer in combination with trastuzumab and capecitabine. Tukysa&#174; is a tyrosine kinase inhibitor of human epidermal growth factor receptor 2, or HER2 (also referred to as ERBB2). We created a test compound library by placing Tukysa&#174; in a diverse chemical library of 17.8&#160;million drug-like molecules and evaluated whether or not Fluency could identify it as a promising drug candidate against ERBB2 (depicted in the first panel below). The binding models within Fluency were trained against millions of carefully quality controlled, publicly available binding affinity measurements for compounds against thousands of proteins. However, because Fluency did not see Tukysa&#174; or other molecules highly similar to Tukysa&#174; during training, it did not know whether or not it was a promising candidate before the test screen was run. In our test screens, we input the protein of interest into Fluency, then select a library to screen, and optionally enter the region of interest within the protein (depicted in the second panel below). In the test screen for Tukysa&#174;, we screened the test library against all amino acids within ERBB2. </font>
        </div>
        <div style="margin-top:11.82pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fluency Test Screen Input Example</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:7.11pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-ph_fluen4clr.jpg" alt="[MISSING IMAGE: tm2115679d1-ph_fluen4clr.jpg]" height="182" width="547" >
        </div>
        <div style="margin-top:10.91pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fluency rapidly screened approximately 17.8&#160;million compounds in less than 7 hours and identified Tukysa&#174; as the best binder to ERBB2 along with a number of other potential candidates (as depicted below). Fluency&#8217;s location prediction for this compound points towards the kinase domain of ERBB2 which contains the binding site. Referring back to our drug discovery flow chart depicted above, Tukysa&#174; would have been amongst the hundreds of compounds to go on to medicinal chemistry and experimental validation if we were searching for general ERBB2 binders or if we were searching for potential binders specific to the kinase domain. </font>
        </div>
        <div style="margin-top:11.71pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Fluency Test Screen Output Example</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="position:relative;margin-top:9.63pt; text-align:center; width:456pt;">
          <img src="tm2115679d1-lc_erbb24c.jpg" alt="[MISSING IMAGE: tm2115679d1-lc_erbb24c.jpg]" height="163" width="547" >
        </div>
        <div style="margin-top:10.81pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Fluency has been used to screen for potential drug candidates within our early-stage oncology and neuroscience programs. We have a dedicated team of AI experts who continue to evolve Fluency and are embedded in our end-to-end preclinical drug development processes. We continue to seek new ways to apply our AI expertise to develop novel product candidates and potentially improve the lives of patients. </font>
        </div>
        <div style="margin-top:11.71pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Signaling Dynamics (PK-Driven)</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Transcriptomic data has proven critical to these analyses because it provides an understanding of the extent to which specific genes are expressed at any given time, capturing temporal changes in pathway activation. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">122</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Signaling networks differ between cell types, and we leverage this to modulate targets in such a way that certain cell types will be more impacted than others. Our platform enables us to assess the signaling dynamics of product candidates, which we believe allows us to optimize the chemistry of our product candidate programs to achieve broad therapeutic activity against diseased cells while sparing healthy normal cells. Modulation of these signaling networks impacts cell fate decisions in many cell types, including cancerous cells. Our computational biology expertise enables us to analyze transcriptomic data that closely reflects spatiotemporal dynamics of biological signaling networks. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Proprietary Translational Planning</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Humanized Models</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In oncology, we are deeply experienced in advanced, humanized 3D-based tumor growth models, which based on peer reviewed research by members of our team and others, more accurately predict drug response in animal models, and we believe in patients, compared to standard models. Unlike </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> approaches, the 3D tumor growth models reflect the complexity of tumor biology given their alignment with the TME. Thus, we believe our deep expertise in 3D tumor models enables us to more accurately stratify patients likely to benefit from our potential product candidates. In neuroscience, we similarly seek to use human iPSC based models that more faithfully represent the biology of a heterogeneous patient population than more traditional cell lines. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;letter-spacing:0.2pt;">Prioritize Indications and Identify Sensitive Subpopulations</font><font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;We are able to leverage bioinformatics to analyze genomic data from large patient databases to identify specific indications where the majority of patients have characteristics that align with our more reflective humanized models, and identify biological mechanisms and biomarkers that enable us to identify subpopulations that are more likely to be sensitive based on their similarity to our translational approaches. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Platform and its Role in the IMM-1-104 Program</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our platform played a key role in creating the most important characteristics of our lead product candidate, IMM-1-104. In the early stages of the program, insights from human data were used to identify transcriptional profiles we aimed to counteract. DCT and our analysis of mechanisms of existing drugs led us to identify what we believe to be novel biology, specifically new ways to drug an existing target, to highlight the goal of counteracting a biologic feedback loop. Novel chemistry was generated to counteract the feedback loop, and the PK was tuned to generate optimal signaling dynamics (deep but cyclic interruptions of the pathway) as confirmed for translational profiling. Our proprietary translational planning has involved profiling IMM-1-104 in a large number of 3D models to identify the types of cancer (and biomarkers of subsets when needed) that we believe will have the highest probability of success in the clinic. Together, these insights enabled us to demonstrate in an </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> model that a drug with feedback loop resistance combined with a short half-life was able to move toward </font><font style="font-style:italic;letter-spacing:0.2pt;">in vivo</font><font style="letter-spacing:0.2pt;"> improvements in key efficacy metrics and tolerability through modulation of tumor cell signaling dynamics. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Early in the program, we utilized human data to generate translational profiles specific to cancer patients experiencing cachexia, which causes extreme weight loss and muscle wasting. DCT was then utilized to identify targets and intervention time points, otherwise known as biological perturbations, that could counteract cachexia. Among the highest ranked perturbations were multiple MEK, inhibitors, but only the gene expression profiles induced by these MEK inhibitors at early time points (i.e., at 3 and 6 hours) were ranked highly for cancelling the disease-associated signals according to our technology. In contrast, the gene expression signals induced by MEK inhibitors at a later time point (i.e., at 24 hours) amplified or mimicked the transcriptomic signatures associated with diseases. These findings pointed to the importance of a feedback loop in the MAPK pathway called the CRAF-bypass, which may lead to resistance of MEK inhibition, and highlighted the critical importance of designing IMM-1-104 to potentially counteract the CRAF-bypass. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We next applied our platform&#8217;s ability to characterize mechanisms of response by generating transcriptomic (RNA sequencing) data evaluating the impact of a recently approved MEK inhibitor, selumetinib, relative to vehicle in KRAS</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">G12D</font><font style="letter-spacing:0.2pt;"> tumor bearing BALB/c mice, which are inbred, albino and immunodeficient mice ordinarily used in research models for cancer therapy. The BALB/c mice were orally administered 100 mg/kg of selumetinib twice a day for 18&#160;days. Notably, when we examined a set of genes known to be downstream of ERK and activated by the MAPK pathway, we saw reduced downregulation of the pathway following selumetinib treatment. There was very little difference between the degree of MAPK pathway downregulation </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">123</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">at the 2 hour time point and the 12 hour time point, demonstrating that the inhibition achieved by a typical MEK inhibitor with a non-zero drug trough was both static and limiting in a chronic setting. This focused us on the need to develop IMM-1-104 with novel chemistry, specifically a short half-life to achieve deep cyclic inhibition. Through the medicinal chemistry process, we were able to conduct similar analyses to assess the impact of varying PK profiles on signaling dynamics, and when we conducted the same analysis with IMM-1-104 in the model referenced above, we observed much stronger downregulation at the 2 hour time point followed by a return to baseline at the 12 hour time point. These observed results confirm that we achieved the desired signaling dynamics of cycles of deep inhibition and release of the MAPK pathway. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We are utilizing our platform&#8217;s proprietary translational planning capabilities by evaluating IMM-1-104 in a large panel of 3D tumor models, and then applying our ability to robustly analyze challenging datasets to assess genomic data from the GENIE cohort to prioritize indications for IMM-1-104 and identify biomarkers of response, when needed. We believe this analysis will enable us to identify substantial translational opportunities for additional indications. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Platform and Our Early-Stage Oncology Pipeline</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We utilize Fluency, the novel chemistry element of our platform, to rapidly identify small molecule hits for a targeted region of a protein for many of the earlier stage programs in our oncology pipeline. Fluency is being utilized to accelerate the advancement of our RAS and PI3K-alpha programs. In addition, these earlier stage programs also utilize our platform&#8217;s ability to generate novel biology by characterizing mechanisms of response to address these targets in new ways. In the case of our RAS modulators, this involves targeting the process of RAS dimerization. Finally, we are also leveraging novel chemistry in the form of PK changes with the goal of achieving optimal signaling dynamics and deep cyclic inhibition to maximize therapeutic activity in broad populations while improving tolerability. We plan to evaluate each of our programs in humanized 3D models and leverage bioinformatics to prioritize indications and identify sensitive patient subgroups. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Platform and Our Neuroscience Programs</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our neuroscience programs began with our platform&#8217;s ability to identify insights from human data, specifically by methodically analyzing challenging datasets by assessing the robustness of various publicly available AD datasets. Given the lack of disease-modifying therapies and AD patient heterogeneity, robust analysis of data is a motivating factor to drive our success in this space. We applied our platform&#8217;s capability to stratify patients into previously undiscovered subsets, identifying new subpopulations of AD patients with strikingly different molecular biology and distinct gene expression profiles. We then applied our platform&#8217;s ability to identify novel biology by leveraging DCT to identify and rank novel targets for specific subsets of AD patients. Two of these undisclosed AD targets, AO.01 and AO.03, have been identified </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> and have gone on to become the focus of our two lead neuroscience programs, IMM-ALL-01 and IMM-ALL-03, respectively. Once those targets had been identified and experimentally confirmed, we utilized Fluency to rapidly identify small molecules that are designed to selectively bind to the targets, and such selective binding has since been observed </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;">. We also leveraged our platform&#8217;s capabilities for characterizing mechanisms of response to assess the biological impact of those hits, and we are preparing for proprietary translational planning by using iPSC models to confirm the differences in response we expect to see in specific AD patient subgroups. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Competition</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The pharmaceutical and biotechnology industries are characterized by rapid advancement of novel technologies, significant competition and a strong defense of intellectual property rights. While we believe that our proprietary platform and scientific expertise provides us with competitive advantages, we face competition from multiple sources, including larger and better-funded pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Any product candidates that we successfully develop and commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key factors that would affect our ability to effectively compete with other therapeutics include safety, efficacy, ease of administration, pricing, brand recognition and availability of reimbursement and coverage by third party payors. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">124</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Our Oncology and Neuroscience Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The current FDA-approved treatment options that target MAPK pathway cancers are either MEK inhibitors limited by their high rates of serious drug-related adverse events that result in drug intolerability and drug resistance through MAPK-feedback loops, or KRAS inhibitors limited to patients with specific KRAS mutations. We expect that our oncology programs targeting the MAPK pathway may compete with current FDA-approved therapies or clinical programs targeting KRAS mutant tumors that are being advanced by certain pharmaceutical and biotechnology companies. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">There are currently only five FDA-approved treatments for AD, and these treatments are widely considered to only briefly and modestly improve AD symptoms, ultimately failing to prevent or slow disease progression. We expect that our neuroscience programs that are initially focused on treating neuroinflammation in AD may compete with products or programs being advanced by certain pharmaceutical and biotechnology companies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Government Regulation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Among others, the FDA, U.S. Department of Health and Human Services Office of Inspector General, the Centers for Medicare and Medicaid Services and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the preclinical and clinical development, manufacture, marketing and distribution of drugs such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, packaging, storage, record keeping, approval, sales, commercialization, marketing, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates. Any drug candidates that we develop must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in those foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant aspects of regulation in the European Union, or EU, are addressed in a centralized way, but country-specific regulation remains essential in many respects. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Drug Development Process</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing regulations. The process required by the FDA before a drug may be marketed in the United States generally involves the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with FDA&#8217;s good laboratory practice requirements and other applicable regulations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submission to the FDA of an IND which must become effective before human clinical trials may begin; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">approval by an independent institutional review board, or IRB, or ethics committee at each clinical site before each trial may be initiated; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">submission to the FDA of a New Drug Application, or NDA, after completion of all pivotal trials; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">payment of user fees associated with an NDA; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a determination by the FDA within 60&#160;days of its receipt of an NDA to file the NDA for review; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of an FDA advisory committee review, if applicable; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current good manufacturing practice, or cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity, and of selected clinical investigation sites to assess compliance with GCPs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">125</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">potential FDA audit of the preclinical and/or clinical trial sites that generated the data in support of the NDA, and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to beginning the first clinical trial with a product candidate in the United States, we must submit an IND to the FDA. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for clinical studies. Some preclinical testing may continue even after the IND is submitted. The IND also includes results of animal and in vitro studies assessing the toxicology, PK, pharmacology, and PD characteristics of the product; chemistry, manufacturing, and controls information; and any available human data or literature to support the use of the investigational product. An IND must become effective before human clinical trials may begin. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the proposed clinical trial. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical study. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments. Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the study until completed. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting, under certain timelines, of ongoing clinical studies and clinical study results to public registries, specifically the clinicaltrials.gov website managed by the National Institutes of Health. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Phase&#160;1:&nbsp;&nbsp;&nbsp;The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans, the side effects associated with increasing doses, and, if possible, to gain early evidence on effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.3pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.3pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Phase&#160;2:&nbsp;&nbsp;&nbsp;The product candidate is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages, dose tolerance and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">126</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Phase&#160;3:&nbsp;&nbsp;&nbsp;The product candidate is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval. Generally, two adequate and well-controlled Phase&#160;3 clinical trials are required by the FDA for approval of an NDA. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Post-approval trials, sometimes referred to as Phase&#160;4 studies, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the approved indication. In certain instances, such as with accelerated approval drugs, the FDA may mandate the performance of Phase&#160;4 trials as a condition of approval of an NDA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee. Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval. Specifically, FDA has promulgated regulations governing the acceptance of foreign clinical trials not conducted under an IND, establishing that such studies will be accepted as support for an IND or application for marketing approval if the study was conducted in accordance with GCP, including review and approval by an independent ethics committee, or IEC, and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an on-site inspection if FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical trials, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. If a marketing application is based solely on foreign clinical data, the FDA requires that the foreign data be applicable to the U.S. population and U.S. medical practice; the studies must have been performed by clinical investigators of recognized competence; and the FDA must be able to validate the data through an on-site inspection or other appropriate means, if the FDA deems such an inspection to be necessary. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the development of a new drug, sponsors are given opportunities to meet with the FDA at certain points. These points are generally prior to submission of an IND, at the end of Phase&#160;2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about the data gathered to date, for the FDA to provide advice, and for the sponsor to obtain the FDA&#8217;s feedback on the next phase of development. Sponsors typically use the meetings at the end of the Phase&#160;2 trial to discuss Phase&#160;2 clinical results and present plans for the pivotal Phase&#160;3 clinical trials that they believe will support approval of the new drug. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">127</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or </font><font style="font-style:italic;letter-spacing:0.2pt;">in vitro</font><font style="letter-spacing:0.2pt;"> testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious suspected adverse reaction compared to that listed in the protocol or investigator brochure. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">U.S. Review and Approval Process</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, the results of product development, preclinical and other non-clinical studies and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. Data may come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA. The submission of an NDA is subject to the payment of substantial user fees; a waiver of such fees may be obtained under certain limited circumstances. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product application also includes a non-orphan indication. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to assure and preserve the product&#8217;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten&#160;months from the date of &#8220;filing&#8221; of a standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve&#160;months from the date the NDA is submitted to the FDA because the FDA has approximately two&#160;months to make a &#8220;filing&#8221; decision after it the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60&#160;days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Before approving an NDA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCPs. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase&#160;3 trial or other significant and time-consuming requirements related to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA, addressing </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">128</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If regulatory approval of a product is granted, such approval will be granted for particular indications and may contain limitations on the indicated uses for which such product may be marketed. For example, the FDA may approve the NDA with a Risk Evaluation and Mitigation Strategy, or REMS, to ensure the benefits of the product outweigh its risks. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling or the development of adequate controls and specifications. Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace. The FDA may also require one or more Phase&#160;4 post-market studies and surveillance to further assess and monitor the product&#8217;s safety and effectiveness after commercialization, and may limit further marketing of the product based on the results of these post-marketing studies. In addition, new government requirements, including those resulting from new legislation, may be established, or the FDA&#8217;s policies may change, which could impact the timeline for regulatory approval or otherwise impact ongoing development programs. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration. Under PREA, original NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or the FDA may request a deferral of pediatric clinical trials for some or all of the pediatric subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric clinical trials begin. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Orphan Drug Designation and Exclusivity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition, which is a disease or condition that affects fewer than 200,000 individuals in the United States or, if it affects more than 200,000 individuals in the United States, there is no reasonable expectation that the cost of developing and making a drug product available in the United States for this type of disease or condition will be recovered from sales of the product. Orphan designation must be requested before submitting an NDA. After the FDA grants orphan designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications to market the same drug or biological product for the same indication for seven&#160;years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity (i.e., greater safety, greater efficacy, or a major contribution to patient care) or inability to manufacture the product in sufficient quantities. The designation of such drug also entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. Competitors, however, may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. Orphan exclusivity also could block the approval of one of our products for seven&#160;years if a competitor obtains approval of the same drug as defined by the FDA or if our product candidate is determined to be contained within the competitor&#8217;s product for the same indication or disease, and we are unable to demonstrate that our product is clinically superior to the competitor product. If an orphan designated product receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan exclusivity. In addition, exclusive marketing rights in </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">129</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expedited Development and Review Programs</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA has a number of programs intended to expedite the development or review of products that meet certain criteria. Sponsors may request that FDA allow the use of one or more of these expedited pathways. For example, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The sponsor of a fast track product has opportunities for more frequent interactions with the review team during product development, and the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with priority review designations within six&#160;months of the filing date as compared to ten&#160;months for review of new molecular entity NDAs under its current PDUFA review goals. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, a product may be eligible for accelerated approval. Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. The FDA may withdraw accelerated approval if, among other things, the confirmatory study fails to verify clinical benefit; the applicant fails to perform required confirmatory studies with due diligence; postmarketing use demonstrates that postmarketing restrictions are inadequate to assure safe use; the applicant fails to adhere to agreed-upon postmarketing restrictions; promotional materials are false or misleading; or, other evidence demonstrates that the product is not shown to be safe or effective under its conditions of use. In addition, the FDA currently requires pre-approval of promotional materials as a condition for accelerated approval, which could adversely impact the timing of the commercial launch of the product. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Food and Drug Administration Safety and Innovation Act established a category of drugs referred to as &#8220;breakthrough therapies&#8221; that may be eligible to receive breakthrough therapy designation. A sponsor may seek FDA designation of a product candidate as a &#8220;breakthrough therapy&#8221; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. The designation includes all of the fast track program features, as well as more intensive FDA interaction and guidance. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough therapy, the FDA will work to expedite the development and review of such drug. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">130</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Fast track designation, breakthrough therapy designation, priority review, and accelerated approval do not change the standards for approval, but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Post-Approval Requirements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to record-keeping, reporting of adverse experiences, periodic reporting, product sampling and distribution, and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual program fees for any marketed products. Drug manufacturers and their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">fines, warning letters, or untitled letters; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">clinical holds on clinical studies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of product license approvals; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">product seizure or detention, or refusal to permit the import or export of products; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">consent decrees, corporate integrity agreements, debarment or exclusion from federal healthcare programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">mandated modification of promotional materials and labeling and the issuance of corrective information; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the issuance of safety alerts, Dear Healthcare Provider letters, press releases and other communications containing warnings or other safety information about the product; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">injunctions or the imposition of civil or criminal penalties. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The FDA also may require post-marketing testing, known as Phase&#160;4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among others. Newly discovered or developed </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">131</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">safety or effectiveness data may require changes to a product&#8217;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDA closely regulates the marketing, labeling, advertising and promotion of drug products. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. Failure to comply with these requirements can result in, among other things, adverse publicity, untitled or warning letters, requirements to conduct corrective advertising and potential civil and criminal penalties. Physicians may prescribe, in their independent professional medical judgment, legally available products for uses that are not described in the product&#8217;s labeling and that differ from those tested by us and approved by the FDA. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA does not regulate the behavior of physicians in their choice of treatments. The FDA does, however, restrict manufacturer&#8217;s communications on the subject of off-label use of their products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion. The FDA and other regulatory agencies have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA-approved labeling. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Marketing Exclusivity</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a five-year period of non-patent exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated new drug application, or ANDA, or an NDA submitted under Section&#160;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovative drug or for another indication. However, such an application may be submitted after four&#160;years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The FDCA alternatively provides three&#160;years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to any preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pediatric exclusivity is another type of marketing exclusivity available in the United States. Pediatric exclusivity provides for an additional six&#160;months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The issuance of a written request does not require the sponsor to undertake the described clinical trials. In addition, orphan drug exclusivity, as described above, may offer a seven-year period of marketing exclusivity, except in certain circumstances. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">132</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Healthcare Laws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pharmaceutical companies like us are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which they conduct their business. Such regulation may constrain the financial arrangements and relationships through which we research, develop, and ultimately, sell, market and distribute any products for which we obtain marketing approval. Such laws include, without limitation, federal and state anti-kickback, fraud and abuse, and false claims laws, such as the federal Anti-Kickback Statute and the federal Civil False Claims Act, as well as federal and state data privacy and security laws and regulations, and transparency laws and regulations addressing drug pricing and payments and other transfers of value made by pharmaceutical manufacturers to physicians and other healthcare providers, such as the federal Physician Payment Sunshine Act. Violations of any of such laws or any other governmental regulations that apply may result in significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, the curtailment or restructuring of operations, integrity oversight and reporting obligations to resolve allegations of noncompliance, exclusion from participation in federal and state healthcare programs, such as Medicare and Medicaid, and imprisonment. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Coverage and Reimbursement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Sales of any pharmaceutical product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. In addition, the U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, as a condition of participating in, and having products covered under, certain federal healthcare programs, such as Medicare and Medicaid, we may become subject to federal laws and regulations that require pharmaceutical manufacturers to calculate and report certain price reporting metrics to the government, such as Medicaid Average Manufacturer Price, or AMP, and Best Price, Medicare Average Sales Price, the 340B Ceiling Price, and Non-Federal AMP reported to the Department of Veteran Affairs, and with respect to Medicaid, pay statutory rebates on utilization of manufacturers&#8217; products by Medicaid beneficiaries. Compliance with such laws and regulations will require significant resources and may have a material adverse effect on our revenues. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Healthcare Reform</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the United States, in March&#160;2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, each as amended, collectively known as the ACA, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers, and significantly affected the pharmaceutical industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and changes to fraud and abuse laws. For example, the ACA: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1% of the AMP; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">required collection of rebates for drugs paid by Medicaid managed care organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expanded beneficiary eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain individuals with income at or below 138% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">133</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">expanded the types of entities eligible for the 340B Drug Pricing Program; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">required manufacturers to participate in a coverage gap discount program, under which they must agree to offer 70&#160;percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part&#160;D; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; and biologic agents apportioned among these entities according to their market share in certain federal government programs; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">established the Center for Medicare and Medicaid Innovation within the Centers for Medicare and Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">created the Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">required reporting of certain financial arrangements between manufacturers of drugs, biologics, devices, and medical supplies and physicians and teaching hospitals under the federal Physician Payment Sunshine Act; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to licensed practitioners. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There have been executive, judicial and Congressional challenges to certain aspects of the ACA. The U.S. Supreme Court is currently reviewing the constitutionality of the ACA in its entirety, and is expected to issue its decision in 2021. Although the U.S. Supreme Court has not yet ruled on the constitutionality of the ACA, President Biden issued an executive order to initiate a special enrollment period from February&#160;15, 2021 through August&#160;15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how the Supreme Court ruling, other such litigation and the healthcare reform measures of the Biden administration will impact the ACA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other legislative changes have been proposed and adopted since the ACA was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year, which was temporarily suspended from May&#160;1, 2020 through December&#160;31, 2021 due to the COVID-19 pandemic. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, the American Taxpayer Relief Act of 2021, effective January&#160;1, 2024, would eliminate the statutory cap on rebate amounts owed by drug manufacturers under the Medicaid Drug Rebate Program, or MDRP, which is currently capped at 100% of the AMP for a covered outpatient drug. In the future, there may be additional challenges and/or amendments to the ACA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Moreover, the cost of prescription pharmaceuticals has been the subject of considerable discussion in the United States. Congress has considered and passed legislation, and the former Trump administration pursued several regulatory reforms to further increase transparency around prices and price increases, lower out-of-pocket costs for consumers, and decrease spending on prescription drugs by government programs. Congress has also continued to conduct inquiries into the prescription drug industry&#8217;s pricing practices. While several proposed reform measures will require Congress to pass legislation to become effective, Congress and the new Biden administration have each indicated that it will continue to seek new legislative and/or administrative measures to address prescription drug costs. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. It also possible that governmental action will be taken in response to the COVID-19 pandemic. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">134</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:204pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could impact the amounts that federal and state governments and other third-party payors will pay for healthcare products and services. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Facilities</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Since 2018, our corporate headquarters has been located at 245 Main Street, Second Floor Cambridge, Massachusetts 02142, where we currently occupy approximately 586 square feet of office space under a service agreement that can be terminated by either party upon 30&#160;days written notice. We also occupy approximately 3,657 square feet of office space in San Diego, California, under a lease that terminates on April&#160;30, 2026, and approximately 190 square feet of office space in New York, New York under a service agreement that currently runs through June&#160;30, 2021 and automatically renews unless we provide 30&#160;days advance notice to terminate. As of December&#160;31, 2020, approximately 12 of our employees are located at our corporate headquarters. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Human Capital</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, we have 26 full-time employees, 23 of whom are dedicated to research and development. Twenty three of our employees hold doctorate degrees (i.e., Ph.D. or M.D.). None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that our future success largely depends upon our continued ability to attract and retain highly skilled employees. We provide our employees with competitive salaries and bonuses, opportunities for equity ownership, development programs that enable continued learning and growth and a robust employment package that promotes well-being across all aspects of their lives, including health care, retirement planning and paid time off. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We believe that much of our success is rooted in the diversity of our teams and our commitment to inclusion. We value diversity at all levels and focus on extending our diversity and inclusion initiatives across our entire workforce. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Legal Proceedings</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, we may be subject to legal proceedings and claims in the ordinary course of business. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">135</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MANAGEMENT</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table provides information regarding our executive officers and members of our board of directors (ages as of the date of this prospectus): </font>
        </div>
        <table style="width:456pt;height:158.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:209.38pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:13.25pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Age </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt; width:209.37pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-left:87pt;padding-right:87pt;letter-spacing:-0.16pt;">Position(s) </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:-0.2pt;">Executive Officers</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:209.37pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benjamin J. Zeskind, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">39 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Co-Founder, Chief Executive Officer, Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Biren Amin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">48 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scott Barrett, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">58 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Chief Medical Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brett Hall, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">52 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <font style="letter-spacing:-0.2pt;">Non-Employee Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:13.25pt;text-align:center;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:209.37pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Robert J. Carpenter </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">76 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Co-Founder, Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter Feinberg </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">60 </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laurie B. Keating </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">67</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.38pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Andrew Phillips, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">*</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:13.25pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">50</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:209.37pt;">
              <font style="letter-spacing:0.2pt;">Director</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.79pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.3pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.3pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Dr.&#160;Phillips will resign as a director immediately prior to the effectiveness of the registration statement on Form S-1, of which this prospectus forms a part. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Officers</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Benjamin J. Zeskind, Ph.D</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Zeskind has served as our Co-Founder, Chief Executive Officer and a member of our board of directors since February&#160;2008. Dr.&#160;Zeskind received his S.B. in electrical engineering and computer science and his Ph.D. in bioengineering from Massachusetts Institute of Technology, or MIT, and his M.B.A. from Harvard Business School, where he was recognized as a Baker Scholar, the highest award for distinction. We believe that Dr.&#160;Zeskind is qualified to serve on our board of directors due to his extensive experience in the pharmaceutical industry and in-depth knowledge of our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Biren Amin.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160; Amin has served as our Chief Financial Officer since April&#160;2021. Prior to joining us, Mr.&#160;Amin served as a Managing Director of Jefferies Financial Group Inc., an American financial services company based in New York City, in their Biotechnology Equity Research group, from June&#160;2011 until March&#160;2021. Previously, he spent time at other equity research firms such as WJB Capital Group, Inc., FTN Equity Capital Markets Corporation, Stanford Group Company and Prudential Equity Group, LLC focusing on pharmaceutical and biotechnology company investments. Over approximately two decades, Mr.&#160;Amin built a strong track record on Wall Street covering small and mid-cap pharmaceutical and biotechnology companies focusing on oncology, CNS disorders, ophthalmology and rare diseases. He started his career at Aventis Pharmaceuticals Inc., a former public pharmaceutical company, which merged with Sanofi S.A., where he served as the Senior Manager in their Scientific Competitive Intelligence group. Mr.&#160;Amin received his B.S. in pharmacy from the University of the Sciences in Philadelphia, his M.S. in pharmacy from Long Island University and his M.B.A. from the Stern School of Business at New York University. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Scott Barrett, M.D</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Barrett has served as our Chief Medical Officer since November&#160;2019. Prior to joining us, Dr.&#160;Barrett served as the Executive Director of Global Medical Affairs of Incyte Corp, a publicly traded biopharmaceutical company focused on discovery, development and commercialization of proprietary therapeutics in oncology and other areas of interest, from June&#160;2016 until November&#160;2019. Prior to that, he served as the Senior Director of Clinical Development of Infinity Pharmaceuticals, Inc., a publicly traded biopharmaceutical drug development company, from July&#160;2014 until June&#160;2016. Dr.&#160;Barrett is a trained physician-scientist, accomplished medical oncologist and a drug discovery and development expert with more than 30&#160;years of clinical and research experience. He received his B.A. in natural science from The Johns Hopkins University as a Beneficial-Hodson Scholarship recipient, his M.D. from the University of Miami School of Medicine and completed his internal medicine residency at the Mayo Clinic in Rochester, Minnesota. Dr.&#160;Barrett then went on to complete a fellowship in medical oncology at Memorial Sloan-Kettering Cancer Center and became board-certified in internal medicine and medical oncology. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">136</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Brett Hall, Ph.D</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Hall has served as our Chief Scientific Officer since November&#160;2019. He also serves as the President, Founder and Chairman of the board of directors of Bioarkive, Inc., or Bioarkive, a privately held biotechnology services company, and President and Founder of Trans Medical Sciences, LLC, a privately held consulting company for biotechnology and biopharmaceutical companies. Prior to joining us, Dr.&#160;Hall served as the Chief Executive Officer of Asellus Therapeutics, LLC, a privately held biotechnology company, from July&#160;2015 until May&#160;2018. Dr.&#160;Hall served in roles of increasing responsibility with Johnson &amp; Johnson, a multinational corporation that develops medical devices, pharmaceuticals and consumer packaged goods, from November&#160;2008 until July&#160;2014, culminating in his role as the Head of Biomarkers of the Hematologic Disease Area Stronghold, where he led translational efforts for Sylvant&#174; and Imbruvica&#174; through clinical development. Subsequently, he served as the Head of Translational Medicine of Oncology at Medimmune, LLC, the biologics division of AstraZeneca Pharmaceuticals LP, from July&#160;2014 until July&#160;2015, before transitioning to executive discovery roles in biotechnology. He has extensive drug development and leadership experience ranging from early drug discovery through translational clinical sciences, including multiple drug registrations. Dr.&#160;Hall has extensively published in the areas of TME and translational sciences, and holds multiple patents for drug pharmacology and discovery. He was also a tenure-track Assistant Professor at Ohio State University where his laboratory focused on the development of human TME-aligned models to better translate preclinical data into the clinic and discover novel biomarkers. Prior to Dr.&#160;Hall&#8217;s career in life sciences, he served in the United States Air Force and worked as an investment banker. Dr.&#160;Hall received his B.S. in biochemistry from Ohio State University, his Ph.D. in immunology and cancer biology from West Virginia University and completed his post-doctoral fellowship in cancer cell epigenetics at St. Jude Children&#8217;s Research Hospital. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Benjamin J. Zeskind</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Dr.&#160;Zeskind&#8217;s business background information is set forth under &#8220;Executive Officers&#8221; above. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Robert J. Carpenter</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160;Carpenter has served on our board of directors since May&#160;2009. Mr.&#160;Carpenter also currently serves as the Chairman of Hydra Biosciences, Inc., or Hydra Biosciences, a privately held clinical-stage biopharmaceutical company. From 1992 until 2015, he served as the Chief Executive Officer of Boston Medical Investors, Inc., a venture capital firm. Mr.&#160;Carpenter has founded and served in executive management and board roles at numerous biotechnology companies, including Olaris Inc., Integrated Genetics and GelTex Pharmaceuticals, both of which merged with Genzyme Corporation, and VacTex Corp., which was acquired by Aquila Biopharmaceuticals, Inc. Mr.&#160;Carpenter received his B.S. in engineering from the U.S. Military Academy at West Point, his M.S. in computer science from Stanford University and his M.B.A. from Harvard Business School. We believe that Mr.&#160;Carpenter is qualified to serve on our board of directors due to his extensive leadership skills and experience in the healthcare and biotechnology industries. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Peter Feinberg</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Mr.&#160;Feinberg has served on our board of directors since January&#160;2021. Mr.&#160;Feinberg also currently serves as Partner and was a Founding Member of Boxcar Partners, a venture capital investment firm with a focus on biotechnology investing, and Founder of Sporos Bioventures, Inc. In addition, he currently serves as Co-Founder of BridgeBio Pharma, Inc., a publicly traded biotechnology company focusing on genetic diseases, Boxcar PMJ LP and Emerging Security Solutions. He has more than three decades of experience in the financial services industry at Oppenheimer &amp; Co. Inc. where he served as a Managing Director. Mr.&#160;Feinberg received his B.S. in finance from Whittier College. We believe that Mr.&#160;Feinberg is qualified to serve on our board of directors due to his extensive leadership skills and experience in the financial and biotechnology industries. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Laurie B. Keating</font><font style="font-weight:bold;letter-spacing:-0.2pt;">.</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Ms.&#160;Keating has served on our board of directors since March&#160;2021. Ms.&#160;Keating also currently serves as the Executive Vice President, Chief Legal Officer and Secretary of Alnylam Pharmaceuticals, Inc., since March&#160;2019, and also served as its Senior Vice President, General Counsel and Secretary from September&#160;2014 until March&#160;2019. From September&#160;2004 until January&#160;2014, she served as the Senior Vice President, General Counsel and Secretary of Millennium Pharmaceuticals, Inc., a wholly owned oncology-focused subsidiary of Takeda Pharmaceutical Company Limited since 2008, and was the founding Chief Executive Officer and a member of the board of directors of Hydra Biosciences. Ms.&#160;Keating earned her A.B. in economics from the University of California, Berkeley and her J.D. from the University of California, Hastings College of the Law. We believe that Ms.&#160;Keating is qualified to serve on our board of directors due to her extensive leadership skills and experience in the biotechnology industry. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">137</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-style:italic;font-weight:bold;letter-spacing:-0.2pt;">Andrew Phillips, Ph.D</font><font style="letter-spacing:0.2pt;">.&nbsp;&nbsp;&nbsp;Dr.&#160;Phillips has served on our board of directors since December&#160;2020. Dr.&#160;Phillips also currently serves as a Managing Director at Cormorant Asset Management, LP, and serves as a member of the board of directors of BiVacor, Inc., Elevation Oncology, Inc. and Enliven Therapeutics, Inc. Prior to joining us, he served in various roles, including President, Chief Executive Officer and Chief Scientific Officer of C4 Therapeutics, Inc., from January&#160;2016 until March&#160;2020. Prior to that, Dr.&#160;Phillips served as the Senior Director of the Center for the Development of Therapeutics at the Broad Institute of MIT and Harvard. Earlier in his career, he was a Full Professor of chemistry at Yale University and an Assistant, Associate and Full Professor of chemistry and biochemistry at the University of Colorado. Dr.&#160;Phillips received his B.Sc., with honors, and his Ph.D. in biochemistry and chemistry from the University of Canterbury in Christchurch, New Zealand. We believe that Dr.&#160;Phillips is qualified to serve on our board of directors due to his extensive leadership skills and experience in the pharmaceutical industry. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Family Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">There are no family relationships among any of our directors or executive officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Composition of our Board of Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors currently consists of five directors. Our amended and restated certificate of incorporation and amended and restated bylaws will provide that the number of directors on our board of directors will be fixed from time to time by resolution of the board of directors and that our board of directors will be divided into three classes, as nearly equal in number as possible, with the directors in each class serving for a three-year term, and one class being elected each year by our stockholders. Dr.&#160;Phillips will resign as a director immediately prior to the effectiveness of the registration statement on Form S-1, of which this prospectus forms a part. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">When considering whether directors have the experience, qualifications, attributes or skills, taken as a whole, to enable our board of directors to satisfy its oversight responsibilities effectively in light of our business and structure, the board of directors focuses primarily on each person&#8217;s background and experience as reflected in the information discussed in each of the directors&#8217; individual biographies set forth above. We believe that our directors provide an appropriate mix of experience and skills relevant to the size and nature of our business. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation will provide that our board of directors will be divided into three classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our current directors will be divided among the three classes as follows: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Class&#160;I directors will be &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, and their terms will expire at the annual meeting of stockholders to be held in 2022; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Class&#160;II directors will be &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, and their terms will expire at the annual meeting of stockholders to be held in 2023; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the Class&#160;III directors will be &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, and their terms will expire at the annual meeting of stockholders to be held in 2024. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director Independence</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has determined that, of our directors, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199; and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;do not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#8220;independent&#8221; as that term is defined under the rules of the Nasdaq Stock Market LLC, or the Nasdaq rules. There are no family relationships among any of our directors or executive officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Leadership Structure</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors is currently chaired by &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. Our corporate governance guidelines will provide that, if the chairman of the board is a member of management or does not otherwise qualify as independent, the independent directors of the board may elect a lead director. The lead director&#8217;s responsibilities would include, </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">138</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">but would not be not limited to: presiding over all meetings of the board of directors at which the chairman is not present, including any executive sessions of the independent directors; approving board meeting schedules and agendas; and acting as the liaison between the independent directors and the chief executive officer and chairman of the board. Our corporate governance guidelines further provide the flexibility for our board of directors to modify our leadership structure in the future as it deems appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Role of the Board in Risk Oversight</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">One of the key functions of our board of directors is informed oversight of our risk management process. Our board of directors does not have a standing risk management committee, but rather administers this oversight function directly through our board of directors as a whole, as well as through various standing committees of our board of directors that address risks inherent in their respective areas of oversight. In particular, our board of directors is responsible for monitoring and assessing strategic risk exposure and our audit committee has the responsibility to consider and discuss our major financial risk exposures and the steps our management has taken to monitor and control these exposures, including guidelines and policies to govern the process by which risk assessment and management is undertaken. Our audit committee also monitors compliance with legal and regulatory requirements. Our nominating and corporate governance committee will monitor the effectiveness of our corporate governance practices, including whether they are successful in preventing illegal or improper liability-creating conduct. Our compensation committee assesses and monitors whether any of our compensation policies and programs has the potential to encourage excessive risk-taking. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, our entire board of directors is regularly informed through committee reports about such risks. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Board Committees</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has established three standing committees&#8212;audit, compensation and nominating and corporate governance&#8212;each of which operates under a charter that has been approved by our board of directors. Upon our listing on the Nasdaq Global Market, each committee&#8217;s charter will be available under the Corporate Governance section of our website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.immuneering.com</font><font style="letter-spacing:0.2pt;">. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Audit Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The audit committee&#8217;s responsibilities include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">appointing, approving the compensation of, and assessing the independence of our registered public accounting firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing the work of our registered public accounting firm, including through the receipt and consideration of reports from such firm; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and discussing with management and the registered public accounting firm our annual and quarterly financial statements and related disclosures; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">coordinating our board of directors&#8217; oversight of our internal control over financial reporting, disclosure controls and procedures and code of business conduct and ethics; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">discussing our risk management policies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">meeting independently with our internal auditing staff, if any, registered public accounting firm and management; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving or ratifying any related person transactions; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">preparing the audit committee report required by SEC rules. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The members of our audit committee are &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;serves as the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable Nasdaq rules. Our board of directors has determined that &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;meet the independence requirements of Rule&#160;10A-3 under the Exchange Act and the applicable Nasdaq rules. Our board of directors </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">139</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:61.76pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">has determined that &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;is an &#8220;audit committee financial expert&#8221; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq rules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The compensation committee&#8217;s responsibilities include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and approving, or recommending for approval by the board of directors, the compensation of our Chief Executive Officer and our other executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing and administering our cash and equity incentive plans; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and making recommendations to our board of directors with respect to director compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">reviewing and discussing annually with management our &#8220;Compensation Discussion and Analysis,&#8221; to the extent required; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">preparing the annual compensation committee report required by SEC rules, to the extent required. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The members of our compensation committee are &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;serves as the chairperson of the committee. Our board of directors has determined that each of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;is independent under the applicable Nasdaq rules, including the Nasdaq rules specific to membership on the compensation committee, and is a &#8220;non-employee director&#8221; as defined in Rule&#160;16b-3 promulgated under the Exchange Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Nominating and Corporate Governance Committee</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The nominating and corporate governance committee&#8217;s responsibilities include: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">identifying individuals qualified to become board members; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">recommending to our board of directors the persons to be nominated for election as directors and to each board committee; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">developing and recommending to our board of directors corporate governance guidelines, and reviewing and recommending to our board of directors proposed changes to our corporate governance guidelines from time to time; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">overseeing a periodic evaluation of our board of directors. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The members of our nominating and corporate governance committee are &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;serves as the chairperson of the committee. Our board of directors has determined that &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;and &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;are independent under the applicable Nasdaq rules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Compensation Committee Interlocks and Insider Participation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">No member of our compensation committee is or has been our current or former officer or employee. None of our executive officers served as a director or a member of a compensation committee (or other committee serving an equivalent function) of any other entity, one of whose executive officers served as a director or member of our compensation committee during the last completed fiscal year. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">140</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Helvetica, Arial, sans-serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:512pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">Code of Ethics and Code of Conduct</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">We will adopt a written code of business conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Upon our listing on the Nasdaq Global Market, our code of business conduct and ethics will be available under the Corporate Governance section of our website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.immuneering.com</font><font style="letter-spacing:0.2pt;">. In addition, we intend to post on our website all disclosures that are required by law or the Nasdaq rules concerning any amendments to, or waivers from, any provision of the code. The reference to our website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">141</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEADC">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXECUTIVE AND DIRECTOR COMPENSATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This section discusses the material components of the executive compensation program for our executive officers who are named in the &#8220;2020 Summary Compensation Table&#8221; below. Actual compensation programs that we adopt may differ materially from currently planned programs as summarized in this discussion. As an &#8220;emerging growth company&#8221; &#8203;(as defined in the JOBS Act), we are not required to include a Compensation Discussion and Analysis and have elected to comply with the scaled disclosure requirements applicable to emerging growth companies. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Ben Zeskind, Ph.D., Chief Executive Officer; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Brett Hall, Ph.D., Chief Scientific Officer; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Scott Barrett, M.D., Chief Medical Officer. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2020 Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information concerning the compensation awarded to, earned by and paid to our named executive officers with respect to the year ended December&#160;31, 2020. </font>
        </div>
        <table style="width:456pt;height:107.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:218.55pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:2.16666666666667pt;padding-right:1pt;letter-spacing:-0.16pt;">Name and Principal Position </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Salary</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Bonus</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($)</font><font style=" position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">All Other</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Compensation</font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:218.55pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Ben Zeskind, Ph.D.  </font>
                <br >
                <font style="letter-spacing:0.2pt;">Chief Executive Officer </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">292,550</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">500,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">13,495<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(</font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">3</font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">806,045</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:218.55pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Brett Hall, Ph.D. </font>
                <br >
                <font style="letter-spacing:0.2pt;">Chief Scientific Officer </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">615,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">160,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">200</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">775,200</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:218.55pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt; text-align:justify;">
                <font style="letter-spacing:0.2pt;">Scott Barrett, M.D. </font>
                <br >
                <font style="letter-spacing:0.2pt;">Chief Medical Officer </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2020</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">504,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">200,000<font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(2)</font> </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">11,400<font style="position:absolute;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">(</font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">4</font><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:9.81pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">715,400 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.6pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.1pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.1pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">The amounts reported represent discretionary annual bonuses paid in recognition of 2020 performance. Refer to the section titled &#8220;2020 Bonuses&#8221; below for additional information. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:4.1pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Dr. Barrett&#8217;s aggregate bonus award for 2020 consists of (i)&#160;a discretionary bonus of $50,000, and (ii)&#160;a signing bonus of $180,000, of which $150,000 was paid out in 2020. Dr.&#160;Barrett&#8217;s signing bonus was paid in $15,000 monthly increments, beginning in November 2019 and ending in October 2020, subject to his continued service with the Company. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">The amount reported includes employer contributions under the Company&#8217;s 401(k) plan and a Company paid cell phone. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:4.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:4.1pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">The amount reported includes employer contributions under the Company&#8217;s 401(k) plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Narrative to Summary Compensation Table</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2020 Salaries</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The named executive officers receive a base salary to compensate them for services rendered to the Company. The base salary payable to each named executive officer is intended to provide a fixed component of compensation reflecting the executive&#8217;s skill set, experience, role and responsibilities. Effective July&#160;1, 2020, following its annual review, the Board increased Dr.&#160;Hall&#8217;s base salary from $600,000 to $630,000. Drs. Zeskind and Barrett did not receive increases in their annual base salaries for 2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2020 Bonuses</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For 2020, we offered our named executive officers the opportunity to earn discretionary cash bonuses based on performance. In December&#160;2020, the Board evaluated the Company&#8217;s and the named executive officers&#8217; 2020 performance and, in recognition of the Company&#8217;s and each named executive officer&#8217;s 2020 performance, elected to pay the cash bonuses set forth above in the 2020 Summary Compensation Table. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the terms of his employment agreement, Dr. Barrett was also entitled to a signing bonus in the amount of $180,000 in connection with the commencement of his employment in November 2019, payable in twelve monthly installments of $15,000 from November 2019 until October 2020, subject to his continued employment. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">142</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:0.460000000000036pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Equity Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We have historically granted stock options to our employees, including our named executive officers, under the 2015 Plan as the long-term incentive component of our compensation program. Our stock options generally allow employees to purchase shares of our Class&#160;A common stock at a price per share equal to the fair market value of our Class&#160;A common stock on the date of grant. During 2020, the Board of Directors modified an outstanding option award of Dr. Hall to convert such option award to an incentive stock option award. There was no incremental fair value associated with this modification under ASC 718. Please see the table titled &#8220;Outstanding Equity Awards at 2020 Fiscal Year-End&#8221; below for information regarding outstanding stock option awards held by our named executive officers as of December 31, 2020. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with this offering, we intend to adopt a 2021 Incentive Award Plan, referred to below as the 2021 Plan, in order to facilitate the grant of cash and equity incentives to directors, employees (including our named executive officers) and consultants of the Company and certain of its affiliates to enable the Company and certain of its affiliates to obtain and retain services of these individuals, which we consider to be essential to our long-term success. Following the effective date of the 2021 Plan, we do not intend to make any further grants under the 2015 Plan. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. For additional information about the 2021 Plan, please see the section titled &#8220;Incentive Compensation Plans&#8221; below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Elements of Compensation</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Retirement Plans</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We currently maintain a 401(k) retirement savings plan for our employees, including our named executive officers, who satisfy certain eligibility requirements. Our named executive officers are eligible to participate in the 401(k) plan on the same terms as other full-time employees. The Code allows eligible employees to defer a portion of their compensation, within prescribed limits, on a pre-tax basis through contributions to the 401(k) plan. For 2020, we matched contributions made by participants in the 401(k) plan up to four&#160;percent of the employees&#39; eligible compensation. We believe that providing a vehicle for tax-deferred retirement savings though our 401(k) plan adds to the overall desirability of our executive compensation package and further incentivizes our employees, including our named executive officers, in accordance with our compensation policies. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Health and Welfare Plans</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">All of our full-time employees, including our named executive officers, are eligible to participate in our health and welfare plans on the same terms. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Executive Compensation Arrangements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Drs. Hall and Barrett are each party to an employment or letter agreement with us that sets forth the terms and conditions of their employment. Our named executive officers have entered agreements with restrictive covenants relating to non-competition and non-solicitation of customers and employees during employment and for one year following a termination of employment. We expect to enter into new employment agreements with the named executive officers that will supersede their existing agreements effective upon the effectiveness of the registration statement relating to this offering. The terms of these new agreements are not yet known. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Outstanding Equity Awards at 2020 Fiscal Year-End</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the number of shares of Class&#160;A common stock underlying outstanding equity incentive plan awards for each named executive officer as of December&#160;31, 2020. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">143</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:127pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.5pt 0pt; width:190.11pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0.333333333333333pt;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0.333333333333333pt;">
                <font style="letter-spacing:-0.16pt;">Vesting </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Start </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option Awards </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;height:58.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Securities </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options (#) </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercisable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Securities </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Underlying </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercised </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Options (#) </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Unexercisable</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
                <br >
                <font style="letter-spacing:-0.16pt;">($) </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Option </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Expiration </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:190.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Ben Zeskind, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">9/20/2019</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">150,000<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:190.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brett Hall, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/1/2019</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">39,000<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">105,000<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:7.5pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:190.11pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-size:10pt;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">
              <div style="font-size:10pt;">5/5/2018</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-size:10pt;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <div style="font-size:10pt;">41,979<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></div>
            </td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-size:10pt;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <div style="font-size:10pt;">23,021<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></div>
            </td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-size:10pt;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <div style="font-size:10pt;">4.21</div>
            </td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">
              <div style="font-size:10pt;">&#8203;</div>
            </td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">
              <div style="font-size:10pt;">2/24/2029</div>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:190.11pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scott Barrett, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">11/11/2019</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">37,673<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:0.614999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">101,427<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(2</font><font style="position:absolute;padding-top:0pt;"><font style=" position:relative; bottom:3.75pt;font-size:7.5pt;">)</font> </font></td>
            <td style="padding:0pt;padding-left:3.7pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:5.21pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12/15/2029</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.1pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.49pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:7.49pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">The options may be early exercised in full for restricted stock as of the date of the grant. The amounts reported as exercisable or unexercisable represent the number of shares as to which the options are vested or unvested, respectively. 100% of the underlying shares vest on the first anniversary of the vesting start date indicated. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:4.5pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:4.5pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">The options may be early exercised in full for restricted stock as of the date of grant. The amounts reported as exercisable or unexercisable represent the number of shares as to which the options are vested or unvested, respectively. The options vest as to 25% of the underlying shares on the first anniversary of the vesting start date indicated and in equal monthly installments over the following three&#160;years, subject to continued employment through each applicable vesting date. In the event of a change in control of the Company, 50% of the remaining unvested shares subject to the option will become vested and exercisable upon such change in control. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2020 Director Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">We did not pay our directors any compensation for serving on the Board during 2020. We intend to approve and implement a compensation program for our non-employee directors that will become effective on the effectiveness of the registration statement for this offering. The terms of the program have not yet been determined. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Incentive Compensation Plans</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following summarizes the expected material terms of 2021 Incentive Award Plan, or the 2021 Plan, and the 2021 Employee Stock Purchase Plan, which will be the long-term incentive compensation plans in which our directors and employees, including the named executive officers, are eligible to participate following the consummation of this offering, and the 2015 Plan, under which we have previously made periodic grants of equity and equity-based awards to our directors and named executive officers. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2021 Incentive Award Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Effective the day prior to the first public trading date of our Class&#160;A common stock, we intend to adopt and ask our stockholders to approve the 2021 Plan, under which we may grant cash and equity-based incentive awards to eligible service providers in order to attract, retain and motivate the persons who make important contributions to the Company. The expected material terms of the 2021 Plan are summarized below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Eligibility and Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our employees, consultants and directors, and employees and consultants of our subsidiaries, will be eligible to receive awards under the 2021 Plan. The 2021 Plan will be administered by our board of directors, which may delegate its duties and responsibilities to one or more committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to the limitations imposed under the 2021 Plan, Section&#160;16 of the Exchange Act, stock exchange rules and other applicable laws. The plan administrator will have the authority to take all actions and make all determinations under the 2021 Plan, to interpret the 2021 Plan and award agreements and to adopt, amend and repeal rules for the administration of the 2021 Plan as it deems advisable. The plan administrator will also have the authority to grant awards, determine which eligible service providers receive awards and set the terms and conditions of all awards under the 2021 Plan, including any vesting and vesting acceleration provisions, subject to the conditions and limitations in the 2021 Plan. We expect that the compensation committee will be the initial administrator of the 2021 Plan. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">144</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Shares Available for Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An aggregate of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock will initially be available for issuance under the 2021 Plan. The number of shares initially available for issuance will be increased annually on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, equal to the lesser of (A)&#8199;&#8199;&#8199;&#8199;% of the shares of Class&#160;A common stock outstanding on the final day of the immediately preceding calendar year and (B)&#160;a smaller number of shares determined by our board of directors. No more than &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock may be issued under the 2021 Plan upon the exercise of incentive stock options. Shares issued under the 2021 Plan may be authorized but unissued shares, shares purchased on the open market or treasury shares. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an award under the 2021 Plan or the 2015 Plan, expires, lapses or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, any unused shares subject to the award will, as applicable, become or again be available for new grants under the 2021 Plan. In addition, any shares delivered to the Company by a participant to satisfy the applicable exercise or purchase price of an award granted under the 2021 Plan or the 2015 Plan or to satisfy any applicable tax withholding obligation of an award granted under the 2021 Plan or the 2015 Plan will, as applicable, become or again be available for award grants under the 2021 Plan. Awards granted under the 2021 Plan in substitution for any options or other stock or stock-based awards granted by an entity before the entity&#8217;s merger or consolidation with us or our acquisition of the entity&#8217;s property or stock will not reduce the shares available for grant under the 2021 Plan, but may count against the maximum number of shares that may be issued upon the exercise of incentive stock options, or ISOs. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Awards</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The 2021 Plan provides for the grant of stock options, including ISOs, and nonqualified stock options, or NSOs, stock appreciation rights, or SARs, restricted stock, dividend equivalents, restricted stock&#160;units, or RSUs, and other stock or cash-based awards. Certain awards under the 2021 Plan may constitute or provide for payment of &#8220;nonqualified deferred compensation&#8221; under Section&#160;409A of the Code. All awards under the 2021 Plan will be set forth in award agreements, which will detail the terms and conditions of awards, including any applicable vesting and payment terms and post-termination exercise limitations. A brief description of each award type follows. </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Stock Options and SARs. Stock options provide for the purchase of shares of our Class&#160;A common stock in the future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are satisfied. SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of the shares subject to the award between the grant date and the exercise date. The plan administrator will determine the number of shares covered by each option and SAR, the exercise price of each option and SAR and the conditions and limitations applicable to the exercise of each option and SAR. The exercise price of a stock option or SAR will not be less than 100% of the fair market value of the underlying share on the grant date (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to certain substitute awards granted in connection with a corporate transaction. The term of a stock option or SAR may not be longer than ten&#160;years (or five&#160;years in the case of ISOs granted to certain significant stockholders). </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Restricted Stock and RSUs. Restricted stock is an award of nontransferable shares of our Class&#160;A common stock that remain forfeitable unless and until specified conditions are met and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our Class&#160;A common stock in the future, which may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our Class&#160;A common stock prior to the delivery of the underlying shares. The plan administrator may provide that the delivery of the shares underlying RSUs will be deferred on a mandatory basis or at the election of the participant. The terms and conditions applicable to restricted stock and RSUs will be determined by the plan administrator, subject to the conditions and limitations contained in the 2021 Plan. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">145</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Other Stock or Cash-Based Awards. Other stock or cash-based awards are awards of cash, fully vested shares of our Class&#160;A common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our Class&#160;A common stock or other property. Other stock or cash-based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of compensation to which a participant is otherwise entitled. The plan administrator will determine the terms and conditions of other stock or cash-based awards, which may include any purchase price, performance goal, transfer restrictions and vesting conditions. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Performance Criteria</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The plan administrator may select performance criteria for an award to establish performance goals for a performance period. Performance criteria under the 2021 Plan may include, but are not limited to, the following: net earnings or losses (either before or after one or more of interest, taxes, depreciation, amortization, and non-cash equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits (including but not limited to gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#8217; equity; total stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial, or strategic milestones or developments; market share; economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may be based solely by reference to the Company&#39;s performance or the performance of a subsidiary, division, business segment or business unit of the Company or a subsidiary, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of performance relative to performance of other companies. When determining performance goals, the plan administrator may provide for exclusion of the impact of an event or occurrence which the plan administrator determines should appropriately be excluded, including, without limitation, non-recurring charges or events, acquisitions or divestitures, changes in the corporate or capital structure, events unrelated to the business or outside of the control of management, foreign exchange considerations, and legal, regulatory, tax or accounting changes. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Certain Transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with certain corporate transactions and events affecting our Class&#160;A common stock, including a change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2021 Plan to prevent the dilution or enlargement of intended benefits, facilitate the transaction or event or give effect to the change in applicable laws or accounting principles. This includes canceling awards for cash or property, accelerating the vesting of awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares subject to outstanding awards and/or with respect to which awards may be granted under the 2021 Plan and replacing or terminating awards under the 2021 Plan. In addition, in the event of certain non-reciprocal transactions with our stockholders, the plan administrator will make equitable adjustments to awards outstanding under the 2021 Plan as it deems appropriate to reflect the transaction. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Provisions of the 2021 Plan&#160;Relating to Director Compensation.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The 2021 Plan provides that the plan administrator may establish compensation for non-employee directors from time to time subject to the 2021 Plan&#8217;s limitations. Prior to commencing this offering, we intend to </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">146</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">approve and implement a compensation program for our non-employee directors. Our board of directors or its authorized committee may modify the non-employee director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it deems relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date fair value of any equity awards granted under the 2021 Plan as compensation for services as a non-employee director during any fiscal year may not exceed $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;in the fiscal year of the non-employee director&#8217;s initial service and $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;in any other fiscal year. The plan administrator may make exceptions to this limit for individual non-employee directors in extraordinary circumstances, as the plan administrator may determine in its discretion, subject to the limitations in the 2021 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Amendment and Termination</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors may amend or terminate the 2021 Plan at any time; however, no amendment, other than an amendment that increases the number of shares available under the 2021 Plan, may materially and adversely affect an award outstanding under the 2021 Plan without the consent of the affected participant and stockholder approval will be obtained for any amendment to the extent necessary to comply with applicable laws or the rules of the applicable stock exchange on which the common stock is then traded. Further, the plan administrator may, without the approval of our stockholders, amend any outstanding stock option or SAR to reduce its price per share, including in the context of corporate transactions or equity restructurings, as described above. The 2021 Plan will remain in effect until the tenth anniversary of its effective date, unless earlier terminated by our board of directors. No awards may be granted under the 2021 Plan after its termination. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Foreign Participants, Claw-Back Provisions, Transferability and Participant Payments</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The plan administrator may modify awards granted to participants who are foreign nationals or employed outside the United States or establish subplans or procedures to address differences in laws, rules, regulations or customs of such foreign jurisdictions. All awards will be subject to any company claw-back policy as set forth in such claw-back policy or the applicable award agreement. Except as the plan administrator may determine or provide in an award agreement, awards under the 2021 Plan are generally non-transferrable, except by will or the laws of descent and distribution, or, subject to the plan administrator&#8217;s consent, pursuant to a domestic relations order, and are generally exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2021 Plan and exercise price obligations arising in connection with the exercise of stock options under the 2021 Plan, the plan administrator may, in its discretion, accept cash, wire transfer or check, shares of our Class&#160;A common stock that meet specified conditions, a promissory note, a &#8220;market sell order,&#8221; such other consideration as the plan administrator deems suitable or any combination of the foregoing. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2021 Employee Stock Purchase Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Effective the day prior to the first public trading date of our Class&#160;A common stock, we intend to adopt and ask our stockholders to approve the 2021 Employee Stock Purchase Plan, or the 2021 ESPP, the expected material terms of which are summarized below. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Shares Available for Awards; Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A total of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock will initially be reserved for issuance under the 2021 ESPP. In addition, the number of shares available for issuance under the 2021 ESPP will be annually increased on January&#160;1 of each calendar year beginning in 2022 and ending in and including 2031, by an amount equal to the lesser of (A)&#8199;&#8199;&#8199;&#8199;% of the shares outstanding on the final day of the immediately preceding calendar year and (B)&#160;such smaller number of shares as is determined by our board of directors, provided that no more than &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock may be issued under the 2021 ESPP. Our board of directors or a committee of our board of directors will administer and will have authority to interpret the terms of the 2021 ESPP and determine eligibility of participants. We expect that the compensation committee will be the initial administrator of the 2021 ESPP. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">147</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Eligibility</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">All of our employees will be eligible to participate in the 2021 ESPP. However, an employee may not be granted rights to purchase stock under our 2021 ESPP if the employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all classes of our stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Grant of Rights</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The 2021 ESPP is intended to qualify under Section&#160;423 of the Code and stock will be offered under the 2021 ESPP during offering periods. The length of the offering periods under the 2021 ESPP will be determined by the plan administrator and may be up to twenty-seven&#160;months long. Employee payroll deductions will be used to purchase shares on each purchase date during an offering period. The purchase dates for each offering period will be the final trading day in the offering period. Offering periods under the 2021 ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The 2021 ESPP permits participants to purchase Class&#160;A common stock through payroll deductions of up to a specified&#160;percentage of their eligible compensation. The plan administrator will establish a maximum number of shares that may be purchased by a participant during any offering period. In addition, no employee will be permitted to accrue the right to purchase stock under the 2021 ESPP at a rate in excess of $25,000 worth of shares during any calendar year during which such a purchase right is outstanding (based on the fair market value per share of our Class&#160;A common stock as of the first day of the offering period). </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our Class&#160;A common stock. The option will expire at the end of the applicable offering period, and will be exercised at that time to the extent of the payroll deductions accumulated during the offering period. The purchase price of the shares, in the absence of a contrary designation, will be 85% of the lower of the fair market value of our Class&#160;A common stock on the first trading day of the offering period or on the purchase date. Participants may voluntarily end their participation in the 2021 ESPP at any time during a specified period prior to the end of the applicable offering period, and will be paid their accrued payroll deductions that have not yet been used to purchase shares of Class&#160;A common stock. Participation ends automatically upon a participant&#8217;s termination of employment. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A participant may not transfer rights granted under the 2021 ESPP other than by will or the laws of descent and distribution, and such rights are exercisable only by the participant. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Certain Transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of certain non-reciprocal transactions or events affecting our Class&#160;A common stock, the plan administrator will make equitable adjustments to the 2021 ESPP and outstanding rights. In the event of certain unusual or non-recurring events or transactions, including a change in control, the plan administrator may provide for (1)&#160;the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (2)&#160;the assumption or substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (3)&#160;the adjustment in the number and type of shares of stock subject to outstanding rights, (4)&#160;the use of participants&#8217; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (5)&#160;the termination of all outstanding rights. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Plan&#160;Amendment</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The plan administrator may amend, suspend or terminate the 2021 ESPP at any time. However, stockholder approval will be obtained for any amendment that increases the aggregate number or changes the type of shares that may be sold pursuant to rights under the 2021 ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the 2021 ESPP or changes the 2021 ESPP in any manner that would cause the 2021 ESPP to no longer be an employee stock purchase plan within the meaning of Section&#160;423(b) of the Code. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">148</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:192pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">2015 Long Term Incentive Plan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors and stockholders have approved the 2015 Plan, under which we may grant stock options and restricted stock to employees, directors and consultants of the Company or its subsidiaries. We have reserved a total of 819,768 shares of our Class&#160;A common stock for issuance under the 2015 Plan. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Following the effectiveness of the 2021 Plan, we will not make any further grants under the 2015 Plan. However, the 2015 Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of our Class&#160;A common stock subject to awards granted under the 2015 Plan that are forfeited, lapse unexercised or are settled in cash and which following the effective date of the 2021 Plan are not issued under the 2015 Plan will be available for issuance under the 2021 Plan. As of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;, a total of &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock were subject to outstanding stock options issued under the 2015 Plan and no other awards were outstanding under the 2015 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Administration</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors or a committee thereof is authorized to administer the 2015 Plan. Subject to the express terms and conditions of the 2015 Plan, the plan administrator has the authority to make all determinations and interpretations under the plan, establish, amend, suspend or waive rules and regulations used to administer the 2015 Plan and make any other determination and take any other action that the administrator deems necessary or desirable to administer the 2015 Plan. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Certain Transactions</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The plan administrator has broad discretion to adjust the provisions of the 2015 Plan and the terms and conditions of existing and future awards, in the event of a change in control or certain transactions and events affecting our Class&#160;A common stock, such as a reorganization, merger, consolidation, combination, exchange, recapitalization, or other relevant change in capitalization of the Company. Specifically, in the event of the transactions mentioned above, the administrator may remove applicable forfeiture restrictions on any award, accelerate the time of exercisability, provide for a cash payment in consideration for the cancellation of awards, cancel awards that are unexercisable or remain subject to a restricted period on the date of a change in control, or make such adjustment to awards then outstanding as the administrator deems appropriate. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">Amendment and Termination</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors may amend the 2015 Plan at any time and from time to time; provided that no amendment may materially and adversely affect the rights of any participant without the consent of the affected participant.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">149</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRAR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:37.43pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following includes a summary of transactions since January&#160;1, 2018 to which we have been a party in which the amount involved exceeded or will exceed $120,000, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock, or 5% security holders, or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which are described under &#8220;Executive and Director Compensation.&#8221; We also describe below certain other transactions with our directors, executive officers and stockholders. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Related Party Agreements in Effect Prior to this Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Series&#160;A Convertible Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">From September&#160;2019 to January&#160;2020, we issued and sold to investors in a private placement an aggregate of 2,495,933 shares of Series&#160;A Preferred Stock at a purchase price of $8.5514 per share, for aggregate consideration of approximately $20.0&#160;million. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the aggregate number of Series&#160;A Preferred Stock acquired by certain beneficial owners of more than 5% of our capital stock, executive officers and entities affiliated with certain of our directors in the financing transactions described above. </font>
        </div>
        <table style="width:456pt;height:107.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:284.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:2.16666666666667pt;letter-spacing:-0.16pt;">Participants</font><font style="border-bottom:1px solid #000000;padding-bottom:2.16666666666667pt;padding-right:1pt; position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;A Preferred</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate Purchase Price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:284.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Merrin Investors LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">409,289</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3,500</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Robert J. Carpenter </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">67,561</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">512 </td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benjamin J. Zeskind, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">29,234</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">250</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brett Hall, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">1,169</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scott Barrett, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">2,338</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">20 </td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:284.43pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Peter Feinberg</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(2)</font><font style="letter-spacing:0.2pt;"> </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">213,215 </td>
            <td style="padding:0pt;padding-left:14.305pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,584</td>
            <td style="padding:0pt;padding-left:29.27pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:11.69pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:8.19pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Additional details regarding these stockholders and their equity holdings are provided in this prospectus under the caption &#8220;Principal Stockholders.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:5.19pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:5.19pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Consists of 66,078 shares of Series A Preferred Stock purchased by PEF LLC, 36,759 shares of Series A Preferred Stock purchased by Feinberg Investment Trust LLC, 73,519 shares of Series A Preferred Stock purchased by PF Associates L.P., 36,759 shares of Series A Preferred Stock purchased by S4K Investments LLC and 100 shares of Series A Preferred Stock purchased by Boxcar PMJ, LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Series&#160;B Convertible Preferred Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;31, 2020, we issued and sold to investors in a private placement an aggregate of 3,619,292 shares of Series&#160;B Preferred Stock at a purchase price of $10.2782 per share, for an aggregate consideration of approximately $37.2&#160;million. In addition, in April and May&#160;2021, we issued and sold to investors in a private placement an additional 2,412,853 shares of Series&#160;B Preferred Stock at a purchase price of $10.2782 per share, for an aggregate consideration of approximately $24.8&#160;million. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the aggregate number of Series&#160;B Preferred Stock acquired by certain beneficial owners of more than 5% of our capital stock, executive officers and entities affiliated with certain of our directors in the financing transactions described above. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">150</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:160.5pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 1.167pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1.16666666666667pt;letter-spacing:-0.16pt;">Participants</font><font style="border-bottom:1px solid #000000;padding-bottom:1.16666666666667pt;padding-right:1pt; position:relative; bottom:3.25pt;font-size:6pt;letter-spacing:-0.12pt;">(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;B Preferred</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate Purchase Price</font>
                <br >
                <font style="letter-spacing:-0.16pt;">(in thousands)</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Merrin Investors LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">291,878</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3,000</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Cormorant Asset Management, LP</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,216,163</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with T. Rowe Price Associates, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">778,345</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,000 </td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Rock Springs Capital LP</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">778,345 </td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">8,000</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Citadel Multi-Strategy Equities Master Fund&#160;Ltd. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,216,165</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">12,500</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benjamin J. Zeskind, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">5,837</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">60</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Robert J. Carpenter </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">87,563</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">900</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brett Hall, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,431</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scott Barrett, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,945</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Biren Amin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,945</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">20 </td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:284.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Peter Feinberg</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(5)</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">87,560 </td>
            <td style="padding:0pt;padding-left:10.25pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;"> 900</td>
            <td style="padding:0pt;padding-left:26.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(1)</font>
          <br >
        </div>
        <div style=" margin-top:6.8pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Additional details regarding these stockholders and their equity holdings are provided in this prospectus under the caption &#8220;Principal Stockholders.&#8221; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:3.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(2)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Consists of 927,495 shares of Series&#160;B Preferred Stock purchased by Cormorant Private Healthcare Fund&#160;III, LP, 276,920 shares of Series&#160;B Preferred Stock purchased by Cormorant Global Healthcare Master Fund, LP, and 11,748 shares of Series&#160;B Preferred Stock purchased by CRMA SPV, LP. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:3.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(3)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Consists of 696,164 shares of Series&#160;B Preferred Stock purchased by T. Rowe Price Health Sciences Fund, Inc., 50,975 shares of Series&#160;B Preferred Stock purchased by TD Mutual Funds&#8212;TD Health Sciences Fund, and 31,206 shares of Series&#160;B Preferred Stock purchased by T. Rowe Price Health Sciences Portfolio. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:3.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(4)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Consists of 632,405 shares of Series&#160;B Preferred Stock purchased by Rock Springs Capital Master Fund&#160;LP, and 145,940 shares of Series&#160;B Preferred Stock purchased by Four Pines Master Fund&#160;LP. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:3.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">(5)</font>
          <br >
        </div>
        <div style=" margin-top:3.8pt; margin-bottom:0pt; line-height:9pt; text-align:justify; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Consists of 21,890 shares of Series B Preferred Stock purchased by PF Associates L.P., 21,890 shares of Series B Preferred Stock purchased by PEF LLC, 21,890 shares of Series B Preferred Stock purchased by Feinberg Investment Trust LLC and 21,890 shares of Series B Preferred Stock purchased by S4K Investments LLC. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Management and Other Agreements</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Brett Hall, our Chief Scientific Officer, is Founder, President and Chairman of the board of directors of Bioarkive, a CRO that provides contract services to us. Our research and development expenses include the cost of services provided by the CRO to us, and amounted to $2.7&#160;million and $0.4&#160;million for the&#160;years ended December&#160;31, 2020 and 2019, respectively. Of this amount, $0.3&#160;million and $0.1&#160;million was owed to the CRO at December&#160;31, 2020 and 2019, respectively, and is included in accounts payable or accrued contract research expenses in our consolidated financial statements included elsewhere in this prospectus. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amended and Restated Investors&#8217; Rights Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the issuance of our Series&#160;B Preferred Stock on December&#160;21, 2020, we entered into an Amended and Restated Investors&#8217; Rights Agreement, or the IRA, with certain holders of our preferred stock, many which are beneficial holders of more than 5% of our capital stock or are entities with which certain of our directors are affiliated. The IRA imposes certain affirmative obligations on us and also grants certain rights to holders, including certain registration rights with respect to the securities held by them, certain information and observer rights, and certain additional rights. Certain provisions of the IRA will terminate in connection with this offering. See &#8220;Description of Capital Stock&#8212;Registration Rights&#8221; for additional information. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amended and Restated Voting Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In connection with the issuance of our Series&#160;B Preferred Stock on December&#160;21, 2020, we entered into an Amended and Restated Voting Agreement, or the Voting Agreement, which, among other things, provides the terms for the voting of shares with respect to the constituency of our board of directors. Pursuant to the terms of the Voting Agreement, the following directors were elected to serve as members of our board of directors, and, as of the date of this prospectus, continue to so serve: Benjamin J. Zeskind, Andrew Phillips and Robert&#160;J. Carpenter. Dr.&#160;Zeskind was selected to serve on our board of directors as our Chief Executive Officer, Mr.&#160;Phillips were selected to serve on our board of directors as designated by the Cormorant Private Healthcare Fund&#160;III, LP, Cormorant Global Healthcare Master Fund, LP and CRMA SPV, LP, collectively </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">151</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:76pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">referred to as Cormorant, and Mr.&#160;Carpenter was elected to serve on our board of directors by the holders of a majority of the then-outstanding shares of our common stock. Dr.&#160;Zeskind and Messrs. Phillips and Carpenter are joined on our board of directors by Peter Feinberg and Laurie B. Keating and, together with the aforementioned directors, possess relevant industry experience and are acceptable to a majority of the holders as parties to the Voting Agreement. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Voting Agreement, including its provisions concerning the rights of certain of the holders to designate directors, will terminate automatically upon the consummation of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amended and Restated Right of First Refusal and Co-Sale Agreement</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In connection with the issuance of our Series&#160;B Preferred Stock on December&#160;21, 2020, we entered into an Amended and Restated Right of First Refusal and Co-Sale Agreement, or the ROFR and Co-Sale Agreement, with certain of our preferred stockholders, many of which are beneficial holders of more than 5% of our capital stock or are entities with which certain of our directors are affiliated. The ROFR and Co-Sale Agreement, among other things: (a)&#160;grants our investors certain rights of first refusal and co-sale with respect to proposed transfers of our securities by certain preferred stockholders; and (b)&#160;grants us certain rights of first refusal with respect to proposed transfers of our securities by certain preferred stockholders. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The ROFR and Co-Sale Agreement will automatically terminate immediately prior to the completion of this offering. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Employment Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have entered into employment agreements or consulting agreements with each of our executive officers. See &#8220;Executive and Director Compensation&#8212;Executive Compensation Arrangements.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Director and Officer Indemnification and Insurance</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the consummation of this offering, we intend to enter into separate indemnification agreements with each of our directors and executive officers. We have also purchased directors&#8217; and officers&#8217; liability insurance. See &#8220;Description of Capital Stock&#8212;Limitations on Liability and Indemnification of Officers and Directors.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Policies and Procedures for Related Person Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our board of directors has adopted a written related person transaction policy, to be effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, setting forth the policies and procedures for the review and approval or ratification of related person transactions. This policy will cover, with certain exceptions set forth in Item&#160;404 of Regulation&#160;S-K under the Securities Act, any transaction, arrangement or relationship, or any series of similar transactions, arrangements or relationships, in which we were or are to be a participant, where the amount involved exceeds $120,000 in any fiscal year and a related person had, has or will have a direct or indirect material interest, including without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest, indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to, whether the transaction is on terms comparable to those that could be obtained in an arm&#8217;s length transaction and the extent of the related person&#8217;s interest in the transaction. All of the transactions described in this section occurred prior to the adoption of this policy. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">152</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPRST">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">PRINCIPAL STOCKHOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth information as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021 with respect to the beneficial ownership of our Class A common stock by: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding shares of Class A common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of our named executive officers; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">each of our directors; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">all of our executive officers and directors as a group. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The number of shares beneficially owned by each stockholder is determined in accordance with the rules issued by the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under these rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power, which includes the power to dispose of or to direct the disposition of such security. Except as indicated in the footnotes below, we believe, based on the information furnished to us, that the individuals and entities named in the table below have sole voting and investment power with respect to all shares of common stock beneficially owned by them, subject to any community property laws. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Percentage ownership of our Class A common stock before this offering is based on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of Class A common stock outstanding as of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021. Percentage ownership of our common stock after this offering is based on&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of Class A common stock as of December&#160;31, 2020, after giving effect to our issuance of shares of our common stock in this offering. In computing the number of shares beneficially owned by an individual or entity and the&#160;percentage ownership of that person, shares of Class A common stock subject to options, warrants or other rights held by such person that are currently exercisable or will become exercisable within 60&#160;days of December&#160;31, 2020 are considered outstanding, although these shares are not considered outstanding for purposes of computing the&#160;percentage ownership of any other person. Unless noted otherwise, the address of all listed stockholders is 245 Main Street, Second Floor Cambridge, Massachusetts 02142. </font>
        </div>
        <table style="width:456pt;height:262pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:27.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:191.34pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Class A Common Stock Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prior to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Class A Common Stock Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:49.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:58.99pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:49.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:58.99pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">5% or Greater Stockholders</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:191.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Citadel Multi-Strategy Equities Master Fund&#160;Ltd.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(1)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Cormorant</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(2)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Merrin Investors LLC</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(3)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:191.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with Rock Springs Capital LP</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(4)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:191.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Entities affiliated with T. Rowe Price Associates, Inc.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">&#65279;(5)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Named Executive Officers and Directors</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Benjamin J. Zeskind, Ph.D.</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(6)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Scott Barrett, M.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Brett Hall, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Robert J. Carpenter</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Peter Feinberg</font><font style=" position:relative; bottom:4.25pt;font-size:7.5pt;letter-spacing:0.15pt;">(7)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">153</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:412pt;margin-left:69.66pt;width:456pt;">
        <table style="width:456pt;height:97pt;margin-top:0pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;height:27.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:191.34pt;text-align:left;" rowspan="2">
              <div style="white-space:nowrap; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Name of Beneficial Owner </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Class A Common Stock Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Prior to Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Class A Common Stock Beneficially</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Owned</font>
                <br >
                <font style="letter-spacing:-0.16pt;">After Offering </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:49.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:58.99pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:49.34pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:58.99pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Percentage </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Laurie B. Keating </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:191.34pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Andrew Phillips, Ph.D. </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:191.34pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">All current executive officers and directors as a group (8 persons)</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:49.34pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:58.99pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.16pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;">
          <font style="letter-spacing:0.16pt;">Represents beneficial ownership of less than 1%. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">(1) </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">(2) </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">(3) </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">(4) </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">(5) </font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">(6)</font>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:9pt;">
          <font style="letter-spacing:0.16pt;">(7)</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">154</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDOCS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">DESCRIPTION OF CAPITAL STOCK</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">General</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">At or prior to the consummation of this offering, we will file an amended and restated certificate of incorporation and we will adopt our amended and restated bylaws. Our amended and restated certificate of incorporation will authorize capital stock consisting of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">shares of Class&#160;A common stock, $0.001 par value per share; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">shares of Class&#160;B common stock, $0.001 par value per share; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">shares of preferred stock, $0.001 par value per share. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are selling&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock in this offering (&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares if the underwriters exercise their option to purchase additional shares of our Class&#160;A common stock in full). All shares of our Class&#160;A common stock outstanding upon consummation of this offering will be fully paid and non-assessable. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following summary describes the material provisions of our capital stock. We urge you to read our amended and restated certificate of incorporation and our amended and restated bylaws, which are included as exhibits to the registration statement of which this prospectus forms a part. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Certain provisions of our amended and restated certificate of incorporation and our amended and restated bylaws summarized below may be deemed to have an anti-takeover effect and may delay or prevent a tender offer or takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the market price for the shares of Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Class&#160;A Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The holders of our Class&#160;A common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our Class&#160;A common stock do not have any cumulative voting rights. Holders of our Class&#160;A common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding preferred stock. Our Class&#160;A common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the event of our liquidation, dissolution or winding up, holders of our Class&#160;A common stock will be entitled to share ratably in all assets remaining after payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid and non-assessable. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon our dissolution or liquidation, after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of our Class&#160;A common stock will be entitled to receive pro&#160;rata our remaining assets available for distribution for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the prior rights of any preferred stock then outstanding. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Class&#160;B Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Class&#160;B common stock is identical to our Class&#160;A common stock in all respects, except that the holders of our Class&#160;B common stock will not be entitled to vote on shareholder matters as required by law. In addition, holders of our Class&#160;B common stock will have the right to convert each such Class&#160;B common stock into one Class&#160;A common stock at the holder&#8217;s election, unless, as a result of such conversion, the holder and its affiliates would own more than 9.9% of the combined voting power of our outstanding share capital, and subject to certain additional restrictions as more particularly described in our amended and restated certificate of incorporation. Shares of Class&#160;B common stock, once converted to shares of Class&#160;A common stock, may not be converted back into shares of Class&#160;B common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">155</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the closing of this offering, (i)&#160;all outstanding shares of our Series A Preferred Stock and Series B Preferred Stock will be converted into shares of our Class&#160;A common stock, subject to certain beneficial ownership limitations, and (ii)&#160;all outstanding shares of our Series A Preferred Stock and Series B Preferred Stock will automatically be cancelled. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of Class&#160;A common stock. The issuance of our preferred stock could adversely affect the voting power of holders of Class&#160;A common stock and the likelihood that such holders will receive payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company or other corporate action. Immediately after consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the IRA, following the consummation of this offering, certain holders of our common stock will be entitled to certain rights with respect to the registration of such shares for public resale under the Securities Act, until the rights otherwise terminate pursuant to the terms of the IRA. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form S-1 Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the IRA, certain holders of common stock are entitled to certain demand registration rights, including to demand registration of their registrable securities on a registration statement on Form S-1 at any time after the earlier of (i)&#160;five&#160;years after the date of the IRA, or (ii)&#160;180&#160;days following the completion of this offering. The holders holding more than a majority of the registrable securities have the right to require us to file a registration statement on Form S-1 under the Securities Act in order to register the resale of their shares of common stock; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that no such registration is required to be made (i)&#160;during the period that is 60&#160;days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is 180&#160;days after the effective date of, a Company-initiated registration, (ii)&#160;at such time as we have effected one registration statement, or (iii)&#160;if the holders who initiated the registration request propose to dispose of shares of registrable securities that may be immediately registered on Form S-3 pursuant to a request under the IRA. We may, in certain circumstances, defer such registrations, and the underwriters have the right, subject to certain limitations, to limit the number of shares included in such registrations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Piggyback Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If at any time after this offering we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of shares to be underwritten for reasons related to the marketing of the shares. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Form S-3 Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">After we are qualified for registration on Form S-3, the holders, as holders of registrable securities, may make a written request that we register the offer and sale of their shares on a Form S-3 registration statement; </font><font style="font-style:italic;letter-spacing:0.2pt;">provided</font><font style="letter-spacing:0.2pt;">, that no such registration is required to be made (i)&#160;during the period that is 30&#160;days before the Company&#8217;s good faith estimate of the date of filing of, and ending on a date that is 90&#160;days after the effective date of, a Company-initiated registration, or (ii)&#160;at such time as we have effected two such registrations in the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">156</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">last 12&#160;months. We may, in certain circumstances, defer such registrations, and the underwriters have the right, subject to certain limitations, to limit the number of shares included in such registrations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Expenses and Indemnification</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders and blue sky fees and expenses. Additionally, we have agreed to indemnify selling stockholders for damages, and any legal or other expenses reasonably incurred, arising from or based upon any untrue statement of a material fact contained in any registration statement, an omission or alleged omission to state a material fact in any registration statement or necessary to make the statements therein not misleading, or any violation or alleged violation by the indemnifying party of securities laws, subject to certain exceptions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Termination of Registration Rights</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The registration rights terminate upon the earliest of: (i)&#160;such date after the completion of this offering on which all shares of registrable securities may be sold during any three (3)&#160;month period pursuant to Rule&#160;144 of the Securities Act, (ii)&#160;the first anniversary of the completion of this offering, or (iii)&#160;the occurrence of a deemed liquidation event. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Choice of Forum</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws will provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&#160;any derivative action or proceeding brought on our behalf; (ii)&#160;any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our stockholders; (iii)&#160;any action asserting a claim against us arising pursuant to the DGCL, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); and (iv)&#160;any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws will also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any complaint asserting a cause or causes of action against us or any defendant arising under the Securities Act. Such provision is intended to benefit and may be enforced by us, our officers and directors, employees and agents, including the underwriters and any other professional or entity who has prepared or certified any part of this prospectus. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If any action the subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and amended and restated bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder&#8217;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated certificate of incorporation and amended and restated bylaws will contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision is unenforceable. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">157</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims or make such lawsuits more costly for stockholders, although our stockholders will not be deemed to have waived our compliance with federal securities laws and the rules and regulations thereunder. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dividends</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Declaration and payment of any dividend will be subject to the discretion of our board of directors. The time and amount of dividends will be dependent upon our business prospects, results of operations, financial condition, cash requirements and availability, debt repayment obligations, capital expenditure needs, contractual restrictions, covenants in the agreements governing our current and future indebtedness, industry trends, the provisions of Delaware law affecting the payment of distributions to stockholders and any other factors our board of directors may consider relevant. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business and to repay indebtedness, and therefore do not anticipate declaring or paying any cash dividends on our common stock in the foreseeable future. See &#8220;Dividend Policy&#8221; and &#8220;Risk Factors&#8212;Risks Related to this Offering and Ownership of our Common Stock&#8212;We have never paid dividends on our capital stock and we do not intend to pay dividends for the foreseeable future. Consequently, any gains from an investment in our common stock will likely depend on whether the price of our common stock increases.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Anti-Takeover Provisions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation and amended and restated bylaws, as they will be in effect immediately prior to the consummation of this offering, will contain provisions that may delay, defer or discourage another party from acquiring control of us. We expect that these provisions, which are summarized below, will discourage coercive takeover practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors, which we believe may result in an improvement of the terms of any such acquisition in favor of our stockholders. However, they also give our board of directors the power to discourage acquisitions that some stockholders may favor. See &#8220;Risk Factors&#8212;Risks Related to This Offering and Ownership of Our Common Stock&#8212;Our charter documents and Delaware law could prevent a takeover that stockholders consider favorable and could also reduce the market price of our stock.&#8221; </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Authorized but Unissued Shares</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The authorized but unissued shares of our common stock and our preferred stock are available for future issuance without stockholder approval, subject to any limitations imposed by the listing standards of the Nasdaq Global Market. These additional shares may be used for a variety of corporate finance transactions, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could make more difficult or discourage an attempt to obtain control of us by means of a proxy contest, tender offer, merger or otherwise. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Classified Board of Directors</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation will provide that our board of directors will be divided into three classes, with the classes as nearly equal in number as possible and each class serving three-year staggered terms. In all other cases and at any other time, directors may only be removed from our board of directors for cause by the affirmative vote of a majority of the shares entitled to vote. See &#8220;Management&#8212;Composition of our Board of Directors.&#8221; These provisions may have the effect of deferring, delaying or discouraging hostile takeovers, or changes in control of us or our management. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholder Action; Special Meeting of Stockholders</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated certificate of incorporation will provide that our stockholders will not be able to take action by written consent for any matter and may only take action at annual or special meetings. As a result, a holder controlling a majority of our capital stock would not be able to amend our amended and restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">158</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">our amended and restated bylaws, unless previously approved by our board of directors. Our amended and restated certificate of incorporation will further provide that special meetings of our stockholders may be called only by the chairman of our board of directors, our chief executive officer, our president or another officer selected by a majority of our board of directors, thus limiting the ability of a stockholder to call a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Advance Notice Requirements for Stockholder Proposals and Director Nominations</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In addition, our amended and restated bylaws will establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of stockholders, including proposed nominations of candidates for election to our board of directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice and duration of ownership requirements and provide us with certain information. Stockholders at an annual meeting may only consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of our board of directors or by a qualified stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has delivered timely written notice in proper form to our secretary of the stockholder&#8217;s intention to bring such business before the meeting. These provisions could have the effect of delaying stockholder actions that are favored by the holders of a majority of our outstanding voting securities until the next stockholder meeting. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Amendment of Certificate of Incorporation or Bylaws</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The DGCL provides generally that the affirmative vote of the holders of a majority in voting power of the shares entitled to vote is required to amend a corporation&#8217;s certificate of incorporation, unless a corporation&#8217;s certificate of incorporation requires a greater&#160;percentage. Upon consummation of this offering, our bylaws may be amended or repealed by a majority vote of our board of directors or by the affirmative vote of the holders a majority of the votes which all our stockholders would be eligible to cast in an election of directors. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Section&#160;203 of the DGCL</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We are subject to Section&#160;203 of the DGCL, which prohibits persons deemed &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three&#160;years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three&#160;years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a &#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Limitations on Liability and Indemnification of Officers and Directors</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our amended and restated bylaws provide indemnification for our directors and officers to the fullest extent permitted by the DGCL, along with the right to have expenses incurred in defending proceedings paid in advance of their final disposition. Prior to the consummation of this offering, we intend to enter into indemnification agreements with each of our directors and executive officers that may, in some cases, be broader than the specific indemnification and advancement provisions contained under our amended and restated bylaws and provided under Delaware law. In addition, as permitted by Delaware law, our amended and restated certificate of incorporation includes provisions that eliminate the personal liability of our directors for monetary damages resulting from breaches of certain fiduciary duties as a director. The effect of this provision is to restrict our rights and the rights of our stockholders to recover monetary damages against a director for breach of fiduciary duties as a director. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">159</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:296pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling our company pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Dissenters&#8217; Rights of Appraisal and Payment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the DGCL, with certain exceptions, our stockholders will have appraisal rights in connection with a merger or consolidation of Immuneering Corporation. Pursuant to the DGCL, stockholders who properly demand and perfect appraisal rights in connection with such mergers or consolidations will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery, subject to certain limitations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Stockholders&#8217; Derivative Actions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the DGCL, any of our stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, in certain circumstances. Among other things, either the stockholder bringing any such action must be a holder of our shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock must have thereafter devolved by operation of law, and such stockholder must continuously hold shares through the resolution of such action. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Transfer Agent and Registrar</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The transfer agent and registrar for our Class A common stock is&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Trading Symbol and Market</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to apply to list our Class&#160;A common stock on the Nasdaq Global Market under the symbol &#8220;IMRX.&#8221; We do not intend to list the Class B common stock on any securities exchange. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">160</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEFF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SHARES ELIGIBLE FOR FUTURE SALE</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Immediately prior to this offering, there was no public market for our Class&#160;A common stock. Future sales of substantial amounts of Class&#160;A common stock in the public market, or the perception that such sales may occur, could adversely affect the market price of our Class&#160;A common stock. Although we have applied to have our Class&#160;A common stock listed on the Nasdaq Global Market, we cannot assure you that there will be an active public market for our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the closing of this offering, we will have outstanding an aggregate of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of common stock, assuming the issuance of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock offered by us in this offering. Of these shares, all shares of Class&#160;A common stock sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our &#8220;affiliates,&#8221; as that term is defined in Rule&#160;144 under the Securities Act, whose sales would be subject to the Rule&#160;144 resale restrictions described below, other than the holding period requirement. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Lock-Up Agreements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, our officers and directors and holders of substantially all of our Class&#160;A common stock and securities convertible into or exchangeable for our Class&#160;A common stock will agree that, without the prior written consent of Morgan Stanley &amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC, as representatives of the underwriters, we and they will not, subject to certain exceptions, during the period ending 180&#160;days after the date of this prospectus: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly or publicly disclose the intention to make any offer, sale, pledge or disposition of any shares of our Class&#160;A common stock, or any options or warrants to purchase any shares of our Class&#160;A common stock, or any securities convertible into, or exchangeable for, or that represent the right to receive, shares of our Class&#160;A common stock; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">enter into any swap or other arrangement that transfers to another, all or a portion of the economic consequences of ownership of our Class&#160;A common stock or any securities convertible into or exercisable or exchangeable for shares of our Class&#160;A common stock, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">whether any transaction described above is to be settled by delivery of our Class&#160;A common stock or such other securities, in cash or otherwise. Nothing in the lock-up agreements prevents the conversion of Class B common stock into Class A common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The representatives of the underwriters have advised us that they have no present intent or arrangement to release any shares subject to a lock-up, and will consider the release of any lock-up on a case-by-case basis. Upon a request to release any shares subject to a lock-up, the representatives of the underwriters would consider the particular circumstances surrounding the request, including, but not limited to, the length of time before the lock-up expires, the number of shares requested to be released, reasons for the request, the possible impact on the market or our Class&#160;A common stock and whether the holder of our shares requesting the release is an officer, director or other affiliate of ours. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the expiration of the applicable lock-up periods, substantially all of the shares subject to such lock-up restrictions will become eligible for sale, subject to the limitations discussed above. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rule&#160;144</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Affiliate Resales of Restricted Securities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, beginning 90&#160;days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90&#160;days before a sale, who has beneficially owned shares of our Class&#160;A common stock for at least 180&#160;days would be entitled to sell in &#8220;broker&#8217;s transactions&#8221; or certain &#8220;riskless principal transactions&#8221; or to market makers, a number of shares within any three-month period that does not exceed the greater of: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">1% of the number of shares of our Class&#160;A common stock then outstanding; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">161</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:8pt;margin-left:69.66pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the average weekly trading volume in our Class&#160;A common stock on the Nasdaq Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to such sale. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Affiliate resales under Rule&#160;144 are also subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule&#160;144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form 144 with the SEC and Nasdaq concurrently with either the placing of a sale order with the broker or the execution directly with a market maker. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Non-Affiliate Resales of Restricted Securities</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under Rule&#160;144, a person who is not an affiliate of ours at the time of sale, and has not been an affiliate at any time during the 90&#160;days preceding a sale, and who has beneficially owned shares of our common stock for at least six&#160;months but less than a year, is entitled to sell such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell without regard to any Rule&#160;144 restrictions, including the 90-day public company requirement and the current public information requirement. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Non-affiliate resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule&#160;144. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Rule&#160;701</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In general, under Rule&#160;701, any of our employees, directors, officers, consultants or advisors who purchases shares from us in connection with a compensatory stock or option plan or other written agreement before the effective date of the registration statement of which this prospectus forms a part is entitled to sell such shares 90&#160;days after such effective date in reliance on Rule&#160;144. Our affiliates can resell shares in reliance on Rule&#160;144 without having to comply with the holding period requirement, and non-affiliates of the issuer can resell shares in reliance on Rule&#160;144 without having to comply with the current public information and holding period requirements. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The SEC has indicated that Rule&#160;701 will apply to typical stock options granted by an issuer before it becomes subject to the reporting requirements of the Exchange Act, along with the shares acquired upon exercise of such options, including exercises after an issuer becomes subject to the reporting requirements of the Exchange Act. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Rights</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to our IRA, beginning six&#160;months after the completion of this offering, the holders of up to &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;shares of our Class&#160;A common stock, or certain transferees, will be entitled to certain rights with respect to the registration of the offer and sale of those shares under the Securities Act. See the section titled &#8220;Description of Capital Stock&#8212;Registration Rights&#8221; for a description of these registration rights. If the offer and sale of these shares of our Class&#160;A common stock are registered, the shares will be freely tradable without restriction under the Securities Act, subject to the Rule&#160;144 limitations applicable to affiliates, and a large number of shares may be sold into the public market. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Registration Statements on Form S-8</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to file one or more registration statements on Form S-8 under the Securities Act to register all shares of Class&#160;A common stock subject to outstanding stock options, RSUs, warrants and Class&#160;A common stock issuable, under our equity incentive plans. We expect to file the registration statement covering shares offered pursuant to these stock plans shortly after the date of this prospectus, permitting the resale of such shares by non-affiliates in the public market without restriction under the Securities Act and the sale by affiliates in the public market subject to compliance with the resale provisions of Rule&#160;144. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">162</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMUFI">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following discussion is a summary of the material U.S. federal income tax consequences to non-U.S. holders (as defined below) of the purchase, ownership and disposition of our Class&#160;A common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or foreign tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or IRS, in effect as of the date of this offering. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a non-U.S. holder of our Class&#160;A common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position regarding the tax consequences of the purchase, ownership and disposition of our Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This discussion is limited to non-U.S. holders that hold our Class&#160;A common stock as a &#8220;capital asset&#8221; within the meaning of Section&#160;1221 of the Code (property held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a non-U.S. holder&#8217;s particular circumstances, including the impact of the alternative minimum tax, the unearned income Medicare contribution tax, or any state, local or non-U.S. taxes. In addition, it does not address consequences relevant to holders subject to particular rules, including, without limitation: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">U.S. expatriates and certain former citizens or long-term residents of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons holding our Class&#160;A common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">banks, insurance companies, and other financial institutions; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">brokers, dealers or traders in securities or currencies; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">&#8220;controlled foreign corporations,&#8221; &#8220;passive foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">corporations organized outside of the United States, any state thereof or the District of Columbia that are nonetheless treated as U.S. taxpayers for U.S. federal income tax purposes; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-exempt organizations or governmental organizations; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons deemed to sell our Class&#160;A common stock under the constructive sale provisions of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons for whom our Class&#160;A common stock constitutes &#8220;qualified small business stock&#8221; within the meaning of Section&#160;1202 of the Code; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons who hold or receive our Class&#160;A common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">qualified foreign pension funds as defined in Section&#160;897(l)(2) of the Code and entities all of the interests of which are held by qualified foreign pension funds; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">persons subject to special tax accounting rules as a result of any item of gross income with respect to our Class&#160;A common stock being taken into account in an applicable financial statement; and </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">tax-qualified retirement plans. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">If an entity or arrangement treated as a partnership for U.S. federal income tax purposes holds our Class&#160;A common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our Class&#160;A common stock and the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">163</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT LEGAL OR TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR CLASS A COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR NON-U.S. TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Definition of a Non-U.S. Holder</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For purposes of this discussion, a &#8220;non-U.S. holder&#8221; is any beneficial owner of our Class&#160;A common stock that is neither a &#8220;U.S. person,&#8221; nor an entity or arrangement treated as a partnership for U.S. federal income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an individual who is a citizen or resident of the United States; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.7pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.7pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.81pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">a trust that (1)&#160;is subject to the primary supervision of a U.S. court and which has one or more U.S. persons (within the meaning of Section&#160;7701(a)(30) of the Code) who have the authority to control all substantial decisions of the trust, or (2)&#160;has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Distributions</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As described in the section titled &#8220;Dividend Policy,&#8221; we do not anticipate declaring or paying dividends to holders of our Class&#160;A common stock in the foreseeable future. However, if we do make distributions on our Class&#160;A common stock, such distributions of cash or property on our Class&#160;A common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a non-U.S. holder&#8217;s adjusted tax basis in its Class&#160;A common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#8220;&#8212;Sale or Other Taxable Disposition of Class&#160;A Common Stock.&#8221; </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussion below on backup withholding and foreign accounts, dividends paid to a non-U.S. holder of our Class&#160;A common stock that are not effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business within the United States will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty). </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">To claim a reduction in or exemption from withholding, the non-U.S. holder must provide the applicable withholding agent with a properly executed (a)&#160;IRS Form W-8BEN or W-8BEN-E (or other applicable documentation) claiming an exemption from or reduction of the withholding tax under the benefit of an income tax treaty between the United States and the country in which the non-U.S. holder resides or is established, or (b)&#160;IRS Form W-8ECI stating that the dividends are not subject to withholding tax because they are effectively connected with the conduct by the non-U.S. holder of a trade or business within the United States, as may be applicable. Non-U.S. holders that do not timely provide the applicable withholding agent with the required certification, but that qualify for a reduced rate under an applicable income tax treaty, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. Non-U.S. Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">If dividends paid to a non-U.S. holder are effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the non-U.S. holder maintains a permanent establishment in the United States to which such dividends are attributable), then, although exempt from U.S. federal withholding tax (provided the non-U.S. holder provides appropriate </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">164</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">certification, as described above), the non-U.S. holder will be subject to U.S. federal income tax on such dividends on a net income basis at the regular U.S. federal income tax rates. In addition, a non-U.S. holder that is a corporation may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits for the taxable year that are attributable to such dividends, as adjusted for certain items. Non-U.S. holders should consult their tax advisors regarding their entitlement to benefits under any applicable tax treaty. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Sale or Other Taxable Disposition of Class&#160;A Common Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Subject to the discussions below on backup withholding and foreign accounts, a non-U.S. holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our Class&#160;A common stock unless: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the gain is effectively connected with the non-U.S. holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the non-U.S. holder maintains a permanent establishment in the United States to which such gain is attributable); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">the non-U.S. holder is a nonresident alien individual present in the United States for 183&#160;days or more during the taxable year of the disposition and certain other requirements are met; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">our Class&#160;A common stock constitutes U.S. a real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or USRPHC, for U.S. federal income tax purposes. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Gain described in the first bullet point above will generally be subject to U.S. federal income tax on a net income basis at the regular U.S. federal income tax rates. A non-U.S. holder that is a foreign corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on its effectively connected earnings and profits, as adjusted for certain items. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A non-U.S. holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on any gain realized upon the sale or other taxable disposition, which may be offset by certain U.S. source capital losses of the non-U.S. holder (even though the individual is not considered a resident of the United States) provided the non-U.S. holder has timely filed U.S. federal income tax returns with respect to such losses. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">With respect to the third bullet point above, we believe we are not currently and do not anticipate becoming a USRPHC. Because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our other business assets and our non-U.S. real property interests, however, there can be no assurance we are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a non-U.S. holder of our Class&#160;A common stock will not be subject to U.S. federal income tax if our Class&#160;A common stock is &#8220;regularly traded,&#8221; as defined by applicable Treasury Regulations, on an established securities market, and such non-U.S. holder owned, actually and constructively, 5% or less of our Class&#160;A common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the non-U.S. holder&#8217;s holding period. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Non-U.S. holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Information Reporting and Backup Withholding</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A non-U.S. holder will not be subject to backup withholding with respect to distributions on our Class&#160;A common stock we make to the non-U.S. holder, provided the applicable withholding agent does not have actual knowledge or reason to know such holder is a U.S. person and the holder certifies its non-U.S. status, such as by providing a valid IRS Form W-8BEN, W-8BEN-E or W-8ECI, or other applicable certification, or otherwise establishes an exemption. However, information returns generally will be filed with the IRS in connection with any distributions made on our Class&#160;A common stock to the non-U.S. holder, regardless of whether such distributions constitute dividends or whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of the country in which the non-U.S. holder resides or is established. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">165</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:136pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Information reporting and backup withholding may apply to the proceeds of a sale or other taxable disposition of our Class&#160;A common stock within the United States, and information reporting may (although backup withholding generally will not) apply to the proceeds of a sale or other taxable disposition of our Class&#160;A common stock outside the United States conducted through certain U.S.-related financial intermediaries, in each case, unless the beneficial owner certifies under penalty of perjury that it is a non-U.S. holder on IRS Form W-8BEN or W-8BEN-E, or other applicable form (and the payor does not have actual knowledge or reason to know that the beneficial owner is a U.S. person) or such owner otherwise establishes an exemption. Proceeds of a disposition of our Class&#160;A common stock conducted through a non-U.S. office of a non-U.S. broker generally will not be subject to backup withholding or information reporting. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a non-U.S. holder&#8217;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Additional Withholding Tax on Payments Made to Foreign Accounts</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Withholding taxes may be imposed under Sections&#160;1471 to 1474 of the Code, such Sections commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, on certain types of payments made to non-U.S. financial institutions and certain other non-U.S. entities. Specifically, a 30% withholding tax may be imposed on dividends paid on our Class&#160;A common stock, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of our Class&#160;A common stock paid to a &#8220;foreign financial institution&#8221; or a &#8220;non-financial foreign entity&#8221; &#8203;(each as defined in the Code) (including, in some cases, when such foreign financial institution or non-financial foreign entity is acting as an intermediary), unless (1)&#160;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&#160;the non-financial foreign entity either certifies it does not have any &#8220;substantial United States owners&#8221; &#8203;(as defined in the Code) or furnishes identifying information regarding each substantial United States owner, or (3)&#160;the foreign financial institution or non-financial foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in (1)&#160;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#8220;specified United States persons&#8221; or &#8220;United States-owned foreign entities&#8221; &#8203;(each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to non-compliant foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends paid on our Class&#160;A common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of our Class&#160;A common stock, proposed Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. Prospective investors should consult their tax advisors regarding the potential application of FATCA to their investment in our Class&#160;A common stock.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">166</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUND">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">UNDERWRITING</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Under the terms and subject to the conditions in an underwriting agreement dated the date of this prospectus, the underwriters named below, for whom Morgan Stanley &amp; Co. LLC, Jefferies LLC and Cowen and Company, LLC are acting as representatives, have severally agreed to purchase, and we have agreed to sell to them, severally, the number of shares of Class&#160;A common stock indicated below: </font>
        </div>
        <table style="width:456pt;height:91.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:364.68pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:-0.16pt;">Name </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of Shares of </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Class&#160;A Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:364.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Morgan Stanley &amp; Co. LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:52.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:364.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Jefferies LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:52.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:364.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cowen and Company, LLC </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:52.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:364.68pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Guggenheim Securities, LLC</font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:52.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:364.68pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total: </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:52.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:4.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.7pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters and the representatives are collectively referred to as the &#8220;underwriters&#8221; and the &#8220;representatives,&#8221; respectively. The underwriters are offering the shares of Class&#160;A common stock subject to their acceptance of the shares from us and subject to prior sale. The underwriting agreement provides that the obligations of the several underwriters to pay for and accept delivery of the shares of Class&#160;A common stock offered by this prospectus are subject to the approval of certain legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all of the shares of Class&#160;A common stock offered by this prospectus if any such shares are taken. However, the underwriters are not required to take or pay for the shares covered by the underwriters&#8217; over-allotment option described below. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters initially propose to offer part of the shares of Class&#160;A common stock directly to the public at the initial public offering price listed on the cover page of this prospectus and part to certain dealers at a price that represents a concession not in excess of $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;per share under the public offering price. After the initial offering of the shares of Class&#160;A common stock, the offering price and other selling terms may from time to time be varied by the representatives. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We have granted to the underwriters an option, exercisable for 30&#160;days from the date of this prospectus, to purchase up to&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;additional shares of Class&#160;A common stock at the initial public offering price listed on the cover page of this prospectus, less underwriting discounts and commissions. The underwriters may exercise this option solely for the purpose of covering over-allotments, if any, made in connection with the offering of the shares of Class&#160;A common stock offered by this prospectus. To the extent the option is exercised, each underwriter will become obligated, subject to certain conditions, to purchase about the same&#160;percentage of the additional shares of Class&#160;A common stock as the number listed next to the underwriter&#8217;s name in the preceding table bears to the total number of shares of Class&#160;A common stock listed next to the names of all underwriters in the preceding table. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows the per share and total public offering price, underwriting discounts and commissions, and proceeds before expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase up to an additional&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;shares of Class&#160;A common stock. </font>
        </div>
        <table style="width:456pt;height:67pt;margin-top:9.99999999999994pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.16pt;text-align:left;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:19.24pt;" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Per</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Share </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:40.3pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">No Exercise </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:43.3pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Full Exercise </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.16pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Initial public offering price </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:19.24pt;">
              <font style="letter-spacing:0.2pt;">$ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:40.3pt;">
              <font style="letter-spacing:0.2pt;">$ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:43.3pt;">
              <font style="letter-spacing:0.2pt;">$ </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.16pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Underwriting discounts and commissions: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:19.24pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:40.3pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:43.3pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.16pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Proceeds, before expenses, to us </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:19.24pt;">
              <font style="letter-spacing:0.2pt;">$ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.3pt;">
              <font style="letter-spacing:0.2pt;">$ </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:43.3pt;">
              <font style="letter-spacing:0.2pt;">$</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:7.8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The estimated offering expenses payable by us, exclusive of the underwriting discounts and commissions, are approximately $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to $&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters have informed us that they do not intend sales to discretionary accounts to exceed 5% of the total number of shares of Class&#160;A common stock offered by them. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">167</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We intend to apply to list our Class&#160;A common stock on the Nasdaq Global Market under the symbol &#8220;IMRX.&#8221; We do not intend to list the Class B common stock on any securities exchange. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have agreed that, without the prior written consent of the representatives on behalf of the underwriters, we will not, and will not publicly disclose an intention to, during the period ending 180&#160;days after the date of this prospectus, or the restricted period: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our Class&#160;A common stock or any securities convertible into or exercisable or exchangeable for shares of Class&#160;A common stock; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.09pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.09pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">file any registration statement with the SEC relating to the offering of any shares of Class&#160;A common stock or any securities convertible into or exercisable or exchangeable for Class&#160;A common stock; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.1pt; margin-bottom:0pt; text-align:justify; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:6.1pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">enter into any swap, hedge, option, derivative or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our Class&#160;A common stock. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">whether any such transaction described above is to be settled by delivery of our Class&#160;A common stock or such other securities, in cash or otherwise. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The restrictions described in the immediately preceding paragraph do not apply to us in certain circumstances, subject to certain limitations and conditions set forth in the underwriting agreement, including:&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our directors and officers and the holders of substantially all of our outstanding stock have agreed that, without the prior written consent of the representatives on behalf of the underwriters, they will not, and will not publicly disclose an intention to, during the restricted period: (1)&#160;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any common stock or any securities convertible into or exercisable or exchangeable for common stock, (2)&#160;enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, or (3)&#160;make any demand for or exercise any right with respect to the registration of any common stock or any security convertible into or exercisable or exchangeable for common stock. These restrictions do not apply in certain circumstances, subject to certain limitations and conditions set forth in the lock-up agreements, including:&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The representatives, in their sole discretion, may release the Class&#160;A common stock and other securities subject to the lock-up agreements described above in whole or in part at any time. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In order to facilitate the offering of the Class&#160;A common stock, the underwriters may engage in transactions that stabilize, maintain or otherwise affect the price of the Class&#160;A common stock. Specifically, the underwriters may sell more shares than they are obligated to purchase under the underwriting agreement, creating a short position. A short sale is covered if the short position is no greater than the number of shares available for purchase by the underwriters under the over-allotment option. The underwriters can close out a covered short sale by exercising the over-allotment option or purchasing shares in the open market. In determining the source of shares to close out a covered short sale, the underwriters will consider, among other things, the open market price of shares compared to the price available under the over-allotment option. The underwriters may also sell shares in excess of the over-allotment option, creating a naked short position. The underwriters must close out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the Class&#160;A common stock in the open market after pricing that could adversely affect investors who purchase in this offering. As an additional means of facilitating this offering, the underwriters may bid for, and purchase, shares of Class&#160;A common stock in the open market to stabilize the price of the Class&#160;A common stock. These activities may raise or maintain the market price of the Class&#160;A common stock above independent market levels or prevent or retard a decline in the market price of the Class&#160;A common stock. The underwriters are not required to engage in these activities and may end any of these activities at any time. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We and the underwriters have agreed to indemnify each other against certain liabilities, including liabilities under the Securities Act. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">168</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">A prospectus in electronic format may be made available on websites maintained by one or more underwriters, or selling group members, if any, participating in this offering. The representatives may agree to allocate a number of shares of Class&#160;A common stock to underwriters for sale to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters that may make Internet distributions on the same basis as other allocations. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Other Relationships</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various financial advisory and investment banking services for us, for which they received or will receive customary fees and expenses. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In addition, in the ordinary course of their various business activities, the underwriters and their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers and may at any time hold long and short positions in such securities and instruments. Such investment and securities activities may involve our securities and instruments. The underwriters and their respective affiliates may also make investment recommendations or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long or short positions in such securities and instruments. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Pricing of the Offering</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prior to this offering, there has been no public market for our Class&#160;A common stock. The initial public offering price was determined by negotiations between us and the representatives. Among the factors considered in determining the initial public offering price were our future prospects and those of our industry in general, our sales, earnings and certain other financial and operating information in recent periods, and the price-earnings ratios, price-sales ratios, market prices of securities, and certain financial and operating information of companies engaged in activities similar to ours. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Selling Restrictions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Canada</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Class&#160;A common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument&#160;31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the shares of our Class&#160;A common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to section 3A.3 of National Instrument 33-105 Underwriting Conflicts, or NI 33-105, the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding underwriter conflicts of interest in connection with this offering. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">European Economic Area</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock is not a prospectus for the purposes of the </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">169</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Prospectus Regulation (as defined below). This prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock and any offer if made subsequently is directed only at persons in any Member State of the European Economic Area (the &#8220;EEA&#8221; and each such member state, a &#8220;Member State&#8221;) who are &#8220;qualified investors&#8221; within the meaning of Article&#160;2(e) of the Prospectus Regulation. This prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock has been prepared on the basis that any offer of Class&#160;A common stock in that Member State will be made pursuant to an exemption under the Prospectus Regulation from the requirement to publish a prospectus for offers of Class&#160;A common stock. Accordingly any person making or intending to make an offer in that Relevant State of Class&#160;A common stock which is the subject of the offering contemplated in this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock may only do so in circumstances in which no obligation arises for us or any of the underwriters to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation in relation to such offer. Neither us nor the underwriters have authorized, nor do they authorize, the making of any offer of Class&#160;A common stock in circumstances in which an obligation arises for us or the underwriters to publish a prospectus for such offer. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In relation to each Member State, no securities which are the subject of the offering contemplated by this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock to the public may be made in that Member State other than: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to any legal entity which is a qualified investor as defined in the Prospectus Regulation; </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation), subject to obtaining the prior consent of the representatives; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">in any other circumstances falling within Article&#160;1(4) of the Prospectus Regulation, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of shares shall require us or any of the representatives to publish a prospectus pursuant to Article&#160;3 of the Prospectus Regulation or supplement a prospectus pursuant to Article&#160;23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of the representatives and us that it is a &#8220;qualified investor&#8221; as defined in the Prospectus Regulation. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In the case of any shares being offered to a financial intermediary as that term is used in Article&#160;5(1) of the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer have not been acquired on a nondiscretionary basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares to the public other than their offer or resale in a Member State to qualified investors as so defined in the Prospectus Regulation or in circumstances in which the prior consent of the representatives has been obtained to each such proposed offer or resale. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression an &#8220;offer of shares to the public&#8221; in relation to any shares in any Member State means the communication in any form and by means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase shares, and the expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 (as amended). </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">United Kingdom</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">This prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock may not be distributed or circulated to any person in the United Kingdom other than to (i)&#160;persons who have professional experience in matters relating to investments falling within Article&#160;19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#8220;Order&#8221;); and (ii)&#160;high net worth entities falling within Article&#160;49(2)(a) to (d)&#160;of the Order (all such persons together being referred to as &#8220;relevant persons&#8221;). This prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock is directed only at relevant persons. Other persons should not act on this prospectus and any other document or material in connection with the offer or </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">170</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock. This prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock is confidential and is being supplied to you solely for your information and may not be reproduced, redistributed or passed on to any other person or published, in whole or in part, for any other purpose. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Any invitation or inducement to engage in investment activity (within the meaning of Section&#160;21 of the United Kingdom&#8217;s Financial Services and Markets Act 2000, as amended (the &#8220;FSMA&#8221;)) in connection with the issue or sale of the Class&#160;A common stock may only be communicated or caused to be communicated in circumstances in which Section&#160;21(1) of the FSMA does not apply to us. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">All applicable provisions of the FSMA must be complied with in respect to anything done by any person in relation to the Class&#160;A common stock in, from or otherwise involving the United Kingdom. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In relation to the United Kingdom, no securities which are the subject of the offering contemplated by this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock to the public may be made in the United Kingdom other than: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(a)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to any legal entity which is a qualified investor as defined in Article&#160;2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended by the European Union (Withdrawal Agreement) Act 2020 (&#8220;EUWA&#8221;); </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:justify; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(b)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">to fewer than 150 natural or legal persons (other than qualified investors as defined in Article&#160;2 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA) in the United Kingdom subject to obtaining the prior consent of the representatives; or </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">(c)</font>
          <br >
        </div>
        <div style=" margin-top:7.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:40pt;">
          <font style="letter-spacing:0.2pt;">in any other circumstances falling within section 86 of the FSMA, </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">provided that no such offer of no such offer of shares shall require us or any of the representatives to publish a prospectus pursuant to section 85 of the FSMA or supplement a prospectus pursuant to Article&#160;23 of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the purposes of this provision, the expression &#8220;offer of shares to the public&#8221; in relation to any shares means the communication in any form and by any means of sufficient information on the terms of the offer and the shares to be offered so as to enable an investor to decide to purchase or subscribe for the shares. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Hong Kong</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our Class&#160;A common stock has not been and will not be offered or sold in Hong Kong by means of any document other than (i)&#160;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong), (ii)&#160;to &#8220;professional investors&#8221; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder or (iii)&#160;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap.32, Laws of Hong Kong). No advertisement, invitation or document relating to our Class&#160;A common stock have been or will be issued or have been or will be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares of our Class&#160;A common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; within the meaning of the Securities and Futures Ordinance (Cap.571, Laws of Hong Kong) and any rules made thereunder. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Israel</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In the State of Israel this prospectus shall not be regarded as an offer to the public to purchase Class A common stock under the Israeli Securities Law, 5728-1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section 15 of the Israeli </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">171</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Securities Law, 5728-1968, including, inter alia, if: (i) the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#8220;Addressed Investors&#8221;); or (ii) the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728-1968, subject to certain conditions (the &#8220;Qualified Investors&#8221;). The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The Company has not and will not take any action that would require it to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728-1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our Class A common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Japan</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No registration pursuant to Article&#160;4, paragraph 1 of the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948, as amended), or the FIEL, has been made or will be made with respect to the solicitation of the application for the acquisition of the Class&#160;A common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accordingly, the Class&#160;A common stock have not been, directly or indirectly, offered or sold and will not be, directly or indirectly, offered or sold in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan) or to others for re-offering or re-sale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan except pursuant to an exemption from the registration requirements, and otherwise in compliance with, the FIEL and the other applicable laws and regulations of Japan. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">For Qualified Institutional Investors or QII</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&#160;4 of the FIEL) in relation to the Class&#160;A common stock constitutes either a &#8220;QII only private placement&#8221; or a &#8220;QII only secondary distribution&#8221; &#8203;(each as described in Paragraph 1, Article&#160;23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph 1, Article&#160;4 of the FIEL, has not been made in relation to the Class&#160;A common stock. The Class&#160;A common stock may only be transferred to QIIs. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;">
          <font style="letter-spacing:0.2pt;">For Non-QII Investors</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Please note that the solicitation for newly-issued or secondary securities (each as described in Paragraph 2, Article&#160;4 of the FIEL) in relation to the Class&#160;A common stock constitutes either a &#8220;small number private placement&#8221; or a &#8220;small number private secondary distribution&#8221; &#8203;(each as is described in Paragraph 4, Article&#160;23-13 of the FIEL). Disclosure regarding any such solicitation, as is otherwise prescribed in Paragraph&#160;1, Article 4 of the FIEL, has not been made in relation to the Class&#160;A common stock. The Class&#160;A common stock may only be transferred en bloc without subdivision to a single investor. </font>
        </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Singapore</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">This prospectus has not been and will not be registered as a prospectus under the Securities and Futures Act, Chapter 289 of Singapore (the &#8220;SFA&#8221;) by the Monetary Authority of Singapore, and the offer of shares of our Class&#160;A common stock in Singapore is made primarily pursuant to the exemptions under Section&#160;274 and 275 of the SFA. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of shares of our Class&#160;A common stock may not be circulated or distributed, nor may shares of our Class&#160;A common stock be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to any person in Singapore other than (i)&#160;to an institutional investor as defined in Section&#160;4A of the SFA (an &#8220;Institutional Investor&#8221;) pursuant to Section&#160;274 of the SFA, (ii)&#160;to an accredited investor as defined in Section&#160;4A of the SFA (an &#8220;Accredited Investor&#8221;) or other relevant person as defined in Section&#160;275(2) of the SFA (a &#8220;Relevant Person&#8221;) and pursuant to Section&#160;275(1) of the SFA, or to any person pursuant to an offer referred to in Section&#160;275(1A) of the SFA, and in accordance with the conditions, specified in Section&#160;275 of the SFA and (where applicable) Regulation&#160;3 of the Securities and Futures (Classes of Investors) Regulations&#160;2018, or (iii)&#160;otherwise pursuant to, and in accordance with, the conditions of any other applicable exemption or provision of the SFA. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">172</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:336pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">It is a condition of the offer that where shares of our Class&#160;A common stock are subscribed for or acquired pursuant to an offer made in reliance on Section&#160;275 of the SFA by a Relevant Person which is: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(a) a corporation (which is not an Accredited Investor), the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an Accredited Investor; or </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(b) a trust (where the trustee is not an Accredited Investor), the sole purpose of which is to hold investments and each beneficiary of the trust is an individual who is an Accredited Investor, </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">securities or securities-based derivatives contracts (each as defined in Section&#160;2(1) of the SFA) of that corporation and the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred within six&#160;months after that corporation or that trust has subscribed for or acquired shares of our Class&#160;A common stock except: </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">1. to an Institutional Investor, an Accredited Investor, a Relevant Person, or which arises from an offer referred to in Section&#160;275(1A) of the SFA (in the case of that corporation) or Section&#160;276(4)(i)(B) of the SFA (in the case of that trust); </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">2. where no consideration is or will be given for the transfer; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">3. where the transfer is by operation of law; </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">4. as specified in Section&#160;276(7) of the SFA; or </font>
        </div>
        <div style="margin-left:20pt; margin-top:8pt; text-align:justify; width:436pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">5. as specified in Regulation&#160;37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts) Regulations&#160;2018. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">173</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLEMA">&#8203;</a><a name="tEXP">&#8203;</a><a name="tWYCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:216pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">LEGAL MATTERS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The validity of the shares of Class&#160;A common stock offered hereby will be passed upon for us by Latham &amp; Watkins LLP, New York, New York. Sidley Austin LLP, San Francisco, California has acted as counsel for the underwriters in connection with certain legal matters related to this offering. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">EXPERTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The consolidated financial statements of Immuneering Corporation as of December&#160;31, 2020 and 2019 and for each of the&#160;years then ended appearing in this prospectus have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their report thereon, and included in this prospectus and registration statement in reliance upon such report and upon the authority of such firm as experts in accounting and auditing. </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">WHERE YOU CAN FIND MORE INFORMATION</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of Class&#160;A common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed with the registration statement. For further information about us and the Class&#160;A common stock offered hereby, we refer you to the registration statement and the exhibits filed with the registration statement. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the registration statement. The SEC also maintains an internet website that contains reports, proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that website is </font><font style="font-style:italic;letter-spacing:0.2pt;">www.sec.gov</font><font style="letter-spacing:0.2pt;">. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Upon the closing of this offering, we will be required to file periodic reports, proxy statements, and other information with the SEC pursuant to the Exchange Act. These reports, proxy statements, and other information will be available on the website of the SEC referred to above. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We also maintain a website at </font><font style="font-style:italic;letter-spacing:0.2pt;">www.immuneering.com</font><font style="letter-spacing:0.2pt;">, through which you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC. Information contained on or accessed through our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">174</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:432.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:158.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Page </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary</font>
                <br >
                <font style="letter-spacing:-0.2pt;">As of December&#160;31, 2020 and 2019 and for the Years Ended December&#160;31, 2020 and 2019</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <a href="#tROIR"><font style="letter-spacing:0.2pt;">Report of Independent Registered Public Accounting Firm </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <a href="#tROIR">F-<font style="letter-spacing:0.2pt;">2</font> </a>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Consolidated Financial Statements: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:20pt;">
                <a href="#tCBS"><font style="letter-spacing:0.2pt;">Consolidated Balance Sheets as of December&#160;31, 2020 and 2019 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <a href="#tCBS">F-<font style="letter-spacing:0.2pt;">3</font> </a>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:20pt;">
                <a href="#tCSOP"><font style="letter-spacing:0.2pt;">Consolidated Statements of Operations for the Years Ended December&#160;31, 2020 and 2019 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <a href="#tCSOP">F-<font style="letter-spacing:0.2pt;">4</font> </a>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">
                <a href="#tCCPRS"><font style="letter-spacing:0.2pt;">Consolidated Statements of Convertible Preferred Stock and Stockholders&#8217; Deficit for the Years </font>
                  <br >
                  <font style="letter-spacing:0.2pt;">Ended December&#160;31, 2020 and 2019 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <a href="#tCCPRS">F-<font style="letter-spacing:0.2pt;">5</font> </a>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:20pt;">
                <a href="#tCSCF"><font style="letter-spacing:0.2pt;">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2020 and 2019 </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <a href="#tCSCF">F-<font style="letter-spacing:0.2pt;">6</font> </a>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:20pt;">
                <a href="#tNCFS"><font style="letter-spacing:0.2pt;">Notes to Consolidated Financial Statements </font></a>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">
              <a href="#tNCFS">F-<font style="letter-spacing:0.2pt;">7</font></a>
            </td>
            <td style="padding:0pt;padding-left:0.835000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tROIR">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:122pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Report of Independent Registered Public Accounting Firm</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the Stockholders and the Board of Directors of Immuneering Corporation </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Opinion on the Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have audited the accompanying consolidated balance sheets of Immuneering Corporation and its subsidiary (the Company) as of December&#160;31, 2020 and 2019, the related consolidated statements of operations, convertible preferred stock and stockholders&#8217; deficit, and cash flows for each of the&#160;years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2020 and 2019, and the results of their operations and their cash flows for each of the&#160;years then ended, in conformity with accounting principles generally accepted in the United States of America. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Basis for Opinion</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We conducted our audits in accordance with the standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">/s/ RSM US LLP </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We have served as the Company&#8217;s auditor since 2020. </font>
        </div>
        <div style="width:456pt;">
          <div style="margin-top:8pt; text-align:justify; line-height:12pt;">
            <font style="letter-spacing:0.2pt;">Boston, Massachusetts </font>
          </div>
        </div>
        <div style="margin-top:-2pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">May&#160;13, 2021</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCBS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IMMUNEERING CORPORATION AND SUBSIDIARY</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED BALANCE SHEETS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">December&#160;31, 2020 and 2019</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:593pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">ASSETS</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current assets: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cash and cash equivalents </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">37,090,151</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">13,782,175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">500,110</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">209,940</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaids and other current assets </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">140,958</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">71,218</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current assets </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">37,731,219</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">14,063,333</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">64,363</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">35,276</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Right-of-use asset </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">613,103</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other assets </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">14,333</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 3pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total assets</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">38,423,018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">14,098,609</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:7.167pt 0pt 0.5pt 0pt; width:327.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:-0.2pt;">LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Current liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">1,480,537</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">294,948</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">698,992</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">210,348</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Lease liability, current </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">76,322</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total current liabilities </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,255,851</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">505,296</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Long-term liabilities: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease liability, noncurrent </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">544,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Liability for Series&#160;A preferred stock </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">3,509,802</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total liabilities </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">2,800,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">4,015,098</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Commitments and contingencies (Note 11) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Convertible preferred stock: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:327.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;B preferred stock, $0.001 par value, 6,032,183 shares authorized, 3,619,292 and 0 shares issued and outstanding at December&#160;31, 2020 and 2019, respectively, net of issuance costs </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">36,983,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 0.5pt 0pt; width:327.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Series&#160;A preferred stock, $0.001 par value, 2,495,933 shares authorized, 2,495,933 and 1,966,043 shares issued and outstanding at December&#160;31, 2020 and 2019, respectively, net of issuance costs </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">21,119,940</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">16,611,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total convertible preferred stock </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">58,103,850</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">16,611,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Stockholders&#8217; deficit: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:327.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class&#160;A common stock, $0.001 par value, 15,733,000 shares authorized, 3,535,811 shares issued and outstanding at December&#160;31, 2020 and 2019 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,536</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.5pt 0pt; width:327.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Class&#160;B common stock, $0.001 par value, 6,032,183 shares authorized, 0&#160;shares issued and outstanding at December&#160;31, 2020 and 2019 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Additional paid-in capital </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">3,252,654</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:37.5pt; text-align:right; white-space:nowrap;">2,165,885</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated deficit </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">(25,737,640<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">(8,697,742<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total stockholders&#8217; deficit </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">(22,481,450<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">(6,528,321<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 3pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:-0.2pt;">Total liabilities, convertible preferred stock and stockholders&#8217; deficit</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">38,423,018</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:37.5pt; text-align:right; white-space:nowrap;">14,098,609</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.51pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSOP">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:237pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IMMUNEERING CORPORATION AND SUBSIDIARY</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED STATEMENTS OF OPERATIONS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR THE YEARS ENDED DECEMBER 31, 2020 and 2019</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:310pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:329.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Revenue</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">2,311,535</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,919,709</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Cost of revenue</font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">1,280,325</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">1,222,970</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Gross profit</font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">1,031,210</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">696,739</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:329.51pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Operating expenses</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Research and development </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">15,003,786</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">4,278,862</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">General and administrative </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">3,109,978</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">2,708,891</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Total operating expenses </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">18,113,764</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">6,987,753</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:30pt;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Loss from operations</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(17,082,554<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(6,291,014<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:329.51pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Other income (expense)</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Interest Income </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">42,656</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">57,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Interest expense </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(351,302<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Loss on conversion of convertible notes </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(1,124,792<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:329.51pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:-0.2pt;">Net loss</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(17,039,898<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">(7,709,448<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:329.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Net loss per share attributable to common stockholders, basic and diluted </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(4.82<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">(2.18<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 3.25pt 0pt; width:329.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding, basic and diluted </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:329.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma net loss per share attributable to common stockholders, basic and diluted (unaudited) </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(2.78<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:329.51pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Pro&#160;forma weighted-average common shares outstanding, basic and diluted (unaudited) </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">6,127,858</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="min-height:579.31pt;page-break-after:always; width:775.7pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCCPRS">&#8203;</a>
      </div>
      <div style="margin-top:61.66pt;margin-left:46.86pt;width:680pt;">
        <div style="text-align:center; width:680pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:29.5pt;margin-left:46.86pt;width:680pt;">
        <div style="margin-top:12pt; text-align:center; width:680pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">IMMUNEERING CORPORATION AND SUBSIDIARY</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:680pt; line-height:12pt;font-weight:bold;font-size:10pt;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; DEFICIT </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR THE YEARS ENDED DECEMBER 31, 2020 and 2019</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:680pt;height:321.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:136.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Convertible Preferred Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="40">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217; Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:15.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:136.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;B </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Series&#160;A </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Convertible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Preferred </font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;" rowspan="2">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Class&#160;A</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Class&#160;B</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Common Stock </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Additional</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Paid-In</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Capital </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Accumulated</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:8pt; padding-bottom:0pt;">
                <font style="letter-spacing:-0.16pt;">Total</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Stockholders&#8217;</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Deficit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:13.5pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:136.85pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Par Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Par Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:136.85pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.18pt;">Balance at December&#160;31, 2018</font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">3,536</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">830,220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">(988,294<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">(154,538<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:136.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Conversion of convertible notes and interest into Series&#160;A convertible preferred stock </font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">785,706</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">6,718,886</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">6,718,886</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:136.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of Series&#160;A convertible preferred stock, net of issuance costs </font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1,180,337</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">9,892,946</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">9,892,946</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:136.85pt;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of common stock </font>
                <br >
                <font style="letter-spacing:0.18pt;">warrants pursuant to advisory </font>
                <br >
                <font style="letter-spacing:0.18pt;">agreements </font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">739,034</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">739,034</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:136.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation expense </font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">596,631</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">596,631</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:136.85pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Net loss </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">(7,709,448<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">(7,709,448<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:136.85pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.18pt;">Balance at December&#160;31, 2019</font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1,966,043</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">16,611,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">16,611,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">3,536</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">2,165,885</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">(8,697,742<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">(6,528,321<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:136.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of Series&#160;A convertible preferred stock, net of issuance costs </font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">529,890</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">4,508,108</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">4,508,108</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:136.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Issuance of Series&#160;B convertible preferred stock, net of issuance costs </font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">3,619,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">36,983,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">36,983,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212; </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:136.85pt;white-space:normal;text-align:left;">
              <div style="margin-left:18pt; text-indent:-9pt;">
                <font style="letter-spacing:0.18pt;">Stock-based compensation expense </font> </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:29.25pt; text-align:right; white-space:nowrap;">1,086,769</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:35.25pt; text-align:right; white-space:nowrap;">1,086,769 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:136.85pt;text-align:left;">
              <div style="margin-left:9pt;">
                <font style="letter-spacing:0.18pt;">Net loss </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">(17,039,898<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">(17,039,898<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:9pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:136.85pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.18pt;">Balance at December&#160;31, 2020</font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">3,619,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">36,983,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">2,495,933</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">21,119,940</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">58,103,850</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="width:0.25pt;padding:0pt;font-size:0pt;line-height:0pt;padding-left:0.75pt;background-color:#000000;border-bottom:1px solid #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.75pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">3,536</td>
            <td style="padding:0pt;padding-left:4.02pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.66pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.74pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:29.25pt; text-align:right; white-space:nowrap;">3,252,654</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">(25,737,640<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:35.25pt; text-align:right; white-space:nowrap;">(22,481,450<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:center; width:680pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements. </font>
        </div>
      </div>
      <div style="margin-top:1.99999999999997pt;height:12pt;margin-left:46.86pt;width:680pt;">
        <div style="text-align:center; width:680pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:49.64pt;margin-left:168.89pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;font-size:10pt;">
          <font style="letter-spacing:0.2pt;">F-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSCF">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">IMMUNEERING CORPORATION AND SUBSIDIARY</font>
        </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11.5pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">CONSOLIDATED STATEMENTS OF CASH FLOWS </font>
          <br >
          <font style="letter-spacing:-0.2pt;">FOR THE YEARS ENDED DECEMBER 31, 2020 and 2019</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:595.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from operating activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(17,039,898<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(7,709,448<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Adjustment to reconcile to net loss to net cash used in operating activities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Depreciation </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">24,328</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">18,079</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Right-of-use asset amortization </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">54,977</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Non-cash interest expense </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">351,302</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Stock based compensation expense </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">1,086,769</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">596,631</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Non-cash warrant expense </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">739,034</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Loss on conversion of notes </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">1,124,792</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Change in assets and liabilities: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">(Increase) decrease in: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Accounts receivable </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(290,170<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">614,105</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses and other current assets </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(69,740<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">(20,466<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Other assets </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(14,333<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:30pt;">
                <font style="letter-spacing:0.2pt;">Increase (decrease) in: </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Accounts payable </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">1,185,589</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">270,496</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Accrued expenses </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">488,644</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">37,990</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Lease liability </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(46,991<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:40pt;">
                <font style="letter-spacing:0.2pt;">Deferred revenue </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(465,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:50pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in operating activities </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(14,620,825<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(4,442,485<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from investing activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Purchase of property and equipment </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(53,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(20,526<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:50pt;">
                <font style="letter-spacing:0.2pt;">Net cash used in investing activities </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(53,415<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(20,526<font style="position:absolute;">) </font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:9pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Cash flows from financing activities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:327.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the issuance of Series&#160;A preferred stock, net of issuance costs </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">998,306</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">13,402,748</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:327.84pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from the issuance of Series&#160;B preferred stock, net of issuance costs </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">36,983,910</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Proceeds from issuance of convertible notes payable </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">3,825,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Payment of debt issuance costs </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">(56,242<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:50pt;">
                <font style="letter-spacing:0.2pt;">Net cash provided by financing activities </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">37,982,216</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">17,171,506</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Net increase in cash and cash equivalents</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">23,307,976</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">12,708,495</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.25pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Cash and cash equivalents at beginning of period</font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">13,782,175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">1,073,680</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3pt 0pt 3pt 0pt; width:327.84pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Cash and cash equivalents at end of period</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">37,090,151</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">13,782,175</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:327.84pt;text-align:left;">
              <font style="letter-spacing:-0.2pt;">Supplemental disclosures of noncash information:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:1.578pt 0pt 1.922pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Conversion of convertible notes and interest into Series&#160;A preferred </font>
                <br >
                <font style="letter-spacing:0.2pt;">stock </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.583pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">6,718,886</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.5pt 0pt 3pt 0pt; width:327.84pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Reclassification of liability for Series&#160;A preferred stock </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">3,509,802</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 2.25pt 0pt;border-bottom:3pt double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The accompanying notes are an integral part of these consolidated financial statements.</font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-6</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tNCFS">&#8203;</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 1&#8201;&#8212;&#8201;Organization and Nature of Business</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Immuneering Corporation, a Delaware corporation, (&#8220;Immuneering&#8221; or the &#8220;Company&#8221;) was incorporated in 2008. The Company leverages bioinformatics to develop new medicines unlikely to be found by traditional drug discovery methods. The Company&#8217;s current pipeline of drug candidates is focused on treating aspects of disease that have eluded conventional approaches. Utilizing its proprietary Disease Cancelling Technology, the Company&#8217;s objective is to discover and develop medicines that reverse a disease signal across many relevant genes. Concurrent with its internal programs, the Company provides computational biology services to pharmaceutical and biotechnology companies. On October&#160;30, 2019, Immuneering formed a wholly owned subsidiary, Immuneering Securities Corporation (&#8220;ISC&#8221;), a Massachusetts securities corporation, for the sole purpose of buying, selling and holding securities on the Company&#8217;s behalf. Immuneering and ISC are collectively referred to as &#8220;the Company&#8221; throughout these consolidated financial statements. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Since inception, the Company has devoted substantially all of its efforts to business planning, service revenue generation, research and development, recruiting management and technical staff, and raising capital. The Company has financed its operations through service revenues, the issuance of convertible debt and the sale of convertible preferred stock and common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company is subject to risks associated with any biotechnology company that has substantial expenditures for research and development. There can be no assurance that the Company&#8217;s research and development program will be successful, that products developed will obtain necessary regulatory approval, and that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees, advisors, and consultants. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company has funded its operations primarily with proceeds from the sale of its capital stock and convertible notes. The Company has incurred recurring losses over the past several years and as of December&#160;31, 2020, the Company had an accumulated deficit of $25,737,640. The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurances that additional funding will be available on terms acceptable to the Company, or at all. Management estimates that its cash and cash equivalents of $37,090,151 as of December&#160;31, 2020, along with the gross proceeds of $24,799,786 from the issuance of shares in the second tranche of Series&#160;B Preferred in April and May&#160;2021 (Note 6) will enable it to meet our current operating plans for at least the next twelve&#160;months after the date that the financial statements were issued.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2 &#8201;&#8212;&#8201;Summary of Significant Accounting Policies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Basis of Presentation:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The consolidated financial statements have been prepared in accordance with accounting standards set by the Financial Accounting Standards Board (&#8220;FASB&#8221;). The FASB sets generally accepted accounting principles (&#8220;GAAP&#8221;) to ensure the consolidated financial statements are consistently reported. References to GAAP issued by the FASB in these footnotes are to the FASB Accounting Standards Codifications (&#8220;ASC&#8221;). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Use of Estimates:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the reporting periods. Actual results could differ from those estimates. Significant estimates reflected in these consolidated financial statements included but are not limited to, the research and development expenses, determination of fair value of stock-based awards, the valuation of common stock, and the right-to-use assets and operating lease liability. Actual results could differ from these estimates. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Segments:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (&#8220;CODM&#8221;) in making decisions regarding resource allocation and assessing performance. The Company&#8217;s chief executive officer is </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-7</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:42pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2 &#8201;&#8212;&#8201;Summary of Significant Accounting Policies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">the CODM, and he uses consolidated financial information in determining how to allocate resources and assess performance. The Company has determined that it operates in one segment.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Cash and Cash Equivalents:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three&#160;months or less at the date of purchase. Cash is maintained at Federal Deposit Insurance Company (&#8220;FDIC&#8221;) insured financial institutions. At times, the Company has maintained cash in excess of FDIC limits, however it has not experienced any losses with respect to its cash balances. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Accounts Receivable:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Accounts receivable are stated at the amount management expects to collect from outstanding balances. An allowance for doubtful accounts is estimated for those accounts receivable considered to be uncollectible based upon historical experience and management&#8217;s evaluation of outstanding accounts receivable. Bad debts are written off against the allowance when identified. At December&#160;31, 2020 and 2019 there was no allowance for doubtful accounts. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Concentration of Credit Risk:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Financial instruments that potentially subject the Company to significant concentration of credit risk consist primarily of accounts receivable and revenue. To manage accounts receivable credit risk, the Company continuously evaluates the creditworthiness of its customers and the need for an allowance for potential credit losses. The Company has not experienced any losses in such accounts. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following customers comprised 10% or more of the Company&#8217;s total accounts receivable or revenues as of or for the period ended December&#160;31, 2020 (customers with an asterisk are less than 10%): </font>
        </div>
        <table style="width:456pt;height:97pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:200.74pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:200.74pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% of Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accounts Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% of Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #1 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">676,710</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">29.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">214,345 </td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">42.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #2 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">570,000</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">24.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">71,250 </td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">14.2<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #3 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">306,900</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">13.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #4 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">250,880</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">10.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">63,000 </td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">12.6<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #5 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">91,975 </td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">18.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following customers comprised 10% or more of the Company&#8217;s total accounts receivable or revenues as of or for the period ended December&#160;31, 2019 (customers with an asterisk are less than 10%): </font>
        </div>
        <table style="width:456pt;height:97pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:200.74pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Year Ended December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">As of December&#160;31, 2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:200.74pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Revenue </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% of Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Accounts Receivable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">% of Total </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #1 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">630,000</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">32.8<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #2 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">559,140</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">29.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">102,240 </td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">48.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #3 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">224,400</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">11.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #4 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">54,300 </td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">25.9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:200.74pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Customer #5 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:4.64pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:13.665pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">21,300 </td>
            <td style="padding:0pt;padding-left:14.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">10.1<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:9.025pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:10pt; text-align:center; width:446pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;"> </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-8</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2 &#8201;&#8212;&#8201;Summary of Significant Accounting Policies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Property and Equipment:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Property and equipment are recorded at cost, net of accumulated depreciation. Expenditures for major replacements and improvements are capitalized, while expenditures for general repairs and maintenance are expensed as incurred. Upon retirements or disposition of property and equipment, the related cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is recorded in the consolidated statement of operations. Depreciation is calculated using the straight-line method once assets are placed in service. </font>
        </div>
        <table style="width:416pt;height:47.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt 0pt 2.167pt 0pt; width:363.17pt;">
              <div style="white-space:nowrap;">
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;padding-right:1pt;letter-spacing:-0.16pt;">Asset Class </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 2.167pt 0pt; width:40.83pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Estimated</font>
                <br >
                <font style="border-bottom:1px solid #000000;padding-bottom:1pt;letter-spacing:-0.16pt;">Useful Lives </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:363.17pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:40.83pt;">
              <font style="letter-spacing:0.2pt;">3&#160;years </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:363.17pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:40.83pt;">
              <font style="letter-spacing:0.2pt;">5&#160;years</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8.3pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Impairment of Long-lived Assets:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. To date, no impairments have occurred. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Leases:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;In February&#160;2016 the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-02, Leases (Topic 842) (&#8220;ASC 842&#8221;), a standard issued to increase transparency and comparability among organizations related to their leasing activities. This standard established a right-of-use model that requires the recognition of right-of-use assets and lease liabilities for most leases as well as provides disclosure with respect to certain qualitative and quantitative information related to a company&#8217;s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company adopted the leasing standard using the modified retrospective transition approach as of January&#160;1, 2020, with no restatement of prior periods or cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of transition practical expedients, which allowed the Company to carry forward prior conclusions related to whether any expired or existing contracts are or contain leases, the lease classification for any expired or existing leases, and initial direct costs for existing leases. The Company also made an accounting policy election to not recognize leases with an initial term of 12&#160;months or less within its consolidated balance sheets, and to recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. The adoption of the leasing standard did not have an impact on the consolidated statement of operations. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company determines if an arrangement is a lease at contract inception. Right-of-use assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the commencement date of the lease based upon the present value of future lease payments over the expected lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. As most of the Company&#8217;s leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate, which is based on rates that would be incurred to borrow on a collateralized basis over a term equal to the lease payments in a similar economic environment, in determining the present value of lease payments. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has elected not to separate lease and non-lease components as a single lease component. The Company&#8217;s lease is reflected in right-of-use asset and lease liabilities (current and non-current) in the consolidated balance sheets. The right-of-use assets and lease liabilities were $61,822 upon adoption on </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-9</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2 &#8201;&#8212;&#8201;Summary of Significant Accounting Policies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">January&#160;1, 2020. Fixed rents are included in the calculation of the lease balances while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized on a straight-line basis over the lease term.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Convertible preferred stock:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company has classified convertible preferred stock (&#8220;Preferred Stock&#8221;) as temporary equity in the accompanying consolidated balance sheets due to certain changes in control events that are outside of the Company&#8217;s control, including transfer of control of the Company, where holders of the Preferred Stock could cause redemption of the shares in these situations. The Company does not accrete the carrying values of the Preferred Stock to the redemption values since a liquidation event was not considered probable as of December&#160;31, 2020 and 2019. Subsequent adjustments of the carrying values to the redemption values will be made only if it becomes probable that such a liquidation event will occur. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Revenue Recognition:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Effective January&#160;1, 2019, the Company adopted ASC 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;) using the modified retrospective transition method applied to those contracts that were not completed as of that effective date and all contracts thereafter. The adoption did not have an impact on the financial statements. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods and services. The core principle of the standard is to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. To achieve that core principle, the Company applies the following five-step model: </font>
        </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Identify the contract with a customer </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Identify the performance obligations in the contract </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Determine the transaction price </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Allocate the transaction price to the performance obligations in the contract </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.9pt; margin-bottom:0pt; text-align:left; width:10pt;white-space:nowrap;">
          <font style="letter-spacing:0.2pt;">&#8226;</font>
          <br >
        </div>
        <div style=" margin-top:5.9pt; margin-bottom:0pt; line-height:12pt; text-align:left; margin-left:30pt;">
          <font style="letter-spacing:0.2pt;">Recognize revenue when or as performance obligations are satisfied </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s contracts generally consist of the promise to provide computational biology professional services to pharmaceutical and biotechnology companies, which the Company has concluded constitutes one performance obligation that is delivered over time. The transaction price is the amount of consideration to which the Company expects to be entitled in exchange for transferring the services to the customer. The Company&#8217;s contracts provide for either agreed upon rates per hour based on the level of the professional working on the project or a fixed fee for a defined scope of work. The Company recognizes revenue over time by measuring the progress toward complete satisfaction of the performance obligation using a single method of measuring progress, which depicts the performance in transferring control of the associated services to the customer. The Company uses input methods to measure the progress toward the complete satisfaction of performance obligations and evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenue and net loss in the period of adjustment. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s contract terms do not allow for a right of return or refund and do not contain significant financing components. Receivables associated with the contract will generally be collected within thirty to sixty days, in accordance with the underlying payment terms. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Income Taxes:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the&#160;years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-10</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2 &#8201;&#8212;&#8201;Summary of Significant Accounting Policies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when management determines that it is probable that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable. The Company has not identified any significant uncertain tax positions as of December&#160;31, 2020 or 2019. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Research and Development:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;Research and development costs are expensed as incurred. Research and development costs consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company also incurs costs to develop software programs for internal use in identifying potential human drug targets which may then lead to the development of human drug candidates. To date the software programs have primarily been used for internal research and development activities and the costs incurred have been expensed as research and development. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Stock-based Compensation:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company issues stock-based awards to employees and nonemployees in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation&#8201;&#8212;&#8201;Stock Compensation (&#8220;ASC 718&#8221;), which requires all stock-based payments to employees and nonemployees, including grants of employee stock options and modifications to existing stock options, to be recognized in the consolidated statement of operations based on their fair values. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The fair value of options is estimated on the grant date using the Black-Scholes option-pricing model (&#8220;Black-Scholes&#8221;). Black-Scholes requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term of its stock option, the volatility of the Company&#8217;s common stock, and an assumed risk-free interest rate. The Company uses the simplified calculation of expected life and volatility is based on an average of the historical volatility of a group of publicly traded companies in a similar industry that the Company believes would be considered a peer group had it been a publicly held company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. Forfeitures are recognized as they occur. No dividend yield was assumed as the Company does not pay, and does not expect to pay, dividends on its common stock. The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgement. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In accordance with ASU No. 2018-07, Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting, compensation expense for stock-based awards granted to nonemployees is recognized over the period during which services are rendered by such nonemployees. The new standard largely aligns the accounting for share-based payment awards issued to employees and nonemployees by expanding the scope of ASC 718 to apply to nonemployee share-based transactions, as long as the transaction is not effectively a form of financing. There was no adjustment to the financial statements upon adoption of this standard as of January&#160;1, 2020. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As there has been no public market for the Company&#8217;s common stock to date, the estimated fair value of its common stock has been determined by its board of directors as of the date of each option grant, with input from management, considering the Company&#8217;s most recently available third-party valuations of common stock and its board of directors&#8217; assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. These third-party valuations were performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants&#8217; Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Each valuation methodology includes estimates and assumptions that require the Company&#8217;s judgment. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to the Company&#8217;s common stock at the time of, and the likelihood of, achieving a liquidity event, such as an initial public offering or sale. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-11</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2 &#8201;&#8212;&#8201;Summary of Significant Accounting Policies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The assumptions underlying these valuations represent management&#8217;s best estimates, which involve inherent uncertainties and the application of management&#8217;s judgment. As a result, if the Company had used different assumptions or estimates, the fair value of its common stock and its stock-based compensation expense could be materially different. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Fair Value of Financial Instruments:</font><font style="letter-spacing:0.2pt;">&nbsp;&nbsp;&nbsp;The Company follows the guidance prescribed by ASC Topic 820, Fair Value Measurements (&#8220;ASC 820&#8221;), which establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value which focuses on an exit price which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. </font>
        </div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:48pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Level&#160;1:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:48pt;">
          <font style="letter-spacing:0.2pt;">Pricing inputs are quoted prices available in active markets for identical investments as of the reporting date. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:48pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Level&#160;2:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:48pt;">
          <font style="letter-spacing:0.2pt;">Pricing inputs are quoted prices for similar investments, or inputs that are observable, either directly or indirectly, for substantially the full term through corroboration with observable market data. The Company does not have any instruments meeting the criteria of Level&#160;2 inputs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:justify; width:48pt;white-space:nowrap;">
          <font style="font-weight:bold;letter-spacing:-0.2pt;">Level&#160;3:</font>
          <br >
        </div>
        <div style=" margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:justify; margin-left:48pt;">
          <font style="letter-spacing:0.2pt;">Pricing inputs include unobservable inputs that reflect the reporting entity&#8217;s own assumptions about the assumptions market participants would use in pricing the asset or liability, which are developed based on the best information available. The Company does not have any instruments meeting the criteria of Level&#160;3 inputs. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The carrying amounts reflected in the consolidated balance sheets for cash, accounts payable and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments. As of December&#160;31, 2020 and 2019, the Company only holds Level&#160;1 cash equivalents, which consist of money market funds of $36,842,373 and $13,375,975, respectively. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Recent Accounting Pronouncements</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. The Company is an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act of 2012, as amended (Jobs Act). The Jobs Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company elected to avail itself of this extended transition period and, as a result, we will not be required to adopt new or revised accounting standards on the relevant dates on which adoption of such standards is required for other public companies. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In June&#160;2016, the FASB issued ASU 2016-13, Financial Instruments&#8201;&#8212;&#8201;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Statements. The new standard, as amended, requires that expected credit losses relating to financial assets measured on an amortized cost basis and available-for-sale debt securities be recorded through an allowance for credit losses. It also limits the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-12</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 2 &#8201;&#8212;&#8201;Summary of Significant Accounting Policies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">also requires the reversal of previously recognized credit losses if fair value increases. The targeted transition relief standard allows filers an option to irrevocably elect the fair value option of ASC 825-10, Financial Instruments-Overall, applied on an instrument-by-instrument basis for eligible instruments. ASU No. 2016-13, Financial Instruments&#8201;&#8212;&#8201;Credit Losses (Topic 326) will become effective for the Company on January&#160;1, 2023. The Company is currently evaluating the impact of adopting this new accounting guidance.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing certain exceptions to the general principles in the existing guidance for income taxes and making other minor improvements. The amendments are effective for annual reporting periods beginning after December&#160;15, 2020 with early adoption permitted. The Company is currently evaluating the impact of adopting this new accounting guidance.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 3&#8201;&#8212;&#8201;Property and Equipment</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Property and equipment consisted of the following at December&#160;31, 2020 and 2019: </font>
        </div>
        <table style="width:416pt;height:84.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:309.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Computer equipment </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">174,317</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">139,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Furniture and fixtures </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">18,798</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">193,115</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">139,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:309.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accumulated depreciation </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(128,752<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(104,424<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:309.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Property and equipment, net</font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">64,363</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">35,276</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.49pt; text-align:justify; width:456pt; line-height:12.5pt;">
          <font style="letter-spacing:0.2pt;">Depreciation expense totaled $24,328 and $18,079 for the&#160;years ended December&#160;31, 2020 and 2019, respectively.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 4&#8201;&#8212;&#8201;Accrued Expenses</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Accrued expenses consisted of the following at December&#160;31, 2020 and 2019: </font>
        </div>
        <table style="width:416pt;height:69pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:316.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:316.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued professional expenses </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">269,302</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">91,632</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:316.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued employee expenses </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">163,668</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">118,716</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:316.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accrued contract research expenses </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">266,022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:316.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">698,992</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">210,348</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.99pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 5&#8201;&#8212;&#8201;Convertible Notes Payable</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During the&#160;years ended December&#160;31, 2018 and 2019, the Company entered into convertible promissory note agreements (&#8220;Convertible Notes&#8221;) for an aggregate amount of $1,450,000 and $3,825,000, respectively. The Convertible Notes accrued interest at 6% per annum and became payable upon demand any time on or after September&#160;30, 2019. All repayments must first have been applied to accrued interest and then to the outstanding principal balance, and required prior written consent from the noteholders for advanced repayment. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Convertible Notes contained multiple conversion features including qualified financing, non-qualified financing, liquidation event and voluntary conversion. All of the Convertible Notes contained a provision whereby the notes were automatically convertible upon a qualified financing with gross proceeds in excess of $4,000,000 at a conversion rate of 80% of the per share price paid by investors in the financing. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-13</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 5&#8201;&#8212;&#8201;Convertible Notes Payable&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon the occurrence of a non-qualified financing, all of the Convertible Notes were convertible at the option of the holders, at a conversion rate of 80% of the per share price paid by investors in the financing. Upon the occurrence of a liquidation event, the Convertible Notes would be settled with a cash repayment equal to two times the principal balance. Lastly, at any time on or after the second anniversary of the demand date, the Convertible Notes were eligible for voluntary conversion into common stock at a conversion rate of 80% of the per share fair market value. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company evaluated all the settlement features included within the convertible note agreements, noting that none of the features was considered to be predominant. The Company also evaluated all features under ASC Topic 815, Derivatives and Hedging (&#8220;ASC 815&#8221;), and determined all features met the definition of a derivative and required bifurcation. The derivative was recorded at fair value based on the occurrence of a triggering event taking place during the term of the notes. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">For the year ended December&#160;31, 2019 non-cash interest expense was $351,302 and issuance costs totaled $56,242. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In conjunction with the issuance of Series&#160;A Preferred in September&#160;2019 (Note 6) the Convertible Notes with embedded derivatives and accrued interest totaling $5,375,167 were converted at a price of 80% of the Series&#160;A Preferred per share price, or $6.84 for total conversion value of $6,718,886. In connection with the conversion of the Convertible Notes and related interest, the Company also recorded extinguishment costs of $53,201 related to the unamortized issuance costs and a final fair value adjustment to the related derivative liability by recording a gain of $21,280. Upon extinguishment of the Convertible Notes, accrued interest and derivative liability, the Company recorded a loss of $1,124,792. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 and 2019, there was no outstanding balance for Convertible Notes nor related derivatives since the Convertible Notes were converted prior to December&#160;31, 2019. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The following table shows changes to the carrying values of the Convertible Notes and associated embedded derivatives for the year ended December&#160;31, 2019: </font>
        </div>
        <table style="width:416pt;height:108pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:294.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Convertible</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Notes Payable </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Embedded</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Derivatives </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2018 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,098,867</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">378,351</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Issuance of additional convertible notes payable </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">2,838,279</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">986,721</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accretion of debt discount </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">345,077</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in fair value </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(21,280<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Extinguishment </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(4,282,223<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(1,343,792<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:294.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Balance at December&#160;31, 2019 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.81pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 6&#8201;&#8212;&#8201;Convertible Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Series&#160;A Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In September&#160;2019, the Company authorized the sale and issuance of up to 1,987,979 shares of Series&#160;A Preferred Stock, $0.001 par value per share, at an original issuance price of $8.5514 per share. In January&#160;2020, the number of shares authorized for the Series&#160;A Preferred Stock was increased to 2,495,933 shares. The Series&#160;A Preferred Stock financing was structured to be issued in rolling closes during 2019 and 2020. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On September&#160;20, 2019, the Company issued an additional 1,122,458 shares of Series&#160;A Preferred Stock for gross cash proceeds of $9,598,847 and issued 785,706 shares of Series&#160;A Preferred Stock in conjunction with the conversion of the outstanding amount of the Convertible Notes (Note 5). In 2019, the Company incurred issuance costs of $200,587 in connection with this offering. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-14</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 6&#8201;&#8212;&#8201;Convertible Preferred Stock&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company received funds for issuance of an additional 468,315 shares of Series&#160;A Preferred Stock for gross cash proceeds of $4,004,975 through December&#160;31, 2019. Of these shares, 410,436 shares of Series&#160;A Preferred Stock for gross cash proceeds of $3,509,802 exceeded the authorized amount allowed by the articles of incorporation, resulting in a liability of $3,509,802 and a total of 1,966,043 shares of Series&#160;A Preferred Stock outstanding at December&#160;31, 2019. In January&#160;2020, the shares that were previously classified as a liability as of December&#160;31, 2019 were reclassified to temporary equity upon the approved increase to authorized shares of Series&#160;A Preferred Stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In January&#160;2020, the Company issued 119,454 additional shares of Series&#160;A Preferred Stock for gross cash proceeds of $1,021,413. The Company incurred issuance costs of $23,610 in connection with the financing in January&#160;2020. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Series&#160;B Preferred Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In December&#160;2020, the Company authorized the sale and issuance of up to 6,032,183 shares of Series&#160;B Preferred Stock, $0.001 par value per share, at an original issuance price of $10.2782 per share. The Series&#160;B Preferred Stock financing was structured to close in two tranches. The first tranche closed in December&#160;2020 and the Company issued 3,619,292 shares of Series&#160;B Preferred Stock for gross cash proceeds of $37,199,929. The Company incurred issuance costs of $216,019 in connection with the financing in December&#160;2020. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The Company determined the right of the investors to purchase 2,412,853 shares of Series&#160;B Preferred Stock in the second tranche does not meet the definition of a freestanding financial instrument as it is not separable from the Series&#160;B Preferred Stock issued in the first tranche. The issuance of the second tranche is subject to the Company meeting certain development milestones or at the election of the holders of at least a majority of the then outstanding shares of Series&#160;B Preferred Stock which must include one specific shareholder (the &#8220;Requisite Holders&#8221;). Each holder of Series&#160;B Preferred Stock may elect to purchase their requisite shares of the second tranche at any time. As of December&#160;31, 2020, the Company has not met these development milestones nor did the Requisite Holders elect to purchase the second tranche prior to meeting these milestones and therefore no shares of the second tranche were issued. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In April and May&#160;2021, all 2,412,853 shares of the second tranche of Series&#160;B Preferred Stock were issued based on the voluntary election of substantially all of the holders of Series&#160;B Preferred Stock. The Company received gross proceeds of $24,799,786. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the rights and preferences of the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (&#8220;Preferred Stock&#8221;) are as follows: </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Conversion</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Each share of Preferred Stock may be converted at any time, at the option of the holder, into shares of Class&#160;A common stock, subject to the applicable conversion rate as determined by dividing the original issue price by the conversion price. The conversion price for the Series&#160;A Preferred Stock and Series&#160;B Preferred Stock (as may be adjusted for certain customary dilutive events) is $8.5514 and $10.2782, respectively. The Preferred Stock automatically convert into shares of Class&#160;A common stock at the then effective conversion rate upon the closing of a public offering of the Company&#8217;s securities with gross proceeds to the Company of at least $75,000,000 and a share price of at least $10.2782 or at the election of the holders of the Requisite Holders. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Holders of Series&#160;B Preferred Stock that would beneficially own at least 9.9% of any then outstanding class of equity securities may elect to receive a portion of their converted Series&#160;B Preferred Stock as Class&#160;B common stock upon conversion. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Dividends</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Preferred Stockholders are entitled to receive per annum dividends of 7% of the original issue price share, payable only when, as and if declared by the Board of Directors. The right to receive these dividends is not </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-15</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 6&#8201;&#8212;&#8201;Convertible Preferred Stock&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">cumulative, and therefore, if not declared in any year, the right to receive such dividends shall terminate and not carry forward into the next year. As of December&#160;31, 2020 and 2019, no dividends had been declared.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Voting Rights</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Preferred Stock and common stock vote together as one class on an as converted basis. Common stock voting rights on certain matters are subject to the powers, preferences, and rights of the Preferred Stock. Preferred Stockholders are entitled to vote on all matters and shall have the number of votes equal to the number of shares of common stock into which the shares of Preferred Stock held by such holder are then convertible. As long as 2,132,029 shares of Preferred Stock are outstanding, certain actions such as mergers, acquisition, liquidation, dissolution, wind up of business, and deemed liquidation events, must be approved by the holders of at least a majority of the then-outstanding shares of Preferred Stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Liquidation Preference</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Upon liquidation, dissolution, or winding up of business, holders of Preferred Stock are entitled to receive a liquidation preference in priority to holders of common stock at the original respective Preferred Stock issue price for such series. If assets available for distribution are insufficient to satisfy the liquidation payment to holders of Preferred Stock in full, assets available for distribution will be allocated among holders Preferred Stock on a pari&#160;passu basis at an amount per share equal to the greater of the respective original Preferred Stock issue price for such series plus any declared but unpaid dividends or such amount had all shares been converted to common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">When holders of Preferred Stock are satisfied in full, any excess assets available for distribution will be allocated ratably among common stock holders based on their pro&#160;rata shareholdings. Upon a deemed liquidation event, as defined in the articles of incorporation, holders have the option to redeem their shares at the liquidation payment amounts summarized above. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Redemption</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Other than described above, the shares of Preferred Stock are not redeemable.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 7&#8201;&#8212;&#8201;Common Stock</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company has 15,733,000 authorized shares of Class&#160;A common stock, $0.001 par value per share, of which 3,535,811 are issued and outstanding. The holders of Class&#160;A common stock are entitled one vote for each share of common stock. Dividends may be paid when, and if declared by the Board of Directors, subject to the limitations, powers and preferences granted to the Series&#160;Preferred stockholders and on a proportionate basis with holders of Class&#160;B common stock. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the following number of shares of Class&#160;A common stock have been reserved: </font>
        </div>
        <table style="width:416pt;height:70.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:363.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of Series&#160;A Preferred </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">2,495,933</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:363.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Conversion of Series&#160;B Preferred </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">3,619,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:363.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise of common stock warrants </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">220,220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:363.59pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Exercise of common stock options </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,286,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:363.59pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">7,622,063</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.9pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company has 6,032,183 authorized shares of Class&#160;B common stock, $0.001 par value per share, of which no shares have been issued nor are outstanding. The holders of Class&#160;B common stock have no voting rights. Dividends may be paid when, and if, declared by the Board of Directors, subject to the limitations, powers and preferences granted to the preferred stockholders and on a proportionate basis with holders of Class&#160;A common stock. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-16</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:52.5pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 7&#8201;&#8212;&#8201;Common Stock&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Common Stock Warrants</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During 2019, the Company issued warrants to purchase an aggregate of 220,220 shares of common stock at an exercise price of $4.21 per share to several advisors, including 143,560 shares to entities related to members of the Board of Directors of the Company, in lieu of cash payments. These warrants vested immediately upon issuance, become exercisable on January&#160;9, 2021 and have a 10 year term set to expire on January&#160;9, 2030. The fair value of these warrants, totaling $739,034, was recorded in the consolidated statements of operations as general and administrative expense during the year ended December&#160;31, 2019. The Company evaluated the terms of these warrants and determined that equity classification was appropriate. As of December&#160;31, 2020, no warrants have been exercised. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The fair value of these warrants was estimated using a Black-Scholes model with the following assumptions: </font>
        </div>
        <table style="width:416pt;height:68.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:361.78pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:42.22pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:361.78pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:42.22pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1.89% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:361.78pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend yield </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42.22pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:361.78pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Volatility </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42.22pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">77.03% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:361.78pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42.22pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">10.0&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 8&#8201;&#8212;&#8201;Net Loss Per Share Attributable to Common Stockholders</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Net loss per share of common stock is computed using the two-class method required for multiple classes of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the Class&#160;A and Class&#160;B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net loss per share attributed to common stockholders is therefore the same for Class&#160;A and Class&#160;B common stock on an individual or combined basis. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company&#8217;s participating securities include the Company&#8217;s Preferred Stock, as the holders are entitled to receive noncumulative dividends in the event that a dividend is paid on common stock. The holders of Preferred Stock do not have a contractual obligation to share in losses of the Company, and therefore during periods of loss there is no allocation required under the two-class method. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the if-converted method based on the nature of such securities. The Company has reported net losses for all periods presented, therefore diluted net loss per common share attributable to common stockholders is the same as basic net loss per common share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-17</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 8&#8201;&#8212;&#8201;Net Loss Per Share Attributable to Common Stockholders&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Basic and diluted net loss per share attributable to common stockholders was calculated at December&#160;31 as follows: </font>
        </div>
        <table style="width:416pt;height:96pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Numerator:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(17,039,898<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(7,709,448<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:289.51pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Denominator&#8201;&#8211;&#8201;basic and diluted: </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding, basic and </font>
                <br >
                <font style="letter-spacing:0.2pt;">diluted </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:289.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss per share&#8201;&#8211;&#8201;basic and diluted </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(4.82<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">(2.18<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.2pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive (in common stock equivalent shares) at December&#160;31: </font>
        </div>
        <table style="width:416pt;height:84pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:311.17pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:311.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;A Preferred </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">2,495,933</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,966,043</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Series&#160;B Preferred </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">3,619,292</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:311.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Warrants to purchase common stock </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33.75pt; text-align:right; white-space:nowrap;">220,220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">220,220</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:311.17pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Options to purchase common stock </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">1,286,618 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,124,996</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:311.17pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total shares of common stock equivalents </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33.75pt; text-align:right; white-space:nowrap;">7,622,063 </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,311,259</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.2pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Unaudited pro&#160;forma net loss per share attributable to common stockholders is computed using the weighted-average number of common shares outstanding after giving effect to the conversion of all the convertible preferred stock into shares of common stock as if such conversion had occurred at the beginning of the period presented or the date of original issuance, if later. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the Company&#8217;s unaudited pro&#160;forma net loss per share attributable to common stockholders for the year ending December&#160;31, 2020: </font>
        </div>
        <table style="width:416pt;height:114.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:350.26pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:350.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Numerator: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">(17,039,898<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.26pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Denominator: </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:350.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Weighted-average common shares outstanding, basic and diluted </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:36.75pt; text-align:right; white-space:nowrap;">3,535,811</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:350.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Assumed conversion Series&#160;A Preferred and Series&#160;B Preferred </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">2,592,047</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:350.26pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Denominator for pro forma basic and diluted loss </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">6,127,858</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:350.26pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Net loss per share&#8201;&#8211;&#8201;basic and diluted </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:36.75pt; text-align:right; white-space:nowrap;">(2.78<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:17.2pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 9&#8201;&#8212;&#8201;Stock-Based Compensation</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During 2015, the Company established the 2015 Stock Incentive Plan (&#8220;Incentive Plan&#8221;), under which incentive stock options, nonqualified stock options and common stock may be awarded to employees, directors or consultants of the Company. The options typically vest over a four-year period. At December&#160;31, 2020, the maximum number of shares available for issuance under the Incentive Plan was 2,017,981 shares. At December&#160;31, 2020, the number of shares available for future grants under the Incentive Plan was 730,363 shares. During the&#160;years ended December&#160;31, 2020 and 2019, the Company recognized stock-based </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-18</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:29pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 9&#8201;&#8212;&#8201;Stock-Based Compensation&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">compensation expense of $1,086,769 and $596,631, respectively. At December&#160;31, 2020, compensation expense remaining to be recognized for outstanding stock options was $1,655,822 and to be recognized over a weighted-average period of 2.0&#160;years.</font><font style="font-weight:bold;letter-spacing:-0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company used the following assumptions in its application of the Black-Scholes option pricing model for grants in 2020 and 2019: </font>
        </div>
        <table style="width:416pt;height:68.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.6pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:70.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:70.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:251.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Risk-free interest rate </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0.36% - 1.45% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">1.77% - 2.20% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:251.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected dividend yield </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">0% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:251.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Volatility </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">67.30% - 80.85% </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:0.2pt;">66.99% - 70.44% </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:251.6pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Expected term </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.92 - 10&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:70.2pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6.08&#160;years</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table summarizes the stock option activity under the Plan: </font>
        </div>
        <table style="width:456pt;height:182.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Number of</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Shares </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Exercise</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Price </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Weighted</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Average</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Remaining</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Contractual</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Term </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Aggregate</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Intrinsic</font>
                <br >
                <font style="letter-spacing:-0.16pt;">Value </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding, December&#160;31, 2018 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">521,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.72</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.77</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">714,496</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.22</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cancelled </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(111,000<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">4.72</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding, December&#160;31, 2019 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,124,996</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">9.13</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Granted </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">245,122</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.26</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Cancelled </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(83,500<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:251.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Outstanding, December&#160;31, 2020 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,286,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.22</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.37</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;padding-bottom:1.75pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,994,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:4pt 0pt 1.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and exercisable at December&#160;31, 2020 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">617,741</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">7.74</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:4pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">963,675</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:251.22pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Vested and expected to vest at December&#160;31, 2020 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,286,618</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.22</td>
            <td style="padding:0pt;padding-left:4.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.37</td>
            <td style="padding:0pt;padding-left:10.975pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,994,744</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">During December&#160;2019, the Company modified the exercise price of options to purchase 418,000 shares of common stock to $4.21 and the related incremental expense of $34,525 was recognized during the year ended December&#160;31, 2019 and was included as a component of share-based compensation expense. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">For the&#160;years ended December&#160;31, 2020 and 2019, the Company recognized share-based compensation expense recognized on the accompanying consolidated statements of operations as follows: </font>
        </div>
        <table style="width:416pt;height:69pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:308.88pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:308.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Cost of revenue </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">108,027</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">166,674</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Research and development </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">503,111</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">305,729</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:308.88pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">General and administrative </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">475,631</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">124,228</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:308.88pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,086,769</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">596,631</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-19</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 10&#8201;&#8212;&#8201;Income Taxes</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">A reconciliation of the effect of applying the federal statutory rate to the net loss and the effective income tax rate are as follows: </font>
        </div>
        <table style="width:416pt;height:129pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:349.93pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Statutory federal income tax rate </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">21.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">21.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">State tax, net of federal benefit </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">6.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">6.3<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Permanent differences </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(1.5<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(1.9<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Federal research and development credits </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">4.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">3.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">State research and development credits </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">0.4<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Other differences </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(3.7<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15.75pt; text-align:right; white-space:nowrap;">(5.4<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:349.93pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Change in valuation allowance </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(27.3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">(23.4<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:349.93pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Effective income tax rate </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:15.75pt; text-align:right; white-space:nowrap;">0.0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020 and 2019, the components and tax effects of each type of item that gave rise to the net deferred tax assets were as follows: </font>
        </div>
        <table style="width:416pt;height:190.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:294.51pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2019 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Deferred tax assets:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Stock-based compensation expense </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">73,984</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">27,521</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">R&amp;D credit carryforward </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,574,596</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">675,646</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">NOL carryforward </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">5,525,123</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">1,797,847</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Gross deferred tax assets </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">7,173,703</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">2,501,014</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Valuation allowance </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(7,127,448<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(2,479,213<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net deferred tax assets </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">46,255</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">21,801</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Net deferred tax liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Prepaid expenses deducted for tax </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(28,671<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">(12,163<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Tax depreciation in excess of book </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(17,584<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(9,638<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Total deferred tax liabilities </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(46,255<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">(21,801<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:294.51pt;text-align:left;">
              <div style="margin-left:20pt;">
                <font style="letter-spacing:0.2pt;">Net deferred taxes </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Federal net operating losses (&#8220;NOL&#8221;) generated in tax&#160;years ended after December&#160;31, 2017 are limited to 80% of taxable income, only carried forward and carried forward indefinitely under the Internal Revenue Code (&#8220;IRC&#8221;). The Company has no income tax expense due to operating losses incurred for the years ended December&#160;31, 2020 and 2019. The Company has provided a valuation allowance for the full amount of the net deferred tax assets as, based on all available evidence, it is considered more likely than not that all the recorded deferred tax assets will not be realized in a future period. At December&#160;31, 2020, the Company has federal and state NOLs of $22,012,360 and $14,280,490, respectively all generated after the tax year ended December&#160;31, 2017. At December&#160;31, 2020, the Company has federal and state research and development credit carryforwards, $1,347,372 and $227,225, respectively, that start to expire beginning in 2025. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As the Company has not yet achieved profitable operations, management believes the tax benefits as of December&#160;31, 2020 did not satisfy the realization criteria set forth in ASC Topic 740, Income Taxes and, therefore, has recorded a full valuation allowance for the entire deferred tax asset. The valuation allowance increased in 2020 by $4,648,234 due to the increase in the deferred tax assets by the same amount, primarily due to NOL and research and development credit carryforwards. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-20</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 10&#8201;&#8212;&#8201;Income Taxes&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company has generated significant net operating loss carryforwards and research and development tax credits, as a result of incurred losses due to research activities since inception. The Company is generally able to carry NOLs and R&amp;D credits forward to reduce our tax liability in future&#160;years. However, our ability to utilize the NOLs and R&amp;D credits is subject to the rules of Sections&#160;382 and 383 of the Internal Revenue Code of 1986. Those sections generally restrict the use of NOLs and R&amp;D credits after an &#8220;ownership change.&#8221; We may have experienced an &#8220;ownership change&#8221; within the meaning of Section&#160;382 in the past and there can be no assurance that we will not experience additional ownership changes in the future. As a result, our NOLs and business credits (including the R&amp;D credit) may be subject to limitations and we may be required to pay taxes earlier and in larger amounts than would be the case if our NOLs or R&amp;D credits were freely usable. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company files tax returns in the United States including California, New York and Massachusetts. All tax&#160;years from 2016 to 2020 remain open to examination by the major taxing jurisdictions to which the Company is subject, as carryforward attributes generated in&#160;years past may still be adjusted upon examination by the Internal Revenue Service (&#8220;IRS&#8221;) or other authorities if they have or will be used in a future period. The Company is not currently under examination by the IRS or any other jurisdictions for any tax&#160;years. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">On March&#160;27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable&#160;years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable&#160;years to generate a refund of previously paid income taxes. The enactment of the CARES Act resulted in increased federal and state research and development carryforwards from 2013 through 2018 of $142,764 and $55,901, respectively, and decreased federal NOL of $759,794 from 2018. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, the Company had no uncertain tax positions. The Company has elected to recognize interest and penalties related to income tax matters as a component of income tax expense, of which no interest or penalties were recorded for the&#160;years ended December&#160;31, 2020 and 2019.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 11&#8201;&#8212;&#8201;Commitments and Contingencies</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Operating Leases</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company leases office space in Cambridge, Massachusetts and New York, New York pursuant to short-term arrangements. The Cambridge lease is on a month-to-month basis, requiring one month&#8217;s notice before termination. The New York lease is renewable on a quarterly basis and the last renewal was on March&#160;8, 2021 which extended the lease term until June&#160;30, 2021. These lease agreements include payments for lease and non-lease components and the Company has elected to not separate such components and these payments were recognized as rent expense. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As of December&#160;31, 2020, total future minimum lease payments for its short-term leases in Cambridge, Massachusetts and New York, New York, was $12,000 all due in 2021. The Company leases storage space for its electronic data equipment in Somerville, Massachusetts. This lease is renewable on an annual basis effective every March&#160;1st. Prior to December&#160;31, 2020, the Company renewed the lease through March&#160;31, 2022. As of December&#160;31, 2020, total future minimum lease payments for this lease were $21,416 due in 2021 and $3,569 due in 2022. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In July&#160;2019, the Company entered into an office lease in San Diego, California (&#8220;2019 San Diego Lease&#8221;) with a lease term of 24&#160;months with no escalations and variable costs based on additional number of employees using the facility. This lease was cancelable upon a 30-day notice period. Upon adoption of ASC 842 on January&#160;1, 2020, a right-to-use asset and lease liability based on the fixed costs was recognized by the Company for $61,822. Effective September&#160;20, 2020, the lease was terminated and the remaining right-of-use asset and lease liability were derecognized. No gain or loss was recognized for the termination of this lease. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-21</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 11&#8201;&#8212;&#8201;Commitments and Contingencies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In October&#160;2020, the Company entered into an office lease in San Diego, California (&#8220;2020 San Diego Lease&#8221;) with a lease term of 67&#160;months. At the lease commencement date, a right-to-use asset and lease liability was recognized by the Company for $637,863. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Maturities of the lease liabilities due under the Company&#8217;s 2020 San Diego Lease as of December&#160;31, 2020 are as follows: </font>
        </div>
        <table style="width:416pt;height:209pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:362.96pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2021 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">111,527</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2022 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">115,430</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2023 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">125,741</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2024 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">161,498</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2025 </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">167,150</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">2026 </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">57,332</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Total future lease payments </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">738,678</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Less: Imputed interest </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(117,589<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:362.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total lease liabilities </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">621,089</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Current portion lease liability </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">76,322</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:362.96pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Lease liability, noncurrent </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">544,767</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:362.96pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total lease liability </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:27pt; text-align:right; white-space:nowrap;">621,089</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:17pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:362.96pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Quantitative information regarding the Company&#8217;s leases for the year ended December&#160;31, 2020 is as follows: </font>
        </div>
        <table style="width:416pt;height:146.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:366.29pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">2020 </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Lease costs:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating lease cost </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">66,652</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Short-term lease cost </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">252,796</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Variable lease cost </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">14,700</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:366.29pt;text-align:left;">
              <div style="margin-left:10pt;">
                <font style="letter-spacing:0.2pt;">Total lease costs </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">334,148</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <font style="letter-spacing:0.2pt;">Cash paid for amounts included in the measurement of lease liabilities:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating cash flows from operating leases </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">58,666</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:366.29pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Operating cash flows from short-term leases </font> </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">252,796</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:366.29pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">311,462</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:30.5pt;margin-left:20pt;margin-top:15pt;border-collapse: collapse;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:361.78pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:361.78pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average remaining lease term&#8201;&#8211;&#8201;operating leases </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:42.22pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">5.33&#160;years </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:361.78pt;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Weighted average discount rate&#8201;&#8211;&#8201;operating leases </font> </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42.22pt;text-align:center;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.2pt;">6.0%</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">As the Company&#8217;s leases typically do not provide an implicit rate, the Company uses an estimate of its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-22</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:150pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Immuneering Corporation and Subsidiary </font>
        </div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="text-transform:uppercase;letter-spacing:-0.2pt;">Notes to Consolidated Financial Statements</font><font style="letter-spacing:-0.2pt;">&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 11&#8201;&#8212;&#8201;Commitments and Contingencies&#8201;(Continued)</font>
        </div>
        <div style="margin-top:12pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Litigation</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company may be exposed to litigation in connection with its products and operations. The Company&#8217;s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. The Company is not aware of any material legal matters. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">Clinical Research Contracts</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The Company may enter into contracts in the normal course of business with clinical research organizations for clinical trials, with contract manufacturing organizations for clinical supplies, and with other vendors for preclinical studies, supplies and other services for our operating purposes. These contracts generally provide for termination with a 30-day notice. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style=" text-decoration:underline #000000 solid;letter-spacing:0.2pt;">COVID-19</font><font style="letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">In March&#160;2020, the World Health Organization declared the outbreak of a novel coronavirus disease (&#8220;COVID 19&#8221;) a pandemic, which continues to spread throughout the United States and worldwide. As of the date of the consolidated financial statements were issued, the Company&#8217;s operations have not been significantly impacted by the COVID-19 outbreak. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 outbreak will have on its financial condition and operations, including planned clinical trials. The Company believes that there may be an impact on the clinical development of its product candidates, including potential delays, halts or modifications to its planned trials. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 12&#8201;&#8212;&#8201;Related Party Transactions</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">An officer of the Company is a board member of a contract research organization (&#8220;CRO&#8221;) that provides contract services to the Company. Research and development expenses in the accompanying consolidated statement of operations include the cost of services provided by the CRO to the Company which amounted to $2,744,051 and $400,504 for the&#160;years ended December&#160;31, 2020 and 2019, respectively. Of this amount, $279,153 and $95,878 was owed to the CRO at December&#160;31, 2020 and 2019, respectively, and is included in accounts payable or accrued contract research expenses in the accompanying consolidated balance sheets.</font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Note 13&#8201;&#8212;&#8201;Subsequent Events</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Management has evaluated subsequent events through May&#160;13, 2021, the date the consolidated financial statements were issued, and determined that no additional subsequent events had occurred that would require recognition in these consolidated financial statements except as disclosed in Note 6.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&nbsp;&nbsp;&nbsp; </font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">F-23</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:27.85pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:96pt; text-align:center; width:456pt; line-height:16pt;font-weight:bold;font-family:Georgia, Times, Times New Roman, serif;font-size:14pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;Shares<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.28pt;"> </font></div>
        <div style="position:relative;margin-top:74pt; text-align:center; width:456pt;">
          <img src="lg_immuneering-4clr.jpg" alt="[MISSING IMAGE: lg_immuneering-4clr.jpg]" height="48" width="281" >
        </div>
        <div style="margin-top:41pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Georgia, Times, Times New Roman, serif;font-size:12pt;">Class A Common Stock<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.24pt;"> </font></div>
        <div style="margin-top:84pt; text-align:center; width:456pt; line-height:14pt;font-weight:bold;font-family:Georgia, Times, Times New Roman, serif;font-size:12pt;">PROSPECTUS<font style="font-style:normal;font-weight:normal;font-family:Times New Roman, Times, serif ;letter-spacing:0.24pt;"> </font></div>
        <table style="width:456pt;margin-top:98pt;border-collapse: collapse;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:11pt;">
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:11pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:120pt;text-align:left;">
              <font style="letter-spacing:0.22pt;">MORGAN STANLEY</font>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:72pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.22pt;">JEFFERIES</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:60pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:0.22pt;">COWEN</font>
              </div>
            </td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt; width:4pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 1pt 0pt; width:180pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.22pt;">GUGGENHEIM SECURITIES</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:84pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Through and including&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021 (25&#160;days after the date of this prospectus), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions.</font><font style="font-style:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:72pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2021</font>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Part II</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">INFORMATION NOT REQUIRED IN PROSPECTUS</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;13.&nbsp;&nbsp;&nbsp;Other Expenses of Issuance and Distribution.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The following table indicates the expenses to be incurred in connection with the offering described in this registration statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimated except the Securities and Exchange Commission registration fee, the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq listing fee. </font>
        </div>
        <table style="width:456pt;height:159pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:399pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Amount </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">SEC registration fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</font><font style="position:absolute;">*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">FINRA filing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Initial listing fee </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Accountants&#8217; fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Legal fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Blue Sky fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Transfer Agent&#8217;s fees and expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Printing and engraving expenses </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:399pt;text-align:left;">
              <div style="white-space:nowrap;">
                <font style="letter-spacing:0.2pt;">Miscellaneous expenses </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:399pt;text-align:left;">
              <div style="font-weight:bold;">
                <font style="letter-spacing:-0.2pt;">Total</font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3pt double #000000; min-width:30pt; text-align:right; white-space:nowrap;">
              <font style="position:relative;">&#8203;</font><font style="position:absolute;"><font style="font-weight:bold;font-size:8pt;"></font>*</font>
            </td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:6.6pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:7.1pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">To be filed by amendment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;14.&nbsp;&nbsp;&nbsp;Indemnification of Directors and Officers.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Prior to the closing of the offering to which this Registration Statement relates, Immuneering Corporation. intends to convert into a Delaware corporation pursuant to a statutory conversion, and will change its name to Immuneering Corporation. Section&#160;102 of the DGCL permits a corporation to eliminate the personal liability of directors of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation to be effective upon the corporate conversion will provide that no director of the Registrant shall be personally liable to it or its stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors for breaches of fiduciary duty. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Section&#160;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee, or agent of the corporation, or a person serving at the request of the corporation for another corporation, partnership, joint venture, trust or other enterprise in related capacities against expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by the person in connection with an action, suit or proceeding to which he was or is a party or is threatened to be made a party to any threatened, ending or completed action, suit or proceeding by reason of such position, if such person acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the Court of Chancery or such other court shall deem proper. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-1</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Our certificate of incorporation to be effective upon the corporate conversion will provide that we will indemnify each person who was or is a party or threatened to be made a party to any threatened, pending or completed action, suit or proceeding (other than an action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such persons being referred to as an &#8220;Indemnitee&#8221;), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was unlawful. Our restated certificate of incorporation provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, a director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including attorneys&#8217; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#8217; fees) actually and reasonably incurred in connection therewith. Expenses must be advanced to an Indemnitee under certain circumstances. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We intend to enter into indemnification agreements with each of our directors and officers. These indemnification agreements may require us, among other things, to indemnify our directors and officers for some expenses, including attorneys&#8217; fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of his or her service as one of our directors or officers, or any of our subsidiaries or any other company or enterprise to which the person provides services at our request. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">We maintain a general liability insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions in their capacities as directors or officers. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">In any underwriting agreement we enter into in connection with the sale of Class&#160;A common stock being registered hereby, the underwriters will agree to indemnify, under certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain liabilities. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;15.&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">During the past three&#160;years, we issued securities that were not registered under the Securities Act as set forth below. The following is a summary of transactions during the preceding three fiscal&#160;years involving sales of our securities that were not registered under the Securities Act: </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(a) Issuance of Capital Stock</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On July&#160;28, 2015, certain shareholders sold 4,180,820 shares of common stock to Teva Pharmaceuticals USA, Inc., or Teva, for a total amount of $44,998,166. In January&#160;2018, the Company terminated its contract with Teva and Teva returned 3,827,239 shares of common stock to the Company. On May&#160;28, 2020, Teva sold 353,581 shares of common stock to certain shareholders for a total amount of $1,538,077. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">From September&#160;2019 to January&#160;2020, we issued and sold to investors in a private placement an aggregate of 2,495,933 shares of Series&#160;A Preferred Stock at a purchase price of $8.5514 per share, for aggregate consideration of approximately $20.0&#160;million. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">On December&#160;31, 2020, we issued and sold to investors in a private placement an aggregate of 3,619,292 shares of Series&#160;B Preferred Stock at a purchase price of $10.2782 per share, for an aggregate consideration of </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-2</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:292pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">approximately $37.2&#160;million. In addition, in April and May&#160;2021, we issued and sold to investors in a private placement an additional 2,412,852 shares of Series&#160;B Preferred Stock at a purchase price of $10.2782 per share, for an aggregate consideration of approximately $24.8&#160;million. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No underwriters were involved in the foregoing issuances of securities. The securities described in this section (a)&#160;of Item&#160;15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&#160;4(a)(2) under the Securities Act and Regulation&#160;D promulgated thereunder relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. The recipients of securities in the transactions described above represented that they were accredited investors and were acquiring the securities for their own account for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time and appropriate legends were affixed to the instruments representing such securities issued in such transactions. </font>
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">(b) Stock Option Grants and Option Exercises</font><font style="font-style:normal;font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">From January&#160;1, 2018 through December&#160;31, 2020, we granted to our employees, officers, directors and other persons who provide services to us options to purchase up to 1,224,994 shares of Class&#160;A common stock under the 2015 Plan, at a weighted average exercise price of $4.21 per share. 194,500 of these options were terminated, expired without being exercised or were otherwise forfeited. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">No underwriters were involved in the foregoing issuances of securities. The issuances of stock options described in this paragraph (b)&#160;of Item&#160;15 were issued pursuant to written compensatory plans or arrangements with our employees, directors, consultants and advisors, in reliance on the exemption provided by Rule&#160;701 promulgated under the Securities Act, or pursuant to Section&#160;4(a)(2) under the Securities Act, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All recipients either received adequate information about us or had access, through employment or other relationships, to such information. </font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-3</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-left:69.66pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;16.&nbsp;&nbsp;&nbsp;Exhibits and Financial Statements.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <table style="width:456pt;height:413.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:28pt;">
              <div style="text-align:center;">
                <font style="letter-spacing:-0.16pt;">Exhibit</font>
                <br >
                <font style="letter-spacing:-0.16pt;">No. </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:416pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Description of Exhibit </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">&#8199;1.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Form of Underwriting Agreement. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">Amended and Restated Certificate of Incorporation of the Registrant (as amended and currently in effect). </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.2* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Bylaws of the Registrant (currently in effect). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.3* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be in effect upon the consummation of this offering). </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">&#8199;3.4* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;">
                <font style="letter-spacing:0.2pt;">Form of Amended and Restated Bylaws of the Registrant (to be in effect upon the consummation of this offering). </font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">&#8199;4.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Specimen Stock Certificate evidencing the shares of Class&#160;A common stock. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">&#8199;5.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Opinion of Latham &amp; Watkins LLP. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.1 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2115679d2_ex10-1.htm">Amended and Restated Investors&#8217; Rights Agreement, dated December&#160;21, 2020, by and among the Registrant and the other parties thereto.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.2 </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2115679d2_ex10-2.htm">Master Services Agreement, dated August&#160;5, 2019, by and between Bioarkive LLC and the Registrant.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.3&#8224;* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Immuneering Corporation 2008 Stock Incentive Plan and form of option agreement thereunder. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.4&#8224;* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Immuneering Corporation Long Term Incentive Plan and form of option agreement thereunder. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.5&#8224;* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2115679d2_ex10-5.htm">Employment Letter Agreement, dated March&#160;5, 2021, by and between Biren Amin and the Registrant.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.6&#8224;* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2115679d2_ex10-6.htm">Employment Letter Agreement, dated October&#160;24, 2019, by and between Brett Hall, Ph.D. and the Registrant.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.7&#8224;* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:416pt;white-space:normal;text-align:justify;">
              <div style="text-align:justify;letter-spacing:0.2pt;">
                <a style="-sec-extract:exhibit" href="tm2115679d2_ex10-7.htm">Employment Letter Agreement, dated October&#160;11, 2019, by and between Scott Barrett, M.D. and the Registrant.</a>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.8&#8224;* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">2021 Incentive Award Plan and forms of award agreements thereunder. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">10.9&#8224;* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">2021 Employee Stock Purchase Plan. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">21.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">List of Subsidiaries of the Registrant. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">23.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Consent of RSM US LLP, independent registered public accounting firm. </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">23.2* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Consent of Latham &amp; Watkins LLP (included in Exhibit&#160;5.1). </font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:28pt;">
              <font style="letter-spacing:0.2pt;">24.1* </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:416pt;">
              <font style="letter-spacing:0.2pt;">Power of Attorney (included on signature page).</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10pt; width:456pt;">
          <div style="margin-left: 0pt; width: 48pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">*</font>
          <br >
        </div>
        <div style=" margin-top:5.61pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">To be filed by amendment. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:9pt; margin-top:2.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#8224;</font>
          <br >
        </div>
        <div style=" margin-top:2.61pt; margin-bottom:0pt; line-height:9pt; text-align:left; margin-left:20pt;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">Indicates a management contract or compensatory plan or arrangement. </font>
        </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8.62pt; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">Item&#160;17.&nbsp;&nbsp;&nbsp;Undertakings.</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="margin-top:7.72pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">The undersigned registrant hereby undertakes to provide to the underwriter, at the closing specified in the underwriting agreement, certificates in such denominations and registered in such names as required by the underwriter to permit prompt delivery to each purchaser. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:11.5pt;">
          <font style="letter-spacing:0.2pt;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue. </font>
        </div>
      </div>
      <div style="margin-top:2.00000000000002pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-4</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;margin-bottom:504pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">The undersigned hereby undertakes that: </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule&#160;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&#160;424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </font>
        </div>
        <div style="margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</font>
        </div>
      </div>
      <div style="margin-top:0pt;height:12pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">II-5</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;,&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, on this&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;day of&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;&#8201; &#8199;&#8199;&#8199;&#8199;, 2021. </font>
        </div>
        <table style="width:456pt;height:63pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:207.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:17pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:207.5pt;">
              <font style="letter-spacing:-0.2pt;">IMMUNEERING CORPORATION</font>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:207.5pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1pt 0pt; width:17pt;">
              <font style="letter-spacing:0.2pt;">By:</font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 1pt 0pt; width:207.5pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 207.5pt; margin-top: 11.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">
                <font style="letter-spacing:0.2pt;">Benjamin J. Zeskind, Ph.D.</font>
                <br >
                <font style="letter-spacing:0.2pt;">Co-Founder, Chief Executive Officer and </font>
                <br >
                <font style="letter-spacing:0.2pt;">Director</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;margin-left:auto;margin-right:auto;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">
        <a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a>
      </div>
      <div style="margin-top:15.85pt;height:24pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:17pt; text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">&#160;</font>
          <br >
        </div>
      </div>
      <div style="margin-top:6pt;height:660pt;margin-left:69.66pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:12pt;font-weight:bold;">
          <font style="letter-spacing:-0.2pt;">SIGNATURES AND POWER OF ATTORNEY</font><font style="font-weight:normal;letter-spacing:0.2pt;"> </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">We, the undersigned officers and directors of Immuneering Corporation, hereby severally constitute and appoint Benjamin J. Zeskind and Biren Amin, and each of them singly (with full power to each of them to act alone), our true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement (or any other registration statement for the same offering that is to be effective upon filing pursuant to Rule&#160;462(b) under the Securities Act of 1933), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </font>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; text-align:justify; width:456pt; line-height:12pt;">
          <font style="letter-spacing:0.2pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities held on the dates indicated. </font>
        </div>
        <table style="width:456pt;height:272.5pt;margin-top:10pt;border-collapse: collapse;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
          <tr style="line-height:8pt;min-height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:162pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Signature </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:198pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Title </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:72pt;">
              <div style="white-space:nowrap; text-align:center;">
                <font style="letter-spacing:-0.16pt;">Date </font>
              </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:52.25pt; white-space:normal;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:21.917pt 0pt 5.833pt 0pt; width:162pt;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 162pt; margin-top: 24.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Benjamin J. Zeskind, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:21.917pt 0pt 5.833pt 0pt; width:198pt;">
              <font style="letter-spacing:0.2pt;">Co-Founder, Chief Executive Officer and Director (Principal Executive Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:21.917pt 0.5pt 5.833pt 0pt; width:72pt;white-space:nowrap;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:61pt; white-space:normal;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 5.833pt 0pt; width:162pt;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 162pt; margin-top: 22.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Biren Amin </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0pt 5.833pt 0pt; width:198pt;">
              <font style="letter-spacing:0.2pt;">Chief Financial Officer</font>
              <br >
              <font style="letter-spacing:0.2pt;">(Principal Financial Officer and Principal Accounting Officer) </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:19.167pt 0.5pt 5.833pt 0pt; width:72pt;white-space:nowrap;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:39pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:162pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 162pt; margin-top: 11.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Robert J. Carpenter </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:198pt;">
              <font style="letter-spacing:0.2pt;">Co-Founder, Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0.5pt 0.5pt 0pt; width:72pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:39pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:162pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 162pt; margin-top: 11.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Peter Feinberg </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:198pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0.5pt 0.5pt 0pt; width:72pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;height:39pt; white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:162pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 162pt; margin-top: 11.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Laurie B. Keating </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:198pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0.5pt 0.5pt 0pt; width:72pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;min-height:38pt;white-space:nowrap;text-align:left;vertical-align:middle;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif ;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:162pt;white-space:normal;">
              <div style="text-align:justify;">
                <div style="margin-left: 0pt; width: 162pt; margin-top: 11.5pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt; text-align:center;">
                <font style="letter-spacing:0.2pt;">Andrew Phillips, Ph.D. </font>
              </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0pt 0.5pt 0pt; width:198pt;">
              <font style="letter-spacing:0.2pt;">Director </font>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:18.667pt 0.5pt 0.5pt 0pt; width:72pt;text-align:right;">
              <div style="text-align:right;">
                <font style="letter-spacing:0.2pt;">, 2021</font>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2.00000000000002pt;margin-bottom:35.86pt;margin-left:69.66pt;width:456pt;">
        <div style="margin-top:7pt; text-align:center; width:456pt; line-height:10pt;font-style:italic;font-size:8pt;">
          <font style="letter-spacing:0.16pt;">&#160;</font>
          <br >
        </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>filename2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><FONT STYLE="font-size: 10pt"><B>Exhibit 10.1</B></FONT></P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="text-align: right; margin: 0pt">Execution Version</P>

<P STYLE="margin: 0pt">&nbsp;</P>

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AMENDED AND RESTATED INVESTORS&rsquo; RIGHTS
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS AMENDED AND RESTATED INVESTORS&rsquo;
RIGHTS AGREEMENT (this &ldquo;<B>Agreement</B>&rdquo;), is made as of the 21<SUP>st</SUP> day of December, 2020, by and <FONT STYLE="font-weight: normal; text-underline-style: double">among
</FONT>Immuneering Corporation, a Delaware corporation (the &ldquo;<B>Company</B>&rdquo;), and each of the investors listed on <U>Schedule
A</U> hereto, each of which is referred to in this Agreement as an &ldquo;<B>Investor</B>&rdquo; and any <FONT STYLE="font-weight: normal; text-underline-style: double">Additional
</FONT>Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with <U>Section 6.9</U>
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>RECITALS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>WHEREAS</B>, certain of
the Investors (the &ldquo;<B>Existing Investors</B>&rdquo;) hold shares of the Company&rsquo;s Series A Preferred Stock, par value $0.001
per share (&ldquo;<B>Series A Preferred Stock</B>&rdquo;) and/or shares of Common Stock issued upon conversion thereof and possess registration
rights, information rights, rights of first offer and other rights pursuant to that certain Investors&rsquo; Rights Agreement dated as
of September 20, 2020, by and among the Company and such Existing Investors (the &ldquo;Prior Agreement&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">WHEREAS, the Existing Investors
are holders of a majority of the Registrable Securities of the Company (as defined in the Prior Agreement), and desire to amend and restate
the Prior Agreement in its entirety and to accept the rights created pursuant to this Agreement in lieu of the rights granted to them
under the Prior Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>WHEREAS</B>, the Company
and certain of the Investors are parties to that certain Series B Preferred Stock Purchase Agreement of even date herewith by and among
the Company and such Investors (the &ldquo;<B>Purchase Agreement</B>&rdquo;), under which certain of the Company&rsquo;s and such Investors&rsquo;
obligations are conditioned upon the execution and delivery of this Agreement by such Investors, Existing Investors holding a majority
of the Registrable Securities (as defined in the Prior Agreement) and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><B>NOW, THEREFORE</B>, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the Company and the Investors, including the Existing Investors, each hereby agree that the Prior Agreement
shall be amended and restated in its entirety as set forth herein, and the parties to this Agreement, intending to be legally bound,
hereby further agree as follows:Definitions. For purposes of this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Affiliate</B>&rdquo; means, with respect to any specified Person, any other Person who, directly or indirectly, controls,
is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer,
director or trustee of such Person, or any venture capital fund, other investment fund or registered investment company now or hereafter
existing that is controlled by one or more general partners, managing members or investment adviser of, or shares the same management
company or investment adviser with, such Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>BlackRock</B>&rdquo; means BlackRock Health Sciences Trust II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>Board of Directors</B>&rdquo; means the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Boxcar</B>&rdquo; means Boxcar PMJ, LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>Certificate of Incorporation</B>&rdquo; means the Company&rsquo;s Third Amended and Restated Certificate of Incorporation,
as amended and/or restated from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>Common Stock</B>&rdquo; means shares of the Company&rsquo;s common stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Competitor</B>&rdquo; means a Person engaged, directly or indirectly (including through any partnership, limited liability
company, corporation, joint venture or similar arrangement (whether now existing or formed hereafter)), in biopharmaceutical research
and development and drug discovery and development, but shall not include (i) any financial investment firm or collective investment
vehicle that, together with its Affiliates, holds less than twenty percent (25)% of the outstanding equity of any Competitor, (ii) Boxcar
or any of its Affiliates, (iii) Cormorant or any of its Affiliates, (iv) Surveyor or any of its Affiliates, (v) Rock Springs or any of
its Affiliates, (vi) BlackRock or any of its Affiliates, (vii) T. Rowe Price or any of its Affiliates, (viii) LYFE Capital or any of
its Affiliates or (ix) Perceptive or any of its Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Cormorant</B>&rdquo; means, collectively, Cormorant Private Healthcare Fund III, LP, Cormorant Global Healthcare Master
Fund, LP and CRMA SPV, LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Damages</B>&rdquo; means any loss, damage, claim or liability (joint or several) to which a party hereto may become
subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or
any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact
contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or
any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein,
or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by <FONT STYLE="font-weight: normal; text-underline-style: double">the
indemnifying</FONT> party <FONT STYLE="font-weight: normal; text-underline-style: double">(or any of its agents or Affiliates)</FONT>
of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the
Exchange Act, or any state securities law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Derivative Securities</B>&rdquo; means any securities or rights convertible into, or exercisable or exchangeable for
<FONT STYLE="font-weight: normal; text-underline-style: double">(in each case, directly or indirectly)</FONT><B>,</B> Common Stock, including
options and warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Exchange Act</B>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal; text-underline-style: double">1.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>Excluded Registration</B><FONT STYLE="font-weight: normal">&rdquo;
means (i) a registration relating to the sale or grant of securities to employees of the Company or a subsidiary pursuant to a stock
option, stock purchase, equity incentive or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration
on any form that does not include substantially the same information as would be required to be included in a registration statement
covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock
issuable upon conversion of debt securities that are also being registered.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>FOIA Party</B>&rdquo; means a Person that, in the reasonable determination of the Board of Directors, may be subject
to, and thereby required to disclose non-public information furnished by or relating to the Company under, the Freedom of Information
Act, 5 U.S.C. 552 (&ldquo;<B>FOIA</B>&rdquo;), any state public records access law, any state or other jurisdiction&rsquo;s laws similar
in intent or effect to FOIA, or any other similar statutory or regulatory requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.14<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal; text-underline-style: double">&ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>Form
S&#45;1</B><FONT STYLE="font-weight: normal">&rdquo; means such form under the Securities Act as in effect on the date hereof or any
successor registration form under the Securities Act subsequently adopted by the SEC.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.15<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Form S&#45;3</B>&rdquo; means such form under the Securities Act as in effect on the date hereof or any registration
form under the Securities Act subsequently adopted by the SEC that permits forward incorporation of substantial information by reference
to other documents filed by the Company with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.16<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>GAAP</B>&rdquo; means generally accepted accounting principles in the United States as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.17<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Holder</B>&rdquo; means any holder of Registrable Securities who is a party to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.18<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal; text-underline-style: double">&ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>Immediate
Family Member</B><FONT STYLE="font-weight: normal">&rdquo; means a child</FONT></FONT>, <FONT STYLE="font-weight: normal; text-underline-style: double">stepchild,
grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law,
</FONT>or <FONT STYLE="font-weight: normal; text-underline-style: double">sister-in-law, including, adoptive relationships, of a natural
person referred to herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.19<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Initiating Holders</B>&rdquo; means, collectively, Holders who properly initiate a registration request under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal; text-underline-style: double">1.20<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>IPO</B><FONT STYLE="font-weight: normal">&rdquo; means the Company&rsquo;s
first underwritten public offering of its Common Stock under the Securities Act.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.21<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal; text-underline-style: double">&ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>Key
Employee</B><FONT STYLE="font-weight: normal">&rdquo; shall have the meaning set forth in </FONT></FONT>the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.22<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>LYFE Capital</B>&rdquo; means LYFE Capital Fund III (Phoenix), L.P.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.23<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>Major Investor</B>&rdquo; means any Investor that individually or together with such Investor&rsquo;s Affiliates, holds
at least 143,022 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization
or reclassification effected after the date hereof) and each Person to whom any of the rights of any such Investor are assigned pursuant
to <U>Section 6.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.24<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>New Securities</B>&rdquo; means, collectively, equity securities of the Company, whether or not currently authorized,
as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become,
convertible or exchangeable into or exercisable for such equity securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal; text-underline-style: double">1.25<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>Perceptive</B><FONT STYLE="font-weight: normal">&rdquo; means Perceptive
Life Sciences Master Fund, Ltd.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal; text-underline-style: double">1.26<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>Person</B><FONT STYLE="font-weight: normal">&rdquo; means any individual,
corporation, partnership, trust, limited liability company, association </FONT></FONT>or other <FONT STYLE="font-weight: normal; text-underline-style: double">entity<FONT STYLE="color: blue">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.27<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Preferred Director</B>&rdquo; shall have the meaning set forth in the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.28<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Preferred Stock</B>&rdquo; means the Series A Preferred Stock and the Series B Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.29<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Registrable Securities</B>&rdquo; means (i) the Common Stock issuable or issued upon conversion of the Preferred Stock,
excluding any Common Stock issued upon conversion of the Series B Preferred Stock pursuant to the &ldquo;Special Mandatory Conversion&rdquo;
provisions of the Certificate of Incorporation; (ii) any Common Stock<FONT STYLE="font-weight: normal; text-underline-style: double">,
or any Common Stock</FONT> issued or issuable <FONT STYLE="font-weight: normal; text-underline-style: double">(directly or indirectly)
</FONT>upon conversion <FONT STYLE="font-weight: normal; text-underline-style: double">and/or exercise </FONT>of any <FONT STYLE="font-weight: normal; text-underline-style: double">other
securities</FONT> of the Company<FONT STYLE="font-weight: normal; text-underline-style: double">,</FONT> acquired by the Investors after
the date hereof; and (iii) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant, right, or other security
that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in
clauses <U>(i)</U> and <U>(ii)</U> above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction
in which the <FONT STYLE="font-weight: normal; text-underline-style: double">applicable</FONT> rights under <FONT STYLE="font-weight: normal; text-underline-style: double">this
Agreement</FONT> are not assigned <FONT STYLE="font-weight: normal; text-underline-style: double">pursuant to <U>Subsection 6.1</U>,
and excluding for purposes of <U>Section 2</U></FONT> any shares for which registration rights have terminated pursuant to <U>Subsection
2.13</U> of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.30<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Registrable Securities then outstanding</B>&rdquo; means the number of shares determined by adding the <FONT STYLE="font-weight: normal; text-underline-style: double">number
of shares of outstanding </FONT>Common Stock <FONT STYLE="font-weight: normal; text-underline-style: double">that are Registrable Securities
</FONT>and the <FONT STYLE="font-weight: normal; text-underline-style: double">number of shares of</FONT> Common Stock issuable <FONT STYLE="font-weight: normal; text-underline-style: double">(directly
or indirectly) </FONT>pursuant to then exercisable <FONT STYLE="font-weight: normal; text-underline-style: double">and/</FONT>or convertible
securities that are Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.31<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Restricted Securities</B>&rdquo; means the securities of the Company required to be notated with the legend set forth
in <U>Subsection 2.12(b)</U> hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.32<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Rock Springs</B>&rdquo; means, collectively, Rock Springs Capital Master Fund LP and Four Pines Master Fund LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.33<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> &ldquo;<B>SEC</B>&rdquo; means the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.34<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>SEC Rule 144</B>&rdquo; means Rule 144 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.35<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>SEC Rule 145</B>&rdquo; means Rule 145 promulgated by the SEC under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.36<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Securities Act</B>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.37<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Selling Expenses</B>&rdquo; means all underwriting discounts, selling commissions, and stock transfer taxes applicable
to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except <FONT STYLE="font-weight: normal; text-underline-style: double">for
the fees and disbursements of the Selling Holder Counsel borne and paid by the Company </FONT>as provided in <U>Subsection 2.6</U><FONT STYLE="font-weight: normal; text-underline-style: double">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.38<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Series B Preferred Stock</B>&rdquo; means shares of the Company&rsquo;s Series B Preferred Stock, par value $0.001 per
share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.39<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>Surveyor</B>&rdquo; means Citadel Multi-Strategy Equities Master Fund Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">1.40<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>&ldquo;<B>T. Rowe Price</B>&rdquo; means, collectively, T. Rowe Price Health Sciences Fund, Inc., TD Mutual Funds &ndash; TD Health
Sciences Fund and T. Rowe Price Health Sciences Portfolio.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Registration Rights</U>. The Company covenants and agrees as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Demand Registration</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal; text-underline-style: double"><U>Form S-1 Demand</U>. </FONT>If at any time after the earlier
of (i) five (5) years after the date of this Agreement or (ii) one hundred eighty (180) days after the effective date of the registration
statement for the IPO, the Company receives a request from Holders of a majority of the Registrable Securities then outstanding that
the Company <FONT STYLE="font-weight: normal; text-underline-style: double">file</FONT> a <FONT STYLE="font-weight: normal; text-underline-style: double">Form
S-1 </FONT>registration <FONT STYLE="font-weight: normal; text-underline-style: double">statement having an anticipated aggregate offering
price, net of Selling Expenses, of at least $15 million</FONT>, then the Company shall (x) within ten (10) days after the date such request
is given, give notice thereof (the &ldquo;<B>Demand Notice</B>&rdquo;) to all Holders other than the Initiating Holders; and (y) as soon
as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a <FONT STYLE="font-weight: normal; text-underline-style: double">Form
S-1</FONT> registration statement under the Securities Act covering all Registrable Securities that the I<FONT STYLE="font-weight: normal; text-underline-style: double">nitiating
</FONT>Holders <FONT STYLE="font-weight: normal; text-underline-style: double">requested</FONT> to be registered and <FONT STYLE="font-weight: normal; text-underline-style: double">any
additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by
each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, </FONT>subject to the
limitations of <U>Subsections 2.1(c)</U> <FONT STYLE="font-weight: normal; text-underline-style: double">and <U>2.3.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal; text-underline-style: double"><U>Form S-3 Demand</U>. If at any time when it is eligible to
use a Form S-3 registration statement, the Company receives a request from Holders of at least twenty percent (20%) of the Registrable
Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities
of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5 million, then the Company shall
(i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders;
and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating
Holders, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included
in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of
the date the Demand Notice is given, and in each case, subject to the limitations of <U>Subsections 2.1(c)</U> and <U>2.3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal; text-underline-style: double">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this
<U>Subsection 2.1</U> a certificate signed by the Company&rsquo;s chief executive officer stating that in the good faith judgment of
the Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either
become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because
such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving
the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving
as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company
shall have the right to defer taking action with respect to such filing, and any time periods with respect to filing or effectiveness
thereof shall be tolled correspondingly, for a period of not more than sixty (60) days after the request of the Initiating Holders is
given; <U>provided</U>, <U>however</U>, that the Company may not invoke this right more than once in any twelve (12) month period<FONT STYLE="font-weight: normal; text-underline-style: double">;
</FONT>and <U>provided further</U> that the Company shall not register any securities for its own account or that of any other stockholder
during such sixty (60) day period other than <FONT STYLE="font-weight: normal; text-underline-style: double">an Excluded Registration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Subsection 2.1(a)(i)
</U>during the period that is sixty (60) days before the Company&rsquo;s good faith estimate of the date of filing of, and ending on
a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, <U>provided</U> that the
Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective;
(ii) after the Company has effected one registration <FONT STYLE="font-weight: normal; text-underline-style: double">pursuant to <U>Subsection
</U></FONT><U>2.1(a)</U>; or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately
registered on Form S-3 pursuant to a request made pursuant to <U>Subsection 2.1 (b)</U><FONT STYLE="font-weight: normal; text-underline-style: double">.
The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to <U>Subsection </U></FONT><U>2.1
(b)</U> <FONT STYLE="font-weight: normal; text-underline-style: double">(i) during the period that is thirty (30) days before the Company&rsquo;s
good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated
registration, <U>provided</U> that the Company is actively employing in good faith commercially reasonable efforts to cause such registration
statement to become effective; or (ii) if the Company has effected two registrations pursuant to <U>Subsection </U></FONT><U>2.1 (b)
</U><FONT STYLE="font-weight: normal; text-underline-style: double">within the twelve (12) month period immediately preceding the date
of such request.</FONT> A registration shall not be counted as &ldquo;effected&rdquo; for purposes of this <U>Subsection 2.1(d)</U> until
such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, <FONT STYLE="font-weight: normal; text-underline-style: double">and
forfeit their right to one demand registration statement </FONT>pursuant to <U>Subsection 2.6</U><FONT STYLE="font-weight: normal; text-underline-style: double">,
in which case such withdrawn registration statement shall be counted as &ldquo;effected&rdquo; for purposes of this <U>Subsection </U></FONT><U>2.1(d)</U>;
<U>provided</U>, that if such withdrawal is during a period the Company has deferred taking action pursuant to <U>Subsection 2.1(c)</U>,
then the Initiating Holders may withdraw their request for registration and such registration will not be counted as &ldquo;effected&rdquo;
for purposes of this <U>Subsection 2.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Company Registration</U>. If the Company proposes to register (including, for this purpose, a registration effected by the
Company for stockholders other than the Holders) any of its Common Stock under the Securities Act in connection with the public offering
of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder
notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company,
the Company shall, subject to the provisions of <U>Subsection 2.3</U>, cause to be registered all of the Registrable Securities that
each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration
initiated by it under this <U>Subsection 2.2</U> before the effective date of such registration, whether or not any Holder has elected
to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall
be borne by the Company in accordance with <U>Subsection 2.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Underwriting Requirements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If, pursuant to <U>Subsection 2.1</U><FONT STYLE="font-weight: normal; text-underline-style: double">,</FONT> the Initiating Holders
intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company
as a part of their request made pursuant to <U>Subsection 2.1</U><FONT STYLE="font-weight: normal; text-underline-style: double">,</FONT>
and the Company shall include such information in the Demand Notice. The underwriter<FONT STYLE="font-weight: normal; text-underline-style: double">(s)
</FONT>will be selected by the Company and shall be reasonably acceptable to a majority in interest of the Initiating Holders. In such
event, the right of any Holder to include such Holder&rsquo;s Registrable Securities in such registration shall be conditioned upon such
Holder&rsquo;s participation in such underwriting and the inclusion of such Holder&rsquo;s Registrable Securities in the underwriting
to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the
Company as provided in <U>Subsection 2.4(e)</U>) enter into an underwriting agreement in customary form with the underwriter(s) selected
for such underwriting. Notwithstanding any other provision of this <U>Subsection 2.3</U><FONT STYLE="font-weight: normal; text-underline-style: double">,
</FONT>if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of
shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be
underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among
<FONT STYLE="font-weight: normal; text-underline-style: double">such</FONT> Holders of Registrable Securities, including the Initiating
Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder <FONT STYLE="font-weight: normal; text-underline-style: double">or
in such other proportion as shall mutually be agreed to by all such selling Holders</FONT>; <U>provided</U>, <U>however</U>, that the
number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities
are first entirely excluded from the underwriting. To facilitate the allocation of shares in accordance with the above provisions, the
Company or the underwriters may round the number of shares allocated to any Holder to the nearest one hundred (100) shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> In connection with any offering involving an underwriting of shares of the Company&rsquo;s capital stock pursuant to <U>Subsection
2.2</U>, the Company shall not be required to include any of the Holders&rsquo; Registrable Securities in such underwriting unless the
Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity
as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number
of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities
to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success
of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable
Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering.
If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering,
then the Registrable Securities that are included in such offering shall be <FONT STYLE="font-weight: normal; text-underline-style: double">allocated
</FONT>among the selling Holders <FONT STYLE="font-weight: normal; text-underline-style: double">in proportion (as nearly as practicable
to)</FONT> the number of Registrable Securities <FONT STYLE="font-weight: normal; text-underline-style: double">owned</FONT> by <FONT STYLE="font-weight: normal; text-underline-style: double">each
</FONT>selling <FONT STYLE="font-weight: normal; text-underline-style: double">Holder</FONT> or in such other proportions as shall mutually
be agreed to by all such selling Holders. <FONT STYLE="font-weight: normal; text-underline-style: double">To facilitate the allocation
of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder
to the nearest one hundred (100) shares. </FONT>Notwithstanding the foregoing, in no event shall (i) <FONT STYLE="font-weight: normal; text-underline-style: double">the
number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by
the Company) are first entirely excluded from the offering, or (ii)</FONT> the number of Registrable Securities included in the offering
be reduced below twenty-five percent (25%) of the total number of securities included in such offering, unless such offering is the IPO,
in which case the selling Holders may be excluded further if the underwriters make the determination described above and no other stockholder&rsquo;s
securities are included in such offering. For purposes of the provision in this <U>Subsection 2.3 (b)</U> concerning apportionment, for
any selling <FONT STYLE="font-weight: normal; text-underline-style: double">Holder</FONT> that is a partnership, limited liability company,
or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates
and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any
of the foregoing Persons, shall be deemed to be a single &ldquo;selling Holder,&rdquo; and any pro rata reduction with respect to such
 &ldquo;selling Holder&rdquo; shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such
 &ldquo;selling Holder,&rdquo; as defined in this sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Obligations of the Company</U>. Whenever required under this <U>Section 2</U> to effect the registration of any Registrable
Securities, the Company shall, as expeditiously as reasonably possible:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable
efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable
Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or,
if earlier, until the distribution contemplated in the registration statement has been completed; <U>provided</U>, <U>however</U>, that
such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request
of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection
with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities
covered by such registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the
Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable
Securities;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such
other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; <U>provided</U> that
the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or
jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities
Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual
and customary form, with the underwriter<FONT STYLE="font-weight: normal; text-underline-style: double">(s)</FONT> of such offering;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be
listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar
securities issued by the Company are then listed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP
number for all such Registrable Securities, in each case not later than the effective date of such registration;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>promptly make available for inspection by the selling Holders, any underwriter<FONT STYLE="font-weight: normal; text-underline-style: double">(s)
</FONT>participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained
by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties
of the Company, and cause the Company&rsquo;s officers, directors, employees, and independent accountants to supply all information reasonably
requested by any such seller, underwriter, attorney, accountant, or agent<FONT STYLE="font-weight: normal; text-underline-style: double">,
in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate
due diligence</FONT> in connection <FONT STYLE="font-weight: normal; text-underline-style: double">therewith</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has
been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend
or supplement such registration statement or prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">In addition, the Company shall
ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities
Act shall have become effective, its insider trading policy shall provide that the Company&rsquo;s directors may implement a trading
program under Rule 10b5-1 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Furnish Information</U>. It shall be a condition precedent to the obligations of the Company to take any action pursuant to
this <U>Section 2</U> with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company
such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as
is reasonably required to effect the registration of such Holder&rsquo;s Registrable Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Expenses of Registration</U>. All expenses (other than Selling Expenses) incurred in connection with registrations, filings,
or qualifications pursuant to <U>Section 2</U>, including all registration, filing, and qualification fees; printers&rsquo; and accounting
fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements, not to exceed $35,000, of one counsel
for the selling Holders <FONT STYLE="font-weight: normal; text-underline-style: double">(&ldquo;</FONT><FONT STYLE="text-underline-style: double"><B>Selling
Holder Counsel</B><FONT STYLE="font-weight: normal">&rdquo;)</FONT></FONT>, shall be borne and paid by the Company; <U>provided</U>,
<U>however</U>, that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to <U>Subsection
2.1</U> if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities
to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities
that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit
their right to one registration pursuant to <U>Subsections 2.1(a)</U> or <U>2.1(b)</U><FONT STYLE="font-weight: normal; text-underline-style: double">,
</FONT>as the case may be, then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one
registration pursuant to <U>Subsections 2.1(a)</U> or <U>2.1(b)</U>. All Selling Expenses relating to Registrable Securities registered
pursuant to this <U>Section 2</U> shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities
registered on their behalf.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delay of Registration</U>. No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying
any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation
of this <U>Section 2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification</U>. If any Registrable Securities are included in a registration statement under this <U>Section 2</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers,
directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the
Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities
Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other
aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any <FONT STYLE="font-weight: normal; text-underline-style: double">claim
or</FONT> proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity
agreement contained in this <U>Subsection 2.8 (a)</U> shall not apply to amounts paid in settlement of any such <FONT STYLE="font-weight: normal; text-underline-style: double">claim
</FONT>or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld,
nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other
aforementioned Person expressly for use in connection with such registration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company,
and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company
within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities
Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other
Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made
in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection
with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other
expenses reasonably incurred thereby in connection with investigating or defending any <FONT STYLE="font-weight: normal; text-underline-style: double">claim
or</FONT> proceeding from which Damages may result, as such expenses are incurred; <U>provided</U>, <U>however</U>, that the indemnity
agreement contained in this <U>Subsection 2.8 (b)</U> shall not apply to amounts paid in settlement of any such <FONT STYLE="font-weight: normal; text-underline-style: double">claim
</FONT>or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld;
and <U>provided further</U> that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under
<U>Subsections 2.8 (b)</U> and <U>2.8(d)</U> exceed the proceeds from the offering <FONT STYLE="font-weight: normal; text-underline-style: double">received
by such Holder </FONT>(net of any Selling Expenses <FONT STYLE="font-weight: normal; text-underline-style: double">paid by such Holder</FONT>),
except in the case of fraud or willful misconduct by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Promptly after receipt by an indemnified party under this <U>Subsection 2.8</U> of notice of the commencement of any action (including
any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this <U>Subsection 2.8</U><FONT STYLE="font-weight: normal; text-underline-style: double">,
</FONT>give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in
such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice
has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; <U>provided</U>, <U>however</U>,
that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall
have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of
such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing
interests between such indemnified party and any other party represented by such counsel in such action. The failure to give notice to
the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of any liability
to the indemnified party under this <U>Subsection 2.8</U><FONT STYLE="font-weight: normal; text-underline-style: double">, </FONT>to
the extent that such failure materially prejudices the indemnifying party&rsquo;s ability to defend such action. The failure to give
notice to the indemnifying party will not relieve it of any liability that it may have to any indemnified party otherwise than under
this <U>Subsection 2.8</U><FONT STYLE="font-weight: normal; text-underline-style: double">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any
party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this <U>Subsection 2.8</U> but it
is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time
to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the
fact that this <U>Subsection 2.8</U> provides for indemnification in such case, or (ii) contribution under the Securities Act may be
required on the part of any party hereto for which indemnification is provided under this <U>Subsection 2.8</U><FONT STYLE="font-weight: normal; text-underline-style: double">,
</FONT>then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to
which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each
of <FONT STYLE="font-weight: normal; text-underline-style: double">the</FONT> indemnifying party and the indemnified party in connection
with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged
omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties&rsquo;
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; <U>provided</U>,
<U>however</U>, that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price
of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty
of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any
Person who was not guilty of such fraudulent misrepresentation; and <U>provided further</U> that in no event shall a Holder&rsquo;s liability
pursuant to this <U>Subsection 2.8 (d)</U>, when combined with the amounts paid or payable by such Holder pursuant to <U>Subsection 2.8
(b)</U>, exceed the proceeds from the offering <FONT STYLE="font-weight: normal; text-underline-style: double">received by such Holder
</FONT>(net of any Selling Expenses <FONT STYLE="font-weight: normal; text-underline-style: double">paid</FONT> by such Holder<FONT STYLE="font-weight: normal; text-underline-style: double">)</FONT>,
except in the case of willful misconduct or fraud by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Notwithstanding the foregoing, to the extent that the provisions on indemnification and contribution contained in the underwriting
agreement entered into in connection with the underwritten public offering are in conflict with the foregoing provisions, the provisions
in the underwriting agreement shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the
obligations of the Company and Holders under this <U>Subsection 2.8</U> shall survive the completion of any offering of Registrable Securities
in a registration under this <U>Section 2</U>, and otherwise shall survive the termination of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</FONT></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Reports Under Exchange Act</U>. With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule
or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or
pursuant to a registration on Form S&#45;3, the Company shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make and keep <FONT STYLE="font-weight: normal; text-underline-style: double">available adequate current </FONT>public information,
as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the registration statement filed
by the Company for the IPO;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company
under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) <FONT STYLE="font-weight: normal; text-underline-style: double">to
the extent accurate, </FONT>a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 (at
any time after ninety (90) days after the effective date of the registration statement filed by the Company for the IPO), the Securities
Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as
a registrant whose securities may be resold pursuant to Form S&#45;3 (at any time after the Company so qualifies); (ii) a copy of the
most recent annual or quarterly report of the Company and such other reports and documents so filed by the Company; and (iii) such other
information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any
such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange
Act) or pursuant to Form S&#45;3 (at any time after the Company so qualifies to use such form).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Limitations on Subsequent Registration Rights</U>. From and after the date of this Agreement, the Company shall not, without
the prior written consent of the Holders of a majority of the Registrable Securities then outstanding, enter into any agreement with
any holder or prospective holder of any securities of the Company that would allow such holder or prospective holder to include such
securities in any registration unless, under the terms of such agreement, such holder or prospective holder may include such securities
in any such registration only to the extent that the inclusion of such securities will not reduce the number of the Registrable Securities
of the Holders that are included; <U>provided</U> that this limitation shall not apply to Registrable Securities acquired by any <FONT STYLE="font-weight: normal; text-underline-style: double">additional
</FONT>Investor that becomes a party to this Agreement in accordance with <U>Subsection <FONT STYLE="font-weight: normal; text-underline-style: double">6.9</FONT></U><FONT STYLE="font-weight: normal; text-underline-style: double">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>&ldquo;Market Stand&#45;off&rdquo; Agreement</U>. Each Holder hereby agrees that it will not, without the prior written consent
of the managing underwriter, during the period commencing on the date of the final prospectus relating to the <FONT STYLE="font-weight: normal; text-underline-style: double">IPO
(such period not to exceed one hundred eighty (180) days), </FONT>(i) lend; offer; pledge; sell; contract to sell; sell any option or
contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer
or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable <FONT STYLE="font-weight: normal; text-underline-style: double">(directly
or indirectly) </FONT>for Common Stock held immediately before the effective date of the registration statement for the IPO or (ii) enter
into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of <FONT STYLE="font-weight: normal; text-underline-style: double">such
securities</FONT>, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or
other securities, in cash, or otherwise. The foregoing provisions of this <U>Subsection 2.11</U> shall apply only to the IPO, shall not
apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, <FONT STYLE="font-weight: normal; text-underline-style: double">or
the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, <U>provided
</U>that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and <U>provided further</U> that
any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers, directors and
stockholders individually owning one percent (1%) or more of the Company&rsquo;s outstanding Common Stock (after giving effect to conversion
into Common Stock of all outstanding Preferred Stock) are subject to the same restrictions</FONT>. The underwriters in connection with
<FONT STYLE="font-weight: normal; text-underline-style: double">such registration</FONT> are intended third&#45;party beneficiaries of
this <U>Subsection 2.11</U> and shall have the right, power and authority to enforce the provisions hereof as though they were a party
hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in <FONT STYLE="font-weight: normal; text-underline-style: double">connection
with such registration</FONT> that are consistent with this <U>Subsection 2.11</U> or that are necessary to give further effect thereto.
In the event that the Company or the managing underwriter waives or terminates any of the restrictions contained in this <U>Subsection
2.11</U> or in a lock-up agreement with respect to the securities of any Holder, officer, director than one-percent or greater stockholder
of the Company (in any such case, the &ldquo;<B>Released Securities</B>&rdquo;), the restrictions contained in this <U>Subsection 2.11
</U>and in any lock-up agreements executed by the Investors shall be waived or terminated, as applicable, to the same extent and with
respect to the same percentage of securities of each Investor as the percentage of Released Securities represent with respect to the
securities held by the applicable Holder, officer, director than one-percent or greater stockholder. Notwithstanding anything herein
to the contrary, the provisions of this <U>Subsection 2.11</U> shall not apply to transactions (including, without limitation, any swap,
hedge or similar agreement or arrangement) or announcements, in each case, relating to securities acquired in the IPO or securities acquired
in open market or other transactions from and after the IPO or that otherwise do not involve or relate to securities of the Company owned
by a Holder prior to the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Restrictions on Transfer</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Preferred Stock and the Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall
not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except
upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities
Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of Preferred Stock and the Registrable Securities
held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.
Notwithstanding the foregoing, the Company shall not require any transferee of shares pursuant to an effective registration statement
or, following the IPO, SEC Rule 144 to be bound by the terms of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> Each certificate, <FONT STYLE="font-weight: normal; text-underline-style: double">instrument, or book entry </FONT>representing
(i) the Preferred Stock, (ii) the Registrable Securities, and (iii) any other securities issued in respect of the securities referenced
in clauses (i) and (ii), upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless
otherwise permitted by the provisions of <U>Subsection 2.12 (c)</U>) be notated with a legend <FONT STYLE="font-weight: normal; text-underline-style: double">substantially
</FONT>in the following form:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">THE <FONT STYLE="font-weight: normal; text-underline-style: double">SECURITIES
</FONT>REPRESENTED <FONT STYLE="font-weight: normal; text-underline-style: double">HEREBY</FONT> HAVE BEEN ACQUIRED FOR INVESTMENT AND
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH
REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">THE <FONT STYLE="font-weight: normal; text-underline-style: double">SECURITIES
</FONT>REPRESENTED <FONT STYLE="font-weight: normal; text-underline-style: double">HEREBY</FONT> MAY BE TRANSFERRED ONLY IN ACCORDANCE
WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">The Holders consent to the
Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement
the restrictions on transfer set forth in this <U>Subsection 2.12</U><FONT STYLE="font-weight: normal; text-underline-style: double">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions
of this <U>Section 2</U>. Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration
statement under the Securities Act covering the proposed transaction or, following the IPO, the transfer is made pursuant to SEC Rule
144, the Holder thereof shall give notice to the Company of such Holder&rsquo;s intention to effect such sale, pledge, or transfer. Each
such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail and, if reasonably
requested by the Company, shall be accompanied at such Holder&rsquo;s expense by either (i) a written opinion of legal counsel who shall,
and whose legal opinion shall, be reasonably satisfactory to the Company, addressed to the Company, to the effect that the proposed transaction
may be effected without registration under the Securities Act; (ii) a &ldquo;no action&rdquo; letter from the SEC to the effect that
the proposed sale, pledge, or transfer of such Restricted Securities without registration will not result in a recommendation by the
staff of the SEC that action be taken with respect thereto; or (iii) any other evidence reasonably satisfactory to counsel to the Company
to the effect that the proposed sale, pledge, or transfer of the Restricted Securities may be effected without registration under the
Securities Act, whereupon the Holder of such Restricted Securities shall be entitled to sell, pledge, or transfer such Restricted Securities
in accordance with the terms of the notice given by the Holder to the Company. The Company will not require such a legal opinion or &ldquo;no
action&rdquo; letter (x) in any transaction in compliance with <FONT STYLE="font-weight: normal; text-underline-style: double">SEC </FONT>Rule
144; (y) in any transaction in which such Holder distributes Restricted Securities to an Affiliate of such Holder for no consideration
or (z) in any internal transaction in which such Holder transfers Restricted Securities to an Affiliate of such Holder that is an entity
and that is ultimately controlled by the same parent company as the Holder (or is the ultimate parent company of the Holder); <U>provided
</U>that, in the case of clauses (y) and (z), other than in connection with a transaction in compliance with SEC Rule 144 following the
IPO, each transferee agrees in writing to be subject to the terms of this <U>Subsection 2.12</U><FONT STYLE="font-weight: normal; text-underline-style: double">.
</FONT>Notwithstanding the foregoing, the Company shall be obligated to reissue promptly unlegended certificates or book entries at the
request of any Holder thereof if the Company has completed its IPO and the Holder shall have obtained an opinion of counsel (which counsel
may be counsel to the Company) to the effect that the securities proposed to be disposed of may lawfully be so disposed of without registration,
qualification and legend, provided that the second legend listed above shall be removed only at such time as the Holder of such certificate
is no longer subject to any restrictions hereunder. Each certificate, <FONT STYLE="font-weight: normal; text-underline-style: double">instrument,
or book entry </FONT>representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer
is made pursuant to <FONT STYLE="font-weight: normal; text-underline-style: double">SEC </FONT>Rule 144 or pursuant to an effective registration
statement, the appropriate restrictive legend set forth in <U>Subsection 2.12 (b)</U>, except that such certificate instrument, or book
entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is
not required in order to establish compliance with any provisions of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">2.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Registration Rights</U>. The right of any Holder to request registration or inclusion of Registrable Securities
in any registration pursuant to <U>Subsections 2.1</U> or <U>2.2</U> shall terminate upon the <FONT STYLE="font-weight: normal; text-underline-style: double">earliest
to occur</FONT> of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Following the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal; text-underline-style: double">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>such time after consummation of the IPO as SEC Rule 144 or another similar exemption under the Securities Act is available for
the sale of</FONT> all of such Holder&rsquo;s <FONT STYLE="font-weight: normal; text-underline-style: double">shares without limitation
during a three-month period without registration; </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><FONT STYLE="font-weight: normal; text-underline-style: double">the first anniversary of the IPO.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Information Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">3.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delivery of Financial Statements</U>. The Company shall deliver to each Major Investor, <U>provided</U> that the Board of Directors
has not reasonably determined that such Major Investor is a Competitor of the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as soon as practicable, but in any event within one hundred thirty-five (135) days after the end of each fiscal year of the Company
(i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x)
the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as
defined in <U>Subsection 3.1(e)</U>) for such year, and (iii) a statement of stockholders&rsquo; equity as of the end of such year, <FONT STYLE="font-weight: normal; text-underline-style: double">all
such financial statements</FONT> audited and certified by independent public accountants of nationally <FONT STYLE="font-weight: normal; text-underline-style: double">or
regionally</FONT> recognized standing selected by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as soon as practicable, but in any event within thirty (30) days after the end of each of the first three (3) quarters of each
fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and a comparison between (x) the actual
amounts as of and for such fiscal quarter and (y) the comparable amounts as included in the Budget (as defined in <U>Subsection 3.1(e)</U>)
for such quarter, and an unaudited balance sheet and a statement of stockholders&rsquo; equity as of the end of such fiscal quarter<FONT STYLE="font-weight: normal; text-underline-style: double">,
all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments;
and (ii) not contain all notes thereto that may be required in accordance with GAAP)</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as soon as practicable, but in any event within thirty (30) days after the end of each quarter of each fiscal year of the Company,
a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for
shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding
securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of
shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit
the Major Investors to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer
or chief executive officer of the Company as being true, complete, and correct; provided, however, that no delivery needs to be made
under this <U>Section 3.1(c) </U>for as long as the Major Investor has access to the Company&rsquo;s capitalization table on Carta or
another similar electronic capitalization table management platform that shows the information set forth in this <U>Section 3.1(c)</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal; text-underline-style: double">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT></FONT>as soon as practicable, but in any event within thirty (30) days of the end of each month, an unaudited income statement
<FONT STYLE="font-weight: normal; text-underline-style: double">and statement of cash flows for such month, </FONT>and a comparison between
(x) the actual amounts as of and for such month and (y) the comparable amounts as included in the Budget (as defined in <U>Subsection
3.1(e)</U>) for such month, <FONT STYLE="font-weight: normal; text-underline-style: double">and</FONT> an unaudited balance <FONT STYLE="font-weight: normal; text-underline-style: double">sheet
and</FONT> statement <FONT STYLE="font-weight: normal; text-underline-style: double">of stockholders&rsquo; equity as of the end of such
month, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year-end audit adjustments
and (ii) not contain all notes thereto that may be required in accordance with GAAP)</FONT>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the
next fiscal year (collectively, the &ldquo;<B>Budget</B>&rdquo;), <FONT STYLE="font-weight: normal; text-underline-style: double">approved
by the Board of Directors (including all of the Preferred Directors) and</FONT> prepared on a monthly basis, including balance sheets,
income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared
by the Company; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>as soon as practicable, but in any event within twenty-five (25) days after the end of each quarter of each fiscal year of the
Company, such other information relating to the financial condition, business, scientific developments, prospects, and corporate affairs
of the Company as any Major Investor may from time to time reasonably request; <U>provided</U>, <U>however</U>, that the Company shall
not be obligated under this <U>Subsection 3.1</U> to provide information (i) that the Company reasonably determines in good faith to
be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the
Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">If, for any period, the Company
has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements
delivered pursuant to the foregoing sections shall be the consolidated and consolidating financial statements of the Company and all
such consolidated subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">Notwithstanding anything else
in this <U>Subsection 3.1</U> to the contrary, the Company may cease providing the information set forth in this <U>Subsection 3.1</U>
during the period starting with the date forty-five (45) days before the Company&rsquo;s good-faith estimate of the date of filing <FONT STYLE="font-weight: normal; text-underline-style: double">of
a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement
and related offering</FONT>; <U>provided</U> that the Company&rsquo;s covenants under this <U>Subsection 3.1</U> shall be reinstated
at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement
to become effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">3.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Inspection</U>. The Company shall permit each Major Investor (<U>provided</U> that the Board of Directors has not reasonably
determined that such Major Investor is a Competitor of the Company), at such Major Investor&rsquo;s expense, to visit and inspect the
Company&rsquo;s properties; examine its books of account and records; and discuss the Company&rsquo;s affairs, finances, and accounts
with its officers, during normal business hours of the Company as may be reasonably requested by the Major Investor; <U>provided</U>,
<U>however</U>, that the Company shall not be obligated pursuant to this <U>Subsection 3.2</U> to provide access to any information that
it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality
agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between
the Company and its counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">3.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Observer Rights</U>. As long as Surveyor owns not less than fifty percent of the shares of the Series B Preferred Stock it
is purchasing under the Purchase Agreement (or an equivalent amount of Common Stock issued upon conversion thereof), the Company shall
invite a representative of Surveyor to attend all meetings of the Board of Directors in a nonvoting observer capacity and, in this respect,
shall give such representative copies of all notices, minutes, consents, and other materials that it provides to its directors at the
same time and in the same manner as provided to such directors; provided, however, that such representative shall agree to hold in confidence
all information so provided or learned in any meeting of the Board of Directors and to not use any such information for any purpose other
than to monitor Surveyor&rsquo;s investment in the Company; and provided further, that the Company reserves the right to withhold any
information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such
meeting could adversely affect the attorney-client privilege between the Company and its counsel or result in disclosure of trade secrets
or a conflict of interest. Notwithstanding the foregoing, Surveyor shall not exercise its rights pursuant to this <U>Section 3.3</U>
unless and until the Company has confirmed in writing to Surveyor at any time after the Initial Closing (as defined in the Purchase Agreement)
that the Company does not engage in the design, fabrication, development, testing, production or manufacture of critical technologies
within the meaning of DPA (as defined in the Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">3.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Termination
of Information Rights</U>. The covenants set forth in Subsection 3.1, Subsection 3.2 and Subsection 3.3 shall terminate and be of no
further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first becomes subject to the periodic
reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such
term is defined in the Certificate of Incorporation, whichever event occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">3.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Confidentiality</U>. Each Investor agrees that such Investor will keep confidential and will not disclose, divulge, or use
for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant
to the terms of this Agreement (including notice of the Company&rsquo;s intention to file a registration statement), unless such confidential
information (a) is known or becomes known to the public in general (other than as a result of a breach of this <U>Subsection 3.5</U>
by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company&rsquo;s confidential
information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality
such third party may have to the Company; <U>provided</U>, <U>however</U>, that an Investor may disclose confidential information (i)
to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with
monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor, if such
prospective purchaser agrees to be bound by the provisions of this <U>Subsection 3.5</U>; (iii) to any Affiliate, partner, member, stockholder,
or wholly owned subsidiary of such Investor in the ordinary course of business, <FONT STYLE="font-weight: normal; text-underline-style: double"><U>provided
</U>that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality
of such information;</FONT> (iv) to the extent required in connection with any routine or periodic examination or similar process by
any regulatory or self-regulatory body or authority not specifically directed at the Company or the confidential information obtained
from the Company pursuant to the terms of the Agreement, including, without limitation, quarterly or annual reports or (v) as may otherwise
be required by law, regulation, rule, court order or subpoena, <U>provided</U> that , with respect to this clause (v), such Investor
promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">3.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Material Non-Public Information</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company understands and acknowledges that in the regular course of Surveyor&rsquo;s businesses, Surveyor and its Affiliates
will invest in companies that have issued securities that are publicly traded (each, a &ldquo;<B>Public Company</B>&rdquo;). Accordingly,
the Company covenants and agrees that before providing any material non-public information about a Public Company (&ldquo;<B>Public Company
Information</B>&rdquo;) to Surveyor or its representatives (or any of their respective Affiliates), the Company shall provide written
notice of such Public Company Information to Surveyor&rsquo;s compliance officer at SCComplianceAppvl@citadel.com describing such Public
Company Information in reasonable detail. The Company shall not disclose Public Company Information to Surveyor or its representatives
(or any of their respective Affiliates) without prior written authorization from Surveyor&rsquo;s compliance officer listed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Company acknowledges and agrees that in no event shall any Investor&rsquo;s confidentiality and non-use obligations hereunder
in any manner be deemed or construed as limiting such Investor or its representatives (or any of their respective Affiliates) ability
to trade any security of a Public Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Rights to Future Stock Issuances</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">4.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Right of First Offer</U>. Subject to the terms and conditions of this <U>Subsection 4.1</U> and applicable securities laws,
if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor.
A Major Investor shall be entitled to apportion the right of first offer hereby granted to it in such proportions as it deems appropriate,
among (i)&nbsp;itself, (ii)&nbsp;its Affiliates and (iii)&nbsp;its beneficial interest holders, such as limited partners, members or
any other Person having &ldquo;beneficial ownership,&rdquo; as such term is defined in Rule 13d-3 promulgated under the Exchange Act,
of such Major Investor (&ldquo;<B>Investor Beneficial Owners</B>&rdquo;); <U>provided</U> that each such Affiliate or Investor Beneficial
Owner (x)&nbsp;is not a Competitor or FOIA Party, unless such party&rsquo;s purchase of New Securities is otherwise consented to by the
Board of Directors and (y)&nbsp;agrees to enter into this Agreement and each of the Voting Agreement and Right of First Refusal and Co-Sale
Agreement of even date herewith among the Company, the Investors and the other parties named therein, as an &ldquo;<B>Investor</B>&rdquo;
under each such agreement (<U>provided</U> that any Competitor or FOIA Party shall not be entitled to any rights as a Major Investor
under <U>Subsections 3.1</U>, <U>3.2</U> and <U>4.1</U> hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company shall give notice (the &ldquo;<B>Offer Notice</B>&rdquo;) to each Major Investor, stating (i) its bona fide intention
to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which
it proposes to offer such New Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor may elect to purchase
or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals
the proportion that the Common Stock then held by such Major Investor (including all shares of Common Stock then issuable <FONT STYLE="font-weight: normal; text-underline-style: double">(directly
or indirectly) </FONT>upon conversion <FONT STYLE="font-weight: normal; text-underline-style: double">and/or exercise, as applicable,
</FONT>of the Preferred Stock and any other Derivative Securities then held by such Major Investor) bears to the total Common Stock of
the Company then outstanding (assuming full conversion and<FONT STYLE="font-weight: normal; text-underline-style: double">/or</FONT>
exercise<FONT STYLE="font-weight: normal; text-underline-style: double">, as applicable,</FONT> of all <FONT STYLE="font-weight: normal; text-underline-style: double">Preferred
Stock and any other </FONT>Derivative Securities then outstanding). At the expiration of such twenty (20) day period, the Company shall
promptly notify each Major Investor that elects to purchase or acquire all the shares available to it (each, a &ldquo;<B>Fully Exercising
Investor</B>&rdquo;) of any other Major Investor&rsquo;s failure to do likewise. During the ten (10) day period commencing after the
Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in
addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors were entitled to
subscribe but that were not subscribed for by the Major Investors which is equal to the proportion that the Common Stock issued and held,
or issuable (directly or indirectly) upon conversion <FONT STYLE="font-weight: normal; text-underline-style: double">and/or exercise,
as applicable, of </FONT>Preferred Stock <FONT STYLE="font-weight: normal; text-underline-style: double">and any other Derivative Securities
</FONT>then held, by such Fully Exercising Investor bears to the Common Stock issued and held, or issuable <FONT STYLE="font-weight: normal; text-underline-style: double">(directly
or indirectly) </FONT>upon conversion <FONT STYLE="font-weight: normal; text-underline-style: double">and/or exercise, as applicable,
</FONT>of the Preferred Stock <FONT STYLE="font-weight: normal; text-underline-style: double">and any other Derivative Securities</FONT>
then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this
<U>Subsection 4.1(b)</U> shall occur within the later of one hundred and twenty (120) days of the date that the Offer Notice is given
and the date of initial sale of <FONT STYLE="font-weight: normal; text-underline-style: double">New Securities pursuant to <U>Subsection
4.1(c)</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in <U>Subsection
4.1(b)</U>, the Company may, during the ninety (90) day period following the expiration of the periods provided in <U>Subsection 4.1(b)</U>,
offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon
terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for
the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof,
the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the
Major Investors in accordance with this <U>Subsection 4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The right of first offer in this <U>Subsection 4.1</U> shall not be applicable to (i) <FONT STYLE="font-weight: normal; text-underline-style: double">Exempted
Securities</FONT> (as defined in the Certificate of Incorporation<FONT STYLE="font-weight: normal; text-underline-style: double">)</FONT>;
(ii) shares of Common Stock issued in the IPO; <FONT STYLE="font-weight: normal; text-underline-style: double">and</FONT> (iii) the issuance
of shares of Series B Preferred Stock pursuant to <U>Subsection <FONT STYLE="font-weight: normal; text-underline-style: double">1.3</FONT></U>
of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">4.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination</U>. The covenants set forth in <U>Subsection 4.1</U> shall terminate and be of no further force or effect (i)
immediately before the consummation of the IPO<FONT STYLE="font-weight: normal; text-underline-style: double">,</FONT> (ii) <FONT STYLE="font-weight: normal; text-underline-style: double">when
the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) </FONT>upon
the closing of a Deemed Liquidation Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Covenants</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.5pt">5.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Insurance</U>. The Company has obtained from financially sound and reputable insurers Directors and Officers liability insurance
in an amount and on terms and conditions satisfactory to the Board of Directors, including all of the Preferred Directors, and will use
commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines
that such insurance should be discontinued. The Company shall obtain, within thirty (30) days of the date hereof, from financially sound
and reputable insurers term &ldquo;key&#45;person&rdquo; insurance on Benjamin J. Zeskind, in an amount of five million dollars ($5,000,000)
or any other amount satisfactory to the Board of Directors and on terms and conditions satisfactory to the Board of Directors, and will
use commercially reasonable efforts to cause such insurance policies to be maintained until such time as the Board of Directors determines
that such insurance should be discontinued. The key&#45;person policy shall name the Company as loss payee, and neither policy shall
be cancelable by the Company without prior approval by the Board of Directors, including all of the Preferred Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.5pt"></P>

<!-- Field: Page; Sequence: 9; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 103.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Employee Agreements</U>. The Company will cause (i) each <FONT STYLE="font-weight: normal; text-underline-style: double">Person
</FONT>now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent
contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment
agreement; and (ii) each Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement, substantially in the
form approved by the Board of Directors. The Company has delivered to the Investors copies of all existing agreements between current
employees and consultants, and the Investors agree that these agreements satisfy the requirements of this <U>Section 5.2</U>. In addition,
the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements
or any restricted stock agreement between the Company and any employee, without the approval of the Board of Directors, including all
of the Preferred Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Employee Stock</U>. Unless otherwise approved by the Board of Directors, <FONT STYLE="font-weight: normal; text-underline-style: double">including
all of the Preferred Directors, </FONT>all future employees and consultants of the Company who purchase, receive options to purchase,
or receive awards of shares of the Company&rsquo;s capital stock after the date hereof shall be required to execute restricted stock
or option agreements, as applicable, providing for (i) vesting of shares over a four (4) year period, with the first twenty-five percent
(25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal
monthly installments over the following thirty-six (36) months, and (ii) a <FONT STYLE="font-weight: normal; text-underline-style: double">market
stand-off provision substantially similar to that</FONT> in <FONT STYLE="font-weight: normal; text-underline-style: double"><U>Subsection
2.11</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Matters Requiring Investor Director Approval</U>. So long as the holders of Series B Preferred Stock are entitled to elect
a Preferred Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board
of Directors, which approval must include the affirmative vote of all of the Preferred Directors:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Effect or consummate a public offering of any Capital Stock of the company or any of its subsidiaries, or engage any investment
banking firm or underwriter in connection therewith;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other
corporation, partnership, or other entity unless it is wholly owned by the Company;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director
of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an
employee stock or option plan approved by the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for
trade accounts of the Company or any subsidiary arising in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make any investment inconsistent with any investment policy approved by the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> incur any aggregate indebtedness in excess of $250,000 that is not already included in a budget approved by the Board of Directors,
other than trade credit incurred in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>make any capital expenditures (including expenditures under capitalized leases) that in the aggregate are more than 10% in excess
of the annual budget approved by the Board;;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any &ldquo;associate&rdquo;
(as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, except transactions made in the ordinary course of
business, pursuant to reasonable requirements of the Company&rsquo;s business and upon fair and reasonable terms that are approved by
the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to
executive officers;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>change the principal business of the Company, enter unrelated lines of business, or exit the current line of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>sell, assign, license, pledge, or encumber material technology or intellectual property, other than the sale of products, services
or licenses granted in the ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(l)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company
of money or assets greater than $200,000, other than agreements for the provision of the Company&rsquo;s services entered into in the
ordinary course of business;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(m)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>increase or decrease the size of the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(n)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>increase or decrease the amount of the Directors and Officers liability insurance;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(o)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>amend, modify, terminate, waive, or otherwise alter, in whole or in part, the election procedure of the Board of Directors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(p)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>adopt any plan, or any amendment of any plan, for issuance of any capital stock to employees, directors and consultants; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(q)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>approve the Budget or adopt any material changes or increases cumulatively greater than 15%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Board Matters</U>. Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors
shall meet at least quarterly in accordance with an agreed-upon schedule. Each Preferred Director shall be entitled in such person&rsquo;s
discretion to be a member of any committee of the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successor Indemnification</U>. If the Company or any of its successors or assignees consolidates with or merges into any other
Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper
provisions shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification
of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the
Company&rsquo;s Bylaws, the Certificate of Incorporation, or elsewhere, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Indemnification Matters</U>. The Company hereby acknowledges that one (1) or more of the Preferred Directors nominated to serve
on the Board of Directors by one (1) or more Investors may have certain rights to indemnification, advancement of expenses and/or insurance
provided by one (1) or more of the Investors and certain of their Affiliates (collectively, the &ldquo;<B>Investor Indemnitors</B>&rdquo;).
The Company hereby agrees (a) that it is the indemnitor of first resort (<I>i.e.</I>, its obligations to any such Preferred Director
are primary and any obligation of the Investor Indemnitors to advance expenses or to provide indemnification for the same expenses or
liabilities incurred by such Preferred Director are secondary), (b) that it shall be required to advance the full amount of expenses
incurred by such Preferred Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts
paid in settlement by or on behalf of any such Preferred Director to the extent legally permitted and as required by the Certificate
of Incorporation or Bylaws of the Company (or any agreement between the Company and such Preferred Director), without regard to any rights
such Preferred Director may have against the Investor Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the
Investor Indemnitors from any and all claims against the Investor Indemnitors for contribution, subrogation or any other recovery of
any kind in respect thereof. The Company further agrees that no advancement or payment by the Investor Indemnitors on behalf of any such
Preferred Director with respect to any claim for which such Preferred Director has sought indemnification from the Company shall affect
the foregoing and the Investor Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement
or payment to all of the rights of recovery of such Preferred Director against the Company. The Preferred Directors and the Investor
Indemnitors are intended third-party beneficiaries of this <U>Section 5.7</U> and shall have the right, power and authority to enforce
the provisions of this <U>Section 5.7</U> as though they were a party to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Right to Conduct Activities</U>. The Company hereby agrees and acknowledges that (i) Boxcar or any of its Affiliates, (ii)
Cormorant or any of its Affiliates, (iii) Surveyor or any of its Affiliates, (iv) Rock Springs or any of its Affiliates, (vi) BlackRock
or any of its Affiliates, (v) T. Rowe Price or any of its Affiliates, (vii) LYFE Capital or any of its Affiliates or (viii) Perceptive
or any of its Affiliates (collectively, the &ldquo;<B>Professional Investment Organizations</B>&rdquo;) are professional investment organizations,
and as such review the business plans and related proprietary information of many enterprises, some of which may compete directly or
indirectly with the Company&rsquo;s business (as currently conducted or as currently propose to be conducted).&nbsp; The Company hereby
agrees that, to the extent permitted under applicable law, the Professional Investment Organizations shall not be liable to the Company
for any claim arising out of, or based upon, (i) the investment by the Professional Investment Organizations in any entity competitive
with the Company, or (ii) actions taken by any partner, officer, employee or other representative of the Professional Investment Organizations
to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive
company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall
not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company&rsquo;s confidential information
obtained pursuant to this Agreement, or (y) any director or officer of the Company from any liability associated with his or her fiduciary
duties to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Defense Production Act</U>. To the extent that the Company learns that it engages in the design, fabrication, development,
testing, production or manufacture of critical technologies within the meaning of Section 721 of the Defense Production Act of 1950,
as amended (50 U.S.C. &sect; 4565), and all rules and regulations thereunder, including as codified at 31 C.F.R. Part 800, whether because
of a new categorization of technology by the U.S. government or otherwise, the Company shall promptly provide notice to Surveyor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Class B Common Stock</U>. The Company shall not cause any shares of Class B Common Stock to become subject to the periodic
reporting requirements of Section 12(b) or 12(g) of the Exchange Act without the prior written consent of Surveyor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">5.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Termination of Covenants</U>. The covenants set forth in this <U>Section 5</U>, except for <U>Subsections 5.6</U> and <U>5.7</U>,
shall terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Company first
becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon a Deemed Liquidation
Event, as such term is defined in the Certificate of Incorporation, whichever event occurs first.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.1<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. <FONT STYLE="font-weight: normal; text-underline-style: double">The rights under this Agreement
</FONT>may <FONT STYLE="font-weight: normal; text-underline-style: double">be</FONT> assigned (<FONT STYLE="font-weight: normal; text-underline-style: double">but
only with all related obligations</FONT>) <FONT STYLE="font-weight: normal; text-underline-style: double">by a Holder to a transferee
of</FONT> Registrable Securities <FONT STYLE="font-weight: normal; text-underline-style: double">that (i) is an Affiliate of a Holder;
(ii) is a Holder&rsquo;s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder&rsquo;s
Immediate Family Members; or (iii) after such transfer, holds at least </FONT>143,022 <FONT STYLE="font-weight: normal; text-underline-style: double">shares
of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations)
</FONT>or, if less, all of the Registrable Securities held by such Holder<FONT STYLE="font-weight: normal; text-underline-style: double">;
<U>provided</U>, <U>however</U>, that (x) the Company is, within a reasonable time after such transfer, furnished with written notice
of the name and address of such transferee and the Registrable Securities</FONT> with respect to <FONT STYLE="font-weight: normal; text-underline-style: double">which
such</FONT> rights <FONT STYLE="font-weight: normal; text-underline-style: double">are being transferred; and (y) such transferee agrees
in</FONT> a written instrument <FONT STYLE="font-weight: normal; text-underline-style: double">delivered </FONT>to the Company to be
bound by <FONT STYLE="font-weight: normal; text-underline-style: double">and subject to </FONT>the terms <FONT STYLE="font-weight: normal; text-underline-style: double">and
conditions </FONT>of this <FONT STYLE="font-weight: normal; text-underline-style: double">Agreement, including the provisions of <U>Subsection
2.11</U>. For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee
(1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder&rsquo;s Immediate Family Member; or (3) that is a trust for
the benefit of an individual Holder or such Holder&rsquo;s Immediate Family Member shall be aggregated together and with those of the
transferring Holder; <U>provided further</U> that all transferees who would not qualify individually for assignment of rights shall,
as a condition to the applicable transfer, establish a single attorney-in-fact for the purpose of exercising any rights, receiving </FONT>notices,
or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the
respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon
any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities
under or by reason of this Agreement, except as expressly provided herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.2<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement and any controversy arising out of or relating to this Agreement shall be governed by and
construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all
other matters shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts, without regard
to conflict of law principles that would result in the application of any law other than the law of the Commonwealth of Massachusetts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.3<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Counterparts</U>. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. <FONT STYLE="font-weight: normal; text-underline-style: double">Counterparts
may be delivered via facsimile, electronic mail (including pdf</FONT> or any electronic signature complying with the U.S. federal ESIGN
Act of 2000, <I>e.g.</I>, www.docusign.com<FONT STYLE="font-weight: normal; text-underline-style: double">) or other transmission method
and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes</FONT><FONT STYLE="text-underline-style: double"><B>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.4<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are for convenience only and are not to be considered
in construing or interpreting this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.5<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Notices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively
given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic
mail or facsimile during the recipient&rsquo;s normal business hours, and if not sent during normal business hours, then on the recipient&rsquo;s
next business day; (iii) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid;
or (iv) one (1) <FONT STYLE="font-weight: normal; text-underline-style: double">business </FONT>day after <FONT STYLE="font-weight: normal; text-underline-style: double">the
business day of</FONT> deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written
verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on <U>Schedule A
</U>hereto, or to <FONT STYLE="font-weight: normal; text-underline-style: double">the principal office of the Company and to the attention
of the Chief Executive Officer, in the case of the Company, or to </FONT>such email address, facsimile number, or address as subsequently
modified by written notice given in accordance with this <U>Subsection 6.5</U>. If notice is given to the Company, a copy shall also
be sent to Latham &amp; Watkins LLP, 200 Clarendon Street, 27th Floor, Boston, MA 02116, Attention: Evan G. Smith, Esq. and if notice
is given to Investors, a copy shall also be given to: (x) Greenberg Traurig, LLP, One International Place Suite 2000, Boston, MA 02110,
Attention Bradley A. Jacobson, Esq., and (y) Wiggin and Dana LLP, One Century Tower, 265 Church Street, New Haven, Connecticut 06510,
Attention Evan S. Kipperman, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Consent to Electronic Notice</U>. Each Investor and Key Holder consents to the delivery of any stockholder notice pursuant
to the Delaware General Corporation Law (the &ldquo;DGCL&rdquo;), as amended or superseded from time to time, by electronic transmission
pursuant to Section 232 of the DGCL (or any successor thereto) at the electronic mail address as on the books of the Company. Each Investor
agrees to promptly notify the Company of any change in such stockholder&rsquo;s electronic mail address, and that failure to do so shall
not affect the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.6<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Amendments and Waivers</U>. Any term of this Agreement may be amended, modified or terminated and the observance of any term
of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the
written consent of the Company and the holders of a majority of the Registrable Securities then outstanding; <U>provided</U> that the
Company may in its sole discretion waive compliance with <U>Subsection <FONT STYLE="font-weight: normal; text-underline-style: double">2.12(c)
</FONT></U>(and the Company&rsquo;s failure to object promptly in writing <FONT STYLE="font-weight: normal; text-underline-style: double">after
notification of</FONT> a proposed assignment allegedly in violation of <U>Subsection <FONT STYLE="font-weight: normal; text-underline-style: double">2.12(c)
</FONT></U>shall be deemed to be a waiver)<FONT STYLE="font-weight: normal; text-underline-style: double">; and <U>provided further</U>
that any provision hereof may be waived by any waiving party on such party&rsquo;s own behalf, without the consent of any other party</FONT>.
Notwithstanding the foregoing, (a) this Agreement may not be amended, modified or terminated and the observance of any term hereof (including,
without limitation, <U>Sections 1.6</U>, <U>1.7</U> and <U>5.4</U>) may not be waived with respect to any Investor without the written
consent of such Investor, unless such amendment, modification, termination, or waiver applies to all Investors in the same fashion (it
being agreed that a waiver of the provisions of <U>Section 4</U> with respect to a particular transaction shall be deemed to apply to
all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless,
by agreement with the Company, purchase securities in such transaction; provided that if the rights of a Major Investor under <U>Section
4.1</U> with respect to an offering of New Securities are waived without the consent of such Major Investor, and any Major Investor actually
purchases any New Securities in any such offering, then each Major Investor who did not consent to such waiver shall be permitted to
participate in such offering on a pro rata basis (based on the level of participation of the Major Investor purchasing the largest portion
of such Major Investor&rsquo;s pro rata share) (b) <U>Sections 1.35</U>, <U>3.3</U>, <U>5.9</U>, <U>5.10</U> and this clause (b) of this
<U>Subsection 6.6</U> may not be amended, modified, terminated or waived without the written consent of Surveyor; and (c) <U>Subsections
3.1</U> and <U>3.2</U>, <U>Section 4</U> and any other section of this Agreement applicable to the Major Investors (including this clause
(c) of this <U>Subsection 6.6</U>) may not be amended, modified, terminated or waived without the written consent of the holders of a
majority of the Registrable Securities then outstanding and held by the Major Investors. Notwithstanding the foregoing, <U>Schedule A
</U>hereto may be amended by the Company from time to time to add transferees of any Registrable Securities in compliance with the terms
of this Agreement without the consent of the other parties; and <U>Schedule A</U> hereto may also be amended by the Company after the
date of this Agreement without the consent of the other parties to add information regarding any additional Investor who becomes a party
to this Agreement in accordance with <U>Subsection 6.9</U>. The Company shall give prompt notice of any amendment, modification or termination
hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, modification, termination, or waiver.
Any amendment, modification, termination, or waiver effected in accordance with this <U>Subsection 6.6</U> shall be binding on all parties
hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision
of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term,
condition, or provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.7<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid,
illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this
Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and
enforceable to the maximum extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.8<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Aggregation of Stock</U>. All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together
for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights
as among themselves in any manner they deem appropriate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.9<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Additional Investors</U>. Notwithstanding anything to the contrary contained herein, if the Company issues additional shares
of the Company&rsquo;s Preferred Stock after the date hereof, any purchaser of such shares of Preferred Stock may become a party to this
Agreement by executing and delivering an additional counterpart signature page to this Agreement, and thereafter shall be deemed an &ldquo;Investor&rdquo;
for all purposes hereunder. No action or consent by the Investors shall be required for such joinder to this Agreement by such additional
<FONT STYLE="font-weight: normal; text-underline-style: double">Investor</FONT>, so long as such additional <FONT STYLE="font-weight: normal; text-underline-style: double">Investor
</FONT>has agreed in writing to be bound by all of the obligations as an &ldquo;Investor&rdquo; hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.10<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement</U>. This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding
and agreement <FONT STYLE="font-weight: normal; text-underline-style: double">among</FONT> the parties with respect to the subject matter
hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.11<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Dispute Resolution</U>. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts
of Delaware and to the jurisdiction of the United States District Court for the District of Delaware for the purpose of any suit, action
or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising
out of or based upon this Agreement except in the state courts of Delaware or the United States District Court for the District of Delaware,
and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding,
any claim that it is not subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune from
attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action
or proceeding is improper or that this Agreement or the subject matter hereof may not be enforced in or by such court.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.12<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>WAIVER OF JURY TRIAL.</U> EACH PARTY HEREBY WAIVES ITS RIGHTS TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR
ARISING OUT OF THIS AGREEMENT OR THE SUBJECT MATTER HEREOF. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL
DISPUTES THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING, WITHOUT LIMITATION, CONTRACT
CLAIMS, TORT CLAIMS (INCLUDING NEGLIGENCE), BREACH OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS SECTION HAS BEEN
FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE PROVISIONS WILL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY FURTHER
WARRANTS AND REPRESENTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY
WAIVES ITS JURY TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">6.13<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Delays or Omissions</U>. No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement,
upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching
or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar
breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or
default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party,
shall be cumulative and not alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Remainder of Page Intentionally Left Blank]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Value: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the parties
have executed this Agreement as of the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>IMMUNEERING CORPORATION</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Benjamin J. Zeskind</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;Benjamin J. Zeskind</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:&nbsp;&nbsp;Chief Executive Officer</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>Cormorant
    Private Healthcare Fund III, LP</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Cormorant Private Healthcare GP III,
    LLC</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Bihua Chen</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: Bihua Chen</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Member</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CORMORANT
    GLOBAL HEALTHCARE MASTER FUND, LP</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Cormorant Global Healthcare GP, LLC</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bihua Chen</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: Bihua Chen</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Member</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>CRMA SPV,
    L.P.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Cormorant Asset Management, LP</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bihua Chen</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: Bihua Chen</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Attorney-in-fact</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">INVESTORS:</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BLACKROCK HEALTH SCIENCES TRUST II</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: BlackRock Advisors, LLC, its Investment
    Adviser</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Hongying Erin Xie</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Hongying
    Erin Xie</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Managing Director</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTORS:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>BOXCAR PMJ,
    LLC</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Joseph Kekst</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Joseph
    Kekst</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Manager</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PEF
    LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Peter Feinberg</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">PF
    ASSOCIATES L.P.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Peter Feinberg</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">S4K
    INVESTMENTS LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Peter Feinberg</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Title:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">INVESTORS:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">SAGE
    CREST LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Joseph Kekst</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Name:
    Joseph Kekst</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Title:
    Manager</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TSKEK
    IM LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Joseph Kekst</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Name:
    Joseph Kekst</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Title:
    Manager</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">ZBC
    CAPITAL PARTNERS LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Marc Hurwitz</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Name:
    Marc Hurwitz</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Title:
    President</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>VALUEQUEST
    PARTNERS, LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Name:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Robert J. Carpenter</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Robert
    J. Carpenter</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: bold 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">/s/
    Benjamin J. Zeskind</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&nbsp;</FONT></TD>
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">Benjamin
    J. Zeskind</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: small-caps 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MERRIN INVESTORS
    LLC</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Seth Merrin</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Seth
    Merrin</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: General Partner</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Martin Lipton</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Martin Lipton</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Harold Levy</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Harold Levy</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
page to amended and restated investors&rsquo; rights agreement</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Brett M.
    Hall</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Brett M. Hall</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
page to amended and restated investors&rsquo; rights agreement</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Howard Kaufman</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Howard Kaufman</TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
page to amended and restated investors&rsquo; rights agreement</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Joseph Shenker</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Joseph Shenker</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
page to amended and restated investors&rsquo; rights agreement</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ELI PINEWSKI
    FAMILY LLC</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Alan Pines</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: Alan
    Pines</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Member</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
page to amended and restated investors&rsquo; rights agreement</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid">/s/ Kenneth Gruber</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kenneth Gruber</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
page to amended and restated investors&rsquo; rights agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INVESTOR:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CITADEL MULTI-STRATEGY EQUITIES MASTER
    FUND LTD.</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: Citadel Advisors LLC, its portfolio
    manager</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 46%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Shellane Mulcahy</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: Authorized Signatory</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
page to amended and restated investors&rsquo; rights agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">ROCK SPRINGS CAPITAL MASTER FUND
    LP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: Rock Springs General Partner LLC,
    its general partner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Kris Jenner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Kris Jenner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Member</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">FOUR PINES MASTER FUND LP</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: Four Pines General Partner LLC,
    its general partner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">/s/ Kris Jenner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Kris Jenner</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Member</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. ROWE PRICE HEALTH SCIENCES
    FUND, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">TD MUTUAL FUNDS - TD HEALTH SCIENCES
    FUND</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">T. ROWE PRICE HEALTH SCIENCES
    PORTFOLIO</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Each account, severally and not jointly</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By: T. Rowe Price Associates, Inc.,
    Investment Adviser or Subadviser, as applicable</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Andrew Baek</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Andrew Baek</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Vice President</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">LYFE CAPITAL FUND III (PHOENIX),
    L.P.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Yao Li Ho</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Yao Li Ho</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Member of the General Partner</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">PERCEPTIVE LIFE SCIENCES MASTER
    FUND, LTD.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    James H. Mannix</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: James H. Mannix</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Chief Operating Officer</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BM LINDSEY, INC.</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Bryan Murphy</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Bryan Murphy</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: Director</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">FEINBERG INVESTMENT TRUST LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Lori Kany</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">INVESTOR:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">BRIDGELINKS LLC</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-size: 10pt">By:</FONT>&nbsp;&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-size: 10pt">/s/
    Peter Langerman</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name: Peter Langerman</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title: President</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Rebecca Kusko</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Rebecca Kusko</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Dana Levy</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Dana Levy</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Jonathan Levy</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Jonathan Levy</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Jenna Levy</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Jenna Levy</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Ilonna Rimm</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Ilonna Rimm</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Josef von Rickenbach</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Josef von Rickenbach</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Benjamin Kany</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Benjamin Kany</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Samantha Kany</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Samantha Kany</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Mark Zucker</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Mark Zucker</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">/s/ Peter King</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Peter King</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Scott Barrett</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Scott Barrett</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">INVESTOR:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Investor Name:</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Signatory Name (if signing for an entity):</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Title (if signing for an entity):</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Signature
Page To Amended and Restated Investors&rsquo; Rights Agreement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: left; text-indent: 6.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.25in; text-align: left; text-indent: 6.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Investors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.75pt; border: Black 1pt solid; width: 100%; text-align: left; font-size: 10pt"><B><BR>
    Name and Address of Investor</B></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cormorant Private Healthcare Fund III, LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cormorant Global Healthcare Master Fund, LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">CRMA SPV, LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Robert
                                            J. Carpenter<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Martin
                                            Lipton<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Josef
                                            von Rickenbach<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; padding-bottom: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt">BM
    Lindsey, Inc.<BR>
    [Address]</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 5.75pt; border: Black 1pt solid; width: 100%; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">PEF
                                            LLC<BR> [Address]\</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Tskek
                                            IM LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Marc
                                            A Hurwitz 2012 Dynasty Trust<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Feinberg
                                            Investment Trust LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">PF
                                            Associates L.P.<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">S4K
                                            Investments LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">SAGE Crest LLC<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">ZBC
                                            Capital Partners LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; padding-bottom: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt">Benjamin
    J. Zeskind<BR>
    [Address]<BR>
    <BR></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 5.75pt; border: Black 1pt solid; width: 100%; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Robert
                                            J. Carpenter<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Rebecca
                                            Kusko<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Brett
                                            M. Hall<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Merrin
                                            Investors LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">ValueQuest
                                            Partners, LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Ken
                                            Gruber<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Dr.
                                            Mark Zucker<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; padding-bottom: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt">Eli
    Pinewski Family LLC<BR>
    [Address]</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 5.75pt; border: Black 1pt solid; width: 100%; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Brent
                                            LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">William
                                            Sahlman<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Bridgelinks
                                            LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Harold
                                            Levy<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dana Levy<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Jonathan Levy<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Jenna Levy<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; padding-bottom: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt">Haya
    Taitel<BR>
    [Address]</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 5.75pt; border: Black 1pt solid; width: 100%; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Mike
                                            Hornbuckle<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Jon
                                            Mann<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">PENSCO
                                            IRA account Eric Bodner<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Josh
                                            &amp; Aliza Katz<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Linda
                                            Jesselson<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Bruce
                                            A. Bauman and Denise D. Selden, Tenants in Common<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">CARRAL
                                            LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; padding-bottom: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt">Premier
    Trust Custodian FBO David Koster IRA<BR>
    [Address]</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="padding-left: 5.75pt; border: Black 1pt solid; width: 100%; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Julio
                                            Triana<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Rochelle
                                            Gut<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Tyseth
                                            Holdings LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Blue River Associates, L.P.<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Eric F. Saltzman Revocable Trust<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Daniel
                                            Giachin<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; padding-bottom: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt">Boxcar
    PMJ, LLC<BR>
    [Address]</TD></TR>
  <TR>
    <TD STYLE="padding-left: 5.75pt; padding-bottom: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left; font-size: 10pt">Adross
    Insights, LLC<BR>
    [Address]</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Split-Segment; Name: 02 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">ST
                                            Detroit Enterprises LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Elisa
                                            and Yoel Wagner<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">The
                                            Livio Giachin Family Trust<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt; text-align: left; font-size: 10pt"><P STYLE="margin-top: 0; margin-bottom: 0">Business
                                            Technology Advisors, LLC<BR> [Address]</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Benjamin Kany<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Samantha Kany<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Robert and Susan Okin<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">IRA Services Trust Company<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">The Kekst Family Living Trust u/a/d (David J.
    Kekst)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Scott Barrett</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Peter King</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ilana&rsquo;s Trust UT Gershon Kekst Annuity
    Trust<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ronald G. Weiner</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">55 Pine Street LLC</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Kenneth Mandelbaum</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ParkEcho Genetica LLC<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Louis Feinberg<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Joseph C. Shenker<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Raizi Simons</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Hali Simons</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Zelda Gruber Family Trust<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pam Genet and Elliot Barsh</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ira Rosenberg<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Jeremy Triana</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Howard Kaufman<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Marc A Hurwitz 2012 Dynasty Trust<BR>
    [Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">T. Rowe Price Health Sciences Fund, Inc.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">TD Mutual Funds - TD Health Sciences Fund</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">T. Rowe Price Health Sciences Portfolio</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Citadel Multi-Strategy Equities Master Fund
    Ltd.<BR>
    [Address]<BR>
    <BR></P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Rock Springs Capital Master Fund LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Four Pines Master Fund LP</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Blackrock Health Sciences Trust II</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">LYFE Capital Fund III (Phoenix), L.P.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Perceptive Life Sciences Master Fund, Ltd.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.75pt; padding-left: 5.75pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ilonna Rimm</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">[Address]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>filename3.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="tm2115679d2_ex99-1img001.jpg" ALT=""><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 8%"></TD><TD STYLE="border-bottom: Black 1pt solid; width: 84%; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify; width: 8%">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B>(1)</B> <B>BioArkive, LLC</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>-&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;-</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"><B>(2) Immuneering
Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"><B>MASTER SERVICES
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 40%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"><B></B></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15in; text-align: center; text-indent: -0.25in"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>MASTER SERVICES AGREEMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Master
Services Agreement (&#8220;<B>Agreement</B>&#8221;), effective as of August 5<SUP>th</SUP>, 2019 (&#8220;<B>Effective
Date</B>&#8221;), is made by and between Bioarkive LLC, a limited liability company under the laws of California, USA, having its
registered offices and principal place of business at 11421 W Bernardo Court (Suite 200), San Diego, CA 92127 (hereinafter referred
to as &#8220;<B>Bioarkive</B>&#8221;); and Immuneering Corporation, a corporation<B>, </B>incorporated under the laws of Delaware,
USA, having its registered offices and principal place of business at 245 Main St, Second Floor, Cambridge, MA 02142 (hereinafter
referred to as &#8220;<B>Client</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -1in">Hereinafter each party
may also individually be referred to as a &#8220;<B>Party</B>&#8221; and collectively as the &#8220;<B>Parties</B>&#8221;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS, </B>Client is engaged in the field
of drug discovery;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Bioarkive is engaged in business
in the field of preclinical research services and biorepository services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Bioarkive is willing to provide
contract research and development services, as defined below and hereby represents that this undertaking does not conflict with its duties
and obligations under any other agreement to which it is a party, including any agreement with any other company or institution, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS,</B> Client and/or its affiliated companies
as the case may be, wish to engage Bioarkive for the purpose of literature study, molecular and cell biology research, assay development,
biostorage, data analysis, and testing therapeutic agents as further specified in a related Project Proposal or related services which
Bioarkive may offer on a project-by-project basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW, THEREFORE, IT IS AGREED AS FOLLOWS:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><B>1.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>BIOARKIVE
SERVICES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
engagement by Client hereunder, Bioarkive, (hereinafter referred as to as the &#8220;<B>Service Provider</B>&#8221;), shall perform preclinical
services, including (but not limited to) molecular and cellular biology assays and/or early process research services which may include
(but not limited to) literature study, molecular modeling and assay design, feasibility studies and other related services (collectively,
the &#8220;<B>Services</B>&#8221;) for Client. The Service Provider will prepare a quotation or project proposal (&#8220;<B>Project Proposal</B>&#8221;)
for each request from Client in which, as appropriate, the project goal and/or purpose, the information desired, the experimental procedures
or general synthetic approach (derived from literature, patents or other sources of information), the estimated duration of the project,
the price, payment terms and payment schedule and all other relevant matters will be described.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
nature of the Services to be performed by the Service Provider with respect to any individual project as described in a Project
Proposal (&#8220;<B>Project</B>&#8221;) shall be mutually agreed by the Parties and set forth in a Project Proposal that will become
an attachment to this Agreement and will be signed by the Client and the relevant Service Provider. An example of the highlights of
a Project Proposal is attached to this Agreement as Appendix 1. Each accepted Project Proposal or any other written assignment
related to a Project Proposal shall be subject to all of the terms and conditions of this Agreement. To the extent any terms or
provisions of a Project Proposal conflict with the terms and provisions of this Agreement, the terms and provisions of this
Agreement shall prevail unless the Project Proposal, signed by both Parties, expressly states to the contrary. Bioarkive agrees that
during the term of this Agreement, there is neither a minimum number of Projects for which Client is obligated to utilize Bioarkive,
nor does this Agreement in any way limit Client&#8217;s right to contract with any other Party to provide services similar to that
which Bioarkive provides under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
the event that Bioarkive perform any work or Services prior to execution by the Parties of an accepted Project Proposal for such work
or Services, the terms and conditions of this Agreement shall also apply to any such work and Services performed by Bioarkive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
consideration of the Services that are performed by the Service Provider under this Agreement, Client will pay the Service Provider the
price that has been agreed upon for each accepted Project Proposal or any other written assignment related to a Project Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Payment and/or reimbursement shall be (a) in accordance
with the terms of the accepted Project Proposal or any other written assignment related to a Project Proposal and (b) accompanied by an
invoice from the Service Provider reasonably documenting actual costs charged and/or fees earned. All fees and reimbursable expenses relating
to the Services described in an accepted Project Proposal shall be payable and invoiced upon completion of all Services or according to
the agreed payment schedule as outlined in the accepted Project Proposal. Invoices received and thereafter approved for payment by Client
shall be paid to the Service Provider within thirty (30) days after date of invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10.25pt; text-indent: -10.25pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If requested by Client, the Service Provider shall consult with Client to assist Client in describing the Project goal and/or purpose.
Bioarkive represents that the Service Provider will provide all reasonable efforts to assist Client in a manner consistent with current
regulatory guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Service Provider shall appoint a &quot;Project Manager&quot; to be responsible for a Project performed for Client. The Project Manager
shall coordinate performance of the Project with a representative designated by Client, which representative shall have responsibility
over all matters related to the outcome of the Project on behalf of Client.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Service Provider will communicate with Client scientists and with Client on a regular basis, and will respond upon all reasonable requests,
regarding all Projects. The Service Provider will provide written reports to Client at regular, defined and mutually agreeable intervals
describing the results and including full experimental procedures, as further set forth in the Project Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">1.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Service Provider shall retain for a period of at least five (5) years from the completion of a Project or such mandatory period as defined
by applicable laws, whichever is longer, (a) experimental records and laboratory notebooks containing experimental descriptions and data
generated from such Project and may store (b) research samples, where applicable, for reference purposes.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt"><B>2.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>COMPLIANCE
WITH GOVERNMENT REGULATIONS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Service Provider shall perform each Project in accordance with applicable laws, regulations, the current state of the laboratory research
art and the relevant Project Proposal. The Service Provider shall also comply with all applicable current government regulatory requirements.
In the event Client requires any special procedures to be undertaken by the Service Provider (e.g., to satisfy foreign standards or requirements
or otherwise) such procedures (&quot;Client Procedures&quot;) will be provided in writing by Client to the Service Provider and require
prior written approval by the Service Provider. Service Provider shall perform each Project in accordance with all agreed-upon Client
Procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">2.2</TD><TD STYLE="text-align: justify">The Service Provider shall provide the following for each Project:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">Labor, facilities and materials</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Preclinical data analysis experiments completed during a Project including an interim summary report;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">Subject to section 1.8 and upon request of Client any data and other research materials resulting from
a Project;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">A final report setting forth a full summary of the results of a Project, including a summary of all relevant
data; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.9pt; text-align: justify; text-indent: -35.45pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">Necessary professional and support personnel for a Project.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">2.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bioarkive
shall assure compliance with all applicable laws and regulations regarding the disposal of hazardous materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><B>3.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>CONFIDENTIAL
INFORMATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
the Term of this Agreement and for a period of seven (7) years following the termination or expiration, either Party agrees to retain
in confidence and to refrain from disclosing or using for its benefit or the benefit of any third party, any and all information, test
materials or data disclosed to such Party by the other Party (&quot;<B>Confidential Information</B>&quot;). This restriction shall not
apply to Confidential Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: justify">in or entering the public domain (through no fault of the receiving Party);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">made available to the receiving Party by an independent third party owing no obligation of confidentiality
to the disclosing Party with regard thereto;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">already in the receiving Party's possession at the time of receipt from the disclosing Party (and such
prior possession can be properly demonstrated by the receiving Party);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.2pt; text-align: justify; text-indent: -35.4pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">that are independently developed by the receiving Party without the aid, application or use of the Confidential
Information (and such independent development can be properly demonstrated by the receiving Party); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.5in; text-align: left">(e)</TD><TD STYLE="text-align: justify">that are required by law, regulation, rule, act, or order of
any governmental authority or agency to be disclosed by the receiving Party; <U>provided</U>, <U>however</U>, that the receiving Party
(i) gives the disclosing Party sufficient advance written notice to permit it to seek a protective order or other similar order with
respect to such Confidential Information received hereunder and (ii) thereafter discloses only the minimum Confidential Information required
to be disclosed in order to comply, whether or not a protective order or other similar order is obtained by the disclosing Party.</TD>
</TR></TABLE>






<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 106.2pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Either Party shall only provide the Confidential
Information received from the other Party hereunder to its directors, officers, employees, agents, subcontractors, and consultants who
are directly concerned with a Project and who have written obligations of confidentiality with such Party substantially similar to those
set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
completion of a Project or at any other time at the disclosing Party's request, the receiving Party shall upon request either destroy
or promptly return to the disclosing Party any and all Confidential Information, in any form or media, except that the receiving Party
shall be entitled to retain one (1) archival copy of such Confidential Information for legal purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">3.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
provision contained in this section 3, equally apply to any and all information, test materials or data generated under the Project and
owned by Client pursuant to section 4, which information, test materials or data shall be considered Confidential Information of the Client.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><B>4.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PROJECT
RESULTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
data and information, including Client Inventions as defined under 5.1, arising from the performance of the Services listed in the accepted
Project Proposal hereunder, (including but not limited to records, original experimental reports, other material(s) and data), except
to the extent such experimental data and information solely relate to the Bioarkive Property (as defined in section 5.2), shall be deemed
the intellectual property of Client (&#8220;<B>Client Results</B>&#8221;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">4.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Client
shall retain title to and shall have the right to publish all Client Results. Client Results shall be retained in the Bioarkive archive
in compliance with regulatory and legal requirements or at such archival site as determined by Client at Client&#8217;s expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">4.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any and all results generated during or resulting from the Services performed by Bioarkive that solely relate to the Bioarkive Property,
shall be deemed the intellectual property of Bioarkive.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">4.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Electronic archival,
if available, shall be kept in accordance with the industry standard and in compliance with relevant regulatory and legal requirement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">4.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
the extent that Services to be performed under a Project Proposal include the development of novel, non-standard preclinical assays for
use by Client (each, a &quot;Client-Specific Assay&quot;), each Client-Specific Assay shall be owned by Bioarkive but (a) be licensed
exclusively by Bioarkive to Client for use exclusively by or on behalf of Client for a period of three years, and (b) thereafter be licensed
non-exclusively by Bioarkive to Client thereafter for use by or on behalf of Client. Such license shall at all times be worldwide, perpectual,
irrevocable, royalty-free and fully paid-up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><B>5.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>INVENTIONS
AND PATENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bioarkive
shall promptly notify Client in writing of any and all ideas, innovations, inventions, methods, developments or improvements, whether
or not patentable, discovered or arising from the performance of a Project conducted hereunder to the extent such experimental data and
information do not relate to the Bioarkive Property (&quot;<B>Client Inventions</B>&quot;). Subject to Section 4.5, Bioarkive hereby assigns
and agrees to assign to Client all rights, title and interest in and to such Client Inventions. If Client requests, and at Client's expense,
Bioarkive shall provide Client with reasonable assistance to obtain patents for such Client Inventions.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Parties acknowledge and agree that Bioarkive has proprietary testing protocols, processes, programming, methodology, techniques, equipment
and know-how existing as of the Effective Date of this Agreement or developed wholly independent of the Services that are its sole and
exclusive property (&#8220;<B>Bioarkive Property</B>&#8221;) and that any ideas, innovations, inventions, developments or improvements,
whether or not patentable, solely relating to such testing protocols, processes, programming, methodology, techniques, equipment and know-how
conceived solely by Bioarkive shall be and remain the sole and exclusive intellectual property of Bioarkive, subject to Section 4.5.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-indent: 0in"><B>6.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>LIABILITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35pt; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Service Provider accepts only liability towards Client in respect of damages resulting from a failure directly attributable to the Service
Provider in the performance of its obligations under this Agreement or for gross negligence or willful misconduct. The Service Provider
shall not be liable for any damage originating from any materials or information supplied by Client hereunder provided such materials
and information are only used by Bioarkive for the performance of its obligations hereunder in its premises under suitable containment
conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of improper, incorrect performance or performance not in accordance with applicable standards or applicable laws by the Service
Provider of the work under the Services, Client shall have the right to demand the Service Provider to re-perform the work without any
charge to Client.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except in instances of breaches of confidentiality, gross negligence or willful misconduct, the liability of the Service Provider for
any shortcomings in the execution of the Services will be limited to a maximum of the fees for the Services that Service Provider has
received for the Services provided hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><FONT STYLE="font-size: 10pt">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;EXCEPT FOR THE WARRANTIES PROVIDED IN THIS AGREEMENT, THE SERVICE PROVIDER MAKES ANY WARRANTY, EXPRESS OR IMPLIED, BY STATUTE OR IN WRITING,
REGARDING THE SERVICES OR ANY PRODUCT RESULTING FROM THE SERVICES, INCLUDING WITHOUT LIMITATION ANY WARRANTY REGARDING THEIR FITNESS FOR
ANY PURPOSE, THEIR QUALITY, THEIR MERCHANTABILITY OR THEIR NON-INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. ANY OTHER
REPRESENTATIONS OR WARRANTIES MADE BY ANY PERSON OR ENTITY, INCLUDING EMPLOYEES OR REPRESENTATIVES OF THE SERVICE PROVIDER, THAT ARE INCONSISTENT
HEREWITH, SHALL BE DISREGARDED AND SHALL NOT BE BINDING ON THE SERVICE PROVIDER</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.4pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except to the extent arising from Bioarkive's gross negligence or willful misconduct, the Client shall indemnify and hold Bioarkive and
its affiliated companies harmless from any third-party claims arising out of the use of the Client Results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTIAL OR CONSEQUENTIAL DAMAGES ARISING OUT ANY TERMS AND CONDITIONS
OF THIS AGREEMENT OR WITH RESPECT TO ITS PERFORMANCE HEREUNDER EXCEPT TO THE EXTENT SUCH DAMAGES WERE CAUSED BY GROSS NEGLIGENCE OR WILLFUL
MISCONDUCT OF SUCH PARTY.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">6.7 &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each
Party will secure and maintain in full force and effect throughout the term of this Agreement adequate insurance coverage appropriate
for the business of the type that is subject of this Agreement and its obligations under this Agreement. If requested by a Party, the
other Party shall provide the first Party with photocopies of the relevant certificates of insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35.4pt"><B>7.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>TERM
AND TERMINATION</U></B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
term of the Agreement shall be three (3) years from the Effective Date. Thereafter, the Agreement shall be renewed for successive one
(1) year terms, unless terminated upon three (3) months prior notice by either Party before the anniversary of the Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
either Party is in breach of its obligations under this Agreement then the Party not in breach is entitled to serve notice in writing
to the Party in breach setting out details of the breach, what actions are required to correct the breach and allowing the Party in breach
thirty (30) days from the date of notification in writing to correct the breach.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Either
Party shall have the right to terminate this Agreement and/or an accepted Project Proposal, effective immediately upon written notice
to the other Party, should the other Party continue to be in material breach of this Agreement, provided, that a notice of material breach
pursuant to Section 7.2 has been served on the Party in material breach and the Party in material breach has failed to correct the material
breach within the thirty (30) day cure period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Either
Party may terminate this Agreement, effective immediately upon written notice to the other Party, if the other Party: (i) files a voluntary
petition in bankruptcy or has an involuntary bankruptcy petition filed against it, which is not dismissed within thirty (30) days after
its institution, (ii)&nbsp;is adjudged as bankrupt, (iii) becomes insolvent, (iv) has a receiver, trustee, conservator or liquidator appointed
for all or a substantial part of its assets, (v) ceases to do business, (vi) commences any dissolution, liquidation or winding up, or
(vii) makes an assignment of its assets for the benefit of its creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;An
accepted Project Proposal or any other written assignment related to a Project Proposal may be terminated by Client at any time during
the term of this Agreement on sixty (60) days prior written notice to the Service Provider.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">7.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except
in the event of a termination by Client according to Section&nbsp;7.3, if this Agreement, any particular accepted Project Proposal or
any particular other written assignment related to a Project Proposal is terminated before any such Project Proposal or any such other
written assignment related to a Project Proposal is completed, Client shall pay Service Provider for all Services performed in accordance
with any such affected Project Proposal or any such other written assignment related to a Project Proposal hereunder, and reimburse the
Service Provider for all costs and expenses incurred in performing those Services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35pt">7.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
termination of this Agreement shall not relieve either Party of its obligation to the other with respect to (a) maintaining the confidentiality
of information, (b) liability and, (c) compensation for Services performed through the date of termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 35pt"><B>8.0&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>MISCELLANEOUS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.1<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Assignment
and Subcontracting</U>. This Agreement and any Project shall not be assigned by Bioarkive or its affiliated companies without the prior
written consent of Client, except in connection with the sale of the business to which this Agreement pertains.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Bioarkive shall have the
right to subcontract or delegate any portion of the Services hereunder to third parties (&#8220;<B>Subcontractors</B>&#8221;) only
with Client&#8217;s prior written consent; provided, that no consent shall be necessary for Bioarkive&#8217;s delegation to or use
of Subcontractors that are set forth in the relevant Project Proposal as performing such Services. In any event, Bioarkive shall
remain solely and fully liable for the performance of such Subcontractors to which it delegates the performance of its obligations
under this Agreement. Bioarkive shall ensure that each of its Subcontractors performs Bioarkive&#8217;s obligations pursuant to the
terms of this Agreement. For clarity, to the extent Bioarkive has an obligation under this Agreement to perform an action or to meet
a standard, and Bioarkive subcontracts such obligation, Bioarkive shall be responsible for any failure by its Subcontractor to
perform the action or meet the standard.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.2<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Notice</U>.
All notices required by this Agreement shall be in writing. All notices shall be sent by e-mail confirmed by registered or certified mail
to the Parties within three (3) business days at the following addresses or such other addresses as may be designated in writing by the
respective Parties:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in">Notices to Bioarkive:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Bioarkive, LLC</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in">11421 W Bernardo Court</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in">Suite 200</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in">San Diego, CA 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in">Attn. of: Praveen Nair, Ph.D. (CEO)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in">E-mail: pnair@bioarkive.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2in">Notices to Company:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Immuneering</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in; color: #222222"><FONT STYLE="background-color: white">245
Main St, Second Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in; color: #222222"><FONT STYLE="background-color: white">Cambridge,
MA 02142</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in; color: #222222"><FONT STYLE="background-color: white">Attn.
of: Peter King, Ph.D. (VP Discovery)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-indent: 0.5in; color: #222222"><FONT STYLE="background-color: white">E-mail:
pking@immuneering.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.4pt">8.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Force
Majeure</U>. A Party shall be excused from performing its obligations under this Agreement if its performance is delayed or prevented
by any cause beyond such Party's control, including but not limited to, acts of God, fire, explosion, disease, weather, war, insurrection,
civil strife, riots, government action, or power failure. Performance shall be excused only to the extent of and during the reasonable
continuance of such disability. Any deadline or time for performance specified in an accepted Project Proposal that falls due during or
subsequent to the occurrence of any of the disabilities referred to herein shall be automatically extended for a period of time equal
to the period of such disability. Bioarkive shall immediately notify Client if, by reason of any of the disabilities referred to herein,
the Service Provider is unable to meet any deadline or time for performance specified in an accepted Project Proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Independent
Contractor</U>. Bioarkive shall perform each Project as an independent contractor and shall have complete and exclusive control over its
employees, consultants and agents. The Services rendered by Bioarkive are those of an independent contractor and not those of Client.
No Services rendered pursuant to this Agreement shall be construed to deem Bioarkive or its affiliated companies an employee, agent or
joint-venture with Client.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.5<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Waiver</U>.
No waiver of any term, provision, or condition of this Agreement, whether by conduct or otherwise, in any one or more instances shall
be deemed to be or construed as a further or continuing waiver of any such term, provision, or condition or of any other term, provision,
or condition of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.6<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Severability</U>.
This Agreement is divisible and separable so that if any provision(s) shall be held to be invalid, such invalidity shall not impair the
remaining provisions thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.7<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Applicable
Law and Competent Court</U>. This Agreement shall be governed by the laws of Delaware, USA. Any claim or controversy arising out of or
related to this Agreement or any breach hereof shall be submitted to the competent courts of the state of Delaware, USA, and each Party
hereby consents to the exclusive jurisdiction and venue of such court.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.8 <B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Entire
Agreement</U>. This Agreement, together with its attachments, represents the entire understanding of the Parties with respect to the subject
matter hereof and hereby supersedes all prior understanding and agreements, whether oral or written, between the Parties with respect
to any Services to be performed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.9<B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B><U>Attachments/Addenda</U>.
Any attachment(s) and/or accepted Project Proposals are deemed to be an integrated part of this Agreement and all references to this Agreement
shall be deemed to include all such attachments and accepted Project Proposals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">8.10&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Security</U>.
Bioarkive warrants and represents that it shall maintain adequate security at its facilities for the term of this Agreement to ensure
that the Services and each Project are performed within the time frame set forth in an accepted Project Proposal, and such Services and
Project shall not be compromised or disrupted by any breach of security.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">* * * *</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties have caused this
Agreement to be executed, by duly authorized representatives on the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Bioarkive</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Immuneering Corporation</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;August
    5, 2019</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;August
    5, 2019</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
    Praveen Nair</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;/s/
    Benjamin J. Zeskind</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Praveen
    Nair</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Benjamin
    J. Zeskind</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CEO</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CEO</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Appendix 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><U>Project
Proposal</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Project Proposal will contain amongst others the following elements
if relevant for the Project:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Background</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Project description</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Deliverables, requirements and general conditions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Tasks</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Experimental details (methods)</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Starting and end date</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Resources</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Sub-contractors</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Pricing and costs</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Description</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Shipment details</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Contact persons</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Reporting</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Payment terms</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Validity</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This Project Proposal is pursuant to, and incorporates the provisions
of the Master Services Agreement with Effective Date August 5<SUP>th</SUP>, 2019 by and between Bioarkive, LLC and Immuneering Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 95pt; text-indent: -95pt">Bioarkive, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 95pt; text-indent: -95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -95pt; padding-left: 95pt">Dennis Garland, MS</TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; text-align: left">Praveen Nair, Ph.D.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -95pt; padding-left: 95pt">Director of Operations</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Chief Executive Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 95pt; text-align: justify; text-indent: -95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> CC:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proposal accepted by Immuneering:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 42%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%"><TR STYLE="vertical-align: bottom"><TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-size: 10pt">BioArkive &amp; Immuneering</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 34%"><FONT STYLE="font-size: 10pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->/11</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; width: 33%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.5
<SEQUENCE>4
<FILENAME>filename4.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: left; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="tm2115679d2_ex10-5img001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Ben Zeskind, PhD, MBA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Immuneering Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(617) 500-8080 ext. 121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(617) 694-3782 (cell)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">bzeskind@immuneering.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">March 5, 2021</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Biren N. Amin<BR>
3 Victoria Place<BR>
Holmdel, NJ 07733<BR>
847-609-3735 (cell)<BR>
bnarex@gmail.com</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Biren:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On behalf of Immuneering Corporation (the &ldquo;Company&rdquo;),
I am pleased to set forth the terms of your employment with the Company:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You will be employed to serve on a full-time basis as Chief Financial Officer effective on or before <B>April 1, 2021</B>. You
will be based in our NYC office once the COVID-19 situation is safely resolved, and work remotely until then.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Chief Financial Officer your primary responsibilities will be as
outlined in Exhibit 1.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You will report directly to me.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Your base salary will be <B>$31,250.00</B> per month (the monthly equivalent of <B>$375,000 per year</B>), subject to tax and other
withholdings as required by law. Such salary may be adjusted from time to time in the sole discretion of the Company.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to your continued employment with the Company, you will be eligible for a standard year-end bonus each December, with
the amount of your bonus, if any to be determined by the Company&rsquo;s Board of Directors in its discretion. <B>Your target bonus will
be 33.33% of your base salary earnings for that year</B>. Your bonus will reflect your achievement of key goals and objectives, responsiveness
and positive interactions with your colleagues, and will also be dependent on Company performance. All bonuses are subject to tax and
other withholdings as required by law.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 91%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 26%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 19%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">245 Main St, 2<SUP>nd</SUP> Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Cambridge, MA 02142</P></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">667 Madison Ave, 5<SUP>th</SUP> Floor</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">New York, NY 10065</P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; margin: 0pt 0 0pt 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">10920 Via Frontera, Suite 560<BR>
San Diego, CA 92127</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">617-500-8080</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">immuneering.com</P></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You may participate in any and all bonus and benefit programs that the Company establishes and makes available to its employees
from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs. <I>As
a full-time employee, Immuneering will cover the <U>full</U> cost of your monthly health insurance premiums for individual/family coverage
under a Blue Cross Blue Shield of Massachusetts PPO, <U>plus half of any expenses incurred towards the deductible ($1,000 for individuals,
$2,500 for families)</U>. Immuneering also has a 401(k) plan and will <U>match your 401(k) contributions</U> up to 4% of salary per IRS
Safe harbor 401(k) rules. The company provides group term life and accidental death &amp; dismemberment insurance through SunLife. The
benefit is equal to one times your annual salary to a maximum of $300,000. The company provides short term disability insurance through
SunLife that pays 60% of your salary up to a maximum of $1,500 per week should you be out of work due to an illness or injury for up to
12 weeks. The company provides long term disability insurance through SunLife that pays 60% of your salary up to a maximum of $10,000
per month should you be out of work due to an illness or injury for 90 days or more. </I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the approval of the Board of Directors of the Company, you may receive an incentive stock option grant under our current
stock incentive plan for the purchase of <B>193,100 shares of common stock of the Company (equal to ~1.35% of the full diluted company
after our Series B)</B> at a price per share equal to the fair market value at the time of Board approval, subject to the terms of a stock
option agreement between you and the Company. One-quarter of such options will vest upon your completion of one year of employment with
the company, and the remaining three-quarters of such options will vest in equal monthly installments over the subsequent three years.
As of the date of this letter, the current fair market value for the purchase of common stock is $5.77 per share.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has an unlimited paid vacation policy. This means that you can take as much paid vacation in any calendar year as is
consistent with you maintaining an acceptable level of performance and the Company&rsquo;s business needs. We ask that you inform us of
all vacation plans at least two weeks in advance, and schedule your time out of the office with consideration of the Company&rsquo;s business
needs. The Company may ask you to delay or change your vacation plans if they are inconsistent with business needs. In addition to paid
vacation, you will not be required to work on Federal Holidays.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You will be required to execute an Employee Proprietary Information and Inventions Assignment Agreement in the form attached as
Exhibit 2, as a condition of employment.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> You represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from
entering into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms
of this letter.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 0.5in"><IMG SRC="tm2115679d2_ex10-5img002.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United
States, as required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work
in the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely
manner as determined by the Company. Your employment will also be conditioned on the successful completion of a routine background check.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in
no way alter the Company&rsquo;s policy of employment at will, under which both you and the Company remain free to terminate the employment
relationship, with or without cause, at any time, with or without notice. Similarly, nothing in this letter shall be construed as an agreement,
either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you agree with the employment provisions of
this letter, please sign the enclosed duplicate of this letter in the space provided below and return it to me by <B>March 8, 2021</B>.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; border-collapse: collapse; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Very Truly Yours,</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Ben Zeskind&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Name: Ben Zeskind</TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Title: Co-Founder and CEO</TD></TR>
  </TABLE>


<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing correctly sets forth the terms of my employment by Immuneering
Corporation.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 43%">/s/ Biren N. Amin</TD>
  <TD STYLE="width: 7%">&nbsp;</TD>
  <TD STYLE="width: 3%">Date:&nbsp;&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">&nbsp;&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name: Biren N. Amin</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt 0"><IMG SRC="tm2115679d2_ex10-5img003.jpg" ALT="">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit 1: CHIEF FINANCIAL OFFICER</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The CFO, a senior leadership position at Immuneering, will be an integral
member of the internal Executive Committee and will be a closely integrated strategic and operational partner with the CEO and EEC in
creating a leading biotech over the forthcoming years.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This individual will:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Serve as an externally-facing presence to Wall Street and the investor community, sharing the Immuneering story with investors</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Provide feedback internally into various strategic decisions to be made by the company, and how they will be viewed by investors</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Lead the company&rsquo;s IPO process</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Provide strong financial management across all aspects of the company;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Serve as a critical thought partner to the CEO on all strategic financial decision-making;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Bring strong transactional experience both analytically and from a strategic perspective</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Lead business/financial planning, reporting and analysis as the company continues to evolve.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">The specific functional responsibilities will grow to include Controlling, Financial Planning and Analysis, External Reporting, Tax,
Treasury, and Investor Relations (in partnership with members of the EEC). The CFO will have accountability for the financial and capital
strategy to the Board of Directors, as well as leadership of the Audit Committee.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">Manage other operational aspects of the company as may be requested</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: left; width: 0.25in"></TD><TD STYLE="text-align: left; width: 0.25in">&#9679;</TD><TD STYLE="text-align: left">The CFO will be externally-facing and strategic. This CFO will be expected to have a major impact on Immuneering&rsquo;s strategic
planning, capital-raising, and corporate development activities. The CFO will also play an important role in representing the company
to institutional investors and managing the capital markets strategy.&nbsp;</TD></TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2115679d2_ex10-5img004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Exhibit 2: IMMUNEERING CORPORATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>EMPLOYEE
PROPRIETARY INFORMATION AND INVENTIONS ASSIGNMENT <BR>
AGREEMENT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In consideration and as a
condition of my employment by Immuneering Corporation, a Delaware corporation (together with any of its subsidiaries or parent companies,
and any of their successors or assigns collectively, the &ldquo;<U>Company</U>&rdquo;), and my receipt of the compensation paid to me
by the Company in the context of that employment and the issuance to me of an option to purchase shares of common stock of the Company,
and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, effective as of the date of
my signature below (the &ldquo;<U>Effective Date</U>&rdquo;), unless specified otherwise in this Employee Proprietary Information and
Inventions Assignment Agreement (the &ldquo;<U>Agreement</U>&rdquo;), I, the undersigned, agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Proprietary
Information</U>. During the term of my employment, I may receive and otherwise be exposed, directly or indirectly, to confidential
and proprietary information of the Company whether in graphic, written, electronic or oral form, including without limitation
information relating to the Company&rsquo;s business, strategies, designs, products, services and technologies and any derivatives,
improvements and enhancements relating to any of the foregoing, or to the Company&rsquo;s suppliers, customers or business partners
(collectively &ldquo;<U>Proprietary Information</U>&rdquo;). Proprietary Information may be identified at the time of disclosure as
confidential or proprietary or information which by its context would reasonably be deemed to be confidential or proprietary.
&ldquo;Proprietary Information&rdquo; may also include without limitation (a)(i) unpublished patent disclosures and patent
applications and other filings, know-how, trade secrets, works of authorship and other intellectual property, as well as any
information regarding ideas, Inventions (as defined in Section 5), technology, and processes, including without limitation assays,
sketches, schematics, techniques, drawings, designs, descriptions, specifications and technical documentation, (ii) information
relating to physical, chemical or biological materials and compounds (including without limitation reagents, gene sequences, nucleic
acids, amino acids, cell lines, media, antibodies, antibody fragments, compounds, c-DNAs, antisense nucleotides, proteins, peptides
and vectors), their structures, compositions, and formulations, and methods for their handling, use, and manufacture, and processes,
apparatus, models relating thereto, (iii) specifications, protocols, models, designs, equipment, engineering, algorithms, software
programs, software source documents, formulae, (iv) information concerning or resulting from any research and development or other
project, including without limitation nonclinical and clinical data, experimental work, clinical and product development plans,
results from clinical studies, regulatory compliance information, and research, development and regulatory strategies, and (v)
business and financial information, including without limitation purchasing, procurement, manufacturing, customer lists, information
relating to investors, employees, business and contractual relationships, business forecasts, sales and merchandising, business and
marketing plans, product plans, and business strategies, including without limitation information the Company provides regarding
third parties, such as, but not limited to, suppliers, customers, employees, investors, or vendors; and (b) any other information,
to the extent such information contains, reflects or is based upon any of the foregoing Proprietary Information. The Proprietary
Information may also include information of a third party that is disclosed to me by the Company or such third party at the
Company&rsquo;s direction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: right"><IMG SRC="tm2115679d2_ex10-5img005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Obligations of Non-Use and Nondisclosure</U>. I acknowledge the confidential and secret character of the Proprietary Information,
and agree that the Proprietary Information is the sole, exclusive and valuable property of the Company. Accordingly, I agree not to use
the Proprietary Information except in the performance of my authorized duties as an employee of the Company, and not to disclose all
or any part of the Proprietary Information in any form to any third party, either during or after the term of my employment, without
the prior written consent of the Company on a case-by-case basis. Upon termination of my employment, I agree to cease using and to return
to the Company all whole and partial copies and derivatives of the Proprietary Information, whether in my possession or under my direct
or indirect control, provided that I am entitled to retain my personal copies of (a)&nbsp;my compensation records, (b)&nbsp;materials
distributed to stockholders generally, and (c)&nbsp;this Agreement. I understand that my obligations of nondisclosure with respect to
Proprietary Information shall not apply to information that I can establish by competent proof (x)&nbsp;was actually in the public domain
at the time of disclosure or enters the public domain following disclosure other than as a result of a breach of this Agreement, (y)&nbsp;is
already in my possession without breach of any obligations of confidentiality at the time of disclosure by the Company as shown by my
files and records immediately prior to the time of disclosure, or (z) is obtained by me from a third party not under confidentiality
obligations and without a breach of any obligations of confidentiality. If I become compelled by law, regulation (including without limitation
the rules of any applicable securities exchange), court order, or other governmental authority to disclose the Proprietary Information,
I shall, to the extent possible and permissible under applicable law, first give the Company prompt notice. I agree to cooperate reasonably
with the Company in any proceeding to obtain a protective order or other remedy. If such protective order or other remedy is not obtained,
I shall only disclose that portion of such Proprietary Information required to be disclosed, in the opinion of my legal counsel. I shall
request that confidential treatment be accorded such Proprietary Information, where available. Compulsory disclosures made pursuant to
this section shall not relieve me of my obligations of confidentiality and non-use with respect to non-compulsory disclosures. I understand
that nothing herein is intended to or shall prevent me from communicating directly with, cooperating with, or providing information to,
any federal, state or local government regulator, including, but not limited to, the U.S. Securities and Exchange Commission, the U.S.
Commodity Futures Trading Commission, or the U.S. Department of Justice. I shall promptly notify my supervisor or any officer of the
Company if I learn of any possible unauthorized use or disclosure of Proprietary Information and shall cooperate fully with the Company
to enforce its rights in such information.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Defend Trade Secrets Act Notice of Immunity Rights</U>. I acknowledge that the Company has provided me with the following notice of
immunity rights in compliance with the requirements of the Defend Trade Secrets Act: (a) I shall not be held criminally or civilly liable
under any Federal or State trade secret law for the disclosure of Proprietary Information that is made in confidence to a Federal, State,
or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, (b)
I shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of Proprietary Information
that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal and (c) if I file
a lawsuit for retaliation by my employer for reporting a suspected violation of law, I may disclose the Proprietary Information to my
attorney and use the Proprietary Information in the court proceeding, if I file any document containing the Proprietary Information under
seal, and do not disclose the Proprietary Information, except pursuant to court order.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: right; text-indent: 0.5in"><IMG SRC="tm2115679d2_ex10-5img007.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Property of the Company</U>. I acknowledge and agree that all notes, memoranda, reports, drawings, blueprints, manuals, materials,
data, emails and other papers and records of every kind, or other tangible or intangible materials which shall come into my possession
in the course of my employment with the Company, relating to any Proprietary Information, shall be the sole and exclusive property of
the Company and I hereby assign any rights or interests I may obtain in any of the foregoing to my employer. I agree to surrender this
property to my employer upon termination of my employment, or at any time upon request by my employer. I further agree that any property
situated on my employer&rsquo;s data systems or on my employer&rsquo;s premises and owned by my employer, including without limitation
electronic storage media, filing cabinets or other work areas, is subject to inspection by my employer at any time with or without notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Inventions</U><FONT STYLE="font-variant: small-caps">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-align: left; text-indent: 1in">5.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Disclosure
and Assignment of Inventions</U>. For purposes of this Agreement, an &ldquo;Invention&rdquo; shall mean any idea, invention or work
of authorship, including, without limitation, any documentation, formula, design, device, code, method, software, technique,
process, discovery, concept, improvement, enhancement, development, machine or contribution, in each case whether or not patentable
or copyrightable and for purposes of this Section 5, &ldquo;<U>Company</U>&rdquo; shall mean the Company entity that is my employer
as of the Effective Date or, if I am subsequently employed by any subsidiary or parent of such Company entity, the applicable
subsidiary or parent by which I am employed. I will disclose all Inventions promptly in writing to an officer of the Company or to
attorneys of the Company in accordance with the Company&rsquo;s policies and procedures. I will, and hereby do, assign to the
Company, without requirement of further writing, without royalty or any other further consideration, my entire right, title and
interest throughout the world in and to all Inventions created, conceived, made, developed, and/or reduced to practice by me in the
course of my employment by the Company and all intellectual property rights therein. I hereby waive, and agree to waive, any moral
rights I may have in any copyrightable work I create or have created on behalf of the Company. I also hereby agree, that for a
period of one year after my employment with the Company, I shall disclose to the Company any Inventions that I create, conceive,
make, develop, reduce to practice or work on that relate to the work I performed for the Company. The Company agrees that it will
use commercially reasonable measures to keep Inventions disclosed to it pursuant to this Section 5.1 that do not constitute
Inventions to be owned by the Company in confidence and shall not use any Inventions for its own advantage, unless in either case
those Inventions are assigned or assignable to the Company pursuant to this Section 5.1 or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 50pt; text-align: left; text-indent: 1in">5.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Certain Exemptions</U>. The obligations to assign Inventions set forth in Section 5.1 apply with respect to all Inventions (a) whether
or not such Inventions are conceived, made, developed or worked on by me during my regular hours of employment with the Company; (b)&nbsp;whether
or not the Invention was made at the suggestion of the Company; (c)&nbsp;whether or not the Invention was reduced to drawings, written
description, documentation, models or other tangible form; and (d)&nbsp;whether or not the Invention is related to the general line of
business engaged in by the Company, but do not apply to Inventions that (x)&nbsp;I develop entirely on my own time or after the date of
this Agreement without using the Company&rsquo;s equipment, supplies, facilities or Proprietary Information; (y)&nbsp;do not relate to
the Company&rsquo;s business, or actual or demonstrably anticipated research or development of the Company at the time of conception or
reduction to practice of the Invention; and (z)&nbsp;do not result from and are not related to any work performed by me for the Company.
I hereby acknowledge and agree that the Company has notified me that, if I reside in the state of California, assignments provided for
in Section 5.1 do not apply to any Invention which qualifies fully for exemption from assignment under the provisions of Section 2870
of the California Labor Code (&ldquo;<U>Section 2870</U>&rdquo;), a copy of which is attached as <U>Exhibit A</U>. If applicable, at the
time of disclosure of an Invention that I believe qualifies under Section 2870, I shall provide to the Company, in writing, evidence to
substantiate the belief that such Invention qualifies under Section 2870. I further understand that, to the extent this Agreement shall
be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign certain classes
of inventions made by an employee, Section 5.1 shall be interpreted not to apply to any Invention which a court rules and/or the Company
agrees falls within such classes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: right; text-indent: 1in"><IMG SRC="tm2115679d2_ex10-5img008.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: left; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 47pt; text-align: left; text-indent: 1in">&nbsp;</P>

<!-- Field: Split-Segment; Name: Split 001 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">5.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Records</U>. I will make and maintain adequate and current written records of all Inventions covered by Section 5.1. These records
may be in the form of notes, sketches, drawings, flow charts, electronic data or recordings, notebooks and any other format. These records
shall be and remain the property of the Company at all times and shall be made available to the Company at all times.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">5.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Patents and Other Rights</U>. I agree to assist the Company in obtaining, maintaining and enforcing patents, invention assignments
and copyright assignments, and other proprietary rights in connection with any Invention covered by Section 5.1, and will otherwise assist
the Company as reasonably required by the Company to perfect in the Company the rights, title and other interests in my work product granted
to the Company under this Agreement (both in the United States and foreign countries). I further agree that my obligations under this
Section 5.4 shall continue beyond the termination of my employment with the Company, but if I am requested by the Company to render such
assistance after the termination of such employment, I shall be entitled to a fair and reasonable rate of compensation for such assistance,
and to reimbursement of any expenses incurred at the request of the Company relating to such assistance. If the Company is unable for
any reason, after reasonable effort, to secure my signature on any document needed in connection with the actions specified above, I hereby
irrevocably designate and appoint the Company and its duly authorized officers and agents as my agent and attorney in fact, which appointment
is coupled with an interest, to act for and in my behalf to execute, verify and file any such documents and to do all other lawfully permitted
acts to further the purposes of this Section 5.4 with the same legal force and effect as if executed by me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">5.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Prior
Contracts and Inventions; Information Belonging to Third Parties</U>. I represent and warrant that, except as set forth on <U>Exhibit
B</U>, I am not required, and I have not been required during the course of work for the Company or its predecessors, to assign
Inventions under any other contracts that are now or were previously in existence between me and any other person or entity. I
further represent that (a)&nbsp;I am not obligated under any consulting, employment or other agreement that would affect the
Company&rsquo;s rights or my duties under this Agreement, and I shall not enter into any such agreement or obligation during the
period of my employment by the Company, (b)&nbsp;there is no action, investigation, or proceeding pending or threatened, or any
basis therefor known to me involving my prior employment or any consultancy or the use of any information or techniques alleged to
be proprietary to any former employer, and (c)&nbsp;the performance of my duties as an employee of the Company do not and will not
breach, or constitute a default under any agreement to which I am bound, including any agreement limiting the use or disclosure of
proprietary information acquired in confidence prior to engagement by the Company or if applicable, any agreement to refrain from
competing, directly or indirectly, with the business of such previous employer or any other party or to refrain from soliciting
employees, customers or suppliers of such previous employer or other party. I will not, in connection with my employment by the
Company, use or disclose to the Company any confidential, trade secret or other proprietary information of any previous employer or
other person to which I am not lawfully entitled. As a matter of record, I attach as <U>Exhibit B</U> a brief description of all
Inventions made or conceived by me prior to my employment with the Company which I desire to be excluded from this Agreement
(&ldquo;<U>Background Technology</U>&rdquo;). If full disclosure of any Background Technology would breach or constitute a default
under any agreement to which I am bound, including any agreement limiting the use or disclosure of proprietary information acquired
in confidence prior to engagement by the Company, I understand that I am to describe such Background Technology in <U>Exhibit&nbsp;B </U>at
the most specific level possible without violating any such prior agreement. Without limiting my obligations or representations
under this Section 5.5, <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if I use (i) any Background
Technology or (ii) any other Inventions in which I have an interest and that are excluded from the assignment of Inventions set
forth in Section 5.1 (collectively (i) and (ii), the &ldquo;<U>Excluded Technology</U>&rdquo;) in the course of my employment or
incorporate any Excluded Technology in any product, service or other offering of the Company, I hereby grant the Company a
non-exclusive, royalty-free, perpetual and irrevocable, worldwide right to use and sublicense the use of Excluded Technology for the
purpose of developing, marketing, selling and supporting Company technology, products and services, either directly or through
multiple tiers of distribution, but not for the purpose of marketing Excluded Technology separately from Company products or
services. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">5.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Works Made for Hire</U>. I acknowledge that all original works of authorship which are made by me (solely or jointly with others) within
the scope of my employment with the Company and which are eligible for copyright protection are &ldquo;works made for hire&rdquo; as that
term is defined in the United States Copyright Act (17 U.S.C., Section 101).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: right; text-indent: 1in"><IMG SRC="tm2115679d2img_007.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Restrictive Covenants</U>. I agree to fully comply with the covenants set forth in this Section 6 (the &ldquo;<U>Restrictive Covenants</U>&rdquo;).
I further acknowledge and agree that the Restrictive Covenants are reasonable and necessary to protect the Company&rsquo;s legitimate
business interests, including its Proprietary Information and goodwill.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">6.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Non-Competition</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 1.5in">i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Non-Competition</U>.
During the term of my employment with the Company, and for a period of one year immediately following the termination of such
employment (the &ldquo;<U>Non-Competition Restricted Period</U>&rdquo;), I will not, directly or indirectly, for my own benefit or
for the benefit of any other individual or entity other than the Company: (i)&nbsp;operate, conduct, or engage in, or prepare to
operate, conduct, or engage in the Business; (ii) own, finance, or invest in (except as the holder of not more than one percent of
the outstanding stock of a publicly-held company) any Business, or (iii) participate in, render services to, or assist any person or
entity that engages in or is preparing to engage in the Business in any capacity (whether as an employee, consultant, contractor,
partner, officer, director, or otherwise) (x) which involves the same or similar types of services I performed for the Company at
any time during the last two years of my employment with the Company or (y) in which I could reasonably be expected to use or
disclose Proprietary Information, in each case (i), (ii), or (iii) in the Restricted Territory. For the avoidance of doubt, if I
reside in the Commonwealth of Massachusetts, the non-competition obligations set forth above in this Section 6.1(a) shall not apply
to me following the termination of my employment with the Company if I am terminated by the Company without Cause or if and to the
extent the Company elects to waive any of such obligations as provided in Section 6.6 below. If I reside in the Commonwealth of
Massachusetts, in the event the Company determines at any time that I engaged in conduct constituting Cause during or after my
employment has ended, then the Company may retroactively designate my termination as a termination with Cause, and the
non-competition covenants set forth in this Section 6.1, and each subpart, shall remain in full force and effect pursuant to their
terms. Notwithstanding the foregoing, if I reside in the Commonwealth of Massachusetts and I am (x) classified as non-exempt under
the Fair Labor Standards Act or (y) an undergraduate or graduate student partaking in an internship or short-term employment with
the Company while enrolled in a full-time or part-time undergraduate or graduate educational institution, then Section 6.1 shall not
apply to me after the termination of my employment with the Company for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: left; text-indent: 1.5in">ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Extension of Non-Competition Restricted Period</U>. In the event I breach my fiduciary duty to the Company or unlawfully take, physically
or electronically, property belonging to the Company as reasonably determined by the Company, the Non-Competition Restricted Period as
defined above shall be extended for one additional year, for a maximum period of two years immediately following my termination of employment
from the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: right; text-indent: 1.5in"><IMG SRC="tm2115679d2img_006.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">6.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U>Non-Solicitation
of Company Personnel</U>. During the term of my employment with the Company, and for a period of one year immediately following the
termination of such employment for any reason (the &ldquo;<U>Non-Solicitation Restricted Period</U>&rdquo;), I will not, directly or
indirectly, for my own benefit or for the benefit of any other individual or entity: (a) employ or hire any Company Personnel in any
capacity (whether as an employee, contractor, consultant or otherwise); (b) solicit or attempt to solicit for employment or hire any
Company Personnel in any capacity; (c) entice or induce any Company Personnel to leave his or her or their employment with the
Company; or (d) otherwise negatively interfere with the Company&rsquo;s relationship with any Company Personnel. Notwithstanding the
foregoing, a general solicitation or advertisement for job opportunities that I may publish without targeting any Company Personnel
shall not be considered a violation of Section 6.2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">6.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Non-Solicitation of Company Customer</U>. During the Non-Solicitation Restricted Period, I will not, directly or indirectly, for my
own benefit or for the benefit of any other individual or entity: (a) solicit business from, or offer to provide products or services
that are similar to any product or service provided or that could be provided by the Company or that are otherwise competitive with the
Business to, any Company Customer; (b) cause or encourage any Company Customer to reduce or cease doing business with the Company, or
(c) otherwise negatively interfere with the Company&rsquo;s relationships with any Company Customer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">6.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Tolling Period</U><FONT STYLE="font-variant: small-caps">. </FONT>Without limiting the Company&rsquo;s ability to seek other remedies
available in law or equity, if I violate any of the provisions of Sections 6.2 or 6.3, the Non-Solicitation Restricted Period shall be
extended by one day for each day that I am in violation of such provisions, up to a maximum extension equal to the length of the Non-Solicitation
Restricted Period, so as to give the Company the full benefit of the bargained-for length of forbearance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">6.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Interpretation</U>. If any restriction set forth in the Restrictive Covenants is found by any court of competent jurisdiction to be
unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area,
it shall be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">6.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Waiver</U>. At any time, the Company may in its sole discretion elect to waive any or part of the Restrictive Covenants, provided any
such waiver is expressly agreed to in writing by an executive officer of the Company, or, if I am an executive officer of the Company,
by the Board of Directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: right; text-indent: 1in"><IMG SRC="tm2115679d2img_005.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">6.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Definitions</U>. As used in the Restrictive Covenants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The term &ldquo;<U>Business</U>&rdquo; means any business or part thereof that develops, manufactures, markets, licenses, sells or provides
any product or service that competes with any product or service developed, manufactured, marketed, licensed, sold or provided, or planned
to be developed, manufactured, marketed, licensed, sold or provided, by the Company, in each case at any time during my employment with
the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The term &ldquo;<U>Cause</U>&rdquo; means (i) a material breach of this Agreement or any other agreement I may have entered into
with the Company; (ii) the commission of fraud, embezzlement, or other intentional act that could reasonably harm the Company or
third parties; (iii) a material violation of the Company&rsquo;s personnel policies, my ethical obligations, or applicable laws or
regulations; or (iv) willful or gross negligence in the performance of my job duties that could reasonably harm the Company or third
parties, in each case as reasonably determined by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The term &ldquo;<U>Company Customer</U>&rdquo; means any individual or entity who (i) is, or was at any time during the one year period
prior to the termination of my employment with the Company, a customer, supplier, or vendor of the Company of whom I learned, with whom
I had business contact or about whom I obtained Proprietary Information at any time during my employment with the Company, or (ii) is
a prospective customer, supplier, or vendor of the Company of whom I learned, with whom I had business contact, or about whom I obtained
Proprietary Information as part of a solicitation of business on behalf of the Company at any time during the one year period prior to
my termination of employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The term &ldquo;<U>Company Personnel</U>&rdquo; means any individual or entity who is or was at any time during the six-month period prior
to my solicitation or other activity prohibited by Section 6.2, employed or engaged (whether as an employee, consultant, independent contractor
or in any other capacity) by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The term &ldquo;<U>Restricted Territory</U>&rdquo; means each city, county, state, territory and country in which (i) I provided services
or had a material presence or influence at any time during the last two years of my employment with the Company or (ii) the Company is
engaged in or has plans to engage in the Business as of the termination of my employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Notification to Other Parties</U>. In the event of termination of my employment with the Company for any reason, I hereby consent to
notification by the Company to my new employer or other party for whom I work about my rights and obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Employment at Will</U>. I understand and agree that my employment with the Company is at will. Accordingly, my employment can be terminated
at any time, without Cause or notice, at my option or the Company&rsquo;s option. The at-will nature of my employment also means that
I can be transferred or demoted, and my job title, compensation, benefits and other terms and conditions of employment can be reduced,
at any time with or without Cause. I acknowledge that such changes shall not affect the enforceability of the Restrictive Covenants or
other terms of this Agreement. This at-will status of my employment relationship with the Company shall remain in full force and effect
throughout my employment with the Company, and the Restrictive Covenants shall remain in full force and effect pursuant to their terms.
The at-will status of my employment can be modified only in a written agreement that expressly alters such status and which is signed
by both an authorized officer of the Company and me.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: right; text-indent: 0.5in"><IMG SRC="tm2115679d2img_004.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The parties&rsquo; rights and obligations under this Agreement will bind and inure to the benefit of their respective successors, heirs,
executors, and administrators and permitted assigns. I will not assign this Agreement or my obligations hereunder without the prior written
consent of the Company, which consent may be withheld in the Company&rsquo;s sole discretion, and any such purported assignment without
consent shall be null and void from the beginning. I agree that the Company may freely assign or otherwise transfer this Agreement to
any affiliate or successor in interest (whether by way of merger, sale, acquisition or corporate re-organization or any substantially
similar process) of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Agreement constitutes the parties&rsquo; final, exclusive and complete understanding and agreement with respect to the subject matter
hereof, and supersedes all prior and contemporaneous understandings and agreements, whether oral or written, relating to its subject matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Any subsequent change or changes in my duties, obligations, rights or compensation will not affect the validity or scope of this Agreement.
This Agreement may not be waived, modified or amended unless mutually agreed upon in writing by both parties. No delay or omission by
the Company in exercising any right under this Agreement will operate as a waiver of that or any other right. A waiver or consent given
by the Company on any one occasion is effective only in that instance and will not be construed as a bar to or waiver of any right on
any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
If any provision of this Agreement is found by a proper authority to be unenforceable or invalid such unenforceability or invalidity shall
not render this Agreement unenforceable or invalid as a whole and in such event, such provision shall be changed and interpreted so as
to best accomplish the objectives of such unenforceable or invalid provision within the limits of applicable law or applicable court decisions
and the remainder of the terms, provisions, covenants and restrictions of this Agreement shall remain in full force and effect and shall
in no way be affected, impaired or invalidated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
I acknowledge that the Company will suffer substantial damages not readily ascertainable or compensable in terms of money in the event
of the breach of any of my obligations under this Agreement. I therefore agree that the Company shall be entitled (without limitation
of any other rights or remedies otherwise available to the Company) to obtain an injunction from any court of competent jurisdiction prohibiting
the continuance or recurrence of any breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: right; text-indent: 1in"><IMG SRC="tm2115679d2img_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
The rights and obligations of the parties under this Agreement shall be governed in all respects by the laws of the State of New
Jersey exclusively, without reference to any conflict of laws rule that would result in the application of the laws of any other
jurisdiction. The parties agree that all disputes arising under this Agreement shall be adjudicated in the state and federal courts
having jurisdiction over disputes arising in Suffolk County, Massachusetts, and I hereby agree to consent to the personal
jurisdiction of such court. The Company and I each hereby irrevocably waive any right to a trial by jury in any action, suit or
other legal proceeding arising under or relating to any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Any notices required or permitted hereunder shall be given to the appropriate party at the address specified on the signature page to
this Agreement or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery,
or sent by certified or registered mail, postage prepaid, three days after the date of mailing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Except as otherwise provided herein, the provisions of this Agreement shall survive the termination of my employment with the Company
for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">9.9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together
shall be deemed to be one and the same instrument. A facsimile, PDF (or any electronic signature complying with the U.S. federal ESIGN
Act of 2000, e.g., www.docusign.com) or any other type of copy of an executed version of this Agreement signed by a party is binding upon
the signing party to the same extent as the original of the signed agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>I ACKNOWLEDGE THAT I HAVE THE RIGHT TO CONSULT
WITH INDEPENDENT LEGAL COUNSEL PRIOR TO SIGNING THIS AGREEMENT AND HAVE HAD A REASONABLE OPPORTUNITY TO DO SO, AND THAT I EITHER HAVE
CONSULTED, OR ON MY OWN VOLITION CHOSEN NOT TO CONSULT, WITH SUCH COUNSEL. I FURTHER ACKNOWLEDGE THAT I HAVE READ THIS AGREEMENT CAREFULLY
AND I UNDERSTAND AND ACCEPT THE OBLIGATIONS WHICH IT IMPOSES UPON ME WITHOUT RESERVATION. NO PROMISES OR REPRESENTATIONS HAVE BEEN MADE
TO ME TO INDUCE ME TO SIGN THIS AGREEMENT. I SIGN THIS AGREEMENT VOLUNTARILY AND FREELY, IN DUPLICATE, WITH THE UNDERSTANDING THAT THE
COMPANY WILL RETAIN ONE COUNTERPART AND THE OTHER COUNTERPART WILL BE RETAINED BY ME. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(<I>Signature Page Follows</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><IMG SRC="tm2115679d2img_002.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B> IN WITNESS WHEREOF, I have executed this document as of _______________, 20__.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
                                                                                                                                      <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 44%"></TD><TD STYLE="width: 7%; text-align: left">Employee:&nbsp;&nbsp;</TD>
                            <TD STYLE="border-bottom: Black 1pt solid; width: 48%; text-align: left">&nbsp;</TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD></TD><TD STYLE="text-align: left">Address:</TD>
         <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AGREED AND ACKNOWLEDGED:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%">
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">IMMUNEERING CORPORATION</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 7%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%">&nbsp;</TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Address: </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">245 Main Street, Second Floor</FONT></TD>
    </TR>
  <TR STYLE="font-size: 10pt; vertical-align: bottom">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Cambridge, MA 02142</FONT></TD>
    </TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT A</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CALIFORNIA LABOR CODE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B><U>California Labor Code &sect; 2870</U>. Application of provision providing that employee shall assign or offer to assign rights
in invention to employer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(a)</TD><TD STYLE="text-align: left">Any provision in an employment agreement which provides that an employee shall assign, or offer to assign,
any of his or her rights in an invention to his or her employer shall not apply to an invention that the employee developed entirely on
his or her own time without using the employer&rsquo;s equipment, supplies, facilities, or trade secret information except for those inventions
that either:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(1)</TD><TD STYLE="text-align: left">Relate at the time of conception or reduction to practice of the invention to the employer&rsquo;s business,
or actual or demonstrably anticipated research or development of the employer; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">(2)</TD><TD STYLE="text-align: justify">Result from any work performed by the employee for the employer.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: left">To the extent a provision in an employment agreement purports to require an employee to assign an invention
otherwise excluded from being required to be assigned under subdivision (a), the provision is against the public policy of this state
and is unenforceable.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="tm2115679d2_ex10-5img03.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT B</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>BACKGROUND TECHNOLOGY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>List here prior contracts to assign Inventions that are now in existence between any other person or entity and you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[ ]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><B>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B>List here previous Inventions which you desire to have specifically excluded from the operation of this Agreement. Continue on reverse
side if necessary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">[ ]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.6
<SEQUENCE>5
<FILENAME>filename5.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.6</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="tm2115679d2_img4.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Ben Zeskind, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Immuneering Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(617)-500-8080 ext. 121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">bzeskind@immuneering.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October 24, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Brett Hall, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Brett:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On behalf of Immuneering Corporation (the &ldquo;Company&rdquo;),
I am pleased to set forth the terms of your employment with the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>You will be employed to serve on a full-time basis as Chief Scientific Officer effective on or before <U>November 1, 2019</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Your base salary will be <U>$50,000.00</U> per month, subject to tax and other withholdings as required by law. Such salary may
be adjusted from time to time in the sole discretion of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Subject
to your continued employment with the Company, you will be eligible for a standard year-end bonus each December, with the amount of your
bonus, if any to be determined by the Company&rsquo;s Board of Directors in its discretion. All bonuses are subject to tax and other
withholdings as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>You may participate in any and all bonus and benefit programs that the Company establishes and makes available to its employees
from time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs. <I>Immuneering
has a 401(k) plan and will <U>match your 401(k) contributions</U> up to 4% of salary per IRS Safeharbor 401(k) rules. The company provides
group term life and accidental death &amp; dismemberment insurance through SunLife. The benefit is equal to one times your annual salary
to a maximum of $300,000. The company provides short term disability insurance through SunLife that pays 60% of your salary up to a maximum
of $1,500 per week should you be out of work due to an illness or injury for up to 12 weeks. The company provides long term disability
insurance through SunLife that pays 60% of your salary up to a maximum of $10,000 per month should you be out of work due to an illness
or injury for 90 days or more. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding-top: 8pt; width: 25%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">245 Main St, 2<SUP>nd</SUP> Floor</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 8pt; width: 24%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">667 Madison Ave 5<SUP>th</SUP> Fl</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 8pt; width: 31%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9620 Towne Centre Dr #100</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; padding-top: 8pt; width: 20%; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">617-500-8080</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cambridge, MA 02142</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New York, NY 10065</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San Diego CA 92121</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">immuneering.com</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Subject to the approval of the Board of Directors of the Company, you may receive an incentive stock option grant under our current
stock incentive plan for the purchase of <U>144,000</U> shares of common stock of the Company (currently equal to approximately <U>2.07<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT>%
</U>of the fully diluted company) at a price per share equal to the fair market value at the time of Board approval, subject to the terms
of a stock option agreement between you and the Company. One-quarter of such options will vest upon your completion of one year of employment
with the company, and the remaining three-quarters of such options will vest in equal monthly installments over the subsequent three
years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Company has an unlimited paid vacation policy. This means that you can take as much paid vacation in any calendar year as is
consistent with you maintaining an acceptable level of performance and the Company&rsquo;s business needs. We ask that you inform us of
all vacation plans at least two weeks in advance, and schedule your time out of the office with consideration of the Company&rsquo;s business
needs. The Company may ask you to delay or change your vacation plans if they are inconsistent with business needs. In addition to paid
vacation, you will not be required to work on Federal Holidays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>You
will be required to execute an Invention and Non-Disclosure Agreement and a Non-Competition and Non-Solicitation Agreement in the forms
attached as <U>Exhibit A</U> and <U>Exhibit B</U>, as a condition of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>You
represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering into
employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United
States, as required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work
in the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely
manner as determined by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>This
letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in no way alter
the Company&rsquo;s policy of employment at will, under which both you and the Company remain free to terminate the employment relationship,
with or without cause, at any time, with or without notice. Similarly, nothing in this letter shall be construed as an agreement, either
express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you agree with the employment provisions of
this letter, please sign the enclosed duplicate of this letter in the space provided below and return it to me by October 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Very Truly Yours,</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 3%">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 47%">/s/ Ben Zeskind</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Name: Ben Zeskind</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Title: Co-Founder and CEO</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing correctly sets forth the terms of my employment by Immuneering
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">/s/ Brett Hall</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 5%">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 45%">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name: Brett Hall</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT A: INVENTION AND NON-DISCLOSURE AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Agreement is made by and between Immuneering
Corporation, a Delaware corporation (hereinafter referred to collectively with its subsidiaries as the &ldquo;Company&rdquo;), and Brett
Hall (the &ldquo;Employee&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In consideration of the employment or the continued
employment of the Employee by the Company, the Company and the Employee agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Condition of Employment.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1.5in">&nbsp;&nbsp;The Employee acknowledges that his/her employment
and/or the continuance of that employment with the Company is contingent upon his/her agreement to sign and adhere to the provisions of
this Agreement. The Employee further acknowledges that the nature of the Company's business is such that protection of its proprietary
and confidential information is critical to the business' survival and success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Proprietary and Confidential Information.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning
the Company&rsquo;s business or financial affairs (collectively, &ldquo;Proprietary Information&rdquo;) is and shall be the exclusive
property of the Company. By way of illustration, but not limitation, Proprietary Information may include discoveries, inventions, products,
product improvements, product enhancements, processes, methods, techniques, formulas, compositions, compounds, negotiation strategies
and positions, projects, developments, plans (including business and marketing plans), research data, clinical data, financial data (including
sales costs, profits, pricing methods), personnel data, computer programs (including software used pursuant to a license agreement), customer,
prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company. The Employee will not
disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for any purposes (other
than in the performance of his/her duties as an employee of the Company) without written approval by an officer of the Company, either
during or after his/her employment with the Company, unless and until such Proprietary Information has become public knowledge without
fault by the Employee. While employed by the Company, the Employee will use the Employee's best efforts to prevent unauthorized publication
or disclosure of any of the Company&rsquo;s Proprietary Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Employee agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, laboratory notebooks,
program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible or intangible material
containing Proprietary Information, whether created by the Employee or others, which shall come into his/her custody or possession, shall
be and are the exclusive property of the Company to be used by the Employee only in the performance of his/her duties for the Company
and shall not be copied or removed from the Company premises except in the pursuit of the business of the Company. All such materials
or copies thereof and all tangible property of the Company in the custody or possession of the Employee shall be delivered to the Company,
upon the earlier of (i)&nbsp;a request by the Company or (ii)&nbsp;termination of his/her employment. After such delivery, the Employee
shall not retain any such materials or copies thereof or any such tangible property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Employee agrees that his/her obligation not to disclose or to use information and materials of the types set forth in paragraphs 2(a)
and 2(b) above, and his/her obligation to return materials and tangible property, set forth in paragraph&nbsp;2(b) above, also extends
to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third
parties who may have disclosed or entrusted the same to the Company or to the Employee in the course of the Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Developments.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Employee will make full and prompt disclosure to the Company of all discoveries, inventions, improvements, enhancements, processes, methods,
techniques, developments, software, and works of authorship, whether patentable or not, (i) which have been created, made, conceived
or reduced to practice by the Employee or under his/her direction or jointly with others prior to the date hereof and which relate directly
or indirectly to the business of the Company or (ii) which are created, made, conceived or reduced to practice by him/her or under his/her
direction or jointly with others during his/her employment by the Company, whether or not during normal working hours or on the premises
of the Company (all of which are collectively referred to in this Agreement as &ldquo;Developments&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all his/her
right, title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications.
However, this paragraph&nbsp;3(b) shall not apply to Developments described in clause 3(a)(ii) above which do not relate to the business
or research and development conducted or planned to be conducted by the Company at the time such Development is created, made, conceived
or reduced to practice and which are made and conceived by the Employee not during normal working hours, not on the Company&rsquo;s premises
and not using the Company&rsquo;s tools, devices, equipment or Proprietary Information. The Employee understands that, to the extent this
Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign
certain classes of inventions made by an employee, this paragraph&nbsp;3(b) shall be interpreted not to apply to any invention which a
court rules and/or the Company agrees falls within such classes. The Employee also hereby waives all claims to moral rights in any Developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The Employee agrees to cooperate fully with the Company, both during and after his/her employment with the Company, with respect
to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States
and foreign countries) relating to Developments. The Employee shall sign all papers, including, without limitation, copyright applications,
patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company
may deem necessary or desirable in order to protect its rights and interests in any Development. The Employee further agrees that if
the Company is unable, after reasonable effort, to secure the signature of the Employee on any such papers, any executive officer of
the Company shall be entitled to execute any such papers as the agent and the attorney-in-fact of the Employee, and the Employee hereby
irrevocably designates and appoints each executive officer of the Company as his/her agent and attorney-in-fact to execute any such papers
on his/her behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and
interests in any Development, under the conditions described in this sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Other Agreements.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Employee represents that, except as the Employee
has disclosed in writing to the Company, the Employee is not bound by the terms of any agreement with any previous employer or other party
to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with
the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain
from soliciting employees, customers or suppliers of such previous employer or other party. The Employee further represents that his/her
performance of all the terms of this Agreement and the performance of his/her duties as an employee of the Company do not and will not
conflict with or breach any agreement with any prior employer or other party to which the Employee is a party (including without limitation
any nondisclosure or non-competition agreement), and that the Employee will not disclose to the Company or induce the Company to use any
confidential or proprietary information or material belonging to any previous employer or others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>United States Government Obligations.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Employee acknowledges that the Company from
time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations
or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential
nature of such work. The Employee agrees to be bound by all such obligations and restrictions which are made known to the Employee and
to take all action necessary to discharge the obligations of the Company under such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Equitable
Remedies</U>. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company
and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement is likely
to cause the Company substantial and irrevocable damage which is difficult to measure. Therefore, in the event of any such breach or
threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right
to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific performance of the provisions
of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Obligations
to Third Parties</U>. The Employee acknowledges and represents that this agreement and the Employee&rsquo;s employment with the Company
will not violate any continuing obligation the Employee has to any former employer or other third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Disclosure
of this Agreement</U>. The Employee hereby authorizes the Company to notify others, including but not limited to customers of the Company
and any of the Employee&rsquo;s future employers or prospective business associates, of the terms and existence of this Agreement and
the Employee&rsquo;s continuing obligations to the Company hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Not
Employment Contract</U>. The Employee acknowledges that this Agreement does not constitute a contract of employment, does not imply that
the Company will continue his/her employment for any period of time and does not change the at-will nature of his/her employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns,
including any corporation with which, or into which, the Company may be merged or which may succeed to the Company&rsquo;s assets or
business, provided, however, that the obligations of the Employee are personal and shall not be assigned by him or her. The Employee
expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof
to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>. In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity,
legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Waivers</U>. No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that
or any other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed
as a bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts
(without reference to the conflicts of laws provisions thereof). Any action, suit, or other legal proceeding which is commenced to resolve
any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts
(or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction
of such a court. The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other
legal proceeding arising under or relating to any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire Agreement; Amendment</U>. This Agreement supersedes all prior agreements, written or oral, between the Employee and the
Company relating to the subject matter of this Agreement. This Agreement may not be modified, changed or discharged in whole or in part,
except by an agreement in writing signed by the Employee and the Company. The Employee agrees that any change or changes in his/her duties,
salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Captions</U>. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit
or affect the scope or substance of any section of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY
READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">WITNESS our hands and seals:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD COLSPAN="2">IMMUNEERING CORPORATION</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ben Zeskind, CEO</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Brett Hall</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT B: NON-COMPETITION AND NON-SOLICITATION
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Agreement is made between Immuneering Corporation,
a Delaware corporation (hereinafter referred to collectively with its subsidiaries as the &ldquo;Company&rdquo;), and Brett Hall (the
&ldquo;Employee&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For good consideration and in consideration of
the employment or continued employment of the Employee by the Company, the Employee and the Company agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Non-Competition
and Non-Solicitation. While the Employee is employed by the Company and for a period of one year after the termination or cessation of
such employment for any reason, the Employee will not directly or indirectly:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Engage or assist others in engaging in any business or enterprise (whether as owner, partner, officer, director, employee, consultant,
investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company) that is competitive
with the Company&rsquo;s business, including but not limited to any business or enterprise that develops, manufactures, markets, licenses,
sells or provides any product or service that competes with any product or service developed, manufactured, marketed, licensed, sold or
provided, or planned to be developed, manufactured, marketed, licensed, sold or provided, by the Company while the Employee was employed
by the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Either
alone or in association with others, solicit, divert or take away, or attempt to divert or take away, the business or patronage of any
of the clients, customers, or business partners of the Company which were contacted, solicited, or served by the Company during the 12-month
period prior to the termination or cessation of the Employee&rsquo;s employment with the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Either alone or in association with others (i) solicit, induce or attempt to induce, any employee or independent contractor of
the Company to terminate his or her employment or other engagement with the Company, or (ii) hire, or recruit or attempt to hire, or engage
or attempt to engage as an independent contractor, any person who was employed or otherwise engaged by the Company at any time during
the term of the Employee&rsquo;s employment with the Company; <U>provided</U>, that this clause (ii) shall not apply to the recruitment
or hiring or other engagement of any individual whose employment or other engagement with the Company has been terminated for a period
of six months or longer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Either alone or in association with others (i) engage in any activity that has a conflict of interest with the therapeutic programs
of the Company&rsquo;s clients, including any competitive employment, business, or other activity, or (ii) assist any other person or
organization that competes, or intends to compete, with the therapeutic programs of the Company&rsquo;s clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Extension</U>. If the Employee violates the provisions of any of the preceding paragraphs of this Section 1, the Employee shall
continue to be bound by the restrictions set forth in such paragraph until a period of one year has expired without any violation of
such provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Miscellaneous.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Equitable
Remedies</U>. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the Company
and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement is likely
to cause the Company substantial and irrevocable damage which is difficult to measure. Therefore, in the event of any such breach or
threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have the right
to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific performance of the provisions
of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Obligations to Third Parties</U>. The Employee acknowledges and represents that this agreement and the Employee&rsquo;s employment
with the Company will not violate any continuing obligation the Employee has to any former employer or other third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Disclosure
of this Agreement</U>. The Employee hereby authorizes the Company to notify others, including but not limited to customers of the Company
and any of the Employee&rsquo;s future employers or prospective business associates, of the terms and existence of this Agreement and
the Employee&rsquo;s continuing obligations to the Company hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Not Employment Contract</U>. The Employee acknowledges that this Agreement does not constitute a contract of employment, does
not imply that the Company will continue his/her employment for any period of time and does not change the at-will nature of his/her employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of both parties and their respective successors and assigns,
including any corporation with which, or into which, the Company may be merged or which may succeed to the Company&rsquo;s assets or
business, provided, however, that the obligations of the Employee are personal and shall not be assigned by him or her. The Employee
expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate thereof
to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>




<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Interpretation</U>. If any restriction set forth in Section 1 is found by any court of competent jurisdiction to be unenforceable
because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall
be interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Severability</U>.
In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity, legality and enforceability
of the remaining provisions shall in no way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Waivers</U>.
No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that or any other right.
A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed as a bar to
or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts
(without reference to the conflicts of laws provisions thereof). Any action, suit, or other legal proceeding which is commenced to resolve
any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts
(or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction
of such a court. The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other
legal proceeding arising under or relating to any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Entire Agreement; Amendment</U>. This Agreement supersedes all prior agreements, written or oral, between the Employee and the
Company relating to the subject matter of this Agreement. This Agreement may not be modified, changed or discharged in whole or in part,
except by an agreement in writing signed by the Employee and the Company. The Employee agrees that any change or changes in his/her duties,
salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Captions</U>. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit
or affect the scope or substance of any section of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 10%">Confidential</TD><TD STYLE="width: 90%"></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY
READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></TD>
    <TD COLSPAN="2">IMMUNEERING CORPORATION</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 46%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ben Zeskind, CEO</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">Date:</TD>
  <TD STYLE="border-bottom: Black 1pt solid; width: 46%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 46%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Brett Hall</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 50%">&nbsp;</TD><TD STYLE="font-size: 10pt; width: 50%; text-align: right">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 12<BR> <IMG SRC="tm2115679d2_img5.jpg" ALT=""></TD></TR></TABLE><P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>6
<FILENAME>filename6.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.7</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="image_003.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Ben Zeskind, PhD</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Immuneering Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">(617)-500-8080 ext. 121</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">bzeskind@immuneering.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">October 11, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scott Barrett, M.D.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">8101 Arment Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Glen Mills, PA 19342</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(267) 218-6152</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">sbarrettmd@aol.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Scott:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On behalf of Immuneering Corporation (the &ldquo;Company&rdquo;),
I am pleased to set forth the terms of your employment with the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You will be employed to serve on a full-time basis as Chief Medical Officer effective on or before <U>November 11, 2019</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Chief Medical Officer your primary responsibilities will include
contributing to our oncology drug development efforts:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-indent: 0.5in"><FONT STYLE="font-family: Symbol">&middot;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;See Exhibit C for Job Description</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Your base salary will be $42,000.00 per month, subject to tax and other withholdings as required by law. Such salary may be adjusted
from time to time in the sole discretion of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You will receive a $180,000 signing bonus, payable in 12 monthly installments of $15,000 subject to your continued employment with
the Company. If you leave the Company voluntarily less than 12 months from your start date, you may keep 25% of the signing bonus that
has been paid to you, and agree to return 75% of the signing bonus that has been paid to you. In the unlikely event that you are asked
to leave due to a change in direction of the company, you may keep all of the signing bonus that has been paid to you. Subject to your
continued employment with the Company, you will be eligible for a standard year-end bonus each December, with the amount of your bonus,
if any to be determined by the Company&rsquo;s Board of Directors in its discretion. All bonuses are subject to tax and other withholdings
as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="image_004.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>You
may participate in any and all bonus and benefit programs that the Company establishes and makes available to its employees from
time to time, provided you are eligible under (and subject to all provisions of) the plan documents governing those programs. <I>As
a full-time employee, Immuneering will cover the <U>full</U> cost of your monthly health insurance premiums for individual coverage
under a Blue Cross Blue Shield of Massachusetts PPO, <U>plus half of any expenses incurred towards the $1,000 deductible</U>.
Immuneering also has a 401(k) plan and will <U>match your 401(k) contributions</U> up to 4% of salary per IRS Safeharbor 401(k)
rules. The company provides group term life and accidental death &amp; dismemberment insurance through SunLife. The benefit is equal
to one times your annual salary to a maximum of $300,000. The company provides short term disability insurance through SunLife that
pays 60% of your salary up to a maximum of $1,500 per week should you be out of work due to an illness or injury for up to 12 weeks.
The company provides long term disability insurance through SunLife that pays 60% of your salary up to a maximum of $10,000 per
month should you be out of work due to an illness or injury for 90 days or more. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Subject to the approval of the Board of Directors of the Company, you may receive an incentive stock option grant under our current
stock incentive plan for the purchase of 139,100 shares of common stock of the Company (currently equal to approximately 2.00% of the
fully diluted company) at a price per share equal to the fair market value at the time of Board approval, subject to the terms of a stock
option agreement between you and the Company. One-quarter of such options will vest upon your completion of one year of employment with
the company, and the remaining three-quarters of such options will vest in equal monthly installments over the subsequent three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company will provide you with a computer, printer, and other office equipment you may need, and provide a budget to pay for
your work related expenses including travel to relevant meetings and conferences. Your input on potential hires is strongly encouraged
and will be carefully considered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Company has an unlimited paid vacation policy. This means that you can take as much paid vacation in any calendar year as is
consistent with you maintaining an acceptable level of performance and the Company&rsquo;s business needs. We ask that you inform us of
all vacation plans at least two weeks in advance, and schedule your time out of the office with consideration of the Company&rsquo;s business
needs. The Company may ask you to delay or change your vacation plans if they are inconsistent with business needs. In addition to paid
vacation, you will not be required to work on Federal Holidays.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You will be required to execute an Invention and Non-Disclosure Agreement and a Non-Competition and Non-Solicitation Agreement
in the forms attached as <U>Exhibit A</U> and <U>Exhibit B</U>, as a condition of employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>You
represent that you are not bound by any employment contract, restrictive covenant or other restriction preventing you from entering
into employment with or carrying out your responsibilities for the Company, or which is in any way inconsistent with the terms of
this letter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>You agree to provide to the Company, within three days of your hire date, documentation of your eligibility to work in the United
States, as required by the Immigration Reform and Control Act of 1986. You may need to obtain a work visa in order to be eligible to work
in the United States. If that is the case, your employment with the Company will be conditioned upon your obtaining a work visa in a timely
manner as determined by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>This letter shall not be construed as an agreement, either expressed or implied, to employ you for any stated term, and shall in
no way alter the Company&rsquo;s policy of employment at will, under which both you and the Company remain free to terminate the employment
relationship, with or without cause, at any time, with or without notice. Similarly, nothing in this letter shall be construed as an agreement,
either express or implied, to pay you any compensation or grant you any benefit beyond the end of your employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you agree with the employment provisions of
this letter, please sign the enclosed duplicate of this letter in the space provided below and return it to me by October 11, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Very Truly Yours,</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Ben Zeskind</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Name: Ben Zeskind</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Title: Co-Founder and CEO</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing correctly sets forth the terms of my employment by Immuneering
Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Scott Barrett</TD>
    <TD STYLE="width: 9%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%">Date:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name: Scott Barrett</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT A: INVENTION AND NON-DISCLOSURE AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Agreement is made by and between Immuneering
Corporation, a Delaware corporation (hereinafter referred to collectively with its subsidiaries as the &ldquo;Company&rdquo;), and Scott
Barrett (the &ldquo;Employee&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In consideration of the employment or the continued
employment of the Employee by the Company, the Company and the Employee agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Condition of Employment.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&#9;The Employee acknowledges that his/her employment
and/or the continuance of that employment with the Company is contingent upon his/her agreement to sign and adhere to the provisions of
this Agreement. The Employee further acknowledges that the nature of the Company's business is such that protection of its proprietary
and confidential information is critical to the business' survival and success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Proprietary and Confidential Information.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Employee agrees that all information and know-how, whether or not in writing, of a private, secret or confidential nature concerning
the Company&rsquo;s business or financial affairs (collectively, &ldquo;Proprietary Information&rdquo;) is and shall be the exclusive
property of the Company. By way of illustration, but not limitation, Proprietary Information may include discoveries, inventions, products,
product improvements, product enhancements, processes, methods, techniques, formulas, compositions, compounds, negotiation strategies
and positions, projects, developments, plans (including business and marketing plans), research data, clinical data, financial data (including
sales costs, profits, pricing methods), personnel data, computer programs (including software used pursuant to a license agreement), customer,
prospect and supplier lists, and contacts at or knowledge of customers or prospective customers of the Company. The Employee will not
disclose any Proprietary Information to any person or entity other than employees of the Company or use the same for any purposes (other
than in the performance of his/her duties as an employee of the Company) without written approval by an officer of the Company, either
during or after his/her employment with the Company, unless and until such Proprietary Information has become public knowledge without
fault by the Employee. While employed by the Company, the Employee will use the Employee's best efforts to prevent unauthorized publication
or disclosure of any of the Company&rsquo;s Proprietary Information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>The
Employee agrees that all files, documents, letters, memoranda, reports, records, data, sketches, drawings, models, laboratory
notebooks, program listings, computer equipment or devices, computer programs or other written, photographic, or other tangible or
intangible material containing Proprietary Information, whether created by the Employee or others, which shall come into his/her
custody or possession, shall be and are the exclusive property of the Company to be used by the Employee only in the performance of
his/her duties for the Company and shall not be copied or removed from the Company premises except in the pursuit of the business of
the Company. All such materials or copies thereof and all tangible property of the Company in the custody or possession of the
Employee shall be delivered to the Company, upon the earlier of (i)&nbsp;a request by the Company or (ii)&nbsp;termination of
his/her employment. After such delivery, the Employee shall not retain any such materials or copies thereof or any such tangible
property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Employee agrees that his/her obligation not to disclose or to use information and materials of the types set forth in paragraphs
2(a) and 2(b) above, and his/her obligation to return materials and tangible property, set forth in paragraph&nbsp;2(b) above, also extends
to such types of information, materials and tangible property of customers of the Company or suppliers to the Company or other third parties
who may have disclosed or entrusted the same to the Company or to the Employee in the course of the Company&rsquo;s business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Developments.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Employee will make full and prompt disclosure to the Company of all discoveries, inventions, improvements, enhancements, processes,
methods, techniques, developments, software, and works of authorship, whether patentable or not, (i) which have been created, made, conceived
or reduced to practice by the Employee or under his/her direction or jointly with others prior to the date hereof and which relate directly
or indirectly to the business of the Company or (ii) which are created, made, conceived or reduced to practice by him/her or under his/her
direction or jointly with others during his/her employment by the Company, whether or not during normal working hours or on the premises
of the Company (all of which are collectively referred to in this Agreement as &ldquo;Developments&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The Employee agrees to assign and does hereby assign to the Company (or any person or entity designated by the Company) all his/her
right, title and interest in and to all Developments and all related patents, patent applications, copyrights and copyright applications.
However, this paragraph&nbsp;3(b) shall not apply to Developments described in clause 3(a)(ii) above which do not relate to the business
or research and development conducted or planned to be conducted by the Company at the time such Development is created, made, conceived
or reduced to practice and which are made and conceived by the Employee not during normal working hours, not on the Company&rsquo;s premises
and not using the Company&rsquo;s tools, devices, equipment or Proprietary Information. The Employee understands that, to the extent this
Agreement shall be construed in accordance with the laws of any state which precludes a requirement in an employee agreement to assign
certain classes of inventions made by an employee, this paragraph&nbsp;3(b) shall be interpreted not to apply to any invention which a
court rules and/or the Company agrees falls within such classes. The Employee also hereby waives all claims to moral rights in any Developments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> The Employee agrees to cooperate fully with the Company, both during and after his/her employment with the Company, with respect
to the procurement, maintenance and enforcement of copyrights, patents and other intellectual property rights (both in the United States
and foreign countries) relating to Developments. The Employee shall sign all papers, including, without limitation, copyright applications,
patent applications, declarations, oaths, formal assignments, assignments of priority rights, and powers of attorney, which the Company
may deem necessary or desirable in order to protect its rights and interests in any Development. The Employee further agrees that if the
Company is unable, after reasonable effort, to secure the signature of the Employee on any such papers, any executive officer of the Company
shall be entitled to execute any such papers as the agent and the attorney-in-fact of the Employee, and the Employee hereby irrevocably
designates and appoints each executive officer of the Company as his/her agent and attorney-in-fact to execute any such papers on his/her
behalf, and to take any and all actions as the Company may deem necessary or desirable in order to protect its rights and interests in
any Development, under the conditions described in this sentence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Other Agreements.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Employee represents that, except as the Employee
has disclosed in writing to the Company, the Employee is not bound by the terms of any agreement with any previous employer or other party
to refrain from using or disclosing any trade secret or confidential or proprietary information in the course of his/her employment with
the Company, to refrain from competing, directly or indirectly, with the business of such previous employer or any other party or to refrain
from soliciting employees, customers or suppliers of such previous employer or other party. The Employee further represents that his/her
performance of all the terms of this Agreement and the performance of his/her duties as an employee of the Company do not and will not
conflict with or breach any agreement with any prior employer or other party to which the Employee is a party (including without limitation
any nondisclosure or non-competition agreement), and that the Employee will not disclose to the Company or induce the Company to use any
confidential or proprietary information or material belonging to any previous employer or others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>United States Government Obligations.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Employee acknowledges that the Company from
time to time may have agreements with other persons or with the United States Government, or agencies thereof, which impose obligations
or restrictions on the Company regarding inventions made during the course of work under such agreements or regarding the confidential
nature of such work. The Employee agrees to be bound by all such obligations and restrictions which are made known to the Employee and
to take all action necessary to discharge the obligations of the Company under such agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><U>Equitable
Remedies</U>. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill of the
Company and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement
is likely to cause the Company substantial and irrevocable damage which is difficult to measure. Therefore, in the event of any such
breach or threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall
have the right to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific
performance of the provisions of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such
relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Obligations to Third Parties</U>. The Employee acknowledges and represents that this agreement and the Employee&rsquo;s employment
with the Company will not violate any continuing obligation the Employee has to any former employer or other third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of this Agreement</U>. The Employee hereby authorizes the Company to notify others, including but not limited to
customers of the Company and any of the Employee&rsquo;s future employers or prospective business associates, of the terms and existence
of this Agreement and the Employee&rsquo;s continuing obligations to the Company hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Not Employment Contract</U>. The Employee acknowledges that this Agreement does not constitute a contract of employment, does
not imply that the Company will continue his/her employment for any period of time and does not change the at-will nature of his/her employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of both parties and their respective
successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company&rsquo;s
assets or business, provided, however, that the obligations of the Employee are personal and shall not be assigned by him or her. The
Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate
thereof to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity,
legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers</U>. No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that
or any other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed
as a bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts
(without reference to the conflicts of laws provisions thereof). Any action, suit, or other legal proceeding which is commenced to resolve
any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts
(or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction
of such a court. The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other
legal proceeding arising under or relating to any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; Amendment</U>. This Agreement supersedes all prior agreements, written or oral, between the Employee and the
Company relating to the subject matter of this Agreement. This Agreement may not be modified, changed or discharged in whole or in part,
except by an agreement in writing signed by the Employee and the Company. The Employee agrees that any change or changes in his/her duties,
salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Captions</U>. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit
or affect the scope or substance of any section of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY
READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">WITNESS our hands and seals:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IMMUNEERING CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
<TD STYLE="border-bottom: Black thin solid; font-size: 10pt; width: 42%">&nbsp;</TD>
<TD STYLE="width: 9%">&nbsp;</TD>
<TD STYLE="width: 3%"></TD>
<TD STYLE="width: 42%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>By:</TD>
<TD STYLE="border-bottom: Black thin solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Ben Zeskind, CEO &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
<TD STYLE="border-bottom: Black thin solid; font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2"></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black thin solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2">Scott Barrett</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>EXHIBIT B: NON-COMPETITION AND NON-SOLICITATION
AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">This Agreement is made between Immuneering Corporation,
a Delaware corporation (hereinafter referred to collectively with its subsidiaries as the &ldquo;Company&rdquo;), and Scott Barrett (the
&ldquo;Employee&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">For good consideration and in consideration of
the employment or continued employment of the Employee by the Company, the Employee and the Company agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Non-Competition and Non-Solicitation. While the Employee is employed by the Company and for a period of one year after the termination
or cessation of such employment for any reason, the Employee will not directly or indirectly:</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Engage or assist others in engaging in any business or enterprise (whether as owner, partner, officer, director, employee, consultant,
investor, lender or otherwise, except as the holder of not more than 1% of the outstanding stock of a publicly-held company) that is competitive
with the Company&rsquo;s business, including but not limited to any business or enterprise that develops, manufactures, markets, licenses,
sells or provides any product or service that competes with any product or service developed, manufactured, marketed, licensed, sold or
provided, or planned to be developed, manufactured, marketed, licensed, sold or provided, by the Company while the Employee was employed
by the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Either alone or in association with others, solicit, divert or take away, or attempt to divert or take away, the business or patronage
of any of the clients, customers, or business partners of the Company which were contacted, solicited, or served by the Company during
the 12-month period prior to the termination or cessation of the Employee&rsquo;s employment with the Company; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Either alone or in association with others (i) solicit, induce or attempt to induce, any employee or independent contractor of
the Company to terminate his or her employment or other engagement with the Company, or (ii) hire, or recruit or attempt to hire, or engage
or attempt to engage as an independent contractor, any person who was employed or otherwise engaged by the Company at any time during
the term of the Employee&rsquo;s employment with the Company; <U>provided</U>, that this clause (ii) shall not apply to the recruitment
or hiring or other engagement of any individual whose employment or other engagement with the Company has been terminated for a period
of six months or longer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Either alone or in association with others (i) engage in any activity that has a conflict of interest with the therapeutic programs
of the Company&rsquo;s clients, including any competitive employment, business, or other activity, or (ii) assist any other person or
organization that competes, or intends to compete, with the therapeutic programs of the Company&rsquo;s clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Extension</U>. If the Employee violates the provisions of any of the preceding paragraphs of this Section 1, the Employee shall
continue to be bound by the restrictions set forth in such paragraph until a period of one year has expired without any violation of such
provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Miscellaneous.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Equitable Remedies</U>. The restrictions contained in this Agreement are necessary for the protection of the business and goodwill
of the Company and are considered by the Employee to be reasonable for such purpose. The Employee agrees that any breach of this Agreement
is likely to cause the Company substantial and irrevocable damage which is difficult to measure. Therefore, in the event of any such breach
or threatened breach, the Employee agrees that the Company, in addition to such other remedies which may be available, shall have the
right to obtain an injunction from a court restraining such a breach or threatened breach and the right to specific performance of the
provisions of this Agreement and the Employee hereby waives the adequacy of a remedy at law as a defense to such relief.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(b)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Obligations to Third Parties</U>. The Employee acknowledges and represents that this agreement and the Employee&rsquo;s employment
with the Company will not violate any continuing obligation the Employee has to any former employer or other third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(c)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Disclosure of this Agreement</U>. The Employee hereby authorizes the Company to notify others, including but not limited to
customers of the Company and any of the Employee&rsquo;s future employers or prospective business associates, of the terms and existence
of this Agreement and the Employee&rsquo;s continuing obligations to the Company hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(d)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Not Employment Contract</U>. The Employee acknowledges that this Agreement does not constitute a contract of employment, does
not imply that the Company will continue his/her employment for any period of time and does not change the at-will nature of his/her employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(e)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of both parties and their respective
successors and assigns, including any corporation with which, or into which, the Company may be merged or which may succeed to the Company&rsquo;s
assets or business, provided, however, that the obligations of the Employee are personal and shall not be assigned by him or her. The
Employee expressly consents to be bound by the provisions of this Agreement for the benefit of the Company or any subsidiary or affiliate
thereof to whose employ the Employee may be transferred without the necessity that this Agreement be re-signed at the time of such transfer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(f)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT> <U>Interpretation</U>. If any restriction set forth in Section 1 is found by any court of competent jurisdiction to be unenforceable
because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be
interpreted to extend only over the maximum period of time, range of activities or geographic area as to which it may be enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(g)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Severability</U>. In case any provision of this Agreement shall be invalid, illegal or otherwise unenforceable, the validity,
legality and enforceability of the remaining provisions shall in no way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(h)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Waivers</U>. No delay or omission by the Company in exercising any right under this Agreement will operate as a waiver of that
or any other right. A waiver or consent given by the Company on any one occasion is effective only in that instance and will not be construed
as a bar to or waiver of any right on any other occasion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(i)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Governing Law</U>. This Agreement shall be governed by and construed in accordance with the laws of the Commonwealth of Massachusetts
(without reference to the conflicts of laws provisions thereof). Any action, suit, or other legal proceeding which is commenced to resolve
any matter arising under or relating to any provision of this Agreement shall be commenced only in a court of the Commonwealth of Massachusetts
(or, if appropriate, a federal court located within Massachusetts), and the Company and the Employee each consents to the jurisdiction
of such a court. The Company and the Employee each hereby irrevocably waive any right to a trial by jury in any action, suit or other
legal proceeding arising under or relating to any provision of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(j)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Entire Agreement; Amendment</U>. This Agreement supersedes all prior agreements, written or oral, between the Employee and the
Company relating to the subject matter of this Agreement. This Agreement may not be modified, changed or discharged in whole or in part,
except by an agreement in writing signed by the Employee and the Company. The Employee agrees that any change or changes in his/her duties,
salary or compensation after the signing of this Agreement shall not affect the validity or scope of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(k)<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT><U>Captions</U>. The captions of the sections of this Agreement are for convenience of reference only and in no way define, limit
or affect the scope or substance of any section of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">THE EMPLOYEE ACKNOWLEDGES THAT HE/SHE HAS CAREFULLY
READ THIS AGREEMENT AND UNDERSTANDS AND AGREES TO ALL OF THE PROVISIONS IN THIS AGREEMENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">IMMUNEERING CORPORATION</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
<TD STYLE="border-bottom: Black thin solid; font-size: 10pt; width: 42%">&nbsp;</TD>
<TD STYLE="width: 9%">&nbsp;</TD>
<TD STYLE="width: 3%"></TD>
<TD STYLE="width: 42%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>By:</TD>
<TD STYLE="border-bottom: Black thin solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>Ben Zeskind, CEO &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
<TD STYLE="border-bottom: Black thin solid; font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2"></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2" STYLE="border-bottom: Black thin solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD STYLE="font-size: 10pt">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD COLSPAN="2">Scott Barrett</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confidential</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">EXHIBIT C: JOB DESCRIPTION</P>


<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 3pt; font-size: 10pt"><B>Title</B></TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Chief Medical Officer</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Location</B></FONT></TD>
    <TD STYLE="padding: 3pt; font-size: 10pt; width: 74%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Remote Position Initially (with future Transition to New York, NY)</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; padding: 3pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Job Description</B></FONT></TD>
    <TD STYLE="padding: 3pt">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">We are seeking a highly motivated individual to
provide executive leadership over our expanding oncology drug portfolio. The candidate must have in-depth knowledge of molecular and cellular
biology relating to drug discovery and development of cancer therapeutics as evidenced by previous research emphasis, publications in
peer-reviewed journals and contributions to IND filings and clinical studies. An essential component to the position is the ability to
independently develop, foster and contribute to advancing early oncology drug programs in a face-paced, team-oriented biotechnology environment.
Immuneering drug discovery spans the entire preclinical drug discovery spectrum, including Target Identification (TI), Target Validation
(TV), Hit Identification (Hit-ID), Hit-to-Lead (HtL), Lead Optimization (LO), Preclinical DMPK, ADME-Tox, In Vivo Pharmacology, and contributing
to the preclinical and CMC, IND applications and clinical studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ideal candidate will:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in"></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 28%">&nbsp;</TD>
<TD STYLE="text-align: left; width: 4%"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Design
and execute preclinical and clinical project strategies in support of drug discovery and development</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Coordinate
and optimize relationships with CROs (heavily outsourced model)</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Analyze
and translate drug discovery and development program data</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Effectively
communicate progress with internal and external key stakeholders</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Secure
and expand Immuneering&rsquo;s intellectual property (IP) and drug portfolio.</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Identify
and prioritize unmet clinical needs suitable for Immuneering&rsquo;s target identification platform.</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Identify
and prioritize novel targets (including but not limited to those identified by Immuneering&rsquo;s target identification platform).</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Generate
and document clinical development plans for IND- and IP-enabling efforts.</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepare
drug programs for pharmaceutical partnering opportunities</FONT></TD>
</TR></TABLE>

<TABLE CELLSPACING="4" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left; width: 28%"></TD><TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: left; width: 68%"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
relevant tasks in support of company-wide activities</FONT></TD>
</TR></TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 13; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt">Page <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> of 13</P><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; margin: 0pt"><IMG SRC="image_006.jpg" ALT="">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>tm2115679d2_ex99-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex99-1img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #? IT# 2(  A$! Q$!_\0
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MSFUU*+X'^$=9^(^D6C),L$S/XKL+2W\%7[12?._]B:]>N ZE8S&DS1?Q3_\
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M]3;XV5_2@GWE_P!R/_T.2OYK_B5_RM(?L_?]HUM>_P#4V^-E?TH)]Y?]R/\
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MM([7QQ\4[G!#!_"UIJD%IX=R#O\ &NK^&<@(LI?_ #'_  ?X0\<?%7X@^'?
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M\4?B4GAHP++_ &"9?#TNKR6RRHZ:>==&G?;"D 8&WF,V8XHRK13R/YT?Z/\
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M5I2PV[/LN[S2D88%PK>]PLS$C#[5#!C,H1]V5*%/+40R1E=WSH3@@#).0O\
MB)&>ZWRW"L?M+-'(DDQM[^\D<, ZM?Z@#=PR7!8K-=<10P/,^HC^R5U"O[!?
M^")?_!Q'X<_9X^'\?[+G_!0#Q5XXUOP#X:FAA^#WQ_FMO$GQ'\0>$-%DDAC?
MX??$2.&TU3QAJWAO05GF7P;XALM)U&]TG2[:YTF_MGTRZ\-/;>]F?"5; 4E5
MH5I8AMKFINER2YFO?:DZLT_>VB[-(^=R;C_+L74=+'T*.5TKS5*K2J.I3DT[
M).GR0<79I2GS/FEHHW5G_?:[;0. <D#D9[&O.OBO\2/A_P#"#P!XC^)?Q0\:
M>&?A[X$\(6+ZSXA\7>,-8L=#\/Z/8VGS/-?WNHRPVSF0XAMK/S$N+RZDAMK%
MDOI+9U_'/XS_ /!P]_P2D^$O@MO$VF?M%VGQ6U V;7^E>#/A)X>\1^(?$M_,
M(FN+6SNFU"ST#P_X8EN+E(XWM/&WB7PBTDKPVACEFN5MIOX@/^"N?_!:'XR_
M\%1O$V@>%X?"DOP7_9R\$:A?:KX-^%5GKP\1ZWXAUV]BFMI?%WQ&UJW@L=*N
M/$\=C/=6NGZ%I-@EGX/M-4U.P.H:O/JDM[)YN6<-YKCL3%5L/+#X6-G*H[S<
MEU7(U"W;5]=M+/U<ZXORW+</.6'K+%5YP3I4U[EE*+Y:CE::UWLEI;>SNOTO
M_P""E?\ P= ?M#_$+XA:WX _X)\ZNGPA^#.@BZT,_%?6O#.G:K\3OB%.-\4N
MOZ?;^+M.U71O!/AIROGZ%%;6UMXRN8S#=Z[<:>S?V!IOXIV__!8O_@JA9:K!
MJ\/[=W[1DMXL@F*:EX_O[W2I'\U)&:YT:VGN](;3QMVK;6>B02>:8(Y)9-/-
MY87OYIG BC!ZMDHC??BCCRIC/U+ GCJ*CK]$IY%E=*$:<*$)**2E)QC>4K)2
M;NF]UU?KV/QO$<39WB*TJL\94C>;E&*;LHW?*DTTK)/1I=';N_[8_P#@DU_P
M<Z^,]6\:^%_@%_P49O=*UVS\5^(++P]X2_:5T[3]#\(MX>FU.2+3-,L/BYX3
M\-:+8>'+[3=1OKF.UA\8:18>$'L[Q["UU'PUK=UJ(U33_P"XNRN4N(89H98Y
MHI((F66+R_+E0J'CN(C&\BF&ZC=9(BK%=BCDDD+_ (BB;]W[MD1SP#+_ *K#
M$*YFQ_R[JA9[G_IV66O]6?\ X()_M#^*?VFO^"7?[./C;QRS7'C#PCIWB7X/
MZSJ3HBRZI:?"OQ1JGA;PO=2L &,\?A*UT*WO@21_:J:D0 22?D.*<HH8-1QF
M':A"I:$J*C;D<8RO-3O9^T>ZY5RO6[NS])X%XBKYE4G@<95E4JTXSG&4G?FB
MW&R[KEUU;>]MKG[)J0QR,YQZY'7M_GUJ/L?J/Y-4B'(]QQ^''^'Z5'V/U'\F
MKX>HFL-63;EHM7_BCIN]C]&:2KTTE97G^6^RW/YK?B5_RM(?L_?]HUM>_P#4
MV^-E?TH)]Y?]R/\ ]#DK^:_XE?\ *TA^S]_VC6U[_P!3;XV5_2@GWE_W(_\
MT.2O;S7?"?\ 8NP7_IJL>#D?Q8[_ +&&-_\ 3E,ESB3ZX'Y@?UJ"Y9@H"D#Y
MLG!Q(P6-WVQY^4NS*N0Q"^7YA)XJ?_EI_G^[3'^X/HU>'%72E>WLJB;7\ZE9
MV\K6M?4]UIR<H7M[2,DG:_+:-KVZZN^ZV\[K_,)_X+=_MJ_M?>&/^"I/[7'A
M#PA^U+^T#X*\&^#_ !CX:\,^%?"/@GXP^/O"'ACP[I^G^!_#]W-:Z9H7A._T
M[2$>[FU1+F_G>1KPW(Q(CF1V3\I_^&[?VW?^CS?VJ_\ Q(7XQ?\ S35]A?\
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MK,3Q9P]@ZE2G4S25:?M)N7.E4G3NUS4[PC!.--IJ*Y6[-W;LF?VRT5_$H/\
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M$ @;DM]!MO&,$41(!$,T\4HW@N%*E3@C_@M?;EB/^&=+K&#RWQ6MSGIUSX
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MKL&DCQ1;>-CJ]CI]]J:R167V^RD\-Z252:Z:.VEE6^.R22-19ON\R+^?\O\
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MK(UM<Z'K.B7['^P_$'A+4[4M8:SHFJV]O+<G5]'DD@O9#&NJ0Z5?V\>C6/\
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M GQ5RKQD\-<BXSRB5%XW$8:IA>(LNA5E*.3<6X3V']KY'[6=.G*=*%>M4Q&
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M=K6Y7UZW=DU?^QKN/H?YK2U_(S_Q%Z?L62'Y?V9OVHNG>'X5D>G4_$0?S_\
MK*/^#N[]B]@W_&,_[3RX4GYK?X6LIY VG9X]NB,YSDQ@#'W@2 WS<.'\ZG&\
ML!*+3:LIQ>SWU47U[?>?9KBWAU.2><8"F^>7NU)UU+>R=J>'JQM+I:;=MTG9
M/^N"50RJIR SKD@X(QEL_I7^3+_P7(GBN_\ @K1^W!<P2^>@^,%I;EQT5H?
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M '/@[\+F_+QEX@ _4_G7]Y]P,K$ASAY@S$>B#<0^?X7"F,\$_.."<$?Q:_\
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M%M93 6\ZS1:986SQZAH<]G/;!"3_ &:^GL(_E;9^K_\ P2+_ &AAX2\9:[\
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MB81^,OC_ *1X;OKB%-[:=87VAZS)K&K$'H-(T&SUK4P<_>LU48W 5^B]E?\
MAOPV- \,)?:7I4GV VWA_1IM0C@O;F"PMH4:"UM7823BTC-F@$?F-^]. !C?
MV&I6\$ZVCRV\$\EK>)/:O/$)OLUPT,]L;B$95HYOL]Q<0+(C*P2=U)VLP/\
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M5*:7:,6E]W-UZF/_ !#K(/LU<RI+^6GB*'+?J_WF%JSN]+^^UIHD?Y?>G?\
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M#GIX:"HQ="$Y14I1LH_R%Q]]"/P:\0..L7X@8Q\39#G.:UL-B\XH<.9M3P.
MQ68X24*U/,\)3K8*O6R_'U,31H5\16I59JK*G)*--U:CE\C^,?"_Q"^(G[+/
MC#P3XGT[3;'XM^-?@?KGAG6M,M[\'3U\7ZYX2N-'U-K:_MD6VBMVU.XN':>%
M=JN8I!NC +?SO+_P2[_;%6-Q<?#7PY<74OFD.?B;X0,DFV%Q#YKW;+>L&\XD
MVNPL2 [?<!/];-%>+X;>.O''A5#/Z7"E#AK#4<_SE9I6HU<GJ5J>'I0H.A2P
M5!3QO-&G3A.LN=25XRI1Y?W7-/Z;QC^BIX?^.L^%JO'N=\:U:W">10R3 8K*
MLXPF Q>)BJ_MJF)QU9Y9B/;SJ\E*,Z:C%.4:E1U'.M-KY0_8I^%_BKX*_LW?
M"SX7^-H-/MO%?A?1=8BUZVTNYCO+.UO-1\2ZIKB6RW%N!;N\<.L ,R8#'<%^
MXV/J^BBORO-LSQ&=9KF><8R-"&+S;,<?F>*CA:7L<.L1F&,Q.-K*E2YI>S@J
MF)E&,>9V45KT7]!<.Y'A>&<AR7AS 5<36P&0Y5EN38">,J0K8IX/*\!A,!AO
M;UH4Z4:M5TL)&4ZGLXN4IRTT04445YY[)\9_M^?"+QI\<_V8/&_PU^'T%E=^
M+=:U+PG>:78W]ZFGPWPT+Q-IFNWMLMS+=6D*2M8:==2()I61A&P\MWVBOY[4
M_P""7G[94BRPGX<:&AG>18Y$\>^"6-C;&&V$1:W74+Z[,@CN;P>6\,9 4,6"
MR1^9_6]17[9X=^/G'7AEP]C.&.'(9'+*\;F.,S*O]?RSZSBI5L;@L)@ZU/ZQ
M]8IM4E'!TYTXJ'NN4T^92T_EWQI^B3X8^.W%.$XOXQQW%>%S; Y)@LEPBR/-
MJ&!PM.G@,RK9C0Q$J-3 XEU*C=>=&I%S49)*<7"2L_,OA9H\WAOP?X0\-W B
M-]H/A#0M"U7R9%ECAU#0])TNP:!7C58B-H<EE4!W5RF0&QZ;117XQB*]3%8C
M$8JLJ2K8K$XO%5?84_94W4Q>+Q6+FXT^:7+:6*<7[SYN12ZV7]+X#!QR_!X7
M TZ^)Q%'!87!X+#SQ<X5<0L/@<!@,!1C4J0ITHU)<F!524^2+<ZT[K1%*^0.
MD7*_+-N"N<*Q$4N%)[#^(]/E4\U\U_M/?L_>$/VC_@]XC^'?B](EO+J(ZEX:
MUE,F?P]XFAM[F#2M8LF3&R6'[3/;28R#;7-Q'@EZ^H:*Z<JS+'Y)F.%S?*\7
M7PV88'%87'8&M&=X8;%8.:J49P@E%\DZD8O$TN=QKI.,N5-H\_B+A[*.*<AS
MOAS.LOP>/RKB#+ZV79GA\7AX8B&(H5:<J45.-1.,E1C-U**LI4\3"C7A.+I)
M/^274/\ @E[^V192K90^"/#.HP/*D(NX_'/AJVM=6:"X!EFA@N;JRO+.'4+=
M"96FEW17K6X:%\F6/]K_ -@#P/\ M/\ PV\#:S\./VA;"S@T;PPNC6_PROSX
MGT;Q+KR:)<0WBW^DZQJ&DZI?2&'P_-';6FGFYA6,VLZ"&=O+VM^E=%?L?B#]
M(#C?Q-X?60<5X+A;%P<Z%:IC*62*GBEB*:A&M6P]26)J3PSQ48*->$'*G4C>
M$X2AHOYL\(_H?^&_@KQC2XUX)SWCK!YC2PN.P4\%4S^G4RK,\/F$:2K1SS!2
MP3CFDZ+IKZG*4J*PT8TE%.=)3G_.M^W!^P5^TG\:?VG/'GQ/^'7@S2/$GA#Q
M39^'9;.^D\4>&-,E$EGX:T[19SY%[=66H21HVD0CYI)(B7#!"%!B]B_X)J_L
M=?'7]G'XP>-O%_Q;T#2?#FCZAX E\-6$=AKND:Q+=W][K?AR[A9TTW4+TQ@1
M:7=%FD"@,F-V2%/[CT5&9?2 X_S/PYK>&-:/#RX=GP[AN&J%LHOBJ&!P=6C6
MP\W56)BJM?FHI5IN,?:J4D^5ZEY1]#_POR;Q;I^,N'S'C"OQ5#BG$\5.EB\[
MA4RSZYBIYQ4J4(86EA*/+AU+.*BA%RFXQHP6KDVLN/*LNX JNWRSWP(BS@^H
MRJYSTH$X+1#LZR2,#GG;NZ\\?=_QK4HK\17NJ"C&E%:>U4*:C&I^[4'9?8U5
MU?F:24;NUW_5*C:4&MJ>'G1@NO/*,8QK2;;YI144VK+F=W=' ^,O#N@^//#6
MJ>%?$NG0ZMX>\1Z;J&E:KIUQ$D\$]M<6TT4NY9%95948-%(,-',(W!R #_-+
M\3?^"4/[1&C>*M9T_P"%&G>&_'/@IM2OI?#-_)XLT_2=4L]!GD\W3[#7+75[
MG3K;[;8J[V]L\%S,?(#;5(+E?ZF**_2_#CQ8XL\*<1F&(X0>7.&:3PE3&Y?G
M>'Q&9Y76J8&<I8:JL%#&854ZT%)PE.G**J1LZBE.,)Q_!?&KZ-_AQX^X;AVG
MX@T<REC>&<6L1@,SR/$4,KQU;#5*$Z>-RS&UGA<34Q&7XNLZ6+4.>-7#5Z$?
M858TYU82_DPT_P#X):?MBO-;1#P%X;T\F6))[S4O'>@W$)DD;RL&'3-2O)VM
M(7=;R[)B6-[.VN$$@G,$<O\ 0+^QY^S#H'[,/PRTWPC93:;JGB_5(%U?Q[XE
MM8!_Q/M>F3<GV6X:,.= TWSVMM"MI6)CMB[%$9I!7V517N^(_CWX@^)V7T\I
MSJIDF6Y6\=4S'%9=D.6U<#@\7BZG(Y5ZT*F-Q%64W*"J-3JRI^UC3J*DI4XG
MSO@K]$GPG\">(,7Q7PC3SW,N(\5EV*RG^V.)LPHYIB\+@,;457%0P2IX/"T<
M)B*DJ="C'%4:4*L<)1>';DJM24LB6[@1H1*6+$[U P/F4^60<CLQR#^'7I%<
MW<09UE52GVF.%05#+EMS"0IQO965&5>"2 0PVY&Y17XM&%.,7!0:@DG2CS/]
MU-.4G.+LV[RY7;HHM)I2=OZ:E]8]G*,:T(U?94H4ZKI<WLZD:D95ZG*YKF5>
M$?9\EX\EW+FE>Q^7_P"UM_P3O^'?[4NH/XWT/5)?AY\2DMY+>Z\06,$;6.O-
M:QB*UC\1:;(BEY8F,?V;4[;R]0MH$N+=&,5RX7\CO$O_  28_:PT*>6TTRQ\
M">+X@["/4](\7VVBBY0$[)9[?Q)<6=TLF,!TCFDC!?Y5*X9?ZL:*_=>!/I'^
M*WA]ESRC*,SRG'Y;&DJ-#"9YE4\PC0I))*E"O'&8?%^PBO=IT7B)4Z4'R4U"
M*45_*WBC]"_P)\5L[Q7$6;9+FV09SCL;4QV,Q_"F9T\IKXJM5C#G>(C+!8G#
MU+SC*;DL/"4I5)-^\W)_R,I_P2V_;0+&(_#7163&\.GQ \+?,00,[O[<\L@[
MCT^;IV!J3_AUC^V;_P!$TTG_ ,.#X3_^7E?UQ45]_'Z9OBU",8PRGP^H))7A
MA^&\:J<I_:J6KYW7FIU':4_WG+=>[&*NC\IE^S<\!YR<GG?B0M=.7/\ *HZ=
M.:V0>]/^:;LYNS:31_([_P .LOVS5(/_  K72!@@\_$+PF"<=@?[<Z]^AX!X
M[B"3_@EU^V7%D#X;Z29WR8YA\0?!*Q0(_P"[DF>:[UPP#:KM'\CK-ND"IU8'
M^NFBG'Z9_B]!55' \"Q]M5PU2=N'<19K#II1:_M:SYDWNM+[K6]0_9O^!,'3
MY<]\2U%3I*M%<0Y7^^PT:SK5<,W_ *OWA&NWRRG&\HI7BFW8_*G_ ()A_LU_
M%S]G+2OBS:?%C1]/T.]\::QH-_I-I:Z[8:U+/::#I\EA)=;]-U&]MA$SW@&Y
M53!* N=X%?JM117\W<7<4YEQKQ)F_%&;T<OP^89QBOK%>CE>&GA,%3Y:5.E!
M4Z%2OB)1DXT[U)>T<9S=U&-G?^Q?#'P\R7PHX%X?\/N'<7FV,R3AK#5\)EM7
M.\51QF81PU;&XO&JA.OA\+@Z4J5">+J4Z,503C"_-*4I-JM=.J1?-(8M[K&K
MCJK295>Q[D=C[\9K_+K_ .#COX:ZQX7_ ."P'[0:)IUQ.WQ5T?X+^+O#ELL?
MFKJT&L?"WPCX(DCC4<?:%\3>&==FL&Z_VA#:#&3Q_J+7(S& =HQ(ARX!"[6#
M!AG@," 4)X#XS7Y'_MM?\$B_V?\ ]NK]J#]ES]K'XCZSXI\.^,_V<;S0WN?#
MFDV^D7>B_$SP_H7BF/QSX7\&^,H]522*%-!\5W.HW5G<6RO<XUBYA1DC<M)S
MY%F,,LQ-6M.S52C*%KI.,E;EDM&WUT[VUM<]3BK))9QA,)[)S56AB5-N[G3<
M4UI*E=+9N\KM^2LC[0_9!_9[\'_LJ_LY?!GX#> =#TS0M"^&_@'PSX>GBL;<
M0G5=?M=*LHO$WB/4BH"2Z]XCUM-8UC695>1I+N[W,VT*H_B]_P""SW[ OB+]
MNC_@OU\/OV?OA5$^EWGQ2^!7PK\4_%_QI#:_:X_ GA+PW/K^B>*O%=Y:N\=I
M>16W@C2]$TJSTN^>&UUW5M5TW0/M>FW&JP:G9_W!?&OXR_#']GGX4^._C1\8
M_%FD>!/AK\/-%F\0>+_%7B"X2.RTK3;*9(E9(PDGGSW-Q<VL6EVT:37.H:GJ
M%E911/<3QQC^3K_@D+^WUX(_;H_X+R_MM?&W2[&ZT/P]X_\ V;3X*^!]AKXQ
MJ\W@_P"%OC3X6Z7,URCL[:5JNOIIJ>-]3\-L[OH)UJU@WN]R6.^52QOM,US:
M,9584J51\ZNDYR:M%ZR<G"[;>KE%)>[HC#/(8*O1R?)ZKI4:[E13C"G!<L8Q
MBDW%<J3G;ON[WENOZ,_^"?W_  3Z_9E_X)V_"^[^%/[.?A2\LI-;DL-9^(?C
M[7[J;5O&/Q$\06]J+.TU7Q+K$PC@7[/:!TTO0-(M[+2-(M99+M+"*ZUB?4=7
M^^:J0NK*K[=N]5EV Y :7+M@\ C=DGU9B> <";+-R,@#T_SS]*^>EB)XJ4J]
M2I*I.I*3<I+5*^D+MZ\JTNDEKHDCZ?#86G@J,,-1IQI4J44DHNRE*RYI6MHY
M-7:N^FK*6IRB**$;X4,UPD*>>S*&9HY6"QD @RG:2H;"[0V3D 'SCQCX#\ >
M.[=[;QAX.\*>*(FA>T?_ (2+0K74CET:-HF^TP2"$/N,<<ZKE"X5<LX0^H2[
MB%)'W&W9QCLPZ]._IVSVK%N[<C" 9/V>Y(YQR[E0<Y]">F.O:KI8K$4*E*>!
MQ>+R[$4HUL1]<P=>IAZJ]C.#=*3I3HU'&459_O8V[22LLL?@,'F&$Q6%S7+L
M!FF!G1JU982OA</7C76'HRE+"XN.+HXRC7IXES4::C1HNA'FNZLI*4?YP?VF
MOAC>_P#!.O\ :6\ _'#X/Z5(OPM\2:@P/AD7\B-:.ZM9^*?"EM<3M]GM;34K
M*^&KZ6E[(;2.YTI8UE,Z0 ?KE\-/VZ?V:OB786VH6_Q7\&^$KV9(8Y_"_P 0
MKVT\&^(=*F$8VV;V^K75M_:*^9YC6MYICW%C+$6*,S!B/BW_ (+2:YI\/PB^
M$/ALX_M+4/B3J&LV_K]@T+PYJNEWOX?:M:LO_P!7 _G0K^_N#/";"?2$\+.$
MN+.)LRQ67<58:699.\Z=&.9SQV593B:.%RI8FA6J8:-2O0I5*T?K*K0JSDYM
MZ3J0?^.?B+X\9M]#3Q_\1N!_#3(>',XX!SN62<39GPGG=+&3H97G>>Y;+,<P
MHY#BJ.+DLGITZSH*K1I8.I2KITW.G"4(-?W;>$O&_A7Q@AE\-^)-#\0PQPLY
MDT+5]-U.V9 \2^<IL;RX=5!=5W,B)\Z@G<5W=KE>Q*^W//UQ_B*_@W\*>*O$
MW@S6[/Q#X0UW4O#>O6$D<UEK.E7_ /9MS9O%/%.&:YP?W#/"B2P8_P!(!$!P
M),C^DC_@GU^WYJ/QZNS\(?BQ'967Q2@TR[O-(UVRL?[-TOQ?9Z>UL\SW%KO8
M:?KAB=YO(!,=]:VUU=1&+[.4;\C\6OHN\1>'64OB3)\QAQ/D-#WLTK1PG]GX
MS+(\RC.M/"0Q6/=:@E*,N>,J;BE-N+IQYE_3?T>OIX\'^+V>T>$.+\HH>'W%
M6;9GA,!PYAZ.85LWRC.I5\-5J8B4\77P>71R:I1KT:>&PV$J3Q:Q;JQE&K1G
M:G4_8!F]#GZCI^8_7.:098Y)_0GZ=!C\_P :K6F"S, !OBCDVC'RM)DN"1C)
MW+R< YYZDU?K^5[0EJE*UWR\U]5I:23VOK:ZOI?J?W['VB34XJ,U*<7:VL5*
M48NZ_FBE+=Z26O=!@$@ \ #/;U_/GGBEHHJAA1110 5!V/U'\FJ>H.Q^H_DU
M9UOX%?TC^<2/^7U+_M[\F?S6_$K_ )6D/V?O^T:VO?\ J;?&ROZ4$^\O^Y'_
M .AR5_-?\2O^5I#]G[_M&MKW_J;?&ROZ4$^\O^Y'_P"AR5[.:[X3_L78+_TU
M6/!R/XL=_P!C#&_^G*9,/OM]/\*?3!]]OI_A3Z\>G\/S?YGT"Z^O^044458P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** &2$*!D9RP'TX//_P"O(]C5.?/"
MA0PSO&?NJ\6Z6)R.I"RQI@9ZX)XS5^HY,87=C8'#.3V"!I ?;#JI_"E*,9*S
M6O?K;3]-/F.#<92;?-%I)0>EFD[N_6[:=K+:VS/XSO\ @\!^,GBW0/A+^R%\
M!]&UK4+'P=\4_&GQ7\:^/-'L+S['#KLOPUTOP#IW@VUU:3CS-*CNO&FNW$D/
M0W-O:N/N<_R1?\$U_P!J.Z_8Z_;M_9G_ &B)]5DT?0/!WQ4TF+XA7RR!4N_A
MSXQN(_#'Q/@CN""K6<7A+4=0+(V<RQQ.0=@K^O?_ (/ ?A/J6L_L]?LB_&N"
MW$VG_#WXK^._ &J<_P"KF^)_@_3]>@G//\$?PDG3CL?7FOX(6@D<.8?WL@CD
M2T)^X)+BUF2,3=?]'BD=)KH<C[/%+G'2OU#A>C&OP]C*$:2:Q#Q%-JZ;3CRI
MRVN^:]TM+/J[GXAQCBJN!XMPU6=64E1A@JT9.\$E/G?(FFTN31-O1IN5KQL_
M]MVWN[?4K>UO+&:*XL[J.&YM9H9M]K-9S0Q'+ <.)(_-:,X91QN(8D#^-;_@
MXO\ ^"S7[4'[*7[07A/]DS]D#Q]_PJ_4+'X;Z-X]^*_CW2?#OAS4/%6H:GXR
MN]7C\/\ A#2-2\4:!XCM-"LM&\-:?IWB"\UG2;*TUGS_ !#8V)U 6DEU#-^P
M/_!O_P#MI6/[8'_!-WX12:A=2/\ $#]GRUT[]G'Q[-= +<7]WX$T+1(? NNR
MG:"9O$W@'5?"FI7.26_M>YU)>FVOY-/^#K/X(^)/ /\ P4<T+XP7MO<R>$?C
MU\$_!=[H&IO_ ,>Z>(/AM)>^"?%OAQ,9_>:380>#]<."1_Q5KX)QFOEN'\OH
MQSVOA,5"/)"$E&C*R3DD[2U;5YQ:EM96N[]/M>)\UQ;X;H8W 57S5)<SJ03O
M%6BY0]UIOD>C=TW=K0_13_@A3_P7Q_:$^._Q_P#"G['7[;OC?1?'/_"Q;35=
M-^$?Q?O-!TW0_$]WXWM$L]1TWP/XM/AFWL_"^LZ?XAT>S\164.OWFG1:]_;3
MZ3:@?9KJZDA_M><E(?,(.X0\(6#,N]RS1MM50%C(\F#C.V%OF/.?\=+]@N;Q
M%!^W%^QNW@W>?%LO[5?[.T7AH1GG^W#\8?!DFG'Z?:(TR#[<=J_V,'BPNP[L
MO'(V"<?> 89!YW$J!C'<X(&,Y\89=3P5>4:,%AZ>*RW&S7+:7L72DZ<F[6YO
M:IJHE[JBH\J4KN2QX S;&YEEF/CCZ\W*.88;#4<1-.3G'$X?DG34;I)4I05Y
M<TKN;5XI)'\T/_!8_P 7:IJ_[0_A7PB\X&A>#/ASI$UK:CH-<\4:MK][JTWX
M:78>'$'3[Y&.*_(>OVX_X+%_!G6(/&/P\^-]I,L^@:QX=LO 6I'A(['7M.?6
M]?L9T&0&D\26-UJ@; &T>%UZ[S7XH"\6ZC5)B=T9V@K]Y0!CGKG. #R> ,#N
M/]7OHYXW*<3X)^'U7*)*K3IY)&ECZ=.*<Z&94ZU=YA":5N>HJTZ<Y:)\M2GK
M))2E_P __P!,;+\ZH?27\5WF].NZ^(XB_M"%.SG.CD&(P>!I9+7PZJ.F\11K
M83!5ZL81Y'2E[2$EHY$<3$%E49:5?*'.""S*01^( ^A-=CX&\8^(/AGXOT'Q
MKX>O)]*\1>$M6L=<TR]B"LUL;*82W@=2"K03V(N89%.01)C&2:Y:.2ZCBF2,
ML;=D8N,?*5) W9(Z\@?B<#)S6YX/T;6O%&O:1X/T&+[1JGB[6]&\.:9">!+J
M^J:C;VFF*#D<B[GB+8Z#KVK]0SBGD>/R/BGZ\J^(RV&62_MVG7<J&$5&%"J\
M.[S4H*I&G[5U(*+YDES2C=V_ ^'OKE+'8.KE<U]=HY[PS6P+PMI9C7QCSK"O
M"K!5J?+B,)C:4$N; TO:_6Y2M*K3Y8N7]SOA/5(-;TC2]:M3OMM9TRWU:V8X
MW^1J$5O=Q%NNTRQS)*RY.TG!Y KJJXOP3H<'A[0]"T>*..,:1H=CI42*V6AB
MLK/3[0PX[_\ 'K&SGLY(]AVE?X:XN*CCLQ4)<^&688SZBVDI?V>JS6#4[-IU
M%1C[\E92DVTK6O\ ]6&7SK5<!@*F(<WB)X#+IU_:T_8UO;RR[+Y5E7P_-/ZM
M755U%5P[G-TIIISES:%%%%8G6%%%% !4'8_4?R:IZ@['ZC^35G6_@5_2/YQ(
M_P"7U+_M[\F?S6_$K_E:0_9^_P"T:VO?^IM\;*_I03[R_P"Y'_Z')7\U_P 2
MO^5I#]G[_M&MKW_J;?&ROZ4$^\O^Y'_Z')7LYKOA/^Q=@O\ TU6/!R/XL=_V
M,,;_ .G*9,/OM]/\*?3!]]OI_A3Z\>G\/S?YGT"Z^O\ D%%%%6,**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>lg_immuneering-4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_immuneering-4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 2@&F P$1  (1 0,1 ?_$ -T  0 " P$! 0$!
M       ("@8'"04$ P$" 0$  00# 0              !0(#! 8!" D'$
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MFAM>DO7>[]'_ )E3-OKCRYR<M;9\3I[7<?=>US0^)M3]9KR^G0(RK$>NF"]
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MN@K%20*Z$^_PZ=]5>&^E:&G<J3)&#0N%>]9R0Y%"$43.51-0I3D.0P&(<A@
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MBI:=T7B1D/MZV+%T%#<F\OY!_*#"2DJNM*6F<CQ8'CWIV8)HE:2!.LJG1O\
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M2F/_ .OF!0^ Y%LOA\HA%PFWYV^KN(_%=W+'SOX#/M+I!V>/]&YQA_R%>_\
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M+_-7%K#C!25[1)3E6XYU^ R'&SD,QCV"\(2L0E"L2+%TC*R)G/4ZDA3#K1(
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M-1<F#PLLAEEL[1TKC4DPQDD]9);4GM*FXN9^9;>)MO;Y"]9 QM&M;-(&@#@
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&31$T1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm2115679d1-tbl_cancer4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-tbl_cancer4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@""@.0 P$1  (1 0,1 ?_$ /(  0 !! ,! 0$
M       #! <("0$"!@4*"P$!  $% 0$!              $"! 4&!P,("1
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M2+<7Z2FF>\TEFG;>ED07Z4OPA6DEL!BR%;6N*^2((J0=5<0OZ4[2@NE HJH
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M AZ. 0]5_BZ(JI?I*;/S226VU8M0+7L=8-%!5^D5VCLP2<C;UC)[8=LR3<J
M2_;MZ.$4+ Q4!EL8EBU"2S!QJB-'$LX]E^X7C+(''O-)SXDI*][;]1[/UZ=%
M5I"A<,J"K*-R2Z_(<9AC:633.V'E,88=H@5](VE@01Y;'_KJ'147Z?7KN I7
M"(*-L(U(>C$W$=2D=>C[F\+%*%@58R 5GH,MQ%^Y$<5%7=MZHB=Q2+L8Q$2<
M'B6*0BGRG9E)L);&UL/E:Q1OX+BSD=&J8<1#4401(%Z[1V[#(IF/I8=Q9Q'8
M$U&!^_&.25<ZN&[LE9QZ,VDTVPM8H$K;AH*DJD)?55[8$5+$1A&*L&AFQ8[(
M1?AJ]YD_+P]WX.R#R<A-9YD^P3)JWL-21'#%/NZ[P(CJ1^S:(XW-=9=62MO#
M;;)).7/_ !-<GF4!?((K$<&A0-H;=QBJ?;TWD2JJR_\ NFZXLY2G"+X,7R,_
MX9"K_EX7<QZ2VDQ&RM'$38+BBA]?N^BIVR(H&4B"D($C3Q@A+BE$HR;5;.IG
ME9V:G?3W?/-PJU\ON$5W"(CU1%W;0(HMC6V:IE*DN.PX_P X^RP8-YN'[>D)
MV\<5+%4AN"70^C:_^JH=51>ZA%,?19#9#*<"6TS8I662L*4/%XAQ:7N5=V"S
MA"3-DF*. 1INZ(J=1V[G"+MTC=7!1B>E>MJ;CE%VS6S>L_W2RZ.2-O\ G=Q*
M89?\QMZ(*QUW;>GZ2D79O_;7"66:S"9K0GV_8V0+^'OMT9J*L?-[;5@PI$KA
MBG5-X_UNO0"*G!&>E=VREL*Q%VTJ.LJ1X2)8\H?[Q"MC_-*0=4Z.*7WKMW?\
M9HBY?2-V[!%8L#B')F'95 -'YV02U6I$;BH=\\3;KV!_K".T2ZK_ $;4WD55
M]WR7<2:0V*HVVM\K*K5/5ZW[W3'1;\Q&_EQ;_04T#=O^_IU_20BI&QC;*P!;
MGMQ6W8155832I.Q>9XET)6UTXM@9/PGP50$3W")]/ZREU BZO"R35KW?,E-O
M17TO&&&2[N;?[MQ6]V-_XB"QD[*(V@MJ**X*CU3^*I%5/?[<#HS#&<C4UN'>
M$QNK*B"LZK[U'.!9H@[8R5 4 R%"ZH1?;MZ&3L4:#$_E!\6Q\(;('&*/8X-C
M$LOGYAED+[_F]SX=QY>Z@JBBC71=J]>VA$'HIO$LIUQYQN&%O-%A1BY7'^/L
MT;@T0>>HQ9;9KO)0^J)]O4D+>)%PYVT2*;;TB*ZW$EI33GV%.-A[2TM>)Q<@
M$K 1DR#)=Z;UZKNV]41.X1%S+"(J2A./8.5YS77)-"#;BV=A8C?5SC=_#>\X
M'4JHKZ=T@3H)-+NZ)T[90BG!?Y\7 G%YI-P1EW2Q^E;9UX6ELK6/PVO,4&[.
M,)J)N(*E]XK]W78$_:H5$T$48M-V69\1MAEI*1B0TYW<--*&8'>R)"L%5]M&
ME4-ID:=PD'JO7N(4KF6D8HL\76ITF*\<CY6L9;)9>5/I7U*#/H2^0 FHS+8B
M)(!"A$)=>G3<<(%6N*?FFX-@@SU0Q9O"8W5C%>MY'W8^Z"S4 [1P1[2.[=VY
M%+HB_IK**D$8J,PA&+8I$"7$.!5*!K-HIZRKA3O;5WSB-RKD*J*(EN$4#^@M
MRHV1=74:)B8+SDB:CT/_ !SQX_1<W!<<='M8X(ST2,XH[5Z-DB]04>O1>[H@
M4[R)W&C;E.QY81)HUMJZP10L=AD-,KM5;ME/ 'ITA40@(^BKM7ZIMZF1=2&)
MVNBQ+,X/RY.+3;7%L/DUR4G?W$CWF[TIUE]9&W^KXZ]=G3]+1%W15575*<KT
MEQBO"PL@9V0\CB"MQLJ*@1GJ,:>RJGO(?N1#'ZKU^PBAZ VQ"[12H:-0W$I3
MD,JHX4G[?VK^XA*PZ2B1%5>AJJ;B0=R?Q%(DD8:QYX.0[*1$*1*.?4--GY]Y
M.\FC5N\JG// VZZ*HJA"*B);_KTV]#(JL2+RA=^219NY@7+WL_X5(KOW#*V8
M\TWYBM!:@RJQR=VJ:&2'T55[:$5%'&.,.K1EJPB16UB+45\AHO+Q21\?;"5C
M>*4\R>B$T?;0#(T0U%/KNW 1<OBP4.W&0$V<#K!K=,1F2%[,#^!KP23CVRP%
M8[79$6N@*"=P"'K].XI%6&1)(W?(*,P G!'N28_PZJ@+8U1.TDYHI@@=D^("
M($HH7V$7V]-I$5,P$,6(@!!M&X8V+!QZ4@=6QK[+YN<17TI[SC,ZIU]>ZB+N
M'M#NZ+U[8D7"("LRN\](FNNPXR7$N,RK;&7L_#V*#%Q]L+!4C2&E7>2@O7[=
MO54+N"1<]-K+2LS'8CK4:6%3.?81V/B3'QM=N@WH%/$9<KKT)-Z]5Z]-R=-Y
M$78PBJU*3Q+(8*VK[C],@N)83+)+^&8Y!'?\U#^);D)WU'H@DRO7:G3MD3[5
M*RI))4SG./3BC01E7+;"C76\$)]R;5'!;280M64?<:.$B;NAB7W==@$5'&1@
M(E:C'F0VF6&TI(TADE>PHOV[+!7<DW6"J^"MJ0]'"+[S$>J]>XA0N71C>+9=
MR/8O1G'I16D!EHQEY1,6+5"-I2$D\28A"(H.T5!"+K_5V]3A2J_J?G$16'6>
MADVET+/^&MU_SS2?MTV_+V+;$VJ,(XH[]_W].OZ2RBH(WB)&A"$:P:AMR810
M*<T,;"@F*_;D=M;.?($1U\HNFT24D%$^G7<J 1<JC*L6/>\R83T5KYUR.P2#
MFR+C7;Z8V(V"I&)1V]4;(>A H]5Z]W1%4KT24T7ENI*!FR"!:I'58./P5<HR
M>I;4?-07K"40"K9$FY4 OZO3H9%"V,/:()%LA@I;-/C0JC@6;=BN4FXN2./)
M.5Q*8I?\SM7[>P*KM7KVM$7+*=7)1')=>DE'@#;6;;&V#DT4(]L+=94 D\@C
MS(Y$2F0=%151/NW=0(HU4!"/LD/QB9BO)2O.LJ086/[>:3MY&!6")*=Z*I(C
MB_520.J)^HI%V>&)MLA6+9%".5*.;1@!K97$[Y"K4+RN?\\'$JV"7ZBFT51>
MO0=NTR*=GHEBCI3#.Q[+(/7XL;:J57I?3E:QUAM)A-C:L-]6S<0-VY4+ZJO;
M$BIHX,BS5H 3F(K2PUIZYULQE8BZ-/:B<V_/Y CD17&E)O::DB.$*?7KO BX
M?&,C-P+H3GVGFI*7,)IDAE9B]\+7 LG'U2P$F&Q9Z-;0445Q%'J/3>1%5N[E
MLB-9JE8",T(UXC/^%UT!;2N5R@EM^:+9VCZ;1 U%"7:I?3IL,BA:&*BP@2-8
MK!"=&<C4:B?R598_,VI'D$Y[SB<.IDN_<(KN% 'KT7JH 2JC%6NL@G'9#[SL
M.*-S*:84&LU;^!ECV<= 9ZI&=$U1Q>W_ .C9U5%[@D7=113CDV^\U(:CSQJ)
MYL*<7$HRU]2CE;>-I8",J8X0J8J?_!U3J/3><*%RXD54?%69Y5Q61.G1())9
M2;%,DBNID;+_ )R.?#M2>CZA]!['W=$Z=HI4J1OZ3]RS#6<XS!"9<*SM@74(
M7[96Z6M!)J@S8QU)5,Q'=T45^[KT BHV0C(S4HT$V,+,9M:)I]@S<PGKCKH;
M\DW6!=]>VI#T<4NAD@]?^,0BEDC&5N>)LSW8KCTQ;*I;:))^23$:J$"UIW/.
M;)F$P/02$=HJJKUV[44R*I^[Y17/D$^0WJU\YV>M9\;\YU7&NUYG;6W0>K7<
MV[]WW].OZ>B*E9&,K4 08GC%;E0RJZLFR\W&YJ!<]RWN'//,WH$A"Z");D!>
MG1"W?81'^WV9Z.G+E@[">2[:89)',TW8ZPV2XYTL$\95;%!V@J(IBH[D_B:A
M%,]]);9C+)N:#,T*^X.,IU]# -^F5^DLA6:(/64O8G;,DW+T7^CIT<E%'MA*
M+ I$L5A#:H\%#L)+*/:+DTIPLE>?\[N+3.225]!5%'L?7;_Q0DJI.B(KBG,<
M<?<9AA;S@CJ$;*6/"M^W6TH+.4(TP#53)0521.B=5W;@(J<E;08B-/O1GF8S
MJ4S[S.]K"P*BBIX^1(MBGE/.(NX=_554T'JB)W"(I)(Q>W/;<BV3T(I3Q3*0
M!<6SM)Z6M8K=Y =\\#"JCNIO(4VB0%NZ)M0#(JL5))XF,]1G)XHOW2QU^-G0
M!M[%6\>BBLQ0;LV )6S<05+JJ%T55V"1?-:"*,6I1H)L1AAF,5+#D,EW\+>2
MDLQ6;D2E8JK\<F55O::DB.*B=5Z]P2*26D8HMH#S<Z5&<\@KB!':+RLN?*FI
MQ";0+Y[9,QVF01M1 AW.@2?3IO.$5<\KB2E/Y%&YWZHM71,?X=$KSN(2E0OM
MK,%L[1X.C0.**$I(I=$5.V4HJ%!B]J$V$6Q&&W+C%#IC%SY&FGK9VA+?V3GG
MD9U3IKN0%4A0!Z]"W;0(N7$;5F;WG)$Q7H()=&PPH#FK7[?E)X^.@-BJ174Z
MH2]M?KMV;NBJX)/4I7!^QE6I9Q)+466-98/,(Y$Q>*4>G[U7<MK/$9,QW:B@
M1KU7HOU'IU,H70QAJV\VL2R6%\JZ94.PULW[/]S,N)D3;RSD<2F"4BR-J(@]
MA=VU.G:T4J8-RN$2SB>E'&K0L;8&-L'(82'>=FGJ@2<81[!@C(G"%.O1P/J7
M7HV14[2-!"KTCE+@"U"VT8RF")<+VX\8=<C$[#^95L.O5'"7J9(/7_C=*(N'
MPAK&G@<:P?ANR9IV-0VV7GY%,ZTRC<U!+8-DU7L*GU$%$2ZJOV[?O(JT5)9H
MFMCNF[@!;P6$^,<K_GC5<>$$FDT-KV?T$=VJ>[[^G7]+1%\]D(Z0:T6H]A%B
MMN02JJQ]H_,Q>4C%JGRUV16)%(A']4V&I"BHG];KU B[OHR4>T%_S)8O1R^<
M:C,D+N:_[N1F^YCB#8HL8>V@AT!1_4 AW?\ &J15)DJR&B&<0S09L AW'84J
MZE@+.I>]16#2S0;=LY*   2IN56S+[>FTRA0--PU8C"$"S&"-LRZQ1$!C90K
M/]R2G/W')<*<IK4%)_F-OW"C"==J]>VA3HN1Z=J2KLAV0\XQ#2XFLQ]D7+8Z
M5UETA4;0SR%B4.Y2)0^OT0>I(6\"(BHC#':ENPW6XKPU$AZ/O9P]M*B%UAY
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MRP1<==*9(3%%F8VB78C;UG7+B(P[ZG%,A)>K@)N=1#!7%:5"543$F,0PWTR
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M.W'5%>"L2MA;W^DW$T3BD/VJ\ODIW&C9Z"R7]+B2&MKF[IXW5-%*E?)HU[2
M,TI;4Y]O'BF8OMSAL1I$+(R5QO<G@H0BFTV0^]-X+U9Z1V(NQ28WUD_N%L&_
ME5AKE7FXOU1_]SK'7!DZQ5!=LC_#^BCY.Y.F_P G[]2GK7"=GH+'CM1RB!7O
MN48S,8_W(%P;K9DJ(@+_ +5M-$ZDX*]I>V'T>ZE"A5UEV*UTDA:C8P'.PWYN
M)].5!_;2=2)48;9VJT/7JWX[6T.J_P O]-%.JFDR8P-S'RO@AMQ3FQGLD2;B
MW^Z+JRZ%%Q7]:*;2><NWKW6W338FXD-6-$U4H(WWVHR06]X2F9/[267CG2"!
M9++(,T^@K(0WC%9:(CBEN'H()(W:(J2,]'*-!>&W:L@G!$:8O5FXG_WBG\=<
M&E)^A%;CJ@ )/(K#;**@*H+VT=17K1'GXP1)YN6352-?',9$Y)N)(G%Z_MZ
MXL/JZRY'1.T8R/UQ?!1>15_E^V*%"JW.TKCD=8C;CCR3I*8MY>.(F1"W:5.[
M+%WB+RE%,A->IMHBO(C@*YVNA2HV),=1BR$R$7P<FQX@94DS%E*Z?2]L6?V=
MT9B"WUCO?RW1ML'MRJ@GW^X6B:J-IQIN.0]QNK6!%CN/5WF8JJ<:"M%:?XD)
M(RX'5]M5;^]7VU$EVHC/=ZPGV+A5:6.ZV@-6"SH\QUJK.9BZ)R2*5%4I7!]6
MQ:3:A(VO3LAT3J8]KM=)353.R(W63(_< ; L),,LJ29C'6I>_<,%K]E*CD90
M19#R^(J&!/[A1"/R-A:(NS"M(Z$<F0BN,M0Y2XOYF-*F-ME8W>S+![0=Y5L"
M;/Z]PP565V CB/=2:JD8=CN18QA."T"QCLI'G>;B2CRITQJ6?9566&V%3LMJ
M[U9&.'1GJG\OO%2A=SD1P8FNK=!$:A+,9>N5F8DG^7Q>)3E\!U.*3*(X)":]
MX7B3JBF6Q6DT4JK!&TEN15AMMNK)*7^TUF8\JR$3)6"7-E3HLI#:<_FOJYNW
M_3;Y&W10J2-(C$$>0EVU("6]!C,Y.D[%%_>;PO7.W&D[$=&ND-1(4[8MGU5=
MA=4>ZE*Z]V.W&DH<YNL^/A-*^RDS$]O%(_M950PZQR9Z-M&AIWO(:VN=43QO
MMT355*DSWO'5L.Y*2SD-X^LS&U7,P:.B[N4=%'O(L!2%%VFT**^G<!55CH1=
M ?CJ225OP)M;%J'^[O+Q92?=7*7&$P7[(B)T&0O@(B DA2/HCGE=3T1<139%
M29Z-Q"AMP7G<>\W%E_80''N5"^ZLBI"D[:2)N-T505V"(H]U(HM[! 7WM3?D
M8CRLQ_-Q3;RH*8TP2R#ZM"*(+?V_:K#>T.I=8^U-$4KTB.)SI!7PB,=^;&=R
MQ9F*HN,.%8U(_M'HY%Z#Y#G0?UFW'.J(AGW%:71%*QV4FC$5D&GFR:EKAJS,
M;5:\#R.P(<U1&Q\SK-< GOXI#N%40$?0]$5*P^P0PG/D@EA/&$U'N?-Q+_O*
M7X:W<2H7M1@;5&VD)].P+'5&E4%[*.BI-5R[(C@U8NG:,P1KV)@2+0IN)=.,
M?\$KG%@J3C!-BALJDE?(1X40T4U[/;%"*H/MC/?B^. O/E,DIB*R\;_QH&[B
MN4\Q5'&UF*44R$E171Z*:;P5WMJA%U9D,(]$D?-B0OR8<1O*_,Q=5OW@NK<$
MPSHW%^OB.;F4[;8.JI*@FKR.KHFJ@!QA$05="&5=#C$_"2;BB_Y6C^W)J)*3
MHT2]'6E5OJ:R&U%>HHC&_1%R9LDO:W-R%F-SWF:3S<41.2 2KI=]Z6YI"3Q1
M)&UVFR&WHK@JVK*(13NR&$-Z0MPR -S#AKEWFXON@OED\5C]C]#87HKSRI!Z
M$"O;NB*?D[3TZ(C*M)+".C+:.,#7R2Q=)>-*N* <JX0,I! ;24JSU A_B&/5
MI>V"$CW4BI6WXYLPE&P"P^1A@L9]9F(?][ _MEUU!^QAMM>C/ZOZ*1F]H=4_
ME^J*352R7XXA)?6X"*$0Y[#V1>9BJ+@QDW2+^W?UXQMHDI%$E[H.DGTWET5E
M-$4RHTM@L98C?=24LK]H>9C7U LB1?WT0J'G;Q-5?_BJNY>FSR-$4+<B.?B.
MI<,N-378##.0#-Q;_?EQ O>N,?IQ^B^&(D2=D6S7Z["Z(]U>M0HW766F9!%*
M;K0@0G5D2$F8DB<4 F,-'T!#CFWL[1=WJZ,AO::JO6-T%"E3/DUY!Q_'!YU_
MS9+>+K+Q5/W>#4JCWY8J.BCZK5D8=5[C:(IIW 4E8Z$U3R(W=9E)?  %8A"3
M+O,Q55G2$R>6RN"?[*O\%]%A=!;&1N'IW%D[CT4+@29Z-@33<<H(0GG:CS<5
MZ<>B5?<"W?"B-K_'$";15)X>B%L% 1[J4J)XV" 0WL6"V$9PV82S<3'_ #10
M<?A;YA(;0IMC B(J@K(;&TZIV-B:(M4KWYR?Q<G*-MOVOL&GWVI+K&1M\&\W
M%)IXZV%8^N.1V7^$7">B3F6%17#:<5!:ZD:.(V27O\/O/ZGZ6_YU8?Q.R_K_
M *'?YEE'B'O_ .G.?<'YI[)X7S!CN4<,\7&S8<@_$0),RPXZ:&YE.#E]U@[.
M._YD0I5@,H9#37QY/O"*JRTK@O+KQ-M.V01.:0\]!_[>B]Q=P.C,S7@QMZG7
M3Z.OZ%BFOYQ_Q<@+K9^TD^:[&B1DL9SG!W- .9Z(5L^*M9:-IPDVW$!MY]"Z
M@$4-RH(KVE<%?;^'WG]3]+?\Z\/XG9?U_P!#O\RO@/Y/O1B7QEQMR[&YY>B<
M?\P9_=<3\:YJ'&^=[\?SVJK<?9GX<Q32>-"N:MK?,;=\RTAC!+NJOD*RC:!Y
M?*7&\Q[>\T5.HT'UKU^=MMK9-W<<:#1VI^I7\]F?:KUZ]1<+;Y ]C,\I..L3
ML;]JHK:*:T%Y991:RKN*Z&04N,XM4W^77,FO: IC_BQG?&90G7T A0A\XH9)
MG;(FU=3U+TEGB@;OF=1O^7HU5R..>1L2Y6P?#^3,*R"VGXCG-?5VF-9E?4(8
M5;9K6RK.Y\'&7\7S3&\<R6M9=!%5COU\1YYEX7&B)3,RH<TL<6NI4>P_9HO1
MCP]H>VNTCUC[=5[!38!C:KC=7X$(''FDEXC_ -U8?MN9_."I-N-"AM]1ZEY#
M2B:JB)'WIJ%5JN[YLFV30M-6*SH\Q]FC69C"#GH)&I.Y?%W&Q3K" A1=I-!T
M--XJ*L]"C5=CE1MSDGYYM &Q=A%EY3,5W1)'[H98_8J;HR)U.0O@]"!7]R=%
M/RNAZ44KEOM=08\9J,45JM?/'@F8S_N4V9WR-Y0(@"JOG*V0IU)P%5A>V**C
MZK"A1 _'=AL$,EJX&Q@?RZK,Q)1Y61<8,_KM8:C$+D<-WZ:1V=@=>GC(J:E%
MQ)D1A;EO+=C%&*<^.]DGEXAUP-POA47&>KT4FA\I>G5'6WBZHF\OJSHI54';
M\AJ+X  ZDD928CYN.?H-_N0C+-4Z"LE#0R\GHCBKO^B!W^NB:JD:D1RC1'AN
M6IP32@LLY 4S$E_?SB-7*IC?5J*W&Z-]"5.T#*K]=B].[UA%PZ['!B893FJM
M*Z&:2)23<3Z<5)^VHKBL(KC#K*)VE1[]87V]CO5?Y;8*2BJ25KN+'6*V\Y(^
M1DABZR\8_P!Z0"QHU/+U0VQ=WP#< E^]M$60G<!7%9VDU75N5%46) Y$)B=C
M&ACER2\3(K1_]S3&DP?JW$V+VGE\'H#0O]2Z"YY.\]$U431,BV+>T(*P6(3K
MU.,[%%3C<"JK/;<"0M&G5Y!($W*^"IUV(C2.:A%SN8*,0"#-CY\=]UJ$4S%/
M^\U%I8*E9%^F#2]&T055.TV@BG4>SL1)352/R(_\]*_<0 #,F;%<R])F+J5
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M,8? 7;E$L! VA8)0Z H)VW-F[M]74*%WEA&<"2PY&@RXTL9<B;2) @K)RR0
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M>D?34CL:!2I[:@ ]R\JO+;C>>P>6\QO,:ZNK/RXP?A,D%L&&[OKR<D065J9
M8VN(!DFE<'"*.A+0USI8L<,]F_DH]7,)_P \K;FWB[V]P#"8J95E_%"<57?#
M6<SL3JZ.XL<K_9N4T]ED'GV=#5,.266[]E])C<=>C2S$88>QET>68>!V1?/!
M?6\8W21>%X3M@U=X;FN=4@:T<-0.TT!WKCT?^&[S/S$/"+3#Y?B69O9!!99
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M.K'^M5KJTIITZE?0O*?,>'@GD5Y;Q2\=XUG/F<;DCNRMI+<NAV7Q%(3'<0;
M_=5X(=4M;2E-=L/ W"]CPGB3.+R>5^>.:%LLBD9/CN2<]9DQEV9XH[.PR)5N
MX]=SJ*LQ2O\ VI"^,(X\-R*\35A-=+N*9MDWO&-QYQT!A,]Q<5>7;IG![A4
M;00UO=TJ!3J2:ZKY)YUS*/G&7CRT6'PN$;';-A\#%P/MK=^U\C_%>R2:<F9W
MB;'/#P"QD8V@M)-YWF'5C7".1+,X;KDI;^.Q*M$GVTPJNJ;:D8HZ%H#D& H"
MH;62;171)11'-YGD%I:K7&IRVBN(V2VGCN@S.[UE\ %,MQ'<.$_%&R&,60'
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M&6-L-E:N0+4>3"?CTBR*+R,6?\B[_P!YY;GR2]V)+^O1 -TTVKM!55Q (HW
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M#4H4JLQ]\YE:N0+,B9+??QM9%$LF\D):U9)E49Q;-%&&P:=Q4,VC5"^X.X@
M13521MJS1DI,WR32-&+*4=I1AV3 7MILQ1H6II/#,@D1-$793ZGU0R=WB)0J
M2(TPVQ7M!$<ALPFX90*EQ['^]QZJ4=FWYUF3=FZV\T31$RG;.0B$ZFWJUO<
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M)JW^I[O_ !NJD<)OJFN1/N4^X9[W];WOT=%W;XX]P&R:V^XF/]IJM<AC%_\
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M]W6M1ITT]:@<)OP17)&@=4_ 9J--/>T[=>NOJ4@\:>X*/-FY[D4<B.-E\B]
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MS/>"0,.)ZO\ 'A18+HN@\9Q&YN333?-]P$4CF%*<14Z@0K]=2SG&)&S=B@:
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M<7N$SJU8[H*"NCB>WH!4U[:*B*[O["-[LOL,#*4D9U-335H'9U)H*=@*MA^
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M8?CKYSXW"Y##39/$MEAD@(JUYJ"-*]KNPZ4/44(U!7I;Y3.X[-P8K,.AFBN
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MAB2X]NQ6>-/5UL9<IXG9:N+ZB;D."MH8[?;?8Y[ 6]QSMH.H;5IK2E"TFH[
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MV?XD#MKZ4[#]M0K3E_"N+\\Q8PO++1MWC6RMD#2^2,M>T$!S7Q/9(TT<0:.
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M7@?7^R_-#ZGAS!6^VK?#'OUPYQUPIGF;<2\B\+5TS _9?DGD#$V8/[)XER#
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M)5WD=S58_306^[-MKNQAU59#:3^ER5/GO,18[:?^DS1-2 7&C025#G-:-SB
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M[?\ Y$\F&16P..<<3Y+C/@P@4&;#+.>LJB6%?7T[6-"\+TBI\V,XRFWY"37
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M_P M!\9G9#N;2;$A!$(2Z(J2,R6FL=M:M/['^8A#@@\4ENKMW_2?YP5/C/\
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M-NYL:JO5JO:>5][>^*HT!;45>B+G^,86TY!F(\7>W]IC+=[7$W%R7B%FUI<
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M VVCF\>WC;2,2F0F(?\ ).:]CFZ:4J6@= K*XL(+GO/,C90*-<V1[2SM[E'
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M:/\ ?/M*1_=M_9'V*+5*K31$T1-$31$T1-$31$T18\<4>UG /-^=Y]QEQAR
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M. W-(T7D><>"N#_7+TDX5X'Y:]A<DXPXBPC(Z./F[F,UUHN0\[SI=A<93DV
MP8&/.R<CA5>6W]G,EJU%&241L&B=-09)PLIPSFO,N?\ G%F.;<6P-ODN57EO
M(;<3/9X6-:UL<,-RYTH$3GP1,C95Y8'DN#15X:,3S;A'"O+WR8PW!N5Y^XQG
M$[*XC%R86/\ %R;G/DGFM6MB)F:R>5\CZ,#S& TO<0PN.NBTM/7K!/:GTFRO
MTWX2]@> XV0<\83QWFN6Y=C^;XMQ]R/BN79-CM-/QJM<R_([B9=6C5;+E)+
M6V&E9> W.Z:-DWWZVMN>9KRSYCC/-K,8+.2082XNK>""6WFNK2:"&61LKQ!%
M&V-A>UFPU<=S2&[07!WSW=77 ,'YH<,RGE#A<]@H[C.6UI<3SQ7,-K=P3S11
MNA89YI'2/#'/W@!HVN!=O(:6YBYMZP<&9%^7^@C7&#^8S;^N,7V(L _<N81_
M(YBI>6[2JK,PW1<@8-KQH%'%;^/!1JS[6XXQ$1J7)L/YD<TL/\*<\EI>['Q<
M@.+;\& TL)+%CWP:Q&M72//BFLPK02   ==S7EIPG(?XM8([NRWLEXZW*O\
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M$ [2#3T$+3>2>8?!N'W4=CRG+6&/O)8_$8R>9D;G,J6[@'$$MW BOI!"MO\
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M^!D7KP(..L0\@LZT%FR"KEEFLL1510DZ+]!C=3:0-"?$I_NQZ6>C371>5O\
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M%]<E;YS$6N<NLA$YXMYX=.Z:AY(K]9&ZOI*QES@,S=X&TQTK8S<V\VO>%#&
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MW*NNQXKSZY_C8A%.^UO#MV[IXB7%H86 .=$^(NHUQH75<3[Q*N/FI>VA]/\
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MWFS(&S(FPYGYC<!RGEOR9_',G)%.TQ,F@GB-8[BWE!,<S*Z@.H6D:T>UP!<
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MC:_:=G0K+/7+UU5-$31$T1-$31%KC_+9_P"[Y]@/_P %7_MMXWUW_P#PN?\
MQVP7_P!M_P#\?=KYY_Q6?_ //?\ V+__ "-HO.4OL1^0Y_$Z>MQ[\==172#Q
M^NBT^37_ +9\465*P25S(0[6SQ^KKH%S*ADB"X<9J0T\J+M0Q7ZZR%YP+R&9
ME);B_P"?2R1B=YDABPEZR0]X[F,E>YT8=V![FN;VT/18ZR\P/\0#\5#;V'E]
M%'(;=C8YI<Y8OC'< :]\3&-D<WH2QKFN[*@ZKX^+^N&>^O'HWRWCV7^R&,<%
M<G\G9QD_+_+W.-?%?E8_B=WG=K2Q[ZOQ-^99XS*KY4ZDJHU;'F,J$AN8^9Q&
M^\K)I=9+S P?//.;%W^*X_<YKC>.LH;&QQSB!+/';,D,;IPUDS7!LCWRNC=5
MIC:!*[8'A6F,\O,[Y?\ DIE<?E^16V#Y+DKV:_O\DQI=%!)<OC$K("Y\+F.=
M&QD3)&T>)'$Q-WEA6I?V.Y(]2N)L8QOD_P!&>:?8F_YMPO,Z)R^SZ98<M3L,
MR2&VXZ%M&SRSS.!15$MVVE--*C,(/#FMFXT;1M.(H?47E_Q_S1Y1D;CC?G/B
M,!!PZ\M)!%;-99-N(G$#8;9ENZ1[0QI=WI#XD9#7!P<W7Y5\P^1>5/%<;;<E
M\DLSR"?F=G>1&6Z<^^=;S-!/B"Z?<-BC<7N#>[&/#D!<PM+75&P/W,]<\&Y'
M_))Z@5E[<9]#C\RXYS3^Z3H,UN*217?Y=\6/R*/]I/PW!/&/+.""3_&Z>:*D
MCG7<NN%^4?/\UQ__  ^<KN;**Q?)B+C'^#XMO'('_-7@$GCAP^-MW'P]_P!V
M:;>B[UYP>7N$Y%_B*XE;7TU^R/,6^0\?PKB2,L^4LB8_ +3\'=M'B[/O!7=U
M5)7^O53[%?DO]\<:S3+LUJN-JK'O76?D^&X7DEAB*YU:O\1XPQCC>17=,<>X
M=H*)H9SJPFGV@D2WF'#5>P*:]9^>77 ?\._"<CB+6SEY#+<95L-Q<1-G^68+
MZ8RF*.0&,2R'PV^(YKBUC7M;3>2O*#@%KY@_XC^<XW,W=[%QV*WQ+IK>WF?!
M\R\V,(A$LD9$ABB'B.\-KFA[W,<ZNP!?(XUXZS:5AWY3O2_%^0<_NL>X:CX)
M=\$R+O)[:=DV-6628MD6?5.*0+T) 64:F:N\,KXH@T2 HF\XK2F\ZCEUR'/X
M>++>6GF[DK"QAO\ +NN8\D(X6-AE9%-%;/F='389#'<2OJ16H8W< QI;:<<X
M]F9<1YG^3N,O[^;'X=MM)C#),]TT+YH9;ID#90=XC$EO$P!II0O=M)>X.\7S
MQS?R3[2>G/ICQ]Q/E=W6\G\E8#R#R;F5WC]I90;AY_U@XUR.'?ULJ7!=&?&'
M-^28K34==^XI(-_<H;E7+\)X;Q[RU\V>79WD]K#)QO'7UK9P1RL8Z,#,7<3H
MGAKAM/R]H27:4#"[0&@6&YSS7D7F;Y0\.P'%KJ:/DN1L+J\N)(GO;(3AK.9L
MK'.:=P^9NV@-UJ7ANI%2;\93S5<>U_*'XQ<*QB^LH$3+J(?:KF)FFG3*UL(N
M#4;3,"FLQJGF ?J;+.8-Q5/,EU9)Q014V]>FE8SA]IY8\;\Q\QD8(WRVLW\&
ML#(UKS6YD)=(S>#1[+=T$S7#O4J:U6\Y/F5YYI\F\M<-C9Y(XKN#^-WXC<Y@
MVVT8#8W[" 6/N6W$#FGNUII16<YMC^E/^:G+D3VU]MN4><.7[/,KW]G8%PXO
M)T.'Q-1,@S'JL%QW&<$7)<3AY3C[N]N2=A,19#@(;\='_)-W;.'2><'\LXJ7
MRNXMC<-Q2.TC\>YO_DW.O9#4ON99KGP9W0RBA8(H^Z"0R39X8;J',X_)K^:,
MM%YJ\KR>:Y;)>2_+VN/^<:VQB% RVBAMO&@;-$:AYED[Q +X]_B.=Y_U\/F'
MV,_%[SW"K^0.0[+D/@3FC,9G#>1VUE:,YZE9Q?0X3G5;C=RZ<R1,FV$VNO;.
MN;B/..,L$^RST5M@$U?\['$^ ?XD<'-/8V$>!S>(@;?Q,8PVV^\DN+9\L8VA
MK6M?'#*7M <X->_WGDJPX"[EWF%_AGSL,%_D).08+,W#L?,][Q=;+**VN60R
M'<7.<YDLT0C<2UI<QGNL 60'L1[ S?:KAKT2XMXWO9])?^Y>9XK=9N]C%K.K
M;/'\#XV99N.9(3$FM<CSX[M+D$8VVW$, >^,>%%5-Q!HO N"P^67+>:\EY!
MR:RXC:31VXF8U[);F[)CL'$/!:1)$02*$M\9A.M =]\P.>S>:/#^#\9X[/)#
M?<PO()+DPO<Q\5M9@29!H+"' QR@@&H#O!>!I4C<RTV#+;;+0H#;0 VV"?T
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M/^81<.=<- L8[H'*7-9G"XK:_@I?B,\*6.(%_P!V?F&2LH[NM:^CAF5KDB[
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M'UC7E#BGA6M]<+W$,[Y!R?-*/GK.[#)&\XJXV4RA(G<PQJM@&YE61TD9O?'
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M_P"G<?C"_P#YF_\ ^C'L'_\ VGUL?\H\A_\ =_\ ZR+_ &UK'\Y<;_\ >?\
MZN7_ &%?;"_R0^E_(?#/)_L%A_,OS'$/#,NI@\DY=_EWRM7_ +;E7C\.-5M?
M 6F"PLGN/*?L&1W0(4H0W]3440E2SEP.6@NX[&6*EU*#L;N8:TZZAU!T[2%>
MP\AQ%Q9R7\4U;2$@/=L>*5Z:%H)Z]@*L<Q^;+\8LE]F.W[.-"X^ZVR!/\/\
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MD5'H()/DYCQM+*>(&N\,D':P%C=)>_J[Z1ZJ&I/Z@?Q%>A67<)P97LASG7+
MY2R[#JC$^/L;?::BRL-XU>JZ&3WKZK^.A.UV9V*P&8KHN[Y<>-',7C)R2\B?
M%?GUYH6/(Y&<0XW)OPUO.Z2>0&HEG!> UCJG=$RI<".ZYQ!:*,:3B+ZZ:X&U
M@),(>22:FKJG4'<>[V@+>/KYK6-31$T1-$31$T1-$31$T1-$31$T1-$31%^?
M7\T7I/DV>LUOM%QGC<_)W<<HDJ.8L7H0!+N344L>?^U>0(;8Q9<N<WC06+T:
MU;: S\ 6'-HM1WG6^^>3W.;?'QOXCF)"VPEE,D)J&_&+"W87GH":%H- 7$BN
MXM!^@?(_DMK9Y3Y".:ULN8F(6]A>70EEMV6\UU;SWMF^%L\,>^X$ =;3.J8I
MR:B1KO E_,-WYOGSI#MA!-78!LR9(=@(\N.D6,CD"(:1E 9I,[014!"W(J]?
M^%?I'=<"[DFED:ZL)!<- \!K28VFE-Y;M;V:U]J^L;:PX=_+.,QMGA\E%#;Y
MN.>"T/B&XL[DWTSX\A<QMOA.+076^Z,LSYHW0$4BD%(UT)]PY%:Y D,QHD><
MZ]6-2'&I+M.T4]";.TD!"9%Y!-1(C(%$T15VHGVZ])))"^-]K(&VK)28]VIB
M&[1TII2AZ^S16UE88RUL<[;<LQ]S<<GO,3;19.6W9/;09E\>/D$L6(A-\^5C
MQ&)6&*.5CVO<'332N9XJWO\ X<?2++,XY+IO:?/*.13\783(DV&$C:@R2\E\
MCPW+") R.D8.%'D,8EAY3#DC) A!^V89!LG1:DMM<-\V^=0V6-FXICI=V1NB
M/FJ$.:T!Q=W7=GB"@#.QA<2!5M>#^=W*<386,>!A#'\A9 8;8-$\4N.QL\-I
MXEI=CYR:">\D= &OD=%XC(215CG.?-^J?7S ODY-$31$T1:K.6?33EW-?RQ^
ML?NK3R</'AWB'@Z_X[RN--N9S&9N7]G3>PD",=32-T[T"97H_P H5NYPYK)(
M(O+L78*'L=ME;6'C5QB7[_FI9@X:=V@,1U->O</9Z%K%UB+N;E%MF&;/E(H2
MQVIW5(E&@I2G?';Z4]?O33EWC'\E_MU[;9))P]SBSG#!Z;'<,CUES.E96U/@
M-\<"^MW4.T\:'!CJN*2MI-RWU7J'T3<NU>Y6UN./VN,CW_,PO)=4:4.[H:^L
M=B6&(N[;D5WE9"SY:9@#:$[JC9U%-/=/:N?QB>FG+OJ%_P"*7_-:3A\C_./G
M&?R)B7[2N9UQVZ"3\GVPN/-IZGP[#^;#JV'>%/K]^G(<K:Y3Y;Y;=\*$-=N%
M-=.FIT4\<Q%UBOF?FMGQIR]NTUTUZZ#5<<3>FG+N%?EC]G/=6XDX>7#O+W!U
M!QWBD:%<SG\S;OZRF]>X$D[:D<IV8$.O5_B^RVN!->)1)E=B;R0%SE;6;C5O
MB6;_ )J*8N.G=H3*=#7KWQV>E1:XB[AY1<YA^SY26$,;J=U0(AJ*4IW#V^A?
M-_(7^/KD;V#Y$XD]J/5CDRLX=]MN#6OCL9R"]22&,Y=C"2K"6U07LF)67;L)
MV =S8-M[X,R'/B6,F',:)EP'&*L'FX+&"7&Y*,RXR;4@=6G34:CK0=H((!!K
MUISV!N+^XBR>,D$.5AT!/1PUT.AZ5/8002"*=,.\_P#2G\K7OF_B'&7NYRAP
MIQ3ZZ4&05=[FM!PNLA_*.07:@S<CJ,<8T^([++<0M%+GQX$%XPEI DNLMAK*
MP9;C>&#[C$1S27SFD-,G1M?\NP$GIN *Q,^'Y/G"RVS,L,6/:X%PCZNI]?Z2
M .NTD++CVI]#,_Y(]G_QR\B<.1\(H>(O3VZB,Y#1VMS85]I!Q*HM\#*DK,4@
M,U-BU9+!I,5-H1>D1^BB";EZJJ8O&YF"#'7\%UO==70T( (+B'5+C44U/H*R
MN3PD]QDL?<6FQMI:'4$D$-!;0-%#6@;Z0IOR5^@&<^R=QPY["^LEWCG'_MIP
M3E=/.QK*[N=+I*S)<3C6"6'PE]95E79RWG:"S3R(0N-DP<:1.C.(0R1V,!FX
M;!DMCD Y^,F::M&I#J4J 2.HT/K /8IY%@ILB^&_QKFQY2!P(<30%M:T) /0
MZCU%P[5M$PJ5ELW#\7EY[55%'G$B@J7<PJ,?L'K:@KLF*"PMY$HK22Q%E6%*
MS9=Q(KSS33SC&PG  U(4UV81"5PA),.X[210D=E1V&G7UK9(3*Z)IG ;-M&X
M U --:'M%>GJ7I]>:]4T1-$31$T18J8*SEP^W7/K]A08A$PUWC;AL,>R*OJL
M+8S.WM&RRSYJ%D5O6I^^9]76H3/@M6:^(SW'/%_K.ZZ9FGXH^5>#9!/=NRPR
M%_XL3GW!MV,^!X;HF/\ PS7O[WB&'ONHWQ>C5R[!LRH\V,\^>"T9B#CL?X4K
M&6XN)'CQ_$;+(S\2YC.[X8F^&VKO"ZN65>N9KJ*:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*6/\ QV/[YO\ MCJIGOCV
MA42?=N_9/V)(_CO_ -\Y_;+1_OGVE(_NV_LC[%%JE5IHB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+"7V7FXY&]@_1F/<45A:6L
MWEWD!K&K*)?#51J">WQ/DCLJ985I5%@M^Q)@B;(LH_#5LR1S>6W8O8?+N'(2
M<$YI):3QQ6K,5:F9CH]YE:;V(-:U^]OA$.HXNVR5 VT%:CC'F/-CX^?<)CNX
M));I^6NA"]LNP1.%C,7.>SPW^*"VK0W='0G=N--IS:UQY=G31$T1-$31$T1-
M$31$T1-$31$T1-$31$T16'YG]8> O85NL3F+B_&\TF4;A.T=Y("94Y32.$Y&
M=-:7+L?EU.3U*&[#9(DCRVT(F@54ZB/3:..\UY5Q,N_E^^GMHW^\P$.C=U]Z
M)X=&[J=2T]2O2.62*OAF@<*'T$>L="K(XE^-?TCPNXN+RIX(J;*?D,V/8Y &
M:9=R)R-67TZ-.<LV95U1\@Y?D]+;/C8ND^I2([BDZNXNJZV2_P#./S*R-NRV
MN,K*V*-I#?"C@@<T$4(:^"*-XTTT=IV+T==3OV5=]V*-H *"E-" .S19MP8$
M&KA1*VLAQ*ZN@1V8D&!!CLQ(4*)';%J/%B18X-L1X[#0H(  H(BB(B(FN;2R
MR32.FF<Y\KB2YSB223J22=22>I*MR234]55ZH18=<E?C_P#3WEJUR*\S/@_'
MEMLP1?W?-Q*XRWCAW+B*T8O''<J3CG(<4#(Y#UU%:EN.34?<<DM Z2J8"J=!
MP_FKY@X&".VQV3F$$/W;96QSB,;=M&>.R38 TEH#:  D 4*]V74\8:&NT8:M
MJ =IH1I4&FA/UK[_ !-Z3^K'"%A2W'''#6-UMYC,+X[&,@OY5]GF18M7^=96
M2PL7R#/[?)[G&XBSKB4ZK<%]@5*0?5/N75KGO,CG')H7VV9R,\EK*:OC8&0Q
MR&@%9(X6QL>:-;[[3T"A]Q-)NW.]\U=32IH!4@4KH!]2RFUI"\4T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31%@'S-^,7TOYRLY%YE'$D>@O)<R583++CZZN
M,';FV,\FSGV4RDHY;&,2[6<3(J_+<@E)>5$WN%T36]8CS)YAA[86<%VZ2S;7
M:R4"0-) %6EW>% !0;J"G1= X]YH<TXQ>NR.+N6?Q%\$4#II(899WV\+G/BM
MG7$D;I_EV.>XLA$H8PN)8&DDKR7%OXD_1SBNR"WB\7SLUG@VPVJ<BY1=914R
M$8>9D#\ABZOPL4M@*3'!Q6Y<%]I#%%$!Z)J[O_-7FU];OM6W7R\$@(<(6AA<
M*U +M7"G91P/I)5[RCS=YMRZX@NLO+:^/:2NDMGLM;<2VCWQNA>^UN#&ZX@>
M^-SF/?'*U[F.<PNV.+5L@B1(E?$BP($6/"@PH[,2%"B,MQHD2)&;%F/%BQV1
M!F/'CL@@  (@@*(B(B)KG;G.>XO>27DU).I)/4D]I*YK)))+(Z65Q=*XDDDD
MDDFI))U))U).I*J=0J$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$6%
MO&[.&#[R>S3]=99.]F[O$O H9+5S:2JC8K"J6SS;X&117S&02[>TL9:D_P"6
MS(K8;<?:';=>W%LZ]R!^7/DQQQEQ';###*9+P7MD>9G//R_B"2,Q-8QK>[L<
MV60NJ=S64%>.<=9AQYV<D?;R7)S1Q6,\9CHV"!K!\SX1CE$KI'O=WO$:Z&,,
MHW:Y]33-+7(5V--$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31%+'_CL?WS?]L=5,]\>T*B3[MW[)^Q)'\=_^^<_MEH_WS[2
MD?W;?V1]BBU2JTT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31%B9SY;9; YL]0H5!GD?%:2WY,S6-E^-O7[]2[R!6,<;7LF%2QZQ
MILV\A.MLFVYBL.**-BUW$7J.NH<'M<7/P[E4U]8NN;R+'6Y@E$0>+5YNXPZ0
MO)K%O83'N%:UV]JY5SNZRL',^)0V%\VULI<E<">$REANF"TE+8PP"DI8\"3:
M:4V[NQ99ZY>NJIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB+%3!8^9A[=<^R;+%*"!@[W&W#88SET3&<9
MA9%?VS199\]6V^4PHP93>0J9"8\:/.=./$[I]A!WGUZ9FI,0?*O!QV]U._,C
M(7YF@=-,Z*)A\#PWLA<?!C=)WM[HVAS]HWDT"Y=@X\P/-C/27%K S"G'8\0S
MMAA;+*\>/XK))F@3R-C[NQDCBQFX[ -SEE7KF:ZBFB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBEC_ ,=C^^;_ +8ZJ9[X
M]H5$GW;OV3]B2/X[_P#?.?VRT?[Y]I2/[MO[(^Q1:I5::(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBPE]EY.+,^P?HRU>4]_8W
M,GEWD!O%)]3DE=35E+8AQ/DAS)60U,S%+Z5D\)^O0VFH\:;4.-/$+I/."*LE
MV+R[CR3^"<T=92P1VC<5:F9KXGR/D9\[$&MB>V:-L+@ZA+GQSAS06AC2=XXQ
MYCR8QG/N$MO89Y+QV6NA YDS(V1O^1F+G2L=!*Z9I95H:R2 M<0XO<!L.;6N
M.KLZ:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(K->Q>2WF&>OG.V88S8.
M5.28IPUR?DN/VC+;#SM;>46$WEI4V#34II^,ZY#GQ6W!%P#;)1Z$*IU35U81
MLEOH8I!6-TK 1Z07 $?4K/(2/AL)Y8S21L+R#Z"&D@_6L>?QG\J\@<W>C/K[
MRGRGDDG+\_R_'<BF9)DDR+7PY-I)AYWE55&==C54.!7M*U7P&6D1ID$5 151
M5556^Y!;06F8GMK9H; UPH-=.Z#VU/4JPX[=3WF%@N;EQ?.]IJ=->\X=E!T"
MSKUAUFTT1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7A.4L@L<3XRY%R
MFH)H+;&L$R[(*LWVD?8"QIL?L+&$3S)*@O-#)C"I"J]"3Z:]K=C9;B.-WNN>
MT'V$@+PN7NBMI)6>\UCB/: 2L:_QY\WYW[(>FO!O-O)LBLE9UGM#?6&0R*>N
M;J*UR17YIDM'&6+7-&XW%!(%6TBHBKU)%7_AU?YRSAL,K-:6]1"QP J:G5H/
M7VE8[ WL^0Q$-Y<T,\C2304&CB.GL"S/UBEF$T1-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T16^Y.Y*Q[B7#YV;9/$R:=4P)-?$<B8ABM_FE^_(LYK,"(W"
MQ[&8%E;S.LA\=ZMLD+8=3-4%%5,YQSCU_P HRK,/C76S+I[7.#IYHK>(!C2Y
MQ=+,YC&Z TJZI.@J318#DO(\?Q3$/S639<OM(W,:6P02W$I+W!K0V*%KY':D
M5HT@#4T )5DF_;?&9N29+B=-P_[(WMSC..V^1.+7\*9/'IK;XK&7\G;HZ?)[
MCXO&'<@NF8ZPX$=^9'&39$,9#1Q=;D[RMR,./M\I=Y;CT-I<W#(ANR$)D9OF
M$)DDACWS"*,GQ)7-C<61 R$;0M+;YKXV;(W.*L\1R*>\MK>24[<=,(W[(3,(
MXYI-D)ED \.)KI&!\Q$8(<5Y?UUP_-<@YKYN]E<SP/,.)2Y/H>.<'Q_CK-DP
MZ7>A0\?0[20SEDVPP_-,G9@RKF=D3[!U<AAAZ(,07.Z\C^UK)<^RV'L>'X;R
M\Q%[:908V>ZN);JW\=L?BW3F P-;/;PEPC;$UPF8YS7EY;M9LJ[&^7V(S-_S
M/->8^8L;O%')P6EM%:7/R[I/"M6O(G<^WN)@UTCI7-,+VM<P,#M[]]&YK:X^
MNRIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(I8_\ '8_OF_[8ZJ9[X]H5$GW;OV3]B2/X[_\ ?.?VRT?[Y]I2/[MO[(^Q
M1:I5::(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MBQU]A.+.4N1(>$77#?+ \69WQ[DDC(J[Y>A+)\)R]B74RZJ5CN9TK%A4SG:\
MQD(XT^R^IQW!4D;,E%0WW@?)>-8&6\L^6XO^)X6_MQ$_9+X-Q 6O:\2V\A:]
MH=I1S7-HX&FX"H//N?\ &.3\@BLKSB&5&+SF/N#*SQ(O&MIPYCF&*XC#V.+=
M:M<UU6$5VN-"/./WGNG6Y-FB'Q]Z\9/AD>KR"5Q\Y3<@9W093964=F.F-5>6
M1KG$)M/5?)R$=*4]$?DMQP(1'>HJ9Y!EEY07&.LZ7V>MLNZ6(70DMK:6%C"3
MXSX#'.V1^P4V->UA<02:5 &.?>^<EMDKP&PX_<X=L4KK4QW5S%,]X \%DXD@
M=&S>=V]S'/# 0!NH2;G\+Y!S+DF+3YW./'>+\9Y8U?RHE?0XEFRY[72\="NJ
MGHEN]<+3TBQIK]D_+9*-VBV-QP/>O<Z#KG+['B./R3(>&7]SD<68&N=)/;_+
M/;*7O#F"/Q)*M# QP?N%2XBG=J=FX=?\PR.,DGYKC[;&Y43N:R*"Y^:8Z(,8
M6R&3PXZ.+S(TLVF@:'5[U!=[6JK;$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$6"GLOS_ ,:W/'ON-Z^O6ZT7+N)>L_*.4AAU^+-?/RW!KCC#('(>=X.JON!D
MN,,V R*Z6XST?@V,-YI]H![+CV8Q]E<,GM;X#=:NN&#<-0UP>.Z[T&E"/2"*
M'K3"9&^MWP7=@3MNV6[W;3H7-+#WF^D5J#V@@@CI7%7\9_/O&_$'X\O13$LG
MMCEY[RY\]AW&G'M(#5AF.7VDCD_-"LIT&J5YGQ<:Q6L1R?<6DDV8-?$953<[
MIL,NY+D%E<76<O)8Q2&*CGN.C6C8V@)]).C0-2?54C&<=OK>TP-E%(:SRU:Q
MHU<X[W5('H:-7..@';6@.Y76JK;DT1-$31$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$6+_*?+O'^5X;[0<6560QDY&XVXJRUW+L,FH4*^@U-_@,ZRH<EB0I"
M 5MBUQ'E(#-C%5Z(DIMZ*9A*8?9;R%M:SQRV]RYOP))&[7=E0ZA'J(]!UI0]
M""L;<W4$L5S;-=^(CB=N;T-"TD'UM/I&E:CJ"%A7^+SEK .+?QM^E,?-<AC5
M=GR"Y9X'@M& NS+[+LLO.5,RCQ*FAIX@.SIZQFC*3->$/'KX+3LJ4XS':<<'
M+<BMI[G/79B;5K*.<>QK0QNI/Z!VDT J2L/QNZ@MN/68F=1TE6M':YQ>[0#J
M?23T J30"JVZ:UE;4FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB*6/_ !V/[YO^V.JF>^/:%1)]V[]D_8DC^.__ 'SG]LM'^^?:4C^[;^R/
ML46J56FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(M$GYW?4ZYY8]>:WV
M5XR:LXG+'K6U<3+29CKLJ)=V_#&2QU@Y]"\BO)F4ZUC .#9EO/M,U:68[5[Y
M(NX\-R3+:^./N*&VN*4KT$@]WKZ>GMV^A:3S;%ONK 9&VJ+JWK6G4QG1W3T=
M?V=WI6(/_EZO5N]NV<B]R^3'+2UC8_5SN$O7F/>294R/24S4IZ=R%>8VS+-Q
MJMK1G3RJXJQ=C:OOVR$.\R)<ISC(L86XJWH"X^)+3M/1H/I-!4U_LK%<#QCW
MAV7N:D-!CBKV#JXCT"IH*>ER_4SKG2Z6FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HBT&?G-]=\]<XVQSW;X'M[C%>5^ ZFQQ+D&QQF2_$M<AX.S!\H
M=E'FBP+B6]9BMQ:..2(;P+%.KLY[K^X&4'6Z</OH?F'8B] =;3$.:#T$C>GL
M) T/6H:!U6C<TL)_EVYFQ);=0 M<1U,;NM?2&DZCIM<XGHL1/_+]^N^9\CV4
MGVTY9LKJ]Q7A6CM.#O6:INY#[]7C;]P[)N>1[K%H+R@Q61H3%\<(76!5N7)M
MK#N*KS/5,GS:^B@:,9; -DF(DE(ZFFC ?3TKKT#6]A6*X)837#CE+HET4+3'
M"#T%=7EH[.M-.I<[M"_5=KG"Z<FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB*6/_'8_OF_[8ZJ9[X]H5$GW;OV3]B2/X[_]\Y_;+1_OGVE(
M_NV_LC[%%JE5IHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*CL:^!;U\Z
MJM(<:QK+.')K[&OFL-R8<Z!-8.-,ARXSPFU(C2H[I X!(HF!*BHJ+J6N<UP<
MTD.!J#ZU2YK7-+7 %I%"/2%X'A[B/ >!N,L-X@XNHF\;P+ Z@*;':AM]^43$
M?OOS)4B3+E..R)D^QL)3TF2\9*3LAXS7ZEKVNKJ>]N'W5P=TSS4G_+L T'J7
MA:6D%C;,M+9NV!@H!^GZR=3ZU<K7@KE-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31%\3)<<HLQQR_Q'**N)=XSE5):XYD5+/;[L&WHKR"_66]7-:ZCW
M(EA7RG&G!ZIU U354<CXI&RQDB1I!!'80:@_051)&R:-T4H#HW-((/0@BA'T
MA6ZX#X/P'UMX>P'@_C& _ PKCRC;I:D9CC3]C.=-]^?:W5O(88C,RKJ^MYC\
MV8X#38')?-1 !5!3WO;R:_NGWEP:S2&I]'H 'J H!Z@K>QLH,=:1V5L*0QMH
M/2>TD^LFI/K*O!JV5VFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB*6/_'8_OF_[8ZJ9[X]H5$GW;OV3]BP9?XAPZ+-E"S)ST4#(DO10^6N5
MGNEC$=?1@OULT<ZPT1TMT5?Y4_IN;7HG34KGGG*#.\>/%2CF?NUL.Z3ZH>NG
MO>\.PK>K;@W&! P^!)7NO^_N/> _YWIK[ONGM"I7>(L/>\C?*SW^:N1OGMO+
M7*S?6R'O]#;[>:#V(?\ ,G_*AMBK]/T_M'IY#GO*6TI/%HS8/PUM[NG_ ".I
MT]X][UZE>IX+Q@UK!)J_=]_<==?^5T&ONCN^I2.<3XDXU+8.5G?;G7K.1R$'
ME?E,#6UCC-!HV7 S(7(T%!GN[H;2A#-5%2:50#;2.=\H#FN$\56QE@_#VWNF
MG7X.KM!WC5PUH=363P;C!!:8)*.>'GX]Q[PK_P KH-3W1W>FF@I3R.'<,E-6
M;#TG/U;N+6/<SD;Y=Y:8,I\4;,&2C.,9LVY7Q4&X?W1XZM1S504@56FME;>?
M<J8YCFSPU8PM'X:U.AVUK6'O'NCO.JX:T/>=6EW!.+N#FF"2CW!Q_$7(U&[I
M2;0=XZ"@.E1H*)'#N&2FK-AZ3GZMW%K'N9R-\N\M,&4^*-F#)1G&,V;<KXJ#
M</[H\=6HYJH*0*K36PWGW*F.8YL\-6,+1^&M3H=M:UA[Q[H[SJN&M#WG5.X)
MQ=P<TP24>X./XBY&HW=*3:#O'04!TJ-!22=Q%A]C\QY4K/5^>N6KZR['+7*T
M3=9,_*=LH?B9HQ\7#_QF1UBQ>S%+J'5M>RSLB/GO*8MFR>+X;-C:VUL>Z=O6
ML)W'NCO.J[KKWG5E_!>,2;]T$GQ'[C2>X&O>Z4E&T=X]UM&]--!22;Q/B4]J
M[8DRL[5O(KV+D=HC/*W*<4SM88W0,'"=BYDR[404'()6Z'$5B&XJMJ;1*PQV
MZ8^=\HC=&YD\58HRQM;>V/=.VM:PG<>XVCG5<-:$;G5E_!N,2![7024D>'NI
M/<#O#=2E)1M'?=W6T:=*CNMI'.XBP^Q^8\J5GJ_/7+5]9=CEKE:)NLF?E.V4
M/Q,T8^+A_P",R.L6+V8I=0ZMKV6=E4?/>4Q;-D\7PV;&UMK8]T[>M83N/='>
M=5W77O.K#^"\8DW[H)/B/W&D]P->]TI*-H[Q[K:-Z::"B=Q%A]C\QY4K/5^>
MN6KZR['+7*T3=9,_*=LH?B9HQ\7#_P 9D=8L7LQ2ZAU;7LL[$?/>4Q;-D\7P
MV;&UMK8]T[>M83N/='>=5W77O.J?P7C$F_=!)\1^XTGN!KWNE)1M'>/=;1O3
M304DLN)\2MRMSG2L[(KRUBW-CXW*_*<!"GPFK%B.408&91AK(J-VKVZ/%1F,
MXJ@IMDK32A3%SOE$(8(YXOAL+6UM[9VA+2:[H3N/=%'.JX:T(J:S+P;C$Q>7
MP2=]P<:3W U%0*4E&T=XZ-H#I4:"D<OB+#YOROD2L]7YF1%E3^URURM&W/0^
M]V%B^-FC7QS:=\MP1NT#GTWH6T>E3.>\ICV;9XOA@@5MK8Z&E:UA.[IH75([
M**'\%XP_=N@D[Y!/Q[@=.E*2]WKT;0'M4<SAW#)[MB_)DY^KEJXT[-5GEWEJ
M*!&R6]OQVHN;LM010OZ181L23Z*BIJ6<^Y5&UK6SQ48#2MM:GKZ:PG=]-5#^
M"<7>7.=;R5?UI<7(Z>BDHI]%%))XBP^6=NX]*SU2O>S\CV^6N5F!+QY#4EKQ
M 8S1L*SH\R/7Q49WCU$NHJJ+#>>\I8&!L\5(Z[?PUL>HIK6'O:']:M.HU4NX
M+QAY>3!)5]*_'N!T-=*2]W_1IZ.BDG<3XE8NVS\J5G:N7;<-JP5GE?E.(!!
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M][UZE/\ *+#^[WO*SW?\-\#_ /-:Y6V_&^)X6SM_O3M^9X_T\KIY6_[^YO\
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M]A_0O$^;,6CL5W/&4XSG.=8A4'R)S</'R<C0;BWI:2)+BSN59U\5#/\ VS$
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M-2X,C:L>;&-'6#<#[M:MQVRNK7DF)EN(W-CEO8"PGHX"=K30]*M<"'#JTZ$
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MHL9LGI$A]TU0&F66@4B)51!%%5=5-:Y[@Q@)>30 =23T"I<YK&E[R P"I)Z
M#J2OS_8[['?D3_(QFG(=MZ9Y?@_KKZV8!D\K$ZK.\JJHLV^SB?#CLS 5V3/Q
M3,)WRC\:1&FNQ(<:MCU\.:RT\_)=ZJYV6?!\)X1:P1\HBFOL[-&'F-A(;&#I
MT#V"E06@N+BYS20&CIQ&#/\ .^>7<\O$Y8;#C\$A8V1[072$"O4LD.X@AQ:T
M,#6N +G'K?/T^]B/>C!_:"R]//=#&_\ ,9V1CTG(<.YZP;$'_P!O%':ARI\
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M<UA<XESM#1U:EIJ*NIKEAZN\]\H7'!N:9/[>XD/#&;\+Y7F&(<A9)<4EUAV
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M+9MYCI8YK5W1S"'#3J*CH1V@ZCM7M]6BO%IU_+9[)>SGK_$]?HGK)F/[6O\
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M&M=MZ 5PO_'O_P"Z/_(A_P#A'_\ 9#C>MIYI_P#$G"?]%_USEJ?!O_A?G?\
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MT20[7.!UJ:[M==23J2L)PQLL6-Y5;R1,MRPRUA8[<R)QCF#F-(THT@-TT[H
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MQYZ-(9VOLO.F8DA$JKE,W=7 YSQ^Z:]S;BXM; RN:2TOWS$.W4I4.  (.A
M6*P-I;'@/([1[&NM[:[R B:X!PCV0 LVUK0M))!&H))!7G^7,3Q7&_Q;^@EA
MCN,X_0S\GY>]1[G)9M+35U7+R&W<I[E#M;R3!C,/6UD:$O5^03CJ]5^[7MC;
MFXG\P<RR>1[V1VUXUH<XD-;N;HT$Z#U"@7AE;6VM_+C"/@C8Q\EU9.>6M +G
M;7=YQ &X^LU*RAYFS7B-GW8Y.+B#TXS;W+]G<>P+!Z'D:59WV,UW%G%=395Z
MSL8HX%YR$-IC^*7U[7$+\E8D5L' -[:X3RSP3 8NUR1XI;_Q/*18O /FD=$
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M'#83K/T7]8)5A*?FR1XIHX2/R7"==2)6G*K:^/O-5+M1($1IEM/_ %6P1/\
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M'=<,YBBXX^PDJ4Z8HA&2KY8J_B%GR>7"2R,QH8V2$ N9LWO<26MT+#^KH :
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MPX<>PU;%&"&U&@+B22X@&@Z-'8T%9/BO <)Q.1]U:>)-D9!1TLA!=0FI#0
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MY-JS"Z,I,BO0I3C0B+SCH@ IOG'O,',X"S_AA9%=8SLCE!.VNI#2#H*Z[2'
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M'GV.0DCMU\;-,-O4"NN9]5'B--19*NAVVVFT,'%985KRQ'+#98W^"Y2TAO\
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M3HJ:Q]QGYY\%:X,,#66LSY&O!.XEY)^BE="-5D;?CMO!R"[SY>Y\EW"R-T9
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MLC8W1H)U/77I2KJYJ:U5;:FB)HB:(FB)HB:(FB)HB:(FB*K@?[=#_P"=Q_\
ME@U[6_[PS]MOVA>-S^[R?L.^PI/_ -NF?\[D?\L>EQ^\/_;=]I2V_=X_V&_8
M%2:\5[)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB*K@?[=#_P"=Q_\ E@U[6_[PS]MOVA>-S^[R
M?L.^PI/_ -NF?\[D?\L>EQ^\/_;=]I2V_=X_V&_8%2:\5[)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB*K@?[=#_P"=Q_\ E@U[6_[PS]MOVA>-S^[R?L.^PI/_ -NF?\[D?\L>
MEQ^\/_;=]I2V_=X_V&_8%2:\5[)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(F
MB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB
M:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:
M(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB*K@?[=#_P"=Q_\
ME@U[6_[PS]MOVA>-S^[R?L.^PK.US^(?_P R[^N7\3^)_67^O_\ 7_\ I_\
MJZ^AW>\?_">O;U7S<WW1_P",].SI]'J77_2S5/Y0JOSE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/RA/SE/]+-/R
MA/SE/]+-/RA/SE=F_P"('_S+OZX_P_XG]9/ZG_U__H_^KJIOO#_PGKV=52[W
+3_XST[>GT^I?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>tm2115679d1-lc_tradtion4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_tradtion4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!3 .2 P$1  (1 0,1 ?_$ /T  0 " @(# 0$
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MM'6C7E^2HEXU#LU5F>[5P\O2JGL2GS[LC)%ND,+<J=<FCMDIV (B55,?II'
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MWO*S9/$-Q%Y#;SW'1=4W?Q.M?(!R.?:8O\]I^U\K-J1]DU3IN'I%OO%4=L;
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MXP:)W[M_YW?-!O+LQN.@T4]'W:S57<LGM^%8RJM$NSO=)F\LC/RIRIOK(O\
M3!8RQDCD5G_#+QHT'B5LZ]\A+7O7D3RYY/[#I,7JR7Y!\H;O%W"YU[44+-#8
MX[4VNXRNUZK5JC4%:Q%)*OFC5H961ERBZ75,/80A%F&CO'!QJTIP$A/&NO&6
M;;_&6*U[;M8R49MZ3B96U6JJ76PV"RRZ5@FJ9 45@E)-Y&QJBS=QS*/<,Q10
M52,5PD"PD4.M3>#74-*NVEY7;_+SG/RXU1QGM%<NO'/CGR7W- V_36MK=34E
MDZ/8Y.'KM$JDOL*4UP!R$K?SEXX0BT$_2,DX(/P(N2NWA1H$ON#=M_U/S7Y\
M\8M9\F=FSNY^0/'3COO"(HFKKYM"WD;&OUOAY!:D2VP-?R6S7C--6QJ0\NW6
M?@)DTE&J8(E1(N8B_!SPZKG#:L<)ZA9^0-,H>JM\VKDAQRV94MG-*[O?C#LZ
MR3L_/,GNE]EPM68.VD;5#VA^U8)SK><<+-' @^7>*D26(1>77/AATS!5WE:M
MN?D5ROY2;JYA<8[SP\V-R.WEL2L3NT*1QZOL7.1LMKS2C&/HT?0->0Y7DU\W
M%,\/(I.)U KM<BA3'0,12<VIX]-+[>XT<:N*]EL^T&.O>+-PXQ7;7TQ!S54;
M7*8E>*#JOO-=M[E(/Z5)PDA'S*M;0":(RCHY1R4ZGME&8B42D4[\(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PBA]SAX.:*\@>CUM%;Y:VIK$LK57MA4.^ZZL1Z;M34
M>SZ@JNM4]G:MN*;1^-9NU=%VN1NX.W<H&175261524,02*O:"\*\E=[]JR>Y
MK>0OF'SHUGHJ^5G9NJ="[<=ZWJ>L37RDO5'E.M&W6NO*?"2>Z)2MG[#H?-%T
MT5E16]PFN@X50$BV)R\X34FBTWRN<FH?1MXYLVGG%HO25/VCQ!):HZEH72K<
M=Z?;Z,A":FLD349NSQ5\E*G>Y&3:#V/'JTW'LTH\S18Y52D76WUQH*J\M.3G
MC4IG&S8OF<Y&3'&#F;Q[WK:FOD)J=QINC^#^B="3CF^7BCS\G.4*AP]QWK:)
M""C*M$*BYFUA;M5DT'!$TNQR1=QG3'$"D:3Y.\S>4T!9K5+6_FO-:'F[]7I@
MT0-;JCC0.HF.G:VE4 91K64*C,P; KI][UPZ,+L1](4T^A,(J_9KP@ZD0T9I
M;6^K>1G(/3&W^-7(/?W(_0')JD/J5]\FA6WDK8K=,[4J[V%D*LO3;/K^P1MP
M6C5V"[--PLT;(E.Y$HN"."+*- >'R%U'RTU+SIV9S)Y7\G>4&O*?L[7U@N.Z
M+#2G52ME#V)$,V+&E0&NJ]4(BO:IJ](EFRTLP0KWM5G<E(/%'ZSLBB2:!%DF
MF/$#I+2=/X TV V9M268^//='(C=NLG4P>I"[NT_R/E-LRMIB;W[*N-430\$
MMMYZ6/\ EY6:P%;(>L=0?4$Y%(+2' K7.B]6\Q=4UZXW:7AN:'('E'R(O<C,
MF@ADZK9^5BRJUQA*D+&(:-2P-=,J(1@/$W3@ _Y]17"*D#R'<;=-\-J#XSM1
MS%4\@M3UYQ+U39=;:K\H'"%P]M6^./<G#0=6KZNN=XZKHVJ[2WL6J=[P<>@5
MT[%FJT-(L_:$:I)K+G4(LN\"W'&3AN3_ )"^8\ SYAR.D=^P_&ZB:YW-SP:S
M4;R.Y06[7<1>Y/:>[)* L4;792M:W3<6>)AJJB2-:LU8IF5-%)N+51'"*W/R
M,^/>J>1;6VE*'8]Q[8T1,Z Y+ZXY6:UV1IE:JH72#VCJJ!O$-37:"MPKMGBB
M-XQU=SORB#;U0=LT![NSO*<BB AX/ZML6R5![S.YY\\^=>N:-:(.Z1''K?>S
M:.RX_P!AM%=?IRL+*;-UYKO750#92<-)-4%FC.1=F8$$%2+(+IK'(!%H7[0C
M5HWFE0-(^+6C:XW5:.0^_P#<NE=@U78E.UY;%M8:)U:VM-KIVZ-NWG:I8L*/
M'(P>HU++$NH0[X))TG/-B^@HDY*14BM?WUP)U#O/7'$/5 R-BUW2.%_(GC%R
M'U1#4KY.F@H_XINBK:[HDL65C9$@4URT23;.RM@0=^BF'I+)C\<(LAV9PSU[
MM3EQH;E]8YVR!;-!ZGWCJ"$I2)8=2E6:N;Z)4TK2O9D74:O+*O&"-22(U!!R
MBB)5E 5(I]'H156Q?V?^"8ZPF.*:OD4YY_U UX^UPU=X=0]VH5>A(2L6E>2=
MFU])[=C:.&UK5J^*=2ZWHP;M\"3E B:#U5TEZY7!%.GC1XS-9\9]O\=-SP.R
MMC6VR<:_'=7?&W4F-D3J:$5-:@JEZI%V@K=8$H2OQK@]^;?4%DQ.JW418JH"
MH<S?U3 <"+;.C>$M T/.<T9VNVRX3#CFYNBP[MOZ,T:%%&IS]CUY6=<.HFG^
MQBVARPZ$75T5T_>BZ6]PH?J<2=I0(H_:9\3NFM*(^,=& V/LZ5+XMX7=\)J$
M9@]5$=A-]Z:MFM4V%79'LJ\U ZT1#3BCEE\L]@4')"^J"A.I!(HS7_P/4ZQK
M;9UEKOG'S+T9PGW]<+===Q\(=96FC-=52CO8<P\G]D5+7UHF:9*7G56K]C2L
MBZ4F:[%NA9.$WSI%(4$52)I$6U=O^'J%=[E5WMPPY;\AO'K=+'JG5FD-G0N@
M6^N[!KC9&N-)0!ZEJ<DK1ME5.RLXZ[4"G@E#1<V@L*K2*1! B74ZJBA%.OAA
MQ U=P:T!6>/NIWUNL$1$2UJMMHOFQ)HEEV3L_8U^L,A;+]LG8=C39QZ<U;K=
M8Y19PX430002)Z:""2:"2:92*56$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:8Y![3?:5U'
M:-DQL&VLCZ!<U9JUA7D@I%-GBMDN$!50]9^BT?*-RM@F_6Z@D?N%/M^'7J&!
M]S>8W' >$WG*[6W9=7%L^W:V)SS&UQGN8;?5X:\MV^;N^B:TIXU67<$XU#R_
ME-MQZXF=;PSMF<9&M#RT102S:-+F@U\O;](4K7P6JY_>>Z=6,T;3N?3E7CM<
M)/F#.R6W7NQG-J>TUM(/6\<C.3%=EJC77+^$2=O$_<*-%CJMD@,H*9BAF&Y/
MN'SWAT#<QSS!6<7%6R,;/<V5\ZX?:M>YK!++!);0.?$'.;O=&XN8VKBT@+)K
M'A?$.2RG&<1RUS)R L<Z*"ZM1"V<M:7&..5D\H;(6M.T/:&O-&AP*D7+["H$
M ]:1L]>*?"2+]['QK%A+V:%C7KV1ETU%8E@T:O'J*[E[)I)&,W2(4RBQ2B)
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M(VNVUH:5I6AIT6L-E3T3MVR<IML4)XG.ZZI7"K9.I%;@QZJ0-CN<J$S<7C.
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M?N.\;0 VCJU&T  :Z  #HO.=@Q49&C%&312.,V]D:/.W1.R,S]/T?:&:&(*
MMO1^AZ?;V]OPZ=,FNMK=]O[HZ-AM2S;L+1LVTIMVTIMII2E*:* 3S-F]X:]P
MN [=NJ=VZM=V[K6NM:UKJN&A:;4*W'NXFNU2MP,4_P#4]]&0L'%Q<>]]5,45
M?=LV+5!LY]1(PE-WE-U*/0?AE!88+!XJV?98NRM+:SDKOCBACC8^HH=S6-#7
M5&AJ#4:*KO,OE<A.VZO[JXGN64VODD>]S:&HVN<210ZBAZKGT$$6J*+9LBDW
M;MTDT&[=!,B2*"*1 321123 I$DDB% I2E  * = RY1QQPQMBB:&Q-
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MW;(6N#B]] 3LK&S6A/2AHVSJ!<R)A%7;S6=WSC-=M#^2[0(%8;RX;; K=CE
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MK'$6ET9</C<%D+;WDQ2-$US=LN7G9'M,C8S+,V-A>UIT+G;6ZJ1+NF657DW
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M=1P9-PT>LUSIJ$, E.0P@/P',6MN!<+L[B.[M<78QW43VO8YL3 YKFD.:YI
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M9"!5Q&M *!K6U.UH J34GNJYB"RY,(F$3"*"_*Z_M3R%'UM9-!;>V'5I38\
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M8NJ-0-+A#2<+:Z]1:DVE;#57+6$F)9<L0U7DF,T#F.?M'Z!GRIP*=5 7B*8
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MU:K9'VXKQN[=Y3NTJS.W5I;XQE%NE8UX,D2LUF/K-;H]>:*,A7$I#I',0#"
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M=I%<M:/SL#B&OZ$D&.<;)S6!X?W]P'UKB7-L^96[*'=3>T@:1S :R0.)_-S
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M5O&"E,JNWQEUP673;@4J)>SO-[H :&I*\U)%=%,O(%$H_P#++\ECDO\ V?\
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MI#BI<VI$P 1,!A#J4O=VE"\R?G,+ZV_M.^9<NX5_U'\4H:3MM[LN'HKYUB7
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MMJX1BLXH&U+$PGFY$UHT+/'L'3$[Q(YCE!9Y"I1KU@0W0O:JFDL=(P";M/U
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MJ8YA2*Z2TKNYN14I!'H!@2=G#K_<'-U=@_\ Y"C_ ,%F_J0M$_$3_P#&\O\
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MR\;+52P+1\2X>-EFQQ]9NLV2<,S]I%.HF <@( U'11@UZ]5N/(5ZOEM<!_\
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M\O\ GJ#'O.?WL>G\S2])P'0JG4>@?#+G:7L%[YOD5_,S.C=44]IM*T](UZK
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M"*.?(>YW>NDU35J'.1-/F-H[0CZ*>[S,,C/MZTV/7;'8#BPBGCEI'O)R8-!
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MI,V57K1^/FR36Y;Y4TD_F["'L.FU9>MW5U66TDD9Q[-\G.,TU_4$H'$QA--
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MNF7D8VL#-QM:CFD+&FEYV<GY5-VX:1,/' LV(NY]E'N'!Q452330;G,8P=
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MZ2CS>+AH43%? @,_O.&<-CM7_:4O:@Q9G1*8I2]Z1QZ="]0');WV<="SU-_
MU<)=JB+_ +W<FR6A:7WQ'XU/,OF$4=ZF@@$=0?0KZ,LJZK3")A$PB81,(J)9
MDYJ;YQ:!-_RG_P 4.*\0O7TEP[9[1+W7IO33#TQ13ZH#U[A,<H]3AU#M+EY^
MGA7-]%?P.JN7'..-^*:SNM?S[HQX'^,L76_W.GCJ.OH"[*N8VNY4PB81,(F$
M51\W_M6:;_?0WX*'N<@N_P"<.P^6/_TYZZ<@_P"6>\^1_P#EK5=UGT.7&B81
M,(JY:OQ95V):O(94-S5%RAK+D/?:4XJLB+F.47E(V*U?6XHMG@Q17=K1LK6+
M7%E6:'<))F3=M2' ABA\8-M=U>A6I[/A;LK>\JL.00$8?*W41C=5M7-;;QM\
MQE"2UT<K:M+@"'-!H0HEZKX?<L9#0W.+7FU"QK_:UQV/J6<UO<I1^Q"!V\&A
M1I;RKS,@HB\>/&"-Z)KQH@_.](W6!9ZJ=0I/I=L(:ZA!ZK!\+P/F\O&>1XK-
M;'9NXN[9]O*XC9=>Y>28WNH26B;R&AY>&FKR2!JI9,WVZ.3>]>.D_/\ 'K8.
M@Z1Q\GK;L*\RNS9.E'D+#>I2@6*@0M,UTG4K%9%+!7&ZUG</'<NNFR17;MRD
M(F110G7W5SAI0!9Q')R#F')<3=76*NL9CL5++/,ZX=#N?,Z"2!D4'E22;XP9
M'/=*X,#FM  !(6ODM [?+XTZKI(:2^#:3"]4"5=U#WT/[Q&/B.7<!L21<F>?
M,?E1BM:8T4?" .!,*9>T %3H00:?+IX_]*M3>,9X=HH..FW=]=-N8'&*K*AK
M<FR=QKNVZ1 O^ET%.NBE=(4"X+<Y*CM-.$7-0(_BAL2@/+&"[,&R%PF=OZOL
M49"&;"Y"0,N[A8)VN"A411 J(@8X&$I1BH=]?"BS>7%W[NX\&:$9^K&82> R
M5%!*^ZMY&LI7=4L8YU:4TU-:*$5GU7R5J.N[&RBJKM\*18.>')+8VUJOHFWP
M54W9;M*7:TW"6H<E1K I/1/MHR0EWC!W(-$)!A*+L_Y+O1**PE@(=3QI4K75
MYA>76.)ECA@O_JZ7DM_/<QV<K([N6TFDE="Z%^]M&N<6.>T/9(6>S5HW4PRC
M<:=IM8WGRM7= [$UY!;XX=NZ;JF)V)M-#9FP[7<TJ_M>(4:WN;EKU;S5^XSC
MZRLSIL0D5HYLR41#UB+ X22!I]K3J%;\;Q#-,AY.ZTQ=W:VV3P!BMFSW(N)Y
M9=ERVDSW32[)7F1I#/,,;6%OM!V]K=\356Y&:EO-CV]K73;O85HA> &B=44^
MOJ2\$S92FW(;9]T4F()^=Q-QYQ:U.*LB,H]$JJ)'+1(Z2"_K&#IZ=P-0-:+)
M;BRY9@\E-G<1CW75Y'Q>SMHF;F .NF7$VYCJO;I$V02/U <T%K7;BN)X^5:_
MN:=?M0W;C=ONL7SD;7[PCO'E%L%]I]P$K;)JEV%FTD7T=5]EV.:C:O">X+%5
MR&9-U&D4@HD0 *!G"Y@!I0@U/BI'%K+*/L+K!9'$9.')Y:*87F1G=:G=*^%X
M#BV.XD>V-E?+@B8TMC:0/%[C&B@<4$DZ_K73=KX&;DDMHP;ZD0-]V-8>46R4
M>,[B%K;V+)-;)AUXC>KN0>*OVS#WS"MHUU$S5RH1'H!$#%&$-\*&ORZ?LK$,
M7PD"UM,!?<9R#\S$Z%DT[\C<#'ED9;ON&%MX7'<!O9 (!M<0WHTA7Z9.73BB
MCRNWI6=8ZXN]<:[(@*1M>9H<R_H;>4=F:/G#DZ;IHV<QJYD3MD'BCANJDV54
M,4B;D"F,)2@)@C8TDUIHH7$ 4\5%B"L_!"0A8I\ZY+;.6=.V#5=TK8MZ;@CY
MY5RHB4SA289(3#1NVDCK"(K$33(D"G7L#MZ9&?,KT'WE#5GI_"K5<DJ8F$7R
MVN _^^#;(_\ ,7\G?^3.6.8]RG_0K_Y^W_RB)7;!_P"D1_-3?VF1?3;S$%>4
MPB81,(M?;5VG0M)Z\MFU=G6)E5*+28AQ-6&;?"<4VS5#M(F@V;I%4<OY)^Y4
M(W:-4"*.'3E4B*1#*'*49,\\5M"Z><AL314G^CQ] \2K[QGC6;YAGK7C/'+=
M]SFKR41Q1M\7'J230-8T N>]Q#6,#G.(:"56]3/-KXZ+>N#1UN:7I3I17TFZ
M=SUQ?F*"_0ACBH,I$5^;AV:0 40ZN7"'4>@!U$0RSQ<EQ$AH9"T_NFN_9 (^
M^N@<O\'G?S%,\V/$17D8%2;>[MG$>%-CY8Y'']XUWI5,_E:Y#P7D*Y5\9N+'
M':\QEUURR-'NGEIK*RDE"KW&^K)J3TLNF0R9'J.N:#%E7/U[56RCA\B;M,!@
M#%^29&/(7,=M:N#H&BM1T+G?,/V2NN?A@[?WW8WMOR'N-SRRDL^02%S6PS#9
M((+8'RV#KM-U<O+1U#PR%PJ"%#W7GCDY-V/D; \6=FI7LNAM;VV=N+JY%1FT
M]9GK$R6)^<3E%=.?5@VEHV.QK[!D9! QW;=PE_C!!!FL); (YG$6[R?):21Z
M!6E2/6:!;AS7?#M_8<'G[C8#W/[9W]M' (:Q^]^;'O\ +CN *2.BM72R2!S@
M&.:[V"/-;6ROEIXC*;<%4ME<3G;73&SH/T'[:JLW3R*IDV^C.U5DZ@GK(QGU
M#LQ3I%%-PW$S)14A!,FW.91T,Y]OKOA.UX_HT]!6A^V_Q*Y3&L. [DL=E>/S
M5:97-:^=C7Z.$C7>S<14)JUU) ":.> V-1!UCQ.YN\Z-\5E3GHZV@UH.B85I
M5W<E>6@1+JRQT<\552K5-D&C5&/M3VQNR=\M94#O%'#5(IE'BJWM R*66]OY
M&NO7.=L%!7T?MD^)ZGQ*V3F^X/:'LWPZX;V8CQQS.9F=,&6YWMB>YH!EG:YQ
M="V)ND-JX,:UY(;$UGF*WOFGPHK/*#C]$ZCJH5^AS>OG$.]U._&.,C UI.*:
M$AU:VHUC$O<-:W(5\1;BF@0Q4546ZWIJ>@4@Q2PB1FT:$=%S7VJ[KY#M_P T
MEY+D?/O+2]:]MXW=624O.\2@O-#*V3VJN/M!SV[F[R1!SDCPGBN/WBIN6LF+
MEA/V^E3E?V[:[&S9J-49^UGM$7&3KQN58XKI-(:EOSLFQC@!U6[(@F(0ZA^V
M3)"&6Y;XC5;;X)W7N.:?$5:Y^9KX<9=0R6<,3G F.'RGOC:::%SYVA[P- YY
M )#16VWPR;(^^/X[]&^X>>[E:']<-;RW_P!U^J]NF/J\S_\ J:6^C/\ UYL7
MCDWG8B*OTF5:?N$T_!1<A?%OQ_[/]^<UY;=MM>^1=L]?G01^:[[MPV96E9?%
MS8F$3")A$PB81:4Y#\@=:\7]0V_=>V95:,IU/9I+.$F"2#J;FY%XNFTB:]78
M]PZ9)R,],OE2(MTC*I)@(BHJHDB114E-=W<-C;NN9S2-H^Z?0!ZRLPX'P;D/
M<CE5KP_C$0DRUV\@%Q(CC8T%SY97 .+(XV@N<X-)Z-:USRUICKQR\D'&3DKH
MF^[ZJMD>UB%U+"RT[M>IW%..8W2AQ\.P>29WTC&1TE)M7\5+LV"IXYTU762>
M&**/T'2:S=*CL\S97MJ^Z8XM;&"7 TJVGW>A\".O3K4+/N?_  _=Q>WO-+'A
M.2MV7-WE)F1V4\!>ZWN7/<UFUKW,86O8YP$K'M:Y@(?K&YCW=;'6'FYYIU/;
MEMWQ=8%[L?C7;KV^A%M>.XA"-K=(1$Q9.(K%(O\ 'PA1BK;"5QPEU(],Z))I
M]RKA$RHE<)87!RC(1W3IY?;M7.^AZ!X!IIH0/36OCZ5]".1_!SVCRG%+7AF'
MF;C^X%K9->+MKR^6X/T7RW%LZ3VX9)0=8PPPFC6/#06.S;GYSYL?E%O.F^)'
M$AE:&&M;*K!6&YA868P<C-VTR'S)RWMS9HN^32IFHX\BCIP*:Z[9Y(IG62!?
MVK!4\6<S?UILM;3<+?0NKH2[T'U-^\3KX JT=BNQEC\.>)RO<[N>^VDY' )(
MK?RG>8R."NP.@+@TF>]=1C:M:^.(ACBSS)FC%M);MY#>$_?RNN=EMY39O%;9
M,BI*')#I>DSFD$@:LW%YH"4@[!G ;&@FPH(RT0NY(B^1*DFJJ)!8/TZ7%96?
M#3;'U?9N.H__ !-]?I'CX^!%WYSP;@WQ<<*&>P#H\=W)Q\88"\U+":N%M<EK
M=TEK(=SH9VM+HW%SFMKYT#N,1^_YYJ^3KR^[ 6G:'Q8UO*O&4-%,3E^652"5
M62<H5& 46_Q*:VC:F2:"LS*BFJ5J02',0C<C!F:3?7UQF;HRR5;;M/LM\ /V
MW'Q/[5 JRWM>$_"3V\9A,((;WN-?QM=+(X>W/( 09I*>U'9PN+A!#4;C4 F0
MS2C;?CGFU.!?E;V1Q=DW*S'6VZCN:;6_>+G,W.HZ3&]:4D5G)U53/Y$K!ZO
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MV0RAK)FMM \-GN8W,D,4HA::O:V6K30.I4+;>I^2-<W)<-9.*-L_5%@HFP-
MV+:+2O1C.R*7^5D(&\U>HR%M@YE:12KJ>N*\_D'46^;K,C2!I-9L=-<J)%2G
MK;/*17TT1MY876\ELZ0 !V\D/:TN!KMV DM((KN(H:56+<H[>Y#B.)R,>:QN
M4@S=AG8K-TKW1"U8V6VFG;!)&&&4W<K6LFC<V01"%L@<PO+2W\U[SHXB;6V6
M?4&N]_:_M6PC+RS6.@XV1< WLCJ!^,TUIE@<M&];O#F+3 RBZ<.\?'32(=00
M A#F*MN086\NO<K:YC?<ZT /TJ==KJ;7T\=I*9[LKW5XQQT<LS^"O[7 [6%\
MCV"L39?XMUQ$'&:W#S0-,\<8)(:#5P!XV_\ /_AIJVR250O_ "%H%:LL':7%
M-L,.\=2"SNLS[5&(772M(,H]TG6(Q-.=:_\ 6#\S>.$R@E!<3$4 L%SR/!VD
MI@N;F-DK7[2#7V3I]*@]D:CVC1OKZJHP78ONYR;'QY7!8&^N,=-;"XBD:UH;
M-$XO ,.YP,SR8W_FH@^6@KLHYI,O6[A!V@BZ:K).6SE)-PW<-U"+(.$%B%41
M6163,9-5)5,P&*8HB!@$! >F7H$$5&H*U2]CXGF.0%LC20010@C0@@Z@@Z$'
MHO+GJA3")A$PB81,(F$3")A$PB81,(F$3")A%7MRQY#:K;NJIKQ?=BU0:QNT
M(F.W3'TN;E(:]M*@:*EDU6C=Y&(?,DX[Y\X8?,BLC"[%B*@I]0*<,F,:>M/#
M10.<.E?%>_J65X?N-B5A'7.\K5:;J=TZ"!@'^Y-GV1I). CGAG"2T).S+F)D
M"I,@54 JQ#%*) ,'TB@.#OIJ-/D0%M=#JI]9+4:C_P LOR6.2_\ 9_W+^#JQ
MX1?/C^Q3?E0\V/\ 4)K_ /"&OF.<C_B(_P!^?V%=<5_&/^0+Z*68DKTF$3"*
M*G.6Y#0N'W(^QE5%!<FI+?",ER@!C(2-LC5*G&+$ QR%[TI";3,7KU ! /HF
M_BC56+-]W&W]V#][7]I:_P"ZV3^J.V^;O0:/&.F8T^ATK3$T_<<\?,>BK,\.
M=1&#XN3MD61[7%VVG8Y!!P*1DS*Q,+$5^OMD@.)A!9-"4CWP@8.@ 90Q?NE$
M1NF6?NN0W\EH_;/S+G_X<L?[KP66]</;NK^1P-.K&,CC ]='-?KZR/!6QY;%
MOY,(F$3")A$PBHS\=1_O<^4_E10#E]!C8&>YF\8V[>SH#?9=>M<$?H"!0_DZ
M[ZP=  B8]_4!$ * W?(_G,9%)X@M_8(/X5S)V3=]3=^\_B#I%,R\#1\ES'*S
MP_D]WH&OR+LCYCJ[=3")A$PB81,(NLKX?%/K1N+E=?""95-Z:OJ NB0R+,WU
MLM-QF2"*"Y/<IF5")$4BB("4H& P"/3IDV5]B&*/T5_  N#OAW=[_P DS^6&
MH>8S4:#\[+,_H=179IZ!6JOORR+J],(F$3")A$PBH9YIF+3O*EP\M@D K.3?
M:'5?+JI^H0/3W%/P<H*2;<2.#JMH@R1R";N_E# 'TBAVY>K3V\9,SQH[^I!7
M*O<<C&]_.-Y"GYM\EAN)'_[8^-V@UJ&4(]=.HT79AS&EW8F$3")A$PBJ/F_]
MJS3?[Z&_!0]SD%W_ #AV'RQ_^G/73D'_ "SWGR/_ ,M:KNL^ARXT5:_)SE+L
M:R[()P\X9^PFN0DHW2<;)V2Y02D:3QMIZYD@=6&S*G1=L75R506#V,:<BIB'
M.03I**'214EN<:[&?2_86J>6\PREWE?L-P3;)R9XK/.1NBL8CU?)H092#[#"
M#0D5!):TV-1B#UK&Q[62?_-9%LQ:(/Y3VJ3'YD]1;IING_LD!,@S]XN4RGI$
M$2)]W:'P#)BVE"V1D362NWRAH!=0#<0-30:"IUH-!T7O84Q,(HY;)Y><8-/6
MM.C;.WMK2EV\X-C+5V;L\>A*1Y'B::S169;$44-!(ND%2J)G>>@4Z1@. B7X
MY"7-&A.JQ/+\[X;@;T8W,9*SM[_2L;Y&AS:Z@O'X@(-07[01KT6VW>Q*&Q9T
MN2=7&MIQVQI:,@J#(A,,56%RF)J*?SL1'UIZBLHVF7$I#1;ETW! Q_5;HG.7
MJ4.N>U"ODF5QD4=O*^XA$5V]K(7;@6RN>USVMC(-'ES&N<W;6K02-%F6>JX)
MA$PBX*SV>NTJNS5MMLU'5RL5R.=2\]/2[I)C%Q$6Q2,N\?OWBYBHMFK9$HF.
M<P@!0#J..FI5->7EKC[62^OI&16<3"Y[W$!K6@5+G$Z  =2N7;N$';=!TV53
M7;.44G#==(P'2606(51)5,X=0,FHF8! 0^ @.%/8YKVA[""PBH(\0>A7FPHD
MPBT%R$1Y!+TJ33X_JTTL^I"3::B=@]TWL(2!FZ7R=6H/EW2=92D?4]0.DJ0&
MH&[!,?M[@R)NVOM=%"[=^*M02\ERRE*N\B7>Q>+]+5>1 M'MLCI"X.;!6@.W
M CV9:(OG(0:LK'$[U"@H(-A5+\1 GQR+V*UH5Y[?J4U6R1T&S=!18[E1%!))
M1PJ  HX.FF4AEE +]$#JF#N'I\.HY+4:\^$7RD^,.VM>Z+^UC;EVEM2Q(U.A
M5CR-^2(D_8G+.1?-HHL\\Y.UJ.7=-XIH^>@U-+S+<BBA4C$1(85%!*F0Q@QO
MELC(L%)+(:1ME@)/H N(B5FW;OB^=YIRVWXUQFW-UF[F&Z\J(.:TO\JTGF>
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MG(:-[&R#:X5"QCB?,>1\'RPS7&;EUM?AI:2 US7L/5CV.!8]O0@.!HX!S:.
M(R;6^M:-J&E0.N];UN/J=-K3,&4/"QQ5/21()C*K.'#APHL\D)!ZX.95PZ<*
M*N'*QS**G.<PF'UK0T;6Z!4&=SV7Y-EILYG9WW.4N';GO=2I\    UK6B@:Q
MH#6M :T  !4B>:#6<Y3IO0G+^AG5B[11+'&5"3FFA>KB/DHF27O.M)D *?Z
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MSRLMR$4$UR=-UOCGM),%JUU6^8PDOH',>\@3ON?*4I"E*4H%*4 *4I0 "E*
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MTO!)C';_ #<'<-8X=-_F1M&O@0X4^XM98RV_W=\9?9=P+=UJ['=W,+<7=O*
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MNUS6&C82P4'9EYTTIHRZ6&'V;3]A"_:2-," J35Q"Q<A21&.?DBV:CI-P?U
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MY^9A5;MY$/(M&RQX9Z6/E42-Y_D?)M7#!XH@Z21<MGS%)0O>DJF;M[3D,41
M<3YRT/XM=-/0^5_;HUM_L-R7)</[JXSDN(\OZQM([QS-[=S#6QN6D.:""06N
M(-"#K4$'5=E.X>&[D)29:6K_ !VY'D;ZNOOIQ=UB['-VNDR*L$"Q5 8V6,J"
M,E [!:-RE$P JFR*=7M#T"!U4#GKR9XP60O(C=H14BH]8'5?4?&_$_P?,6\5
M]SG [N167MV[XXX;AHDI3=$^<MDMG'I5I>0*^V3H9@:A\-/%>E5%Y%[-)8MP
MVZ59%0>V=[+2U/91"WT3&5J4#6Y1$(_HH0H]S]S)J#T$.XJ9S)C&RUC ]K4K
M6G)OBD[B9;)-N, 8,7C8WU;$UC)W/'HFDE8=WCI&V(>HN <M0N?!5II2[$DF
MN[-CMM>=>Y:HGA:XXM@F$2F$C>]B"46B@'T@*!X!50"B'4XB B:#W-M>IV_T
M?T=%DT?Q>\I;B3!)B;%V;\)O,E$/W;?5Y/3I< ==!X;#W-X8>.-IUXQA--.)
MG5]_AO45;VZ6EIBX,K093M[VMNBW[XJ2)1 G1):+*R]N81,**P?0&)]JPMHS
M1RLG%OBHYSC\V^[Y2V+(8:6@,+&,A=%3H87M;4_NFRE^[H'-ZJ6G![A;3^&N
MMEZ^R=M+/L2T+)/]@7LC$61Y99N*H1L)%HK*KN&E=@DECE03,?N66457.!3*
M FG-AB$3:=7>E:V[M]U<GW1SK;V5KK?"6X+;>WW;M@--TCR  Z60@;B!1K0U
M@J&U,V<FK4Z81,(F$3")A$PBZF[#C+SRK')3DOI+C9%;)US3-BW.Q1-@NB24
MC1:;+ZQ1M4G*U55YL$S%-4(EQ$R1159Q3A5P]3.J@*+@A3DRBC?=PNDBMW.8
MU^AII45TU^;JOHY<\Y[,Y3@G'^7<^?87^5Q]K&^* [;B>.[,+&3;;;<1O#V>
MR^9H;&0UX<PD%3MK_@RU<75JD5:-N6X^X'()N@N$&PCPI40Y]$0&)1J+X@24
MU%IJJ#ZC@\BS<KB0AR V+WI&]%FW;J3O6H[WXNN0'D(N,?C+8<8;IY,CG>>\
M5^F9F^RQY T:(WM;4@[S1PU'6KOY1_$ZHVCXXY=Z\<&;H$6T6NWE[SK]BT44
M B:3<$?:WG4[KL4 "$(=&'.[4Z 5X8/C7V>5R>*HUCM]O^2[4?<\6_<T]15Y
MR_&_AT^)=KKBY:<-SUS:F1I9;W+G :EU=UO>-])(=.&#K$%X[(S\I/E7?- V
MB\7T;Q[=KHODX52,E*-0#M0.=5JZ8TU=ZK=MF/1)])LXD5EF!3AU(X;@8.L-
MYD<EE32=VV#\D:-^]U/W25'B;?X<_ALA<>-QC,<X:"TR[V7%S70.#IPT06C?
M!S8FMD(T<R2BFK5_#+P\B:K'0MC:7VV6) A325R5MS^%>2#@?I*@A#18E@V#
M'NZ@FGZ*JQ"= ,LH;J<:46L0%#4E:TR'Q3=SKG(ONK%UG;6)/LP"%LC6CPJ]
M_P"<<[TFH:3T:T:**>RO#?M77]J4L_#;?LC5&DPBZAI2,MMFL5.L<9!RQ?;R
M;%&Z4*.4&R0SI%02K,W#)J(MR]#'<G'H,(@EB=NMWEI(IH2#0^%1X+8>#^)_
MC6=QHQW=3"QW+XG-D8Z*&*>)TC-6.,%P[\U("*M>U[_:-0(PII\)_&+KGB=/
MM-GSMHD=D[B3C'[!&;4;$B:M6@F&XMI0:W#]SF06?KLUE6IWKMR<56ZA^Q!
M3F 8XK=L9W$U<M6=U^_^<[CV3N/V=NRPXN9&N,8.^678:L\U^C0T. >(V-%'
M 5>^@5G^5"Y^3")A$PB81,(M*<BM'USD?IB]Z9M#I6.C;I%I-D9=NW([<P<Q
M'/FLO!3;=L=5N#D\7,,$%C)>HF"Z93)"<I3B.0O8)&%A\5E?!^6WW!>56?*<
M>T/GM9"2PF@D8YI9)&30TWL<X5H=I(< 2%6SIOPI\;*,9N_VK8[ANJ51'JHS
M75-0:>J)3]Z9_DE=D'5B[R]  0/-J)'#X"3H.4[;2,?2)/X%O?E'Q6\[RX=#
MQV"UQ5N?Q@/>)A_VDK1%]Z $>E>\T\)W$I&SR,TZG]O/(-R[5<1]/^M$*WBH
MU%945/8?,DJR-C>M&P#Z:(G> N"8?RBBI_IX]TCK76BE2_%?W)?CV6L<.,9=
MM: Z?RI"]Q INV&7RFD]749MK]%K1HLSO/ASX66F%2CJY6[KK:3;M_3)/U6]
M3DJ\=."@ D7DF=Z6MT8N4R@=5"((M1,4PE(9/Z(EB-K$1I4*U8CXH.ZN/NC/
M?3VE_;N=7RYK>-C0/0UUN(7C3H7.?K0D.U!AK^HOEB6(D23DNL;5:LB25>L/
MJ4Y1L0N$$%T&X$8!9EJXO(D07,B5^?M,FFH800$.J9I?NA^CN]BM:+:'_%W;
M&R-T< W[1B,L:[SP8Z$@GVO*$H;4!QC%02![?XPDE=O"EQ9FZ7'P=*G-AT:W
MQJ!B?7E>93M9YQP/?T7LM;?)L(A8A.X.A(L8C^*'4P_'K$;2,B@J"L%Q/Q7=
MP[3*ON\K#8W>,D=_>X88?+'HBE:7/'RR^=UZ=*4Y\KN#H<*+[QVBG.PQV#,;
M!L#^1D'*%>"NQD8A7['5&L>U9-U)67=.E5R2BAUE3J$#KVE*0.T3GE-A\JXC
M%:DO'[(73W;SNW_O7P>=N8[+W*ULH UH,GFO>9(IBXN(8P #8 T 'Q).M!]$
MC.M%^?Y,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$44>5U37M,1J@9"IS=]U]"[<@I/9U-@6:\HXE*N:$L,>R?OX9LLDO-PL!9
MGK%V[; "H>DGZQDS%1$0C8:5]-%"X5^10\U/J^MZZW/JZJUK4K^/VQ0=S[59
M6&Q'H\BG7'^@)UO<GU<MRUM68_5]>2;MY*)9QRZ"X2"9DEFBG0IS$4F$DM)K
MH0/OJ$"AT&M?P*W')"F*/_++\ECDO_9_W+^#JQX1?/C^Q3?E0\V/]0FO_P (
M:^8YR/\ B(_WY_85UQ7\8_Y OHI9B2O2818Y;KA5:#6Y:X7>QPM2JL"V!W,V
M*Q232(AXUN95-NFH\D'JJ+9'UG*Q$DP$W<HJ<I"@)C% 8F,?(X,8"7GP"HLC
MDL?B+*3)96>*WQ\3:ODD<&,:*@"KG$ 5) 'I) &I"Z_WF[VS7+SJ[BW"T&P1
MMRKU^L%TO<5*UEZVF8J50K\="5V,69NV*JQ'*B[BUND2%3[A!1)0ANTY>F7[
M"Q.9+*Z0$.: -?7K^TN/_BFY#997 8"UQ$S+FRO)IYV/B<'L>(VLC:06DUJ9
M7@4\0X&A%%;QKRKIT>@4:E(@F5&H4^LU=(J)>U(J=?A642F"1>X_:F!6@=H=
MP] _A'+9([>]S_22?OK?6'L6XO$6N,;3;;VT40ITI&QK/VEF.0JXIA$PB81,
M(F$5"G/4_P![SR4<0-FD+Z3)P\TZYD3=G7W US;DDA,D[@;NC!ZL ^02ZE3.
MH3^,4!-V]+U9?G,=-'ZG?A;\ZY3[IN^IN]O',X-(B^S+O7Y=VX/\#UC<T: D
M=1K1=AVK[CU3=KC;]>U'8=0LEXH*OH7.J0\ZP?3M<5*O[58DI'H+'<("U>?R
M"_P$&[C^24[5/HYCSH96,$CVD,=T)&A7:=AR7C^4R5SAL=>VT^5LS2:)DC72
M1FM#N:#44=[+OR7>RZAT6;S,S$UV(E+!/2+.(A(2/>2TQ*R"Z;5A&QD<W4=O
MG[URJ8J3=JT;)&.H<P@!2E$1R  N(:T5<2KI<W-O96TEY=O;':Q,+WO<0&M:
MT5<YQ.@  ))/0*L#CYY7M+\@^2$EH6$K<K7H>0%\UUCL:9E2$;[#E8PHJKQZ
ME:4BFKFK#*-$5EHP5W:ZKLJ8)JIMG"A$!N=QBIK>V$[B"?QAZ/N^/K_;"T1P
M[X@^,<QYL_B-K!)#;/W"UN7OTN'MU+?*V Q;@'.BW/<7@ .:Q[@Q:1\A'D_N
MG%_D32=3:QC:Q.1=880=BW(A+,EW<B^+/KIO6U/BW1'K4L(]3J?IO0<]BO4\
M@W$0[$U$U)V/QC+FW=++4$DAOW/'[_["Q;O'WXR? ^9VO'<%'!+;P,9)>A[2
M7.\P[A"P[AL=Y5'[J'61G@UP=;4XW7K9KIH=_.+(T2U8%$3V-]9##_)FK"T2
M280630 154?KMU"IIM2@*YW)@1*45! N6KR9/.\BGYW=2GKZ+H=_*,''QG[7
MOG:,![H+GS?#RBS>"!U+B" &#VBXAH&[15OUWR.:EY9<8N8)JS$RE'N.O-';
M9F0J%JDH[WTW6STJ=;Q,]&/&)A1/ZLD=)J[0(!SLW+A$O<J"R1C7%V.EM;F'
M<0YCGMU'IJ-%I.R[U\=[A\$Y(;&.2UR5GBKM_DRN;NDB\B0,D:6Z:NHQ[14L
M<YHJ[<TF.GA<B@0XZ;(F1  4DMT2;  % "',C$TBD+)J>XZ]5TA5EE"@7IT3
M,4W01$P@%5ES_=#1Z&?ME:_^&J#9PV]N?%^3<WIX,A@/7Q%7GY"#Z5<+EJ71
M281,(F$3")A%1UYMH3UZ-H.Q^F(_*K9=H3UO1.8"?6"'@G_IBN ^FF*OU:Z@
M00[C]G4/@0<O.'=[;V^D _>K\ZY>^)RUWXO$WE/XNXF96G\HQCJ5\*^7T\:>
MI;F'S)5R Y%T+53R#@7>E@BJ77[YM)23D'4W'VV9K[-:9FFRQW"4<K6:O/OR
M-'XJHG<*$:N7"9S *:8T_P!3N=;NEJ1-4D-]5>GRD=/N!9B?B7LK/FEIQ^6*
M)W%_+@CGNMSB]LSXVE[P:AIBBD<&25!<0R1X)]D&T3E;R>I?%'24YN2T(?/R
MMU&$74JRRD4&+JZ6:8[S14*PDCH/4FJ)VJ*SMPY!)?T&+994J:IBE3/;+6V?
M=3"%NGI/H'I_H\5OKN#SO%]ON+2\EOQYP:6LAB:X-,TK_H,:X@@"@+W.H[;&
MUS@UQ :==\*^<VL>:%.>R=<;_4[85=^-RUC(RR,I*0K=584F<S%R1647]8JX
M\ZE)[LC5 R+@12623$4Q4F7MC+9OH[6,]'?M>HJR]L.ZV"[G8QT]DWW;,P_Q
MUJYX>]@)HU[';6>9&=!O#6T=[+F@[=T-/+%SBF=1P<=QKTE+R2&Z]C)L3V"7
MK#AR2?I-6D5P1CXV(<1RA'K*Y71SVIMA2'UV[#O4*!%'#54*S%60E<;F<?F6
M] >A/S#]G[JUG\0O=6YXY:,X1Q:1XY1>AOF/B)\R")QHUK"WVFS3'1M/:;'5
MP +XW+$_%9SI?S53O^@.2-JD6E]TM&V6U,;/?'[]:;>46N*.G%TB+&^E16?J
MS&N%DCG$%E#KC&&["D C%0<BREB ]MQ;CV'D"@])Z4^7]GY5;NP'=B6ZQUYQ
M#FUP]N7Q;)96RSN<7N@CJ9F2.?5Q?;$$ZDN\HT I$2JI$^1>\.2WD=B-L:(>
M1L#L:W7M6HZ;/8DVZ<36ZXK"O:=!O9M!9-9!55G65#OWA3).>]WW@5%8.U$U
MUL<396HJR*+WA[VR/=M%72-:&!Y-*[FM :T]0T !:(N.X?-.=]VHLYQ^Z?#<
MNE?:V+7N(CBMG[VAA;TVN#G32MHX.D<X[7:!=L_B=Q7JO%NBR$0UEY"];)O$
MJ>V[@VU8Q,XM>R+J\ QWLG(.W"KEVWB&BRRA6#(5E"MR*'.8RCA9PLK?FM#1
MZUV-PSAUGP_'.@8]UQE;A_F7-R_62>4]7.)J0T$G8RIV@DDESG.=*?(EF*81
M,(F$4"UN&^P:7:M@2W'+E'=M%5':%GF+Q:=<FU_0=EUJ+N5B."MAG]?'MK,K
MZE&F'/<Y4:D.Z9 Z4$X) 0$TB0;2/HF@6LW<!RF/O;J?B>9N,;8WLSII(/(A
MN(VRR?3?!YHK#N-7%H+F;C7;2@&907#&@5:D:%HU?L-I(UT=N\N_#SLTNUF[
M-L6].HJ_,K!(7*3.@T34=V)_L%R[65023!(R2:21")% H>[0 !Z"J^V[?XNR
MQV,QMK+-LQN1]]WO(?)/,6S![I74&KW3N<2T"E   W151;UUQ:;-4-X<==<Q
M/-ZGOK_=KNK"<7X_7K)[H<UOLUN=.D=@17(A6DI-8CC]*2SLUA>1!9MJV*\4
M60.B4>J9I;AH0*_)_P!*TER3$WMY89+BF*9R."6ZN)BS'-@#K+S9)21.V^,-
M&V3G'SW1><UNXN:6^!NII.C8ZG;9LVW23SU],6G56LM6O8DS5!&-;--:/+6^
M:RK54#G="XE%;8J"B9Q$I"I%Z"(B.30-:KH7'<;BL,Y-G1*YT\UE;VY;0!H%
MN9"' ]:N,AJ#TH%'Y?@Y\HHNFH;6VYK/0-AZ(OFX;O0MDA5ZS:"@7>%DM\[=
MX"<IDX0\'*1Z[.W'9HJ@=)RB5 JA%"F.<#0[-!0ZA8N[MQY&-Q]OB,A-:Y7&
MW-U-#<>7')_?DDKYF/B?[#FD2EH-0X;00:DKQM.":"L+R=:6S>.Q+Y8>6.M:
MS0]E6NRQE7(\8OZPQN$6PFJE%04?#PD!%(QEO.@C$IH"@D#<AA5.H=0QFSK4
M]5XSMJUUOF8[[)7=S=YRSCAN)9&QU!C$K6OB:QK6,:&RD"("@V@U)))G7$1Y
M(B*C(I-0RR<9'LH]-4X 4ZI&39)L50Y2_1 QRI=1 /AU'(ULF"(00,@!J&,#
M:^F@HN0PIJ811&VNWN&S-YP.EXK9=TU=5H_54ALR:D]=.8Z+M4[**6UK6(J,
M&;D(^4&.BH],JRRA$DNK@R@%-\"E$L;:!NXBIJH3J=OJ66\9K+<)NH7* O,^
M>VSVL]JWO67UL7:-V+ZRQM8>MS1,M*-6A$VJ4FI'/TTU_3#H8Z?<(F,(F-X^
ME:CQ"--1KZ5(S(5$F$7RE>+W^]E[@_\ ,A\C?^4>368KS;_9BY^6+^W1K8':
M_P#VUMOYB\_R*X7T-LT(NA4PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A%US_/"<[:P<77;<YD'24?M@Z;E$PI.$SM
MWNN%4#D6()5"&14,)B" ]2F$1#H.6FY<X7A )H(V$>H[GZCUZ#[P7<?P>M$E
MCR"*0!T9DLP0=0:MN0:@Z:C0^E=V3.NU\5TPB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB815]6-EM/:\ER,O4'N^^:V-I&V3U-U[
M5*I\E)4G#JH46KVUW*7=@^BGJ]K+.2,X=,4CJ)%;HE "]P?1&9[( %*U4!J:
MFO13%U-:WE\U9K2\R**+>0N>OZ;:WR#<!*W0>6*N1LPZ10 PF,"*:[PQ2@(B
M/: 9 10D>M1 U%5L#/%ZH_\ ++\ECDO_ &?]R_@ZL>$7S0/LG?+?5W%'E-R-
M=[;^<1]7V/J>H5GZT1C$\HUJ[MC<CR";^;C6H'E5XE4@B0YV:3E=(W:/HG*)
MC$LV:M);J!HBH7-=6GIT\%BW(^XN [?2VDG(O-987LKHO-:W>(BUN[<]H]LL
M/0E@<X&GLD5([3W,#G)N/F5N2,XO<'Y>?;5)D^,K*7FK2<A5WUU?Q759]+K6
M1!1D[@-;5\0#L.)DOF+CH<?5 S5,;79V45G";F] W^@ZT^YXD_@^^N=>Y7=C
MDG<GDC."=K)9FXYCZNGB<Z)T[F:N>9 6F.VC\#4>8[7VJQM7+Z \HV\^,5M0
MT-SUI]HD$(H4&2&PU&9%KY$L164;-Y28]!0T;LRMCZ?PE&2IGITTCG[Y!4>W
M/+C&07+//L2 3X>'W/R3ZCI\BJ>'=_.5<&R XGW;MIWLCHT7&VL[&U(#GT]F
MYC_^JP[R 369QHM8<I.0FQ?*+OV$XW<>5GC'0M7DB2SVP/&CIDVFRL#$:R>S
MK4S<%:/6T)$E>'0A8Q44UW!U2G4*1PN5)K-M;>/&0&XN/X\CIZ/W(]?I/[0U
ML'<'FF9[[\MBX5PXN9Q&!^\R$%HDVZ.NI0:.#&5+88C1SB07 />&QP;B]"[7
MI'+O3'%S9AY%ZSKFWJV$"W4]T]@7%-L5JBY*:LU724-\(&:C8M5VLD0Q").4
MURJ@FN5QTK3/$^U?<Q]2PU]-0.A]86J(.*\@QG<+&<%SA>Z*#(Q^6#5T9ADE
M:Y\D0/\ 8WM:7D"@#@X.H\/7;XS%E]#4PB81,(F$3")A%0_YKH1=H3CE?6 B
M@[C9&^PBCDI4S"5<P5&9AA#O$?B@HP=&Z"4Q1[OCTZ=#7K#NKYC#T(!_97*O
MQ,VSXQALM#I(Q\[*Z=?S+V?>+7>D?MP*H.H.6NC-?TCR$T=^^%P:S2T]****
M/GL^-==/4T3V>Y,E5"+3M.O#Q5VB^ 3B?VYDW!Q[%P52K9);6=[K!XTI3U5]
M ]!'@M4X? =PN*8JU[P8I[_,\]\CC5SI/++@#+,*UDAG<7MDUKM(>31VYLHM
M_P#.'>'DN=ZUXRZ/ICVCQ-B8Q<ELZ/-(&5;2M@8&]>6>3,VT!0S75=6,!'*1
M%4BN';GL%1(ZY6J64MO90XW=<S'<X?1^3^N/]'BL_P"9=U^4][WV/!^+6SK2
MVF8UUTW=4/D;J\O>.EK%HX C<]U*M+A&U<YR\\<C/CSHN@;?T5(SJ]^TN9E+
M;,L"#MPC)S7I/4I,FQ(5NFJ885>FSI2"F@W_ .:C!!510RC0ZJRUOS/,Z*<#
M8_H/VO74?A^51]PNS;.'<6M.1\5?*<OC"U]S("0Y]'!PN& 'V#"^E WI'1Q)
M,9<[2?%CC3;/( ZY4[KVA)+OK5+QCUI5+&L06#!;<4PLVL+59,K4$VB$/7HN
M-;L5F92^F@PE4P(4!(3I.N;AMCY4,0]@=1^YZ?AZ_*%C/!>%Y'N[+GN3YYY?
MD)6.$4A]EIO'D2 BF@9&UK6%@%&QRB@% M"LM^<B;1HRO>.YC&2@G#<SIJ,4
MJHY1L"BIY-!-KJ^0:'*5)I!0E]!W*N/5'JFZ[1,)$V_QG&"W;.<@2/H?<_??
M*1HL7CYAS*_XE#V:B9)_I,C:21)](4M7#H(V7&^5U>CJ5HUBWGS0X*VSAY6:
M=LO6-AG)2JR]-3UYMF29J*E^76>>A%(.PKJIE %$:-?TG2R*22P*%:.>B)U.
MY=L4)-G>MNW&.4#<#5OR#4?=']'BLE[D]K<AVYLK;-X.:5]C);>[W;FU]F21
MA9(3XB"X!+0'5#7>R75<P*U#Q&Q0Q_#V+=B10GSW85XE0,<Q3%5!%RQA.]("
M_$B8##"40-\>\IA^X(9;<H:W9'H:%O?X>[?R>W4<E"/-O)W_ "T+6:?P*?*"
MK.LMRW@F$3")A$PB815(^9:%!_Q?J,L0@"M [FKBQU!%;J5C(5.[L%TP*3JE
MU4>*MA[CA\ )T 0$W0UTQ)I<D>EA_9"Y]^)&V\W@UO.![462C-=?HNBG:?5U
M+>OH]>M=O'+QV2.[^&VP]M$;O$-GS,N$IIAF<PI(2D%22/VTTQ.F)BD4^O<B
MY=-&XJ 7T7,8V5 X(J*@>ON+\0W;8O[&![7RGYOVRM.\-[.S<G[<7G( '#.2
M2;K,= YD.X/;_P!NXN8VM*.B8ZNUSJZKUS-;\Y]6_C=Q7MLV_4I^F8N2C7;\
M$7(/H:G,I(JD[9+(HN*I74Y$5])E 1?K%(F0Z;9(>U1PX44F2-@L6R73![;S
M^'P ]5:D_=5EQ%[R[NW?X3@61E><;C(W-+J'<R%KJODD)K5[(PRWBJ  0QNA
M>]SIB<J>+.P^!NQ8KESQ"?2414(E^F%FK"/O95&H)O3$*\9RS<YU#3>L+$9,
M$G"3D_<Q<'3 IPZH*(4MM<QWT9M+O5QZ'T__ *0_"MB<ZX-FNTV:C[A]NWOC
MQ\;QYD8W/$0=])KQ^/:R='!QJQQ%"/8+<V\;O'JV[LV/8^=?($SF?GIVQ2TE
MKT)A'H66L2JIV\E>DF8E!LC$5X -'0B!"^BV41,9(B8-6ILEY"=D,8LH-&@:
M_)Z/N]3_ -)5S[,\1R/*,W/W5Y>737<TSW6^\?3D)HZ<#H&1_P 7"T>RT@EH
M'EL*XKR9\&+W-[$8[WX_4Z=L3V\%6A=E5JG-%EY-&<69*,"VE)BR/ZZD=9H@
MYVLIV)@D59/U5A,+M00BQUZQL?D3D -U!/['W/#_ *%([U=K<G<YIG*N*6TT
MSKJK+F.$$O#RTM\T-!KME95LM!2HW.KYA49^+^CY/0_DZXUZG?*GD;+ 36OI
MBU$1$JZ3*>G-<$N-B8-E$2@1=A!#(J(E6#X*)(>H/3J(!58F[FO)KAT@ A9<
M;8_6SRHG5/KWN?Z-*#UG$\)Q1O$N[O',(UQ??B&&6X%:ADSQ,Y[6T &UD88*
MBM:%U=2!W3,R!=VIA$PB81,(F$3")A$PB81,(F$3")A%'W9_'2N;0N,?>UKW
MMJAV2/K05('NL+VZI)WD($HO,>UD%6#11T[*+]?O[3*>GU(4>WJ7KD0<0*:$
M*$MJ:ZU6M(SA15X3YA\FWIRFB/F\H[G);Y9NZ88?,YI_Z?OI>0]HP2][*/?2
M)ZSA3N54[0[C#T#(O,/H'WEYL]94S<EJ-,(ODK:OVIK?2?VH_D!M#;MWK6N-
M=53R.>0Y>RW6X2S2#K<&C(V3D;#,%9.5?*)-6A'<M)-VZ8G,'<LL0H?$P9C?
M+K:XN^/7%O:L=).[RZ-:*DTE830>H GY LV[>7MICN6V]W?2,AM6PW0+GD!H
M+K2=C02?RG.#1Z20%W9OUMOC'_/PXN_TO5'^<<TQ]G<]^J7'\!WS+>'VIXY^
MO6WZ1OSI^MM\8_Y^'%W^EZH_SCC[.Y[]4N/X#OF3[4\<_7K;](WYT_6V^,?\
M_#B[_2]4?YQQ]G<]^J7'\!WS)]J>.?KUM^D;\Z?K;?&/^?AQ=_I>J/\ ../L
M[GOU2X_@.^9/M3QS]>MOTC?G3];;XQ_S\.+O]+U1_G''V=SWZI<?P'?,GVIX
MY^O6WZ1OSI^MM\8_Y^'%W^EZH_SCC[.Y[]4N/X#OF3[4\<_7K;](WYT_6V^,
M?\_#B[_2]4?YQQ]G<]^J7'\!WS)]J>.?KUM^D;\Z?K;?&/\ GX<7?Z7JC_..
M/L[GOU2X_@.^9/M3QS]>MOTC?G3];;XQ_P _#B[_ $O5'^<<?9W/?JEQ_ =\
MR?:GCGZ];?I&_.GZVWQC_GX<7?Z7JC_../L[GOU2X_@.^9/M3QS]>MOTC?G3
M];;XQ_S\.+O]+U1_G''V=SWZI<?P'?,GVIXY^O6WZ1OSI^MM\8_Y^'%W^EZH
M_P XX^SN>_5+C^ [YD^U/'/UZV_2-^=/UMOC'_/PXN_TO5'^<<?9W/?JEQ_
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MA^7QHK?E,1AN3VAP^;MG3X^0@EKXY6BK?:!W4;M((T(<#X>-%([A]YI_&O\
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M6]M)K-^?]TFPF1:76E_:3-NK&Y:T@/=#/$#NV$C<TM:\"A#"""?;T1R\TUR
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MO(/^1;R*_P!7KS_*$?D_-_Z*G_>?MA5_._\ 9#(?S!_9"W)4/R?*Q_J;A?\
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8)A$PB81,(F$3")A$PB81,(F$3")A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>tm2115679d1-fc_discovery4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-fc_discovery4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!S .2 P$1  (1 0,1 ?_$ /,  0 !!0$! 0$!
M       &! 4'" D#"@(!"P$!  $% 0$!              <!! 4&" ,""1
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MLU-I.^IJ)E;6UJD8,HY)8FC+KPB:66?3%I:T1;/%1@2-S;(G%&B2@&<PF'#
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M H!0"@% * 4 H!0"@% * D3;VJ<>I4?BUJ CM * 4 H!0"@% * 4 H!0"@%
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M2V "M4(]1,'+PB=-#,9DRLTM^*=#LGEJ3D@\7$P,QF!D,W)_&3CV1P+3=ZN
M-QV37!ZJ@*5FZ230X_84D^H5NU%PKYJH7-DN,Y6[+TTD9Y(PY)<!H@M6.G''
M#NQ(<E$SUZ Y)S4#-V(NY+R#@')R3"A6'<"\LW2"Z,7[ D@U.-^H6!APC$Y8
M;CZ3S%R-=612P9&+5MB &-7B(/38WS=OR6K6O:$I-'36T+TK&N36)2F7/)WP
M,CZ>]4VG_57''R4X!R:R9#;8L]VC4M1I$SPQR:'2 2%,Z$LLRADI;6.81%S5
MM2TE402Y(4IBA*: XNPBQ!%<#576UT@RK2ME'3GAN'X-R+E:39GSOI:Q[/9R
M4PO+)AG!^-=1FH5BP.@F$IR2K0@8'Z?.KTK6$,<3:SU+J8).)<N D;RP&*0.
ME- * 4!(FWM4X]2H_%K4!': 4 H#C1#-6G2/Z@<FZRFK37B;18I@&E/5#---
M*)-F;)6;HI.YX]0S&N+LDC<.<P['LSC+$D>$F4$J,H\=C;D'$F#&0(%@[X$%
MQ9TY."I,;IDE>7TS7@G&NHW2')\[MY+TI?)U/T^6X;F9'B62XHA[# &=\<,C
M-;;S!Z<0.+8WF&'-C=SX91";B<,#?V;=(KHGQ]BG$F;)'J&A)F.,]%JC<+.\
M8*?YT[92 VDV/>A0>'0=FD4UD7<T6+X6LF;AW:!>I6< 5KVH"D=NDDT.,V&,
M?Z@5&HN%+L5Y6>W:,8X>(\FDDJ?YE)H[=P#*(TQ8^C#$[Y$62.(":E(7E!9J
MLK9Q$#LM+(N&]J O,@Z071C&,'8\U(.>H6!G8:RXN.:<5RMB-=92KR.]I#'8
MISCT'B,8;'B:RF2,1C X6<FU$W'+FR[>JYV43S<[< S;A/.N(-1V/FS*F#<@
MQS)< =E;HVII%&U8CR4[PQKCFM]879$H+3N;#(V%S3F)ES<N(3KD1X+EG% '
M:]J YIZC-=.M/ ;+GO4JYZ4,7-6BW37-GEAEH)YER71K5/E3'L0>T,=F>:,2
M00K&:S&1; )8L/515G<I!9PF"%#819J$Q<C+%4'86J 4 H"0?F#[I^4T!'Z
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M4$)2=*E3%!++ &U@@ &UK6V6J@*Z@+HS=L"NI-ZV*@/-U[8*>J!UL% 6^@%
M* UIUH1*23_1YJP@D-9UDAE\UTTYVB448&\(1KWR223%TI9F-G0@&,L UCFZ
M+"B2K7$&UQCMMO:@.6>*YYF/-O1^M'1W^2/K1T^Y9E^@-_TQ%9NRAC2(1W#F
M/\E(]++M!D\A<Y@PY0?)&E:KRM $IN4$M8CCE)R>UP%;]Q  U!TW8#R[)99H
M^87'!O2J.&4-+P5LN<HSJUR-A"&:-\%3B#X+G^/6UH@LOB6-ERG-L:F;J[AB
MK2WQ$XI*.,/)JMQ6(0)N:'U!!<2XUUO9'F'1N!EV-M<J9!I\U.83F&;,,.VG
M323I7T/:7D*&&S*'.K-@>%8XC967<M1Z%R.6V1M#JDD,@9D$9+4JUBFQHTQ=
MP,D-4 U%MNF/H]>CX7Z&\]O64M'>O+1)+<K9]41:)#P.."X2U81B5R_5! ,F
MFR4:J9.V5(@<I=W)O2([/[66\NX74!(DX^= ?4E5 * 4 H"]L/MPS\&'UTF@
M+6J]LJ/MYO7!4!\T.NS23J1R1&/YA5'!L/RZ3*M4.&]'##I^);4R48\JO$#Q
M&H8Y@WQ;B*R[*%$?=A6(46,X5@F7Y+WMRT!5](QT?VH=HUKZ7,Z:08>HEF"]
M06OK0KE377BYJ$221 )UIJS7#9.Q:N(RV&*DZ1-V<QFVN+%.[IP6-6B;V=:,
M!Y]CC0 98T\98SEHUR_TDL=>=!.L_,A^<ND!R3GO$$DP_"<9K,>R^&RK".GR
M 1[CS6<Y8@Z2/F*9/CE>!0>K)"E2)MPX9E[;P0@94TE:#M7L+P-'UD@U<9!T
MF9DRIG?4CJMU%8WP?#-->5(8JG^IO,COED['YLES9AK*:[F^-69Q*9!*V!4@
M3+E/.3PB-!=,8"N@&@T@TQ8E:-;W2+3K5;T6^JG5*'+>HZ(3+"^4<40-ODL6
M68U0Z=L-1)4C+6F9HQX:!0FF\==;" )&9?DV\2]KV#8H.BV#L6G2+6?HLS/"
M],F2\&X(Q=T>FKK#S!%\MQAJ9I3B"7KM1VDYM@L4<T1$FF0F=YEF/\>R!:VF
M$N"DQ0Q[]S3 7-&35 <_7K'6L?!ZB*%,6*,Y8S@ZS6KTNT^79TTRZ7\):E=5
M<"09FUA.DLP6QX]9<OLDS:,88=SWC)V6.3P_(F-U,/LUMB119O ,*FJ@Q=B/
M!>K7$0L"Y@R%I#U69E.QETPNHO5),8KD0>$9OJ"<\*Y%T(/T0A^;9 /'*V-8
M;?,@,LJD*=2)GC=RN;R=N$TMX#%!:<9H&TP,(9[SEJ/2ZO6K3OD_%$"RCTEV
MC">-V/,AL39&<H)\8:=-,^6\:S347DR%HW-<9"29=(Y:B9DB->;=\[$L2$]6
M018\D@J@)AHVTKYJAF>=!$LG^(7MH:\1K.GJ<)&]/+>@,!!U^ICI!8%/\&KA
M'W..-;UF4<4%N2UN-)]6:VB. .X+#$ 508G:,?92TO:F\?:@WO"LFR.J:M<?
M2UN['IYA+GC@G.\TQIJ8?\4/K+J8PICZ<32&@R0C@Q$'LA>BVY59T2LDU/4\
M,8;&%&@;>=#=)GB=7Z3N?O6('/!2F==*/E:2 QL]J8HL?F3C:8=(S>N-E"B#
M/,CB0)TO=V]2=)$J-P7=C)&)>A//&J3'WJ@.WS#ZQ=U)/V#Z CM * 4!PY.Z
M.B.Z@>D[U[Y@U PW.;9C-^PWH98<*S+&VH[47IX9Y<\1=IU"$96;SC=/67L8
MFS-1%C5[$'8\@5V;KK;\SN5SI5Q ,Q2;11"\0:B.BUCVG/!K=&\"Z<9_JMDL
M@LRHQN3=!''(NGZ:LR"7/[T^K'&0.<HF<SD)P#W94H5N2Y:L,&><,1@Q7 T6
MS3C75MBF8ZD); \-9!:HA/.END>:3<S8DT[XKU*:B\8XQ5='=I\QO'\RZ;L7
MY12/T="YRG+,==8F\/X&EW<&UL/<+!0&E*#3RJ@U^8=-FH-SBFM.<YJT]=))
MDM).M5>C;->-LKF3_ F/-?<9CL%P\ZP(W4?C..X9BZ#%2R<8RD+7S3YN.QZ9
MP!$7,-EQ)ROBMYP%#(-/>O?)^-FK)4B;]9\\Q9@'7GC+.<2?S\88!TY=)=ES
M&:C3'D#!N09RKBK&T$PF=3+"$AE[,9&54B96J5OS(W.*8H!8R&@\T#J=T9&(
MU[7F#5%GQ3#=>#2FR1&\'XY29&U\2N"H\G9:*Q<;DYV"<VX9BD$C$AA4:@(L
MAC1HGF0JAN+U=<>22C3)&\DY70&RG2)XSGN4\78"9L>1=SECI&=?71\9,?D3
M4668<UP+%^L/#L[R!*%5C32K!;(K$&%8X*A6O<04Z<=PA%?9:X&_5 * 4!(F
MWM4X]2H_%K4!': 4 H#@7IXZ*[&>6LO=)//M6&.\[MH\J:_LFR#'*)BU0:H,
M-03(N#7/!NGYJ;GY5CC"V:X-CZ6-CW)D3\@4*W1K/6KB4MTB@9B4A.4 #;^(
MZ8TN,^D9P_)\<8?:H=I_Q/T<,PP'!W*.L+8VQ*#.AF>\7O+3CI@ G" QJ$HB
M4;$?P2@V 82EVC%<5K4!R<;<=ZR\"0[3A'4>*=0N(8HWY#Z4EP>LSZ3M+N!]
M1.K&*+\Q](7D3(F,,:M8LR,,Y;,/85S#B-U2R%2[(V186N5(6T"L]OLG*$;4
M&/8;IFSY"L"1-\S%@'I*XADE@UXZULFLVHC3U/L.2O6QAMFS@FC<@B$KFV.8
M+%W[$&H&'9Q:E D,V(84*AL9'MO 6G2F%AYTE J%&G[72J3Z1M2><6'6CW)X
MNE&NG&ZQPTE8^P9A[6ZDQ[GZ;XFG.*]1>6<"Q!LE4"43"?.&/'EOFZ.,)4TA
M$0Y-KDJ3A4&NZ,('9#HLL0+\;8WSU,U\$U1P(>=]1#YE$L.L*<0629RGA:;'
M>-\=@RE,(ACZ)QAFQ,NEQ4% 2%C5&.#N8E;R'!>:2I6F(TU :/9GR_F_/6JF
M1$ZFM"^O:0:3M-V74ZS 6%<-XGA+]!=14SQZXV4,&HC/LE>\KQA?*HBU2=*4
MY0F$%(T[8F.2$.SP-P5"2HVT#Z(Z 4 H"0?F#[I^4T!'Z 4 H#YX^CXZ'C S
M_I18PZRL,YB49+?,U:II'.<33;4KJ<28C>&-UU=YHD^.;O\ IP9<U)]/CC'I
M# 5#*YC0FQP:-RNHYTL)-5''F# W9@^!)4SZN.DZG!F-.Q\3R]@32G <8OH6
MAM)0S$F!XRS8T/T491EVL,Q!''.2I21I1! 06-7;=#ZJ] <DX#"M<>'H;I$Q
M<LQGK&PDFCG1BZ#,0$230MIOTJ37-N4<I0+&3HVY.PKJ$U':AH].$."VK$DL
M,)+8DYY+0SD#=W%=9T,&8:054%@B6F[.6'=,'1T=UV%ND8P-G3#^G+*^*GK4
M%H6<8%E;)<$DX\NE.YN#,]Z?Y!$Y'&<K8=F8V=/(6F1ITRA)SU);;9 4J"<8
M!;HWI_UK8[F^'=0NIN)Z\HF&?:,X;@Y5YM")X6C4YQJ^X8SUJ DL'C68\#QA
MJG+%#2\NX>R;''M>7#3NYQAFJ5U0GV"FL@.*;(.]G1I8<68,T>X]A2^ Y4Q8
MI<I/ES(IF/,V9!AN2LHQD65\NSC)(K31^QW'(O!6R1OYDIN[+F1J3G(F!:X&
MMQ:I99-SHV@.;,H:LQ:FM1FE*7G]'SDO3?K\Q#J%Q^?GG5L@;6I!A9LTMXXF
MCG\ZL&BVH5.[I7;/F-]0.-1FMC##!H#3FUQD=W%<C;U+:<=>H/H9J@% * D2
M_M,AZHCK!M 1V@% <)\09!S-T>>5==^.I5HSU5Y[:,[ZOLF:L=/N1-.,$8,B
M0>=,N;XM!356/I:\CEK0/$LQA4\C[@WK#9&2WMAB 1"PE0:4(0K@:.P""9,Z
M/">]!'%LMZ?9WF[)6*]*/2<O.5(9@1J9\GSK$DBRY/-(DDD;M#V(AV1G9 #!
M'G)'<RXW8CEB@QN6*EJ:RE,4.XP,S0/$6HC#&>87TB\BTFY@=\9RW5;KIR@Y
M:8H2SQ.5ZB,(PS5'B/2MC/&^:EF+FF1#;'.8NCGII?G*3LS(X+)$SD9356&4
MI/)="JJ#((7G.#'JCQ+TBZ[HX\DQ?"J-1J_Q:9B'&\%AKQJQ0%YV3:2G.-ZS
M\FX<8W9&H-G4\<\ O\8>4:16XRQMBBEF$J*-N-:G1@63#VG'/4_U=82U7R+3
MG,L3XURGTIV:-4GS339MC14FQ!C-'T4DJTOQ3*F58\RO+XTP^=9=S;$$KL8B
M+/4KD2MU0C4C L$< AM EN2-*N9UVDGI0H6Q8?>3)AFWI-8]FB LB%M;RG&?
M0-)D[2"\G3M#8!H K41+= W4^YQHK&V"WF7V;0VVT!^BM*^:EN9H(\.V(GM;
M'6GI_P#(>JA4J7MZ!4@185'H*RS!8MEVX#SC @9"<IN+:C2*+!XY+D(D80AN
M&P[ 0S5+AK)T(U7YHU)7QSW1LK%TBN@;.>-L:*)% HI(M6!, T6S3"TLA>%K
MS^2Q>.3++L!<I09)F5G4+4JAP<(:$E.8 P)9@*@SAT=V2GS,O2:=*CDUWT^3
MK3N6[X<Z.%C(C>3R84CR5(#8ZDUA@O),ALT$D\R;HM)E34X(@)6Q<X#=@1L+
M2K/*(*6)R[4!W"H!0&0/>] 5% ?']TP,;<6/7#.G5:$5DLQB>.Y$T7O>]PB0
MI8BW1$W=Y-EMCG%E/)_IY?3KN'J%JX),B14T:_Y\4TNM^V1SD_L5#\]/B/HY
MX>L>:LE1?5Y::'4_^V-K5P_:BG+^WI?ZMM]G_P!:FI&HJJJ[) #7.;AAW%_X
MG7'4_?;T7VA'^]60_P ??O\ P_TUS]DA,.NB_=S@_P#FATOGU=;J"RVO_P#9
M_P E/Q+>3H<<<7V;?_\ *\[_ +;GEO\ ]:\[6B.Z^JU-KV>[[\1=7IZL^'&C
M5-GVDS[DIR1MR>E:_+Z=MMMG_P!:Z"5>$;JIH397Z3F!/$CQT*Y78'>;H*F%
M<HR5G"2V",+:@AL<:C!\NP:Y<[*CRBQ;/4VOP$HQ>CZ(:YI^(R>.*WV^B546
MH=*]R]Y,$P\)UQ\+-+))<;G7M35I6QL8G?=BN/\ Q/I;KDT[0% * 4 H!0"@
M% * 4!#7KV\/[67_ +M 6F@% * 4 H!0"@% * PVJT]8179T;-3*[&,16Y\9
M("HQ>R956-9:J6LD#6.:AW71YF7'W,"U)W!:J'S@U. M0H*O8DPP1(0@L!F2
M@% 71F[8%=2;UL5 >;KVP4]4#K8* Q9EG+6-,$XWF&7\Q3:/8YQE &8]_F$T
ME*\IM9&1L(&62$Q0>9M&<J6*SRTZ5,2$Q2L5G%$$%F'&%EB U3PATD>E7/61
MV/$<;>\JP'(DS;'1_P 81C4%IXSYIK79DC3.F-7.$@PX+/.-\>I\EI$C808L
M.3M(U+@F1%#4'IRB0"':N -[ZH##;SJ Q(RFY!2BE1CXY8HFV-\=9)8X3'95
MD*1PJ9Y;%"1P-DD,;@C'(WYO,<VS(S*Z*3AIN;M3&O Z+S$S: Q4 #,E 0^>
MSN/8UBR^92J[[9C;53,C57C<1ELY>.._/;='F[FT8@S)(Y,N)NYNI/'-(1F%
MHT^^I4"*3E&F@ F% * PW(=0&)(V=DA$JE1CP[8A60%OR7'85'95D.50]=D\
MY""#I':)P)CDDE H>DSF0MN$"4=TC8;9<IX*/:?0&9* 4 H"]L/MPS\&'UTF
M@+6J]LJ/MYO7!4!X4 H!0"@% * 4 H!0"@,":@]+>G?5;%FF&:C,/07+\=C[
MV5)8XDF3*2O51F1$ISD87V+NY=R'F-NXD*DU.-0A4)S3$YHRABN6,0;@3#$.
M&<3X Q^Q8JPECJ'XKQQ&@J[,<+@K"WQU@0&N"P]Q<U@$#<224<XNSDJ-5+%1
MF^H5JC1G'#&8,0K@9M8?6+NI)^P?0$=H!0"@% * 4 H!0"@% * 4 H"1-O:I
MQZE1^+6H".T H!0"@% * 4 H!0"@% * 4!(/S!]T_*: C] * 4 H!0"@% *
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MF/TJ='JC EX4 H!0"@% * 4 H!0$->O;P_M9?^[0%IH!0"@% * 4 H!0"@%
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M!0"@% * 4 H!0"@% * 4!(FWM4X]2H_%K4!': 4 H!0"@% * 4 H!0"@% *
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M H"0?F#[I^4T!'Z 4 H!0"@% * 4 H!0"@% * D2_M,AZHCK!M 1V@% * 4
MH!0"@% * 4 H!0"@,@>]Z J* XJR652[0+KOU+YIF>)LI9!TY:NX_B5Z!D'%
M,07SM5CB?8Q85L6O&Y@T-H K$:1Z,=5:DA1ZD @*$Q15CQ@4W(F*GI:3/62+
M=9Z.JIJ?,-IDG;P4\B1)-%,Y'Z\;ET*K=5J*G><JZJ*W6@:JK*WJXZQ+K?JZ
MBK*G*][BIW<-3QK,L$T#%CU)6MTHC]9SD=L>,Q$UE1^K!HJPY1U.9,UV:V#\
M/Y$QEC][T3SG3/@F,3R/K&;(F2D:AM5RUQE@8=<HYR3)UCRV$DH+!WPJ@*P
M*N:8 W<OJF>V9;MUDR:VKIZFO9>8ZRI?$]'10JBI&C.$V%5&JJN^SJJJX(J8
MX^CIKOFR[9BSZZAJJ2VR6"6AI(YF*V:=%:LCI."P5R(KFHC-G61R(W%47#$Z
M;"$M:M*/0N(6O$DF0R6#ZO<*R*>I4D%=B7Z'MCC,'!TF3U+BBVNSC'FU4>G3
MG.)ZRQ)-[E%"-OL #9E'7JEES1G!\M7&ZFGM-0R)5D;JR*D:-C;'XV#U1%5&
M(W%=*X;*F&;E^MAR=D..&BE;54][I7S(D3D?$UTBNE=)XNLQJJB*]78)H3'8
M0KXY)R=,*G71@S.>CW(.IS)^<]6LBR[C&+E8S<Y+!L_0:7.L=60HHZ=#BTIC
M;4G@)B58X*2U99P&XXXTD(>($W=\ZBF7,K;)>K)=J>VVVBM3()G\,C)*62-K
MTD_RM=CW++BUB*U4UT1%70J'I2U;<I/S#E[,%CJ;M=KA>GU,$? .DAK(I',6
M+&7@Y&-2'!SW(Y%1BJK43%'&6W]]MI1UZ9OSEJ"P)/W_ !OGC3YBB,XJ=,;8
MW5Y=9\>K(G$&UAGF!!BCS:-.@-D[RB,-(WRDJ!:38%Q;I0AW+Q4$'2C(]%9;
M#701W&AKYWSMFE2!TJ/D5T53XZXKJ-5$72YS5QPQ7#'-5-1T.ZQ;AF#,MNJ9
M+5<;93QT[H(%J6PK'&UDU'XC<&\(Y%5-#6.3#'!%7#67&&G3.$$Q]T99,BQC
M,F$HW7W*\P!@); YK56$<72YS;EL>9YB!"E.*BY1)1)BTT*JR?FHEMRC@EG@
M-+#LERS!9:ZOS&M/4PO5+$R#A=9$2IF8U4<Z/%?'VFIJXZVKBBJU45=3M&5\
MP6ZV93;54D\:+F22IX'4<JTM/(Y%8V7!%2/!$5ZZVKJZV#D1R*B21<J-T]Q_
MI,=/.9-.&6LGYBU39:S+*L+2B*XD>9LQYFC>368*+&#<EEC:W+D+&;CF0'B<
M5!9AMA,QRL?-;#4%6"*W8U+]/ER_VBXTM-:+92T[*ACYVQNIWPNQF56*J*[A
M6IJ(J)_F(U-;!JEU(]V6:;->6;[:ZVKOEXK:J2EDCIG2LJF3MPIVI(UJHS@'
MKKN15_RE<NIBY,%OL#QUE;1AJ/TC9(SCB/)N=V-IT!QS3P;;$T./RQ(,2Y72
MR@UW TGL;28M&F0FL(CF!(Y &2G7W4*+ '<LH[;X5UPM><,O76W66KIJ&9]]
M?5?Y\B0-G@5FKK(YV&*ZV$KF*BJW!N*8JA<VZUWC(F:;+=<P457<:=F6V42^
MKQ+4/IJA)-;55C<<$U,86O141^L[!<&N,%X3Q@[3KHV=;\JAL3+@.1-/'2$Y
M/U)8UBQP&\\>/9'AMBQ5(UL<#9L."A,.9(@%S;062&V*$98/#N(&RU\W>;E%
M1=8EEI:N7A[?<+!#23/TIPK*AT[$?IT^-)J/\9,<-G2:]8+3-<.JO,%90P^K
M7.V9FGKH(UU5X%]*RG>K/%7#%D7",\5<,<,,4.K715LSS*\0Y/U8S%L[&3;6
M3F699?,1F@O92RX_0.*J+8UBW%%_2*6YH:FY0H1F"O>XTR\(MM]NV\7]9TT-
M+=J;*U([6HK11QP8[3I51'S/[RN<J(Y.ZTF+J>@GK+)5YSKF:EPOM=+4X;;8
M4<L<$>.VUK6N<U=MKT4ZB5&A+@H!0"@% * AKU[>']K+_P!V@+30"@% * 4
MH!0"@% * 4 H"Z,W; KJ3>MBH#S=>V"GJ@=;!0%OH!0"@% * 4 H!0"@% *
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M0_6!]-7B7SE]Z@/AA3L S)SVA\[Z,?,YE+W?<?,^E'U@?35XE\Y?>H#X84[
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M/G?1CYG,I>[[CYGTIG+3ATS6G#49F&(X90P_(\ >YRJ.:XX]30N+ 853_P
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M?RN-;C]+K8-R5 Y?E:!RJ:LZR>(I_B"<,IR]AS.B[!B0D<_A32&Y=CDX"V]
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ML'S)FI+=M=GS#LEP3-T[;BY]=H8N,5JW%YFR0$'G*Z!R54$E*-)<X@U>02K
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M+I1C6MVC9JM9-O% * 4 H!0$B8?6+NI)^P?0$=H!0"@% * 4 H!0"@% * 4
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M60YMU"J F*ME]P"JZB<I;DD7OLVB!88K?[-.U_K#VKC_ ./2^A'85U5^ZO\
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MDB,2-&P&+Q6'V0+4N3B4D*%R<.R,XIJ../M?EV[Y9>STMM- "$R4""J[)HV
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M.$=OEIP)FE6$Q-8/H#%< KW_ /+:B8;8(^09*+H58E*-@ Y6N#F)1#DXF(3
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MUP5 >% * 4 H!0"@% * 4 H!0"@)$P^L7=23]@^@([0"@% * 4 H!0"@% *
M4 H!0$B;>U3CU*C\6M0$=H!0"@% * 4 H!0"@% * 4 H"0?F#[I^4T!'Z 4
MH!0"@% * 4 H".R:(1*:H"6J91>.RUL3JRW ANDS(VOR A>42H3%+24;JF5)
MRU9:=4:6$RP;#L P8;7V"O:]]07.Y6J9:BUU$]-4.;JJZ*1T;E:JHJM5S%15
M:JHBX8X8HB[2&.N=GM-[@2EO-+35=*UZ/1DT;)6HY$5$<C7M<B.1'.1%1,<%
M5,<%4TAULX9P\P:4LY/+%BC&K*[M\(5*$#JT06+MKDA/LM1!L>C7(VLE4F.L
M$5[;P!!%LOZ-2UU3YIS/6]8UHI:RXU\M,^K1',?42N:Y-5VAS7/5%3O*A"'7
M9DS)]OZJ;Y64%IMD%9'0N5DD=+ Q[5UFZ6N:Q'-7OHJ*83Z&G^&&=_X\R?\
MR]Q=6V?%+^H%'_1HOYFK-*^#7],*_P#KT_\ *41ULKFLZU)$O[3(>J(ZP;0$
M=H!0"@% * 4 H!0"@% * 4 H#('O>@/\Z'6__&EJ]_\ RAS]_FO+*_03)?\
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M?]&B_F:LB3X-?TPK_P"O3_RE$=;*YK.M21+^TR'JB.L&T!': 4 H!0"@% *
M4 H!0"@% * R![WH#_.AUO\ \:6KW_\ *'/W^:\LK]!,E_[.M/\ 3*7_ / P
M_+_/_P#OR]_U>L_F)"HQEK0U"8?9\1,4 EZ)E;L&SJ59&QR"\<85IS5*9LS*
M8_)5*Q0L0''.Z-R9UAI DRJYI 0#OL#;;7S<LGV&[35<]?$KY*V!D4OCN369
M&Y'L1$1?%5'(BXI@O?/JTY[S-9(**GML[8XK?423P>(Q5;)*U62*JJBJY'-5
M4U78IIV"6L/2#ZIHV[M;\VSMN[*L^=ISJ11*U<1C"T8<MY&8G6-RM^.LI:S
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M0_,KK-_4*\_U&?[ZFFU;<:,* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0'<#H7]<-\&Y7\G3(CSP,49E>" 1E8N/%9%#,IJ0DH6PZPA"N!*U3@!13<
MION[H%H49M[EEV4#O"77-DCVY:ND5N9C=:-BZZ(FF2!,5=]+HM+V_P!W732N
MJAT/U!=8G1V]=%;I)A9:^1.#55T15"X(U>\V;0QW<?P:Z$UE/K_KD,[G% *
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MA;(TA?<(Y0TN83R/>/XQS%E,K(<H12DZ;+5T2CXWUI8%9J.1I&>[&6<3PKV
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MD</-FCBHECZP7$ E4WA5EW7G+Q'IBR+DVW=&NF9\P5=GH(+2^M5M5>Y8'O\
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M::=7/ C5DJ-1N60O-<^=IL\QG(CVU/)Z5_F2D39)U;P$YM'=>JLKLG<##Q7
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M% * 4 H!0"@% * 4!>V'VX9^##ZZ30%K5>V5'V\WK@J \* 4 H!0"@% * 4
MH!0"@% 2)A]8NZDG[!] 1V@% * 4 H!0"@% * 4 H!0"@)$V]JG'J5'XM:@(
M[0"@% * 4 H!0"@% * 4 H!0$@_,'W3\IH"/T H!0"@% * 4 H!0"@-2=>'\
M(&?O[AJ_QY#4E=3WZG67\8GW7$2]>_Z07_\  .^\TU)Z&G^&&=_X\R?_ "]Q
M=4E?%+^H%'_1HOYFK(D^#7],*_\ KT_\I1'6RN:SK4D2_M,AZHCK!M 1V@%
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MY-:7C.TO=^F5_P!RE.WS)W-KGR<'Y@?+-GSG=HY6H_*CZO)K2\9VE[OTRO\
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M -;?TJ,Y?M#D/ORG0#)/NJAY)FX.TWK"]\W'EW[H\O\ UM_2HSE^T.0^_*=
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M#[S= NKUBUF:?8_D<JZ-#/&40(KE2-IKV+LS35 E(,4K$:41AAH&"2)C0+D
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M<:L\=*S?@7%'9&68NU)RF+J33U$C4+Y+/"4C:FGEA!"XI5Z<)20C_IT@";E
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M3#ZQ=U)/V#Z CM * 4 H!0"@% * 4 H!0"@% 2)M[5./4J/Q:U 1V@% * 4
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M% * 4 H!0"@% 7MA]N&?@P^NDT!:U7ME1]O-ZX*@/"@% * 4 H!0"@% * 4
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M6)6<(Q-.'CM0QLU8FRH^NCZR,>-,@/+U%G!$T29H:H;(W%TCCJY.789N;'U
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MNRU<-RJTXWT4 H!0"@+HS=L"NI-ZV*@/-U[8*>J!UL% 6^@% * 4 H!0"@%
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M$-8JJ:6CJ9*2?4X:-ZM=JO9(W%%P75?&YS')CL.:Y6KLHJH66O8MQ0"@% *
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M5^OHT.)BK>HA#7#0'.-;&(8!%,V9K?,Q8BU"11VQ9#L=/[E@J9+$D-A.6)U
M6V--2:"RB'/:P*EM<26Q M4(T1]@;U@7L"T9#5UD=]HLFU<\MFHV4\]*]LTD
MK4J8T622".57N65DC4P>Q7N:CG-QV=-\^>BH9<MW#/M#30W^ODJ::MC=3Q0/
M=22JD451-"UC4ADB<NLQZ1L>YK788X:)7&=.C-B[4'AK1Q!FS$3ID72]IKS)
MG_-4M?<.-.9IU+,BSG@N+%&(/ S'J-EY R=!8<[-AT7;EJP]I),6#5F)5ER
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MIL,UL51'N>B=7*BHFD4 H!0%T9NV!74F];%0'FZ]L%/5 ZV"@+?0"@% * 4
MH!0"@% * 4 H"]L/MPS\&'UTF@+6J]LJ/MYO7!4!X4 H!0"@% * 4 H!0"@%
M * D3#ZQ=U)/V#Z CM * 4 H!0"@% * 4 H!0"@% 2)M[5./4J/Q:U 1V@%
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M1$3!-@_M * 4 H"Z,W; KJ3>MBH#S=>V"GJ@=;!0%OH!0"@% * 4 H!0"@%
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M%':4,^U@#9A0"@% * NC-VP*ZDWK8J \W7M@IZH'6P4!;Z 4 H!0"@% * 4
MH!0"@% 7MA]N&?@P^NDT!:U7ME1]O-ZX*@/"@% * 4 H!0"@% * 4 H!0$B8
M?6+NI)^P?0$=H!0"@% * 4 H!0"@% * 4 H"1-O:IQZE1^+6H".T H!0"@%
M* 4 H!0"@% * 4!(/S!]T_*: C] * 4 H!0"@% * 4 H#4G7A_"!G[^X:O\
M'D-25U/?J=9?QB?=<1+U[_I!?_P#OO--2>AI_AAG?^/,G_R]Q=4E?%+^H%'_
M $:+^9JR)/@U_3"O_KT_\I1'6RN:SK4D2_M,AZHCK!M 1V@% * 4 H!0"@%
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M>-CW01X:[D15:W67!NLJ)@W670F.&*Z$+77H>(H!0"@% * 4 H!0"@% * 4
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M#ZZ30%K5>V5'V\WK@J \* 4 H!0"@% * 4 H!0"@% 2)A]8NZDG[!] 1V@%
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M'A0"@% * 4 H!0"@% * 4 H"1,/K%W4D_8/H".T H!0"@% * 4 H!0"@% *
M4!(FWM4X]2H_%K4!': 4 H!0"@% * 4 H!0"@% * D'Y@^Z?E- 1^@% * 4
MH!0"@% * 4!J3KP_A S]_<-7^/(:DKJ>_4ZR_C$^ZXB7KW_2"_\ X!WWFFI/
M0T_PPSO_ !YD_P#E[BZI*^*7]0*/^C1?S-61)\&OZ85_]>G_ )2B.ME<UG6I
M(E_:9#U1'6#: CM * 4 H!0"@% * 4 H!0"@% 9 ][T!_GD](=_'1JR_QYR/
M_P!QK:[[R#_LJU?@8?N(?F5UF_J%>?ZC/]]37SYV\B_-'\Q'=.J^:7YQOG;[
MC.:MO,OG%[F>X[NGY[S+LOSKN:_Z3A<XYMN>JX>_ZJL][*M_M7VYP:>U?5^
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M@1B.>N*HU'4SE1,5T8N5>^I!7/H"-%K8),'NPUBN'.4P%.\V2#%"L)&_>]N
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ML,_D\T$"W-#V[AKE._<-MJ1/QK\8(-[U7+;9:UZ8#$\$DEYVI)3=@),FXP[
MYPK:N"F*VVO?>.-XXMP%MGH[+TP^@8G\52;FR@Y/W/2=1P3!E\=*T\5.;N7O
M;B$F\X#Q"Q;-MK[+;;4P^@8E0I?N;)$:OL,_J.>!'?FR9NXJM+N;O(L)XP>
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MF][U0J5% * 4 H!0"@% * 4 H!0"@% * 4 H!0$->O;P_M9?^[0%IH!0"@%
M* 4 H!0"@% * 4!=&;M@5U)O6Q4!YNO;!3U0.M@H"WT H!0"@% * 4 H!0"@
M% * O;#[<,_!A]=)H"UJO;*C[>;UP5 >% * 4 H!0"@% * 4 H!0"@)$P^L7
M=23]@^@([0"@% * 4 H!0"@% * 4 H!0$B;>U3CU*C\6M0$=H!0"@% * 4 H
M!0"@% * 4 H"0?F#[I^4T!'Z 4 H!0"@% * 4 H!0"@% * D2_M,AZHCK!M
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M% * 4 H!0"@% 2)?VF0]41U@V@([0"@% * 4 H!0"@% * 4 H!0&0/>] 5%
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MT4\C"WL #K[HAJ"R31;H]PL5PV"+X]K0K5K1LCE=(UZ-<J-35;C^\JXZ$^G
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M_P#=H"TT H!0"@% * 4 H!0"@% * NC-VP*ZDWK8J \W7M@IZH'6P4!;Z 4
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MJ@=;!0%OH!0"@% * 4 H!0"@% * 4!>V'VX9^##ZZ30%K5>V5'V\WK@J \*
M4 H!0"@% * 4 H!0"@% 2)A]8NZDG[!] 1V@% * 4 H!0"@% * 4 H!0"@)$
MV]JG'J5'XM:@([0"@% * 4 H!0"@% * 4 H!0$@_,'W3\IH"/T H!0"@% *
M4 H!0"@% * 4!(E_:9#U1'6#: CM * 4 H!0"@% * 4 H!0"@% 9 ][T!44
MH!0"@% * 4 H!0"@% * 4 H!0"@% 0UZ]O#^UE_[M 6F@% * 4 H!0"@% *
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MG#V7W2P7OLOZ%9"U6RKO-PBME"W6J9G:J=Q.ZY>XUJ8JY=I$4N*6EFK*AE-
MF,KUP3_FJ]Y$TKWCO#BS&['BF%-$.8P6&!$5QG)P$"P#W=W/"$2]S4\HA6$H
M-ML+!>XN$2$!=K[H+5V-EVPTF7+3%:Z-,48F+G;;WK]9Z_2NPFTU$:FA"9;=
M00VVD;2P[";*[;G+LJOT_P!B8)M&1*SA?"@% * NC-VP*ZDWK8J \W7M@IZH
M'6P4!;Z 4 H!0"@% * 4 H!0"@% 7MA]N&?@P^NDT!:U7ME1]O-ZX*@/"@%
M* 4 H!0"@% * 4 H!0$B8?6+NI)^P?0$=H!0"@% * 4 H!0"@% * 4 H"1-O
M:IQZE1^+6H".T H!0"@% * 4 H!0"@% * 4!(/S!]T_*: C] * 4 H!0"@%
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M!JG:=GCGWF:?T0Z3WSC_ /!'O!Y7FHCQA?JG!_!JG:=GCGWF:?T0Z3WSC_\
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M,Y_[KN/XN3[RD*7O_P#;U/\ UG?\2]P3"J68PB&RXR0'H#)5G^/85,0@;BU
M$25\:$;F*0 /$K*$>>G$JW+)[A"$5K;>);;LJZM.5X[G:J:XNF5CJB\1T6KJ
MHNJCV([A,<4Q5,<-7!$7NGK1VIM5215*O5%DK6P888X(YJ+K;.UCL?VF65&D
M9,1FTG&%IL<.-7ACA,54QLS WTQ#8ZK(VM1W;;+[EC4$25,%+<-CMZ_$#>UK
MW$&U]C?U<L;FE+"E4JT/JKIEFU-A&O6-S=76PQ25$;AK8Z4[J(N2=EIJ79+?
MPJ^K\$KU?J[&"JU4PQV==,-G;*=STGHTD'RW*$<T4JG/&LDFC.C9C&4HD#ZW
M0FS:I='$2NS@9=(<!M6&'7*" S98KT;AWA!^)^KR*.U7&OBJG.GH9YV(Q6(G
M"-@U5<['6T+JJKL,%V-G#%4^9,N-;25-0V55D@D>U&ZOUDCP55QQT:%5<-.P
M0O(VGM/ ,)PC*@Y.<N=I0YQQO<8R)L 06R"D<47RY,$:_G@S35);:4FN(NY(
M-G'OMO:X=E\5>\FLL^5J7,"SJ^HJ'QM=%JX(SA(G3)XV.*JC4;HP3ZW>+6NL
MK:.TQ7%9%661S45F'U=9BO33CLX8:,-LAF"L1AS#+U;(N? Q>/LS&O?Y!(S4
MP5)3:C37)2I06 :>E(&>L<%90 A$:&]P;X@V%<.RL9E/+B9EN3J667@*.*)T
MDDBIBC43!$V51,5<J)ACL8JF.!:VBV^TZI87OX.%K%<YV&.")H3N;*JFWW2Z
ML>#5*N89LASTZFM:[$$$G\PN:2ALH ]FPM0B*3)K!-4$"2HWDA8$X!UM\007
M#?=OMJXI<J/DN5TME5(L<MMI*B;%&XZZPJU$32J8->CL4=IP3#0>D5H<ZJJZ
M65VJ^EAD?L?6U%3!-G0CL<<2*X9QR3E6=I(<H=364I2U/[E=>2D M&"[*S+'
M4)5DXU"8-[*!)=R]]_U-A;=E]FRK#+%D9F"[-MCY%B:Z.1VLB:WU&*_##%-G
M##9T%O:Z%+C6)2N=J(K7+CAC]5JKL8ILX&*ZUXQQL=B[!C',HRUR>8SVT'2R
MR:DX\A!); :^FN\B-()-&K<!!<6\ML9$QRDHD1M[CO<P=]NX$-KCW>P93I+G
M01U]RK/5(ZBJ2F@1(UD5\BHBXN\9J-8BJC<=.E=.")ISEOM$55 VHJIN!;++
MP<?BZVL[NKI3!J8HF/=[FW<H#I\8I"_O4,E^2$L6G"2=+\>M,7:V%3)ERQU;
MP'V-?5UB%B$2"*W4IQ%65;HK;?5"W ;MQ>UGR=1UE9+;+E7-I[JVK=3LB;&L
MKE<W'&1V#FZL6*8:W[5P3#'[H[+#/,^EJ9TCJTF6-K$:KU54Q\9=*8,Q3#'_
M ((:XO#:8S.[HSFJ$JHUJ<5S::J0F\X1*3$*DU*-0C/W0\9*<(JXBQ[+;P+V
MOLK2:F!:6IDIG*USHWN:JM7%JZJJF*+MHN&*+MH8.6-8I71*J*K7*F*;"X+A
MH[W<+;7@? H!0"@% 4"C_B7_ /"WV**?:;!XU0J* 4 H!0"@)=!)L_8[E31+
MXVING<VA38T(17%S=8F';AJV]86&]N*C6IQ"+,#Z.R^VU["M:]LG9[O66.Y1
M72@=JU$3L>\Y-AS7)MM<FA?"FG!2YHZN:AJ6U4"X2-7]BIMHO>5-"G=K%V26
M#*\-:YA'S-A*P-R'! 8,(E3.[$6#9:V*[!V;#"!BL( MEK&DC 8&VZ.U=B9>
MOU%F2U1W2B7Q7:'-VV/3ZS'=]-I=MJHY-"H3);J^&Y4C:J#8793;:Y-E%^C^
MU,%VS(=9LOA0"@% 71F[8%=2;UL5 >;KVP4]4#K8* M] * 4 H!0"@% * 4
MH!0"@+VP^W#/P8?72: M:KVRH^WF]<%0'A0"@% * 4 H!0"@% * 4 H"1,/K
M%W4D_8/H".T H!0"@% * 4 H!0"@% * 4!(FWM4X]2H_%K4!': 4 H!0"@%
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MW5#Z>H6H5RM5JN1\2KCJIJHOC+L*BZ-LU1GCHPO<VEKQ%FRS-&W.1/"YB:K
M 39 U*EYYR%/8@J]RDU@)QA_H@7N KU@;W"&U1Y=YZ2JNM34V^/@J&2=[HV;
M&JQ7*K4P30FC:30FPFA#7:R2&6KDEIVZD#GN5J=Q%70G>T;6UL$3K'%L* 4
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MYO7!4!X4 H!0"@% * 4 H!0"@% * D3#ZQ=U)/V#Z CM * 4 H!0"@% * 4
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7 /@#V3W30$C]1_K_ .%__1__ !H#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>tm2115679d1-tbl_phospho4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-tbl_phospho4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!G@.. P$1  (1 0,1 ?_$ 0X  0 ! P4! 0
M       !!P@) @,$!08*"P$!  (" P$!              $&!0<" P0("1
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M-B?=/ .OH8"C53]H$"@071$RHL 2*6.22 A45&QF($;+HF<M?#K")DR+")F
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M.<@(-B'*).U;.AQ PG,[,<S9D*IC1Z"QCG7.B60,=5! J#A1T@4I5A2 $W9
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M<X# \5;))<+Q=,KIX"IB:$.L4IY(0Y3L") 4:>XBU)$ G"82@ >(,MJ,NX3
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M]AD"A3&$"+?%$2J'3,302/&)1+XXB1@%JV0=G S-,HLT!23-Q&23$4T"#XE
M1=',0"(DW$SYL4$Q$3/7Q  'J:@B9VB+Q,H-%2@V6,LDF)RHG$$G! %RX$'1
M"$%P\B*OU=:[$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB4
M1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(M)_P P_P"B;Z!HBQQX
MY4*GU YS*H*  JTLPO"N0RY3F(M=+@ (T3^]=')R.,.'3D@45S?92, \F\2N
M)X!7,<]N=N<FL>8%4)$HI^"7<D5!XHZ65 6"8 M)$>"F)U$R"!ID0%='A(40
MKEJN*+K-Q%03#'&XQCU!XF*[@3#(E4;<P3$  ="\ O+!<OV94 \*EPJ!K1%O
MI.$!61T.PU(_?&+HD?C(=NBJQ$Y5-.%DLD7[DS@VI$"_VO'58>*BA<$'#8B9
M1 8PG(BB'*(,'#($21KD03$"J@88M!@9<>$BFHP0G$5^/GET*5SE%6_/5*)8
M_5-]'I:#&.1,04^4^(02A_!3IB;G$2'4S0?U\XBE]FG2BV$5VYQ(']K3\82J
M>@,EUN('ADW*I *&@N?%F#F*(%T/,B'BD1*F40HBD5FQT>;K''YR#4XJ"Q7<
M@J$B+1 3>,( )217H ! .0 "7T!!+A,0PT1;C=T@0Q3 >/*(O.8!B$.U$3$0
M:LN,'"A1*HH4@@CXK^QIET8"'-#BHE%QN>V2;)B'PQ($XX52C\-<QQ"%CETD
MR'*5;B%@DPXN$#GU"$$>!8#"8!H$6^"K<!%$/AY>6ZC$P3^'N$0(*)47R9/A
MQM5FIFYE.:FF81&/$?&J:I' H$6R19NH+8G]K3\T\LGPA&N7G&#DI7RI"H)Z
M'=>*,F"RB11 TH)?')<*21BT35'+EJHV,8QXU0%8UH<1.U7DRG+)K B(B* %
M%^D_X.  +H,UIR4> Q!&B+Y ?,.B++R5_6BO+OL?/#:(EL4LNGNW9VR8*YRH
MDM*6OY.Z\\.XA4RS]NM$W%*.KM@(] P\ \1V39H;[2 #0KC[X>19M?-,L;RP
M+AQ1B*8\S']WL'C:#R]$,<77#.JWW:3LF3PAKL2A;98W'CH4+E8Q+B'9/5'#
M9=0(N,,T3*\ RY6QR0N1ITKYL?.0O/J L_SUO+EN_H,L"P\T9VA.FJ.<X'L.
M^WIF5CW.55AETG%-N9Z_L<+QK=E9;IU()G>7 Q5!9!-0ZIQ-RSRN#J[A3C16
MU7W>O7_YX77;B#H"\P]#I;Z&KJZ>;Y<7S(8TA[#OBU<FWRBL@64N)/&#NY+K
MRNVOZ1E(6.4<MB1L\U8/$5C2"9'I$A.1Q05)H=%E"_K6?539;#&?2?T+S&3F
M>-87J%RO;&3,[70QC9F;<V]@6U9A[%JS3Z(@(R7FYR,<W<Y+*)&:-5CS3NW2
M\A,02.45>I2[A[*QN=/G6YT%8+_K#&#<G] N6XJ<Z2^J+'F.^F?(D2C8F3+%
MB+-N-];=OXOM9DYCLF619<@Y3=758]LR:T@W;B03/7I%5BE57,9P7&OG:=*N
M%\U^^.K^P?ZQQ@6[.@[%>.<T=2<7T;0:-E6'DJ18PED.F 2&<VES.Y![*Y*Q
M&TA#PL$5=5-):>:&:J)@B;FF*)#*U4NKNTXK.MT"]3OG"R2^>;H\U7HZZ>^G
M+$>-,1(WS9$K@M_"7)<T_-VN]/+R=K.8F+ZG<W+-1B+99K.6I%FL:6-='(LJ
MH!!X#*ZJ17WRM$E/ZP+T(^85A[JRZ:,$P.;F>0[EZ.>K>XHY;(6,+?BK?&*M
M? ]YW'+ J\A\A7!(&7$&YM$2-3 HZ+XLQTR%$@%&X$&E:T6$KR;.H/S^,?=
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M4R%T&+3Y$20Y=(]=D"1(UT($ O-XAB46 KCPD/J,$)]5^/GET>1%R@4;@(D
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MB_BC H9!JN"?AU' )E5,W^^!L BFHGH^$06'@HBX^I#MD^ &BG''"4O!*K2
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M@<Y2&,$6 @LB*AU!+12I3 #*MR@1L)OB'+ H.S+'YAF:+@J16IUP246,W#G
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M$4IP X !RE,&)S5[/8VS9;<C>9 -172CC[H68P=C;W]T8;@$L$9.AIKN:/\
M.KB F5PX?N41X>$.$RCTY# 4JA3 H0SP2J@OS!%4# /.-H8_$8 $*S]XLEUL
M^2K3]V\7\%_RBGQEP;>BB/V6I=JCT1'PB@J)B81>?:.KQ"5<P_:<IZ$5$Y
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M/QC1.A-?7OV]M$\J?@^6B)W:?D[.[3;1$].[Y:)VIZ>JB)V]_P"'N[]]$]Q
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M\11,8I"#7GYDM[&VOFQ6C1'*&#O& DM:_J!/'1>GE>XO[K'NEO'F2$R'NGN
M#G,ZW <->"V?-ISM??3S@+&U^V+?<ICPX]0N*8BZYV*4(F=2R7LJN>YF+L3H
M..)@XCT#<T"EXA*794\M6<-]>R0S,#_R#R ?A4T]FJCFF^GL+&.>!YC_ *0P
M.(^#77V**V;IUZG\P>9MU;7)<V&<R2>&>C?INE6$>^M>W7C2-RCG>7=F7=-)
M.?:+HRBD/8DHNP$I1+R%BL@%+[+I90S;(7V/M>7\8V.[B$N5N!4$ZLC'4.%7
M#W>P:X['Y*[YCRKI;.8PXBW-"T4#Y3UD:T::=FG:=+6>K;K SU'=9^:,5YEZ
MQKZZ#++M+X>7I[);F)%[JL?)<0<FIIVZ+H0,9[P.'!RF65!-=%,!.B )F2 A
M\CC,79NQ45S:6K+V9U>\J^CF'J _RZ]:K&97+7S<Q-:WEV^QA;3NJ,W->.MQ
M_P#U'1T*X+K.ZD^IFQ/+'Z?LG.^I'';+*ET9QL*S[MS_ --LNZF+%GK+DAOY
MNM-L59RW+?6(Y+&1C925:@S1(21:*E)P%T(7Q8JPQ\W,$]N()#;-A<YL<HHX
M.&W30GI)H:G0A>[,9'(P<N07)N(Q=.F:UTL)JTM.[74#H W"G$%6[X[ZHLJV
M)U>]*5@8+\R*<Z_(/+.0?V<RG84E8[2/:VQ:!"H^-GC2:!GR;(S=FX7< H"J
M1TA: 8X&3X@'W3XZVFQES/>6 LGQ,JQP=6KNJFGD]E8^WR5U!EK6"RR#KYDL
ME'M+:;6]==:=)]CJ7U'^GRUKM;,3T^2B*?G[/Q>O=1%'Y**%RF/\-9[=='3?
M<&W^RE'7UUW6_P!89\=ONA=-Q]7D^([W"KH*VFM3)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1
M$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41:3_F'_ $3?0-$*QP6)_+CGO7_I;!W_ *5YZ57N9OJ+?IA\URLG
M*_U]WT)^<U5WJCJ]Z)\WIN"B=*>OOU_']-$3=W?3Z!1$#T]!HI3Y0V_3NHH3
M?[?Q;*(FW<.O9Z;^ZB>ZG;]&WY-OOHB#[-/36B>ZGR;?;L_+1$W^GU41/:._
M:._TUHB>ST]^_8 43L3?W^WZ/=1*)V^^B=*;_?\ 7\M%*GL^GM]OJHH]U6F=
M7%DSD[:=FWS;D8ZG)'$MY$O!_"QZ1G,K(6H]A)>VKM&&9IE.M(RL9#S!GJ35
M/[YV#8R*)3K'3(:Z<AYJ#"<P1SW1VVTC3&X] W4H3V @5[%7N9;&2]L*P@F6
M)V^@XD4(< .DT-0.G@-=%;C%R<;-1[*6B'S63C)%ND[82#%=-RT=MER HBNW
M<(F.FJFH0P" @(U]2-<U[0]A!:14$<"%K44(J."X-Q7%%VM%.)B756(V1.W0
M10:-G#^1D7[U=-I'Q45&LTUGLG+2;Q9-!LV1(=5=8Y2%*(C75<7$%I ZYN7-
M9 P5<XZ !30DAK02\F@ U)/4!UJF%JXJF^G25\3?<:: -U$OPR+,/E7+=Q%1
M6:)<S]M+8]=RC8QF2<N2QH6&!KJH*;YPR>@W.H"90&@\G<WVF;O;RU<X-E,Y
M?$#H71T:WVP1J.HA9+(8>;%LCED;YLK07'B!)4U;7XM*==#15KU[?3Y*V*L8
MO'2\(.3[EMS"\.H5Q*W/*0TM='*!19.V\=P$Y'2UT3$R9N148XLRQ9'BHP5>
M$',D\3*75--8R=,YYS=OA\!.U[AZU,PL8WI)=H33J ))*R.+LGW]]' P>8'!
MSCT!K377RTH.TK+'K\E?+"VTL7N9>CN7S%YD>+LXWQC&R<@]/5O=*UQXTN$+
MR2M:X&B=^O+WN"9C&Y+0G/%/5S)QDF4Q'B;82)"<2@H!M0JPVN4;:X&2TAD>
MR]=<AXVU'F[0#YP[1PJJW=XEUWS#%>S1,DL&VI8=VT^=N)'FG7@>-%:S9'2U
MUS]'DEUE8:Z9[2CK]Z:LJ65>,YTQ<R_;3A7^%\GW@V!(D0=A=<['R2=NPJLD
M[-Q)F535,T:K?V15P4,C-D</E&VEUD'%E_&]HE\UQ$C&]-0"*F@]LCH"QD.,
MS6)=>6F.:'X^5CC#Y[08WNZ/.(T%3[0ZRJ;V_P"1LQ/T4JV1<65\^H9X=XWF
MKB7QTRS,E^XHN<5X]]+P[9Q:A8Q:%<QA+E%LBY=@YXU>$ZX*E$0T]#^;W?:W
M?,B@]2$@&[N_RG=UH?.K6M*T%.RB\T?);?L;N))9_7C&3L[S\EWFI'FTI2M
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M(E$379\OS_BHBT+*I()*++*$1113.JJJJ<I$DDDRB=1110XE*1,A0$1$1
M-1HG1V+@0\S$7#%1\Y;\K'3D)+M$7\7,0[YK)14FQ<D!1N\82#)5=H]:+IF
MQ%$SF(8HZ@(A4D%IH[0A0"'#<W5IX45MEU](F,)R4>SMIRE[8BFY1TN]EW>,
M9J/9Q<JZ<J*++NG5EW;"WACXC]PNH8ZCM&(2>*B/VU3   %KQ7.W,>'B$%K/
MN@ H&O >!Y*Z_AIV+!W?+F+O']Z6NCE)J2PTKY006U[=M>U=UCSI=QC8,ZRO
M!<]TW_?$8*HQUXY$GU)Q_%&614;JJ04"Q;P]D6VX406.0ZT;%,UU"G$ISF*
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M33TTHH3TW41/39VZC1$HB;>RB('LVZT13MWZ=V@^FRB)Z=WH%$7)8['C,?\
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ME;_\OSI4_P LEG?QE3[,R/Z&3Y)3[7Q?Z>+Y03^E_P#*W_Y?G2I_EDL[L_\
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M3;)\TEC<O<&M%Q'M:XG_ ,QF]C>KSG-696W[1PS=D%#71;%J8TN"V[AC&,W
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MD#HT.#ORZNO6XNI'/6:\5]/%CRL.SS'U.W;U/9.OZ[$6:B>.,+JX[PU9_P
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MYS57;T]/55'5\]U3^/TV[*(G;W]E$3L]_P"'Z:(K*>K.$=7C=F!\>Q74;D/
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MD8"P0?O6B!B,K=MYJJN[=1]H6[SUBM$CJF45455<*Z*K& *=?WS[Z;>X48-
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M'U5I#967-&#OY+B/<V5[@2-U&4V@JIO0EFF?SMTQX_NV]ETU\DP(SF.,I&2
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MW(?6OTRVE=44JJA)P$MF.QTI..<(*&0<-7[9.85.S=MUB"11)3A43. @8H"
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M=^5LS;/@;:XRZNWRA[PU[A+;B-O=-IYY!U< 10:J[<=^@?+7A6SUBJ\ZK_\
M)X9'W?RY=#FX=?\ Z=G3762Q/UYOQ)/YMZQ>9K]GN^/'_.L657N^;7=ZZQJR
MG:OA+_K*?G4Y,C,EWYY</35-O+*MZU&<=%=1>1X5ZJWG[LD[BM]G+N,6P3U
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M&CI[23V*ON2<9V=EFV5;4O>,&0CO%MY-@X07492L',LBJECYV!E&QB/(F98
MN<$G")BF AS$'4ASE&I6%_=XRZ;>6+S'<-.A'N'K!Z0LW=V=O?0&WN6AT1_
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M,X")EW3%)I;-@).>8=)9"Q(+[E4R8<L\DX>'()DSD&M=9B_%_=E[/S+11O\
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M!-;VT^S=ZW>A[A0'AWQ =KIH0L/A(>9,MA8,F[+2,EFCW4[BW+0=?_+!IHJ
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MOFZKTM*^7>4)C'=RP/Q!S:%L)P]SFB7]Z2BJ:ZJ4DZ39LVB:(%,FJ8P +2B
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MP8O\($@ULERK-2,I%P\K'>#!8R+-0OBUF"I%>([=$3<LW._+8VWR-JX-M&O
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M=6^/-]/C,@;.83R.?9W$;'B1Y.NP$[J2&E"VO;0:JJMH9^L.S^OG%62NH-E
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M?R;GO$3I'N+N^,9VEKG%U&@DGBNCN;6UL;7+6\DUSBH\N^:9[H]GI!K2\,:
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M01Y"*$+MDCCE88Y6AT9X@BH/E!6ZQ8LHQFVCXUFUCV#)%-LS8L6Z31FT;HE
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M:_$;_H7<M+ L2/9M8YA95I,H]C*DG63!I;<,V9LYM,J9$YAJU19$0;RI"(D
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M_"4KZY'P)X?C;:<>)](?BZ\=%/V3G:@>JNU(UK^+NKPZ/1/XVG#503/4$H9
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MZN#:4=U$BE5I)GZ",BDK^[G,9151;K"B:V;1!9,5GRS(4%"AD Q06;E1YZ@
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MN_77U"(44)J&T/8.GX*(@Z::?(&NOKT[=U$6GO$>[;OW^\!VT4K5J&O9L'0
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M1$HB41*(E$2B)1$HB41*(E$2B)1$HBTG_,/^B;Z!HA6(9_\ \8#+&G_<-O\
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MMY3Y+RTG=8N[>RY)H&;P=>K:]NXGR.5]?SASWAHN]R]DR2VH"7['#3KW,=M
M\K57;&'7CB*^7",3<Z4ECN:.4  9T6R]O+*B)" BC,ME 424$QA'1PW0( !L
M.(U@,OX>9K'-,MOMN8@>#:AX\K"/<<3V*R8;Q+P63>(;K?:S$<7T,9[ \'C\
M9H':KU&;UI(-D7K!TV?LW! 4;NVBZ3ELN4=-%$7")SI*ICV" B%41['QN+)
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M_P W,M8<W_\ =%I_N$W\["NCL/36^_\ SHY#[>P+E>;]H53/%S_O%W^YVO\
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MVG__ $JP_P 60IC\&!Z(ENOFP+U&(AUM^;]=ZW7W_P#A(X"&X0'32J3XR_\
M?4W^[6_\RQ;/_AU_]J;'Z:Y_GY%Y:Y_Y4IT-O^P"P]?5K<.3.SLK;G@G_P!C
M2?\ -KC_ -/9KYQ_BHK_ 'BVG_)8?_57B]1@W^2''NS_ &LL/EX#!NTVAH-:
M%\2/^_<O_O\ -\XK[ \+-/#?!_\ +(/YL+T[80#I[S]J.Z7RF ^WPY/PUM'
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MJ/K#T]6W;1%VD((?&8??_=1@ !K_ *+2W:5[,?\ 7X/IF?."\>2_LZX^@?\
M-*R:U]5KY!2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HBTG_,/^B;Z!HH/!8AI'^7
M_+.H"/ZA;X[Q_P"Z98?=6JO%+\Q9_'D]QBV_X2?G[WXD7NO7LM@ZZ[?5M]VS
M?MUK3JW8@;-WJW?2(;>ZG2E503*D\\C;LMME;41).KM<0$VY+)L;X>6,1O;Z
M$A$I.V2SUE#3ZCT7$@N@<J0MP .6(\P!V#O/P?Q.=R-M?RXZ_BL\>Q\0>U]N
MVYWR$/+"&.>P-VM#ANW=-*'B- >-O/F$Y)FQ[[^QN+O(3LE##%<&WVQM+-P<
MX,DW5<6D-V]%:C@?68CE&DO:!W;>,=1+DL_<C6;;O)=2><K7 TF'2,R]/,K(
MME)('CTAE"JF21,8I@^P732J5XEV65L.;I[?,7++J[$<1$C6",&-T;3&!&*A
MFUI V@D"G$\5??"W.XOF7DNVS.(MY+:UF?*3&]_>.$@D<)"9--^YP)W4%>H<
M%XZ5PY'Y4E<L7LX:X_;.,;S"4$DG-XY;7._GS1>-[.ODKF3F%9Z,632,-S@S
M(DFGJFDW P'$3:%V)R?<7N-Y:QUI#?96.+(,D>6PW;H8X]UU/;D-C#' D]UO
M))U+J4TJ=*>(_,$3.=;]CL;BIG6+H6[Y[<2R2?T:"?SG[FD =[L  - T&O0*
MR6Q(!,6U;TL5LFS"4@XF1!HB(\EKXU@W=>&1'0GW2'-X2[ V!NK1>3MC9Y.X
MM"XO[J>1FX\7;7%M3VFE2OI_%W/KF-MKS:&"6"-^T<&[F!VT=@K0:="L"ZQL
M"]#G7F*G2_U 14#=-ZIQT@I:D['D%I>5A3!B =;]E+Q32$L=. 1#FJL#'41<
M)IB59(^ZK!B8^9L':?>"Q:]EA4!U?1<.LLXEM=-U-#P*K>9DY4S][]V\@YC\
MAM);3TF'J:_@'4UVUU U"^8T67F6?U=3(BDFF66ZHO+ME;C62!L$D*$ P2EE
MRE2,NU TS*8EOU%LF0 6Y)X.26+P\2AA$$KQ7EWGZWVZ6V?#>K4T]H/;_P#,
M/=U[MYF\.+C=K=\MEW7H*GV3&[V-KC^#ZA>D'S#>D?KAPM/WUT_73$RRL1;D
MU+WUB&611@+\M5<6SAQ*,+DMI0O$HV?KJ&+\1:^*8.15U*L8PF*%$FY>S6.S
MEM9W9='-)<1LCF!+FU+FAKFN_%T(&A%."V-;<RX+)X"YO;$,DACMY7R0FC74
M#7.<US?QM1NU!KQ*KC;>%V&+9G&-V*V]8@EO3F,H@L"2]4Y"UU'ML/9LHI*W
M%=,]&/$BLVIFIA2:,SZ'XB\)=4QW'SYF^8,URU>6-YE\E<V]HYCGLG[CNY=L
M@CX11,>T@G<-SWC2AJ?.6@/##(83[X6HML+C[6:=D@9)"Z<OC\PNI^4D>P@M
M&T[6L.M1IHO?W]9#?)MR6C8CA.WT <1EU7,65G+="Y3,_@*ULQQF3)D:3BBH
M&D!N,#**BH;0&X%X!XN(M9\'[-[WY'(MNKVW$+86%MO+W)?WID(+G[7U#.ZT
M;MU+JU%*';?B39V>6=8XB\MK*X8_OI0;B 3AAB[IM&L+F@%W>ZNKH&TIK4=U
MCN();4(]M9%")2):]P3D("D+%#"L7OAGRBH/0C!>/_"N'!5]50YQP,KJ8- ,
M!2U7Q+MG6W-TV^>XN#)%%)NG?WDGG1M.USZ-W;> -!H **P\AQ06_+L=E;0V
M\$,$LL8;!&(H_->?.$8+@TFM7 $@NJ=*T'F[FL.7ON]7R-OP<&L\A[5MI22E
MI3(>0;.6<-9*6NXL;')LK,:+(.TV"L<Z5YJYN,!<B4H  "([!\+K;+GEJ2XM
M<M/96CKZ1HB9:P3@O;% 72%TS@6ES7L;1HIYE2J!XC<O<OY_F1C<EA[._O8;
M&(][-<7$)#'RS[8PV%I!#7,>ZKC6KZ +U6.'4>[L.U'$5%)P<<I"LP:PZ+E5
MXE')IDY?A4G:R::SI-,Y# "ARE.<-I@ 1TK4?-]M>6?-%_:W\YN;V.ZD#Y2-
MID<'&KRT$@%W&@-!P6S^4Y+.7EJQ?CX&VUEZLS9$#41M H& FA(;2@) )Z0K
M LI9 D&&1;[D4;9L1=A;=S*-EF+^WG;IY-!%H,>>XD)%.:;)"Z>[N(&X@0H%
M 0/H(C]B>'WA9%E_#"TR;\ME89Y[.1X;'*T11ZOHUK"TG:*:C<*U/!?)7/G/
M++#Q&O(CB<3,VWO&-+I(-TLFT,\YTFX>=U';I0<:*_\ O&618V#<$PO&-))N
MC;3QX>)>!Q,G:9V)S"R=?8,!FRH'X#AP[2Z[ KXTP=G)=<Q6UC%*^*5]TQHD
M;Z33O W-U](<1KQ7UQGKZ.SY:N\C)$V6*.S>\QN]%P#"=AT]$\#IP7CK?P:T
MPC>D,<&>+7"UV0]PLDY"Q\9RMARC$L4K"O5&[ES(Y$ODDA'O@4#B2(1L8JB1
M#<1@V!M/GW)Y#-<N&6YR&8N(H+J(]W=W;;F,E[90'-#8(=KVTI4[JM<10<5H
MKPFR=D[FE]I#BL1:2R6<A[VTMW0R4:^*K'%TLNYCJUH-M"T'54EZR^M3I8Z+
M,8/;UZH;_A+;M^636C(NTU&BEPW3?#E9,Q!A[>L]@BZDI@50 >:H*16C<FIU
MU4R )@U/AL5E,I=M9BF.,S37<#M#*=)=H![IZ 5OG.9C#XBS=)EWM$#@1M(W
M%]>@-U)[>CK(5H2^+&%UVG9?5]T%W<$M9-[VZWN^*C+?7.5-]#KD%98\.W>'
M 7:15$5$'D0X)SD7"1DRE$^J9=B8[F6&XW\M\ZL!D:[;WCAT\!NIP/2)!I34
MTXG6>3Y6GMRSFGD.0B-S=_=M/1Q.RI\X'@8SK7A4Z"Z+I_ZI+ S8^@X:]XB(
MMO+MN^++&HR;1(Q5GJC86,NZM61>("M%O7C?B379\9%Q3$2@*I ,(5SF3D^^
MPC775DYTV)?TCBT<0'@<0.APTZZ*T<K<[6&><VTOVMAS+*^:>#B-"6$C0];>
M/54*OE_V>ED6[;,L?BBH]PXCKHG4[@>Q;N5>1Z<4$,W48QZ+2:@E$2R0R)15
M.98Q>%$ X!$0,6X^#UO)WM_?MN;J%D;(FED+VQ[]Y=0N+F2 ANW0;:U/'KPO
MB=CK#-NL<-?6UI.UYED#IXS+LV!@\P![*%V[4UX"E.E<[%D0G;3*[;221C"F
MM6]Y6'7D(M@O&DFEACH:4^*NFCF0EEDWRI),J2@BX4XN2!@X0'A+A?%JTDMN
M:&227%Q<=_912 S.#WL!+V[-S6L!:-I(HUM*TUXG+>&L%K98&7&V=O;V\-K>
M21TA88V..UC]Y:7/(<=]#YQK2NG >)N7$+?*UYWN_C;'M)^ZM1G!,IV5GK_O
M^UG<P=>(4E&J"4?:+!PQ519,%"I@LN85#"82Z 4H:W3D#-\SX+E>W989R]L;
M*YFE+(8;>WE:TAP8YQ=,X.!<X5VM  I6M25J/Q2ON6/O=+!?X*WOKV&"+?,^
MZGA+@6ES6[(FEI#6Z;G$DUI2@56+ =1[RR;5=1,8G"QJL#&'8Q"2HKI1C;PB
M0),DUA(F=9-N7[('$I1, :B ".E:6YBANH,]>0WLIGNVW,@?(10O=N-7D5T+
MCK2II6B^@^6KBUN^7[*YL8A;VC[6,LC!J(VE@HP'2NT:5IJK77=Y.B-YN3"S
M&Q\>-K_N1F\AOWKY"3%ZLTR-(Q4I,#9B;+]C04D+A25D19B/),930Q^(1-7T
MS:<I\RNY1AE9GI6SNQ,;VL]3MZ-C=;->V'O]W?4;$1%O]*@T%-%\G7?B_P O
M0<_S<MNP3G6[<Q)"Y_KTX#G^L.:Z7U>G<^=)60L]$DZFNJO0W]FN[M^6ODQ?
M9B  Z=FH]H:[/KV?-12F[O\ 7O[]_P GT44*0T'Y>\=^O?VZT4I](=FW:&S7
M9KMHH4;==V^B>13] =GR>S4:(FX>[VZ[^W3=K1.U1Z:;0[_H&B*0#L'L =^S
MN[?KHIZ4[M@::_C[==>VBA1MTV;-^P-=/I[:(I[AV;]^_9^3OJ5*"/RA[MF_
MU::5"CW5&\1#V .SNT[Z(IW;=O9V41=G!_W:B-=_Q5AIO'>[2#V_57LQ_P!?
M@^F9\X+Q9+^SKCZ%_P TK)K7U6OD)*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41
M*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B+2
M?\P_Z)OH&B'@L0K_ %_?_EC7_N&W^X?^V)7U[-*U5XI?F+/X\GN,6WO"3ZQ>
MT^!%[KU[/3;W;-N_40U^?8%:=6[5(AZOF^O7T"I4*W;(.S+MJAW8\NCO#_;%
M;.ORZ5],^ _]B93_ 'JW_FYE\5_Q9_7\)]#<_.A7H,$_[$YS7^<+('_PHD [
M![ZU[XU?]^S?[K;?S#%N3^'7_P!J;'Z:Y_GWKLF65L<8SM?J84ON\H.VC/\
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MC@3,=J^58J6U;")7!XM\FVDVY><@<@\Q(H@8@AV5KWQ@_+9^UFBJZ%N.A87
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MQ$_;/ZRG[&X0_G?RWZO[T\T:=O\ K#4?N'^R/U=1_B'3_P#>?UE/V-PCJ/\
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4$2B)1$HB41*(E$2B)1$HB41?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>tm2115679d1-fc_prop4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-fc_prop4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"%@.2 P$1  (1 0,1 ?_$ 0D  0 " P$! 0$!
M       ("08'"@4$ P(! 0$  04! 0$              P$"! 8'!0@)$
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MR]/H?RT_E9:W_F_Z$,>N^!/^19O[O]\3Z*^T_P#]SZ?]W_+T^A_+3^5EK?\
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MW\U^UAL6L_C$DX^1DZ_5K&A3+$YG8#ZE0B'"+)X+19J9X":*ADQ4*;+>\<"
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MH][A&2\HZ:3[TUWN4#;[.+Z8>R,NC8K586[F;6<^N*S:5=&41%,2)]LD30Z
M--Q"CF)9F"YIM!%%\GBSIJQ= 26Y;=9IW8.W-K7J\UN[;#M:J+FQ2]>X_P!]
MM^A]<PIUT4TB$CXRM47WIB@'564E'S@XF.N8<IEQV,9M<3YK JYD]O +&@"S
MG%3YU9EDZQU&'F?_  6=V_VE.O\ RQGFY>'O_6NG?W@>8KG7BU_XWUC^YN_*
M:I"^-?\ @0:!_M>L/]W-IS1O&/\ \EZK_/1_T,2Z']GO_P -Z'_,2_\ R)E.
M3.9KLR81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$5 FFO]9KS/_\ $7_]G*=GUAK?_AGAWX3?
MR)5\,\+?_<3Q=\!W]) K,,Y$OH)>/-UZ LK-*/L<'#V!@A(1LL@QFXQE*LT9
M6'>H241))-GZ*Z*<A%2+9-PV6 H*(+IE.02F* @(!O0$BY>QA%X\17H"O_-/
MD,'#PGSN8>V&:^41K*-^;S\EZ7S&<E/9HH^_F'_HD]=RKWK*]A>XP] R@ %R
M$DWKXH^F4^(;V)I%52M1C6WR4G,VQM'P46R;VB8FDB(3,M8D6S5-.;DI9!,I
M'*[D%55R% #F, 8H!LO5:DWFY8'0^/.@=63;VRZPT;I[7%CDB+)R,_0]9TNH
M3;\CDXJ."/96O0D<^=$74$3'!10P&-\1ZCE QC35H /,JN>]PHXDCE*V26O0
M!)]:UD@X@EH<Q#:O.+(6-9%GUX!D]=R3.#6F 1"15B&DB_772;&4%%-990Y2
M@8YA&Z@K7:K:FE-B3U>@+5$NX&SP</8X-_Z'OH6>C64Q$O/:N47C;W<=((N&
M;CV[QNFJGWD'L53*8.AB@(4(!%#<@)!J+U^=CK-;N,*]K=NK\):J[) @61@;
M'$L)R%D"M7*+UL#V+DV[IBZ!N\;)JD]1,W8JF4P=#% 0$ BAN0$@U%A7S.*9
M3W<P[L+JJ5IS/OZU]&/IQQ!1:TP]IXNEWPU1W)J-3/7%:%ZZ56]B<XM?54,?
ML[C"(J"_:JU-*5L6IOWJ/%O\FO0/[CFN_P!KF4P,W#J5W>2>^=UE;>D*G5I:
M)8P,K6H"3@XMQ#NXR%D(:.>Q,<ZKSEL\@'+&.<ME&;1Q!O&:*K,Z9"F;*I$,
MF)3%*(5H+MBLJ0:@VK]WU=K\I*P<])04-(SE84D%JU,OHQD[E:\K+,C1LJK!
MR+A!1Y$J2<<<S=P9N=,5D!$A^I1Z8H*UVI4TIL24KM?FW<*_FH*&EWU;D33%
M=>RD6R?NX"6,S<QYI2%<NT%5HJ1,P>+("N@*:HHJG)W=IC -: WH"1<O]@J]
M 5:,2A:S!Q%=AT'$@[1B8*-91$8BZEI!U+RCE)A'HMVJ;B2E7R[IP<" 99PL
M=0XB<YA$ !8+D))M-Z_*NU>LU"-"&J5=@JO#@[?/PB:[$1\)&@^DW2KZ2> Q
MC&[9J#N0?+G674[.]54YCF$3"(Y0 "P7(23:;2OU@J] 5:,2A:S!Q%=AT'$@
M[1B8*-91$8BZEI!U+RCE)A'HMVJ;B2E7R[IP<" 99PL=0XB<YA&H %@N0DFT
MWKV,(HP\S_X+.[?[2G7_ )8SS<O#W_K73O[P/,5SKQ:_\;ZQ_<W?E-4A?&O_
M  (- _VO6'^[FTYHWC'_ .2]5_GH_P"AB70_L]_^&]#_ )B7_P"1,IR9S-=F
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PBH$TU_K->9__B+_ /LY3L^L-;_\,\._";^1*OAG
MA;_[B>+O@._I(%)WD)HR"VA$O++(WW>E.D:K5)[Y:EJ;?.VM1QCA5-LN_2<S
M$3KNVUV/G'B*Z0 15TFJH1/[@"!1Z9Q][ ZVI',2/,OH6-Y::4::G: ?.J_M
M :_DXWQUMN3J^Z.3-@VY8.%5MN;Z4M_);=UN@T;7+:GDY52Q1E4L-WD:Y%3+
M"23*NR<MVR:S%4H&0,0P=<A8WY''5V+#O.Y3O=\OW=&X<>X;U%=[NKBO7N),
M7L&'YS\J6W)4ND:[-038O);DE<R/-\/:<P<Q<([HURF9_7,O'R]_5(S<M'[4
MT9[=8X&.B0 6)'BC$=0]V.F\W^928)#+A+&]W7<+O/<K/.3NP-L1_&/4FN49
MAW3^2/)R7U'HI.8IS\6;^F6J\,&TCN>YUZ1B' NXTE HD/8I%H_9&,=HX;MS
MIF >PV3R%V -N>Z@]OJM6/&UO>%U\;:GVO+1:%?[BV4'BRY+%EKU9D-_\9J#
MO/1UWOL=.3+"XAL+3+=_$0UZ2M"+I*:&>M]0^3V('Y%@74/* IW]PB.68G>K
MNJ>VT$=(5^!OK+: 8'$&G(=GL+QXK>FV*EPVYDZ"VI>+%^^2X\<3=HWVA;82
MDW\1:]IZCD]66E_JK=\-.(/QF N];E60Q,^Z07,X93[ C@RW>[2,+&X1N8X]
MMK3;O%+"JX&F5CVCY-S@"-QK:/:Y%Y6U;3)&NFF9/E*]Y/\ [TEQQ8UC*Q%F
MT;(;J3KCO=LB+E6\RF^[#Q_?H;>3<(0?RM:(,[4^1G.=RJH)G/7I1QM'>8N[
MPBZM_+2U5:+"(\/>XC?2[DK8L9V#L*0KO!3GE=^/?+Y]M_4D-4XB7T+9(S:%
MKL6]]'S*B*25ZI=JV$_=I7M)FWD2-W,!\R='F6S1PN@NH9,B)C4<ZD+RQU6[
M+;0JM;69@D;1U;;+#NLNYU>;F6L-4W[ WMM%#F.[WQ&7JQ,N*NCMW:QX5WRF
MH2DBA19ZR;/K\O\ 6FTI:.3<'CEY77NW]A46OE=JH_T,DVD4P,3J<Q\9SW=[
MCJ>[!#>O;T&BRFL;W6"GRC@7#HV=(!*W5Y%]4E9\>^17("N;6Y$T78-%TQ:9
MVLIZ[Y%;EH%.CY>L03QS%O\ Z$J5SB*BNY%<H&7.=H)G(@'J";+IF]ASP7!P
M&PE60.[;6$-+2=H!\JTCS(U_)\;?'=R"VOK#=')E#8#[6&NUV]EM7);=UWD:
M^[=W>E'>2%27M=WE3U21>)/ED5G$>+=55NH9(QA3$2Y;(W!"YS2ZM-Y5\3N\
MG:UP;AJ=@6\58&:Y@\D]_P!0MVPMEU30?&B9I&M&&O=6WZS:M7V;L>PT:$V1
M<++?[=19"O7U>$KS"U1D=&1K21:M#+(+N5/4$Q0"^AD>020QME!94WJRHBC:
M0 7NMJ16@NLK8OUJT;:.*_+G4VF(78NP+SH3DG2MIJUNF;/N5AV38-2[*U&R
M@;*<]6OUS?S-V=42U4^4<(GC)%^^!F^9D4043*J=,P QR!H)+' WVT(0D21%
MY #VD765!Y%&;Q5[[V_#T72VK.2-^L^R2\B];.MR\=]L7B7D9^P34A'*./QL
M:1L5DFI!]*2UBIAD2ST.98QS+03Q9(I^U@"1(\N]U UYKB%0?.%)F6-+BZ,
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MI-UB")KMS8G*5FV/?OI" +8KK8E+(<BJS2(%%BT:HH%5=")E L=$][7DT#G
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M/JE=G[1+F5)%5N%E)^3.@D*ZY(^'8KR+TR*)1 RRI6S<PE* ]3#\,H305-R
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M:8M!*5CU'#MP93H[+(-B&,82H )C"/?N-O!KA3C/,2:F_O<IKDE*S1FH<0
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M%%),"II)))E I2E  * = ^&<><YSW%[R2\FI)M))O).TE?03&,C8(XP&QM
M %  +  !8 !<%03IK_6:\S__ !%__9RG9]7:W_X9X=^$W\B5?#?"W_W$\7?
M=_20*S#.1+Z"3")A%JS>?]Y+<7^*S8/]R4OEK_0/,5<STQSA5:Z/U#S+WIP"
MT;IU78W'*C::VEQ-U51)*;BM?[$L&U6&J+7J*!AG[-J$K=FE,-=']2>&:JNS
M(>U0<*G622ZE3 (&-E?"&U:&EHYZ460]T3)W/HXO#B;Q2M5(KC; QU6YS\VJ
MQ#IJ)1-<TEP0@8M)54ZZJ4=$5_?\>R3574$5%E"-FY0,<WQ,(=1^.71BDKP+
MJ-]E62&L+";ZN]A>7Y(K+8)VK::XSTJDV#9ECY#[4B#6R@U67J<#/SNB]0.6
M.R=OMF4S>+'5:K'$FVL9'0:IGSU%!5&843#U%#$063DD!@%2XW<@M*9< $R$
M@!HOY38+EI[1=QMU?:^0W0M^UA9]+K/("]<H=5T*Z3E$L$TG0]Y5^UIW\K%_
MK2VW2GA#Q>ZJY,N2(I/ 71)-) H0!$ "UI(#V$4O(Z>;E5[P#W;VFMP)Y1=?
MR+3>I"FX>\?^+W(=@(L^._)#B/QYH')1@F9)O$:XVZYTE3JUJ??_ *9A(V9Q
MEK440J]K7ZHE 31CU05#)*Y:WY)C7^X<T5Y#2P^P5<_Y5[F?RC7$CE%;1[(6
M"Z?TQ4>05>\;FI+J#M*&MOC(VH@C+1B@-YRL3K&>XW25:M];>]!-'V6IS[-M
M(,'!?BDZ;D'XAU :-:'AC3<8S["N<\QF1PO$@]E;LU=N6X7SG!PVU/N4S9'D
M;QTHW,W7.Y$VQ4T&MK*M7./#^A[B@VQ#=R=7W!5TRR;<!(EZ#XCUKV%%J(9<
MUQ,K&N]-H<#Y+>E6.8&PO<S]&XM(\M1T+05'KT%;M4Z,JMGB6,]6[)YM=^0,
M_"2C=-W&R\-+5[D^PDHU^U5 R;AF^9KG34(8! Q#"&6  M -W>GV5(20XD7]
MR/86<WVP3^E[GQ:X,;(EI"6D-6\X>.%QXXW*;= ZD-E<:'3^X1<+'/'AC=[V
MY:3DU$Z[+"8B1EF?RYV4@E<&,%Q):6Q.O#A3E'\"M: \.F;M8:\A_AO4V>$9
M[ 36_+N$K+BL-M_QW+_D\XMWU>W?KQ?U=-71W):YE[(PB7+"<7JLCK-6!%B9
M R'J1R1"(B )_"2*N%P'IXC_  >10S4Q-)K@PC^'RK[.(>T[7;^4'-376P8+
M08[%U8QXWENE_P!'PMEBCV^1ME=V.X80=S7L\W-/'\C18:$;MV_0Q1;@Z52-
M^I I*QN)D<TTQ"EW2DK0(V.;BPFMAZ%8SDR@3")A%&'F?_!9W;_:4Z_\L9YN
M7A[_ -:Z=_>!YBN=>+7_ (WUC^YN_*:M3\9/'SQJY,<*])6&W51Q6=@2-:G
M6V'1W982Q.56]TLJ*"TPV40>0%@4*@B1(57K-9SZ! 3(J0"E$OH\:>+'&7!G
MB/J64R$XFTIDS*9>88XP##&2&&H?':2:,>&XC4M-37P/#KP*\/?$3P@T?/ZK
ME79?7),O)7-9=W=RDC,3 &0$.BE- &UDC<_" T.;04@)R+\2/(G4 O)S6A4M
MYTQ$%EA/6&9H^]1[=,#J?T?2EG+I:2'MZ%(,4X?JJ&ZB9%(.F=5X0\>^$>(,
M.6UFNF:B:#Y0XH7'[V8 !N\]ZU@&QSEP_C[[+G'O"N/.</ :UI J?D6X<RT"
MWM9<EQ?N'<ND<3:6-"TEQUY\\E^*LF2OLIU]9Z?&. 826K=C&DWT;&E:'!!=
ME#&<K)S-->-RD,4$VQR-RJ_%9NKT[<V3B[PKX,XYA];DB;!J#QB;F<OA:YU;
M0Y]!@F!OJX%U/1>V]:=P#XW^(?AGF!D89GYG2HW87Y/-8W,9AL+8ZD20.%HH
MPA@-KXW4HNB?B[Y(>/?)CY;7R2P:SV<] B7XOKF];H&D7ISE3!M4K()&L3:#
MJG,'IH%!O(G #&]J!2B;/D;C;P>XLX,QYLQ^NZ*VWOX03A&^6.UT7*[M1BP=
MY4T7WMX;_:!X$\1.[R(E^CN(WT'JN8<!C==2"7LLFKL:,,IM/= "JL"SE*[F
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M89?]B4;5=6DKKL6U0E-JL2F)WLU//DF30I^PYTVK<#CZSZ0=>F)4&R!5'#@_
MW$R',( /HZ5I&IZYGF:;I$$F8STAL8P$GG.QK1[ISB&M%I("\C7->T7AK39-
M8U_,PY33(A5TDC@UO(!6USC2C6-!<XV-!-BYXN7OF MER&3HG%Y-[1ZL<%6;
MW:$DV*E=YE,1,DH-68*BJC46"Z8CVN5"J2@@8IT_9*%$!^M> /L_9#3L&J<;
M%N9SPH1EFFL+-ORKA0RN!O:*17@]X"O@[Q4^U7JFK&31?#</R>FFK79QXIF)
M!<>Y::B!I%SS6:XM[EPM@OQTX0\D>7TRI9(>+?,*I)R"SB>V[?UWZ<.\<J+F
M-(+LG;H%Y>Y2QE>_O!H58H+?!PLCW=V=.XO\2^#_  _RXR>8>U^?8P!F5@#<
M8%.R"!1D+*4IBI9Z#74HN,< ^#GB#XJYLZAE(WLTR20F3/9DN$;B3VBUQK).
M^M:X X8K'O96JZ+>,?C4XZ\<DHZ;<PB>T]E-?37/>;PR;.T8]Z3M-ZM5JYQ<
M0]?*BH7N26,#J03$1_HH0Z%#Y%XT\9.+N+W/RS)3D=&=4=S"2"X;I9+'R5VC
MLQGWFU??'AU]GK@'@!L><DA&I\0MH?6,PT.#7;X8;8XJ&UKCCE'SE+%87G)5
MW=,(F$7/KOYW^](\F+O:5N 8W5'(ZJ(,C6,Z7;&Q3HS*N1TS[I8J94@6BK;6
M6CIV;X&0CY,JAA-U-W?67"#?KWX-MT3(=O7=(G)[NO:<,4CF4%]'12.:W>^,
M@4LI\*<=R?Z7_:&?Q)JGR?#.OY8-[VG88<,3)*FZK)X6/>?<Q3!QK;6SI!=%
MRBBY;+).&[A)-=!=!0BJ*Z*I 426153$Q%4E2& Q3%$0, ]0SD3FN8XL>"'@
MT(-A!%X(WKZ$8]DC!)&0Z-P!!!J"#:""+""+BOURU7IA%YLS#QMAAY6 F6I'
MT1.1KZ'E62AU4R/(V3:JLGS4YT3I+$(X:K&((D,4P /P$!^."*BAN0&AJ+UY
ME,J%;U[3ZI0:;%I0=0H]:@JA585!5RNA#UNM1;6%@XM%=ZNY>+)1\8R22*=5
M114P$ZF,8W41H  *"X*I)<2XWE:%V-PUXX[8O4KLN\4%Z_O$Y&PL/,V"(OVR
M:BXE(VNINTH-J^;T^X0+%R2+3?+ B)TA,7U3_'[P];'1,<<1%JO;+(UN$&SF
M"RO7_&O2NKYNO66ETY1C/U.J6.D5V8E+/<+3(1-7MUC96VR1;5U:[!-J@$M/
M1K=958PF<=B)$BG!$H)Y41L::@6T5'2/<*$V$K)[)IO6=NN"=_L-49R%Q3U_
M:=5_/O=2;1XMKRZ.H]]9:HZ*Q>MF[V,D7L4W6 %B'.@JGWHF3,8PC4M:34BV
ME.A4#W 80;*UZ5_IM.:Q4U"CH1>G13O4#>@,]7)45[[I]$A0H^"1K3*NG4=N
M%GZK=K"MTT2*G6,X#L _J>H'?C"W#@IV:43&[%CKVZUKRKQJAQ]T[0GFM']1
MH[&%>:>U_)ZLULN@_F5S5:@3"L"M)5QH5Y).".VSI6L,!%5R"[@/;AVJ!U-W
M QHI07"@0R/=6IO-3SKT'^D-42>WX+?CVDQ*NX:W5']&AKZ47B,RVJ<FNLZ=
MP:H(.DF3YF+APH=/W"2IT15/Z9B=YNK W%CIVDQN#<%>Q6Y8[%\9=%PK. 81
MFO8YHSJ^Y)?D% H$D9XY8[<4\E8D9>\)F5E5#JOGJ5LD ,@H)V1?<F[40[2=
MM.[8-FVO2JF1YO-XIT+(MAZ0U1M>P:TM>PJ3$V>RZ=M9+OK.;>"\0DJA9B W
MZR,8Z8NFBADUQ:(F6;+"JU7.@D91,QDDQ+4M:X@D6BY4:]S00TT!%JP#9W$3
MC[MZVJ7^X4F1:WIRQ9Q<E<Z#?]D:DM4]%QY#I1\99[!J>WTJ5M4='I*"5!"2
M5=)(EZ 0I0  "CHV.-2+>0D>95;*]HP@]GE /G65:CXZ:0T,K,+Z>UM7-?KV
M&&KD%8%J^BX05GF53D+9+0:\V=9PN:6F49*\RJZ\BX%20>J/#"Y65[$^RK6,
M9Z(HJ.D>_P!(U^[^!;JRY6IA$PBK:\D&X8V(U8GH>OC\[V5M^1@(UG78XA7T
MHUA$9YB\*Z,S2,=8CB=E&*3!F02"9P*BPI_>2ZAUWPDT&6?6CQ/F_D]'R#'N
M,CNRTO+'"E391C27O->S1M;'+@'C[Q3!EN&QP7D?EN(-5DB8V)G:>(Q(UU<(
MMK(]K8XQ2KJNPVMJK@>-6KW.E]!:CU:_,D>5I=%@8F;.@<BC<U@%H5W8!;*$
M^ZHV&:<K^F;_ +8G01ZB.?.G&6MLXCXJS^MQ5$&9S3W,K?W=:1UY< ;7E7UC
MX>\.2<(<#Z5PW.0<SE,E&R2EH[W#BEH=H[PNH=HHMWYK2W)1!Y)\'./?*)HX
M<7VI)Q5U,B1-GLFI%;0MU;BBF"38CY^#99K8F:"90(5"11=)IDZ^EZ9NAPZ!
MP=XF<6<$R!FEY@R:;6W+RU?":VG"VH,9-^*,M)/I8A8N5^(7@UP)XD1.DUO*
MB+5R*-S<%(\P*"@Q.H6RM L#96O 'HX3:N<+E1XT=_<:1D+/%LS[6U<R%9S]
M<4]@Y"1@V2(&5]Q<*J11Y)0)$4DS'4=(G>1R10#O<D,8"9]@<#^,O"O&6#)3
MN]1UMU!W,KAA>392*6QKZFP-(9(=C"!5?G_XE_9XXX\/.\U'+,.I\-LJ?6(&
MG'&T6UGAJY\5 "2]IDB IBD!("V-Q*\K>X=&#&4_;0R&X]8-_2:IFD'G?L.L
M,DR>DF6"L#U4"3;-L3IVLI(QONE*FBY;$#IGC\>^!?#_ !-CU#0<&G:V:GLC
MY"0W]N,#L$^_CI>2YCRO?\+OM-\5\&=WI7%'>:MPXV@&)W]:A:+!W<KC\HT?
M-RDW!K9(VA=*>DM^:GY$4]&[ZEM\?:(@?12DFJ1A;S=>?K)^I\JL<*OV/X>0
M(!3="JD BQ2^HB91(2G'XXXDX6UWA+4#INO9=\&8M+2;62-!IBC>.R]O,:BY
MP#JA?H3P?QOPQQYI0UCA?-1YG*V!X%DD3B*X)8SVHW<A%'#M,+FD$[BS7EMB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H*\PN?.
MHN)$8I%R2@77:[UD#J"UI#/$TG9$UB]6TG;)($W*=8AE/M(8Z:KIR'_ (*%
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M.NEB<?=PR#M,==6ECAV7AS26GE=YJ>/;9G$J24LT:H[O>FGKTB43?&;3TWT
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M])KL6CQQ$2E@ADG;,72)%?2./O/37*F8PE!1,3)J=.I1$.@Y3"=@)"NQ-%Y
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M?_R[3: ?TY%*&*N/IK333133113(DDD0J:2292D333(4"D33(4 *0A"@
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MS-J\=]+;&V% $;)Q-SNNM*A9;(V28G*I'(FEI>)=/'2,6J7O:$6,H5HH(G1
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M#FZ4\FT%:A>N15.?[M=3L]:HJM?T/;XQS1IU:><-5@8*E2>)]DT<L8:T/>#
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MP<]>1;+_ 'HW(;\S=^]4_%]_[>_^8?U72/RIOQC_ /*CZE^C/^1G]&?^D?\
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M*WSZ$6_G%X.KL7[INZGYA&$BG3P[9H55<K5LJJ)?33.8 :X@D D"_D5"YK2
MX@$FSEYEYM-V-3=@.KNRJ,Q\V<ZXNS_7-S3^7RK#Y-<HR'@YY]#]\FQ9)R/H
M1-D9*^X:"NU-ZW:543D4*6KFN;3%M%1S(U[7UPFXT/.LVRU7)A$PB81,(F$3
M")A%\SUFVD6;N/>HD<LWS9=F[;J=137;.4C(KHG ! 1(JD<2C_('%UJ$5%#<
MM9:>T;J'C_55J3I?7M:US6'4L\GWT76V!6H2D[()MT7DU,/%#+/YB67;,T41
M<NE5EO0022 P)ID*6]\CY#BD))4<<4<3<,8 ;78MK98I$PB81:UW!J:F;QUM
M;-67Z."1K%NC%&#PI>TKMBY(<CB-F(Q8Q3@VE86112=-E.A@*LD7N Q>I1]G
MA_7M1X9UB#7-*?@SN7?B&YPN<QPVM>TEKAM!-*&U:]Q7PQI/&7#^:X:UR/O-
M.S49:[WS3>R1AV/C> ]AV.:*@BH7&W?*?MW@CR:]@D]/%WO5MD:SU1L:2"A8
MNS0:HJ'B9A%$3@5Y!66)4.W>-N\P !W#14>\BA0_0W2]0T#Q0X+[US<>EYZ$
MLECKVHWCTF$['QNHYCJ;&2-L(*_)G6])XJ\%?$7N&O,6M:;F!+!* <$T9K@D
M KVHYF$MD94WR1.M#@NNGB]R(J7*#3E9VK53)ME7Z8QMJ@/7!9S5+>P20^=0
M#HW0IS%1.L19LH8I1<,ET5NTOJ=H? O&W".?X)XAFT+/5<UIQ124H)8G$X'C
MGH0X6X7AS:FB_4SPWX]TOQ'X3R_$VF4:YXP315J89V@=Y$>:H<PD#%&YCZ#%
M12%S4UO:81,(F$3")A$PB81,(JV_*GKC7DKP.YE7.4H=,DK@PXX[*48VM_5X
M-Y9&2C"KOS,3M)UPQ4E&QV1OBD)%2BF/ZGIF5DW.&88T$X<06'GF,.5D<0,6
M VTY%1G&<B'G!SP*<1M]:3I- B.1&R[([TW4=MNJ'79FSTQ_;+3NZ3E;8@X<
M1#UY)RJ%1IKM@U*L5RD!W).]%=,HHGSS%ZQJ+XY">Z J16^E/;7EB8Y72HY8
M@!,XT!I:*EUO4%]O&WF!R/TOR_XL5*D<I^57-_4.^;E":SY#06_.->TJ CK.
MP6R8A*_";!HECN$ 4\-7&4K.J.%6J3LB#=DR5(Y36]9%9JE@B?"\N8R-[15M
M' UIL*K#F)H\Q&UKY)8WFCL32*5VBJC)LSFMR_2VMO97DSSTY \!.2<%MJ78
MZ&U3:=-V8O$)Q1(Z48)0R4Y+4NK7B0GF:S-PY(226K$PS<-T6KU5T]*Z4]O*
MV"' WNHVR1%MIKVJ]-/.% _,YCO']]*^*8.[(([%.@'KH=]JDCY,*!M[:_+#
MPK7&7Y0'^I^03QA%Q-ETBYCY_5^K[RP;\?RVG;>@9:6B8Q[,1NPI:RHR*/S%
MN0I48]J %#[_ %BRKF,AG:&6-WWD6V'F4^=9))F,LXO[3]K;@>S4MYUU2V&-
M=PVH9R'?R[RP/XK6\G&O9Z1*D20FW;&L+M7,N^(@!42O))9(RRH$ "@<X]/A
MGD U>"++5[CA2,@VG#["X^?"]M/RJ4WB!)Q'#/C'H';VHC;CNCQS:]F7].LV
M-.XK05.)-1)(X^Q*L)HUFQ19G25]L/<=8X=YNG0OMYYF4=/6=[FOPBX;+>1:
M]IK\\W+TRS&.CQ&TFEMG*%@W .3Y$T_P,\I]M<8=C6K7&RM)\TY_:3UW4SH
MYGZ%":@T)'7R&DDW;=TV4AXVO3"LVN!B=?\ B@  0 1 ;LR(G:@QDH!8Z.G3
M4T]I6Y0S-TJ22 EKVR5LW4;7R6]"N,B^9.U>9WD.X$Z\T!L2QTW2$?Q/B^8W
M)6)J;QK[*82V SCW52UK;3G166,I$SR40V<-Q.0X-9AR'03%/VX)@9!EI'2
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M7HQM!;(VYNR2E8&J0T#*04(=G!UMY(LS+*H.WRA%D.WLDPT+WD,%9#:^Z@V
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M$ZG99\DM8G=,)79^TIQC=FG)S3B#"-E9].&:';M6I'KXZCD&J9DTR ;L*)0
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M VE?G3D]0S^G]YZA/-!WT1BD[M[F8XW$%T;\)&)A+6DL=5I+02*@+I1\(/\
M!_VS_CB4_N*JN?''VE?^J\A_]/\ _P :5?H1]CC_ *&U3_ZL?_CPJZC/G%?7
MJ81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB810;\AW(U;C;QIMEC@Y K&^W!1*AT Y3%]RVFIQ%<S^;0)ZA5
M"FKT"W=.DU0*8A'94"G#HH'7IGA+P@WC'C*#)YEF+2\N._GW%C",+#_./+6D
M6$M+B+EQGQXX_?X?>'F:S^2DP:WFR,MEMXDD!Q2#;\E$'O!H0'A@/I+GR\7G
M'$N_N2L5-6!F+RB:?(TV!9P72,JTDIE!YVTR <',4Z1AD9M$7:B2@"5PTCW"
M8_JL^L/&SB\\*\&ORV4=AU34"8(Z&A:PCY9XV]EAP CT72,*^%?LW\ #CCQ#
MBSF>9CT72@W-35%6OD#OZO$=G;D&,@V.CBD;M77CGP&OU03")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(HG<JN&VG^6M5^4WN-^56V,;JDJ>QH5!
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M_ KR=JE%UB1UU7!QLC8$>=PH*A_B=PSHK>]RB"IQ,)A*LB13[>H=>@#@YKQ
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MA5M3P9\W*"BZ?5!KKC<3%!,ZY$*1;PB9T4$Q^_ZL3?6%1;F=@F G!%JZ=F.
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MM(L28G%0(IZ],V*V+\Q20$5H2;;$%RF0W5!9$.X>J9'5= XNR9RY#9*CM12
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MOHO4'5U&-O9<;Y&#?O>W;M<WM6D.*Y5Q5H T^3U_)MIDWFT#W#CYFNV;C9M
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M8#[E@W\PJYW+5=L7'S15%XUZ>H^E]=LQ;5NE1";$':Q4PD)V66,9U.668.F
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M*+B<\:=SG>,_D<UM5[ I\O7>W^Q\?;PR!82(K/+&[>4YNR5/W$*=)G?&\>N
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MHGR7;EFX5 S5:+VI4-P11VZBJ/KR-EBJOLMRZ;N#)IF*J:P2:X&,4! BY3
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M\N+^*H@_Q>&EHM-=\E-B&(0R\]=*)2TE#$3%5%&I0<U..")*=YEDR.3W5(5
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MV5K^]:8J9[YLG5.YM47W4^TJY2?;.W3:V?1ERA(V0EH-\DQ4!-9B+D"G$A%
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M818?L.]5W5] O.S+>Y.RJ>NZ?9KU9WB9"J*-*[4H5[/S3E-,ZB1#G0C8]4X
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M$$7<C$&@@@;#7;S[UF,FBRN8F]8(:7.#@3M% +-]+J+!J98*?<.6WA?NFO\
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MEG'<=9=97MD)VER+M40$RS0KQB % I6)!,94.A\.<?9G2XV9+46=[D&@ %H
M>P>0/ W&A^^V+3=:X1@S[W9K).[O-N-2#4M<?*6GFJ.1<L.]N.>ZN--P5HV[
M-?SM&G ]52/4D$"KPL^S24],9*M6%D=Q"V&.[_@*K1=4$S]2'[% ,4.QZ=JN
MGZM!ZQI\K9(]M+VG<YIM:><<UBYKG<AG-/E[G.1N8_96X\H-Q',5_FBJ%J?9
M%Q0JVUMT#HR/D121C+E(4-Y=:NB[.82^C8E(NQ14K!-SB)0(X(U=H%$1%8R"
M91/C4<SG<I 9LEE_6'"]H>&.I][5I!YJ@[JE,E!E<Q+W69F[EIN<6XATT((Y
MZ$;Z*[^O_P 7\E+9"1=EJW,"A6.NS;-&0AYV"UTZEH>58."]R#R.DF-_79O&
MJI?B4Z9S%']/.>R^)C(9#%-D9&2M-""^A!W$%E0MQCX'=*P219MCHW"H(94$
M<A#E['_P[=S_ "IJQ^Y5*_MYRS_5&#]S?^L'YBO^H<W[RWXA_.3_ .';N?Y4
MU8_<JE?V\X_U1@_<W_K!^8GU#F_>6_$/YR?_  [=S_*FK'[E4K^WG'^J,'[F
M_P#6#\Q/J'-^\M^(?SE6=P5CW6F/)=I6I23U-5]4.0,AK!Z]222!)T]7?3>O
M%SII*+*IIIO7#P0#H<YB ?J43& .NV\1.&?X3S$[!V7Y82 <E _R46O:*TY3
MB&&)QM9.6>4M7>#GSBNTJ!WE$_U=/-7_ *-VU?[E7^9&4_M,?P@L7/?V.3X!
M\R@=SM__ .?B1_Z'W%S_ /?:;S(R_P#B7X;O96+FO\)_]MOL+=OE VFOI9+A
MQ 19]/Z3H<]NES$/N5^S]/06TJMQ+<5>ARCRE/J?7I@C6NT^VWQ5-6!C9==5
M!K&-17[@[#"=*S*,[S&3B<X-]$&F*VVN^EZDSTG=]V!A:TN](BH9064V FX%
M5QZKVE7K'SOY(2COE)<N3Z5]\6&Q:?0=RWZB4K6<%LF:J-\MUML-:T9'T6E4
M:LV^D4^OJ&<+OV:3\RDD$D)G:B:92IY+V$9=HP!E)@2 2:5 OJ30GVEAL>#F
MGG&7U@(!( K0DT;0 $#SUM6Q=O,&++^+@:?19LVC1(=4\'G_ *39NB@G[Z2Y
M':)?2+SL2(0ONW[UXLLLIT[U553G,(F,81M8?^)NYW_DE7R ?0[?@L_*:MH\
ML+7H;67-_<EE3YB;3\:?(*8UKJQX^V/<(2B7#CMRNIT'$OV\3)1=-O\ '2D1
M8;'J9PLM!ND4'T/)$%P86R2OJ*. LA$CX&C )8ZFP5#FGG&^_:I)W1,S+CWC
MH9L(M-"UPYCNNV+4>@-@W?:.Y_"A=+U2*?3GLIMKR2_(9.B:Z7U'6MI4Y'0U
MR3J^Z66M'2*+NHGVK& 67414 ?<G<"Z)VIN"$+?(UK(YVM)-C+S6AJ+*[:7*
M.)[GR99S@ <4EPI4831U-E;U#G97(R7VQP5Y,0LGR9C=%[#LD)R.&;\6W&#C
M#KB"L=&>Q=@LAI]EMJ:<TBQ['"'"/BQL=OLZ8UYNX;.G@>N)S)E&=D09F&$,
MQ-&'Y1SC;S6TY +5C/F,F5>"_ \AWR36BHMVV5Y2;%9#=]QZPA.1/@;VU(W.
M'2UE,Z?Y)Z_C;VBHN^J[JZ7K3.C*E3ZT678HN6B<K8[*S69-$SF**JZ*@!_P
M9Q#%:QYBS# .WB::<@))68Z1@FRLA(P%KA794AH ZU$NG*K4G5VE>0EJB)B;
MT-QU\T7+>][S-%1KZ;1HL),VG8].J>X9N(CD73Y:!UE:9U%PZ70177:IN>\A
M!#NZ3N[3W1C](Z!H'+<:=*@9V6-F=^B9F7%W)> >@JPMYNG5G-3R3\);/Q9M
MT5MFG\5*3R:N.]MJ4GU92BPT?N'7D-K[7VLCV]LE\ID;/.V/K,'C2KF5;H1(
M*BF(]YD<7NWP9603#"YY;0&^PU)IY%E]XS,YR)T!Q-C#BXBZT4 KOV]"A1KY
M@Q:?Q8.3(U9M&Q'''G9+]<C=NBB59\OO"S.%WBI4R%!1VLX^^=0>IS'^\(]?
MCF0[_%OPAYEC- ^A/P#^4MU\B.1#JC<NJS3[)R"U1X_(:*X;:W>5CDQ.:'H&
MP]P\@(Z0F'SV=U33-@[%B92$CZKKJ;(B\&N(M9!XYDWPN"(&]8HIQQQ8H2X-
M=(<9[-2 .4@;]ZDFF+<P&E[8AW8H[""7<@)V#=O4!4K;$RGC \NE95N5SM5R
M;>2K5VQI13:L&QINW9:E[.W/P]4U_L>\41E 5,M3)LDM5DG+) (F-3 &JJ16
MR(HG2)D4(S<)H WNB++14!U0#;=SK%Q Y+,-J2[O@;;#0EE"192M-P787GBK
M85Q)>;&<0EO('LA@EV^I6*?K"#==HG$17<4B)LI>\#$(4IO;6%/X%$P=O0>O
M41 /H'P_C+.&8G&Y\DA_'+?XJX_Q@\.UR1H]RQ@_%!]E30C/XO+>'\='OE^3
M=>8+/&35VLQ<ZIERN&2KA!-91HN4]V3."S8YQ(8!*4>XH]0#[,\%_B?EVO+1
ME'$ D5[P6\OH+UV\"3.:"<RT$B[ ?SE]O_P[=S_*FK'[E4K^WG+?]48/W-_Z
MP?F*OU#F_>6_$/YR?_#MW/\ *FK'[E4K^WG'^J,'[F_]8/S$^H<W[RWXA_.7
MR/\ ^+U66+9.Y*3Y94V.CF#=9X^D'^LG[-DR:-TS*N'3MTXOB:#9N@D43'.<
MQ2E* B(@&5;XGQ/<&,R4A>30 2 DGD&!4=P)(T%SLTP-%Y+#^<J4^1NJ=-Z>
MM85#5?(1AR%<,57",_9*O1'5;H[)=$XI%;0=C?V>5/;%>\AA,NT;?+A3$AD7
M2_4Q2;_I6=S^>A[_ #F5.5!]%KGASSSM#1AYB<6\!:AJ&6RF4E[K+3B<B\AM
M&]!).+G IN)6!:CTOM7?-R8Z_P!/42P; MS\/43B8!GZP-6H*)I*2,O(+G0B
MX*(045*"KQZNW:I"8.]0O4,R<]G\EIL!S.>D;% -KC?R 7D\@!)W*#*Y3,YV
M8091CGRG8/.3<!RF@73IPF\'%5UL^K^S>4UB^M;O&+MI:)UM3).2C*?79% R
M3EBXG+0Q4C9ZRR<>X*!_2:F9L2*D[3&>)#\>1\0>(<V;:[*:.SN\N10R. +G
M#;1IJ&@\M3\$KHNC\&Q9=S<QJ3L<PM#&DAH/*;"2.2@YUT(9S%;TJ3?/=!KR
MW":N/TA,"=8W[19QSVE(("@XJ.Q*T4#B8Y!*7W-A3^)0,/=T#IT$1#H'AM(&
M<0/:;WY9X_&8[^*M/XV87:.UP]S.T_BO'LK7?\7OL:+KC3NJHE.B+B#WFI8U
M4R@/N"HVJ@T^,0.J/JB HG/3E )]PH@8I_O&^ %RO$Z(C5LO/L=E\/Q7N/\
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MN^Y<;]7 W3^U,KR@TF3J!#K&_P"W2>3:($#H)31YP$% ZOH/#&OG#F=>S^<
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M //_ /L?_C+SOL)__P"T_P#+?_\ (+';/_KV&W]L51_]V"%R&?\ \ICX;/\
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MP7+[\HJKXW4='OCM%'S%F\48.2/&)W39%P=D\3 2INVAEB',W<D*80!0G0P
M/VXJ52@-Z_M)FS0<.G:+1LB[>^C[UTD@DFX=^V(*3?W2Q"@HX]NF(E)WB/84
M>@= PJT%Z^G"+A#VRX_?;>4*Q,H[T7\9M#E5'4N.<$*FNV7IT=<H^F,I14I3
MF35;!4H<CE7H80$@&Z".?1N2'T)P@US['PY(O/PBTO(^,:+BV:/TIQ&X-M;)
MF0T?!#@VOQ15=WF?.2[2F$3"+EN\Z$GRUF=O4W7<'&;%<\=9NI0AZ]$TN/F7
MM;M]\^8R03*%E)"(K?,[&Q,9L5JQ==P)H>FL@GW*J''L/AVS1(\C)FI#$-4:
M\XB\@.:R@IAK<TVU(VU!-@7-^,W:H_-,@8)#D"T4#0:.=4UK2\BR@.RT+5W#
M/P;[3VA\HO7*5_(Z=HJWI/$M>QX-S;5G6P_>(E*>Y2=1E"07*("8KDCJ2* &
M(=JW,('#,U[Q#R>3Q9?1P)\Q=C/Z,<UQ?T4;RFY8VD\&YG,TFU(F*'WH],\^
MQO34\@73]I#C[IOCA36]#TM0(&B5Y($#.RQ383RDX[03%(DE99UT9Q-6.5[#
M"'N'JZZH%'M*($ "AR'4-3S^JSG,Y^5TDNRMP&YHN:.0 +HV3R.4T^'N,FQK
M(^2\\I-Y/*5N3,!9:815^^4S7:VS. _(Z%:)&4?05/:;!:B0#F42)K:P0]YD
MS%*4#=WJ0D"Z3$! 0[3B/P$ ,&S<'9H93B3*R.]%TA9^L:6#RD+P^)(#F-$S
M#!>UF+XA#CY 52+_ !>[:*<-N7>VGW3D2$ONOX"[QB2JGX(\EKN;7BW2#4AA
M$"NW4;?#*G[>@G29]3=03+TZ#XG9,R9#+9X#]'*YAYGBO55GEY5IW N9P9N;
M*'W<8<.=IIYG>1=7F<8734PB81,(O/>1$3(.6+Q_&1[YW%J'6C'3QDV<N8Y8
MXI&.JQ762.JT4.9 @B9,2B(D+^D&5J0J$ VF]>AE%5,(F$3"+XH^,C8E 6L7
M'LHUJ*JBPMH]H@S0%98>Y5446Z::?JJF^)C=.IA^W%2;U0 "P+\/DD-Z,BW^
M41?MYA15:70]@T]&467*!%U9%+TNQ\HL0  YE0,)@#H.5J4H-UZ](I2D*4A"
ME*0I0*4I0 I2E*'0I2E#H %  ^ 9157]81,(F$51'FZV:A0N"-JK0+ G([=O
M%%U^Q*0P>N"+26'8$HJ!/B;VYHVD*-U#].TON2E$0,<O7=_#[*',\1LE]S!&
M]YZ1@'E?7H6K<8Y@0:*Z/W4KVM'7B/D;3I4+?XO%K99M5>2&X'+8!;S-@I6M
MH1X*8=2+5J-D[1:&Q%1+U$%26N(,8H" ?<*(@/PZ>_XH9L&;*9$&UK7R$?"(
M:W\ER\C@3+D19C-$6%S6#H!)_*:NDG.4KH"8185LFAPFT]=7[6%E,\)7-CTJ
MU4.P&CERMI L);X)_7I4S%R=-8K=X5A(J"D<2& A^@]!Z=,R,IF9,GFHLY#3
MO8I&O;6ZK2'"O)4*',0,S.7?EI*]W(QS32^C@0:=!5!VD?XOYKRK[ >3F\]O
M/MH4.,?E5K],K$*YHZUA;$5$Y2W68++RC]FU,D $4;1:J*QQ'N*\3 .PW2=0
M\3,U-E1'IT AS)':>XX\/P!0 \[JC[TK2<GP/!'.7YR4R0 V- PU^$:D] ZU
M?I0=>475=4BJ-K>HUZCU"$1]"+KM8BVD1%-0,/<JJ#5FDD15VZ4ZJ+KG[EEU
M3&.H8QS"8>:YG-9G.3.S&;>Z2=U[G$DGKV;A<+@MW@@ART0AR[&LB%P H/NW
M[UF60*5,(L0O]&K>S:3:=>W!HJ_JUS@Y"NS[)!VY8+.HJ4;G:O$$GK-1%TU.
MHBH( =,Y3E^T! <Q\WE8<]E9,GF!6"1I:X5(J#8;1:%Y&OZ'IW$VBYKA_5V&
M32\Y ^&5H<6ET;QA< YI#FD@W@@C8M:\?^-6H^,=;FJEIZ!?0$'/S@V*3;/I
MV7GE%I46#.,%<CF9>/%T2>T8IE["F G4.O3J(YA:3HNGZ'"[+Z<PLB>[$07%
MUM +R3L 6M\ >&W"7AEILVD\'P/R^1S$_?/#I9)29,+65K(YQ PM:* TVK?.
M>JM[48-K</-#;JVK3-T["K$E*[!H#:NLZQ*M;+/Q;5FA5;'(VN%*M%QS]O'O
M!;S<JNH854S"H4P$-U*  'AY_AW2M3S\>I9QCG9N$-#2'. &%Q>VP&A[1)M7
M,>*O"#@3C3BK)<9\09627B#(-A;"]LTK&M$$SYXZL8\,=21[B<0-0:&H "II
M\T9"*<@.,J:A2G3/7'1#D.4#$.0UU9E,4Q3 (&*8!Z" _ 0SF_B4*ZOD0;L!
M_+"^-_MG .X^X9:X M.6=4?[RU6$6#Q*\,+#>7-V5IUFBT'T@:2>TB"MCV*I
M"SA98[ARFA'MT?F\4Q<*J#_0S)\V;HDZ$1(D0 *&WS>'_#<V:.9,;V@FI8UY
M#.6R\#D:X 7 !?06H?9-\&=0UQVM/R>9BC?)C=EHIW,RQ))+@& =XQI)]".5
MC&BQC6@ *?K?7U&:T=/6:%1KQ->I0'TJ2E_*69ZU].>U]B,*>(.D9DI'':")
M#)F()3 (]>HB.;8W)Y5N5]2$;/4\&'!08<-*4I=2B[['P_H<6B#AJ/*9<</C
M+]QZMW;>Y[G#A[LQD82PML((H=JKMGO$!PNFK$>=;UR\UYHJO[A6L0-W?)UT
MQC'$ZB9"RC:5FFR"@F_4(O4RD#X)@0  ,T^7P\X:EF[T,E8VOHM></E!(Z#S
M+YXS_P!D/P8SNHG/1Y?/9>(NJ88LRX0[R.VU\C0=S9 !<V@4SXOC9I: TM,<
M?*Y2&5=U3/0LM!2]=AG3]FO(-)Q 6\LY>38.CS;R6?)" '>*N%'0@4H=_0I0
M#98]%TV+3':1#$&9![2TM!(J'7U=7$2=Y->5=FROAOP9I_!<WA_IV29E^%9X
M9(I(8W/:7ME%)"Z3%WKI'"^1SR^P=JP4\;5/%/2NE=57/2VO:[(16OK^YL3R
MSQ3JPS<HZ>+VJN1U4FC(RDB]<2#,'$)%()E!)0H)F*)R]#"(C%D-!TS3,A)I
MN386Y28N+@7.).)H8ZTFH[( L6%PKX5\%\%\*YW@SA_+21</Y]TSIF.EE>YQ
MGA9!)1[W%[:QL:!A(H144))317%/2O&^M6RI:FKLA!0=V<E=V%L]L,W.*.UR
M,%(PIDG,N]=KM0!FH)>B9BAU^/VXTK0=,T:&3+Z>PLBE-7 N<ZME+R32Q.!?
M"O@OPXTW-Z3PGEI(,CG78I0Z664N(:66&1SBWLFEA&]?-QXXD:.XL_6'XF*W
M(U[ZZ^G_ *D]_8YVP>\^F/G?R?TOG3Y[[3V_U"Z[O2[?4[P[NO:7I31^']+T
M+O/HUA9WN'%5SG5PXJ>D33TC<H_#WPEX'\+O7/J9EI,OZ]W7?8II9<7<]YW=
M.\<[#3O7UPTK6VM OE=\/-#/N0I.4;BL21]RD<LGA; %EGR, 7CZDA2&IOD!
M7X0H@2NMB)"'H]#'#U!^^/7+7<.Z4[5_ITL=])5!Q8G4L9@'9KA]$4NY;U%+
MX0<"3^((\4),K(>,@YKN][Z7#5D RS?DL?=V0@-]&_M7VK[>0O$G0O*&/8-=
MOTA"9DH=)1"#M,:\=P=KAD53F4.V:34:JBLXCS**&/[1T#AGZAA4]+U.A@NU
M?A_2M<8&ZC$'/;Z+@2UPY 1>.0U&VE5-X@^$O ?B?EXXN+\DV;,P@B*=CG13
MQ@FI#9&$$LJ2>[?CCJ<6'%:M$:6\8/$K2%L87>%J<[<+/#/$)& D-@SPSZ$$
M_;&(HW?1\0S9Q$(H\;+)@HBLY;.%4%0 Z9B& !#RM-X'X?TS,#-1QODG::M,
MCL6$C:  &U&PD$@VA:+P7]F/PFX(U6/6\GE)\YJ<+P^)^;E[T1.%H<R-K8XR
MYI%6N>Q[FNHYI! *L)S;U]!)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PBY'_/QHT]1Y!:ZWK'-!)$;@I8U^<<$(02C=-<F;,3+.5$RE%,7U0E8
MM)$JG4Q_8*B4P@42D[9X:ZCW^F2Z<\]N"3$/@/M\C@ZO.%R[C?)=UGH\ZT=F
M5E#\)EGE:1U%7N^+_D CR(X7:BL;E\+VU4B()JF\^JH*SLMCH39K%MWCY4WQ
M5=S]:-'R:AOT3/1#[0'.<\7Z8=+U^>("D,CN\9NPOJ:#D#L3>A;KPYGAG](B
MD)K*P8'<[;+><4/2K \UE>XF$3")A$PB81,(F$3")A$PB81,(F$59WENW^AH
M7A-LXK5VFA:MNMOQ-U5#U *NH-U:.T+6[3*4?73"/H[>2.18H=$W1D $2B<H
MYMO!.F'4N((<0^1@/>N_ (PCI?ALW56N\49X9+1Y*'Y67Y-OX7I=3:]-%3W_
M !?G1JTYM;;W(239B,50JJVUS6%U0#TE;3<W2$K-NF@E'O\ =P=<A"(*=W0G
MI3(= ,/Q)O/B9J(CR4&EL/;D?C=\%E@KR%QK^"M5X&R1?F9<^X=EC< ^$ZT]
M0%/PEU:YQE=,3")A$PB81,(F$3")A%RG_P 8*THM#;3TSO\ CF(EC+O4GVM[
M([0( (IV.FOEYF#6?&[0$7LS V%9%(>INY&($.A>T.[LOAEJ DR>8TQY[<;Q
M(T?>N%#3D!:">5RYGQSDRS,PYYH[+VEAYVVCK!_%5Q?B:WNGO?A!J=T[>@ZL
MVKVBNG+645?562=41%JTKBJZANBJJS^BN8IPH<P=3+*G^)A 3#HO&NFG3>(9
MPT4AF/>M_#M=U/Q#FHMLX8SOKNCQ$FLD8[MWX-W6W"59+FJ+8$PB81,(F$3"
M)A$PB81,(F$3")A$PBBMS:WRAQIXL[GV^#LK2:K]/?1]-$3)>JM>[*)*Y3"I
M(J& 7)&UAE$'"Y2 8Q6J*I^G:01#V>']-.K:SE\C2L;I 7? ;VG?B@@<I"\S
M6,Z-/TV;-5H]K"&_"-C?*03R57+EX-M)+;-YD!LI^V,O Z+I\S;5G*J9U6Y[
M9:$'%0K#%4W7H5T9M)R+]$QNOWXT1#X@ AV#Q#U 930?5&GY3,R!OX+>TX^1
MH/PESC@W)G,:MZPX=B%A=^$>R/.3T+LVS@RZTF$3")A$PB81,(F$7DST)&V:
M#FJY,MBO(>P1,C"2S,_ZAU&RK-9@^;'^W[J[5<Y1_D#E\<CX9&RQFDC7 @[B
M#4*U[&R,,;[6.!!YC85PF:.L<QX]/(E"EMBZ[=GIO<$U0;L[.D)0D-?2Z[ZI
M3,^5J!3@N@[J$O\ -FA>GWC B8O:8 $/HS48H^)^%W=R 73P![!N>*.#>APP
MGI7%\G([0M>'>W12EKN5IJTGXIQ#H7>*DJDNDFN@HFLBLF15%9(Y5$E4E"@=
M-1-0@B0Z9R" @("(" ]0SYQ((-#>NU @BHN7Z91$PB81,(F$3")A$PB81,(F
M$3")A$PBY'_/ER 0NV^M?Z!A7P+QFEJTM.6E-%0.P+UL)*/?D9.2D.8JBD13
MV$>JD)@ R8R2Q>GV]>V>&VF'+Z;+J<@H_,/HWX#*BO2XN^*%R[C?/";.LR+#
MV86U/PG4/D:!UE7N^+O1JN@^$FEZU(M!:66W0RFT;6FH0R2Y9?81RSK)H[1.
M4IT7L/658]@L0?B51J/7.<\8:B-2X@S$K#6)CN[;S,L)'(78B.=;IPWDSD='
MAC<*2/&-W.ZT=0H.A6!YK*]U,(F$3")A$PB81,(F$3")A%A5GUMKJ[/&,C<Z
M#2K=(19!3C'UGJT%/O(Y,507%-BZE6#M=H05R@?HF8H=X=?MS&GR63S+@_,Q
M12/;<7-:XCF)!HO%U/AOAW6YH\QK.0R6;S$0HQTT$4KF"M:-<]KBVVVPBVU9
MKF2O:3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$5?WDUXP*<JN)-^IL+'C(;!IP)[*UHDD'5RYM=5;/#+0K< ()E5
MK/77;Z-2((E)[ETD<P]"9LW"6KC1M;BGD-,K)\G)\%U+?P7 ./(#O7A\1:=]
M)Z6^)@K.SML^$W9TBHYR%SQ^$CENGH[D$_T7<Y,66O\ ?RC"*C!=J=C2#VO'
M&.C5G'X4>UJG:6JZT2L!2@99V=CWB!$?AT_Q!T0ZCI@U'+BN:RU2:7F,^E\6
MQPW#%O6A\'ZIZGGCDI32">@'(\>CU^CSX=R['<X4NL)A$PB81,(F$3")A$PB
M81,(F$3")A%Q;>8_E?\ OF>3Z&K:$Y5F=?Z+5?42"^5J*OTK5L22>-TKK+QZ
M#8#$=%3D&;>(:>F57UO8'62.8CDI0[YP)HOT3I!SF9&',YFCS6S"P#L [K"7
M'=BH;ER/BS4_I'4?5H+8(:M%+<3SZ1'31HYJB]=.WCZXR%XE\5M;ZJ?((DN:
M[1:Y[*71$A_7O]J*B]F6PK)&%)RG76I&T0BL4 !9O')G$.XPYR+B;5_IK69<
MZW]!7#'\!M@^,:N(V%Q71=#T[Z+TV/+']-3$_P"$Z_JL;S!33SP%ZZ81,(F$
M3")A$PB81,(H/>1;C0'*SB;LK6T>S!U=(IHG?M:]"&46+>Z@BZ=QS%L4I3]%
MK)&+/(<3=H]A)$Q@^( .;#PMJWT-K46;<:9=QP2? =83^":._!7C:]IWTGI<
MF7:*S 8F?";=UBK>E<V_A1Y3FT+R8>Z3N;L8RD;]%G6!+(B+8D%M&$4=A35E
M@7Z':C-'=NH=5,"E,H[=M1.(%1^'5N/]&^DM)&H0"N8RU76;8S3%U4#N8.WK
MG_"&I>I:B<G*:0SV6['CT>NUO.1N793G"%UE,(F$3")A$PB81,(F$3")A$PB
M81,(N5+ST\L6]LO%0XFU&1%:+UPLA>=HG;K&%NXNTO&=M4KR@$.4AU*W6Y%5
MVN @<@JRB1?NJ-SAG9?#?13!EWZU..W+V(_@ ]IWX3A0?!.PKFG&VIB69FEQ
M'LQ]I_PB.R.@&IYQN5IGARXON>._$F&L=ECP9; WN[:[-GTU4/2?1U9=,$T-
M?0#HQ@*KU;0"AI$R2A2G;.95=(P=2"(Z=QWJXU36W11&N6RP[L;BZO;(_"[/
M*&@K9.%--.0TL22"D\QQGD%.R.JWD)(5L.:6MG3")A$PB81,(F$3")A%RI>?
M#BVM7=@TKE?68[I![ :L=?;)4;IG$&MV@6*QJI-O#=3 'U#4V8L>H 4B9H8G
M7[ZP=>R^&VL"7*R:+,?E(B7Q\K''M ?!<:_A<BYIQOIICG9J<8[#QA?\(>B>
MEMGX/*K//#CRU2Y%\7XRA6.4]UM#0*491)]-TOZDA,4TK8Y-?V@W<'J+%4BF
M9XQ<YC'5.ZC#JJCU7()M0X[T0Z7K!S,0ID\S5[=P?[MO6<0Y'4%RV/A/5!G]
M-$$AKF8*-.\M]R>JP\HJ;U;CFDK:$PB81,(F$3")A$PB81,(F$3")A%I?D/O
M&H<;M+[!W5>'!4X&B0#F3!GZH).)R85$C.O5M@82G#YC8YQRW9("(=I%%@,?
MH0IC!GZ7IT^JY^+3\N/E)'4KN%[G'D:*D\RQ,_G(M/RDF<F]!C:\YV <I- N
M++AWJ:Y>1#G@P>;"!2=96.XRNY=W/Q(I[%*H1TLC)RT04HBJ+./FWSII LDB
M]0;$>)@4 33'IWW7<[!POPX6Y7LN9&(HAMQ$4!Y2!5YWT.TKD6DY677M:!G[
M0<\R2'9A!J1S$T:-U0N[,A")$(FF0J::92D33(4"$(0@ 4I"%* %*4I0Z  ?
M  SYS)K:;UVA?UA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBXU/,APLD.-^
M^!W[KR.=L=3[JGG$Z5W&$5;MZ+MI51>6GH(CAN<?EZ,^JDI,1?04@ 1=((D*
MFS 1[OP)K[=5TWZ-S1!SN7;2A]W'<T\N'T77^Y)M<N3<6:0[3\[Z] ",K,ZM
MGN7WD<E?2'2!<KXO%GSRC^8FF&U?N$HW+OW5\:QB]A,5#I(NK9&) 1E%;(CV
MQ1*"J,R!2)R8)% C64$WW$T5VP&YQQCPV[0L^98 ?HV8DL/O3>8SS>YWMWD%
M;KPWK;=6RG=RG^O1BCA[X;'CGV[CR$*TG-/6R)A$PB81,(F$3")A$PB81,(F
M$50OEJY^-.*.I%]8:\F2DY ;9AW;.!,Q<@5[KNG.1582U^<^B;UVDFOT5:0G
M44Q,]!1R43%9'34WC@KAIVM9T9S--_X9 X$UN>Z\,Y1M?R4'NJC5N*-<&F97
MU: _UZ46?>MN+N?8WEMV*GSPH<)'.Y]N!R:V##BMK#3<N12GIR"/>WMVVFP(
M/(Y5$BI# YCZ&FL2054 2])(S,I1.!5REWGC_B 9#(_1&5=_7)V]JGN8[CTO
M]$?>XN1:IPAHYS>:^D9Q_5H3V:^Z?LZ&W\].5=?N<.75$PB81,(F$3")A$PB
M81,(F$7&_P"9KAE(<>-\DY"Z^8.F6K]VSKF:7=1A5D$J3M[N4E9V,!PW(4L>
ME:#)GF(X?4 YE@>IIE(FU)U[MP'KS=4TWZ+S1!SF7;2WW<5P/+A]%W)A)M*Y
M/Q;I+LAG?7X 1EIG5L]R^\CDKZ0Z=ROH\7G.F.YD:.:L;3)-R;VUBT8P6RXQ
M0Z"+JPMR)@A$;&CFR?8"D?9$T^UX"9"%:RA%D^PB)VQE>;\8<.OT'42Z$'Z.
MF),9][O8>5NS>VAOK3=N&]:;JV3#93_78P \;]SQR';N-=E%9QFHK8DPB81,
M(F$3")A$PB81,(F$3"*$G/GF35>%FAIO8#Y5@_V#/).Z]J6H.% %:QW!5N $
M>N&I#%7/6ZL1<CV34 4R^D4C<JA5W* &V#AK09M?U)N6;495M'2.]ZW=\)US
M>6VE 5X^MZM%I&2,[J&=UC&[W>T+SU7D+E/\<_%BV<^N6+RV[/4D+-0ZW83;
M3WQ9I4!6&UR4K+.91K5':Q#-^^0V!-)K%< F)!2CTW:A.AB)E-V;BG68>&M%
M$&3HS,O;W<+1[D 4+AR,%*??81O7,] TV76]4,N9JZ%KL<A/NB37#SN-_)5=
MQ)"$2(1-,A4TTRE(FF0H$(0A  I2$*4 *4I2AT  ^ !GSR36TWKLB_K")A$P
MB81,(F$3")A$PBTMR(T73>2FF;]I6]H@:!O,&O'%?%;IN7<#,)&([@;+&IJF
M(49*O3""+M$!,4IS)=AA[#& <_2]1GTG/Q:AEOTD;JTV$7%IY'"H*Q,_DHM0
MRC\G-Z#VTKN.PCE!M7$]J386Z/%CS4?$L,:X"6H$RYINR:N@H=&-V)K>65:/
M#JQJRX) JRFXTC.9AG!P+V.$VQU2] 42'Z SN5R'&.@#NB,$K<4;MK)!46\H
M-6N&ZM-A7(,K/F^&M7/>#M,.%XV.8=W.*.:=].9=Q6J]H4?=.O*GM+6\XWL5
M*NL0WF8*5;]2^HW6[B+-7:!OPK*2CG2:C=TW4 %6[A(Z9P Q1#/GG.9/,9#-
M/R>;:69B-U"/:W@W@[1:NQY;,PYR!N9R[L4+Q4'[MHN(V%; S&4Z81,(F$3"
M)A$PB81,(F$3"+_#&*4HF,(%*4!,8QA "E* =1$1'X  !A%QO>87GPER=V8S
MT-J25&4TOJN<4]Q)Q9U%VNR=EIE<1CF89&2,8DA7ZVDX58Q9B%$KE55RY(=5
M%9L).[<#<-G2,H=2SK:9^9MQ_DX[Z'<YU[MPH+""N3\5ZV-1S R65-<I$Z\>
M[?=4;P+F[[3:"%>EXF^$ZG$?CZ2:NL8#3=6XPC+3?B+@ NZS$(H*FJ5"$>A0
M26@VCY5P_* =WS)XLF)U$T$1#G?&G$ UO4^[RYKI\%6LW./NG])  ^] -A)6
MY\,:/]%Y'',*9R6CG<@]RWHK4\I.X*U#--6RIA$PB81,(F$3")A$PB\N8FHN
M 8JR4P^;L&2(=3KN#@0O\HH?:8W\@/T/C]F9&6RN8SDH@RS2^4[ L7-YW*Y"
M YC-O;'"-I6CU>2^M$W0H \>G3*82"N1DY$@B _JBF!(4A(/Z8G#-J;P-KSF
M8\#0=U15::_Q&X;;+W?>.(WX31;EKMH@K6Q+(0,BWD&P] ,9$P"9,PAU[3E^
MT!_D_$.OZ.:SG=/SFG2]SG&%DG+MYEMNGZGD=4@&8R,@?'R7CG"]_,-9Z81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(M2[STEK[D5JNWZ>V?$!,5"XQIF3LJ8D2D(QZF8KB+GH5V=-4&,Y!R"
M:;EJMVF*55, .4Z8G(;-T[4,UI><9GLF[#/&:C<1M!&T$6$;N58N=R<&?RS\
MIF16)XZ1N(W$&T+B/VGK3DGXJ>5T:_AY1Q&3E<>N9?6]_08K#4MGTE<P-W2#
MMFH<4';1XS6]G,Q9U!59KC]T_P#X,Y/]!9/-Z3QEHI:\ QO%)&5[4;]E#L(-
MK77$=(7'LSE]0X:U,.8:/::L=3LO;]UCAL/05UT\&^=FJ^;NN L-463KVQ*\
MV:(['UF_<I&F*U(JD*09*.^_ZDQ4))R!O9/RE#J >DL5)<ITPXCQ%PYG.'LU
MW4W:RKB<$@N<-QW.&T=(J+5U+1M:RVL9?O(NS.WTV&\'>-[3L/70J<.:\O93
M")A$PB81,(F$3")A$PBK\Y\^0/67"&@++OEH^U[EL4>H;7>KTW@%=O#JBX;I
M6>T W/[F(I<>Y;G!17[JKU5,6[?[WJ*([-PUPSF^(<S1M69!A[<E+OO6[WG=
M<!:=@/AZWKF6T>"KJ.S;AV6>R=S1Y;AR<HO'G0W(#RF<II^7LD_(O#R\LE:]
MS;1?)&5C*76G#KT6\?#M%#E:E>':HBQ@(9$2ID31  !-HW652[/JFI:9P=H[
M61- PMPQ1B][MY.[:]QW[7$ \RR&2SW$FI.=(XFIQ2/V-&X>9K?8!7;UJ;5=
M&TCKFH:IUM!H5ZDTB';PL%&(_?.5%+N4</7SDP>J_EI1XJHY>.5.JKETLHJ<
M1.<1SY\SN<S&H9I^=S;B[,2.J3[ W "P#8  NPY7+0Y/+LRN7;AA8* >WO)O
M)VFU;#S%60F$3")A$PB81,(F$3")A$PBU!OK1U Y':GN.F]F1@R53N4:+-R9
M$4TY&)?H*$=1,_"N5$U2M)F#D44W+902F+ZB?:<ITS'(;.TW4<SI6=CS^4-)
MHS7D(N+3O!%A]M8N=R<&H95^4S K$\=(.PCE!M"XF+?5>2/B=Y?-'4>[.VGJ
MH],_JUC]F\2I>X=:OG*?KM7;8QR@\AIQHD#:3:$6,O&OTQ])8JZ"#C/H"";2
MN--#(<*QO%'-J,<4@VC<0;6FE'-O%"0N/RQ:APQJH+31[35I]S(P^P;B+P=M
M0"NP[AKS*U7S2U6UV%KUT$=/1P-6&P=?/W22UAHEA62,<63T"%1%_#/Q14/'
M2)$R(O42&^ZFNFN@CPS7M!SF@9PY7-"L9M8\>B]N\;B/=-O!W@@GJVDZMEM7
MRPG@-'BQS3>T^R#L.WGJ!+C/$7J)A$PB81,(F$3")A$PB811_P"2W)?5/%'5
MDUM?;4X6-AX\IFT-#-3(K6*XSZB1SL*S5XU15$TA+/C$$1$3%1;(E.NN=)!-
M10OIZ3I.=UK.-R62;5YO)]%K=KG'8!UDV $D!8.H:CEM,RQS6:=1@N&UQV #
M:3Y+S0+BUV9L+DCY6N6<>A$0RS^?LC@86ATEHY74JFK* T<>LNN_D3(D(WC8
MQ%4SR7DU$RJ/'1Q[$P$S9J7OF4RNE<&:*2]U(F"KWGTI'G<-YN:W8+S>5R/,
M3ZAQ-J@#!5[K&M]RQO*=PO<=IZ NRGA_Q5H7#S2-<U!1TRNW#?K,72U*MR(2
M-UNCY! DQ87X%ZBFD8&Z;=F@)C>U8H(I=QQ*8YN$:YK.9UW4'Y[,6 V,;L8P
M7-'G)VDDKK&E:9!I63;E8;3>YVUSMI/F&X !2ASQUZ281,(F$3")A$PB81,(
MF$3"*I3RI^/!KS%UTC?M=,FC7D+K6*=!6CB+=J38=:3%9\XU]*/%3(I)/0='
M.O#N5C@BW=**)*"1)THLENO!O%#M"S7JV:).ERN&+[QUV,#=L<!:10BT '5^
M)=!&K9?OX !GHQ9]\+\)_BG8:BXU% GC@\@]SX&[,E]6;;8V1324Y8G$??Z:
M\:.D[!J^X-W"<8^ML5".TB/47S$6GMYB, J:CI)(# 47#=,A^E\5<,0<291N
M<R19](-;5C@1AD;>&DBRAK5KMAY"5H^@:[-HF8.6S0=ZFYU'-VL=<7 ;Q<X;
M><+L[HMZJ&S*A7;_ $"Q1ELIMLC&\Q7K##N <Q\G'N0'L52/T*=-5,Y3)K(J
M%(L@L0R:A2*$,4."YG+3Y2=V6S+2R=AHYIO!^ZXW$6BQ=;AFBS$39X'!T3A4
M$7$?=U+*\A4J81,(F$3")A$PB81,(F$7,MY8O*['/(ZQ\7N+UG]Y[SW4)MS;
M< \4(V(V(H=O(T*C2;4Q/>>\[!2E)- XH"@)FS<RGJ*G3ZWP7P8]KV:QK#*4
MMBC<.I[QLI[EIMK::4%>=\3\3-+7:;IKJUL>\>5K3YS=2P;5B/AM\:[RPRM=
MY@;V@#-ZO%G0F-&4R6;%[[-*%-WL]F2[1;J9. B3%]2%2.0#/G7:] 2MT4!=
MS\=\6-B8[0].=68V3/'N1MC!]\?=[AV;R<,7"?#YD<W5<ZWY,6QM.T^_/(/<
M[S;<!7J7SCJZ2F$3")A$PB81,(F$3")A%7?RAMK^1O U8%3DC(%HT-Z "($7
M>/6R3PZRA?@ B1)<I0_E?RL[1X?Z=!#I7TA0',2O=:=@:: #SK@?B7JV8FU@
MZ8'$9>&-M@VEXJ2?,HPCF_<ZYDMWZ"M\A7-A0;-)908Z>>$B7[;O/Z1Q=AZ3
M=?TP'M]1)?L'KT^(!_(#-4XQTV'/:+-*X#OX68FG;8;1U56Z\":I/I^OP0L<
M?5YWX'-V&H-#T%6?YP1?2B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$4;N4_%C5/+S5,KJK:L5ZS5;O?5F
MS,2(DLE(LA$3I,['7'BI#^BZ1[^U9$W5!X@)D5BF(80SU=&UG.Z'G6YS)N[5
MSFGT7MVM<-VXW@VBU>?J6FY;5<L<MF19>"+VG>/NH185QJ[XXW\L?%SO.'MT
M/-S4$1C+.5=8[NIZ2I*W:V!3=YHN4;N"NV+9\Y8]"2E?DBKHJD[R]'342K*=
MXTW5=%XPTYT#VM=5ORD3O2:=XN-*^B]M"/O38.39W3]3X;SHE82VA[$C;G#<
M>7>T^46J_P!X.>:+3^]F\30.12\)I/;8I(,TK$\="SU5=WG;V^JPF'RIPI$F
MX$HB+.36]J8W:5!XHHH5 O-.(> <]IQ=F=+#LQDK\(%9&#E ],<K17>T 56\
M:-Q=E,Z!!GZ0YK?[AW,3Z)Y#9N.Q7>$.14A%$SE434*4Z:A# <AR' #%.0Q1
M$IBF*/4!#X"&<](I8;UN*_K")A$PB81,(F$7X.G39BV</7KA!FS9H+.G;MTL
MFW;-6S=,RJ[APNJ8B2"""1!,<YA I2@(B( &5 +B&M!+B; J$AHJ; %0_P Y
MO-EK'4S27UWQ6<0^V]F&268NMB!U?:OIBYP @N(MRD8B>PIA @B9(&I_E*:@
MD,=PX[%6H]'X=\/\WG7-S6LAT&4OP72.Y_>#G[7(+"M+UGC#+94&#3:2YCWW
MN&\WOCS=GE-H5'7&+B!R?\F>XYJ\V&<G5H"0FO=[1WU<TEWK!JJ!4Q4B()(1
M:I3L^FS[$F<4R%)JQ1](J@M6X$'.A:OKFD<)9!N7B:WO0VD<+;#SG<VM[C4D
MUI4K3=.TK4>(LV9I"[ 3VY'7<PWG<!8.0+LRXX<;-3<5=8Q6J=/U\(: 8J'>
MR4B[.F[L-IG'!$R/;%9Y4J2)Y.7=E2*7N[2)((D(BB1)%--,O!]5U;.ZSFSG
M<\[%*; !8UHV-:-@\I-I)))76M/T_*Z9EQELHVC!>=I.\G:?]@L6^L\U9J81
M,(F$3")A$PB81,(F$3")A$PBBWRXXCZIYD:I?ZRV:P]%TC[A_2KJP;HGLE#L
MAT?31F8993L]9JMV%(^8G,"#Y .P_:<J2J7L:)K>=T'.C-Y0]FY[#Z+V[CR[
MC>#R5!\W5-+RVK98Y?,"V]KA>T[Q[(N(Z"N-V^ZVY>^*/D3&S#20=U:=;"N-
M3O\  D7D->;1JIET%'T6X3=))MI2/<"BF60B7I".VBQ4U0*40;.3=VRV;T/C
M/2S&X!\9])AL?&[8;+C[UPL(J-X7)Y\OJO#.?#P2UX]%PM:]N[E&]IM%^XKI
MCX->6C1G+!M$4J[NHW3N]%4T&JE0G)$B%8N,@/II"KKVPOE")O%GBQP$D2Z,
M22()A(E[LB9EQY+Q%P5J.BEV8RX,^G7X@.TT??M%U/?#L[\-:+H>C<49+4P(
M9J19WWI-CC]Z3^2;=U;U;'FEK9TPB81,(F$3")A$PBK=YM>3G0'#:-D8%Q(M
M]E[J!L Q>IZQ)(^Z8N%2F%!Q>IQ))ZTIL>4  XIJD5D52'(9)J=,PJDVOA_A
M'4]>>) ##I];9'"_X L+CU-&TUL6OZQQ%D=):6$]YG-C ;OA&W"/+N&U<J$Y
M/\P?*WR,;(%;N[K;'0*%BH5@#J+UGJ.H*.$2N7 ^H=XUJ]<;&!/W#I8RSZ07
M A1,Y<G2(;LL<6A\&:4341PB\FV25WDQ.W 4#1N%5S1[]5XFSX%KY3<!8QC?
M8&\WD[RNMO@=P#U?P=H"L;!&2MFT[.U;#L/9SQDF@^EE$NQ4L!7T#"JI!T]@
MY+WI-0.91PJ +.#G."94N)\2<2YSB',XY.QDV'L1@V#[YV]QW[+A2VO4-$T/
M+:-!A9VLRX=I^T\@W-&[;>>2>V:VO;3")A$PB81,(F$3")A$PB81,(F$5-'D
MS\5L!RT:O-P:<+$U+D1&, !\@L5)A7]NLF2)4FD78G0&31B;6S;I@FQEC@8B
MB92M7?X$$7#/?.$N,I=%(R.?Q/TLFS:Z(F\M&UIVMZ6VU#M2XBX:9J@.;RE&
M9\"W8'\AW.W.Z#90CGJXM\U.4/C5V?/4"7@9@:TRG1)LO0-]!W$-AD?30(K+
M0CA5NY<U2Q.6!4S(R+5-9H^0]$ZR3M(J EZ=K&@:/Q9DVYECF]Z6_)S,H;-Q
M]\VM[30@UH6FJT73=7U+A[,N@>T]V'=N)UEN\>]--HL(I4$477%Q,YX<=N9$
M F\U;;4F=R;,RN;%JZSG;Q5^KXE^"Z@Q0KJ)3L2D;I_1\<HZ: !R%4.DJ(I%
MXGK7#FJ:%+ASC*P$]F1MK'=.P\CJ'=46KJ.EZUD-697+.I+2UAL<.C:.45'3
M8IE9X*]9,(F$3")A$PB81:HW)O+4G'VF/+_N6^0%!JK/N(#^:="#F1= 03A'
M0<2U(XF+!+*$ 3$:,4'#@Q0$0)T 1#-R&G9W4YQELA&Z68[!LY2;FCE) 6+F
M\[E<C"9\V]K(AM.WD O)Y "5RA\__,=?^1[6<U%Q^:S.K]+R2:L5-3;A0K;9
M&QV"Y!2=LGYX]PNA5*O(%.*1X]LJLY>(]0<K@DLHS+V?AG@3+:46Y[4RV;/B
MT#^38=A%?2</?$  W"H#ES/7.+)]0#LKD08\H;"?=O'+3T0=PM.TT-%O#QJ>
M'*5MSJ"WOR\K:\33"%3DZ9I&907:35J4, '936Q&@F1=0M=2Z]Z40H!';\_0
M70)-@%%WYW%G'3( [3M#>'3W.E%H;O##M=]]<-E3:W,X>X3=*6YW56TBO;&;
MW<KMP^]O.V@L/4XU:MF+9NR9-T&;-F@BU:-&J*;=LU;-TRI(-VZ"12)((()$
M I"% "E*     9QTDN)<XDN)M*Z2 &B@L 7[Y153")A$PB81,(F$3")A$PBK
M6Y)-%#7]Q+&0! 7Q3M#EZB/>>*]-LDL(F^P5V9T3=/L_1#.Y<#2-^AQEVFN$
MU^-:1T%?.OB-&[Z=.9(IC&'XE@/2%$YY<8QE:HVHJ$5,^D6QG ."F2]NW.)7
M!T6ZW4X* JL1L(@'3_MB?]U\.B1Z;/)D79]OZ-II2VNRT"[:N7R:IEHM19IK
MJ]\]M:V816X7UJI!:89*N-@0CPB(+_)URR?I"(@"JQ%"(-4_NCU$PN%BB ?[
MT<TWBB5K=&EC+J=ZW#7DVE;WP;$]VO0RM&+NG8J<MH"M8SY[7T^F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PBPZ_Z]H^U*C-4+8]5@[I3K"T.RF*]86"$C&O$3!]PXI+%$4';93HH@ND
M)%VZQ2J)'(H4I@GRV:S&3G;F<J]T<[34.::$?P;Q<18;%%/!#F8C!F&M?$X6
M@BH^[EO&Q<SG,OP16.%5F+YPYF/J6%$RSU72MODTV]EC4A[#&:TJXR*Q&%A0
M3,<WIM991HZ313 /=O%C  ]:T'Q&BD#<MKK<$EW>M'9/PVBUO.VHK[EH7/-6
MX+D83/I)Q,^;<;1\%QL/,ZAY257'IKG)SN\?]A_%HYD+5#1< H@9YH_>->EW
M<(S:=3>BG%1LT,;9:M&N@ QTS0[QDV<"/J""OP'-JS_#O#G$T7K8#'/==-"X
M D\I%6N/P@2+K%X&4UG6M#D]7)<&M_DY := -"!\$@%76:1_C &C;*BTC]\:
MLNNL)@W8DO.TY9KL"H&,4@>J]<(*# VF*24/U[4$6DH8@? 53?;F@:AX::C$
M2[39HYF;G=AW-M:><EO,MNR?'&2D ;G8GQOWM[3>?8X<U#SJS+7WD5X.[.31
M/5^3FJ&ZJY4Q197&PDUS)*G5,0A$$HS8257?K.A.< ](B9C_ &_#H CFI9KA
M;B'*'Y;)S$#:UN,=;,06Q0:]HV9'R>9BK]\<!ZG4*DO$[2UE/M_=P6Q:)-->
MB9O<Q-NK\BW[5B JD/K,Y!9/HJF(&+\?O%^(?#/)?D\W&<,D4C7<K7#SA>BW
M,Y=XJR1A'(X'V5^4UMC5E;0!U8MEZ_@6PIK*@XFKE78M 4FP$%PH"KZ203%-
M %"B<>O0H&#KTZAB/)9R4TBAE<>1KCY@J/S66C%9)(VCE<!YRHP[$\D?!C6#
M==:Q\FM7R*C?U"G8T6:-LN1%=(0*+866O4+,LBOZ@]H@J"8%-U[A*!3"'L97
MA3B+.$"+*3 ':\=V.M^%>=/Q!HV6%9,Q&>1IQG\6JK"WE_&!M3P2+N-X^:AM
M5_E?3.DA9MB.FU*K#=?J;L=MX6,4G+%.- * =4ECPZ@B(_> "AW;=IWAGG9"
M'ZG.R)GO6#&[FJ:-!YL2US.\<Y5@+<C$Y[M[NR.H5)_%5+>UN6G/#R+6M+7P
MO+A=6LBN"S'3&GX&2CJ6V3]P4Z;F4A(I1VXDV<<J<!!_/.WHLR]1%<A>HYOV
M2T3ASA:'UJD<;@+992"_H)I0G<P"NY:CF=4UK7Y>XJ]X-T; 0WI OIO<33>K
M3N&7@A=BXBK[S+F$46Z2B3QOI"FRH.%7( 4I@0O=XC%P1;D*IU!1E"J*BH7M
M,$@3[R0Z=KWB,VCLMH+;;N]</R&'SO\ B[5LFD\%FHGU8V?-M/Y3AYF_&72;
M4*=5-?UJ'IM'KD+4:I7V:<?"5VNQK2)AXMFE^H09L&22+=$O41,80+U,81,8
M1,(B/*)YYLS*Z?,/<^9QJ7.)))Y25T&***",10M#(FB@ % .A9)D2D3")A$P
MB81,(F$3")A$PB81,(F$3")A%K';^F=8;[HLMK?;M,AKQ3IE,0<Q4PW[SM7(
M)J)H2<0_1,E(0DRS!4PH/&BJ+E$1$2'#J.9F1S^<TW,MS>1D='.W:/,1<0=H
M-05C9K*9;.PG+YI@?$=A\X-X.XBU<L7,SP>[=U2XEKUQ;=2.Y=?H^O(&HS@4
M$]M5I!/O5%"/;MTVS'8""!"?@Q9%;RAS&*F1DL("J;L6@^(61SH;EM8 @S5V
M/^3=S[6=-6[<0N7-M6X.S65)FTTF:"_#[L<WONBAY#>H_<:O+5S$XGO24.\.
M'>VZ= ."QK[7VWS2R%NKA&BA2.(V&N#A,UI@G"*28(IMY%.29M"AT3:EST]6
MX*T+6F^LY<""=PJ'Q4PNKM+?1.^K<).URP=/XHU73#W$U98FV%KZXAR!UXYC
M4#<KX-&^;_AGM))HQO[^U:(LBP$35:W>'<3584=&*4QB1]OJ:,JD5H7J(>O)
M-(L.I1^Z'4O=SC4?#W7LF2[+!F9BWL-'4Y6NI;R-+ENF2XQTG,@-G+H)/OA4
M=#FU\H"L[U]N_3.V&Z#K6&V-<;"1<)BHE]&76N617H4AE%"*(1$B[7060*0W
MJ)G*4Z8E,!@ 2B :CFM/S^2-,Y#+$1[]CF^<!;'!G,IFA7+2QR#[UP/F*VCF
M&LE,(L O&U]7:Q:&?[(V10]?LBI&6%U=;?7ZLW](H"(J K.2#$ABAT^T!S)R
M^2SF;=ARD4DKMS&N=Y@5!-FLMEABS$C&#[YP'G*K4W=YIN$6I47;6L6Z=W;9
M$.]).(UE".%8DKCL$43.KA8_D=;48G-T ZK!:14('V)&'X9MFG\ \0YTATS&
MY>([9#;\5M75Y"&\ZU[.<7:/E01&]TTFY@L^,:"G-7F5$W)SS2<KN0(.ZAJT
MJ.@*7*+&9HL-?O'LCLF60=&!)%D]V =%H_;+'.)>SY*TB5A$PD,=0H],Z-I'
M .BZ92?.?UG,"VKP!&.4,M'QRX<RTO4>+M3SU8LM\A"=C;7G\*_XH:O4X?>&
M?D/R+?,KUO4\QHO6C]R$B[7LC)17:]N1<&!TL>(K$GVK0GS 3B R$QZ9R&."
MQ&KLO4!LUWCS2]+:<OIV',YL"@PGY-O.X7T]ZWF+FJ_2N$L_GR)L[6'+DUM]
M-W,#=7>[GH5U<<>N-.F.+=#;Z\TK2X^J0H"DO+/P#W=CM,DF0Q!F+5/K@,A.
M21@.8"&5-Z;=,?20(DB4J9>,ZIJV?UC,G-:A(7R;!<UHW-;<!Y[S4VKIF0T[
M*:;!W&38&LVG:3O<;R?-<*!;WSS5FIA$PB81,(F$3")A$PB81,(F$3")A$PB
MAORYX*<?N9U<3CMJULS.VQC,[2K;-K/MHV]5H@J'7(U2DE&[A"7A?74.8T>^
M2<->JASIE26,"I?=T3B/4]!EQY)]8":NC=:QW+38?OA0[ZBQ>3JFBY'5X\.9
M;24"QXL<.G:.0U',;5RM<F_%+R_XA3QKWKIM.[3I,"\"2A-G:B2E&]PK0H'$
M[=[.56*<K6NMO&I2B<[QB9ZP0*'<9T01[0[)I'&>AZY%ZMFBV',.%#'+3"[D
M#CV7 [C0G<N:ZCPSJNE/[_+XI86FH>RN(<[1VASBH&];&XX><;E/I]-C7MO,
M(?D)5678W%:RK#5]C-FZ*942()W:+8.FTD9,2B=164C7[Q8PB!G ?H8NJ^'F
MC9XF7(EV5F/O>TSXA-GX+F@;E/I_&6I92D>: GB&^Q_Q@+?P@3RJZ'4/G!X2
M;%29-[I+W72TVN5--PUO%6>2T(5X;H!DVMBI/U(D+,##]UP]08!T^)BDS0L]
MX>\094DY=L>8C'O' &G*U^&WD!*V[*\8Z/F !,7PO^^;4=;:]9 4^:;S XI[
M!115IO(_2,\HNF10K%KLVH)RZ13IK+%!U".I9"89*"DW4-V+()F[4S#T^Z/3
M6I]#UG*FD^4S#0-O=NIT&E#T%>Y%JNF3BL68A=R8VUZJU\BW&E>J0NDFNA<:
MJLBLF15%9*PQ"B2J2A0.FHFH1X)#IG((" @(@(#U#, Y;, T,;Z_!/M+*$T)
M%0]M.<+!+1R,X^4E-56Y;UTY4R('436-9-FTJ#]-1%1)%5(P24VV$%4UETR"
M7]4!SE+TZF !R8=*U/,&D&6G>?O8WGS!0R9_(PVS31-YWM'G*A5M'S!\"=8I
MN4T]O+;'E6XJ!\FU=6IFSJ.!3Z@/MI]RWB*8H!S? H_-  WVA\/CGOY/@;B3
M-D$P=TP[9'!ODM=^*O'S/%>B9;^5[QVY@)\MC?*JB>0G\8 V38T'\'QKU7%Z
MX:J@X00O6PW#>WVP$C@(-WT;5FB:-4A)!#[1([5G&YA^ EZ?;N^F>&F4B(DU
M:9TKO>,[+>8N/:(Y@PK5L_QQF) 6:?$(Q[YW:=T-]$'GQ!5UZ]X\<\_)1?0N
M:S:];%*]7,@_VYLM^\B==U]H+DQ'#:+EGJ)(LK-BN ]8FOMEU4?M*U O40VG
M-:IPWPGENX!CBH+(HP"]QY0+:GWSR*[UX,&0UOB&?OCCDK>]YHT<QNL]ZT'F
M72SP@\1FB>*"\1?KF9'<^[6(H/&MJG8Y-*J4V12'U"JT6KK"X(A(-51+V2;T
M[AZ4Z95&X-!,8@\FXAXWU'6@[+0?U?3S9A![3A]^[=]Z*#8<2Z%HW"V2TPB>
M;Y;.#W1'9:?O1OY34[J*VO-*6T)A$PB81,(F$3")A$PB81,(F$4-N7]5=+4Y
M&S0I#$E$7*K(ZW:!D4574<Z(P=K )1*4"NT4B")ONB(E#.F>&VHLCU,Y#,$=
MR\5'014=5:+DGBOI;Y-(&HY4.]8:<)H*TJTAIY.U2JH@<FF0EC^[-)_.RN"%
M.*XNOF8.@[03 1.(N?6  #M_1Z=.GZ&?6#'Y49?Y(L&5(.[#;O\ 97Q6\9SU
ML][WASM16M<5FX>97(\&JK,O(AQ8[6F[.]C6S5HD=X BJH\4</5R$="H43G<
MLX\S<3]P]X', F^/7/FSQ7U'+1YEN0T\@0O)) W67;@7 \X7UEX+Z7F9<J_4
MM1#N^91H)]\:DULM(!',58OG%EWU,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81:LVOH_3^]8#Z8W
M#K:G;&A2 M[5M:X)C*+1JBY2E5<PL@LE\Q@WIRD /79K(+  ? V9F2U#/:=+
MWV1EDBD^])%><7$<A!"QLUD\IG6=WFXV2,^^ -.8WCG"J"W%X$.+-U7>R.I[
MIL72SYR*@MXHKEOL2FL1,)C$]&+L:K.VJ 43=!!2>, E  #H/41WC(>).L9<
M!F=CBS#1M]!QZ6U;^(M5S?!.FS$NRKY(7;O2;U'M?C*NR\?Q?;DQ$JJGU_M_
M3-T8IB'8$^>X4B86*90A %-@A7K=%E$I#"<X'?EZ%*(%$QN@#M.7\3=)>/ZS
M!F(W?>X7CKQ-/D7@S<#:BT_(2PO'+B:>JCAY5'J0\)7D 9+%2;:^I4L0R15!
M<Q^SJ>FB0XG.44#%E9",<"J4"@81*F).A@Z&$>H!ZC?$#AEPJ99&GEC=[ *P
M'<'ZX#01L/,]OLD+]8OPC<_I!84G=%HL&0.SHYE-FU55$W<<"FZ%A74NX_!A
M]XW5,/A]G4?AE'^(/#315LDCCR1N]D!5;P?KCC:QC>=[?8JMM:H\&NT;S<;;
M1[5R4T+7;+K]W#M;[5Z:K:=@7*H&L$%&V2#-+U^0BJ&W(25AI5%=!4CP[94I
MA*545"*$)@YWQ#R>7@9F(<IF712@ECG86-=A)::.!?<00;*\E*5RLMP;F9I7
M0RYB!LC",0;B<YM0"*@AMX.^G*K2]+>!SB;056LEM6PW_>,HAVBK'R3\M#I:
MQR=ABJA"518ME P*%'J52<51,4>TQ!^(CI^?\1]:S(+,FV++L.T#&_K=V?Q
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M0FEY%EVSGJMH&\*GD' P@&K*N8 $0 Q=I:^[3  _J@[I\IN@_P D ',3Z_\
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M+=M2?96\:MPQT;4>4&Z.7D9$S3C;V_:5!Z_V0:5F3R53DJS7X6GP#%DUK#A
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MXM4 %GM$36ZJV=M3M:ZXG9F96;)#T5(0RQ.H"!>@U=,^9K(7D!C;!R*C<O'
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MY1<J!Y#[DGYR4K*-.J];+JR#,YA&\Y)5]63]24L=K0?FE0C7+-XB@#*.(P5
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M%@"]_(E>F$3")A$PB81,(F$3")A$PB81,(F$3")A%C5Q!4:Q,^B'4_LS=?\
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M$=IK0T=-I7(_%3.%N7RV1KV7.+CT6#J4?M#I>OM&L$ .H X.H;[/U*9!./\
MN? ,W'B]Q9H,YY!Y5H7 [,?$V6VMJ[R >RO/\F4R4B6K(),0%14UDDG'0P@8
MB:'RE!N42_J1*J=8P_']$@9=X&Y?MY_-N'8 8T<]I\P5OVB<T W3<FT]LF5Q
M'( T"O(2JG?L^SX?;_\ +\!_FAGT)?>OF,66B],77)>F$5IOCC<)_,)],3%
MX%D6P%^'<)E4XMV ].HCT]- WQ^'V=/T,X+XUQN]7B=2S$T] J/.5](> #VC
M,S-KVJ2>7 1Y&E;/Y1HBELXZ@%$"KP$4H4?T!$#NTS]/Y/<3J/\ +SQ. '!V
M@T-XE<%L/B9'AXCQ;'0-/L++N)<R9"=L,*93HF^9H.DTNOP%5 5>]3I^F4@
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MVW@7_JK*_P#N_P!#(M=XK_P#,?@?TC%A'"?^"+QP_P 3U&_L&US==4_Q*?\
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M([B+L*S6[33"29N-K:EMK@KUJ:(570:BXGV4<FRC[!#&!7VX23=JUEH8#$4
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M=U*OQ\"YO]O>WZY+,2'(>PW&1BH:$?6"0$ZAP/(.8FOLD#"7M+V-B?#X"(U
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MVC8N,CVB1EG3Z0D'BJ+1DS;(D$ZBJARD(4!$1  R]C'RO$<8+I'&@ %22;@
M+25:Y[6-+WD!@%238 -Y*YE?(3YL'+XT[ISAE)K,691<Q-FWX"7IO'@=3(.V
MFJ6RY>]DV$O4GSY<@+F$3&8II=J#X_6^&/#\-PY_7A5U[8=@W&3?\ 6>^)M:
MN=Z[Q>3BRFDF@N,OYGYU_O=A5%L%QQW??=,;6Y0#7I$=4:Y7AU;3L&QKN4$;
M)8K9=8&HIQ-;<NB*N+7/DE[*1S('((HM$"',X6(LHW27Z))JNGY;/PZ/B'KL
MH.%C?<M:PNJZGHMHVC=I-PH"1IC-/SD^4EU+"?58Z8G':7.#:#WQJ:G=M-:
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M$<!;9OPTKUE56W5X+^U3CD?B 2"[8@_H"FQ$&28A_($C<!SZ$TN/N=/A8/>
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M9"Q[&V#.-6*\M)-*W#.I"(CDV<'#-57DC(2#QC&1[4G>X<I=Q -8]X9?4DW
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MWTM:KMRWHT'$[ >/^&=>>V'9\L$/ $@[ G%L+(ZF8W7SD]I!Y,2D,_J3^.<
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M[GM>V;%U2K;=9:7V_&RM7CHVT:%M*TS'0DO);:B'E@23CZO5EIN/<2+V)6F
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M\SWS.';_ ".3V,QTTC3&WRMW((3,G\Y4JC\.]FW<)M_;_AS) =/O.:3*UPN
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MDU%>:]:2M/$#=U3T9RPXSZYJ,_;]>S'(OCINW0EAM&QX.:L,[%RVX-1;&WW
MS4S<+8%@&0I=BI,U-"[ES$7EPENB"KMSW)A88WACHVBHJ"+>4$J\2L+VR.-'
M82#9R$!93Y)N'VXMJ,7FQ.+L6RE;YL"*IVJ=[T)U,Q%?9;'UE7KS#W>IVM![
M8)2(@4KSJJ>BU :JK*IK.863>MBG,8B")[IHW.[4=YL/*/X%3+RL;V9/1%HY
M#_"K$^0=7G;QH3=]*J['YI9K?J'957KL;[EFR^8SM@IDU$Q#'WDBX:1[3W<@
M[33]5=5)%/N[CG*4!$)G@EI OHH&$!X)N!"@;7+!S5/QGIO'6J<0K3K6]H:=
MJ>GEMN[(V[H-SKREN6M.CZ;,WPL5K?9E\O=@&$!-1\Q8)1B1G9TR$550 1'(
M@9< 8&D&E*DBGD*F(A[PR%P+:UH :\UH 7V3'".2L^Q^+NI7JE_K7&?B%QW.
MPI5^H6SW^M;O;-WRB$-KIJH5]0;)&7V$^F=:0,BN[<E,V;/5;,HB4ZQ2K%*,
M57-;;@:W?2V[S>=!-1KG6=XYUQ%;+]ME_F6TN-?'NV\:N0&^("N-[G9./NW(
M&C[8C;O>=D.[[98O>3('U(V)7YM_<;)+[$G5K34XF D4)!<BK5(&:K<5P,"*
M07,86/(%<!MOV[>56R2"1C2:8Q9=2S9R+-M-ZOO54Y7<S=E3\'["D[7_ 'NW
MT!-?,X=U\_\ H76\I 6K_BYE(.9:*^52SDB7]&H-O7Z]R/J$ 3!5K2'N)N-%
M:]P,;&B\5KTE1WI?!Q;<-MY*;=Y).]RT:U;QV?8(1O2-<\A;S1H-QQ_I$4AK
MO54+<HK45V952PN)RN,WLNX1=&=G0^?+(*]J@KE&P18BYSZ@D[]EPN4AFP!K
M8Z$ ;16V\WJ3?"ZG[3UKQVI&J-OQ:[.S:B4G=60TPM+0<N6ZZ[HDV^@-7WA)
M6$D9#V@V/7S..46;O ;OT7150602'H&7Q!S6!KKQ9T;%'*6ND+F7&WIV^50%
M\W']X#4_^.%/^XNTYMG"O]LD_FOXP7F9_P#1MY_873=G!%W-,(F$3")A%&K?
M>Y7-#21KE=]/ZBD6H.57A^PY8IF=0R9%"I& Q3NG IF G=\"@'7X_#-XX0X9
MCU=YSF=-,FPD!NU[A0D;Z"MM%SOCGBZ31(QD,@*YZ0 EWS;34 TMJ32P%0?H
MKAV_V)4W"ISN'CNWPBRJAOB=15:6;&6.;M#XB;J(].G3.KZPR.+1,PQM&QMR
M[P.8--%Q?0I99^(<K(_M2OS+*F\DEP5HM^.*=2ES]>@ 1H!A_2(+YJ!^O\@2
MCTS@.D#%J,0^^]@KZ8UHENF2G905YJBOD51L@KZ[UVN(]17=.%A']/U%CGZC
M_)$39](0C#$QNP,;Y@OE#,/[R=[][B>FI7QY*H5]RE70<1:-O5;-E5V,D:&:
MN#MR&=-O<,U%UC(N#??33.0.TP!]O=TR$:@69CZ-!(#F8S;8:&RQ9!TYDF5^
MDRUI?&_ #2T8A6_9NZ5\.3+'7]$^W_L_3_\ HQM5S:7F\>T3YZ*US3K@7>O8
M%4P]>YJF(?'[ 4127'X_]\J.?._$S!'K,HY5]1<(R&70('G:U0,W^=9#;]I.
M7JB<B\6JDHG]P_\ Z)8'36 P=![P^'0WV_ ,Z_P<&NX;@:;06O'XQJ%PWCLO
M9Q7FB*AV)AW>X;0J0O'_ ':_L#Q"CVE0%WP-S_)I40(FHY! .\6+HH 4IUB(
M@(D,'Q,4O00^'7-+XRX5AR3':KD+(L0QL][7:.2JZ!P)QEF-0D;H^ID&?"<#
M_?4]R>6EVU2^SFRZNF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PBI7\\W\""*_QYT+^Y^\YOWAO_U"[^[/_*8M0XU_P<?S
MS?,Y2=U-_>KUG_B_IO\ <Y&Y[>9_M$GPW><K2&>@.8+8&0JY,(J]MMO8^F^1
M/BW<;VY094VWZ#WUJ#7DM)* A$1N[):W:HMZ,0+U<4V3">N= K4BA'IF."L@
M+)5)(ICDZ9"ZR9I-U"!SV*=EL#@V\.!/-;[*W]L3;&M8O>VB=+R=32O.T+D>
M[W*MF:1L%+.M3URGUQ=*9V5..'ZOS&J14HYED8%HZ;E!9\\D/;D[B OV7N<W
M&&WN/DY5&UKL#GUHT>7D5?7"C3&Z+CK'8L_3>7VVM20#KE#RN3:T:J:[XY6&
M$C5&O(+8+=TX;2FQ--W"U+J23A,RZ@+OU2$.H)4P(F!2!#$UQ:2'$#$=@WG>
M%/,]@< 6 G"VVIW#<5%]O6K<.BJ=4F>QI9.[I^<B^01-K/:]5'<XM8T-M;-9
M*7A[6&T3'4I24>OTS/%6:+%O&@J<2)H)H@4@6 '!2MO>FWI4E1C)I9W(LZ K
MFM;ZHW_5;:QFK[RLGMIUEN@^3>4Q_J#5-1;2*SAHL@S7/.5:(:3+88]T<JX%
M3.!5!)VGZE$0S):UX-2ZHY@L1SF$4:VAYRJ2M!;5C.$VN:'RF?)$^D-RU/G-
MJ6TL1*X3;36Z=,<E^1FV^/; XMP[5Y>Z1#BV0" &$BBBQVB1#?H9B,=W31)L
M(<.D$D>R%F/;WSC'M!:>@@ ^P5L+5VH)'1C7F[KRPN5']U:^+RCV79,JL<BJ
M\QM*^..5MXV9**KE(05P>7BPOS)&-U,"/841'MR]K<&(&_NQ7GMJK7.QX'"[
MO#3F&&BVKI"EZZV55^ ]5J^V]O<=^6$3XX-)62D[*HJ55<5F\:N/7*BTG*#-
MUZ^15GJFP3U:QM495Q&'8(N&B3Q%R5P)!.4E6@.# "6R8!U>RK7ES2\D!T7>
M&SEZ+E*/C[<MM0'+39/'[=<[JK<]MKVB*;L")W[2==--=WU"K2EYL42SUAM>
M(9S5B8-WGO?6EHDK)9HT61.X7]J4RGW9&%PD+'4)I6OL%1O#3$'LJ!6E*U'.
M%Z_&7^&/Y*?\:G&__P!U+5V(_P!+)SCS!4D_11\Q_**CYQQH/(.U;0YY2&J.
M0T)J6NH\X+ZS>UR2TI#;'7>S2>G]&KN9LDY(W"OKM4G+%PV0!H")B$%L*@'$
M51*6R,/+GX74&,[.0*21S UF)M3@&VFTK8WC_IQ;-I7E3K;<B,5L6TR/*KD;
M0=]6I5L+.)W5,KIPD#)V=:KI$195&/E:,I'Q01#0QV[-!B $5.(BH-T(JUS7
M6G$:\JMG-'M<RP801R+&?'!JEU'6;?MRN]TF=EVG1^P[/PDU1.6)NBD^JFAM
M*OH^2A8GU$5E D+#9GTV@K-2*@ L_-&,^X !+XH6T))-2#A',%6=UC0!0$8C
MSE6NY.L9,(F$5"%]Y-T+B5YA+#MO9C*?=TXFO8&K2BM:9MI&3C/J/7=?;-Y7
MY>Y=LO>,V2Z117(FIZ_I"8R9%#E!,^QYG2,SK?"(R64+1/WF(8C0'"XV5H:$
M[-E;Z7JNEZC!I>M#-9@.,6$@TM(J!;3SKIFT]N_4N_J>TONG+[7;_5W?80S^
M!>E67CW)B H,=-QBH(RL!+)D, G:/44'! $!$@ ("/%<]I^=TV<Y;/1NBF&P
MB_E!N(Y02%UK*9S*YZ(3Y1[7QG:-G(1>#R&A6U,PUDIA$PB81,(HR\UOX&O+
M7_HR[Y_R5VO/7X?_ ,>R7][A_I&KSM7_ ,)S7]WD_(<JK/$Y_ BUO_;!L7^[
MF<SK'$7^*R<S?R0N0Y/] .<^=619X:RTPB814^43CA/;DUAS#CXE5WK_ &_4
M?(1O'<7'G8$C&*H*5G8, -5=5.?2!XU,$C3;.0%XJ5*0BJ+V)>.2 !C=HEQP
MPN:ZEC@\D<ZRG2!CF5M:6 $<BC?IZ*WEM'3NU.0B^D+G";0T[Y4F_)>RZ'6C
ME4[78H^JZ(UKK#:U<H97AVY+(\8L;)-NH$Z:G_&RT:DB0#*J^B,;0YS2^AQ"
M2M.@54CRQKPRHPF.E>DD?PJ=.X.;FL=K:>O.N^.*=OVUO/9--FZ/3-;,==7^
M&E*]8;A$NH)O,;04LE8B6&N*Q4E'PO)5Q,*LP*@V.FEZBQTR&E=*US2UE2XB
MZA\NY0,A<UX=)0,!OJ/)O6(<BM93'%70_##;U-C9V_3O HNMZ+9V-6B5).R7
MK1\_2X72.U6$-"I)J+O) Q BYY%,1[4S1/</:( H2CVF-C7"TLIU7'VU=&X2
MO>TV!]3S&\+5^R]07JK>';>#*S0\K*;MW-KVW[PVE&M(UTXG76TMSVEM?;!"
MC%-6P.1=U=*51AR(II?@T8TA0Z@7N&US2,L:^D14\Y5S7-.:;3T :#F%BR^D
MR'B_B+G496HJ;-2M<99X"0K"KM#FPY:I6%E*M',*HY;3Z2\$X;DDDDA.1Z0[
M0Y0$%BBF)@RX>K@BE_2J'U@@@TI3[U>GJ7D-JOC]R,YXQ.VY.TU9Y;N1-;L]
M9%'66S[*RFH$NA=20II)C)U.G3L8H@25BW" AZP' Z1@$,->UCWAUG:]@*CH
MW/C86VT;O&\JT"F7&O;!JT)=*F\<2%<L3(LC$/'47+0CAPT.<Z95%HJ=8QDN
MQ.)DQ^XX024#_N>@ADX((J+ECD%IH;UD^55$PBQ^V?\ )6S?VOS/]CG.7Q_I
M&\X\ZM=Z)YE!O^+]?P-=E_\ 2:N7^2O3&>;XF?X]#_=&_P!)*MSX&_PF3^\.
M_(C5Y^<[6YIA$PBQ"][ H^KZO*7;8MMKU(J,*CZ\I8K/*LX:):%'KZ9#NWJJ
M*9W#@X=B2)1,JLH($(4QA !GRV6S&<F&7RK'23NN:T$D] \IV**:>'+1F;,.
M:R(7DF@7.MS'\\3%J26HO#B ]^Z,5PR7W7>(TZ3)L8061%U1:.\(5=ZJ7N(H
M@]F023(<IBGCE2B53.HZ%X<..',ZZZ@O[IAM_#>+N4-^.+EH6K<:M ,.DMJ?
MG'#\EOLN^*52SICCKRU\B&UIB4KZ%DV+8)&114OFV[[*OOIBN^L*8$/8K4](
MZ[/:M3E%M&,4W#SVQ.ULU%-/H7?\_JFB<+Y)K)<$40'8C8!B=\%H\KC05O=5
M:CE,AJFO9DNCQ2/)[3W$T'.[S 5-+@NK#@WXI-$\0 C+M-D1VWO-!-)?Z_L$
M>D2*J+PR/8X1UW75#.$882B82_,5S+R9R]W8HW34,AG&>(N,]1URN7C^0T[W
MC3:X??NV_!%&\A(JNEZ-PSDM*I,_Y7.>^(L;\$;.<V\URM.S3ELJCYRNT@CR
M0XY;ATD=PBS=7^ER,9"O7/46C"T,C(S-2?O *0YS,F-GC6BJP%#O,D0P%$#"
M AZ>BZ@=*U6#4*5$4@)&TM-C@.4M) Y5@ZGDQJ&0ER=Q>P@'<;VGH("HG\:W
M*&/JD"MPOWPJ77.Z-/STU5*_%VHZ,2-BCB2KE;Z=0<N#I-U+- /W*J";8! S
MQAZ"K<5NU82]DUK)>L$:OD?E,G,T.JVVEE_,1U&H-+%QZ%SX'G)Y@%L["10\
MFS[MBN0S6UEIA$PB81,(F$3")A$PB81,(F$3")A%\<A(Q\0Q=RDJ^9QD9'MU
M7;^1D'*#)BR:($%1=R[=N3IMVS=%,HF.<YBE* =1'IE6M+B&M!+CL"H2!:;E
M1KLZPI>3WFUIKC]J,#V'0>DYPURVK>4&QEJ]+LVL@P-9739SVBFM&.6+ D+#
MK#T*[>R"RI2J-0(J.PS2CAC0IM0S1PYZ9N&-NVI!P]5<3MP%+[%73LH[6-3C
MRT8KEV'$\[,(-O7Z(Y3N75#G"EV1,(F$3")A%$GD-#-XRLJMFQ@<S=QFU)*4
MDG)2 L6*K48N_,@D(=?1:- 33 J9.@"<XC]IASHG!>:?-J ?)V<IEH@UK1=C
MD=05WEW:-3NHN5\?Y2/+::8XZ.S>;F+Y'D6B.)A<0W<&]D64OJM):&H<@OLZ
M#<OTDRH0@.Y5REW=RB*S=@@9H54G:42'(^D4@Z#_ /:)'#X]N;3Q?K, T*6*
M$GO)2&#<17M4Y* ]!!VK3N!M#G?Q'#+,!W4(,AW@@=FNXXBWI#MUL];XEZM-
ML)1^/9&JK?[K<2+]?YJ><CT@TU.#^< Z[%W#6P3I&8W]T[R"JJ!./4?Y/Z/\
MO[?_ ,.?2C;&CF7R<^A>2+B3YU_.55BVZV9_^Q^2<F3$Q?GJ*I5.S[I%!79M
M@ 3?9WB0#]/TPS6Y)/\ ]RL945[F[DH2MLBAIPE)-0T=-?RU#:=3:]*U%FR+
M4U_1/M_^3^;E1[(2^SD5J6CR"7658$?AWQ[4WZ?V-6Y/_P!#/GKBLUUV<;G4
M7U!P8*<.Y<[VU48N2](>KW^*E6)2"6Q1K9$PG,)"@Z8.VD683& #? $W[?K^
MCV@(_H9OG >JQ,TB3*S$UAD<?P7 O_BNIRT7-?$C19Y-<CSD-,,\0%OOFN:S
M^.WF 7J\=(!O),9F!ETA:/D7<7<ZX_3 I7C19JY?PCU1(W4J@ DZ9BBJF;[I
M@,/4/B YC<;9M\$T6=RYQ1EKH96FYP+6O%EUK2*&^Q9G &1CGAFR&;!$X<R>
M)P])I:7,-MGN@:BZU3A* @4H&'N,   FZ '<(!\1Z!\ ZCG*N:Y=G%UMZ_W"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB814
MK^>;^!!%?X\Z%_<_><W[PW_ZA=_=G_E,6H<:_P"#C^>;YG*3NIO[U>L_\7]-
M_N<C<]O,_P!HD^&[SE:0ST!S!; R%7)A%A&Q-:Z]VY4Y&B;0I58V!39?T1D:
MS;H5A/0SI1LH"S5P=C(H+H%=-%B@HBL4 514 #$,4P .4<T.%'"H56N<TXFF
MA6&ZDXZ:,T1\W/J#5E-H3RP>@$]+PD0B6?FTFO7V;:8L3GW,[)LF/</MT%G!
MT6XF-Z92]QNM&L8ST0 JND>_TB2MA5*E5*AQCF%I=<B*O$O)J=L;J.A&*$>T
M<3UGEG<]8I=5!N4A#R$U,OUG3E40[E5U3',(B(Y4 "P*A)<:FTK6]IXU<?[Q
M4I6AW#3NO++2YV]RVSYFKS-8C'\))[$GG;]_-71['KH';N+'*/91RJNZ, JJ
M*+G$1ZF'*%C"*$"E:]*N$CP<0)K2G0L+HG"3B'J^VPU\UWQNT[2KI75UW,%:
M*W18.*FXEPY:.&#A9A(-6J;ALHLR=JI&$H@(D4,'V#EHBC::M: 55TTKAA<X
MD+8SK06DWU-A->/=5T1W1:W;CWV J3FMQB\!#W52PR=L4M,?&*MS-6LXI99I
MX^,X*4%!<N53B/4YNMV!E,-!0%6XWUQ5.*BR*1UAKN6E+A.2=+KC^8V!46U"
MN\DZBFJSRU4ID69*TJTXN=,5)&$;EL+X"-U!%,ONU>@??'K7"+32TA4Q.  !
ML!JL'NW&7C[L>D4[7%XT]0++2==,HV.U] 2-=8F;41E$1S6(C6]-7232>U<C
M.*8HMB>Q50'T$BD$1* !EIC8X!I H+E<)'M)<":F_E7OZIT?J#1D0^@M0:WJ
M&NXV5=E?S"=7A6D<YG9 A3D)(3\BFF,E.R!"*&*5=XJLJ!1$ -T^&5:QK+&@
M!4<]SS5Q)66P]*J5?G[=:H.N1$59+\]B9*[3C%B@VD[2_@81E6X5Y..TRE5D
M'$7 1R#- R@B*;=$A ^Z4 RH !)%Y5"20 ;@E;I52IZ]H=5:N1%?<76SN[K;
MEHEB@R4L=M?QT7$/+','1*47TNZBX-FW.N?J<R39,HCT*&  +MJ$DTKL"_"K
MT*ETAS:GE0K$-6W-XLSRYV]2&9(L/J.VR+=JTD+++$0*1-W-OVS% B[DP"JL
M5$@',/:7H  NVH7$TKL7[UBE5*E_4/TG7(>N_5EGEKK9OE#%!E\]ML[[?YS8
MY3T"E]W,2?M4_77/U.IV%ZC\,  7(23?L"R?*JB81,(N;#EOQ?NG+OR7[,U!
MKZ8@(>VJZPK]HB3V91XVB)!6N:_KKDT2N]8M7JS!5^142IK"BHF4_0#@!1$Q
M=QRVL9?0^'H\]FFN=!WN$X:5&)QMH:5INJL:#39M5U%V5@+1+@)%;C0"RRZJ
MK\F*_P O_'UMA(7J>QM ;&:]PLY*.>&1B;+'MU0$X-)./6?U&]UTRH@"B8'?
M,S&^ZH7N 2AZ\<NA\3Y+L]UF<J;P1:T\H-',=U'<H'LU70LU;WD&8&T7$<XJ
MUPZPKO.*?GS:F0B:ER[HZR3DHHM%=NZW9E4;K$Z"3W]IU^)B*MU"=H'<+Q"R
MH'$P^C'I@4"CS[6?#8U=/H<EE_=2'R-?Y@X<[EN.F<;B@BU5EOOV><M\Y;T-
M70)I_?FE]_UXMITQLRH;%AP31.Z/6Y=NZD(HRX&%%O/PB@HS==>G*41]N_;M
MU^GQ[.@AG,\]IN?TR7N<_"^*3[X4!YC<X<H)"WG*9[*9Z/O,I(R1G(;1SB\<
MQ 6W<P5E)A$PBC+S6_@:\M?^C+OG_)7:\]?A_P#Q[)?WN'^D:O.U?_"<U_=Y
M/R'*JSQ.?P(M;_VP;%_NYG,ZQQ%_BLG,W\D+D.3_ $ YSYU9%GAK+7^&,4A3
M&,8"E* F,8P@!2E .HF,(]    /B.$6/L[;59!RDS86:OOGBXB5!JSFHURY6
M,4ICF*D@BY.JH($*(B  /P 1RE0E#N7L'>LTW2#%1VV3>N4U56S,ZZ173A)#
MM]=5!N8X*JIH]X=YB@(%ZAU^W*HL?F;Q2JY),(>PV^KP,O*@4T7%3-@B8N2D
MBG5% AF#%\[0=/ .N'8 IE-U/\/MRA(%A-JJ&N-H!HLA<.VK3T/=.6[;W+A-
MHV]PLFC[ATMW>BV0]0Q?5<*]H]I"]3&Z#T#*JB^C"+%QO%*+8?I$UOJY;9T*
M;Z8&P1(6'M,F"I1^2B[^9=#)"!@_!?$H]?LRE16E155PFE:&BR155)NDJNNJ
MFB@BF=5994Y4TDDDRB=1550XE(FFF0HB8PB   =1RJHO!KEOJ=P;+/:C:*[:
M6;94$'#NN3<;-MFZXE[P167C'+I))42_'M,(#TR@(-QJJD$7BB]EJ]9OB'49
M.VSQ-)95LJHU72<$3<-SBFNW.9(YRD61.':<@_>*/P$,JJ(V>LWH+BS=MG8-
M7*S)R+9=)<&[QN8"N&BXI'/Z3E P]#IFZ&*/V@&$7TX18_;/^2MF_M?F?['.
M<OC_ $C><>=6N]$\R@W_ !?K^!KLO_I-7+_)7IC/-\3/\>A_NC?Z25;GP-_A
M,G]X=^1&KS\YVMS6$[!V5K[5%:>7'9MUJ]"JS !]S/6R;CX*-*H":BI6R3F0
M70(Y>KD2-Z2"7>LL8.TA3&Z!F1ELIFL[*(,I&^68[&@D^39RW!0SYB#*QF7,
M/:R(;7$ >7S*B;E1YZ=6TY%_6>*M36VI9 !9 FP;HSDZ[KR.5 3$(YCH XQ]
MPM8@8@]2*_)D@ Q3E55#J3.C:-X;YR<B;67]S%[QA#GGG=:UO1B/(%I>I<;9
M:(&/36][)[YU0P<PL<[\7G*Y_+?L7F)Y"-IMF<H[V+O2[NUE5H6H5]BY7K]7
M9JG*DHI$UJ*20K=0AFQ#E*X>'30)VAZCE<QNXX],@RNA<,9,N8(LMEQ>YQ[3
MCRN/:<=PMW +1I<QJNNYFCC)-,;F@6#F L:-YLY2KNN&_@>9LQB[US*FRR#@
M/0>(Z3I$L8K%(Y3$4%K>KS'*E5>]2]Q%6<(HD0# !BR*A1$F<]UWQ'<[%EM!
M;07=Z\6\[&&[D+_BB];CI/!0%)M6-3\VT_E.'F;\9=%M(HE+UK6(JEZ^JL!2
MZE"( VB:[68IG#1#%+[3>@R8HHH@JL?J=100%14XB8XF,(B/+<QF<QFYG9C-
M/=).XVN<22>DK?88(<O&(8&M9$+@!0>197D*E3")A%7]S$\;/&_F<<L_>8F2
MI^S6[1!DTVA1E&<?9'#1H7L:,+&U>-'D3:(]N0I2$]TC[M%$OIH.$2_#-FT+
MBO5=!^2R[A)E":F-]2VIO+:$%IYC0FT@KP]5X?T_5^W,"S,4]-MAYCL(Y[=Q
M"KU)X2=RQQ095WR1;>A81N(DC8HE)M1BL6W<)BH@9CON+:&$#&$1%-ND41']
M2&;7_J-EG6R:9$7[3W@MZX3YUK9X&=7LYQP;_-__ ,0+^_S*V_\ _:;;A_81
M=/\ K%8_U%R?^5Q?K&_L53ZC2?OI_5G]HGYE;?\ _M-MP_L(NG_6*Q_J+D_\
MKB_6-_8I]1I/WT_JS^T3\RMO_P#VFVX?V$73_K%8_P!1<G_E<7ZQO[%/J-)^
M^G]6?VB?F5M__P"TVW#^PBZ?]8K'^HN3_P KB_6-_8I]1I/WT_JS^T3\RMO_
M /VFVX?V$73_ *Q6/]1<G_E<7ZQO[%/J-)^^G]6?VB?F5M__ .TVW#^PBZ?]
M8K'^HN3_ ,KB_6-_8I]1I/WT_JS^T3\RMO\ _P!IMN']A%T_ZQ6/]1<G_E<7
MZQO[%/J-)^^G]6?VB?F5M_\ ^TVW#^PBZ?\ 6*Q_J+D_\KB_6-_8I]1I/WT_
MJS^T3\RMO_\ VFVX?V$73_K%8_U%R?\ E<7ZQO[%/J-)^^G]6?VB?F5M_P#^
MTVW#^PBZ?]8K'^HN3_RN+]8W]BGU&D_?3^K/[1/S*V__ /:;;A_81=/^L5C_
M %%R?^5Q?K&_L4^HTG[Z?U9_:)^96W__ +3;</["+I_UBL?ZBY/_ "N+]8W]
MBGU&D_?3^K/[1/S*V_\ _:;;A_81=/\ K%8_U%R?^5Q?K&_L4^HTG[Z?U9_:
M+_4O!=/6ETT:;KYW;BV?4$'":ZU>2J[V*=&Z'(90S21MFS-CQC-P<I [5!C5
M>TP (@;ITRU_B2&-)R6GPQ3;R_$.D-8PGXP5\? K,7]8S3WQ[@S">LN</(KA
MN.7%[2?%*BEH&E*:TK,6NHBZG)54YI"SVN21(=,DI:)]P O99V0%3^D01*W;
M%.8C=)),>S-#U76-0UG,^LZA(7OV"YK1N:VX#RG:25N&0TW)Z9#W&38&MVF\
MN.\G;YAL 4@<\Q9R81,(F$3"+26VJ'*6SL=1Y@<*_*35UBSZ=I6BDW+L#3$L
MY6'J4&Z4.S,GT !-U,/V]0#-FX?U:#3B63"C.\$CCM=W;78& ;\;JK4.*-%S
M.I@204=)W1B:TBP=Z]G>/)W"-I'^U970:$RIS0S@Y$E;!(MTBS;Y)14Z"RP.
MWT@*;4JH%%-NDYD5 */:4QB 7N_4@ 8&JZM-J+PST<FP]ANX86MMWFC1Y5Z6
MB:)!I,6.@=GGM^4?[XXG.LW"KCL&Q99/M@>0<RT$.ON8M^@ !]O55JJ0O3^2
M CF#DW]UFXI/>R-/40O2S\??9&:+WT3QUM*IO=IBBZ<("'045UD1#](4U#$$
M/]SMSZ:B<'1-<-K0>L57R/.PQ2NC/N7$>4KY\O4*E,RB#'XMRST"?>^ID'O4
M?M%)&509B(?I!W+#G/ILS_\ O^.+_P!##UMQ+I\&4)\,Y9O_ .8Q= <&^<J+
M.=!7,2*+_2__ (\K9MWH*VD7T5MVJV QNNJ<T-U[BP,>H;K]O5= JP?H!\ *
M< #^1GSAK\W?ZSF9-G>N'59["^K.&H/5]!RL>WN6GK%?97W72F1EUBE(]^4R
M;A-)V,:^3,8JK!XX9KM2.2=HAW@D*P'[!^Z)B%$?B 9!INIYG3,P)H#V"1B;
M[YH()'L=)4^KZ1E=8RI@S [8#L#MK7.:6U]FF\#<M::TUW,UN;*_DCI(*PY+
M'%&!$IU&LK'3\DVL#-9HL8$S![!^9P4P&* _A.G0.GQ]S7-:RV?RQC@%6RF-
M]M['1M,9!O\ 2:&]2UWAW0<WI^:[S,&CH1(RST9&2.$@(V]EQ=UE;\S4ENZ8
M1,(F$3")A$PB81,(F$3")A$PB811OY <O.-W%E_K*,Y ;7@=9OMQV=2GZX0F
M6DV[&Q3B"D8D\*)X6*DTH>*CE)IF5W(OS-8YH+I(%ER>H3K+'#+-4Q@G"*E0
MRYB& M$K@TN- I(9$IDPBJK\GFW#:M=\-V,YR&L_&75NP^1LI4MN[,JUKA*4
M\9U%#2NT+''-'%DL$5-1<:V<6Z%C@[E$#=QA @=!, YF91F/'1H>\-J!?;4>
MPL#.R=V8P7EC"^A(-+*'V5%O8^W]-PO&KEYLGBEY.MO\A=J:IXR;4ND;7%][
M:XV&SJZC:&]M'756%K5$B'R#N&EUT ;.#+>D1=0 ,4W4 R5K'F5C9HFM87@7
M$=%ZA?)&(9'P3N?(UA/I TY;E:WI3D/"['V1L;1I(V>+<M)ZQX]76W6*0]A\
MGL!=ZP-TD(<L09!VH_,\CC4%V+WUT42=RZ7IB?[_ &X<D1:T2687%P'13VUG
M13![S%;B:UI/X5?:6C8GR&U:\:_U-.:ET]LO9VT-X63><)KS2T4[ID+/_)^.
M^RY_6&R]@W.V6"QL:52Z!%SD,W!)VX>*.G2TLQ;(-E7"JB:4ARQ:XA[@&- J
M;?="H VDJ,9MKF-,;7.>XNH+/<FA)-P'MA>58_)9KVBZ9V5LK8&HMP5:]:3V
M[K72FX="DC:[8MG5.W[5EZJQIKR%^G)^2K5]K=DB;@SE(MW$/7!I)H?L33!T
M!FY:C*N=(&-<TM<TD'907\URH[.L9&Y[VN#FN#2W:":4NL(MJ*+*JCSN:-]C
M6?6_(G2&PN*\A$Z-MG)*!F-D3^O+1 3VH=?/6#/8D@]E=9VBW,8"VT,LPS<2
M<.95PJFU7]5-54@=1M=E^R'Q.#QBPV5O-U]+#O56YKMEDS3&<)=;0V"^XFT;
M0O%I'/J9L4_JE.V\4=Z:SH7(=*2)Q\V%9Y#63UI=I="H2]ZKM>NE<K]UE)[4
MDUL"MPZBL(G,)]JRH@@Y,T7 R05=EP <+VES;Q;9LLLMIM1N:)+<4;FM?Z)-
M+;*T-ME1=5>LEY#M5/N*FF^4T-4KQ+L]Z;$HNH:'JMLE!H[&=;5N>Q5]9NJ&
M[;.I=&%;3E1G(N34DRB[$J2$6X,43"4 %ZL_OG0DCL@DG90"M4]<C,#9P#VW
M  ;:DTIT6UYE/[,99:81,(F$53OFJU]*7K@5>WT0T7?+Z[MU'V"Y;-B*JKA%
ML)4]>EW8))%,)T(R-LRKI<1Z%2;H'4$0 F;IP!FF9;B2-KR )6/9TD8@.DMH
M.4T6L<7P.FT1[FBIC>UW0#0]0-3R+]>(&S(7;?&C2]RA7R3TRE K4+.$(HW.
MJPM-<BFL'98YR1N!"HJMIABKV@)$A.B8B@$*4Y0S;=2@?EL_+$X4[9(YB:@]
M2Y["\/B:X;E)+,%2IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$51W")XG
MO?S"<C]O5@XO:+JW7+VJ$FVAR*1[F8;-*=KQ!L5R1(Y':4P]B)IVU.42E.@U
M[BG,4  ^9Q>X9+A#+Y.2R>:8&FVG:>3T5:#RE>KPE&9]<DS#?T<<1MY30 =-
MIZ%T ['U?KK;]6?4C:-)K5^J<D']%0-IB&<NP%4"G(D[;INTE#,I!MWB*+E$
M4W")OO)G*8 '.4Y7.9K(S#,9.1\4XN+20>:R\;P;#M72<QELOFHC#F6-?$=A
M%1_MY;U0IR?\!= LIG]DXJ7Q774H<IU4];[#7DK#2U5N@]J$1;TBOK;7T!
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M/N,*3YC7" :E5]UV] ,BZ">2^ B!_B';?I7AKDH:2:O*Z9_O&5:SF+O3=SC
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M3%E[-.^AM576;:W%B3>E]1%J)G'N ]R#8%Q[@MP2TPXNSOI;UUITT5<<-<6
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MA$PB81,(F$3")A$PB81,(L<N*B:-1M*RRA$DDJY.**JJ&*1--,D8Z,=10YA
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M2=)(JRR28+&*!S%+U$*L87R-CN+B!UJV21L<3I3:UK2;.0563UB^0-CHE0V
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MFLHH'2/$H]88!-@=A<TD@V5(I938;:\BQO2=YW+RZG.%VCK1OS;.NJ\CXO\
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M:'2-BQ&N\N%!T#SJCI)Y9@6/+8G38!3<UIJ1SFMO(MVSNS+_ ,7+?Y$--O\
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MSB'-I=2C32@H10VW[5('8&C-B;CVWK*>M-;XC\^=I4#@OH.#WAQKY$FNU&/
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M(*=1,90/AD9F>7-<:58 !T7*40,#'L%:/))Z;Z+4 <;Y%YO3BG76T7),./\
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MCV[>9M?TG'*Q%9^>OTR O(_(HM8[=KZ@F]%(PE+T <H7.(#2>R+NE7!K0XN
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MC?0FM]JW#555LS)?UFTG7YK;%;B!,U714;.GJ#9$X@*A"GARQH)'-],1FG6
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MM$FQ5B(G7!2PB.&)S@T%PE+16V@IY5('2SSL:7N:PP!QI94D^3H6NZ'O;?\
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MG /254V]L[3]8W=L[>L/L&7U/-Q=?M,G&47CI?-CP#-&3EX.PM$$4K+6FYE
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M!Q/(213GJ%KBH<];"KO+0>@-R<3=WZ&N')5:\+:ND[3+ZQM577B:%KFQ[)G
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M4Z;QZV[1K)+>L]F6Z$_\MM-H8M?0C#/7*WK^HDF=$BBA(62,#I238YI Y27
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M(O7^C;AJF_P-+FIV>C:)*VB =7@SU!%65;M)$C!1)!R)U41-1DD9FEJ:->'
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M-JI]#Y35JP:\FTD#UVQ2-2,B[0<@,JJTD#MVU6RBG:]*I-P/E-WE5'1&YMU
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M&HG")BZ+NR1V0>V 33?>+R*=*VY:/(%O^8Y!;SU3K.8X@5&S:6V@6AU;BOR
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MB*,M> \/:+0#8ZF_GVWJDV5FE#HR6.C<30N%7-!V#99LN6I];U#E=7N?W/\
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M'4O%0N.Q]AZ^N\%LR!7<&"(5^DAI9C%:K!^'<&3 WX/OR)DS6Q=V17MAW(0
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FA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>tm2115679d1-tbl_target4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-tbl_target4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!N@.2 P$1  (1 0,1 ?_$ 0X  0 " P$! 0$! 0
M       &" 4'"00#"@$""P$!  $% 0$!              (! P0%!@<("1
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M:\F*?#/]6<M=$;YL"MSD)J.:/*AJ^7E)"?C892#K]B6<61XB](#-%=-NU4,
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M$PB81,(F$3")A%#Y4G6Z5 _A[@IV(VUAXF*>=S2V_;+!>TM[+QZ'C))?L_\
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M 3.4IP5[\O9]D.N+#:23-<\%C6M(!+B&[379M^ J])<,C<&T<YSA44%=@_\
M%:BE?C0N-2;6BOZ9$;NV^RO^E%>0<6OI[35OOBT3J]G8Y.HRTS:(N.;IS-?=
MP=EAW#)ZT7; X;N4Q2,7M^URZ,=<5<'EC"U^GM. VTKLZ]B@;N+86ZG MU;
M3LW)+?&@<<47<F6G5[>^WH."U3KO=M@N&G=*V_8%7KNM-IU^7M-,L<^\B4/'
M1 2,%7WZQFZ[8CI(6:R9DP43.0 QUQ3M%C7%Q: YP!)!H0/JD(;R+[4.< T&
MH%=AVA36[_&&\<*BYJ[2"<;,W"M9M6UG>*I=#ZCV%MX:IIBY-3/ZKLR[%IT"
M_/6:]86":CADBN'G)V@BH=%J<I1'(,L;AU2[2RCBWM.#:N&\"IVD>;RJ3KJ)
MM*5=45V F@.XFBSFWN>_&#2NF]5[^M.P22FJMT24,RUY9JE'NK"2:82]:E[D
MO95&38J;YA6*W4X%Y(3#M=,A8INW/X@"'#L92*RN9I70-;^%9O!V=-*?"2:#
MK57W,,<;9''L.W4\_P!C>I5O#EMJK1-DJU$F8_9.PMEW*$EK7 ZPTIK.X;<O
MRE+@7#5E,W>1@J9&2(P5292#Y!J5Z^4;INWBI6[7OU@,F6$-K+,TO&EL8-"7
M$-%3T5.\_!]55DG9&0TU+R*T )-.O9T+_&I.8>B=YVZH4W6%CDK&_O.CR\@Z
MZ]-7I>(CE]>^G"^NG O0FFT?)Q-DC[<U5:.HQTV1=-CI'!0I3%$H5EM9H6E\
M@H&OTG;TTKYJ=*,GCD<&L-:MU?4K3[*T0R^,ZT%8%:$TH-'Y#[4D]BZ[FMJ0
M</J_2]BNLNSI$!L>PZID9B=81*RBT2D2YUIPW+W@"!BF2-U^6 &7CCIVZB\Q
MM#7:35P&T@.V?4*M][C--(<XD5V"NRM/LJ2;*^,;X\:D?I1MXC]RL%XG7>O]
MJ;6/':6V!/M^/5)V:9V2JR6_G$##R*>MG:IHQZ+EFX%1XT38N%54BI$[P8QV
M$\HJS1M<6M[0&HC?IKO_ &55]U$PT=JW G8>R#\KJ5[D5D7**3ANJDNW7236
M0714*JBLBJ4#I*I*D$Q%$E"& 2F 1 0'J&82R5]<(F$3")A$PB81<W/C3OZL
MS'^D^J_]$V?.JY/_ $L?\B[[+5H.9/T</\HW[!7 [76L[OMFPFJNOX3S_/DB
MY&:,P\Y1$5TC8E'Q$@Y\5-/XUD/AT?+V.\[P_L%*(^3/1[J[M[*+C7+M,=0*
MT)VG=N!*XFWMYKJ3A0#4^A-*@;!OWD*!YDJPF$6^&_&;=SJU5VDH4GO+/:]>
MH;5@(STDJ)?'T)R1XHC/>-//%CVO;(P5'PJRJ;T.QY40ZEZZXY;'B%UP9/P+
M)>&XZ7;'[-E*5Z1M IY5FC'7AE;"&?A',U@5;M;U[Z=&[?Y%H?-BL),(I$PJ
M5GE*_/6R/@I-U6:P>/3L$\DU5&)BEI9VDRC6SM\( W([?.50!-(#"H8 $P%[
M)3"%ITT+)6PN<!*^ND5VF@J:#R=:N-BD<QTK6DQMI4] KL&U9J^ZSN^L7-;:
M7F$\QN+=48>]UY/SE$27G"J3ZCQ*)E>W$/Y C3Q9X]8.X7%)RGV/;IEZEZV[
M:[M[L/=;NU!CRQVPBCA2HV@5I4;1L\JG/;S6Q:)A0N:'#:#5IW'83U?"H'F2
MK"81,(F$3")A$PB81,(F$6\=0\;]T;Y;3CO5%,]*F];78-II3TBJD'X):33=
M*L2=BR3L.=SWY&2H]4@4 O9]L(=0ZZZ^RMACBUMY)H+ZT[+C6F_T0>OI6;:X
M^[O0XVS-0;2NUHW_  D+[[<XS;NT3'1$MM6D^BL?//5XZ*<>DE1G/%/&R .5
MD>ZKD],+H=A >UVE"D(/L (CY,666Q^1<YEG)K<T5/9<*#]T EUC[RR:'7+-
M+7&@VM/V"5IJ'AI>PRK"#@8Q_,S,JZ291D5%M%WT@_>+F B+9FS;$47<+J&'
MH!2E$1S.?(R)ADD(;&T5))H /*5B,8Y[@Q@)>3L VDK_ !+14A!2LE"2S51C
M*P\@\BI-DMV>]9R$>Y4:/6JO8,<G>-W*)B&Z"(=0\@X8]LC!(PU8X @]8.T(
MYKF.+'"C@:$>4*64_6=WOL5=9NIPGG:,UW7E;5<7/G*(8^9X%$3E4?\ <R3]
MFXD.R*8_*FI%UAZ>0F69[NWMGQQS.TOE=I;L)J>K8#3ZM KL5O-.U[XA5L;=
M3MH%!U[3M^HH'F2K"81,(ONV;+/'+=HV)WCATNDV03[1"=XLNH5)(G;4,4A>
MT<P!U,( '[(Y0D-!<=P50"30;RKC.OB^.8#-NLZ5T\N=)!,RIRM;KKA\X,4@
M=1!%FRN#AVY4$/8(F0QS?L .:(<S8-QH)Q4_M'CZY;1;8X/*@5,7[YGWRKC1
M-6W_ &7>&NMZ767LO=W:LD@2 559Q#A%6';.74H1^XFW,:RC#,DF:@*>)52Z
M*%['[L2E':W%Y;6EN;J=X;;BG:VG?L%*5)K7H^%:^&VGN)A;PM)F-=F[=OK6
ME/JKS+:XO"%_6U8:M2)]@H616HGJ[<B3J0&PHO#,%&")FRJS5P'B"#T634,@
M9/Y8!Q3]ME1=6YMN^:QW8LU:MPTTK7]C?T;U0V\PG[MI/'U::=-=U/\ #8MO
M[.XB<@-0596Z7BC RK3-=FSEY*+L%;L)8!Z^,FFV:SJ$#+2+B,%1=8B7>G)X
M?O5"$[SM'(!L&TS>-OIN[V\E92"0"US:@=50*_9IT;%E7&+OK6/C3,I&-Y!!
MI7KH33["AR''??3I-NHAIG:"A77B>X_ZCV,IE!:)IJK%[!HXIRG$BI13*( 9
M41Z$ P^3+YRF-!(,\.S]NWI^K_X*T+"].Z*3YI^)0MGKV_2/@_-]'M[[SC"N
M;)'^#K4TZ\=7F3\\4\GF?<,C^*A6DHF9LJZ)VD$W!13,8#@(9D.N;9M=4C!1
MVDU<-CB*@';O(VTWTVJT()W4TL>:BHV'<#2OP5V5W560V9J^[:@M:]+O\(Y@
MK W8QLB9JN0_=*M)1HFZ16:.1(5!\BD<QT%%$142!RBJF!S"0<C:7=O?0B>V
M<'1$D?5!Z>KKV[:$%5N+::UEX,[=+Z ^?[/5\-5K_,E6$PBW]J3B]O3>D+)6
M'5=&]*8>(E!AI%YZ34^$\/) T;OA;>'L=@B'2OSJ[3-VR$,G[;IVNH" :V]R
M^.QT@BO)-#W"H&EQV5I]JT]2SK7&WMZPR6S-3 :':T;=_20H]MK0^V]%OXR.
MVK2G]37F4%G$2LJ\B9:.D"-A2!T1I+P,A*12SAKWZ?>HE6%5(%""<H 8O6Y9
M9&RR+2ZSD#PW?L((^$$ [>@THK=U975DX-N6%I.[<0?J@D+SV#26TJKK:J[=
ML%1>1NN[L\\!6;&J]B5$Y!T)9!1),\:W?K3$>5TC%.%$#NFZ)'"2?;3$Y!*(
MRBR%G-=/LHG@W48JYM#LW=-*&E16A-.E'V=S';MNGL(@>: [-N_HK4;C2HVK
M8FMN'G(W;U287K7>NO2&JR:[YNQE/2ZBQ/?K1KQ9@])X&<L\9(I]R[0.3J=$
MH&Z=2B(" YBW6<Q=E.;>ZETS"E1I>=XJ-H:1N\JOV^*O[J(301ZHC6AU-&[9
MTD%1.3XW[XBIVQ5Q75%T?RE4>+QL^%?AU[1',))M#QT^YCO/=;\[0KJ0;0LL
MV=*((.%%2(K%,8H .7F97'/C;*)HPQXJ-1TDBI;6CJ&E014C>%:=C[UKW1F)
MY<TT-!4 T!I45%:$&E5#9S5^R*RZDF5@H5PAW4-",[)+HR%<EFQHNO2#I%@Q
MG9 5&@%9Q#J07(V(Y4$J(N3=UVN\]KE^.[M9@'12,<'.+11PVN&T@;=IIMIO
MIMW*T^VN(R0]CP0*FH.P'94^2NRO7L4@EM%;9@*%([)GZ+9(.JQ5E9U20<S$
M/)1KII*/6!)!%1TR=M4G#2.%-P@F#E8$TCKN4DB"<YA +;,C927(M8Y&.F<P
MN%""" :;"-YW[!MH"5-UE=,@-P]CFQ!VDU!&TBN[JW;>L@+4F9JQ5^I?@?\
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MLS?-YJ+"NA$WJVR=P83J[%2.\Y#),74D+99(%^Z,D'>%'M>TR\<3/WC6V1G
MX\<I%#JJQH:16M*&E0:5Z%;&1BX.DL=Q>"^/>*4<XN!W5J*T6C=\[&AMM;*E
M=@P\5)POG^.K_G2-DW35YX>7BX-A"NP8.&J*';CCDCB&3%0H*B(F$>G4"AL,
M=:OLK1ML]P=I+J$;-A)(KY=JPKVX;=7!G:"-0%0>L #9Y-BTYF>L1,(NFO'N
M1UC%\'MJNMNUZR6>E^OJMINXRIRB$1,^*4K\$#5T@Z<B5$Y&P]HQDQ,3O/('
M:#V<Y+)MNW\P0BR<QD_=G4+A44U%=%8NMFX:0W37.AXXV--#N"E_(77RVP"<
M1-&Z2A2$X]W!TYD=<W,LK)V68=R%B=)O;N-E-(()^8'E/0.[74CTSJ%[!%#"
M8#)F0;V<9<BV[[D,@[_\FP4>V@: &BC--/2#M@U?!UU-V^@,_=;.S'^PO-6.
MJ2:GTJUW:=NS_P !:K8-?J>X:QO'C]5]IZJLT2VHE5C=":SK-A3?7.HV+3<2
MY4=,WC(C)!$QIQ\U%NN=%14[=L E$# )NFFMI9K&6WR<T,S'F1QFD<VC7-E.
M\&O0-HZRME/'%=1S6,<D3FZ (V ]IIC'5Y3OZ@J?LI;34'P8T";=5+N%PCC[
M$V<C$,ZG8$:X[82*<U*BY5?*N$E._2,A[4"= $IO+F\<R_DYAN>X2,8[A1U+
MFZ@10;EJ@ZT9AH.]L>]NM]-)I0U*T%K?DM2]9^CT=!5*REKM5WOL_:,*S4EF
MBKY*LW'7;:AUN#<.S 4%YJ$3:E47<B $4 1[/01S97>)GN]3I'LXK[:.,FAI
MJ:_6XTZCT!85OD(K;2UC7<-LSW@5Z',T@?".M>)CR-I[B!95&PU:RJ0"_&N%
MT7-.H64BVLN24@=ER.Q6E@B_',WC([!=99%JHBJ4J@%[9RFZ@4!D[%SB0SQ/
M9Q.]F85!(H8PPM-"#7>:A1;?Q%@B>UVCNXC-"*U#R^H\G0OCNOD;5]MUN_0R
M-4G8-S8=H5K8]>4/*,'K=D$9KN'H$E$3'1HBJY#N8PRZ"R/8$YE [92@40,Q
M^*FLI8Y"]K@V%S';"*U>7@C;Y:$%+S(1W4;V:2"Z0/&T=# T@^:H50<WBU2_
M4OP/_JE:8_D2;^ZZPYY!S%^FI_NA_!:O2,+^BX?@/\(J(<^/Q>:I_IUJ_P!Q
MVP,TH6R=N5O:-]B-?_DIE_%T\HI*5X1,(F$3")A$PB81,(F$3"+G=QD63?VO
ME9+M#%7C7O)[8#9F\3,4R+I2-:P[=V9 P&'O4"J&#LJ![0X#U*(]!Z7G;A\"
M@W>?A5LLBI)A%5-G*IZSYPPCZ8-X>O;\U.--B9!4O91+L"E2_G-O&*.#?*T2
MO8%4")%$0,LZ7(0H"/LU(JSR@J.Y_P (70O+2FF$3")A$PB81,(F$4/E2=;I
M4#^'N"G8C;6'B8IYW-+;]LL%[2WLO'H>,DE^S_[)-X=?NA*Z]LGVO;UZ$Z5,
M,HB8182RR2\- 3$JU(DHXCX]R[1(N4YD3*(IF.4JI4U$CF((AY0 Q1_X<NP,
M$LS8W5TN< H2.+(W/&\ E5L]>MN]SJY]*2?UWS>>R;;Y3_./B6L[_-U-^O\
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M[-U/.-864[F"@/3J 5\81:)U>>'(=Q8F9$G!8U9N#]NF1%1\).YL&,YPLK?
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M13H5G6ZM/)S;XDG!5Y@5T1I!1SHJH*(1"2;Y8GA@'N3$5.42B4P@,S8V9B?
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M]0:M@=-T"$H5?5</$(PB[B1EGOED)V;D%C.I>:?F$Z@^(?O%#& O:,"20$3
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M834< +98 2'L!VLBT'^TQ[1Z05J<_@7?<E<N.?%VM>M."O-+8]#G7U7O.O\
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M7.379IA%6;EAH!UR1U>WUXSL#>M*HVJ)L8R+EJH[3,2-9RK46W=)"!@,J,B
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M2<W"24%95&$["1[E%BP;IJKIK>)[PJ/?D0;IAW@B*G:F\ES*^50: UU/(NI
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MG639+C'7=LUPTQM9/2E22QW#-#791LI<=AJ&^0+=9!\5KE;*\<TZY726VJM
MT2-XHJ*'55\#6--1I+]FQQ5K<U"WB81,(F$6OMG:XAMI5-S5Y=U)1*Y73.8K
MUF@7!&5DI]HB5?$P=JK;\Z:Q6<Q$.@[1!,0Z2R9CHK$41543-N<%F[G 9%M_
M;-9(S2YDD4@U131/%)(I6U&ICQL.T$&CFD.:TC0\R<O6?,V*=C+MTD3]39(I
MHCIF@F8:QS0NH=,D;MHJ"UP+F/#F.<TZ)E=A.9-ZXU?;D7K;8U$0B'$G(.HM
M"'BMAPK^-(W3V/3FK:1ED$8*3FFKE!=B+A5S$ND^X6$2F067[&SPT<$8SV.+
M786[+PUH<7OMWM=4VTQ+6$R-86N;)I#9F'6VA#VLX6]STES,>6LJ'MY@L0PO
M<Y@C9=1N8 +NW:'O B?('M='K+X'C0^H+'OT[LO=FG=,>AGK=VEK[6/K%N43
MKN@^GMO@:GZ9WR=[WS-3JQY\?,O/=DE.Y-W#-OWBZG9'H4<R9)8HJ<1P;J-!
M4TJ>H>58T<,LU>$USM(J: F@'2:="V?EQ6USNL')3F=&<J8[CE%<7N,,E#6&
MJ7[:E:O\AS2VK$R;C4-#V-1Z*O*3E);<#YEK$;(D6NP8]Z2!;S;^,34(X0&:
M$$TUUL)T]T+C@"..A!(.L[@0-W#W[1LK3RK/;;VAMN\&22H(:1PV^D03OXF[
M8=M ?(H_>OC4.-E>K=\NM,E)78-3UOJW=FQYMRWU_ONO2%M7TVO#Q4E"Z;>2
M>CE=?;:8Q]G?+Q-GDHZQ$2J#Y-(CQ-0#.Q8T?D(&M+FU<UK7'<X5T_)[-#MV
M$UV=/323,9<.<UCP&N<YH&UIIJZ7=JK=FT CM='165ZE^,4TU:X'43/:;GU=
M[2V;&T5>8K52J?(/8FKM;3FU908_5M0V'O6?X]:LJ^M[7L '3(D5'7)G59"3
M=O4DF*#M)9JX<RCO8G-;Q.S(ZFP!Q KN!=I !/0'4KT54);"9KGF+M1MKM):
M"0WTB&ASB0-M2W4!3;3;3%[P^-'XJZ:H_(&S(3]MNTYH2@;KMZD%$ZPVY'5?
M8\_H9J_3V#K[6FX9'7H:EO%IJE@9#'SR4-+R9JR)%W$H1LW9NE$J2Y"WB8]U
M22P..XT.G> ZE"1TT)IT[E6'&W,SXVT :]S174VH#MQ+:Z@"-HJ!7HK4+;"W
M/3BVWO=2UPO>[.E9KB[U?%-%3Z:W>6IUFR[KCH65U+1MH;"'7/H!IO9&PF5E
MC1BJU;9.$GW1Y)HF5GWCE BESO=OK#*G4:?:NH"[<":4:344!(.T;%;[E<Z#
M)I&D5^V;4AOI$"M7 4-2T$;#MV*.\T>:2'#J2XREDM=FNU=WSO\ KNF[=8PM
MQ*P34E6F(Z0D)C:KQF>MSI;/$5%%D#B09]_&]U'E7<^)#N.[/&ZNN[&.K:M>
M\-)K2@Z]VVGU%*SL^]B2CM+F1EP%*ZC\G>*5Z-^U:"VU\: 77>T.=NOH+2K:
MV17";0:>UE;L^VD%:B-CWMM"56Q6/6(():]L1JE'U>+O<.5W/D5ERE>+.6PL
M069JE&S)?Z))F!M1$RM:TJ=A(W&E*C;M^#8KT6-XD<#R^AF?IIIK05(!WBM:
M'9L^':I<7G%M>LZJV]MC8FO^'\S%:QBZ<[:Q/&KG#9-^RL@\M5TB:H*5K"<X
MD:<;4F+;-I([E!V4\H9VHW,CW*0=5BS[W(V-TCVQ$-IZ,A=O--O8;3ZZAW.)
MTK(HW2@N)].,-W"NRCW5^LK-:0Y'L^0]INDAJRN-I_CY5%7M7A>0)+,D,+M'
M9,#..X:Y0VJJ\UB'1+7KVE.V"S![;#239FZG$%F<<W?)(+O$K\4_&<3&*PC9
MJKO/30=('77?L%=ZL36YMVM$II.=NFGH@C9J/03OTTW;33<K,Y?6,F$3")A$
MPB815AYG_P!5K=O_ ,%.OXXSSNO#/_GW%_\ F1_!<O-_%_\ Z:9G_P F?X35
M5[_\'VSM/_F)>=?_  ,OT$Y\=+[R3"*'7G85&UE!&M&P[9 4NN$>-(\\W9))
MK$QA'S\XI,VIWCM1) JSE0! @"/E$,V6)PV6SMWW##6\UU>Z2[1$TO=I;M<=
M(J:#I6HS>?PO+=C[3S]U!9X\/:WB3/#&:G&C6ZG$"I.Y?9W>:<PM<31GEFA6
MMQGHE_/0U:6D&Z<S*0L68I)&49,3'!9PQ9&. **% 2DZ^4<C'B<G-CY,M%!*
M[&0R-C?*&G0U[O18YVX.=T#>5.7-XB#*182:YA;EYXG2QPEP$CXV>F]K=Y:W
MI(V!:SI?)_CQL6YN->T7<VO;5=&XNP"OPMDCWCUX+ IU'P1(IJ]Q-"T12.HI
MX,Z_83(8X]"E$0WN4Y#YSPN,;F<MC+RWQ;J?A'QN:UNK8W7LJRI( UAM20!M
M("YS#^)7(',&8=@,)F+"ZS#=7X*.9KG.TU+M%#232 2>&74 ).P$K^VOD]QX
MHMV;ZXN.Y]=5R[N%$$1KDM:(QH^9KNR%4:-Y45%P;PSAVF<IDDW9T#JE.02@
M('+U8_D/G/+8IV;QN,O9\4T$\1D3BT@;RS95X&VI8' 4-=Q3*>)7(&$S+>7L
MOF,?;YIQ X3YF-<TNVM#ZFD9<*%H>6D@B@-179J5WJ"]Q=Z]1LD,K>6$ A:7
MM3(^0-/-:XZ>C'-IM>. _B4XU=^442JB7L"IY.O7-"[%9)F,;F702C%/F,39
MM)X9D#=18';BX-VD;Z;5TC,SB7Y=^ 9<0G-,@$SH X<5L3G:!(6;PPN[(=NK
ML47VCNW4FE(YC*[8V)5*$RE%E&\6-BEF[)S*K(BEX@D6P$QG\EX4%R"L*"2@
M(E. G$H" YL,!RMS'S3.^WY>LKB\EC%7\-A<& UIK=Z+:T.G41J((%2M9S+S
MERKR;;LNN:<A:V,,I(9Q7AI>12NAOI/TU&K2#I!!- I94+E4[_78RW4>R0MM
MK$RB*\7/5Z2:RT4]3*<R2G</&:JJ)E$%B&34)U Z2A3$. &*(!KLEC,CA[V3
M'96"6WOXC1T<C2Q[3O%6N -"-H.X@@BH*VN)R^+SV/CRN%N(;K&S"K)8GM>Q
MPW&CFDBH(((W@@@@$$*2Y@K8IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%1?GQ^+S5/\ 3K5_
MN.V!E0HNW*WM&^Q&O_R4R_BZ>44E*\(F$3")A%7;EM:G%,XT[JGFBAD79*%,
MQ35=,QR*MW-D3)6V[E(Z93&(LV6E@4(/L 8H"(@'E"3!5X'E47&C2H]IFK-Z
M3J76]4;( @6#I5<9KD#H(G?A%ME)-RH)?:BL\D5%53B'0!.<>@ 'DR9-35!L
M"V7E%5,(F$3")A$PB81,(F$3")A$PBJGM(?,7*SA]:R=$TWLMM2C29@ 1%RG
M8:<3S,@<Q2J' J$@110O0O3M?NC%+U')?:$*)](%="\LJ:A]0<>("S_/]/?]
MS<)QOUJ!.P#3NC-P\!9_GQYVK@VZ]'P_*NHB3Y63V,J50*89153")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(J?<H&5&K-KT7MVX5V5F&Q+@XXTSK]E.MH
M>*B*/RND*S1' VIFM"R*EA@Y+:,'4&@-2NXSN7"Z;KOU!0!LOM;"-][:76+J
MWAR1&7214N,+7.(!J*'AND-:.J*B@K4<[G8K1LEO=W;'/B<\VSJ.H!'=:8SJ
M%#J:9!$*5;0D.J::3X]K/MCS/&W8(T"+!MMW1UF:2,#$ LQ.,XZT[;(*[QD0
MRE[DY4;(DVGK1BBS4=NW*0II3:H'73$#*!A<ORP.NVPWHTPZGPO](T#FEK7[
M*N- YLG2:C<5C/FO9\',RW9IR5E,6AM:ZN ]KV4<\G\=#IJ7&OX0U(WJXC-X
MTD6C60CW39\P?-D'C)ZS72=-'C1TD5=LZ:N4#'1<-G")RG(<AA*<H@("(#EA
MS2TEK@0X&A!Z%U37->T/806D5!&T$'I"].454PB810K8=_K>L*C+72U.'"45
M%E;))M6#920F)F5D72,="5VOQ:'SS,6.Q2[I%DP:) *CETN1,OE-FTPV'OL]
MDH\7CPTW$E35QTL8QH+GR2/.QD<; Y\CSL:QI)W+39_.X[EK$RYC)N<+6( !
MK6ETDCWN#(XHF#;)++(YL<4;=KWN:T;US+U+<7F\MT;EW>.P'TO#PZ,!I]EK
M%Q#*-6FJ9R'*M+6^"9V!D[>UFY]N7*"AI9BJ8SWMAVRIH)- 'WG.XV+E3EC&
M\J]S9'<RF2\==!]3=L?1D,AC<&RP]C8(7@:*;"7NDI\V\L9>;G7G#+\Z=_?+
M:1"*P;9F,M;921U?/$V5KG0W'X3:9XW$R5VAK&Q R7>?%[C]R8]6_KZU35-H
M>J'8,/M/6_I.U7<>BM\@NUYMG6/AW#;O^[[7RUJOWS-SV2=\DIV"=G@YK>&?
M3QFAVEU17H*]-AN9[;5P'%NMNDTZ0>A;ZR\K"K]):;DWW*FF<@R3+$D/6./V
MS--KUXS=P,FZD[WL;4UV:3*+H!\*1BP:ZZ7043,'>&4<D$OD*;+)B)N!-78&
M%M/A(/\ B5\2@6Q@IM,@=7X X?XU1V5^+LN<CIG7VL";%K";^F\7N=V@G,H:
M*E1:/9?EPO6E:[8$$0-WR<;40@S@]2-\M7[P.ZZ=!S$-DXQ"/4*B.1OSZ4/U
M*+,%^P2NDTFADC=\RM1]6NQ0*^_%5R5IWY+[(;3^GIBG[-L_'RZ[--L&H[&L
M%ZK,OH^CZIUO-PVLFD/LFOZUD(+9%*T[%HI*3T0Y<UR37=R!/.('09MH/QY=
M,7U:6N+2:@DC2 -FT#:&C>-AJ=NY7&9(-@$9#P]H<!0@ ZBX[=A-07'<=HH-
MF\S"P<$.3LUH#<_#AGR'UE7^-%UUERVU]5G++5$E([=FX[DG6-I0U0@=FS,G
M:%:XG$:?EMG><%7\ U82EH7AV953L$3OT7LS:3F%UMK:("UX&S;V@:5VT[->
MC::#=MK!M[;-G9=\-QN YA/:[(T$5(V5[5*4-0*G?LI!-J_%X\J=U[HJ>UM@
M[NUI)-H??O$?D$I A,<DS1%.'CW=M)7>X:AUCKUMMN-T7'0UOL>K7\@VN$K4
M)*SF2EBQ[TK@6;210A)97$LHD>]NQ['?;;-):2 *Z=I&\@G;0[@5<BO[:&$Q
M1L=MC>VO8VZ@X!Q.G5L!II#@-E1O(6^MR?%L438=:IFO8*[[34HC1]O=6\!N
M7?/('D=;WC3<W&39O'PA:=;]][+V78:KYA<7I"33;-7C9D19L=9-(KE0RAKT
MMBQ[0P%VCM5U.<X]IA;L+B2-]58AR#XW&1S6Z^S32UK!V7AVT- !K2BKY'_%
M>;<6TCMNI7#<='N&X=X<7-V:OV7?7U<ED(:R[JW;O*R[EF;HZC4>C@M'B49Y
M&$9L@#Q",8P;I%]JF4,L"PDX3FN<#*^-P)IO<YQ=7X.CX%?.2BXS'L81$R1I
M KN:UH;3X=E:]96VK9PLV_M[1^]-#[#H/"/7%5W#4H& >.-$T2X0SB9-%W2
MFW<7=&\A'L$92NNJ^T?MRD*)E2+N2B'0@GZW76LDD3X7B)K7#[4'KZ?(K++N
M**9DT;IG.8:]HCJ.[RUHK6ZHXW^H/;MNE--N*W4^/6RXD9NT:,8Q/FB%HFXH
M[S3')7W4#.)23A*S!;"KJ!R6F#*@@R6F6;>7:]V]>3)I#(C@X,A,5!"X;6]3
MNMO54;QU[=Y-<>6XX\0$U3.T['=);U.ZR#N.^FP[ *6MS(6*F$3")A$PB815
MAYG_ -5K=O\ \%.OXXSSNO#/_GW%_P#F1_!<O-_%_P#Z:9G_ ,F?X355[_\
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MO-OFNON^TN'AYJ1\\-.X:GZ+J^)2[)1[PO51*A%;;5D?&=]9()+S=.Q]7?\
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M74KPQC6BKG.<:-: -I))  ZUCW=W;6%K)?7LC(K.&-SWO<0&L8T%SG.)V -
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M+E*5=9!JDF<YB$*4+DO,F>FPS.7I;N9V$C<'-A+CH!!<X;.H.>]S6GLASG.
M!)*MP\I\M6^?DYIALK=O,,K2UTX:.(06L:[;\IS8XVN< '.:QK22UH"V/FD7
M0IA$PB81,(F$4>D:E5)B>KEJEZS7I2ST[SQZ(V.1A8U]/57TA9DCI_T<F'+9
M60@_/D>D5!YX51+Q*)0(IVB@ 9F09'(6UI/C[:>:.PN='&C:]S8Y>&[5'Q&
MALG#<2YFH'2XU;0K N,5B[N^M\G=6UO+DK3B<"5\;'2P\5H9+PI""^/B, ;)
MH+=;0&NJ-B_DS4ZY89*LS$W$-).1ILJXG:NX=E,KYEFG43(02LJS2$_<%?\
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M^)T?J6"7UBYB*)!,%],,[#'ZM5026 U)96R/+%6-O"]I<W=)R\<0$5NWV^I
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MHEZE3=7'5X(SK:65-["BR%5(1F0O[!3_ +(B'21VQ_ 5'<_X0KLU!QX@+/\
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M#.7 HI= [""!.@J*J',!2@(@7J/E$ ZB&PQ6,NLSD8<58@&[G>&-J:"IZST
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MTLLP+'J$5*9)8'/>M=M@<%<<U0/PL<D4;(Y!,YSVDMBC /&G<00=$+6-D>T
MEP;L((H='SWE++EZ Y6X@=/--"88F _C;EKVOLH V@J^6<Z8W:VAKCMJ#5LS
M4KL+8-+T/30*R%.L.^++*2]\B9AG,O)V41):S7GD-'.I K!;PZ,NW%]"-GST
M4VY4)!JFB<>TW*.RY=SV2NKUW.UY"'>S+.-C&C2QD,PB[M9Z6.<"X12@3:6
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M=M>4*I:R:5L8&^K2:\V9HT<5Y"P U%VW%@D*,&S!DSY&2ZV 0@N.G8"]]02
M!T[^BOD4WVQEMHHI(.%(3<D,&K:X,CTD DNK44ITTK3:MUR_.)]M3;LS6I[G
M$RX\<297D+R=KE<Y24E]H6#AWJ^IM(<.[3J71<#MC9M"N&MVL7>'&U=AW)*7
M<).G\PWIHLV[Q1@J9(UPW.N0@RZ(-;AJ&GH:PAM2"-M7&O33J5D60BB#FP<2
M[$;"6'4?2=('.+00=FEC:;AJK2JT[2=RVDG(V8NU?Y(3/("<VCL'XM*3@JGL
M'5^FZ.6Y4FR:ANX#L^GZZF]6LMC:W0N-ECU?"2:+\S=DM)K^$6 #I&+;;([C
M:@\O+C'L( J"#M I45/V5>?"SNX8Z,1M:V:I#G&A#AV20ZAH.BFVFU>)CSHW
M\TT98+SK'FFOO':]D^+VW)R!WM5GM%TP\:\)>255D-3LJC76]2KM$AI?7S1*
MQ6NTUHU)OR\S,O354SGO?$,IA=T%S*(BYDFIYB+G"@[#A2@I39O(HZIV?"JF
MQ@,X9+#HB%PUK35WX1AU5-2=NP-.IM -5.D4Z^<8)':E6Y(\K-"7W=M\WM7*
M#5>.NS*=9=G0^LXZXPCW<*&WHZX5HCG55 UK77553D-7-WT>BI&"X9*OW*)5
MS-@;HH9\)>V9\3W%P :032NVM1L V;%J+H1.MXIXV-8YQ>"&UH=.FA[1)KVJ
M';MH.FJOKF4L!,(F$3")A%HWDM^(?9__ ,,K_P 8;9VGAU_SOC?_ #(^P5Y#
MX^?]'.8?ZO=_"8M.?_1USLO_ )97C/\ _696!X[?UV.;/^ZK[GU\^=,I^@,?
M_G/X2_1>P_2]Y^X^PNA.<RMXF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA%1?GQ^+S5/].M7^X[8&5"B[<K>T;[$:_P#R4R_BZ>44E*\(F$3"+GS:U0V-
MSH:M3_+X?COJ(7)""(G*SONT%R@8PE$1(GXBE@F(>3M]I(!\H=.EUNR/X2H;
MW_ %:?**28150=(AM3FMKNLIAXBO\>:1-;&L/0WSN-SNJ2,)5XQT0/; ]CXX
MR<FW'R!T[74>G4II'9'Y2H[WTZE-OC!0 >-,Z(@ B6Z:T$!$/8'TZ@PZA_8'
MH(A_Y!R,?I?41_HK?.%),(F$3")A%K/<&TZ_I?7L_L6S(OG47!)M2^"C4B*O
MG[V0>(1\>S;@J=)%,5W;D@&4.8"ID[1AZ].@U U&BH3056K./O*W77()JX1A
MRN*Q9VSIVCZ)SSIB,F_;-$47*LC#F;JB639H(N"=^)2E.W./0Y0*8ASU<PM5
M&N#OA6#Y66"GW7C1?F4/9H&4&TT64ME6!G(LG?I#&4=_#S\L_A@(H<'[>+*D
MD991+M=R*A1$0'IE6@AR.H6JXFM-CU>STS53LEBAU)2_T=G/0; '[?QDP2,B
MHE2QGCFQG"R[H(1Q))D=]DR@H&. ''J.62""?(I BBI=R!N%-K'(;BKO.NV:
M!?0FT6%GU%,2$=*-'*-@K3Y=@_K,FP4;K&([BX:U2A3.W =I-'MHE,("8N76
M Z2T]"B2 X'K5GXV\4Z9]'/--H@I'TO82,I5?!2C1QZ0QT3X7SH]A^Z5-YP;
M1_CD>^.EV@3[PO:Z=<I0J50OY'7>FS05T(NSP,F%QCY&3JX,Y-FY"QQL3X4)
M5Y#@FJ8)%K'@^1[XR?:!/O2]KIUQ0I4*HG%J]06I-SSFG8FPU>>TYO"7L]^T
MA-561;2$'"V1D8JMJUX9TDX620<(Q(-54T -V4C@F4H"=ST+5XJW5]L-Z@TT
M-.@KI; 6"#M4-'V&M2\=/04LW*[C)B)=HOHY^U.)BE7:.VYU$5TA,40ZE$0Z
M@.62*;#O5Q9?"*&OFO;OE<>>9K*OW%:M+?S\TG?#52-\2_K)_-LS7?/;?SI+
MRGA^VR<^ <^%3;+E[U+O>AJ]"*991%H#E7;K'0>-F\;K4)16$M%6UG;9R ET
M$FRZT=*Q\2X<,WB2+Q%RU5.@L0# 51,Y!Z>4!#.P\/L=99?G?%8O)1B6PN+Z
M&.1A) <QSP' EI!%1U$%<)XGY;(8+P[S69Q,IAR=MC9Y(I  2Q[6$M< X%IH
M=NT$>1?E0_63\W_R_6'X/4;[UL_03^P_PK_4\/TD_P"57Y@?WB?&?]>W'T5M
M^13]9/S?_+]8?@]1OO6Q_8?X5_J>'Z2?\JG]XGQG_7MQ]%;?D4_63\W_ ,OU
MA^#U&^];']A_A7^IX?I)_P JG]XGQG_7MQ]%;?D4_63\W_R_6'X/4;[UL?V'
M^%?ZGA^DG_*I_>)\9_U[<?16WY%/UD_-_P#+]8?@]1OO6Q_8?X5_J>'Z2?\
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M)U5EE3D323()C"!0$<M6UM<7EQ':6D;Y;N5[6,8QI<][W$-:UK6@ESG$@-:
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MG;N+++$C'3E-W&K$7<1Q)Y\"!S )D0>K@00[Y3M;"WYB\/[5S7VM_AHWM:X
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M&)YOMSD;]YL<%;7EJ^[?93W,,DK@'/U6@="QLK7!X@>9'1-T-)U:BZ<7'?\
MR1T5/[19M=K63:[J1^+\K_)1@6VUZHBG4-B/]APE"?2=9CJ_ 131K5X"&?N9
M'P3HKL%!1*+I1P)#G/JL;R?R1S99V$DF/@Q\;.<9,8[@R35FMFV[[AK9722/
M)ED>UL>MI92I$;65 &ZR_/?B'R3?9.&+*7&4EDY#BR[>/%!2"[==1VSGPLBB
M8UL,4;GR\-X?72#*Z2A+MCVG9UHU3HS?[^I<RYO<5^9<?JAM>&B9J!J<C.4&
M0E7;9J^M49:(.+;P)H&P.7?9;0;ILLNQ2*F?O%"G%0^DQ^"L.8>;,/#D>68L
M9AW9B:T>]DDS67#6-);$Z*1YDXD8%73L<&R$D4!%!T.3YDR?*_).=GQ7-\V7
MSK,#!>QLDB@?):O>X-=.R:-@BX4I=1EL]CG1M#3J<':G078FP.2E&<\;M6R6
MYMGVT^Z:M==QVRYTU32VN;<J[:U2L/6.O*C/;1=Q=$A*I47HN))RF90S]VT<
M=UY"@)\VV%P_(^59F\_!C+"W&+N(+*&&87MS" 996NN)H[4.G?+,W3$TT$;'
MMU;]BTG,&>\1<))R[RS<YC)73LQ;7%_/<6YQ]I.7""%S;6"6]<RVC@@=JF>*
MF5[':=@VJ WCE+OB8U#JV.E=JVZ'W$RT)LS;DVAIZ6T"UJMEB:Y:IFOU'9UP
MVL_MD]5U8Q!K '*^JE<:NG[MX9<!4;&(FB&XQ7(/*5MS'?SV^/MI.6G9>ULV
M&\9D#+$^2)DDUK#:-ACE#B9 8[NY>R-C-'9>"YRT.:\3>>+OE3&6]UE+N'FY
MF"O+Z06#\6V"9D4TD4%Y/>NGDA+ (B)+*T8^5[]?:C+6L62I$[>-C<G>,VTK
M9MF9C;#<.!S"^222#&G,XN6D$I2/:2U.28O(-5+S5>)5N9^\22Z.?$J&(V.B
M@!42X^5M,5A.0\[@,=CHI+.VYN=;M)=,7L:6.+)BYL@.N!A$;">SI ,@<^KC
MDX:]S7,/B3RWS-E<K-'?W?([;EX#8&L>X/:U]N&NC(T7+P99 WMZR1&6,HP?
M72VW-E[ IG#_ %9*[I><?ZA<-#[@V;.7^E0^OZDXL=NJU_F8F,KK91]7O1J(
MBZ[&IA)/6K%LW.\14."I@$Q%DX\T<N8/#Y/F3/V^+;F,E;9>SM66\[[B81PR
MV['ND.F3BO?([\&QSW.#' :10%KI\G<U\QYW$<I<L768?@<3=X._O)+JWCM8
M#-/#=2,9$"Z+@QLB8.+(R-C#(TD.()#VWZO]F;W#XO;;-B;;%;[;2D.+FW@'
M9;6MGJ"-U69Z]M+!S/!6CF/YG4>.&IQ.D40(!P$2 !!  \AP]B_&^,F.LGV1
MQSF9^S_V8R\8P!UQ$X1\7[<-!%#OI2NVJ]TSN19EO 3*Y"/(-RK9.6;[_;&P
M\ 7!;:S-,O!_^F7%IJT;*U(H" N>-A)H0>._Q?YM.AJX.4867BWYL'70UH-E
MC(!6X4-AA</1@0GCQ(('6&9"3ZH J("O[?/9[(\W^^G. YE[_P"X/ RNKO/%
M[MIXK^[\'B_@]=:<'A=JGH;%X#?CD;W Y$/*7LS^TSO&&T=TX/?-?!C[UQ^#
M^%T4+N\<;LZO3VJ?V7E?M:+UOOD_K5*TNU<^,KE],U!HH2LEF6FHTK%7F[2L
M,XM2/[QS%^;P? 5T=)1P8I%![X1((ET]CX><OW&;Q ]GZL5/R.R]F/X70;PQ
MR$REX=0/U<.K00W:WL[=N^R/BES/;<O9P^U-&9M_$:3'P-/!XC;$2Q!L+6%M
M2S1Q*/+2X@.[>S9L/7NW[=;]D778FPN5<EJ5:H<Q9W0\'H=:MUJ8JMAIT8JA
M'UZG*P"3!*Y*7.\&6,NE8 =J))&*<$FXE O=Z7,\MX[&X2UPN&Y?9D6W/+4=
M_)?B25DL<S@723"0N,/!@II-OH!((U/K75O\!S9ELKS%><P9_FB3%/M.;I,9
M'C###)!+;L(;%;F(-%P;BYJ7"ZXA:T@Z8Z4TUNU9<)?1NJN:LJXY![&CK!(\
MY=@ZHC"0]7US9;7,6-:P5-%[>&#"84J$+"6R\LDU6;F1=NDX.,(B"K=IWQ2D
M/V^?QMMS7S!RO;LPUD^S9RI;W;M<MS%$R,1S%L#G,$SWPP.(>V-C#/*3I?)I
M)(\[Y9RUWR5RQSC<R9_(1W\G.MU9,$<-I-/)*98 ZY:V0P1QSW+0Z-\KWBVA
M#=4<6L &./=J;.ONOO1+9-BL%D'5WQCG'VNUI:X3-*M%PB8AZ#]VI 6*VZ\;
MM:E97L6\2.!W#4IRE6.H0IQ3*F1/-BY?P6(S'M'!P0P=_P"2<C)*(63Q0O>W
M2!)'#<$S1-<TBC7D'2&DBI).OFYGYDSF ]E<Q7$]P<9XA8N*$SR6\T[(W:G&
M*6>U#8)G,<#5S 0'%S0=(:&_H<SXS7WVF$3")A%K.,W3IR:V),:AAMLZSEML
MUYGYPG]7QE[JS_8D'']E$_CIBE-956RQC/L.$Q[U=L0G10H]?;!U(O17]O:F
MMMUM6M:KM#7=FV-1$T5KO0*_=:U,W6FI.5 2;JVJJQTFYG:\FNJ8"D,[01 Q
MAZ!U'"*"5?ECQ8O%*V7LFE\EN/\ ;]=:74FT=Q7ZK[DUU8*5J=6LLEY&R);+
MM,38W<'1%*_'M55WQ91=J+1%,QU>P4HB!%OM%9)PDDN@JFN@NF19%9$Y5$ED
ME"@=-5)0@F(HFH0P"4P"(" ]0PB^F$3")A$PB811ZRVZITM@G*W&SUZIQ:KE
M-DE)66:C8)@H\6*<R+1-Y*.6K<[E4J9A*F!A,8"CT#R#F;8X[(9.8V^-@FN)
MPTN+8F.D<&C>:,!-!7::46OR.6Q>'@%UE[FWM;8N#0^:1D32X[FASRT5-#05
MJ:+YSMTIU6B6\_9[96JY!.SMDVDU.SL7$1+I1X3O&B;>1D'3=FL=TG[9,"G$
M3AY2]0RMIB\G?W#K.PMYY[MH)+(XWO> W826M!<*=-1LZ52^S&(QEJV^R5U;
M6]B\@-DEE9&PEVUH#W.#3J&T4.WH7BEMBZ^@9RMUB=O=-A;)<AZ5"O2UGA(Z
M<M0]2ATK<2\?(OYP>I@_Q5-7V0R[;X7,W=I/?VEI<RV-M^.D9$]T<7^5>&EL
M?[HA6;KF# V-[;XV]OK.'(WGXB)\T;))_P#(L<X.D_<!RSS*<A)*0F8F.F(M
M_*UUPT:6"-92#1U(03M^P;RK!K,LT%E'$8X>Q;M)RB1<I#*-U2*% 2& 1Q);
M2Z@ABN)HI&6\S28W.:0V0-<6.+'$4<&O!:2TD!P+3M!"SH;VSN)YK6WFBDNK
M=S6RL:YKG1N<T/:)&@DL+F.:]H< 2TAPV$%93,=9*81,(F$3")A%')^X5*IF
MC"6FTURM'FG@1T,6?FXR&-+2 @408QA9%TV%^\$#!\J2[9_*'DS-L\;D<@)#
MC[>><1-U/X;'/T-^4[2#I;Y30+7W^6Q6+,8R=S;VQF?HCXLC(];ODLUD:G>1
MM3Y%XW.P:$SN##7KR[U!K?I1BI*1E'<V6&0N$C&)%7.K(L*TJ]+-.V*9&JHF
M630,F )F$1]J/2ZS#Y>7&OS,=K<NQ$;]#IQ$\PM<:4:Z4-T!QJ-A<#M'6K,F
M>P<.69@);VT;G96%[+8S1B=[!6KVPEW$<T:35P:1L.W85FXN<A)SSCYEF(N7
M\T2CN#EO-<@TD/-<W']WX^'D?"+*^"E&7>D[YNKV5D^T':*'4,Q;BTNK71WJ
M*2/B1B1FMI;J8[T7MJ!J8ZAHX5!IL*S;:]L[WB=SFBEX4KHWZ'-=HD;35&_2
M3I>VHU--'"HJ%E,QUDIA$PB8147Y\?B\U3_3K5_N.V!E0HNW*WM&^Q&O_P E
M,OXNGE%)2O")A%1;G.H-F@M+:73$#EV_NBJQ\ZW'J/?4JJG/8[,;N^G146YT
M6B@%'H ]/+T]D+D>\NZ@H/Z!UE6*PI+P2DG'PD9(S,L[18140P>2<F^<&[#=
ME'L&ZCMX[7/T'LHMFR1CF']@I1PBKSPWKKR^3&QN5ME:.$)#;#\]?ULS?D K
MF!U'6G7@XLI$_(#56R/V7B7!  2*"W36*8>]$12&E&#H46[>T>E7CEY1E!Q,
MI-R*O<Q\/'/91^MTZ]TRCVRKMTKTZAU[M!$P_P#FRWOV*:Y_<,63]UJ!UL2:
M3%.P;FOMWVI, ?RJ K89M9JS+V^@=4#QT8DJF ="E*KY #J.7W[Z=04&[J]:
MMGD%),(F$3")A$PB81,(JB<BU3:]V3QRWTT'N2U+9#?7UQ6*7H0U%V8B>&D'
M;\P^U4;PCDG>(E-Y 7< 8! >@A(;6EOD47;""NC665-4]YG:ZFK)KN)V=2$C
M'V5H6;)LJIE2[?>2<;' D>WUHX)]HZK::A&PG,D4IC.%&R:7L'$!G&:&AW%1
M<-E1O"F6OKQ![)I59O=;7!Q#6B);2C00.0ZC<RI1(Z8.1((E(]C'A%&ZY/\
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MBT+_ /G4_P#]7W_]T9F3_P#A?]Z_T:L?_D_Y#]^G_P"=3_\ U??_ -T9C_\
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MDHN8IX]/J/4#I%ZG5<*=B]76VO2-Z@.R:=!5IZJOWX6/Y]JCWN;7,H=:J3L
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MCM8=,4DH#7-A+QIK5TI<* ;ZX([JVQM-/?58VW)S4U+:IVB6LP\E;JK3Z9>
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MHA1<:;!O*\>D-2Q6E]>Q5-8.5)22[Q>8M=B<]3/K/;)02K34X]54$RZIG"X
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MY,E[N7>P48JNI#UU[)H]4UUF#=LJJD8Q#&$AC%'89'G_ )SR^(&!R61N9L4
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MK0*M%1J)%%ZM>X+'8OEVUPN+MX(\!9MAA[N0S@]S#1!)$X2'08VP.)TN-':
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MOQB\=-D"W6(F%VFM*^2M#3X:'X%GOTJV?\R7/]4C]*O_ #\E_B?\R?\ -/\
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M3*UGCYK*U;<VDSJ3^.L]DK],J-0EKS(.E("->*/?%OJ["KK,4E 3%YV0!,1
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M[2,EW/?<:*4OFF=(2^%D\;#VMP#+AX+&Z6;B&AVHNZB_\1,Y?X[V2(K&WQW
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MYFGE$QMHC-"^Y8([@P/(K'Q&C=M$;B7PB-Y+E6K.Y7G281,(K1\)/ZWG&_\
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ML\W=OY7LX^4L>^ETPZ[]S3LDN'-+>[DM.V.UC<Z(@&AF?.X; PCC.3+!O/\
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M^8WGT,GWJ>]7*_ZRL/Z1%]^GK;U5^4W7WPSKGURQ[N\P?F-Y]#)]ZGO5RO\
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M<TNLI;N3AQO=&%?E)))NDD@@DFB@BF1)%%(A4TDDDR@1-)),@ 1--,@ !2@
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M)>#'2@#J4RG&)?<U&Y1;XU7L6R1*NM"LGR.CJPM8*!%.FM>K=VFKZTD*;KB
MD&4RA765#WS!U1Z]"+(0%Z2B=RIW[HJSN]E197&*M[NV:>]5'%=1YVN:&4<\
M@BI?$Z0#5NE--@H+^&.1MLW=6-V]O<Z'@MU,!#6O+P61M(.D,G9$3IWPC4:N
MJ[HD]CF,B4A'S9-R1,PF3*H B!3"'01#H(>40SF"UKO2%5U<D4<HI( 0%CO1
M>O\ N4U_M'^3R/#CZ@K?=+;Y#4]%Z_[E-?[1_D\<./J"=TMOD-3T7K_N4U_M
M'^3QPX^H)W2V^0U/1>O^Y37^T?Y/'#CZ@G=+;Y#4]%Z_[E-?[1_D\<./J"=T
MMOD-3T7K_N4U_M'^3QPX^H)W2V^0U/1>O^Y37^T?Y/'#CZ@G=+;Y#4]%Z_[E
M-?[1_D\<./J"=TMOD-3T7K_N4U_M'^3QPX^H)W2V^0U/1>O^Y37^T?Y/'#CZ
M@G=+;Y#4]%Z_[E-?[1_D\<./J"=TMOD-3T7K_N4U_M'^3QPX^H)W2V^0U/1>
MO^Y37^T?Y/'#CZ@G=+;Y#4]%Z_[E-?[1_D\<./J"=TMOD-3T7K_N4U_M'^3Q
MPX^H)W2V^0U/1>O^Y37^T?Y/'#CZ@G=+;Y#4]%Z_[E-?[1_D\<./J"=TMOD-
M3T7K_N4U_M'^3QPX^H)W2V^0U9[)K(7/;CM_78YL_P"ZK[GU\Z;*?H#'_P"<
M_A+1V'Z7O/W'V%T)SF5O%X)25BX.-?3$W),(>(C&RKV2E91XWCXV/9MR"HN[
M?/G:B+5HV1( F.HH8I2@'41R];V]Q=SLMK5CY;F1P:UC&ESG..X-: 22>@ 5
M*L75U;65N^[O)(X;2-I<][W!K&M&TN<YQ : -Y) "@6O-T:BVV$GZK]F478)
MH8Y"2R=0M$//K1O>B8J"CU"-=N%FZ#DQ# DH8H)J]D>P8>@]-OF>6.8^7.'[
M>L;NS$H['&B?&'4WZ2X $CI VBHJ M'@.<.5.:N)[M9*ROS"1K$$T<I97<7!
MCB0#0Z210T-":+9F:)=&H]5;;5+U L+52+-7KC6)3Q7FRQU6:C;# R/@7CB.
M>^ F(AR\CWG@Y!FJ@KW:AN[62.0W0Q1 ,S(8[(8F[?C\K!-;7\=-4<K'1R-U
M-#FZF/ <*M(<*@5:01L(6!C,KB\W8LR>&N;>[QLNK1+#(R6)^EQ8[3(PN8[2
M]KFNH31S2T[00I#F&L],(F$7F;O6;I1XDU=MG*L>Y!D_2;KI+*,7@MFST&CP
MB9S&;.19O$5>[.!3=TJ0W3LF*(S?%)&&ND:YK7MU-)!&H5+:BN\:FD5&RH(W
M@JVR:&5SVQ.:YT;M+@""6NH':74W'2YKJ';1P.XA8>Q6VJ4]O'.K;9J]5VLO
M,1]=B7-BFHV$;RE@ECG3BH*.6DW+9-[,2:B9BMVJ8F76,40(41#,FRQV0R3W
MQXZ":XDCB=(\1L<\MC9M?(X-!+6-'I.-&MZ2%B9#*XO$QQRY6YM[:*69L3#+
M(R,/E?L9&PO(#I'D$-8*N=T J0YAK/3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J+\^/Q>:I_IUJ_
MW'; RH47;E;VC?8C7_Y*9?Q=/**2E>$3")A$PB81,(N=G$HOAF/(6),!>\@N
M56Z8A4Y/[TJH@_B5Q41 0*8J71R   @ ^3+SNCX H-Z?A5M,BI)A$PBJ-S7,
MK(:9:45L=0CK:>R=;Z[;B@H5-<QY>T,Y$Z2(F$H'.LC#G()>H )1'J/9Z@,F
M;Z]047[J=:Z*(HI-T4D$$R)(H)D112( %(FDF4")ID*'D*0A"@ !^P 994US
M\I1 KW,OE+ E#L-[;7M07QDEU 0(9K7EZ_+JE$5#*F\7(&[9NOD*(=   Z=;
MV]@*@/2*M1D5),(F$7P=.4F;5R[6$01:H+.51*':,"2"9E5!*7_C#V2CT#]G
M"+2WQ?+59'B9K%VZ*)7LTXO4V\'M$$JBDAL&TG15(5(1(D55F1(W8#]R(CU
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MF5N983G765.8BJUM#BC0_BO2S6A-E[GGN26FX[4/%K?',"O:[T]'Z[FE.'/
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ML</(^MB^8?OD]7/QF?\ XHN*7_VK5]_^^!QQL-ZF?Z1OWB</(^MB^8?OE0:
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MXN;4+V?Q!Y,LGQ6_B/?7Q@L,?CK(S0"'B23]QN1>VT=O*)&F&6:X<(2>%,9
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M^)_Y_@?I[O\ X)/U)?*K^?\ Q]^%6Q_^ZC']Z7P__,\S]%;?\6G]S7Q/_/\
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M<YGG3_N+Y)YCY3R.!LK7*LO+NSEB87Q0!@<]I +BVY<X-J=I#7'R%=?X?_\
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MC>V)]=+B#I=0D=EWHN%0=H)&Q;.WO[*[>Z*VEC?,RFIH(ULJ 0'M])IH1L<
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M>VOH:6OTY>=;[@U]N6TP[Z>T[5-:54CFC,926A974IFS]YL*5K29&R35<UD
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MK8Z[=+ T5).\FMC'^'/(^*LK3'X_&VT=I8WG>X  XEES2G'U$ESY:;-;W.-
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M7O'[3$BTL3![KNO.6=MOK;:%D;J(KBG,; 9JH+-;4\ ' ":405:IF*8.A>I
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MJ#W:&%^^@JM%>O[_ &3_ -/?ZFS;^Q_Y3][_ !E@>T/VGU_V$]?W^R?^GO\
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M#Z25\LLHM[<C8>V=A+1L.FGRGUH-E *G?1:^^N+JYN6X_'.8&M>#<25:XQL
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M>RVM,#)NO[22&22XN)KMQ:&6\#(XV2/: 7%[GME?'$3M>3* UIT]MU :UH\
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MJ0%)(R"KPXE14[ =JL6'BAC$4;SPP^%PJ*T$+6- KTU#!4^7<J39R:XE,\K
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MC5T8N>U:M6+5LR9-D&;-F@BU:-&J*;=JU:MTRI(-FR"12)((()$ I"% "E*
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M6B]-Z<MFSB)B4#-O2&WS!*.V37 0$#.6[,I'*/7]P8G:*/7KDCLC/E*CO?\
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M26TUN#6ASJ:G!K020 L7ZI=J_DSV#\#+'];<R/>+E_\ /[/Z:/[Y8ONKS/\
MJV__ */+]XGJEVK^3/8/P,L?UMQ[Q<O_ )_9_31_?)[J\S_JV_\ Z/+]XGJE
MVK^3/8/P,L?UMQ[Q<O\ Y_9_31_?)[J\S_JV_P#Z/+]XGJEVK^3/8/P,L?UM
MQ[Q<O_G]G]-']\GNKS/^K;_^CR_>)ZI=J_DSV#\#+'];<>\7+_Y_9_31_?)[
MJ\S_ *MO_P"CR_>)ZI=J_DSV#\#+'];<>\7+_P"?V?TT?WR>ZO,_ZMO_ .CR
M_>*S/#+6>R(SEAQXD)+7]WCV#/;=*</'SZJ3S1FT;I334RJ[ERNP31013*'4
MQC& H![(YPOB;G<)/X>YJ&"\M7S.QTX#6RQDDEAH  ZI)Z@O1_!_ESF&V\4L
M!/<6%[' S*VY<YT$K6M D%226@ #I)V*!;_U;LUYOC=CMIKJ]NFKK;>R'#9R
MWJ-@7;N&Z]RF545T%DH\R:R*R9@,4Q1$IBB @/3-OR?G\%'REBXY+VT;(W'6
MP(,T8((A8"""ZH(.\+1\]\L\R2\[YF6+'WSHG96[((@E((-Q(000RA!&T$;"
M%TQ^)>I5RK.^-J.[)4K/7FKC4BC=!S.0,K$MUW'IE6%>X16?M&Z:BW=IF-V2
MB)NR41Z= SPS_N>RF,O^4L?'8W,$T@R()$<C'D#@RBI#22!7I7T=_P!GN&R^
M-YWR<N1M;FWB=BB 9(GL!/>(30%S0": FF^B_2)GQ(OT-3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%SVX[?UV.;/^ZK[GU\Z
M;*?H#'_YS^$M'8?I>\_<?870G.96\6 LTE5HV(<#<I" CX%^!HUV-F=1S6(>
M [25*:/<>=5$V;@'2)3@*1NO;*!O((=<S+&#(3W+?9C)GW;.T.$'%[:$=H:.
MT*&FT;C18&2N<9;VCO:\D$=B_L.XSF-C=J![)UD--17LG>*[% JG7]#:K,A&
M4:$U'K@]Y.S=-H^IQM-IYK@HY-W,>Y0:0Z,<-@.N=WV43E*L)A5Z%$>UY=OD
M+SF[F &?*RY&^%H' NE=--P0-K@2\NX=*5<-E*;=RT>+L.1^6"+;"PXK'&]+
M7!L#+>#O!.QI#8PSBUU4:0'5K0;U_*KH#1='EF,_3M-ZOJ\]%R,W+Q4Y!42L
M1DS$R5D9!&S[R*E&D8D^C%9B-*#9QW"B8*M@!(P"F %QD.<.;,K;/L\GD[^>
MTD8QCXY)Y7,>V)VJ,/87%K@QW:;J!H[M#;M3&<B<DX6Z9?8C$8RVOHI))&21
MVT+)&/F;HE<Q[6!S#(SL/TD:F=D]G8H@VXV\4[$TF$F6EM(SC%S;5)J<(TI=
M/DFIKE']\FX</RHL5DDY9J#Q0BJ9NAB@L<IB]#F =E)SOX@V4D;I<IE8I6VP
M9'6>9IX+J$!M7 Z#I!!&_2"#L%-3'X=^%^0BF;#A\+/ ZZ,D@;;P/;WAM02Z
MC2 ]NH@@[1J(([1KLF-U%J>&7A',/K#7D4YK4Q-6*N.(VE5MBO7[!9$@0L4[
M"*M8U)2*F)]$H$>ND!37=%#HJ8P9HY^8^8;EDL=S?WLC)XF1R!T\KA)'$:QQ
MO!<=;(SM8UU6L/H@+HK?E3E:S?#):8W'Q26TTDL19;PM,4LPI+)&6L!9)*-D
MCVT<\;'$K&S6BM*V.M25.F]2ZXDJI,6-U<)2O.*77AB']N?&$SVU.F)(\J"M
ME>B(]\_$/%*@(@900$>M^UYLYHLKYF3M<C>LR$< A9()Y-;86^C$':JB)O1'
MZ Z L:\Y)Y.R&.DQ%[BL=)BY;AT[XC;Q<-T[O2G+=-#,[[:7TW;:N-5]IC2>
MGI^BQNL9O5U E-=PW<##4E[4H->L0YVP+ W6BH8[(6,:X1\2KV5$"$4#O#^7
MVQNL;;FGF6SRS\]:W]Y'FI:ZYVS/$KZTJ'OU:G T%0XD;!LV!3N^3>4K_"1\
MMWF,L)>7X:<.W=!&88Z5H61Z=+"*FA: =IV[2DEI/3TQ0V.KI35U ?:WC%&Z
MT;17%2@U*I'+M555V[AC!"R\W,W":JZA@433*<14/U'VYNJ#FGF6VR[\_;W]
MXS-R ATXFDXK@0 0Z35J(( %"2-@Z@EQR;RE=X-G+-SC+!_+T9!9;&",P,+2
M2"V/3H:0234 ':=NTUQK[CUH62K4A37NEM5JU25E4)Z2KI:!5D8=[.M69(YM
M..&"$6DW/,MH],K=-WV?$$0 $P.!?)E^+G+FZ"^9DXLID!D8XS&V3O$I>V,N
MU&,.+R=!<=19Z)=M(JL>?D'D>YQTF(FP^+.+EE$KXNZPB-TH;H$A:& &0, :
M'TU!O9!IL4ZIU*J&O:]'U*B5B!IU8BBJ%CH"M13*%B&G?JG7<'181Z*#<JSI
MPH9553L]M54QCG$QC"(ZG)93)9F]?D<M/-<W\E-4DKW/>:"@JYQ)H   -P
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MSOXSD\UW'EC6C= 49<G[_8BD[ D[MI;FT3(,R% O:1!$J;8>P!1[73RF*7J
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MNOYG5U6?U"R6^1O\O#+-5N[6N\L?MR-K:NR+DD(R?<F$>KIJJBJ4#& H@!C
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MBLF15)0@@8BB:A0.0Y#!Y!*<H@(#_8PI+Z815HYBSOH[QFV\_P"\%,7-9)!
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MBASB!2$(4!$1$0  #"+F]H=^KNO<6W.3JZ9_1N0,74>GC*E$!5H-3?G5F9M
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M$PB81,(F$3")A$PB81,(F$3")A$PB814?YE7:=E&=/XTT%TJUO&^7#N.FI5
M!'T3U;'%[R[3:X@8 !218@=FBF;H"Z8N"%,54$^U<C'VQW!0<3Z(WE;>I]4@
MZ+5H"G5MH#&"K<4SB(QL'0QRM6:14BJ+J 4O?NG!@%1900[2JIC'-Y3#E2:F
MJD!047GO=K946E6VZ2 D!E5*Y-6!P4X] 5)$Q[A\"!>@]HRC@R()D*7VQSF
MI0$1 , 5-$)H*J+\(J<]J/&ZA.)CMFL-Z));,L*R@"51Q(7M^M.-55"& #)J
MA"+M"' >H]L@_P#D",AJ\JC/15LL@I)A$PB81,(J2<]8URUTY [/CDU#RFD=
MH4#9J (!U758L)I.&E&W9Z@"C8[::[U8@^U,1$>OD <N1^E3K"@_=7J6\V;Q
MM(,VK]DL1RS?-D'C1PF(BFNV<I%6063$0 1(JD<#!_P#A26MMSZNB=R:VL^O
MY82H#,,3'B9+H85(6P,Q\5!S"(IB54!82*9#'*4Q151[:8CV3CE0:&JH1447
MLXD[@E=I:T/$703(;6U;*+:\V>P<*%%Z:?A \.WGSE]J=1M96B/?@L!024<E
M7*GU*GD7MTG9N*--1MWJTN04DPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3"+EQL&^MM4\Q]K7G955O[Z.=ZWU_5M63%:I\O98_T9%$\O<$#.&*0I-%26
MY,WM>IAZ 81$H& !O-%6 "F]6R:.)/4MC1G-#C-)M?$AM2)CCD-W:[*:C9Z'
MD6RQ1$JB*K*0BD%A.D<! PD Y.H>01#RXT.ZE76WK6M^0]_K6\ZYK?1VJKA#
MV9YOBZQ,3*/JQ),Y-2%H%>>(SEQF78-U3G8F8I,B **W='6(59, $2F+E6@M
MJX] 1QKL'2NG[%DTC63..8-TFC&/:MV3)H@4"(MFC5(B#9NB0/(1)%%,I2A^
MP 984UZL(F$3")A$PBB&P:;&;$HMOH<R4!C+A6YFNO#=GM&12EF"[+Q20=2B
M"[0ZH*IF 0,50@" @( .5!H:JA%11<XM&<B:=K6AI:FWQ:8R@[+T^Z]7TS'S
MRCEN:7C8@ID:U/PYCH&/)1C^"31^7$[7:$H*CV2+)":\6DFK=Q4 X 4=O"W7
M/\K..E:B(Z<DMNT]:.E70,V9H-ZM:'@K]V94P.8NLMY>48))%+\L471233,)
M2F,!C% ::'=2EJ;UJO\ 1MO:W=<V*%.Z7N#"V,MWU&9J^U82(;R!2-7E3AEY
MFH6]R5RS03"0!%EX)4IA*=NV3.(EZJCUJX'A]KH401KV=*ZPY85Q,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB815LV/]E3C^K9_B1/QC_95^X7_P 8
M_P"9?W/_  =K)#ZJH?J*E_$'^M#LS^J3_FB8_$Q_G_\ S@Q^QC_W1[J__9NQ
MEQ_H#TOJJVWTCN76/+*NIA$PB81,(F$3"*I^VOQF,/ZI_P#F%+\;7XS/9>_X
MA_[A_N?_ -IDQNZ5$[^A55T/_6%E?_E[?YDMWXG/LP_S*?\ S?\ _P [_P":
M^,R;O1^V^JHMW_:J]FL/\YROXD?W:_XL/\Y_NR?YU_\ 3_N_^'IEL_54Q]1;
MNR*JF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
E)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>tm2115679d1-tbl_pipeline4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-tbl_pipeline4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!B .0 P$1  (1 0,1 ?_$ .<  0 !!0$! 0$!
M       &! 4'" D* P(!"P$!  $$ P$               8!!0<( @,$"1
M  8" 0 #" T)! 8'!P0#  (#! 4& 0<($1()$[,TUE>7&!DAT5)RDK)3<Q0U
MU998,3-TU!46UY@:(I/3%T$C5;5W.%$R)':W.0IA<8%"0[9X)38GN+'!>1$
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MCPM)[Y."N^/5#6/RY0GW$?\ C.'C:+J[N&G%'A:3WR<%=\>J&L?ERA/N(_\
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MN36:J?73TIA^R<X\LR1R-?RR+JN1?J^I?TG:<0(EP
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MS^Z-\+/M@!US^Z-\+/M@!US^Z-\+/M@!US^Z-\+/M@"]01C9=J=.<Y_[,?\
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MTV_8$5LY*R+T=U^UGD:W@Y7]MI5"1SU&3ERHV^C]#@J65$NN!D4
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M^P?HC.4:?NUL^B_L_P#>RI.OVHQ8_2GD-^U&_76;]V:G[ICN:I^C/0!E
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M[+IQ%09.H]W)PB:32?(0R[9XR2.@XJ@,$0&\.0W$K';&\?+]SZEY6M<3-/\
M%;:O'KEARRI%8V/?-3/N4E?VW$R$+=(S5U.J+?<SR*O.N6N:M'HP:CQ[(RJ,
M>5H\+E-LJ!B#AIR>WU5.T:XCZ=C]T]J'MG2W)V@\C$=GN>TEXVU'2=8F;MJV
M@1VPJQ<.,:*&MM1WZNM,.4G)'\6ZCGT82*DVV,.5%R$RE0&G_#1IS*XC=AOQ
MS[2RG<Y-AS2&C-:U&X-^&AJAJY3C#:^/D9L]&JSNH'*1Z4KM/&YK-%K.'9;8
M2?PJVFU\1Z#0C4I5<5!N1R$W3L_C[L#M\MIZ=MKRCW^)YM]C77(^R,6<6^<M
MH78M'X&:WNC K:98R4>9.>I%MD6"AC(Y.FFZ,=,Q%2D.6@,UW>#YH\J^8/:X
MT>M]H)O/C3JOA_)Z$+Q\I>E*MIPBS6_W#A=K3;$H[V-8;OKBVV"UZR3M<JL[
M/7FCJ,6?+R#GNKXJ:3--&J @NC.1/+/M,IK@MHU?E%L'B<QL/9::=YZ\@]A<
M<X;7,/M;<FS=IW1_JZ&K-6E[]2[Y7:'1:U+TB3FIE!C%&.N>79,^G"&<&3 W
MC['_ &/R4N-9YYT'E%OY3DI=>-_:*[?X[U39ZE5J5,4?:YI6FN/4[7F3JNTN
M+BH2.ER2%N?.9),A5>Y2CIRF13*)$BEH#LQ ^&*?HQ^^H@"WO_#77SZGQL@"
MD   8$Y5_P#*]R1_X";A_P##RQ #S,<3K+VE_(7L5]%\/]3]G+K9>A[HX.U[
M1->Y([<Y>:X3H#>E7G6)JEG:LYIZOTV;V,?Z/%2&7K>&)UG:;G">#G_L&P:H
M,O0?"C;).TUUMQ,I?,;<VBZ_H?L+.%>L=@[8THPH#;=>TEM7<@.0M&K1V-MV
M;3-DP],BI:6B%9:8.WC%)-Z8B35-R@BHYRI0%,UYH<@9SL[] 0VW^;>QZ#NI
MYS2Y+\7[E?>-_&U+;?,SE=3N-6T=ST4D+Q[U'4J/?:_4MCST-48EY.V T"YC
MXINBHIDZ:[I,BU< 030G*#M%K'JKM<]%<<K?S ONR./-8X9WSB:_Y[:PU#KG
MF$PK^_YK8#?=S,T6_@ZI2[%)DJ6KI1_KM.U0<:OF8<HM7C0[?N13T!2ZO[2Z
MT<7]0=H!9U^1'.R^[.TMQ(G=TZ^X:]J;QNK&MN1%9V!6)D]8F-H5_;VMZ[1:
M)LG16)VUP*+V$8%DW+=,N7+=X@BKTN*@D''+D1S[J&^>+DY&I]LCOO\ S9VU
MKVB\MJSRXX9:9H'%Z*H^PECP$[M[3TSK*#@K+HB.U+-3"$UAJ=U+L9*%:K(N
MLE.5)4E >F'=.IX;>6L+;J>Q678-2@+JT9QLU.:LO,_K6]I1:$HPD7\="7FJ
MNF%EKJ<ZV9&8/%F+ANZ,Q<K)IJI&/A0H')KL4=2:XT,T[3_3>H:E&4366M^U
M.VM4Z548?Z29A!P47Q9X?(M6I%WJ[N0>N#^RHNY<K+.G2YSK+***G.<P';8
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M$6N6NEF+KR^,5[#*.I>+BTH64KQ4V_="2)%G ';$    $IG/ V_SI>]' $6
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MK]MJW;JV"MLBV6J\UJGL:@ZMCN>>1C!^:5M>&9Y"2*8QFWT]PIAHDT:%1:I
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MLY;]L\H-M?YLSU=^ALS,_P!F5:1_8$!^R(AUUNZK(]13KK8P;IQ^0 ;0@
M DSSZD;>];_% $9    !K7LGBMK':G)'C+RFLR]H3V9Q.BMZP^KD(N5:-:PX
M:<AJU5*K?<VJ*6BW3N661C*<TS'F1=-<-U<J&/A7!L%*!FJ]TZ)V'2+E0)\S
MPD%>:K8:=-'CUB-WY(FS1#R%D3,7"J+A-!X5F]/E(YDSE*?HSDIL8Z,@:K+\
M#=(.-(\,M *.[U^XO!6U<=KAI18L]'XGG4MQBJ.:7K<MXD,P>6TZS7AS=,F1
MN@Q,Z6_M)F1Q_9 &HMT[$OC7>EMY5J3WKS4B>/7(6S[(O6PN(=3Y%/ZGQO->
M=L+24K=K+#P,#6V.PV3>6M\LM/'@E+*O5E)8W65BU&__ &?-<036^]DGJJQ6
MZN["UAR<YJ\7K\STSK#1&PK=QJW-6:&_WI1M.0SB UVXV]&SFM;?6I.X5N*?
MND6TW#L863;INU"(K)IX3(G0%7;NR&XPO*?QXK^F+=R!XEV_B]0YC5VI]S\9
M-KJTW;2>N;/))6"WTN\S-O@[]6]HP5MMB7[;>IV.)E#XFE%7J!T5UECG8@V?
MXB\/-9\-J/;*I0[%LW8=DV1?I?:6V=P;MNBVP]O[8V'-,8N(<6>[VH[**8G4
M9P4&R8,F4<QCXMBT:D(W;)Y,H8X&O>^^RZUAN;<U\WS1^1',+B9L+<,-5('>
M[OB7NB/UE&[Q94>+5@*D[OT=/TJ\$:66 K*QHQM-P)H2;28]"97>,E(8H&[.
MBM':MXTZ@U]H?2E39T?5>KJXTJU+J[)P]>DC8MJ918YW,C)N7LI+2<@]75=/
M'CM99T\=K*+K*'54.;(&60  'T1_.I?.$^-@ 9$ $0V!7D+=1KA5G73EO8ZU
M-PBO1CK9ZDI'.&>>C'3CI_/#U4-0M+6PU*?J2M7_ &.0\-SIDK;=/2.W)(GM
M_P!K5/ Q=Z_(5"Z6VI2J!F\E6;-.U^01-@V,HO8>3=1[I/'3G/20J[?."Y_)
MG'LXSD?2ZSUL5SH(:N!R/C^ZQ:47%-QOJ]/T'R:S+:5L]UFIYDU)4JI="Z%P
MQ=Z%]!FSAS['+#CET^Q__,5&_+['Y9EO_P#ZR(YM%]C)%S:_0Y:1V"+HQW-S
MUDAV8-<_:!9W,15;]^9I33ZS8CF%[/:47#./9Q_G34L]./9QT?M6*QC/L?Z,
M](A>4$U]A[6LTN2AE31IT\HW1^DR9G73^85[TTL970HY?0U5C=@BKZ%7!<$4
M^_:Q&QGFWL3JYP8N*]0/[6,XSCI_<V&Z<=./8]CI';L0<G@EC%^ORS]'I^LO
MH/#^8?%^?WJS2U*=F*IZ/93=.;N<*&R4B9,G,?/5Q@N.D_6-G!2=7'_M,;&/
M_>,N.>R*3EWJC6QL=BJK@B8X88KN)CAZ3!+*-]?JTN"\C)(W%V&A,%T8KN'M
M_P"!NN'VJ>)^FJ;)IF0DFU73E7[4^.@[)U8G;F=59GQUC8ZS7,AW//1GHSDO
ML#YUY\N#+EFZNJ(UQCY941?0N"88HOI30?539S:UL^2K?1+Z($7_ &JJ_P#$
MV^$1)L                !;Y7ZO<^])WP@ @X
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M^H@"WO\ PUU\^I\;( I                       $FA_J]Y[Y7O)0!&0
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M=_6*G62D0/(7>F_J(4]@B]5,;G'0\Q;=::[I5+-]*GD&B+<\TJ5!$RZ!B+9
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MJ^#84P?^W@_3T^R -NF'AK7Y]/XV !<)[PQ/]&)WU8 60
M       !>X'PQ3]&/WU$ 6]_X:Z^?4^-D 4@                      "3
M0_U>\]\KWDH C(                        ),\^I&WO6_Q0!&0
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MSZA^E5<N*JOTJ9]I:.DH86TU#&R&E:F#6-1$1$^A$T(7X=1Z
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MOJ( M[_PUU\^I\;( I                       $FA_J]Y[Y7O)0!&0
M                     29Y]2-O>M_B@",@                      /H
MC^=2^<)\;  R(                               +?*_5[GWI.^$ $'
M                       !*9SP-O\ .E[T< 18
M  !5L/#6OSZ?QL "X3WAB?Z,3OJP L@                      "]P/ABG
MZ,?OJ( M[_PUU\^I\;( I                       $FA_J]Y[Y7O)0!&0
M                        29Y]2-O>M_B@",@
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MK(;F;.5-EJ[6FTSPR2R7:J6!CFJB)&J*Q-9R+I5/;30FG0;8"+$R
M         M\K]7N?>D[X0 0<                        $IG/ V_SI>]'
M $6                       5;#PUK\^G\;  N$]X8G^C$[ZL +(
M                 O<#X8I^C'[ZB +>_P##77SZGQL@"D
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M(F"(GH1-Q#["AR        "WROU>Y]Z3OA !!P
M  2F<\#;_.E[T< 18                      !5L/#6OSZ?QL "X3WAB?Z
M,3OJP L@                      "]P/ABGZ,?OJ( M[_PUU\^I\;( I
M                     $FA_J]Y[Y7O)0!&0
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MX88<HV-[4>NA-*IK+@F*K@F&9I_BEQ\LJ^BEY/6D6D7C/*(3.C6<))6"LQ5
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M=,Z2-$155C-5N*-75>K5;[**O7X8G,V@         %OE?J]S[TG?" "#@
M                     E,YX&W^=+WHX BP                      "K
M8>&M?GT_C8 %PGO#$_T8G?5@!9                       %[@?#%/T8_?
M40!;W_AKKY]3XV0!2                       )-#_ %>\]\KWDH C(
M                     ),\^I&WO6_Q0!&0                      'T
M1_.I?.$^-@ 9$                               %OE?J]S[TG?" "#@
M                        E,YX&W^=+WHX BP
M "K8>&M?GT_C8 %PGO#$_P!&)WU8 60                      !>X'PQ3
M]&/WU$ 6]_X:Z^?4^-D 4@                      "30_U>\]\KWDH C(
M                        ),\^I&WO6_Q0!&0
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MU\^I\;( I                       $FA_J]Y[Y7O)0!&0
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M0V..-477D:JZO*IZ$9K(J)CI=@JI[*HJZ2B9$!
M                                    #U,=AES0_>>L2/#[8$QW2P4Y
MM(6;3;I^XZ5Y2H96RZLE*155Z#+N:L[7,^9I=8ZN8Y=<A"E08XQC5W;CDS[K
M4MS?;V?^/,J,J$1-#9-QDGT(]$U7+H371JKBYYN1^73/_P!\HW9%N<F-3 CI
M*57+I=%CC)$F.ZL:KKM32NHKD3!L9Z)QKP;3          %[@?#%/T8_?40!
M;W_AKKY]3XV0!2                       )-#_5[SWRO>2@",@
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MM(DY/R?[3EGO'+6LCJ$_TVKO?HFAG+NRXH##K59-)%O]'<I2&>Y/.F0)UO\
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MV-*=J4SXVPNA@:E-1L8JZ(W8-UI<$:CGN>K4TH>50;/&GH
M                                            =6>Q]XV7/>'+:I7N
M(D)>MTO0KUAL"X6>*7.T76>8.X0KE);."E-USW%RFLF\2-C!#PZ#TN38,9,I
M\5[7LR4=DRE+0S-9)6U[5BC8Y,4PT*^14_\ MI@K5]$BL]&.&:-A>4Z_,6=X
M+E Y\5OMKDFED:N"JNE(XD7_ .ZN*.3<6))/3@B^V8:5'T&          +W
M^&*?HQ^^H@"WO_#77SZGQL@"D                       2:'^KWGOE>\E
M $9                        !)GGU(V]ZW^* (R
M     ^B/YU+YPGQL #P"]H=_ST<LO^/.Q_\ [C>C?O(/^BK5_ P_Y$/F5M-_
MJ%>?_D9_\ZFFPEQ!@ *I9\]<H-6KAXZ<-F)%$V3=9PJJ@S(L?NBI&J1SF3;D
M54_M&P3&,&S[.?9'%&,:Y7-1$<[=7#2OZ?6<W22/:C'.56-W$55P3'=P3T?V
M#+YZ9F2.,\=&CTUS.DV.7"N69'1R=S,Y(UR?N!5S)_V<GP7K9+['3T!J,U^4
MP3E,,,<-.'JQ]0Y216<EK+R2+CABN&/KPW,?I*4<C@
M     %4Z?/7WT?Z:\=//H;5%BT^E.%7'T5DWZW<&;?NIS]P:H=?/43+T$+TY
MZ,8Z1Q:QC,=1$3%<5P3#%5W57Z?I.;Y)),.4<KM5$1,55<$3<1,=Q$]";A2C
MD<
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MB(QG^%NMABY57= 0PGX         !>X'PQ3]&/WU$ 6]_P"&NOGU/C9 %(
M                     DT/]7O/?*]Y* (R
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MXR#HQZG3LK?+M://_K#Q9#S<VG=1B^%FXX\C]C_>,WQD'1CU.G96^7:T>?\
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MY4O45]MZ54E=!BK.5D:]C7*BIK:J1M]I$5=5570NG#%$5.G(QD9>
M    O<#X8I^C'[ZB +>_\-=?/J?&R *0                      !)H?ZO
M>>^5[R4 1D                        $F>?4C;WK?XH C(
M           #Z(_G4OG"?&P /"MVMO\ YBG)S_O15O\ PXI@WHV5?T_MO_2?
M_P!Z0^<.VC^IUV_ZT?\ V(CG*,@F+P
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MKY]3XV0!2                       )-#_ %>\]\KWDH C(
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M"HJ)B074LH
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M^?4^-D 4@                      "30_U>\]\KWDH C(
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M-''(]%:^9L.NO*N:NE-97K@BX.U417(BJJ)H*)R8X
M                                    ,S\?-$WSDIMZEZ:URPR[L5PE
M$FIWBB:IHZO0Z6<+35GFU4BF,WAH".*=PN;'2<^"833P=4Z9#6;,%]H,MVB:
M\W%V%/"W'#TO=^JQOK<Y<$3T>E<$152_Y8RW<LVWRGL-J;K54[\,?U6-32^1
M_J8QN+E]*X8)BY41??1QRT%1>,>G*7IC7C7N<%4H[N3F26233DK).NSY<SEF
MF#I]/=9.:D5#JFQUC%13R1%/H223*70K,=_KLS7B:\W!<9Y7:$]#&IH:QO\
MA:FCZ5Q<NE54^EN5,LVW*%AI[!:TPIH&Z7*GM2/72^1W^)[L5^A,&I[*(B9P
M%D)$      !5L/#6OSZ?QL "X3WAB?Z,3OJP L@
M "]P/ABGZ,?OJ( M[_PUU\^I\;( I                       $FA_J]Y[
MY7O)0!&0                        29Y]2-O>M_B@",@
M         /HC^=2^<)\;  \*W:V_^8IR<_[T5;_PXI@WHV5?T_MO_2?_ -Z0
M^<.VC^IUV_ZT?_8B.<HR"8O
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M!9                       %[@?#%/T8_?40!;W_AKKY]3XV0!2
M                )-#_ %>\]\KWDH C(                        ),\
M^I&WO6_Q0!&0                      'T1_.I?.$^-@ <T.6_,3LU>/\
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MJ_\ *M3_ ++#RXVO]=E^-DXP\V-A74(?P^/BCUFG8R>1&K_RK4_[+#RXVO\
M79?C9.,/-C85U"'\/CXH]9IV,GD1J_\ *M3_ ++#RXVO]=E^-DXP\V-A74(?
MP^/BCUFG8R>1&K_RK4_[+#RXVO\ 79?C9.,/-C85U"'\/CXH]9IV,GD1J_\
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M?/J?&R *0                      !)H?ZO>>^5[R4 1D
M           $F>?4C;WK?XH C(                      #Z(_G4OG"?&P
M /&=V[?_ #_6+_A?K3_=CP;F;$?]"1_Q,W]Z&@?YA_ZD2_PD'^53C:,NF#0
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M?4^-D 4@                      "30_U>\]\KWDH C(
M          ),\^I&WO6_Q0!&0                      'T1_.I?.$^-@
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M?40!;W_AKKY]3XV0!2                       )-#_5[SWRO>2@",@
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MB29)O5.ZH;%/RU%,CT:ZF<N/*,P5JZ\3\556XMP5SETJC-71\3,Q^
M              !WF[$_@]G;&Q3\I=CPW==<ZIE<-M=,'Z!L(6S:#7N+A.:3
M(H7JNH>@)G*MUO8*I+*-\%,;Z*X3&"-M6=^RK=X7MS\+C5LQF5%TQP+HU?H=
M+N?1&CL4]IJFR7Y?=G?;5U\976/&U43\($<FB2H3!=?Z6P[OJ616X*NH]#UL
MC4TW<        "4SG@;?YTO>C@"+                       *MAX:U^?3
M^-@ 7">\,3_1B=]6 %D                       7N!\,4_1C]]1 %O?\
MAKKY]3XV0!2                       )-#_5[SWRO>2@",@
M              DSSZD;>];_ !0!&0                      'T1_.I?.
M$^-@ >5CMD>(O)_<G-:=NNJ=";3V%45]>4".1L=2ITQ-0ZKZ/CW2;UH1\R;*
MH&<-3FQA0O3TESGV1M;LBS7EJT9-91W2NI:>K2HE74?(UKL%5,%P5<<%]!I7
MMRR5FV^9]DK[/;JRIHEI86H^.)SFXHBXIBB88IZ3E9ZO'G1^$W?/FXL?ZD,G
M>/LE=ZT//,WS#WEEM"[FN/,/WAZO'G1^$W?/FXL?ZD'C[)7>M#SS-\>66T+N
M:X\P_>'J\>='X3=\^;BQ_J0>/LE=ZT//,WQY9;0NYKCS#]X>KQYT?A-WSYN+
M'^I!X^R5WK0\\S?'EEM"[FN/,/WAZO'G1^$W?/FXL?ZD'C[)7>M#SS-\>66T
M+N:X\P_>'J\>='X3=\^;BQ_J0>/LE=ZT//,WQY9;0NYKCS#]X>KQYT?A-WSY
MN+'^I!X^R5WK0\\S?'EEM"[FN/,/WAZO'G1^$W?/FXL?ZD'C[)7>M#SS-\>6
M6T+N:X\P_>'J\>='X3=\^;BQ_J0>/LE=ZT//,WQY9;0NYKCS#]X>KQYT?A-W
MSYN+'^I!X^R5WK0\\S?'EEM"[FN/,/WAZO'G1^$W?/FXL?ZD'C[)7>M#SS-\
M>66T+N:X\P_>'J\>='X3=\^;BQ_J0>/LE=ZT//,WQY9;0NYKCS#]X>KQYT?A
M-WSYN+'^I!X^R5WK0\\S?'EEM"[FN/,/WAZO'G1^$W?/FXL?ZD'C[)7>M#SS
M-\>66T+N:X\P_>'J\>='X3=\^;BQ_J0>/LE=ZT//,WQY9;0NYKCS#]X>KQYT
M?A-WSYN+'^I!X^R5WK0\\S?'EEM"[FN/,/WAZO'G1^$W?/FXL?ZD'C[)7>M#
MSS-\>66T+N:X\P_>'J\>='X3=\^;BQ_J0>/LE=ZT//,WQY9;0NYKCS#]X_!^
MSTYRIER=3B?O<A"_]8QM<V+&,=.>CV<Y9?\ 3D/'V2>]:'GF;X\LMH7<UQYA
M^\4_H <V_P *^\O-Y8?U,/'^2>]:'G6;X\LMH7<UQYA^\/0 YM_A7WEYO+#^
MIAX_R3WK0\ZS?'EEM"[FN/,/WAZ '-O\*^\O-Y8?U,/'^2>]:'G6;X\LMH7<
MUQYA^\/0 YM_A7WEYO+#^IAX_P D]ZT/.LWQY9;0NYKCS#]X>@!S;_"OO+S>
M6']3#Q_DGO6AYUF^/++:%W-<>8?O#T .;?X5]Y>;RP_J8>/\D]ZT/.LWQY9;
M0NYKCS#]X>@!S;_"OO+S>6']3#Q_DGO6AYUF^/++:%W-<>8?O&1=2=F3S'V1
MLNE4>=T5L[74#9)]DPGKU;:;*Q=?JD'ULKS$X^=/R-&RAF$:BJ=!OW0AW;C!
M$$\]T4*+==MIF3K=;9JZ"NIJB>.-5;%'(USY';C6HB8KI7!%7#!J8N70BEUL
MFR+/EVN]/;JFVUE+32RHU\TL3FLC9NN>JK@FAJ*J-Q17.P:FE4/;KJ'5-+T=
MK*E:EUY%EB*=0X-M!0K/&2F6.1+)UGDB^6*4GTJ5F)%=9X\7SC!EW2ZBAO9-
MD:3W>ZUM\N<UVN#M>LG>KG+_ +D1/4UJ(C6IZ&HB>@^A=CLMOR[:*>R6MFI0
M4T:,8GIT:5<J^ESG*KG+Z7*J^DR.+:74        )3.>!M_G2]Z. (L
M                  JV'AK7Y]/XV !<)[PQ/]&)WU8 60
M        !>X'PQ3]&/WU$ 6]_P"&NOGU/C9 %(
M DT/]7O/?*]Y* (R                        "3//J1M[UO\ % $9
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MZOPY:N^]5L_PP^7VS]X5/ 8/F?OW==)SD@_J,=U?ARU=]ZK9_AA\OMG[PJ>
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M3OJP L@                      "]P/ABGZ,?OJ( M[_PUU\^I\;( I
M                    $FA_J]Y[Y7O)0!&0
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MCQ@55TR4Z:-3Z70Z$3UQJW1[#E.]8P.;*        !*9SP-O\Z7O1P!%@
M                   %6P\-:_/I_&P +A/>&)_HQ.^K "R
M          +W ^&*?HQ^^H@"WO\ PUU\^I\;( I
M  $FA_J]Y[Y7O)0!&0                        29Y]2-O>M_B@",@
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MX]2-L.&+$C]O%S457:SE=H17(O P9S-<0
M SQQ?D]O0_(;3LAH0CA;<"-\@24-LAG.$WLPY=%:FCY/^VFGFOR#%=9"3PJ8
MJ&8]1;"N<)]?(L69XK1-EZLCOV"6A8'<JJ^AJ)CBW_&BHBLPTZZ-PTX$DR?-
M?(,T4$N6D5;ZE2SD43TN5<-5W^!R*J28Z-17:VC$_P!#UEEZ9DT-(IM4I S5
MOE^DR65<,DWN4B9=)M%UT&RZ[4B_6PF<Z:9S$QC.2ESGHQ\]7ZFNO)XK'BN&
M.A</1BB*J(N&[@J_I/J/'RBQM65$27!-;!55,<-."JB*J8[BJB+AZ$*H<3F
M     !*9SP-O\Z7O1P!%@                      %6P\-:_/I_&P +A/>
M&)_HQ.^K "R                       +W ^&*?HQ^^H@"WO\ PUU\^I\;
M( I                       $FA_J]Y[Y7O)0!&0
M      29Y]2-O>M_B@",@                      /HC^=2^<)\;  \9W;
MM_\ /]8O^%^M/]V/!N9L1_T)'_$S?WH:!_F'_J1+_"0?Y5.:>B=^[.XW7A38
MNI9EI!6M6NSU5.^>P\7.(YA;*TPREV^&4NU=M,*+M\=!5.IUT\^R7.,C(U[L
M5MS#1=GW5BOI4D:_!'.;[3%Q:N+51="^CTF*LNYCNV5K@MTLLC8ZQ8GQXJUK
MTU7I@Y,'(J:4].&*>@N&EN2.VM L=E1&N)Q@TK^X*:YH6R*U.P$+:*Y:JVX[
MMC#>0AYYB_9E>M"NERMW292.6Y7"I4SEPH?&>N\9>M5]?32W!CEGI)DEA>US
MF/8]/2CFJBX+@F+5T+@F*:$.VPYIO.6XZN"UR-2FKH%AGC>QLC)&+CH5KT5,
M4Q75<F#DUEP72I2;5Y";4W.WU*VOL^B^)I#6M6U+K=2.BXZ$<0=)IA,IUYB=
MS$MVBS]\QQGI^EKF.Y.;&,F/G.!SM=AMEG=5.H8U:M;4OGFQ<KD=))]=<'*N
M"+^RF"?0==XS+>+ZVB9<9$<EOI(Z:#5:UBLBB^HF+4155/VEQ<OK,YW_ +1#
ME/LVM[)K=MND*ZQN"ET/7^SK QI=6B;==:MK=\_?U9A.V6.C&TFY614E72;I
MQ@Y7#]LN9!P=5$J9"62@R!EBVU%/44L+T^Z32RPM61[F1OF1$>K6*Y43ZJ*B
M;C536:B+BJR&Y;3<X7:EJJ6MGC7[]!##.](HVR2QP*JQH][6HY536<CG8XO:
MNJY5:B(F#*!R#VCK/66W]/56::):[WJQKK'8]=D8>,EF\I^Z;YS)UYZP6D&R
M[B%DXQ^ZRJ1PT,DJ8Q$^MDV$RXQ>Z^PVRXW*DNU4Q5N%$YZQ/1RM5NNB(]%P
M5$<BHF&#L4W<-U2/6W,MWM5IKK'1R-2V7%K$G8YK7([DU5S%15158YJKCK-P
M70F.XAN+&=KGSBBZHRKZ6PZRZL$97,U*,VK):YI<CMQC7NYY0*P2O3N(5?JJ
MD;F,7Z4L11X8YLJF6,O_ *T1&393DN6J=.M/(D#I.46%)9$@5^[CR:.PW?U4
MP;Z$35T$YBVU;0(:-M,E5$M2R+DVU#H(G5*,W,.55N*Z/UE178^TKE=I-&]8
M;>OVH-HUG<M)FOHNPZE/&LT/.RC5M.FQ-GPXPJ^?-I=-XVDE5LNCF/W<I^N8
MW3GIS[(FMRM-#=K9):*UF-!*S4<UJJWV=&A%;@J;B;F!CVTWNXV2[Q7VWR87
M.&3E&O<B/]O3I5'8H['%<<<<38+2W/ODQQ_LFYK7K6UU]A+[^L+*T;1S,46H
M65E/3$?*VB::+HQT[$/F48DG(W%^IW)N1-//="XSCH3)U;#>,BY<OM/1TMQB
MD=%01JR'5DD8K6JUC53%KD5VB-J8JJKH^E236':/FO+=57UEJFB;-<I4DJ-:
M*-Z/<UTCD5&O:J-]J5ZX-1$TIZD/CR&Y\\I.453B:#MO8+1[0X65+/M*;6*A
M3Z1 +3Q$G""<O)-JG!Q*LL[10='*EARHJDCTY,F0AS',:M@R+EG+54^NM5.K
M:Y[-59'R22.U="ZJ*]SM5,4TX(BKZ55,$..9MH^;\W43+;>JEKK=&_72*..*
M)BOTIK.2-C5<J(JX:RJB;J(BJJKIN)<08
M /5-V('![%+JRG+_ &3#93MEV8.8K3+%^D8JT'1W93-YBZX;K)X,B_N?1ENQ
M5QT&Q$E4.0QDG_L:M;;<[_?*KPA;7_\ B0N1U0J;CI$TMCQ3T1[KD]Y@BX+&
M;F?EXV=_<*-<]7:/"MJ&JVE14TLA70Z7!=QTOU6+[O%454D/0R->S:(
M   )3.>!M_G2]Z. (L                       JV'AK7Y]/XV !<)[PQ/
M]&)WU8 60                      !>X'PQ3]&/WU$ 6]_X:Z^?4^-D 4@
M                      "30_U>\]\KWDH C(
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M]1 %O?\ AKKY]3XV0!2                       )-#_5[SWRO>2@",@
M                      DSSZD;>];_ !0!&0
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M+WHX BP                      "K8>&M?GT_C8 %PGO#$_P!&)WU8 60
M                     !>X'PQ3]&/WU$ 6]_X:Z^?4^-D 4@
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MKZ6IIB];<8]&JQ%](0UQ-K@        E,YX&W^=+WHX BP
M        "K8>&M?GT_C8 %PGO#$_T8G?5@!9                       %
M[@?#%/T8_?40!;W_ (:Z^?4^-D 4@                      "30_U>\]\
MKWDH C(                        ),\^I&WO6_P 4 1D
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MG<HS#!G%_P#\J'M/O^]'$7_QEB1>\R_U0RU_TJ[_ /'<1[*7]',V_P#6MO\
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M@F/H3%57!-Q,55?6JGTRC:K(VL<Y7*B(FLN&*X)NK@B)BNZN"(F.XB%4.)S
M      E,YX&W^=+WHX BP                      "K8>&M?GT_C8 %PGO
M#$_T8G?5@!9                       %[@?#%/T8_?40!;W_AKKY]3XV0
M!2                       )-#_5[SWRO>2@",@
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MT]&,?D!D;(TU8VHUOJ1,/[A)))*[7E<YSL-U555_WE(.1P
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MT,:N[R<:*K6)HQ76?@BO5#>L04R.        $IG/ V_SI>]' $6
M              5;#PUK\^G\;  N$]X8G^C$[ZL +(
M     O<#X8I^C'[ZB +>_P##77SZGQL@"D                       2:'
M^KWGOE>\E $9                        !)GGU(V]ZW^* (R
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M-[F.3!<EP;:>E,XSTG*7/3@NH"YS[&?^D//#/G4:'F:CIQ\NVS3O*X_$4O\
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MB1Q1X*Y%U5<N*X+@F&LN/3P8Q,O@         $IG/ V_SI>]' $6
M               5;#PUK\^G\;  N$]X8G^C$[ZL +(
M      O<#X8I^C'[ZB +>_\ #77SZGQL@"D                       2:
M'^KWGOE>\E $9                        !)GGU(V]ZW^* (R
M               ^B/YU+YPGQL #QG=NW_S_ %B_X7ZT_P!V/!N9L1_T)'_$
MS?WH:!_F'_J1+_"0?Y5.-HRZ8-
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M4,UD];5W',<B;CF.16N3UIHQ3!3+HM!?         E,YX&W^=+WHX BP
M                  "K8>&M?GT_C8 %PGO#$_T8G?5@!9
M         %[@?#%/T8_?40!;W_AKKY]3XV0!2
M)-#_ %>\]\KWDH C(                        ),\^I&WO6_Q0!&0
M                  'T1_.I?.$^-@ >,[MV_P#G^L7_  OUI_NQX-S-B/\
MH2/^)F_O0T#_ ##_ -2)?X2#_*II7PBXOM^6&[?W$GK2I1==4^EVK:VW+L@V
M(\>5?6E';-UIV08-EL90,^=/7[1FDHI@Z;<SKNQDU<)]R4F.<\RNRM9OOT$7
M+W":9D$$:K@CYI%7515W<$1'.5$TKJX8ICBD#R!E)N<K_P!G5,RT]K@@DJ*F
M5$Q6.")$5[D1=&*JK6HJXHW6UE1V&JNPES@NRTV5K7::.GIW?.@]I:[KSNP:
MZD-RR$;<JKN[]G+(I&K#MA4(A_(5FX3I<XPT[GENQ;F5RJL8Z2:A4[#1S[3;
M=<:5;LRAKK942(V5*=%C?3X_KHLCD1\;?UL<7+A@F"JF,EKJ?9#=;56-LDEQ
MMMWI8E? ZJ5LL=5JJG[M4C:KHY7_ *N&#&XXN54143$6M^S>YD[9US$[1I.H
M57U;LL:]F:6QDK;2J_;K[$1J)74A*4BE3]BC;396#=F;"Q%6[4Q72><9;]VS
MG&,W:X[0\H6NX/ME;5HVHC<C9%1DCHXG+H1LDC6*QBJNC!7>ROUL"RVO9;GF
M\VMEWH*)74LK%=$CI(F23-:F+G11/>V1Z(FE%:WVD^KK&!)SCMN:N:WH>VY>
MC/6]"V7;;!0J=+(R4$_?/[I5I!6+FZO(UJ/E'5HK<XW>H'*FWDV3-1R3'=$,
M*)]!A?(<P6>HN,]JBG1:ZFB9+(W!R(D;TUFO1ZM1CVJBZ58YR)N.P701RHRQ
M?:6U4UZGIW);:N9\,3D<Q566-RM?&YC7+(QZ*BX-D:U7)I;BFDSO!]G+R[F]
MD;*U9G6T5#V;3C:O.-H/9[9&LXVG4H]L8-9*LQTM?#6]2FFFIIF]3.BP0?+/
M,8R;)TB834R6QS;0<J0VZFN?WESZ:K5Z0HV&99)-151ZMBY/E-5JHJ*Y6HWU
M*N*8R*GV7YUJ+I5V?[JQE70HQ:A7SP-BBY1$=&UTW*<EK.145&(]7;N*)@N&
M:^/O9\2IMS<I-+\J:S:Z/;-)\/=J;^KD=!3T&9)_/U=S3RU.1_;3!*PP]@J4
M@WG''=,-%<&.H3J953434)BSW[/L79%LO&6)(IZ6LNT-*]7-=H:])-=-5=1S
M9$5J8:R;FG!45%+]EK9I-V[=[#G"*:GK*"QU%8QK'LTOC6/DW:R:[7QN1[L=
M5=*IABBHJ&"]=]G;S!VIJUEN"CZA=2U1FHV7F:JU6LM0B[C=X> P<\U*4BAR
ML\RN5J9,2$ZQ3,V2N76,XPVPMG.,"]7#/^4K9<W6FMJT95L<UKUU)'1QN=]5
MLDK6K&Q5_P 3DU?UL"/VS9CG>\6AM[M]$KZ*1CG1HLD;996L^LZ*%STED1/\
M+%UOU-8M^F^ 7*W?5+@=D:VUHVDM>V*R2-18W.6O.OJS"H6"*4*@ZCY7]X;3
M&R$0HH[4(W;9<H)E>.5"(M\JJ&P7/9=\]97L=8^W7&I5M?'&DBQMCE>Y6.TH
MK=1BH[1I7!5U415=@FDZK'LWSCF.@CNMJI$?;)971I*Z6&-B/;H5KM>1JMTX
M(W61-9RHUN*K@;0Z-[)+?6QHSE>SO$,^IVQN/$='05>H'[Q:Z:9N.RYN/CK
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M.!IKN:%W3?E%14Q3</Z        E,YX&W^=+WHX BP
M    "K8>&M?GT_C8 %PGO#$_T8G?5@!9                       %[@?#
M%/T8_?40!;W_ (:Z^?4^-D 4@                      "30_U>\]\KWDH
M C(                        ),\^I&WO6_P 4 1D
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M@;?YTO>C@"+                       *MAX:U^?3^-@ 7">\,3_1B=]6
M%D                       7N!\,4_1C]]1 %O?^&NOGU/C9 %(
M                DT/]7O/?*]Y* (R                        "3//J
M1M[UO\4 1D                      !]$?SJ7SA/C8 'C.[=O_ )_K%_PO
MUI_NQX-S-B/^A(_XF;^]#0/\P_\ 4B7^$@_RJ<;1ETP:
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M!M_G2]Z. (L                       JV'AK7Y]/XV !<)[PQ/]&)WU8
M60                      !>X'PQ3]&/WU$ 6]_P"&NOGU/C9 %(
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M>P9\C>AOY*X_^& >#-N'6Z[\07IAX_\ RZ]1MWX6W^7'IN]@SY&]#?R5Q_\
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M;AUNN_$%Z8>/_P NO4;=^%M_EQZ;O8,^1O0W\E<?_# /!FW#K==^(+TP\?\
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M7#V55#I@,:&7          "4SG@;?YTO>C@"+
M*MAX:U^?3^-@ 7">\,3_ $8G?5@!9                       %[@?#%/T
M8_?40!;W_AKKY]3XV0!2                       )-#_5[SWRO>2@",@
M                       DSSZD;>];_% $9
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M-.LQWZS%1<$7%$VH$6)F        $IG/ V_SI>]' $6
M      5;#PUK\^G\;  N$]X8G^C$[ZL +(                       O<#
MX8I^C'[ZB +>_P##77SZGQL@"D                       2:'^KWGOE>\
ME $9                        !)GGU(V]ZW^* (R
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M2V.)%H9JA8)%=)3-<BL?'CA@YN*:R8_7UE75;DEQ^A^S5X5UR+A*%2-K[YY
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MTCI" 67:'4W6[R9=N%-3PUCJ)\S'053*A&JU%QCDU&IJ2(FG=]6C!44R=?\
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M>[+-;?+-<IZF6@IDF>YU%+#2S-PQ>VGJ'K^\5B8_JXNP3%&X^SQT&6S!X
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M(J8HJ+@NG2BHBHOT*B*GI0J!Q.8      $IG/ V_SI>]' $6
M           5;#PUK\^G\;  N$]X8G^C$[ZL +(
M  O<#X8I^C'[ZB +>_\ #77SZGQL@"D                       2:'^KW
MGOE>\E $9                        !)GGU(V]ZW^* (R
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M (L                       JV'AK7Y]/XV !<)[PQ/]&)WU8 60
M                !>X'PQ3]&/WU$ 6]_P"&NOGU/C9 %(
M         DT/]7O/?*]Y* (R                        "3//J1M[UO\
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MK7Y]/XV !<)[PQ/]&)WU8 60                      !>X'PQ3]&/WU$
M6]_X:Z^?4^-D 4@                      "30_P!7O/?*]Y* (R
M                  "3//J1M[UO\4 1D                      !]$?S
MJ7SA/C8 &1                               !;Y7ZO<^])WP@ @X
M                     )3.>!M_G2]Z. (L                       J
MV'AK7Y]/XV !<)[PQ/\ 1B=]6 %D                       7N!\,4_1C
M]]1 %O?^&NOGU/C9 %(                       DT/]7O/?*]Y* (R
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? =Q5^24^ ;V@!]$DE>ZI?ZI3\X3_ .0WNL?^P ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tm2115679d1-fc_highly4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-fc_highly4c.jpg
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M 0$              @0! P4&!P@0   & 0(#!@4"!@,! 0    $" P0%!@<
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MX?%0_]H # ,!  (1 Q$   'W\
M      !P9Q&_1YD<=#DZA;I8;=H_,LKJV[75NR%S^G)_-ZW>A,
M                                        :O9JUQ]#Y:"^WYW$;JP
M  [D-LS\?OV0\[ZK?J/0
M        '5E&K_I?)5P]%Y3KRU@    #]QF=.)Z2V?E?9YG5N
M                                    U:S4I%[/P&B7^6       -AK
MW+M>,^@2-S^D                                             !IU
MNG0_W'SG7[%,        =V&V[GB_H,L<OL
M                   8+=HH#[SYKK-FD         ._KW7U\-](WVCT
M                                        /PHM[;Y[%'5X8
M   VVI?]!?!?3._"8
M@GM^?II[#P(           LGYSUUKO+^P
M                X<X\[/H'S#5[5$           =J&ST7^??4M@T6
M                                     !"W8X=)_9_/0!5CD=_6=>VS
M72X^MZM^HZ]N8Q.!*=Z;K5.J5#I;[9HR&GN=FI!G/ZLA6J77C+-;:\!T>G(E
MBK<OM^; %H/,^RM#YKU@
M  I/[+P4+=GSP J-QO1:WJVY[*/J?0C+3ONAV?/ZL:%S^O"T$N7N9GM=C.3U
M1QHM;5MT2)8K0K2O[YNT9*>NU?:\X -QI]+T0\!],
M                       ^6/-7Z+\KQ6ZL            !Z._//JNR5[(
M                                         U6S5\Z/H7RL  "HG)[L
MCV*>.AMD:Q4XH[-"U;MPW:,WG&I0GP0GV,N_LTY!G7X2TJM>LQUN"  +P>*^
MB3#R>T                                         (PZ7*H;[GYL
M!Y]<#T\O7*&B4.MK<-F3S&O-'I6_Z_"K-RNYO%WF3MMUQ#6MXR>C&5[ME.GQ
MN,LSV?.@ "W7D_<6'X'I@   !4 V\S).Y%1KY'Y;4%6B#R536R)CT5-H  *W
M$B$FE;BR(!3\FLHF3X7% *E%M3R?+K%(R5S;#<#A-T)%) *:ENRB)?TC(C@L
MH          "(NKQ:-^V^=@  :5IL=?&=CG"&J71^\2W^S1AZIT)+W5]HL5,
MS*'3Q+C8YV>U*'3Q+.[-(  M3Y;VMF/.^I    'C68@W4Q)7\WXZY;P^C(%W
M3R&*TDKF%) .X5@,R3H=@G,HP:D6P(J)W.X7V-=*Z'"024]/0HL<>8Q>P\]C
MT2!Y;G])948H>=\[9D"K):<WHJ&6Q*G'J>7".V        "*.IQZ*^W^<@
M          "V'E?;V1\]Z<    5 -O(E*\$'GIN5E/DOX1(0>;41L3J1P;0;
MT5C.8L41,=XC(ULF R1B#LELRB1/Y78P!F24CT *:&ED/DH&;+/E;R8"OYO8
M-?*[&\D[D+&!-C+N$@';        !HMVCY\>^^7@            "Y_CO?SE
MQ>^     !5DF<W\%?BP(                                .G*/F?\
M1_DW%*.0U[^W"75E''[-'YG           ]!/!?3M]H]
M                         #\8Z>W37#T7G\3MQUIPZTH]B,NU"?1EIQ>R
MMJEGGQ[T.28    ^\2D3G=;;:/1S=6UD-._[Q+XSCH[M&+WUK>^8]CSXD
M                                    !QYCB;53%V*W'*$5]&E#_3H
M  =^&S/UMVE6N3%G3X?YG  &5U6)EX?HM[Y/8Q>(]?,0 !M-7=)/.LY"6W+S
MW]^6T                                      8RQ6P=RC\9B!CMD*P
M]_C\6<   #MPGL-7;#'5\YH>)<49YFS3F_D=R3.%W\+G6   !*_*MYK1,#NR
MV;!LM]J4P   -=.8S@!@S.  ^#$F9!B3(', 8HRH !^&',R84S0     !C#)
M@ &IG4-W-7,H90Q9E     ?+&!O4,;OK  "&.KSXROTP  !BX3KQLA%'KO(=
M#T'G?W=I_.-V99\5[*T?D?32'+4   ,[HV2IR[3  ?N<Y[99S$[  %&2\P/#
M8E$E(P97PGDL&5Q(P,D6C*&$Y&/.^8 E,C ]0#R +B$@%<3 '?),()/LG\KP
M0L>Y1Y0F*,"3\8HP9*16 R)Z:D!E(3'$Q&UD*@THM>1@1Z2F7"+E    'RQK
MM_G='=H   Z4XUH[W'Q\X@ #5].^GOI_,8_Z7\Q_)1  _?+>JN'\:^MSKJ
M#[QF6N5;RFF0  &8V6,_LM   5X( -D-@-:)/-I.,KP;R:X=LU\[IM!T3D-H
M)J*>&Y$O'&5:.<ELPIM1'Q'YL9?,JR8TBTA8L^:X65*KF^%JBJ!&QLQ(8(@)
M.(E)*)%(]*9%ZBXH   !K]WGXVQ6    TRW7@#L\OY !U,9I/U^1A_K'R4"Z
MGS7Z7._E?5>6GW3X4!^^4]7?GXK]?W^6H #?Z%C<J6X   #.;+.;V60
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MJ\M?_P"2_5_-7[3\8 X/,>H]3_@WV:6:>SLPR      !RYEN._H?H
M                        .EMT:UT.:       !P,^4?3HQG]_^  6S\![
MW';M<$>J\M?_ .2_5_-7[3\8 V+YG]*]AOCOTGZP        VC==[\MH&AF^
M    A0FL   $1$I';-9,J9$_"&29S432R8C13>@#3#Z-Q!P&#,$8$EXC D\$
M8$G@T(BTW$V,WLU0VL  &%MTL/:I@       "J->SY[_ '3XCS^F\QM=#H>F
M_P 2^UT_^A_/8(]5Y;UH^ ??/.;['\?@7U?D_P!U[+C?G']!7CX5T
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M!)3]'=>CQ(VVO6B%>QD( #[SG=-_1
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MQA3N6RS6(9=C?,8@V4[-8A#"4]XA>37J &1GNV;;<
M            '1W:-;O\T         =7$,;C2  ,[0O\-/( P.<X\Q9LYK!M
M!CC&&>.8@;,I&QB3<1 &>V6LSLL                               #Y
M8U+J<GXS$        #Y,-&O^, #[Q+/\GH]37         !EMVZ_V<S
M                           PENEB+5,         8W&GJX@ ,Q7MN;M_
M,         .[+9M6Z\                                .*4=4Z7*^<
MQ         X4<5'3^,#ZQG8.7TNII@         -GW7<A+:
M                   !BK-7!7*          QV-74QK&<J7N*A)@
M !D)[MGVW                                  -<O\ .Z&ZN
M !\F)CH[NK=W>7:X(Q         Y<RVS=>YLR
M           ^<XUJ_P WJ;=(        '+KGR<JQT=>L        #ZSG:=MW
MN2V                                   ?.<:]>Y_0W5P       .YJ
MW[%0Z'#'&L::7#B(       ')G.S;;O=EL
M          _#$V:F&MTOG.      /UG,5+F8JV_UD<6(ZYKJ="&H      #N
M2V;'MM]C,P                                    !PRAB+53&6*WSF
M(   '[C.2T6<Q5M\\-@  QD-.#A6Z\8     <V99O99RL]_Z
M                           ?&<='=HZ>W3UMFKAE'YSCZ.6$^S#9W-.[
MOZ=_WB0   'X=&.K&0T]&.O@Q  #FS+NRV9*6[(SV_K(
M                                   '#B/3CK^&/MGMRV<^9     #_
MV@ ( 0$  04"Y44432(\N$ STXR,@&E<ARQM#>Y\1_.K!I/(4R72&1@TTN\
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MEF$[&6BT05+@OSRJ?D&GURK<99^RV7*MT>.[%;/ (V%?+>/FT9^>53\@@;-
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M\(W3Z"<AN4]P\(H7;M;E],OA&Z76;D5=+H'P8AOHQ>D4$?4%0_6/@R%$YB$
MA>11 !!5(4Q\&5#UM+?I\( "844@2+R.( (*H"3P22(J:*4"@HD54#D,F/@2
ME$XHH@D')2C;?0@(#WOQTFVX#$*<%4#)^ 31,II-,J8<F&(4^CM1#0@(=T "
M.B-C#HB92<:C8IM'2.GWA$SGTFU*'*(@ Z,V3'0M3:%!4->FIKH/KTSZ!!4=
M U/HK8@: H%[LS9,VC-#AH4E"\0)G-HK50=%;)EU\.:C=&A^EU_Q-!]+HOI]
M[__:  @! @ !!0+E0 $=%:+FT6/'0,$M?1(:^B0T+!+0Q^C,URZ$IB\SII**
MBFP*&BD(3N1*!@48IFTJW52YC !,*+'0  !WJS(A]'(9,>7TDCK&10(B'@%$
MB*E7;F1'EU%$RQDTRI%\$8H&!RW%$>6TR&4,DD5(GA#% Y5T11/RTU0](GAE
MD@6(8HE'EADCUG\0^1\N5_CI%/TD_$" &!0@IGY69)]:O XW%10IV^@5**GU
M">Q7)!,@(B=X90IEU?Y(G-]*!$MS+>FX2]0XK'/L90RYUQ$IDR& P;&50-_.
MX'Z?*[$G2CP.3 1158K@#&!%T50X$Z@%9O\ U%?-RD4PF';Z0%F6YDB*NTU!
M0%0-F1TOIA46VT7TS+I)D.HA_)4X%R=:/*Q"]!/%JEZ%.5$0ZE>-051<$(L!
MOJV^CJII@19(^@=("*BR26@63,!%T5!,Y1*/U*'4HLFEKUDN@CA%0R+@%%.)
MZ&R_*C0-W'&L5(SI(K4ID0#Z0HE*<#D]98YA2 Q".?BCL!C$ -Q /H3;@Z.4
MH(+@ +("'K<4@'\SE1E]QQF3(;0)IE'I* *IJ#I%$2#Z26E$E1,BEZ9033*/
M277038Q"FUT$V$H#KI+U<4A\W*C/[CQDA\W*C<=E_&/AW6Y4 =A#S#7477J)
MZZR#XAR;J7Y4 AM)@J8GH$'7H):])+7HI:^G3#72L77K+ET1RD;O#.D2Z%Z.
MA=+CKUE]>JMKUE]?4N U]:8-?'E+;?0)Z  #L0'N#%*;0$.GHKD-^(YRD [P
M1T83'[A4?+6^M^3RDWUMMP%'I'X]R)0, >HAHBQ%"BNB&OJ$= <IM*N]M#N8
M>Y..YNW?DTI-N- WEW!C 4$$';W2, @&B1<>31H]B;2L$P4TYA';?NCFV#BW
MY**7;N 'I$H]0<1S@F$?$BMH   X7\6B]!1-1!3C.;J'C >2"%V[I(_2/"([
M!$L_JU>V?>+HZB7S@CSME6 /$0XE#]T'(Q"[]XDIMPJ=2AD$2MT>U\P1?D8P
MJ#-7@F6WT[S@4/MW@<B!YZ -N]35VX(A/U9+L= J+=P,VT)"+*KLW B5NW<2
MSL\41^1/LGDNMEVG4Y13#OR*"313@;0_"O\ ]?ML?V5?^P=?;5S[WMEO..#X
M"(!HRF_?AR& ;!W^^V@6\J^</JNVQ_95_P"P=?;5S[WMF3=,<*NVA$1Y2('Z
MO!1BWT[[ML?V5?\ L'7VU<^][;&N )^"#D%/P9@U%//JVNG2HH-WTLL_2K_V
M#K[9B].P5BGZC]/1S%3+(.A=N?!!R"G\O#N'?,W:C%=NX2<I<<U*@MX0.02_
M+P#Y !0V^774;7GU]7EN;6_D83!KJ'8#:$3"7M$-]-7:[%1G+-7?"X=MVI9"
M75=@/#MY[:VUMK;6VMN2B_+P?'7Z@UM^G]0AY]6PZV_5L.WZMQ 1T :_5MPB
M72,@^; %@>!K\A=Z5F)!;0[F$?@/ .@U\.T>(>1B_+XL?ARJ3Y>$/B;S$0Z=
M&^8^AVT'I[Z$H;_#75Y=6X]T;Y>'RUMV;=FW;MK;D=/A-\.CR\]#N;6WZ@ =
MM=6MO,?F^4?,-%#I[M3X</\ #@#@_B/"'()/F\6J/GX0.0@\P\48=QY63'Q2
M@[!X0.0P'8?CXDX[CX0.1"&\0H;PH<C$-OX8QNG0^?+A3=7A##MHP[CRZ4^_
M@C&VT([\P%4\ 93AV\!MR< B&@4[P5 T(B/'MWVW*0*#KU UUEUN&MPUN&NL
MNO4#7J#KX]WMK;N-M;<V>6O+7EWW_]H " $#  $% N5/AH[QL31I0FC2BNOW
M)QK]R<:"36T64#1'S8^@,!@YF4631!63'1U5%>Y*<Y!2DE2Z1<HK\QB(%!Q(
MZ,8QQ[UO(')HBA%"\OK+$0(X=*.!\ BNH@9NY(X+RZLL1 BRQUS^"(<R9FCH
M'!>6U%"I$77,N?PA#F3,W7*X3Y:>N?6/X9NN*"A3 8.6'Z_I)^(C5^6/AIPK
MZROB"F$ADE 53Y6?J^FAP-.D$DCI.M"B8J/TBNYF:A2.BE*DP(D8C9#_ )()
MD^M%18 *AZK1P*296Z:>B)$;)MBE.150@IF 2(N2!]-P1BOERM)*=2_ R*8Z
M*"!FIBD,Y9&1(8_2(-W?]% 1!FL8@%#?Z\4)$0*L=!@JD#H$C ,BFM]8"+<1
MT;U2M7"JB:+K_D(\#13TW'*RI_45\6D?U$N5%C="7&D5$&JBC<Q?H76DT%53
M';+IZ%DZ $FZRP&;K$,HU72*5FY.'T;GI2;K+:^F6]11JND5PT%%'B8#NVY4
M>CTM>-N98K)8[PY')C?7' QDA34%N@F0JPE449_!?<Q"J".BB/[D38629C"Y
M;&,9!T _3\49_1Y4?_:\955" 994P"<XBBLD&G#D%"^NOI)9$I'*_K*&55,'
M6<=>HIU%.<FO44Z@,8H=9^GBB_Z?*C_[7QD7_2Y4<ANW\9'%V;\J"&X&#I'7
MI*Z]%;7I*^(:EZ&_*@J%#1_1 _KGUZRNO54UZRNO74T/H&T+5L?2C)<G=@ B
M)&+@^@8)AH&K4- DV#70AH4FXZ^E:#KZ!(1Y2$0#0JZ$1'L6#N ,8NC"DKI1
MD8 XDTE%138D+HHE)K<1XR?'0''0& >3S*;:$1'@$-P[D!$HG*DYTHW52.#5
MP;7T;D-"FH72+'RW H=R4-@[0,(: 0'DPQ]^-4O<E*)A779LM+6!<='E9 ^B
MR+XFDIU^GIO,LW.A*(=R4-QXBGY*.?J[@0W 0V'B(05!D)8$-"(F'A82JS,2
MF353XP#;N"FY(.;?NCDZ@X0#?4L\^D2[8!FBJ$LR;J,^V*?_ $:QB](\)0[H
MIN1E#;=XH3?A3Z4RKK&<+=K&068'?32SQ+@B7'U++@*7O"COR(([ ([CWAT]
M^"74]*-[&@I%<M_V5V><121>-@ SEPA%-"2JC!0_9 *]+SM O>@.W(BH]^8@
M&T)1+H/C8!V;]M=^]L/WS3[JQ?9=L1_<3?-H"[=^0>0Q'<? "EYSY?\ B=M=
M^]L/WS3[JQ?9=L,432/3N/@ \AY!..Q?!2*(N6';7?O;#]\T^ZL7V7;7D?U>
M"+\.0%?!D'4LS^D=::) NY91*+%6P_?-/NGK)-\E*L$V!]$(90[5N#1MX(G(
M*GS<.P]\Z:IOD'#=5JKQQ$;],'@R_'D _P W 4-Q$P[_ #:Z2Z\NCI#?8FW3
M^HH%'72&XET % P_'L =M.6R#Y-Y$.FO"W:.'1F$4BR$WQ[1'81#SZ="773K
MIUTCOTZV[/+;A#X\@&^;@#RU^@=;[F_24=PZ1,&M_P!'4&^Y>D! -".MR=7!
M_$JFVEF;%R(P+$=?L#+247&HZZ]@+\QOCVF,.X:VZ0_CYAH?A_'80 ?@'8;X
M\BG^;B^'?#QE^8?CW8COW ?'D!3YN$?@3R #=6B?(GH-]#ZFV@.;I^;73Y].
MP=H_'B3^?@#;;RUTCK^'2.MM] 4=]M;>>VA+MQ%^/("O"7;?U/,-M!L76_Z1
M$.KXZZ==7D'R^1BCL(F$#!VCQI<(;Z'X#V#\=!OK^&O_ )_^C>7"3X\@*!^G
MP@\9/(G%N/9N/&/GPDY"$-A\3\=#X4/(.050\*/"D'A2AN/(0AN ^7A!X?E#
MPA0V#D-0OA1[4PV#PA0WY&.7;PQ"]6A'?P@!OH VY&^.C%Z?" 3KT/EX4H;<
MD?'1B;>"*03: -M"&^A#;P7QT!=N2S)^ *GP;;Z$NW@ *(Z -N31 !T*8Z^'
M=@F.@* <8D =" AW@ (Z G*0IEUZ0ZZ#:Z3:V'72;70;7I#H$PUL =V)0UT#
MK8>+8== Z @<U^6OT:_1K]&O+O?_V@ ( 0("!C\"Q4@%=!;SE:2LJRJPE;KE
M=%0=8<9]P*-4Q4&"',P=:%N;I6\+,8X"]35NY0%W/1IV.4K[\8)6JSBS]!E>
MO[,7I6J5O0Y77*(^WBY(V]2MZ+*ZY0_3BW$\9Z/*5*;\69SPCI/K#MQ8@$&=
M)E-R+#DQ7FR-P6,!(!)N7JM<XMR@KTLL$XG])0:0X$YPJD?ZDV0G+X(%G$Y4
MR7&UU\>M65G1^9.G.Y*O6J6#(%4>TF @-J]*B8-%YV)E.8MIY_BIJ;YJ66)B
MG^I4<V!_J@BQKB^G#!%3LQ7FRG!IN==$KT:-I/@IG\):JE1E\R9![G[RJ?,J
M8^;4BQUU,'Q5.;AGVJR6/R_!$/NE1HU;@+.I1/$;>\KUJ7#E"#B(^W(33[;M
MS*K. =Y'VYZQ@EN*X;F'3"W3BJT:>8])CI1+&Z*B]\1U+BUJ9YL6Z5":U0>8
M%%P-@4K#:H$VJ6:U;Y@O4CN*5AM3F]V'UXJMYB%;AD\U]*$W6JG:J3JG#Z?B
MJKV6ME0WF0S!/]7+"'4JAI\$_@F1J@VV;NRY5BF]?FG;\ET+-J,KIA.,D%2A
MG5099L,'1BJ.8BX E1:T ]2E $$!3EDS$6(N?"8YKEPM[ENR%F9PN4'6DE1:
M "KKU+ 2K> *E@)5$WA30$V&W%4=-;U8JMZ^FPT8JQ4>2\+B"O'2''3BM:\P
MT+>B>U7!<(7"%NQ':MUY[;5OM#AH4+G:><OB="W&]ZR!<:XRN-9"MYJCBE8K
M59R2\Q!R^B;,QN4M7==X8<7F 4*0[2OJ$GF(8I6JS CS4'7+<WJ>;8I@5Q!<
M05A"EI6N\%,^UV+=M^'+S,77+_CMA3_J-W\]ZF]PYSW]PVJRDWMMUJVDSNAJ
M6X"PZ#MBIJ/U*>B_NV16GF=.*.GF(A1&'$H>Y]]=D;MV=Z@+L*<;ON,^W^8H
MT:PA4&+$<O-6W845^[K?9:=T9S\,!E"D2T.$3L3*9<33>8$' F9_V&W:=&S3
MVX<HQ0CSDKKL%M!G&XP3:+.%HP):ECA<5ZT2^H+M&#ZC?MU+>W+M[<& Q0@H
M<[!UV!,;F-)\O/E>*'WI3#K7J>X<]K(PX@=14]9Q<Z<W]B>YMX8=2]/V]1[G
MPCQ0UIW[^,\;(D'5R^IE8X>-FS @W%&//Z%9R57:!@-_*/\ 5R_S/DJGR.U)
MWXC_ +-P*O5YCDM4!=BE#H%B@Y5&9V1[C\<!OY1_JY?YGR53Y':D[\1_V;@5
M-,-84 K<96/=PQ@>VS ;^4?ZN7^9\E4^1VI._$?]FX#/;Y8S>0\^[%2/1!'[
MK;#M[>1]9M[6DH4JC6@!T;.W:O\ ,^2J?([4C5I@$EL+>S8G/J "4Y.0O?8T
M!.K&XW=63&CU6791G"%:B8M/,?MO;GZ(O.<[->+A"B;N004,O)D@M*M6C!GH
MFS*,A4(R5LQ\CEUX,U=P&ON1IT=SV_B>O9S^C$V",;U#)R!17:HP45=!2X<*
M50RYC;K5K:9[]JL93\=JA-*W^W;?XJ9YB[H&C^'\R"B%%038W*R_D"@T**LQ
MFLY 5!:((Q05Q65!:%'*H=(CRPQBA_$F&.4<<X=(ABWIQSTXYZ>A:<8;>@68
MQV*WG+%;_P" /__:  @! P(&/P+%6UUNA;C3_/>MUK5^E?I6\&K?:KX'2HMM
M&,\:A@H41WKZA)YF+"05"IO!;AWLV,<3<I:'?L4SK3STM:UOC\5,PQ&,$[U;
M8S-T&9BLX\V+T[U._H<S+'*W[@Q<+W7!3NZ+.R\*87Y<6Y6_;'1YQ=E4S;CB
MS(WC=JZ3Z#NS%DOR=)#VWA"H+CBO#*ZS!JO+6N+0+^U>@]C&O-Q 0K'A)@F
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MR8 7'<Z4QR(YI=VWQVJB>'$H4J6.?8VEE+N+64*,D2.6;,Y;-D:*CR<B+'C
M&)B;E\&:^_B1)K*:JKI$M=94B!71(AI*[G/UD%CA&\R[W*OF5?%>)3@Q8PG3
MB\^:HP"8LPRB8!2RE:U.H*H!-9N=JNUJ)[$X%6>G0/3@<CD5_21^B#TA&&B\
MJ+R^0/IC":X>C?(YJ*GLX;'MZROM0,?S& LH4:<%A-%3F-')&5C7Z+[?;P.
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MFE5JK6!%DM'NCY%';NV?3RXSG3"KX^&G'<3N]):Y6YKD)*G&7/UT3$,75U;
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MH]I!FOYY(L:8=J**,J)M&[S:?AX[&VL>74,C]L^L]>88\QII?45E-#9Z0UD
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MD/%:89$JHCWRXT5P9#R2B.*)B.&BHWSN]V1]K%L<<^L%OD"VL:9U=GZ.R/\
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M<B<J7$75=?;],-^S7\7#6#TV,:C&HWV(UJ:-3\2?>EJY=./(GXU_P<>957[
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M3'?N<37?&9O_ +3X$[^PI/\ Q"LX;_94/_:R>*;^U:__ ,V+B#_;L;_A]G\
MO^I-_LW<4KEUU6JK]5=[57I1(J^/MU7C8-JN=\GN^55]B)PCRZ$+_D,_!\:_
M+]O4:^[Q;^_\&Z!6FFG;?9-=Y5+6<0!'#L+Z3U4P,;D1HR,AC)_1M=O>B>US
MN,XHWI8R,=SVP=:66.FDA;55E@78^1)H6QHL>77/D2A,.OTI$:4;59M1-.(N
M0DR+.,LL*R/(C47USR0EY'QX,H?(.E,#IHS8JOB_1:KO7E^'%Q'=;YM I+B3
M(L%Q6NR+E8M76THG,-<5M(>%)BBGJJNV\SF"&CO*Q-&[8V2%MLMQ^U96LI;
M^*7Y:/UZF852I5W7)"]\B(JN5%Y:B>K5T5WE;M9V^_K?T>-='R"KF,FBCW-)
M:EFFFBDU,V+$"R,Z$Z0Y@M1OT&NCMWMXR>LM9.29@;,(T:%?7F879K>_E0X+
MN971AV+1Q5C#KC(CQ<MK7(]K555VMTBY"3(LXRRPK(\B-1?7/)"7D?'@RA\@
MZ4P.FC-BJ^+]%JN]>7X<&Q[(HY#0B%#* :,98TZOG1E5T6PKY3=71ID=7+M=
MXIHJHJ*U53BZLBW&793?7=2:B/DF87GKEW%J3L5I(4"2^*$,<:KHO]&Y?*GN
M\.*7&*TLH\"BKP5T0LYXB2R CMVL=(> $8+BJGMVC:GR<0+LEOE6+Y#6Q"5\
M?(L,O"45QZ:4O/?7ED(&2(T12N5VBLU17+HOCQ38^"1><NHS*LSPMF>P'+N;
MO(ZR4V4R7>3I<4_6))4;6%VM$[8U$:K>);GS;I.L[DUO=$FR1!33(*L< <>&
MS6N=I3O2N9O&NIEU70J>&D_.&&FK;6./P<<-'<0'I[8-?-DSPE$)(R24E.-+
M<CE4JLVZ>5/;QC%4&;=.CXGF<S.:YY9$%3&MIQ+DI8\US:YC"5S77A=K6-&3
MRM\ZZ+NRW#&R[=:O,IF33K,[CP^O 7*BE-8-@%2 D<0PN,O)Y@BJU/G*[BML
M0Y!FV,64"@B8Q(L,2R#T23=TD'3IX5VK(91RV)[]K1ZZ_$C=N3=O8LO(DQ_*
M+5EU(5]D EC76(EJR#/5SG0=XU8>G"3Z9#^=%]RZ<5$UN7=PZ7(JNGCT4G,,
M?R?TK)\@K(GB .1S105C69&/\REY+"N=\YRZ)Q&Q^A"4<*.\YWEDF?*FS9DH
MKCRY\^63Z25,E&<KGO7\":-1$29D?K>9XO8VT,%?D'U/R!U+'R6%'9R11[P/
M2R4EC2,O*739J/PX<4<20V [MY_=BZCY[?2EQE9AIK]= ^H^HE?(<CC=1XHN
MNF_S<5!)66]R[7ZNS:^;C8K;*A3HN/+6R@R0QZF(2KZ4$5Z1VC<U6N7EIY5:
MOFXN+)F29_10LBE%G9#C6.Y4>KQF\ER6HR<>QK6QRN>^P1/IMA&;N(UG4WN;
M8),!45U"0N!Y(6@ZZHJ!J&LA3V+'F,..$%=K%\';43Q\.(&.4,=T:LKF$0+"
M%)(,0AS$DRI,F09SB'DRY1GD(Y?:YWQ>'%O:!R#/,=!D4E\S)*'&<I/58]D$
MHR(V2:TKNG/S'RTUYFQX]VY?>O&+9#$25"+A]!-QJFK8KP-JAU<UL0:L*%\<
MDESXXX3&C5I6HB>U'<6F&2_4YM79Y!891U!I@Q6E==3[!UFDRKFPHT18CX,I
M_P!"NCEV^5ZO15UEW<BZR[-;R5 =4MM\]O5R*;"J2O0DBL@JZ/& "))*W<_R
M*Y?9KM546#.%9YE*I*FT2ZIL%GY(:5A%1:,(IXTN#3."A=\0[G/9S#D35R[M
MR>'&59#5VV0N3+YQ+2QH9=@(^/1K4[F.DV=; 2(PL6;+Y:(1RE?N:B)[&MVX
MSFBVF05-UB[2@"M-/%%BVM<>0&2>IN@&B2>LK3D#YF-4:K\>J-5#/]1S$.-R
M;3UF3V_CY&4.!GL'$0Q"OHVQ]Z(0C=5:TS6HG@FC?#C(+ZU">Y/D% '%70K)
M8Y*VIQQC'I)IZ6."-'?#B6)2<P^YY'N(B:.:B:<83)]7R&S-@55>TM,2UEP)
M#SUUZD%A V3PUD=TGH(]>(4=6\M48GGYB^/ )@K+,'T4.Y]?A8&;(2$P2);-
M.LH4L-%TZ+J"0Y7-:XKF^Y45OAQD6/FL,ACAR/,SYX2P@V$:+:U>0&/&D-+3
MRF0-D848D5.7S&%>W5?,JZ*F3^KEM,@;F..X[C=^RYD@+UD7&HTR/$F\R)$A
MG':25FN*8R._ID:X:#TX@7Y\BSK+9-*PS,<C9GDI+RNQKGB6,1U+#Z:,P#^D
M^B17\S:Q$T\R:\*GKN>+C/J'J/\ =^N52/J(ANKZ[EI2(!"=-U7GY?.V\6%5
M-:KX=G"E5\MB+HKXTT#XQVHJHJ(KA$7@7:_/A7 'XO*9C_J<3=!+,%CSV>@7
MM++E1S1Y<:53O#JJC(UI>8-R;V+IC,*RO,T=>8DA4I<\%D+AYT+GE4I^?>=,
MK)*D]GG"NQ$\FW5=<KQ2,6[-]=P2 Y/DD^Q9.RFV?($0*R9%E)BD IA(9ZL3
MD\M'O<[;JYVN'5#;#**F?@<!E;C>5T=PRKRJ'$03 E&MA'A]*_J1LT=^KIIJ
M[9MW+K?]OAFO4A93*'/R&^)8!DY1;V(YT6>L^993(<B.^24T1N[Z#9HKM&HY
MRKQ2XG;DM@Q\==6EI;:MF#AW=?*JXW21Y8)?3$C\]P/G:A5FOBC45&JEQ>Q;
MO,IUID6*S<4OYEU=AMY%N">X:FM9<F;7DD^L(T VM<Q[([6C3Z+YVM56ON<[
ML,?K9C;(V+3\D:_&KBR8I-L^UJ8]?& LI!.:-7 Z?<QB([75^ZO[ENDV;;VM
MQIV+ AL-$2H6O=+FS.:2.L)9BRT).<FJ'1FU$\OQX_@K+/)UJ,;R\.:P9#IE
M5ZB6T V6UH)94I4C/KU28[5K!,)X)Y^(/<H-MD]1D$6+&@RP4UNV'57D&(5I
MA0KN*L4I9<-7#9O$THV/V-U1537BS[KS,'R/$:*CI@18;<NK?2[&YR9(B5B3
MQ05(1BQHU<YZ-*QY6:B&NNYRHS"8#H4EF.884V;V5@8!&0YM\L>948U5PC/:
MC),B'U$F6?9KR48)':*1OPU=\:_<"L(QKV.]K7HCFK^)>)#X3]OT;OH":JWV
M?H$\7)^/7\/$T#TT>A$73\&[7_K? G?V%)_XA6<-_LJ'_M9/%-_:M?\ ^;%Q
M!_MV-_P^S^ 1?XCF_P".G+_==Q4CE.V\FM@C5C?GJHXPFKNU^9[.-HVHU/D]
M_P JK[57[@:[XE_-[_S?>$OR^7\OM_-]Q/;\;53A3::,DD*!RZ?I)M>S_&5W
MYO@3O["D_P#$*SAO]E0_]K)XIO[5K_\ S8N(/]NQO^'V?P*FK:U7=;.$TR)[
M.D"O.EJOO\H6Z_BXT3V)]Q)_%\O^#\WP+CT2;UOH%[88S;?JTN/TEW5<KKX7
MZV '/Y'/;](/>)VOE<OVF38ENF=%#RGZE2#LAV)FCR?JQP/2] Q"/<YLLJ,4
MJ(H&K[7^"_:<KER;=C081M^M+V1IQ_25=%;.1KV@C$?)?TKT=M"A%37X^ R0
MNWAD"&83]'-W"*Q'L=M<C7-W-=[TU^Q8WMQ(Z2KJ(<BPL)7*.?IXD4;BG+R8
MHC2"[!MUVL8YR^Y.(LZ(_FQ9D<,N,7:]G,!(&TP7["-81F\;T71R(J?8U7V<
M8Q9Q[EIH&9V7I&-260[%66EAI,7DL_5-T=JI +H0R#&NWYWBFO$V]O["/5U-
M</FS)TE5006*]HV^#4<][R$>C6M:BN>Y41$5>#6N'78+J%&D+%DN8&7$/'/M
M1Z,/"L(\2:%'M75BN&C7I\U5^Q!Q4TW9?65;+MX4#IY;N=7P2B!*D=4T"PQ\
MHIVIM<1'KKX(OP"8QUK/714[;\E>@S*\=0^6^ R8XJ#Z=&OEC<Q&[MZZ*NFG
M%?D%%+ZZHM0=3 E\B3&YX5<YF_D3 QY(O,Q?![&K]EY2O8(0F.(4I'(P8QL1
M7/>][E1K&,:FJJOLXA7%499-;91V2H,E02(_41B^(CL%*$$W*,SS,<K='L5'
M)JBHO$[)<EG>FTE;TW6S>FF3.3UDR/ C_J\"/*EDYDN4QOE8NFNJ^&J\4>*^
MJ_U]DE0Z^I8/0V7ZY5,&4KI74]'T<?08'+L*1A/#YOV*/#9MCR<DR4$Z32UW
M23R=:&MCGE37]6**^!'Y((SUT*5BNT\-5T^R&VRBQ],KY%A&JPR.DGS=\Z9S
M%C Y5=%EF;S.4[S*U&)IXK]F-B9+6*F22X!+0%.BN?,6N$YS'S'L8UR!C[V*
MB.>K=RIHFO&77)\@V5N"7'H&5R?2KMWI5MZ@.KZ3DLK7'G?KY49OC-,/QUW;
M?'BCQ7U7^OLDJ'7U+!Z&R_7*I@RE=*ZGH^CCZ# Y=A2,)X?-XGR,?M(MM'K+
M.3339$-RDCCLH@P%DQF'VH(_*9)9JX:N9XZ:ZHOV)9JN4DEL"RG5$U%$<!8M
ME6F4$R)(CR1A.(@WIJFK='C<U[=6.:Y?A,;^%?N,Q!#U*U_-&[7V/:UNGN_2
MTT_'QYO![55I&K[4>WYWAX?8K*TKWC%.FQXKWCTWL:8B,5S-R*W<FO!K")-F
MR"&ADAJR3R-B,(:.=7)RQ,=NW1T_+PW^RH?^UD\4W]JU_P#YL7 :^7(D1QAF
M#F(^-R]ZO&&0!&KS&/;MVR%_)Q!C0Y,F2V5&>=[I/*U:K2[-&\IC$TT^Q_R3
M\_$G)I U0:L= JMR>UB._6Y+?#])Z;$7^6GW&YOQIK^3_IXLL.FX!TW;R/',
M^+EW3SV;MD)IP2?5"&6IG=7+7D]*(:'%NW.71COL][Y6/VDJGME_:5M(T6?$
MD2(Q!=7DV*1GM>^*4)GQBL*K2LW:$&JM7P7A.VC>[O<4U)DF%DS&\M#6<5<A
MC3*RX2L=%Q>PZ/E8U7S3SV/>,(E5&#V:Z>/&'T ,YN0W,+]HR9VQ;E1I!"6$
MVHC>N08Y+=O-&RY>URM)RY&]A2#9OW:<91AH\YRW+:>Z[3Y5EL&1D]IZAD&.
M7-+^K=3&M0BCD'"D]1]&U$&@R-33Q35<#NV=Q,LE9-WFL^WN-R;.XLO4*W$(
M=]$E2EF8U5E8UD:Q? &P)3$(0AC?2;FO77C&\!9W#S7*J#N=CV91C/RBW=:9
M!C5I1U09([JIN1-B3((BMD<MC6JU&E\VJOVN;VG[?/M[&/ET3+[6L[@38MG+
M%8.KNUKG-MDF2H[QS5;E!'PMSWN3F\YR+NU5>,NO8Y/VBQV-;D5W6XE$[=XT
M*;V]@CII9(<2->!4[5OY!' 19:/:Q1N<Y-')HG%'87<*90W-M0PRVL%1'@3:
MRQDPVI-&P4IB2(I 2%=L1Z;F^&O&8D@Y-DD^:_\ :'BT$-<@L4MH8)5-F')C
MWSXK@@0MU9%D(^>77]94;?!NG'HQ<VR_.JJ[[=9/E!X>636V1(]YCY!2-]2H
MAAZ"'*'N8V,-NUF[]+RJVJSNO!^T?D&72Y$.T-6_51TCL_9UTDXWSJROKX9I
M!APG0G.2/,$U2:HB[$5=R=QDEYSE]5CF"66 6E?CU1<$@ULZ3/QJ%,E1;5I$
M+K2/Z%5+$&@FF?(>YRZ\7'<C&<B[S6T>#8/GP\J--K,4[6/AI?-@C%#P@[K.
M1;5R(9L<>X_,.[SO8B-<G&7XVG<+,,2QZ)B&&W3H.*VY*^:L^4&6C.@DEZAM
M;$5Y'.E((:.DJ@T<OEXI\3+:959V7]Y^6]OK#*<(JFV.9W5)B#'&9(IHZF"+
MU>?O8QYFOW(,!'>9VY5[KU0@][@XU'[79+D-'D/=NKE5^2U&30()Q$B5^1QU
MV21R!';(!JX90/CKL3VN7]G24&ZL1RK_ #+M;'MI K*2R1=1)^.S#V ; K3(
M2QC32HUYFD5[2.T5VO'[4U[6Y?FKI]0R5"B.D9 54Y\NHK+9EP]0"CF]:KU9
MT\:0U[5%%56:>_B=ARY[E>&4V'X1BMH-,1M/2K>ZNLAB/,^PL9W+*>9!BM8C
M'A^:KM%U1SE7BLK+Z]^LMM"C\B7>K ;6/LMA'\DYH;),QHY"1]C2.YB\QZ*_
MPW;4[C=TY_<7)H)W@SJ)'PL,P(\.B4%1,LZ=U-84:@7FVTB'&79)WM*A'L<N
MY>,5PL3N\@,>J.V^,6\H79>M:?(9]C9@V#/863B#? JHHHS6L1K2(4F]%T\-
M,<B'G9QB=N'O9C.,4N19A4R<>OK3&[(9GPI&1P.8D2T9',51R6[B1Y* 3F:K
MNX;VW)W)SK(*#N%A>13WS+2Z:;*\8MJAT)JV-)<-C)Z=%ELE*P8T'RVO3WJF
MO'[/PJK)KN//R;N4(X)LZ0RQ9C'.JLBKRMQR*4;!1   !QQ"=O;U3U<O@NG&
M6=O9.895F%)]3Z3+*TV86*7%K7R#V,NLF1TL.4!7 ,YFY&HQK6IHFFJ*KJ+M
MM71V'RS-[!\G&3R)0XD"G-B2QKR5>3WOC3ED1X#6L_5F@(LG>K/+\Y+O&\IA
MW+N\F3V,LN<-#7Q0TM="Q2M"&CL0$#T@VX]8U\H;8A6M.<T@SN9Y=KN*"JQZ
MS?1V&:9MC>%K?A8TAZ2+=%D.E3XZ/T9U/*B\H:ZIHXJ:*CM%XH8!<SR7+8SN
MV>92Z^3E<YMG?UY.LK$DC=:L%')(AD*UKP(YNHEW)JJ<81>_6&W]<FS<,">Y
M]6F>K2UD9E$C3!%L.HZPZFBH]A$5Z[AZHOAQG$"1G&84F-8;&P"[%34-V6MB
MS9TR))*L><KFFTI3C@EZF.+E=0XB.<[5C>+CN1C.1=YK:/!L'SX>5&FUF*=K
M'PTOFP1BAX0=UG(MJY$,V./<?F'=YWL1&N3B;=+DF6-=_=A69/Z>VY_JQSIM
MG9U/H;XO3ZNQV,K.J%&W>6:JEW>[CM!@9<[R7'HUGV\LLTR/(*JS(/+;TT.[
M95QJ\%[*ZB2%S.:I'KYE<Q/,BHB<=\,&'FN0VTK"#=N)>,9A*ED'DD2)EMU6
MJ2KM+:(X1I,B.QBIS%\QQ%=JB,5&)V^J2=QLRS&OSVKR]M]#RJ<R=$#98[6Q
M;)DZCC(QHZ:.<\O1 ,UV,3:KWIII(KHQ21URB\QO$CR O49!0,@NHD&SVN:J
M*G/KG%%_/X[:=GJ3(;C",>N:FUMK.QQ<Z5EP8%/$ENA5578(-ZPD"VN7<C4T
MV$U<CMJ-X[M4][G[,]##O:,=0>1(Z^^J*]N9T31UV067,WRK'8UKGHX;5&3?
MHJMVHWLQ1!M[,-)-[5%ES*84^4.JERA5UGRI,FO:5(AY ^4W:]S%<FU/BXS7
MN:_NSW#!9XEEDT5-6AO3K6N"&QIQ'':J;F3K,;VS/HA/+R HW^C<CG)Q^SJ-
MUQ8@@Y1@MS;7M5%FR8]3937XE/GM+,K1$9#D*"5HX>]B[%:FGLXS/N,SNY?X
M+9U6<2J2BJO54K<)IJNMD5NHKZJY7*GS7Q9ZM;S%\Y4;S-V[RT>%TF4=Q;:X
MA8H"TL,<[3]'B+7S9"L%Z]<9G.LY:1:N2\PT'$Z8PQ,>CE+N5-V,SLELI-M8
MQ.[%=5I.F$0\PD:)U:@25*^=,*/FJG-=JYR>U5XOC!(\)@TMH411/<,@B#@G
M<P@WM5',>QR:HJ>*+QCV2MRK(F9+)N#!?D#;NS;>&:F;7D?EOM4D]>]J0P(/
M17Z<MJ-]B<5J?6;+8G-PN)E'ZE<\A1]!9F%]71?JSMN+3>BW'B?YQQ2+N3=X
M?M5!M;>SLPU/=4%=5"L)\J:.LKPY]6M%!KV22D;#AB:U$:,>UB(GLX[38F'(
M+^LI+OL].ZR'56TJ$'JGU%L$5F..UZQ/4X>UK@F<-SAO8U?=QW:N,6S+-X.0
M5^27XZR+"R&5&A/+CGI-J:6D:)TQ"7=U%0D8Q%)M*BLU;Y>.T,.@M[&!45.'
MKGF?#J9\F)'E61>77AH;'I#A'+#%N8WB!Z;7B*[5J^*)E-/'U2%E/;VDS"6)
M$\C+FHN).,OD(B-\"2ZWIVN775W(3V[?#X2_(B)^_P#O_"#77&48[4V$A6)'
M@6=W6P)AU(K4&@8LJ2(Y%>KTTT3QU3AKV.:]CVHYCVJCFN:Y-6N:Y/!6JGV-
MKB#:[EN+M<]J.Y3-$>315UY;57Q7V)P"PK)L2Q@2F<V+.@20S(<D>JIS 28[
MR!,S5/:U53[#9%G/A5T=YP16'G2@1 OE2B-#%C-)(>-CCR3.1K&?.>Y=$\?@
M2+"RF1:^!$&II4V=(%$B1A-^<61).\80C;\;E1.&O8YKV/:CF/:J.:YKDU:Y
MKD\%:J?8>$B:M>U4X)-C)N 1562)NFJ>_G-;^#V_]/".1=47V+]H2 #4<(*M
M?:34_P R#7^A$JZHL@VFB>W\B+P"%$$T,:,)@0B;[&#8FB)\:K\:KXJOW&WY
M=4_-\#)J%TZ\2)E>>/[AV)&R8'4ANGV5;:+&A/6L48ZOJ*L:;'L(78KOI-=%
M2/G:FF^KQL9DXJR.A >G+7R[.-:D,X73=2LQ)$5J([FHS9KY=?'C$,?K(60W
M57D/?D66Y1RD*<U9&R&/=NN)22:J)'?5U4(AVHPS_$*JFXBKIQDCGVV69%<9
M53GH+/)\JO'7>0I3F$0:5\28:.T$>.'F;FIREU<C=V[:G%?VYLA2IU#5U555
MPC&.T=J'T4 05UB.;%%'0-F#D([>QC6J[7R[55O!\B6YRW+LA)#]-CWF;WKK
MZPKJU5:Y\"N?T\0,8!7L1578K_<CD:JHN2]QX*3$O\IAQX4\9"QUK@#"D3FD
MA 9%&<1ISX(WF5Y2;GIJB)JO%O:!R#/,=!D4E\S)*'&<I/58]D$HR(V2:TKN
MG/S'RTUYFQX]VY?>O$*LKHXXD"NBQX,**)-!1HD4301P#3Q78(3$1.+\B7F7
M,A9#F%=G,BF2S@OJ(60U]FZU=(JXQZDI(;+*4[]93>Y2-1J(K=K-*C-Y!9OJ
M=-36=%'BM?&],-#MGC?)=* ^*^00R<ORZ%:W3VM7@7]<YP3&H]@RSC]OS90<
MF"!D#D]6-K*-P-ZQV'\>6XRM]R^'&7Y/'+,+.S5U(ZU!)?'?"#Z#6>E1$@B9
M&&8;2QO$O,(7<[V;4\.)-27(^XJ8X\DDU=BB97NQNAD2'O(DBGK30"M&6,\K
ME9SG'3Q7=NXRXTR=GN-Q(.(X9"I<PQNPE4,R8H@3(UK7MMDAOK9Z&8T2R1HQ
M5:Y&_-]];@P8DZMK::6VSJ+&LL#QK^MN4>4K[N-;KS#^IF)((KWNW-7?IMT1
MJ)>EE6&39C8Y)5NHK>XS>[+>VIZ-Z$:^H9*Y45 02(3S-8U%=HFJ^"<4$EM_
MG=A]5;V!>8W%M\C;80:1M>0Q6T];"+ Z>-422$:I4:WJ'<IFA4\V[/+!UUE<
M0/<6I=5Y%31+.(E)S' A1O6(4*36R5!<M!"1J%<][4:]Z;-%\*RV%=YAB=[6
MU0J/U_#+[T*UL*@*?10+(J19 9(6/\W@-KM?#7:B(D#&\?C+%K*]I.6TA7G.
M8QROD2I4J055(>5*D$<][E]Z^&B:(E^=]MF=769,Z7*M\7I\B=$Q:1<3!O1]
M^M.^*<3K5AU0S=RN AF-7EJG@M#(9<Y=C5UCM.*@@9)B5ZZDOGU D;^HRI0X
MY8YP.<U7*G*31SG:::\81AU#67]]!F=W\5M,KEO)/M;N=&F%E O+Z[LHK$D#
MVQ7-:23]&T+4;XMXL+P5IE&37UC$96ON\RNR7UG'J1D0S:F(=X0-# 0K47;M
M5R[4U7PXQ^OBWF72J[%<N7,*"#8V<&6"LE+#E0_28VM4TPZ+;,>_DH[?S?-O
MU<_=-SUIYZV\['(N,%CN)']-; ASRV(RC"D5)*2U,945RF5FW]'7QXKA6QK:
MML*66L^CO\?L'U5]2RWM1A#5T]C"(-2L:FY',>U=$735J*E;DX;?,[/**^2<
MI\CNLGES[:ZBGC+'6INW[11YE4-VTK1(-GTK$555-46;CF01W'KYO+=N"102
MXDD!&FBSH,EOGC3(IF(YCD_ J*U518^6I?YGD=^&KGTYK'++UEY(G09Q([VB
MED+!&3;!;'V@:-1C:USMS7*NO#HK+K.O20V0+6EH'Y)SZ+&90;,5F]:&MD02
MA!U3Q\HCC<\BB>[1R.7=QE.6A+,)89=%HH=G'.^.^ (6/ F1X?1B;&89CC,G
M.YO,(1'+IIM]\FI+D?<5,<>22:NQ1,KW8W0R)#WD213UIH!6C+&>5RLYSCIX
MKNW<4&;"N<EA7%%0LQH@X5A&%7W]0-9+QQ\AB.@$2=RSRWE;L46A='>UK=,2
MQT5AE%9)P@)(^.973VXZS+(03OWR1^I183(SV2/#<G3Z)IY=%U5;[#$DY 5F
M4SX%ID61R[(4[*KB?76,2RCR)MG,AG"1>=#1NWDHS:Y^B(]RNXQ/+))IK+'#
MF7[*P(" ;".F1PH\&;UPWQB'(HA1D47+(+1VN[=[.+JB@E;'ME9&LJ.0[30-
MY32P6M2KG*K48,DV(T;W>YCUXQ.[O09-B615X1V%=85,D^/97C<V2,7J,%AC
MQR[$0XMJ[AN1=NX:Z+N7*L*25DA!YK,@3\FR23: EY3:RJVS#;12GGRH!H:J
MDH2Z_J_CS7K\YV[C%<VZNW]5Q#''XQ6Q^?#]// (&0!2SA=!U!)>V2[S,*-F
MNGEXR'MJ*PR%U%DMC)LYTLDNM6V$>5(A22-B';4MAL$CX#-$>!ZZ*OC\6 90
MDRYZ_MQ1GQ^D%U$+HY4.15%IWDM1^G<X\E(QE5%$0#=_Z.GAQ;SEL\RJ*W(I
MX[3(<4H\A6!BMY8,-U#I5A6+$,1Q"'\_D*S8[Q9MXK;N--RG%95?11L8(/$+
MTE("SQV(T8@4MEM >0^"V.)!*@B"5XT1'*NUNC< %99..@%EK<PC:3JQTV)-
M8S8R *02F>CJQOQ$:\^O^=X+'.-I0'&\)A/3<P@BM5A!O;[VO8NB\2:)U_W"
M2D?,ZZMI_K.,M7C\AQG$,2GKY%::*TDACU&\DAL@JL_21RJ[C'\^?;Y/29#C
M\>/"87';9E:&TK8\]]BE7;L=$D$D0#%,1I6,>+F#(K7*OET[C8\6QR-(7<[)
M$RF^(R76))B6"7 ;ODU#W5#A A]4%&[3,._E^&[7QXQ7-NKM_5<0QQ^,5L?G
MP_3SP"!D 4LX70=027MDN\S"C9KIY>,PRZ@;W$R&):&)82<%JCCO8Z3+&=%2
M3*Q_'^7"<^=MV[WD.0G3#5-5T1.,JRBVH#XU8YE>&D5]).8YMA3XU&(9];"E
M,(T9HYE-*)N8YC';6,54]R9MGMI"DP&$%"PC%X\T!(TIU#02)4FQM% 5K"CC
MW-],*H-43?' PGS7M7X;_P /P<MR*"C5G5%#82X>Y-6-EL Y(Y'MT<CFB,Y'
M*GO1.(#KO&J?*+JVKP3;W(,AKX]K;6=G/!U$Z9UDYAY$3><[MB"<W8W;XZIK
MQWPQ>G>Z?7=MJNNR?"P7#Y$X$"!>5,N<E"4B2!SBP*^="<@]3<Q1N]J<4.89
M9BF+Q>WUY(IHIA5UA8.RZA'>&CQ8%K;LD?U2L<AY+-\<*O(+?M5^J>.:.)]4
M'TXL4K.N8[UET[ZLH2[?1,B-7]5]8=8K^N(_]7Y2_1^;CLS)QO%<9ZO.I$BL
M6@KHY*:HANZ&P/%2L1LMS*N&*4%KSJYLA4#OV,5^G%QV_P#JYV_=F];#A7?K
MK;"^9@XJ.=SAB0X%&3("VCI(^6UC4:QR(]ZJU&INA7EWC.-ENX?<:JP^YJY\
M8EM2"LH>51ZB38UHRE&49@.^EC.<YZA(B>+M/&WOH\SL_%Q()F#IQWC<T+DL
MYY!MY4'IJS]5E6,@Z.V-%Y=OBY41'*F$LR6OP^@[CYMZH80,AL2X[B-#7P7J
M1D^Z/,G29;2=*>,G2--SR%(Y$V[5;Q;X]EUA@=A:5=!)R@=UVXO5N\=FU4-^
MV>!S#E)-K;*O1[-6&=],UVYG@B\93D\S%,:B]OLCH"K71HUC/?FM=6SMJ5UU
M8L>WT:7$-N&X@Q*PHQ/W>;;XUO\ [A#_ /+C^SH5B:Z.373XVJG[_!#5X^9'
M5=71_=^$2^Y?D_Z.-BZL(G@X3TVD1?>FU?;\'5RHU/C7][XU^1/'@6UKZ^I<
M]J%L2L\Y6*J:MA"712:_POF_+^BJ5U:%!!&Y=5]I"O\ 8I3/T12%<B>*_O?9
ML'L<YCV0I3F/:JM<US0/5KFN3Q1R+QCN76G>/O/"GVE5ZA*Y&>D961B->9%<
M@I4(Q.F8@]7(\J^'OX)D^;W*6 JG(;C&8MU%BN+)RAL"V-6U,B'$B,59LZR8
MQ/Z-J;E:KET\R\'J"4&:8Q?-@2K.%0Y;CI*>TN8,,:$,:F'U$B/-5-=-G,1Z
MK[MOCQG]OE\3(:6#CU_>3%M;VG;65<"F"=(T.A8\12*MY4ACZ2XZ-5Z&?[7N
M=Q#IST&;8NZV(X6/V&78T>EJLD(C'E0=--<8S3$)'9S&M(@G.8J:)KX<7^.!
MQS.\ANL;D#%9P<8QQ+=XXQ(4>;ZIO'-&$5<U)*,5Q7#?S$71JHF[B)W"]2(3
M'K!P@0N1%,:QE6!COBLJ@UXT<=]EU(W,4?NVJY5V)NXR4[\>S:JM\5IUR"QQ
M.ZH&UF4%I6NVNL8$&1-2-*C-]Z\]-/QIQ37CAS;&-D$^BKJ<%6()Y<X^0E$R
M H1FD1AN&@B<TB[_ "B8Y?'33[$]\?-,K_O(A]QF4\?MG&?IB?U$%8 (EI+J
MTCN#T9<?+SG63SL7>NSYRI\)G\IO[OW@O_E+\&UH;-G,K[BOEULMB:([D2PO
M"16*J+M(U'ZM7W.37B)BH<)INX<2 (==59@W+8>.O2"%J!AFR&IL 'E'DQPJ
MWF],Y>8@UTU<[7CO!>Y7/C66:9E165GD1X W#K8:1*I\2LI:SF_K#J^IB^1C
MB*KE55XQK!KW&Z.HQ41,9G7>;1[T<QV0U5.:%:QH]5CS!CGU%C,+$"A5,YXV
M+NVJJ:<3[^OQP5OC&58E7T4^W9=0(1L?D53K4[7EK)6DFQ;+)(8Q.3\U';E7
MPTX_9_ARZKE2<)L9Y\G'UU:_TP1J2XB#=O',>R9ND2F-_5U*OCK[->,KR<T/
M91V6(8W5PIW417<Z= FV)98.F:998^4,[5W.&C%U\%7BUIVU&ME)[UERX,?K
MZSSX\[-0VR6'-6;R&_U>U2<I7(;W;-WAQ;97=]I?KY IK*8#M['?GF*T=/35
MHY+FQK=E5)6>8]S/ (9%,;8\:KHC&Z-1F(9U/[<4*Y-BY;V--[9Y+;TE_675
M19-&-O)N5A%J@6C"11F YS6M9JJ/7B]+==INW_:VOL:"92"CT Z>PRPKK'4$
MMYKRCC0:X-;T[=4"C'O>]6JKDV:+/[2BQ.@D1JZB2EAYD#(HC/7:BO1!UU?#
MH)2B+!M)<8 Q%-).P#$5SDU71.(02IM(&)&$1NJ+M>,+&N35JJU=')[O@/8]
M$\?D1?W47C>UK>9IIO1K6%\/X[$153\/#NG+S&I^A(8O^U8CET_$G&BUJ%_U
M1AL3_P!<Y%XT;4$3Y5DQ]$_(_7AO.6+";[U1KCO_ !M=HS_*X;(G[[*4W;HL
MO0@FZ?P0*G+T_E;N!,8B-:US$1$1$1$14]B)X</_ )2_9LO_ '"9_P"7)QAV
M17.)MG7%A6"F3)+[G(6,D2$.5-SX8;8<+:J,35B#V+\7';FUHZ(AL=[=YA6V
MUA0T<+FECTS84Z LZ#7A3606J-+:7:B;M%<_7P5>.V\C NMM:S"[*YNL@R-]
M595M?!9(IW00TPSV$2,0\^<:0Q7#:FG+;KJJ>SO3V^J>O?F-1W,NLJE4(0S(
M5F>E^MD2SCEKI1(CH[I,R-$<^-MWJKT8NW1S57&ZZM[D?M!YM;0\@JYY<?L[
M"7*A4-A5RDE,E9)ZU0P:^*""6.[F*(SB^5R#U=IQWR?M3<N58ZU7:>96MQ>&
MK6JOM5&J]=/P\8#E8JV7;5F$=Y\BO;R#7QB3)@ZOZQWD5]E&AB:YTAU60S2:
M)XHGCJB(J\.7%<8'D%7$Q^5$L^X<JM+6]'U14VXM#]3J06,QLO>XA6M(P;--
M=':Z\5';F> CJCLB2[LXLH[2-2P%=M;'P)6:E?S5K:.=)8KE_P X'WKQD"8V
MHTR!:6S2D4OS$M>C-T&NOA_XG;[?#X^,9E=M(F0A_:!J(X8E]0S,?O9MG>EG
M,BAR(6:39H01Y49IT;(')=)U%HW3:B^7'ILR;;S[-(SX]S(O*\M79>L@,1EH
M$\0K41G2S-PF[-S-K/!?@M_"G[OW@O\ P_#L*.WC]75VL0T&?&YIP<^+(8HS
M"YT8@9 M[5]K'-<GQ\ BQV\L$8(HX6;G.V""Q!C;N>KGNVL;[555^VK^'['L
M3C^C;^3CP8W\GV1?ZQG_ %DX?_+=^[]KFQX4U:V:>))#$L&@#*= DE"]@)K8
MTA%!(6*54?L?Y'Z:+X<6\FRNCY/DV23QV619')AQZXEB<$8<.&(5?$<Z-!A0
MHPMHA-54;JOVAO\ *3]W[P5^5$7][][X*N<J-:U%<YSET:UJ>*JJKX(B)Q5]
MY9,@J8WW+RZWP51&5S(\;' M! P&RT(B(%)%K2R'*[:U%2?KN_A=E\=R&'ZA
M3V5WEK)L/J)47G-!C;I8DZB$>-*'M.!KO*]-=/BX?W&[;!GX\?'9E7)O:EEQ
M;V%7D5"6>&%90YL2TGRD<<<>6I O:YJL</P\5XKLSB;E=@?;O'<HE-9NU)2+
MG,ZER!NU/%VE)<G?X>/E\-?8H\2@F1PY%!DN=VSAJ_\ W)B=2\]=YFHK-DS(
MYD/V^U!K^/\ 9L_O&_\ ^,^K]YZS_O;V?5&@Z'_<7]:_[SY/]%_.\NO%*SMZ
MSF9>(DF53IN[CMT)%A2#R'_UVYM8NR&PBZ%\%]WCIP>+(;S 20ECF9N<W>(S
M%&1NYBM>W<QWM147CM12P<5Y%9DMEE@+N-ZYDA.M%68O)L83><:X)(C\F8-'
MZB<Q7>QVJ>'$KMKV9[9SLIGQE'D60UXLF],K:=UJ 88SY=YDI[)>NG1X#59'
M31NQNY/'7B^RFJQ&T-<8G/-!R?#)LAL*\KUA*(MCTVR-,'/*.O+U &_1I):F
MU'-=X<0:+$8HKZJ] !D&09$.?R8]".T$TM#6K&2(?K+:S9J]P5(!0";N75?+
M\!?AC^157\B*O"K\:Z_ H.WF)757B,JXH[&^D919UPK<C1PYD6O'64U9)-'A
MR;%SY7-<A%=Y$]GMU;499;5V=XS*KCG9EH*RNQFSJ[,)&JR!.IHLMXI4:6,B
MH,@&JK=GGTU\?JY>9A6P+A'(PL5S)AF1'JQI$9/F1HIH->[8]%T.0?';*DKY
M[/0LDJLWF60!BB&'/6JA4IZHS);A$.-@EF/<G*(UI-WFW>''U8N,RK(5TUZ"
M-'>V8^/$*OCRI]D&,2KKRM_2:<PU;[^$O,GNX536.<U@9)G/(LHCAN*T4*/&
M8:3.,X3%<C L>Y6IKIQ=YWBE[6V_3(ZOJN9&L7C7(#@<2!!L8+11[")S=N[Z
M5 HK?TD]O';&TJ\T4</((F3\RC%C$PZY?+I:QB6+!S30V2J-<>FC(5$1J=9\
MQNY-.%S<5J-<7;7R+5UJX$L;6PHO,Z@CHI ,G-()P7-47+YNY-NW7PXO[F5E
MR^DU^ U>1MQ<V-SAK#'/GRA0[\MHV'UY%LR*R,L)6[X_+WN:W5>,6).MHZ9-
M>%F5DF("MM8D)N00(0[:?5QSR8[HK5!7R6.'J=W-:B['/<U^D;&72OZ[EUDB
MX#";'E/_ *MBR!132BR&!=$CLZ@[6-0CVN>OS471?@L_E(OY/'[P6N_"G_+\
MOP;.MQB'.EWF1DB8Q")"C29'IJ7IVP9EO+?%"984.L@$*5QW;6,5$\R:IP:D
MK>Y/=,ZPH&M'4V&5 )C8;."/FU6M2VL",$4$UC%:C'L</]%R*FO'8;.[#!<X
ML)M&?(7Y524N-6$V[ASB4+J4KU@E9%Y<>38:D$\CF-('S-5WAJ+!Z[M[G&)4
M%A8UA<LO<ZJ0X^@Z6!.#82(-7"69(DSYD]\88T5BHC$5=?#QXO$GU4U^,7'8
MTF,R;%8<CTM\B9E4CGUJ3MB1>NZ(O,Y2/YB,\VFGCQW4EY/463LE!@\CMECL
M3I)I)UG4XM5S1CG08S@H>2F0VDUSQJQJ\W8W3=\Y?V=,C3$,QR&/B=)?#O(&
M,8_*MK6"6?A]34@%(B_0,C$ZLBZH9XUT&_356Z<5]3_=7WEJ?4)0XWJ5W@_0
M5,+F+IU%A,]3+TT4?Z3MJZ<?6G^\3NE-_K";8?5RPRWJ<5_7>H_4?2/3V?U?
M$ZCZ$?,\FQOBNG'9F=%@39,*KM,T)9S 13FBUPY6(RXT9\Z0-CA1&2)#D&Q2
M*W>]=$\>,SR5,+RG,\9[@#Q^6AL-KV7-Q3V]'6NJRQ)E9SHQ70I(6M(PN[:Q
M=4\5\$[BY\7"[3ZU9[DP"X[AL<2V$R$U(4:EIY%Z6*BA@QT4:R);W[6!$GB[
M<J)PW%903WU%FD?UTV15M.O+J,T" ;;N!8K71& @4,\:-= >5&-8YKA^U?@)
M^#X97_P1JGXW>"?!B87W7H*L.-SJOKZ#*[J6X%>2V>4D2QJ1S6!C.HIL>+L+
MS>K9O:Y/8K4XH*#M=F,W+,3G5E_)S&H^L),KI<9;'C@?13X%L5\Y\4\N:[IE
M#U#MS?%?%%7C,JJU[\X]VYDCR;)VY)B.08/B<Z><IK*7*ZMLR\E1[/(@V$<R
M%$YC2:;]C/8G'[.%="MS7\2+AG<4<"WE5DNF)-A>GT#H)'5<USI<,;8SF-:U
MZZ[&IQ<T.1=_,<P$XK"^C97A-]@F(SI_5DL9CI1''MI@;?(.O1W.81&/>B/1
MJ>QO'[.]ADMVZSPRLQRZK8.47D*14067<BJBNI)]E!M'N-5%/ %H%9"ZBV:Z
MMVJJ=^96#Q"RYY,4CNR?*:PSI&+6\L<8S8<>(85B6!)M(<=7*8@H[?*[Q([7
MC]FZ;53X5G#6KS\*2H$H,R.IH^'P 2!<Z.\@^: [%8]NNK7(J+X\6?[/HPDZ
M/*>X$3*@*QA5 /MW8\[*<CB<S;L&C+BM+$1%5OED>UVBIQG;6IHB=EJMK6M3
MP1/6<C1$1$XQ*=C,R'89+V^AU610!0Y48YHE[CVLV132T8I'1)%C5$*!PW[7
M;3HJII[<T[I"15@7<BOQC&'$1S7MH,< JRB(Q=-&S;^;)7Q\?HT\$]_P/Y**
MO[W[_P!X*_Q?'_E^+[E_!\/Y2O\ \EG_ -[X+X-O70;6"7^EAV,2/.BD\KF^
M>/)&43_*Y4\4]B\.BT%+4T<5[MSHU170ZT#G:N7<X,((1J[5R^[W\ LK?&<>
MM;&*YCHL^RI:Z=-C.&YKAN!*DQBG"X;F(J;53143B'8F@0C6%<R2*OG%B@),
M@#FM&R8.')<Q3162V!:A$8J(]&IK[.!7%EC./V-L!&("TG4U=+L0H/\ HT%-
M/&))&C-?#1WAP:OM8$*S@2&[9$*PB@FQ#M_@FC26$"1OX4X=3UM-55]0YI6.
MJX-?$B5SF2$5IV.A $.,K3M7SIM\WOXKO3<;H:_T=TU]1T-/7Q/2GV3=EBZN
MY$<?0NGL\#*/;S4^=KP*Y?6P'W (KX(+5T..ZR#"(_F$ABG*/JAQ7D\RC1VU
M5\=."6K8,-MH:*."6R;%"D\L()'F##),1G4/BB,5SFC5VU'.5=/'@L'M+ P7
M&)]M8N?=R)]6>$#I9,60*39Q&4 @K)OQFY2C4^K'(B[E]G%'BM<JNBTD 4-I
M7-:Q\DJ:DE2R-9Y4+,E$>5VGZ3_@N=\:Z?D_Z?O!T^/A6_$OW)I\)&I[571/
MQ\(-/8)J,_&GM_/]RM;\GC^%?%?O"1_Q^"_O?<NOQ_!<9?8-/+\KU\$_)]RI
M\3?,OXO^?[PU:OOX5%]J?="(GBJ^"<- GZ'B]?C(OM_)]RZK\YWBO[R?>)O3
MVI\[\'Q_B^Y=?C_=^SSW?.7P"G[K_P 7W+JOS6_G7XOO&U3YJ_F7XON73A7.
M\!,^>OQ_Q4^5>/B1/!K?B3[D1J>__EKPC4_Z?E^\;1?%%X_BK[%_>7Y?N33W
M>]WQ<()$VL9[$_A?QE^/7[DT3Q5>/XR^U?WOP?>1HOBB\:IXM_<_#]Q?$WX_
M\'&C?!.-%]ON7XN-'?\ ,OX/N+1J:KQ\;E]J_O)\GWEZC\/XON_%\7&BIHOV
M[1/'C4G^+_A^!HY-?^7NXU3S-^/XOP_<'Q-_A+^]\?&C?QK[U^\WS)K^[QY%
MU^1?;_@7C145/P_:M$37\''F\J?GX\J?C]_Y?AZM\J_F_)QYD\/C3V?;/*FO
M[GY>-7^9?B_1_P"?[T?%$7\/'AJW\'L_/QX.1?P^'^'CYOY%3CYCO\5>/FN_
M(O'S'?XJ\?-_+HG'BJ)^?_!QXZN_,GYN/!$3\'VOV;5_B_X/9QY51WYE_P '
M'BQ?R?OI\+P:Y?Q<>;1OYU_-QX^9?E]GY/OK\VW^=I^_Q_FOQ:?O<?H<?YO\
M>G[_ !Y=G\W;^]]M_]H " $! P$_(?"@JTD6-R%S:48KAE&[ U5)N75C9J>!
MZJDA=AQ=<NDSETV#L7\6BV1XM (L)&43P;&'@U:2)F70+8(]=7P%R*;:PERJ
M(K8F;;U@I?RC$-W>)Y*6D-5%\A(F <BFL ;HUKT<*;H06Z;17.P0[&YO;E,0
MBH^_ Q M<(<X1AFK28Q(8EP9QX9CQ'?UC8L)>"5@W;4_D+@^4,,8%OLD-*/V
MG_E+FSVJ($"" 9$+B-1Q9ACB2X%NST):K) %(U,!M",7QX@5IDAI"9[*XD2>
M[<EI>'&C"K*&=Q@+=Q-R8D-1GBO<NAO4,B%$=BZ%W6)+:GAY;06T$<2Z%"#N
MDU#_ & *H+<<U**7N9E;1 ;<0#"2##:E\"[ L0-R-TV3PYC4JQ<I9,>:%U@*
M:E9)FBUB25EU7>ZYV$E:(,BV24(D-"W?L)A@KE$<7DJ?#2@4 *C !=5; %3Q
MP"1B*ZA$]&P]W(T7J3#91@30.+5I &R,P,MLEP1\,K#IV@;):(33N=4=Y?8;
MZ,V1@24@>&,J4"^'*NBRU)H7T!7 &&6NO>5L98W$@CU*,,#5F>SM;XU"?"[S
M:-2 0!+0H-4ZL,@2^V;TX-80H3=^4O\ 1P"8P-J(9*7-YM0!(C*$&Z./>[QZ
M&(J#0=AEH\^1 !.FFPSH#NYZRDI8*#(1895RLA2H*64:'*'%4E)BAZA28,Y9
M T%($ B"R1AKZ(S4VJA(>L9*SDL&=OO>I^D&Z.H:=<IVA8@9>UE1)KHDF0K(
M-6VD(^@.RO,N0T1)H8%!>2AG%8SPJB]IV\0N[)^5KFCN]2H$B&42-8ZGIDI.
M>&5PCC\+I&XP6*+H1XIU<WTU@>#FJJY@*:;16/M=E#U0??XMVQ#0#;S:CW(
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MF;>%998(Y2R*.9Z=@W\@,2\NF&&3?2/!=/L/04PP"S=RV8X(:M$DP1%8?"Q
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M'(?V.UJ4%I(GV#.K^LW++*(T48."^]G,C R20^N?LS+E.B3_ ),UZLS&TS%
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M7B 1@6$.:W&47U"[&$>8-$((WZRE /FPE$H+L+A^>^E!:I)1,\PB 2D7VO\
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MD@PQ:_!H.E2BJ2?'X(<2@;4X.5>SJ^LM]H9[.ZQSW3.+)?@YZR4S!W(1&+=
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ME3<U,TKT+S3M045'5R?2.U'>Y3U4C6A0IR,72[R2\[^AQ$UZ-!N3;,I6',%
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MJ@#_ )A%7@=*M@J##E%XFP%/AS->;!4/9(>]AE(Z8IIIDOGHRS5\?)%L)'"
MZ95-IK90\D@<@X*=#@[,]8RI&OS*A! 8JWHK&UN@$(FR-<@^&]+!DY)+1_!)
MI2)P\M,3-2(1&_CC6,441<^#=RSTW]W4:?4A^#K\*(^=R5QD/<SU(+HJF+$"
M A@%" X-\0[L#2NA-M5CKD7,%#5C8<&]9;"F(00DV6\H+$R#(DE. <&B8,V&
M! 6H#PX9GS1)%FN41.N268XI6>K+BYI"]\ !LE*5F4KS"-J)$A%L=,<G>CG8
MIXC.9HQ-<&!MP3J0'_L?QX!YJ%]&3[=7->,GOV*2WJE 9NFX1N+7)(BD[*))
MG^ TI3%DG>T<T5G \A:@1U,]&/ 0(*+5]OZN_P"4]G1&N#RD#8SE0%7^G$X^
MX6UI7OL_M>4VYDDA0B-RV) F44F @_CR+[#)4:)FU:4X_KR(T(Y-@A;T078R
MW.DW-X>S_O7$MO.#GTO5:2+5DK'<(A,4I'Y'!]A9&4%!B/7&15<DZDNNU,;M
MH79R8PE0V);:^P-E*+,VJR41>OX:6@G^>)'F6!*RMH$,9U,\$6GH"4'3:#[C
M$BV+"H!>"  !Z "P%9(MDZ:D"@8<4&3TAL@D!;^(ZJ$?];P#2;5!]+/R[K)+
M=\-NO<=W\1U1/(0<U(<F^-PUK7JPV\0I2RE;TH\VD;N!U21@H#8["@?HOKF"
M)+=G;+G-1.ZU?DR58L:<I>R_:).Y$B&)4*2R@4$\8K[L14W^0]5G(X7>I4/^
ME'7)<,# *:6053()A@8J*4B%-D"M!D;).K%MP^B7P" %8"/)LT[66.>SZG=)
MC<)20HZ6ZIF2(MU0?-2-DAQ"_FY=UW2)>067P% ''NS+U/KNO#5_KKU21\*6
M+-XP?2E55NK*[KGNF)_\D>O@-B$$<G1]&C*A(?.SW21-<G,_O4!.2 958#U:
M"*)9/^0;'=;68> ?D??@2S=FS<_;Z=UG1QEP_P!=,N61F^(-A8_Y2JJW6ZNK
MW2QVL_!_7@:S]^WF6V[H 1PYI)'H[E;PY\+?\^E)/$*-@\!W0<;^P-5P*Q8F
M75:KB^!G1P(1K>:>8T?/=&>D7_#NNU2:_/2WC+N@P:B *W1_PG!X(=& A&IN
M??UX>#CW)*<.=_#>T'*#YXN[6(@YZ_1VJ,T;.ANNY'9A\<5T"I9A>4Q]O!92
MB6NIS?\ %*E!D2'M@4 IP!*^E8O2/[_"@ @ # 6#IM./D=UHU+2;+(X?W'<'
MY#>"W]*AQS/D?!IT#L=')R5<H/(]_P#"EY1L$^^R1D+8*^Q5W? S_)0<0.JN
MN?73_H9?ST>E?M*?KIZ]HC#[G YJQ4"O X?M "Q8,!X0'@C8#]UJ(XI]DJ/]
MT?XK=/,?LTAGRFL5Y*_*%QY36*U"<WV,T[X^5[6?-9:G%^"[YHJ#> /??LLU
M>SBK"C -L_M/RK$7C<?(=;WK)1[XK*#XOP6?-7R7FK/V: $  8 @/3Q6ZW*/
MRWK8[:7'_]H " $" P$_(?"B$$M7FUQM_OQ6CCD3_*%D^Q^4;?NKA^ZEX/M_
M*?\ L>?JL8!P?[%,0/$MXGA"/'3WK,!L6/?/U1L <.QBP<2KG+W"KK)O,?YZ
M^(S!JJ(W/*_^5"L!VN;-3'*]'^>E0TCQ A#S="M==7ECN,0)/DY5<]UA_O'P
M]H4U=JCO;[[FG"765JQPX/AP7D>9H%ZSN]U:!+J?;K#YU\-^M-PX?WNZ7-H[
M-)[)?#/_ $M?\S[=YFU);DT?SPP"M1H ,A?GKWESE$5G87_/"]Q8)]=/[Z=6
M^3I*-J'@M),VX?\ *0B8RX5!*!$\^%86NV!^:'DH6<.50G+*SG*](L1#%[DW
M?8I("B-AB=5( F6(WH'I VXVP;T9(H9;!N[O/^0PS488O)3:@7]?U^9G".9W
MY;.?\H.EMP]$_P I&B63^E(7Z,K,,XG7T_.KB^;\_?"]P99],'5:Z#^%7C))
M88$T^G(XQ/G%"JB.EP=8JQ A=("^G'HLB6$HQ$:<Y1\4BN@GE,Z"&"6ZEQX'
M\*1*4+W&G/SM2ZJBYR5!#:1O&_GZFC16>B8>/#TI$*79@D-K_P HNXH.>-JV
M);NYL\O[PZN]42<R_A>(= [YMN+VT\*\53V [@F:DUKDH\3Y*0L_#^*$@'C6
M?:E4G@G7'K4-CT/W$4H2CG^45/7:C9?6?92:.&,.?:K"*?/7CBE@F/-^J2L9
M,35P7U_I4[2)TN#+UY5V#^?GA7WA]/8 (..Q>6LE3MSD6G;.)=JED$OU+>VE
M:!4"X/\ BB@!:<.)]-_>I4DPAX_E(D1$CBR]6TPO_'M1+E! $VTU#G:G*+R_
M31$"\'UE4\0TD0B1OA^U<,M@G6-/:H0!<>EJ,])X:Z]?F+ZO^^%?@/UV"?-P
M&N/) %#H#R1:]84WYF":TUK @&Q7KW!_*F=FM\!!4^@HMK7TY5R@8!04P-UL
M\]Z^#$$>U:'&X-*3Q-((]J3 '!PY5\Z8O[]?XK^>%7'%GZ>^NUQ>%9KY3;OL
M3L/Z^%8LY&:0 P]">?<K_LE& GJ=XV(L]K?GA57"C8(D19CC6N\]4#5_R:7H
M_ 51^3J'JP.'V:5F\*Q_G9J!+BK?\A_GS3_U?E?A1_:7RO8*\H4#A>PT:SG'
M\H-;YC^4JI9?"0E'44%]]78"P"5=X>8_HJU7/RY/7ATHTY>2"DY^E]J ,=>'
M>>B5 ?!ZW6% $=0HG2A!)CL8I#3*GN\G-^5BF,S:.=9'W)^J'HS4Y)1MCW-'
M]J[CQOSLN7'4$4(^"PFQFBNZY++D[&344:UG9]&_H>BN+,1_LN<G*LC?5]C0
ML>C/X41ZE'X^J* L%LC^WJ7"AO#8:=CSMUS=X)";&:,R]@<,Q0CB[#O J^_#
MT?-]*!&!P'6<PQV.O#><<.):IR%N><SIUU EQ5QT[#0?!$*79+-EZP2,%3A3
M"3&YR^3R3J3C$0LMX)>\[VTJ;KT%+X2<([:6ZD*K<O9J^?LV#127SUIMCLEI
MX&F2P=I\,<.KI3?NK0CG]>:W>/4.SX;DG/,=2I%U@ .*+W]?3JG 0/E^W5.*
MNT4^! J% (=KY]BA&YCI#]I&'Z].F1Z5JPV6NQ%$6R!S(6+C@:8P"2I8BCB0
MR.R*FI)(0LD)N#*4;IHZ%CB=>F,)?IX7#W?9U(-S?M1CPF[=G;0<US4)U0/N
MO\ZK#-Y[4\^W=5@8'#\48*!G"FTG;GIX3 )38T_V:@+0]AU3#-Y[4\^W=5@$
MK,!Z_E- -6E9[@+/@*;D[F+B'Z+4X##Z=5AF\]J>?;NJP%.4G(GW%[F8> 3G
MN;6H6/'^?H7YSMT#<)P<6)H2C)RF0&JTS>>U//MU+5Y&40JTBCN<3+:=5Z%*
MEE=@NU9P2S86'M=XSX4CK$+*3U)FYT*&>I,7>E)* WL=#8YZCH\)*^1 AU$T
M3S;L$68EC2T-SOJN6!5F_<\O .+JN5*R1+0L#!BH( J7,8J1 +U?M/I4V:$S
M5Q^RHA,3J[$,:4P8)T8Z1IEHY,'$^G)0@^(\OL?#@ZN)%L:N63];T.3J>5!P
M>JTE;])FFS$4X#H.RI5*I3%2J+QT0=89\ X.752$-$5D\:4)DJ!(YJ@2"R41
M<-"GHBL76B74C2]0$;FE(S($4F-1CJ)/0>T)CT)1Z11T>F#S]*6\K\*F@6T$
M>UQI+L7*LKS6LG*LNDS21I3.[18S6LZ5<VK IRE0A2VDUHS5]:9>!L7702''
M;/7S\J<]HL^"7UB>"L?RB"<7HQCBM%H4Y(<ZM;*O^PZ!D%FI'>5= 7-*+#".
MH]=PNJ!$M8<:E46:E4+1=>DJ&8UK]4[,5%IZIGP"[)U969-.(6ENAM2LQ#C3
M)T;B1%,DX;%$F/@K6FA9.=75A51 QN:1;'J/7<=63$E-Y-.:WIF:R.]2M-.M
M?BC!SKXM6'59^ 7'-W5[8)>B7HEJ7I'>EEGP-+,TKG>FQ-7#NI8\!6>ZWJV7
M5[J)? :0*$$F.\8OW9A!X$B9X[J],)'NHGP-!A[L(<:4I[H$T$>!A1DS0#N@
M3?-)<[J$>"!1DS16O<@U(I<TDTD=RS01X+@M41N8[;%VM#J8FF'<"5!'@Y1.
MVA&YV2A=HFY[!3*D3M 6C=X1%,4'-Z-8H36N.5QBN.4AK3I32N+4KEV:*G4/
M6AJ= \5VZCMVO__:  @! P,!/R'PHH);%64'U/JU&RGBA]41B<Y?TKRC_:\H
M_P!HS='J?K6O3DS]Q5D],CYQ\U- X%_$\4GV>13<(WR]L?=/3S3'M@['E*!J
MTIN8?X^;U\H%GSR\1N' ZUG]_P#C]?:D*JZO:BC)FH3G>CR]:)&7Q!)&VAJN
MQ7I@_P!;O<9"\S1YU/+1GRR>'O;0:K4X.1H'#N81D-:AUF8_3A]>'&CCS13?
M!H;'G/=3:0U&+6EL^<>&[WW[<7?^?[W<O)M;GG%!TDI/#/\ S8U/YWF%<6?T
M?OOX84$N"GY:.1C^]YM\--8(3_IZ>%YD_P FOQ;UZI8Q!"2C*$&Q7"<>^O"H
MXL%>9OPX;U)(&)P/1;YK?'@D^-*&0D,$3C.],]N)08PMZM%#3G"SH>^3E19S
M& DQI_F]) @9Q4II0F&FYV/^7BH,"KP2NQL<OFZD9(>!8>/2/FM_97W_ !IS
MP1,>B0&^[EFT%VDQ<Z@>HP\)O\5<\R.T;;\:19L0(A&8T];GKU9M,L_?/'PO
M!#^AN_$=44Y"*6X%8))@P:8G69X5' N1C,_W[IXA%PV1A.>-,T5L(5@<P?VO
M-<*6$@WPJRHT\H?MGG18\!SB%+%:+VUCDFSTE?E#M MPQZ/\=ZU$P\"#[FA=
M TP8?+U+3,5.)8"8/LGV8QO1-3( 4>))G35UGBC\%.8U&'UJXS)E9;FT_IQZ
MNY*#R;?[X7XP+Z:?'?-X!?CPK$^?I=A%F^ ('3^4I\M"&O)_I21W-I'.8OPH
MD0#!<9=K+4IN!O\ 29I9''</M*>;H+,^W[4FQND?I8H#(*2^#ZU<3QG:;<)G
MXOI0*L.1]I0JF@3%L;S,/I5BK?(_31"5FHLL0?>/7KW_ *D^?"LYW ]T.PY"
MBP;$-1:13>*<9AO0!%@^T'W+.]:NJH9;/N_.],46:V:/6,&C!:D"&(4^%]FU
MM8:*)D1,W6?WA(UIA@?&;^]ZNMTU<7UT+C)]Z. ME#A5BSTDCWO4=4H#0S.,
MOPAH<V%6)(G6U\\:F(;6[-]5/(,;W0G5UW9\K'A7YGT=ARL,CZJ3<Z*3[H>\
M<*LD8O1-[OM!ECWGZK6S4N5N6^.>N+%>9OVIZ7Q^2ECX]:LA$2;VUYUP5BI*
M;PW&?9MZ5%!.W,^^:G[_ +*?5!(2M99]\T\$R YY[U]_#&^,=?X/Z\*B?,P[
MZ+GE8\*Q3B^">^\[+^?GA606$I5R$>W0-CW%?]M_*2S[BD1ASW>V<-_O?]\*
M8KB%1PK3-V>%1_3%+:Z_[U!:ZF^X%0X\HVKTRPD]_P#:!B-V_P",TD6<]E E
M>"@)#BX_WXK7/D_6AXD\8?567U"OW7_!H./0J?5((]-+[I.B<!^E$1&'A("<
M*TJY1T63L+LI&A8!Y+_5<L T<S7T]J1&'/6D,\F7!ZUY<IJ_\H'D1GWIN%+U
MQ,MJE,4#-ZYIX/"R]I"<NI-*D1ASV,\8H%' '7D\^E3A*XBYR5?O4V^XIROB
M_M:Z6XE3!G1UN>WWRHB9LG[VP<LK"Y\%J!+BGZ\1,->Q@U-"- W?\<U%<$(_
MXARCFK!ST?04U/KU^E.7R] ]G[II&\NZ7^/0.-7W._L>0=;&*DMEX)4"7%(H
M.PE,Q3S.P[S"(VX^W%[#BN.'5Y7+UB4[-WDX[?DX-ZT$U?S\X=A C7PAD_LA
M>##K(H9:CTB87L''#@2Y1ZA3!@W"TL-\1M#4B'0 -KPQD=GGU'D+D'18/3[M
MR%6@Y.M'=X0B!'+W%9Y%:]+UKYCEL<@L=2(C-<,8>";_ !6Q,!EX)@@WM?>.
MK?26_J]IZI)=CM(W'P($C%)(SVT6,]*?F)R_'KTPQP%Y)NL3/M4X$2$BTA-D
MRE Y5H$$S=1P"&FXB2BB! WWA8N.!IB)"N;YMF3IDTMT<;'L'NI(8[A$B:&2
M3P'H^WOE&HZ%L$M[!_?OK<D/EFWJ\E#47S&@6Q17.?",Q4QW @D.*"@ZG8]U
MUG)#Y9MZO*,L2OFW@IDK$T $'<%<\!3''N=\0^HP>L)Z];DA\LV]7D_Z0&/8
MCW=S<^ :QW-"Q2Q.;]_4^G0N2"29O3=N:2%6@=!#Y9MHFW,4R U&A]]%LT>
M= !00&ZV*N[A=NKK[XX1W-W3P"YZT:X,=1$LYZ 7'4!;&>D8O3&SEJ;GXFI[
MU\8!)HFH_P",(G8/C!>TNKL_@ME06;]S<'P#EZL"L5CF I"5G*IE9C6/.?FE
MIC:M8^R@$!8NJS_10ZB8^]61GF+T="Q]JR=*85@D8,G!^S#K2+P5S![G-?BZ
MN?%NZ.>!][4E)8\K7BOL45W29JT/8J6-%%[15X**";4))M%<PJ5L0T)8VZ(T
M"W/6Q\_ .;GU4J&:9;HX4'"-2TO)0I38TEXZ1#<JS9M;1@!UM4W-+6A(A*?2
MC(^E.>HL64N52[7Q#FH7UFGI,YK^_F@:3"RAJI][*K,QX @KY!67GTF:"P;4
MY4<I4EW5C8*8FP.C.>IHW)OM2+>:0F^*AEJ$<'5,^ <O7%4F:;W[7+KW\I6?
MGVG(!V&#P"(ZT'")_M)69M3/)-09-7\H0RY5?W7ZU&ORHM>D(;D5"+(JTILX
M:5)8SV89J;L]0:E3,DLT*2%J FN2A20M0E!T",)M4N)0VT7FF3%(8G3JX? (
MN=5FX%&1*"S2^*%VBZ11#S<5#-2:(@DN_M,2?DIE]!3(];582#<JZ%C-0)8?
M74SZXOL]48:M29F&LA)4W)\*U"7K5TA0!HQZ/W1CA/FC"C:_#5@ZL> <G)W7
M'KB[JOKJRF*5<U!AJ6H+#:IC%2YUJ6I8C2ITTH2<VE*>J;+X!22*D.Z&_6!4
M&:B0<".ZF \!78]U-^K<7C[=UY3X#"905+/=!)U 5@S2 '3//NO.'P)(1SW4
MZ].[&G][K.EP>!I\G=#>DBIV@S4CAW1%!0"#P,@(<4Z[H91I6DL.Z K!FA/'
MP0@(<4UYW- !&%&8:10]R!4%%S^"Y;Y4B,.>V!;&:U?96,=*!#3W'<'*:$P>
M#;+0U[Z1L<]D"V,T[:=A*\%FLIVF HB]SX10;-*Q:G02D]*X#7#:X#0^E&JE
M#S>CLP7PITJ3R=8;!0V;4'-_%;NBO17IHY*-L=K_ /_:  P# 0 "$0,1   0
M                                          T^Y@\
M                                      I1))))(
M                                  '!)))))/>
M                              'Y)))))))-
M                           $)))))))))%
M                       &))))))))))*H
M                    5)))))))))))>
M                 )))))))))))),
M             $9)))))))))))/
M          $))5]0QKVT75))@
M       %))*_[E*'2'7))
M    ^))))))))))))))
M Y)))'OU%C5KQ))-                                          A)
M))Z&9*IKJ1))+     $  @$DD@  D$ $ @ @@ D @  D           9)))
M CF+61!))+     @$ DDD@ @D$$ $ $@ D  D@  @@$         !)))))))
M)))))).     $D@ D@ @@D@DD$ D@  @@@@$$DDD         !))))))))))
M))).       @$                                 WAW1))))))))))
M)                                         #<-H.>A)))).K_ (?0
M                                       ![GDDDD(D2295K;;=(0
M                                    !6V4DDDELP9?;;;;6VV@
M( (  (!(    !!         ! (      .6VVTDDDE8&^U;;;;BVV*  ( !!(
M  ((()!  )( !!)!)( ! !((    !VVVVSTDDA%MMA;;;56VVW0   ))!!))
M!(! (((!)!!!)(!))!!))     VVVVW2DE;MB]LA;;:VVVVV
M                       VVVVVWDDGMG=MK;:2VVVVS
M          ) !(((  !ZVVVVVV"JMH=VMG+86VVVVV^(!)!( !))) )(  )!
M((!)(! (!(!)(  !6VVVVVVS+-LVMMNBBVVVVVVT  ())  !((!! (!!   )
M!())! ! )   'FVVVVVVW4=LVMMHZVVVVVVV\
M         &VVVVVVVVP-LVMMC6VVVVVVVV0!    (   !(   )!   !!((!
M))!   "VVVVVVVVVMI6LL2VVVVVVVVV8 )( ())( !!!) !!))!  (!  (
M   (VVTF"RVZG8=MMADVVVVVVVVW@ !) !!(( ( !)  ) )(!!  ())
M"VWA2^I)'FT3ML,6]Z(2S76VWP                               "VV
MB)(,HOVWG@.9&]:IA,NJVW0                               .VVVJV
MVVVVW[\K>6VVVVQ&VVV0                                VVOL>C:<
MVVK;;<&W@\]KN&VV0                               ,VWK+W EYFV+
M;;>VVL>%S,*VW                                 VVVVVVVVVVK;;:
MVW,YQN(\VV@                               /6VVVVVVVVVI;:*VVV
MVVVVVVS0                                FVVVVVVVVVS;:2VVVVVV
MVVVV                                !,VVVVVVVVVZ+?FVVVVVVVVV
MX                                  VVVVVVVVVW+96VVVVVVVVW
M                               !6VVVVVVVVWL"VVVVVVVVVUP
M                             ,VVVVVVVVVRVVVVVVVVVV&
M                           &VVVVVVVW/&VVVVVVVVV@
M                       !,VVVVVVW4P'6VVVVVVVZ
M                     !UFVVVWY0  -&VVVVVQ
M                   !(GL4>P   !!\VVW^0
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MUS]%@ROPJTVP@U5*ER3COK^)&/,V@2F!HW#0T9LFT5-7?V!@T*.'L0V62W]
ML/[[0K C1[!$T!<B*"ZE7$?V[[ZJ!H/Z\_(9YKHJ7B9AUK3EU->%3""T#*84
MJ] EV1,.8+Q<3%;0!>LHV=2G"$PM/'%U(UR&!V<< H<=K@8:)4-T5*RG'.T)
MO$=9#4F@P&#  RZP;=LP\4!%M@S*0<H*C[B:O<LL#S49*9/M'/$2(J1.5Z7B
M>'E$HK*IZ;U"U,<'ZC384W'1)<5J@U%5@Y'>(F0@MG2G+30),*@"8=+ -'D:
M2U>K>5.A,IO(\ 8XCY" 1;M=W=*"U&C% ZBDNF(49:C_ $L_0PNH+1S,9!R=
MZ ,[25->3IN;S0"@*Q<DG[983$D%4%)TP^5L#@T< &S+5W R"AIJA49DX'/?
M]'N"+I:V0"[0\)5\_I<;5G&K1CD>*7I965 DNI6%J/C*'TP;:+ 3M:4"5L$H
MP=!5&(@G2XP<@S==%GHZ!#_H1$NXB]K%)/-4U?1860!8 V1HIGCV  %>FMSG
M\JUTK&>BU7,"2U!)&LG4M;W5=F.#H'IY?')?YR*O)])'_'&4/(O?*@/G+?:'
MM-:4%$80+40BGL8?-*R#N%;HAI4<7RO:+,/I&4+M=V,+ESJ IAC=:;ICXN2K
MKA%"#(C!7B02T]J*3)S*&.*-7;A6D3 )J$B(G26_6-;5N):V:TIEG7*%(:JO
MF@H\])QQRA=B<_@[. I]41RQ4\:9I>LHJ]S"8#$*V1,($MH7?5BP):SO!,%T
M\#V;-9>W/<[SM"KM2@K:,(U (7H"V6V_(2XQ)G%142,:JP T+.^: X,K0Y2!
MJI:*:O1 E"H%=>D]3 >PXDJ'QPETNGAX:547!++JP)>]A6 @#?-S62&R?SZ4
MVY2M@[!$.:O!1UYDU@Y(.U,>I,"+#4<J1AH@N_/COD;/$4YZIL%(,B5$G8VY
M*<\ W0+@#4HC%)@X,FP$'2^F?"0P\$S_ ,E^90M1?XH6)H&Y S!EJ5:#*_.9
M&FWY.AM$8 SWC&_D8JR7NG]#-YW1D%;%:ZS@]Q/4#-? JG?R06*7CM"W") :
MEM*+G2H)'DKYF-&H<E=,\I J$]7& =([0KS6"'*K;;AF(]R=G>5Q(JN-/;8G
ME)[R$_&?YB>%K</A6,H7?4CQHD,D^D1A6."6*3K\>8,:W#CUZ(<^PZKOZYQ@
MA0LR@X?]S,PN:)(,Z%N@DIS517B=#ZB":U! (**"NUU+4$EH)A[<PDUXAP"5
MDS"!N31H@=JK2!4OVKJ<LJ$T.--</U7,K":1D]'@@EZ >P 6$VP+8UUC9RF;
M(%2<$2T$B5Z*@^^D9EJDI!9 !&<ZV#)2=G"ZRSR:W'MCQZ;T :(Q:5/<?",1
MBTH_O11;H4&<K)8*04]Y#Q(_ZXRO,[P+_>1=S:)!C,JF6&<WV</?%G-185#%
MEH4 9D[: R:BQ0#?5#VDX5AT"<Q=+KI04=D?G0);MG7@-B;#1#&1@:6%!KVP
M_H&F84"H JL 75< :K21<<%QR:SV+]%U@/EEX7 B8HG,D4B9P"@A"$"7.[GF
MO-:R(!D+QV>%$0E=0 W5@*D@1;#Z)7T57*D?A5?I"YVO3IFS(N< XJZL*\LT
MFF9L,%[@U[0>/0ET?<7"Z=.871I$%9HJ)(HQQ35*[M*&]8%%F"T7'-&AE+$0
MB-RQ"BY>Q;[ .%-'TQ<;@412"A$$1&$1N(]DILY/$)0L *T*'1MR[FRF9QB9
M*GRX'P&[8V,71JS#Q.>.). *B J32#1"#$A RG"8+ON]'B<P=NJ"$IBODUS3
M*]G-0@]+A=;&K,Q@R<N0CE,"TN0+E.=O;PECQ=L>$E!?J[KF F%H"T]XYB.5
MXFP<%/*I=S(>P,>F'0DG#4LJ%$*)=!V$U<B*42%)^L-J3AD,@ !'F"2TJFEU
MRCL579Q":S)TB9P"@A"$"7.M+40"Z,![A4LBE=F#^ LL%W+Y L49E-20I0WE
M!84M2- #<,] @#'7>;%(DB;0I@DO"'!H81V"KD@U#(;(;.PQGB*)C4M91:QL
MY6TR=O!]I!DDE>9BX,&^E*F_56&8*)6@!U(?!*4@1A%0K6S#6B:#L0+2T[%'
MXR=21DK!!1V"6J,XRR9$;&R6H TF9X(H@4*0&S2:DT"Y$8"AB#8N=*9180QV
M40D!%TL:Q2E)+!XDE+!OI3, M 1$04)$!%H:5T:PI,2;>A7U8 ]DL[R 1OM"
M 33C/4=&-$JH%M]8Q$\#6-,3$",HF.*8UCLFV+WFI<DH0\29&J9\'?L:.?4*
M3KR8LQH@9R]1Q),];\B6 *L4#W9@[MB-<*9'IC<9;\_C,K@"C#;2$4HA)R(C
MU/\ B3TY6K5PGJG04\.4  2K8*![LP=VQ&N%,CW9L=8?+S\EI&*\BDMI*"\/
M45D/,']1/MTJ*4[RR@KH\=& =[ UJX25U)G-Y&\4&5@J3;*@B@,4*<==#V>2
M<%+0#*M3!NBZ&=<+',Z[==HY45I$ 6A;;*K)[&S[\0F'N++:R-+%:,I@:2HQ
M$-Q0T=H[@X;B0J!+1Q@0,:XM^)E4["3_ )%M4B(E$UH=H)&^:'KT*H,9.-H2
MLT@X>?7*1#0)5V-I\*1:*2R.4.>L$XJ)J#42Y4S"BQ3H8B;Y<->P;%@>GKR:
M9=H\!"7>])B?OV-]6"\$VA*5LWW%29YJG1DP-EN,8R7!C5;32R4T(/6=G.F#
M^%Z8Z4H;02&IQ[+ID$MJBU6%Y\CP)N*.@ F#AM@',"0*R]E^>_UU5P\!(."'
M2FFB$(]7_1Y]*"B5RC,32YYE\94RCRW*OH7?<MU6H(YXEHUPS9&8JL/7'731
M0M(>+,?*,=L#^K;1"?OQ!Y#[[+J/Z:U?;EL41)H.?4'%Z7!(K6Q\W<,7/B9!
M#]9(:G'LNF02VJ+587GR/ FXHH$?X2\HV,WUHC5?U,?I#;\*: '1Z8D0X=U$
MM^Q<YV\P^=&11"?OQ!Y#[[+J-V**T2(3I0?MD[45V,Z$PJ2R93\[8"2M^:%F
MDJ3GYK00 +4YAF'O*J/'<H7VJO\ K#2-Y+6E5<X"@_$3I3VX[;JE0Z<+;VK7
MJ0J0I,8K).T@=3WG@2*!<E-]3823O<]"55S@*#\1.E3:>QH#A'\&DW-?J4XY
M5JP HJS.@VB3UK*H)D8TJ_VS.05#!T[0;36P9<.A!&KZTDB57@6/"2QY%HTF
MJ@$](ZJ<>-^-EI^URD=N-B*.B]9#_$QN,C>J <R)Y_\ E6ZT4P-CJ>WO;]T0
M8219^(%,TI)1$_-FN].$"4,S"#0/4Q!J0<794X*6@&5:0)JK%C8-9T-.?86Y
MRN+X99!LX J&,A09_;J@:I5 0ZS9PA3JYW: JPC3A%D72W!TP$+(K52I5RK*
M\UZPD7AN690IM61)F&FT9(+ 0C =UP O"4*':J104W((I8!3&.Q,2O8*U%1J
M5MDN98]2V.NHS&)>2/&/BA.R"1;NP9YNEI+YL_D487XDI1J,O3:J>?6.75^-
MG9?@7M!!7N337 %*+36^;CO =9XUJ>0K/FWN9CU?9?Q#?P; XZ&./V2A.W/_
M '7[(A6GS$H6DP/\XC%^*>VJC-!><7)&97E1Q%F!-5KIE%G='23_ 'LLX&>"
M@.:20L\T<+ZW5\[W[-VCY/QI%?+7SJ5[Z8*X0ELO'PMCHLH!+["'HN6LJVOF
MX[P'6>-:GD*SYM[F8]35BB\+V'RUX(*SV6.GHY0&?'^I!%/7HR5&KRK*W$+%
M;+R?C2*^6OFYT_V/Q!P+#1HJ5?\ CV:6*'(..LTZZU3R82#QB_#6S9^^: S'
M2"YMEGAA(GBP/HD#]4\KLUNVF!3XPU+)TJRT/(W*>HI%IM'UTK$S(E&^?)$#
MN'H91/(.ZFS]  .S6[:8%/C#4LMA*Y2XOX#.T$A"@?#4R1*J=F077GADHS;$
M2N$*Q1Y> K)%3@!@X/>]ZGJZRM^,XIN69:=P(R*G=-CAAK%$5YO4W.FP1I<+
MX%1VJE;CM%]OXIZREP\*K*GJ/M3*-BH>U$R<P$%-@%%@LZ/G*S_NCL\>%39J
M$/Z>*]NI1%OZ]2@GE9^[+2VL4YSBN-%OMV0UUQB]5\!>LDY*5/TQXL(@<B-Q
M.J,UQ$,TUI8NA1):X)TC<18"@2%'I'A5N!U#+@TE*&6<<43#C^&AZ@UZW3X;
M EF6%#2NYN (* &%UO%2*U: 1%NJF\7@[%6_N25=G7W^FW@9;09 W9AC:Z&Q
M/#M!#5JR$$5AC!+5K(HBD$"B)")9$;B/4G7"9S#9#-A-'5P!GR@&P( E;J[?
MJ+BE Q53UQ9*(!6D&I#\#,LW5!C#0+)  F2FA;.H[X ,ATFL!8B_@BGQP.R%
M$11$1&$2XB82BQJDYQANL1L>9UO7 Q=Q[:[J&1"CY,3C,^J!FN H/$:/KA<!
M%D=G0!&( 803L,A",@VDUUDO6HBN;:0<);417-M(.$M/WN(44!1Z  .F19'&
MO31:?5Z*7JQ8)P8;:^+>PH7+-%">^;H(Q>G*%XA"O?!\IU\S=J 6T^[E/2"^
MFTRNEC,B+'H-M\C/VD_='3_TVF5TL9D18]0A7_8#E5>Z1T#\G)M-!;;M$05S
M<FTT%MNT3!T^O+!,^Q+3'%PFG>()9EH&GN-9Y+68%O95#W;4;(D0L:Q2K8F!
MW,&%PE@.Q6M!?DW7;9AIC8>MUP'% <6D5EZV&."0' [5*)@V*2DAF4(RI*'!
MA@L!0%"@1Z!QQ>\0"9G2*7!4MQ!!<&Q"63ITJBS1XQ$,2MD;5N$-%H<9S+#3
M1)F0HFD B"4.U$P",!#JJUD%;-#12'.<RX0T%=+M_%]&+%)&W3H5IO"M0V#1
MD*4^4N;ER8E(W@Z4E#EHUTR<**^Q90     ( @ P=I=,G$\%@_,QLPZ5 6-M
M0DDT34R/1L[.AGX2QE*>FK3. M=%;7**A3#F$GKZH# H=^]Q3RJH@@J-:-T1
M_!?#(JFG@V=FN?#U@)(=^2.0'BLRBZ)T "1"S!= QF)O4\65M+3//0#),BJ6
ML<4!^Y8+3 ($0&LHN4?A33H)(R\AX-0ML;IP*HA&]6TW8OPC%61>^30UZ6/+
M2<CMQ_%K24HJ(/#M3N0/E/)*!8X.M O?L0JBE3;+Q^1\]%53PS&:3AS-+V>7
MK(,>TE@*KH2,8#UX&POS5MRJ6DG4/55P2HQDP9.E\#-6*;0%?T,CZ_T3>U+O
M L=M8M5=3LD2KXG6J>BXOKKRLR:^Z(FL2%*9KNDR@\W"GD%_<#DR+5PQ7>^A
MU'61<C"[Z;/S]>:#<G7WKG3C;T#2@8_2\'&Z*:7W26\*#3IQ;V<?JE/8X#T(
MBT3_ '5H,--9]?AA,4U(6$__ )O#2H#GH+EIJ<]X1_5VH .%&YQ.725\CSR(
M0$SI4-R)BHR"PII :#S>BF' $:3 B:G*U9E(E]<6PEFZQ.7@@!L4X#(/C:8-
MS_041*L %U9QO#9- N!<:AP/QULU]2JQP9-]Y^N3>% 1A& ZT8]IO<EJF5C@
ML"13*.ZA)C-$?]<;F[:]> 6C*5WLB8$MU)M+N8T-FIFWYRJ#%"%N<2/Y+7Z]
M?MQ$.]Q^1*.7;A$&'!&#TD6&8!8E62@E"2X@"0BR!)PIFYI/DI<G5#"EG#7B
MU[G9S3*V:!D08")?7T6.-9=#,OJ,T#F*:JBU[-Q&)$!<H%2B'![G$HLT"-!)
M>VE=>4V](^:#FVZN-?5I\KJHA67L.YYDLDWGV1/81=A;!2E\414X1)JQH>8O
M2&Q8:%E^:G@"DBDZC+LQJAVM@5$$KL98/P*B>PB["V"E+XH+Q&;I/SM*3@[Z
M29BTMLE5*\ L/K1N.G'0K4N)KB&X%7(A-?39.=F BSKG+D7B)2IG0SA"II9'
M,/LY)<VB4HQ+4;(!#7)04 V.,1NL0:-$)BM[$^OUL]/*/&UL*PZFYJ)[3,M)
M1SBB:TI@]Q71>*PKUM#W&ZPBF6(TE!"4H5UDE!$M"Z43]9D4$*;] H2@;GVP
M1PTK!JC"RI+U!DYC?!.EG&T]&8+-5$'@. M(T9D(4-RN.[7;GJ6Y0,I@,\HI
M.2]):^W7FA9E'>.IB.QH^PWZY0RE9$>I^H\:!ED;LIT'AC$S!Z(98("US6N"
M_@9#M8(T4U"',A*E30>IMF@JAG4K8O&BVS&#VT./'Q2A!1HFX\?U,GND0I4C
M#T!<:9@IN$P0&4F0BQPD&0U$.#9@C 6,64<5)1!L6C+'",Y*+W$J:I3!V.*%
M*[!I!FMC-1/<;]'V+8;LA1X;O)<4S3)+>R77FMM=($J^SIB#9_(E$[FMH0*#
M1VG2H$.Y4 RWD.<[%E*:L]_+.\U@D6"!Z/-T]PA= ,\D,E6;8VZ@EUID3+\8
MLK$\#UE(E"D< 2KR"I5Y('D<LP].X0UN($1)X0$<B27J3%O:L[),84E@M26T
M:@8I1"2*=G-,K9LSVK$W2\$F^G%)4@+0BI&;Q#PRHN_A0DA&"347N$R%@#*?
M)D]:1(0(80D3@CX!@0PO(21ZD[D:6'=,YG2I+&N2,  JZ9SCLYIE;--(] 0:
MPXB% BCL(>!P! ! &#N4D,[Y1'T CT[6)R;H+H4U^'SH>Z[CL;:BBUG#A;-O
MIVO/%3QIFEZP")T>MHU>BQR%"%Z47J274B8Q%'04\.4  2K8*$5*[+P4];PB
M]%+C>3'(-F(!\ @#WLHS6I%^L4B(/4_/L*(D/#^,78I9F;NH@KI_VL,6HO0G
M_8%4\UF*0!:=Z!2R,^8CV]#.O3;_ 'OO3_7,9-0(EI!ZJOX$4]1BO5O2^JJ,
MW=+#B&H(WZKDN-5F[\9F:$<'B@_KF,FH$2T@TD]/5G".E:?L0+F1"_W&_#7[
M; T WD>W\G<XSY !5!86YL9J["%CW"U $2N5=&I'W;3#.W87&AS[8<JO69WP
MF$Z#*V5,MG"KUF-L8D=Q9J+O0!#<1T$:H91D751UU(!=8J"<#54F983F5%1W
M.!S8=LVOB#[5L[.AGX2QE*>F.A:US\!!1 #$B!U_!P^R42DF?,[7!\<2X"\[
M$&NL6+P,])K>^ISH)@KB#K[F6]/)(!3.VP/\T;>6'A$)K$A2F:[I,H1V)B2D
M7_".$26.!(^9/ ?$5*<W(1Q'+<MND+XA=M^K4QG]0.SB:A7746V:BMF<.A$I
M64E*A-: J7M7RH(H0?7&)C<4GZ" 7R8#LWK3\-> 89_I7 $T9$HRNF> 5$P4
M"2]J5X\-+:/$0I B6,VH^6W4"A#H_H/JM%D/AJ%MC=.!5A==(M+2\IH] VS3
MW+"C20%)(9.INTC-CT'/C,FT!CWL*\<&P2^228J"5ISZNBHXE8T>J,5%E-.%
M[. HMMY7,'B@):,S>G$B8PB>2&*@8V3$#@:F#*0K9G#H1*5E)0!C2;$9F;S)
M<3^('VP-.G6HPT!EHSNG!!M$UZXG&[]EGF\*/\O' ILN3#J()5]D,@=/9/*)
MU@Q]!0X6J2MEZXJ%4[\78;>7JN/1W-UNT4KFGNQ\@["5G9)KG8-$/;'#54OT
M8,0M>PPE72#4O;_H41]LF.>CQS^59D00:.ZP$4>#PX80?G!#BJ)SE"AUJ'4_
MQ_[V@"_[J9$3U-K[A$>V"V#P:@5D1IM'YT[ JD$VY$5'%P*ON:$/7_P@)ZS5
M\E"]%6<Y$F8U+DE0Q5?4"*/0"1T / (6H$A2B'..F#=#2(3(]#&1#N4Q'V#\
M73&@\MG9)B_.XHU+DE0Q5?4"*/0XG"$!4$F21HUPIH4 N65@,5W9IHE ,-F%
M B,*$03KYL76@'H*4HA\W8$3AT"SMX0962 )<%[EP]S;\Z=0AE 57AX$D52Q
M0QZ//V26->BFD6ZP1UE3,R:(BQH'SFZ32:M][L^VH[LK!6R>V'WG&5IJ42WJ
MJ];)@L+U0> X"TC1F0A0@QJ$1JSF@.59:?3U:TS7Q@0*F7G:VQF\MAT$20U;
M_)PU;U=6<Q6UM2FSBR4G:#;.6TFA)TQ*\_S[."V$]%6IJ#UC_)PX"_\ [84F
M=D<)*I\U<7BTP\-1"[DZX.A^4V&DIY_6FQW5*BHC%E>@9E<,R/1_#XG2$;_7
M8F)-)(Y#UA@H="(Z&-SLAF.%'/X2:-Z6>!^F#DLE]H\N!7U$6)-6IQNZ04U0
MTIMI6+'P&U95[#IXKV78%H*.P&/M3CR/0)Y]%0XBKOW)0. 21$3=/(TA=%G-
M@U/6P3ZH[0;9RVDT).FAT=$3(S6]2ETCH[;\8^H2&^B1!,&E'R"N>5.CN0Z+
M^% </1G@Q\9&QM(LEJ#MX0 ,")6CS19CUHKUR#)?;H](F1INK"U*%$,I FN_
M:0@IF3P7?%K +T!%HCLL1@3+Y-51="4'R7#/U,3&C6_>,M^%&1H BF9I%%?9
MLH<TMT- 0&5@X$"@"#M*HR'>8*N!6-Y356R\HJ](F1INK"U*%%?X-BSALQ2%
MT!GH;>IR"X-24!XZ1O+;+@^OY(=OBWV.JO'T_5NXQJ60#/=5\*6K6:##BI[!
M]&6I O!:S7+7DJGBJW)6ZX0WUFA)NFF![]L_[AS]!A:64QJMLM97XEZ$*B9*
MS<B>BAM6MQZ:<(&"*OG;B!9BA"$=YY[]_P#6K=T(/FZ8YXPZG4BS6 '0Y@E&
MYA09JW2Q*-D,C2$BA56$<,JBZ:80$R(ZL'M1#=BZY[X$,*G9::2%"[N$0T3/
MN)Y\-AE  Z=,+%V0F8JK !$2K3$9PHK^%!4F@1T!H19;%2&Z'MQ4A0I$9CB@
MKZYUXRI%]F:'TI1>\)Q\!F@AU/CT&MMZ04L#8.P.5F8P 6-!8EQS1/3C4VWB
M)@O%$^*\=!$)A4K\U9((.M5]4B:,R(>J? /F>[JM)P0*3UDB!$CH([X2#F<P
MRN(A%N :@I83MJ+9T.@U#Z<K5 JGFO2$$+I)Z;(Y8?9N7--WXP3;<I61.!/&
M7VTT3=#$Z;"&_3?.##0-C^WWP'%#0!6M,P'8VH:!JK.ELIRS,7TL5RI*W4\
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MP(%E0H0UTBF(1P558G 6 ->= 6LL>$84+45PY45''H2'JZ88HA,/[]&M#@"
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M+X%3<$9"\XZTD6;)9'3JX1-A^M@?>HUU >I"+MPU'B:\J)<(A."H<,T# V
M'BKR9M_%9N'/I1'\=!OF_P *8UPCXK!FM'H1'M[7_]H " $" P$_$/"@-2X
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MUEZOQ%Q[2SN.?[X$18!3+*>U&=O6:/\ '[I%18G0$L4JF$B,0)]))C4@VGI
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M7^&W^4I< _56N ,, C$R1Y]*"-;/6X^JE\P@YK?V*Y#XQQ,VQ32T;\UM+TE
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DF/I6: ]_/O5QN<?Y0 08\5?Z44[_ *_G0;/OC]K_ "H[7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tm2115679d1-bc_tumor4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-bc_tumor4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!C .2 P$1  (1 0,1 ?_$ 18   (!! ,! 0
M       %! 8'" D#"@L" 0$! 0 !!0$!              $" P4&!P@$"1
M  8! P $ PH6# H&!@ 7 0(#! 4&!P 1""$2$PDQ%!5!42(T=+0U=18*87&!
MD;$R4G*2LM(SD[,D5-2U%[=X.<'10B-3<Y0E57<8.*%#TT1%E;8G-[CP8L*$
M-G9C9*0F&7FB@V5&:.&CP\1GIRA8*?&"A:7&1U>IN1$  @$" P0#" \$!0<(
M" 4%  $"$0,A,01!$@4&<8$'46&QP3)RLA/PD:'1(D(S<[,4-'0U-@BT%74W
M4H(C%CCA8F/#)&0F\4-35%6%M7:2HL*3A"471]*#HT1ETT5F&"C_V@ , P$
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MM=VM-HI'%_D3PDSGESCSQV.=Y&1K;$M)S-BNLXAS3D:OO4P7)F++4799:=.
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M1G)5N:DT7)Q\N0)(!(Z0PLG[L#U*E"H_?(J&[=MXB!4#D]"HH40'0A??0!H
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M@[S9QY?^!V8^.5WXZ+W'B/P3FN)]]H^6W&2FM,RY)6)WQ\!^A'V:H5A]-U"
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M_+".KD/3.WK2)W$]%JY\C#/2OBLVX%9NNR54$$@5A:JK?=)_&;B1SSX2RZ>
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M1RK7B/0/V9VCT3"F@IN4$!#9=$BY0'=8H[E*?8>CPZ;K&\</N^C?O-]\9O\
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M#K+ .P[:;K%3@&_1OWF^'X0-_P#+Z;K&\CG7N[!N9,#M'H]J@BX*)00V JY
M4*4=U@]$4!Z=MPU-T;R.'W?1OWF^^,W_ ,OJ[K%3F4NS!-%NN9H\ZKD%A(
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M8C4IBCT^$! 0TI1%69&5D7)5#@!6>W7-X8Z.$?EA\T6@B/Q=*5%:G&,DZ$/
MS#_^&QOF=/FM-M*)#VB?)R#A.1?$*5IU2NEBAUH^/.;8%#?+&.U$QA^"(B.H
ME5!D#RDZ^99?ZLC?P35H!A(/W!#M>J#7T3!B8>M'L#])FY!';KMC=4-_  =
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MJ-4"\1 \I.1Z-F>W3_HV-W]::45"-X=\OPQ$3,F9AVW%JW$=@ H;BD0>@I0
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M942J$JNAU@^-OOG.UYQSUQ_PZ]X=0]899US!BS$(V1MR!D)YS60RW<8.BIV
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MG6)W;5%\T=,G *"W>-UFJX(KKM5A1<)F24[)TU41<ME.H<>JHF<BA!Z2F 0
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MLYM7=0JR:PEY,ZJY3/G)@!A(*!UE3#L=-JH<AMA_=%,'AUBU0JK[A"\LRO\
M2#O[,;66ZB59/BY625D62:CYR<AW*13%,J8P"43  @(#J-450JU('EF5_I!W
M]F-JT0Q#RS*C_I!WT /^.-I2A&V3Y25DD9*033?.2$(]=%(4JIBE*4JZA2E
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M.,7S-1JA4W[A!\M2O](._LYM7=1C5DMA+R:CUL4[YT8HG-N4RQA =DS[;A\
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M,EO922]7N_MZFHLAMZR '[ _(U2#&5].?]UC_P 7M=2.0%VJ!M(>DX?VM/\
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M96+-9$&3GV.C/XM[Z]/HLWU%>2%NA!E_HH/; ?6>I[/=&SK]\6ZH)C?TL_\
MXE#UTCJ2,D0]4Q&,7Z96]K9?\5O-'XRK/J8NT(3XGV3C_5C?[:71Y @F^6-\
M\;Y(ZBR*!?#\0?D#JO(+,83'LK(^K7/VX^@>8O+X?C_('1Y$V#&3^NM_:^-]
M9IZ++K)MZA;H48.?2,9_$N?7SK6*S*+]9$&AO8A+VP5]:I:GQALZQ7J@8M/2
M<E_%-_MX:CS1DO)?5X1=JF(SBOKKKVND?62^L9%[O0*]9(@SA_91AZJ2^F#1
MY%68N'P_&^0&HF&!?"'_ $\S1Y$)\O[*R7J]W]O4U5D5YL7Z$&$E]?2]11WK
M!MK&(VB_60&3STK&>HU_QF]U%EU^(HMU2#(_L.W]L77K9KJ?&+L-/??P?JF.
M7?J3!G_,YA/7(.5/S/P[^(:7Z>!A/Y.?FOP,Z=W<GM<C.^\"J"&+LC!BVT_D
MAS$8EK]QL!>NI'@WJ97L?Y"LAR1H^.@8H=L(]=/J^A\(Z]&]KG#EQ32\/T<Y
M.$'J+DJJC=8VN^<.XOQR?+_#9\0MPC<EO0C1MI?";QJN@[=UNO6<G>%N\WQ+
MF/*K3+;>C\&37VLSR>.ZUCU^Q<9-HW*N#GHETTJZBC*0:I)XL8JH*'V4(=94
MNXAMMYJXWPN'"-<M)";G%PC*K26>RB;[AN'+''9\P\,>ON6XVIJ[*%(MM8*+
MK5I9J2]\Z(? C^^KP3_2AP#_ +61FO6'//Y5T_WC2>E$^7C/X7KONM[T6>A[
M2/[]&*?T0.6/Y\N#>O.?.V6F_P#S/"CB?9AY6M_J>E<-S[?ZPA_$I_2%UU^=
MO/,YM &@#0!H T : - &@#0!H T : - 6;O[ANUEC+N5T6Z";!N*BRZI$4B
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M8]RFJLV?LG"*&XKK(.D%4D0 HG$55$U#$3 "AOTB'1TZ[KJC\P3F8V&OE\=
MT[#%$S%P4 &48AN8>KL4-U^DP^=X=26P+Q')$R<:\?-DVDBQ=J%624,FU=MW
M!RI@LD43B1%0Y@(!C &^VVXAY^L9^2^@L/+CYR\)Y>F-ET"Q^(Q,LB4"SN(1
M,)E2!U0+:*OUA'<P; 78=_.VUT':C+_ZC5HZ?O.7IL_874WK7_\ IDH[\=[^
MY>F5*JM?J]O"AZ@7EF'=NS(M9:,<K***BFBW?M5E5 *)C&$B::ICF I0W'8/
M!KOV.1^/"R1^$FX9N[(FXEXM!1)<A54UI!HD=(Q3AUBJ$.L4Q!+YH" ;:KR#
M:.1W.PB\BZ*A,Q*QEGS@J)4I%FH94QUS@0J92+")S'$0V -Q'1-4&TZ*'?0*
MIE[SOD@!E"%$83 (@!CE =OR$T(-]A$/-#72W:>F^):>B;_V9_2'ZI_H(NVH
M=GG&E.48M\=MYM+_ /;V>Z;<>$,Q$)>]X;TS4E8U-V;B7S\3*U.^:D<B=67Y
M%"D0$#*@J)E .'5#;<=]=P\):_=.G6WU%OT8GA;G:</[Q<;557][:S;_ +Q<
M,$N_P433Y-\7NN<A-^'L> =8Q2[B&1IC< W$.D-=8]J<92TFBW4W_;7/1B>F
M?T#3A;X_S+OM+_9-)FZ?\Y?-COO<J6BVG#_D(DZDX]LJ?F?>U"IN'K9%0R8X
M"XV%!0I%%2F%,3%$ $.C<!\[7*N2$URUI:X?V;^EN'GK]4DHR[>^8I1:<?K-
MC+'_ /8Z0[)V/54EW[A5%1-9)2. Z:J1RJ)G(9PB8IR'((E,4P#N @.PAKE<
MLNLZ#CF7:U@9AH T : - &@#0!H T : - &@#0"6Q^P<GZE4_8U5F1Y&.ZTQ
M$-E3(N96-;K)B7KHKOVJ*I!, &*!DU%2G*)BB AN'2 ZS;1IM8$J2L$ M)/#
M(SD.J4[I0""G)LC@<3'V*!>JN/6ZPCT;>'4CD5YD=S*1C-0$7DDP:+"0% 2<
MO&S=42")B@<$U52'$HF(( .VPB ^=JMH$J1L5?.9J)9V&,!8UB4W5E&(]4Q4
MB@8H[+] E'P^=J+(K1'7D8YJ5([J08MB."]= [AVW1(N38INLB910I52[' =
MR[AL(>?K*J,3G<6*O^(1Q G883D([ Y0E&(F*(O#& # "^Y1$H[AOX0U$U5]
M1EL1'/)QJ;9-XI(,2-%3 1)T=VW*V5,('$"I+F4!)0P@F;8 $?E1\X=6J,3%
M?-W.S N [5"8QMQ\DV:Z3M?<WQK#8FQ+D'+:K2K-Y#W.FDY=6@04ZA$)JRP"
MDF5P8ASB B "'3K4L6+VIDXV(N<DJX8X&AJ-7I-)%/57(V]YX;V";2J\>@J[
MCYRBQ-R:K=VM&-'%M9LL<WE;'%U89#HUIQE8:_;4JC3KV$>_KUVC8>6216JE
M^B7B2XI=BJF[+U3"(& )<MW+,W;NIQFLT\T9VKUJ_;5VQ)3M2R:R>S#K+^H6
M" !N^*,Y#@)DD0* RC'<P@Z1$0 .WW'8 W^%K2;1K(^6\E'.P5,T?LG14  R
MQFSM!<J)1 P@944E#@F40*/2.W@'SM9&)S1MBKY'"HGG88H#'RI0$THQ !,>
M-=$(4!%<.DYS  !YHCMJ515GU,CMI2,>*"DSDF#M4"B<4VSULX4 A1*43B1)
M4Y@(!C@ CMMN(>?JU1"3'3T$C*,P6FXA(4GB(*@K)LDQ3$BP <#@9<.J)! =
M]_!J-JA2*G,P[A8$6\M&+JJ',5-)&0:*J*&Z3=4B::QCG-U0WV !Z-$\ S\5
MF(ALJ=%S+1C=9/<%$EW[1%4@B7< .FHJ4Y1$!#PAYNC:"=&2Y2P0*LH^%*;A
MU 5>K]D*<FR/VG76-U>SZJX]?K;]&WAU:H/,CN)2,9*@B\DF#1;J]?LG3QLW
M5Z@]8 /V:JA#]41*(;[;;AJ-JA"1(V&OG50$L[#&V8,"CU91B.QB-$RG*.RX
M[&*/0(>9JI^$4=>HCKR<:U*B=U(,6Q'!.T0.X=MT2KDV*/71,JH4%2;' =R[
MAL(>?I6F8.9Q8:^9G'$+.PQC$2<@<H2C$1((O7)@ P OZ$1*(#T^8.L5F7WC
MA4DXU)NF\5D&*318P%2=*.VY&RIA X@5-<R@)'$03-X!'Y4?.'6540DFL=>\
ME)I^7H7M ?*&$GE5CU@*+9, ,)>WWZHB&V_GZQVUV%V=9'+)1QVQWA'[([-(
MW44=D=H&;)G 2@)3N"J"D0P"<H;"._2'GZRJB',UL, 5I(E-.PP&.F@!2C*,
M0$P@L B !V_3L&L6U5&2\EG"A(QSHBJC9^R<)H%ZRYT'2"I$2]4QNLL9-0Q4
MB]4@CN;8-@'SM951B<\98J^15P)YV&*!H^0 !&48@ F,T6*4H?O_ $F,80
M\(CK%M5*EGT$9M*1CU04F<BP=JE*)S)-7C9PH4@& @G$B*AS 0#F -]MMQ /
M-U4Q1F%'>.VQ&)X$\Q'T':0B)UCQYRDO&2,'8314Y'R"-8?B@YBY",>MI)C(
M(*ANFH@<BI#!N40$-]5;K=,#&3:55[,# )]@W#6'\T<)[-BAW;HJQ3?*6LUF
M9$<[YEM[64K4EAS,[Z3BI&NVK)-A@GC%9_&-5C=HT,)%$""42[=/.^8^%\,T
MG"XW]);A"\[D4VG6J:;ZNJB.JN3.8>.\1X]>TO$;DIZ6-JXTG%*C326-/#4W
MI*3,.W6,BXEHQ!9,PD426D&B2J9MOE5$U%BG(;8?-#7 VU0[6Z27)3\$M*ON
MQFXA7M7[@$@2DF2@JBHN;LP3 BXB<3]8-MM]]]$U0REF^DC.)6+9J=B[DH]J
MMU2F[)R];(*]4V_5-V:JI#]4VW0.VPZ51B<TA8J^99,2SL,8 9L"B)91B( 8
MK%N4Q1V7\(& 0'X.I$M'4XW$E'- 3%V_9-06 3)"Y=MT 5*&PB9,55"=<H;A
MN(;^'654#G=V&OF;1P%G881*T6*8 E&(]4PR+PX ;9?H$2" A\ =1/V=0. \
ME')MTG:D@Q3:+&ZJ+H[MN1LJ80.(%37,H"1S;)FZ $1]"/G#JU1#G/8J_P"2
MD$_+L-UP?N3B3RHQZP$%NV #"';[@41*( /@';6-5O%V&HOOV'C1WW2O+I5J
MZ;.4O%L'%%5NNDNF!B\F\)B8HG2,8H&* [B&^^VN0<JM?WFX<]G[PTOT\#"Y
M\E/S7X&=1CN)7S)KWB]/6=/&K9$,,YH**J[A)%,#&0J'5*)U#E* FVZ WZ=>
MGNT:<'^[J-?+7MJ_Z(ZRYYA.7+LU%-OUUK_VCM;Y%>-'K'O9E6;IL[2#NW\=
MIBJV72<)@H$#SW,*8G2,<H' I@';??80UYNYR:?&8--->HAXS[NS6,H\O34D
MT_K4L_F[1T4N!CANES2X+J*KHIII<GL!J*J**D(1-,EKC3'.H8Q@*0A #<1'
MH ->F>>9P_NKI\5]HTNW_.B;KQA-\+UR2JWI;WHL]#C'T@P?<Z,6>)/F;SL^
M('+#M :ND' I];.7!T"]<$5#]7K"0=M_#L.O.O.LHM:>C3^4\*.*=F4)1EK=
MY->1FJ?&N&ZIO]80_B4_I"ZX =N'-H T : - &@#0!H T : - &@#0!H#2+W
M^^Y^[4Y-MU!%1NO_ &=$%FY_1MUD'/*O";9RBLB;=-5)RW4,10I@$IR")1 0
MZ-;=QJ<[7!M7=MMQNQTUQIIT::A)IIK%-/:<Z[+=-I]=VG\NZ'6V[=[17>.:
M"%RW<C&=NY">KM0E"<))QG&49-.+3C)-IIIT.J1W/F&<.Y$[P#'-2R!B/%U[
MJKO&.9GSRLW/'E/M->=O(Z'@%(YVZ@YV&?1;AU'JJF,@J=(5$C&$2B&XZZX[
M--?K]=Q+4QUM^]=@K$6E.<II/?I5;S='0_0/]8/)7)G >5N!W> \(X5H+U[B
M5Z,Y:;2:?3RG%6&U&<K-N#E%2I)*54GBCLK96Q;C'"L/WI-9PSC:@8AK3KNU
M*1/NZWBREUK'< ZGW;'GZQ=3KJ'I\7#1SB9=,8=F@HZ,F9<Z+5$AC"5,@%[>
MN12FJ94\9^;7,%BUI];&-B*C'U:P72SIC\1\?T*Q<D^$D'/T6F3D-9>3W&*%
ML<1,56!DHRP0LUDNJ1\S#SK!ZP7:2T5,,U3I.FS@BB+A,YB*%,4P@/27)_%.
M(ZKFZ-C4W[URP_7K=E.3CA'>7P6Z85HL,%2F*J?J)^H3D/D?@_8.M?PK@O"-
M+Q+=X>_7V='I[5ZLKVFA/^UMVHSI<3^'C\)U?QIU[WV/L#8,PGSMP\?"V%<1
M8=4LO$WE*G8SXHQG2L<J6 D7FW@YY-)-FIL'##*EC1DW H N*G8BNIU.KUS;
M]WW%%+!(_,3F+36-.[2L14:MUH>>A9(" <QEDDW4!!NY!>RV)5=^ZAXY=ZX5
M4N[]-55=XJV,Y554)T&,8PB(#T^$=='OBG$7V@QT3OWOJCXA&&YZR>YN[R5-
MVN[3O4H?I]PGD/D>Y^DBUQV7!>$/CLN4;MUZEZ+3/4^MW+M+OKW:];ZQ-)J>
M_O)K!G?'SQQEXW8:RMW?MLQ!QZP5BBV+\W:W .;3C/$&.Z#9',(\XU<G7+R(
M<SM2K<1)+QCUW&-UE6YE114503.8HF(40[QNVX[KIA@S\R^,Z;36=)"=J$8R
M;56MM:'4,[P>!A)?GOSA>2L-$2;S^TID1'QR1BH]^\[-%.*!%,'3MLJMU$@'
M8@;[%\S71O/7$^(Z/F;U&DOWK=CU=I[L;DXQJ\_@J26.W#$_2S])'(?(_,'8
MM;U_'N#<)UW$7Q/71=[4:/37[V["4=Q>MNVI3I'8MZBV'8H<\8N-4!W0_%S+
ML%QUP)"98/ACN[[,?*,/AS'$7D8]DGK=QV/.6(UY85E"U#/3)I%P9V]\;!RY
M,NH*AS=<V_>4XQ4&TL<3\V[FCTJX*KRMQ5WU$'7;5J.)J/[].*BYGO0,N&F(
MN-EQ:X:X_E:^58]I)"V(I$W 5"("_1<"B54R8&,!1 #" "/@UT]VD\0UVAU6
MDAH[UZU&5J5=R<H5:E&E=UJO6>X_T0<G<I<Q<M<Q:CF+A7#.(W[7$]/"#U>E
ML:EPBK5Q-0E>MS<5*B<E%I-I5R5-C'=W<7N,-O[F&XY'MO'#C_:LBH8_YN.V
M]^LN&<;3]V1>5JX9I0K3E&U2]:>3R2]>0C6Q&)RN %H1NF5(2 0H!VAP)N]P
M;27;K<KLK%MMMU;;BJMO;7:SRKVB<)X=I.=N8+&DT]JU8M<9UL+<(0C"$(1U
M%Q1A"$4HQC%81BDDE@E0PK[[EFRF)WNV4)ADTF4"<&"+D1EFZ,FDFX$^)0%9
M--Z58A%Q(<Q1. =80./3TZX-VC:K5Z/AUB6DNW;4W=:;A.46THR=&XM56'O'
M=/Z(.7.7N8^<>-6N9>':#B-FUPN$HPU>GLZB$)._!.487H34943C5)/=DUT9
M8^]_>,G&K+6"^4<KE7CG@7)TI!\LU*_"R60\.8ZNTA#P(<=..DQY&BGMGK<H
MZCHGRM,O'?BZ)R(@Y=*J@7KJ&$>1\DW;FJY8TU_4RE<O/UE92;E)TN22JW5O
M!)=Y9'%/U#\N\#X1VU\?X9PK1Z;2\.LRTGJ[5FU"S:AOZ#3SEN6[<80CO3E*
M;I%5DV]I93O#HR-_^#YW<,#Y-8'@VG*O(#!I!"R;J0[=A'5;F&1@R;Q9DA9(
MM8Y)JF""92 1$J9>H =4 U\?/-^_IN7;MS2SG:NJY"DHR<6OA;&J-5VXFS_I
M0X)P;F#MQT7"^.Z73:SATM-K6[-^U"]:E*.GN.+=NY&4&XO&-8X-56)3G<(<
M?<!Y5SARLC,I8*PQDR-@L2X+?P3#(>*:%=&,,_E+IF1M)O8AG9J])MXUU(-6
M"!%U4"D.L1NF4XF!,FWQ]FNHU6MX/?N:^Y<N75JJ)SE*32]7!T3DWA6N'6=J
M_JZY4Y;X!VF\.T7!>&Z#0Z2? ;<Y6M-8M:>VYO5ZR/K)0LPA%S:C&.^UO.,8
MINB5,O\ F34JI1NZH[T^D4JL5VG4B$[QC'T/#4NJ0D97*C$1#K+_  :%U$QE
M:AFS&$CXMR+Y?M&Z*!$3]LIN7T9M^3\;G.UPG62MMQG'376FL&FH2:::Q33Q
M36*/,/9YHM'JNU[@/#M5:MW>'W>8.'VYVIQ4[<[<]=IXSA.$DXRA*+<91DFI
M1;35&:N^YCPIAC)//2%JF1</XJR!6%<$Y?E#UN\8YIML@#2<?,8T*PDCPT]"
MR$:I(,$W2Q45C)"HF550"B ', ]<]F6OUVOUVJCK;]Z]"-F+2G.4TGO9I2;H
M^@]S_K"Y*Y.X%P/@-W@/">%Z"Y/7ZB,WI=)I],[B]0FE-V;<'.,7C%2;2;;6
M)V*LJXNQEABN]Z]5,/8XH.)ZLKW=N/[$M6,94VMT"NKS[RM\ZV+N<6@ZC&Q$
M8K,NF<2U15=&2%=1)LD0QQ*F0 [;OI0:W%1X>ZZ'YV<7T]JWQ*-JRE"/JT\%
MMJ\<:HZ=/$7#F*LF<G^'5 O6/JI8Z=?.0>&JU<(!U#M&[6P0$Q*))RD3(+,4
MVCQ1H_3#JJE!4O7 >D==(<E\5XEJN:_4:G47KEC=O?!E.4HX9?!;:PV88;#]
M-OU4<B\D<#[ KW%.!\%X1HN)QU?#DKVGT>FLWJ3FU->MM6XW*22I).5)?&J>
M@#QNX$<-N*-Z>7SCAQXQ]AZXST"I39JPTYK)-I"3JSV7AYMU!NCO))X0S!Q+
M0+-<P 4#"HW)T[;@/=K2V(_*BK/-]"NUYY&-7KRNP#QX\L; [QX[A8QR[>'=
M7)LFZ.Z<K-5%W)W":@E4$YA$Y3"!M]QUTI;XEQ#^_JTKU%_ZK]?W=SUD]S=K
M2F[O4IMI2G4?J]=Y$Y(C^DG]_+@O"/W[_=*Q?^L_4M-]8]=*U:K<]?ZKUN_7
M'>W]YNK;Q9WU<V<:N..&.0W=WVG#?'S!N([,]YJ3E?>6/%V(\>X]L#N!=<).
M:<@Z@W4U4*[#R;F(<OXEJNHV.J9 ZS9(YBB9,HAW?<BHQ32Q/S2X[I=-8T49
MV81C-RHVNYNOQG3@Y\0<+)\W.=KZ3AH>3?%Y/9N3![(Q;!\\*1M-K$;I@Z=-
MU5P(B3H('6V+MT;:Z,YVXIQ+3<U.SIM1?MV%&S\&,YQCBE7!-+';@?I5^F'D
M7DCC?Z?K?%N-<&X1K.*RN:]._?T6FO7FH3N[G]K<M2G\%-*/PO@I*F1V55>,
MO&RL=UMPLR[6>.^"*YEA2M=US8%,GP6'L=0^159^R92XQ^Z&=4O,?6V]H/,S
M_E5UXZZ%T*[KQE7M3'ZYM^]'&/JZO.A^:NJTVG7!E?4(JZX1=>FAI [\B3H*
M/>G\B4[O(TM)P%-X]C'%N#N (Y%H;#]=[;Q$)TP*^*BZ _6%,.IUP'?IWUU)
MS_+CT==8_='US<]5+>]3ZVE=[#>]7A7N5QH>U_T<V>R*7*/%[G:(N6'Q)\3M
M^J_>G[O]8K?J4GZKZ[\)P;6.Y6.]7&K-K7 WC#Q:NG<>3&5IWCKQZMF0%<%\
MSIMIDN6PYC*?N)WL!;,YDK,JSNCVMO9PSB%:1K4K!PFZZS9-!($3% A-NS>%
M1G^Z=.[ZE]8]1#>WJ[U=U5WJXUKG7&N9Y7YQT?!7S-QJ?"H::7#EQ36>I=G<
M]5ZKU]SU?JO5_ ]5NT]7N? W:;N%#"COU&#&9SCPP0F632821X1PRR*4LU;R
M2:*Q[B0JBJ2;U-<B:AR= F* &$.CP:Z[[1==K=%H-)/27KMJ4[DDW"3BVE%4
M58M8=[K/0OZ(N6.6^9.9>/6>9.'Z#B-FSH+#MQU6GLZB,&[V+A&]"<8R:>ZV
MDG1)5SKF5W G%SC+E?C-R(F\J<<<!Y-FHCF-9*_%3&0\,8VN\K%P"''7C-,H
MP<=(V:LRCQC"IRTV\<E:)'(W*X=K*@0#JJ&-RODJ[<U7+&FU&IE*Y>E&=92;
MDW_:36+;;>"]PX'V_< X'PSMFX_P_AFCTNEX?:O:50M6;4+-J"EP_23EN6[:
MC".].4IO=2K*4GM+!]Y1%1A^Z9[L6!/',#0;?.-F9-H8S)L:(;,H[''(<C!J
MWBS)BQ1;L4VY"HIE3 J0$*!0  #6W<_:F_H^7+M[2SG;NJY#&,G%XR[L6G0^
M/])G!.#<P]N^BX1Q[1Z76\+N:77;UG46H7K3<--<E%NW<C*#<6DTVG1XK$X>
MX#XY\><L91Y<M\JX"PCD]M7\?<>5H%MD7$N/[NWA%I6QYX+*+1*%FKTHC'+R
M18] %SH@0RI4$P.(@0H!\'9SK-7K>%7YZN[<NSCJ&DYRE)I;D'1.3;HFWA4Y
MC^MKE_@'+7:'PG2\MZ#0\.TMS@<9SMZ6Q:T\)3^N:N._*%F$(RFXQBG)INB2
MK1)+M8%XU<<"8N?8.+Q\P:3"4G)%FI+#),1X^)B:0F22C.<)+OL;DKH4QW*D
MFXYN\!PHR,L#M!-7K=H0I@[!<4U0\9QN2C+?5=[I:Z\&L480WC@EP?C.3> 8
MJ,X8<2XV+E\4\D7<I&1_&W##.-DW41/<=RQ+J1CVU(2:/G,624= V46(<[<'
M*H)B4%#]:VX6]^D8I*F.'0;YP5RU6K]7JV[L%!M*6.(S@^+>)).Q\]^,V-JA
M4\#8^S'QTP]4)9KARDU6DQ\2]R-"<C*A+6YG6J_&Q$"[L2<>* ]JJEUUP:)$
M4,)2% ,[L(U22PIXV8<<MV]-KXJRDHJ$72F%:O/Q['T&GYQW"N%N)F6N*N49
M7+CK/,$XY.8UH\YB[(F",--*=98FV1UG8+ISQ8Z)7/)-FATR+@V63.@LJF43
MAN4!UM'#^!Z;1ZOZQ"[JIRW987+URY'%?T92:PV/8=@\5[5.,\Y:2UR]Q/AG
M+FGT3NPDYZ/A.ATE]N"=$[]BU"YNOX\4TI_&31M_H^#\*X0[R'%J&%</8JPX
MC8>"O*)Q8$<3XZIV-TIYQ%<AN%:<6O-ITR&A"2RL:G(+E;F< H*(+* 3;KFW
MWBY%)I++$X7S!IK&GC;=B"@WO5IU%O.?G!?A%6.(F<K-6N&O$ZNV2.A()W'V
M&"XX88B)UBZ6O%927<LYF.I3>2;.%DG!R'.14#'*<P"(@(AK0<8)KX,=YR6-
M,<S8]/?ORG&S*<G:JE2N&>5-J[QSYOXX<>,)\JN[,L6&,!82Q#89;F'DFOR<
M]BW$N/\ 'LW)0*W 7FG**PDA+U"NPT@]B#R<2U<&;*JG0,X;)*"7KID,'TSA
M'<=.\<AX]I=-8T<)V81C)RHVO-9UUN=/=,\\[ER(YFYBA>);>YT6Y99SCDRL
MY"-DWC8@H^IDQ+3D_#RQHZSY/C;FQ,VB3E-XNJR3=)=GU"I];JAKKOC'+W,&
MNXR]9HM:[.BK!J'K+J\E1WO@KX'PJ/:ZUQ1Z3[+^VSL4Y1[,8\K\V<JPXES;
M"&J_VMZ'A]YMW9779_M;\O7/U>_!-[K<5&D%@F;G+EQDXTTW@/PMRK2^/&!Z
MGDU2U]V++ADNJX=QW7+^>1LF;..:4_)C<HBM,;+X_/(2;@KU;QGM'17"@*B;
MKFW[#NQBHMQ5,3S=Q#2:>SP57(0CZVB5:9^V;?,D<0N)>8+6_O>7.+7&[*MZ
MD4&C.0NN2\$XLOMO?-(ML1E&M7MEM=3EYIVVCF2)$6Z:BQB(I%*0@%*  &AN
M0;K**?2<5AJ+UK"U.4<=C?@R*<D.[ZX#M3F8M^#?#A%F+5L46J?%_!Q&YBNF
M:2CDHHEHH)B1=14PG#;8W6'?PCJI+JJ8RN3;JVVV5QD_C%QHS>^A93-7'7 V
M8I2N18P==DLK8=QUD9_7X05A<#"P;NXUN:<1$3XP(J>+-S)H=<1-U=QWT<(/
MRDFN^6W>O6JNU*49/N-KW,GUFL_A]PHX92N1N?D?*\0^+<I'U;G+*URL,9+C
MUB&095NO!Q7XH398"OM7=.60A80)J<>O :-2I-P=.UU0(!U5#&U;4(;M*+V,
MY?P;36-3HY7M1%3NN6;Q>2-A?=6%*CPHXPM$2E1:-<%5!!JT1*5)JU;HI)(H
M(-FY *B@@@B0"$(0 *4H     &M.YFWWW[F!Q"6%V<=BG+PFR;6F T!^ (#X
M- ?N@#0!H \'AT : - &@#0!H T EL0B6$DS%$2F!JIL)1$H@/1X#!L(:JS(
M\CRT>^=01=]ZSS:,\12>&2R-0$DS.B$<&32'!.)5133,J!Q(GVBAC;!T=8PC
MX1'7IKL;X)P;B/*]R_Q#1Z6_?6NNI2N6H3=$H4591;ICD;7K[ER-U*$FH[N5
M3>SAGCSQ^)W+6(,LA@?"H95'BMC"T_E-_)30ORB>Z@R5<5-92W@:^-H+8#K&
M%07OC8.>T$3=?<=]=:ZCAO#X\O7+ZLVO7*U-[VZJUK*F-*X*BZ$=62XOQ-=H
M*T*U%[ZG]92W-^6Y2F6[6E,,5W:FO+WS,0CGO-J\F[(1VFEPVPPJD1T4'!4U
M%,P<D2*G3!8#]0RI$" 80Z1 @!Y@:Y5V(\*X7Q.QQ&7$M-I]2X3LN/K;<)[N
M]&;:6]%T3\2.U]=>N;T9)M-]S#8NX9R=S7QQX\9#[M.2N60< X0OMP1OW(QJ
MG;;KB3'MJM!6L-8Y5.):A8)ZN2$N#>+23*5L0%NJ@0 *0"AMKY^+\'X7#B/$
MH6]/8C&&JOJ*5N"45%NBBJ427<2PV'3_ #3QKBVFYFM:?3ZF]#3TL_!4Y*.*
MC6J3QKM[IB1WZRAW?&+N3R/#"[34X6KN%$W1C.$U%B8KXN]58Y%NN45"BJ;8
MWA]$;SQWV?L;T.AXES%?M\0L6=1:6CG)1N0C.*:G!)TDFJ]_,[DU[E&+4&U\
M+9UES?>^6 L$98Q-RC?Y5PEA[)S^$S33X^%?9%QA2+N\AX]QBVOOG#")<V:"
ME%HUDN]6,L=% 2)F5,)A#K"(ZYAS5PCA%KF;46+6DTT;*5FBC:A%*MN+=$HI
M*KQP6;.H>>^+<3T.IT_U347[<96'51G**;4YJKH\_>17/>PQS")[DKBQ7HI@
MSBZ_&]Y9EJ%C8"-:H1\''0T7<.?S6+B(^(9IHQ[*+C6S-%-NW23*BBFD0I"E
M*4H!UQR%H])JNT+2Z/56K=W22OWDX3C&4&E;NM5BUNNC2:5,TCM#1W;L^"V;
MLI-W9:>VW+:VU&K;[KJ8]>]L,$X.S-R3Y11F8<+8CRU&0>"J)(0D;D_&M+O\
M?#R#K(,FV=/HIE;827:QSURV3*FHJB0ASD "B(@&VN4=M'#>'<-XGH;?#=/8
MT\)6)N2M0C;3>\J-J*5:=\^K13<HR<_A4:SQ.QEWLF(L3X3[I#FY6,+XNQQA
M^LR=3KT_*5O%=&JV.Z])SKW(^+X=[-R,)3HJ&BWTP[B(QLU5<JI'74;-DDC'
M$B9"EZMX!;MW>/Z"W>C&=J6NTZE&23BT[T$TTZIIK!IX-'UR?P);JI\%Y=!T
M[^Y>QKC?(W> 4*J9#QY1+]5G>.<N/'5:NU/KULKSEY'UQ!=@[<0D_&R$6LY8
MKCUT5#)"=(W240W'7I;M!X!P'2V-%+2Z+26G+434MRS;CO+U-QT>[%55:.G=
M1U_S=Q#6Z/@-R_I;MR%Y3A1QDT\73-.IVW8#&6-L0Y#[PVO8DQW0\55][W:^
M.9Y]!8TI]<H,*]G%K%SB8+33R*J<;$,7<LLQC6Z!G*B9EC(MTB"82ID //7-
M^FT^DUZCIK<(1>G;I%)*M98T6&Q&KV>:_6\0X/*>MNW+MSZQ*.]*3DZ*,,*O
M&F+?2=#7AQ7:_8>3_#"$L$!!SL+8^2_&2%L41,P\=*Q<_#S65Z1'S,1-QT@W
M<,I6+EV+M1%TW<$41<)',10IBF$H^B.;. \"L<EV]38T.CAJ7+1UE&S;4OAW
MK*DMY13^$I/>QQV]_=>):G40X=JYV[DXSCIKS33:::A)IKOK8>A)AO!^%,/\
MY\#NL18<Q1BAU.X$Y.MYQSC+'%-H+B;;L;GQ>48MY9>IPD0I)(,U'2IDB+"<
MJ9E#"4 ZP[]$<XZ/2Z2W8>FMVX;TI)[L8QK@NXD_;.)]FO$^(\1GK%KK]V]N
M0MM;\Y2I633I5X=1YU'(-)%?+/(ITJBBJZ_+9G(WC2B29W/61RE:2)F%<X"J
M82D#;<1'HUW7PC@7!+W9;]=N:/2RUO[LN3]8[-MW-Z,726_N[V]WZU.?7KMR
M.JW8RDEO95.^=>N/''[%UTX$6_&.!\+XWMRW,/"$>K:Z!BFA4NS*,)&EY!4D
M6)Y^M5^+EC,GYDB"ND*W9K"4!. [!MU#S1H-%IN$*Y8LVH7/60Q48IT:=<4N
M\=7<A\8XIK^89V-9J+UVPK-Q[LIRDJIPHZ-X-59U%N^ 11==Z+SK,Z11<G3S
M2BDFHY2(NJFF7&E!,4A%%2G,!"F.80#?8!$1\.NU^R/@G!N(\H._K])I;U]:
MJ\M^Y9MSE1*-%O2BW15P5:([5UERY&\MV4DJ+:=@6B\>./K?N;L!97;8%PFV
MRFKQDXNV@^36N)J VR&>S/UL8JO[(:[(5Y.RGGWRJZAUGHNA<JG4.8R@B81'
MJ_7\/T,.6KEZ-FTKZLI[VY'>JY=VE<-AU1IN,<5EV@_49ZB\])]<G'<WY;N[
M%R26[6E,$\LS61[Y-(1UWI,HFZ*5VDCQ>P:=$CHA7!4S*W'-H*F2[8#]F*A4
M2 ;;;K 0N_@#;F'8GPKA?$]+Q%\2TNFU#A=L[OK;<+C583K1RBVJ]Q43HJG;
M>ON7(;FXVJIY/OF6?=>U'B;.]VPF6^\8F&2LNNG/(UBPMI.#N0<R2KQ\%VO+
M6J-F64(#"%QC73B-(#9N@"<J<6 IE2'LA3ZI>-<;ERYH^*<1TEV&FA>AJ]1&
M,=Q?!6\]Q1HL$E2G<.NN-:3F^[QSUW#9:G]W4M.D9M1PBM[X-<<:UPQ+4=_K
M%3$7@_N<ZY:HZ382\+P[DXZ=K]B:.VLG$S\51.-#"38R\7)ID=L)F->%60<)
M+$(LBJ!R' #=8-.Q?A^AXES'J;'$K%F_:AHVU&Y",TGZRVJTDFDTG2O<.RM?
M-QM[UMORZ8/9C_RESO>]W'_ N6L(<E)'*N#L-Y/D8;D)%P\/(9$Q=1;N^B(E
M3$6/'YXR+>6B!E7,?'G?O%5Q11,1,5E#GVZQA$>5\Q\&X1;YIUUFWI=-"S#U
M&[&-N"BJV4W1))*KQ?=>)U%SYQ?BFBU.DAH]1>M0E9E51G*-7OO%T>.&!R]Z
MDR9QO<>\)8&.:-6,&P[Q3+<.QA639%K$,HF,>=X0A&Q;.,0(FR:QT<@P0(@@
MF0J2)$2 0H 4NW7W9UH]'J^?]+H]7:MW=*YZBL)QC*#I9O-5C)-.C2:JL&DS
MM>W<G^ZK5QMNX[5MMU=75*K;[YBM[W[PWA_*^>N2T3E/$N,,FQ<-AS&\C#QN
M0\?U*[Q\2_=W>V-G;Z+96>(E6T>\=-FY$U542D44(0I3"(  !VGSSP3@NGYA
ML6=-H]+;M/0MN,+4(IOUS56DDJTPKW#KSGOB?$-#PVQ<TE^[;G*_)-QDXMK=
M6#:9M?Y35>M4+ND>^JI]%KL#2JA!<W<=1\+4ZC#1M9J\0Q?5WNW7;YG%U^$:
ML(B/:O74BX56311(111=0Q@$QS"/3FGTNF_OYI=)ZN#TKXCIHN&ZMUQ<[=8N
M.33JTTU1ITR.7\KZC4:GEC3:C43E._*Q-N3=9-J4TFWFVDEB:#NY;QKCC(_/
MZH53(F/:'?JLXQ7EQ\YK5WIU<MM?</6#&N&8/%H2P1DC%J.V)ECBBJ9+KI"<
MPE$!$==]]H? N!Z6.@6DT6DM;^IN*6Y9MQWDK+:3W8JJ35:=TV#FO7:S3<!N
MWM/=N6[RG;2E&4DU66-&GM6!VR)'&F-\0LN\_K^),=T3%4"[[LRH3SR$QI4:
M]0H9Y.+$YZL5IMW%52-B6#B768Q;5 [DZ8K'1;)$,82ID //'-NFL:;B-NWI
MX0A!Z>+:BDE5N57185/J[/-9J]?P6=S6W;EVXM4XISDY.BMVW2K>56SH>\2&
MV/T^2?$1;([>F$H:O(/ );XI>$8,*>O57%\K2=D2N V HPB]=<1:JH/B/=VQ
MT.MVNY-]>B.=>!\ T7)4=99T>CMWU+2MS5JW&5'=M;U9**=))O>QQ5:FY\0O
M:KZCJO42N>O5B[N;K>]O;DMW=2QK6E*8U._MQ&#A>WYQ8\)Q,1XM-)-7C-R.
M&[AQS0Q$SD3L$\K<1@A1M08P31<J,B.%'(-?'-TP.97L^D3:Z$YJM<,B]/#0
MJRFW+>]7N]Q)5W>G"IQCL_U''KEW5+C+U3@HPW/7;_==:;^>2K0\[F]LVC^T
M9!5>M6[M9SD:^%76<H).%EP_*%,I&*LHL0YE2G2#JB!MP$O1KN_1\#X)+LC7
M$7HM)]?_ '1.?K/4V_6;RC)J6_N[V]AG6ISJ=R:U^YO/<WUALI3N'JD4+AUQ
M"Q[-UN\4'BEQFHUWK?4?UZYTW F**Q;8%^JP68JOX:RPE18S44\59/%4CK(+
MD4,DJ<HF$#F ?+:;W5+;0W.32?P4D>=!WJS9![WF/.T[M%)TH/(ZVH JY3(L
MJ1+R7 $*1-10#G(5/K")0 =@'P!KU'V2\ X%K^4O6Z[1Z6]?>JNQW[EJ$Y4K
M&*^%*+:I5M=QXFUZ^[<A=^#)I46UG96J''3CU&=U5Q:RK&8#PE&91/A#@I9E
M,E1V)J RR"I99B;P6K+6)2ZMJ\G93STHJ^7.Y>"Z%RN=8YCG,)S"/5&LT&BM
M\L_6(6;7K_JT);VY'>JXQ;QIW_\ *=4:#C/%;O/_ -3GJ;ST:ULX[F_+<HG)
M);M:4PR-0'OC9,KOO5KZ1V4KLB/'_ '8E=$3<@EVR%]%7L@7*H5,513*)MMA
M'8/.#7.>Q/A'"N):/B$^(Z;3WY0NV5%W;4+CBG&Y5+?BZ5[U,CMG7W)P<=UM
M9Y-KN&PWNYN.G'FX=SM+9"MN L(VF_HX^Y;NT[U9,2T">N974!:\M(P+DMIE
MJZ\G2N81%@@FS.#CK-B(IE3$H$+MLG%.&<-C?XE&&GL)V]5JE&EN*W5&4MU+
M"B2V+N8'4G,/%^*6>;8Z:UJ;\--_8? C.2B]Y1WL$Z8UQI3J,;_?#6[NG=T^
M1V(NTS\0[(N=-V(N4S+A \<P[84UA.7M=ECAUO#Z(?/'6AV,<.X?Q+CNKM<1
ML6=1:CHZJ-V$9I/UMM-I23HZ851W#K93C:C*+:>]LVT1=SWOKQ\P#E;CEGV6
MRI@K#&3I:+Y.O8:+E<B8KH=XDXN&+A7"DB$/'/[/ 2KME$ED)-PX!LD<J(+N
M%5 +UU#B.^\Q\&X3:YLUVFLZ73PL1]6U&-N"2_L;#P222JYR;HL7CW:]3<^<
M7XIH=5I?J>HO6HRM.JC.44WORQ='CE3H*3[SANW;]Q1W>T0W;HMXIMS=NT>V
MBT$B(QK=@QB.=2;)B@P2*1F@S9)M$@12(0$TRIE H !0#7">S30:+6<^V=-K
M+5N]I90OUA.,9Q>[:FX_!DFL'BL#M9RG^[H7*OUCMPQVU>98OWOIA;#>5\I<
MJ6.5,18MR<Q@\?X:=PK+(F/*?=V<,[D+)DY*0=13:SPTJC'.7Z35$BYT0(94
MB*8&$0(7;LOG?@?!M/S%;M:;2::W9^I1^#&U;C&KN7?A445\*B2KW,#K;GOB
M?$-#H=/=T=^]:N2NS3<9RC5*,<'1XH[0G=^8<Q!.8KYQX3FL48SF,+'YV9'B
MCX>E:%4Y'%1XQGB;C?8&<:?'3R(6IYX]I/I$?)(BR[-)X0JQ2@H4I@Z!XU:M
MV.+W[=F*A"-S!+!+!94RZCG?+-^]J.7M'J+TI3O3LIRDVVVZM5;>+,K6/=Y=
MWZV2>.6_!'A>@X2*@5-='BO@A)4A%5#@H0#IT$H@4X%#</-VUMLI3EY3DUTM
M^%F^UVM)HN?2../'?&,'<*QC/ 6$<<UG(3 (K(%<H.)J!38"^18,Y"/",NL+
M7*]&1EKCP82SM#L'Z3A+L72R?5ZBIP-C3NDZ,"UT=W=?=\ HN<.!O"PIV[)X
MN@H3BK@=,Z*Z*!U$54SDH)3$.F< $H@/1MK*4I-4;E3I;\++7!]!<G&7&;C;
MA2>>6O#''C!.'[2_AG%>?V;%>(,>8[L+ZOO'\;)NX%Y-4^N0TF[A7,E#M'"C
M114S<Z[5%0Q!.D02XM$6&1GPW]+H?Q*7AZ1^4+YH](ZTS4.;0'X(@'A';0'[
MH T : - ?FX;[;]/G>;H#]T : L/AGD/0L[V+.]>H))UX3CWE][@RZ6!_'(L
MJ[*9$AJ?4;A9XRI.P>*O)EI4R71M&OW"C=NFG+(.6Z8J]@<^@(^*.1M$RUDO
MD#B"':V6%R#QLN57J60H*SQ;2/.Y:WFEQ-\I%TJ[AA)2;>:I-LA9-1-H[$R"
MX/8]XV6025;G 1:&0&A T!I%[_7]6UR5_C.-O_-CA'6U\>_ M9]UN^A([![(
M_P";/+/\?X=^VV#K)=R7^LAQG_5+G'\25[76/95^)ZKYB/IGZ1?K7_*?+W\4
MO_L[.R/RB^N=Z%_\K['_ -K[PW7=-WRUT>,_+KF;[?'YI>&1TNN%O]ZC@5^E
M?Q/_ #L5'707)/YSCTW_ *-'ZU?J5_P_+YOAW[3I#OTO/[]F _T4.6OY[.!V
MN_[N74?D_P T>5:Z7X6><;/?^'9__P Q6#_;I]KS_P#_ ',A_%(>FC]8N"_X
M-+/_ )+N^A=/0AY@?^.>[Z_3UJ7_ "Q\J]>@[ODOS7X#\IN/_8;?3'Q'2RY[
M_P!_#G#^DUDCZ6)UY][0_P U_P#Y5H_5+]&'\C;?\4XAZ43M!V#]2)Q:_1][
MMG_:OC5KT#/Y-]9^7-W\!_\ AH>")HN[\/\ 6?YD_J9X^_B>YZZ1[4OMVB^:
MGZ43W[^@BG]U.9J_]K6/H[IM=[GKA)@S-_=RT"<R&ZS6[-=;3R,B+)!5WDQR
M+HU-D(I3.63H!U'!1J1E"OT]LSD(M,4W*:3$A7(G.94#F.<QNT^!M_N;2I/!
M:>WZ*/!_;!J+]OM5YDMPE)0_?FNPJ_\ K-PPJ]\)0,55>0W#>KP+0K""K/&?
M(5>A&)5%EBLH>#NN/8R,9E6<J*N%0:L6I" 90YSF NYC".XZX+VG8<,T_P \
M_0D>IOT$U?.O'F\_W5;^GB7K[@"^Y0JF$^5S.D<?;MEN+5Y;F>.IZLW?#E89
MQ[X_&OC>F>'79Y&R#4)9=VFV;IK"HB@HW$BY2@H)RG*7DG(DU'E32QV_VGTL
MSK_]4_%;/#^WWF&W=C-RG]2:I3_L_2K:T;E<$<*Z):.&N$L$\QL'8WR)(T.2
MM=M<4:^1E8R-"U>TSMQR!(L'K%T4)2$4FFE8N:C4[EHH<H%<+)E.8HCOREQC
M-4FDXUK1I->T\'UGE*.HO6;[U&FG.W=QI*+<9*N#I*+354VG1XE(8)XZX'XX
M<\\PUC 6(<?8=KL]PYP!8IJ#QU5XJJ1<I.CG+DO%#+/F42W;(.7_ ).8HH=J
M8!/V:12[[ &M;3PA",E!)*JR26Q]PY5P'6:O6ZB[=UEVY=N*$4G.3DTJMT3;
M=%7&AK>YY?JS^]D_^93C?\[_  /ULO'OP?6_=KWT<CDW9I_.OES_ ,R\-_;]
M.:YNXO\ UBD#^CYFO\<8OUUCV4?;]7\S#TC] _UK?E_E[^(ZCZ!'88Y/?*=Z
MU_\ +5QO^)>?>NY=3FOZOI'YF\9_%8_-+PLZ?/ O^^AP,_2@P/\ CA+70'(?
MYO7FWC]6OU=_X=+_ -\X9Z<CT;V0@5VV,80* .$1$1'8  %"B(B(]   !TCY
MFN_F?CYM1YFLUQ]Y'4VOG=7#C+RAJ<7 V&./.V*S<9L]0%2A6R-U9]K)2URE
ML=-*G'PY $IA>JO2-.H8#=IU1 ==16^6N-?WT_>CLOZA]>W][>CY-=ZM*U[V
M5:][$_3&?;IV57/TQ+D&/%X?WO?+%K2?5_J^LJM1"$(NV[OU;U%:Q\KUNYBO
MA9L[Z/+3_C1W<OZ=<K_R,<XM=Q7?(72CP/S']@AYZ]%G2&YU_P!]/G=^E#G7
M\>+Z\^<^_FZ7FV/11^IOZ3O\-UKYWB/I7#M8V+]3IPH_\A]T]^=/BIKT&_DN
MIGY9:O\  5\W#Q&YJ3IU2F9 SV7JU<E7IA(F9Y)0<6^=G(GZ%,AG+IJJL8A"
M]!0$VP!T!L&M!K#;[;.#;WP=E?=]O.G>R-2.*T$&O=:\M6S9%)NV;I=Z0BW;
MH)D10011S?R@322113*5-))-,H%*4H   &P:^CXC1SGA?X$O,9HS[\/_ (\<
M-/T'X7_;)/74':?^&Z+YV7H(]D?H)_-/,7\/T_TR-F_O<7^ZER9_3<M/_+'Q
M0US'D+\I:3S9_23. ?J,_GES'\_I/_#=$8-]Y/\ JKN[*_KZN7YN^1NML[1_
MRQ>^<M^D;?\ HU_Q$<.^Z<0_9+I<_P![B?\ %?FC_5WQI_VCY!ZV[LN_!]1]
MY?H6SFGZ]/YD\&_@,?VW6':VUV8>&3&+(W]ZKCA_5!RA_'_&C5M_*=7C1OW+
MWV_^I+P$?&O]Z[DK_55Q<_&/(;6=W/\ J^-CF/[>OFEX64KS/]+<5_TTL$__
M -5:6O+?FL^+A/XE9\[Q,2S'ZR;"OZ!_+#_F)X0:MWREUF_\R^1:Z9>(9]XO
M_<HS]_Y<KW^WE4UH2SCYR\)Q?2_+P\Y>$HKEY_>3[KK]-K(G_P#SXYQZ^J?R
M;.6\Q?8K?G_^RS,3,H!^1_+(?_BPR!_LE,:^5Y5.$K$U8Y0_5B<)?;3NI_SU
M\9-?1=\CK.<\5_ EU>,W+G^7/\,_[.M$X.]HRF/3P^I6'K!MJ+QE8KU2&OGA
M=_Q1[QG]/^4_Y0^'FM6UDSG?+_X=+SWZ*+Y]UA_<PXT?U'53Y!-:-S_VI>$X
M3/Y>YY\O";)-:8-47>"W+F9B6RX,L>#N1U%HE+S-R0P!QQ6I-EX]Q.0'E>4R
MK8'<%-7AO;%LA5YS(.&H%(JC'G:)I )1 5MAZ %U;YHW[$5SE,+7%#(_*[+T
MWR[@^*, :J4G%.'X".MP<-&7)V8L($D<@*(,,9MZW6I-^_=.73R8;O'*C9HS
M=IIMR*1%:P0VQ-WJ=(R(M2Y*T84RIB:AW:_\D<.,[Y<G^.)".89=XFM<@.\T
M5M]%5&Z6&9+7(_\ )58T8N9*D9*1<0ZP&0;I*M%7)BF-&3>'?>Q<=>9^5J]B
M/&LA!K6.ZX1DN0513K^5\+Y/<M:'#35(@Y:"RA#8NOULG,0Y1CW&18E8T#,-
MR HBHX*DZ4<,7S=O2&).5^?O*JM<\<SX/QE88>]-\:\B.)6,*QQG8\;K]9Y6
MYXIS'7,33^;,G3'(NMR:=4Q<OBBN7"<GB'FTO$1:0P)*$-VZ9M"X%\K/WJ-;
ML&%7UZ98[S+B.L9BXO<DN0'&'+ZT7C"U*W2KX,J2EF=3C:F*W)R%?MDQ4WS:
MSUZ(GRHMI&*] ^58NBKLDQ'DWL2+C1_>/)-YJZUQ'!V7+;6<*7KB7BK+&8 >
M8NB(LMAY7U#"<_49^#JONU"PS+6K_EPB5K.DFT:@P;"JHP\HF("&I59%+N\&
M^2>6N2$'F*5R3CB.I[.@<AN0F)*[-Q,U'/&<U&8ES!:L?Q;=S&)24C)(32$5
M!I'>N3=DV<N#&,BF0FQ05J&J%[<\\C*-Q]/B%E;&5HFIW.>9*I@['-<IT4UE
MYN8N5I:3$N9PLB^D8IFQKM:K=>D)65>*KE!K'LE3E*HIU$CTA,S[GRI<<ZA6
M;W>XNTNZK/Y1Q5BE_+UB+:2R50D\PWJ#QK4[/:T7$E'N6=,;W.S1S60>-B.U
M61'95SHB@191,5*I?/0@: 2V/V#D_4I_V-5$>1Y:O?+?K6>;O]95 _,-B/7J
M[L/_ "C=^_W?1MFT<0^67F'8UPY^H:P_^ASBWUM6M=7:K\LW?F;GAD=.S_F8
MOO7OFI7WS#^LX@OT,\+?GBY+:Y9V!_9^)]-CT;AW)K<X>S8C:3W'?ZJ^6_K%
MY0?[2R^M'C'XIQ3[YJ/#(Z0YQ_-EKS;'@B:W>_/_ +LG<F?H3.OS5\6M;!V'
M?F2_]QG]);.]^(Y/S_?,J?>V?_!OEO\ UZTG\T=9US?F[\V:GHL?10.D^T;[
M1IOF)>G<%O>Y?J8>,O\ \S_-/^V_>"ZZO[.OYE:3[Q?^CNG;>@_ M/\ =[?@
MB4%[UG_O0\M?T?\ 'GYR)77+.W;\6X?]WN>FCZ]#Y$_.7C.P]WV/ZJSFA_5Y
M5OSL8]UU)R[^8>'??]-]- ^V7D/S3I5=SADS'^).?- N63;A!4>JH8\RU'K3
MUC?)1T:F]D:VBDQ:F<J[$!9RJ40('A$0UZB[4=5I])H]!>U,U"U]:FJO*KL7
M*'7_ #1H-9Q/@ES2Z"W*[J'*#48JKHI5;.VO5LL8XS/>>\/N&*;G W^J,>[@
MH%8=V"LO"R42A86,YS:EW<(H^1#L DVL9.,W"B/6ZY$G21A  .7?S-S;K--K
MM;ZS2SC.W'3T;3JJUDZ>TZGU\@<+U_"N%NQQ&U*U?>IE)1>='&"K[::.BQP@
M_O9<%_TJN*/YY,?Z]1\X_D2UYVA^GTY]'%5_\LUGW6]]',]%J _OP\<OZBN4
M_P#MAQ6UY[YZ^1TWSDO CAG93\KK_F[7I2/-<S]_Q3Y$_P!=6=_SJ6K7>_ _
MY2+^$W?09V5?^V?UEX#T)\Y+)'E> A2JIF,',_ @]4IBB.P4G(A=P !W'I'_
M  ZZ6YMDI<#JO^EAX)'4/9U;E#F::E_T%WTH'2^[WG]:)SM_KM2_-EC[7</8
MM^2Y?>[W@@=QZ[Y9=".S%2OU%W'[]$?BE]-BS74_$?RM=^87I'3&E_F4OOUS
MTIFFCWR+^M+E_P!%S!/^V><-<S[!?LO%/GK/H3.ZN(_\WT,[(OO=H/\ ]59A
MT/,')G(H?B_EQN^WQMM=.<ZI?WOXI]_O>$^RU\G#S%XS4S[ZFZ<C\&?_ "7R
M-_'>$=<\[#$ES5K*?]1?TMH^;7?(KS_$5)[VL_X"<IOTE(;\R^--<QYF_-O$
M/_A_H4=*]HWVS1_,R]-EL^]>_4I\,/\ YDV:?QCWB6NM.S+^9.E\_4_07CN:
MW^#6OF;?@1C=[WBNE/IG(3D\XM]KK=50?84QFBR6LDY&0:3Q5&]W ZR3523=
M-2.%$2' 3%((B4! 1Z!UVUVAWK5GF332NRC%/02HVTO^>?=.M^?[%[4<+T\;
M$93:U$FZ)OXJ[B9M(Y=S$3/]U'WVTM!2L;-Q+WG)C)5E*1#YK)1SLA:SW:B)
MS-GS)59LX*FLF8AA(80 Q1 >D!UTCII1GVAZ24&G#]YZ6C3JG_:6LJ'-.5+=
MRURKI;=V+C<5B=4U1KX4WBGDS1QW%/ZQZE_U0YE]85C7HOM)RX?]YN?02.,\
MY_EV[\[9]([9&51#QGO./_E;TL/ /\/W@8Z\U<Z?BEK[M#PR/L[,?P*Y]\E]
M';.B7W?+!C*<V. D;)LFDE'/^6W%IF^CY!L@]8O6;C*503<-7;1R15NY;+IF
M$IR'*8IBB(" @.O17:;%2[-+D9*J<=+[MRVCEFD=-9AWSU)*MC^A5653D*M1
MZ=67ZQ2LUGU=J\'!O%F:CA!=1HLYC&#595L=9 AQ3,82"8A1VW ->2[:2E%]
M]>$W2<I27PFVU_R>,\E&X?\ B6\_UDWS\XTUKUIHOY+_ /<MST9FU7?Q'^NO
M CUS&/I%KZC0^U$UY&7R:Z%X#=9YOI/,;[TS]9?SL_23MOXNKVO7/8U^3E]^
MN^E$VGB/RJ\U':RKWZF[BQ^CKP#_ !M@'73NO_*2^YP]&!TQPS^8K^_W/2D:
M(/?%WZUG(/Z/_'OUOD#7/^P?[#Q+YZSZ-P[HXCG'H?B-MW=A_J1YO^K?F9_M
M?F36P<5^U\5^]ZOTI'2_,WYSC_\ #^"!@5[X3_\ "'=._H?67\1\;M?/V&?F
M'6_<5]-;.\==\A#SWX#(3WN]ASD!D3C1R)F\3Y\HN*8%CRE?QSV#M&!7&5'S
MZ82P9@YTK*(S:.7L>%8LU6;I!$K7Q582G1,?MA!0"$^/M(XYKN%<\ZVWIMS=
ME"P_A*N=F-=NW=C[2-@U_*?"N8(6]3Q#UOK+:W5NRW52K=<GC5E9]_'@0_&+
MNJN%.#E;>>^N*3S4 [NWF@4JP$X^M>(.85V?N$J^E*S9(INB]LBB*27C;@03
M3*(G$1'6V=DLI3Y]TTY>4[>H?_Z,SD.H@K>BW(^3%12Z$8H>]M?^+G+W^K?!
M_P#M/E37;?/GYEM_<X?27CJ7M%_#]-\_/T8G9_[N?ZQSA_3\R?\ F/XZ:\W\
M?_&M1\YXD=A<I_EC0?,+PLV3M_2<A_W/[:IK:#D/OD+0#".^6>>UDCZU4U'D
M59/H%X> ?A?LAHP9%M_2Z'\2E](76F:A1>2X6]V*D3\-C2[LL;WA^U32K]VD
MJDVO3&ONBNFZJCMQ4G<O MYLBC5-1+LC/$  5.OUMR@ @:4./'([F'(UN+R=
MGCDW$66MK]X#8>%D=2\;<:J7574H\J?)Y[B*,L<_99G)$NJP@[9 U9RG)),V
MIW;$9'M6IU#MRE4&2+_U7O3CWJR8CK53XGYN>J<@K]R1QGA.3D+)AB,C;79N
M+-KL=;R=(SX#D=U)4NF&1JK]U&OW391X](U.3Q),3M1=0G@*8RMWU'&G$L10
M7%D;H0EEMV IKD3+TO(66,$8AFX*MUZTS5&D*!!N,FY+K<5DC+TC=*C.QL;$
MP*[UBX6AE3N9!FBX8*NZ'[A7O/KF?9<7<-,+\C,%7J-I$5FO,W$*M,\A6/&T
MADHU:Q5R*R-2X*9M">-HURUEI^>BJ=:#.T&")S+J.4P2*4QAV$,NX6;XS=X[
MG&T/K#B6Q8ANW(C(I;-F"S8?OM7QH?B['9@XR8DK>%2R.8Y"C9XM$9*5Z3E<
MM92D*;#H-058SSV!6?$.R8&[8I"G=*R0[S>K(KY'RW#0V7\BTM[B'NO+10<,
MLZSC" FHV<[P;-61<,T9O'V*3NL>#FV.[.XC$;.REWK>.A$XDHL7#@Z[D"P4
M*DFN\*R<_P JX6Q=2^/\BVN+_EWD3C#F^BVBUTWQZ.<UGAOD#E+6Y;']PB[&
MI77S"PQD=#NBN7B9%"-DWK15JBY,@IJBAMBT(:.6R','B7E'D:XX6UCC'R[P
M1G+DO<\B2U:O_) N%<E8)Y(7IK7D\K8G-*MZ7?ZM;(&5LC#RZS8')'6".=3#
MELJDX2*W5$94KB9?<)>.&:,?W#D+R=Y/2=$-R0Y6R^-E[=2\4+RS[&6),=8=
MK,C6<68OKEAL#=C.7:3B$;!+2,S..&K$DA*RJQ6S5NT20)H3 V$:$#0&D7O]
M?U;7)7^,XV_\V.$=;7Q[\"UGW6[Z$CL'LC_FSRS_ !_AW[;8.LEW)?ZR'&?]
M4N<?Q)7M=8]E7XGJOF(^F?I%^M?\I\O?Q2_^SL[(_*+ZYWH7_P K['_VOO#=
M=TW?+71XS\NN9OM\?FEX9'2ZX6_WJ.!7Z5_$_P#.Q4==!<D_G./3?^C1^M7Z
ME?\ #\OF^'?M.D._2\_OV8#_ $4.6OY[.!VN_P"[EU'Y/\T>5:Z7X6><;/?^
M'9__ ,Q6#_;I]KS_ /\ W,A_%(>FC]8N"_X-+/\ Y+N^A=/0AY@?^.>[Z_3U
MJ7_+'RKUZ#N^2_-?@/RFX_\ 8;?3'Q'2QY\]'.[G&(=(AR9R2.P^;LG%C^QK
MS[VA8\V)=VW9/U0_1FW'L+MM?]J\0].!V2\20_+?/_=D\1L)5SBY'Q-?F,#<
M&G#+)LIGW'IF1JM0/R*79>RJU)"/&>2/*5ZJG.DQZPKIJK%3,.X".N_I7(R3
MC1T]G?/R;7'K5[A<=+NNKM1C7H2V9[#3+WX!@/WGV8C!X#89X^B'P0&'N0AK
MI3M2^VZ)_P"BGZ43]'/T#_E+F;^+6/HKIV%^X@_5E85_\]<B_P#F+RGKM/@7
MX-I?F(>BCP5VQ_S8YD_CFN_:;IJ*]\9?WIN*O]0.6/SB477!NT_\,T_SS]"1
MZL_01^=>/?PJW]/$S#][8]/'3E_\#F8XZ0^!Q=XR^:&M^Y%K_=?2]WX?TDSJ
M+]7_ /B"X[T:+_P_2G8TUS \SF$[+]8?DK]"#C__ ,P/*+6M9RETKP,Y3RO\
MI>\V/A9IXYY_JS^]E_\ F4XW_._P/UL7'OP?6_=;WT<CE_9I_.KES_S+PW]O
MTYKF[B_]8I _H^9K_'&+]=9=E'V_5_,P](_0/]:WY?Y>_B.H^@1V&.3WRG>M
M?_+5QO\ B7GWKN74YK^KZ1^9O&?Q6/S2\+.GSP+_ +Z' S]*# _XX2UT!R'^
M;UYMX_5K]7?^'2_]\X9Z<CT9OV==_'X^&"W>9%+_ &".48[!N&-%!W#P[C/P
M8?'VT6:Z4:EF*]=&BQWEX2/RT'_?1W<OZ=<I_P C/.,/DZU;WDKI1S;F-?[!
M#SUZ+.D/SK_OI\[OTH<Z_CQ?7GSGW\W2\VQZ*/U,_2=_ANM?.\1]*X=K&P_J
M=>%'_D/NGOSI\5->@W\EU,_++5_@*\R'B-WP_7Q_C/V=:+R."?%-.6,OU7?+
MOX7>F?GRY0Z^CXKZ3G?"_P "_J,Q\YR]U!E+GG*\9LMX\S1CW&R5'XUUS'4C
M"W:GV6QJR*CMRTLR,HQ=P$W%D;ID(MV1DU"'$1#K /F:X?S!RU8YDTUFS?N3
MMQM2<DXI.M4EC7H.;]BW;?Q?L4XGK^(\(T6FUMS76(6I*]*<5%0EO)Q<&L6\
M'4KSN><6-^&=0YH\=,G92Q[,6ZA<WG/C\VQ=)5..ET;+P]X<VEBZCH2Q2SB6
M0;HMIHK8YCJ'*==NH8H@ @4N]<!X9#A'"[?"[,I3A:WDFUBZRE+9AM,N:^?=
M5VD\T\0YXXE9M:;5Z^[;E*W;<MR/JM/9L+=<FY.L;2DZO-NF!K$[R%9)QW57
M=CK(*$615SM<%4EDC HDJDICGD68BB:A!$ATSE, E, B @/1KBG:-CRQ>I_T
MMOTCL#]&O^(?A\OBK1Z^O>_V6XO"Z%U/>X@"&5^: " AOCKC4(;AMN 63D&
M_&-T?##6V]EWX/J'L^LOZ.V<V_7M&4.TK@\9II_N&.?WW6':UUV8>%S&+(W]
MZKCA_5!RA_'_ !HU;?RG5XT;]R]]O_J2\!'QK_>NY*_U5<7/QCR&UG=S_J^-
MCF/[>OFEX64IS/'=#BL4 $3#S1P2(  "(_\ UU>=_P!.C2UY?]5^ ^+A+2XE
M9K_2\3$TT E[R;"G6*8N_!#E@ =8IB[[<B>$'@W -_!I=:JC?N96MVU3_.\0
MS[Q?^Y1G[_RY7O\ ;RJ:T99Q\Y>$XQI?EX><O"43R['?DGW70A_^FUD0/_\
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MWN7ZF'C+_P#,_P T_P"V_>"ZZO[.OYE:3[Q?^CNG;>@_ M/]WM^")07O6?\
MO0\M?T?\>?G(E=<L[=OQ;A_W>YZ:/KT/D3\Y>,[#W?8_JK.:']7E6_.QCW74
MG+OYAX=]_P!-]- ^V7D/S3J3^]W#G)WHV.#$,8I@Q#G7I*(E'HJ* ATAL/0(
M;_#UZ%[<_P OZ+[]_J;IM^@7EO\ S5X3O:<H%%%N-7(CM5%%>K@?,/5[0YC]
M7?'=CWVZPCL ^;Y^O+\U_9R\U^!FYQ\N/2CR]^%,&]LW*O@Y7(ZP2-3?SO*C
MBG$,K1$-(9_*UUW)9@HC%O-QS&Q1LQ O'T6HY[=))ZT<M3J$ %4E"")1]>=H
M-VY8[-G?M.EV$-)*+[DHW+-'[IL5O3VM6YZ6^F[-R$X2QHW&2::3V8'I7XDX
ME3=#S35\QW'D=E?,4M5*==J-7X&X5?"-;@HYID29H$K/2@CC+%E&EGD@!L>L
M4T07<J()D.I^]B8P&+Y6U_%M?Q-16MFI*.5(I)5SR2,N$\O\*X&[DN&6Y0=U
M)2K*4LLO*RZCS#\^IIK93Y$)*D(JDKFS.Z:B:A0.FHF?*-M*<AR& 2F(<HB
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MDXHO'>3RG>)8J=<D<]YAQUDF8DXM_7W"%*FXMGC->N*1C<&"!7AHYRZ41,N
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M 0ACB'%#EL(@0HF$ #-G X1$=O  >>/1KO\ NY=1^3_-'E6NE^%GG&SW17;
M'FA8[ &WF[C>GW[>O/W_ -S(?Q.'IQ/UBX+_ (-+/_DN]Z%T]"'F 4XWGN^-
MB'$3\]:EU0 IA$PCQCY5[   '2/3X/#KT)=\E]#\!^4O'L=#;2SJO$=+'GT
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MX>RV8S9P !B_((B(HG  #W(S'2(]4   U'2E#X4:J<G]/=B\)"@ B(RO=3
M!TB(CFOC)L ;>'?7T7?(ZSG'%?P)=7C-T!F;OK''Q5SMN?\ Q"OF[@'1U=^G
M6A5'"&,)9JY.]$2-US!XLQ#<J*@AN5BV VP@7;H'H'X.HF@Q;XD\^]7'V%3Z
MG65409/VKDS>) K=<PDCA*8 14]";R@_'8?0^'8?^FX:B:JRO85+1D%TI)T*
MJ*J0"Q$H"HF<@"/C"0[ )@ -]M26766.9='6!F=);OQN6_*S%?>-VS'.*N2V
M=<6T.)X]X*L#&H8WR?;*5 )SMEF<MI3LLI'5Z28MEW\BE!-"J*J%,<2H% !
M V'KGGOF'BG [VEAPZXH*Y&;E6$95W=VGE99O(]N_I&[&.S_ +5^%\?U/.VC
MGJKN@U&BC9<;]^SNQO0U3N)^JN04J^J@UO)M4HFJNNI8.>/.L1 !YL\M-A,
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M<42K)B?;KEWU;323JTL5W.^<EY=OV;$[KO3C!-1I5TVONEB\5X<Q/WD7%+O
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M4RAURB(C8HC8  ?5>NM_[M\=CBM'JWE_S-SN^:>X[/;3V/0N1;YJY>IO+_\
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MVRM'_(HED!1U&Q[%*Y,YLLLA!PC!/LSF3[(M)5;3:,0!*4 ';< VZ/!H0^M
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MYFXVJ^IMN+HMQ&)7OJO8+OP-3+T)(U/DHFBF'0FDD21P80A$B!Z%-,I V H
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M4L59J'?[G*UR C<B9@?9-CF]<?+H559NFM%BV;RC9)DU:2B3EVVD$GJ(DZO
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M#T8TDLK#M3. 2ZH+"V3ZV_5#;6M14L_9D<EX!IM/J%<]?",Z+"J+F->[([O
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MO4K7%XUKWS2=BU*[ZY_*5J=F%)($$DD2B(E2233 3" B)2%*4!,( '2(!T[
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M1,9HG'4K-RE]QUCAZ@^E7.6P2200;.$RILA.*@"<"ZK;G+>?<\9>(:Z6OO\
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M/[6G_&<AK'XQ7LZ!3K(A//[%-_;!YZV8ZGQB["!JD,8LC?WJN.']4'*'\?\
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MT<C:I?;UYZ/68KG_ (<@/:2*]8-]>2%Y*Z#==AYI?>Z_K1^=G@_XW)>'P?\
M#+'^O5_8M^3']\N^")MFM^670CMZ=V+@SNXK;PPX,P5APGPVLF>7_%3C;:[
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M6L#,-@\[0!H T : - &@#0!H T : - &@$UA QH22*4HF,9L< *4!,81';8
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M^)N?O=?[$?\ :U:BDNX3W;9R+:, $%=P9K 8.S.(EWD7A@W#J[@(E$!Z=1/
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M3IZ1\(:C6!5XA?USB AUS] ?-F\\//$0T:H0R);^ET/XE+Z0NM,U3FT : -
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M[OL?U5G-#^KRK?G8Q[KJ3EW\P\.^_P"F^F@?;+R'YIU)?>[WZT3'']4.=?\
M9!#7H;MS_+^B^_?ZFZ;?H?C^:O"=[/DW_=JY%?U#YA_-W8]>7[GR<O-?@9N<
M?+CYR/,=[OC^^OW>WZ8W#W\^&.M>M^T;^6-SYG2_263:-']J]OP,]5EMZ9;_
M ,<C].77DE9&[;#R1<\_\5^0G]=^=/SIVS7K?@?\I%_";OT<C:I?;UYZ/68K
MG_AR ]HXKX/^CV_F>;KR1'R5T&ZG1G[R3NB>\CS;SZY99CQ)Q<E;UC/)F4$;
M-2+6RRUQ[@49F&]PU/AC.#0]RR]6K*P.21B7!!(Y9('V( ]40$!'N_L\[2.
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MZ_=[?IC</?SX8ZUZW[1OY8W/F=+])9-HT?VKV_ SU5T# 5= PB  55(PB([
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M<W55.([!U-QV#PZ50HZ$3R9)?>#S^3+?4:50HR:QCWY#.^LQ=EZT<_*7=NJ
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M@#0!H!-80$822  W$6JH  >?U=%F'D^@\MGOF"B7O6.;@&#80R70-P'P_P#
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M2P@(%,.X"<?. =$\!B+_ !=8/\6?Z$W[6K4@QD453': "9AVCV #L CT@W*
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MHPK1O46YK"J_H-N+=6U%2-.#>\HRK5K)JE>AF/%#[T[O%<TRBO++&4?R.R'
MR/(I]!M^(] X766Z8(-Q]92Q(^1('(>NUZ0DQR[%HF.=T8%A(18H"8Q2_<@;
MMJN3>5M"OW-K'I+5U:7>^LSU<8WO7M57]A*27JWDL/?,?63D]Y)M5RILKW3*
MVQ<E^?/(.7[TS/V'^343Q]QIW>\YF3'N/\%NL4U*V-\A.<,5*T3=OL>1)JP-
MCS43*SC2O&6B#(G72;OE03.B"#93QG8[7">6N%V^#<-U^DEJM7Q2-J<[RN2C
MN*[*,8QMI.C46_A5I5+.KPRK)N33HHX9=SNFZW@#E*\YOX<\4LN9,F"V&_9"
MPSCZT6R;*PCHL).;D8Y!1X[".B6K*-9@JIT]F@DFF7S #7!.:-%I^'\?UFAT
MD=W36KTXQ56Z)98NK?6:D75)O:D=>#NO^+O%[-?=B\V;)G7$F,K#(1><N6'7
MR58*G JW2I1==QU3IJ,?1%V5:$L,,2NR*JCQ $71$B*F.(@/7. ]F\X<9XSP
M_F[A]GAM^]&+TVE_LXREN2<IR33A7=>\L'55H:<(PE%[U,6_94E8]Y=9\JG=
MB=U+38WDM9<-7K)T!EZ!<U_%^#IGD3RWRMC_ !=>;;5\7Q6%J">#?U-I',*Y
M&1Z+MY,O8L5VO8':KJ @Y15:O@?#;W-_&;\M)"_IK,K<JW+JL::W.Y&,KCNS
MJI-N3DTHJ5'7>2JFHI/U<*NC?6^]3QG+A/O,>:$;Q5QKR?RM>YJ6I''KO%7'
M&OE82R8QI]5N$_QYL[*N,6UNO\$Q8.24V]8YL<N1FLE&.D.N]>HH+G7[,RA\
M.(\H\ GQJ]P?16XQOZKA7K]-NW)2BK\:MPA)^7"<55.2>";5*T$9O<WI?TJ/
MH[OMFY'A!R#RKR@SISMOZMR(^XPXLSXEQHP/4FT/")ME+/BBL0Y<Q7\MD:QY
M9B=8V:RR:)XXRCQ5N1LJ<I4R"0NW!>8.%:/@_#>&Z90IQ>]I_7WI5?DW)/U4
M-VM$XQ7PL*UVXFHG6JV)T]_W37!W]_&27L&/D.45GS+?9*MT*[\>:AB_ C1Q
MY.QM6+-.Y.9QMTR3+MB+J^Z2U3<+)@Q;&.DCXBW*?T:O7*5+E79KQ>%G5O@]
MG3VE=NV[\KEYJMR45;;C;3^+%-;S[K[FW3O1K#>QPIT9YEX>\H@[!=N\6X'5
MS#..,>YWSQ6,9<B;:OAO/Z#=#CR&*YJ'&NNKS8ID2RTBRNK2TM4VL<BUB) '
M'098[8J)#GV_E.Y:T_*O$KNONW=-PV=VQ'UMGY?UB>\H16"<-W&3<E396IG/
MRTE2N.96W<()UZ*X,S5+CU9]O<\><D,W4[,56EF$='PN/\LM9*&E;'1Z"6*F
MI]D[H4/&S# [-R5<!<.5G*@IIB82AH]I+N7.9(ZB2B]/=TEF=J2;;G:::C.=
M5%[[:=53!)*I+7D4VINO2;P8L \84Z/]'R_XJ=#KK]FI_E\#%P?+?'_9U=AC
ML,A6'I%EZD;?:2:TWF:Q+T : - &@#0!H T : - &@#0!H T!:"[^S8>H$?I
MUM9(PEF4VW])2'PFOV_63S1"#JD&,9]<=^ULCZT5U)9%0N'PC\/5(LAC$>R;
M'U2E].&I+(JS0NU2'T3Y<OSQ?I@U'D7:ND83'LK)^V+[UTKHB;6+=4#"2^OI
M>H8[UBWU%XRL7:KR(,WOI2*]1K?C.0U%G[.\78A;JD&)_8AO[9//6K#4V]1=
MG6+M4A.0]*._GFOTZNH]HV=9!U0-(KY=][5R'V@VH]G25"O5(,X;V48^J"?(
M-J,JS%H^'X@?(#5(!/EB_/!\D-'D"=+>R<CZN>>NE=2.17F02^$/B_('5(\B
MS%_X]4*Z\@,/\B9A:PEO^$JW:X&FH,I%HA756.0ZN$'/C-QJD:N[?.",W)A;
MF3<H DH "8#AN [3J>#:75<8TW&KCN+5Z6-R,$FMUJY&49;RW6VTI.E)+'.I
MSOA/:'Q_@O(?&.SK1K3OE_C=_2W=0Y0D[REI+BNVO5S4U&*WHK?3A+>6":S+
M<S7#K$LKGFV\BF+JX5>^9"QB^Q1D1G6)B.8U:^5UY&KQ*<A9X9W"2"KJQQS(
M6I6SQ)=$4_)[8!*8"J@M\E_EG07N*7.+QE=MZF]8E:N*#BH7(RBXUDG%O>2W
M:--*L(NCQKOFB[8^;=+R%H^SJ_'1ZK@/#N*1U^DE>MSE?TMZ,U<<+-R-R"C9
MG+?<[<HRKZVY1KX&XHNO ?C]<^)5$X>65C9I3%=/BXX:M*+2[$+W!OX6SSDB
MSF8^P%AP8H2PIR#IHHH#+J*,G2J1B;'$0T+O*?"M1P*/+UWUKT=MIQE6/K(M
M-O>4MW=K\*47\"FZVJ5Q-UX7V_=H?!>U?4=L?#+FEM<UZQS]?!6Y?5;L+D%"
M5N=KUF\[=80N)>LJKD(33P*AQEQ'Q=BO,<KG2#?W*6O4GB6G820/9)EA(1,'
MCZDM:^WC(N!8-(:-.R5>JUILX>*'55[9SUSE G7$-?3P_ES1<.XC+B=J=Z>I
M>GA86^XN,;=M0244HQ:;W(MMMU=:4J;)S/VN<T\U<FVN1-=;T5K@%KB^HXDU
M9MRA<NZO4RNN=R[.5R>\HJ].%M*,=V&ZFY;J95D?QIQ["\@I_E1#N[/&9'NM
M*:8TN,8SDV2=-L\17SQ[J%EIB&-%'?+66-2(DW2=D>)@5L@1/LQ 3B?6AP32
M6^-W..VY7(ZRY95N<4UN22I1R6[O;R48I/>6$5AF;=J>TCF#6=F^F[+M7#37
M>7=%Q"YJ]/.4)?6+%RZFKD+=S?W59FY2G*#MNLY.55A2W_(7AS0.0EOI>27%
M[S+A_*5"BY* K^3,%W\U#N!:W+*+*OJ\]<N(J=C7D4JL[7. "V!8@KJ "G5.
M)=?+Q?EG1\8U5K7RNZG3\0M1<8W;%SU<]QU^"W26'PGE1XNK:=#?.SSMDY@[
M/.#ZWEJUH."\8Y5XA=A=NZ+B>D^M:?UUM)0O14;EJ<;B48KR]UJ,?@U290@]
MVSQP-Q^B\$,#Y)A&M7R8TS+ Y3AKRY99H89>,9\1;));SXBJDI9W+=84CB=D
M9J! (8B!54DE"?&^2^#+A<.$P=^,;=[UL;JG2\KF6_O[M-ZBIY-,$TDTFN1P
M_4GVD+GS4<_:A<-OWM5PW]W7=#<TL9<-EP_"FC^K;R:L)K>25S?;WE*;C*<9
M?<)W=V V>'<P8=M\ADS+#?.\TVLF3<BY1N86/*D]8(Q-J%=ET[4UB8ENQ<U9
M9F56/!)H":9Q,"I52',0V=GDWA$.'ZGA]]WK_P!:DI7+ER:E=<EY+W]U8P=7
M&J=:O>WDZ&AKOU$\_P![G+@_.?![?#.$W> V79T6DT.F]3H;5J;EZZV[$KEQ
MRC?4G&ZY7&VJ.+A)*1CEC7@!<<,=X%@S,52F\I95QK5L$9"K%^RKF?)["ZW=
M&<<PEG@:E7$6Z_D=R6"BXM=HDW381Q$$Q5.=4QE!4-K8--RGJ>&<W:/7Z:6H
MU'#X6)*Y=O7(SFI.-R,8_%>ZEN))1HN[@Z=I<;_4#P;G3]/O,')O%['"^%<S
M:KC6FOZ70\.T4M-IG:C.S<OWFUZQ>MG<4Y3=V\Y/=BHI1449M<I.)6->7-<I
M=:R3-7^ 1H%R0OE9EL<V1O59]C8VL>\C6KLDJM$RJJ7BJ3TYTQ1!)4BH%,!P
MVVUR[CW+VCYBLVK&LG>A&U<WXNW*,9;U*+&4999X4=:8G0W99VM\S=D7$M;Q
M/EJSP_43XAHGI;]O667?M3LRG&<HNVIP3WG%)[V]%Q;3CB4SQDX 8!XZ9!>Y
M&KXY R%DJ;BU*RKD/,EW?Y!M<?65TP\9K\.[=(L64;'NNKLH8B'C)R"*8J]F
M(DU\7">4>$\&ORU=KUU[63BX^LO3WY*+5'%444DU@W2M,*T;1OO:#^H#M [1
MN#V.6N(?N_AW+-B^KRTG#M+#26)7EY-VY&+E*<XUPK/<3I+<WDF6/A>ZDX^0
M?D1BVR)R-<5:EY/8Y;Q=07V60<8_Q+;6=D-:!5HE2]SA8I%!W(*J$5/(DD78
MHJJ=5<BBJJBFWV^0.$6]U0U&N5FW=]9;AZU.%J2EO? @X-=YN2DVMM:R?+];
M^J_M#UROWKG#N7(\5UO"Y</UNKAH*:O7Z>5GU%-5?]:YMJ"3BK+LPWHQK!QC
M",:-A^.>2<Z=Y? <G\HX(1Q1C_C[3IFK4F;>7" LLAF*YMYN:C:A;5(N(<&7
MBH6'K]B=OF8.$4G+=PDW*<QQ]"G\UK@^NXKSG'C>OTBT^DTMMQ@]^,G>FI24
M)T6*24MY8*F[%-LWO4=H_+?(OZ:+_9=RMQZ7%N8.8==:OZFU'3W;,.':9V[<
M]1IU.XJ7+ER[9MVKFY*4)PE<:2SEMTD.B0D/5SP/_:%=O.\S782R/)#S,9JI
MQ9Q54LH\ALLMD)N8GN3S"K164X>P/VC^K.XRI5Y[5V+")BT8UHY9M7T1(*D>
M%6<.>V$_1U Z-;)I^7]!I];J]<M^<]:DKD9-.%$FJ12BFDTW6LI=ZAV-Q;M4
MYLXMRMR[RE<E8LZ#E>Y?N:&Y:C*-^,[]V-^4KDW.2E*-R$7;<80W:8[SQ+$8
MU[L; .&LBT.W15OSG<('$<B^LF&<39$R8>T8EQ'/V%('CF7HU7-",WC5\S6=
M',U,\>O025$%A ZY2*EVK0<D<*T&KM:N-S5786)N5JU<N;UJU)NM81W4TT\4
MZO'%U:378?-OZF^?^;^ :_@NITG ]'K>+V;=KB.OTFC]1K^(6K225O57U<E%
MPE1*:MV[>]%;E5;<H/8+KF)YU&3[TO%>UP_C&1U-I7L*HH/LF\]0CZX0U)%C
MF77U@9AH T : - &@#0!H T : - &@#0"6Q>PDGZD5^E'19C8SRX.^<:2"'>
MJ<U%5(J9[%UD2@.FJZ<-*N&[EO\ D)Q*@*S=PW9JHK)@L@<@B4P[&((>$->D
M^R#F3E_@W+MW3\5UFGT]]ZR4E&<U%[KA:5:/95-=3-JUEJY<NIPBVMQ+W6=Y
M7ND$'#7NR>##9VV<LW2'&O&*:[5V@JV<H*! -Q%-9NN1-9%0N_24Q0$/.UYZ
MUDHSUM^<'6$KTVGW4Y-I^T;AL70O 7?Y@3O*Z#H595XC5^FSUY7OU*1L@7AD
MH\B6M*6ML"UF^Q%I/1T@W779N50<J)LGQ2117ANUCUBMWR/R/#(M$S*:%7FW
M-;JSFRM08V)Q5H%:>9 DU0*SF56"*DHU*BRF+"R2(W>F.0"I2#Y,H!L5PL&R
MAD1+-$[61!@Y](QWPGGVU#6*S?25[!?K(@S#V'4]LD/6SG4^-U%V=8LU2$]I
MZ4E?4C?\9L-&4@:$&45Z:4]KY?\ %#[4>:Z1[S%NJ"?%>R<?ZM:_;B:/(JS(
MJ_UT_P \;Z8VB(<6@&$O[*2'JM?[8;4611?JD&<G\LS]KF'K8FHLP\^H6:H&
M;OV.B?G'OKH="[!9H09&]BA]L">MCZQ^,5>2+=9$*:OM%A<HXQRCC*R*/T:[
MD?']GQ_8%8I=)K*)05UC%ZS+JQCI=N\;MI%./E%#(**(JD(J!3&(< $HZVFU
M%S2:JUJK5/6VKD9QKE6$E)57<JL2[#"Q7NW.-#[@Y%]WU.1]LL>!X*+>1\&]
MFYF+<9#AWR]PF+RRLL;9FT SCFEEAIV=7\6<$CP3\6'L%4U4SJ@IOJYJXO'F
M)\SVY0CQ.4JNB:@UNJ+BXUQBTE55SQ5&E3#=CN[E/@E68KX$XDQYFW"N>6=M
MRM9<B8"XK.N*%-D;=9:](MI3%\8>?EV#JVHQ]/B7,S<&WE06_E!-9L"R*)#+
M)*+BJLIHZKF/7:G0:CATH68:74ZSZS-1BU2XTD]VLG2.%:4=*T3HDC-)5KM2
M,<;!W./$>5D^6TC!2.7\>)<U&D4QS+$X_M]:AXA%DQN,;?))I2F[^CRZ]<:V
MJQ1PGDTC*N4UD'*Z"1445.H7=+?/7'(0T,+BL7?W>V[3G&3=7%P6\U);V[%_
M!RHTFZM&"A'X6'E9F8MWX=X0RMQ<_L46*">M<&.\=53$C.,AW;=I-PE;J+:&
M959]#RCE@];H6&#4@VKE%THV5 SE+KG3.!C%'8]-QSB&BXRN/VI)\15Z5QMJ
MJ<IMN2:JO@O>::KDS*B?P7D\"K8; E#C./49QAF!F[MC"/P^UP4]);9(BUBL
M6/VE/3H8MIV;@6M?.K+NJTF"2KYJFT<"K^_%,57T>M"YQ'4SXF^+PW;>L=_U
MRW52,9N6_@G7#>V.JIAE@*>T8/8%[I; ^",E8HR,;,?*W,Z& "2QN/N-L[YH
M)>L68/>R[(L:I*8\J;"JUP["0CHP/%V0N7+I)L0"'!,5T6ZR7(>)\Z<3XEH[
M^E]1HM.]33U]RS:W+EY)UI.3E*J;QE1*O0VGBHI--5PR[PNF>Y=XE(9BDK@T
ML_(./QB.;5\]J\4(_+2C7BLKESM %:X#C-*OEE$EUSD 1;IRQ&Q4@!J1,K(
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M?@8N#Y;XHZNPQV&0K#TBR]2-OM)-8/,UB7J - &@#0!H T : - &@#0!H T
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M_3"GJ"8_%3K6++[S\#%P?+?%'5V&.PR%8>D67J1M]I)K!YFL2]0!H T : -
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M"/FCL >;J-U*J^X+_)3SYE#^6,OPG5WB#"+CW24BS,8B75!;<1!VS,/24P;
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M+>G1]2Q_XO:Z("[0#)]Z7BO:\?QC(ZBS*]A5%!]DWGJ$?7"&I(L<RZ^L#,-
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M&U;@8&&>D=F*";@TJ=,HB9$X%F\-TKC\G[;^D5_L"?U>F\-U%%3%>MC"ZTZ
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M6RX_M 6&XQ85YK),9Q#W.0%NFH"DSHOVBZJ/;VZFQK"540ZW7:J/!1. '((
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M6)0[$A5BD%P0H*%W*.^IO8BGM%?_ )/VO](K_8$_J]7>&ZB@3PUT#)*%1"N
M?&2E(=6)?(0/V8.T;VE/-8UK30@16!X9LXKZZST7?5[,IT@3$>L(!K&N-47=
MPH5]^3]K_2*_V!/ZO66\3=11MBK]IBK%0XFNPHSM<LTY*1U_GU7C1DI28)E5
MIV:B)ALR55*K,*R=NC8^,,BD!C))O3+& ")F,$WJLNZ5E^3]K_2*_P!@3^KU
M=XFZB@\A0USJL-&/\=UOW=S;N[8YKLI$N7[.%2CJ);;[6ZQDRXD=N5TR.'-
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M<91ZQ0-YX /_ -KXFH#ZT : - &@*(M&3,;TARV973(-(J#QXW%VS:6BUP,
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M./[5D>D7">O#*32QK9643*1DFL[CE(:8A^U\806;"0^BPQ#7=-W<>5(C!D5
M3BB5HV*B*ADSG%($2 F)SI"*1S=3;<2^A$?!T: EZ - 8I3?.7A_7G%V9R_)
M/#;1]CJ89U^Z1X7F$<R5?FY!X>/:13R-:.EGRD@=^D=$R22:AR*D,4P%,4P
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M5>:+M9Q8I5WG9HF7/<&3%*E#= '@#X6H#]T : - &@#0!H T : - &@#0!H
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M4PY>V3"N:-T/'G&N0L34J;IEYR;,Y6CV=VL#K'5CM+U26N,?C1Z$>M6JU;[
MLT:N++.02_C27CZ@*++MNQ[5110#''$IJQN>'X*RYCL&..161N-D_@&KYYS_
M ,@9RJV/.<,G<,KV?)$-XEB;'MWQ]+(PR%82PZVE%T"*.WSIN<D?&+))E.!^
MPM7LS)3NTH;8N,D'*UGC?@"N3LBPEYJ PMBZ%EI6*GPM<7(R,7281D\>QUJ
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MJ(P5?AT8"%L,5*M6[8KHQ99\5#KOD$CH)=9F"['._BI#9]HT?+P6%\69/O\
M7[QBV?G8BX1=;C+!DC&%&N;*S6O$T;D&4B7;F!/:8Q)=!NFX<-HUPHJ9L[51
M:N7"@*T(U4M#QWPA)/N4]3SK4>&,5PJIM-Q7?,=72.GVF%&MTRM(V64JTA5$
MX:%PA9+S 1T%2AA'BBLF]D&KYP9\#=-NJ@)U"4M-M*(V 9^LUUI>#<P7#&T8
MQFLAU7&=XL5'B),!-'R=LA:U)2, Q>I@Y9"NV<R;9,AT^W;]H ]7M4M^N6>
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M677BF*JRIS?+'4540,<YA\\1$= 2V43%18*>38R/C^UZIE?$63=KV@DWZ@J
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M"(@8-4GM&^9 ADT$4SE2*8B29#%1*)$2F*0"B5(@B(D2 0]"'F!J%.70'X(
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MSO&7R:*26X))D3 3'.($*!0$ZAA.H<0   3G.(B(^$1$?/T!R: - &@#0!H
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M]^J7?;;?8/!H#Y,DD<IB'3(<IP,4Y3%*8IBF#8Q3 (" @8/#Y^@J)X>L5JO
MY+ 5Z$@RO%17=EAXIA&@[7'PK.09((@NJ._RQ]S?!T!2V5J [R;1I>EL;]?<
M8N)4S Q+GC*890-SB08OVSXQ8F4?Q<RT;%>E;]@OUFQ^N@H<H;".X 8)USNU
MFU2L5PM=>YE<UXRP9#G8JR7N2;Y5J!'%MFH2O0]3C'\VH&-MW2[2LU]DQ*(=
M7[G;D+X0ZVK4&RY,@IIIIB<Z@D(0@J*" J'$I0+USB   G-MN/0'3J ^] &@
M#0'X8!$I@#PB @'PQ#0&"#K@!C%WF1#*9[QE8E82S&AR'4P02V-APNXSJU2
M[?):D">&-/DE"31"RXLR21(PTR0'@MQ5$VZM09&4;#$)1\G9@RNWF9V7LF9G
M5+/-I2SEHK'0,70J\> KT!6F[5BT.SBDC.W;Q4%CKJJ.WJIQ/L)2E#;4O)H
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MSU2[B/5+N/A'8-QVZ W\_8- '4+\R7XP?M: ^O!T!H T : - &@#0!H T :
M- &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H
M T : - &@#0!H T : - &@#0!H T : - &@#0!H $-^@>D!Z! ?-T!\]0GS)
M?H0_:T!^@ !X  /A 'F^'Y.@/W0!H T : - &@#0!H T : - &@#0!H T :
M- &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H
M T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &
M@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T
M: - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0
M!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : -
M &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H
MT : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@
M#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T :
M - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!
MH T : - &@#0!H T : - &@#0!H T : - &@#0'R81*41 -]OV_@=.@+286R
MJXS!3U+8ZQW?<9*DGIV#]S>1H@D)83%A7IV@2A61%W #'/P+ND?<.L(& .L4
M ,8"1FR=L5=QK/2-1D(N,LRKFO1$(XE',6T!9_8++#P*4=$+SIBP(6R8"2%I
M"%?[L#S"S4KDID!4*(&'3;E+;,=-G=3E(Z]9!R(6>20+5\F5-.LW*M0(0#66
M=/;#)X&I-YJ]F:2+I8I(MU%0S=OU3G(Z5 Z!CG!Y8%SJ;R4D9R_PD6YKLHTA
M\@UMO9X:+L"2<'.4A-GBN"O3^%F& QXN7,BL]E#HK@JH MCICU>L78NFT;"D
M87F'?K1[GUJUA6)?,+-.X]I<6\?9*\G#[L\C\?*MGN-0<MPISPR==A8^=59O
M7A3&<#V::B#943G33#%Y'&UYQJ2\S2(J Q-/2@V"!QK(V4436E\I6Y+*+@&<
M2T;N8"B3D"\BZ^H8'$H[>OXLQ6('4;).%""CH"EJ!RLR])QF&VS^C0%CR!ER
MBXTD$89"Y(U^C,'MP:9ZG@FP>C1']B:'6B,7H>-MS'>I)=<B;<O7257=L.H>
M%DYUR8R98+1CM&A076D[/:,7LY"BSEAKC2NJ)7#"O(:U2L(2SITES-QS:+L^
M/6CI=X47B[M-B0C9%N"RR2KP#+I,@%N2<4SQ7CW,,I7UXFH62=+#7A=U(I*G
MQ^0R-BB!>J*MFZC><;?E BF<00Z9D2*D?E<%'8O9F LRZYL2RM;C9.(Q@T/8
M%@:04W5Y2SSII*"R-&*V\N0:,$=4*%<K',.:8G7F9CN6L<= Z<JBHJ*"0 <X
M8E2T?F O<<B8XJ;G'2M7KN2*O2YJ'L4_.235P]D+GC5ID9-C!%/4R52;+$>.
M!%N&XS+>9%T0ZQ& M@*J<"M+9R0>5BXWID%&(^QWBY1..O\ <C6N-83K&:<4
M%7(:"-?ICUHD>R,$XDS9N<R;Y-XH[=@"#98B2IREB/ 4./*C(:;ZLU5QAR%1
MR!=EZ*_K$&3)A74#[E,B0>1I2$D9RRI5 %&$O$N<;/$I!JV9O$>S.11JNX$1
M3 !2VY?WM=.!:GPM&H3UX8XNDJ+'#DA-9F]9Y&L4I4E5+')$J130?D.7C/&!
M!!%^9>.4 X 1P46PACUB=QSCGHN"B)B>PV9@K=(D%<?LHZWOK(M)S<?>HW'M
MA9V!O TI]*Q48QEY'QIJLQ:2CIVP3$1;).# AH,:=\=,.9LVY82DP[Q _C(N
MEXXL^0\A&E9F7A))DUKDY:JZW:U"'L5-A9*P(6-[ (KLW#]*(*1HX,98I%$N
MS.&RHRE^2%QK4V5"[5"-K,W%T+*$V[JL;D:!L%5E)"&E^/;>HJ.)9M33W%O(
MOARX#1!NFW;N3J@N5&/E!7C%2MI2TDARUR';4H=[",38^<LWKZNV6#48JR:*
M\O'<@^*U/&09J7.GUNRMFCVDY7D4 2=1S)0IW0J=F)TFZQ7>)5MKV=PRTQ#G
M)]E.9>PQJ@$(M6ZX92[*>6!?$@KZUO=VH<G2VP!'-A?%8O* ^<^-'[ QVJ[1
M0$NJN!@#P%J&G+:R-_<HI9\6,X9KD-.GR-#68WA*:4?P<QFO$N&+&ZGVY*\R
M- OHIYEUA),D"&=D>MBF244;+$.4H9').<O'L/)W/JX]0=US&\3GBTW26):A
M3?HU?!TJC"NE(*+""53E9VQ/GJ'9-E7#5NW("HJ.-RD*H#*<M7('D#"WJLQY
M\7U1L];4;+-GL%(;Y.BG\-)Q=698PFXB>"WEI9YV-DF+:Q2# K 6"*+ET8%>
MU.U[-<H99DN0YM%1N5:B(G'"\[6+ E6FXR4=-R;B>83=LQVUR#$QCYNA45J)
M&N.Q?H-#MGMC:2(BH#@K84#)F4#:4\QYURKVM(K!BM)&]N[.UA"TX97(+E>'
M8N*[(6-1Y:(]EB!S?(AXBG'':D*G N&+E<W:(NSH)JG(> *B7Y07>[GH;VDT
M5[4ZL[R-@^IWN0M3Y%A<826R&A5[1*5$U)DX!7MV"59L[5LM($=MW2;M<W9(
M=1(ZH!M,[R  %+MX-@_Z?"T!]: - &@#0!H T : - &@#0!H T : - &@#0!
MH T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : -
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M;>,;>*]7]Z]-_=/RO\)Z+S]0KS'&A T : - &@#0!H T : - &@#0!H T :
M- &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H T : - &@#0!H
) T : - &@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tm2115679d1-bc_comparisn4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-bc_comparisn4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!H@.2 P$1  (1 0,1 ?_$ /T  0 " @(# 0$
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MHO=S>)Y%.5&@]=1ER$+[CXYIUOWJ->_:SM]Q0-_WW7W(NCGQ;UX'/5%[N;Q
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MGG?1$157Q=B;5HA(UESFOPP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M'A+"#YB,/J[Z],I[CX!,9/3TCIV[? 3&90ET# & , 8 P!@# & , 8 P!@#
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MQK\BI(NCK$LD3+NG1,S^J:&]0]-(E-\U@W*=MCH<G&N0;4-Z\\@?I& [R3C
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MY>!K , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M^^T\S)O9CY>\^1'X7GS^_P P3]CZ8^LWWS+8M79EP^9(P!@# & , 8 P!@#
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M>2;A#;4WC=;UW?T?DTVE[B!HCC ECTY2J'1Q,+,- E*4.,61H2A"+*%OJ::
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MU57V5KW?8V$A"V5L=)W8I.[L1$3O)1$V)W]ILKDV=!@# & , 8 P!@# & ,
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MG>0QSH[2><:ZU/9:1R!L;LYOYDBB1[D8Q7JBKXSEJC4HB[3*659;0P!@# &
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MC%O6M==X] 3XR\/ZQS.[3:?3Z/\ 9?[G^_CT!/C+P_K',[P]'^R_W/\ ?QZ
MGQEX?UCF=X>C_9?[G^_CT!/C+P_K',[P]'^R_P!S_?QZ GQEX?UCF=X>C_9?
M[G^_G*6*(J+B78NX<SO'[97'F, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M#]NC_P!.7_ROM_PA_LO[C_7R#PW_ /K>JU/SOWQEWG:+WP?^0V+_ $OV=O\
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M[:'M;9)G"Q-?Z+<N3"E%Y;UV+W:X=M? ;UMKRT/(##6AU;74LD>BSC&U<E7
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M<_ULX/CI$%"60R)K1(ULCCKA%7<;FRM3JB9).4<R.AQ913HG6DICA!/("6H
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MN(1'F%)"=F*#"B#1Z!L!8Q!Y/(UVIGRA>.OD394;IRB>:G'"VK5F'SCZK5]
MK4BTDED@^K[ Z2E\^5,K<O.6K?E4<9%BT_L#OTTR8PS?0(=[P#>_ & , 8 P
M!@# (T.4GZ?WCP_$OFG_ !.J'*>X^#]V\F<G\MQ\!N;E"7., 8 P!@# & ,
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M4_BH=F8^S/Z!<_EF_-/EO]O_ -;]/_NV;SZ%C7,EGS_& , 8 P!@# & , 8
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MW@MV1,?E]W$USDE>QZMYDC456M5&HN)U&(KDL(YDDT.& , 8 P!@# & , 8
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M+D(:!^1Q=<T=X[O<UJ>VQU<CBBV/'S!.TQQ2IETL1.TZA3.@;HY.DLH9CZ_
ME"L4[6'%(EYZTHW10!IM!&(S*/9'%IZ[U9'EV>6"7LD[9$B5TB)%$K89GN=)
M"L;TGK1N!%>Q&*F)4?5$3%?:_+J*STC+F617ZV4<#HUE1D:K+*CYH6-;',DC
M%@I5V-48]ST7"BLHJKE3FW8TLJCBM<TY@SD%EES;&TC:POH@ ,W'ETI?FB*!
MD1(#0C)$ICY;V)85HS6R_5(#W_1ZY"=G&46.>:VR_+,R9S+!\RN>S\8D;'R\
MM:;:/P8%IMHJTVD[VDYO?9%H?,<SRQ_+OV0HUC_Q;I7LBYB5V5CQXTKLJU*[
M".>^I':O&2?N_':O[NNE]9+<KCCV5J<6%,W2Q9M6\GG'(9MIN9S&.2J2FK%\
M=*DT07F"+( +X5 [Z <B 1L7:#+6F+3(]995'JS-<MRZ*YL+R^_ P1-@AN(X
M;%UW#%)%&B-D6.5J55?&?%5LBNIMQ#JF\SS1>:R:1RK,LREMK^SL/PT\SKB:
MWDFOVVDTL<LE71\R)RT:GBLEHZ-&UHFZO'(,DKSDAR*H$4[G]AP"+PFD[)B:
MVRIH^V'*HDZ3L,\9)+'%,NDI[B_+&YT,A2=P2)E*D6DFQG>EKL-Z QUJU;3-
M=(Y3JA+:UM,TFN;RWE2WA9!'*V'DOCD2*-&L1S><YCG-;XU&XMJ;<CZ02\RG
M6&;Z56ZN[O*H+:SN(EN)GSRQ.GY[)(UED5SU:[DMD:USO%J[#L=LWKS&ADX8
M P!@# & , 8 P!@# *=OE/\ T\KV_FP_,W7F;Q=CW\N<N_2/UJ8UZUSZTW7Y
MOS,9'UF2RTQ@%J[PQ?HA.?\ +%-/O'#LTY[=_79GU&+Y\IG3LY]7W?6'_-82
MTYA@OT8 P!@# & , 8 P"/GRG_H&WM_-A^>2O,R7V/?S&R[](_59BT]<^JUU
M^;\]&4[LWB->A@$@OBP_3RHG^<_\S=AYC3MA_ESF/Z/^M0EV:&]:;7\YYF0N
M)9HZ;"C & , 8 P!@# & , HU<MOTJ^37^T'<_YQY)GT(T7ZG93^[+7S##63
M/_V[>_6YO..-?<N4B1@%Y3B3^BIQE_V?*8_-Q&\^>^M/7'-OWG=>?>;-Y!^P
MK+ZI#YMIL'EM$L, 8 P!@# & , 8! IYT?P4XY?C#9/WMAV;&_9Y^F9I^2@^
M=*8L[3_(6?RY/ PKIYM 8A& 3$>$G]*NP/\ 9\E?YQZHS!W;]ZG6W[SC\Q<&
M0NS7]NR_5'><B+1^:AF;Q@# & , 8!!/YMW'QX-_^HS_ *_C!>#[\3R<:R>/
M?Y%CDI/P%M;^2_"*IO\ $O3/WQK75/W:#ZPO8+Z&4EUR?$YU?A;*;RLM>=X_
M)I\';7<3L95E&, 8!0(EOX5R;\87K[Y*<^DEE]#B_)-^:AJG/Y=_RU\)U_*D
M\A@%Q+G]_P"G->W\BB+_ .Y,^6?:#^P<S^2_YY]&OLT?SLTM]?C\VXHEYJ4?
M=X8!O#XUOT[N,7\IB#[WN.7/HOUJL?RZ>!3"7VD/Y&:F_=KOGL+[&;6GPE&
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M,NTRD\EM)<W%_=/:Z:>XE6:>3 W#&CGJB>+&VJ,:B(C:JM*JJKG/+:+F& ,
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MMLFM+QCY97(YR,8C')548CG+M5.A%4J0_P!%1Y __#;)O^TU>_\ >_-;_P"
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M2^Q[^8V7?I'ZK,6GKGU6NOS?GHRG=F\1KT, D%\6'Z>5$_SG_F;L/,:=L/\
M+G,?T?\ 6H2[-#>M-K^<\S(7$LT=-A1@# & , 8 P!@# & 4:N6WZ5?)K_:#
MN?\ ./),^A&B_4[*?W9:^88:R9_^W;WZW-YQQK[ERD2, O*<2?T5.,O^SY3'
MYN(WGSWUIZXYM^\[KS[S9O(/V%9?5(?-M-@\MHEA@# & , 8 P!@# (%/.C^
M"G'+\8;)^]L.S8W[//TS-/R4'SI3%G:?Y"S^7)X&%=/-H#$(P"8CPD_I5V!_
ML^2O\X]49@[M^]3K;]YQ^8N#(79K^W9?JCO.1%H_-0S-XP!@# & , K0_K&G
M)?D#QS_HU_R#W'8=1_E*YDLT-G_U D[G&OKA%#OJ[ZL>D/RT\CYFTF?$&=2#
M>X&^_?L]N4-Y(]F# JI5Q7V3&/QXT1:-[I9>RN* 8 P"@1+?PKDWXPO7WR4Y
M])++Z'%^2;\U#5.?R[_EKX3K^5)Y# +^T2_!2,_B\R_>U-GS;O?IDOY5WSE-
MK(/(,^0G@.PY3'J1S\9_'NAX_P!D\D)]);OG5W(>2\A^MDNA\\9H^E9VV3%+
M#1(GU H:@ 6C=&]H$6@).Z@&624$0=Z'KNSHQJL<KD5=I[OG5[6HB(BMW&UO
MPD[K+M^5Z<[)@I7VS4H/"HL"-I];Z[TTK5 RP3%N(!U[4Z@0' .M:" T[V!U
MZ[%[RG2K7].QWN&2HS*6"8-8'B..1+DAV<:E-$7HPH]&M3[#I2@<$9X"E;>O
M3;%KU"3@ ,#K>M[UTWK>^JHJ;%.JHK5HIV'!U*QWZUQR OCCAX\:7G7'B[+<
MH:;N/-.NHPX3&F+(F572I=&EE'<BW=7'EDA@[RQNZIC5.S&B5&)!G"3C4(R#
M! V,HL0:#,'.; F%52KJ>U120RYK73KB1%HVOMU0M(7KR$HWC%73Q;7(:V8#
M3-;,0?\ K&8V))FN,,VE BS#"&U$<Y*"3'5Z7:*$%*A2A.6*S.@"2ACWH.X0
MG3M%96$QVQ (E9<81R)%&9PRI))'"Y9'7:(R!3'W,.U#*YN,7D"9#(8^)X;!
M%*RT;BF2.!!)X *DZ<_1A( .]8 P!@# & , UQ-Y1UJJL3D?3T132ZPK<XMU
M;75JV37$/CPS) M;K<;;0<ZTC$.5OZJ/QJ13*7E5*Y@(2Z7DIR334H5"@GUM
M[ !FJ&R$Z71"*RM3&Y)#%$GC;'(5$/F25O0R^*'/38E<C8W*D32YO36CDC$-
M3M*N*3+%:<M44,)9QH-:&(#K<@L):Q697%=$UM9$A0V"SS]V6V;'VM@4UG6Y
MD%*C)J1GL=U725ND+6\6!N1C P 0-;D4I&V+?B3$FBRMG@=>X\\@:NY2U#%[
MTI=[522LYHJE::,/JQH<F(UU!#YE((*ZK -3PF1NB5*:^1E3Z'KDE&&$=@]@
M#W=- 9IP#1*:<Z6ECYKQ?@[!:)NFWIV. P^U+@L*%)8*AJWC_7E@R*61>$OU
MA/$OFL<?'14_ND'<]@0L3>ZJ@)T_J;#[=A"!O;@# -;Y/R@@$4Y4U+Q"<6B8
M'65<E/VW=<8>T3>RF0=!%::D-<1J4-[\Y'R!,_I9 O7V>@&@*3MBI,:22HV:
M>0(!830-D, ^%S<D+,VN#PYJ I&UJ0JW)P5#"8,"9"A3F*E:@0"@#-$$D@H0
MMZ"'8MZU[-;W@&D4<\B''V9JN WU++GDI8_(^7-E?'B5(8VD;64AJ@]'RJ_U
M;Q8*.2/3')XTC>8/$3RT19#<O5_,#2BE!*<O9AQ8&]> , 8 P!@%;GS:<6N)
M4EM/B3(FG@;0G*#R!<GN0:>L:;W;Q0HS6DA#$*8F:N3R?D_(6:/O$@G%/U17
M#.)8!A(_QTY:0C-2ZWM(+6@,0\*ZAEOCJYQ<8(!R[\:?BGJ^7<KSK'KBAN77
MC;ADU8]U]9,<K63SU^K:=Q^YXW^4!F)G\(8'!*D=V1=\./18BE0-$J3@I0+,
MEI5TW6Q!'V .TCL")-[_ /+/B)#5L^E-83MO^5/#>]%?(IS"G-GDS'\6>VA(
M5?#*2_B49IJ<SN*-,"(#0*N/$_0$%@].5\\VOS!LV)4L&G5#!$;!Y=WXZUZ[
MNU&.,7?J]6OM9I9PB@BIM9)1#6YQ):0H0-!1R4LL*;1( EZ D]P!@# & , A
MSO66V\\^3CBC&YG3S9"JUC$2Y2@JZS$MFMDJ7VH2O@E4'R YP@:6.MJ^O=QY
M?K2< 5"U?M;K?J!V7K7;DGEWPE(W,?)]_82%Y+D(, 8 P!@# & , 8 P!@#
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MG&7_ &?*8_-Q&\^>^M/7'-OWG=>?>;-Y!^PK+ZI#YMIL'EM$L, 8 P!@# &
M, 8! IYT?P4XY?C#9/WMAV;&_9Y^F9I^2@^=*8L[3_(6?RY/ PKIYM 8A& 3
M$>$G]*NP/]GR5_G'JC,'=OWJ=;?O./S%P9"[-?V[+]4=YR(M'YJ&9O& , 8
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MPD_I5V!_L^2O\X]49@[M^]3K;]YQ^8N#(79K^W9?JCO.1%H_-0S-XP!@# &
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MG]%3C+_L^4Q^;B-Y\]]:>N.;?O.Z\^\V;R#]A67U2'S;38/+:)88 P!@# &
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M<LE=#?1UPO;TIB:K5I6O2URI["E/=VEM?6[K6[8DENZE6KT+145."HBFM?\
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M5W&4<OM5L;""R5V)886,K2E<#4;6FVE:5H9&R+*L8 P!@# & , 8 P!@# &
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MJ4LG25 [W/,Y-;S=*7UC):C9$.'0B*,[3#I-&7),[2:0(5HSERDX:9*C1F"
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MIA"A*88F4EA-)&-,K*(5$"$6/6]@,  8?=O6MYUZ#HJ46BGW8.!@# & , 8
MP!@# & 84Y*;E.N.E^[@H5XIMJE+4W#@M77YF*4Z@K[]7@MO;L(OC]NWH^CT
MWK?J=,N+1_H7\6Y7UGAZNZQMN;B^#R^<S'B_U<-:]XMS6/IW\(YKU9BZRZMN
M>5A^%S>2_EX?];%2G?(TJ4=>/\9N3A/(:6=*Y8H]'^$5JO-]/\86,+4A9Z];
MFJFW"+N]MN:<:9(V@1RU.[J##W09:@I8!4,_>MA,WK,.HH-4WFG]1VFHF7<M
MW+J2V99,D1[G/G<Z[;(RU:M5=6)8FHV-%:K%8C>X8;TW/I2RU#IN[TX^SBM(
MM-73[U\:L:C(&MM'1ONG)1&TE25RND5'(]'J[NG&\J'NA+$MFYZPAIE.OMD7
M=4$ :I[>5]3^!HZMI.O'F//&X4HJ A>/ZT2N6O#2[G/I*-G-+;M+3T*Y4L+"
M+0,]M$VVJ,IR++LYS!,PBRC+;^=T%G903+<WD[)&<Y+I6_@XHF.:D*OE19,#
M98V1JJ5/'7%SI;-L^S')<N7+Y<XS/+X&SWM]/ EM9P/C?R5M$=^$EE>URSHR
M)4CQNBE?(B*B&:YW5T/BW*WQNRUHD$CF+RH'9T.U+G2>RN1L[]'F'BC-"6]X
M:8ZKD3C!V=0_Z2 6*E;6C3F+SC-FFF&[%L6[<RS.K^]T/J^PGBAM[=/1Y>4V
M"*-['OS.%7,=(D;9GHRJL:V1[D8B86HVE"Y,SR3+['7.C[^WEFN+E5N8N:Z>
M61CXV99,C7MC61T+%?1'N=$QJO5<3E<JU)/\PR9I& , 8!C^U:KKJ\*XFM0V
MW#V6?5I8L><8K-(=(4WQ;0_,3J0(A6C4@"(LXDS6MZ&2>2,M0F/  XDPLT !
MAZN:U[5:Y*M4[-<YCD<U:.0A$Y3>.'G]4%1<7:0\('(VF>$U7\?V.;(9#"[+
M;%TA!93W+GAC<M2.5/CU5EWIGYQ3G)G%688K:=FG+G$WJ9HK982*:2&9K6MM
M51K4W]WW%*J.>%SG/NFJ]R[NY[J'9/'E0GGOKFU[&=_(US9XQ7Y4;E1\O8JU
MB]2Q2.,S['[V622%*8=-'=0U\1Z6/.C33&4+XG4%#<5Q8CEA.]H#MAT:0A9=
MM<JS.:K:=S?P0XF?9N:B0L<CJ[:[N*FA/^J'^MX__5+X(?\ Y/85_P#FYL\N
M7F'XQGW?^D]N9EOXM_'_ /(WVYA4)Y[YG5'#5HX9\V>,52VY"J/:F+FI*+!B
MD<<F*W;V*C<%3.TTKQ.NXCV80V1I5)D#^H 4G;HP7HE:3K2 &@Z*3^LC+M6M
M2-S4<B>-WUX+_0>,3[-'.65CE:J^+3N)W]J?TCQY4)Y[ZYM>QG?R-<V>,5^5
M&Y4?+V*M8O4L4CC,^Q^]EDDA2F'31W4-?$>ECSHTTQE"^)U!0W%<6(Y83O:
M[8=&D(67;7*LSFJVG<W\$$S[-S42%CD=7;7=Q4T)_P!4/];Q_P#JE\$/_P G
ML*__ #<V>7+S#\8S[O\ TGMS,M_%OX__ )&^W,*A//?,ZHX:M'#/FSQBJ6W(
M51[4Q<U)18,4CCDQ6[>Q4;@J9VFE>)UW$>S"&R-*I,@?U "D[=&"]$K2=:0
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MG,!IQ3G&U+DA.2'ICP&[*5)Q&2>7?"4CLQ2L?#PDB>Y(WA#W;3OW3V^S45E
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M06]Z)WVZUUV+>PZUUV(/5085[W%#V%(F\.]AVG?=[UHS>^V+R8>NA6S]"Z"
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M: /85!A7O<4 )(WF;UH*=^UU[/MXK*"M?3$2'779C.#6NFSP]>OVNM"WOIH
M]A4&%>]Q0 DC>9O6@IW[77L^WBLH*U],1(===F,X-:Z;/#UZ_:ZT+>^F@#V%
M085[W%#P&2MP]ZUI,_ZZZZ_2B<I!KIV@%[=C9@ZUOH9KV>_KUU[P[Z**,*][
MBAYW)&_6]AVG?NN@['OI%91O70(##-ZT+3/L.Q=I6^@=;[MBWK6M=1!UM085
M[W%#R*1-X=[#M.^[WK1F]]L7DP]="MGZ%T$!H$$6]_#B[=:WU'U#V]>\'<H*
M+WN* 4B;P[V':=]WO6C-[[8O)AZZ%;/T+H(#0((M[^'%VZUOJ/J'MZ]X.Y04
M7O<4 I$WA%H&T[[UWL6NH8O)A!ZA&<#?486C8-:[B!=-]>F];#O7L&'8E!1>
M]Q0?6)O[@ ^'?>H]ZUK?U7DW;K>Q@!KO'\H["]=P]==BWK6M==[]FM[TH*+W
MN*#4B;][+U\.^_VS8-!ZQ>3:UK8]$"UZF]M&M%:UI0'KL730=Z%K?38!]J@H
MO>XH8-O:KHO>+/#BCY#9$!E=?39IL.O9]"8TX!D<5E+:B4M^CP)9!$7YB<FQ
MS9WY0C7(ER,],H(-,",/<7O8+ETSJ6XTW<7#FP075C=VSH)X)L7+DC<K7456
M/8]KFO:US'L<US7)5%Z2V=3Z7@U-;V[73S6M]:7+9X)X59S(I6HYM421KV.:
MYCG,>Q[7-<U=J=!PE94I&:L:65(S3VZEKL.R9%;5A2):TGZ<;CFDN:-MCL98
MJ9) B6\#&20J1[2(6HEJ C^5IB]"V!.< =1G.K9\[GDDN+2R;!Z'':P1HU^&
MTAB<CF\A5D5V-5Q8WRK(KN9(JI545M-DNCH<C@CCMKR\=/Z9)=7$CGQXKN:5
MJM?ST2-&X$3#@9$D:-Y<:(M$5'=Y:H1"F6WYE>"8V=F2F=P>%P-V;SHX]&,*
M9F@CA*GEH4H$)44+=4[HI/EBD*D1RHTL80%! 66+0MCC9\\O+C(+?3CVQ)8V
MUS-.UR(N-7S-C:Y'+B5JM1(FX41J*BJM57923@T_:6^H;G4C'2+?75M# ]JN
M;RT9"Z1S%:F%'(Y5E=B57*BHB41**J_C35?0:C(@X16+#G3L6\S6=6"_OTEC
MSPODL@E5@RI[E3ZY.ZEJBC0F4FEJ56TJ?84P!A1)TX1B,'O1AO;4.?WVI+]E
M]>MB8L=M# QD:*D;(X(VQ,:Q'.>J;&XG>,J*]SE1$141.NG=.66F;!]A8NDD
M22YFG>^1S5DDEGE=*]SU:UB*M786^*BX&M155455RSN2-X0]VT[]T]OLU%90
M(7LV?K[0+/L?^3"^Q]D/W8.Z"H3V%>]Q0;DC>$/=M._=/;[-164"%[-GZ^T"
MS['_ ),+['V0_=@[E!A7O<4'UC;^G=\._=.[L_!63]>O?Z?7M^3]W;W?LNG;
MV^WKT]N**,*][B@U)&\0>[2=^Z>SV;BLH"+V[(U]H)GT/_*0_8^P+[@?:H,*
M][B@U)&\0>[2=^Z>SV;BLH"+V[(U]H)GT/\ RD/V/L"^X'VJ#"O>XH-21O$'
MNTG?NGL]FXK* B]NR-?:"9]#_P I#]C[ ON!]J@PKWN*'C4E;M@$/29_Z!UU
MWK<3E.A].S0_H@VS:&+?:+W:UO?7V>_6]8HHPKWN*'G4D;]Z%OX=^^AW=>L5
ME&M[[0GBWVZVSZV/V)Q=.G7KO8=:]HP:$H,*][B@U)&_>A;^'?OH=W7K%91K
M>^T)XM]NML^MC]B<73IUZ[V'6O:,&A*#"O>XH-21OWH6_AW[Z'=UZQ64:WOM
M">+?;K;/K8_8G%TZ=>N]AUKVC!H2@PKWN* ,C;Q;WK2=^ZA]_=%9.'7VPP>S
M8F?6A>T&_=U]G3?NWK>U%&%>]Q0 DC>9O6@IW[77L^WBLH*U],1(===F,X-:
MZ;/#UZ_:ZT+>^F@#V%085[W% "2-YF]:"G?M=>S[>*R@K7TQ$AUUV8S@UKIL
M\/7K]KK0M[Z: /85!A7O<4 )(WF;UH*=^UU[/MXK*"M?3$2'779C.#6NFSP]
M>OVNM"WOIH ]A4&%>]Q0\!DK</>M:3/^NNNOTHG*0:Z=H!>W8V8.M;Z&:]GO
MZ]=>\.^BBC"O>XH>=R1OUO8=IW[KH.Q[Z164;UT" PS>M"TS[#L7:5OH'6^[
M8MZUK740=;4&%>]Q0\BD3>'>P[3ON]ZT9O?;%Y,/70K9^A=! :!!%O?PXNW6
MM]1]0]O7O!W*"B][B@%(F\.]AVG?=[UHS>^V+R8>NA6S]"Z" T""+>_AQ=NM
M;ZCZA[>O>#N4%%[W% *1-X1:!M.^]=[%KJ&+R80>H1G WU&%HV#6NX@73?7I
MO6P[U[!AV)047O<4'UB;^X /AWWJ/>M:W]5Y-VZWL8 :[Q_*.PO7</778MZU
MK77>_9K>]*"B][BAXW)&_6@[^'?OI]O3I%91O>NX) M=VM,^]@]B@/7KTZ;T
M+6_: >@J#"O>XH-R1OUH._AW[Z?;TZ164;WKN"0+7=K3/O8/8H#UZ].F]"UO
MV@'H*@PKWN*#<D;]:#OX=^^GV].D5E&]Z[@D"UW:TS[V#V* ]>O3IO0M;]H!
MZ"H,*][BAXW)6[0 CVF?^@M==:U$Y3L?3LV/Z0-,VQAWVA]V]:WU]GOWK6**
M,*][BAYW)&\(>[:=^Z>WV:BLH$+V;/U]H%GV/_)A?8^R'[L'<H,*][B@W)&\
M(>[:=^Z>WV:BLH$+V;/U]H%GV/\ R87V/LA^[!W*#"O>XH-R1O"'NVG?NGM]
MFHK*!"]FS]?:!9]C_P F%]C[(?NP=R@PKWN*#ZQM_3N^'?NG=V?@K)^O7O\
M3Z]OR?N[>[]ET[>WV]>GMQ11A7O<4&I(WB#W:3OW3V>S<5E 1>W9&OM!,^A_
MY2'['V!?<#[5!A7O<4&I(WB#W:3OW3V>S<5E 1>W9&OM!,^A_P"4A^Q]@7W
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M;GQE0Q=L.*=.FF_32J5A,3]=G=@_9DGEWPE(W,?)]_82%Y+D(, 8 P!@# &
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MS/J,7SY3.G9SZON^L/\ FL):<PP7Z, 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@')LG[[MO^>I_\('/"X\@_Y*^ ][;Z0SY2>$S=EN%S# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$<WD1YIV5Q29Z#KSCS2B
M'D!RGY:V\;2M!U]))<"OZ^1.K9"I)8<TL*RYD)"XJ4$)KZ&194N5)$1)CDXB
MT$A/H'49Q0$>7!6S^5GCCLCB?XZ>5/$?C!4U%\BGR[&KC9:7#6[KRM2$1"XS
M2YWR5FU:VFT<E4AMIEK)Z>ND;@@=$[BL;TRL&D916DN]#2 6)L 8 P!@# &
M, ASO6]ZOL'R<<4:BBCZYN$_IB)<I2+%:%4.FK*@9C91!*H<V0+?)GV.ML5E
M6E2(&Q#VT+5X4^_H';+']')/+OA*1N8^3K[!(7DN0@P!@# & , 8 P!@# &
M, 8 P!@# *=OE/\ T\KV_FP_,W7F;Q=CW\N<N_2/UJ8UZUSZTW7YOS,9'UF2
MRTQ@%J[PQ?HA.?\ +%-/O'#LTY[=_79GU&+Y\IG3LY]7W?6'_-82TYA@OT8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MGU&+Y\IG3LY]7W?6'_-82TYA@OT8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M "5\![VWTAGRD\)F[+<+F& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8!#G>M/I87Y..*-EE6);TE46G$N4IRF%3.Q'F2UK
M!-QZ"50@ 75T*6_]600EW"+U7 *7V+%&M&#]NLD\N^$I&YCY.GL$A>2Y"# &
M , 8 P!@# & , 8 P!@# & , IV^4_\ 3RO;^;#\S=>9O%V/?RYR[](_6IC7
MK7/K3=?F_,QD?69++3& 6KO#%^B$Y_RQ33[QP[-.>W?UV9]1B^?*9T[.?5]W
MUA_S6$M.88+]& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MS3GMW]=F?48OGRF=.SGU?=]8?\UA+3F&"_1@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , Y-D_?=M_P ]3_X0.>%QY!_R5\![VWTAGRD\)F[+
M<+F& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8!&ERI_3NX ?B9S&_BG4V2>7?"4C<Q\GP\)M9DN0@P!@# & , 8 P!@# &
M , 8 P!@# *P'D1X?<FK2YBW!.Z]IF92R'OOY/\ Y0_M25*8@7_+*NA+,O\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , Y-D_?=M_P ]3_X0.>%QY!_R5\![VWTAGRD\)F[+<+F& , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!&ERI
M_3NX ?B9S&_BG4V2>7?"4C<Q\GP\)M9DN0@P!@# & , 8 P!@# & , 8 P!@
M# -'KAYEJZUEEMM49IF2V5$>.L?C$FY 3%IE$=8S82VR9JW*0IXW'';JLG#L
MS08&WE:0 Y"64E&4$)HS#-!UDC(.SZ/.+&PGO,QAL[_-I9([&)T<C^<Z-W+K
M)(W9"U\WX)BJCU5R.56HB5,:Z@[0Y,FO[^"RRZ:\L,HBCDOI6R1L6%LC>;2.
M-^V9[(?PST16(C5:B.5RT,P71?[154!A<N8V!=8SS:<NAD"JB*LR]$S&3253
MTL]8PD#>'?0$C(T%LR-2X+%9I8_AD28TS98MA[<@-.Z6GSO-+BPN96VEO902
MS7,KVJ_DQPJB/7 W:]V-6L8U%3$]R)5*U+@U'JJ#(\KM[^VB=>7%]<0P6L3'
M(SG2SHJL3&_8QF!'2/>J+A8URT6E#!)'-&5.!AT$:>.\L<.0;;;9M42"I?K<
MS$L4?]. %VD5.W.T]-IK"GA+E"5!1J(TQ*6L5K#-)@)^O0>[F=V>6,2)F<^;
M0,TJ^P2Y9=<IZO?^']&6%MMB1ZS-F14>B.5C6)C5_<+8;VBWTJKE=OE$[]6,
MOUM9+7FL1D?X!+GGNN<*L2%T*HK%5J/<]<",KM-@..]W OJ!N$K.BBJ$/L=G
M$WKB7152]M,F*9Y; 7]4P/:9!)&,>VQ^;MJ$VA%*2@EZ'H6]=NNG7=K:LTXN
MF,S98MG;<VTUM#<12(QT>.*=B/8KHW^,QU%HK5K3>75I+4B:IRMU\Z!UM=0W
M,UO+$KV2(R6!ZQO1LC/%>VJ;')2NXSOELESC & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M@# & , 8 P!@# .39/WW;?\ /4_^$#GA<>0?\E? >]M](9\I/"9NRW"YA@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 1I<
MJ?T[N 'XF<QOXIU-DGEWPE(W,?)\/";69+D(, 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & <
MFR?ONV_YZG_P@<\+CR#_ )*^ ][;Z0SY2>$S=EN%S# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , C2Y4_IW< /Q,YC?Q3J
M;)/+OA*1N8^3X>$VLR7(08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M%1J$N'075R8M[WW=F],#QK0>H3]![M?7'>Q]!B*WOIL/70!:]G?K8'I]QO\
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MX=7VVY>*CZDN'3]\F+N[^O7Y \=.SOZ]O;]<>O?Z?L[NO3N]O3I]''I]QO\
M<3WAU?;;EXJ PEP[>@G)BV/V?2"P/ 0^]/U^AN8BW[@F_LOV8/N-^H]/N-_N
M)[PZOMMR\5 82X=O03DQ;'[/I!8'@(?>GZ_0W,1;]P3?V7[,'W&_4>GW&_W$
M]X=7VVY>*G[)H>ZI3"3RW-A^(), 8 >H^\=FA@$G%K?IBF(^OVAOOW^S!]QO
MU.'7L[VJQR^*J4Z$]X[,LK=CD>U%Q(M>E3O*4*H"<H*TY.H5Z!T/.2IC$:<P
M?7?4124Y6N,)!T^QLXS?]?*0JSZ, 8 P!@# & , 8 P!@# & , 8 P!@# &
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MBEQKY/Q=+(8WR"+LMSA5S\Z:DXQRBPE21%$62%)8#'8-/%XBFH;H5-292C
M]I$B"9L0$H_%;G7QVYCJ[%9*=>9TAFM2G1;\HU96[4EH45:<4;)VUJ'J!R5R
MKFX(E#)=]49PU(SSFEU+2#0K=)S@EF[,*, $#<' & , 8!@7E)R'@_$KCC=_
M)JR0KCH/1=8S"S9"A:@E#=W=)%&94Z%,#, \9283U(59):%'HT996U*@'>,
M.HM 1EU+R(\R12GCK<MY<:>)DAH&_IA7+7-*3X^N=PK^37%.#VNG+/:[ G\[
MF#F96MRHZMVL3ZF*1B8&4TD(C1MPEA9.S! 9UC7EOX7V1.G"K:RL"3.TN=R;
MA;*AE\AIZX8M1-ZS:CFET<+)A]+7O(H6S51;3U"S6=5I>F87E6:(I(H,3[-*
M*$9H#6'A1YP:(Y6<=*B=GYX_)CR@M+B_,[F:6694ER,A7'R73BJZ_42RY8_4
MEFO\&5-EM,]0+4YGSY-&7)[=2$:<\1 5 RA["!WE!YP^#U=5?3;IR'NE."P)
M!QTXR7M<TEI6@.5\LH2N8_R2AT9=8993I.':FB%-<TW-Y(_@3,*B7?*W@L"@
M@AP2IE@3RBP,IMWF6X#.4.EDK+L"T$3K$[ KVK_R3O/&WD4Q7_+9K;\;>9E4
M+57E O-7H;>GY=I0Z.KW9D4-3.I3*FU"H4",++3G" !TEU\SO&9?;G &O*L;
MIE9L=YS73<U$JI21 ;HCTDH>?T_$W96X1BR*R4TXXR1DEP+$(0LCRUOID;-C
M;4K.D:P?R1"I4A Z\T>;3B%7585@JY#6H7(;CEM""Y+21CXM\=>7UJQ!OHP$
M[L>#+;E( .E1RN-5I&W.LG(AX6/Q" ]L.3A&>4 E6@&I Q7RR\S;=QOLK:QH
MD]&6%0OY8_&Y&UBB(1'D1,;?CM/<UXOR$E3Q82UI88<3%)RX29LJ=O,@2"&J
M)*Y'_P".E.J DXYM+/ E7XM\PZ*YB1N:2"EGN4#75G.%U:VC K&KN>U!:M83
MQO0('8V,6!5UH1V*3F+.![0ZIE2?:I" E20;U*&/83-  V?P!@# & 18>5[F
MK;W"BM^,3O2ZGC@S2GD)R_@W&Q?,N5SW)XW2L!8)74EW6&JE\F?HH\LCBU?!
MN-7)4P31F&$Z+5#ULO8M@$$#4CC%Y7[RLN8V34]HNW!AV?:HY3\*J3'R#XYS
M>[+4XS7*U\L]RU6XUM5[JQ1&3N;)R(K]%&4Y"@AW7BCB90\(C7%4@(-#L8&W
M-5>8W@AR!FC/6U(VO)GV3SQEM@VJ)7*Z$Y$0:H;$E5+1ITE-FPV*65+JO8(W
M*Y57;&TGKWMJ;%"AP2HTYN]%B,!L&@,&0SSN\'XK4-6//(6[6U;9[C0U(WG<
MSIQZX\<PIC2$ A%UH"]QNUU,HD-((GB%TZZO!A:8A5)0('-&:J3$K4Q!YH08
M!LK!_+KP*F]=\A+4%;<D@4+XOL<!EUN*[>IFZJB>V^#6X)633LXB\-L.OX],
MY[&[A5HC$T6$RMZY4]K!%)TQ(SU*8LX#7^^/.7Q9JJ@UMUPR-VQ.'V+<D^.G
M'6SJ1F-.<@:@NNK%/(:1%@9)C,JN?:1?;(;F<ZO$;D_1X0V4""7JD1;*WKOF
MJLDC .VMGEXX\5[N<(N0%DL;K*';EOR%X[<?Z_XXT/RYLRQIJ*CVV!N[A7S[
M!M4P=(EUYL#=.$YSP6SD'QPTLW0F]8H"G6[( UYYG>:MEK?CVDY,\1)51-J0
M20\,N2O)&$1*RXMR!8K*ELFH2W*KJ=V1E-R6*1^)QF,P622QU:98VO[NSR8I
MY*2EH$J@DI<,D"2?BMY#N+G,>42V#4U)ITEG</BL9L-7!K:IRVZ*F3Y54V/6
M)(9;T-C-QPN$O$RJV4+&\\E*]-Q*A)HX 0&B+$:3HP#=W & , 8!I-Y&N6R_
M@IPIOKE8U0@FQ':IHZQJFF*KG-2RLJEVEDTC4";':5/*- YJVB$Q9?*2W5\5
M%D#&G9T2DS7;L/=H#2SCGY![Z;U4\L;EK-^ 5E<*8Y13_<JCG/PDM5T=:EK%
M\C#ZC+55=:<9F,TF\@<G*4Q=UTL8G1C4'?'*6T],) 6<J3EE@=ELGR_4F\<<
M[ML[C88^.ML4LOXYJWNHN0E.W30\OU >05R0:NXQ9!4"M*,UM-7J!R5@D2U4
MS/2 LUN.5)P &9U[BA ;D$\]>)RAN;G8FUN]O=N7[WP*;U'U&LD/Q'+&.RE_
MA3S5/I"AP3RO@Y-%UR;YZ,(8T9Z'J <!%#+,&!ILN\\?C43O*=C;+/N*4JG:
M33&OX>?$N(_+*0(+(MBOI&",3.G:Q6(J6$38-I1U<<4>I:6K:HPM >6K[OAA
M>K@&973RS<(4=/4#=;)/YY83#R@,G)5&0RJ*+NVTKFG1E5+US7;NDM)0. /U
MI-A=1.;6I328Q:U)BF=23LD\031E &!H5+O/Y0\W>^2T6XSO,)/8Z;X]<>;Z
M@_)6X8/RM_(/+06_<?Y-99%9,S0#CROF,<.B)!B1*B4IU"TQRD2U2WC3)QL+
MY\*!O6/RZ\#]7V'CB39\V53XCD"5Q1?'LFA;[!4\4Y)KG0QDC]*2FZE5:IJI
M:)]+G4OT6A()W%IQ[RQDC$4:4,8&@S+YRVV#<EHE55WD1.<UG,*_YM/C9)^)
M%&<N+AFWU\XQ<N$=+M4*.@VJX%-2RXS5"!^<IJZ:8A1\EW933&UT/;S$PE0$
M[%,7-5_(>J8#>%*S-IL*J;0C+;+X),V3XD+>_,#J5ZJ54!.O3HW)O5%"T(I2
MD5D$+$:DLPA044<6,L(&3L 8 P!@$>W,'E_-^.G(3@]4$7C,5?&3E%)>4+)+
MG-^"[[=8^GHOB=:?("/&QS;>Y(DFCG>2P-,B6_%%J [0G&>EHLWM,"!%MQ:\
MZ\[NKP\7?SMG-.P]AY7U$\(:T;Z#CY[V",32VKO)KQSX@DM+>[/BF4?5.V&B
M\8B,\07$PTS_ !\91I/I[+3@?E2/G+M"7<GO$C35HU373!7WD;X70N[9I.8X
M7*@GUK>MC$6'N!PQI&XR%>D!"96\P0#0E"J)4K=N+@3K:C0?9@&Y'$_R=2;D
M_P"4[G?P=:X1%T5,<2X/#5L0LQ.%\U+9[. R,V!VNE5;4.(V+ZOPRRF=Z8"_
MATH#MK&8_8S!=>P(&;.37/:04-S'X4<3&N@;$?&WE5:#C#GN_'=$W-U-Q= V
MU);MA#C$>>2'TR0/UL&K:\3#$@&UEMI#2<><-7Z^BB1 ;HW39JJG*QE-DHJQ
MM*Y549);32*TI9@:)/9TI&Y/3:S:3Q9C?Y#%&=:<ATX_%J=J'%*62B3G&;%O
M8-!$!$#&_+99T\\>_#'DG N/T9<^4//:]3>/%&4)(YTXQR%L,R'-[;1+Y)94
MQ;V*42%OA-<UI43D^2 ]O;5APE!04B<.A*"1: RO5WE(*8./O+F9\P*_8:SO
MS@[<(:"MRJ*5DKU;#5:UERN,02442CX[*'2,1.6RL[D4"RV=MCC4O;$CH2\G
M&IE0  *V>(#93QL<L91SDX34=RHFD#;:PE%L(9LK>("TNI[XABZB*V7,X*!M
M+=U)9)K@=HB+@&<9V! (X8^S6@=N ;RX P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M0F4DGG-ZH1!2D*9:44,8TJ@28\!F@&:"+8!A%TZ;UO /LP!@# .-;GEG>-N
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M!$\"=A[DQD$EW/Y53LV5N+P4448I6*:WD3CM::$)>S]",Z=G=UT!O#Y&./\
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M14C0X$$.:)MN;FH^W$ZV5:P&T*Y,9IV:ZOI./1UO.,+ <4B<WLA.I 6O6E[
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MW>^I>]]-Z ZA,>%563?D)PTY*.K_ & GG7!V'WC":G:F]UCA43D+5?\ "(1
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M Y3 & <0Z/[*R[T!T<T:,X:!T="DIAP=K5#>R$E*'=8D0@[UBLAN*/+V=LH
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MN(5JXVZ%,KZ05O>S&QU/96B1$H5.MAUH)YC(_HU.M:ZZ]-0#?7KUUH#E, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!JMS5HBW>2W
M&ZP*9HODY-N'MFRT4;VP7_7L>22>4PTMEE#,^NJ=$T*'N,'G$R-J;3FXX:9S
M0*"RE0A!-V'0BS -D8\W+VA@8VEU>UDF=&QG;&YRDCBF0(W"0+T2(A,L>UR1
MJ3(VM*L=E!0CS2TQ)2< S-A+ $&M!T!T&^&5UDE'7-'6)">YO;_5-B,K,VIM
M:$I<'5UB#PA;T*<(A!#L]6K/ 6#6]ZUW"U[<Y;L<BKO.%Z%]@ZE9,3?GVQF=
MZ3M3X]M<6K&;.[&VHY*Z1YG566E>XJHB):L:%>D2[<S4A:PL@U2 THDHPW>]
M=-[UOE%V4[YPO2:J5U7-K*EK@UO;'/6>)/C[0ZM<D"=+HSI44WK+/(LT2PY?
M:<^?UAQZ0QG3NRXQ4W;> A ;I&$OH:9W54[G3M.$1?:.W&5+:+(QFJ8 "9-L
MV4%<IHL@6N,O?UA*.-%R.4I:*;P_.W\YO0(R6- UB:CM]FTXA^L,81&'"%Q5
M%7;T;/ZQ1>YT[3CHA5\R 9!W9V9;'5L<;O>%2!"SN*5TCQ[$C+ATB;'Q_31_
M5HSMP-9=2)P;M+M&*/3.&2I/ G,*//-/*J;?8"(O3WS[(?6=GBCL*D,B2ST<
MYC2?ADF1B6R=^%M"!"N@J"]3#6[3Q\L5J#F,UT+>C#RS1J"P"WO8A!#O"JE5
MW;?ZA1>GN[#K**N[-V[.BQ=#+0/GKG%H$@@DV2R52B9(Q)6B;6(L<%LLZ2EN
MV>D1LCFD&=ZZ9<%0@V8C 'J?Z)_-4IW*"B^V;GS]8]S2K[#25]MU)D99,DC:
M'257IC=5#BSK3FUT3,;OM6E W+EP$YQ*);ZY'H'C 9L96P;$'HFQ4J=EVIL-
M;U<4.&D:=HZENTJHD\HD2EU@>IDO^MB]U61>/)6-^2M&YVE=&^*('M*N+^#V
MX"U\T/TY^B O6E >U>^F(Z^TM#I[37-KIGDDY_BUC+;04L="$LUA(96+<99W
MJ-(D 9^;*E*63H4SL,M"682XFF(U@'D'<07LW8^W?-4[E*;11?;.2.JZSGUE
MD"U[(L33^S5S5P88-++I(V'II>3<=QKI2L1A;7M* Q\30]4T:,/,[AZ0G *U
MO8!"!G%4[W3_ $(**?%8%6V8VNTA9HT@G6ZI;[$E*UH9F@Q\EJ_>W:J:1/CS
MDV)CK/@SU\H3S@F7 T;IP-)0NBKUMD!UH*@CE%;W>FG]*_U!47N=!S;?7-F,
M,S*5_ 3E4^.PJB5RJ4"=E9R-]TQ4O/(Y(S%^T;VM:"%@)H-*,\@K78(XTHT&
MQ@[1YQB2G>_K&VI]46K:QHKN#A:TLY#\RC?%USG9SA)7UV.52YGG#B99:EP-
M='=8(I6%@-!IR 3V$G)@EEB"(!980E5%K[8HO@/RHIE?ZR31EY=(98\.;(M6
MKV@M3<C>#75MD\@5O<6W"S(RRBD[L08:RMR=RWH9*=)\"D4!2;"(8M%%';=W
M2&I3@93OV,">IM5CNX06=3J*LK-929^10)Q.;G),J> 0S3'M5M+(XPI5ISU3
M>9V%@4;],XL!X@Z"3LP'#5V+MHIRY-O>,61&J[2?I#%6*W?KDZL!(&X,J$"7
MOA3:XJ4M&PEJ-"X.#,[HS'4L,U3JQ#,T+TSW,L:CIW;[M\JJ?Z/W;3A$7NGY
MQF 6O(U%*-D_3SHUD%':,!9!9L@=T 3ES70=\)9JF?#FYT3GGA/L!>QE.0.[
M852@PC1G?K6MA*K=M._X4%%V5[W])Q>ZHMQGBC3N&@G225/--V<SRU2OEK\Y
MKE;HU675'U';-'/DL1E)9"*N02!*TG@6(3  &+6U1.^A@54[N_WQ1439N.,2
M5?/PL\1>#6:QUVF.?60;%D9I#I&U\7022EUC$@5IHV38DO6MT>4SU* 1>E2H
M8TYIQQFBB4RG>A\U3O='](HID.-UU/@2%#,G1--12-OMVJB$1RJ2/AB)+7H*
M#K=GF^RV<3L)HVW*ICMU OV(@0SEI/J"ZC++'KJJI2G>_I%%K4QG7==V:C.C
MA[M#+/3V4I(XR*4\[/DBDF.-@8O *R16^5+"=RDG2U:K2-+FA6Z/0JANII@"
M0C$(O8R>RJG>IM_J.$1>_789%Y>1ZU),/2.OHQ)'!0CKV2JHT],(GM:(B<C-
M]5 2F3-UE5^UQ9[;0H2%"5Y7$O/4!AJ<A(8,0BS>&84Z=YRZO<.:_)[/@S9-
M,VC4I32-PNRS4@G-S?'Q0T(*S<:;GH8L YA5.!K4FC(;$(9C@%A2Z&%;VBZ:
MV(?7BJ4HN[^D46M>^*"AKRR6+\V5P>Q(P654#1'I.ZSN0'/X7VP4[^%3(5C<
MJ42>2&*!+-Z]4Q8#T2EO4(@Z%V;WHY=G<Z3E$V^T8P5PJ\/C;L3QEEG98G_:
MM8*0/BQ<C?C$H;;8W!9%8]M/:P8M,B7>LS'8IL7)2HVM;4Y:9"-2 9NA$=JM
MV5I]R'%%VT/P+KJX$\<;UC2VSM:<VIK;51Q*J(!&7II:E:JFCD+"TH5\\E"M
MF)?5,9>#D*54Z %OU1 [$Y0BRPJM\'])Q1?N]HRD5&)G9,S4*)/'K"9X"]WD
MY.YS$[/"]C,W!">,\196W3@2P/NQI&%;8Z \WX+1P?\ 'A"]<H)@C0[XJB)L
MZ:?TG;:OL5_H,8*JIN%LA$:^K14]+?GNIV0JT!+)&_/SL[.#38]?J'-M])XF
M;3HZ0;@0GH@DHE>A-5).]*$\&Q%[#SB2NWHJ<46G=Z#P76%BIFB.O6FJQU[N
MCAO)ADB1QHW-G<(J=)XTT@@J,UB)GLL/:FYP6H'#;:%2J/,1#/2EC"F]). E
M5/ <47PG;AUM8Y!I$K3)9R.7++&L]N7J#)*^G *KM=0\^)CR,AM-=Q-:1I-L
ME,T&$>F2$P#B(!FMZV(6]\53H[W])S3NG&1B!3Q-/'%=N&V0BF+E9='/R*?#
MD)Z>%E0Q@JNDFBUT3TWZE!1:M>ZI8Z[M9NC6X\:Y:8EV$0](A&)E4IW*47^D
M(BU,AWC%;D5RX\-<J7[;([M:.?[.1NAY!"&:U2T2,]GBFQ_$A^#;;(?EL;+.
M("6,@Y.UKO4!O9^]YPU4IM.5K79T&'1UU?BF;1U_>%,]+5R);$IBUC:P&.R*
M"KWJ:N<CF,3<5HK,C3;'4<995:="J 8UN*=V;4X4Q6U!@=E;[5;38<4<<K-*
MKL8;64^E(YPJ$]VU>2R>(DAS]*W18P@L6: I=2DC7Y2H-HN.-\6/*^&*1*@@
M($I2J3$^]D:.3D<G1WD_K"HONF>I-')X91$"9'$$NDSRV%UQNR6YO=BT$YDS
M"V&MHI>W?-$$@)+5/"@LK8EX"'(6G$LL\D!IWKZT9U14Q+0YVT,#R.%3Q4VK
M2HW7UR-I1\%6-E"$G3\\U36MA"FDY7!DLW[YF2-M:5+8XL)R4E5\Q^#9V\]N
M%K0S-I#>:IWN^<47N5.^*JB>WV;MSP^(YL>G>+]G2*3##,)4B0CILVL9FL9&
MP:-"^IDB>)J[ ;V<7HEEA]50+M'K99A@1<8J)[1S3;[9CUNJ.QW".+A/:>R
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M,^UU]I]N5_=/M?[H#W?V?W/]ETP#WP!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & = K;\'5/X ?A)*O]&WX._A X?\Y__F3^%?\ [0]7
M.5Z>Z<(<O$/WJ5_@O^%$W_!#]ZOPT?\ _G?_ /-'\.?_ &U\5A0AVC.#D8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
.. , 8 P!@# & , 8!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tm2115679d1-lc_selumet4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_selumet4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!V .2 P$1  (1 0,1 ?_$ /4  0 " @(# 0
M       '" 8)! 4" PH! 0$  04! 0$             !0$" P0&!P@)$
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MY$>H'Q3Y[>?!)KA/K+OI\YSY'F2\K.>N?+[<YZ^\R7,Y$# & , 8 P!@# &
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M'^IPE-N4CQ$Y5,:^QI,#'0@S$Y7H*MR%"CG#.(;-22)(ZR B=JD<# FJ/V0
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MZ*(MU!2:I>[=]+R*N,%'62)8<5;[.I1,PU2?Q2TG%PU /&N'L>Y*HT? P=*
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MSLQTP1'KZ4I<EJ/8_P":_LW7^I_C>?VON[_Y?9Y?=GKDO5GH9PPP!@# & ,
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M\+/@=<QU)JJ,HQM81NLM?1^M3)%0-KQC3*XTHQD"+I.BHFJ3>-3@!2*Y034
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MRMJU;,6S=DR;H,V;-!%JT:-44V[9JV;IE20;MT$BD20002(!2$* %*4
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M^T*Q=X-H+E54K)(T!J^NRRK9/L*#J76<&+Y')SGM8+<Y0# & , 8 P!@# &
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M<B(.1547.:,8V16(5FR-6PJ^C(X?C!-2F7\8KE2(9,ARD45*<#O\ 8 P!@#
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M)A.)BX%!X[7<JK*F]+"0K1HBF42I(MVY")E*4.F =_@# & , 8 P!@# & ,
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M7_JA^; R/>93[\O_ %0_-@9'O,I]^7_JA^; R/>93[\O_5#\V!D>\RGWY?\
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M %0_-@9)*8'.HQ9J*&$QU&C<YS#^4QS(D,8P_P#"(C@H<O & , 8 P!@# &
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M# & , 8 P!@# & , 8 P!@# & , 8!+<;_BYA_YDU_\ $)X!S< 8 P!@# &
M, 8!5??\KMMI<]3Q^LW^V(J/>2$DZN,C2Z7K>VTA.$CG,.NXC[BC:X:0MY[!
M.MQ49PA(A["LVHJNGS]TOZ1K&O@*2.IKZBBSYG-5"<W?(UV0J$R9*AWK4_&*
M%M\,=TUV6@YEIS9;082#D-J59).ON8F&;5%M6G4H[:M%'TNP;R\A@$4[JD]C
M.MT\ 2;X/ILEO4Y3WG\)E[[;HN"Y;3NNT8K=R;&35U;4J[#4-1F>EE@5)M2,
M$HLA52]2@V<'.B4#;C@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M+&19WAO?(N:;L=6RGMCQO,2,21&8!HV<C%.TW:(G(!M!P!@# & , 8 P!@#
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M P!@&/Q'\8<R\VJ D*[7!@S%0BZ A$PBCE!%0Y%NU)0CF17>.$5R!VK-5TA
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MG1T2 ;*\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MI QBSWTKM2<9JOB/FYR)JG2 #G V8X P!@# & , 8 P!@# & , 8 P!@# &
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M-I'*Z_O+&19WAO?(N:;L=6RGMCQO,2,21&8!HV<C%.TW:(G(!M!P!@# & ,
M8 P!@# & , 8 P!@# & , 8!C\C,JE<A$PR*<A,F%/U!3&,#"&;'[#&?3"Y/
MX,?$<!;M"B#EX80[ (B59PAKV7-2\FE=UWM]T5[Y/^"/WI>S"[I1E-3CX.GZ
M[D).KCUGMQ]^V2S\E47X]5B=K_5U+[SE8ZZK/9&1#:'*Z?.7'JY-T7R2LT[!
M--=9-$5%2(%'KV,HICY#^!N4?&D F,/<H=10]:J8TYLD\VO[TGXOX?"*]B\%
MX^+;=NYOW;[AK4Q\O3@\5TQRTF\)OWSMGA=\VNZ322Q",(1Q1/8[&;778T..
M>75RB9=%659@>/I3)RBJHV,1[<W2!XUYX7:1DUTHDDJ^;"'51N " CJ+DJ[Y
M.&A%WR65W+I4FNG6QK#Z]&JU9*/MB3<O26SQU<=GU-=7QU,DFJYXGMSBTI9A
MJ1DK(9BU*$MEZU-GA&UM/%2-OZ^M5GO]'VU==O56M4C2LI\S6-5Z;Y=H$<YK
MDU'6J2C(\SMT\DK&[@HNLJ&EI!P\C6W>B4B:0&!RA'<AS'';>UR%'+[NY55H
MZ4^^>?DJ3A)62BLMRFXQ@_,FY0CE82^]&OW3T'ZIX3A_2_)>AO3W [NYZC]0
MT_3T*'Z_=LC?59K5V3[8PKHC=9L16M1"K8LQ-RE-ITV;>#H-;9S7(UMNR6S^
M$XK>[MGFGM1GC%*S9>3DG&OSR4+?-FQ,NI,.X_4!$44W,;!.4P]R12]VD4DF
MY6S4=&,=OUOC<Y-2AZ4[T]?7[>R>[*+[HVWQEW-:_1.%37SI>=8E%1B=)9=P
M?]W>4^"](3JV?QK\B4>5Y16+8U_3U=D%7=I<?;4JHSY1MRKV-RN7^[SE]#J3
MG:[;B\J=94KL:BJXD)6R6J1*QC4!2?J5:.=22#)^FW0!"N)L48NLQ;1590$C
M$=';MT!4(5P]$3+]VM9ZU2<I3MVY82Z]B;2>%B&%&$5EX^;"64I3ZR^;9<Q#
ME=R4*JJ-/A*G.R68+9LC6YP<I9O<W9L6248]R=:G.?9*56NDJ_,NHJ6NW;!,
M,GTW))*O7+B9?SUC5DW;J59I,);O>*3"CPL=(,T4T3,_*9J#=%)+L[$DP*_8
M^E**\Z,IVIMN3E/N;DL2Z]V<-)+MSVX26,)%'Z[]0U6S^@LJUM.2A&-4*:%7
M&-<W.K$%4H]\)N4U;VJSOE.?=W3DW)V2AQHP!@# & , 8 P!@# & :[2RE%L
MO/\ ?-Y;6[J&OU*1K$'7[Y(3FWVPVR)K^G+[8F$C 0)-+*Z>?PK4O(.R1*ZI
M[HF\,^CC_H?*W*W4 V)8 P#79S,^;?Q^^G_Z#\5/D[^<XE\P^Q?@E^$GN?X6
M[.]E^??F7_V[_,G3S>S_ "O_ ('Z>?W7X^FP#8G@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# .B>R;I1RK%PI&Z\BD5(SQRZ$QH^((OVBF9X1$Z:[MX= 1
M43:IF(8Y0#R*($.10=:RV;FZ=?#M6,M_=CGWXZMXZJ*QGVN*:9GA7%15MV56
M_!+QECW>Q+/1R><>Q2::,%?Z[J+-TY=EAT).SW1RQB9N?DSG4E'S)$B*\PN5
MVW\(0BZL-$]"&CDVA0<(M0 " BB*4?9Q>E";FH*>WL-1G.7WFEAR>5CL?;']
M!1^90\.V.-VOD-N<5!S<=:E.48K[J?A%8?WEW2_3<NCEXY>?)Y'D?S )1,E/
M,W8 K!Q4FC,OY &*;)8%;=+)H2?N<8LJ@*B#!,[LCDI9 @%,D $,8RRI6W]M
M,[(SZPC)2E+&'FR6)=T7CI!.2E\_3'3JA8ZZ<VQ@X_>DNU+.?Z..5A]>LGVX
M^7KGJ0)M7>TQ3K(VT5Q^;J[CW^,=&"-0?C')T#4\ NQ,U87'=MG@XQDYJ4$<
M"E=-X\BAYJ8$GC9-_&<5"0?*\Y=I;*X'T]G<Y_MC^K?;Y5$,85FS.$4ZX_I*
M&799C$(X>5.<9PE6WKOF^>:U."[G^L6?-ODGEUZ\)2:G+]%RQY=?C.65APAI
MOZ;]?I7)PO*K:5@8[:VZ^92,[+V4\4E58%IL.4,5I[O6:%&%581Z4)"!Z1DN
MY>.E>SJLL11\(.RP7#?AO3I>J?\ JOE;([?*RBY2GV^7%72Z=T*HY248_+%N
M4GCJTY_.37+_ (A[&YZ;_P"F.,KEJ\3%J,8=W?)U1Z]L[7U?=+YI)1BOT4U#
MY#9_GJ1YJ, 8 P!@# & , 8 P!@&O/@1O=/>C+8TI)5RCP=PB4ZNI8'5%U.T
MU_!3:=CG]DSKB3K]M2VULYQM>GR%\<6)XRF11AT7+QX^<@BHN[<B0#89@# -
M:FJW$&K]5#EDA&S-#D)=KQCX[%L476MA3-IM\"Y5G;JK'M]CTM^Y5B]8RC^+
M,DYCFC B2<G%*(/U0,LN<P@;*\ 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MN@E=9ENN#3;5=3A**M4'ULG-SHMFE&%=E5<;KY2R5.+& , 8 P!@# & , 8
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MTV\XPW+:7<%*G#T-M@;YN2[1=1I=IV$5^_:J&;)5.EV'TH",@Q=^ KD@&UK
M& :U-5K5E3ZJ'+)*(<:K5GD.,?'8MM1I=H/,[";/3SMU4B2;CKYDREJ$XK"B
MB>'0*8P.X(6SGX"ITP#97@# & , 8 P!@# & ?.K]?;ZOVDOIN0G'#5^T]9[
M4O4OM_:^F]VPDAK\E2/&QD!Q1Y1<?]N7*)E1L=CA'(3%CA8@[:,\*:B(NC%\
MYTD^IP W4<4>1%8Y;\:M&<G:7"3U:J6^=8U+:5<@+0$>6Q0\1<(EO+L8^:")
M>R,8$DU0<@57P+K)=X#VG$/C@%@L 8 P!@# & , 8 P!@# & , 8 P!@# &
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MHE@8QE)9J1C*G,86XB)Y-DD5%P/Y5DB@0_4H &  K%:*;O+7H,#]Z*G<$2P
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M.?([V_51&6KH2=ETT_/V6VYWRD\R4'+K"E>"_P"\N??9;+MG"BG* J55*D5
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M+]A7M[0 O\$"9OM8!X##20IB3YML &%!5'R@VJOD!11SYRN@ :R*7G12_0E
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MQ",F\)&0C%.'J+R;FY.<LLNJ1C%1[1LN^DWRA&S5)58Y2"!0O6^@-Q?4<O\
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M@OG)BD:Y=PN\EX>KS7(:,L5SHK3LI*D$VDDC2*S^9%J4R[J0<I+.C ;P\ 8
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M , 8 P#KWLM&1QB)OI!FU55Z @@LX3(X<&$%!*1LW$WG<JJ>(W:0A3&,)1
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M6=@VN\1O^06OVQ)=HZ@2UB4LL1.Q;"346.;V-NDV.Q P#9U4V+&;_P#IZ/\
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M\**SC"<I83(3U'^(GJ3U#=8O.GK<=*3[::GVQ2?LDXX<WT67+IG+48IM%_@
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MB!%ESB'0H]RA?&!Q,@L4T8M-KYE"OV=)WUKQ;]G="7L_-UQU1B[/;A?EDO\
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M%KKH>7.-F[95YE<YK6C;%6V+6IKBMFSMGYURV[.:1(5-K\O0[4IQ,#!O'NY
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M ?ER1C&,%VP245[%T.4MMMOL=MTI3MEXN3;;^UOJSVY<8Q@# & , 8 P!@#
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MP.@^;'OW9K_SO[3 Z#YL>_=FO_._M,#H/FQ[]V:_\[^TP.@^;'OW9K_SO[3
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MJ8YD<:8#O&8Y':L9$3,B05S[$@U&QE',>I*MTTG2$BJV7478)^0A2',8W<4
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MYNF/51?8TDI1<\XS7[4NYF+:V=C8MEVNQ5Y^ZF^U>SI\,_ M^-V8JKB#JR;
MGUD0*8[>M5NZ$AF\@T.B@X31>5N&,=,%UW(=&K^1<@"8"81$$U% Y/Z6]1^6
M%-<7[9V5]S3ZKI.7L2^]&"Z_:D:/9+'112^+6?WW_ CA.[(\CH*8?P.H;;**
MJQ;HA6BP5&-7GC-E%VJ#*4]PL:DZ=%R9$JASK-%U!0.!RIJJ?HQNC3YE\(7[
MM45W+JG8U'.&W'$.WIX84DLK&4NI51S)*5B77X]/WL?OG-JUMV*YA(@%Z K6
M.YDB#AHE/,3D8.$W*R#I-I$=\8;T2I4?,V\BR"HI+$\J::@'3+;M:^C&Z?;L
M^;\W1]LNJQE9E\W7V/":RGAM892<:U)XGG\G^$[GW>_J)]CDTP0.PISGAV,"
MT>"8K)10Z3<\M>IMDF=1X)"!Y$3E+T$O7M,"Q</;IIYBX_Y4IM>/M[:HOPZ]
M&O\  [<5^S'Y6_\  D<@7$^<ZA':U^?(=BO:F$O6HTG>;QH@=-Q"241(]X)F
M.8H'4[ ZB80[RI]MN:TDX.F,OLL?Q\)*2_,L_DR.GL[<_E_PY.F>S==_3H3;
M1R[*FLNF8L_882940$[LJ+CTB4E:'[IL454@,*2)2G'Q 4""H4I,S0KV^DJ9
MXRE]V,XYZ96<02?VOWYSC++DI_HO\R:_P$?Z@V/5;#34U-2M']?JIIB01 %4
M)J7>-SMI5XR=.DH*./)"U3EVL6*B"CEP@!%5NY1%11-1$^_R^CNZVYV\M-6;
M78GT<8IYBFEW/MSVN6&DGE+"DDTUDOJLA9B]YGCX+V>_X9)49&DA=M9$D9-R
M$D4CLR,W:Y9JBJR;/ ,JH@P19G?K1!W8^)-1%%DU Z20"N(G2(4T7.:[76[(
MQKZ?+!-Y:]K;PI8ZM-REU?R]&V86^F,I+W+]W^$[GS7%T0GFG6T4"I5 <(QR
M+N0>-0.W A 82T@Z29JK(.>IP46C3$.7H040Z"8</=K1?2,IX\,O"?7VQ2SA
MKIA3S[<^PMS!>QO]WN_[3B5*/LL VDD9BYRUI5?RSJ41=/@6;JL2/"I"I'-R
M@]<)DCT5B&,BF0"%1*<2 ': =+]N^G8E&5-2J48*.$\YQ[7T75KQ?7/B5G*,
MFNU8PC*_7/?OCK^Z%?[/-0L'KGOWQU_="O\ 9X!D=8<N%GZQ55UE2@S4,!5%
M3G*!@6;@ @!C"'7H(X!G> , 8 P!@# -37*SZ?O'V4XZ[EB+BC:=C6.WZ5C>
M*^E9.UQ=/L$KJB/N*\]J_1U'HK&$9:O924;7;OMI$I7UEE%GZY.Q23F?&D=P
M0"78C@IP3W%K).6KNBJW"PU_JKQ)E+QK%_7K?7PEV3A@NLT.LX65@K57W)SE
M 3$.+5ZA\0-V_$#*O]G%PM]@]@_ >H_XG]G]Z['?O_\ Y%Z+W3W'U/\ CC_[
M7S]G\-]KM_H8!U:/T]>&%%HZ#<G'2%NRE1JZ#9,RS1:<O%M4@XLB"9EW+B0C
M6TK:)T[8!455.V25=*B<YDR")B@1!Q%X.<,+-QCT8]<ZMI.SI>+UQ6Z=9]C2
MK0CJ0O5TH#(M%O%L=/XJV6N&E5)^WUQ\Z]:QE95@]!0%VKUVW43<* 3/3?IK
M\+:=4*K4?P1KMI^5JW!USYGN1W<Y;['['&-8SWZU37F:^[V27]+ZA\Z\2?J'
M2AU.TO=T #IV/T]N"FI=='4L>HJK(5ZA5N1E)ZZWI5[,38PT(U<RDI-V*7(H
M@9XHT8HG.HH"0#XR? /A@$+\/.&_"/86E&<HCJ^B[)=,;A?6;ZTOSP\N[6"1
MMDI:H.+5>U6^7B'_ ,!5.QQS,J(2)G+4J (.46CE-5JB!8"J_37X6U:,=1GX
M(UVQ^JLERL?N%J.[EY-O\XV^<MWL+5WYF_BK=6]\]LAFO:/H8AFV;=Q_%WF
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MX<6F44L=.CW48]XC;CK:+6M2UN@XJYV,DBISIE2N'=/I[Q_+MV'B(:578D9
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M#BV[)P\917JGP0T6HND;TC$%UP9-?&@"AP3 X@2Y@# & , 8 P!@# & , 8
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M*0%8)#G/]0C5T&C-671JUWJ=:EN5-]V+=[WH#9^F6SK4% V5S5L^JE*E)N[
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MA]#["E+9 4>/G-A0-OJETEO/ 5V K<$REA0C(R/2F%VB0&S7 & , 8 P!@#
M& , 8 P!@# & , 8 P"#=E;_ *?JVQN*O.P.PI:2;:=V-NPQZI1YJPL5ZQK.
M;HT!,0S%ZS2!&2N4B^OS0S6.;BJ=-LDLN[,U1\)U@(O<\Y^/,#+BVV-;XW3E
M4<L7SB!VAN&TZ[U]KBT2,,SH+JQ5N&FYN[)2"5BKZFR(Y!5!\S9$=*E<"R.Z
M3;*J% L]3[E4-AU: O- M5;O-*M46TG*O<*?.1EFJUDA7Z0+,9> L$*Z>Q,Q
M%O43 =)PW6424*/4IA# ,DP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M568V];.8C*URQ<89KDB_K*K>_1L^JS16CZW:G2\D@X?23ID=5!40-M> , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& =;,PT18HB5K]@BHV=@)V-?0TW"3+%K)Q$S$2;55E)14K&O4EV4C&R+)<Z*
MZ"Q#I+)',0Y1*(A@%'(S@Y%TU&FRFMK-3J]=:90="4M.8L&IFEBKEK>:.U;N
MG3"%@O=9A;A3)*RK3&O=SK-&R(RR(QAHAB7RN6J9FI@(VU#KDO'?FMJ31=)<
M\DSZX<\.-ZS$G-;?Y#7G<&O]BV37FQN'M=K,A2:?=MRWUQKZ<U_%W:70?E:U
MRJ1JJ<\FDQ!X@@)&0&S[ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MM?LCI!PMY(GS^=P!L3P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# -?$JQ\/U1=8/_E?9$;Z[A1RB2^:K!?/
M>]:6?T>XN#@>BUQ0/Q&G_D28KGG[9]U\M5SWH[MD;U$KZ3N9@;!\ 8 P!@#
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MHS.<W!M^UP\!'VS0U4D; U0@;5>IJ$=)R,A,.7 ^H;K"FNIY$Q(<I3% V48
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M8YI*;AE]KFHMQ4NW'<DVD\X;74Y>7F 8 P!@# & , 8 P!@# & , 8 P!@#
M& , U;77G#N"FP,T]E:'JUC>:]&[ .SU,E:)R1F-KR]>W=NW5#A/5-GFD*.H
M^A=0US53*U6UXM!J K"S +'+#)II*N (9VAMRU;T3X<62SZEV^^5JG,#5D4&
M^-?7RCU#BK./E-PM(9^ :UKG+B[6+:\>9&!;MH:6D:W86S-\HJY:*Q:BKQ-
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M[@@Q23L,[4JO)4JM2DD'7S.X:J3%OOTI L5/AVMUYF24)T^*QNOP R+ & ,
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M)U0CW=GF1E"*[HM*T-CN-1I[87MMM5<JS,"'5%W8YR,A&P)IE.=105Y-TU2
MA")F$1Z]  HB/Y,ZW:WM+2CW[MU5,/?.<8+\\FCQ#A_3OJ#U#=]-P&CN;VQE
M+MUZ;+I9;22[:XR>6VDECJVO>1J/(S2[@O= WAK>AZ ()ZNB;#MA<W\&/:1O
MK2(M:YS@50#"4"B8"]1$.@"(1?\ U/P4OZOL+8_U$9[#_-1&QG9+\'OQ(J>.
M5XR?%KW\G;K\6O;XRY&W5BET:RWAO"\6L^0[F<OA :KIS==L2$P *H5*(U^
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M\*[("*28%_\ @!]3G9W*7A[I'=5/XS<R-Q2&P86Q23RQ3ZG%>"*DJUO%HA$
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MQ[>[%#VROQCVTKTC6M*IL*$E98QK U4+-2ZVTFB(2KI!\;UA$4T3F$YD^_\
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MKGJNN[#BR0UXI$=:(Y%P1XT1F(I-VI&R"7Q;RD0Z.3U</+M#]#(.VJB+E X
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MXM?U)/S9#& >TQGW%K^I)^; 'M,9]Q:_J2?FP"$=4Q<<:]\F %DV$";N@2E
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M]G\LMT[AULOO0D;,[#<0L-\M[ILE:=R+)))&KQU:7EG!V  W1.@!]26 , 8
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MQ<^BS=F5<M#Q:JSM%$#<K@# & , 8 P!@# & 4$^J+P]LO/S@3R+X@U"XP=
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M5FB;-<J->M^15\"';.&J-6V$PW??8J_T%R5RHH=R^H=RCGT4HZ)T1>^E!PD
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MOQ/XGB.:UK]/EM?F].%M-U<JK:YK9JS&=<U&49+W229G]*_ZFU+_ -68'_\
M"FN2&E_4J?\ 50_T4<QZB_\ $&]_;+O]I(R;-HAQ@# & , 8 P!@# & :Z/J
MA,HHG%R=LMAOEHI]9K=@IRUEB8&R-ZHQNL,K=JN]7@I&?<:_V0$#()KQ*:T<
M_+'B*3DOA,<".#X!.?"J%95OB[J&MQTZSLD?78.3@&4I'OAEV8M86RS<8A'-
MY\M>J;.TIPB34&/O#.+CXZ8]/ZUDW2:+HD "TF :Z^>27?;^%BOH-J./#RTU
M"'KZM+^DU;'^2_TT.W:\1[VR]X>/.WMKQO1/O3.BN#=4.[N.!L4P!@# & ,
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M[O & :^)5+M^J+K!7T6R$?+PHY1%]=8)3U.LWOCW%P<_1ZXBO>'7M<PS[O\
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M2GJ=9O?'N+@Y^CUQ%>\.O:YAGW?](#^C9^I.HR^VOX^J8&P? & , 8 P!@#
M& , BO:>B]);SCXJ)W;IW5>XHN">+2$'&[3U[4M@Q\-(.40;.'T4SML1+MXY
MXNW $SJHE(<Q/LB(A\, J5RDTO3M'\?ZQLKCQJJJT9QPUV$WY-U;7FIJ?%5*
M.F*S"L9Z)Y#4^ J-.BV3!_8=EZ$MUL81[<&QRK6-RP<F*=5!,P 7U@YN(LL+
M#V.OR3.9@;!%Q\W"2\<N1U'RL1*M$7\;),7*0F3<,WS-<BJ2A1$IR& 0^ X!
MVF , 8 P!@# & , 8 P!@# & , 8 P!@# & , ^:OZ)-*V>7<NZMD5:]49;1
M$]1J>WN$#&M-%&E[_<W4K:G-!V#78C6O&G1^PM*4&,@FS]O#:YL;Z1)3T7CI
M+SRCQVNO&@?1I::Q$7*!?5N=)(&C)#TIEC1,W-UN5068O&\BQ>1E@K<C$S\-
M(,G[1)9%RT<H+I*$ Q#@(8!!,[JS4^CZ]>MI4IQK71\W#:]D(U/8^P_=I#5.
MO(9C$5MHYFIVJ+[!H4%'0)F5%A1FU&<I!.95"%9@[?#Z1 Z0$>_3A>^Y<%N+
MTC[O#V#W#4\"]]^KR7A@)OU0N%_=X-'W2;\4/)>3S-B^M>=J)RAYU?X0P%V,
M 8 P!@# & , 8 P!@%3.:E MEPT<_MFL8IQ,;JT+9*]R(TI&,0.$C8;]J=PM
M-.-<-%4U$C-V^\**I-4)^H'4Q(JT.A)T/VF "P.NK_4]KZ^HNTJ%+(S]&V53
M:Q?Z7.MRG*WFJG<81C8JY+(%4*50J,E#R**Q0, & IPZAUP#,L 8 P!@# &
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M)$3%5(>],\?R>A+D].>DK[J(334I5JON<6G%Q_6UV12>?%14LI8:ZI]/Z/\
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M>N2C&<KUCB8Z=@9J,<)O(V7A9=FC(1<I'NT3&1=,9!BX3524((E.F<# /0<
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M866H7X6)'K-[E$5*>UAZN%A)<5I#8-:@R/S3OO'N?S.P/+J,5$S-#KN2HD2
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M+62LUI[8U(2]["V!%[!F(!Z6)!R=-*+<R+EJW4,(E,@T* #\ # +(_.3?_\
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M?J\EX8";]4+A?W>#1]TF_%#R7D\S8OK7G:B<H>=7^$,!=C & , 8 P!@# &
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M,:Z2.<QF[7:.NF].U+R+KK0OC3:1+)_ .M?V)DU(<RTC*2-C>B0/$L<P%V<
M8 P!@# & , 8 P#B.V#&0*@5^R:/2M7;=^U*[;(N2MGS-0%6CU %B'!%VU5#
MN34+T.0WQ*(#@' 2LE=7G'-91GX5:R,FQ'KRO)2K%2<:,U 2,F[<Q)%Q?H-C
ME7((*&3 @@<O0?B&9GK[$:5LN$UKMX4NU]K?N4L8;Z/IDKVRQW8?;[SRD+#
M1+V,C96<AXR1FUQ:PS"0DV3)[+N2]O<WC&KE=-=^N'<'4B13F^(?#*5Z]]L)
M650G*N"S)I-J*][:Z)?:$FUE)X1^^_P7N#^(][B/=8MDG)2<9[DS]PCHY;N%
M)^_9>;U+1DJ!![55"E3-T'H/PQY%_EQM[)^5)X3P\-^Y/P;^"ZC#QG'0[-)5
M)=)-=!1-9%9,BJ*R1RJ)*I*% Z:B:A!$ATSD$! 0$0$!ZAF-IQ?;+HT4/9E
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MY.G04BB;_N0$?R8!^^ZQ?Q#W)A\ ZC_'&_P#HF/4?TGY.BI?ZX/Z88 "5BQ
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M="]A0.?J/DZ!VD$!'^D ]< >[177M]SC^X!$O;ZUMU[@4*D(=/)UZ@J8"_\
M=" ?EP $M%";M"3CQ-\/L@];";[0B!?@"G7XB'PP#I+&E"62$?0JUE=1*,@F
M0AI*NV,\%,M@2,B][V$NP<).V9S)IAW&(8!%(P@/V3#F&^I7U.IRG%2]L9.,
ME[>C75?XB1XGDI\1R%7(UU:]\ZFVJ[ZHW52RFOGJFG&:6<I-=&D_%&"3M,8O
M9#2"C2V)JM]2WE]:'2UAF%)>;GFBNH]FZV!!:4<+G<.90KV_H.55EA$3D1.
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MZ 7N#\@?#M^'Y/A@'X$8V#I^DD/@!0^,M*C\"D,0.O5Z/4>TX]1_*(]!'X@
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MV#K^DD/CU_++2H_E[.O3J]'I_!AT_I?'^F/4 $8V+^120_*!OC+2IOB!P/\
M\IZ/P[@_)^3I\/R?#  1C8.GZ20^ %#XRTJ/P*0Q Z]7H]1[3CU'\HCT$?B
M" #VQM]K])(?:#H/^%I4/AV 3[/1[]D>T/RAT'K\?R_' /WVUOU ?(_Z@(C_
M (UE.GQ4!7XE]9T$.X.G_ 7[/[GX8!^>V-NXIO)(=2].G^%I7M'H)A^T7UO:
M?]V/Y0'K\/Z0= /P8ML( 7RR/0/Z4Q+@/\&"?Q,#X##]DO\ 3_=?:_="(X!^
MFC&QOB*D@'01'[,M*D^(B41^!'I0$.I0Z!^0 ZA^01Z@?OMK?X_I'_Q'J/\
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M0?\ Z.@?D .@'N;LTFPB*9W1A$H%_C#YZ[#H'3X@#IPL &^'Y?R_\. <K &
M, C7<VU*SHO3^U]W71.26IVG-:WK:EL2ADF:\NK6=>U>4MLZG%(2+^+CUI(\
M7$*@@1=TV1,J)0.JF7J< -(?T/Y6GN[GS2;5>:>.I%],:YL]V8N34IZ\L-[#
M:7*K5]UW%<7]$Y,<DZI$[+V7<=2R+61A:ZYAJ4A$U^)E8!H5K-*)H ?0-@&!
M[0L/REKJZV;Y[H>L/8JW*RGXB;09^X:ZI?HVJBWS'=67SEKSU5;B^WRNB>^Q
M/<D40]4C^[ "L?TX7ON7!;B](^[P]@]PU/ O??J\EX8";]4+A?W>#1]TF_%#
MR7D\S8OK7G:B<H>=7^$,!=C & , 8 P!@# & , 8 P!@# -,U$#\+>96F^)[
MLQ4FNI-[;LVMJ!N!44BGX[\B]'[EN-2CVK= XH,(W7.V8B[TR.9)E &L!6XP
MX@4'!2@!N9P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# -2WUFJOIFQ\0
MTEMK%U%'2T/MK4,EK^Z[5KFE;JIKQ_'[(JTU;[Q4]?;T;K5/:3ZIT.&D)5_5
M$S)NY^,8+H)&*J"9B@6,^FU"Q=?X)<78R#C86+ARZJA7L8E7'U)>P#UC++.Y
M9M.PR>MD&VOH:-LJ3X)%&)A4R1<*1T#!L4$FQ0P"[N :Z^>27?;^%BOH-J./
M#RTU"'KZM+^DU;'^2_TT.W:\1[VR]X>/.WMKQO1/O3.BN#=4.[N.!L4P!@#
M& , 8 P!@# & , 8 P"G7-R&EH_4T3OBJ,7TE>>)EVB^1\#%Q::SB2LE7I\5
M.06[J-',6Z*RDI,[ X^6FUP\0@("F2>>,' @86Y0P#@\39N(LNS>>-CK\DSF
M8&P<J]=S<)+QRY'4?*Q$K]/O@R_C9)BY2$R;AF^9KD524*(E.0P"'P' +IX
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M.8Q# 'D1 RCZ>W_R"\'O_P"$#C3_ /!BE8!;_ & , 8 P!@# & , 8 P!@#
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MD3.OG%FE))*V.EVT8W,,@Q!!JH)Q$I  P= /I@P!@# & , 8 P!@# & , 8
MP!@# & , 8 P# ]H6'Y2UU=;-\]T/6'L5;E93\1-H,_<-=4OT;51;YCNK+YR
MUYZJMQ?;Y71/?8GN2*(>J1_=@!6/Z<+WW+@MQ>D?=X>P>X:G@7OOU>2\,!-^
MJ%PO[O!H^Z3?BAY+R>9L7UKSM1.4/.K_  A@+L8 P!@# & , 8 P!@# & ,
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M["W"EV.!M]2LL:UF:Y:*O+Q]@KL_$/DBKL96%FXEP[C)6->(' Z2Z"JB2A!
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MN:.X9VRC&7NKB=*[@/:9=9)[Y&Y3&<>'PGZ$.(X!$>X>.C>I7_CG#Q/*#EA
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M+V%#'KE^J%7O%>5<(.U(&WP$39891TU,)FKD\7--'K$[AL8PBF<2=Q!'X"&
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M%E'QT>R1(V9L6+-L1)NT9M&Z14TDDRE(F0H%*   !@',P!@# & , 8 P!@#
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M_?RLCW@5)-):64;-4FL<V8LFH%DL 8 P!@# & , 8 P!@# & , 8 P!@# &
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ML*;><L*#AT0OC3Z%5 .TOY  DC & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# *"?4WG>85;X5<@IC@]%,Y/?D?J>_O*8+1.3E+\VL3>M/5
M*V?5U5:52U1EMO!YGQ^E92!$FBA@ IA-W=  T0_[O9M7Z]]^VGOEM]3>N[43
MULPA]:&JCCDKKDNGY1LHZ>W<EF5U62I:NAV-LF"E1CQD&\BX2201!(4SE,H8
M< WR<MEN6D;<Z9%\>#SSZK;NKJFDK3-1;>LN%..EJ?W:K2+7D@Q+-1CD#HUW
M3SR\"HD\!^Q>6>-J[(6@$=NE# 5'UQNOZM-HV!I6S;!T[JJGU,420NVZ#5Z1
MLU\S9K7#>W!VIV>,>REPLE7=)7'2>NK3L^5B[7#+3M/L3..<F1:KD;)N%0,*
M3Y"?5N=ZFX_6%'0D1'[9C+A5@W-K5QK*YM*M6::_TUN^-D)VV["<;2MTUN1F
M>9)6[<>$J,8PG(J8;I5QR[=O7!3+@6%V=<.?<U4>.LVQAY*KW>7J.V%+5$Z7
MK2SRARFY6NY]',N/Y+^RVE6EM@435-OT>:[R-B;2?M_LQU3-5WI9="(.H!E&
M]MQ?4.JE^VXMIW5&KK/K6E25E&@Q,_KF[/;-L*)K.G^/%V9E"^QNZX2&BEKQ
ML.]W:N-705Q<D::N$6.@\$BA%P*81'+[ZC?)?CQ?M@<>*A3IS8^LMK:1:T]*
MMTJ7U[KO9JTH;@E8-BTF7E;1?-K%M=1IJNPMS0UADH*48('1KK 6[INH0[U<
M"6X'F)RXW3$<PM:5""AFFT=>\6>04[1F%-U18JS>J3O"->2U<X]Q<X\M.S]A
MUDUJVA"HI68E<=QS1Q!NU#Q*R\B:.=NE0,+>67GT%T@&ZLAR"4X_I[*L7N]N
MK6O+*6XK:U4G. !$4VM:L6OD=]%=1KIWN $3NH4'B[0[HS7RLV\>=,"<MB[_
M .:>H-1:I84RFJ;&VCLG9?):(H<;L[6TK8;M8*)4X7:-SXXQ%[C=?6K6,;KJ
M<OK6#@8F0FY(@D@63\CV<:H.D9+P 6LXQ;+Y+WZR;18[ZUQ#T>%K[>M&J;F,
MJ=@JQTK0_MNUV%PH(R,]=+6WVA'TVGP%1D$+E$MXJ&FU+"LD@U169N6[<"W^
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#YS?K8?[P7
M!_2 M6DJ='\3KIR+E]JJ;/2G7D]9=B<<ZK6C:_9:K?QXTJ]6?CU?*1NQ.:0V
M48K\]<D%B5]=B1%Z(+.DR$ V?_3>YU0?U$.*.K.2T7K2Z:E?WZIQ=BFJ/98#
M8AH2"=RKB32284[:-QUIK2M[@BT4XT14E*^@NR24.":@D.)0,!$=N^J/4*!L
MIEJ2TZ;O#J_L-D;DUQ?JO3I6,FY:ER-.>%F](***SS6H5]=QR6TP*]Z@4GTA
M%(HPL7(H@NZ>MT&[L#'8[ZO^F3.ZPC8=7;1KS6_["O-1UF^5:Q:@[#AJG5K[
M8F,I#Q;YU$3M9LTF]J3*+=1%F:P*$<^F"=7ZR+5TJF!GE0^J'JBP[IM.C)C6
M>U8"X5[=U:TLJW:QL+958%_9:_H9)M,;!0AY<R,&BVVENQ2M+E@5K2T:H0:T
MPY=MXY4%$@,^8<XVZ6U-I5"SZW]GH6OJ7RFND?<HNX'G+;,L^(<UI* V<WF-
M>.:E!L:VI-/MU(+5\R4])>O8LA77*S]0D0 ,'#ZI.F$K!!5"0U3ON)N%N<;'
M9TRLOX75@OK6]U#3ZGLC9;2.?LMN/("-4J6M+S%SRAI-XP2=MG(M69W,HDNP
M3 P>+^KGIYUL^1I+[7%\)6YG4%0W-J6T1+B&=RE_K\Q;=G:SM,5-5^?6JL)2
M[) ;9UT2 CX\DW+/9HLB:5*BVA(V5D68&;;>^HL:F4FBW/6^B[5?S6TW+)I(
MU>;?6B,M,!.<1+5(T2\P/M^G]:<@D'ZTS<81XU:/U%6D*BDFFNN](58H !BM
M<^I;,7&N[DV%5=)U>4UIHFAS>S[G-#NY<]EL-*AN3G+WC\D.L*]$:DFH&ZVB
M=A>)3F<CF"DW'(OGT^UBD71^SW!8"=-C\_M2:SVE)ZAE*;M29M3;:]9T3"*P
M$52E(BW[BMU,T]L.#H4"\F;["KLWCBE[JCGYI&61C(1,K)ZB9Z#DC9%T!:?5
M.RJYN/6M%VK4 D"UG8%7A[7"I2S4C*5;,IEFD\39R;5)=T@C(,Q4%)8$E5D?
M(0?&HH3M.8"0, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M$#K"?Q(!G/\ ->J> ]/U>;RNS77\\8]N>Z>9?R(YGA+YF\=%U]QT'"^EN?\
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M% R+.8@IZ"F&:,A$S4++1ZSAA*1,HP<)KMG*"BB*Z*A3D,8I@$0.VP!@# &
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MC*&AHMJ4QC%;1T7'(-F+)N4QQ$")D*4!$?A@'<8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8!7G?O%30')VLIU3=6M8&WQJ4Y%
M6%!T9(\7.MY*)714(=M8HD[*<;)/FJ9FCHB:Y0<-%#I&^ AT@^:]-\+ZAU_I
MN6UX6UJ:EGPDFG[)1Q)971X?6+:9.\)ZEYOT]L?4\3L3JL<)1QXQ:DO;&68O
M#^997223)DK%0J=*BVL'3JS7ZI#,6C-@SB:Y#Q\)'-6,>B#9@T09QK=LW2;,
MFX=B1 *!4R? H &2NOJZVI6J=6N%=44DE&*BDET2222PEX>XB=C:V=NQW;=D
M[;6VW*<G)MOJWEMO+?B52V1P'X\;;LLE<+ZVVA.69\WN$4SG%-V[:0EJW5=C
M,+S%[#HU3DV]P3D*[1[C'['ED5XQNJ1LR2%B2/!F6&A CLY@,XV%Q$T/L^U#
M<K94G"TT%3A:0E[7.3$)'MJS7M?<D=7Q$:TBHIXUCVJ;.E\LKNU**:91ZR**
MG[MFU,D!5O6/TJN/U,9;+@[J^LFTJC?=6,-!QE&L,M8 IM/TA#S]XGXBGQ<%
M)6.P(%E$AV)+,5'C86+%*+<J-&$>P1=2!7@$B:=X Z^TEOUON6GW.Z%K\)5Y
M* J.LG\S/RL/#.YC7^F-5.Y63E)NQ2WS I&:[T'7(N+,9H@]:-T%06=.@4*5
M,#BLOIE\5&M<CZXXA;]+)PVLJGIF"E9?9US>3,%JZ@4^[T>B4V*<C*)MFS&I
M0>R)STJXHF?*+R!E'"ZPI-_"!(MSX:Z]ME05J[>S[$A).5W9K7>UKV"A<9MW
ML:S7#5[NLGKPN+4N^(ZC&;>*J$>P2;-"HL46J E],8%G + <*B<!N,&LXR2@
M*129J$K+S4MQTA&U?Y^O<E 5;7.QHNAQ.PX>J1\O8I L.ZNZ.KZ\M(O $[M5
MY& Y*H1=R]4<@<*&^G_QOB;]6=IN(>Y6'8U3-&>U6^S;!MDM(^G@I34DM!,7
M+8\DE$*,89SH^N@BD5L0HD:J^3O,Y<&4 ZS7_P!.'B;K!/Q4ZC34>3VW4D5T
M7N]M?_Q+1]&V#KG72?5Y++#W1-4V?,H*F_=.SN"J+"=1),Q0,)K_ -)S@W4Z
M6]H%9U0\@JR^3M+95M&7*UM7@1]UUMNS5-FBQE$Y4))Q'R51Y$6],I%U51;*
M2:8H"D1A')M ,K>_39XJ.;!5+8UK=T@[51JG7Z;4+%7=F7J$EH"(JMXIFQH
MS-PQFT@5>,+=K^+<&.L54KE) [=<JK999)0"XU HE4U;0Z3K*AQ)8"CZZJ-;
MHE,@B/)"0)"U2HPS*OUV)*_EG;^4?%CHB/11!9RNLX5 G<HH<XB80,NP!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M3)%+W&!0#D**DS8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M*DGX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
,P!@# & , 8 P#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tm2115679d1-lc_immbini4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_immbini4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!_ .0 P$1  (1 0,1 ?_$ .8  0 " P$! 0$! 0
M       '" 4&"00* P(+ 0$! 0 " P$! 0            $"! ,%!@<("1
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MENVK5.NW_9_O]1.-Q\BU=N2NMJ.YZ-4W/_%]WI/I(SJCN!@# & , 8 P!@#
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MKLSI#OA@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M'O@GII4A:'1,SS1O E$E3F('6(+'=J,.+T,\!R9U(,"/0@FEEA76A(V"C &
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M-:IG#%(B=,HA"\HC32_,8'?D\?#87@1KWJ^%#5(93MIMT-Y_: 0.2,$/AO<
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M.QZ%H8@7C[2S6"C & , 8 P!@# & , 8 P!@# & , 8!CW9S2,K6Y/+AM0%
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MECSEU'WJL9FEZA\AKYV;FX_NWI Q*C<81+&6.R:*+""MZ"-"O0)%286O(84
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!JTU5S5!%W=774?
MBTJFA))(F%@FLP=H#%W)0)40!04[R]B@UDNS(24B$:8 9+&X"&: )>P "/9H
M *H?'XHDROGAZ4S-H8F"6']4]\FR)EC$B<)='6MW'W?TCM:A990ZQ>$N3\VI
MS]["4J/:&TTX&M"$G*WORZ$70NQ@HP!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8!43Y _Y"^V_P#")TG_  :F>"/H
MRW>"C & , 8 P!@# & , 8 P!@# *"?)(=:A?+EE @C=7ZR)FQ)U#9*F6O,C
M;9$@:-.<>]D;!T3,PNK:[.0R!+-F@7J$101A)T$8M"'L%1C*M"_>0R& , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M7*+(U)6)R=9(W3 B*BD!LO&^/Y"DYP&J"J&J4Z-V9L8MBPA*E/6=@<AF, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M0MKDJ;0'^.BAGIR31 \-B '?X89(]-2[&"C & , 8 P!@# & , 8 P!@# &
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M$G41E7(HVI4=W](F',[TIADBET3/<D(][+-$W.B])L>M^F>8'P%L1="[&"C
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MA=C!1@# & , 8!7@F+/S#U2\3W;8L<HK9M%PJ [=DY/N$\/DM/3BS)2G2+]
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MC^H/+?\ H-R9? Q7VF6[R&0P!@'/*S^X7V2:8V'@&L8AW5+MW2NIFUGR'WG
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MNS5-/VVP7%02:L$:E7N\9*)$02$*@S1XQ)JC&70OWD,A@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , @&#_ ,PM^?U5I'_1K#S5M?O=W_+#_>/-<?\
MU/R7ZG$_!?)^S:/2C & , @+J[^5OI/^P*X_X=R/-7/_ '&]^JG_ *6>9[T_
MH[EOY9E?L)D^YM'IA@# & 0%RC_*WS9_8%3G\.XYFK@?N-G]5#_2CS/9?]'<
M3_+,7]A V>X;NJR@XH"9VQ,&^*-"QS2Q]A2C)6NLDF4J<0'#:(5 (>R)7*5S
M^=/NTXPM[(S(ESJN&'82"#-ZWK-H]*W3J5:%$.A^N-@568IFO*7.*D6S$M01
M*1 9.E[@:#0"+UJXK)BBY0;0<2<R![,^W(8X[EQ@-D#62%K'[UCW2:OU(N9
MJ_@]5PZ/U[6L1CD#@L4;P-<:B$29T+!'6-O 88=[5M:6TA.C2EC/-&8/R@UL
MPT8ABWL8A;W#+IT-OP" I'_-)3G]@72?\1.4<U9_OUO]5<_U6CS.5_6.!_+,
M_P#;\<3[FT>F& , 8 P!@# & , 8 P!@# & 0%U/!H[9G.-UP&6%04R/2RN9
M.S.8K,D#_$H*E)5-QNBW&1RV*.3+*HDC:S] 4A=6M8C<FTXH"E*>2>468$1]
M#DA\?#*T1'O^WF9?*.>;$D\OYU>+1:GGGV\[;N1A@8)7<[0;;+>K9YT_O#/7
M+E<U@[325R4;,4KI6[)%*@(R0-YX#*^AC'[7@=[,AF, 8 P#5IJDFJ^+NZ2N
MI!%HK-#B20L+_-8>[3Z+MJ@*H@:@UWB#%.:V=GLDU$$TL "7QO$ T83-C&$&
MRA@50^/Q/)DG/#TFF;NQ/\L(ZI[Y*D3U&(ZX1&.NCN#N_I'2U<RQ=UE$V<F%
MM4'ZV(I*>[N1I(-Z")0;O7FV(NA=C!1@# & , 8 P!@# & , 8 P!@# & ,
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MQYY'F!S./&36U:O$K5N.ZQJUF(4"3I&)C"A1A3Z"69HW19?EA4DG7Q+C8*,
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MY1S5G^_6_P!5<_U6CS.5_6.!_+,_]OQQ/N;1Z88 P!@# & , 8 P!@# & ,
M8!77JM!RNKI&3J^SSZ4;N?65=&G25/\ T"[Q&-UI&7C[C:VZ&/:Z539:V,D6
M?2I<XHB&E=I4F5EN9Y 4QFCQEZV(Z4UZ'._XVNK?CVGSK4\(XAB%2-;OTI1%
ML=%6J?65@0>PI=!GFAY'S9" 5Y?;ZR/,@EZR>#2=-I!MA3LI\R%$W*0   )H
M-977Q,8N/2)V:R&97NZ*056O9')$\3R%.RD\S="22[US:<W&+C)<E?\ E+IO
MFX$>2*0+$P6=0F6]!$NVU(P* B*:QI_3T(\)I0C5:%(;1^.JS>D0JZXZ7OF
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M/D-?.S<W']V](&)4;C")8RQV311805O01H5Z!(J3"UY#"@"UO6HRQZ%X<%&
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MUDF3N<>+*>)NFG=EPJ6+VY:!>:,H,;:Y"KT%$=ZA!8A)PGD670OWD,A@# &
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M5LA[_F1K2B]ZGE]::TKZJGS+LF'<\^"XB$^T.(> \3%3R'FV7<=MV[=;SM?
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MG\XO7']0>6_]!N3+X$7VF6[R&0P!@# *B?('_(7VW_A$Z3_@U,\$?1EN\%&
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M)Q5)5IZE;:6^2SHFPZWA[(M<:"<NJ;JE?-T)@53O?.W6?-K=41]QQ6RIU+K
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MD:YJ%9*U#5KQ1[0JCQ:<LD9*MX'=ERT\B/3KQ&B 5I <N-T(L7J@+#L A"$
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M*#KP"  0A#K\FLSN7;EZX[MZ4IW9.K;;;;]+;U;]I6W)UDZMGOS @P!@# &
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M 8 P" N4?Y6^;/[ J<_AW',U<#]QL_JH?Z4>9[+_ *.XG^68O["!/N;1Z88
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M*(5HQ%G(&F*HU2?7,VDJE,240>G_ '43E(^37T3RF\)I6UK&1LI/X;U[G?@
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M@# & , 8! ,'_F%OS^JM(_Z-8>:MK][N_P"6'^\>:X_^I^2_4XGX+YD;TO\
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MBZWFBAUNR,2I<T$&:D*1\+:%!!!*D*P9&BS<(LJ4.MF0S& , 8 P!@# & ,
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M2<73&.&]J7107.C6XJ+L97(NOUJZ>(Z]U*EZ8NMD8I"E+.LLM5[0L:0>PI!
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M'**[YBE!U>IZPJYPZLCE@0ZW54??(] 66T7LD$,MN6,L>3/#\O31]IDBQ,0
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M^A;-+).&2/0!;UH(M@WK6_PWFVKMMW':4HNZDFXU54G6C:ZI.CH_&C,:.E?
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MICA\YD+@KB\N4)7N(-K(O0Q!8V-.C$;K(A/#TV"3I0GJ=' V22KWL"8WS _
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MBE[39>D_]LOQ^?XNYG_W"^V\!]5[2W>"C & , 8 P!@# & , 8 P!@# & ,
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M\1AMD@)<B:3@*CRB24\C+:6,#H$Y( LW8])"?((S8/#?E\VX9&TX P!@# &
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MDU%W-KV[JR27VW"$II)*4HQ;6BI7)NM-(MUHNGW*KH8DROX&;(PS$V$Q$R7
MV'8)29&V8<C!L ?*#87P2+;F'8 _AKP-_#6:[X;AY9RY.6)C/DE_YWE0\W_]
M3;O^^9>;=V>7NEY?HJZ?5T-C1-Z!M)&G;D21O3F*W!P,(1)B4I)B]V7J71T6
MC*( 6 2MR<UARE09O7G./-&8/>QB%O>[:LV;$7"Q",(.4I-122W3DYSE1?E2
MG*4I/K*3<G5MLP;;U;J_[-%]X]0@A&$01!T((M;"((M:$$01:\-A%K?CK>MZ
MW^.LY&DU1]"&K-D$A#*VJ6=FAL5:6A8O*=5;4V1YH0-JIT3J2%A#DI0I4924
M]>2L2E&@.$'9@3"PBUO0@ZWKK\?B.)Q;$L7%Q<>WC2FIRA"W",7--24G%12<
ME))J354TG6J1F[MR3W2E)RI2M7T,^H;T"H]*I5(DBE2B]Q[-0H3$G'I/=D[3
MJO:FF $8G]RG%L!GDWKS@WY=^.OPS<G9LW)QN7(1E<A7:VDVJJCHWTJM'3JM
M&8IM*B>C-73U_%4*J-&M;2C9D$24.R]D865$@:F!,[O"0UO/>OIR%(0';F2W
M+%9!8]""#0%I^Q!$,01 Z^'"\=9N6)8]N-JSC2G*W;A&,+:G-.+GMC%>^HRG
M%/I2<ZIMIK-W9M/<ZN5*MZNB\/9T^I&YYVIQC *E=YPZZ[!XQZ<A?.4T%7EX
M2.F)RV5O,"Y-]D*&>0FLJ@1>T4Z\-B@;BO2@-2IGT.PB95!P%H1!$1H6B)*M
M'3J<B/A[BA#7TG<CY3%12/DSFQ30T28W_G*>]KP?K>23OHAMGKDH>KTC[?$;
MROK<'9&N)*@LK@[#<6[<M/5I#S$@A) G;K,8==.GM/HLR&8P!@# -6FJ2:KX
MN[I*ZD$6BLT.))"PO\UA[M/HNVJ JB!J#7>(,4YK9V>R34032P )?&\0#1A,
MV,80;*&!5#X_$\F2<\/2:9N[$_RPCJGODJ1/48CKA$8ZZ.X.[^D=+5S+%W64
M39R86U0?K8BDI[NY&D@WH(E!N]>;8BZ%V,%& , 8 P!@# & <\OD6IR#R7GZ
MWK77?>;?/XC6HD,<D$6L^SH0)L)1O!BQ.,MMALP86<Y8 ]W4>*@U.-0( ] $
M/8 %A#48R6E?$N+6%2P:G6-;'( A>6]H<'4U[5$/<QF<U4"<CT:)"::4XS>0
M2)R2DB3-Y6O1*. 1H0=BT#S"$(4*E0DC!1@'-WLF*%V3=M;5T^RVUV2%F<=]
MRV&N8:SNNX*93O<NA<MX\8HJYR514$Y@RV4$L33/7DE.D<352((7$[?H[$+Q
MU3%_B-!X#BA=;2NN(9'Y;;#I$W[X_.8K#51VP[KN"VVAOESFY2IJ7N<816M.
M9F1#25+:A(($D:-(47I$%AT5K0 ^!DCZ/4207P;8TAZ/,O\ M/Y NUIBPL5G
M"GU;<Z0J=1&BJ B[(C?=/4=@$SCE00V,2RYXXS$EEHCRY,]+"'E($0'$A5LP
M>]BTUK5DG4=\>'#7-LT<[+I'E6DH%9[P[OCZXVDA@K0Y6B>YR0Q88^&ALA^)
M=9NG3N7U \)B<I>!/Z9H@:!H&_+DJ512Z(N5@HP"HDS_ )].;/\ ")VW_&7X
M_,$\2W>"C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 4,^4
M"N3;9^/[JJ EVK Z5*?*K<C7"Q+5E+C"*L;69E<&U_?&*SY@T+$+M&:WG+,U
MGL3\N2F;4)FER4#+ :/6BAU=3&2K%HY0_"8^T;8?2?35J42B^/GGF-.M*4W
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M$H\Q(E&:#6A"*+WO8-0R/9@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# .;OR]QA\F/QK=<Q^-1T,HD"NLRE#,U%P.4V@Z%N+5*8Z[)7J+UU
M#O!YFLXC)J'3DP-H]@;E3TD2@<1 ;]JA:JZF,OLLJM\3-HS"?SVU$<FZ-NV[
M2V^$L*DEJM?XKEWQ])6,\UY$48X-\Q41"-I;"<% ?Z,UL*&;I*'^GT'6M^.&
M2+^ZAW+R&8P!@# .8GRHJ>>">?G(JWY]%(G8ZAD?PT5'GZW55>NTVDNGB%Z=
M&Z-0XB6Q\JT%B96-K"-$8C=-$"4EA],/N=Z,J,9TIJ=.\AD, 8 P!@# & ,
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M04M:ESZS5RS(EOT-M. F6/;N]OC7%XVSEK#"5!: MTD;XD(,4B+-TF*,$;L
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MCX<=B.4%<:@I7,S*A=W)-*L[<81G7K%)/0P_4S6M=W:W2SD:]:6X\@4$C/$
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MGM_XRE$W[JDI>NIUV):RKV^4\J][EV4:;;-&HRHJ_FJZ^-&O50N3GBCN!@#
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M&>RQ&3CZE))5=$CMLON&%_&GC/ P(NXG2:A=WPW?X&[S2I^36+]=2\&?2SS
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MBG,NCHKM4B5$3.<RXFNY#6\5CR^?L+\:X*B7YI>VUX6'(%[<M4@5+6XG1HB
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MY7;EVU"<9RG-RE.M;DHTE*3;2BM:4HM"3L](>8& , 8 P!@# & , 8 P!@#
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MXM2U2HO-KCB<-E<&E(:S&K+?-U]&'W;!I9+&5Z!&S#1JT+LL$!.Y;6%D$%#
MH$9XSY\=P<GS?=2Q\C'OVN)PW.UCW+D+D/.IM\Z<=RC;E%SIME"-90V.4FG%
M+9[:XA\7QD)W<:.-EW_>G%*Y_P"C%^9.<JQ3U5523:H=O\^''H!@# & , 8
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MW.=G_A\>6]P=ORI2R+G(1N0K%3UDH7+35C;":=UV/HAA[\RN-6QB45C&T9C
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M0L+T.UDB)AMDF8UF2QU!9J6<,#/(+(F5:Q4A,JEL+C9.S1?2@D(7LTK6C3B
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M5]:]2PN>:.P& , 8 P!@# & , 8 P#9H]_R%7_Z17_X#,QD9Q-CS R& , 8
MP!@# & , 8 P#F?\H)].-?.\^-F]:+Y1/)5!76.PN7M- 3FT0QP"!Z8C]D2>
MR(C7\J9*E9-+WH!Q*B0.3.A.%H\THP7MU(BM;*PL/.MJSFVK5ZRG7;.,9JOI
MI)-5U>IP9-BQD679R(1N6I=8RBI)^U--%OXI"H;!4*MLA,2C,.;5S@8ZK6^*
ML+5'D2QT,3)$!CDJ2-"1(0H7C0MZ<G9PP[,V406#>_* .M;=JU:L6U9L1C"U
M%448I))>A):)>PJBHK;%))&T9F48 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&]MO\ [ F__=__ (]YQRZG
M(NA[LA1@# & , 8 P!@# & , 8 P!@# & 42[S?Y:5'><ZQC4]E]6M70/5=;
M4U8%@0!X#&9JQP-?%K"G;BU1J7>W.4Q%SL%X@2"+A<4@T[FG"]B^GGDKQ)C
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MMAY_F5FD ,\GD!L1@@@VW(49MW[]+Q_W >L?^FW"'_C5QN0H_0:C7W6%C6G
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M0&"#HL3<*,D#[S[*_P!T^O?^U"C_ .IS&Y"DB/ZTOWJBUHXY2B+\F0XMM:[
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ML7;5632\^,>N:3K<\*6P[AYBORK($J&N"V!332P:JE<2BQXG(:A(!O"2^.Y
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M-5Y=%>1RJYA$S)VVIX+&37KV+%&Q6%*%D?3F(GR,Q-2U&"0JM;)3%I?0 C]
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MTK]WV3(XP2_NY061+IX2HW54CC1)PBO9#0BV,EU;.@>0R& , 8 P!@# & ,
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MOJM^BG#H"%W!"7MRZWF-TRITI%'%+*4*[:U2K97, 62/5RO W=FC,3KMO96
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M:UY1AWM1BJ9Z\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M,HJ0AP.+GT1B41G;JRJD"U*$V(3=RE3*P/K4X'$!;GA*8]0ES2J0)S3#T)Q
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M.M&>F+R^/EWX*>/@*KIXGKP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M(6'#>'>YH:GJ]PCC>XO?*:?FRR!<Z]1<:*+*Z??+);&*")B^2>HI5)W2$V-
MK50096Y2^+  P3!S= C($H4M1VPB+HSZF<AR# & , 8 P#G+V5+)HELN.M,:
M8)!*CZUY5ZPZ9@,$C;4L?GJQKXK4NK8+5+<UL*-,<8_JXJ?:BPY.E\IX /+D
MV+-Z).1IS=[5B,=C;:59QBWZ$ZM_73ZJFID2EO22;I"4DO3)42_#]=".2Z5Z
MV5.5L02,6=:#H8Q0KE!N+F=B6[8%=-LPM!FC]PK+TFD'E#/7T]3-[+(T$CAR
M-4S,K:2SA<&<XT>REFU&SL_,L44FEJY:))T6E$]5Z]7Z3#R[]91BY:*.K;57
MKN:='ZM$J51FK2YVLB6TSS'5EK@F<ZEW]Z:MG26.,?M*SK$BS;"HE/M72^.5
MAO0X[7B5_85\6K+<=3CD#.)&WK7PLA(+2TU*HUC"["-R<X42V.FB6K5-.OIK
MH_#T%G9G*W"%RKEO5=6U1.NO2O2FJTKZ326I?3+AUS/KH>JAM6F4//DJMVU'
MB;N?*W3ADGNR4LE3+J;E4X<[F<JD40=13S378U((S$(\\NATD4)D#J40F$C*
M2'Y-35A6U*,G))4W1T5:TI6M:]6UIJC%.V\AW'&45!MUVRJW2C=:4I3HD]=&
M6.[/LA?'93R_7*1ZM=E8K!M24OEK#I-CFDBL);3M>5;,%;PVMS=6;6\V6G;7
M>SI#$$*Y:P)_J:)(K&84:F\-JB>*Q%-3E[M5'2M*5;7ITZ5ZG+D3:E"%9).3
MK2K=$GZ->M.FI0:'J.]!RZ!L]@N_0$=418^GWF )D,!LJ<&J*K!)7J>3H-QS
M"*21EHV5V4?7J#<+D2"4*W=Z*4)4ZYA2&NC@!2JV9?#4;CM=:UU2UZ*E=4JZ
MJE%Z=$:L?BMR4]ZI2FC>E:NK6C=-'6K\5JRXK*'H&L^"I%:CI(K%=NI9U3[5
M-G]#,%YKTY0">R]-MR%#8#7+L B)I)#6^Y2-K:FA.VEGR%R;$A"LM6H-T$7
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M>];\,#KU-T2)$J!*F0H4R=$B1)R4B-&D)+3I4B5.6$E.F3)R0@)(3D$@T$
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ML\0!C"'>]:WK6\!-/H3?@HP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MQJKH?1Y1+@QO>XSJ0_>3' PEUTU&E,OTXA.,X6C3+'KXTIXG:C(9C & , 8
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M*B)NF%5[-4EB51TE$;;>JZ4N#?5G2"4^OEVG>JCP.ABI8O4H$BE,80@7#//
M@4#GI4N'R=VN9>\7*2VA5$TI.TFGG6FND'Z-2#41<V]_KBW6R6!;)9$!06<V
M)[4D$CKYY2GLJ]5IX;P@3;-"9I268(5.OM*J).U.RXU4G/77L_:>;73G3J4Z
MM"HY4<1B-BM=V4>AZ%CY+A13U*K5<+8D<#N]42^O32@EK8UQ6(EMQ:M2J0."
M\I'K2D2KI7P9M/-G4O8PM\!RGI:0<R6% /D&C#>DBR:D*:M*CYC3=H._+\WZ
MR:FIY#.^B.B6FU(2I@=4R-L4.!'VNK1N8$ ])SRE1H$PJ;TKXDIS7Y-*FK><
M6DUSVL[?BE2TS;;Q1%@="NB""FURW6DU4:EZ#TVM["USIRM!WC2N#K2$874I
MA](#\I)1B+T7L]20H-R^@G7G/JE#?C_,(2[558E+6)#8'4%M+(+8ZF".+JJJ
MN^0STJL)BG<JYF4XCQ8G1YJN2M2U 8L"L0.3(HUL!B4Q(J4PJ=3$7;T1.JF:
M>4[&=(,&&5S:5QUC5M_QN?%-KE8E/;OED70ZK"AO5<3>5UN!]:.DGZ*15]&F
M7/K(80[GGHG 99!1Z@&Z4*:23Y;855J=^DMF,S$NC5A7/U!'^7VAHEU;U8[3
M"E>-CH'5UT3M]F70%K5W!)1)9!?[DXIHFW-!J4YY9'-H-)).2E.#N&T)NH>5
M#\K1P9AT G>*JDXJ<:+=CU;T%?4>CT;7,.MRWXR:>[Z8&JT*\D5R12R7R5F&
M2.0DF;;T+(V%I%#&A,4%'[='%,H3=]7]Q[I[\H4E#14HLZGJ-G$Q:XL=7T-6
M7H_1J,H::#:CW'J^F,N9'J ,US.EL1B/-C-,36HIR-&H;2I66%M"M6%B3JUJ
M@<M*HG?FOY,:"ZDO!\I"N2U9CBF;[8=HR_AF-42(J0-M+6&U5G,CWZ(0NP9+
M8E5J'5Y>2%\?32MH9U#VR^HI+ 6<0H2DJ%4DW1$<\]=EW_8M]P!+/$%/:H#H
MJ9=K0:EF.)12:M-NU^OY!MQR@#4[V7-7BQ)##[!1V[%XPZNQB9LCL;'&%6DR
M+UG<)ABHH$W7U,RL@^3QL239?"H=RCT=/1AGG3=8Q^0M[GSU'V&53'DA:<1;
MH&[[IO-I>$,>&D1J1LRY:C3[7GIAD&DI1;+$-0;O:>JJ?E0IRWW.DG6-5A<*
M*E>A9]*ZMK7H)]*K)JK[<ZK_ )UL;I:=M\M9S[)U8<8:([$JFD+1M>)F/)/D
M+2I*#K2#T'%0H%)/V%8>>_F6;WUTZGC-_01:&;T83&KC2PFG8J6F>X/S?:'*
MO*UYTZ@M3=AV>0G>[CGUI= +X(WZ8]EHE#JU^JL2M+>2H<=J$4^M2YK]W ]*
M:#[SF313\KK"Y^)(#-W"00BW!0Z01IQFS=SJV] PTUN=ZKL-](E$)<662-I:
ML8%K4NT=[A/Y21EZ,P6NC]*.>$)^4CIQ/]>:Y297<]7[@W-,\97J1<'=C\!F
MMW[V^LZ7Y_FL:9:SZLMZ43&^VIIBUHFKM2Z+*4S&P.>FTAQ+/^II2C%";G]V
MA/\  .O^T$</KWIFS'WER5<ZS_LX?*KC5,*IBUJXN:"-<W[1=N**IFB.VWWH
MZU899CFCGRUA7OK=]EQDLUL4K34R@D:4LE0%7UTI4M3<'?4-IVXIM5CK45OO
MS'4C-0DENFWF0BOBZ\K>.=(3J1UU7KH:0\3YLG$K$VOL66*GTAJ9U1S8T%;4
M@"H,$4F-4*Y49E^9^XX5TR_1IH9Z[L2!MUH4HW=*4-))IN%FM5UT(Z/;<RI+
M"CJ>*2V2.\8%Z<D87 ;8_IFQP"VR1O'Z>U&EZ9!"IU+N8*, 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , \;BWH'=O7-+HC3.+8YHU+>XMZTDM
M2C7(%I TRQ&K3G!&4H3*DYH@& %K81@%O6]>&\SMW+EFY&]:DXW823BTZ--.
MJ:?@T]4R2C&<7"23BU1I^*9$] 4+6O,U3Q6EJD9S&2"P\MQTUI5*CWB\]0[N
MJUZ<U[DOV668N7K7%P-&,P6M;\-Z#K6@A#K7;]P]P<GW1R][G.8FKF?>:W-*
MB2C%1BHKP2BDDOIZLU,# QN-Q(86(MMB%:>G5MMM^+;9,F=*;A42].#N3>EI
M)(Y;>-0-]@/\L8*/B[^L<9/.6\E<Q<X6M*[MII"%N8I.U-B/[2LJ<.RXPT@D
MHYU(7&(7$:M!Y4H1&D^I&]C_ !<\26J3%@2FL9J@50FU^@;PBCU7_0_2=22A
MCL_J>5+)K?DC12VJ+>A<G"38<C<#SCF\2L38B*-$G1)TR;?I9:DVIFGO/Q!\
M*2 ,%,=XET K>*T+G::$S#^_1W8GL-E;K,-B)\W9/WE)>DR9^Y1Q[401J-^F
MJW(] F-2^=.24(T[9BHVHVE\^*G@600!@J]90"5#!HU2EL\\-3)&[%MV'B_=
M'>\DC<PN6..;K$Y^RO3\Y67)8FC6/#TO4*7U8;Z_G6;"L5Z/58VQ)EO7BKF+
MI0,?!<E6I9,"+5/=]%L);5)YM!2V^H>CH&EK.YH $%?R6+ 41Z8PU E3Z*-T
M9MM4(TRQ )*M3$*"X5I/J?H+B_F471]?]<_NM0E]%5?4A]$PJRR)%,4Z]NJ@
M\Y<?]I.#(1(BXM)24QKHIVF5NB%8O2^X-T2>7HP?B%%6OB3',:O@T_D54RN6
ML?U9_I"?.-H5>O\ J;P@^V)R[5=9-+N#Y[5L<$:)Z]Q6EO2)M]LXEJT8/J'N
M E:5$)CR12K"?XV>*RG>PW933'ULBS6"R8P]Q24V+;$OK:-LEQ/!,BM5)4E4
MRF=/%9T0984@3EKW<^$-,>4+EI83S1B-"$>K4QVHEVF^5:0H:*3F'UY'I.)'
M9R\]SL:16#:=L7+9,[6FQY%$R#)=;MQS>>6I(2VJ+MQ#<W%JGDTIL1$@)2!)
M+#H.0J21KBKB3F%9#G2 *:R]2)/7.<%Y,<VG[SL$'N>?JT,?S83 /?ERP+F3
M]%'*%V_JI9P'M3Z_].L-\A?D"B* 3?X?F.VNLC+FMB>QJ0TD7<<[O(-0QYMO
M>'NC_)I_5<OJQU89(B:^E!<[H$JE!,CSGJ0L%<,LLF"9.F1/2]4'WY[E:F.V
MKJ^AT8EO(W/\UD+_ #!\@HA3*16O!+R52Q%))4A?4-L5M!6RL8A+V-20]A)8
MQ)J[:0,3@W)2RFA^9SU:)U2+DJ]<2IAE1%(N#?C'<N1+E=+FEMG1::N[=1B3
MG. LL'8+L8&!FKPF6L\P5&_1[CZ.O]J@K5I;'4!+-#8.GBT*BY05GL4.PK@E
M)*V2,:%MI!PERI*DLP1OU5!<$\]A_5$"E0!36Q4XG&+=K36"V)TN@)-22X@U
MJ56)-*U8UY*U&).N8#4 0LQS>68< R%HCU1WA[EJ)#A0XW5:=HU739STS0LE
M)+)X%*PM7*;3+6*@4*9&.4C2')Z_:9RZ$ T< SZB%3K:_P!T(HG9:HVH_JEN
M(.6^=S(,;355)82*ME5T+(7[653EU S']"2*.2FVOZ-_D[L6XDR-WB+9[<I7
MH\IF2(2DC:%&D#Z& DET/YM'B'F6Y;5:[GL2OG-XG+?]D?4@-UE6K%(-/?W9
M2!1*ZV_?#5$1F[#55X?N]D:HQ:Q_>+*^?25 O,E]+>M> -)NI./[KX+^]']]
M'T/_ .9?V#^Z_P"Y?J;Q_P Q?N+[K^A_1_J'T#_X_P#YQ[GVOO/_ $/5]/\
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MRHU!8K/:M>QFKG&8VD%GG5HPZ&0NGV"D8BVUA83LQBD%=F1N'1M,<D.;#"#
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MAUO>]^& ><US;25Z5J.<$)3FN)4*$3::K(+7K$Z3R>Z/2HQF:4*"4WJA]00
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MH0S/32[G,;D:S/1+8XHUYK.[D%E''M3H6E.-&WN1)1X!#(-T T(1AWL/AO6
M>U8L1MR-4X."I,@0($QZQ<N6'E)4:-&E*$>I5*E)X@$ITR<D AF&#%H( ZWO
M>]:U@'XM[JV.Q9QK4XH',I,I,1J#6]8G6%D+"0@$<E.&F,,"4I*"8'8@"WH0
M="UXZ_'6 >_ & , 8 P!@# & >-P<6]I1*G)U7(VQN1$C4+7!P4DHT21.7KQ
M,/5*E(RR$Y(-?CL0Q:#K_+O #@X(&A N=75<C;&ML1J7!R<G!22B0-Z!$2-2
ML7+EBD92=(C2)RA&&FF"" L =B%O6M;W@!$XM[D \QN7(UY:98L;E)B)22J
MG<&]0-(O0GC(&8$I8A5%"*.*%X#*,#L(M:WK>L ]F , 8!XV]Q;W9$E<FI<C
M<VY:2!0B<&]22L1*TYFO$L]*J3#,(4$CU^.A %L._P#)O /9@# /&G<6]6I7
MHTJY&I5M9Q*=S2IU))REN4*$I*Y.0O(+&(U&<>B4EG "9H(A%&!'K6PBUO8'
MLP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M; +RDD1E!$^=K:?UR91'W*=Q9K8+6;&W[B9K]@K^6Z0N1'6D\!?R&V$(GDU
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M^GQAV5$.),C.>%!2 !'TA$A*3C4A!UKXF@CK6[(M$HK'8PZ6Q#608>@UC?\
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M34P\/[.Z?O:^J,PF,,D.95!+9[52U:&!N,D):B+$F:4B<@AULGSPK($DZ/H
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M_O'Z/]1]IZ_D_H?6]+S_ )WDP#,8 P!@# & , 8 P!@# & , 8 P!@# & ,
J8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>tm2115679d1-lc_imm1bin4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_imm1bin4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"  .2 P$1  (1 0,1 ?_$ .$  0 " @,! 0$!
M       '" 8)! 4* P(!"P$!  $% 0$               $"! 4&!P,($
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M_"L=99ZWQJP3'E"Z+??9AYZ%0X$QU.PIE)FAB4%)-Z.T!Z;< 8 P!@# & ,
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MQ]R(C_?+$925# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M;$(U*6R*R(Y@7Z+4IWP+8G"ZE"T(XM(/2H)I2><K#">%@C*OBY/%)A4EKR6
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M@# & , 8 P!@# & , 8!0#Q5_P"[CXP_H @7^2PX!?\ P!@# & , 8 P!@#
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M 8 P!@# & , 8 P#6!XTO^<7DL_]3^_?]%M!X!L_P!@# & , 8 P!@# & ,
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M0IC_ &(47RAVG WM8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & 4 \5?^[CXP_H @7^2PX!?_ & , 8 P!@# & , 8
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MO288'H*J;^2NM/Z/X;_%QMP"0, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@&L#QI?\XO)9_ZG]^_Z+:#P#9_@# & , 8
M P!@# & , 8 P!@# & , 8 P!@'#<'%O:$*MT=5R-L;6].:K7N+@I)1(424@
M&S#U*M6I&6G3)R2P[$,8Q!"'6O7>_3 ,7A-D5W92%4Z5S/87/VU$HTD6N,)E
M+'*D*14('R!3*E;$N7ITZ@1?ZV@#%H6]?I]/3 ,TP!@# & :?/+I&IRX5K7L
M@9J&Y[FL.9KSY!!)KHG5BO##>-7&G]GT0%(DJ>")>>9VURY&[C, 6L&HG42V
M26<;O1:CVZ :!N#P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , H!XJ_]W'QA_0! O\ )8< O_@# & , 8 P!@# & 1_
M:EHPFEJ^E%HV,Z+&>%PYO"XO:YMC\CEKM\9JI.@1HF6*0YH?Y;*'QT<59*5$
MVM:%8X+E9Q9"<DTT8 ; T8TI>O1W?ML2IJ@'DIL_F%=]GLB4UE4M9^.H$"B#
M]"ZUL-MK.6N8[&\@-(R"<W#(*IG#PB8IR0T-D(,:GM>6DVA2;T$XT#<7SFP]
M-Q:).D;Z@L*I[<E#.\:31:T:N@;_ %4=,XK] D&4OGE:.LFG#1%IHF<=GE*!
M,[RI;%P @4%)T'OVC* L'@# & , TH^>R&RF3^/#IQRC_)W/G1:&+<H==.\A
MG]T3INB4OYN;2Z/?3QVA2C6MHVVCI?/$!*,U:2B(=(@8)4U)0?<0;-T<F VW
M5-_)76G]'\-_BXVX!(& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P#6!XTO\ G%Y+/_4_OW_1;0> ;/\  & , 8 P!@#
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M$X0C&6!NOP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M<]4W\E=:?T?PW^+C;@$@8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , H!XJ_\ =Q\8?T 0+_)8< O_ ( P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP#6!XTO^<7DL_P#4_OW_ $6T'@&S_ & , 8 P!@# & , 8 P!@# & , 8 P!
M@# -='DTLJM8[SRX5E-YXUQ)ZM%PC;@Q1U^%:;9'+6C%7V37,RM&H93+JHB$
MS?XA$[;A038FZJ]HE7M;W\X7TBTH!R<8%'?#$)B=7RPEL0B=94XQ0RN6^OE5
M65BZ2A:GD2,RWK/F5=2E[9SJQKVOHJVUO!G\$7CY#0:O7'H_J"U@4B5&U%;
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M <7 4H:5(PKC]F;.]1Z, ] V , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M3'3#&(]48,: 0D@BM[ D)V^Z_:G/[%]O^]_;UOV;[M]3]J^Z_3&?;_N?T?\
MC?V_ZOV?-\7[Y\?K[?UO3 //G4_C([^;V7J5QO:X.&K:O3IB,I-R?HF94+.;
M<DSXZPV<,<PK6G7NM+4?W&H(]RRSH$*QJ%&H^T-YZ02O3N2::] VN&!W!/C
MZ\;.@W#R!1VP.96#L5=T;'K8,IE"ALLKE156Z/E=XY7E$'7RPEL)L<VPI,W/
MFY*.5EL1>M+T"- :W')BQ'[ P4[PX]30FJ++J6HN@*+^C[5Y(F_,7=LHG$ F
M!:XB1VC?74%ZS>ZZ#8XZYZ3.+HE'VG8+&UL+ZL0)B4P6=08L%](:E. X_F2X
M7Y4J'@3JB6U!XH^7[DF6^2.F3Y;T456_+L3M.C3HK1;Z)EO1RE\UC:*Q)U,&
M(THQU+/95!K[]6U^\L6CS"=X!Z!JF_DKK3^C^&_Q<;< D# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"AW47DJY'XSD)T;Z)D=S0X
M].TQ]Z/?X]R1UU:D )12EW$P, #+.J.BYW7 7)Q?=!1A1;=?K JC"RAE!&:6
M$0$X\[]-U1U+%7J9U#^:&V!@D!D8<3+2H*^N?77;N4W('4P#;'.@*TK&1O;>
M!$YD[VM1)%"+Y!"*^;Y0# $"P& , 8!K \:7_.+R6?\ J?W[_HMH/ -G^ ,
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MZ_ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8!JD[YL.EZHZF\?4\Z"D$+B=6MCIU"WNLCL("+421.[O4K.G8DZY0Y$'H"
M%BY46("?WZT(8];T']. :[/$I:= 67:?C!:J3E%?RB35KXG>S62Z"8,%O-<(
MK(9!>OC#,B[;.#VY.6).Z.H8R\"1@4CV89I$JV#] #/0#TW8 P!@# & , 8
MP!@# /*GU!R)5$5\E?5DONOG[RP6S5M[UE1DYATUXOL+LEPKLJ5(W2V6ZU:P
MGA566M&24HO>Z(%S0UH2QLS6W*U "@HCSS-*P/2E0;+7L;HJEH[4<350*J6"
MI:Y9:Q@JY$L;5L+KUKAS,AA<36-SBI6N"!5'(V0F1F$GG&G%#)V$8Q"UL6P)
M:P!@# & :)?V@]AK]XX OA7,Z6ZOM-W9N9.MET*DO.L]LJ'P&J7T%*N1A4PZ
M0:8)=-6,LRJ],J(3J#T+\V2MN&B1K@";QEFG%* -S53?R5UI_1_#?XN-N 2!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!K \R7^[
MPN+_ *?\M_\ FTHS -G^ , 8 P#6!XTO^<7DL_\ 4_OW_1;0> ;/\ 8 P!@#
M & , 8 P!@# & , 8 P!@# & , J9W&.S0<R3S=2(Y8LEHWRJR5YD @L)LZP
MFBNE%O0(BXI175?6,PRR$S&Q(A41CXZL*!P:'DI0[HTX0MR\SV)#@*)^-R-]
M&16];CCEQSSI>QTD2@88?)W6Z>;*:Y[KUKLZ/6]/FI(Z4Y)*7YJH"'WY$[5K
M- TR!.N0*Y25$R1?1*EQ:U>:D3 ;B7]2[HF)Z6,#82]/R1I<5+(S*%P&Q.[.
MY",XUM;#W(PLXMO)7K @*$>( ]%!'L>];UKTP#3U ^I>VI+,[7IF+S#ERYK'
M@E1U>]VE8D9@,PC%&\EWI)+2BL>LZKID^BN%\;K>,@=/O+W,"(\E?F22$ABP
M"'10D#(VLQ,!&3#WWTE,E1C7$Y"NG]/I+-N-NB'9-"\67#=42N:O*SK2AWTY
M;':YADDDI04J*R[2D;"1*$#BIC\H_!QP6CY%@]IA 21,>^K661&]>@*6G=/3
MKG7D6 \X2Z9*#Z[DBZ1=*-UD5]#+PLR2PJ0IK#86ZK$.Z2GK89%TYC8]#+D)
MA_W#9J8 4V 0SY.>BJ6M)EC$8C%X]7Q>5P[I?E2(KJD;.>+;C-$V"]-G:-*
M7G3R?3KF@YH.3M6T9HT"YMF#4WJADD_&8HT8#1H'H&P!@# & , 8 P!@# &
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MX\BFJ.=IA'V)=;UU[2]G46,*^MGM;:<:>6I*P[)T:JTEC;YH8$YFA#*UO8@
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M@KO&I#(9-E"-0- G5IVJ7#+4.B06FX>RM$J0-O%3?R5UI_1_#?XN-N 2!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!K \R7^[PN+
M_I_RW_YM*,P#9_@# & , U@>-+_G%Y+/_4_OW_1;0> ;/\ 8 P!@# & , 8
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M_0(V.*R%$18Q*)$J-)$O/;D_U:='ZG:#H8@ ;6:F_DKK3^C^&_Q<;< D# &
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MAMUULY$URXK>@ 3 :=K2M+M?4$E>TWV >@; & , 8 P!@# & , 8 P!@# &
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M1TS))!-FM12+E/5,OCK/:MXQDJ:H9#6SG"XHECQ<)M&+LD"51]X7 6KU*!$
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M1_#?XN-N 2!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MN/Z@%\?CC^NW]Y_JR=;?@7^JE_6K_+'\0?DJY?#_ %M/ZO'_ -!?DW]5]/\
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M$)0C4X62;14LT:<&C2U 1# 8!NOP!@# & , 8 P!@# & , 8 P!@# & , 8
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MJU;6]Y73)VIEP5K#XZ[EK!G1]O$=6C7[2"PC"'0#->O[YOT _P!*S & , 8
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M&+3TB ;Z]N4E>3M'N*I:O4*'-^>%2L\PXTPPP\\8M[WO> 21@# & 4 \5?\
MNX^,/Z (%_DL. 7_ , 8 P!@# & , 8 P!@'EK\J=M6W4G=DCCW)+C,EUH]0
M\_5SSU>+<IY+I+H.-I2T-<]OW12<!K9XM7H.C%/YC6['*PG)2AH6MTLAH?MR
M$YQ"G//*1N &^?@\FL$W#O&:>DGB52&F".4N=R:B?YT6G*F[Y6!50P\$!>)B
M4DUI(5*G.*!2'. 2OWL*L9F@_H], M;@'G[YQYWH[F7HSS1-LZBDNNRH?RNY
M)NJTQ7^YN]]/5O.K)6MY3.6+7Y798GQ!(U2?;"E*1MQ)138V!3)2$J9.644
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M3^SZ("D25/!$O/,[:Y<C=QF +6#43J);)+.-WHM1[= - W!X P!@# & , 8
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MZG9'6-59MA+@K"%GW6D<?52Y\C]?_;]%_9D2P\Y6D;OA*.&,P(A; FS & ,
M8!I1\]D-E,G\>'3CE'^3N?.BT,6Y0ZZ=Y#/[HG3=$I?S<VET>^GCM"E&M;1M
MM'2^>("49JTE$0Z1 P2IJ2@^X@V;HY,!MNJ;^2NM/Z/X;_%QMP"0, 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# -8'F2_W>%Q?]/\
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M^O*;,EA,!/M.^W.,P-T(Y[@K7/3#&1>OF?V0MN=4BM.J^$Q$KT0!5;]H)C,
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MUL9DR,A28<)T7%)=ZT<+V8!8>GK;9[IA^IHR1*U(4C^Z+FG;)<-63FGY@$Y
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M/D_E6M?#Y>[>NT]AKHHK7G[BF_O_  L\Y_\ VF5[M2VMN,E_\R4)?^Z\Y_\
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MS_\ F'1?]I2=?Q9@N<Z^GW](\@_YBV?YG6.E?47^C^.?\M:O\]M%E,Z*<U&
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M)H).6N/P(F?WOTA;1<RY:A3 O6E;;8'#^OYS%6>.O+BV)-%)F=:8JT(E2E.
MX_F5\</'E2<-=3V/47BOHVY)]_56Z7>);T(0GIF'SVC5T1I%[4LEX.3C,OH)
M1.Y$QJ"!NH0LNC73:AL]0!^4TK6P/1I4W\E=:?T?PW^+C;@$@8 P!@# & ,
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MV\=. ;/\ 8 P"H'D)_U!>X?[('2W^AB:X!G_ ";_ *K'-']G^FO]'4<P"P&
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M_>PR"20M[B=E+W2#N+D6O <*'*@1Y&G$WA]I&DY6PZU[C#1#U3Q_P[@[/ _
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M1X_1\$AQ>(0O\<Y>VY0DVI7O6X_NE)9?S?=TQ\$C+>:;&YO;OFL^2S.=//\
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M P!@# & , 8 P!@# & , 8 P!@# & , U@7S_O</&]_9 \GO\=O'3@&S_ &
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M-;6(NKMSFD3."I/(TW2!=4\]L^NU*P9103M":G]S3_&:'6S=&:&  &:8 P"
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M&33G&F2IKAW8S\TG5)-9_D9ZIIE-KA[*C#T]R37VJ+[4L_EQ_ 6DS6BV& ,
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M;?Q9^\D@8!6ODO\ D9#_ $L]&_\ F*M7.=?2O^IZ_P!J\M_O;=.D_5G^N?\
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M3(DJI02E7N453B5HT8=N  C&:G VLU-_)76G]'\-_BXVX!(& , 8 P!@# &
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M&";:A%MM13?5J*Z9?5XR^I7CG/\ ^8=%_P!I2=?Q9@N:!]/OZ1Y!_P Q;/\
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M7^2KE[?ZVGX2_P"2_P F_?[/J?N_^)?;_N/N_4^3 -S53?R5UI_1_#?XN-N
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M,X?R/YL8EZ-9SG#;T.1UGLU7QOJ[\*2JE4NB65B;;?KZKI\/5,M]FF&7& ,
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M1^1?)"*269=TY66/HJD53\OE*FG*K42=T6&.+G(SZ]B)S\XN!I^E)JY>[F-
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M]*G?["12B9.4DF4HYMB+*2\QES:X>1#(V0VL*1>U)!QMU:W@\U46B+.4@=0
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MK-3)'--$U*+3BI(.$V'%[^G, ] U3?R5UI_1_#?XN-N 2!@# & , 8 P!@#
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MJ<(UQV1%7FVHO/*=HJ])H5N<S>(NLFL[47+<%<C=7^%R"/O9HW0]W5?4DA4
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M OZ]<+_M;3_UBL[ZK?Y,:Y_Z"1#^+[?E]XS_ %;X_P#\#1_-0+'RG^L_(_\
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M>-?KN=ZD4.B<I)4/#0VP9.U+9&UD.R^+R$Q02_Z9'R-EG;3JRC_:8%:6(D0
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MN[^[=G<U:^1:3]J5M<;,2RHOL<E+$FGAXP\/!(99@#0 -*& PLP 3"S"Q:&
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MS[F/OJW^X1_>Q?X3':.YC[ZM_N$?WL7^$QVCN8^^K?[A'][%_A,=H[F<)Q6
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M1\-X;>JVH0A[4]W$;FG*2E5*R,]BJ$7+LJ6THM7NI1=DI>Y/NLBFI_R^-L&
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M^:M7_P Y$"_SPCW\(XR@/S5J_P#G(@7^>$>_A'&4!^:M7_SD0+_/"/?PCC*
M_-6K_P"<B!?YX1[^$<90'YJU?_.1 O\ /"/?PCC* _-6K_YR(%_GA'OX1QE
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M^:M7_P Y$"_SPCW\(XR@/S5J_P#G(@7^>$>_A'&4!^:M7_SD0+_/"/?PCC*
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MQ]Y]-7[5PI(",A?%XC3)#J'@?M1J2[A8YAL_Z;44!-M-/X5$_;/U\?P:5_\
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MMV]8TUW FIQ3&(W!MA<60+TANM:-2K4;&A3*DYNM;WK1A)Y8@B_3O].L S3
M& , 8 P!@# & , TY]W\#]+WU.^DUG.=DT=!H+W5Q<Q\1]0AM2,R]TE$3C,8
MD5RA8K<J<,4,*12N9$UUTC,F@;0[J6I%M4!I5;6" E-2F@17Y!/#7P<_\2]H
M.U6\&TE->G%/)5_AJN6M51QMZN:17.EI65(ZY=F9W1M07=RL99+TZ$:,XG6E
M!CCL&P:T+>M8!.L"\*7BF_ T+_$'CEY,^_?A..?>_N-'PS[A]W^SH_N7UWRM
M?R?6?6>_Y?=^M[_7U_3@$>Q;P"^,EBOZX[9=N1.7I)7MC5[241A=)*^?XB3'
M:ID59.=P+9S.61S&L6)5[E;R6Q&9.O*+;4(TX(LFV,Y7\H0I@(2\COA2X"_J
M2=!?U:?'+SY^>?X4;/R[_+&CXS^//N_XLCWU7X<^TM?W'ZS[1]3[_B_6^'W_
M /!ZX!=O_8I>(_\ ^W+R!_V'PG^"\ A*O_ +XR8E;M^V%(>1.7IO#K9=JY7U
M[5[CS_$4K-222'0%OB<E;(ZN-6.9#F3/) C,>U(BD3;HI0>( @GBU\P@(1\A
M?A2X"_JSC_JY^.7GS\T/ZP?%_M_+:CXU^*ORZ_KFT#^=OI]J:_K/PW^2?XA^
M^?\ Y+[']7\O[U[\ NW_ +%+Q'__ &Y>0/\ L/A/\%X!"-0> 7QDUY).@'F9
M<B<O6DV6U=QUFUXP/7/\10I:1@IE4U3 @5!'#3UCX!S82I; G:2Z4%%-A?UD
ME4%_2:$6)0H A+M_PI<!?:.8?R*\<O/GUG]=OF'\T_P%1\9^;\C/QS_^E/\
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M %@[D_K)?A:CXU^%?RZ_J9=(_@O\S/HVOZ/\-_G9^&?H?J_WK[Y]%[/WWX\
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M3*B664/I[A6B51T%<ER0Z6PPJO872VC26U(XN:E8%,JE)AC4V.;T%$2 "\=
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M**@+#9LXL Z9.$O?[)98XVD3!:^2&=$%ODN7'.A@A#=M&JTZ\0MF%J#M;]V
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M-:UH. 0;Y.'2K8S3-?3&[.@>B::K2,W%'CE]><IRVPH1>_6$K=H]*6.ON:(
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M=)6L]Q&36C3M5V3)( X$NT#D$^KV)3%[A+JG7(G1.YQ%VD30XKXVX$.;:G4
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M:M7PBPU#"G<AIC7$AE.ES&[F-9+@8C)$>$C9831% V+6]A#Z <5)S)S:WR2
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M'F]_:98=/*X\=5^]OTYU!V'0ERT1&Z4C,,;:$Z?MRG:S7DS?IJM86_.\OKV
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M(+/Y>JO4'HWJ?A^FNB+@JVUK)' (;3?=#7/%$3NYG:K-IN&2@QOJU\AJ=L>
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M:7E?'7 A(I,+"2H.0* %B$(DS00.VP!@# & , 8 P!@# & , 8 P!@# & ,
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M'&@;?< 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#JV-C98RRM$;C;0UQ^.Q]K
M;V-@8&-O2-+*R,K2D*0-;0T-: I.A;6MM0IRR4Z<DL!1)0 @ '0=:UH#M, 8
M!U;DQLKRU.S$\,[6ZLC^C7MSZS.3>D7-3TWNJ8Q&YH79O5$FI'%&XI#1%'E'
M & XL6PCUL.]ZP#[-C8VLC:WLS,WH6AG:$*1L:6EL2)T#:V-J!.6D0M[>A2%
ME)42%$E* 6446 )998=!#K6M:U@'.P")X_0M&Q*R9/<L5IBIXS<$V3GI)E:T
M?KJ(,UDRU*I^T?4II/.6YG32A^3J/L"#W@5*C0C^B3^NM_"7[0)8P#H9'%HQ
M,6].TRZ.,,I:DC]%I2D;)&T-[XWI9/!I.T3:$R-.B<TZI,2_0Z9QY [M2P(=
M*&]T0IU1 RSR2S @<@3 Q"?2I0)E:128AI/8"9$)N1[?26)4L3N*EE*=]D_<
M"VE0X(RCS$VC-$C.* /8=B"'>@.VP!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#JW=C99 D*0/[0
MUO:%.Z,;X0B=V](Y)"7J,O3?)(V[E)UI1Q);I'Y$TI5Z%1K6C4BU,4>4(!I8
M!: [3 & ?,XDI04:0>46>0>6,DXDX 3"CBC [ 84:6/0@&%F %O0@[UO6];]
M-X!TKU%HQ)%4<6R*.,+\MA[\&4Q)6]-#>Z*HM)PM#O'PR..*%R<\UD?@L$@7
MH=+$VRE&D:Y03[_C.,"(#OL Z]V:6I_:G-B?6QO>F1Z;UK2\LSLB3.+4[-3B
MF,1N#8YMZPLY(O;UZ0X91Q)H!EFECV$6MAWO6 8/5E.5#1D6U!J2JNMZ=A6G
M!2[:A]60>,5]%M.JTI.2L<]1^)-;0TZ<%9*,H!IWP_(8$H&A;WH(?0"2, Z$
MR+1@V3I)L;'&$V9H&%PBR&7&-#>.3HHP[N#8[.L<2/XD^W5,PN;JR(E2A& T
M*<Y0D),&#8R@;"!R&=@8H\4M3L#*TL9#D[.K^XDL[<C;2E[Z^+3G)[>EI:(D
MD"IV>'%08H5*1Z$<H/&(9@A"WO>P.VP!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# -3'>'FX\=WC8M
MZ.49UO;$H@ECRNMVBV&1H9*JL:<I5,(?9/,(>VN1CM$(Z[MJ=0<_01R*VG&8
M$\ 20C$'0# ;$!:+AWO+FGR*TPJO_E.8.TWK!'-GRO5#R\Q"30I8&4QQ R.;
MLBTSRQL:701)".0I1!.T5\0]CWH(M["+T N+@&FA]\^_B\C5'6MT,\WR\(ZV
MI;H=-RS/SQ5;9(Y WW,M:7Y]0Q]!%P1D3V\MZUJBKH<4X)2348@MRC]\_>_T
M@9XW>9GB]\N*:TC&TW3$KD]=7Q*N;9S)8ER+T=)ZKBML0>9#@LP9WVVF.N%U
M>-;7&GP'N6N)SB!"F1;TJ,-"GWHS ,/J#SQ^-FZC2B(U:-D1TUVJ.S+Q@PK+
MY]O&LT5KUM3D6=)K9CW43S-8&SL=E*(E%V=0L4)&E2I5C)+%LHLSV#]H$\!\
MJ_#?YB\150?</T,\\AM7L=Q<N,CA%)6AW+X'*HJGET2<G]8I:"T,(62U"H^F
M;4;J8E5*W$ D@"]GZ]FP/FG\K?#BIQOQD36VH/D',G2]:<E71'BX;+A/D2N6
MX)\AK&N$&V[[-H]SB\HFZP:$AZ2Z.; C2*1#." @8M 6C!T?4(;IL7G]?)_L
MEFU=4<1O:4M3\@6LS=^4TS>9K'4$V9GU>22T/C.U/M?N25U&F.,VU'!)TJT7
MI21LP#!DO:_.:SF-XZY*G(@4XP<XJ.LG@U0SNJ>=-U"EP5=926<KJS.2@GB$
MEUA;>8L1I3D!:M1^@L)?R_J: EERN:!-\D@<9)7N#X;83I-F9I?(NRNLHAS,
MX5\QKGZ3D3>9,25?&H+]*F;C2"MNRE)I0N#]*7[C]Z+P#%R>G:.4VLFIM)/F
M=9,%5/O][%J$9NE42#6<7F;5 'Y]/FI&QQ<@QNE#R008G&JT>$.Q#V'V %O0
M'97/T+4M!4Z]WS9$H$FK)E#%P:>8RSO4[7O[C.I,QPF",,/CT*;WY_F$BG,S
MD[:TM"%M3*5"]>N(**"(0]8!PJ,Z3J/H>N5%H5V^.A$=:Y9)8!*&Z>1:35C,
M8-/H<^F1J3PB=PBP6F.2J(2AH>@!*$E7)"1'%G$G$;-(/(-, D]NF\+=U"1(
MTR^+N:M>SCD*%*W/[2M4+& M4:B&^)"$RLTQ0S@6$#)VI!K9.C0"![O=K>L
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MHU+T$X;,G!(6@1[L!.ZIV)0)L*"LV8O"0^*RD8]E:'H*LT!._0P6@[ I=?\
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M_"WV_%G2"QF5.;%&63M;F3QZ4ITM8UBDMJ%041NSJ\LCJ](U_<M>\Y*ICY0
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M8_.<@=8W/B9Y7<35#=@H&J-BB<@-3-NOO)9PEI(&TW & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & ='()-&XFW_=I5(&.,M7SEION<@=D#,W
M_4G:%LE/]8XJ$R;YS= %[0>[W"]-^FOT93.<*UW3:C'[6\%OL[>KI5>]N6UU
M4YQW3DHQR_19DTLO[#N2S &@ :4,!A9@ F%F%BT,!@!ZT( P##O81 $'?KK>
MOT;UE1[IIK*ZIG[P21:9>5*$QYVEQUP5:5%&!^%%7V3F6!$P1YEDX=%B%''9
MZ$[Z;6Y^"$X&]HSC0*-:'K]3].L ZT[HOGQ/)388?>U-D3 A\'&#HH=9\)+D
MI,E+7[:C(\:Q#? NA;X6Z!VF$DV5I1I1KX]@]_Z, YT8O>CYL![,AMRU3+01
MII4/\C'&+$B#\!@8DFMB5/3V)J>%>FII3:UO9BD_XR0:U^D6L R0FQ:^4*X6
MWIYW#3U]D-JAYKM$3)V0U7/6=&UE/:MUA:8"X1TI;4K*>!88>A">4!*,)NQ:
M+WH6 ?G=D5WI*Z+=SV%Z1L<L)@3TKW*6/25GG*A0WI"(6Z*/KOB;Y8>K=DA0
M&XW8%@C%)0=%[V8#6P.5()U"(DXQQHE4QBL9=IBY:9HBUR"0M#,XRIXV8F*T
MU1Q$Y+$RE\<MFK"0_ E":;[C0:]OJ(/J!]&V:PUYD4@B#/+8RZRR)!;QRJ+M
MK\U+I%&0.Q&E34*0,J54:Y,P7-+OY$^U)1>CB_U@>NOTX!DV , QN,S*(31.
MX*X=*HW+$C2Z',;JJC+XV/R=L>DZ5&M4,[@>UJE1:)T(1N"<X:<S830E'ECV
M'01AWL#N'%Q;VAO7.SLN1M;6UHU+BY.3BI)1-[<WHB1J5BY<L4C*3I$:1.4(
MPTTP00%@#L0MZUK>\ C^$733EF."MIKBV:SL!T0(]N*YMA$\BTK<$3?HXI-M
M<K1L+JO4)D>E!X"_E&$(/>,(?7UWK6 29@# .*N7(FQ$L<G)8E;VYO2J%R]>
MN4%)$2%$D*&H5+%BI0,LA,E3$%B&88,00  '>][UK6 =;&Y/&IDR-\FB$A8Y
M7&W8LPYKD$;=D#ZR.11)YJ4TUO=FM0J0+"RE) RQ"+,%H)@!!W^G6]8!QY/,
MHA"$);I-)5&XBV'&*R27&3OC8P(336]G=)$O*+5NJI(G,,11]C6KC@Z%O9:-
M&><+T+*,$$#), CMNMZIGA=+&MHM"NW1R@2=:KG3<W36-+ET+2M@SBW)3+$B
M9S-41Q.WF)S GC6!)"5LL6A;UL._0#Z0:V:KL_[C^6MEU_8?V?Z;[M^!IE')
M;]K^L^;Z/[C]@<G#Z'ZKZ<SX_E]OO^,7M]?;OT D# & =2:_L1#VCC)STTDR
M1Q;5[RWQ\UQ1EO:YG:U"%(YNJ-J&=I>J;6Y6Z)BCSP%B*),4%!&+6S :V!^F
MQ\97H3F!F>&MV&RNBAC>0-C@D7B:7I(4G/5,[F%*<;M Z)B%90S$YOL-  T&
M]AUH6O4#K]S*(:9VB1;E4;U'Y L9FYA?=OC9]G>W"1KD[7'D+0Y_5?1.2Q]<
MU92=&42,8U1YH"RM"&+6M@=HM=FIN4M*-P<V] K?W QI8DJU:F2J7IU):G-]
M.;&D@\P!KBX%,C*L6"))T,P*5(<;O7QE#$$#L, Q>)S>%SU"L=(-+XO,VUN=
M%3&X.,3?VF1(4+T@ 08N9UBMG5K$Z9T1EJ2Q&IQB":7HP.Q!UH6O4#*, Z]V
M=FI@:G-]?7-O961E;UKL\O+LM3-S4TM3<F,6.#FYN"PPE(@;T"0D9IQQHP%E
M%@V(6]!UO> ?EH>6>0-R5X875M>VA:$8T;HT+DKDW*P%FF$&"2KD1IR90$L\
MH0!; +>M##O6_P!.MX!ULLF40@3(IDTZE4;A<;1F)B5D@ECXV1QD2FK#P)4A
M2EV>%2- 08J4FA++"(S6QF"T$/KO>M8!CZ&WJF<V)KE#;:%=N$9?#'LEED2&
M:QI6Q/!L9;71YD936[D.9C>X&1]G8UJM<$HP>TB9&>:;[0%&""!](-;-5V?]
MQ_+6RZ_L/[/]-]V_ TRCDM^U_6?-]']Q^P.3A]#]5].9\?R^WW_&+V^OMWZ
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M)L>I7&8?*:X@*Y:Z06N;)@\7?V:'6Q7L,<W-4H:F.3H7=J;CU9XTY!8CC=C
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MVO;+#V)Y<*IL^OTU('SJCJIY8J*77;%*$D'.KC(JY:X%);P@UA,D=0Q9N;Y
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MEP:]=XL>8ZGNQ-BGQE%,FVN$Y")L4Z<;&D,6<"US2P)MG.[NG]XD2=1\1N@
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M6#'9!7L05V9"G>O(U&ZT.:H/,7!8_P"D,CE?WR1DIE9>T96AE8!M<P!@# &
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M.$*D7.E1R*M;5L&S*-L:V;!(L%Z+1QV90V(OZ^OPI31L2](-L3*S#D^M"*"
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MK6]/"A*7I;JI)6TJK"I&A0P0"$6;6*:[2J]MQA9616<D,*E+8\?<"#S0+-J
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M,H(#2!", A=![#K1@-[W_P#BU^[FM'B>3J0SFP>AGJ9]+VFB<&Z;L7AE\M7
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MP)[_ .!H\H"\$-8>A$])FL_)*V]F:)I32QRY)1BODI38[J]D-^@1L+P)]4*
M@= +O8!)]A0YFK>2=XQ"4RB82BA%WDV\?A?1CQ<,\D$\3E4G+J:YA7R9FFS_
M "]S7"34PJF+BUH'YO4"U'R(LI6D+2P-8E>] 0=T:KLUWY,\EU4\YTY-I/XY
MOQ%UI(H587.LLH>-P!%7\4XXI#[Y4,'122X*R=BZ14=DG6<YRM3$D3L0<C8E
M,>3)E13JL+2@7I[Y>FA?S1XQ'RP'"IZ3:E?4=)JG]7UA'XC.JMA.SN4.B-!2
MVBPM-M12&O9>E0@$%:3RXE,%>80,"@WVZ+, HFSD-29>^#BLAI2P80^>5ICD
M\;M/EF/IH3RY+#%7BDM*.N[15L$;Y;8;4P22)*HJ$J6'I)+(2G![4#-&K(4:
M/:VX":.3G;E.55SX;D?'CE0[UU/'(Y0ZB[%U &P%TF,5HLGE9Z)Z"1='.%>A
M5N;)"'U_);$1:61[ 6KL'['LL'UZ8LY.!(W5'5EJP3IKMUGBO7SE$9_1#3QF
MY\N<C%HJBVW7;,[8&:C>H.X-DGAKI8L^0V^^A3QSV,CDA41L:T:\)Q)XD9Z8
M#.N0NJ+9L:W>4MK^A7"R[!O?^LZ9UKRVO1UF6FY125D:]C:BD+)&H@P6+ 5E
M.6:4SUR<)^7*Q2;[WM:I >J+)4D ;RL 8 P!@# & , 8 P!@# & , 8 P!@#
M & , PJP['@M3Q-RG5D2EHAL1:!) .+\^*=)4*8Q>K)0(B=C]!#,.5+% "P
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M=W&6+78^'LR5*3HUU,VK]2 ):\C/E#WPO8/,$"8XMS%(2.E(3?\ .4=B=/\
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M//1G:/;'I$V/;.Y-Z]*<E6(5R9,M1*R3"%!19Q8P! E+ & , 8 P!@# & ,
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MK>MZWZ;P#YI$B5 E3(4*9.B0HDY*1&C2$EIDJ1*F+"2G3)DY(0$D)R"0:
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M3C##VGS1=7-CA7Z^UG^YE'W*M*.8[C&HA;"SLT;0)DS:4F7@7&[+6D =]/\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M;$/VQO1M_P!8N</I""R/K7-1]6X*O9KT^98I]A?S'C_=$+VZ]=Y22<[ & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
*# & , 8 P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>tm2115679d1-lc_kras4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_kras4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!N@.2 P$1  (1 0,1 ?_$ /\  0 " @(# 0$
M       '" 8)!0H" P0!"P$!  (#  ,!              $" P0%!@<("1
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P#'ZS^YSG^$%L_E5,X!D& , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@%<;'QFJ-ZMDS8-D6[86R*[(QUPC(S5UMEH%37%
M61OM;DJ=:U8.-AJS#6!RXDJG-OXX@RDG(E:-'ZY&Y4N\$0$4,19\-*$RB%")
M7W;:M[1L54LD%N%W9(![LNJN*+6K#2J?&P#EU4U:BG#0=-N$Q&=PYAW7C4)=
MX=X+EPX46$2<H/$'5Z1J6A&2U[A82K0%(K4]6HZPMCQ&TXK7-A?6ZG%V>K)1
M,A-3KR,M<L^D%W+1XP<2:[]P5\=TBH*0"*%@JDV;M(EPBU01;(A8[DH"2"9$
MDP47M\XNN<")@4H'674,<P].IC&$1](X)(6WOKS:.RY2B0-?<THVIVTJC-[0
MK\S*V"#LEQ7A):(DZS7D)2+@IYF%+%PV67EV1DD5I04T&PN$FIG:;@,2K+O@
MQ;Y2;V,^E[3".64S);6L=0".L-M8/6MNNG*"C\E]?V.-:2\=9ZSJ-[K2:HK8
MCU*!CW;&ZR7=2,XV<*-DDLDBAEM$XM;BIE>T_KJ5O%=O^NJYL>[[OVO\X)F;
MC[7=MKW+>%@W?%E(^:U=ZS=437UGL0O64>D6(4D)%@Q[U1!BDNQ=!0V$9!(P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@&/UG]SG/\(+9_*J9P#"M[6F9HVD-R7:N.$VEAI^J
MMAVF!=+-T7:3:9K]1EY:+<*M7!%&[E-%\T(8R:A3$. =# ("(8(>"/Y]?_YA
M?S4O^.E4_P#N5U%_L=E:D59VA/(1YT<D>=>D-]7/DG<(NY6*A[AC:C6WL74J
MS42-8)U1("=5:K-*O&1;1VIZR?*G!50AE  W9Z]   LMA*Q-\N"1@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# ,?K/[G.?X06S^54S@$4<I?Q9.1?\Q&W?P?V'!#V,_DMY0J=
MWK^RI?BS\J_ZP\)^"RJ9=;"R.U#@D8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8!C]9_<YS_""V?RJF< BCE+^+)R+_F(V[^#^PX(>QG\
MEO*%3N]?V5+\6?E7_6'A/P653+K861VH<$C & , 8 P!@# & , 8!Z'2BZ35
MRJU;@[=)H+*-FIEBMRN5R)F,BW,X,10J +* !1.)3 7KUZ#TP#^<_P +]<ZS
MY^\IM[RG/;:?J_<DS-I2ZR.T-H$U'#HL4!MZFSI%>;FFKMYZRU<G#1#&(J[=
M1N1%BZ75, -(M4@>2:F=W368+213AV5[/;ZSQ+1V[.KU$WKI-3VXNG;MZNA>
M\7%\D;8EAT=SHY0T'0]YM%YXJ%LS:EP+]\)G$)>#2G).CT;4EL6:$9L8U*_6
M;5)IQVF9%L@J>.2?J@D5-KU1U^)4EIH3N)*]5>3%=E3:X16.LN6[3;T]'Y?-
M?;3W2TNS_P"S95]O:KS:4]HV5*DEE9VRKV68O%1ARL($ZSB7?2,FS/K5T#,D
M8T,<ROZJ<O93$0-T',4>*W:**@J^R9Y<$LU<G<:6W8C41Y56G6=LYW6"VZBF
M+@ZU?K!S>:M1;4Z1-!W&?6W8A9-&ZF27]6!W4);',1;W5G=H$$")L:_($*?J
M0IAW.(7<FDRSIO)T5/&S0X59SZ[/;;W<*NOMI>_[#,\>4C6W)0WG ;PY*R(3
MV^-=WBQO:A+V:?LL5-4CP*^X$Z^SK\(WG8V+=M']MJ%>JI6SYF_;Q+$R+-%-
MLHZ0.)RN67I[=E?FI+'VE\+\)"A:OK4WM0_ST=F-.E]'M+P&R>C^9QNWCUY3
M?%/5U1?3]ZY=\FZ$^UQQ^C@*XE;K7(YCO'<6IV=N1CC ,BH5E2H"LL*J*G:)
M(RS@RR0+),W90U9:2-S77)RHM/!IOMHG3WS=CK9VN'6H1J]5--+KI5I/W$7_
M /)IX#I:6JS*]3$@I+.F$XZL5JN+=VX7^E_=ZD6_A9B;8S13_P#J#5&IF<[)
MP=?5[:R,S*.I28[0$=H(-]'6:EZB[5?HU@E_;K.CH-(M+9QQNRQD_#[R^'I.
MPEFH;PP!@# & , 8!I@WUR.K&C_.$TZRV[OB!U!IB2X%W9ZX:;'VA'T#6#^]
MJ;G\/%.UD+/.1-5=6U2):+)MU# 9X+=(Y2#V"F -ZW:=S12R1<I[Q;%5TIY#
MFW;T;7$([R:C;W3VNBK7PX5,#\R7G#HFZ5'BA6N-7+_4MLO$KSTXNLIV T;R
M IT]:Y*B/+-*,[(TEHJ@VUU+O*DZ,X;I/DUDS,SB=,JH#VB@-M+I[D93=V$E
M'=RVI[?96TKK-5:E&W&S<BY;V/HR5:5\#V%QKYSWL)=P;2TWQSXG[IY32VAG
M,+'[ML](G]542FTZ<G81M9&U0@IG:%VJQM@79G!NDUGD;%)*F:F522.?O3B4
MF".G613NSC!2V5JV_#@L$;$]5+>2MV;<KCAZ35$ETTQ:J_ CY8OS.=(3FO>)
MFUXVI;-3U_RPW<?CM&S$U"14$\U-MT9.;KS2H[4B7LUXB,=.[36WT>51B9\A
MWK?M@<4CIG-+TEQ2G!M9H1S=JZT%K;3A;N)2R7)9>Q]3]DL!LCE;K[6?('67
M'B792KNR7S6FUMR66QM5HEO5]2ZMU0TC_'W?8KN0D&CIA"6"<DB1C!1NDX#Q
M2:@K=TF3MCBC9E.V[JV)I=K?0C+._"%Z-E^DXMM]"2Z7Y"H[CS264=6&F]IO
MB5R4A>%T@M'F9\KWK&@&B"5R5D&L?';.DM--[HMNV*U$]*Z(\3FE87OACSIN
M!: 4XE+G]4J]VIPW_P 7'VJTI7P5-?UZD=Z[<UIOC8>W2N:GAH;3VKIJ^:MG
MS%RW>,GC=%TS>-5DW#5TU<)E6;N6SA$QTEVZZ1P,0Y1$IBB @(@.:9O[<5L.
ML?RDY+[N;\W-B<W*=L.[17$'R\N0/'[BKM>FQ4Y+I:_N\9L EDAN3UQFZRS7
M]7S-GU+.[-KS)$KA!80,FBL44C(D.'5LVK>X5B26^NQE)/I5/17LT9Q;]^[Z
MR]3%OU>S.,6NAUKF=.M51M$Y[W"RP.Y/+/;5BTSD+&7#FO#PED;P,V_CF%IK
MRVH]F/\ U1.)1[I%O-PJKIJBOX=<%4#*)D/V>I2B&KIHIPNU6*M^ZC=U<I1N
M6<K:3NX^'!D(\/><VYKIR8Y\0&]M9[1HNF]/7!E,M[/?'VI&]3XYU*NZ?AK/
M,URWNJQ:'DT^6M(%<3J#A LH@@U6[*ZZ!BBB6]_3PC:MNVTYR717SG7H\ABT
M^JN2O75=4E;B]KI2*I7&CZ=O22@;S0VD1 0&Z;YQ,Y'ZZX>6MW!)PO*JSM]=
M!7V4):'[2/K>PKIJN.N[[;]'U?.JOD%6\P^B"CX9RW54;IE5^#3U2K=N,XN^
MOP<?:3I1OP5,GKM$KL[<UIW^%AT]+5:I>&AFEU\Q2+B.4.P.(>N..^[]S;>U
MX34TM-*4IG5F]':TO9<4$W(767N,U/LF$!%4U@J@FJ@Z(5Y)NW*:+%)<"K*(
MQ'3-VE>E*,8.NW;5=%/"6EK$K[T\(2E<5-E*4?37HIX^@YC8/.R::['V!KGC
MOQ8W9RM5TM*H0>[K7K64UA5:A1[$>/9S+RC0,MLR[U,^R=D0T._07?0T,FN+
M0SA%%58JYCI)1'3IQ4KDXPS;*UJ_#@L%X63/5-3<+-N5S+Z35$EX,6JOP(^6
M=\RK2(Z-TUM_6E9V5MZS<AK9+:YT[HJK5]I&;@G=F5HDS\]Z99H.S2<3'453
M6R]?>!8WL@Z*RC4T>]*HNFJW%8M+<WDH3:BHJK?13H?AKT!ZVUNHW(*4G-T4
M5MJMJQV4Z2H%<Y9;.VSYJW%O4MVU3NSC/8JOQ^Y&S>PM.7FR5^8J5I:S)J8-
M NT).ZYM-BU_L%@@K"RK9-R0YEXUZ@X0$I#=1-G=F$-'.<7&:<HT:V]-5CBC
M65^=S7V[<HR@U"54W@]E'@VG[A.7G?W*WZ_\KWD[;J%:[)2;9$?0MZJL]1G)
M2MV&,\?R&U-&/O5\U#.F4DR\;&O5FZO=JE[Q!4Z9NI3& <>@C&6KA&236.WY
M+,O$Y2AH9R@VI88K#\)$9[FY&V_S!]XWC@APQVB:CZZU:K$'YJ<IZ586Z%JK
M$6^D7J*&E="*,W7BW-[M+B#>,Y2Q%*>-A44'"(&6<@*![0M+36UJ+ZK)^C%[
M.U^#P=)2Y>EJ[KTNFE2$?3DMJ_NQ\+Z7L1@7,?6M;4YV>6KQ;D=G;BH^B)'3
M?)I&Q,JYR VE0I:Q.:)5JQ(560ME\B+E&6:QS*4HEWAW;]ZNY<J+*=LYA5/V
MKV)/U>[=2B[F:/0GMVX4*:B$?6K-ARDK667X36Q*E76IC?(NDUWAAMWA1,\/
MN26\;'LS;7+/6&IKCQ_MG)B_;YK>U],60)H^RIF1I-^MEM5@C4.,:D<DLJ7<
M-H8JQ^]'M+)B$VI._"XK\8J$8-IJ*5'T8I=/41>C'37+3T\Y.<KB3BY.2:Z<
M&WLZ^@MIYJMXO4M2= \/]/7&S43;O-?>]5UDRN%*D743<*-J2E.&VPMX[!@7
M[)9NZ25K-0B$D5BIG(8Z$@<.T4.HYAT<8J4KTTG"W%NCV-O!+VS8UTI.,-/;
M;5R[)*JVI+&3]HY#RT]Z;*O/!U[ 7,KZ[\E>)\OM/C1M*(E91T[EK'M713AY
M%0*<E.2)COI%[<JT$,Y7D%C*'6<O%3F44,!CC&JMPCJ*QPM3I)=C][$:*[.6
MEI+&];K%^%Q]]4-5_"B"XA<W=:QU]Y1<_MTH\ZK1)3ZU]JG]*BS\=[?I*V(V
M*3C&].U-IWUO78B+BJN@T;D(*<=*(F=&$ZG8%4$";=]WM//+:MQ]76SS<R?A
M;-'3+3ZF"G?NR]:=:K,XN+ZDO![)MRT!-<N^+O$?9"W)N&N?*W8>G]A6N&U:
MXU86,MFW]ZZ3";@66N[-+1Y58QHI?#,95T>0264\1X1@"JRBJYCJ'T[BLW;R
MW5(1DL:[$^GV#H6GJ+&GEOT[DXMTIBY1Z'VFQB.='?1[%\HT<L%'C-LZ.Q>$
M!-XR.X1(L9H[3*)BD<MS'["@ (@!@'-5[3;6*J:_HGFKMF4UL_W@VX@766TW
M%M;=.OIZM;7U=)7-2I4J0FF4U.QE"FI&LGD'22,$LN2/\>FZ6('82!182)FV
M78@I[O.L^'0Z5?A-1:FXX;W=O=8XIJM%X,"YU<O7SJG&Z<+#G=TF4H%6O5?O
MQ):(!G.?.=W+E3AT:T=R2V,3LXEBU>B[<M$FBQ7Q4DSF617(3 XT6/I5I0V5
M+,\/1HG7M\9S,#=*=:32Q*Q;*S8SP#HS"=+ SL7+FA7Q!5 [.6+'NG QKH@H
M'ZIK=@X=@WH] Y#C);4U4E2C*N5IT/6G>J0LZEV*-QJJKVOQ2<[/,T[#$'=0
MD(JAXI*9EVY7@JQL4JU_5"N%@(B9/X0&Z>G&66VCHQFCLJJH^V.M%:EX$EJB
M;%!2E74:.7Z=DCI9@]@3L68K%>/"3#9PK'F:-#-U 54!3L)B0W:$.R/0TTZ-
M8DJ46LR:R]9Z86X5*R0GSEKMIKD_7.JY?7\+-QDK"=IJ<4W1?6K%TNQZME $
MJ@=Y\ 0Z#T'#C).C3J%*,EFBTT1ZMNNM#NJC:6C"I34A==<;MV"%@BI-@\C(
M0VC[CHJFS]:DDFZBJY9I\]WJT4*7J7PY6"I5  QR9;=O=N;Z&E[:;]PIO8[Q
M6UBVI/\ %<53_P!(DI]9JY%Q4E.R=@A(Z$A3N4YB8?2K!I%1*C-7N'9)*0<+
MIM&)VJ_P% 5.02']!N@Y6C;HEB7<HI5;5$>;6Q5]]%,)YE.P[R#E447$9,M9
M-DXBI%NY3%9NNPD4ESLWB*Z11,0R9S%,4.H"(8HZTZ15-5JJ&/VB^PM>UQ9M
MF,E6]D@*]39VZHJ0CYHZ;S4;"0SN9$L9()'59*@]0:"5-4#&3ZF >O3)46Y*
M#P;=")32@YK%)5*>L>9.RHBJ4C:.T^+%MHVFKB>AB[V'!;-U[?5:7'[(?0L9
M6;':ZBP<Q%@)6$'U@:A)N&!'[B.1.9<[<R"2JB>;<1;<(33FJX4:K3J-?UB:
MBIS@U;=,:ITKLJNKK+K/+E4(^PQ]2?VNML;5+(F<159>3L6VL,FW)W@F7CX5
M9T22>(E[D_4R:9BAV1]/H',&6369)T-C-%/*VLW4?LK<*E!2T+ 3=IKD-.V1
M0Z-=A96;C(^6GEDC)D52A8YVZ1>2BB9UB 8J!%! 3  ^R&%%M52=$2Y132;2
M;(QV/O2 U"SO]DV1&KUV@T>.HCE"X%EX"0-8Y"YR\I#.(AA6FTE\X(]Q7W#5
MJ=15XBBB[3>"9L93P[CN[QMN=%'&3KAV&.=U6ZRGA!4QZZF=L;>J\M\K!'B4
M4*RA5:+/5^\!8ZXYC[5*V^4O3-]6XZ$;2*EA:+5Z/JK!X#UPW38R1)DB;-19
M1F]*C7+YM>FKP[*?V]@NI5E3\&BQPQK7WO9KATF8&<-RN$FAET2NET5W"+8R
MI <+-VIVZ3E=)$3=XHBW4>)%4, "4AE2 (@)B]:ECA(&W52TJ2J58L]>L:L$
M_4BIQ*!FHV74AI1$QRJQLJ2/<N#1S](R9@,BL!%"B4>H>C)<6MJ:(4HR]%IT
M,AR"1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@&/UG]SG/\(+9_*J9P"*.4OXLG(O\ F(V[^#^P
MX(>QG\EO*%3N]?V5+\6?E7_6'A/P653+K861VH<$C & , 8 P!@# & , 8!A
M^P[O"ZSH%YV19/$A7=?4^S7>>%DB+EX$+5(5[/2GA&X" KN? L%.[( AVC=
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MO# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MZ_!6F!=D?P=EAHR?A7R8&!-[$S#)"1CG9 , & CEFY(<.H=>AL$G,X P!@#
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M@_L."'L9_);RA4[O7]E2_%GY5_UAX3\%E4RZV%D=J'!(P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# (4WJOU@*-%)JKHNYS=>DT&AFDTSA'9O46S*W=)
M%)%5X4WK!!:%J[HKMDE^K.V(K)E$.HC@AGS: 4585>TT1PX<.7&KMCW*CD4>
MS;>>D0A#/$;?2RR+MN1(R#H*%;(L005*"R20D[7:Z@<PDG3 & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & ?!*RD=!Q<E-R[Q".B8=@\E)20='!-LQ
MCH]NH[>O'"@^A-!LV1,<YO:*41S+8L7M5?AIM/%SOW)J,8K;*4G1)>%MI(P:
MK4Z?1::YK-7.-O2VH2G.3P4813E*3?0DDV_ =:3:WF?\J]^;%G*SQ<,PUK1(
M@CY^VD';2F-YD]8CUD&JEIV#<]A'5J-)C%G;A'X0*L$&QW"38[E<YP%3[!X;
MW0=W?(W+\>,]XMR-[4T2FY3N1M1G*KW=FW9I<NM)-8YW*CFH12HOS^XQW_\
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M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"K'.
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MT*DS%AL%6KIYVYD;1$Q:P8!8'R+E*R$?K*201B':*JLH0O=AV +U'JR0I2F
MO=UO(.HX99X->X;:EPS3W)SMV\]VD9W,N=IJYF>;*MK:PPH'?E\<.'VNX?4[
MO1T$MKR M,K=8>LFG;F5JRM$Y'LHN5ETW1+(61.L\81R*9B'6,D4$P$I0$1$
M62%*4P$^ZWD&YPJWP.?#;3X5:O2NQMY[M%<G%1E*N\S5<8I4;IA@CZ'/ +B
M[UA&Z9<:3@U=91%Q>7^.J8SEQ!HUN#^++"O)LCLMC+*&77BR@B*9ES(@'I @
M&].3DC2E,"T^[#D.YP:'+\^'6WP>WJ'?C:SW:*[*.1SKO,U7'"E:>"I,.DM
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M^WP$7%<NPN7;&V,7&'NM=KP797I*\\&(FB(\K=-.N%M-Y;T[5S;3.Q&_.?\
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M^:D*\[NE.GZTC+Q2Z#5^T];QR[)0$'3AH^3:>)25,D94$CG2(H)B=#@40ZW
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MHZT2_LO9Z2]?%';?)C:7S]_I%:@T_JGU%\UOF?\ 11O5INKU]ZS^<?S@]?\
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M-8)F=XV$@-VP*-S$.=158J8CI)HP2, 8 P!@# & , 8 P!@# & , 8 P!@#
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MI?BS\J_ZP\)^"RJ9=;"R.U#@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M\9)WA)-5WKO7[PCD7"\;,5URHVMRQB$(Y:G;1)BB!'7:P"PF , 8 P!@# &
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M6*4\,>>MUD>@0TU;+(Y:-VJ+V>G'1.^<*@F0HF$"E*4A2E 29Q@# & ==3S
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M GMT;#XZ?1<]L-KF-O5K5NK30>S-<05^9.)RURM8L,G!SQUYSP,?&,XV86D
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M12G!1FG:FZ*5.GJ:Z&8I:UPMS<X-7K:3<:]#Z4^E>PBT&\N8M4U73>-UFIL
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MCQPUI0F6Z(*DVR]0FL=H:CL]G4/0[DC2H:P3%5B+O V9-\R>K-RM'3U Z7:
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M-VT;';R3E1GVEE$A54PSN*<+_G*6$$FE2M&MB,]NTX7-,LKCC-M-UI6+VO\
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M/#A@# & 9!4_]::U_""&_P#B+;-37_N-_P#4S_)9O<+_ (GIOU]O\M'?S#V
M_,#^YGY6'[AG[@# & , P#:>TJ#I/7MLVMM&QMJCKZC12DW:[*\;2#QM#Q22
MJ2*CQ9K%-'\BL0JJQ0[*2*A_3[&6A"5R2A!5DRDYPM0=R;I!;6=;GS++QQ;B
M=I[ZH=%\PW67'2W;HFN.>P^1&DMIZ9V3L"K2=WUA]%VTM2[)JMBIL.W?4V=G
M:C6J\E,M4C/VDLS*052MGA3JYU-+&\X1E*TY1CF46FDZ.J:QVXUIU''ULK"G
M.$+T82DXN46FU54::ILPI7K[38+Y7-XTON>T\C=V0G+V#YD<C;2GJJ)W);ZE
MKFQZJHNN*+%HWDNI-<T.F6%D11E!).@L#I=V+IR[DG9C+.@(8$^UK:N-R$8V
MW#):5:*M6WA5M^T;>AE:N2G=5Q7+SI5I426-$E[?:;@,TCH# & , Q^L_N<Y
M_A!;/Y53. 11RE_%DY%_S$;=_!_8<$/8S^2WE"IW>O[*E^+/RK_K#PGX+*IE
MUL+([4."1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8!X*?K:G_8-^E' .J?YL7^]^+_QDO^F:
MY]2_=D_?>+_JM/\ E7CXD^^=_#> ?K]7^18-3V?7)\$C & , GSB7^-OQ5_K
M#ZH_E9'YZK[Y_P#\>Z[Y*]T]Y_=S_P#RMP[Y3]PG_;O)B&J?(#:BK3B+Q9E)
M:N;;OW@K#9D-R6!P^DXVW2Z;:=FX!SM-*M23Q=RD#E9#PR;85A'L$( %[/B'
M!^0N=.-<LZ/3:OC^ICP6_HK-;4(VDU:E;BU!25I2PCYM7)^&IY]Q_O2[N.7.
M<N(:S0<K:2?,>EXAJ*7ISO24KT;LT[KB[SCC-.5%%;<$L*?)K6SVK:%/YE;X
MW=N6V5S7&PY[6E+W(UU]18&T;#V799)W/6F#HU."0F:JPI-;;1393QXK2+6.
M<-"MFATW!2"0FIS#PW@_#N8>&<I\O<-^LN*Z'23W5J]==O3V8))2NS663N3D
MY5V54FY53H='E+C''^+\H\9YZYLXO]3\#XGKX;^]I["NZO43;DX6+;<HJS;C
M&#CMHXI0HU4X7>:>MT/*NAE-0M]UL:= \Q+FG57^Y74"E/$<HZ=BC2KJA)U%
M5>+@J.G-=^DDU0>/#)RB+T3K"8PD)X5PC17I\T\=L<7M:6&IM\)S.W9;E"$E
MJ(T598RDD]KI@U@>QN/\1L6^2^6-1P*_K;FCN\=<5=OJ,;ER+TL\S2BJ1A*4
M5@F_.3JZER=OO'8<\_-#3,X<+(M."&X%6K91=51% YU.-YS@W2.<Q$04,4!-
MV0#J/LY'#(0TO+O)%^Q%*[+B*FZ+&4E>OI-];HJ#B]R[KN:^\C2ZJ<G8APJ5
MN-7A"#T^E;2ZE5MOPE9MG(\7W?%+@Y#[-E.3K:NRFB5-@L%-)5C6<Y1E-JR]
MZM:.T)E]*W39=(DU-C05A9)L5R@U6)'QZ+-))?H8Y"9.7[?,W'-7QK6Z;A^A
MUNM>L<9WK]V<+MJ&2+MQBE&25NE91>&9YJK IS5>Y-Y9T/+O#=9Q7B7#N'QT
M"G:T^FL6[EB]<WDU>E*4I1<KJE2,ECDCD:?G%GJ_LATCN*]7"I-MYU&]5GR:
MKLU4O>YHNK5G:=U5C-CZS;4[:3XM0N%S*$^_K0MB@^7=IO3':D4[!>A3FX.A
MX*[]W@_".+3TNHX=>YCH[=F<IV[:E^DLU<8JF?,\L,T?/>-6TO)>)\Q+2Z?F
M#C_ K6MTG%]/RBY*]J+<+=V[*/Z'44C.<J[O+'-<RS_-Q>6B3>O301%!XD^9
MK7E73UQ!EKG%R\(1CEXY<-&MO?;L7C)"RM4EE#@WG)!@0J3AR3HLN0A0.8P$
M+T]B\R\%X9H>]/AFATMJ,-)/2ZNL4L*+1WI)=BE%22V)JIZEY,YDXSQ/N1XQ
MQ36WYSU]O6Z#+-OSDWK]/!R^4X3E%O:TZ,M/+7C9-(W;Y>&P*31I3<[JJ>75
MHV>M&NFE@<1,_+UB3T188&YV>N2PG55C;978&9</$':9#+=L@E$0 PF#PS0<
M%L<0Y U4(:BQI;T^/WX+/1*XU.SNH-/"4<]%E?FXGL3B?,>IX5WIZ.=S2ZG6
M::WROIIO=YF[47;OJ]<36,)Y,5*/G>:1G3X#2EATGRF'B%M[=M*C4JO4K]O7
MC9O^CTZ1:S\'%W)@WC;35MA5Y69@$)J&GWR7<JHE92L@F %4$@ 8F>6\N:F_
MPWG_ (?IN;>$V;'%9RE;T][37+D(6YRMS3;L-UE&Y%-2\^4([<KVKP+G'1Z?
MB_=3Q76<B<>OZG@=N,+NJL:RS:N7+MN%Z#2CJ8JD9VIN,HTMPN3V9UBG0O/I
M\^*!@# & 9!4_P#6FM?P@AO_ (BVS4U_[C?_ %,_R6;W"_XGIOU]O\M'?S#V
M _,#^YGY6'[AG[@# & , XJ=4F48295KC9@\L*45(J0+.5<+-(MU,D:+&BVT
MDZ;I+N&S!=\!"K*$(<Y$Q$2E$0 ,E4KCL(=:/+M-(]7W;YT4/M'=[6\ZDX:,
MZV6P4D->Q=\W%/U"GQL:.NZZK8$M766,URC:+_$.;$LLO*.9OJX82RJS1M_F
MB2.;[MZ%PCE<ZT=:*KV]..'L=!S(W>)*<LT;=*JE71;.ATJ_#7I+7<--C<L[
MSNC?;?D_LKC(5..JFJ'=#X]\?[BG?7^NFCY2YMIN_6>QR-0K5H.RV"]CB(LT
M7+A\@FI&+ D1L "+C#?C9C;CNE/:ZMJE=F&WH-C33U$KD]_*&Q4C%UIMQV5Q
M]PV/YJFX, 8 P#'ZS^YSG^$%L_E5,X!%'*7\63D7_,1MW\']AP0]C/Y+>4*G
M=Z_LJ7XL_*O^L/"?@LJF76PLCM0X)& , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!$DVTL2FWZ89G9U&40:F
M7=TXA@BVJZ3DK&PZQ*NF=RHH"@*.DW1BE4[(G0 3=C\\. 0SR:79'O&B8J:B
M=CV.OR4AL0TG6]9RMHC9J268U=JO'KN JD_7'[EG'+F%00,N)"B/42C@AF0:
MSLE?J]EIU$JU&V#6(Z_M=C3[T-G3EM?6-D[HB=";)&:-K;.VAWZKE4K5T 4W
M**9#MC""8F,8<#9@?"OON\R]ZC]>TRD5]S*25SVY6#3$[87K2)AXW58T=1:>
M?MV44X?/32J-L,DFU0Z&!T5$#*%2.JLD#(>97G=CY_JL[M>'DY5?FON>DQS-
MO9)AG'.J]#ZRY/(&CK$8T8W\57:F>(:O&C4I%5'/J]+];7!,Y9(]\DR=Y,OZ
MB]DJ-;@US7;\SV0E04K%/VL]<UH>,7US%[,-<W3F7(23;"SBI9./]3E557<R
M8IE*Z(W4.X0@FI\S/DQ9["M7:M1X/7UTN$QL^8UDK8(6ZJN]9F)'ZP6V>A=H
M^9CX^1?.HT(PGAG4:4#N4)-%9J"YTRD>'"IF'*IXLTU;7@=)V5RB]VMIN,FX
MZBOYF-L$Q&26PJ\SF(:'<PLC$S':E&JIT0(FY2.H0_9$P=1P&5[0MD/2++L9
MO!5W=E/IB/&W;-JDJ'MVT[';)["LE=- .F#S6T].6.S/JQ(5N "2;S)XY\R>
M"658N2(*"V[],-A8MAL[9%H-;@UA4:P_B=:%AH9\VM%@F$)6Z6A>EUVZOJY7
MGS5B^3AFL=%65DU+*/BO3.9$ZQ#-DTT.^7"I'R_*6RS%-VAM6EU"!=:UU71J
MOL]TYFYAXA9+A4YW4M?V^\C(=@Q:*L8.>8UV8,4BKA9RV57[I/H!3**)!4S:
M6W%LRIRK^ M%-H_KMY04]@PB;:[A#P-=8,[A6ZK;6UVM%B9,V0QU-:6MO)JR
M+1(JCYLV<I(,N_*@5P%2/T^6S@T=L)"MI:ZW!-4F8XZ,HV5UG<0^9UI)R$VL
MMJ]C&$DU"SJ,1/5MY'N%E@*X>ME2*-^ITC&631"I\KC=T[1-WVZC6!2&G-K7
MBIZ3C*10V-AD6-,)//'&U3SLT>5EFRBD!6&;=LV\6[%J+M\N5!JV0<.UFS<T
MD5Q.;NO*YG6)78I6\UJ(K/4KM2,GJS8-@-(/8M^DHR"CYRR(42O*G/ZN.Q*^
M%I&)O>_-,R2*B'5FCW;Q6":DO:[V5;M@WK8L>C7(.,U_0+*>HHSZLN]<6&T2
MRU6J%K;NF4*6/1:Q<2S9V;NUCKKG656Z 1,A4Q.H"9%NRJ2+S9=KL6TZIM2\
MT%:+KA=?2.MI^RG;:Y!@R6"PE4I%'L<1>5;E(SG5XC+QD=*KF:@@W*HV,@4B
MP&%L]KWNIRWK6(N,9MC7-0XGSNQ"S$F[?Q,U<7]5<RP-I:19I1:R#6RO7,:D
MS?BH*9B!WYS)$6#N "I)TUNB^UVMU";NWT,:H;7%J_ERV#8&PF[: KZ:B=?-
M6*0LW=.:_(66\S995THX.R,2.9 R$A%')U$A.!BM"W7>=I[/T%+0"4%&T2Z:
M?W_+62$]=R#Y%S.:]VMI^E.IB*<$A&Q)-!B,DH,.JJ5J99I).1731.5,I@J0
MO6[K-3B"&Q7==:FH<%Y?]&V37ZHMLC8#J?AFUJI]Q>R;1"RK#ZT<660/$DC7
M$XJY-*&9MTG(+>),H4 +4,=F;)M(VL-65&K2D9K=.&AWS*SV.5:2URM;BG0%
MR>U> D@9KLX-NPBK&Q;%EGYGA7$@JJ11!(C<5E0,.W7R==:=+<I>=/K"NLJ7
M $LS"B6[8$0CM3:$6V@&4[.&IL#"OY'U0I&N%UXQOXE)X#V09JF-X=D*3Q4*
MG$S>PKO&S_(T+8V8SM,JNV-'0%9BXZT6.#E([YTJ:?*U!-W%M6*R#(BMA-(.
MT2KF(Z<]XV.4[94XB!F4KO2ZM:C=MQLJK7%M04":NC25;N):03O,O5-;S\I7
M;U>HT4VAH)DE&N(&0=,8Q;O#R+!J0YG351R"2(>0^1'?&P#0$CL1S3:NVH,'
MO"QZ>>LBST@XM4K'Q&^)#1J=VC%2QZ46Q\-(H$=*Q;@ISK$25 CDG5(3 <QR
M;:V:3:Z7A:C;9.ES<QNR)093<:JKW1';#7^QIV+0FV":J*<[7%)J(;&?QZI@
M3>-B&2$2B8#E!D=7;?9(MUJ_8$TA+1*E*A][&VE08MZ=5TVME$HC60?U@J*Q
MV*$L95WV%H5PX(DF\:/&KLG83<%-@5,IV-M'<5)KHM+3!4J+E=@5:]-:9(5F
M>FG):C?:]KZR[ )7)IP_B4C3B1ZS5I1=O*M4FH>*CP(=F!%P42#$SEC,VMYQ
MC/8+&[;IVUSIB1EW4A#/'AP%XK4'+QG(HO5D&+LD@HD*:RI@(7NW(F @B4"F
M$.@IG R549P.C%]?1?)&I[.LUDT_'_/*Y2.[HS73U-[)0,C>&=F<[(G5:).1
MUHK360;LFA&[AR\D%VQ6()KBDLD!/+/EM$OY5K)-9O4KBK/=C(:\;5!OL!HX
MW"HV<W8M#1O'S:2 R16@2AP?*0XD\6E!]79G ."C'X%3DI_?^R&.K[EO&#HM
M7E=?0+JQI0<"YGY-E<IB#KMA>UH]S<N@BU89BS?.6)GA(SLG7+%B"IG/B1\$
M 5Z3.GV\'3/5^Q-AA76ZBU&V';:.E%C(J%2D4JUL4U%3D5'7@Q.V4=I%\2*8
M$.!#? [0A\+ KA4P$NX[6WLWS)UW1XM[/6W<.VJH:1M=TGU8.(4I$+%33NSO
M"*M9601CW:2XII1,>5-$KCNR$%%-15=(*GPSG+:)CI:UOFTWJ4*W2;Y(T23J
M4AL!HWV[.!6K&-4N<]"U<@&%JO!S+9X#&)526<3*#+O"+M_$H@ 5&V=I;0L&
MG>0UNH<#!)4^FPNY:A'K*3TK'7R8?Z_;6*J7"T0+MDU/&0JM<M4,_3CVAQ56
MD!8 87#,5B]V#J2]ZQD/V\\_W%^L?_$K?NA^WOS_ /XS_P"E_/\ U\$DXJ?K
M:G_8-^E' .J?YL7^]^+_ ,9+_IFN?4OW9/WWB_ZK3_E7CXD^^=_#> ?K]7^1
M8-3V?7)\$C & , YBMV.Q4NTU6\5"75@+;2;'$6RKS:+*+D3Q<]!/$W\8]"/
MFF,E$O00<I%,*3ANLD?IT,40]&</F'@&@YFX7<X/Q-2>BNTS*+HVNJJQ5?!1
MGDW*/-?%.2^-V^/\&<%Q"S7*Y)22;Z:/!T\*:ZT+#/R]JGYRT6!YZPGK),2<
M_-OQ;M6@OI>8>K2,D\%JQ0;,FWB7C@Y^[1332)VNA"E*  '3T>DL:#1VM#I5
METUFW&W!5;I&$5&*JZMT22JVV^DXO$=?J>*\0O\ $];+/K-3>G=N2HE6=R3G
M)T2259-NB22V))&7:HW!M'1\I:WVL[4A$QM^914??JC/5:HWFDW-"!5<N(%2
M<JMU@YZ'5?PCEVHHU=)I)N$1.8H'[!SD-X1S-W<\$YGXC;XKJ)W[&OM[+EF<
MK<U54=)1:DJK!XT:Z#V9R9WO\R<F<'N\"TMO2ZGA=W;;OVXW;;H\RS0FI1EE
MEYRPJGL9D]YY);UV=0;YJW85_-;=?7]W!/W%7D:M2T(RI.Z\")6)M:-HVNL$
M=:-54D (NVA"L6RY#* <@]^OWNAH>Z3E/AVNEK]+'41O2LSMO\[-YE-4D[C;
M_.O\);S-25)+&,6NIQ/O[YZXMPV'#-:]+*Q#40NK\Q;61VW6,;24?S"IYKW.
M3-!RBZQE)/GK5RWY%WAWZSM6Q4928=ZFL6D+#-_,C7S:9MVM[6XJKJ<A[-)M
MJLD[D7SI>DQ@ED ,201!N()+$*JL"CA'=+REP>[I[MB-^3TVI5^"E=FXQN1S
M96HYJ))RD\J\V3?G)X$<?[^N>^8+&JL:F6F@M9I'IKDH6;:G*U+*IJ4\N:3D
MH16=MRBE2#C5F(:FW]N;2<$M3Z'<F!Z(,VYL\?1[O0]?;+K=;L[P4S.;#4&>
MP*O8S523<&)VE? F0264,8ZA#GZ&"G%.Z;ESB7$)\04]3IY752XK-R5K/';D
MDX..:/@E6G09."]_/-W!^$VN%2M:/51L2S6I:BS"\[<Z44X*Y&66=/PHTKTU
M/0YWGN-[?MB[-?["F9.Z[<H$]J_9$W+-(27<6BC61U O)2 .62BW24*W%:L,
M 0/'%9JM$6Q4D#)I"8@]V'=_RO:EP_<Z?=V.&34[$(RE&,9IMJ;HTYRK)MYF
MU)MN29XQ<[U^=;UOBRU.JWNIXU!V]5<G&,IRMR48NW',FH1RQC&.11<(I*#B
MC"J_;K55J_L^I04XJQJVXXBIPFQ83U?#NDK QH]@-:*P0'[V.<RT4>-G#BMU
M9.&PK?G%>\3^#F]J^4>#:_CUKF/5PE/B5BW.%MYI)15R$K<WE32DW"<H^<I)
M5JDG1G-X?W@<Q<+Y6O<H:"Y"WPC47K=RZLD7*;M7(7;:S23<5&Y",O,<6Z4;
M<6TY*_I)\@$JMI*LL=H2$6KQR68CIFU1E?J+.Z4Z.C(>3KL=7OG2C EEIRLM
M:_,.6/J^04<M%FJ@IJD4+TSPM]S'*#MZF-+]=5)N=9R<:MIND*Y4VTFY)*6"
MHSV-'[Q?/RNZ.;>F4=%%1A2W%3HDXI.Y3.XI2DE!MPQ=4SF+ORGWKL:J2E*M
M-JKS>MV!ZSD[3%TC6NM]:(V^2CU_%,GMM4H%5KKJQ*-7?ZLFFZ440(MT4*F!
MP P=GEKNVX!RYKX\6C*_JN*0@X6[E^Y.Z[46J.-M3E)0JG2JQHVJT;/'.<N^
M/FCG#A4N RCI=%P2Y<5R[9TUFW95Z::DI77;C%SI)*5'AF2E2J35?<]A'J88
M P!@&05/_6FM?P@AO_B+;-37_N-_]3/\EF]PO^)Z;]?;_+1W\P]@/S _N9^5
MA^X9^X P!@# & =6[GCQMAMF[L\Q"9VKQNOVW=XTT../)'C'<'E5LUBH%BXM
M:>>:-:;EU)07#5Z2MFLQG+FTMYB ,B#^2&3\4FFOV2'#K:>ZX0MJ$E&V\T9;
M*YG6C?BHSAZJRIW+SN0<KJRRBZ-K*LM4NBNVJVXEQ?*9#BX.]>:+W@K1HUMQ
M,GV>AK% [#:T2?JY5=L/HB[H;%UE V"ZQ,9<;%4JJT:QDB2-6,JWKDK+/TD0
M23=II%PZS>[NWZP_SRKA7HPH\,*OQFSH-QO;GJJ_T[RNM*8XU6.+2ZNAM]9O
M,SGG3*O3W)5"D77D=7K[41AJYQ]T?6.0:MFA9[YPO+1K^>';B#PIJ^I"0WJ*
M?BW>FI,"M@>/DW"2R!^^3,8Z9 ,#:<NY]64B]?O]1)1>YK):-<0-6I[F_%4J
M$G';,UQL7:D7-OKXC3C/XL(6KZ@LZ<@V"#<*)R$:1)$5TG*;C #7F8C+1T38
M(76[I:NQ59UE8MO.).ULXZ8URKLS8=BU@2#B(IK#RK.[RU+L],EQFNKV+13:
M-4SM%'BBW<D M[6?W.<_P@MG\JIG (HY2_BR<B_YB-N_@_L."'L9_);RA4[O
M7]E2_%GY5_UAX3\%E4RZV%D=J'!(P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /E.R:*/6\B=LB9^U:O&39
MV8A1<(-)!5BN];)*=.T1%TM&MS'*'H,9$@C^=# ,2G:0UG;G0[FJ^<(.J'\Z
M/",DTTS(/_G1%(Q3CQ*AOU1/PJ:(')V?9,/0?1@'#7O7\E9+!3+G6;&VK-PH
MX6%G&NI6#4LT!(0EL;QR,_$S$&WFJV]6!96&9N&Z[=^V507;%ZBHD=1(X@PN
MAZ!:TJTQUO<7&<LDRTFMKSSM>3:L$ ?O]MNZ@]ER]EH5--HSB5JB0K-%,O93
M15[OV"%$0H>V'T9ZLL$+*+VD7<95]WW;=]<C4H0&KY*4V!3MG5>P04S*FEG2
M$I').=GN73-1%HS51*V324[\1,K@4/&?T.D^M\OL6OVQW7[VO=HR\0,JM$M9
M>+C'#773#6<I7Y:',Y8+3U9L,"S[QRB5TS<D= DJBNF= AL"AS$=J:34G*=:
M[;>Y6T66K7*P70Z@,$XR %>=HC^@%@:] F>R1ZU6XV,>^(31\4[<*O.]6674
M.L<V <]M;7SC9-990C*QN*G)15KJ%QB9QO&LY@S25IMA86*/!2-?G(U=-UG4
M>4BA3"'P!'IZ<$D8RG'R;N03"VS-LSMS=N*%>Z'74VM9K%7AZTCL2(+"V"PA
M'Q;91Y,3_@$B(H&<//#((BH!40.H93!!S*NE[!%.+66@[(=4V+V"C%&N+<U;
M:3<DWF(VJQ5+4M-#DE9-@VJMADJ] L4UQ>-)EAW[0BY&I%3KF6"A\IN-U2;Z
M[W)K*%D'T+6=MTA&@IH-TDES5""9ZDB=01Z449P<YGIF4)#I+%[\1$RO4!$0
M].!0^_;.AXW:DW%V)>=7BI."AFC&(14BVDQ##(1>Q:'LJ+>344Z60+,1R<U0
M&R+AF*B/?-UE!(JBL5)4@4.!?<?)2PV69MMMV*O*RUD5T&YF&L;5V<-"M%>/
M&X5MO5!M6&:LI*R,7%2;^1?-I!-Z\DW"@N@5372!,$C 9M/Z4K5FFME3$NY>
MG/LBMT6OKBU!)H^KKC7KZRRM<L,!*)@+II.1LQ8@>M5O9:NFB2A/A .!0QDN
ME;?'J6=M7-M/Z_#[#<LY?8!&=79EL)K,:#BH"R6'7-@;2S)#7[NV-HA-=P15
ME+E:O3J.&GAU3F-@DE&FT=I37U\>M7SEZ:]W9>[.R."$*#!TO6JS6Q8H'*)C
MK(%0K*:O;/\ #$ZI@'T & 1]/:EN*%PM-PU?M =?K7T8MS=8>3I<9=8A_.0\
M,QK3*UPR;B2@WD/9#5R*9,5C*K/6*R+!OU:@8AC* 8C_ $8&#*,""AKG(IQ,
MEI^]ZCMJTW%-Y>?GTKT]EIY_<&THS>PC")LBMJFW+UT L7+-<BHHI(MO@G*(
MH9W.:FDU;54+K4K4P@K#6*4]UZHO/54EL:KUN1=P[YTYAVY)ROKP%D!S"I]E
MR"SEHJF;LN6C@$T13$F-T?0#N@S>O9>+OCB5^8;?<L(?YQ5YLZ?SU8W1=ZGL
M*;0>/(B2@VC6RQMDI[?N'Z37PIVJJJ9F/;$BI!%#YX3C1!PE)5I*5FEEVJO&
M>J<:!?*-&97 0=4B;%$M[,"91[OUL[3L1SG1_62F3* >@1P*')K:3L,6O;D:
M!LIW28;8;:-^>+=.NHRDTUG&%7BZ8O;M?S99B-2J%DDJ]!LB+&=-)=F5RT(Y
M3;D6.N=82<!:N-CBP1>Y:G';!>0%+WK&N&EX*6OMYF_]^YH,3KI8D;?9F5=)
MGAW,%"(BJ@_C)!V"BB_<NT"J$!(10YN3T0\FG5]-*W-)1AL68U5;)Q!I6O"O
M6]PUBO23%>1CU2>=-T*_.M:.@0[!5LLX;J+'.5V<O93 #U2.@G3R)M% 1O*S
M73UUL5AL%DI)J^BO.G0N$XXLESI\/<?6J*,;2+7+2#T7392,=/DF[]=!J\;)
M@@" 4.?/I&*/KB4UR,Y( RE-ISVTE)+P[;Q23^>WN_WLM%$2Z]T9FWEGXL"G
M'X8MR@<?AX!G%QI#6XOZ$_<OG#,]"N[>[M$T$TU"OW3>MV:N%8N14]*3<R%E
M.H)B_"[:10]@1P219L3C52MDWLUTF7LLT0E*-;*);J['G10C[0TLT$O7&TVJ
MY GC(NR040^<((O&YBJ*IB@53M>$;=V(H>]WI.<M1XTNS-BKW%M68*S0]4+'
MUAE6'2,C:JM(4N0NEF63DI9K/7)&LS+]J@HT;Q48F20<CX$3&2%$*&=PM#=M
M]4M]9V&<0E3DIJ])=3T/$'@07C31BT(U=HQ;R5L(-GZ46*?>"+A1-5P4RA2)
MD,"1!/10^29U7'3-!I=$5E'S=&D36IYR-ED$T2O5G6I[55[0Q25(/P"-Y[YL
M@S> 00$6KI4I1 1 < Q:!TW8JPLA 0.RY"*U<UN+JZ-*DR@D6UH:JO+(M;W-
M.0O:,J0A->*S[A3JQ]5B^&/.+'QWAO@8((EW+HF]ETMM*AT.Y/W=/DV]DGZ[
M0F=<;*V\LG+RZ]F5IK"Z+2_A1HZ\ZZ5[#(\4+]-H<&I'Y4"E( 4,YLG'>2G8
MJZ4UIL9W"Z[NUV4V&^A6E=16L[2P/;&RMLQ&MK:M, U&HRUA:&<JLS1@O []
M1$'GAQ!$ H9=#:1BX:YL;FE.2"SEC=]CW<C)1LW*@HZV/%1T4]8F4*/> WC4
MXXITC!\(XF$#>C H?"CINQ1+Z?CZKLN0K.O[3=7]]EJVQ@D?G*PEYV8^<=MC
M:I=DI5KZB@+A8E7+U\16.>OBK/W7AG;8ITP1$G!V3C[,2]=V?KZ&V8_K>M-K
MKW60FX)M6V3NR0,AL(SU[<F]0M1Y%!K&0-FG9-X^>H.8QZ][]^Z%L\:B=(4!
M%"8?F.U_;SC_ %'^8_ZVG_X7]O?^8_O?SN"3-CAU*8/JE$/= 0P#13SFX0;%
MWUL9*<A%#-&3,SLQ%"MO$]]XHR?H$!51 G8[KZ_7KGL[NV[R;W=U>U=ZSI(:
MKUJ%N+4KCMY=VYNJI"5:YO!2AZ8[X>Y[3][>GT.GU&NGH5H9W9)QM*[GWJ@J
M.LX4ID\-:]%"CGY*7;OW34^]9?MS/:_]3>M_E%K_ '$OH3T7_1CPW^?W_P#:
M0^G'Y*7;OW34^]9?MS']3>M_E%K_ '$OH1_1CPW^?W_]I#Z<?DI=N_=-3[UE
M^W,?U-ZW^46O]Q+Z$?T8\-_G]_\ VD/IQ^2EV[]TU/O67[<Q_4WK?Y1:_P!Q
M+Z$?T8\-_G]__:0^G'Y*7;OW34^]9?MS']3>M_E%K_<2^A']&/#?Y_?_ -I#
MZ<?DI=N_=-3[UE^W,?U-ZW^46O\ <2^A']&/#?Y_?_VD/IQ^2EV[]TU/O67[
M<Q_4WK?Y1:_W$OH1_1CPW^?W_P#:0^G'Y*7;OW34^]9?MS']3>M_E%K_ '$O
MH1_1CPW^?W_]I#Z<?DI=N_=-3[UE^W,?U-ZW^46O]Q+Z$?T8\-_G]_\ VD/I
MQ^2EV[]TU/O67[<Q_4WK?Y1:_P!Q+Z$?T8\-_G]__:0^G'Y*7;OW34^]9?MS
M']3>M_E%K_<2^A']&/#?Y_?_ -I#Z<?DI=N_=-3[UE^W,?U-ZW^46O\ <2^A
M']&/#?Y_?_VD/IQ^2EV[]TU/O67[<Q_4WK?Y1:_W$OH1_1CPW^?W_P#:0^G'
MY*7;OW34^]9?MS']3>M_E%K_ '$OH1_1CPW^?W_]I#Z<?DI=N_=-3[UE^W,?
MU-ZW^46O]Q+Z$?T8\-_G]_\ VD/IQ^2EV[]TU/O67[<Q_4WK?Y1:_P!Q+Z$?
MT8\-_G]__:0^G'Y*7;OW34^]9?MS']3>M_E%K_<2^A']&/#?Y_?_ -I#Z<?D
MI=N_=-3[UE^W,?U-ZW^46O\ <2^A']&/#?Y_?_VD/IR4M3^4;=9*UQBMKNCR
MNL6#UH_!RWKJ+XRAFCA)P5(2*RS4"@IW?3KU$0^IF&_]Y;77[$[/U1:2G!QK
MZQ+"JI\T9]+]S?ANFU-O4+CU]NW.,J>JPQRM.GZ?P'9H#V _,#/F ^U#]P!@
M# & 5,YW;TLW&?AWR*WO2FD<]N.M-7V&?JJ4ND9S%)V(4B,(5[(M"'2,]91T
MB]3<*MP.GWY$A3[9.UV@S:>VKM^-N7HMFOJKKL:>=V/I1CAVE&8. Y<\..2/
M#R,V+S'NW*.D\I+G<M1;=J.R:=1H9K7+\TU-;]FP%ZU"ZJ$#"NJK"-9.DN6:
M\2X.Y;G9.@Z!WI4U$-ANS?M3<8*$H)---[*I4=>W::R6HT]ZVIW'.-QM--+!
MT;JJ;-FPW,YHG1& 5RF^--6L^RMH;"LUOO,^PW!JJ-TK>=;2 T@E D==1*=X
M\!!H^!I#*\-Q2=[)G7!EPG!654D3%.8R*3=)$10QIEQ H[)!)^2];0<; 8V*
MF6.#VR]E:D[O==5U]4+)0:G&1#=:E&HGJ>.IEUG&"B3F$<'>$FGBSDZSE0%B
MB:'UI\0]:-4*O'Q4S>HB#A:]0*Q98%G,Q;AAM"+UC:9"[T\=ANY:!DIUV_:V
MR:D'KQS&/(I>5/(+IOC.$1(D0"?::R:Q\,X:LTBH(!9;JL"91,( J[N4\[<'
MZG,8W51PN8P^GV1^I@$9<I?Q9.1?\Q&W?P?V'!#V,_DMY0J=WK^RI?BS\J_Z
MP\)^"RJ9=;"R.U#@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , \1(0?2)2B/UR@/\ =# /
MSNT_L9/DE][ '=I_8R?)+[V .[3^QD^27WL =VG]C)\DOO8 [M/[&3Y)?>P!
MW:?V,GR2^]@#NT_L9/DE][ '=I_8R?)+[V .[3^QD^27WL =VG]C)\DOO8 [
MM/[&3Y)?>P!W:?V,GR2^]@#NT_L9/DE][ '=I_8R?)+[V .[3^QD^27WL =V
MG]C)\DOO8 [M/[&3Y)?>P!W:?V,GR2^]@'Z!"E])2E ?K  ?W P#RP!@# &
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M_BR<B_YB-N_@_L."'L9_);RA4[O7]E2_%GY5_P!8>$_!95,NMA9':AP2, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & 8_6?W.<_P@MG\JIG (HY2_BR<
MB_YB-N_@_L."'L9_);RA4[O7]E2_%GY5_P!8>$_!95,NMA9':AP2, 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8!C]9_<YS_""V?RJF< BCE+^+)R+_F(V[^#^PX(>QG\EO*%3
MN]?V5+\6?E7_ %AX3\%E4RZV%D=J'!(P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & 8_6?W.<_P@MG\JIG (HY2_BR<B_YB
M-N_@_L."'L9_);RA4[O7]E2_%GY5_P!8>$_!95,NMA9':AP2, 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8!C]9_<YS_""V?RJF< BCE+^+)R+_F(V[^#^PX(>QG\EO*%3N]?V
M5+\6?E7_ %AX3\%E4RZV%D=EG8^Y-0Z=:1<AMW:NM]6,)MVJPA7NQ[Q6*.TE
MWR"15UV46YLTI%HR#M%$P'.FD8YRE$!$.F"3V0VWM36.[2FM*]M#7<]L:#B4
M9^:H$-=:U*7:'@G!8X[>:E*JQDUYV/B5R3#02.54"(F!TB(&'O2=H"1, 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M+,D7[)15!0 414.V<%$Q#>DH^@?3@'+X P!@# & , 8 P!@# & , 8 P!@#
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MW4[Y<B@G$4BA@$OX!ZUB'415325,@H=,Y$URE(<R)S%$"*E(H4R9S)F'J &
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MFN]0BFK&.(Y\*@0I^Y13(80Z]D.N 9?@# & , 8 P!@# & , 8 P!@# & ,
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MZ)@+)69F+L5=GHBG-H^6@YZ#?(2D-,Q3]LHFY82<7)-4EVZZ9BJ)+)E.40,
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M.S$,Y=+6>YBJL9-)-!,3]FQ%+\%)(I0]'L!@BB/?"\4]!5U\$E"4((U\"2B
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M5]!.KOWOO?XU7#_3^ >PFCM9$#H6 >@'7K_K3;A]/L>W/#]3 /$VC-8''J:
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ME![^ .V3XQ?E![^ .V3XQ?E![^ .V3XQ?E![^ .V3XQ?E![^ .V3XQ?E![^
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M#$5*/9*R<''+(=ZN7U8Z2 2MN!M(>?\ B5?S2_I"Y>.PA[2&[9^[;G_%M_\
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M3QM*A[\@D8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MA&B_YKV/3Z;ML,A2]>G3T*E,?M=>OI[/L9DPW7AS>\1^%[!8.>_U2+_YM/\
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M9Q^8/X7/MC^4B:\\R/78P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M4DWFCV^XR6O%J?4)[@_X68ZEZL>+4^H3W!_PL5%65XXG.E X[ZM]!/W"<C[
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MVQ]O,M_]*^TI:]!%D<Q%R!;$T<'Y-:E<E>*$13TCO[M-@Z]@_9O7&TI@'H8
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M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 4&Y><?-D;CWQP!O\
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MSB\PM_5<_E1_*1.C)918AQ4'J(&  ] !Z.G7V@#/-))+8>O(NI]N5+# & ,
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M.;"=MG,FR>6-G#LW,<T*T(1$B*AX?Q;E3\^ZD'3AP8"BKV2YK]YWYJ;25%3
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MQ:T:BG&5?OL/8*/>J4YC'LF1\I%NXT;K6Z\C:("63C7 M)6*,]C'0(F%)P<
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MTZ]GKZ>GL=>G7KTZXJQ1'[X='[&7_K]_%6*'X*" !U$A0 /2(CUZ 'NXJQ1
M$$! ! A1 0Z@(>D! ?; >OL8JQ1'[X='[&7_ *_?Q5BA!3%2._I,V>/[]KX[
MZ"Z*[!EWZ?B_#%OVPTCN?#=OONX*HH4HG[/9 Q@#KU$,R5>Z_P 7N$=)/<\V
M0^:91[LO7Q:?I]/V93Z^=VK? 8_+_P"IE.&)?7O_ +M^1%3>0R*)= ;R'L '
M33VS/3U']Y4W]?.-;_21^4O*>8W$MW+L?D)89H(>#:]"%$/#(=! 1$!#NB].
M@]?2'3*%J(^GN$?B![H^_@FB/SN4.HAV2]0 !$.H]0 ?8$0Z]>@],$41^]PC
M\0/='W\$T16KF0BD3BMO\Q2@!BZMM@E'T_G@C%>ST]/I'M9EL_I8]ICNI;J7
M8RRO<(_$#_K]_,1DHAW"/Q ]T??P*(A+7R#<=L[_   A>T$]K[M  CU#KKJ$
M$.H=?1U#,DO0C[/E*12SR]CR$V]PC\0/='W\QEZ(_!10*'42E /8ZB(@'I]
M>R/MX(HC][A'X@>Z/OX)HAW"/Q ]T??P*(K+H [%QL#E^F@JW7.WY+,TER)+
M$4,@H'&SCH44U2D.(IG Q!#H;H/4!S+<7FP^3[K,4$LT_E>XBS7<(_$#W1]_
M,1EHB%=V*1[1GK3Q*S9L+K=.LFK4%UR(BX<J3H&*V0!0Y>^7.DF<0(7J82E$
M>GH',EOI^2RDTE3Y2)J[A'X@>Z/OYC+T0[A'X@>Z/OX%$?@(H#UZ%*/0>@]!
M$>@A[(#T'V0P*(_>X1^('NC[^!1'X** =.I2AU'H'41#J/U ]/I' HC][A'X
M@>Z/OX%$.X1^('NC[^!1'X"*!@ZE*4P?5 1$/1[/I <$41^]PC\0/='W\$T1
M#6Q%HQML;0;5PX:(.GMWMI6;=9PFDN[%+55Z,J5LB=0JBXI@8!-V 'L@(=<O
M'T9=B\J,<DLT>WW&3+W"/Q ]T??RADHC\%% H"8Q2@  (B(B(  !Z1$1$>@
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M"1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P"OF^=/3&VI7CY(1,M&1:>GN0=7W#,$D
M2.CGEH>!IFP*RO$QOADE"DDUW-O14(*O92[M(_4W7L@(%@\ XF>]=^HYGYLA
M&#8_54AZ@":4<I0WKKPBOJOULHR1</"1OCNQWXI)G4!+M=DHFZ!@&F5UY3EP
M3UT[TV]Y&V3:6L]F43156WHTV#'5*CS\A+:6Y+U3>3BPZ[FM$4#6TG%2NPXR
MT[&2F9.3<OI]:5E(=P60)X)4QYJ5RETM><;]H5HG&F"M=SJ%CA.+>QK<M4;
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M "@)U%#'44,(!Z3&$3"/I$>N:YL'G@DXN,B6\45P5NHN<'"O>F!8X'[(^D
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MO^*=?^[J9T>#_O\ 'LEY&<CF#^%S[8_E(FO/,CUV, 8 P!@# & , 8 P!@#
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M[(?Y0YCHB3P%V8#@D+CHH8!,5,5  YBAUZF G7M" =/9R: \^_6^R'^4.11
M\3.%"@)C+&*4H=3&,?H  'LB(B/0 #%$ 1R<Y0.1<3D,'4IB'[13!]4# (@(
M8H@>7?K?9#_*'%$#P\6/>=UXC]5 O:%/O [P"_&['7M=GZ^30'NG%UOFL =Z
M?IXI/T=H>GZ\?._)?_\ /Q_6?]3,/#6_KU_JWY$5'Y+3+&'X[[UD)B49Q<>E
MJ+8J2SZ2>(,6:2CNIRS-JFHY=*)(D.Y=KII)@)@$ZARE#J(@&<2S5W8I?&7E
M/,;CI;E7J9+4+)H24/%2,<_0D&#Z-9/&3YDY3=LWC1RV26;NFKI ZB+ANND<
M#$.0PE,40$!$!S&ZUQVED\#D^^5^R&]T<$U9X Z$3F3!<!4* "8@* )R@/L"
M8H#V@ <8D5//OE?LAO='!-65AYI2[&+XI;[=R\FSC6/T;6)N=U(O$&;7O7;0
M6S= R[E1)+O'*ZI4R%Z]3G,!0ZB(!F6Q5W8TZS%>=+4NQEF4'I72"+ELZ(X;
M.$DUV[A!4JR"Z"Q 426153,9-5)5,P&*8HB!@'J'HS$]IDJ>WOE?LAO='!-6
M5[UA9H>2W3R2B8Z?BY"5AI_6X2\8RDV;J0B1<:[BBH!),D%U'+$5S-U )WI2
M=H2&Z=>R/3+--6X/M\ICBUGDD\</(6$[Y7[(;W1S$9*L\#NA2#M*+@F41 H&
M.H! $P^P'4P@'4<8D5/+OE?LAO=P35G[WROV0WNC@59X%="<3 1<#B0>R<"J
M 82&^*8 $1*/UAQB*GGWROV0WNC@59 ^^K+#P#'5YYZ>BX5.0W=K*.8'EI-G
M&D?2"LT*B+%H9XLB#EXJ5(QBI$[1S 41 /0.9;2;S4KZ+*3=*5?2B>.^5^R&
M]T<Q%ZL=\K]D-[HX%6>!'0J=KNUP4[(]DW84 W9,'LE-V1'H(?4QB14\^^5^
MR&]T<$U9ZSNA3$@'< 03CV2 =0"B<WH]! $0$P^GVL8D5/9WROV0WNC@FK/S
MOE?LAO=P*L\2.A5+VDU^\+U$.T10#EZA[(=2B(=0QB*GGWROV0WNC@59X&="
M4Q2&7 IS]>P0R@ 8_3V>R41ZFZ=?:QB14\^^5^R&]T<$U9^"NH "(J&  ](B
M)N@  >V.,15GB1T90H'37[P@]>AB' Y1Z#T'H8HB ]!QB14\^^5^R&]T<$U9
MZQ="4Y4A< "AP$2IBH ', =>HE((]H0#IC$5/9WROV0WNC@59P-IE6L76;#)
M2D@VCHUA"2KM^_?NDF;)DT;L5U7#IVZ<'30;-T$BB8YSF*4I0$1$ R8U<DEU
MD-X8["/N/LNSEM#Z8D(F3:R<>XU70!;OHYXB]9K@G5HM%4473915%7NUDS$-
MV3#T,40'T@.6NU5R2\+*P=8*FRA+_?*_9#>Z.4+U97]2QPX<HVE>&=C L)M$
MOY (,9)H$R:/"^1Z8/@C.^\:+,% $O>]CL=KJ'7KF2CW->C-[ACK^<I7&GNE
M@.^5^R&]T<QF2K($Y4R:$?QCY$NY!^@Q:)Z/VJ55R\<IMFZ8K4:<12!198Y$
MR"JLH4A>H_",8 #TB&9+57=C\I>4QW7^:E\E^0E>G2K:4J-7DHR0;R,<^K\.
MZ9/V#I)VR>-5X]NHBY:NFYU$'""Q# 8IR&$I@'J Y255)KPET\$254%U@G6P
M@H<![IS[!A^P'SJ\$_B$.R7D9Q>86_JN?RH_E(G9@H=0B@G,8X@8  3"(] Z
M?7SS21Z\BZGWY4L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :K^2'EWV7>GF*\0N<
M,?LZ#KT#QFK[F%E=?O*X_?R]L.NYN[@%X^=0E&S.+*4+:0.BC=81[D?C!T#I
M-J& , H)R>X1N^3U^L%PF-P6ZA(QV@9#4FI$:0UK9'M.M-NNK>^WN]2Z]DKE
MA+)*NK'KC7;N**T%FZC7-64437 70]@0U4CI?RRM=[(I/)J*W[-/[?>^2S3;
M$:^N->G+@C&:V;[IT97]+7>9UG0+1/S^NZK<EXYG(=F6;1";Q=D]%JX.JB==
M-6:D9471TU'\BX]"20WW9M-V0S=A"LH%WJFGW*J+/GK4'Q)V<GD+5<;2W:)R
MP"U,VCFO:!B8BW:=N043!*"V))[S_P 2K^:7](7,D=A1[2(;3^[+C_%M_P#(
MDSC:W]X?8O(</6?O#]CR&&/(MH^7:.5P.*C,_;2[)^R41[13@!PZ#U #$ ?1
MT]S-6M#5H<JE^NI?XPGZ8,1])=I9;3/Y4A5';I,P=2G^ 8.O3J4R10$.H>D/
M0.<?BW\1N]J\B/9.@_=(=C\K.$C8QK%-Q;-.\[LRIUC"H?MF$YP*4?3T   "
MD .@![7U<Y[=3;2H<AD$G&.8EH[?-)!4%/$,PZ)=D_0@]#"<O;+T'KV#&$0Z
M"'U^N37"A%.DY/(),%V?KBJ;@UU=]67EFYD*=L*L3-0LS)F_=Q;MS"SK%:/?
MI-I%@J@\9+F;KCV5$S@8IO3];)C)PDI+:B&DU1[",.+7%[5G#[3T+I#3R$^E
M3861F9<BUGFE9Z;?2L^^._DWSUZ*+1L0ZRQ@ $FR#=N0I0[*8")A&URY*[+/
M/:1&*BJ+86)RA8XT\4T4DD94Q5/%HI&2(('$$^@E.3J8G3TF JA@#T]/3^9D
MUPH13&IR602?,[:I/6RS1<#"DN02'[!NR;IU 0$I@]@0$.OU,; ?C)FBP:HM
M&_:[I HE)VS=HP]3"81,;H'41,81]H,-U(2H?5@DXP(EF$F,L!5/%F2[H1[P
M>['X )]OL?'[L +[/3I[77TY-<*$4QJ<M.?ZKA_YI/\ RI\[TO\ R_']9_U,
MP\-_CS_5OR(J-R.X^Z]Y3:7NFAMJI3*M#OA( )L*]*&AIE-6L6F$N4*X82((
M.2H*M)^NM51 Z:B:A2"0Y#$,8H\.U<E:FKD/27_@>8W(1NP<)>BS*-0ZKJ&C
MM8474- ;/6E+UW6XVJUMO)2#B5D$XJ+1!%L#R1=F,N\<& .ISFZ=1'T  = "
M)S=R;G+TFR8Q4(J,=B1(V5+'&HQ31"07DB IXEP3L*=3B*8 (E$PE)T] F[
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M9ZX,MPFF1),B290(FF0J:9"AT*0A  I2E#V@*4.@9A,IYX!QT=%-(LBQ&@'
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MLJ6& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MGZY:VVBK1E9?P5ZUUZU3/7XV;2L5?G;M!5:5KRWK0%0C$W2$[WOBFX Y3,B
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M2EZ^SV0 /[F=0XAY8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M])<C<M0>ZE.Y#+=<,[G9SWKO9WCTT, 8 P!@# & , 8 P!@# & , 8 P!@#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
K!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>tm2115679d1-lc_nras4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_nras4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!L@.2 P$1  (1 0,1 ?_$ 0   0 " @(# 0$
M       '" 8)!0H"! L# 0$!  ,!  ,! 0            $" P0%!@<("1
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M4!* F%9B\@$6X@?V2E D@IU#VQ$/F8!RV , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M ,?<_OJAOX/V;]T:G@&08 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , Q]S^^J&_@_9
MOW1J> 9!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M1OARQ38DHHS\2[.0B7;[91$,HGC!(P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!6ISQ3U;(6=6<E
M3V>6@37.Z;':ZY?S*9Z!'[ V)6+%3[K;&\<BQ0FUWE@@KC,$4:.9!Q&)+RCA
M=%JFN)%"!@]*+XD:TBH)W$DFM@/I3M:R+7[I+6GUG<Z:STPJ\6U9&UN7=QZB
M'@Z@>4>^E\@^6E?6#OUFH^%RL)P,^H&K:?JMU78"KL53"G%;+E'\[++!)62<
MFKI?(J]7"8F)A1,BR[NR7*?>R3A-,$FJ:[@2H(I)%33(!,F 00?34FU=\A[)
M!7^2B-@;Q8M(Z"MZD2VDPU8PK]!3J5)8P$,[>>'E6%8L;F2L0HKJI$=2<NZ
M033.  !'UVXKL['3]+ZQKTM3*UKG2SO4KZM)O-;'L&PX9WJ.RUR>BG=(O(W2
M(C:<\E6E7;,W*AH61$Z1UNUVRJ=V41@MQ@D8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#'W/
M[ZH;^#]F_=&IX!D& =$#SL?, YK:.\R/>^L=0<G-P:XU]78O41X.H5*W/XB"
MC#S.G*'.RIVK%L8J:9W\O)+N%1](F45,.0RK;R<#Y,OF#\W-V>9GQ>U;MOE#
MN/8>N[8ZW*G9*;:KC(RL!-$A..NX+-$%D&#@YDEPCY^%:.TNOTJ[<A@]C"83
M>3ONY)88 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MY^C%I;^C/062?OFL8Q>23Y8K=E'M7#YXX,!S%0:M$3KN%C%3*<YBI(IB80*
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MF29!(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MRJUNJR&Q=1<?G6X;2@BXAI&6J>V=FZ_#<$C;[5 M5[6:!F(6768RCA,CQ9A
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MM WY5WDC^Q.D/YAM:Y#*/>8WY"OY7#A[^K=\_P!5C>>0MX6]'THLL7& , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8!ZSQXSCF;J0D'39BP8MEWCY\\72:
MLV;-JD9=RZ=.5S$1;MFZ)#'.<Y@*0H"(B !@%+WY)@G%Z\;0D22S*8D[*[Y(
M%9KRT;5)&+AJQ>(O8=5A9":517CVK=C1*DP9O3NBF36;E536[*9C 41T%UR'
M(H0JB9BG(<I3D.0P&(<A@ Q3%,41 Q3 /4!#T"&"3RP!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P#T)5\$7%R4F9,5BQS!X^,B!@(*H-&ZC@4P.(&
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M&?GWWD_NT>[[NIW$YIWCY3+F4N8Z/2RL@IW0E#,6OG15,6TEEO:O#DI_P)U
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M',:SPE'A$;"4W0!0FG+8'THS  $2@5B]='1 "^] "!TZ!T#/P*?U-)NP!@#
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M.[_=#OYRSF4=7SCO/9S#0J$TZ7HJJDY2BU&7'&V37!)J6,>EC#QD:4XT<O\
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M+[XTAS+T5I^KW*A;XU3?4M1W2<U5:9*1=JMM766,GYM:T,*A9'BP2"<I $\
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MFU*'7/8\=3.29Z'W9HSG[QTXY<?J9QMO(\7/+FJ"VE&_)>T;$JM;1G9':$O
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M</-\\S"_VJG0%CMM UQPBA*;+S<6SE%ZXQO.L;RO:!B0>HKD9.Y7XG,"'73
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MX/8JL<O+6+9D$I&)K)(A0-J[$UTDX(N8AS#(MJ59(-M)*$,3WAUR*'( B "
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MXO8A&BJ%LKXQQ;)8;_#9T$4;L\N[BIOZ]S>R[S3+9%7.X1<= [$E]9;9VMJ
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M\PVM<AE'O,;\A7\KAP]_5N^?ZK&\\A;PMZ/I198N, 8 P!@# & , 8 P!@#
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MHDF0ZA!#)V  * %* %*4  I0     .@  !Z   P2?W & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M:?\ FQ_BC[S/[Q<]_K^J_G1^-CRG_I+;_P#]\FQ?XQX^X7<;^Q>4_P!4T_\
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M /\ ?)L7^,>/N%W&_L7E/]4T_P#-C_%'WF?WBY[_ %_5?SH_&QY3_P!);?\
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M/WR+4B9130S'45ZIKM+EZ"\:PNI)G3IK=%%]E0_3EXGEO?EMK:;6<XSN& ,
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MC$R@D(5P1$JR8"FH01SNJ=-CK?1^-=#\J-:+HWU*V.S/1X'N:\C+#YD;# &
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ML(@K%KY=HH1DZ'LCZRW[%M\AB?'_ ([:.C_[/!>9-+5M*7F+1PDWQMNP3KV
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MZ3Q#9CT5NW-KRL]A5(5E&"ZSAZHXC $(]T=\[.[9E-W@F(W=&6%=),PK'ZE
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MY2C%OA9V:,]^/QD, _@@!@$I@ Q3 (&*( (" AT$! ?0("&   "@!2@!2E
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MKO)']B=(?S#:UR&4>\QOR%?RN'#W]6[Y_JL;SR%O"WH^E%EBXP!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M/$Y@(0QS 80(4QA A#J'$"@(B!4TRF.<W0/0!0$1'T & 8%1K^RO!["1I'3C
M 8*;>10C+5JT01'"+<2 DNFI886)(HX.(CWB*8G.B'03@':+U BEML/>-JM.
MR(VAT[5*L!0;N>DD?6Z\V^*F))TA5ZO9%WAH^&H$ZR;-^EF*D0 <G,/="(@'
M4 P1M)B0N\"TK<_/6&>KC E$9N3;&>-97OH.I/XB!:6&PIO9!VBS5;LXN,=D
M<BHX21/X4Y%#D)VN@"2.-F\D-6:RA[P[?6:)EIZA0[N6FJE&R")YI &H,.[:
MO2%*J2*6>GDT"H"X[ +"8>QVNP?LB,GHM^2>O$+7=86?GH6&AJW'U&8BYT[M
MRN24A+'"C+/9Y^BDS$(2OPHG3(N_<&*S2!0IE5$^H (DD:S;7US3G+-G9+A#
M1CI]&>O$D3+G<G1@ 4[H;&_!DFY"+K150$HR+GN613 ("KU < ]D-F:_/:H^
MCI6^"<6^51%RPKK1^D[E5V81)ISUAX5L*ITHT8L"J@Y/V4![Q,H'[:J93 1]
M=]@;-;[-8ZWUO6*)++FHBEWDI*[VFP5]))(+!ZA28L4H&IV8[A0Q_P!$,93N
M@ /0'7!&WH/"E[?F[ *T19(6HU.V5W;AM36Q@-R=RL))2/Q 9[";N=<S(UF-
M=69Z\AIID<6;QG&G;&2?)J'$[0.^#)F\7MS6DU8PJ<7<X1[.J/9.,:M47!O#
MR4K" N,W#P\F9,L7-3,(#1;QC1HLLY:>'5[TA.Z4[(DX-/D#I5;L"ELNJJ(K
M-/%LW9)$IH^3#MM$O!0\B!? 3,SWK] G@&BBSWMK$+W74Y0$,G,'W#K,E>8V
M@;A%&AY.7>5^.,GXE62?6&.\:,C76L$FW/.KV"-+&N#.&)6PNT"-U#*)E*F<
M0$91Z[K=NI641#SKK8-91C+ >21A%3R*??RCN&DV<+,1K)B "_6EXF9D$6CI
MF"7BF[H_=*)E4 2@&4>M1ML1-EKQ)J>4C:RX>[9VIJJ$8+R)55)J3UYM2]Z[
M8 P!1)!9S(3;&E'D#MTR&\.0RG4QDTC*8!S$3MG6\[8AJL1<85_.B\DXYNU0
M<&%&0DX0' SD5$2)DRQDU+08,U_'-6BRSAGW"O?$)W9^R)/?I>Q:+L9FO(T.
MTPUMC6Q(Y122@79)&-$LJP1E& HR#?MLW(K,7!#B"9SBGVNR?LF]& 0-';CW
M%88RP;%J^N:G-ZWKEHNM>/5V5EFWFW9IA0+7-5&Q2T9&M*^I7DI\SR#<+LH
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M6V:6>OT4Z(:FO':TJ:VSK<EA332:SA-9)AUQL[AOJNG;[U94X#D#();ZUJC
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M9'-RMMIM[ULU9/+58INR.V;$@I,6CF<DW4FNV9IB(BFU05="5,OM$  S]/\
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M.2-:E:K(MH]XK0->[(W[>[#3[[KEF@FV73 ';IK,3"9E5'4I%2AC&.88Q@U
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M]R,'Q6:2K)O86YS1CMXE+$D68MVZ"I 054#H-B."2'-\IG4UA:"$*)C#&N0
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M\/E'^#WO3_N_S;^KV?[H^3387X%V3]J'GZ5C_$GN!_;'+_\ GP^4?X/>]/\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M?RN'#W]6[Y_JL;SR%O"WH^E%EBXP!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!'47N#4LY<I77,+M
M'74QL*"2D%YNB1=VK4A<H9")5:(2JTK6&DFM-QZ48M(($<&60(")ETP/T$Y>
MH'H,-ZZ1E:S/76+W'JN2IM5=MF%HMK#851>5FMOGHM"LV4]/-Y=2*AW;LS]
M$DW"J9U!63[(#VR]0.<B+%7[:_J=EJL[#V:N354L+^'GZ_)LIF%EF*TC4Q2>
M1DK'+N6+]HJ >]424.0WM#@&<8!\X'^T#?E7>2/[$Z0_F&UKD,H]YC?D*_E<
M.'OZMWS_ %6-YY"WA;T?2BRQ<8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , Q]S^^J&_@_9OW1J> 9!@'S@?[0-^5=Y(_L3I#^8;6N0RCWF-^0
MK^5PX>_JW?/]5C>>0MX6]'THLL7& , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , Q]S^^J&_@_9
MOW1J> 9!@'S@?[0-^5=Y(_L3I#^8;6N0RCWF-^0K^5PX>_JW?/\ 58WGD+>%
MO1]*++%Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# ,?<_OJAOX/V;]T:G@&08!\X'^T#?E7>
M2/[$Z0_F&UKD,H]YC?D*_E<.'OZMWS_58WGD+>%O1]*++%Q@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M5+3(5.1/$6EA7+%$3CVM2R:[MJI%S[6,>.EX:1(Y8+IB@X*FJ"B*A1+U(8
MRO & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M_HE5L^4;+)RH"S,4'("D C*)DP2, 8 P!@# & , 8 P!@# & , 8 P!@# &
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M44[N#15\B=4K["6=U*)>W^&D9@+KJ2_ZU0*VDWE&>-FO@'5S(Z.)DC]M- Q
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M[J[S;.Q_+[L>MV\JBI<8.C4;?%9MTG"@4_B&M?GYF;L,7%2)S"7L++LG*90
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M;3Z>FFZ_ ?F!LNQB'T1U.& ?P9+:O7T4S7PA\_9MC ?H?)(.  DMJ]?33-?
M'S0V;8Q'Z ZE# /Z,EM3I[VFZ_$?G[+L8!]$-3&P#Q]9;6_ O7O^\ZR?^$>
M>026T^GIINOP'V^FR[$(?1^2<, ]IF_V.=TW)(52DMF)EDRNW#/8$Z^=(MQ,
M *JMV:VM(Y%TL0G42D,NB4P^@3E]G ,VP!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , X!T42V6(7, E1)!V)(ZH^A,JJK^KG23,<?>@=0B!Q*'7J($'I[
MX!S7?H?9DOMA/=R<,C*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=QAC*'?H?9DOMA/=
MQAC*/Z"R)A  53$1]  !RB(C\P  >HXPR<H_3( P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P#J7<XO[1'O;BGRTWIQWK?'W4M
MI@M3W0]8C+!.3MQ;2TJV+%1D@#E\@P=D9I+]M\)>B8 7H4,C)5ME4_\ FIN2
M/]%[2'^L=\_7N,C+'_-3<D?Z+VD/]8[Y^O<9&6/^:FY(_P!%[2'^L=\_7N,C
M+'_-3<D?Z+VD/]8[Y^O<9&6/^:FY(_T7M(?ZQWS]>XR,L?\ -3<D?Z+VD/\
M6.^?KW&1EC_FIN2/]%[2'^L=\_7N,C+'_-3<D?Z+VD/]8[Y^O<9&6/\ FIN2
M/]%[2'^L=\_7N,C+'_-3<D?Z+VD/]8[Y^O<9&6/^:FY(_P!%[2'^L=\_7N,C
M+'_-3<D?Z+VD/]8[Y^O<9&6/^:FY(_T7M(?ZQWS]>XR,L?\ -3<D?Z+VD/\
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M4)!!R*Q1GH@!("!B"53KU]@?:R5J])G9;7GUE\I#T&O2RZ+L>I+Y"S@594
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M7RA:#7O=1=^1+Y"<_BLM]^:[^VZ7UF1[9H_MJORE\H_9_,/L+OR)?(5TN=4
M_*/08J/ZXJL34O(Q1!R,@W.#;LSW'Y,X N*8F0.L5;H !], &^9D^UZ3&>UK
MQZR^4AZ#7Y2["[/J2^0L7\5EOOS7?VW2^LR/;-']M5^4OE)_9_,/L+OR)?(<
M?+U0YXJ3(I+5M1,\>]*HF:40.50AFR@&(8ADQ*<#%'H(#Z!Q[9H_MJORE\H_
M9_,/L+OR)?(0/Q#JX#Q.XP';2%>:(J<>=+*D;&D$&QT.^UO6E3)J-RI@"2I3
M''ME]HW7)>KTB>';7GUE\H6@U[651<UZDOD+$?%9;[\UW]MTOK,CVS1_;5?E
M+Y1^S^8?87?D2^0K,^JH!S(K ^/KOB#\9[WU>A((=!12VEKGHV,Y[';Z@=83
M 3V/2(Y/M>DQGM:\>LOE'L&OW=A=GU)?(69^*RWWYKO[;I?69'MFC^VJ_*7R
MC]G\P^PN_(E\A7?E[63$XG<GSJR5?<I)\>-U**-R22*YUBDUM93BD1$2=%3G
M .A2^V/HQ[7I'L5M>?67RD/0:]++HNQZDOD)MK54.2N5\B<K7$DR0D44B02J
M) 3(5@W J8$ @ 0"%#H !Z Z8]LT?VU7Y2^4G]G\P^PN_(E\AS?Q66^_-=_;
M=+ZS'MFC^VJ_*7RC]G\P^PN_(E\A6RGU0A>6N_.[?5Q-R;17&!1=X#YN0'('
MNG*1(B?B03 RYT"-@[11'WA1+\W'M>DQ^EKQZR^4CV#7YQV%V?4E\A9/XK+?
M?FN_MNE]9CVS1_;5?E+Y2?V?S#["[\B7R'ZHUA4BJ9C35= I3E$1];)#T !]
M/H @CCVS1_;5?E+Y1^S^8?87?D2^0FJ'2!&,9) JBN":!2]\W4[U!3H(^^24
MZ!VR_/Z9O&49Q4H-.+W-;4<TX3KDX6)QFMZ:PUUIG)9)48 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M=UVB_-*/7T9K/YD/5^-F4/GS];XD6=S(U( Y(O\ U?0:XIX=9QWF[>.9.RB
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M;YV>2Y+%_M"'5+S,X^8_T5]:\Y&<RZ1&8E1 P]!DGP_2C_G2OSLY];LUEO\
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MK&E5-E4]?7A*_.KP\//),BSVR:G7I0#1<\QD8ISXB)E%TP[U$_8$_:+T, "
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M;;BS.5 ..7'P/$B;J40)LGDT=,X= Z=%3K&+TZ]0$@_^CP;_ $*]9^9'LO\
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M]1'S3F__ ).[USF\[#QPP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&/6JHU.]03VKW>L5ZXUF
M2[CUC7;5"QMA@G_AG"3MMXV(EVSR/=>'=($5)WB9NPH0I@Z" #@$/H<3.*S9
M9%RVXS\?F[ANJFN@NAIK7*2R"R1P426153K93IJIG*!BF*(" AU#&6"P. ,
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M$A*;J< $Z?7WX 'L^@!]CYDQP]X>>@Y(O:$I1,  82AV@ >H ;IZ0 ?; !R
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M5VC@'4O:$!  Z=?;Z^UFM..T63*[]&RS2!E3(HF7(":QDDS+)@(&!-42 *A
M, B!@*?J'7KZ<R-#]<$E8=(+/S[CY@IN&Q$FI-UTON5@. F.(<;-$$( EZFZ
M@=N4IA'T=D1Z?W-9_,AZOQLRA\^?K?$BSV9&I ')%9^C0JX+!L1P<V[>.8*
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M1GZE+_A&SWO0?T*KU$?,^;_^3N]<YO.P\<, 8 P!@# & , 8 P!@# & , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M/1\SP;_0+UGYD>PKY[ZOE+09D6./DTGZS0Z<:NFV="8G954+V@ H&ZG />G
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M3;:PBDU)M<+QM-A,-_EZ7]XK_BS9W<E_\A#JEYF<O,/Z*^M><C"< PRTP!1
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M+1"U"X_)397B\O.QX2+-6F1K09'8T*W3,V?$:RMCH#628,W H*>'<N2' 4S
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M/F?-_P#R=WKG-YV'CA@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M*4U%L+9J5<>%8P;TUSKAPSEQ/)=+,#4XITR>K/V;E!^=!LA_V[4"B)5_?=1
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MC]]Q^X1_7N/N]^N^C^</O2OL/I_F#Y,D?ON/W"/Z]Q]WOUWT?SA]Z5]A]/\
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MH_9]GV.HYY[3U=A3&G.>%8SNR>M:S4>U:F>HQP\<LXSG'EPO,>]FQS# & ,
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MUC=VYZWWALNQ;'?5FXT.4H$3#5A:HJ3W@TG;*Q319,$^^,BS$>ZPWDE+!6^
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M-&R$SI_:T/$LW$C*2NMKU&QL>T2,N[?2#ZKRC5FS:HD 3K.'+A4I"% !$QC
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
+P!@# & , 8!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>tm2115679d1-lc_amgimm4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_amgimm4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"2@.2 P$1  (1 0,1 ?_$ -@  0 " @,! 0$!
M       '" 8)! 4* P(!"P$! 0$  P$! 0            $" P0%!@<($
M!@,  0," P(&#0D'  L" P0%!@<  0@)$1(3%!4A(A8C%S'3)!@X"D'1,E*2
MDU0EEG>W6!DSLS1XB+C8.5E10G)#=#4F-[5A<41&MM:8N3H1  (! @4!!04$
M!P4%!@8" P ! A$#(3$2! 5!46$B$P9Q@9$R%*&Q0@?PP=%2(S,5X6)R@E.2
M0R06%_&BTF.3);)STS1D)K-4-44(_]H # ,!  (1 Q$ /P#W\8 P!@# & ,
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M/Q/^=[G;RY6%;-=4K3]TUJZ5%#62:O:ZT2X,! YH'Q[&Q)TC7N)RR1*-K"5
M/>/Y@%@]G\ M[_##5"1EJ*W]H_UF+G#GOHN2\E<P\[7KWY?<!7NC38;'0Z+_
M /%(P]L*H**21M*_H&:92*3O\55:$2Z?;V0YM1*=?3B6[4 /*(JB\V1S2=$3
M3XS_ .L$<P>0^Y73EF0UG:O)?6C8WK')+1UWHTI!TM+:&K[S(6Z%R$HMM5+9
M''6H UJEK<VQH7FMH1*TQ2@DE7M*<:8E4D\.IOMS)HT4]^?UAW@'QO\ 0[ES
M'?Z&^'6RVB*1>7N>ZTKZ.R:/(D$N2GKFA&<Y.T\C2G[GM"4$XPO2?8 %G%^@
M][WO0=*+>)ER2=&66\9_EOY7\KC';D@Y@;[70(*6=8@S3#5IQ%FB:@U7-D<@
M6LVV8MGE<I"M)"3&E'S",$3L M@UK0O=O>HTUF5-/([>P/+#QW7W>5+^.,V6
M/,PZ3NQN<G%L00%*PR>)04;<VRIWTT6>_)Y(2IB4A6ML.6'E-_TBA7HD1!II
M992@D8U'2HU*M.I(7D"\BW+WC-I %\=22MU9HXYR%+$(?%XFS"DL]G\K5I5;
MCIAB3!]4@3'')6IO/5*52U4B;TI16M&J &&D@-)-Y!M)593OQS^>WA3R7VN_
M4+49%TU)=[-'%$N0U7T3!6*"R>6QM !*<[.,34Q6:3^-N2AJ1+TZLU"8O(<A
MH31*B4YJ8A4:17%K$BDG@;J\R:& , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!%%\VFGHRC;G
MNQ6S'2-+3U46+::F/)UH&U0^IZ^B#Q+3F8AQ,3+"T!SH6T;("<(DT)0AZ%L
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M"5L:HP0E493?&4'>S-[] Z]=Y'DBQP;+O_U/."5Q&/'9TWTPG9D<FNN5=(6
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M , 8 P!@# & , 8 P!@%1?(%_0,[;_ZHO27^QJ9Y5F1Y'@=YM_\ ^,[R!?\
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MVOTI&&6.HV*,JE ME#.4*/ISCC-B%[Q;.ND1IJ=#WT9@Y!@# & , 8 P!@#
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MM9(E3BH=/HTY1!:$G11)M)41$FW61ZRLR;& , 8 P!@# & , 8 P!@# & ,
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M_>XJ<WOBMB>H0QQ=F,31]([)O<E?'?>MK Z]F]"$,NN553J94:.O0]2&9-C
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M: YN , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MV87N5M3>Z-QQZ8E826K1J% #B!F)5!9FM"UKU /6_P"S@5,[,MBL2H(7:&[
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M<%D&:'0BS"AB#J6>P48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M66^3B)(WAAFKE5U-OJ65PN85^M;I$U*6 LA&-4A.1K5Z=7HT$*GT>9=G(48
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MF&$PA2F.-)-!O0@BWK?KD*9/@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M6;VWNRL;B$H7HNCC).,D^QIT:?M.SS!QC & , 8 P!@# & , 8 P!@# & ,
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M999L-8]"KGBIVJWXX.+-K@)RUN^>Z]VL+2&F')2U6V<O:@"8XXH@TU.$WUT
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MM13.5*>!<^!TV/>D4[M-]F:NNVQL(9%R=E>5VF5_;EZD],+28:DAL-"6/7O
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M22Z(Y-IM+>SMN$&VY.K;Q;9;7.B=H8 P!@# & , 8 P!@# & , 8 P!@# &
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M=J6Z[D2,YU$,A0!>U)V\Y0S[-]PBQ)3#+5T(TD\$>@#,FA@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P"LE]]@4/S*J2);D>9\Q!5L"V4:<8U1MZV:PHF)N,4%KUSQ)*NK:9Q]B^BT
ME&8:4M4IS@$ZT;L&B]A'NTJ2J0H3L"A^FE2M+3;S/GT*1@12C;C):-O6LF%:
MQ.)B<M N9Y):-;0R/OOUNE0#"BD2E0<,G>S= V7H0]*4%4RS>0HP!@# & ,
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M+3XT^[4\MK-9"4UC%.$O\<)2"'$V"W#>HTX+EJ;R#JPO"-0S$F*C0M(7%02
MO8!%?-L)8K3O)7N9LKR%& , 8 P!@# & , 8!H]ZW55:+R'\6)4#YV4;:8.R
MH>)Z8Y+%>QD_&:9LWQW>8BCZ^E<DAJ;C=;+Q(1I!'%1]Y4.^G$QR"87I66Y
M+JR,O,WA9#0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8! ?5G]%WI+_4'<7^SR18(\ARG_1=YM_U!
MT[_L\CN LB?,%& , 8 P!@# & , 8 P!@# *B]H5W"K,JYA89YP]$.^VA)/F
MMW34[-&7GY^:XVY$1V4HR;+3H^D'AD@Y;@SI5YS6 Q*:)VT6\C"4#:<2K8:B
M/XD8^)XDI/XUN(R"6PME)(YTK<DIG*"D 4TE%L9 "VPH" 0T("T 0Z*#HG>R
MM:!^3>P^F'F(Y&PC(48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MD;+/7 4DIU(%AP-Z$;HPL ]#WOW!UOUUH\Q'(V$9"C & , 8 P!@# & , 8
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M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!0;GO\
MIS>0[_LE_P"R!ZP19LOS@HP!@# & , 8 P!@# -'G6[7""_(?Q8Z)8/V4EFY
MW94/*<9S);4Z$7\9N2+7'=Y@ BKZJGBXW+GIDEY:8H@HY4U0UO7C<4[D:-0(
M]0L.4U9&7G[S>'D-# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@$!]6?T7>DO]0=Q?[/)%@CR'*?\
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M50WDJ'C97M"6%*67:.A&TW@ST 9DT, 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 0'U9_1=Z2_U!W%
M_L\D6"/(<I_T7>;?]0=._P"SR.X"R)\P48 P!@# & , XJY<B;$2MR<E:5O;
MF]*H7+UZY04D1(D20H9ZI6K5'C+(3)4Q!8AF&#$$  !WO>]:U@&NQW\C216M
M"JI[BSN_HNN]B%Z7%5-/0)@KM<F :(O[K%BKVMVF)]8T>4%@V<D=(PQ/3:XI
M_::C/4 ,*$9:$K[2WU+7I7=^Q=7*:]6OH=-#J;'95%YG$)775@P63ITB1<JC
M$[KV=L\?F,1?242\@\)*U&5I0E/*4D"-3'%&CA4ZFH[O*[NE95V6^<JTB1UP
M%CJ[B>/],K-<<;Y\9IVY3NS[:M.NXLZ2N3=&26.15Y9H @I18:UPQ$<6HEKD
M\[TJ^1"A/&FJR,NM:(K^?TO>_4]2]A]&U%V58D>:N.N'.>KEHAVK:#0R"5U=
M%JRGEUSZ@E=H7#5TK:K =U\6GBA0U,9D-&]_#'D)"XHI0-P, O)O<*MXU$CZ
MKZ0L.B^P?(JP7A:E>ZY=OZI(E67,S,1"C*==ZM8(9S1)[8C%CLKA$%<EF<IM
ME5;$C+)>/NB54QEZ:]H-$_2J-+'<*NE39QUQ;=-21Q6TC9U8^1A>3#W]BDNI
M7R/"^\Z\;G1Q418TY(F17AR&Y05PF# G;Y2,M<T[>%36%T(#]0GVL0$B(B*_
M>=AXGM$Z\:W$>DP7 "?7.E;Z( [#7FN@2=,9'Q!<C'4PUT,< @]-'"4B$HV9
MZ[,WL?KO#S$<C81D*, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & 4&Y[_IS>0[_LE_[('K!%FR_."C
M & , U;WE5O1EI7-/)D^2MY@M9<]SA)+:J*C]/4)84J6UYKFY,^FV1S^]VE!
M[.):>F2^ABGF++]/"=,C!!3=E(4Z)8M"Z++@3$GRI[,I[I:DZYK&]9/S5:MH
MS>K(<==%.-$MK.S(VKGI45;'6PVMOBJ9_ER)X8F.2DJA$C -84620$P)P]!T
M9MUP&9;PUK;U#6:R*4I:IJ/;QM:A$K]RHI2WFI]I#4JG:@1@U!9R86P#]^Q;
M'K>_7>_7>0II[9?$H<]1RGJ-O#H!':'(W,M36_2W.E.,5-D0&PFF$6W0<NY9
MV1=%Q*[)G#7;3A!.?Y\\L#0<V12(:/&MVM= N*H 1YK5\3.GX'V=_%5,;DCC
MFR]9]4"N1UBW+S_RQSW*X%23;4CU4K1(Y55,[<KJD93[8MNM=A]!*)E0T+6"
M=DA$;80A91DE,I0%A_K*C3VEM>>.7+*@5T65TGT1=<8O6\9Y6M<4FT.D"IP^
MC*^@E35H^3B6HV=AA3E:-R/JJ5S286 M<9$ZJ7\PA8-*A)1HD"=)HH8J75YE
M>^R5W0@^J>#$+Q%Z:(YZ+[ABPXK*&V=S=7<RU^WR9T<)0FD$#55RBA#8T =C
M'( #TTC5G"3%)A[*T,TTLDLB.M>ZIM=R&A@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P" ^K/Z+O27
M^H.XO]GDBP1Y#E/^B[S;_J#IW_9Y'<!9$^8*, 8 P!@# & 5HZ9J:>7$VU/'
M(I*W^.1%OMU"[W2VQ.T9_3,JE]4J*_L2,G,\=L.L34<O:G..3Z1L$GTD)6(2
M'@J/C;E)X4ZLT(Q&:WJ\ZWYHX8O2\:0N+JF83-1%8=S['W)H-3=.]+3,RVDL
M-?Y1:EM6,?'Z\G47IJ6W BFS /<-;7,Q(G1LY#L$A-]W^$-I5$K0W,Q:1,DR
MCD>F<</,6,4M8&:1,B\]N7M2I8R/2 IU:3U#:[)$#NWF&(UP1[3JB25! A["
M86 >A!U#163H+C>#W_+&ZP-63>-*6"G@KQ53U-Z#L$,"D$QJQ\7_ '99 I2-
M:RR)N5-Z)V&:J:W),G2R!A4*E0VMP1B5J?E$:J05,O%!RK)F@B'1TZV:EJ]S
MHNM.8[.J.IK(<(M7UX4!4#>[,L!K"U4:E$[OR]L:8W(7%I/<6EP:'QQ:5YR-
M8N4)Q!+#:C2C,9WXW>?Y_9TGGZYXM=CBMB6!5=LVW0D5G7V6@[=M"E$T*0UM
M.)U" -)SCMQ9$-9QHA4D:W)L:7LI@1!=$BWXM^Y441(G:%H1NIJN89'*.TZB
MX4;UL^:V0FW+H.JDF+2)8ICLI7%UR@%<$DB\:V_NY+:8YE:(4#7?3M!_L+V5
M\P@0,C'Q/'@4^-;B-26Y)W@M1SI6YX'=)\&TKJ UC(,"Y)MI1F)MIUP1?*#X
MQ"+]HM>W>]>F\KS$<C81D*, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 4&Y[_ *<WD._[)?\ L@>L
M$6;+\X*, 8 P"D'DP0%.?CO[B0J&9YD*=1RG? %#*P.:=F=').&M9&,],6XJ
MVYY3)THR@[^I]Z%<$:;1@/I5/N^ RK,CR90?@:*@0W)6SP"LO!0Q@'$G4T$G
MX&<=*+D&!5#U7M.K8K5>,NA1)PT9Z*_1?O6F<8_Q,_@$?O(O<;U\AH8 P!@&
MCWK>+UZ1Y#^+)2CYBN5BL-;V5#TSKT^Y.#(.F9D@!QW>9!<;C[>5;[B]E.Z5
M(D3(AB,AZ &U+4IWH\0=A-4U9&7G[S>%D-# & , 8 P!@# & , 8 P!@# &
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MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MCD;",A1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /R,8"P",,$$
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ME:T[4$#LB+;]%QXH(!;3@1;%5D9>>1O"R&A@# & , 8 P!@# & , 8 P!@#
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M^H2@C%KW:_#\=8M[>_=A*Y:A.5N"K)I-J*[9-*B]X2;54L$8A4ME-=MUY#[
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M$ O%[WMY&M??_,!UBJA%,N@@*D_CJX7>G:O*@^WC%HPMEOFZCQGSVX3C4VP
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M"U2)V>8]VQRY:]5T>Y.9D67'+3[(F#IRC5T%!*4/N'M![7X!1[H$LM-\^A
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M1"O7KV8?>CY_T1I_YOX[551^KMUIBZ5[*JOQ7M( O=SZ*6N]"RB]:=I."UA
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MVMPO'&45&2E&6BVIPFF\?+BXRBTZ^%O-VUHBITE%-TH\_N54_86>SYLX!@#
M& , 8 P!@&NGO3RC\F^/-G9DEQ2IUE]S3@1".I.8ZA:_W@=#6X]+U&T+0VP^
MNVP\*TE*Z./\G*<'$:)N$?\ L0'#/V D=2;(VEF>(KS3>.[S%^2QUEOE%O#E
MNI.8*II7E)\<F^H7.X4#E;D'H2GCK2N8_=BH!I_1TM-4BDKFK.2)R&W9(#$R
M(U(G5DGAS::6!QR4GBST%?U:#Q3]<>+F#]<,/5S/!6APN.5U [PH,(FR*9E'
MHX8T6 C>Q.)J-,GT@,+/D2;XPB]?DUL6]?W.9DT\C4$UF>H',FQ@# & , 8
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M0T$F<O:(6G03:/N4J8G63P%9,(:]1AHL2/,0VT+RY1):YD%"-,;RWA,<)&M
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MZC6@K^+*CB?:6WMP_G$F"44M5KMD@-U&V_8:44O:2QY6?_*Z\DG_ %!^P_\
MN\6)A9B63]A?C(48 P!@# & , 8!0;GO^G-Y#O\ LE_[('K!%FR_."C & ,
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M_*Z!YKVGH!R&A@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& >6'^M2S=HM/D6L_'I5*9YM#LSINXZ^E%0T! &A7)IV]PZ K'Q?*)HY-Z
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M&1H"9<>)2M$<L(#KV&CV<;L0];W[Q>ONV>8CD;",A1@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@%=^K.J*2XLH2Q.DNA)@CAE8ULR*'9U6&F
M)A.KVO\ C&%GB,3;5*I)M_F4J<- 1-B LP(U2HT(?4(?<,)*N!&TE5FDCB+D
M^\?)!T;%/++Y*( YP-CAB@ES\;_#,D6*%3/SW#S#4[@UW];# I)(3.70$O&G
M2KTOU!)8VO91!XR2S4[80UZ;I@B)5>IFT>Y/_,5X6_U!]V?_ *SY&R="O-%^
M,A1@# & , 8 P!@# & , 8 P!@# & , 8 P"KW;C#6<IXZZDC=SS5QK>IGR@
M;8:[&GS.C,='6'0Y9"'HA_D3:RE(G,<B7-3>,9Q39]*KTYC#I+M.?H[90ZLR
M/(TY\/W7;?1W3_-\GZVG;C'GFJ%73U6\\5\BXF%R\XR*S(;$&%AL5-=,B_G3
M]/$M,Q6U(N-?F^#H-1IN&%&>L4D:5LZ9(FKR(JMXGHMS)H8 P!@&J'LG^<)_
M.IX,^\?N:_F\_P ^&+?I7[;^M_WS??OYIG1_U'Z@^J__  C[1]V^Y>SZ;]M]
M-]-Z_G^7*C+K7NJ;7LAH8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8!K_ /(UY#:H\<]')[*FK0]V19T^?TM=<[<]P8 EUG7];SULM/'X/#VE
M*F<'#2/ZQ22)S<0)5 &].8#02E"L]&C55*I&Z(IKXQO';;;#94D\F'D;<$\_
M\CUZ-"Q&ACH5A;E7W%].NAZLQCY]IE$4H5MJ)>B95>BGYU(&<8:>:H3%*%'S
M.+B\&^BR(EU>9O*R&B@_CS__ $>=%?\ 7X[Q_P"]%9.5D7ZR_&0HP!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & >7#KHV6RSM3IF&<^K>F:\J^5AM!J
MO]BK#K^"4A$^CNC*6Y2J&T96P-L6D?-MO2RE6YTHB11UA=)JR2N(+G=U"$WZ
M$PE*!Y4:1AYX'HLYV>:^D?/U%R&I6 Z*54_4Y6+S6464)?H%$:KYTA+(NAC
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M[KWZSZ3Y/I?JOLY?U'TWS?MOI_F]?9[OS>WT]?QRO,1R-@&0HP!@# & , 8
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MI4R,Y&>E4&@0R58JTM6K@B)":!0615D1Y^\WA9#0P!@# & , 8 P!@# & ,
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M+ $( AUK6LR;,IP!@# *#W)_YBO"W^H/NS_]9\C9>A'FB_&0HP!@# & , 8
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M#\YQH@@U^.\ \VW5/??:]DR"?5K6]56)7-&6U'E4)C48N/P\]4VI<136\0Y
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MYNE;_%]U^J^Z?']C(]GW+Z[^6_7^WT^;YOVOR>OO_-ZX>8CD;",A1@# & ,
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M(],N%N=DNV)0A)'\JO<C,-3[3$E@2'!'L9+ .O4W:Y#0P!@# & , 8 P!@#
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M$G5G)!-+$](&9-# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@'ECZMBM1V#W-VM0<NXWYW[[ZEM51!UM$3F;]"\XU];/+4,<J#K5
MLAT%1Q6ZY/'+[K&*PF=)'29II+333)?KCWXXX[1;Z6K*WI9&'FUFSTL5#&9=
M"ZFJ^'6!+3I_/(G7<*C,VG:C1@5$UES%&FQKDDM/T=K1VCI&\I3E@M"_-[CM
M^OXYDV:CO*%UG7E063$^?&I.&I[?Z$J!Z8K'[(_<%-[55T9S.H?G%O<V&+*(
M! Y>\R^TYI(0K@Q5@6B+CK2K)4/CKHP*9,VN]1EOH4SO&%<]5 EEDJY=FWD4
MK6[T'C@Y9I_QY(Z[A$_/K:W6.IX1:+MS1&8*BC\#<E4Z7MLML(DB>Q6RPMZ9
MN"J+7+D*9&,*\FXDP65<CCVB79"*F/(CQQ8T FPNT>NNPJ:M*J$L0JJ?2&&3
M1+/8ER"F06C%;.1,#C#4T,YU?*U>$SHO<7=.HC9,/"+?L^1M^I=CZ#HT\S<3
MT\&T:]>W&R7SR.USR;43^[LL?BS)9U7TD!A;G[<;^4]D26%9,G83GUW?3F%Q
M="TPM_,63\H2P[*3[%J&G[3X^*$SY?&QQ*;]>2Z_+SK7!GW1/HD*=R][(2+Z
M\C280T^B5GK\@=%BV#VBU[=[UZ8>8CD;!LA1@# & , 8 P!@# & , 8 P!@#
M & , Z*3RB,PF/N\LF<B8HC%8^A.<WZ32=W;V&/LC:GU[E#@[O+JH2-S:A(#
M^(S3C %AU_#O6 :,;4\_//S_ #5UI/QRTQ<_E'OQN$%.L9^96)211<34F['H
ME58G23\W"@#!'C?0'L=&XMX;A&&!*$> S>]!UI[<#.I=,6:H_)QXPO/YY>J%
MB2*\YIQ52#$RVZPV#$.*X@XOJM/$BRH;/F(,VL[H7[',54@LJ(I9#MI UL6S
MHXXE/*M9H:<:1.294XHRU*2Q*C_U=CP7=J\R=TUYV[8[I2!]-5=+>S:%DJ6-
M3J0.<T,G%5RBYN5),:V,:N$-J!4Q&6=!UIB50-:48:U[+/$4 P6R I235!"+
M3J>__,'(, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!'=O-
M6GVIK09-UI'KHT\5W-6K=.RX]D2Q2V-.$:<TFZTDZF2MSQ'$\>G?S?:UIC@D
M5(@)E0]GDF%:$ 0&H[AGQX=,4)T BNEWL6O^8*%)8GMM!X[^;I]T!=-&FKWE
MJ/2-TA=II><L8H;%GF-*#21EI(%6T.0'"2%!-&>#W[,TVC*3K7H;KU"=.K3G
MI%9!*I*J)-3J4R@H!R=0G. (LX@\DP(BS232Q;"((M;"(.]ZWKTS)HJA5G O
M"=&3-!8U)\5\E4[834E<D+9.ZLYQIVOIFW(GE >UO"1!*(E#6A[1I75L5&IE
M)99X0'D&"+'H0!;UNU9*)$A5GS!S32J*<-M-\\494K=9RI0MLE!6=2P&!HK"
M6JRE1"I7.$L6C[41+%2DA<< PQ>%0,8#AZWO>AB]95EHCNJ?H.BN>F!PBE!4
MM4U'Q9V=U$@=8W3]<P^M&!S?E9912I[<&>%LS*W+7=242 )BDPL1PP@#K8MZ
MUK HED:ENMXO7I'D/XLE*/F*Y6*PUO94/3.O3[DX,@Z9F2 ''=YD%QN/MY5O
MN+V4[I4B1,B&(R'H ;4M2G>CQ!V$U35D9>?O-X60T, 8 P!@# & , 8 P!@#
M & =))F3]2QN01S[N]L'W]D=63[]&5_VJ2,GW5 H0_=X^Z?$?]M>VWY_F2*/
M8/X3P '[=^GI@&G=GYGF*WM^PZ'/[5[IW7\;Y4INW&Q.&_ != 3&;6Y>T-?3
MCG/](_*<WF,D ;@E$;#[2S F#UOU'OTO0S3&AN7;TGV] A0?5+%WT*-,D^M<
M#_J5ZOZ8D!/U2Y3[0?4+%'L]YH_37O'O>_37KD-%6.KN[.0.'(EN:=7="5K2
MS6<C/6M+9*7XH<RE!*86P'@A=?M07&<S504,.]"+:FY8,'IO8M:UK>]5)LC:
M69J#_P"*GY#N[_\ -/B7X =V.LG?]F@[E\@PG>F:3,;E/\G)DM<5$S[/LVT&
M@_Y!'I5Z0PS1.R-!5-HO?L ;1+,FIOY4=S'?!.X](/K59'E][+NOR$RI$N(?
M6^B&YT<*&XUA+N >CB@L%-5RX-*A_5-?L+3Z<5"I#]T3E?R]&=[]A"K3(::_
M-B;S*EIJHZ$@[76E(5C :AKQD]^VJ$UK$F*%1="8:$L!Z@ADCJ%O;]+%6B@[
M..V7LTX6O<,0A?CF3661K6\A-]?7G5U5T7H7KB>OE7]<<CV?)GJO^4[SF4'.
MAM;7)7]DS-SCLX8X4KC4G$S1I"?ZEH5!XS59(TY>A&Z]N5&6;&*9N-EN^*K)
M:Q0ZVX.E0OJN/G,]S5)/Z:E1JE(A;7 2]'&+&88^\KV(XET  I>048D-/+.)
M"9LT@T (:);P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MHLQ0']CK6LK(JFTK(48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@+6IL2./M,]IBDW00^D;;"BE[3;[D-# & , 8 P!@# & , 8 P!@# & , 8
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MX"/&O3DZ8R-%D+AJ3E"D:PD&M!-V88,>QZW[A;WZ[W7F(Y&PC(48 P!@# &
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MP>'^PT?7":CS$3@C1\S'WSP:HB49L%/#AJER9['6#-;.D*53HM\^A+? Z_\
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MG3D@"620026$)91)18=!"$.M!"'6M:UZ9#1]L 8 P!@# & , 8 P!@# & ,
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M=BV$2O6]!TGU\F]_WGYOX/QSD5B^U50G3V/V?>72S\;LJ':V+7WE'L0!" (
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MU2V?WJK_ !0/XW 'ZI;/[U5_B@?QN /U2V?WJK_% _C< ?JEL_O57^*!_&X
M_5+9_>JO\4#^-P#MD#BG<2QFI]&:" ?QB^0.@[]WMT+\-:$+\/06"'.P!@#
M& , 8 P!@'B'\@OA496OO&960E9+X'"N\^I-II;9!#S5\Y9TZ^P(I*)\^MD$
MKQL8F24Q$YA<"W%(4:_+%9*HA'M1\FBP"T+[WT;RUCC]MO[5Z-N7F[>B<I*-
M&HSSJG2+K1N/B4M,4GJP_3OR[YO;<1M.6L[B%J7U&UHG.2CI:C<6-8ND7JHY
M1\:EHBD]>%MJF\0<MXWJECCG(_1MA-ZN%*I"J5'.@X[+J_F"N0.9DI.0RRHE
M;5'VJ#+SOO FPU:%9KXVE.3L90CA&F'>_P +ZKXFSLK?"<OLK=W8QU:&UY=Z
M"E<G-Z+T/YD8RDY1BH8RZT2I]5Z;]<<#MN,L^FN>XZS?XN&ORVUY6XMJ=VY<
M?E[BW_-C&4W*$%;59/YJ)4D%#U1>]*NBA3V3SY-8V6RJ-!/ZMYE1N,TA0&A.
MX)M[<YK"UIBI;#(^Z:9A;+/)TW?(0'7L;U  :UGJS]-<-R]M1]*;ZU<<U_\
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MR=:1<=;4JHD_///*& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & =NP__=D7_P 9G_,F8!*. , 8 P!@# & , 8
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M%K?M*T+0?;K6]:"'TWYTG\ZC)=Z2^U4?3M^]EU=M&?G:9^(#K29T1JP@UO\
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M& 8=[UO6];UO6\J;3JL&@?O(!@# & , 8 P!@# & 9]$_P#H2G_ZK?\ S1>
M95@# & , 8!$C-?5-2&Q;;J5ELJ).5B4+'H)*KHBZ5U)&KK!CLQ++7"#*YHH
M_!O8CI UP9S6%ISS@J2D) %)I99"A,8<H*]"$JX\@W&5L,UA2*%= 0M0P5;
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ME)*5,:'<YQ' , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M[*X?#(JDUDSCZ9?B#L*)U>D7NUH(Q;7[=!"]I9X ;UM_*=_BV$1_O]0>WW"
M'0O<'6P[UYU?GA!^[3V?NZ?TK0NKM2_3V&#V BM/3 $< >FPQ[3N"<6DREM0
MI#7%"?Z)#"U#DX&.+>ET@$H^K-$6C]YP"/B+T$0OS=W83XSS_P#CH25EQ>*;
M=&L<$J-UII5943=7@;@[6KQIZ3,$BM[1)$I#DUJ7-42G)+4KVU2V&%J30!&
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M_76'F(Y%[LA1@'1.T?0.P3MF@"6<H3B2*1_"2>0N1B]/D0NB%26:C<T)H/4
M@&@%L(!"^,0!;]V<]K<7+35,DZK--/MBUBGWKWU-*31#,KKQM5-!S!*&-#(X
M@H"46H9'0DE]CFO4LI,,38GD SU$7.5[,&42GTJ)2I"1>H7 (M:+SV-KR%R-
MU7]M.5O=K*2\,^WQ.&$Z9MZ7*3SM]3FA=:>J#:GVY/[,_P!,"C$OX(BZ/<A>
MJ2E,\I1:^-JUK?55;*W!VC#DA7IEB)8EG%5KU"1P7LZH!BC8 MQ@B %"!HE*
M?O\ ;Y]IM/6^YGY=GF+5C>0A).*O)1FFFFG;O)-*2P^=5K6LH_*=^&_FZ*^H
MS2>&K/W2[?;\34Y3-+W#%^JG"(QN,.-Z+:/>Q2=[8HM.&Z))9"V-:Q&8U.2=
MRER96BTFVZK$1ZE">C/&=\8TQ@-;V(8?U#E^8XG<^F([K<7([*&]AHC*=MS<
M923U)J#3KI4DI*2I523Z'JWKUF6U4Y-6U<5*M5I\/?C7O-Q"_M]\B?R*+.Y1
MZ&BQNQ&?4/+#'DKJB]XDR/>U+I,(JZ-Z-9\:=&</W:;Q!&667Z "#W;U^30]
M&6=U2/&\IL+JZ1E-IYO!6YIM8M+YLV\:GCK8QG_*NVW[7^I_M,B;?(AR?+ E
M-,FF^V93\^C/T_;M=R%L,"=]2M2[-+?&E@<&%!HD(@^P9I6C E^ON%[MF>S@
MN>@?5&UK=VUG7&GS6+L7T3^64E)]Z3I7NI7+X_=PQA&J[8M?=6I-$?Z.Y\=2
M$88C?L0;SU "226Q'/(_-D0SP@;OC!]F6+U\F:49:9&824#XVD @[.,$7[_:
M+7CW_3_/6F_JMC=E%9MVI6WU_$DH2=6F\9]%6F!PRV^X3\=M_!K[<OO)B16$
MX#2E+DS>GG#.:$TPI]@B=W/^I+++6*1");%*12W#" HLDH'PNR@9R@8PZ #V
M;UGDSX^"DX2D[%Y?ANN*IDLTT^UXP5$EBZG"[:R;TOL?Z?J.W3V?$C3RT:LQ
M[97 81;$A?HO)&@X&P#0%&!T<L:BT2C0#7,D/O)-,*%[_4(MZ"+>N&7&[I1U
MPT3M]L9PEV]DJK)X-)]QEVITJJ-=S1E 'H)P F)VQX/"9K0BOY#M+LW0M&[!
M^"\Q)\.AZ+U_ROLUKWA]?3UWZ=9V6G24H)^VOW5^RIG3VM']VYK=:]?TZ\[W
M[=B]NCX_ZZWHLH?L_%]T'W;$9L/\/I[@"_'V^W8GEP_U(?"7_A)1=J^W]AAD
M_D4\:63ZV%1$UV<R7!(4<C7EHE>E2)2>:AV)$6@D24X!Q2DP@\8S=Z++2?((
M7H(/H'N;#;[&[>T;RZH6G%XJJHTJXU@^E5ABY4-VXVW*DW1?IW&5)7\HE.0!
M]T8U+BTI(UXU:0U(V 4?2A/4[)<MFJVKX@[T+?MTK-$#6O06][UG5E8;DW8\
M4*X4=72M%AA+_NHRXX^'%&0 & P.AEC"8 7XA& 6A!%KU]/70@[WK?XZS@::
M='F9. H9VE6=I2J;$"A2'X_:I.2$&*0;*$(96P*!%[. (HP>Q WH6MA%OUUZ
M;S<;UV"TQE)1[*NGP*FUDSBZ8RRM:^B<GE"+6M!]P7(YP#[0E;)!H)+U]T3
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MMB(AC]W-%QRERZ D;O\ S3>A-',THIL_FQDBT?8B'$*U,6K(LIX-&D0)#MI
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MIE226:1VV<9PC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M4\70]4VV/8EZAJ;V-IEC0WRAP;T2(\2IU?H>I>'-P2A=%!!P20:3)2Q%%>\
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M6$:=M,FM!8L>"2"CCV23,,49#M>PMPW\FT3;%350T1RL9)9AQ"D\H91._B,
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M';W7'VK6VU.23BL].+>26?7WF^O/P\\$SZ)_]"4__5;_ .:+P#*L 8 P!@#
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M2VM9S$2,D)* \>A&AS[+UAZ4AQ&YVMNW:A&-RPFZ0O9X]B2=$J5E-7'6LXK
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MMQ*%.6O8P@5:&6,_Z* :<T2HKYQ$"(3JFVXE@T!IXE17M,.+'HH"<TPP&@F
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M.]V>[M.S?A=HXOIX4T_9)4DL9.CQG-UG*U;#_P#=D7_QF?\ ,F9X!\N2C@#
M& , 8 P!@# & , TJ=\<EV/=\EZ@CT:X1YKNIUZ:YW9:1KGJ=_D<5C4VI5R
MSS=G$Y6\*8I7>9ELE:2"6ADL865ZE4NRA4#:=04C/3)7'*F9:[B)IOP[UV@K
M[K#BACB#1:-3=BWY6-L./7#_ &2R,BZ$1-SC= ,?12>Q*X6FJ)N]VBI<*A>E
MT6$S <&E;M]1!<52/:14(ZU68H\B]G7'.O.Q;BMNZ=5#UU;TJF+^Q,+HQ<WW
M3TZF6)?HHL:B0O6ZXKR\X##X^P)6Z+DIU2E&D)^5<H+,-"8>H,-W*E:1@/B_
M"2#QW<7A3D+$I >=*O"0F<!'C7IR=1E%HLA<-2<H4C6$@UH)NS#!CV/6_<+>
M_7>SS$<B]V0HP!@# & , 8 P!@# & , 8 P!@'5&LC8:=M4%+I,K$((C%: P
MYN5'>T[:C0%"A"8G.5$;/%L0BS-C+%O>_<'?KOUY5>NJ.FM8]CQ79@G6F'58
MEU/+H=6N8UB@G9(U*)[2Z+WO2&1-Y!XMG )"63].XH2TPD6A&!]XS!IU1GNW
MZAV'6M:SEA?A%UI*$NV#I\4ZU[E5+M-*27<^XPUPB*'9A(E,<* ,LTT92@U"
M&4I"3U:E9[_A<DNT,V3'K!J?>:,7N2$@%O7I_#G<M[N=&HW,&L570\$NCK;=
M*47XF;4W3!_J_L_6=2**QUU/V=\TA0.!6BB]NC(\;EKD@&:4E"F"G4R! \2V
M-GZ*<Q>GP$)0)RO>,0P:'ZBY/J=Q:5*6Y0?X91\M/.M5%QMS6'5RJ\*.A=<D
MJ84[U3[J)D.V#S PV4T.POHJ<L/;DA6HT3K-Z]:7UU;C34Q*;2E),4*H4G4N
M"?2??QFB7@& X\1IFS= "5OU]AZDO<==BJ[O;Z9)N-N[*,7C6CMM:$G7%:7@
MJ*E:G-;W4K37SQIV.B^&7V&OWEKQM-94#>3.@*0:99*3)L_I6M:KL&<1M4CC
M[.?IA"#35&I)'D2A(L<T!JY(>9KY5"4[>]["'X="^Z]3?F%<>^@N"WL[6V\F
M+DE:MS3E):OFG";32:C)+!277&GH;KDGYB^GFU#2NB>.?5/V%CM>-ZJRM!"S
MUNTQ9.9K8ST37:5R'(]JAHRR_JM%F3PLWW!5$?GULP>S"1@#K8-@W[OG_P#J
M#R;QN[B=V7;*SMTZ5R_E/H^Q4=<ZX=;^I7?Q2;_RQ_8/^&['M':$V/LEB*06
MPC/11>X+, %48!7\P!*#7?3H+UVB&),+V_V0!-#O7J(O;_J%?TTN0MW9]'.Q
M9PPZ:=/7'[.\?U*75)OOC$^^_'+H!1A**Y[5;@&AUHW2*T9T I4,L*H@HU60
M:K.T/82U&A^W0M:#^U+UOT.T,G/_ % JU*>SVLFNVS;PR>#IW?<^E'/ZCVP@
M_P#*CKB?' _IQ$&-O2EX1LT)(RE!T>LZ2E&G>]&F(#K8EI*G^3E'I-"T7KV;
M$4,)>QZV3H9O(_S!L2JKG';.XJX:K,.U]E,://MQIC1:_J47G:@_;%'8KO'=
M-U_P!-[-Z24 ),T;H$AF:N6)2QA4:4Z&6VN DJ;9NQ>FO?O>MZ'K8_Q]VR]<
M</7VRA6G$<>F_P!VVH/*F:J_TIWD7(P7^YM^Y4,>)\8CTGWL175-@&_LPE%@
M<(3&'0@D/Q&IS-)TZ]:<2F")./0 _&$&PZ]WX[]WX=B7YD699\986/2Y.->N
M+25<>TKY-/\ W4?BS)$'C^MED" 4>[6LYG4%;#\1J>%,6BOP"67OYR$[XEVI
M]"@[]GN'^S&+8M?CL7NZ\_7?%WG_ ,1P^VG%]MR7V-Q=/UY=AE\A:E\UF+7M
M902W/'+,#ND8$R3.WEDQ16F2YO4^L34<."^MCLD^0A&6<W$!/1JG"8JBP$HM
M[-$/9I2DP_\ *7[A_<<5^8&T7I^_>V>T5J>V:C:M:UI<7B\<TK:QEADXJ.=%
MZ%GD8?32<(:7#!*N%/[.ON-D,&\:/.C<H3O5@-<SM)U)+#H@RRIP[OA^_3V;
M)-<TS,-D9S#B"0Z*TFT6H3E:]VOD/]0B#^?;W\Q>?N1=G8RL[:T_]&W&*_RN
M6J5'G6J;[(GFSY/<M:;;C!?W53[ZER(I3%.5\3_^&5=740+)+_.<PPZ.LYOL
M!L!@C%"M&WD'F[T(H(A#,&+>]AUO>_77KGR.ZY?E]^_^+W.XNM])7)R^";:^
M!TYWKUSYY2E[6V9I]\CR0OXP.C46 K8@Z(3JDPA!V$1&A@+3$#$/8M#5E^H0
MA]?4P/\ ?:]>GY.XFZN,JOJT_O?L?P,:9/HS]B>TNA!+ E>#3!CT6$(6)X '
MUV:,K8A'GHB4Q8 _&(6Q"'K6P^F]>ON#[BLRS;@E_BC]R=?T]I-+[OB?G;DX
MBUK1,?<-#$#0M;5JV@@D(MI_ET P:=Q6GAWHW>BM^A0O07KO7J'T%MY=OK<C
M3N4GU[TO;F6B[3%9NFL)QC;B1$QMC.^E; J;SRW49^UGTBLHT389I8PE$I=N
MJ((R_E]_H0:(.]^X&A;SM;*6PM[B,MUJG8>#6FE*K/"57I>-.J[&:@[:EXZN
M/Z=YW#*U2I(T-J!XDZ5Q7)T"8A>ZIF,*16L6 3F%JE8='N"Q&7\IX@C 'X-Z
M#[?3?N]WX<-Z[M9W93LVG&#DVHN54E7!8)/+O(W%MM+#VG9[:E0P^PQ_>1AV
M'VBUK3.0(7Y2@^[Y4K00< 7N+V+\H@Z]1BU_<^W0>/S8K%6X5_S/[Y/]$9JN
MQ'#61&/N0@"<D1KE\8@C !P<'-<2$0%/U8/0A4L.)] *-:%K7M]->T.OX AU
MK<-WN+:I;DH^Q)=*=%V%4Y++ XGZ"B03"S26<I*:2,)A(DIRH@)1@2C20C"0
M6?I.+T+-WK81 $$6@A]VM^P/IKZ[=4HYMI]J3_57]'VLOF3[3M=-KFG+#I(^
MJ!C++V66!S0MZM+K]F4 &QE-Y#.J'LO9>Q:]#P^NQ[]?77MT'C\RW)^."Q[&
MT_MU+["53S7Z?:=<I95)IPSS&V/+U!HA"VXD_6QYR)]XP WLI:E+=EOS!2$%
M!V8 XK8MEZU^4/IH.XWHI:5*Y&*Z833]STK-O"CS*I+M=/B= XQQ(M,$:MC[
MQ[_9HU2=K<=D)0Q!,&X&$E*'DQ8_[(&<+XOC("3K6@ZT ( ZT+.Q;W$H80N0
MIT^>'=E&D:]:NO?4TI-9-?:O[""Y7S=2TF,4&O$(A!ZH_0@G*'N)_9"E1X$Y
M:,9ZE5*V:4)'4Y6K$7H0P@ 9L&]:T,?X^_V]KZAYC;I*U>O**Z1GJHJUHE"4
M'%)5ZM=RZ<\-S>C\LI4[G^QHJGQ5SW&JSZSZ+E3*8TFM!B)<TPI,U,ZE(VMK
M6XR)"M>BFE26WIV4*=(J1DIM:3[(#L'K\!>R/78?IO6//;CD?2W'[:\IJ[J4
MKCE)-N2@U'4JN56FWC7^\]6?:WNXE=VEN,JUZX]V'>;:\_+#R3/HG_T)3_\
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MI0'?IL!)>]Z$%XT+0O:0'T%K?NT+8A>ON&/8IY\^R'^Q#_P_I[D3ZJXNEO\
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MRG8HR,HAEN90T 0(1EKPBT:'9.M%;T/\FM!],/,1R+W9"C & , 8 P!@# &
M, 8 P!@# & , 8 P#A+6UO<0@"O1)E?QZ,T4(\DLP9/RZT$P1!@@[,(&+6M?
MF!L._P -?C^&LW"Y<M_))KV?K[2IM9&*N\*)7_4F(79R:5:H@:<Q44;]0HV
MT"TH0]KS-@>A;*+7C^$O:OZ<@00["5^&];[5K>RMT4XQE%.M,ETZ?+TQ>FKZ
MLTITS2:_3W$14C6]MPB,.*":6"HD#RJ?W0\I0J+;CBBVU'I(V,XR@Z0*32P.
M1#;M48#9_NT%5O6]%G^_8?5YGD.*WNYC/9V%;LJW%455BZN759-Z5A^'K&AS
M7KEJ<JPC2-"9=,LI]=Z',A&%[_+L/V!O+,V#W"#_ ,J2:6()FR1[]1!T']H$
M(M:T'0@#\CSMKTLX_P")_I_95=ZX:Q[/M/SN/OH@>PR3;'K980"]J1S)]V_A
MV6/>QD2$M0#0Q@+%KV& &']IZ"]1Z$"_46*U5K[5^N%.WIV888M4>S]/@?H4
M>=!>HM/(=&;_ #:W[I5HK1NA@/"+X0S0 ?B^HV9Z@UO6ME""7Z^T'YHMQ:_<
MP_R>S_3[*>_'-C4NS[OV#]..&A;WIY%[-^T.P[/E@A?&$)Q'H$6YGZ!,VD-U
MKW:UZ_-KY=^HM!T%]1;I\F/LA[?]/M^S :EV?=^P_GZ96&:$%0\&&!WZ;"6'
M;P83[_B+T,8RG)_<PCWI02 9>M>WX]:V'\=C&(5^I@OE@J_Y?U173/M]R&I+
M)?I\#^_I,O>MZ&I(-]!!&7\[8E5:), :$T!I8%FU!03B]B-]H_;[M;,_]FO3
M;ZM]$U[)-?=3N^ UG\_1;7Z U[]>@=AT+7V6)^AA80FD[*'_ /COX%C2F:)W
M[?;OXBPZUO6_=L4^LN_I*?\ X^W'VL:W^E?VD<O%%M#I94.L<M[<D2^*('1)
MHI*G9TOU!BPL6DIY8436E2EF:4*CS5.S"S?J-[ 7O6BM"!OT+/-W;7'7N/<(
MRMW9)XN3I3-8MO))*C5,7GB<D;[5J5NBHR7M,J?8]FFJW@XW8MB$/;TZ)P;W
MLTLWTTF1*DJ, ="+UK6@EZU[?4/\ A:WY/G2I1*"7^&+^UIO[3AK[ &/,0?3
M>VAN,%KVZV:<C(4'"]A9Q1?O// 8</XRE!@ ^X6_0 Q!U^&]ZRO<7W^.5.YM
M+X+V(:I=IVX0A $( !T$(=:"$(=:"$(0Z]-!#K7IK6M:U^&LX6ZXO,A_< 8
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M^3^ML36F5R_'"E4Y+I3&MRYAA'!)5RP21WR8ZSV?[82ABD5&E"%$4\;2-Q3
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MIB8SC&ZOK.Z$L^R:E@(1N1IB@*>J:JEC+%R@!W].64SA"1H)&B]:M11$R_\
M#'\?G^Z-2/\ H<C_ +>041#53>(_CV&O=X+YS0=,S=MGURKIQ6[<?$QFAKNO
ME%>UU&TT!3:6FC+)3II7&79TT!/[4_N=1;UKW['O=J*(F7_AC^/S_=&I'_0Y
M'_;R"B*;5;X\.,W'N'KV(NW+]8*H%&*:X_=88QK8MH<<9WR3N'2P)HL8DY@O
MHR%[P6P-6EXBOSF:3)_?_<@R]"452Y/_  Q_'Y_NC4C_ *'(_P"WD+1$-?\
M"/X]_G"?O)_<'3/[JOW-?H?]UWZ3']+^\'];_?OU]\'R_:_J/TY_F[W^WY_;
M^'K[/PRU%%7N)E_X8_C\_P!T:D?]#D?]O(*(AJ;>(_CU^MVD9I'*#IF/0.!?
MO)_>/!BXF,!%A_JF,)&J(?4%)S0H3OTD\DC6 ^HT+V['ZE^@O7+441,O_#'\
M?G^Z-2/^AR/^WD%$4VZR\>'&<:FW#Z2'<OU@TH)=V4Q1:>D,D6T0G?(0=SYT
M4]J&:1!2B]BA@,DC&V*!%G?LMJDQ M_F"'*B-(N3_P ,?Q^?[HU(_P"AR/\
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M!.F2-<Z46Y61:%@-U61&!('R:35OB:8IU6)8;%I''FSZU<8:).08E2@WHL
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MH&?ZZ*EBAB:6HY-06T/WY15 9%)$A)KSMX [A;?E>0LXV8H2_:@J;5,A1@#
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M6Q:]0/M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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ML(P"UL(@[WK>MZW@'0'0F&*$S(C41&,'HXTWJ6F.)3F!J-31]K6M(F%8VLA
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M8VHUX7C=G]V.V:<N>)))G@P!9KU*Y4^+%+FZK1A"-8XJSCA:UL>]8"5,"6<
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MQTL^U.LZSZX^P;NNU;F50)^HJ$1F"T;&I/=5D+29W=+I&=QX^2.*AS**;"I
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M0%-12#QV;-%FLD59*VB")D;;+8%B9Q9+(3(2VC1(;":7%$2H3OF];="E!0#
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , K%U1U/7_+G
M/W0]X.Z^/29QY_I2T[A55P7,65BD4I'6<!?)V"))#%7UQ[8Y20MG"E(-$D/V
M6,\(_B,U^7=2(VD>12,_UUJKI')(_'O^'].D'WU[:F;ZXWH>.F%(ONB].A^K
M-+_=*5[RT_S^\6O<'UUKT]=?PYK08\Q'MA99M#)(J,0QV71A_6E)QJS4;*_M
M3HJ+2EF%$C4F)T*L\X"<!QX ['O6@Z$,.O7UWK,'(?28O9L9B,ID9!!:H^/Q
MQ\>R4QHA *4&M38J7ED&C!^<)9HR-!%O7XZUO\, T/4EYFY[:/B6E7=+O244
M9^EV65U_5C+SVBD+R=&Y):W02NH7GFQE0.AZ?<C,;)U6O0L.>U@P%#&G(4JS
M-;T21L8=4QH9U>&O4R:+>2'KR\5_)K)1\,XYAKI>WC<YT[MG"OHRR+.BS,SO
M-XG*$BN 0<^(Q]]4.J-A4$>X)JP!9HBM^HM^OX9*"K^PG.U.I.[(2+B^IHS$
MN+Y3T/U--+Q9G-X)GUQ*.?6&/5- 7VQD*QAD+?$39PXNKFRL_P!,> QO^ M;
ML00B^/7OQ1%JS!9_Y)>A.?ZU[$CW1M&59'.GN6JHK.]XLBKFPI1,*,OBG+3G
M3M7K7,(J]/T3A\XB[S$9;&7)L?V1>C,-1'?0J252E,O!LM0E7US+ =>]]J.8
M[XI.L&V!(IE"EJ5BG?5LZ.?!MH^>:6L2THISY5,]-0 3*/N89+<$Q-4J/D]I
M"2,1&0+#! ^E",*A6Z,QJ\O([OG_ ,C=*<=3JO2R:7N*GHP^*+\3K5A@:]N>
MQ[,F5?5+#9HV%D&I6^&64ZPLQE1.PA "3)G)M1F["%8 6E,*BM'3H371'8C?
M8SQ>[5/VQ+$15SV_,>.X )D02:0[ES@Q06'3-E<WL3>V.!<>5.9;ZM <>HVG
M;"-)2]".",T(1!4^W773=ETU):"IF@*JB%P=#=*2N:,T#C]D60YU/645B59P
MI;-K$LBP)FP0&T),2R,!6VUN(1MC$N5K7)Y3 _9%:-- 0;[,S(N3.I==%T4[
M6C-83^YZ;US.K>J:\ZX'(RYNDKBSJ*FD@A%@M;9,$+.R@F,8-4L&W)H<RT"0
M;@T+$QPDY)A@B0 G@5L;?--XTWM,6H8^C%C\)QB+7/(B@8J/Z)>GJT8HY:UM
M0ZTDP-=2JWN]?TK^?]1D0U.^*8ML@_3P6AV0=\:C&I$@3?RK\!U]&*BF<BZ$
M;CXQ>-8%W;7[M$X%:U@$ZIHP1!?[V)T5 H))551UN2J.VG->Y:!D;259"A.8
M<$Y,H+*48JB%NQO)X33M5P"V.<8[%KLB<WY6E'8J>2NZM^960=. >*2C%8+2
MD^DR%Y0KK3=KR3*V\"LDLWZ%C<M")T85O99(-]A:>?>0?CNM([9\KE%UM1K%
M4%GL5(357$HS.K#.%=DB*T>BIF%MU?1:4.=H6VB*WO;E&HP2\/;/[1?7IDVP
MB]%&*HS[F_K"@^P89+YOS=8J6?L4'G#G5LM6&Q>8QE9$;+:(W&92[0R2QF;,
MD2DC;(6!IF3:-P1'$$'I#SA)3OB5$GE%3()IY%5F'R%C0^/2U>O;(@:=FMFA
MT]O5W:%'L"\]:>/IRHYP]5*34,7/5Z X*OWJV<B;2(L,X(37!OD+:?KUTH"+
M=IC05PJ9;7?DFY@=I["N>YY;<>0]'+'%FK":I(Q";9442FZ,);$I<QI2+=#+
MH:92+C8#;*OJ$">-"DYDCV> *8:7:KW%XHQ59=2)N0_+?SCT(^,E13N8M, Z
M,D-[=04JSP%-%;.,A2YZH>\;A@T<BY5ON,1!5(;7EM4UNDE0HJ)]"^B2+_F(
M1B3"*&(T123]IE(?*OR57-4T],+WN^(;DMJP5XL9.315<=!6VQD0)EDCG&W"
MRW)IC%6O<\K^JD#BVF)3Y'*FYF: +$Z@'U'H4+>E&6JZG\@WD]H[;!U'85N2
MZ*1:K:>ZV8^:Z;DL#)E5J/%\II7S)SUT+$5U?PZO&>72ZQI7)D]R+MHFZ,M[
MD8H:6S2L -EZ.&%0FI=2YU =&4SU# -691LT+F<3+>W2+NFU#%)HA)8O*V/9
M'WF(SB"3AEC4Z@4N:BU9)BAJ>FU X$DJ"C!$Z+-+$*-4-9FM%@[)\B-Y5F]]
M><O<]<V2WE@DR6O]2U9.["LAHZ=Z3JV%N;L@+G40?V>-K*KK!SM5*RF+H<SN
M:9X"K0JD0W!:WC4F%IK19=3-6\5D<]3WITGT5<-/PO@6+<T2:OK4X>J[M5+-
M>C9/:4:5F1RUYI((RQ1Q WUI')5\+F@2-11BTI5HL:=0(TK>_<#>L4[15O(N
M-QITW*^B8U:\>MFM6^G.A><K=<Z,ONMF66CG,6;Y>FA\,LB,3"OI:K8HH[R.
MM;-K&Q&-_9E2UI;E99:XQ(>5]0D.%LT5.OM,/A/D]X8L6WV>BX?>R5TL.03B
M9U<SEG0"U6B%+K4K]VD;-*JI+M9[@K=50+30K(FO&3&AO07Q<D*"J2I3TIQ)
MQBC%4<VI_)9Q'>-N-M'U?>*.2SZ1+)DW0@9D&LYA@5HN->?6BG3=35O26%,]
M1W0X1(AM4G+R(H^/!J9.F-.&'110QA48JBW"B>Q9+/VBKSUZH,V?8=(IZV-@
M69\,1'Q:*/47CSZO-D)3:.-HU25VF;<6!$<K+7*0'#-)),*(4#*A37OU+VST
M%7MS3REN4N9H7T5(:$Y]8.F^A#YU>+A3A33"YH]V2R5U659 ::GM+4KN.P]5
M!)%:4ET&QLZ%.W$_4*][6E[)J7:1M]"SAO8?/[3RC#^UIE.T,#YVF-9U=;*>
M>2<E26B:8=<"6+*(2N>@-A+D8D"L,F* HT8=#)($=L8QA*"(>I3&@JJ5Z%5#
M_-'XU4:1:K<>BEK2)EE*2*2ML>J.Z*99#7YSF&/B9I5:$7=JD1R.K*LD/ZJ0
M:;)G(DK7$7,1_M2N1P@&:!:,:D29:OE$X3I.UWRE;,O=/'I[&'^)0^3Z)KRV
M9#"XS.9X%K.AU>2.TXS WFK6&RI$C>TBE-'%;R2^#1J *?I=$;^3%&-2R(SO
M7R"O]5=C5CSXU0V)*JN>+?IFF;.M&1/BIN-B\MM3GCLSHUY0-^@#+:DIU>P3
MFZ,+EXEPM%F(YN49K8/I][&I@1NC[B5YEY-.(H+ JKLQZNHQPA]XN$O2T\KA
M-97!9+O9C7 C! F,ZA<4KJOY3+'^IH^3LI0HF:=".)Z1*DJK3CM,K3&FJ,M4
M9'*>L$=A\2S?KWB;4<Z32IZUF]B5$WIMOS>S6X97BMX*>(LR'#0HG@IS?U,8
M7MC:=LCXA. B1^AA&_42F-&*X51BUP=NLC74G(D^H=.Q6(Z]MV12<>I0MX7[
M3LPZTGC ;<5FVL\_:U8E6V*L.;HQ(9&;LDSX!K4B5,:<4!1\NE!7L(T>O+1R
M+)ZXOAZH*S4=BV%6'/=T7Q 6*102V8!"[G:*BAKI)EKC45B36#QB&79$ 'I4
M_P!6Y0MR?$Y*-0%1\GQ""9M0:ET.IK;RS<OW90=KS2M;=@[?;E2\AO/4TK9;
M%B%U1.MVJ+L\+6N;K8C1(UE>D.%P43%9>C$A=9% @R8HH&M%E",5')RC5&-2
M)A=/)EQ9%K48Z+EUY-2.T%[K7T1=C&J#VJZU=&K!LUO9UT'@4ONI'!E-15[-
M)B!_0B:F.0OK8\JP."3VIO<I)T-1BJ(7JORT<^AYBYRNKI%^%75@7_!Y//$-
M5U=7MQ7I)D4;B4J6QE]EFXA4<%L&<MD#:#@I@*WQP1)VI.H4:+&H"+TUBA-2
MIB6EZ#ZKCU>\(WSVO3:V*6Y'*ZY4MKI6MU2%XVIAMAHH)5$BLF-E!>FH1AOV
M21;9RBC#B?VI99HO36AZ],4QH5O"I43GWM[IY?T50M%]&Q3DA]1]+5S8<X@[
M_P HW#.)I)*[.K6/QZ3N8K;@L]AC$>BAKVBD92!,]H%QP$SYM.B.(W]84:%0
MB;J19&/(KU]>S%X\VWG>JN;4=B]ETCU;=<M!=$ML]LA4+;>;IQ1\-(:(XL@\
M?D+ZX+I%NX?F'M2G"67I)Z:%KU]-J"KP+R\B=.6C;,ROF@>C*QB55=)\UKJ[
M439!6TT<Y]5,_KJWF1[=:OMNMW^0QJ'2M*Q29?#Y U*6QT;2E;:ZL*HKYE17
MQGC,J?1YG6;\GO#&KK+Y[W>R4-G[M=71"M,*O[5#"62ZDSJL9$]3R>VQ0752
M1.Q'UV1"(:&=S?$B][,&3IO*4_.1\BC%56AS4?DLXC7WL7S@DO%&;9YUC+Z;
M3F_H:SBZO57*V"/+7TRDOHV% HA7<*52F,3CBI4D&_Z5 $1])\VM@Q1BJK0O
M3D*, 8 P!@# & , 8 P!@&'36PX!6S:F>;%G,.@+0M7 ;$;K-9,RQ9M5N1A"
MA46WIESXM0I3UPTJ0TS101;,V66,7IZ!WO0'E#\EG]:XB/ G74\YC@_(L<Z@
MCD-9(*[I+CBG6;9&&20&S"'M$H5H$S.T4192%.8P*702(P07<_9@R=BV$K>]
MEATHU53#G1T-E?B3\WM->3'G&:WO8C)6/'KW$[MD=2):SFG1D5F#H^-;#!*W
MF)$Z3N;Y$:F5D-[FKGI[> @+<>6$QL&/2D8AB*)C5&6,JJINZ2*TJ]*F7(5*
M=:B6IR5:-8D.+4)5:506$Y.I3*"1#)/3GDCT( P[V$0=ZWK>];R&C4+<'D)M
M^I_+_17#RV)UN/EZV:%@+L\6$H;)7^]*/=!VLX=AKJ[9M/1,GW#05_(&'DE8
MW@3G,OUVWIQ)]%OL,"2&TPKU,U\5.A4"5^8CI%,\>9IXBL"I ^LN%.>7FW>2
MGAR8)XN<;'=Z\L#H6@[+/MA>BL5O;)-%@7QS3(TS>!@)8S0-Q80&*33M"-U:
M9$U/$N!0'3_1TPF+V%^[U\3W1S#&*]GDQ=*SY5K^=H;:5_88\K,:'5,XK.X+
MF1H(XVR(Y%]R$8Q&_*G,V2 Y.:8 T,I[2U?<0'77;_DGAW'_ #1Y$.@A<2V/
MS1:U<\V6W<=;TQ5%XU#<E45IT2W050KE<7F$[Z#N>%V"LJ,4^(5N+6>U,NW9
MO0J=IU:<[918K15H*NE72A=1A[Q51R$>3RT;?9F(N&\']#2ZLH@WPU&YI)).
M8K'^5^;;M9F5=IT>'DEYLR86!<RQD;M(241"GY&].!+M1\AJB4R+7/N($<_(
M3TC!/&EV_>MJP2GHWW1PI%+=3VM6+4GEKG3&IU&H.WVY5+LWMRB7))RN@,^J
M69QUQ,]'<HW2TY:E)5"^FV9EICW$JZ5ZHR^*^1V9S>(<'*$<)C$.M&XNX7'B
M/L>JI00ZN#W1UEP7F_I6S[(CT5.0/[=\2@<WIEH6QUU7@7)'B$O)"X";U7)S
MR)05^\V0HK?BZFJ'JY%S;-8Q$H\S360/".<0>40:7(&J!*7LA[5JH;+6QFD:
M4E06P'*4(S4X +T1A*DC8R#RC!0T:S>5.Z^JYY8W)172]24A"*L\@=032V^;
MP55*YJ_6'5RV-P^,VVR5A>NY,W(XW)'V1T[(5"\;O'])4:)W9E*':8THU,K'
M6D93?7J6$Z?\F',O)5B/E4V8"XW^=Q*G&/HJ;LM34;9UL!@= .TEG<37W+,W
M*$QUU:X_ XD[URY:>%!QVCD16B1_$/1P/52I6TC%([Y:^+WY+;KLNE%D0F-U
M)4C;?H9785+VA#6&V:1>I &),MI4(<\1@E;<<2?98I1MC:8RD*#W16YH0HRC
MPK$XS%&-2.1$O*AS/+XQTP[#:+OKF6<D43OH>[ZPO6C[)H^>1.OE;9.7=@4C
M;K"CS2E=3I&A@"TQ-MN.6E^@BP#$$[WE 4&I$/<<^263RYWEU,=C$U_%NIDO
M3,?YTA%049$)TX/#\O1<?\GWW;+^NCRN3V&Z-T/K.=WH\IW23*U*!B;&9.W@
M5&:5C^56H1/MS)?9/*]R._V_$Z?1'W2699%TN_/536JKY_MU/0-NV[&3Y"BF
M$1KB[Q13=>2!1$W*)N292?M:2F4FH%6T)BLM*J,)49:HF&>]!3BM>UJ'HZ4-
MD4!1W2-4V<DKR6DHG<J8M_3%2J&^:KZ^>G$QZ,8%C!8-'JW9W9BBFXA6E4PQ
MT^92>!4F*(4P[Q7&G0K0K\F++%KKZ*9)3'7N6U?"K99.:>=8=1E4V+;W0][W
MG7U?%V/U:Z-$8B1[H ^L:=!+V6/J%HFMO1-3VT.VECH;M0B3EJ"I@%C^7ZOH
M];O'2.OXC95D55T=7O:(I) XGSO=<DZO8[PY?E/-S"751-/)$3=)86[QM+9L
MH/E29]9O:40TIU)*LA/Z"6J$U9$SF^3WF80:WMT-X19MYRFO(=Q=.B)<ZFM(
M=CJFRM;;I"JU3@E<4RC0&5QB\LL_<97P4^-*Y:[25Q2%HAE"0JDJI0:E[J$>
MK_*A&YI:?+U5U/"IY!IK8O7D(HZ]*OZ@I&T*=M>(538O,'6%V0FPX=&Y0.+:
M.)E4JYV"A2.GH[H %I7-&>F*6@ ).H-1.M2>3#F.Z;,AE=0_5QI&VUW%_9:-
MN.645:D1Y^OUZC+,]2-W:J:NA^C**$3)4..1MR<6X0%)1+\WMZA2U&+B"A&:
M4+5'#Z:O?HMTZ'KSC3D-15$1M*2U1([ZM:[+KBLEL6&TY4K5+V:OXV4P55$I
MG7#I8UD6/*W!>!L3J9"SM:!&Q+5"DTX?P)C2IFPZUHBF]P=_]A<MU/V]7%S-
M?/\ *NK.8Z+K+H*EK2C,,GS+1E\U79T^>*O2R&45&;9;G,()+X+,XJM2OS.G
MF1Y*C2M$J1GED';*+473(E6O:3\BOGO+F^\>=X=V2MY.MBF^F[(5T5'K%YMK
MFVZ6E-5W&L@TRL""DS&'6=<]ZHYG!YRCK]P:M+4#@V*FUV4(_D(.(,&,##H,
M5F62Z@[FI+DV5U57=@MULS"T;R:+*>:?JVE:@GUQ3^PD]0C@@K#)8V&#,SKL
MI1&VVQ$"\[ZLQ,5] 6I/T/VIC/12I6Z$-/7E@Y+3Q:J)%!M7C=[I<,%E%FQV
MNJ)Y\MNT+3C\!@DJ50&?R.QX%'XL8]UJ7"+";U4><$CV!$X_?42I"0G.4I5!
M9:C&I%R(5?=7V=13-TC5SXNLRI9/78K1B;S XY(Y&]RV*_9C7L@$;A:)J%,G
M22JTY(B"F8"#3L)=_)-I]*?4K4+7J11UUU"?S?RA+.B8Y"5DODFT]8L%:U]*
M!.4$.?K-O2P(34E21>8C<6LYYAB-98EC-2=W$<B&K;4^S][(V:7\>59D;HJD
M;\H]%="R*\;SY2ZVB].,]WU'7]-7<PRJA%\T.K2PJ?N]WM2),ZE.SSXLZ31V
M4PR=4N^-SB6<J/)6$&(U1&B]&&DE'VA-UH\S ;'\OW%]53^90.7.ESA35I:Z
MNBK.L9AYYN655/7EQ[9TKQ&ZTDD_CD.<V<<TGVG!*E8FY#M:J7+5J,G8"Q+D
M6U"C&I'9I_*YRXHK=WFXF7H)+,VB^BN9#.<%G/EG$=2+KM4P=%:J*'-5&;8]
MRY>2LJ)<"6@= @^S@CP#51BH'PF@ HQ5'%<?)'7]K<]++.Y0TOD4]7]5U[Q@
MQQ*XJTL2NG)@O*26! X[831,Z^F)5>38G]S4)E#G(7I+[T9VT["L)*,$<#01
M*=HKA@8OR5Y2*IM:IF9TNZ70^-VXUP?HNY+C:X$PRHR!TI1])6]:L'06+:KT
MJ72E'6;;(8Y7>S$8'=S+5/BM.N-;DXDR8_28T$R8>;?)1SGU#;26BH6SWU!;
M7=*@>>@F"'WESQ;M**Y/1[3*(7#B;0C2ZPHJRM#U&GM_GJ$E&$E0)=O>COF3
MD[*%K%*!-/ S"J^C9<MZFZPYKN)+#(^=5+16%WTE(F<AS8RYGS/9<<6,:QVE
M.GM\>T)\OKBZZ]E;8[JT9R-)]K.9SQHDHE'N/@KC1E-:A\N417UJPSJVX':4
MG>;/+E]\06#<O\X7?<[[5O#[]8$KC_.=T] ?I!#,ML+I:T"B@I&$HHM(M6$G
M'DH&D[3:J.%:$4CJ'KS.4U7E^]!QV>IY/+N<J_IKE:^H)<-#TC;EK-;!35[0
MN6RV371>$SB1$BB\4JY F;VU0V*A)F]48@$L."2M*2*C4B@U+W%DYUY$J?I^
MP;IC4XF:BP5<;L:F*QJFH*,I"TIW=,FF5ITH9<:.,-),>7RI!;JQWB+8X2(#
M@S(&AJC["E,^Y';$2-2)0M2(F7RQU+([PC(2'M!"N9&SD'L.]+P>[4K^PX%=
M516MRM>W,U3.]<2J%/NT+RPN#:FN-U M9!L*QV<W #=MM.&6:$M8H35CW4+:
M\Y]OU%TI+Y)73!%[SJNRHW&D$[W771-&651$QD-<N;AMG0V)$&JQ&!GU*(E]
MZU]$J,2&&*6M8(LE>0E,/("::H5.IKDZ=\@_0T!ZZZ=I.*=3^,?EZ \]5G2D
MW92>V&&P 2^SEEDQ6:R.0_;Y6P]0U6A:H]'#8F40:H21EY/2!6A&(I0+02C"
M1&W7H9<;Y+[S7PUKF7[GHM6RU\\,UA>1T=>3Y!)W*50ZYXV"*'M-<2-8E?HO
MM7!T@'\PM<F$WMST:, =[/1#T80%3[Q7[C],?5?D3I.%<R]$]2JN-;4YKO27
M\[02P2Z$JVZ:5LZCU74LCA=?5C-]J+&OF\XQ9,4:;-L-G:WQ( EC6)T:L2U.
M8?\ $)-MAT%7F\C81U%V-2W(2.LSK<-G2MUN:;+JUJF)UO7$SM"8SRP4D-DD
MX30]@C4(9WER-=W=GBJH"3Y0%$#4^PL1@/=[M$JE;H5_/\K/*FX%7DK9$MZR
M^;V=,K)KF-\Z0_G^TW[IM)/:7+;S[EBLLI1-'=2F$+*J3.Z(UZ4NX4;<04XH
MAEJ30KT6U"@U(M]SYT%5?453QRZ::?EC_!I*H?FTH;LP/T2D;)(8E('.)3&(
MRZ(2IM9Y/$I?#Y6R+&US;7!*G5)%B88! ]-:WN-4*G4FG & , 8 P!@# -&O
M>?@.\?W6</ZPL!@YDK%-V9>5<VT?";HE<RMEI:VJ_91!WEL@-@R5)'9 [-J5
MO99F:A7+-IF-;K99(Q?2*!;V4/2DU[#+BG[3R$1S^IC^2U'(6%7(;NX,<&!*
M\M:A\0)[0Z&VH6M!"X@UR2$:WS"DULY2B", ?4TO\PM?G#_#K6M&/+?<>ZCE
M+Q)>.KA^RUEP\K<P1*H;+7Q9SA2J6-,DL)\7CB[PM:W%S: $RZ82! 02M6,J
M48QEDA-_8ZUH6@[%K>&V\SD44LB]T[:%D@@\R86X)8G![BDB:$(33-%%"6.3
M0L1I0FF[UO19>SS@^X7]C7XY"GFWI7Q,=40:=\:L;X"OR:%A7'_($EZ.CI,J
M*/>%/>O(/&%I<C1(AE*2MQ1;[!W)!-HJZ;<A'>@%=?)/4'L, '-5,:7[C\E>
M-NZ(>JX:76;XY>5/("W4?XHN6>/9=#[QG50EM=;7?41BHZ:O$._>A5=EH'1O
M6D'!2@7(R$@CR]?B+8?RXK]Y:985P+8RZF>KV3_A]6K0_CZI&J3N2[ Z-"X\
MB0*_JY@<!8(7:M4OT'97:&R^-56UPU")8_R10XJFY,Q V$?OV(>QF['D&/88
MI>/%'976U?\ <5O6Y!JHK&]+XYYJ+F'G^BH?:R^?,L%K2N+3?+:DK_9EI+X=
M"69VL"PI9+#?<G;VT;<T-C*C**4J#U*HS%4*-F?/GB<9NL9GV+;'9,UOZ.2+
MI6:OU;M4 HWJ2X*N@1')%=-"F TA";"AU7S)A@UC+G4E;()@N3/B5U*2.$U7
M(-[&2 01*T&FN9P*XX$NZ\GH:/OEHC4N9IKXRH9Q?<TBC\D0G/4NM>O;VG[X
M"VX\602H'&7F1,8FB9MBTO\ ;,;ZH  &@GH];T;[!1]>PD_QK\_]F<DU7:,7
MZ')B-XVA:?<,XF4HLYCEJ*,A?:>=(#!H>UWN[,YC0J+%.I$97I*MTC*?2?1:
MUR-V2<$DH(1&%59DS]HT]?3G:O*'4O-L.A=JV-S+(;<:7RG)S/CJK16'6%YP
M J+2C]-V'J+S1!'YI%9/&V%R2EKFX2->B(6)A'IC#"C,(KKFC[<A\WVM4_+]
MN,-L:B!5[=$6;TQ?UA1^$O2][@D-F?0LQE$I;*]CDF=FAA7R!K@; Y-K.<ZF
MH4GW%4C.5A(* <$L)YA+#O*]\P\37)5+OX<%DK9XHG(XE\;EJ\TW7MO>D:P3
M7<$S@_#K"A#%PEIP??FQ6X49)M'N!7LUH'Q"%K?U.&\R)/#N1II<7V<^)!$9
M )Y(>2R[0N[QI0VJ)Q&.EKV=*:886X51<'6RV,22G)695$S8>D6UV27DH#)*
MZC9^IH!8F;3BDQB9T+-3W/XF?E^!;6JO'CT?;?BFG=?RF,)XO=%J^.#QR\A5
M-%7N0IF1VBT!H2A:^E4T"^.)18Q065+;VLJ<I5)&A&'F)F)K.-'[M$DIC>/O
M+1Z?<='>E)3/Q?1&@!HG2HBN8.-N[2+7XI5W58SK!X8XPWI*D.EH+:7//15P
MJHC-"JKD=6R6S75Q@MH2SZEF<OK6MJ>UY+D/:TY6H>'L+O>%&9RVVX5WU?LF
M:ZU1-W0'D8LRR82XTS,S[*J20Q-%SKR[6PG& V<9&XBFLM U2JOG1G<']&W)
MVUU>VM<>BV:D&2<9&6/5]YE%A<(6E)>]FZ6-!L6)X@GMH5)VA>$1-<E1,A=>
MP^=H:^UY 2$4=+,^UJ(E,3T-<3!<HT2$TJ05<2,T9@G#?L5P[Q3'N-?]8>(:
MZ(%;D;K^043"[*K6,=B*^B4?3TM\BW=B..'5H5T0NZ"C3:;PC#IO%:G*Z*BK
MH<F)2*2S0PH;JC+>51*HT1Z(ZU)I+H0'A2]8W0G'%?K6J*$R>F?*S>_7MA!3
MR%(--JHI_P!%]DV/&W%$L 0'3K(QP^Z(_P#*BUK1I1FS2MB_8;]97[BI.GO(
M!Y=XS[]X29XK+JLI&B>BI39'(=8\V6K7]@7L=6A=53:E[8Z5G4+E3-(R*OGK
M=-:DE[-T(:3(FPC29U(6MQ1J<"L)XP)K5/XA)HC.9^)_KB31URG\U8ZJL6T8
MEWKOI974M4WS=O'$!N.NY7X[.=.5K 1UA:%-.H[/HQ_9K+KER51E L6&MYS,
MGVC<A?3K=^Q5$TO[3:QXT.69-S)65M'36IHE2TKNBYW"SUL&CO1_176#^B:"
M(+!8#&C+1O+HV6R-\FMF 98660K-94S6PIF\A$D3DG"3&+%$;J:2H42307S#
M\<<_Q;B_C*@^>;/C%-'2J'TOT7/K31-C0Y<_?:Y<55,6FM>JW**RR%7/6 '%
MG1F+414K8)']F]QNVW3@:- PS)XDJ(^U)<\=><AS#E>=<X<@&6G!(5XP:$Y
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M?K$F4@O^.E(H^-L;&1G9V14?]Q5K3PECE4*-YE4>'_"]8/,-K<SIY55O!JR
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M6M:P#D8 P!@# & , 8 P!@'%1H43<1],WI$J%-\RE1].C3E)B/J%JDY:L/\
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MB.84;J<G7.)>RQ%D^U0G$:HV74B/NI_(5,JDNRNH%4T8A,L@RF1\$LEI2F3
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MNK.-N:WJXN-7)3%GE<?*5U<63TCSM8#S.W,J4$(II&'&[^87\3?]N"A!]O\
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MWI9BHF+U91<+=SG$UM9N/N1+GN.P7]I.?GX,8K"O;,O!Z)4R)S6I$)2+;>@
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M%SQVH'B%BYX=Y05(U H-T+QEUI=O33-*I60T-QOO@<E3V,A95 4IBA68E,<
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M&+PQPN;QYWLWHFS;*'V++Y7TA8DALWF*\[^YM@K _P#1[LUJ7N#Q-K@$^9Y
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MSPB3.&DB06I7KU%'ET-]N0T, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@&
M+HYM$W"4.<+1/[<IE+,C)7N3(6?ZK4R4[9>ODV'>M%FC3_.3L\ !"&F"H(V;
MH&CR=C[$MIN8;>.ZG"2V\G12Z-_VXT[:.E:.G;GL=Y;VL=].W);2<FHRI@VO
MVT=&\)4E2NF5,HSKG4& :?ZZ\E5G&*?)I-+_ .<U]&5MPI1\%OR)P1Y>V=YN
MZ3U^Z5A<=G/KG9&XE()9!XL_OC56I.VYB0&K%+06=L*]2:J,&E1VG89KG4@Z
M2^2SL+DJ,O3WVY7//<I=+"X>MGKWGMAYS)G\6TDG=/NE-L,BYHLMVGDQGY#X
MX+'CH:+Z2S9$4R-0B2G 0FT.RR=#M$Q5K,N5S'T#UHCZ:D_)7:*/GMTGZWGN
M.=*5K.>:F&Q(M#U$>U.EM<V97DICUES2>/0G^!2)8R&H7HA8F2OZ)U&+2!":
ME,*W/855K1G37EY;^6^>[/MZMI['>@E*'G><5= ^A[5B%'RV75%2#C=,0KZ9
M5@Y3J6LH5"@YJE:2S&U*#30C=5B19L>E2<@G91QJ@JC\D>6CG8N(6<\2*N.F
MX18E96=6-0_S=)A2#NV=#V!.KM:5;]3C96U=)W)<&1%V*S-3BJ2F&K4@4"9H
M7G.?T)20X85!5'3O_DUBMD\U]*S3GB+3J,WU4=G0'E5IK?H>MWZ .L?ZPO4^
MM(O4L8E435+$[@^,#9++D8SW(Q J"D6H"E!J1;M)LM=M05P[SA<L^3"%SU]L
M6J+<D;4ON:']'=Z1MP:(%'58&FK^:.5>D;@J:-W->3L>Y*6*MX\O8J]3I/KW
M!6F&_/8C@MJ0P)2@"8UUZ$3,^H#RF\_=#6S5=.L%?=*U_(+[A<UM"@WVX:+D
M]=PNZZI@B%D<G6R:_DCH::F51Y6WR5N4)TRT*%Y^F<$IYR$DA4F,-4*FF8UY
M"^V[5YHE%>1^D(FP38R!Q"4=<=;IG="K<ET9XCI^112-6H9#"43NU&%6[(RY
MDI<8J68!60O!$75.(G6]A-+)!NA$_;GD/MGF_NCQ^UK"05V\<K7I'GJ2]"RE
MS;7!<]M4=F5V<Y\R4]*HE+D+N2RL+$7;W4$;.<%"M*H3'(!"U\I&MZ,U4JKO
M(VZKL(DF?ENL"M?('W-"I8RQ1PXAX[XIZ'MX+BQLRP-H3>\^7T'(\LM%F99*
MJ>_L*I@3H>H 1DI-]"#8)(VJ &*-:)&':F'>-6+["<U+WY8(''X3>L\N7CMW
MD[ZNC3U+N""Z\'738WPEX?&HJ4Q&"=7S.Z"W9SM.OHLN&?M[<HV7'WAT3&$:
M;$1*@DPF8#'J7,\@?3:KC3B7J'J!K1LCE(Z8IJ9RV$M,F*6G1MZL4#88W5NQ
MR EM<&AQ-9'N>+VY(K"G5I3]D'#T6:6/T'HLRMT52KW'G:5KVI45^S=\LOGW
MMJPZJ71-J;Z>XFIBR* GC6_OY*H"9CE;)U=?D@$)NEIQI*MFD*L^.,HVE&L5
MZ,4EAWLHT$V1G#?(STG,^!Z3N;]U-11?KKH_LZR.,X-7R]VE#[2=>S"+];7C
M2VWR9OC>X()/,FB 5-2[B\.(V\UK')79'LI&6V%K22DRF/<2KI7J7"XNZ"NF
MRY%TQ172S=6)=]\K6C&(9)I32K9*&*J[)A5DU=#K9KF>1J,3223*40I>>VRA
M4TNC,L>'4:9>T&'E*C4ZHCVF5-]<RK4)LKR-=E,T^Z,Y?NGG*C*:8[(MF#<\
M5%:%!R2T5M[-U+6')*Q=9G=%FM-P1%UKJ/6;,(0X?94\=:!K6=D/3K5.UZ@6
MT86'4F+Q1&\:[:ZW[1G?%,/Y=GM3<ICO;C'H7I"VPV]0SSTHMC%ET#=U T++
MZE8TC'>-#$A;V2<6>]%_>1*C]+"FDH84H-*-[*M$A5O+# O'QA?UX3F9=(\X
M=/I:W57YRU+8(B=I[3S2_P 9K:W*QMN'_K"K[':H5*9','^OI"J^WNS4],9S
MP[$IG!I&H3*QIE1194=.A4WDR/&'RS<R2"VSJP31?H!&PH.EY;QP^WPZ4T_(
M.>XYTY%K#=ZM3U"\V0:HV$I[ETT;4Z)H6E)#F=0H=4"<U80J4:("HQ5'/B/E
M5YIF=I12!M<<OA+ ;"MU[H"L^GW>G9"V\N65=K"\O<955S#+6.,WMP<'"5QE
MR:&QR.0)V!X=4)B1 O4G[* 8H*HOT[S$IGF,-APXY,7$V9I90J*D;1'%KC#H
MWJ+I6Y481,I&3_(HVJ?=.6@-8#OQ7&DG!!^)>\A2A/3G0/6BSIJ,<E<7(^>V
MN?HN>Y'TI94YZ58;$E,/3Q[<Z15S6=>1:/5I-(&]!?Y[(D;V:N>CUBE*P(FH
M MH%QJHLK5]I'6M$9A77?==/'CICWD3LUC>8% 4W/N[QM&+M9.Y6\0DV/,IR
MBQ8TT[2:3?JD49?VQ<C2J"M%A<"R ' T'1FM:4QH*X597:2^:CF^*;LA&ZT5
MVZ7(ZKA**YY;#_YKLO3R5+S.X)G<]+U%I,X+42!+30S&!<1L*M2EE %*)04)
MFT-.=HM0FI&4W[YB^3.?#;'<7EAZ"L:NJ8A<*FEU7/3=)2:PJFJ(%EQ5JG%=
MQN=R5 -,K0RF6Q"1M#D A.C5$-J%Y0GN9R$D_0]*,KDD8AUYWU9=*=(-4.B*
MZLV6D(%:_#]5WA,)PF,]4#]U'8D]5SI$!^-?6=JB@:OHV%-;R>J5A,(#J7)3
MA;V!.8#"1&\>XE]Y\I?/A4+J*8P2"=&7,?T$[V!JAH14]+/K[85NUU5Q;0.;
MWU$HJ\JXZI)HIM%(&[25_<AMX7?3FA&W%*REZ(Q0H6J)?K#IA+VCQP]]!<7.
MPDKM.HU=;)2+K<$'?XXF26C6LKGE6)=SZ!.YC')T#$ELZ$G%JTA^T2X2$._7
M1!@O0#)XBM55%8)GY")'*>$^8+OIY#%HWT#U[,*BIR&Q*>)U"N/59:SH\*_Y
MSQ4[;RG1O7F(>5(97M@.CZ4%1^4R(FE#'[1;'BF)*X569F4*\HM*6DO;V:)P
M3H*%(+1B4X?>8KAMVD)5!:3Z351""2.Q=$U5*708'!2<Y0:+KI"VI7Q$PJ7Q
M@0J%S<!2G*&8%0M2LG,'F)B-U\J5M(+*8[7I*\)KX_7+J-+:,RYPER*A["E5
M:TQ&I;T"ZT8VN,H:G*QF:J):_P"E&F=0X- WMK]AC:O4I#-.&JUB12JN\L,Z
M^5F@84N:HXY,-^6LDB<4IIRO^\*FH"3NU.46ON*(1:8Q,^VE21V=G*)*'F+R
MUO?538U!DBB/L[BG.<3"BA@.'*%J8-3/E"(%1L&?+-KVS+GZ"L:Y^Z(S%*4Y
M5JMRFTS5U5RMV);=!$V ZM:Y^1Q^*1YEC<=CJ9P<G=Y0EN;XX:*0%FG&_3%J
M? B>'>72(ZDB5F\@SSJ&CUBI>@::SN!_944RC+[&GN/3VIT\N9)1![ A3\0S
M2..2F#6%$%K,^-2H"=4D7(3R!;UL/NR%KA4T[\1^32Z[7M7AF*K>U^".WU/6
M\>4K[@HCF. ?HB[>/B4M!2"XW"<3AY9>H;W9ED2B$Q9DT*>$C^SQA>H=GA%M
M%O9X#T.]-&4\<ZDE-':G:M[QOBB)U/8E(4U8G2W5ODOJ&43V743(+ACC+!^-
M;<Z+C%?%M5?HKIJI48^O<7J- 0XJQOFBQ*CC5 " AV$C2B+5M%V^6;SZ10]%
M7!QIURX5-.+,@56UW?E8W72L,DE8Q6U*BGTHG$!<$<FJR43RT5T#L* S2!C
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MDH$2=&C3@'HLX\Y7H$L:L@4GQWVXS\:0&H8K8]=M70M&=OV]VS34N=VJ1O\
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M3ZB!R?H1L #:89ZWWHE7J1K7Q;,5^\4QKW'GO[?A'3%(P+N;QST&H4+7+LJ
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M)_(*#HP%ZC=RZDF(N6S(7KG8'+P^>OT*99([&U'#JY*TXBE&WD3N&2"&H E
MC%I"%59="4>?4O'QIS/8%#%WY85VV-&K2Z!ZEN<-U6[(H+$7*!UTRJ6BLZ\I
MV"5[7L6=Y++'<F+02N:P:T85S@N/<G57L]4HV#Y"R"3*E3VEU,A1@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
=# & , 8 P!@# & , 8 P!@# & , 8 P!@# /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>tm2115679d1-lc_imm1044c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_imm1044c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"F .2 P$1  (1 0,1 ?_$ .P  0 " @,! 0$!
M       '" 8)! 4* P(!"P$! 0$  P$! 0$           $" P0%!@<("1
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MAGDI\Q'&?BO;X(5T<\3J26!9WU1\!IFG(RWS.TI(U(59+>L?BVIXD$3CS0R
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M=P)2WIFTZ$;"YQM]+0J5J$I_B[R0H;EP2#CB0JTIF@&##K0MQX%3JJFEPO\
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M7#J\)E2QC)E;"D<GMLVA?TB%0-"O;EZ]M5B2J"BU CDRDLHTUF5-/(V'9"C
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M;7DHDRW;O) O3RS@3M @*=!T,K9H_=K?Y<J50W0V7Y"C & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , \3/$?_XXAY$_^0.1
M_P Q^5<V_H.-?6>=)N2KZDZ%\E7?\>2JCI#P7YM>5+,=5",OW'@K237GW.FE
MS?[PE&;V2_2B-1U$:4/82#RCA '[M["'=[+P,>/9E]_[08XH.N^K?+9>K:X)
MY57O!7-?!G,\&>4)Q*QF)E]Z7C ;46N#:H#K\B@CY)@UC$'7J;L!GY]EA!K:
M."1J6+?@3YY^?_Q<?P8_R!XT_P"PHJQ'ZF)?2C[&]#;\>WCW_M-7"@7$3&X5
M3U2Y,M(LAIX$:]76/>[V76+>BCQ(BBA%$LM41X;PI"5H))7U0AE;]YP=CE*M
M,5HFCL?!%5;'PWYX.X*NE #&5NYO\44:(L,TM$,U02\0V,<!/5F.VV]"6:<<
ML5R$EQ5C**",8S3-ZU[A;_%+Z?F(X2^1Z9N3/[0%XP.W.@8!S#SO<\OEEQ6;
M^JOT?'W2G+2BJ%?^BX5)+"D'SO\ (XNW,R#Z6+1-<>'YC@?*,O18/48PAWEQ
M:Q-J2;HCRI?VD/Q1\F\*OO)O0=%I;,W9?0W6KFGL=RGEB.LU1J4XAH94 AH1
MN1(?M1*=S6"T4$ Q!+(T$O6M!#K-1;>!B22HSVV]W^1?E+QM5W#[4ZVG#S!(
M7.YH&OXVXLD)EDX4+)0-C=I&%$:WQ%I=UJ0G;2R*!_,: )7N!H/N]PM:WE)O
M(Y&TLRKT6MOQ[?V@SCZVX#7<YLJ<T$GL*/PZP'"/I)W24J3RV+?INPT#:A7O
MC0U/!C>:0K1B4"*+&0>48,D6_P"ZUIC%^)*J2/.GX0N7JIXO_M-/D?YBI!(]
MH*KJ;C&2M$022-Y.D+V2C=YYQ)*%@5[RH+*.7&"=7U1L(A!U[0;"']@<TW6-
M3,52;189[*36Y_;)F-!.DQ+VDYYY'2&UHE6%$*TS2I'22N1D*=$+"5  '('R
MX7A8G$5\8R58BS@BT,._5_ 7^,QYRDT2YF_M?=A2M.X-D"@MI\3268WJ['_
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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ME6(UQ7SH5:981[QE_,E/*4%?(7OT&7\A(A@]X-_AO7KZZP#DX P!@# .H:Y
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MQBT#6]A#K>]_A@'(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M@@EE$E%AV(0A;T$(=;WO?I@&(H;)KIT6)FYLGT+<7!8:$A(A0REC5K%1X_P
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M$NCSBR=J51@##"TR?1@@[.4# 4(6@!]1;T'>]:_#> <C & , 8 P!@# & ,
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M:F=%KQ)>++EM=;5<E=7 ]2['1ZC'14\MS4YNAXC%"X"JMEZZ*KMCV8-0B&:
M6Q#%O>!T-F;$\))"R,[^@V/:!\:F]X1;,#L!FTCFD)6IMF %K0@#V2>'UUO\
M=;P4[7 & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M%5&->*PNMIX0O%L;/SM7\,;8X@%[OA_7-R$OCM)I$,'N" :UNA;$WH$AFPB^
M(EQ6A +7S&AP3J:XXT".V[S\^7[9W+\QE*28#D,\F?2+?*(<@NN%HTK^X+B'
M^F&Q=MRD37%:C;""TZ(@I0B >2UC,TC5ECV)12="V=25W5G4DUZ#GUHL3'<+
M+'9FT4S6ILS0)7LADA;'64"DZQ_CA1J8A,Q/DU>IF:X*7!$4E6;%\80B+ 6
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M7XZ%H'KK>];UO8$F8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M=N1-:$K>_=LM&WIBDB8O8M:UK>P$DAUZ^FL%.QP!@# & , 8 P!@# & , 8
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MG?4Q!VE!"=Y;$3H02H#K80GE%+2#RRS@AWO6A:UH6M;_ &X!VP  + $LL(0
M $(   '00  '6@A"$(=:T$(=:]-:U^&M8!^L 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .E2QN.HG58
M^HV%E2/CB'V.#RE:T)#JN#^3\JQQ*( L4A_=A_ 8Q:_+K_>U@'=8 P#I4L;C
MJ)U6/J-A94CXXA]C@\I6M"0ZK@_D_*L<2B +%(?W8?P&,6ORZ_WM8!W6 , 8
M P!@# /BH3IU9)B9402I3G!]AI"@H!Q)H-_C[3"C B ,/KK]F];U@'VP!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MTI\@CC&]G)BA"&4G-=6Q*O,(*&/\XBRAG["'>_QWK7XY"F1X P!@# & , 8
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M0[LJ>.+Q^9[VQC*&SM1E]2MQ_46SSHG:& , 8 P!@# & , 8 P!@# & , 8
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M .^B*5U9F99&T:J?Z+JV_D##OYNMV0JR,^P48 P!@# & , 8 P!@# & , 8
MP!@'G2\^,05O4U\84A>;)?Z4J]L[ 31:<W2P+RFE;53C,@Q4V-S5 \K2%#1&
MG]D;HR[J&YX5!V6T'E?5?W)8\^,]VVW.[L9RF[5A;FDIK#0W2DJY)JCI)Y9G
M]/?].6]A8V'NW;6-I;W_ "\^$=RUM9K4MQ&UZFNTXIJ5R$Y7+<9VHXW$]&;1
MJLZ=.M-JC/F XHHWHZV.NN8*_P"::1OA-,+'LQ7=#U6$XCEY49*YQ"4EB(M&
MI3D+C  RA<M2D! 0$#1L"C05!"TXSP-\]Q&')<7M;US<;"%B%RLI:W&2N0<H
MZO&.IM>&.*;/V'VE'A[V[]D>_?</%[/A?=NYY7=;1VK%A;6-^U/:;NW:NNR\
M4XWO0A&3JZW*Q\LK<5>JZ+5KCHR_?[._&*'E\=FDF8U*>SG]HBKLW.+K!X#&
MZZJ=RDB>6)&-2M51@X2").B8Q(H" .SFM249[?A%GK;G<6=[N^&AM)1E->9I
M--QBHP;K3+)JG@UT/SS@>'Y3VO[;_,W=^XK%VQM+B=B$KD91C=O3O;B,';<T
ME<5;EN2DJX7(M5U%V/[1%_\ 4K+M_EE2W_O7BF>G[R_^P7?[T/\ QH^"_P"F
M3_\ [#Q__P #=?\ ]/<-=,JX5Y*9O,+P/2[=1T.3U39_%+[+;/@/Q+S(S94E
MC3583HU/<^:S5PT\L7Z>HXWKU(UNC=K5Z$A0I^4TL(M>-<XGCH^X]IMHVH_A
M[FU;E'I)I2:<EUQ2>.;2;/T_9_F%[SO_ )(>X^>N\A??,;3GH6]O>P]2Q;N2
MLQE"S*E;:TSG"*C31"<HQHFT:Y'OT@O#/0=+_4OL:Y":/.INN;F:6-P>1IXY
M0+<W:,$PFJ@*%CBEC8%<90*-F"^0>W5"B%[_ )A^AWBR_I<5>VN,>.7*Z9I5
MPMKIWI@OFEUS_4-O_P#4/S!XSGJ6[OO:?Y>>OM93C&L]Y*7UTHHN=)S5,%Z<
M[BII7EO6^*O';0_F\XDF/(CY4C154*YXZ.L:[!4O)6R1UG']1_F>^78$@$)C
M<G-B02=5 V<![D$DT!AZ8A*>>#Y3=FF^M-\-M/=.UN\<[:V\;-R4]#3BJ6KC
MK@VJZ5CX4;\?SS;P_,[W%^0//['WK;WL^8W')[&QM?Q5N4+\]>^VD='GC&;M
MJ])J%4TI.<8NBHH9Z^ADCD/A;OOMBR&PUMM3O_L&#7^O2*Q_,MC]3D2![CE%
MPK1_Q%Z/:&.$IQ+6\7J9OZ5U#ZBUOU #J\C:G/VS>Y2^J;C>;F-SX0JU;C\%
M'%>#/=]D[_:[;\^.-]A<7-2X?VWPEW9IK!3W#A&>[NTZ2G=>F>7FMOXN?^4I
M3<4+(\TR:\XXH;_,.T4I8-DIYV@< O"TVFWBJ6YPB,?H;2$XPIJ9:X?0H3RB
MD C JCE+.4(2G:,)97<X^YN;7^9K=1I[D5J4M6?D<%16^RBZ99UCG3#YSWCL
M^#W\O8<_;UU2_)">_LV':<=*_$QW$HW)[NJK*5^&I-SII4;[6C6V]974,.\:
MS9X6^7)94;I6']<QZ>HJ1.11^5IE5S.[XIV]+K>:K,CY+@:];A[0Z$)C6_[@
ME+3I?8W;1F: H_?^%O[7"1]LV+FW=O\ S-M:J/SMXZU)9T3I2JHO+3/']7]H
M[[\U+OY[\OL^:AN_^1;=NX[6NVUM8P6E;:5B=-/JRBY*>B3E*MW6JQ\O^A!G
M["?YIC & , 8 P!@# & , 8 P!@# & , Q>02 Q 84S,Q25RE;BG4&M;6>IT
M220466;K[R]B*T:K11].I"$HT\!1@A&F *+"(P8=9QSG1Z(XW'DOVOP\3N[7
M:JZGN-PY0V4&E*256WAY(5HG-JK2;6"<FTDSEL;$4S 5F#5'N3HY'Z5.SPL
MF L<#@%A)3A$!&0F2ITB%* ))!18 A  /J+W&",,'804*]9/-]SCW.YEN'%*
M*A9@J1@JTBLWFVVV\6V\7E1))=[FSK# & , 8 P!@# & :H?)LAZ$''Z:7,\
MHIHCGDON'Q6@E47<H)-U=S+7[?DSY7"G4Q^>);&10AL: .QC:,9"F.*SA)BE
M(-&Z&:48353YF77Y&U[(:& , 8 P!@# & , 8 P"N)7('+9$&4UF30-5%5\M
MGH;25PT$-9PQU18P$2=M#-CFO2;Z4<D"@2%$Z5[#\OQEA#Z^FL[?X_>NYZSN
MS]51TUJZZ>U>W@=?\)MM'I^G'T]6JE,*]_B9>+G^D16)+K;%5,#W9\^BQL(F
ML]W&VS]52F(G(FEM-CKX\_!]:XM)C<Q(B-DF"$'9*4H']R#6M<?XK<^E&QKE
MZ,954:X)XXI=\7]IOT+/J.[ICZDE1NF+79_8=(S<M\Y1XBJ$K'2=;-*>BETE
M<J;(011J3%UDX3%R \2I9"P%I]:85$@= :4*Q$>S9QNM"%Z[S<M[NYN;E<FW
M=2UXOS4P5>]%D96VV\=*C"*T5TX95SIVJ? OE+FHIIM5B*HNKRF:\G0A[N%K
M*A[,6ALIV2NRQ^3.$R3@2A+?%*=Y<#U0!'Z%[#SABUZ;%O'X[>:H2]6>JTJ0
MQ?E5*8=L,!^%V])1T1I-UEAGUQ[DVL;(T1EE9XW'VU&S,$?:V]D9&AN( E;V
MIH:DA*!M;4*8K02DZ-"B3@**+#K00 #K6OPUG7E*4Y.<W63=6^[9S1BHI1BJ
M12HC#Y;4E8SR5P"<S2!Q:43&JUSJY5O)GMG1N#U"'!\ WEO"R,KU!8SVE0Y
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M0>>UR&^LV7M[5V<;+Z)NF.=.WR.*>SVMVYZURW%W.[7Z5^99C.F=D8 P!@#
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M80,FHS+(VC53_1=6W\@8=_-UNR%61GV"C & , 8 P!@# & , 8 P!@# & ,
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MXL9M)FK0R0@>CM'! E-4CRKXA]Z=3T,9DT, 8 P!@# & , 8 P!@# & , 8
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MHC1RDW0ME)RMFB!HP\S0-^T&O46_3?IK .3@# & , 8 P!@# & , 8 P!@#
M& , 8 P"@_;G](?CL_Z?$<_[+O565$?[2_&0HP!@# & , 8 P!@# & 1 \]"
M4''+8C="R&\*@8;SF3<:\1"EWFRX6UVQ*F@DI8><Z1NNEST1,'QN*(;E Q'I
M49I00$&;V+T +T4%5EU,.7=C\AMET YN<NJ>;V_H@QS;V0NA%UXUBDN@QY=F
ME,_M30"K3Y07.!N;FQ+25J=/I#\IR0T!P [+$$6U'F2JRZF5Q/HSGN?69,J6
M@M[TU-+CKHLTVP:FB=GPB1V9!"B%92 \V90-G?%DIC!9*XX!(Q+DI&@FC"#?
MYMZU@M5D:X/-'**]C_)-JHYKT[<M!.CWSGU&FB<0J]O9%K#="\%9DE&QNPS7
M:H++4)&A$H5IDI8DRY@'LEV5;V>/80&)JLS,LC:-5/\ 1=6W\@8=_-UNR%61
MGV"C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# .A>7@:+9;<V%IETB7$GC;&LY5H@/L)#Z#<G$183E*5D2'#  ]
M0$HS>AF + $1IA8!8E*GECC-Y+]K\/$[6WVZN5NWFX[2+6J25<_X8Y)S:JU%
MM8)MM13:^[0T!; 'F&J37%Q7&[/<'-2606H5"]P]D$! G++*(0H"A_$G*#K?
ML+UZB$,T1A@[&.G/&3Z_I]QB_?=YI1BH68JD8JM%W>.+<GC)]7DE%)+M\T<
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M*9&V:0:R)?="1H?RGQ8S:3-6ADA ]':."!*:I'E7Q#[TZGH8S)H8 P!@# &
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M;LA5D9]@HP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M29<P#V2[*M[/'L(#$U69)9&T:J?Z+JV_D##OYNMV0JR,^P48 P!@# & , 8
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MHUT.:Q$(UQ111+J>(8=E"."(@_AU-_\ D-# & , 8 P!@# & , 8 P!@# &
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MIUSN'S0P!@# & , 8!"?2O\ S<K_ /\ D3M7^8K]@JS)LP08 P#5%U9RW0$
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M1JI_HNK;^0,._FZW9"K(S[!1@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8!_-[UK6][WK6M:WO>][]-:UK\=[WO?X:UK6 8J*6)51@
M"6!"NDHA&$A&J:PD!9R"S-H1B/&]K3DK6H"4F7:-V!,8>=L(!:"#8M>W./U$
M\()R^&7VY=>AWOP,X+5NI1LX/"5=;SPT).2JXTK)16*JZ8GR^ROSR7K<B=QM
MQ!@-?(QQ-:L0EA^1.I).)42D($,@6?&8< THY&%I%H90?< 0=BUN:9R^MT79
M?OS^RA?Q&VV[_P!TMZY+^.ZD^J::MXP6334O55'@TZ&1-[8VM) TS6@2-Y!B
MA0L-*1IRDX#EBPT2A8L.T4$/S*U:@8C#31>IAHQ;$+>][WO.2,8Q5(I)'4NW
MKU^2G>E*<DDDVVZ)*B2KDDL$E@E@CG93C& , 8 P!@# & , A/I7_FY7_P#\
MB=J_S%?L%69-F"# & 58[EA,SLKB[K.O:Z1.;K.YOSA=45B3(R-\9=7F1/S[
M74B;6Z,-"":*T$1/<Y,H4:0)_N9Y* !JD(CQA+"+>JLR/(U2^/74)27M6[:T
MTIYA("\(XH^I/KNKO(,Q]!<ZM DL.6E*6]WKAN[_ +H$_&>TL1#.H+A.P)5G
MPG^Q#H'O*K^1E9]3T YDV, 8 P#41Y.S[CT121#;=M M=-B[;\5PI!2+O3DI
M<N@)&[__ !+^7MDO,7N0CI-DBT?8B'$*)28D/K5W-&D0*R=*P"4EJ$51EFW?
M(:& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & 4'[<_I#\=G_ $^(Y_V7>JLJ(_VE^,A1@# & , 8
M P!@# /&=Q"_<IUO;O--.@H7P(6Q8$.N^N8 V]+QN86M8_64KDC19K:QMEIH
M[&<O'9]JG_3(W(D"\3UN:-B!SE@=J +FT@81I]OYG&OD>S','(5*G'>?%U9W
MFP\R6!U%2$.Z%E#S#8['J8D%A1YML9X?K#4H4<%9T,54+0.I[C+5+HF @)T7
M[U.SR_9K?O#ZVC)55IU#AWGQ<U=!%\H./45((^E37ELCI=&GV%'@6:-^>65)
M(VMG#$_K?NNW)<Q+B599/Q^\1)@1>GIO%'F*JM.IFL(ZOYBLNUI;1=>]!TU-
M[F@?W7]85;%K'B;Y.X\*/KR&J2 <8PW.JAV*,BSLK)2.H=%;$UJSRB56B332
MP"E&*K(U]^:-^J)GY)M5-970-RTP^.G.?49$!C%7O4G:V&UG4-9DEJ&&PT[!
M$I(C<6A*L4HDY8%IZ O1+DJUH>PB,$75F261M&JG^BZMOY P[^;K=D*LC/L%
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!@%E63'*JC!
MLKD^U>T 5J1N(3H )A*U:U8(?QDE#7*V]N(T6048:,Q0H)*"64+\WN]H1<.X
MOV]M;]2Y6E:?IDOM9ZG$<1N^;WBV.ST^KI<FY5HDNKTJ4GBTDHQ;JUA2K7 B
ML_56/'6N20AG5(F5Z0?5)'J8I3FL9!@R#0;*#%RS=/2M4V.I0DRLE2-L+WL
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MZ<C'AV(C47;B6MJ*<74X!9K@L E(#H9H@ZV,7X^F9-I45"8< 8 P!@# & ,
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MNC:T)5"<E:,D$27!$F:E(/G#HT1J>HRS<AD-# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!@MBU=6=OQHV&6U7<%M&'G
MK$C@=%+%B,?FT:.7H!B,0KC6*2M[FUF+$0Q[$4;LK8R][WL.]8!K@\3_ #S0
M%?\ /2&Q8'1M/0FP5=N]C115.HC6<+C<R4Q9!V+=3<AC:B3LS(B>SF!$WQ]
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MHNK;^0,._FZW9"K(S[!1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M1MLTDED7GR%& , 8 P"@_;G](?CL_P"GQ'/^R[U5E1'^TOQD*, 8 P!@# &
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M"+>MZ_4DB2GE)S-""M+][/']&I7=R$G5I@>\2O;<G,). :G-4AWO6N/5.?\
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M#YPZ-$:GJ,LW(9#0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M[WK6L \^]U>92Q.D+(DW*/A5I]N[(NIC5;8[)ZKE!C@T<,\Y*5(#O8NDMEI
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ME9;:,O2,LWA9DT, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M'F4NC3$&18]JVJ-M)JI 0XO[H!'].C)-4)R1J# :,-*![C AD5WI'IWI>S[
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M@B,60 ;&)G*5+EP4*(!AANB]K'-4M<59@S31#&8><8:,8M[$+>]^N0IE^ ,
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MW:3*5VBQ;)VNV&HDLC:-5/\ 1=6W\@8=_-UNR%61GV"C & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & 8.Y>LO5*X\2+?Z:3?5H94J"$8-NIHBR"QQA$(Y$8
MG4H#R%!P')20<$U.,O28'[T9HD_#+^JW!?X>3\?#X=WTRSR]*S_N$([J7_&.
MCMK^58_U'1U4DTG;BU22>M^514\XSF/-& , 8 P!@# & , 8 P"#;RZ!@5"L
M21?*#E;K(WT[:"&0*/D[<9A,W@8@%)V]E:B?<>(L2DT #% M:**$,(?41@RR
MQBTJ5>9*>G=MR%DMSK%$F<G$2\)U.\QH%I)\1BAH@?+IUFFCQ!329_1(OWRX
M9NC"4Y 3-;+,$,I$3B<M/C)Y+].W4[6VV[OMMO38@JSG1M173+K)X175M5:5
M6LGYKYIJFKKWZ/GK!%VA/.'&5-*96\(D!2)*A#+X;$YM*T<;0[$H.9&5UE+B
M:H EV>?\ /0 1[]3!&=/;<=MMK?GNH+_ 'BY74_BZNG9-XT;9['+>YN0Y;8V
M>+N:8\=M]*MQ26JD(>G!SDDE*:AY7)1CJS:RI>S.^?.# & , 8 P!@$)]*_\
MW*__ /D3M7^8K]@JS)LP08 P"H?D!ED>@O"W8DLET3=9U%67F:[E$CAS)+G"
MO7*2,9E=2%,ZM!-A-/\ QK7Q*M$>,)S\ET)2RD>]:4$9A 0[JS(\C0CXZ4'2
M%7]M5/$[/?'DVO4]G]&<S[2H_(YY!NDH\GL6IZ)2VE'FPJG+^F(JR5Q*7U4_
MD/[$\'HE6D!"30-$I%1R T=>1E5J>I&1O0(W'GZ1&-KR\EL+,Z/1C1'&Q0]2
M%U UH3UPFUA9DFMJG9Y7!(^)*F+U\AYX@@#^(M9DV>*&*]:=)2_J7MSI"9U_
MV96/6EU^('N-QIVHYYR]T/6T3Y83U8I,F7/U?LL@G5?1AJ&(I-$!+W^8[4%,
MCO8\@^U(3_<:V$&;P^53CJ\<ZT+%]C0RO.4:TCQG!;3&JL9K2\'_ %-+[^?Z
M81LT;6OM<PB2\9IJTZ'E#O&4[:H>K$;(S:=AJ&Z6*]JW0T*MQ/"(8BS!ABQ^
MTKPR[&U:DZOJWF_R5S&LN/ZSK.O:PD/C:AE@3"KZK0L$#KMVGT6NU^B= 2IV
M2Q9L,;$+[+H:JDK9M^$D5JU[:SDA,$<! 2#)TQ*L'AV(P[>-Z.EK+1TPN7A7
MG"OQI.[?%XWJKR8.B45IVA$D /))RR%N0L*%7S-!G=<C=5ZW[><4!\1 3I5Y
MYOH;K0B#:J!U[=3?+F30P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M0Q;WL0QBV(6][WO>=M)15(X(^>NW;EZX[MUN5QYM_I\DNBP1R\IQC & , 8
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MMM&7I&6;PLR:& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M+^UXNAV-]S/)<A8AM=S=D]I:24(?PQ45IBEWTQ\L7)MI-XXNL@9S'EC & ,
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M1DMS0R,C0W$IT#6U-:!.62G3DE@*)* $(0Z#K6LR;*1]Z?\ TF'_ $^>=?\
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M$)=X]J2;GLEQ>324:H)LK:PI4*I0H!I286%(HJH'7K3,WF9DT, 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & ?%0H3I$YZM6>2E2I235"E2H- 2G
M3IR0",.//.,$$LHDHL.Q"$+>@A#K>][], \N]O6+87]H%O:5\G<X2]RAGB%H
MB8-;/V+TE&3%J!U[1GS"X$O"GFVB9"0(C9E7H=I4XGU^2&: H 8 \ C$IC<!
MTU].+S,?4Z+Z3TL5M6T!IV Q"K*LB#! :Y@+ W1:&0R+-R=IC\<C[2G E;VM
MK;TH %$)R"@?_7$,6]C'L0A"%O)LS; *#=Z?_28?]/GG7_Y\,$?[2_."C &
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MNC2Q5I:M0B"<$T"<PBHRS>%D-# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@'F.ZFOVV?-/T#.?&SPE8KW7W#]6K%4=\C_;T-3;$&9&?,0F<.1N
M<Y5O9[6[O<D1&'%2)S+ 8DTC]^A".;];2/NE@JO,P_,Z+(]"U#T54_,U00"A
MZ.A3-7M5UE'D<:B$58DI:9(A0I="&<J4C"'1SB\NZTTU8X+CQ&*EZX\U0>,P
MXT8Q9S-I4P1+> , H-WI_P#28?\ 3YYU_P#GPP1_M+\X*, 8 P!@# & , 8
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M';B(*)O-3?"R'Z$+1>SQ J,LW4Y#0P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , \X7<G5UZ^1?HZ3^)7QN31]@;1$U7V_P D'=$<1F&LG.D&5$K"
M7"BJM>@GI .U]3G9!J X2,[1C7Z&D@& 1#HJ:-)4Q9ANKTHW8\G<ITAQ/05>
M<U\\1!/#:OK=H W-:36RU#N]N)POJ'N6RMU 0G&^R^4.8S%CBM& .SE!F_8$
MLH)98,MUQ-))*B+&8*, 8!0;O3_Z3#_I\\Z__/A@C_:7YP48 P!@# & , 8
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M^K[O]/LR&YOO<7-22C;2I&*RC%9*O7/%O&3JWBV=SFSKG2NDA:&<U.F6J_\
M+E?MVD;$A*AP=50!*"4HCT[6@*4KS4A!R@&CCM%_"0$7N-$ &MBUF4XQP;Q?
M3-_8=BSM;^XBYVX_TXYR;48K!NCE)J*;2=%6LLDF\#JOJ)6\@_R5*3%$1H ;
MTJ<M$N<@]AI =CT4UIC!M#<H*,,W[##E"S7N!Z#3^F\Q6Y/+RKQQ?V9+[7\#
MGT[';OSR=^XND:QAGUD_-)/JE&&>$SFI8NTD*RG%46:[NI!IIR=S>3?N"M&8
M<8L'O;<$P.DK5H):XPK6DI9/[G>@;]=:UFE;BGJ>,N[Q^SMGT..>]OR@[,&K
M=AI)Q@M*=*?5UE]*?F;QQ.]..)3$FJ%!I1"<@HPX\\XP)1)))0=C----'L("
MRBP!WL0M[UK6M>N\VVDJO(ZL8RG)0@FY-T26+;?1&)_?W)Y-,319OWM*6+91
MLG>"CDS,$81'EF:9T._A<I(82(!8]& TF;3RC?4I:,8!E:XM<IX6UAW>7R6;
M^Y=F=[\+9VZ4][+SO%6X-.?3ZY8QMUQ5'JN)KS6TFF=DV1QO;U6W,S9KF^"(
M/2F/KGLM0Z?2*CR5!Z%,:$LLIM;##TQ0]I4H"4^QE!'L&QZ]V]1@HO5G/N\_
M]"\%@<5[=W;L/15(;:J>B.$:I-*3ZRE1M:I-RHVJTP._S9U1@&-GRIK J$@0
MZ5OB\L[9!Z5D3"7A1G%J2$QY+BO#L#4UJ$XE&AB*4J"C=EA$((1:#OTXW<C6
MD<7X?MZ+YG<CL;[AZMW3;M-53F]-51M.,?JDG2B<8M5HFU4XGQ3!X#KYE"6'
MHQEAWL#?],^2/U,( 9K?U:]*9'FL],I]2S"_I74LTO7J TO>];#*79_V5]K_
M '+['\3>K8;=^52W%Q/^*L+>?:+]22:Q3U6VGG%]>R01IE;51B].C$:XF>[0
MG-Q5+'=ST5LY8>%,6Y.JA:N)1DC7G?$0 P))03-A $(?PS2MQB]27F[O%_:_
MB<-W>;B]!6I2I:7\,4HQR2KIBE%MZ55M5=*MME<NP+MJBCZIT^VT.!&L;O(F
M)E3)+#?6UACY:M4X$A)>%JM> T9"=G/V6+YRP:T2<,O8S2 ;$<#H\GN]MM-O
MKW.C0Y)>9I+//'M^E,SZWV%[<YSW)S?X;@OQ2W-NU.;=B$ISHHNL$HTJY*JH
MWBDZ*3I%RK1TTC-B5#7<UAJ-C;XM(8LV+6)#&7!"ZQU(W:)^ A.QN+:2F1JV
MDK1/HG&$HG>RM:]Q18_<6'L;2[;O[:%VTDK<HJE,53P:Z=CQ/<G';SB>>W?'
M<A*Y/>VK\E-W(N-QRK5N<9-M2=?,JO')M4;E7.R>(, JAW:?4*;B[JE1?J:9
M*Z7*H.TAV6FKG0/XAFQ+4/=?NH8"8<:G2IIMHG\6DY0:2F(7Z*,/,+*",8:L
MR/+$TY^.KGCM5BZG9IWU?4G82N'I)=<MOPB2VNJ\=44@T%MBVX5^FI98$]9.
M;.B[(M&;SJ2Q1,8PH"T+.VL#5MV6'#;B/DT<FKI3 BK7$]&*X10$2L9^E6R
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MG_I8<3K24<SHX_+I/&B:ZDNS8-'I<[=2)!O4C*:W1,@$Y)F8W85*@H[:+]X
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MG<\BM:1AQF,S= M# U_#I4LV0I5"T-2<!.06 A(4<>/8S3->X7M]A0-",,$
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M?I#Z[[?]/_%?_B'Z+[G\'^2?><JS)*E#:-5/]%U;?R!AW\W6[(59&?8*, 8
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M!I0ED)UCT$*E$,1X&X@0TK+#&EV^S;+T8<:@1'G@" T\9PM;%GR0>-9WOO\
METBG3P7C4YZ[C=6FK>G;\;J5<6H8/#4\9W91UUHE.:BVXQ45AV9C&YOXQ"DR
MD)+6+0P!B[4>9M$I*WM>0+[\Y;*3*G<I8B/*V8C" E( 81 ']4'T'FG"4_\
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MC+:[.%S<_&=Z\I^I*G5VUAF79IWD;AWFHU$=3U&T#6CRG&26DD;;&HH&:F&
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MGDMY+&S_ &..ROGZ$,#A\[^%*4I^H=$OQ(QFF@^0P "C"H'7[S=GD-# & ,
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MA]_[E\ZU[(XVMGML9/U]SG1-JVLG1O"5ROF3TN"BTFIW$Z&0-C0VLY1I+<E
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M1<Y%',,@>B):GC"=W4-ZA:D  YH/,VI<DVM#T(0!EU&6;PLAH8 P!@# & ,
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M,,T0003H8M^PL ?0.O)G)2FY1BHQ;;HJT7@JMNBR56WW;9Q/,Y.9 P!@# &
M, 8 P#2<1XGW^\NIJL[6ZONBM_XH5)8C-9U>1[CB@(%1216;'7] \1J/VYT#
M)PV;T7>,25-[:46Z-X'R,,CKH\T V[1&]%BM>B,Z:NK-V.0T, 8 P#5;Y>V*
M7._'-[J8US+35](6SFCIX]_EUH3ALB3]3*056J#"Y)7C<OJ:QSI*[K"4YZHP
M@E:PB"<TI0[/%LT)B>K,CR-BE4_T75M_(&'?S=;L@61GV"C & , 8 P#&U$L
M9BEHFQ,<<[N@!@+-;V5,<YGI!F*!)@_<C4P1(V<'S%CU[UAI /W8OQ_+O.-W
M()Z5C+LL?M[?.AVX;'<2M^M-*W9IA*;44\*^5/&>%,(*3Q7<XOMESR6'8AIX
M<E-+]=@*TE?),$!Z9*:#U.- 9&F5P0*OF*-!HM[3GA]H@& _W9_4E_97VO\
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MYJTLJ1.C'+Z2A'57!G/$5M6"@DCDATO7,DI<R6U N*.V<H]Y/S5JA$VV;O\
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M-.A]G'MTA<:YDT AP9<X[LRM)VA4LC O$O(:YCN&JT#*^RN.#5MAY0_MPAC
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MWCW4+;A"-Q*W&5NY/SNY;AJFW"B]-R@DG5MR5.5VX*SZBE66I*BKA@\ZI8_
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M8N1JI):HYJJJOE7],\CN5_1%6MSXO9U+F^[1-$G30EYF2:&RU97;+,52]*U
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M.0Z(P"IW>#=4;QQ9U6U7T^R6,4RY4#:B*R9'#&\]XF3%$U,.=B71VB+(0W/
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M_D##OYNMV0JR,^P48 P#%5KZH6J5;-%MH5KHD'].Z+U(CS&F.G&%%F! MVE
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M(0AUZ[WO\-:P5)MT6+9'3G(0NB8I5MQ51R**!)])7<O0"WV7FFE)G%.WQ-$
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M_>TI*Y*<>T_.LJ93U+)))TJJ*F2(3?>O>2(OKV@Z),2&@!\6SV)REEB;%Z)
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M_P!;QS,M30FO$K;:#22>KTCM]W>7R9!$J4B,.7OT4988X";Q_#ZH"A,C"G"
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M & , 8 P!@# & , 8 P!@&;Q'_!KO_/(_P#1-P7H9C@@P!@# & , 8 P!@#
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ME)VY1E&<;BC34XN+>2:;3HTFFT3#G0/GA@# & , 8 P!@# & , 8 P!@# &
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MTL9#)C'K BK#-(FXE.L=DC<0Z-2XK\-&IS];]2S2]_G(5)C0B*.*%Z#*. (
MM:$'>L^8WFSW/'[NYL=Y!PW5J;C*+S33HU^F9V9146G%QE;E&,HRBZQE"<5*
M$XOK&<6I1DL'%IK!F3YUC(P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MA6E<<KTEZ4KBK65JYQ]B4[;E&Y"$X7,U&5Q6W.-M["L^ //& , 8 P!@# &
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MS+ & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , RJ)_\-4_^R_^M+P7H9]@@P!@# & 8Q&H3#(9
M]X_1\1C$4_43NJD$@_33 U,7WU^6^WZU[>/M:1+]S=U?MU\JD_WG&>FO<+>
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MC;_G@HRIAHKH48J*BKK1'_!KO_/(_P#1-SY@ST,QP08 P!@# & , 8 P!@#
M& :^O)<^="-/)E\IZ6K"FI_%W+G;H8FUWBT+WF]0OT*80UJO D<J\C<4YSN]
MOL]W.;U#F:8A<G6(DE')$I6E9@59IR(,>A-==?T?03^1L8_^4B' ,RP!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M_=B"?M3)]B$5ZJ7'[^N^[%'_  &"V60R_IKZ-05]3H(/>)>5OX]['[?76@"
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MB;0E45E\O;+63KSC+CK J3IJQUR&F.@QQJ0T$]6HVQBNQFPMLVZOUMM]?69
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ME4Q"6V;3L4:-.-#O[R Z6.A!: 7R UK38:"%J1.X?BV+?J:!%^;6M>GIO8M
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M:3F<=CK^18<H>UJNUVZ,U$\J7R,IRM K\*].A-.-.7B,,KP1%5NO@;^\R:&
M, 8!TDFCC-,8W((C(T?W&/2ED=8X_-_U"I)]<S/:!0V.B/ZM">E7)?JD*H8/
MD)-+-![O4 @BUK>@//S6$FYCX?X\\J,HM:BV)SYZJ#R)6 Z0FAX_7S*)DD+Q
M'F'F=52T<@T24("(RWG%V>VM1K:X# 2A9U:;3@:<2!*8<#6+,X)/L6A\3\R@
M5T[Z3Z547I7MT]+WM)ZX>N@&RI$4B25;2+'&HR[,-+T;!U<FCT=>)<@@\<+<
M?K9&L)TL?W=2L5;*1I1(T2:/L%WZFX#(:& , 8!J.[YI> !ZS\6]XME>M"BV
M%G?L=A3_ &26T;7RE'6[7Q-W@X)HUIZ, H4,40%)%Y2@],0).E5+]D&'A,.
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M$DZM[X<Y;)9"\B -3))>X .2_4J51YZH*4*8KW!(+( &=!_%\C;CD-# & ,
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M"?19OH'6O=^&L D@  %@"66$(  "$   #H(  #K6@A"'6M:"$.M>FM:_#6L
M_6 , 8!U$@C[#+6%[BLJ9&B31>3-#E'Y)&Y VHGEAD#"\HCFYX9'MG<25+>[
M-#LWJ3"%*8\LPD\DP0!A$$6]; B*L>7N9Z3?E<JIGG:BZCE#@T*(^ODE8U)
M($_+6%6M0.*ID5O$5C[4X*6A2X-24\Q,,P1(SDQ0]AV(L&]*L4)788O&8L!U
M+C$=8HX6^OKK*'LMA:&]H \R9]4?5/<B=0MZ=.%P?7E5^\5*SO>H4&?F,&+?
MXX!WN , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MJ;Y24XS21*X? WD9#0P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & :HI)Y7V&,W*509_"OD0<[-7QB<3I@8F>D:W5?JB
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MD9BI*4Q0&,JG1H:E#@/8_5YD#6B++,.6%ZP#I)GT;6L'M^DJ1<E:]PFU]/\
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MQ.#:(>A(E0T:FU[BCK@6:UPY(#973G/2E?*9Q7R#H9O\B';/0<S96QD%T5T
MPR=.]TU6T98VH!+"C;6^QX,RO*U"E*.21B)09C9QC4&NP51<J*=#<-D-# &
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@$8S*GX#/)O5-D2%H,,G5*/<B?*ZDJ%>M;7)F%,(NOA\N9E(T1Y)3S&),Q
MK]:6-BP)Z(Q6D1+-%Z6(49Y $G8!BDZB""P85+8*Z.DK8VV8QQYC*YZ@LND<
M FK2E>V]0W'N42G$/<F:51"1H2U&S43DW*TRU&H" TDP PZWH#%Z1I6M.=*G
M@E(4[&B8A6M;L1,>BC 4L<',Q*B+-.5*%+@[O"M>\/;R[.*HY8O7K#SUBY:>
M:H/,,-,&/89'UG=/P&S)-5<JF[08_+Z7F2NQ:^1*5ZT#(U3P^+/T,1RQ8R$G
MEMSV[L4?E+D6VB6%GEH%"O:HD 512<\D"3L 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M,4C=*R3R&+LLI1$.;V]?9&)"[&#1!&I,(4;)M%U%7T,%?_)W.916W'KSSCS
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MM/>U7'QL=+S;J+R'<]]#Q;L'PD=,W_'>?5D JNGKGA,YD7,DAFKF91+?7J1
MZ6A1T-8)!]M<%SU]:Y:4?$I&<3K>R1S"OS+C3%]"B<)\BWD$2U3SQS#R#([1
MK%FX^\-?C_N!&56'-U'WJCN6P["YB@\K1CO247?+XR.IZ#:4R1.RG.,8+$Z)
MU9JQ4:H%HHA-NT6;[DJ\EV-HGG@L2P+<_LT]U6C;$"%5MI6!4G%,OLBN?F I
M)A,[?NEN;7&6QI J+7.7UC4TOYZ@I&<(\P9R4)8Q^@Q;UJ1^HLOH-?D<YQL#
MBCRR^**S;PXPXJX:BLXLJ[*1C^O'5+'A\D%NV#:57*&*(,%W1V1M=>KAU2P+
MO528O0M;H!&H,UI4,G1I&]7-$I22PH:W*-N8_P ?',OCG\DB U0UMY:#S6<H
MS-U(T<$2Z4/3M<MM\P1G1A1I81&.]U1LT( CV$(1;^3W:]GKJYMHF6/Q,3@-
M&R#F^*Q/PH24]Y4A\E=S^$R^E\:6)U1QI<0L2#N<G[37+S2OC2.4>A%M4F@*
M*WKV'F$E@]P1"(,,"KU%*>7O0]@7FJL-QKW_ .$K]OCL!D7ZX\V?!M>+OU[
MXO._L3=)?XJ_4R*%_JAM<OT;/FSZ(/VY^;OIW1N]YGP' ^0?KA=?@;ET^)IM
ME/DX\FL8Y2[0\BY'6E=O$%X<\GDUYB%QZ30-7J3;LJ-#>E?5T3$Y#8B8A+/&
M*>)&&S4BEHVS_1J-HVT]0L,7;5 TDM%4SJ=*^)[1<R<@P!@# & , 8 P!@#
M& , 8 P!@# *Z]4\Q5[V#2TCHBT7FR&&'2=<PN*]SJBQ)-5\R)4QQY1OC=I'
M*HJL1N):42U"#YB![,(.!^ @;WH.PU.A&JGD[\I?]E.?KX8:;2<$W6X(W>-N
M\T467OMWI>\9VUF-SFBCA49U7A3;7-H";7 *E$M^XB&6CT:7M/K0C/;O0-*5
M,S#A7(R[Q@_V5\NC*DL"/=VW3+U=B.]C#>8@/BOI^[X/ @PO<984(0RIO<8+
M61JN7_?$BO>S@I% ?HMD!^;U#[ QRKD50IF>K/G*A(9R_2L#H:O76=/D.KM
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M[N :6Y]H33I+HQ/Y#9DHJGQS%TTTQK=D.+?#5$E71^W@#2DN[JVL!2EQ-&X
M3) G"]BN*[%I@_@=2Z<H]9USU3*^NFWG1_N^-U3VC4-T):3:I76K7-;4A1WB
M3I7DR16;51D^F##!U5C4M:B%W*2M[TX,Y[B02OTB4@,,3"/5)1UK^F1%W1G%
MG:?;<LO6:MO)44X^0W/QSV-%H5&BY!6#;/9++)/?OCHL*&-G4LBK]ZG,)373
MTBT<^2I$L5HOU(VL<9*0$.BE4J*.2;52#39;3Q^\^W<;UXGZ$M>I?(%""X%S
MC,*=U,.YNF^6K"<UL@G<VK:3O]=5Q7?-+1)A2>NVHZ!E+RI2]R!H+TJ 66A:
M![4+#2#RH59U(;ZPY1ATE[]ZSLSH+Q7]#=V0"V*PYMC=1S&H':CTK"S#AD3G
MS19$>D/\1^I*(>FP2Y>^M^@FEH5Y>P%#%H8/;K0RR#SR.UHWC/L>+,M$)+1@
M3PH=XAXDO(_SH8E4V&QV$MKV17#T;SY+>6^=7J>GN_SSV5PNBH85'U,@!L]
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M6JM4NVB7O;2Y_1;6&:2"* ,0=ULRHKJ;[<AH8 P!@# & , 8 P!@# & , 8
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M=H86IMD,T51UI)8(^IECTC2$N4C4,3$G+1(QK#3A)4@ DE["6'0= 9/@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MZ4%,06%O5H,5.L85O\.K'M62RJ26!(V9_:(Y&(E":O<E2M0>G^+0OC!L81F
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M=EHGD5A(E*9M2$M"-0C0D#&L(-7)R!*$;+ME]'TF50L7Z<>[$C42HR70N V
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M'5J5C'[?A;C!).MDC>SN:AO4GJHG(7&,/(#&U:0O("2Z-AI2@)(SB-:,!OW
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MA,CE3CVW#*9A=UE"F3RV)0IN?MEJ*E?8/MI,1+(=)XHZ)R5H%:<X7SJ" Z.
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M;-!*PAL<@,-:1K#A*%8FR,11M:61 )4H'L9FRB ;&/>Q"]=[]<#+(D# & ,
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M2DJ%ZK9JLXI,4 9FPE@UH#)\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MIH/F("9>E25QH890WD+JN^^R^M>)66)3B,V3R8**;>)!)"&4$2LI.^Q^+O\
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M?46O4#-SWMF2NS:P*G=L3/KPC<W!H93UZ0EV=4#(-N*>5S:VF&A6+D;08\)
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M,CVI4-9#X$@9FR2O>(O>_8'U]NLO,TL54FW & , 8 P!@# & , 8 P!@# &
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MYE,90Y/<OF#R4T-J9&4I<URHXE&F)(+$$DHL 5:BB1/6 , 8 P!@# & , 8
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M5J4P9 DB]&H+/2G'%"T/#5 G4LED*, 8 P!@# & , 8 P!@# & , 8 P!@#
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M,B(5+"(B2W)W4MT3[<?70WZA_P"*I[#LR;& , 8 P!@# & , 8 P!@# & ,
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M-L:VQ&F;VUM;TQ*) WH$1($R-"A1I@%ITB-(G+"6446$("P!T$.M:UK6 <S
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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) , 8 P!@'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>tm2115679d1-tbl_a549tum4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-tbl_a549tum4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!)@.0 P$1  (1 0,1 ?_$ .D  0 " P$! 0$! 0
M       ("00&!PH% @,!"P$!  (# 0$               $$ @,%!@<0   &
M @$!! ,+!0D(#0D$"P(#! 4&!P$(  D1$A,4TQ46(9)4U)755E@9"AHBDY26
M%S%!(W0U=K9X.;*S-+4V=[<8P3)"<L)S)$2TQCA(>5'$=29&-Y>X.F$S)8>8
M<8%25=97U]A9*1$  0," 0@'! @$ P@" P$! 0 " Q$$(3%!49$2$U,%87&A
MT5(4%8&Q(A;!,D)RTG,U!O"R,S3ADB/Q8H)#)$1T-J+"L\-4)=/_V@ , P$
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MKR&[+MQM%K32M*#V'.H,N?7PZ>[2Y.#4LD5J85MBY6WJL%UBY#+PI1'F)C\
M'A;C P8-+SV9_?QSI-_;'-7-#@&4(\2I'GE@#0EU1T+?*LZW'3QM66M4+26T
M\PIW?5R=M:%-B0F0QE@5KE0NX00HDOEES"R@&/\ )\9P4)".]G&._P!N<8SK
MG_;G-8(S(6!S0,=D@G5E/LJMD7.;"5X8'D$Z00->36K:.<)=10NV(W]UGU;M
MBIZ7N&8+F.<7&:WXC29&T'N#<UH761$19M>I8XEF *C[(L>!G "I,P(& I%
ML]@2LYYT;3E=Y>P/N+=H,4>7'+05H-)I[PJ=Q?6UM*V&4T>_)KICH"FCSG*X
MH6[9]0/5G2LIG3WI8.6V42-,)='8#&FE=*9P\( G&)O6(&5L+&!K:S%!)A92
MMP.1ICS2AEE&#, (..C8\JO>8U-LRK!E<30#VG+U"JIW5_;6=-^[XCD Q/\
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MC#71+,V!DE$1D;*QC+6%C4>*G5@%W0Y +N>),]E:/M77EA(]T;' .:\ .%<
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MV/1@L][&2R2,AP,6.YCT$\T?/^67,<8&\BD.ST[.+3_Q"HUKD11OY3?0O?\
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MLW-YW1ROR!N8Z*;+B:9R* =JYOJUY<SNCY?$U\;<I.?IK4 5S92H'ZMW._[
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M5J*BF; JO8S/NX7&X#7.;(1@,/AI0XU7S]!/_?/U*_Z[+M_HFK3D\T_MK/\
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MWV(%"I((H12C/<67-9+2VEM)&[RVD;39)P:=(P/T8T.9+FP9<3,N&G8F8:U
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MW,' [W<_<4C(+>S@F(,S7-)SX- !/M.NBY7)V.EFN)8Q2-P('634:AJJMO\
MNYMK5M7R/:2G)X^L,$M$V31.2EM$K5H8\[N[)'$$@9'U&3ZS$E//-A3IVY5I
MQ"[Z;S_?P#&,FYQA^[()I3!<1 NAH148@$T(UC)U+/\ ;\L<8EA>0V6H..&
MJ#J^E<NI^RJ_MW[R.3/*O=&Q[A3C*;$:6YZ9325#0\.,0TZE4.DKJVK$_:F<
M$+C*&!:<4J*R,I4 >#0#&$>!9W7$,L'[1W4X(D#6FARBLH(&HC#,M44D<O[A
MVXB"RI[(R#VA<RO>%3EDZYEK1]?LPJT\?[&=SE\&OP]A;Y @2M<IK5J/C;.$
M3W)H>A3(Y"2E&P!486XP6X \K@(LYSC&ZVDC=^VV/$/F&L&+*TR.-3@#D^MD
MR8K7.Q[>=.:9-RYQP=2N4892,N3KP79-A-4(+(-HZ+K/97K*.EFWTT.\6558
MQ!U:D<V6(W"1RU%AGCV9#7]H/[3&'=[>&<DP!#D82,HH11^0X*- (RO:7TK;
M*6:SY>&6Q!VCO ,@Q-'-!( .;J6Z>U8ZY9'<79=."-D;!.4Y*AQI7I6\=9S^
MU3Z>'_Y*?_,8Y\U_M[]%N_\ C_\ QK/F_P"IV_\ P_SKU:\\0O3IPB\^/7LA
M+791&@]<OAZU*RS_ &G;82\*6PPDER3M<J QL3@>WFJ2%2<I:2D7C$4(PHP
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M6R/!Z*N=2JQMW <ZN&G EC:=-&MJM;W#LB%27K,=-.NV%_;W:65PAN%;-FQ
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MP, 5=W2>--& LHOJ U.8888+  %@!+H4(8QC%G 0@"'';G.?<QCCD7]M??\
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MU6SD4#E]<KG9>:YO++5\P,CD4<EJ@[!R@9<=<6Y\0,)!^>W&2&K#>G#C.<@
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MJ;G7,+BT=9S.#HG&I)&/UMK+UZAAD6<?++2&X%S$TB0##'#)LY.KMQ71-N-
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M ")LAL=CQLT=5BTY"0D3%$'9[P!8+) '7RWF\FW>R<PD_P!"!X#<&B@J\4%
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M(LX B:27^9.[Y)7DTDD&,G*52D0CCQ#$ !)>0$E^DB:]D89(XO>!BX@"ITT
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MEQ+9Y)5WJ"!1+SO?\F6\O@DZL\]>JP#(BT*!.M7C+"(S!&2P#&'GW_,[3EK
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M)7U(>I2NSX]%9;4IYY06X&%TA4YS@.<]H<AQ_N>;;SE5I?1QQ7 <61C"AIF
M^A86U_<6KWR0D;3\M173WJ9?X@'J(_2.J/\ X7MGQ[G/^5^4Z'_YBK?KM_I;
M_E4&:OWPV J&%;-0"&N,6)CVVR*1-]PEN$93+U:Q/*&F5LKKA@5#. )C&-#,
MUN 9!@7<$(&<?[3'.E-RRUGDAED#MN C8QT$$5TY J45]/$R2-E-F6NUAIKD
MT92N4:X;'6MJE;4?NJF7TIBF\>3NJ$@Q:C+<VAQ;7MN/;7)K>FD\04SHWGDG
M]_!9GN%J"BC@9"86 0=]W:07T!M[@5C-.O#."M5O<2VLHFA-'A?!O"XI/?\
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M+@KBZ50F8_6+VSNV%SRFSDT6"S<]VH^[_<3K%O,V.C; & EM 2X 8N-6Y\M
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M[K.#*Y_.YDJCC8JP8L4(V5L4!1H@'@PH5")*$<6$8C0T6\S)Y8R_+*R/ V6
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M&POLY!\5,U:5!T8@.!.!R+TMHZ+F7+AR][@VX8?AKGIDZ\#0Y\Z:E="8VA;
M<+LZ@T]HDVC*Y:WY4LBJ&2NZN.R4]0V*&Q,YS%^DS##4K#&FSS^5:?!9@EQZ
MY.2$020XSXB__<OFHA;<J;+YEY&-!48UH ":DY-%$M>2;B3?7[F;EH.%<#UD
M@4';5?-Z4>V&G=6]1[9R 5(E15'KU?"1DC=#JY2]OGE%3_7JH9:!$H=YHZ+7
M%L!98W9U7MA+@>6: S*1OP$*DT!0LN>6-_-RB&6?_4NHJE] ,CN@#[- #3I.
M11RNZM(N821Q?!;OH&U)RCKTXD5Z!E6FZT]$?:2EM[8'.YX5$F;6^B+;:;<3
MW&=-XN)/)(W6T@(F4;2%QH#CF4M+HO&U)BW'+@C1H49>% PJ30@*\;9>?N.R
MN.6.BBVC=RQENQ0X%PH<:4(T4))PPT86_)KF&]:]]!;L?M;51B :C#+UUPZ5
M8!J/LK!MH>N/L?+JT<DC]!(1IBZU7'I0@, <@E.(G;M-JGI[;E!0S25;2;)7
MI:2C4%BR6J2$E'@_),QSE7UG)9?MN&.84E=<!Q&BK7T'70"N@X*_:W#+GG4C
MX\6-AV0=-'-QUJN#I9?VW=Z_SKVV_IH[<Z_._P#UR/[L7N"YW+/UE_6_WIK-
M_P#4=23^L%MI_H?N;B\_]2'Y47\[%-M_[ ?S'_RN4V-9O_J(]P/\U+S_ $8H
MGG.O/_5(/OCWO5RV_7Y?N_0U<M0])6^G[JUXV5C*N)/NM!6UCKL4NM!JFD76
M&MTDC%H+)O)ZJ614IQ-E )4T62U*F-1W$8TB<!0A&J"S@#)!N//;5G(O)OVA
M>;@1[)!R%M ZN2A::Y:]&=:ARN=W-/,-H;;>[>U490ZI;3+6N"[_ %UU%J"'
MUI[E9ULUC".NY72\3UYB]FG.B<F+.5F0%\S*A(/7QBKU0!K<W60O#20L$,!*
ME>C3%DY&%0 P=:;E-U\O1N#7;ULAD+:8[+A3)EK0 TT$UR+?'S"#UAX)&[+
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MVCIMVE:IA>&5$Z(U^2#<F& .*R/ LFS6TL-O+S>$ET8<PN(+FAX(!VFT(^,
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M+!F6A1DLL&"4)F<UOW/RYUO+ZC;X1R?"^FDY^IPR]/6M_([P2Q^3FQ>S%M=
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MN*4-*YEA\E$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X16"5S_9F;1?UK=6OZ!;
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MY>!\OF,#I7Q/,>^A:7;3,,26T::.(&&(RU%:C(KUG*(VO:'[N5P;1V.%#4C
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MKEZ".A+<G6S"9VV%%MAXN^D+82PX'V*>]VX<MBE?S.YN)VQ%S7[.T*[0^%M
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M+R4:^'R NH)'%[<65@I51*129;-5M96:E'$)B"41(J5NJM0F4)!MZY(G/$E
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M&'7FQ]>B;^L50RV-9E;V6ND1D<C 7-M7UPR3EE0MB5*$SRAJ1R*G!HS1C_+
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M>2L4X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X19I?\
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MC.PMM].AOUOC$/BL4HN0DMLB?H[!=B4BQ=:2VP8A"G7QA <S%"1.J3G?\J=
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M(4JCJ(?_ %25I_\ @N-W_P VM<<E1G6T_>2[1C<>Z75IT.5X;_=&W$QJ.B*
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ME&2E%KFVO1?T]V\NAZV&?W:_:2N.:1Q%#K2FVM-TR*H%UPQ-M;DC.VQ^SD:
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M  ]-_P 9_L9Y#LBD95FN*4)BT\>5:0O(A!_(,&9@8?X,&/RL!*%C';V?^7D
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M'9%(RK].O\H*?]\#^]@X;D4G*OG\E8IPB<(G")PB\O+VHZA^YG6#ZF.K]/\
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M-DUK;-,[@EGL3.BD3I)S86QNJI"_-$; >*0J"L"-/CJ-WR6+.#\<*#6BN'V
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M .ENL**I8#KS+I]--C@L8;,AS?+S)')'Y(@C1%.)P+4J0Y(V@Q@UR4I\&=X
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MY(]]1^36I=3=U)#K+0MK;:,:N2.DR=MAT&PW(!FI6^HX]#"@8BX$ LL_>&O
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MNTFX/WEG7*;9\*+W=)M=*S=5H2 *3VD$NU6?6=,_(2C!!#ESCZU26N2B[<9
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M&G5+ZS7/J/ XU8Z2E;\7GN5CM;M=%HR"3+52EM96HT3+.'F4+)9&2\HV!-C
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MZ:ZL<VC76>79F_W.NFF<S%O0--@!ED?FR<,57)GD#G&8LBD492&D-"0XM 2
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MA'10U';-U69,K@G$9A8Q9$.)PUQF3FN21-H-[PPF"0D$JSBC!DF'#)%DOA*
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ML5*TY7>O515M1=21\N+5E4L+CT @T? J6+Q-D:C#:G:FPE2Y.)ZIR=5XTZ?
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M@&*#@(R%)3CG6URRBMU85O9U#[NZ1-ZZ9[(BL.Q82BW8T\VGAK^US"$3]/!
MM940:; 1(6A0]Q26LI:A2B*5.K:SE ,&0$*L28TTTF?!63=$.Z*WMK3N4QJO
MM7FS3ETUXV2N[7BW*$C,M%.H%%+MA;PVR&QU-=RO"I4E=XD\NDR"IQE,(24A
M>-4028H+*"J/*0H(=?"H&J_=S>B'3;W+K#@;386RMZQ]=,*FEBF"V/'R#H57
M9^5\0ER0A4I8'8 B,!"> L>< $+'9[O"@YE+.+="6EXG)XY*4N\O50=5,:?F
M>0)VM_W=E;HQ.1[,X)W$I ]-AD: 6XM*PQ-@M20(6,'$B$#.<8SPE%H_5X /
M5C:WIG]3YL4>K(]45Z9U%V;4A'@A&?KEM6#V<32F3J!A[F6&I9ZF+<2"\##D
M2]R+%V"[O: ATJ).IQBG:#6KKS]4QY*$H;MN(YLO3^NK@/NFHSM5-4*9GE8P
M%]8!A#@M&3-I"%Q,="B<B+-<FS)F1#%VCR3,2H\U4CALB6?=.8C?Y+&JUU<=
M>K3=FUIF&4PH$_;+-.O<!#2223D..1M2F0)'A9VQ@D_ !*'8X117BB'DK)-"
MFYU((=131UW>A]+F!MC#9L1*7S:!/82AG3H4\FD=8L]0JBH XS3"<GS:E,UR
M)0]IV50>(.3,#7E!R8$CL()G4!>F5"^JE8TNZBLRU>G_ $WHW8#GOCLG%MEV
MO9NMK9E6R!$@Q,%(&R.3-QC"L\DJIP,1(4\:;B\X:2RDJHLD.32U/84"JU:S
MZ4F-%]#;KAQB37OJK;H7;8PF1O$,T]!+D=04):J^RJ6*M>KFM@E3>E+A@BG9
M,D6^I$!IR)!YG.2\%!-P#A,RL'ZZE$T_5WW=B=1J UU$HNU4=$M0GFIP,S&W
M-Q\&D!]YTA$E\FCZE$G(-;Y*[Q^3N2=:O+R%2KPX*,FC$(T><E)R+OFQ,;CJ
M[[POH,-:P,JP:_1O:%P7"5-2%0)8O;9"PD-RU4(T@>5"M 22 !)@^T900XP'
M.,8QQF3[2OYY"E.$3A$X1.$3A%G-O^'IO^,_V,\AV12,J_3K_*"G_? _O8.&
MY%)RKY_)6*<(G")PB<(N=V[5D,O.I[/I.QVX]WKRX:\FM63QI2N"UI5.<,L&
M-N<2E#<F=6TY,XMAZUC=SRP*$YA9Y(A8& 018QG!%2RE^[5])M,B):,U-<*A
M@+("A,CIVT>PY;&J:^YX1S0>A26,E#AL4ILY*,++R7_!BSC&<?N\E10*QK/3
MWU!2Z@2/0^-4TQP;5N5QM?%GRMH,M>(SYYN=5A#@Z*U,F0N 96MD#HM3 ,5.
M:A:<XJ1X[33AY]WD*:9ELZ33'7]%=5';!)XLY@M'76FG>@ZI>LRB0C1L=9/A
M#<F<69:S"<,M3VK.):R<86*RC50.[G.!X[<]LI1;$Y:M4R[;1QK<A='EYE^1
M*FGB@V.4!D#T6VIJR?I47,W-F,C %H8^I5G2 O!N%AB<2H ?R CP#W.0BCPJ
MZ6NF2W625Z@J*]?AT3-;E4WY(8SBP)H%Q5V:KL%!9Y[R5)0O6'Y*D%,6TE1Y
M,L\*7!8<E8!X><AY*4&12'O75JF=CW^AI-;,>7OKQK7<L?ORHU"*0/3&!ALV
M,(G!O9WE:0T+4A+XD3I70X(D:P)R4S(L9$#.<8[(1)MJU3-A;$TCM1*8\O6W
M1KS';)BU62(F0/2) R,MM-:1FG"=9'TJTID>C') B+"68K(-&FSCO%9#G.<\
M(H);+]#WI\;27%)[[E]?SZOK3L)+A!:TCHRW)_3Y-MH.Z66<GL5CB#RC87PY
M<6#(5:L"8A<N[W:I/-$$ @2HH%)%;TW],5&E;ST]D%)L<?U/?(WF.+*UC[@]
M-QG;A]22PB1BD_K$V4+9FGE[>G=L.RI6H6FN! #3AF^[C,*:9EK%8=,75FK6
MK4%M;T5ERQ7HQ(K4D^NTAL"TYC*Y%&W.Y .2>:!?'%4X%!EB 2%T,3(DR\LX
ME 0$ 20A[F,\E**0=,ZM4S04^V!LRLH\O9I?L]8:2T[B7JY ]/!$@F:%E)CZ
M9Q0H'1:J1L) &M.$&4Z(!)&<X[V0][W>0BX3).F3I_+*KVZIA[@+XIK_ 'DM
M1=<^QK47/)BG4RZP')QC3HK=6IT(> .$33&+8BA%A*VF)DX<%9Q@'8,6,RE%
M\W:'I7:1[E/T+DNQ%3J9V\UW5;E3\'6>V<Q8C8O%7%R:WDM>RF,#TVFH)>T/
M#*E4H7@L07!*87G 3.X,P R4!63I1TP=0=!72<2RAH3(E5G6600@GMR6C.)/
M:5L29E1J"E2&.J9C+EZY4W1U*<F)%E&A E(4F)B3% 3C22QA(!16#<A$X1.$
M3A$X1.$6:9_)Z;^,J?[@CD9UE]E87)6*<(G")PB<(G"*JG;_ *,>B&Z]LJ[V
MM>#SJ,6\^QLF&3J>4Y:4UJEXLZ')4"-J21FQRXNYIVV5MR9I0$HPF'$85B1D
ME)QG"))(++E* J2Z/1#5UEU /T2B5<>PNLA\.4P;$$A,DD\<<"&1>Y9>7(XJ
M9(7<,RR_.SP88K6.8UPW!6I-,--.&,8A9A.A2ABT;:H;&(Y$&(L\IDBK"SQM
MG*5*U"]44U,;>G:V\M2N6&'*UIX$B4&!FFC$88+&1"SD6<YX1<6IG5JF:"GV
MP-F5E'E[-+]GK#26G<2]7('IX(D$S0LI,?3.*% Z+52-A( UIP@RG1 )(SG'
M>R'O>[PB_+SJO2T@V@AFX;O'%JV^*^J>0TK$)(:_/(FEE@<J?02%^3)(ME9[
M/ >'!># 1N/E_.Y3?P'B>%GN\(NK6)7<&MN"2ZL+-BC'.:]GL?<XK,H?)4!#
MHQ2.//*4Q$YM3FA4!$4>F5)S<XS^X(.>P0<X%C&<$51]1= 'IF4W9D)LMEJB
M>2_%6/P)/45=6G=%GV94=5/Q2G"Q,YPZO)=)')DR>D5A"<3ZQPX!*/  T.,&
ME@&&5% KH^0I3A$X1.$3A$X19R'_ )Y_$5'_  .0<W6LA]"P>2L4X1.$3A$X
M1.$3A$X1?.=VI$^M+HR.18CFYX;EK4O* 8,D1J)P3&I%1832A!,*$,@X6,"#
MG @YSVXSV\(HO5SI-KY5&GQNB<$C3XR:XFUE8%18C)<RE!T@(A-G DP)<C2S
M@YT'+4KBJ]KEPB%I:L*I((P(B1@R6#."="SYCICK?8^I[?I)9%<IK"UN;JRA
M52E068.[Z\*S8C7;:RML,,/EAKD&6YD[![.HE2=Y"M ZEKTX%03\'X\3A%$W
M3_HRZ):36PGO2IH3/)+;K-&3H3")W<-IS:U7>M(6I1J6U5%JZ*D[HH;8LV*&
MU88E$,HC*L*0PP@!P23C@&2E %G[=]';1O=&U@WO9\)G$.NU0PI(I(+5I&T9
MM3\OFD60$%I$3%.#X<ZHFV5D)$)!28M0L3&+@(R"4V#\)R2B@$H"I;:J:C:[
MZ2U T47K'6;/5];M*U:[C:VY0Y.CH^R!SR5ETDTKDS\M=))*Y(XX(+ 8M<%2
M@_!!)1 ! ())*!"+)FVK5,V%L32.U$ICR];=&O,=LF+59(B9 ](D#(RVTUI&
M:<)UD?2K2F1Z,<D"(L)9BL@T:;..\5D.<YSPBD/PB<(G")PB<(G")PB<(LTO
M^3U/\93?W!_(SK+[*PN2L4X1.$3A$X1.$6F6)7<$MN#2NLK/B,?GM>SEC7QJ
M80V5-B5YCTC8G0@2=<V.K8M+-3JDQY0OW,X[0BQ@0<X%C&<$5*9'W;WI7DN:
M$DVM;A<*R;'XJ2-U NNR%UN=&HW4A0)628"&+)B<J/3A5F#'DHY:869@P8!X
M$6(0,RHH%9YL-IGKKL_J^_:;6G $V==)"SP6/**[A2Y=7S>W,-:RB+R^%,L>
M/AI[.JCS4Q/,-;O"3HQ$E83D>#W?"$(.84J230U(F)I:V1M+$2W,[<B:D!0S
M!G"*1-Z8I(E+$::(1AH@$$AQD0LY$+..W.>WA%6"X]&70%R%,D9E7R=+$)_M
M-&MS976;9:-A-=7.>P46R\^2E88$@D*>/H6I<%\-"N9TY132L"2FP:G%A(E\
M&4H%:?R$5?:[I@:=+X]NI$C(!("(OU Y 5+-G8\CL*;I6B6RGOK3G&11]"4^
M8)@KQ(%*\1KD>T81C7& +R;WO"+P&4HIHUS 8S5->P2KH4C.;H;6T-B\!B3>
MH6*G$]!&8<R(8\PHSW!<:>M7')6IN* (XX8S31!R(8LBSG/(1;GPB@]M[TYM
M0=\'^J)%M351=IJ*69;C88"@72.3,S0W(;VBS1$)^>H01]V:P+';+:P(CVM>
M+/G61Q2E+4)J=46 W!*+GFF?2>TOT5G4KMFF(5+7RY)DREQ5WN&X+$EUMV01
M#B3$QI,.9)#,7)?F/1WQ49.32D11!BK!!05!AH22<%R@ "K?L"L)UU,NL%JM
M/)=I=>E#T%TKWJ\) \W1L# F^$ V(NP^11YIJILHU:B>'H$^J*,2.%)IDU2
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M/,6_B["GM?#/I0W_ *.Y_$>/)7?@.L=Z>8M_%V%/:^&?2AO_ $=S^(\>2N_
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M@W[Q]P6E<M+2G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(MUA?\
M[6?S*??_ #7E6Z_Y?YK?I6Z'[?W"M*Y:6E.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$6ZH?\@9#_../?\ 0WGE5_\ >,^X[WM6YO\
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M0C2G]F<E(DS)'C*CC<Q_:D?.#8"448@-;U(GSR?K02H)2O!62,&!R4'6)/\
MJ3_J#8V:[-.C+D]JSV?]+ZOQ5RJEJJ.J#=&^'5GE\"BG4R%K)K@PVQ&(WK%
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M$# KZ[IO#2NQ.B^R6R.FUV1^?HX/2=S.K)+8V2J3NT-G<6K-[DC.5((G+6E
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M?5!U$U$HZNMD9W-UL_I*U90;#X18]&(V^W(B\O921Y6>"1(XP[FL)A!H(ZX
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M29AN[&H.P\\<-A!R6NI%4\ND-G-399TJD+K/6A#**^=J[BBP#;"9154=7+7
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M#@-G2KSON^LHU$DW3BM_&O5;?LON5E _LNUK,[25TEDI?)XCB;N"*3(QV>C
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ML@]RORZ5=<-%.]>;J(U''^[ZAJS5"F:X9.Z7DH/JB$1+66,MO=*R(>2P^2;
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MA:UQRII[@\E92Y)" L&@6%L'[>S[*X+:;B4MV:]ZNM"$( A  (0  ' 0 #C
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:W<LIMG@QN IEJWZ#5;K=C!,TAX)KH/<O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>tm2115679d1-tbl_a375tum4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-tbl_a375tum4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ PP'( P$1  (1 0,1 ?_$ .8  0 !!0$! 0$
M       ' P4&" D$ @$* 0$  04! 0$              0(#! 4&!P@)$
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M==U]<V2K(Q<KE-U">"RF=D5D0JQ')$:[LT]&E=5:F+RB.DMIC['71L)95&5
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M^3#A[NM;XKX24_'M'Z(2XN=!/#)"\LD843P,890KQN7C96"M;8Q*LHW&C,J
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M,&:1E2:7>(1 :UH07=?D>8!O4DF<M18LA+,XI$7!W!6+RAC:V-W!%Z\4RK#
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M,EQN _O BMCPCJ?&?$FLR:ED_&AIZZF%(BFTY,2-%$3F)XI4ZXRKO%9-T[[
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ML3J(X))2(U6<=U,%BZ<]F*N#@C-GTAE2&?\ %(UM-/$!*J-YHI&*L& (<2(
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M1T965E)!!\]Q73<.\1:7Q3I,>LZ0SMB.SH0Z/%(DD3M'+'+'(%>.2.1&1T8
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M .;RULL]PN)21WC+\_QQG>'J%KE3G$W1Q0)U2Z.N"U-W-6L:%!H!&(5"A+^
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M065>U!8I8_JD33.5M@1B6.S-&I%,P/LFPE5-2)>G;WAQP::0H,).-+#T9"'
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M%<F9 M_*;\@L>^XM[O=3XHR>KATAPY>$M0TUI+W*9&3)@M&=WE:,""0N1;8
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M_5SCWI(<OD=QX4-/^=S=F7WU/&OJGY?Q^UO]WIZ\^5_5SCWI(<OD=QX4-/\
MG<W9E]]3QKZI^7\?M;_=Z>O/E?U<X]Z2'+Y'<>%#3_G<W9E]]3QKZI^7\?M;
M_=Z>O/E?U<X]Z2'+Y'<>%#3_ )W-V9??4\:^J?E_'[6_W>GKSY7]7./>DAR^
M1W'A0T_YW-V9??4\:^J?E_'[6_W>GKSY7]7./>DAR^1W'A0T_P"=S=F7WU/&
MOJGY?Q^UO]WIZ\^5_5SCWI(<OD=QX4-/^=S=F7WU/&OJGY?Q^UO]WK-:^\:.
M3S:5)(X;0#"W@4MTB7Y5%V$X*!@RQ1MV?@%X*%$R<9PI&V8*SGK?@X'UNC/1
MT9UFL?[8,'2]/;-76)G*O&MNKJ/XDB1WOTQY-Z_Z;6K<:#_O#U+6=333VT*"
M,-'*V\,IC_#A>6UN@'+N6Y=E[UA7KSY7]7./>DAR^1W-GX4-/^=S=F7WU:?Q
MKZI^7\?M;_=Z>O/E?U<X]Z2'+Y'<>%#3_G<W9E]]3QKZI^7\?M;_ '>GKSY7
M]7./>DAR^1W'A0T_YW-V9??4\:^J?E_'[6_W>GKSY7]7./>DAR^1W'A0T_YW
M-V9??4\:^J?E_'[6_P!WIZ\^5_5SCWI(<OD=QX4-/^=S=F7WU/&OJGY?Q^UO
M]WIZ\^5_5SCWI(<OD=QX4-/^=S=F7WU/&OJGY?Q^UO\ =Z>O/E?U<X]Z2'+Y
M'<>%#3_G<W9E]]3QKZI^7\?M;_=Z>O/E?U<X]Z2'+Y'<>%#3_G<W9E]]3QKZ
MI^7\?M;_ '>GKSY7]7./>DAR^1W'A0T_YW-V9??4\:^J?E_'[6_W>GKSY7]7
M./>DAR^1W'A0T_YW-V9??4\:^J?E_'[6_P!WIZ\^5_5SCWI(<OD=QX4-/^=S
M=F7WU/&OJGY?Q^UO]WK-83XT<GERF1)S* 84.&.%RN6 $"PG _*@R-M![F!$
M+ HF5V8%8B>ID>.G(,9Z>KG[7-9JG^V#!TY(776)GZ7*BB_PZBW2N%WOXQO:
M][>7SUN-&_WAZEJLF1&VA0)T&'//_BF-S#&7"_P!;>M:_D\QK"O7GROZN<>]
M)#E\CN;/PH:?\[F[,OOJT_C7U3\OX_:W^[T]>?*_JYQ[TD.7R.X\*&G_ #N;
MLR^^IXU]4_+^/VM_N]/7GROZN<>])#E\CN/"AI_SN;LR^^IXU]4_+^/VM_N]
M/7GROZN<>])#E\CN/"AI_P [F[,OOJ>-?5/R_C]K?[O3UY\K^KG'O20Y?([C
MPH:?\[F[,OOJ>-?5/R_C]K?[O3UY\K^KG'O20Y?([CPH:?\ .YNS+[ZGC7U3
M\OX_:W^[T]>?*_JYQ[TD.7R.X\*&G_.YNS+[ZGC7U3\OX_:W^[T]>?*_JYQ[
MTD.7R.X\*&G_ #N;LR^^IXU]4_+^/VM_N]/7GROZN<>])#E\CN/"AI_SN;LR
M^^IXU]4_+^/VM_N]/7GROZN<>])#E\CN/"AI_P [F[,OOJ>-?5/R_C]K?[O3
MUY\K^KG'O20Y?([CPH:?\[F[,OOJ>-?5/R_C]K?[O3UY\K^KG'O20Y?([CPH
M:?\ .YNS+[ZGC7U3\OX_:W^[T]>?*_JYQ[TD.7R.X\*&G_.YNS+[ZGC7U3\O
MX_:W^[T]>?*_JYQ[TD.7R.X\*&G_ #N;LR^^IXU]4_+^/VM_N]/7GROZN<>]
M)#E\CN/"AI_SN;LR^^IXU]4_+^/VM_N]/7GROZN<>])#E\CN/"AI_P [F[,O
MOJ>-?5/R_C]K?[O3UY\K^KG'O20Y?([CPH:?\[F[,OOJ>-?5/R_C]K?[O3UY
M\K^KG'O20Y?([CPH:?\ .YNS+[ZGC7U3\OX_:W^[T]>?*_JYQ[TD.7R.X\*&
MG_.YNS+[ZGC7U3\OX_:W^[T]>?*_JYQ[TD.7R.X\*&G_ #N;LR^^IXU]4_+^
M/VM_N]9I6_C22>>6) H,=0#"VE3.:1:*&N)=A."DQ 7(GQ"T#6EIA1,D*@:4
M*S)F 9&# \AZ.G'3T\U>M_[8,'2-%S-576)G;%Q990IQU 8QQL^[?IC:^[:]
MC;S5N.'O]X>I:YK^#HKZ%!&N9F0P%QE,2HED6/> Z 7W=Z]KB]K7%<1=A_V_
MWG_C%9O]]7OGU1P9_H_2?Y9B_P!PE?&7'_\ KO6_YOF?YB2H=YTM<C3BE.*4
MXI3BE.*4XI3BE.*4XI3BE.*5,5,^^4__ ,';2_NHMYS7$W\##_F6+_>K77<'
M_P"(S_Y1F_W#5==<Z@:[OL<V$O,E6Q)L30FPIBL>VYD#(EA!,%AKS+!D$,XG
M!J[Z-6%I[+ <'@%^%]C[/,?C7B2?A71!JF- F1.V5CPA&?HU)GF2&Y?=?=MO
MWONGDK*[ON$\;C3B$Z-EY+XN,N%E9#2)'TK 8V/)/81[Z;V]N6MO [=E;ZT[
MKY2,88);;0G2,R2N)5K:=94$==@X,_K"X)(&6\V.K9#B5Q6L5;^[.I1B@E2!
M"H;NT[4M6 0@8"6,>?(^)>,N*<_+QN'1'/!K>/K@QITTZ>,&>-\&3*CZ*7*$
M:(;%2ZR6L4(!)(%>X\(\!<&Z;@Y?%1EQLCA[*X=.7C/JF-*PQI8]2CPI>G@P
MVE=P2'$;17W@X)4!233K9CIN8G[$RL@.H+H1 *IJPV-RE1 ;OBU'L3V_6^F8
MW93)&!Y9LV(;(%K0\=R"I3(QH\F&).G(0%GC#.MY?$VF)HNGO^)(WS-0RA+$
M,C!ESI$CPS(@BD1^K"-73?*LX>PDM<L@-/#N%PAJ[\0:H@X3E3 TO",,QQ=1
MATZ.27/$;F:*2/K1E:.3HPZ1F.YBO8*[#.5^N=%.EO65!)*GK6 *6+1X5B3N
M>19MF*BF&*:J++@IZ:RZC2OQPWZ0H!UN]ED)\ILX1N2\P9:<(!#%G&IAXUXL
MQ^&\'5L$YV8DW%?5H,>5H1FR0#&G!Q<PQCHXV&2A9M[UXXP&<D "MU/W?<$Y
M/%FHZ)J*Z=@R0<%];R<F%,@Z?'D'+QB,S!64F65>J2!5W/JYI2RQA22:T]V>
MA%4PRTV"%MC2*&4RCJ=))*NG\80%R^2W(E?HZ>ZQV=RMQ<%[&$PZ3RHH2%:2
M2$@B/@)-))3&#)%D[TK@/5>(-3T";5)Y.M<3-J)BRL>5C#%A&.0))!$JK)LB
MB/2(S;S9!96:0!AN^2]Y.C<+Z/Q-!H^-$</A!-+6;"RH5$\V>LL1>+)G=VCN
M9IP8Y%4*N*%9$C8H=_'*#KNH)516V<SL3,I#)*WA$ 7PA6P-B1Q*:5\CLN/1
M_O@B%4HCY*@YQ6*2&Y1@X!P$K8L5*2@F*2B23,WB_6N)-/XLX=TS1>K]1SLK
M(6<2,5+K'C22;MQ%(0%4-(MB"TJ1HQ5&9EU_ O#_  GJ?!/%6L<0=9&HZ=A8
MK8[1(KA&ES(HMZS31 EV*Q-O!@D,DLBAI%1&V?W%:Z.KQ59,#AW[K;(Z-;+%
MB&Z'):MO+%PHE+K'XTXJQ$3@37FKPNN<N!JL)N5>2,)L]G]D[\#G!]VF1Q7K
M4>#J^I_'Y<>264M,<K!ZFP2251>#>ZUN>J$MN;V]M_=VUZ5WN8W!>@2:CH>D
M?AF')BAA"8XPM2Z^I>*%VMD[G4]_UBX;I-W<]7]_94T;-TM2D;:MNSR(GKGB
M(54F)8H<U4\U6@7>\ L%[<&<F%*K&,<4Z6'IX:IR)82N4]=4B.R,!1(^]8#C
M'+\"\4<49V1PXCY&M?$M08R3/F/BG R,=%<SC&W29C,/4:-;(ZV+,.CO78]Y
M'!W!VG8O%;QXO#_PG2U$>.F F8-2Q<J1XQCMEEPL QS]8LCW>-KA4/2@5@M_
M4!2=;Q*[IA6;/"IY:#?7%$NJ^K^JX=TH6NIG6\622:U,,YH<)Y7-7*9A">,O
MM34S(B?$RTXH?;A"#;\(<8<4ZWJ.E:;KLN5B:"^;GHN5ZM\_)AR93%B;XVQ0
M+#ZH-@T[P/$K#<).DX[X$X-X>TK6M6X<AP\[B6/3]-=L/U]W3,3(Q(5FS>C.
MR?(?(LQ&\4QX\F.9U.^ .;%"_M.:_P#R]8/_ *=RKGM_%W_T4G]MC_YB*OG;
M@;_4D7_Q\K_*3U#O.EKD:V6H^G8'.8'<EGV/*Y9'HI3(*\4.;?"HTVR*0/Y<
M]D*Z-$ID&7A\8FMM-2KRB!9./,$7@H0^@(AX 69PW%7$NKZ3J^F:#HF/CS:A
MJ9R K3RM''&<>-926W$D9@5+"RB]P-H%R/1N"^$M#UK0]7XEXARLK'TO1QBE
MUQX4EEE&3*T("]))&B%6"DLQ(W2=A8*K;Q1?4*#LT5VLITYM;I_9'G-73/1T
MY5HCF5\3B>J-L'8UI1DH\JSB6QWDD;A93:L3#$:'"DT9019_!SSRK/[Q]5R=
M0X?XE5WP]$Z#)?.@#!XSN9V/IKDM8%DBEG,B, /5 8CEKVG3>ZC1</3.*.$6
MCCS^(>LXD>G9+*8Y!TFFY6K(H7>(22:''$,B$L-]BH/(:E-^I[7!CNN5%-,-
MJ]IA,+T8EDH3.DW8Y;)82=.X#M(YU"99S\T1/"V4.I[VS,0LBPC+$8("C'07
MC[/1S^'Q+QME\+X[9&3GR:IE<611%()(8IQCY&E+F#%C>;=B0(\@_?(%UY:Z
M;.X2[O<+C'*7%P],BT;#X)GF#Y,<\V.<G%UE\$YDL<&],YDCC-^C!)#?NU =
M;P&C+KL:Z&=RD>O3?#XUJ;(I9BQ:RK^UHG$((_M]JP1(KD"B.6&B:Y2]3)KC
M2]0!.%*5E,K"M)3%C[;)G4Z_6]7XLX6T72\F"#67U*?B*.'JV5D8DLT\;8DY
M$8DQF:)(7E52V\=Y-QG(W;7X;A[0N"N,N(-8Q,C(T"/2<;A:6?K>'BYL$&-*
MN;C*TIBRE2:3(2%F"A%W)!(D:G?WMV#]GH15,,M-@A;8TBAE,HZG222KI_&$
M!<ODMR)7Z.GNL=G<K<7!>QA,.D\J*$A6DDA((CX"3224Q@R19.ZO@/5>(-3T
M";5)Y.M<3-J)BRL>5C#%A&.0))!$JK)LBB/2(S;S9!96:0!AN\5WDZ-POH_$
MT&CXT1P^$$TM9L+*A43S9ZRQ%XLF=W:.YFG!CD50JXH5D2-BAW\<H.NZ@E5%
M;9S.Q,RD,DK>$0!?"%; V)'$II7R.RX]'^^"(52B/DJ#G%8I(;E&#@' 2MBQ
M4I*"8I*)),S>+]:XDT_BSAW3-%ZOU'.RLA9Q(Q4NL>-))NW$4A 50TBV(+2I
M&C%49F77\"\/\)ZGP3Q5K'$'61J.G86*V.T2*X1I<R*+>LTT0)=BL3;P8)#)
M+(H:141NHK7K'KR?9D9F1U7QD<&*JIIJ)QBN!*O)+A?SB;"907(SR<JLG!<<
M55-Q+Q P/J#/2!%@.,9SSP3(X[XS30Y],7/G&K'4'S%EV;ZZ>HGB,8-K;O6X
M.C!M<*Y%^2OI?&[M^ 7XDQM7?3<8Z*-+3!>#UMQ]3<X\PE(O??ZED&4B]BR
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MLZE'% PUTZ2T;/ZZY0C26YLI4PE)%*R*S;U[@$6)D-KT4M!6IF@'R=4S!FV
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M/*70*P!6"PY.$3@&#"NMUPVN,N%H>,-&&BY+JF.<K'E:Z=('6&9)6C*[R[)
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M<K$D\I)-:#+RI\[*ES<D@Y,TC.Y"JH+.2S$*H55!)-E4!1R  ;*E&F??*?\
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MW 2Q9N-WN\-28\V7G0:CA8\>"V9&<B#<&3C*5!DQ]UWWKETLC]&]G5BH4DC
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M5D$T:Y$^1%?9ACE$3&UGF6']$8TLI\."-EL+S5*#'#) 6>,L36<IQAO#E0+
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M+"S.["+5]_-3BQC!Q(.\%,G(=9LHY3-O+OICB)Q%CRI$">BL@GFC0Y 0H1O
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MW0]F@]W3PM=R_P NR.UY/O*>JXT=^BV1^DJ<?'/'B%[U?MT/9H/=T\+7<O\
M+LCM>3[RGJN-'?HMD?I*G'QSQXA>]7[=#V:#W=/"UW+_ "[([7D^\IZKC1WZ
M+9'Z2IQ\<\>(7O5^W0]F@]W3PM=R_P NR.UY/O*>JXT=^BV1^DJ<?'/'B%[U
M?MT/9H/=T\+7<O\ +LCM>3[RGJN-'?HMD?I*G'QSQXA>]7[=#V:#W=/"UW+_
M "[([7D^\J_Q_P -?3*/G.AK36L@3F.C ],"[)EAS,_!K4\H3$3DG#@UV%@L
M9R8S(<##T#!G/3C.,\Q<OOY[S<U47(S82(Y4D7_MX!9T;>4[$VV(Y.0^6LW"
M_P!M7=#I[2/BX$ZM+#)$U\K(-TD4JXVR;"0>4;1Y*L'JN-'?HMD?I*G'QSS*
M\0O>K]NA[-![NL+PM=R_R[([7D^\IZKC1WZ+9'Z2IQ\<\>(7O5^W0]F@]W3P
MM=R_R[([7D^\IZKC1WZ+9'Z2IQ\<\>(7O5^W0]F@]W3PM=R_R[([7D^\IZKC
M1WZ+9'Z2IQ\<\>(7O5^W0]F@]W3PM=R_R[([7D^\IZKC1WZ+9'Z2IQ\<\>(7
MO5^W0]F@]W3PM=R_R[([7D^\IZKC1WZ+9'Z2IQ\<\>(7O5^W0]F@]W3PM=R_
MR[([7D^\IZKC1WZ+9'Z2IQ\<\>(7O5^W0]F@]W3PM=R_R[([7D^\IZKC1WZ+
M9'Z2IQ\<\>(7O5^W0]F@]W3PM=R_R[([7D^\IZKC1WZ+9'Z2IQ\<\>(7O5^W
M0]F@]W3PM=R_R[([7D^\J_QCPU],HR\DO#+6L@2N)*5U2EG&6',U(,$.C4M:
MEP,DG.PR\Y-0+308SG'2'(NMCHSC&>8N;W\]YN?CG%RLV%H2RDCJ\ VHRNNT
M)?8R@_IY*S=/_P!M7=#IF4,S"P)UR%5U!.5D'9(C1ML,A&U6(_1RC;5@]5QH
M[]%LC])4X^.>97B%[U?MT/9H/=UA>%KN7^79':\GWE/5<:._1;(_25./CGCQ
M"]ZOVZ'LT'NZ>%KN7^79':\GWE/5<:._1;(_25./CGCQ"]ZOVZ'LT'NZ>%KN
M7^79':\GWE/5<:._1;(_25./CGCQ"]ZOVZ'LT'NZ>%KN7^79':\GWE/5<:._
M1;(_25./CGCQ"]ZOVZ'LT'NZ>%KN7^79':\GWE/5<:._1;(_25./CGCQ"]ZO
MVZ'LT'NZ>%KN7^79':\GWE/5<:._1;(_25./CGCQ"]ZOVZ'LT'NZ>%KN7^79
M':\GWE/5<:._1;(_25./CGCQ"]ZOVZ'LT'NZ>%KN7^79':\GWE/5<:._1;(_
M25./CGCQ"]ZOVZ'LT'NZ>%KN7^79':\GWE/5<:._1;(_25./CGCQ"]ZOVZ'L
MT'NZ>%KN7^79':\GWE/5<:._1;(_25./CGCQ"]ZOVZ'LT'NZ>%KN7^79':\G
MWE7^/^&OIE'SG0UIK60)S'1@>F!=DRPYF?@UJ>4)B)R3AP:["P6,Y,9D.!AZ
M!@SGIQG&>8N7W\]YN:J+D9L)$<J2+_V\ LZ-O*=B;;$<G(?+6;A?[:NZ'3VD
M?%P)U:6&2)KY60;I(I5QMDV$@\HVCR58/5<:._1;(_25./CGF5XA>]7[=#V:
M#W=87A:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)
M]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3C
MXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![N
MGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U
M7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\
M0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[
ME_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&CO
MT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K
M]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV
M1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/
MTE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[
M-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)
M]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3C
MXYX\0O>K]NA[-![NGA:[E_EV1VO)]Y3U7&COT6R/TE3CXYX\0O>K]NA[-![N
MGA:[E_EV1VO)]Y5_BGAKZ91641N4,5:R!(^1M_9W]F5&V',U1:9U9W%.XMR@
MQ,>[#(4 )5IP"R 8<@'C'1G&<9YB9_?SWFZC@S:?EYL+8L\3QN!CP E'4JP!
M"7%P3M&T>2LW3?\ ;3W0Z5J./JF#@3KFXTR2QDY600'C8.A(,A! 8 V(L>0U
MO.J_25'Y<[^T%SQX<E>\GEJAQ45']L2AWA%667-(^V^67Z(0"92AD:.R/.\J
MN[!'7%U;6WL4P1J3N_+$@"NJ7C(Q=;H#C.>CBE<N-+W:?PVY]5F!;L+;%_,F
MV'A\3;9NTE5F31/-FMIMB!S#5!+'II7:5,D+;JVC%J-VR,B!AC:.Z1[)$:2Y
M0I0C3JC!S4"IED#CL6S^);7T67W:F75+9FEFY\FK^G6J& 88O#)555L: ,,=
MF\U=3'QZ=K*FQY]NO985(L-K>VM1P4J1" XU>L7*GRUI9!;MV-HV7PJNK;37
MY+L1"<,$PG,$8+.@EG6K,IXHU>D;RHKSS\E5FQN$-M:2Z15+95N&,1TA;US2
MQ,\;0%-:(B2)HXF5%;S[Q3 ^::[4:X5W8,\A\>NS9;3&-#F%:RN2UQ,5M:6Y
M=M?-CRF:I,PJ6B31_P XHF^#),R480>$L[(<]7/3CBI-<S]XL[(TVXV'I]K'
MM)>P7.=HM*)A7LRG=EN\WL2DK&MW:U]J$#&JM%[&=,WNLKB1L@199GM>IPG
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MTV"*3;/V5L QVO9E22-PV&8")Y:KE8[201,T[$IR1)X&!> AJ5$J0X3F)21
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M5N1$QE<P?A2":O3PG*)9R%(62+M#,C0M^#,94'FJ 5T\Y%*<4IQ2JZ?[9OY
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M6KA^G^W,,VO+9I;!)%?UT2*;R^>JXNHCQ+RMD>$D>;W$TQ,V'9&I)5J6J3;
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M<#$RKMQB,4VUV>\/23R62L&P(44QMVR=?&6],M6KEBWH7*3K"E%<_-76:V<
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M&#!02@P )-]78*&9E%A968&YY+FUR0#R7J3J):,(T:EBJ*S7-V5""%.VPO8
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ML]P)?S7'7,OVLG.;TTZEA^QBYJ^BL6F[Y7=;Q"2SZ<G1^-0^'LR^021^<49
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M/+2EZ"/M#1!KM)9&\V+*H \M)C9@:AP>VX+>TMR]-VLT4>$5-S:MB4' _P!
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M%U.*CR^2O/MOY&_=GV;\X_FJ\WOW3+G\O>>WG[Y \C>8$D\J>=OS5_\ U/\
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7.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>tm2115679d1-fc_brain4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-fc_brain4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!?@.0 P$1  (1 0,1 ?_$ .P  0 " @,! 0$!
M       ("08'! 4* PL" 0$!  (" P$!              $" P8%!P@$"1
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M;)D3VOP-28Q[(KCEIZ;UVMV;"#DXUIN1FQ-YDRT]9QE41^2R9(BFF8=(E,?
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MK5 T]HN=26.WURJ(2JR)NLAK^GC!B)<( $+A\8-0!1!;EPS0!)49'@@X0PX
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MJV;_ .(,S_[1N7-ERY_#U!^IR/T334<U?Q1<OU^H_3/->\YDX < < < < <
MO Z:7).S(MOW=6VI7E*U5I&')2SK@@&B=DZ$J>JCFU8$TH\L25<65DHS @##
MD \^(<X^3GE7ZFI#ZF;ENFES'2IDRNFM1[?B8KEIT1S8*BQ:JQ3:FU-Z'M/Z
M0*B722<VU<V6V=*E6V2]9;H87HU*I58Z**F%R)A6**D%W*9]IYN]3=H;)U9
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MKXHV7C=A@^;B72F\5I4M96F=6-!]UO=^W)"9:6=&+?=*)LVL39G$UZI^0/"
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M(DT.A]0PV0SUFL9Q=G\",T>5L7"J6,1[<?DHDM",<H0J0*51X""?1P;XB,+
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M^M-.LEJ-2:DN<V$V"S&^I%%19TQR8%:D5A""'RK+L*LRKMB+;V/:(5!7"4W
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M%H^7;WCI)T>X-?S+O*2XUPU6J759DDD?J5&^HVZ5NB1X=POKV<]&C6HDF41
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M"6$U2XNL:;%RU08$G 2@F'*3Q"S@.,!QG/R?)R#(;$X X X X X X X X X
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MV1KG*UP2"A/2DLOW#I$%62WAJ$9X8+$'!A9#["$7L=O+A.06' ' ' ' ' '
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M[==IVAFT-<S#&]R3Y+,;93"Y*D #+M"Y]%EN"WF'S)B.'Z:QO6E%G%"^7'F
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MEVBJJ*@:E2[8Y&JUL8X4VK#V;8Q6&R)[.>:B;&. . . . . . . . . . .
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MU-U?/QYO _7>E#L>?_G^!E:QH>//^4/\KP%\OY6?E_LYY 3<2(X)' ' ' '
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M<+&N.1 $<M0MRGT$XT< @*8_X3'6\ 0)T:$K(P@P8><(<!$A]I8KP2. . .
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MQXXV>L S/E%YQX\/XS_D#XY^7P^7QS*E6[OO4NKY!8< < < < < < < < <
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MM:&5E:$A+>U-+4W)"RDB!M;D*<LD@DH 2RB@!"'&,8QCD%SMN . . . . .
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MJ)X4[$_UJ>Q5&C2-Z1*@0)4Z%"A3D(T2)&04F2(TB8H)*9*E3$A 2G3IR0!
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M]SB$^M:0ID1AJ1KN:\'IF4X7EY$:H;&<LM'@T18\8"79L(;XEQ'H"Y!<< <
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M9)35/514"!T4OB&JJU@M;HGM:G)2+'A)!XNUQA.ZJTJ;(DZ92X$M>#C"R\Y
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M#BK5J)M2*%[BK2H$*,D:A6M6J"DJ1*G*#D1AZA2>,LD@DL./$0A"P'&/W<\
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M3<K@@QY!Y_YH!BP@,2=L4)DTWV:=>6P(D9%.[J:T3AS7B\B6/H+?A:&5F&>
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M->'@2):Y!:FHM2:6-P<A-S:I48()P,W)"<P?E\H!9QY:/:1V7 ' ' ' ' '
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MNB.J&O>OC\S2]VM^1-2Y3'U*@EWC GU$PP&-OR,:)R<BRE.4Z@HQ.40:<68
MN8%5<B)[5/,=VQ0KM*EVOD1E?8-ME*HE?FW<^9Z<TWZK]*G@,0BJB92U4A1)
MU%S3-&%<\SIIA.%Q"ER3FC>BQK5"9*!Q284YPFE#&Z,-N]>PGM^$?H=ZUTJ?
MLCJ68C:%E@U7O&\4M-75E\%*!>\U-$T;"N]@Z&$DJG!I ]*EIB3)F,8]([U,
M!#DT6.'$RT@B_:>O#E3*. . . . . . . . . . . . . . . . . . . .
M. . . ?EF?BR>RU5M-OPWZOU=*%&:AT84.,7-6,J\PI.]['.1J,ZSG\I0D,)
M'E17HVY'&DWGQZJ%Q;G,9(_(JSX@>ZWHL[%TO9AUVU!=3VZIUMU0=/\ L;V)
M1A&7A47;4%;V\E;)3DX/+@E/8\>5H)$5@ <$E"<S$X<Y$G'X 7#< _/?_$7;
M,N.LO:QKQ/\ K[JR!5[L#J%'FBQ]@+DB,)8VE"_RW8^1-D=B< NY<WA:T#\V
M/L83!+4"<!A5G)I$9@"@&08&59-VTP3%@Z*;T/5%UC]N58;Z)GRG+'C*W6K>
MJI0":[VU/L$9K7*VAU;PB+<)-7N7,M*;-X$MR7[@I0EP:<C(.*]QC #"#SX5
M#*UR+L[2VI\0KG-E>&UL>5D<<G!K<$+?(6Y,V+7!A7*TAQ"1Y0HWI$Y,ZM8U
MJ# GE%*TRA,8,& FEC!D0<P6/&]I3W?;=ZE]I&P?6QW96E79+2C1KEM([(_4
MN(5)""RF-K<)A&WIP4Q]K9693![GKXSUDJE0(Q4TR%"!I'C)YYX4P&9=3O:G
MV-=P_9K?4PJ67(:@ZHJ ?C!A85=4PE9+[!2C3*&>MX69.Y!&G&0-TNL4QM-E
M$@)2JO%@;/% 4:6:>C5& 7N]B/:9K/UP1:.YM%3(["NJRC_A5(ZU52V"E-RV
M[(#E!*%(C86!-YL-;/EP4EEG.*S)9.,YR60%2I\B8R42)5SD;O/)KVL=IG?:
MRQ*O !;:_P! W+8<V7+J9U3J["*R=Q7&JX?'U;[,[/M2;.B)R;*NC$::"AB$
MK3%QYT">4:+*4HM*H/)E$0QN<]/<7Q_AJ=?:?A'5/JE=+/6L+2W/;<9L63V'
M;68VS&V5+U3Q<$]S@M]F^4@Y$O0$HTI!928:G))8"\?D8%YLYA=Y>6B847M/
M0;R"XX X X X X X X X X X X X X X X!0LWA#UE]J2ML%CX/IEVU2D2]K
M&,S),=J+L.:&LP:YN*QG_1VU'M/%4630!^42J2H,!#Y ?)F=Z%?A=[E_I+AM
MB+D9M=J"NR_9$WK79BI.I["M=W:FT.!.#HW5_$W:5*VU%YL>0*I>2U9*+$/P
M  0\"%G <9SB"R[-I^9$'\7!VN8V%S:PGZIS*@^LV5H=:LUK' 0H,1RK%_[N
M8G $6+2$Z_#<X#\3&[CSA4'!N"/2SE/F^%#Y_5=&/8?ITT1;3'?M(4]><92J
MT,=N2KX%:3$A7X\%R)HGT6:Y2W(UF/*#P5)4CJ !GR8_+#GY,?N<H?1O*IMC
M/4G'>OUM1( \B)I+4#=Z\E9/F-,P V=KZHIIN49)"1Z1.?!4I!@P0Q8SX^7^
M+%Y?5GL*K\2%V'(+#@#@#@'FV_$-(0VG)>HC5=VQZD'V$[-J?)GZ(SS81N\;
MA:92)2SKLX"(L9"P$G$/ !8SYC"0BQC/DSCDH4?V)[R/MC5]4>G/=A>5![.0
M^)R'0KO+KUD5I&V:-I9]?H]MJ^* Q+HLXGJ\A(:7R=B<CE"=2G$4I$[/C>(L
MP R?4*=A&Q'P7<I][CTR[!NCRO+@OSK*V.AUHZ,5W'I19\NT9V_+ELK2U@TH
M,*7=]%1<_C@RY$G;R GFGA1'K&PL(2\F*S5YOB;Q%%WC"YNUN[V$U^LR;[:7
M1LW/K/FNP[O:-=(*R/1[+,+0N:736B.[4319"Y/"J2U);$XGYP8&76FJ2S4$
MS>L2-U329^?@"R7E0G-.+*62,2^WD%CQ&;@T7;=N; 5_IEN%N5>9S79&]5;L
M&U.N@Y3\62;5T)/)M8$EUCNO5:)K%"-?$:OCY>4T/LF-1A.K3QH]ER\. %1B
M'"Y38Q*BKL7VD\^Z]E0R9+UU]&>L21OIN(;GV0G;+(;H$A):T<&U(HLA'()D
MTMR!(6(E,0\B)]8KU<!PK.:!%"&+!IW(3VDO[&)VG)B=;0K7;\2_2%<0=A00
MRO%W35BM*QCK:0!O;$;96UQJ<$,3>$!. +,M[%'<#$#&?-X%^H+/Y./%V#=,
M^X]._(,AT$KE<8@L9D$TFLA98E#XFS.,BE$HDCFC98_'F%G2&KW5Y>G=Q.3H
M&QK;41 S3SSC %E%@R(6<8QG/ *Z2.Y_J=4>7)78=J7X#&$&!&7/#R X$+&1
M>(Q'N)82P!P'Q$(7@$./#QSCQQR8*5QM]IW:/M^ZKE_A[?L1TV^7 LA]QL-6
M*+S>3)6!8!E9(T_G%C)P?DQXYSX_)^YGP048F^U#(2.U3K+4A",GL%TR& 0<
M"P9G92H0%^&?'PQDP<M"# LA#D6,9SXY!CS>'E^7D04G$WVG:E]G/7 ;D6 ;
M[Z<>8/AY@BV3I\ P9R'S> @#EX1!%@.<9SC./''CCQ_=QR8*1B;[4.X3]C77
MRJ%@*?>?3\T0A^D (=DZ<\3#/'&,EE8S,L9-&'(L>; ?'(?''CX>/(@I.)OM
M0E1#YE$+"C+--(#*HY-X=(DF'"/RR(O;9)(T^(1#&5A:T/C,I6-CDER:4(/J
M$FC!Y@YQX^.,\$F2< < < < < < < < < < < < < < < KRWIT%1;J**Z<,
MVBJK5RK\F1(PF8B!,Q1.J*0#:3Q@$D^LD6/1*DI[2'.#/7- ( \A]/&<8%SN
M72?5Z;I>RMD_(-KI%8LMW_&62YCI>--_I34<BH_=A145(Q[#S_K?H1)UDF6^
MH_>;K;44"36Q]!*AKVS58OP^M(5KFJQ-N)R*BPPIO(\:Q]1B;7:\(-<RF_3Y
MKF#J71:FCA%8%Q?"]2X,CDRE^N[F6!)/1(3A<A&""%+D1F0XQ@0?'QYN>>_J
M+F9SRK5Y999TI?FVM:LQ:KU<*->UZP9\O*BJX81Q;(Q@IU_IK])\K3[.M#G"
M9?G5OR3GN22E&DG$Y\M\M(S%JIT$3'%41D5A"*;R9V]VR(-7]<Y?/&]245-W
MG (97!)@2S<BF+ZG4X3.7H&A&4<5'&Y.I<AA&')9GM<%"_E,>/6.DV2%SYG2
MFM,YJK:I7YZI7:GYF6J1;%-J+,<K9:*FU,>)/A.XM<=14TST]J[Y3N1+U._Y
M>D18+_S$U%@^"[%24Q'SE14@N!&K\1XKU*E0L4'JU9YRI6J.-4J5*DT9ZA2H
M/&(TX\\XT0C#CCC!9$(0LY$(6<YSGQY^G[&,EL27+1&RVHB(B)!$1-B(B)L1
M$3<A^-LR9,G3'39KE=-<JJJJJJJJJQ555=JJJ[55=JJ>M+JEUC'1.O9$YDK?
MA+85VX;9<Y!.+\JQIAH$PQPAB-P+&!DFC1+37$\&<!& U=@HS'F)QX?GA]06
M>TS9G%;50OQ6:UXI+8;GSH_GYB>U,34EM7<J2\2;''ZK?2WIJ[(^06WNXR\-
M_O6">^*>)E/#_EI2]J*K7.FN38J.FX7)%A(W<?1C6#?>MF^KMH:T3SYACSX7
M+(2[(WN01*:5W-$R8U,W32 S2*.;/(XQ)&W!OF+-(48+,\N '%FE^(,]"GIH
MU*SU]?N@.DSW&:7,OWLPM.M7(YQ@4;OJXH*R7'-H8Y35 (Z'+KC?&)G:71R@
M5>GJA-ZIR3J%SNM2 (&,&% ,$ ><G2'\5S"M@^T^8:\6[%EU-:F7$& 5QKJ[
M3]/%VZ751>+8UEM\G:[7>(ZXN;2HCMI3I:H;4BO"Y60TGI&\61%)U:TU.![1
M^ =6:^,J=Q)9SWAK)=E <#3M9K@D+<3P9_<$2B&=A2:'/_*$.<< [3@#@#@#
M@#@'FP3@*EGXJ-\1S$LM2G@'4H296R):6 TKS/\ =21(_K491@O*((DTA=DQ
MV<!%G(3<A%^3G')["G_J?<1STP=*LZQ=W=M^G#<9LB*;3/;V:RG9#1I^M5"V
MJ:DD#'89^3)]K^_N<C)S' .C,J;DY2).I$4$2U (>,8.<46#&_:0D&JK5W*:
M[N_K#KG7Q!!K_P"J';'<8.BMGWN?%-Q-=M(K-?=@X$AJ<3?(A6,HIF,5^^+Y
MJCDSQ(FA/&SC6M6X+F/XWA8# $B,9.9C[2,*)M:JP*E^W&PI#5M%1GI^UZIB
M+->V/9?<]177:6K->,T?4P[56N4I$.C&K6ND5;BR"&=JO:2H86QN\WE6?:*S
MS$JI2H'E$Y)S2:F1$,BZ57=\TTN[>+\-QV'$(*D4;2JWQ!6%JPH\ANRLMF30
MAN:6W+)-E"%D7S*'W!!FYG<(@%Q 5CWZ(32H1X/=CDA *D4@7JZ$::)Z+[';
M%VRNW51FH]QJ_526P;8"]']J;J^U=9;8B$V:A)[XU0RX/((JSQ;8:I2U#Y*D
MS>VM2.&*$IZ<U0%2O7$F2J["J)XHK[#^=4)'#.S'\0#LYLRBF<3M?7[K2HVK
M:HUA<(J^-,N@SE8FP,;4R&76<P.S0H7,3NJ3%)WUO"J)&;D/D1BP/ TX/*W(
M0GB?'L0VGT@*00K=OOHHIR#A'(6+L2<KK*;3/*4?F*7JVO;S&W ";TPFA1J4
M3&$19OCZ9N!8\F,>&?$I+-ZI[ST?\@N. . . . . . . . . . . . . . .
M . . . . . . . =:\H%#JSNK8D=W*/JG)M7($S\S!;1/#(H6)34Y+NU!>6Y
MX9Q.3:89@XC"M(J39- 'U230>8 @/S</Q!_X=C5/K<TQQN%0]P;8V;9;OL3#
MHM8([[FU8S9E71VP6:P'![D1PX735=/I4J4S5 V9]\J7J"!A4'EC(&:<6:4!
MZW>G#IRU>ZR&*26IJM=&TLNBFT%<UP_2. W5.:MEL(":G1YD<3E3.GAE'5:]
M)I,V-LD6(L*!GX)/2+!X.39, 0(@"\3@'C H73EM[/TOXG=M?4J!3:=N[7/N
MOE:NCED/@QO&K2!Q6TCC)YQ>#FY"*2H6LI6,)F0B3$_R?@'\NVZ!BABQ>TVU
MJ5K?KSWGZ-4S8<WD4OUG[3]'0)]=YUL)5KH?%MBZIMJGRLQQ&MFX2%+8YRV-
M3%O1@<?26B!DA<>N(1J2#"U01-R^X(B/;_YD.AL'93MHUTL9ST<WZVFI@ZJ8
M_2Z&[B]HM8F-_@NZNP$3:K0:*[@M$U6V*WQBCC-?5WSE2D9E"ED9W@UM1*,Y
M,,*-6$+N1L)\2;'+L*"/Q'TF?[H?.O32:01-RV,[3:;IZ1+=CIK7:11+9LSQ
MF9ISK"@&NK^GB;/@RSII7T+*,>79YPG("#S'.11!6'E86G@ND8;=Y:!T]W1"
M[EZ)8C6^H8['K&6Z<7I]=.Q^IM?IH[1+9&[ZGD)4O626RZQL!D DE('U^81-
M[NB1IA%J5@(.HC"<S).$ON 6,"SKI&UDJZ8;*[N[LVW>X][]C(G9<6J:J=M7
MI.R/4(2:]'5%$9;!5=5NC2<M9F2>N4:D_P /FR<'HN32Y(C4Q@0@5''+94HU
M$BKNTC[H] 579C*^X;MHFQ0I&&70G8[1C1AH6)_=IX;24$KYW;7*3QXD2926
M2X3QR=$X!')@X-]<QU"+ L*LARW; GBB[\1:-^'#D262=+.C2A*9ZGPN%V#&
MU/B+&1%JXY<UCM"@H>,8QY,EB2>&,9^7P\.%WDL^!"[SD%QP!P!P!P!P!P!P
M!P!P!P!P!P!P!P!P"&/8#I['-ZM4K0UX>791%9 _H$DCJNPFXPU.]5?<D-5E
MR*K[%9%B41:U&MC,L0IS#<D#+--1B.)P,/JYSP0J12!H_KKV/,WUTY?83LG%
MFQ/?=;GS/4W>&I7$M,(A):T50&1*>A4MA(2R@Q6T6)4!Z0>F'*<2)S](H9F"
MLBY)"+%-N\H#*_!>:@ V"+G1FT-PG:]@D>'O-"BBC "3FM8' "T,1-N4#U@[
M+(8GQE*8<!@ XY(SXA4 -\#<,2E/2;'W'L<BT88(3&(Y#(HU(V*+1%A:(Q&F
M-N*"0WLS P-Z=J9FI"0#P"2C;FY(624#'R! #&.092FF"^O./Q"%_/7E+,;Z
M'ZNJ6KK&<"&,25ZN38::S\[.< &(@@Q4U0PG L#P$T8"PY^4& YQ/85_+^XN
MTY!8< < < \H'=W)K%N+;"@J]33S7_5I+HQ;U$[;5#<6Q)%]HFZX98)#+5TC
MB;(^P&K9C7J.%-BED;T#H8K6@<2%.1"]'TO)@V4,;MJ^R!M/?$,A[=NIZ"RI
MRUP4OYI^TP&^1.FO1+W?\VA,#K:Q9Q ''8W3A6H-I%ULI8_%MB,38:K1D)_A
M+HL..0J@)<8&W*2OB;]Y+WK>U=VA@-E2:RK65WG&:,DU*I*Y)JO;#9A[V>O:
MR9&B=V4<<LZQF4GW5-T4>QPQ&M:LQZ)J51+D!S$:Z8RM)R:,I+47[BX*#P""
M5C&D,,K:%1.OH>UC6&MD4A$<9XI&VXQP6'N"\:%C8D:!L2"6KU)AQN2R@^H:
M8(8O$6<YY!;<9;P#&UT0BSC(&R8*XU'54Q8D#@VL$L6,;:LD3&A=,!^(HFIY
M.3Y<T"%?DL.3R23BP'>7'GQGPQP#R13'0O=O6W92L=IFZKKTOG>*N'Z8-%1;
M&LEKN&QVJ]RI[==WY/-H[>=$V=+(1/=,6QUC\J/P8YPU<HC+0,GS$%J#<A*,
MML,<%18]OX?B-K]NDWE4*[:-$KQI=\U_K*V-/:?DDTM>1[4["P+7>I[;HV^%
MDYAV*GC3_)0*)8_25L<((\Y$M;VUQ0L1[VC4J"1YP(OD)N)=\2*F]"[WK[W3
M#O)4T[L;,.BT24U_<<KJ!6IKRSR+IJZ8'1QBB<B+EE:VJCB<*0S2-*4LO+1F
MGDH"P$.B)6G\P_2\V8+(L2-'?R_G1_I]WE$E'D*N1U@RP)+@.!Y$8=8UAPR"
M8(Q@L8!9R>"0Y!C]W'Y7RA%CQ#F4WD.^%2<<)U#UG9(1$6!5KQ1RLQGBT>:%
M!JRI8 H/4F-C2B1B-4F&1P(CCAB3^(A"QC.1?+X8Y!,$,4L2B>O2O$C<HMFF
M],X,A>U8F]H/L2O*1C*1W7A_C1(6TV2M"$E>L#Z_FR65D8\>?Q\/EX&P[$.A
M^ACPC)5%Z;:CN2!<02H3J2=>Z=5)5B4XH R#B3RXB,I2F.)R'(<XR( @^&<>
M..!!#@&]=/7X?GQ.T;U!,SCRXQD6MU.^(?(,1H?+GZG?D>!HO-\GA^5X9_=Q
MCP""%.'9#2>G:.9P3KZTAT/TF?=Z]CFX]:.1J=8Z<<HOJ=1Q?KHI9LI9Y)<,
M$C*4-I!AJ6+MJD0#G=U'CT@F!*R4;*%70W(B1+L=)M2*VT4U;I[5*I3795"*
MAC9C.B<WU5E6[OCNZNB^1RF1+Q8\"2%,AE#PL6B()" @C)_IEA" (<<@LB02
M"$J."1P!P!P!P!P!P!P!P!P!P!P!P!P!P!P!P#0FQ.M54;108,!MAG6+FY(N
M^+,CJT.!K4_1QYPE/1!=&=< )R?UO:J1@$2I)4I#<9QDPH>0AR';LF9XS#D*
M[?O?+TQK)[F8'L>U'RYC(H[ ]NQ811%BUS7IV.2*QT34'3C*VIMD2Q9JDO?3
ML?ZDM\MZLFR9F%6XY;MJ1PN5%:]KV+^4Q8)"F:/]*;U'K_B"]984<F.OC<]I
MGV0$.J=<V3I>WMIOO0P]4SI4BME7$NYQ9:10N+6IO%*,XT)!9@2RA^FJSZH:
M6LR?4RI5'/ILXOE++EJQ6ND-<Y,/K(]51[58BJ]LM6.\2-:KW(JN3Q]0?1I6
M6_/E)/G7"GK,@RYR39J/1S*ES6+B^766UKI;DF*B,=,28SP*]R,:Y&M7T)
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M(T9*L\6)B0C518E;4CHS=:(=D.Y^Y<"CVZM6778KT]TLUQC635"AYQ1=ETA
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M4CLB21L<V"^&HRW!E-3!)<\*!%^4 2)4JU5:D-F\]MO*F4< < < < < < <
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M1:Z:&L.-6A6,R186L$LBS@6O0*/+GR*4*L&/*I;'=N/QDI6B4@*5)3@Y+-+
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M%O4D+4"]*G6HEB8P!R96D5% /3*4YQ>1 -(/),"( @YS@0<XSCD&0Y7 ' '
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MY824Z9,G)" HA.04# 0 #C 0AQC&,8QCD&0Y' ' ' ' ' ' ' ' ' ' ' '
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M3>2CKZP83:T%B%FUS)FF8P&?QQGET-E;(I"J9Y%&G]"2Y,[PVJ<8#ZR->A4
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M"W-"0(6/*KG51S)B=1^ <^)+7\N<9#X9E=J1$O8Y6J>X#E3,. . . . . .
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M#\/P["T'KL543[/P_#_2:_Z*ZH9Z#1=F%%K)%(YE9=:]EMPIYI.++>QR*Y[
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M*=,F3DA 40004# 0 #C 0AQC&,8QC@DY' ' ' ' ' ' ' ' ' ' ' ' ' '
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M6%+J0:W:5SN?R9ZF4RD[J8]/91CG(91(EKB]O3@,HH(<G*3S3,A#C&<^&,<
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M2&NM74O5SFH@UEQ)[J26R6;-LO:V)]#-H?!:RL^2JYJYSTQJ9U![O[MICQ2
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M"TD!P:  Q! CL@6P>/$7,\@N. . . . . . . . . . . . . . . . . .
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M^0AZUV9F:(XT-4?C[4VL3"Q-J%G9&1G0IFQH9VAL3%(FUK:VU$40C;VYO1D
M*((*  HHH 0A#@.,8Y!D.RX X X X X X X X X X X X X X X X X X X
MX X X X X X!'_;+_P!+&R__ ,O]R_\ EU(^ >:S6>G.QO<WK1ZO=/970-'1
M#7=%6/7/>1^]31=2==(VFF:7;Z>O.!12OJ%/B!4YBFQIK+&F^)KWD;D?'Q!P
MX+"S?27A2I@+E9]U9Z\,CQL5L'JW$4]*;SVO!]AS('L4KGEM/Z6%W9>,2F+?
MBR%,)=)H\PW*=!+93EP&F3M/I$A#D*8HOR@#@"B2INHK:1;8.BUE+>O.E*&M
M'5W:O7*TMB-D; WLGNUNP6QS7"74E':,EK8^6M;BVP>-R(XPR3+43F[)7%6:
MG3-J=$4 KU1 6%6/UR;+R;J[[8-46MKAX[=V]VPWKM^FD9TL2$L2V&W]L,NL
MBO#Y ]Y(R0PN"F,GA&K(,"(24[^+%G.?EX!8-?&NEDSOL2Z_MF&%.RYJS7"I
MMZ(G9RY:\$(W9$[7TU:Z)J_PU-1@,F.B4\RLW3W9@1!PEP O(O'U,> %1W5!
MJ\)I[3^Q65LLY8["U9TOGE@57ILDCQI3A%JYF&^+C!MPMKH*P*$IAK0F65C(
M3VAH#A)D624SN>G-'ZN#"B@,HB77MO%KBUZW[)5! ZOM38#5_;SL\FRS7R16
M>1"6:X=:]^KK>)L:FB]I"9'AEAUL,2&.1=Q1EN:;X=C.%B50:#/ER(#BW1U]
M[U[@T_V077;M<U=3^QFXT1U"IJE=<&.UTTZ;JMIG5NZA64>LLZW4[ R1=^L:
M=.DI?' 934G-;F]$0B2@4''#.R "2RJHNQW3[8;<@K3JC*/OZF=Y[D2[$1RP
M;!NP55O.JMZR:KJ\J*RG*SH:KB4E<+EJPTNM&J0-26.'I77!@53<:6 )I2P
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M7 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' *
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M#?A-]1=:2@!:IOM072R&1-^,X*>#@V(]NVUTP/-"$ #\>Q&T-[2H!GRFA*4
M(,QG&1XS.]2KMDM$]IB/=XT+=0.@'J:ZZX^2)#.KN=*S<I"Q)BS#5+FMC<3S
M8=BH,$E!R,TTRY[D:31^0.<B.QC <> N$WD/V,1IEOXCN!*XA1/2)TY5WZ&7
M%[>8&TO;:DP/(<NT088-0\.>,E),FY/ [O4ZDR@X0!>.!%9R#S>;/EA-\29G
M8U#W01:!1F)P.)UPA:T)T5AL:CD49VQ4C3GHRFJ+-R)L9RO:F@,(QA*G;RO)
MCPSY,AQG'[F.09C,^ . . . . . . . . . . . . . . . . . . . . .
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M^LDH'&(\T, I)(OA;8Q_'GX34C29>'KX(RHT?NE'J'^U2$E>;TR@!"!E7 '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' .,L1HW%&J;W!*F7H%R8]&M0K""E2-8D4
ME")4I528\(R5"902,0!@&'(1ASG&<9QG@&MJ?H^F]?8>"OJ*JROZ?@I;FY/1
M</K6)LD,C8'9X495.CB!F8$2! %8N49\Q@\%^87AC'[F,8P$(;C:7 ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
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M&97 2HL+!%Y(#C/'80K569'L/6GR#*. . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . ?YD(19#D00YR 7F!G.,9R$60
MB!D0<Y_YHO(+./'']C.<< CYJ[K)6&H-.-%&4^5("H.S2:Q)<F^L[V=('DQZ
ML^P)-9<I.4.)I2? B3)++%620 +!@LGRXSYA^88[.<KUBN\JQC6)A;N*6?Q
M-VZ]477M6V^S38^.]EFN"ISV%TJ:8!!I!8]F/S#%"E1UU16?1R'DA=D>KE@U
MNT.[=,7!S5H&9 62!;DPX]$!,=+4=#_R_P"SO*3%:BI_7[/P^XG+U+:K1.AM
M4H):[D]LUK;'[91UEV2V9V/*3)CWRYK(N)("Q%2@AY 248. 10F2 :HVC) F
M2$-",@8$Y1AAF,U55W=A=J(B1[5+.7%N;W=O7-+LA1NC4Z(U+<Y-KBF(6M[B
MWK2!IEB%<C4@-3*T:M,:(LTHP(@& %D(L9QG..06-$ZSZO4MJ!6?[&M?HPM@
M]7)Y5*9:R0DR3262,L35S%U-?'IGB ).[/"B-1/#NH./2M"0PMO0B/&%.447
MG ,2JJNU2K6HU()N)!<@L. . . . . . . . . . <;*U'C.<95IL9QGPSC)
MY6,XSC]W&<>?Y,XX!_GOD7ZXE_X@K^_X ]\B_7$O_$%?W_ 'OD7ZXE_X@K^_
MX ]\B_7$O_$%?W_ 'OD7ZXE_X@K^_P" /?(OUQ+_ ,05_?\  'OD7ZXE_P"(
M*_O^ /?(OUQ+_P 05_?\ >^1?KB7_B"O[_@#WR+]<2_\05_?\ >^1?KB7_B"
MO[_@#WR+]<2_\05_?\ >^1?KB7_B"O[_ ( ]\B_7$O\ Q!7]_P  >^1?KB7_
M (@K^_X ]\B_7$O_ !!7]_P![Y%^N)?^(*_O^ /?(OUQ+_Q!7]_P![Y%^N)?
M^(*_O^ /?(OUQ+_Q!7]_P![Y%^N)?^(*_O\ @#WR+]<2_P#$%?W_  ![Y%^N
M)?\ B"O[_@#WR+]<2_\ $%?W_ 'OD7ZXE_X@K^_X ]\B_7$O_$%?W_ 'OD7Z
MXE_X@K^_X ]\B_7$O_$%?W_ 'OD7ZXE_X@K^_P" /?(OUQ+_ ,05_?\  'OD
M7ZXE_P"(*_O^ /?(OUQ+_P 05_?\ ^Q9Q)V,Y)-+-P'/AG)8PCQC/_)G(<Y\
M,\ ^G ' ' ' /\R((?\ G""'Q_<\<XQX_O\  /Y]0O\ G ?G!_N\ >H7_. _
M.#_=X ]0O^<!^<'^[P!ZA?\ . _.#_=X ]0O^<!^<'^[P!ZA?\X#\X/]W@#U
M"_YP'YP?[O 'J%_S@/S@_P!W@#U"_P"<!^<'^[P!ZA?\X#\X/]W@#U"_YP'Y
MP?[O 'J%_P X#\X/]W@#U"_YP'YP?[O 'J%_S@/S@_W> /4+_G ?G!_N\ >H
M7_. _.#_ '> /4+_ )P'YP?[O 'J%_S@/S@_W> /4+_G ?G!_N\ >H7_ #@/
MS@_W> /4+_G ?G!_N\ >H7_. _.#_=X ]0O^<!^<'^[P!ZA?\X#\X/\ =X ]
M0O\ G ?G!_N\ >H7_. _.#_=X ]0O^<!^<'^[P!ZA?\ . _.#_=X ]0O^<!^
M<'^[P!ZA?\X#\X/]W@#U"_YP'YP?[O 'J%_S@/S@_P!W@#U"_P"<!^<'^[P!
MZA?\X#\X/]W@#U"_YP'YP?[O &# 9^3 P9SGY,8P+'R__=X!_? ' ' ' /\
M,YQC&<YSX8QC.<YS^YC&/ESG/_UN </XB@_6R/\ "8X ^(H/ULC_  F. /B*
M#];(_P )C@#XB@_6R/\ "8X ^(H/ULC_  F. /B*#];(_P )C@#XB@_6R/\
M"8X ^(H/ULC_  F. /B*#];(_P )C@#XB@_6R/\ "8X ^(H/ULC_  F. /B*
M#];(_P )C@#XB@_6R/\ "8X ^(H/ULC_  F. /B*#];(_P )C@#XB@_6R/\
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M!EL<_D%/Z4'\#@&1\ < < < Q>2?ZE_O/^0X!B_ ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' .4A_IJ/_ &I/
M_C0< V-P!P!P!P#Y'_R!WZ(S^!G@&M. . . . . . . . . . . . . . .
M. . . . . . . . . . . . . . . . . . <UN_IZ3].7_;X!QS_P"7._2F
M?P\\ ^7 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ,MCG\@I_2@_@< R/@#@#@#@&+R3_4O]Y_R' ,7X X X X X X
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M?='MV]!9IHSLLIHN4; 5/&U=\P'8.#6O#XBB=E[NB;;(KR-L[,VO.$K"O,"
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M_5U8+9<KRWQ1'8<_B<*52=?@PDG*&/)Y([-AKTKP:H+#Z2;!H_,,./#Q%CQ
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MNI4Q?*]V1VBJVGYU'H CM!RB,O=5::0B@[@[B86YX:VI*A5+'XUQ=P"(3HT
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MC3J?F,NM3<"V;SM2RY)J[=U:+D$86ES=J-BLIB8FV1$*BS8V%E]87M!IB\B
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MD+K*[MAS"Q0ME#'3HTWQ)\^,I$:^4B793-_O,#$KP![(N . 9;'/Y!3^E!_
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M+KADS[(,CPY!-\%V%F, =GV0_P#KOOC_ /YV.R'_ ,XZ'X!'MMU0UQU]I/\
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MU:_AA5.RX"Q]?:3<O;;.U>9,([-3E28_:V>%4N=:Q0Q?"/JK[#ZW 6&+@^U
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M ,:#@&QN . . . ?(_\ D#OT1G\#/ -:< < < < < < < < < < < < < <
M< < < < < < < < < < < < < < < < < < < YK=_3TGZ<O^WP#CG_RYWZ4
MS^'G@$)MR-A-A*225DQ:VZQAV%G-EOLB0.+_ #*RB*7HBF(W&6 3NNF=Q6D*
M*3I8T%.2TY.B:&U*U'*792,T(#2?1SD0%<R?NHDL:U-W.NBPM8F1[N[1N_Z$
MHBQZBHV_X_:$ LD[8&>TU%8E):BN0J&MZ=R6%L]NX4F,S@T(SR7-ORVJE"4P
MPTY(!G-J]F>SU/+:AH.;:O:\L&[%L1VQ+070.1;GMD5UUJRD(;(&2.-$\G%[
M2:HVEW=)-*W]_"UH(VRQQ>K5*$"Q5ZY20D8@ 2VT*WD*W%9[?CDKA$?K&]-=
MIPSP*XX+#;2C5VP#U9/%6V9PF<UO:T33(&N802;Q]P$-,(Y(@<T*Q(K1+4I)
MZ87F J&L2:S)V[P;[L[:.AT"O6W0;4.$79&;)/VJE*=IU]@381LE.5FP[10[
M%%6:.SR;6V[P$MB=&AP4B.8&]G(696K"\EI"@):P/M)VF0FZVV]LQH8AH;3G
M;B?UQ7596F@V(9I_;=6.EVJ$C;0[OL14I4 CS/$6*U79T0D'&M<A<\Q<]<40
MX8&/Q%D#^E7:IL2L2]@]JQG2J,JM9>NM9N3#[%L:1[)98)K9MD:KUK([-;6Z
MNX&FIAY"1$9>A1,S>XN:M:(30N>SL)R7+#4?A0!AP.V#=A#*]9&J0]:)"5!O
ME%755IXS->T\75S<R9LT(;K.4M>R"!PKAI:*DBO[+\N<C5+VI1)G!L0M(TPV
MX]Q-PD* [HWN/EM85=L V[(ZQM$(V^HW:FI-0VJAX9>S \5K:UD; 5['K8IU
M]9[[F,5A3+!8,XUN[K'I]7/3:$3 UM"@XT!IV0I0@9I2/;.I3SRP:PW/@=)4
MZ_177^U=H(O.M==F([M%54NJJC4K,XW$V+G-!%H'+8;8=?M<B1K!(%K5E*[(
M!''HU(O;G%A @AM1O%O-<$>ZW9A8&ER_6W7K8_LCZYGFKK%C&R#=-[*;(E([
MZ@SZS139"M6>(Q0F%I[;@:D\_*=N=W],W*0A:',/K'!-R!Z#MH[@L.C*8D4_
MJ6A)ILU9A#C&(_"*8@[FBCR^5/\ +)(UQQ*>]R]T1N#3!H7'P.0G%Z>E2=04
MVMB4XWTC1X"4,"M>E>TFX55X7QK5LQK]3$/MZK=0)KNE$3]>=HT%\P63P"!/
MK3%I#!IHXJ*WA$FK:<DO<C:S$AAK6O1N*!::<5@.4OE4 8+3?;=L[,$NAER7
M%H,@IO4[L D]35G7,[1;(-=@VW";#NB$KY57#M+ZR35C&FU15TX6MAI36Y)W
M<*_#48G<%R-$H/PU! T9OGV/;7VQI-V-S[7'3=1(M.(;4^XFOR39Y#L*VQ2Z
M%TGA44L*HII?=84VGAYI*RHZFM)K684K3)6@>U#8V*'-$E$80%&8!=56MA*H
M#HU +67)5$G6PK5"*V$L0JW,Q*JD*J.5 @DBA*I>3DSD:G4.QJ/(!J1$J! $
M9D>0#SCRY J49.Y';\Z"Z9WG(>LXY'2N_1,'@VN2"/;1Q-ZMM3>EFU2\6;6[
M1/(^\UW%(O%J=G),:<AII.%R4K$<?3!=EK6G/."T! E+3_8IL&YH][X!=^F#
MB@V@T?B=73K]B^N-F"O1!>\=O2.S5YJ<JMI&Y0>O71$\+W2!.3<YD+6OS(?;
M^ZQ@PL>"L 8[179+L0KW(I_3_;G6BDJ=E.Q<(M.7U<IHK;9FV->(6\5(T()/
M)H#=D;S6]<+HXM%'EAX4KRWY6MJMQ0&D%!$$0C20(WTEV9RR.TIUM57IYHJO
MF4DWACF[3M7L&FVVLD7L-,&ZR6DSI9 [V9<EC0&8323PV3"FZUR&I"4)P;3"
M4S4A1K<*"1)P-:;K]F.X\JZQMUW^%T$+7_;;5G9N&:Q; (HEL63A!73&[JZV
MEK=<M-6:BKU,YS9JL9DGK"TD-IB%A=VPE^5*QG8$W  K L(NO<[?N'K8I%Z_
MT0JUN?$=-1FS+LL>_=N$E7:ZP.<R U^ HHVMK0(IUW7W1,&)''E"YP<@-;$V
M($(B!'> S_(4!JJG^PZK]OW'IVNDVA9&U23:NS=PXO$A@O=Y V4'/J*I2_V*
MUAJFR")R8%LG&9"LJYX968]U*2I"4ZQ,^)B25A99( --INZ79U11>-T577D@
M:-*8;>\AI2V9^;LZUN-JEMK'L6X:[++9JFM05,W)9M"6.0$I\K4R]R9W(3EA
M:D)*RC1!=E0&];Y[5+/:M@;IH_5:C:#M-)K(\L,8N>8;![DPC5T$BL-SBC'.
MU]3TFQO4,FBJ52%EB\F;\+GIV-9V1$Y*/:"&;DLPP '^-_;5,=C$6N<8Z^M:
MD-^6_>5#/>R$R8;>N%MI*"Z^US%;*<*8?&V?S%GBEGJI+.UES1E]C#>W,:)4
M0>>R+5^5/LT_B:!]>EBV;-N=I[*I?;D,F%838CM#N*/NU33.6)ILKJI:RZZZ
MJIWB"L<D;3C&1WB;=(Q+3VU8@ G1N"92%8 @K*@0, 75< < < < < RV.?R"
MG]*#^!P#(^ . . . 8O)/]2_WG_(< T]9L'_ &F5[,Z^^N$ZK_ZY1QTCOUWK
M*0?52PHK\42F)?CL,DOM%_P.1MWJ>HE5>B;Z)H<"\N?#PX!YKTFG]FG]N#_I
M$/LJ[2/V--G7+$-J4RH.VZS$US9KYLQ-ZC6IS7SZEY0"B^(K'DX@),(L'!5Y
M&9D_(<X+P!O-VVKV-U=['KCU=JVJ]LM^B(3H!IPZP>O$UCU\C$A5QZ6WK&+-
MN>T;+MV5P&"I+#GR!J90JS$P#GJ4.9?\0CR40H,3 2N)[<ZMFE :L6Q0]$WW
M>-J[F*+/:Z-U?8VV#0ZV?C-&O#C&+Q_:8[3R:L-=UK&:=E[?AJ?W=4[G)B%J
MM* C"CUP9X!)?47<A+LZLM> R^E[/UJV$H5QBB"Y*%MHR'N<@C:&>M[JXP*:
M1F85Y));!; KB;EQYT);'EM7"+.5M"T@998T^<9 P&<5WNFNVT;9K&7QD-UY
M1W'K^YJ6,RWY3'5"ZGV2B]H(U;3(? FV'J6?+NUW=.89(B/!?@R5$HP)7 XA
M*SI2%($9[>[A7>H2;,MEUT VV5Z6TI93O6MK;=JQ5+&6IGQ&ID5 918D5HR1
MV @O><U2Q2,[Q&]I&0 #T1)ZDDLP!7@(#.+U[47:NKTV5UUI/2397:>QM3XY
M6T\N0^M%U3QF',5?6/ E4];WI+)+#GD<$\R82)&<G01Q"F5/3L<C5B3D^DGR
M8,#%*V[E(C9LKU=?F[4K9V-ZE[BS:-5-0VW\S0UNPQ"2VU,&5W>8U'7.J,SQ
M5<T9B+\>PJVU!)%[.0W.3D5C*/"A :2O, V\N[3J<0ZOV+L;F 6.H?:TVJ<-
M*'NA$N(F9;"S9(B]FBAVBOFHG,C!&U!TE<9$W/Z(X:XOS1M:6K&$(O$K $:H
M;OT#6Z5]MEBWR_VE:$8J?>^HJ1U_J&(D*)O/I#);0URUL!!:,H^'*EZ,E0^S
MJRIHH.(1%G)TP3U:E4<,LH!Q@0-UPKL@/FKM<U!;+ZP;$:2WDPZV6#L+%(I*
M)74\H4V;3\72&-DND5+6S5,TF<)'8\"7.*+W[.K.3N+2->D49+-)]81(&$QG
MLP0,54:35IK3KMM/NS<]TZ3TMM.FA"B95(VV9$=>9+$F)%'[.V,MZSIK"("H
ML>:NP524!2(]0<_OJ!QR5@H 2\F =_TX;+37:VL-R+/F2^TL$)NQ+9J(PN&7
M(G6ML]J2%,!$!RV4^\QU<J6"B:JO7%:L0GM91HR$:L)P "%C\K($1&/LKORB
MME.V-F!K)M7N7 =<]CXU+'Y;7LAK5!$]>:!+U8IJ3N[9#2+5L&(JYM*%+\0^
MNY<2BZ98K%YS%"D:7W2;*@"TZGNP2D[JN2&5%&D\B;0VIIC6N]U0SF0%M+9%
MK$HRP7432L-;\&NGQ=MDT%,7-)[PD4)@@3I7I(9@W.!"P$"'SIW55\HANE#[
M6FJVR]NS'L*;MCW/5JKX>BKA)*I:@U\D<7:P/<G<)%.VB*P:)SZ*RHJ5)75<
MOPE;8TG./6Y*48+2F ;%9NW>FVN@MCK4N^H;MHJW-3YI"ZRN;4]_9HW,+T,L
MFUC&9/2$8JU/")&[Q.UDUZ+G],1%7)N<0H5XL'F&C3ITYIP0/ZK_ +.INYSB
M0TG<^A6RNO\ L<OIB9WM05,2F343*A[/1.!&M2:5Q:JK&AUGN5<([8C1T@;A
MND;>W%L5MR1P(4F"R1Z@RP*AJM[0]N)CIWTP;)V9"MC'2?6WM[)J_L:'UXFK
ME&^[F-;MK5<[]$ET-B<2E3+"6^N'FR5S>E3$R,V/D-!\>-7+@)41 %0@+<81
MVW5ZGKK;^0[,4'=>K%HZ/?LK%=E'2G,#LJ5.H+^&H1Z_@J*2U;+9%"K.67$_
MD? VHI,M(SA_SE(;D <8.$!F%0=CL@>[?B=-;1Z;; Z3OUM1Z:RNA7ZVWRG9
MY$;3;:^C2R<2J+J'JE;#L#Z@VTTP%L6OAL7=RRE>6UM6F%FF"3"!D##-7^U!
M]V=E%*.[3HEM9$M8]G#W@C7S:M1^R2=PB1EM+,]OB=WM*#UA8LPL:AHY(4D<
M5EMZZ1H"2AJ<DE*/;",%Z0&NFCLL@%3Q22,U:UYM+LY=-L=C>Y&K%2TU*Y[5
MI4ED=ITM+YR[V0V1.?V!+(97U;Z\PQIB*OZLI7%=EP2M^4J0*<TP0\E@;V03
M:ZM\JEAQ[15^QVC]ETSMI"B[BA%ES1ZJQY5,=9ITTHF3+$II4!\PA.P]3V<T
M/I+&0I2..6(PU2<N-\RMG @4 2XUOALQHW6"H(5<TZ<YQ.JSJ.,-UFSY^E<F
ML%R>I$P1T@<K=ULWE1()?-?36DG>#HX$EN#B6#!YQ19I@BP@06U?[4'W9V44
MH[M.B6UD2UCV</>"-?-JU'[))W")&6TLSV^)W>TH/6%BS"QJ&CDA21Q66WKI
M&@)*&IR24H]L(P7I 1:TW[7;X>ZL[ [:V0U4VE<<4ING*:EI^O8G$:DEDZ7F
M/K]"X%#-8X\QUM,U9"J=5R[KBE4B?792!E"2[^X"ZJ E& * EQ5O959$HL>U
M*!MG038JD=FX9KR\[/UK2+A-Z"L,^^ZN892U01U)@%C0*SG.M6J:MTTD#:A4
M-+TY-XB,.*<X1OIB'DL"&6B?;O<$LZ_],YI<&NE\WONGM(=.F>J:RAA-'QIU
MV*10)G9I?.+_ &IS,F\7K2I:"C(IBC9E2U\-:EB%:$HO#>(!Y S )<+.WBMH
M/2%^V!>NOU\TC=FM4LIV!65JM(RJX?+,72G8>2)XA1"JOIE'YZKJ&9P"T9*-
M4D023#\E;2C&EQPHR3E(+ @)*ZI;96?>\JL>MKMTRV U!LRMVJ)R0]NLP^O[
M K:8QF:&O:9I60&[:>E4SKB1/K:ICYX'9GRJ(<6[ R1"+& 8A%@3<X X X!R
MD/\ 34?^U)_\:#@&QN . . . ?(_^0._1&?P,\ UIP"B';&UZNC_ 'O=554/
MU,N<FM&?5!M,XP6YB+BFT;;*V;V&H+<<7QK74ZUD#A-C&21O;E"4"IS&$UN$
MJP>3XF$@X! IR_$)[H/&KNU6XE;]>]9.U$Z5;0R:C;JDLAV16MSG)&1F?H%'
M4>:XCQ%="7F2I.?.DJQY,69]DW(U:3VH'$P:H*0"<]Y]OMQ/^QNHNHN@FL\7
MO*\-EM6([NG)%5TV4KJ^OZGHR4H#ED>1R!UCD<E[D;,'D]*-,/RD^BA.4(?
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MF9IKA-[)8H%:,GI*[K$L1_IJR-?;N'+V6+5-9S)F2)EC@E<E"%>I:SE" *M
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M7S5#&_Z?6#JW)Z'TVA5F5Y 84<[X3K(U,HXJE$</<[/D+\]M9:B0.KUEJ7"
ML$ &%.490E &*']!VQYO3'K?UKXN.DL6K2^VR?8-^G>39W^SYUC),TLR3"96
M@>(C]8\ON4DW3EXP<A*3^H49_&>'ER(";6S'57<5V]BNP&X[!8E:-,&MSJWM
M;1-DB[P.48EC;8D^,?AMLO= HH^J9\0M'AV!Z^2E)B[\D7E(%\GB!&Y?TA;
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M+3&I;/YQ/YP[E*5*DUG:T[:E0%)R0GA'D8 +/. . . . <UN_IZ3].7_ &^
M<<_^7._2F?P\\ ^7 ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' '
M ' ' ' ' ' ' ' ' ' ,MCG\@I_2@_@< R/@#@#@#@&+R3_4O]Y_R' ,7X X
M X X X X X X X!HZJ=:* HR6V_/:AJ&"5Y-[^FAUAW1+8PPHV^167,CS%AX
MWN6.X "7.9P%3DK/+*$/T"E"U2<  35)XS -X\ < < < < T=*=:* G%VUUL
MC,*A@DFO>HV)[C=8VH]L"-QF$%99$%2!Y1QES4@,&UB6E+E!>32\8. 4J/
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M('.)RMFRXM2E6C^*QF5,BUL<$_G]9$X)#DYP0'%& "!D' ' ' ' ' ' ' '
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M-U2V@4Y-1K>D2S!TKZ'V8D)9E1A@PNZ#,6G* 8CP8"$)PAE^'B#.> ;SX X
MX X!U3Z^-$89'F22!P3-##'FIP?'MU6F8)1MC0TI#E[DX*S<_(4F1(TXS#!?
M_:@#G/ ,;J^RH3<]:5Y<-9OI<HKBUX-$K*K^2E(G)M*D4)G3 WRB*/I3<\HF
MYX0%NS$Z)U 2%:<A25@SRFE@'@0< :!L[<^JJ>D2B/6)'+<C0!;%:\:OQ^2N
M582-%#)W9NS0XREKLVO)4M)3-$VB+:[RDAN?71O,/3LSF2H2G^!Q!@, 2WX
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M!N7)]@6#9*JT/U >[<6*==I'54P[ FO6APJV;4Z%&4R35.JA,K,5G/CH-7(
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M"N+728GT]+MDXKI4_.T9KR>M$JBA/A%7.7N5;)#G%R91 -QE2ZDHSDV%6?2
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M2R7:G%$PN"4V^W,V7EIE3609)X2S*BW<:H)S,>B<E*(E(D&L&BRI*4@8BU;
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MH;!VM)8&&QHG1<HCTFCXH#3+%%J\8:OK9H0&2M4[>0MA5X7/HL*UN%(0ED
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M+>)U\5;*4"FOM2864GI!1<==DV\H-."(1)9-:F2,,S-,-"'.0X"BSD6,9\.
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M>UD;/A;\.0I90T:^VD\5XVSC*L3>W@2'2]*UA6B2EX.*39,\@#C<8P/($R>
M<I#_ $U'_M2?_&@X!L;@#@#@#@'R/_D#OT1G\#/ -:< AILIV#:?:A2ED@NP
MUS((#.91#7.>Q.$D1*P)I,9E&F=];HXYG0N+0")RE^F#ND<W0O(FML3JG3*4
ML]5A/E*F4'% ?)G[$=*'W5<S=A#L3!"]8"#CT2JTW03RQ)$+VG?L18R*.,8?
M&ENFS=.!2,0$);$>V%O)JHPLL"80C 8$!U=)=DNE.Q$-N.=53=J9T:-?(VIF
M5U-$H@MG5E/ZWB*5D<Y']:)-5=GPJ'6:DCRUE9E9Z-9AH&G7!3F!3#-$'(>
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M*^7.[NQI'E[@5AUPM/<6,\"=P"&-6=%8;*<),#,"(E5E%A*J*$$P@PPO.!9
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M_0LW<[7#L&L)W;HBZ16?45,(Y"#E<0B-X/4=0*1GADBLV.N*(TQ:G;B2BO0
M]5UWFRF2Z>V\>^QHQEFS_K5/S7F'MZC#X:TREUJYV&XQI"K1EYP\&('8\:4H
MPH/^D9!@0<?E8QP#SF6);,ZU\T\Z%$CP=&=5&EIT=@J)[WOG&F[]MA.]:+&2
MZOTC&B*1B<00HQJZDD=W-ZUR(<7-S)R2H+C_ +3!(S &8 !%F,5_<UDU-V>6
M [1S9#:J*I=_^L;;"S&JT-8R*0MG<752J&RH)+: XUKTBA4#9UK,^,<#7'M3
M/\-3.#DUM)6%Q8W,\T!H$[=\=P]:M\M==Z4VG^N<PN^5,/6?L5&Y1M]FAYQ
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M2_UF(A7<GLP"B(CGJJY'8I;(&;U?CSFG7HCBRCR!C\H&A*6JN(V'4'3E$)/
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M@FO=J2^*6G4&QE')$##9T<M9DBZRK2F2)E%K,N:18[I70U:CRV($RQT.)1C
ML-U*K"7-/9C"Y\^U])FQJ;>CC3.L"IBZQ9V0M:*7(K^NQZEU?!?E:$I$1)D*
M8MM5.#7ZN%9)?MS#2@AR7G($'JTHNQU=O:QCD5/SD]G8_P 1UV97(X&.\!D(
MFYH@[DT[6NM<VFM,5M7MT$1<WY4UGLST9D*)0J-3"3G"&,K.0,EW;U;NRV[W
M[F3ZXIF13LA]BG2Y:R.$XCN6]IV?9-9+8N&RK@J.-OSN!#'Y7)UD(C)" 23!
MR@0E)J%"?@ %1>< 9,\[;0W;KN+ZF9-"M;=D:L20V%;WL[U8^QU 3*@'5T>G
MFB658HJF.ME@MS1)96H@9S<<>\'D$FLZ%4M*+2J3S#E'D WGW:5?;CC*] ]B
MX6_[%1>K]:KGMAPNB8ZHUQ&;BO.JFRSJ>=H=%+HCU6RR$6(AE<<A;H4>VOPT
M;2L=FUI?SEB,L0B!^ %?<0(FDEA_9+MKKXEW3[)I$ATLB]'1N2;R:KP""4]?
MOEL%VE;G#(7K^=2%$V;>ZBDFA<[.!J9Q:O:N:A><SIQ>H>4,0'%H:0VE=O9!
MU46Z5L!O1N15U5S_ &4CDOLVS=!F_3;6:C'F<Z;W#'&&%1V.H:/KB5K9([20
M\EN$M5+GIH;2"DR,Q>8H/(&8!M-=2%F)OPS^V57H:CGI-M2U9O>X KI-!)$&
MQ)&N?][[I<(TK)B &OZR.BA[A>&]0A$!./*EMR0:5YB<@%D#_>URD[;3[^1K
M7>JFA:.G.\N+TY16QCHSJ5PW&%/VG%@1^96U/<)_4 E3AGVCRUXC1H"L@&J"
MR%B,&#"<(P@>C/8(V3Q/6N[CZEJR/VG,XS1UE&UG2;DC2E16QY.S0)Z'#*L<
M$'@2B+C\O=4R9I-)_(*PF49#\@> >0")RBZ;Y?>K+"6V-VKO;:-W>TZ?+9H5
MKZTVW3;3S2(AGRHB3C$5&4]&QJ4N"NM5SR2S-@$,C?&AF91*U2T].GP5G(%L
MU>4Q)PZV_B*2'*JI!B17-LGN>&&IE\)<_B]J1%5HW2C/#OJNF4-GNIO'U<I5
M.R1NRD"I3FKQJBB?$WU0\ T?KE8_W=%SUQ>6U%37RIK78?JPZ[JBK&S*_H2U
M;@5U%96NT2GP;*UKFT5K2)2V=PF26*\6*VO#=E6WIFU2K1*"3CBSTP_*!.'H
MYCDDC^K]^J)%2$UUR+EW8!NS/8O3<_BIT.?X-"9E=#N^1)A^#B((1>P:6946
ME(.19,;S0D>*<P97E%D"NFW%=^4?4/87+8_3SJF;)/WV()J^6](M6%NS#YKY
M1A.O6MJH6Y=04:ZLZT5ENM?SR&I6]M=6]*X!:3E*I>4 TQN&# &)ZOL=RV_N
M_M):&9SNUM1%K/ZA+8J^MMCMFM5V[6-DLJ8H[71+BX#2L!8Z>IS+7'2B),0J
M2%O+:0YNRQ2O4)0G(R,G\ T"GQ-%%3=-&S+=8.[5#TYK!H$IT6V%LK7O5YXF
M5P:H[',$(UT2R\5B4[;=$6!,?V72?ZC+&);)8Q&UHO=H$@"U@D:K):D#.)'1
MSK<.C_99:4$.WOV?1[&;(=8$=1V-M+143K5XV$8J*VNI@R56!6%)PNHZLL+Z
MCL<*>A-[L]2./D#6H6 .0>4EO4>0#V0\ < < YK=_3TGZ<O^WP#CG_RYWZ4S
M^'G@'RX X X X X X X X X X X X X X X X X X X X X X X X X X X
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MW!6E.(6]$%P(1#;"%X4A&%I+<8:2>8WE*L%^N6B&>G+'DK L%Y& .<X\<8\
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M!EL<_D%/Z4'\#@&1\ < < < Q>2?ZE_O/^0X!B_ ' ' ' ' ' ' ' ' ' '
M' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' ' .4A_IJ/_ &I/
M_C0< V-P!P!P!P#Y'_R!WZ(S^!G@&M. . . . . . . . . ?R,82PB&,00
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MW,;#8%1,KUYG4-K>?M%C2&!PRPUDMBL;FSPYM(UD=3*U#DXI4@4Q8$JLU8E
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M"4!6'>'9=N7M!0W4[?&K59UQ&U-L=B3I2]JQ,O9UZ00B=6K4C)L;&DU7$3J
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MB:,,>N)DE2MKB.P=NP]37DNKZ[JB<6PE<GF$:8'M$XI"PI%*,(1IS\""=G'
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MHC:,$<6]Z 0)<CP0:C<TRI$I(*.(%C($K^ . <I#_34?^U)_\:#@&QN . .
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0_<QD:4 ?'/\ ]7.,< __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>tm2115679d1-fc_recursi4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-fc_recursi4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!'@.0 P$1  (1 0,1 ?_$ .D  0 !! ,! 0$
M       (!08'"0(#"@0+ 0$!   ' 0$               $#! 4&!P@""1
M  8#   $ @<""@0("0@+ @,$!08'  $($1(3"105(2(6EA=7&2/6,3(D)=6G
MUQA8"G>869DSMN<X>-@Y:4%10E(WE[>Y&K4V=FBHN.BI84.#L[1%994F1E81
M  $# P("!@<$! @+!@4%   ! @,1! 42!B$',2(3D]-505'2%!87&#)4E AA
M<2,5@:%"4C.T=3>QT7*RLR0T=#4V=I'!X6*BXD-38W/4DI75)E;_V@ , P$
M A$#$0 _ )^V-[BO:++84\9VR]G](VM,SE#:WI0,$*&!,A0O:Y*D3A&;&3#1
M!)3E!#K8A;%O6OIWO>?2#"<EN6%UAK2YGQ,+IY+6)SE[2?BYS&JJ\):<56O
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M_GMQW5MX(_4G[?\ S^D/W>@W[K8^1_*OR>'O)_%'U$\Y_/;CNK;P1^I/V_\
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MVO84M=PIC5HFJ,P2,/SD%&0,HLY6)"U0U6JTF),. $1GE\H=C#K>_IUE+?\
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M '4]OC??IE=-(Y(H$MHHWM9'$U6)+(K4J^J:D56HZZ6O+CE2RQS.]+6PMKW
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MN:^74U9'-29$,^Q%7=:](I#V&:RZ0-'!94Z22]YM>5CD":--B".&2*%MS@L
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M.<3:=-D%?.3ROD#6HDU/.SQ)X<\.A!:5Q<88^&H@"9%JM+HTK9_IF'@+4G
M,(3-ZRX7>&V-=;OBWLW)I#F61-C<D5XQD4S&JJM;-&CNNU%HNFJ-56M5454+
M59;@YC6>QIN7KL0L^!DF=*Q9K!\DUO(]$:]]O(K?V;G)5-5%<B/>B*B.5#YZ
M!L/JOF]=)3:]@$F5L<U;R6J:0J7U@\2>&2Q$EVHVD+>F-:VA":8D^+."6:4,
MHW19QA>Q;+,&$7O>&&Y?;WB@;F;R!MW:O5\$\-TR*:%RTJK)&NX(M$JBHJ51
M%I5$5/&Q<_S/Y>37#L#87+[*\C1EQ;SV<DUO.UM=*21N9Q5NIR(K5:ZCG-KI
M<J+?,_Z%[-L"5U;*#H"ZQ)-2SZDDU:PV"4ZMC<&C;ZE6)EHG$N/%-1X%YJHU
M*$)@51AP-%[& L( F&:':L/LWECA\?D+!MY'<R92%8KF:>\;+/+&K5;I[17I
MI1$5::4:M:*JJK6TO6=W]S?SV4QF2?8RVL>'G;-:6]M8.AMH94<CM:1(Q4<J
MJU$76KDI5&HB.=7C.K[ZOG9%U)#J92Q=#T WQ)#9J&%TJ\,!#RHA[^_R=$^:
M$!.H4:D;H]254<X+C!FGK1"#YQ?5UC$[1Y>XE^+D;DW7$N'?,ZU=/>LD5B31
MQQ.CZ43LVLB8V-B(C6<:)Q(9O?/-'-LS,3\.VV@ST<#;QMOCY(DD6"669LG0
MJ]J^29[I9%5SI%5-2\"L5_TYV?6\)KN%L-8 6[J9:H.KJ822BAR.>1)J<'$+
M@\1EDDSJSJ%#<PO>M;3JM%  J$CWH@)X"P%Z!39C8G+#-Y2]REW?JU,BU$N8
M8K_L[>9[6Z62OB8]$=(S[3:JK$?UE8JJY5J\%S)YP;>PV/P]CC4>N*>JVD\V
M-[6Y@8Y^N2&.9\:JR*3[#]*(]8^HCT:C42VT5V]5)H+<]<+:;)?XG>$QEEA2
M)!(J6=G<4;G$T;3FEZE4$-4)?&-O0$1@=)#M:.$B$4 1'IB\VQ5TNUN7TF6Q
MF;BR:PY'%6T-O&Z.]8SM(('(]D4Z(O[5FJNMO5UU5'U2E+=#O/F?'A,QMZ;$
M)/B\U=SW4K9<>^3L;FX8K))[95;^QDTJB,=UEC5J*S2M:_0LO_LA=8$TLQ1
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MGWT?M#X5W/Y;?_AY?8'X2VK^6=@_<R1_T;CXBV_]_L^^C]H?"NY_+;_\/+[
M_"6U?RSL'[F2/^C<?$6W_O\ 9]]'[0^%=S^6W_X>7V!^$MJ_EG8/W,D?]&X^
M(MO_ '^S[Z/VA\*[G\MO_P /+[ _"6U?RSL'[F2/^C<?$6W_ +_9]]'[0^%=
MS^6W_P"'E]@?A+:OY9V#]S)'_1N/B+;_ -_L^^C]H?"NY_+;_P##R^P/PEM7
M\L[!^YDC_HW'Q%M_[_9]]'[0^%=S^6W_ .'E]@?A+:OY9V#]S)'_ $;CXBV_
M]_L^^C]H?"NY_+;_ /#R^P;$^W*^GKI3W!B9LA$O<5#3S.U(75.@C3RK.;%H
M3T6Q(W I.B,&B5!UK?B69H(]>'\&:7Y69G$6^Y-W/GNK9C),Z]S%=*Q$<VCN
MLU5<FI/TI5#H#G-@<Y<[2V/';65W))%MQC7HV&1RL=5O5<B-56N_0M%-=GX2
MVK^6=@_<R1_T;FZ/B+;_ -_L^^C]HY_^%=S^6W_X>7V#TQ^S-'9!&>7YV@D;
M$\1]<;?4H5E(WML6M2LU(97M7$@5%IUY!!PTXSB# :'K6P[$ 6O'QUO.&/S-
M7MG?;\M)K&6*:),1$BN8YKT1?>+I:*K55*T5%ITT5/6?1S\H./O\=RUOH,A!
M-!,N<F<C9&.8Y6K:V2(J(Y$6E45*]%45/0;;LYU.JA@'GX][*'RV42CGPR,Q
M:1R("-@L0"L;$R.;N!*,YQB(B0J1-Z51H@1NBQ;#H7AL6@[\/X-YV)^5O)8Z
MPL,RE]<00JZ:VIVCVLK1LU::E2M*I6AP=^<K$Y7)Y/ NQUM<7#6076KLXWOT
MU?!2NE%I6BTKTT-&OX2VK^6=@_<R1_T;G5OQ%M_[_9]]'[1Q5\*[G\MO_P /
M+[ _"6U?RSL'[F2/^C<?$6W_ +_9]]'[0^%=S^6W_P"'E]@?A+:OY9V#]S)'
M_1N/B+;_ -_L^^C]H?"NY_+;_P##R^P/PEM7\L[!^YDC_HW'Q%M_[_9]]'[0
M^%=S^6W_ .'E]@?A+:OY9V#]S)'_ $;CXBV_]_L^^C]H?"NY_+;_ /#R^P/P
MEM7\L[!^YDC_ *-Q\1;?^_V??1^T/A7<_EM_^'E]@?A+:OY9V#]S)'_1N/B+
M;_W^S[Z/VA\*[G\MO_P\OL#\);5_+.P?N9(_Z-Q\1;?^_P!GWT?M#X5W/Y;?
M_AY?8'X2VK^6=@_<R1_T;CXBV_\ ?[/OH_:'PKN?RV__  \OL#\);5_+.P?N
M9(_Z-Q\1;?\ O]GWT?M#X5W/Y;?_ (>7V!^$MJ_EG8/W,D?]&X^(MO\ W^S[
MZ/VA\*[G\MO_ ,/+[ _"6U?RSL'[F2/^C<?$6W_O]GWT?M#X5W/Y;?\ X>7V
M!^$MJ_EG8/W,D?\ 1N/B+;_W^S[Z/VA\*[G\MO\ \/+[!EROW+H^LX9:T#BU
M=2\J/W,P-D;FQ:VNW]8J/;&E4J6(P-RD: (F\X)RP?F&'6]BUX:_\&8YF(-D
MYW)X_+W][;+>8R9TL"MN8T1'/1&NU)JZR4:G RO W/,+;F'RF#QF/NTL,Q R
M&X1UK*YRL8YSFZ%T]5:N6JITF6R;_P"R"+39;B+@3Y]M&"KBJ?;S]U4][;@P
MPE&I0 (-0?!^F:X?#JQ^*C>_-X^&_#Z,QUVT.6;\!+MI;R+]US7ZWCD][9J[
M97(ZJ.U<&U1.J96S??-UFYX=W-L9OWQ!C$L&K[E)H]W1JMHK=-%?1R];I*#
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M?U&U>1^W=P6O-G!7%U8WD=NR^:KG.AD:UJ:7<5<K41$_6I[&L^:9]<1@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & >1[_-=_^C_BO_Z8W=_\B5KE
MXQ'VG_J3_O*:YZ$-<'!/^7:Z)ZNK^/7)<\Z;^;JUF"%"]0MM6QTV7V9*HVY(
MA*T$EW&0NK$WQ=E<BS23$>UZSXU23L1FTI9(B#3JJXR44+E9&FIR=/H0EL@<
MY*KP0E)9G^5@L-FE,8+KOKVN54$=7-,V2!VLF%O,5D[28J)&!)J.LS*ZR)HE
MS@O<?(24D-<&H6_/K>C![UY<\19-9$6D3E>C57J\>"<55?4B)Q5?00DC9%17
MO:UJN1$JM*JO!$3UJJ\$3I4JMT?Y5Z61VOG-]IGK6.2>:M#4J<3&&SX"; HJ
MXC1IPGG$!ES1*)68R V$LW83E*(PG6]!T8(H&QF \Q97M'HQ8UJJT2G%:K^B
MG$F>[*O!JU7]1J1]HVJ+'H_WI>8:MMJ-+HE/HG8$O2/C*N,2J?)I534X<6UP
M;W%O/5M;PQO+4L(6(%R,X]&N1'E'D&&%& 'NHOO]E?6J*G!47@J*BT5%1>**
MB\%1>*+P)<;7,F1KDHY%/TM<QHKA@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MWB/=9NR=,T<XXB/KP-A/J&D97?TG;S_AWVR'^S*EA-ICB+><F$ 3'!4*>7$
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M]8 $, =@"(00[,%L!>A"UK8QZ (S80:WOQ$+0 "%X:^GPUO?_@P#E@# & ,
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MS=#'XBV!E[G[F+GOE2'+8#SE3L!IN)NKTHDKVU06/HV<4CDJM.F2*I)*'$L
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M]1B/7IV^R%, 9VQR6.R4:\TX!3F(1P-G"'K6O/O>X'I$3T$D\$1@# & , 8
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M(+7DG]K1@YXYZ36E1UFW%8+?)HCT8R='6+NNYC&X*4\,9Q#&MU,7R'-;5&%
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M/Q-*O)9T2H2!*J<$R "I044<<,H $O\ ]!7VGO\ "G_7GTE_;%@#]!7VGO\
M"G_7GTE_;%@#]!7VGO\ "G_7GTE_;%@#]!7VGO\ "G_7GTE_;%@#]!7VGO\
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M>)/_ .SZK\Y5_-1_>#9_V-%_6;L[M_(I_='D?^H[C^I8\VSYS2=I# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#$MJTC7=T*JK66
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MURJ%3F-L<PA\H8U92]EDD6DS8E>H^_M"XG8B5K6\-*TE0G-!O83"C BU]&\
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M8%4]44I,(92;/]I+;D*2<M"!OKN*B0K'-/,)8)X.;C&>%N#>W*3DCR:'38L
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M1"IN-*2RI>YKCU)S@#059IYPS!&;&,6]@59IA$+8' 3LQ1"+LKJ(MY)$YM+
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M37C,G_26'O[VW2RIH9(I!X-\ZC"]H)6*CT9R;:QG3J2%&Q@T6(H#]"O]7?\
M[L'W?O\ 4K_Y2L ?J[_]V#[OW^I7_P I6 /U=_\ NP?=^_U*_P#E*P!^KO\
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MDE\  "P!++"$  !"   !T$  !UH(0A"'6M!"'6O#6M?1K66PI3E@# & , 8
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M2QP'*EA_\J1(SE(#T*(Q2+0$Q(@QKP/*MZR*G0;]\@>Q@# & , 8 P!@# &
M0*]P'L]ZXUK6)/D"J1ROVUYS)GI/%:A9'8UG>'B$UC!91<MX2E,L*:GC03HA
M4<"=!-I)A993I)5;2U>J6<XD[V!9O3_9ENQQ]XIB'&<#H^[WWM91.W*"R6X[
M7G-45HEA4-IT^YTLF!(()4=P219]I8V3K2,K3/H.QF@\XP!V(00+TY7ZNMBQ
M[:MWF'J*E8O172E01.!6=\#6]G+[@IZUZ=LESET<CED5C.7V 57*_P";I? G
M5J>FAVCZ%8UG@2F:&>4L+$$##=A=8]U2+K'HCGGDWG;E>PF#FR'T=)98_7QT
MI:M.2>4K[J8)>_MK)$&F#<SW2Q:^"*AJ@@2EP7HP:-.*WL.P>?8 +HA_NI\R
M$<\0F[^A'A1S;)Y#9EDT-)*2DI#K85EQV_:5DT@A]NUPP1^LV21R*Q$<2=HR
MI6%O#6VB2'L1R1P-"E+4A+"!\;O[M?'Q=U\45'$;(C<Y;>XXW/)76=A,SJK!
M'4C3$CR6-D I(&RFGFNDMFX5C+I*>-":U*VQ7I=Z(RM%# S)0/N,<3]26,NJ
M>@^@8G8T\21]XEJ)I;&Z5-J*5Q2/.Z)B?917<C?X^TQFSHVS.KFF*5+XZL=$
MI'Q)(AF: :6(0$U\ Q[.+<JFL1MY=E6=7M>C=@GC:P3B:1N)C<@)M@"I$WA?
MG)OVL"GV8'0]E^;0-BUX^'CK +\3J$ZQ.0K2'DJDJHDI0F4IS0'IU"<\ 323
MR#BA"+.).+%H01!WL(@[UO6_# .[ & , 8 P!@# -0'"?_:8^^-_I_XB_P#=
M[T+@&W_ & , T0>[5+)5'NW?8T:V"2R!C;)5W?*6F4-S.\N+8@DC474CHH+;
M']&B4D)WAO H#HS1*@)A>AZ\WAX_3@$$X'[W?N#R-+RQ<SU3/'R3G;H+W85_
MM7'L;>?<F[C!*9'+)7&8%;J1S/DIL-C\=8Q1D[;NW&)794XB(\4YB$)X?1 B
MGS;[MW??)?''65X= O5*W3.;7]Y"7</T<[2AQOJ4LM<7._O"TB:G29D:$[G*
M#N6JO@<$\\2C\8(!(3Q ,3B+T:<7Y@):-'OR=<OM3MM7L=+4:[=DV#[A-+<,
MTK;SM!^C:SXRG\<N]@>I:Q]!?8:S-1V]B&V,(8LXM+O&270Y:4O]%00M/ /2
M40'*U/?'[MH6FO=$7V11/+DCO;V\^@.,Z*8F> N5E%5O:QO1C@C0OTB/62"4
MEO3!\P3*RE;4D&;K;,)3\*M-7B3C/- ^?O3WB_<KX'B[5'[=%[7C?T+%J4G-
M_P!D5'#$O7]WOTI8DUHOK7"8'#HS =-KS4S635+26L<;'FYZ>,*WX:A.6B1I
M4OQ!P%ILO9?=UV^Z%:ST)^K--RZ]>R+&.IM4(X3.X"4\9KFV([J3J5T=!'%3
M*TZZ'463HEK6OG@00&(D TF-)6:T'0%;X-]Q[LZ[ZVX<XO\ ;ZJ_F2'V*7[=
MK?V9;TUZUE70UF0-BC3[:T@K.#U/"#&R<FVW(Y8[/;?\6N?7Q\<$Z) IUO0#
MSB-)C0,EU9[WG7?7#A[9L Y=I3G:"VEW17/9WXC:OQRL>00VG;5X]=C8[(#F
M<^NW5H=)="7UP:%:E(C#H"P\E6D)&M2B H/T!M>]H?MZP/<+X1J[IFV(5$8#
M9[W(K2@T^CT 4.Y\&U)JLLN4U\M=8F&0+'%]1LKV"/@5%IE:E4<F$:(K9QV@
MZ,$!LQP!@# & , 8 P"*76'$/+G;L.;H7TM4C#8)$>7:>(1*@'.49LBMI"7L
M(T\EK2S(LM9IU GY,<6 >CVQ>FV9LL(3=& \0[ UPAA7NI>W.8 =:2)X]V7D
M-N4*33JVL]Z8X?[AM41LL(QE$0NX'5>U5QU*C:4X1FB2R,EEE"T7I)DZLW>O
M,("<W'_N,<H=NE/;13D_.:;:A0CDUH<WVHTJJQZ3J-R2F (6MUC4S*-I9:S!
M2*3-%_'D%*FD\>_V"L[7TX!.7 & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P#1["GJV9!P5OB-DYGZ#0VU.ZRFE'.<DG%:+(=4T*16*MD,??I^]3B0
MN#:F6L\3C;^:XDIT!:M>O4%%D$$"\XA@W#=PXR#>OQ?-D+%<7#<1W",CE22:
M18D:YL38VHJHY[VHU5<K6M1557)2BYI,RUCSG[Y?<VZVC)&R(C7ZGNT45&HU
M$6BN5*56B(G%5),L,E>N-[9Z$;Y#3M[697]T3&)6U7D\IZL'^WUQCVAIFMZG
MDU=31!"TZMUBSBE7U<4O;%JY*F9C4SKL!BPLP@?CCTUO#NO&6+X+NRM[ZTB?
M#+'/,V!-*SRS,EC614:]%296O:U5D1651BHJ%M?&S+VMNZ.:".>%CF/;(](^
M"R/>CVJ[@Y*/HJ(JNJWHHI</0Z6\;K]N>_TDHJU1'[CL:E[8(9Z@C0Q220-I
M3T%^*@<56&(%"\EUG XR-!IT C$),%U&>41L10 #%(P3L-B-^V+K:Y1^*M[N
M'5._J-73I[1Z51-,>O5HU<=%%=155"78+96>X(%BEU6D<S*R+P1:4U.XTHVM
M=->.FBKQ-A&8,6$8 P!@# & , 8 P!@# & , U$<^^Z"=:?3_=?+<]K1/ )3
MS?*+-'S])?CUY\;Z'@M1L$0,LLI*I/3Z)06!5\BFC.-[;BCMC^42-N5$E; %
M09H"O0[W;^7X[S+QW<72TT#6]E=0\C5#U8XU;7->7%=CI"HC/J_BTIDTL>F>
MIH'/Y)$*EC#X_FH-29_(;VGQ3#T-3H91V@ 3%CO8?,,M;K&>8U=<'>6.IJ?@
MO0,_?T+@:;'V*D+,BTEFD"M8M^^'TT/,#E$8AKLK3.2 Y4FV%N4 $()A0@:
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M/S&(1.TY(DWB<!Z(L 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M$4134@3+4:^R%'3\%.E)BQV(4*@FB:4?I /"3Y1:+]08&*_[JGO)?[7J@/\
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M)C7,X9TLAA4_BLAA,O8%VA"1/D7E30L8I SK A$$0DKFTKSB3-:WK>P#W].
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MTZ-.0D2$$I4J4DI.F3)R@$)TZ<@ 2B2""2@A+)))+#H(0AUH(0ZUK6O# .[
M& , UDW'[.'MN7];$\O&V.:T<FM.SG1"]3R6)K0NR+G21V;6-KC:)>M:XC9+
M"QEJ$[&RI4VME)2_$!(?'QWX[V!C?]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\
M7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\
M7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\
M7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\
M7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\ 7GTE_;%@#]!7VGO\*?\
M7GTE_;%@#]!7VGO\*?\ 7GTE_;%@&1ZA]G'VX*&LN&W!5'.?V5L:OW@I_B,B
M_%V]WSY2[$E'$%J_E$DL]X8E_E*/'KTU*4XK?CX[#XZU@&S? & , 8 P!@#
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M.LNGJ"L^91V3RBNX]TSSQ8=+)[-;(1IM-FQ-?R"2-VXW(GJ)(WE*J7-P%87
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M/Y0P0F$Q&/7%#W-_E,NE3LD8HW'&-M3.(U+@\/CRO)2IB"P[&:<:$ =;WO6
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M.YQWPWOR!6F>"2Y:LU"@QO3[L18B!.6U.R]:%HOQ\= ;P, 8 P!@# & , 8
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MN2L01JG!RC#(N7*1@+ 4 2A6J0FGG""4 (=;$+>]!UK7\&L ^'\)JK_+2O\
M[FQS^C< ?A-5?Y:5_P#<V.?T;@%MS+GFC)_$)5!)74U?N<7FL;?(E)&W[*,J
M3Y@P2-L5,[PA^*1HR%:;XMN6&%^H4,!@/-XA%H6M;P#PARW_ "1$R/OX[4)[
M>B:#E]9(#%Q1TBKA[67FQ1@U: \,: V(7(F"R-X1H!"3:>!KVXHXP 5&VX&A
M;3A ]Q-$\?\ .W.E+U90U<5?$RH)4,#C%>Q83['V)Z?U+/%FE,TI7"0/1[6
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP#'\QJJN;">X+(YQ#6*4O592#<K@2YZ1 7#B\E]()1;XUE';VG+<DWI@,(-$
M 0DYY99I>P&E@&&NM,E?V,,T%G*^.&X9HD1JTUL_FKZ:+T*GI151:HJH3X;J
MXMV/CA>YK)&Z7(BTU)ZE_1Z_6G#H,@90D@8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M8_JKX8W\'M)UWUS!Y$F(@*]O%=QO353HJU0N+*:9*E>H,7$#TOQ9I9X7/:P
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MAD#&SKHB7/4[XTE)ANC7'-M6M%JW#20T#?688646,TT8"BB@",,,,$$!998
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M25N-6-IL$M!Q1I'LA<E5)C_(HTGV,(0A Q=_F"[D-H_VNKDE*I^E,<AK_/\
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , B
MKU;=*6E&VA5:J33*,ZLOJJA:6(,AD2ALN->U5ERSY(1&9(5,W-K*C\->Q?LG
M)V;=GO+>3^T1DFF?5P#SG6![FUS1:)=LVFC]V_GUHZ%H3K'MFMZ1]M)_K/G"
M5SNU4M#])657%%T9J)15<S=0N+M=,=B[8VI75'X+"3G(#@(PP@LS8@)B]E=?
M7A!.J)O#+@[<E'M:TVVU?4CMSI-73FF 6C0US3J4M+DJLK\<NB;/K.:06&?A
M_-5")C,C21^A+DH;P:<"5YFE6A)@)!N%N]H=%W+3G(L,OJK^=):P<05/UEU/
MT-SG&(Q>3=)I3<$ME5<P&(<P&WO&7:&):SD#[5$N>C'Q]CKVMVUE-B<HDHP\
MQ5L"ZI;U=>OMWT F4=PN33U'8,KZ=;>?.99340:RI^67ZWSF+JYG!U5PI;,D
M51\^4K.6@B.R-&Z* /J2/K26=*:D"6M<2F_ -@?/]PFWQ5$:L]55MK4LO?#G
MY"Z5E=4;11BPHLZ1J1.L9<4[DF9W>11IX:5RMH&K:GAG<G)F>FH],N0JCTR@
MLS8&9L UL^[5RU.^O^';&JFKF.-2ZQV27T]<<+@,S.+2Q*S7BCK9AMK#JZ0K
M31E$M[=8[;%%#-\08()*<U: PW?I!'D4/+DJAJJK&*^T9V;<$D?Z_FUO^U+[
MDCB).VW/5-=VV[\;=(I9L(DP]80]50]^-/7R M4<<80^IHZ^D.24P)XC?*:'
M6G'^ \II5?4XFW(O;S]QE0E1,,9]Y6>/4.:ES0Z,K7?O"?'MW/R)R8'!,[,+
ML?*D,:K0YR>F=S2%*4RTY,)42H+ : >AA#O2J$=+O7_$?<JX"[MDS6L3]$>]
M?TF?#"0Z6. .?J Y.Y5<22"/ 1PE%@D5]8\I;TFR_'0]DK4^M:WX^.MZUO2J
M#2[TJ:G[NKKVS"&7HSD'VZ*S+]R/W(NI*JF5*3>Z918THZB4TZPV.R*(@\V?
MT%U)+'66Q*H8M $Z[:T+(R*T"Y:YI241*0H\[1@8\?3T'E4;T-XN/4M0%6AH
MZAZ3I0#MM^#3]1UO5H7W:;X+;T&OX:S1/3MM'ZI_PFW'31ZWI><?I^?R^;?A
MXYY)B<$H9<P1& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M5U*]9VJ):52145"3^;:-5# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M.H0G>3U#1',GII/.9L OB-!>1&B],.O.+T@F_5W]'B+Q#J . 7);LHPS<>>
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M9K?CKTQ#WX:WXZUOPUL#GMP5Z&I#IC=-A(T/91FCF7R+?*:$L.DVMO&C ;,
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M+V$PS8GP)&P'>?>@^08A:\F_-H/U?$#F)P5Z,4 TQ.H@D^?TS0G,GIJ_(9H
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MLTS9S+Y$7F-$6+2G6GC9@]E@#HS?HA-UY!:\/$7B'0'#3DLV X?R!WT(L0-
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MX_1D0<MN"O7Q/\Q.N_0_X+>CF3^6?M0E_P F\7G7E^H+9G[;TOJ!WK^-X!W
M#3@KW\-_,3KKU_\ A=[.9/Y'^U$7_*?!YWYOJ!T9^Q]7Z@M:_C>(= =A*Y2:
M8, V=Q3A ,  FG&M BS B,\@C0:3NAYN@%A^OOS!"+R_P:V+ZN 5' & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# ('\A6-'()$6/G.?B6P2W(V\3'R1
MJ6)?E(9,FD,VDLG;5T/<AF#;Y$F,0.Q8=Z),]79H1Z" 0=:'OG?DKN7%;;QC
M.5VY'.Q^]X+[(R-M[AJQ>\17&0NKF*2T>[]G<L6.9E>R<YS751S4I4Z"YS;<
MRFXLI)S.VZUM_LNXL[!CKBW<DGN\D%A;6\D=TQ.O;O22)U.T:UKFT5'+6A(C
MI#_F]7K_ *'[)_XG/.;"YP_W2;I_Z<R7]2F-?<I?[U=L_P#4.._KD)7*5_\
M0W4O^C.!_P#%9JR_;(_Y+Q']EVO^@C+'O3_G'+?VG=?Z=Y&B^;*BUASJHZAK
MY0JG$VBU^57,YDEBZ0QV;H5'8A)"UKXNE3P3OY:TC3%:WKT1&"/\X=AV#6_H
MS57,;=>(W-F<9L';+I,CN2VW%B[FZ9;M[2.S@M+Z&>9]W,G[.%49&Y&QN=VK
MG=5&=--H\O=K9;;F'R6^]R)'C]NW.W\G;6KKAW9R7DUU8S00LM8E_:3(KY&J
MZ1&I$UO65_16<>;]-$C & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M5SWKQ<Y5XFE-Q;GW!NW)OS&Y;R>]R3^E\KE=1*U1K$^S&Q*]6-B-8U.#6HG
MO;+\6(8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P",G6_8_./"M0*+ZZGL,RL:I2R2/1 Z3DPR?STW[1RI28C8&PJ.UI%9E
M*5!CBI*$ (RT(B@;_CB#XZ\0, \B^[3[?'==B/\ 4?,/0R6=6C&HSN9N=?22
MM;BJ"7F10"U.W*)"S,%T5[7CC)&E$M5DEJ3FXM6!,(T'J[!YP^(&QG & , 8
M!@^U.CJ>I2:4I7UDR=P8I;T1.%-<5$VHX9.I.1)9@C:C7M0V+WB*1I\9(<G
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M\0_LU^&GS#[:?R7Y-\X^>^G_ "GX/X7]O@&;\ 8 P!@# & , 8 P!@# & ,
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M![JL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M_:3U&W[7_*?EGSOU?0/^4?:3X/\ E_J?#>I\-\5]/I^;R?1XX!<F , M?_\
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H P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>tm2115679d1-fc_neurosc4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-fc_neurosc4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!$ 0" P$1  (1 0,1 ?_$ -\  0 " P$! 0$!
M       %!@0("0<* @,! 0$  04! 0$              0,$!08'" ()$
M!0,! @02!P4& P<"!P   @,$!0$&!P@1$I)6E@DAT>%2<K(3<],T5!4UE197
MUQDQP2(S%-480;.4U!=183(C. JQAK9Q@9%"=3=W8[2A8D-5M39V$0 " 0("
M!@4(!@4("@(" P   0(#!!$%(9$24@86,4&2TA-1T5.35!55!V%Q@:$B%+'A
M,M,70H*R([,U-@CPP6)R,W.#)#2T8W2BPD0E)O_:  P# 0 "$0,1 #\ ^_@
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M\3]ZIXSY1_B^_P#_ ,_^+^\<CP7D7_GG0L7Y?_X9N@,"9<
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MRCOKX<!SKE7H[CLP[XY8O]^CKEW!\IG49QTPIRCOKX<!SKE7H[CLP[XY8O\
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M^=I>27_E>)U?L^3IZ?N^DVO\K4\J_P"!L=?3JZ/O^@V&&,+\
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MJ\+J !YQ?>4J\+J !YQ?>4J\+J !YQ?>4J\+J !YQ?>4J\+J !YQ?>4J\+J
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M>%U  \XOO*5>%U  \XOO*5>%U  \XOO*5>%U  \XOO*5>%U  \XOO*5>%U
M\XOO*5>%U  \XOO*5>%U  \XOO*5>%U  \XOO*5>%U  \XOO*5>%U  \XOO*
M5>%U !-0KIPNJL594ZE"IEK2AJ[=E=[9MI_W # ?/G:;MP0CA0I"J5H4M*[*
M4I39T*=  8GG%]Y2KPNH 'G%]Y2KPNH 'G%]Y2KPNH 'G%]Y2KPNH 'G%]Y2
MKPNH 'G%]Y2KPNH 'G%]Y2KPNH 'G%]Y2KPNH 'G%]Y2KPNH 'G%]Y2KPNH
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M4*L0E;KEE6YZIUH;=7;K.#HJD-UIJ5I7:/J_^7O"694W1K6M+9^B*7Z",O\
MFEQI855<6UW5VNG3)O[L3IEIMYZ/)UK/F,!J%AFM_6V=1)%6ZHAJA%79&)5K
M6AEED$.Y1LP1),O1*<J:QZ]&J@Y-Q=\@+&I0=WPU4=.MA_PVVU)_;T+ZCM?!
M/^9:_A75EQ7352ABL:J6#BNO'#I?UGT:8LRO8.:+,B;_ ,;7&PN:V9A&BC=Z
MR4I4Z"U*4JLR?-S;%V3YL:NZHDH4IRU_9LZ(\NYOD^8Y%?3R[-*<J5U!Z4^O
MZ4^M,]?9)GF6<19=3S7**L:MG46*:ZOH:ZFCT08PRP
M   %"?\ CKKOZG;5 &(                          +?&^B:]@Y[90 5
M                           !:I;T8AV2'[HP JH
M         S8[QYMWTOU@"2G_ +]OWHW;@"
M $_ ??N.]%[< 1LCX\Y[Z;Z@!A                          "U1WHA?L
M77:5 %5                            73\K $H /R<Y$R&44,4A"%,<Y
MSFH4A"%I6IC&-6M*%*6E-M:UZ%*"4G)J,5C)D2DHIRDTHI8MOJ/CXYRS6K,Z
MF,M2=G6I.+4PKCN3=QEKL&E5$6=R2S0QFLE>3[=4K^..[.51-A4VPB3.M*E+
M0ZAS&]N?*'Y=VW#V34\XS*FGF=?"3;Z4NJ*\F&.GRO$_/[YZ?,ZXXESB>0Y7
M5?NBC-PP6A2DL,6]/7^@YE?3LILZ%:?9V;?HILZ%:4^BI=[9_P!P[5<.#FJL
M.CR'GB.,VJ-S%N2E@OL.A/-HZ?,4:C=0SFS,PNZTMZ(LV1N6/@221HI2Z)II
M-P,<A$F=)G3<J()M)%=<R21RJ'[G]-24-2O*OG#Q3G'#/#U*ZR!.-Q.KLREA
MM;$=EO'!_3@OM.U?(KA'(N*N+;BQX@PE94Z&,:;>&U+;BL$_I3Q^PNW.E::L
M-:;LP6Q$8=+2*87';/GB7M2LDM)F@WY'RR)5DS.#K.6[9ZBEO%24/797;4M*
M%K08_P"3'&.?\2Y56JY[+Q)TZFS&>RHXK#'JP3\F@RGSXX+X>X.SVA#AV*I4
MJM'&=/:<L'BUUXM:#E_MV?WTZ%=E:?XMO]M*_LZ-?IZ'1'9U&=5Z-#1P)2\%
M.<EBI8HZ <WUK'N'2SEV)2D95R;$]W/VD5?,,H8ZS-JBNI1%*XVR-3T*@]BU
M#[YS$_QH4,6M*UW=G)_FKP!8<2Y-4KVE->^*2<HRZ&\%I6/D?1I.Y?)GYEYA
MPMG=*SNZC>1UFHSCTI8OI^M?1]1]F4;(LI>/8RL:Y2>1\BU0>LG2)J'2<-7*
M15D%DSEK6AB*)GI6E1X2JTJE&I*C53C4BVFGU-=)^B5&M3N*4:]%J5*<4TUT
M-/2F9HIE0                    H3_ ,===_4[:H Q   '"GG6&>5LH:V.
M:6TI61J=U*:8+#U*7IK/994N?2]D9MC;($NTQ)IMKE:SFQ)>3M^[()5%K<MO
M%(<KN,=4HU=."I=R5.54@'BVHG'>J;F>6N,M7MHZ^]5^KC2U'9NP_C?5WA+6
MK=%BY7F&.+<SWY!XE;Y4Q#D2W<>6+-VM=F/;ON^,<%B*E(PEDU3T<+E*G0BL
M@W-FM<^FO3GG_G7;ZR?E?4X2*T@XPT@7UF^UK\<VM/X L.,R#8F0W6/VFDZU
MH!6MY-KPR8NQJA=J4QW)%].^;?PIRHT6.6 3^EGG4[8U#9XM_3=DC21K(T<Y
M4R'CJY<MX<CM4>,+>M2(RU8=HN(1"YZ6W,VE>UY)1U[6HE<+1Q+P<B1HXCV[
ME&ICG.L0@ UYN;G^M-EONYF_F>G/69=.C&ULDJ8JN[G!+:PTQ?Z5(.X6MVGL
M25N5*=/=B%[S>+H"\"&C'EQ,X55I^/+W%N5P8Z/=9P![KJ.YVS'^&L[7EINP
MSI>U=:X,L8DM:U+WSQ$:1L9P-]Q6%+=O>)7N"SX^\)ZX[QM*/<Y O*W$BR,+
M;["KIY),C54(8M2[E8!<+.YV32GD&W=#=[V9_46<Q[KWR;=F$\:7Y2VH:+@\
M:9FM. N.74Q5G./G;HB[LLN]IV5M"3A8YJPC9@JTJS-W0Z30Z+M0#TW(7.&:
M>L6ZA,RZ?+Y7NJ$<:>-)U=8N<,LK1\&?$&,\:+7++6]&6Y<<RG<AKPKDF=:P
M#Z591;6#<)+Q;:I_Q%%E$4%0-5,2\\YC:_L@XCM[)6D37#IBQ=J+O"#L'3OJ
M+U"89BK1PYDV[[L[J2PK>?2$3>=P7)CN5RHKW*EJ)3L<S\]46+T43_8J!D3/
M/)6 XU 9IT[8DT<:Y=0MUZ;<GS&,<^3N'\78\D[0QZZ;6S$7#;5R*7)<F6[:
MB)""O=21=-F*1EVTHCYG?+.FC="C([T#V&1YU'38WT<:8-:T-#Y1O"PM8%[8
M.QC@_'EJP5IO<O7#DW/%PEMF Q\X@GU[QMHH7/:<FWD*3I$YQ9NV)$/*ME7=
M2)46 Z4@    M\;Z)KV#GME !4        &LFM>Y[ALG1IJWO.T9F1MRZ[2T
MR9ZN>V+AAW2K&7@;A@<5W7*PLS%O4#$69R,7)-$ET%25H9-5,IJ5VT %+YM^
M]+LR1S>&@O(E_7%+W??5^Z+]+EZ7I=EP/5Y.>NB[+IP?8TY<=Q3<DY,=S(2\
MW,/EG+E=0U3JK*F,:M:UJ -?]27.HVCA3.5T:<\0Z5=7FM7*V,(2V[FSE$Z4
M\:P%W0^%(F[8T\W;,3>MR7=>5EQ!\A7/ ;DA&6\R4<O73$]%352VDH<#(O#G
M==+4#I9PYJDM"%S1EY'4%D4V%L/8(QIC1])ZBKIS@R=7%'W+B&0QO,/H0MGW
M=8LE:,FC.FEWC)A'U:5-^(4*LVJN!D:3.=%L74CFG(.FO).GC4EHUU!8[Q.7
M/3['&J*T;8M4ERX2I/LK5>9-LR[+8NZZK;G;8A+ED46$BJ9="C5V8R?VS)+]
MR XR<Y[S[C*].;KU,WMI<Q3KJPS:USQ[*VM+_. )XQ<V5A3(=XP.5;<8R=;'
MO6(N9U?EI1EW0D3*H0LI,Q$6SE*I+M#'0=&2;K ?6T         "U2WHQ#LD
M/W1@!50!\R%Y:F]0K+2A_N2[L:9FR*WN73;FC.D+@*=2NF4))X?B8+31C6YH
M:.Q\[HO1:V6<9<,FX>(D;5(5-PL<].B:M1(-O.9MUF9@RCCY]H]UFR?XC6OI
MUQ]CF\)"Z7:IJ%U)Z;LDPC*5P]J1MQ5RFW7F7#QDZ+!7:9.B]65S,S_B52K/
M*)$@')FW<ZZH,Z\S7S$[B4U::E+!R9J]YP[%N"\VY\QEDQU 9RN&P+Q=ZOX^
M58TO>58W FX633M2+.C1\T>MBJ1S>IT3T2+0 ;I:M--VL#FL\*7;KJTZ\XSK
M5U0PVGDL3D/.FFK6Y?F/LS65E_"$))$)DF&L^XX7%UCSV+;WBK8>KR<?)M#*
MT4<,"I+E.B>I0!]$UHW1$7O:EL7I;ZYG,#=]O0MT0CDY:$.XB)^-;2L:N8E#
M'H0RK)V0U:;:[*U^FH ^3BZ;TQ7EWG$^<UL[5ISW>I#0!$88SEBJU,&XCLO7
M=A+35;#RS)W =A7/<$C$VEF6V+D=R**5TOUM]>-,BV(JL:ARU4-M!@Z-X'S'
MI'T'Z6=7^KZT><LU-<Z;B7&$!:4]DCSWJCP'J]G,8>RIIW<A<;>P+/&=M6M/
MWJC>!%I%M+29/QR,8T.F9*B)NZ@7?&?/48=OS-N"<973ICUE8/QIJKG4[3TN
MZF<UX=:67A?-EV/HE2;MF"AU*W.^O:VELA1B)U[:-+Q#+SNVH5<I4T3E/4"3
MSCSP%LXZR[F3$>$M%>N'6:OINE6MOZ@[VTSXIMN?L?'5U+V^QNQS8;"4N^^+
M0>WY?\3;4BBZ>1L.V<E0_$(I56[JI4A -+M7W.S6E'Y4YD35IA6ZL]W=I7U,
MO-8TA/X>P_:<_<&1,\RJ.GAS!8CQ6XQ-%.R$NB_H[.LBTCV+1RN5@PFMJZCM
M)LF=T4#:U?G/;?U%Z9^<,LV$QQJ'T>ZNM,NE?*N1)S#F>;;C[%RK;47*8IO*
M6QUEZP9>U[BN6 N>U5)J+W$9*/?568R3?<722WFYU@*OH0U'1E[7'S3]K9*R
M]JKN34+F/F><>9TF812Y;7?:;,@T6M7!A[ZR;EII)+FR!-:@5+IN.E8Q^C0S
M*K%V]_$&[L<@ \U@O]QQIKN?#MFZHX72'S@!M'TF]:1F2M4;[!%OIXPPL_>7
M.:T#ENU:*R)-/KGCH":.@27?VR2:8L3N"M2++R1%F"0&[^J?G1<<:=LS6IIR
MQQ@34IK-SQ/XX1S5.XUTF61;E]/L>X:=2QH6+R!?$]<UXV9:T8UN>1061AF:
M;U9X_42+M(BFNV56 ],YO[G#,)<Y%C/)^5L$VWEBU[<Q-G.Z]/ESQ^8[.96'
M=)K\LNU+$NV?.WMI&X)V381C1OD!JT,23)'R*;YLY34:$(1-14#?N.\>;=]+
M]8 DI_[]OWHW;@"     !QKY\:],HVCI.Q%&8FS!E'!<_E#6WI$PQ-9$PW=*
MEFY"B[+RKE6/L^[$;?GRMGR+1VO%2)JI]W;N6_=2$JHBH6E25 T'YP'!V=>:
M=P%76;A3G4]>^:,FV#D/%47;>F;6+E_&F:L>:G"7ADJTK.F,.0=GQ>*["NA*
M[)J%N!=PW?1*SA\R3;'5*5$A3.D /29/G*LFZ>^=<YT#!Y\5:NM8YXJP]"%Q
MX%TX:?[:I>[7'4 IBB_Y/.U]=VN:?MNQL>0TI-SMND=;SNDA-RCAJDV;+]S7
M4;@;Y)<\'I.=:'[-UUQL3FZ7LW(&1VN#[/PA$XO<O]3,UJ$=WC)6&GI^0Q6C
M+5;HY7I<T,Z1_"*R9&)TT>ZD=G242.H TM\Z=;>?-126DW+&E+5?HUSW-X\G
M<K8^M?4G9%K14!E*QK7D(J+N9U8=XV5>5WP\I.VVZE2'?QZG<%$&U2JT,?>J
M0H'A5D\^_@.^;IQ_*Q^F/6>QTJ9<S1&X#Q9KID,109-,UYWY-WB[L"WI5&30
MO9:_(K&UR7@R/',I]U")MZNZE(NFWIOF(![OJ2YU&T<*9RNC3GB'2KJ\UJY6
MQA"6W<V<HG2GC6 NZ'PI$W;&GF[9B;UN2[KRLN(/D*YX#<D(RWF2CEZZ8GHJ
M:J6TE#@;G:7M3>)]7^$[1SWAB3E7UEW8:98J1UR0KVU[RM&Z+7FG]LWC8M]6
MI)E))VO>EFW-%.H^18KTK5-="IB&41,FJ<#F;SW^H#7KA?21F]UHMLJW;2C[
M:T^9/RCE75G=EZM8U;$MO6E%NCJV;B.Q8UJ_N>XLV7>S*H:,EEJ-8>WR$_$*
M*G<F0*G(.I>F^:EKDT[X%N*?D7DQ.SV%\6S4U+2"YW3^4EI2QX)](R+YRK4R
MCAX]>+G55.:M3'.:M:]&H@'M     )^ ^_<=Z+VX C9'QYSWTWU #"    !P
M UWV;EG4ASLVE[23!ZPM7FEG%$_HDSGF>XJ:3LL1^,9VX+TLG+-@6W!K3"L]
M:5\0;UH2*NAP0^]'_B/LIT(L0M#%,!7<>-<V:!>=*T<:1+=UXZC-:^*=7V/-
M24IE[&&K*\+(RQE;3\?"V/V%\6)F.%O6SK/LF8MVT[ZN!:EM%8R3)-BZ67.=
M$SE=/:T U)YO7GTE<3Z ,=WMJ2POKRU(PV,[^S[":J-95N8T-?N-L15=:F\H
MIV)'W3==RW7#W1?#>S,82]N'E%()E)-H*)6:H]T5=$.S2 [7ZJN<SQUIVOG%
MV',<82U!ZQ<[YAQL]S19^)M+UG0UU2+/#$?),(I7*]X71=-RVC:-L62^DWY6
M3%<SQ==X_,F@5*G=2'J!Y=:?/1Z7Y/2GJ(U07_8&H?#+_2ID&&P]F[3ED;&*
M3/4="9?NES:\=8N/[;L2)GY6.NV0R1+7@Q1@'*$@1H[35JX<*-&Z:RB0'HFD
M?G-;8U-9JN73;?VF+53H^SO!8N+FV)L/4_8-NVPC?>*:7&UM1]==DW+:5X7A
M!R*D!.R#9O),7*C1VW.X^P18J3DR(&N#SGW,$(K2N18_2WK=G]%L#<KVUYC7
M_!81:2&F-L2+G5[?E\A-'2=V4R/+X5B))N=)Q=36 5:%43/4J1D2]VJ!VZ9/
M64DR:2,<[:R$?(-6[U@_9.$G3)ZR=)$7:NVCI ZB#EJY04*=-0AC$.0U*TK6
ME0!\N.J_#/.,8#T=:D.<RU(\Z%F+ NI_$#;)67;(TW8ZE\;R>A&"A+:NJ62P
MSIVD[$?V$RF,KRN3XI*)AJ3KU\T?UE9HE%D'*K>JJ\@^DG"5WW7D'#&(K]OR
MUC6-?-[XPL&[[SLDU')36?==RVI$S-Q6L8KVA7E#6_+O5FE:*THK_D_:^UM$
M ]/    !:H[T0OV+KM*@"J@     #YE,%Z9LQ:^M6/.@R=Y<Y)SE&"8# >MN
M8PQC7'>FG4/;=AX]AK+;XJQM>"2)("[,6Y!60=DE;G<TI^&<-V]$MVG<=ZAC
MF U*SOJVU98+T,\_#@NUM962<]TYO]_I11TYZTS3$0SS6@XSE(6M-Y&Q)=>1
M\?(14'=-Y8<60I'O9!%--_6DR=!V5$Q2M&X':/$//'8CR;J'Q!@NYM->L#!5
MN:FUYQMI0S]G#$3.R<.ZA%[?MQU=IT+==GN=Y=]HO+IMIK61MYO/Q,<YE61B
M&,FV642;G A,T<\Q9V/LCYOLK#NBK7/JZM?3!=4E9&HO+FG7$ULS6.L>WE;T
M4PGKOLJ%>7=?=HS.0+RLF&>=VEF48S.FU,= M%ST7*:@%RRESP>G^U\9:1;W
MPIB_/^K2\M<EFS.0].^%M/\ 8L;+Y)F+%M.%AYN^;MO5"Z;BMB L&$LFDZV9
M/CO7O=C22E4&Z:Q4G"B(%RQOSK^F.\](F:M8E[1.7,"VGIOO:Y<6YWQ?FJP%
MK=S5CO*]MN[?CT\;.;)A)&XT;@N>ZY&[HAO!DBWCQ*27DT$:'(O1=)$"IZ?.
M=CM#+F:,?X,S!I(UG:+;IS<6</I\F-5F*H*S+1S(Z@89Y<SRT(>X;7O.\6ML
MY/3M:.<2)K>F*,G)FZ)BHG66V)U Z$YU:YG?88RDQTZ2%AQ&>7UAW.RQ!,90
MK+?T[ALB.XETWM29O-."BIR7<V]$RZB3ARBW:+J+II53W=AJUH!\\V!9#43I
M?YR[2=IFMOG*,R<XC?.2+8RRZYRG"U_35AWO:&FRL5C0EVV9EJTT[+M"&=:9
M8A]DAZQC(RUY9=1>9CY1$B29:'043D'TX"      73\K $H -&.<ARY(8:T>
M9;N&%=&9S]PQK.P(-RFH9)=NZO9VG"O7394NPR;IC!KNUTC4Z)3I4K3HT&_?
M+/)HYWQE:6]5)T:4_%DO*H--+M.)S?YM9[/A_@2]NJ+<:]6'@Q?D=1--]E2/
MBGKMJ;;7Z3=&M:;=FW]M*4K6M=E/HI_</T,510@DHX4HZ$O(C\OW"4ZKG.>-
M9O:VO++$]\TXXKL?,.0S6ED')\-B2!\R2$G2ZIPAE&1GS1U')-XS=+MV*.B/
M%#[?[$ZC5^*<\S'A^P=[E-I.\K:/P0PQT_7Y#<N",AR_B#-_RV<WM*RMTL?%
MG^SBNHVBU<:-'.CBV,/93LG,%;R99.5=N[7N&W2.8<Y(]"'B9AA+,7R"I%C(
M2#66(8E:5IM+7;7Z:C0N!^/Z/S"S&XR3-K+PZMOIE&>#2>+BXM>58:3IGS ^
M6MU\M["VXCR?,5.C<_LSIXQ;T*2DGY'BL"+TAZ4YG7#)Y4GKSRV\MXV.H>*F
MIFXKA,[G55H]T66.X77<N55%DT8Y"+,:O1K3<K7^P??&_&UK\NZM#+LNLHS_
M #$_PQIJ,=.C!8>5XEI\O^ +_P":M.YS'.+^4(6RTRJ-R>&EN6/4EABSPC4Y
MAG'N$KSA[;QUEV"S%$OX$LH]GH!,R;2-?U?O&AXI6A]E>[)HMRJ5_N/0;?P?
MQ#FW$-A5O,RLZME7C4V8PGTRCACBL#3N.N&<BX8S*GEN47U*^H3I;4IPQPC+
M'#!X]9K7MW.C2NRM*_\ XTJ6E-O]VVHW2456PHR73'2<[ISE0EXT):(RUGV,
M<U+EU]E;2-::,L[,\E\?2#^Q'2IS5.I1I%5(K"E54-6ICJ^9G"&]6OTU'@/Y
MNY%'(^,:T*:PIUUXB^UM/[TS]+?DGQ#+B'@6A4F\9T'X3^Q)K4G@=*!S ZZ
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ME4W]6+_UXGNW_+#XDN#[F33\'\VTOL2_U8'<0>?CTN
M  4)_P".NN_J=M4 8@                 #^+A*J[=="BRS>JR*J5'#<Q2N
M$*J$,2BR!CD4(59*M=XM:E-2AJ4VTK]  T0T/:$8G1PIF^]+@S1D_4OG_4G>
MEOWCF[4!E\EL-;PN\ECVTC9F.+49P]FPT%;MOV?8-L)'1CV2"%>YK.W)Z&HF
MHFBB!OJ    "WQOHFO8.>V4 %0                            6J6]&(
M=DA^Z, *J                       Y>ZI^;@NK-F=%M2& M;NIS1?E2X;
M#A<:Y(IA]U95TX^R1;-MO)-W;LA-X\R1;MPPL=?$&276;-IED9!<C2I25)4U
M-^H&R>C+1YC'0_A<F&\92]\7?65O2\\HY&R;E&X"75E'+N6<C3"D]?F3LC7&
MBRC&TM=ES21R]V41:MTBI(ID*2FYMJ!MY'>/-N^E^L 24_\ ?M^]&[< 0
M                        GX#[]QWHO;@"-D?'G/?3?4 ,(
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MYL=5                    *$_\===_4[:H Q
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M=40SG8&430=)(.D4W\4_25H10A%"T/L,6E=M! +4 +5+>C$.R0_=& %5
M                      &;'>/-N^E^L 24_P#?M^]&[< 0
M               GX#[]QWHO;@"-D?'G/?3?4 ,(
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M$YSJ3=2;QG)XM^5L_0"E3A1IQI4DHTXI))=270C('P?8
M   !0G_CKKOZG;5 &(                          +?&^B:]@Y[90 5
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M@V40<METTUD%DS$.4IBUI0#:$ 6J6]&(=DA^Z, *J
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M4=.$7BV4K#Y+_,+,:^RLNN:-.6C:G'"*.I&F?F4Y=*2C+GU*74P18M%D'?\
M3^TE22#EV9,Q%/PLS.G(9@BC4Y=TY6U''="5K3>+7HCC7&/S\A=4W;<+T9PV
ME@YST+[$L'KP.]<"?Y;96%>-YQ;7A4V=*IT]+^IMXK#ZL3Z!K1L^V+#MZ,M2
MSX2.MZWH=LFTCHJ+;)M6C9%,M"TH5-(I:5.;9M,:NTQJ]&M=H\UWEY=7]Q*[
MO)RJ7$WBY-XMGJZRL;3+K:-I8TXTK:"P48I)+4606Q=
M     4)_XZZ[^IVU0!B                          "WQOHFO8.>V4 %0
M    !J[JQTEXYUBV18-@Y-FKV@H?'6<\/:@81S8DE!1DDZO+"=X,[UM6,E5K
M@MNYVJ]LR$JR(G((HHH.E6]:E1<H'V*4 VB                     %JEO
M1B'9(?NC "J@                         #-CO'FW?2_6 )*?^_;]Z-VX
M @                          !/P'W[CO1>W $;(^/.>^F^H 80
M                    M4=Z(7[%UVE0!50
M  %T_*P!*                                    "A/_'77?U.VJ ,0
M                          6^-]$U[!SVR@ J
M        "U2WHQ#LD/W1@!50                         !FQWCS;OI?K
M $E/_?M^]&[< 0                           GX#[]QWHO;@"-D?'G/?
M3?4 ,(                          6J.]$+]BZ[2H JH
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M]G6M9C*6<Y96S2IDM*JGF=&"G.GA+&,7LM/'#9_EQZ&WI^LOXN#)@
M     !0G_CKKOZG;5 &(                          +?&^B:]@Y[90 5
M                            !:I;T8AV2'[HP JH
M          S8[QYMWTOU@"2G_OV_>C=N (
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MB                          "WQOHFO8.>V4 %0
M          6J6]&(=DA^Z, *J                          ,V.\>;=]+
M]8 DI_[]OWHW;@"                           $_ ??N.]%[< 1LCX\Y
M[Z;Z@!A                          "U1WHA?L77:5 %5
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MG_CKKOZG;5 &(                          +?&^B:]@Y[90 5
M                     !:I;T8AV2'[HP JH
M   S8[QYMWTOU@"2G_OV_>C=N (                           3\!]^X
M[T7MP!&R/CSGOIOJ &$                          +5'>B%^Q==I4 54
M                           !=/RL 2@
M           H3_QUUW]3MJ@#$                          %OC?1->P<
M]LH *@                            M4MZ,0[)#]T8 54
M               9L=X\V[Z7ZP!)3_W[?O1NW $
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M-IB__ECYPLZREO#\Q1[2/6:5I6E*TK2M*TVTK3HTK2OT5I7]M*C93)G^@
M       "WQOHFO8.>V4 %0                            6J6]&(=DA^
MZ, *J                          ,V.\>;=]+]8 DI_[]OWHW;@"
M                      $_ ??N.]%[< 1LCX\Y[Z;Z@!A
M             "U1WHA?L77:5 %5                            73\K
M '#/6;_J4R1_R?\ ]!6L/)GS-_QO>_\ 1_\ 7I''>*O[^K_S/[.!J^-#->
M                               "./\ XS]D;_C4?+Z2NNA'Y$$@
M       =8M&V=O:^#)C"YWE3W/;3/>M]VX4K52;MUO0I:-*G.:M59&#+L+LZ
M%3M-RM*5JDJ8>DOE9QC[TLUP_F$L<PMX_P!7)O34I+J^F5/H^F&#_DR9TKA7
M.?S5'W?</_N*:_"W_*BNKZX_HP\C-Z1V W$          M\;Z)KV#GME !4
M                           %JEO1B'9(?NC "J@
M        #-CO'FW?2_6 )*?^_;]Z-VX @                          !
M/P'W[CO1>W $;(^/.>^F^H 80                          M4=Z(7[%U
MVE0!50                           %T_*P!PSUF_ZE,D?\G_ /05K#R9
M\S?\;WO_ $?_ %Z1QWBK^_J_\S^S@>;8.L6(R9E:SK&GG,BTB;@>O&SUQ$+-
MD)%(C>)D'Q*M5GC-^V(>JS4M*[Z)Z;M:]"E=E:83A3*;;/>(+;*;N4XV]:4E
M)P:4EA"4M#DI+I2Z4]!8919TLPS*E9UG)4IMIN.">B+>C%-=7D-KL+:4<;9'
M2R62=N&\(QS:V3KAL*W#L9"$2;N$HY"JD<K+%=6\[,N\5,6M#U2,@12NPI"E
M-6@Z#PQ\O<DSN-\KNM<TYV]_4MZ>S*"345^%SQIO&3Z\'%/H23-DRKANPOU<
M*M.K&5.XE3C@XX/#HQQB\7]6&/41VFS2C:.4[<G)C(LK=<&\:WJ^LR'9P#R)
M8_B'D-$TDI;N])6"ECK&3^V4M253H7N"E*TK7Z*'!'R^R[/[*K<YU4N*52-U
M*C"-.4(XN$-J>.W3GCUX88?LLIY#PW:YC0G5OI5(255TXJ+2Q<5C+IC+_1,Q
M<;:7K(OO3VZR2:9NI&_5(6^Y&'B6[V(+ /G=IK/:-FGX12"6DE#.DFY*'*5W
M0U:F,8NPI:TI\9)P%E>;<&RSQU;A9NZ5>4(*4/#DZ3E@L'3<M*2Q_'CI;6A'
MS8</6EYDCOW.HKS8J.*3CLMPQP6&SCIP\HL+2[9$_ITELLW#,W4TN[V,R/>,
M#$,'L0WB%65EIO$69WK5U!NY!9%=ZW3,K5-RGOHK%W:EK7>#*. LKN^"ZG$-
M[5N(YC^6N:U.$904'&BI*.TG3<FG)+'"2Q4EAATBRX>M*V1RS*O.HKGPJLXQ
M3BHX4\<,4XM]*6.#6AKH-%1R<T\W-M[2['R^G.0R@O*RR61%XF=O*V[7(Y8$
MCWMDVU(QK26>KQQX]65<.:-555DU$G!$ZT7;%W-IJU-TVSX"HW/!<\^E4J+.
M73J5J=+&.S*A2E%3DX[+FW@W)-22_%!8:=.U4.'H5<BEF#E+\\XRG&&*P=.#
M2D\,,6\,7BGAICH/+\6XKMZ]\89TO66>3+>5QE#6S(P+>/<,4H]VO,K3R;HL
MNDYCG;EPDG2+3[G1%5O6E:FVU-MILP.09!9YKD6;9I<2JQN+&E2E347%1;FZ
MF.VG%MK\"PV7'KQQZL=EV74+O+[R[J.:J6\8.*36#VMK':Q3;Z%A@T>:8ZMY
ME=V0;$M.25=(1USWE;%O/UF)TDGJ+*:FV,:Z59J.$'*";I-!R:J9CIJ$H>E*
MU*:G0K@LELJ68YQ:9?7<E1KW-*G)QP4E&<XQ;3::QP>C%-8]*986-"%U>T;:
MIBH5*L(O#IPE))X8XZ=.C0R9S'9L7CW)]Z65"KOW45;DRK',7$HJW6D%4"(H
MJ4,Z5:-638ZNU2O1(D2FS]@NN)<LH9-GUUE=JYRMZ-79BY-.36">EI16.GJ2
M*N:6M.RS"K:4G)TZ<\$WAC]N"2^X\Y005<KHMD"547<*IH(IEV;RBJIZ)IDI
MMK2FTQS4H,+"$JDU""QFVDE]+Z"Q2<FHKI;-^E-*F+#3+O#S6_;H5SZRM*EQ
M*-S-(ZE@N)+S:E*>8$*U9DEJ*G;K%-1:J]:41KW2I-[:E3KLOE_D#N9<-T[R
MN^+X6_B881_+N6RI>&OP[>.#7XG+]G\6&/X3<WPYEWBO*XUJCSI4MKH7AMX8
M[*T;71UX]&G#J//--^EY7+[AE/7?+TMRPW3N4BV56$E&H71<<Q'LUG"S&#:N
MV\@1$D>5.JSE19 U:I)FH0M=M5$\/P3P%+B.<;O,JG@93*4H1V9156I.*;<8
M)J6&SAC)N/0G@NM6.1<//-)*M=2\.S;:6#6W*26.$4T^CI;:Z%H76M3Y%N1I
M(/FB=3&3:O'3=,QZTJ>I$5SIEJ>I2E+4U2EZ.RE*;?V#GM>"IUITX_LQDUJ>
M!K<XJ,W%=";1ABD?(         !''_QG[(W_ !J/E])770C\B"0
M  )JW+AF+3G8JY(!ZK'S$*]1?L':5?M)KHFV[IR_X54%B5J11,VTBB9C%-2I
M:UH+NQOKK+;RG?V4W"ZI34HR74U^E/H:>AIM/0RK0KU;:M&XH/9JP>*?^GWK
MK6@[MX:RI$9@L:-NR.HFW>[*,;@BBJ;YXB;033,[:;:UWS-E.Z450/794Z)R
MUKL-O4I[$X5XCMN)\HIYE0PC5_9J0W*B2VH_5UQ?7%KKQ1V3*LRI9I9QN:>B
M?1);LNM?5UKZ#U8;&9(        +?&^B:]@Y[90 5
M         !:I;T8AV2'[HP JH                          S8[QYMWTO
MU@"2G_OV_>C=N (                           3\!]^X[T7MP!&R/CSG
MOIOJ &$                          +5'>B%^Q==I4 54
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M+"T=Q7Q5>M@]GR17[.*WGCB_(GAHTFX8Z@;2        %OC?1->P<]LH *@
M                           M4MZ,0[)#]T8 54
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MTQAHE+J;V8Z4Y8;7POD_YZX_.7"_[2D]"?1*7D^I=+^Q>4Z_#TZ=0
M   +?&^B:]@Y[90 5                            !:I;T8AV2'[HP J
MH                          S8[QYMWTOU@"2G_OV_>C=N (
M                  3\!]^X[T7MP!&R/CSGOIOJ &$
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M6"\[^EO2_I+*+\N          "WQOHFO8.>V4 %0
M        6J6]&(=DA^Z, *J                          ,V.\>;=]+]8
M DI_[]OWHW;@"                           $_ ??N.]%[< 1LCX\Y[Z
M;Z@!A                          "U1WHA?L77:5 %5
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M84<SM(W5'KT-=<9=:?\ J\JP9Z.,Z7X         !;XWT37L'/;* "H
M                       +5+>C$.R0_=& %5
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M-2XRFE&=*G)1DW.,=+6."VFL='3AT8H^,OR7,,TA*I9P4H1>#;DEIZ>MH0V
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MQ0KT;JA"YMY1G0J14HR3Q336*:?D:.NTZD*L%4IM2IR6*:Z&GUF:*I]@
M   !;XWT37L'/;* "H                            +5+>C$.R0_=& %
M5                          &;'>/-N^E^L 24_\ ?M^]&[< 0
M                    GX#[]QWHO;@"-D?'G/?3?4 ,(
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M6C%Z4E@].EK$UK&D&!          (X_^,_9&_P"-1\OI*ZZ$?D02
M     '6/0JZOU>P9E&;)4UC-I+<LUPZ,I1W5U4ZU9ULPH:E2J0J+FA:T-MH4
MKHRI2[:T/0GI/Y/U,YGDM6-VO_ZB-3^H;QVL=/B*/_QIX?5-R2QTX=+X.E>R
MLIJM_P"&I?U;?3C_ "DO]G'[\?IPWH'7S<         M\;Z)KV#GME !4
M                         %JEO1B'9(?NC "J@
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MK3>G]"2^A+0BIC'EL          1Q_\ &?LC?\:CY?25UT(_(@D
M  #V[ N&I/,U[-H5.BS6W(VJ3^ZI=,O091M#UW6J!S4J3SE)F)5) M=NS[2E
M:5*F8;=P9PK<<59M&U6,;"GA*M-?R8^1?[4^B/VRPPBS+Y+E53-;M4EBJ$=,
MY>1>1?2^A:^H[DPD+%VY$1L#",D8Z(B&:#"/9-R[J3=JW)1-,A=M:F,;93:8
MQJU,<U:F-6M:UJ/7EI:6]C;4[.T@J=M2BHQBNA):%^M]+>EZ3L%&E3H4HT:*
M4:45@DNI(E!<%0        +?&^B:]@Y[90 5
M    !:I;T8AV2'[HP JH                          S8[QYMWTOU@"2G
M_OV_>C=N (                           3\!]^X[T7MP!&R/CSGOIOJ
M&$                          +5'>B%^Q==I4 54
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M]RYM[-6[+']!,U>ZZ]^3TAX$.3.*_AUWZJ7F'N7-O9JW98_H)FKW77OR>D/
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MF?3*6]+K?U=274CU8;&9(          M\;Z)KV#GME !4
M             %JEO1B'9(?NC "J@                         #-CO'F
MW?2_6 )*?^_;]Z-VX @                          !/P'W[CO1>W $;(
M^/.>^F^H 80                          M4=Z(7[%UVE0!50
M                   %T_*P!*
M  "A/_'77?U.VJ ,0                          6^-]$U[!SVR@ J
M                         "U2WHQ#LD/W1@!50
M      !FQWCS;OI?K $E/_?M^]&[< 0                           GX
M#[]QWHO;@"-D?'G/?3?4 ,(                          6J.]$+]BZ[2
MH JH                           "Z?E8 E
M              !0G_CKKOZG;5 &(                          +?&^B
M:]@Y[90 5                            !:I;T8AV2'[HP JH
M                   S8[QYMWTOU@"2G_OV_>C=N (
M          3\!]^X[T7MP!&R/CSGOIOJ &$
M +5'>B%^Q==I4 54                           !=/RL 2@
M                           H3_QUUW]3MJ@#$
M       %OC?1->P<]LH *@                            M4MZ,0[)#]
MT8 54                          9L=X\V[Z7ZP!)3_W[?O1NW $
M                      )^ ^_<=Z+VX C9'QYSWTWU #"
M             %JCO1"_8NNTJ *J                            NGY6
M )0                                    4)_XZZ[^IVU0!B
M                   "WQOHFO8.>V4 %0
M  6J6]&(=DA^Z, *J                          ,V.\>;=]+]8 DI_[]
MOWHW;@"                           $_ ??N.]%[< 1LCX\Y[Z;Z@!A
M                         "U1WHA?L77:5 %5
M        73\K $H                                    *$_\ '77?
MU.VJ ,0                          6^-]$U[!SVR@ J
M               "U2WHQ#LD/W1@!50                         !FQW
MCS;OI?K $E/_ '[?O1NW $                           )^ ^_<=Z+VX
M C9'QYSWTWU #"                          %JCO1"_8NNTJ *J
M                       NGY6 )0
M      4)_P".NN_J=M4 8@                          M\;Z)KV#GME
M!4                            %JEO1B'9(?NC "J@
M           #-CO'FW?2_6 )*?\ OV_>C=N (
M    3\!]^X[T7MP!&R/CSGOIOJ &$                          +5'>B
M%^Q==I4 54                           !=/RL 2@
M                     H3_ ,===_4[:H Q
M  !;XWT37L'/;* "H                            +5+>C$.R0_=& %5
M                          &;'>/-N^E^L 24_P#?M^]&[< 0
M                   GX#[]QWHO;@"-D?'G/?3?4 ,(
M          6J.]$+]BZ[2H JH                           "Z?E8 E
M                                   !1'Q3?C77V3??J?LKUU0!B;A^
MM-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;A
M^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;
MA^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I "W1U*^:JTV5V[CCH;.C])
M_P!@ J.X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;A^M-P:]( -P_
M6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;A^M-P:]( -P
M_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;A^M-P:]( 6
MF5I6L8A2E*UK0R'0I2NW[HP JVX?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:
M;@UZ0 ;A^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]
M:;@UZ0 ;A^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#
M]:;@UZ0 S8XIJ/FVTIOO:?LK_> )&>*:JR&RE:_Y1OHI6O\ YP! [A^M-P:]
M( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;A^M-P:
M]( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;A^M-P
M:]( -P_6FX->D &X?K3<&O2 #</UIN#7I ">@2FHLOMI6G^47Z:5I_YP!'2)
M35?.=A3?>U_97^X 86X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;A
M^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0 ;
MA^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I !N'ZTW!KT@ W#]:;@UZ0
MM,=2M(E>E:5I6I7/0V5V_P""O[ !5MP_6FX->D &X?K3<&O2 #</UIN#7I !
MN'ZTW!KT@ W#]:;@UZ0 ;A^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I
M!N'ZTW!KT@ W#]:;@UZ0 ;A^M-P:]( -P_6FX->D &X?K3<&O2 #</UIN#7I
C !N'ZTW!KT@ W#]:;@UZ0 N>RO\ 97T9L^C]O]G_ &@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>tm2115679d1-bc_vitro4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-bc_vitro4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!E .0 P$1  (1 0,1 ?_$ /,  0 " P # 0$!
M       ("08'"@$$!0(#"P$!  (" P$!              $(!08"! <#"1
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M^52$IO,3$KS6-/+'MH.=BT)RTG0[9/@S!6QVF-NS.VO:&XP
M
M    !\UY>6B.M#K() ZMK$P,3:N>7M[>5R5L:&9H;$IJUR=75R6FD(FYM;D1
M&YQYYV^A1)6FV^^V-<9R BE\83P%_P"_#Q _>6IC\-0$@Z[M.L;>C^LLJ:QH
M':$6V4;I-9+7<OC\UC^RHLLH[=-J\QIP<V[*C0H[3;.GA.]C7?7/9V9P SP
M
M      '^85UOX_;_ %E>J9U$2:).V>ZVZ4?$J28(RCU.<F][_$=)6U;<+&A*
M;BC"MIL\3J8RDA&7IL<H6I(OICM["L%%AVU]!+FCKSJZ6/%ZV'5T\]+$A43U
MHJW=S3"S%_XQJ=+31-6YNF2S3==7"91DAKD&V/I<]QWUSW=.WNX"XH
M
M          !$#J$^\%YP_! Y+?H8FH#_ #8^C;5OR<*8\1W)WZK%C>2O)W6X
M)DC0-GE?R28^]5I+)$-XHJ\2J=O51?/A7<YTQW]MO&MN[V&8[N- %G_R?>#0
M!OZ\'*%SZ3$BMA_Z4T;JLQLLM_G6\C3QMY<W2'MF\*:4I<P2-+^[.B6XB'(^
M-'N2(I\*CR=PP9G))AQJ@/\ 0<
M                                $-.H=RQ9N#'"+DWRQ><H]]J6J>12
M.-HG#7;9"]6$OT*CE81M7C4TG?">46,]M3=MG&V,XPJ[<>;@!P(]%7IL=?V9
M\9YMS&X'<L>*5!P3G.[/JJQR.0\<03*Q;:3P25V!%CGU]3RWB%?:-)'7:0/C
M_L5JF<B-7'51L><3MKL3L GG\E_=K<Z;?45YW=%CDX[,.DSRA9;BA/DXY/J^
M$NL_B,<8%4C60,][9(ZYKDMGTW+V=[*4*VY$;NWQG&-]--\8+R'>,
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ME"7]YL6)K8RK?W(\]ZDK;"IE5B[=(J7;G*DZ-W3I/"Y3D)BB@ZQP
M                        $0.H3[P7G#\$#DM^AB:@/\^'H1<D_D[%3\)7
M6+]4J.4$Z\ES+QGCJ@4V7Q1MRZ)%BL%<?@Y,6*TF$(IR=LQ3;H[)7/)2/*[!
MY&^=]MBM<&:YV#>/"&7\7K7^4S4)+^A5#I9"^)R*KU^O*@QCC,ZA%1/;,G9;
M#3V+(2H5*R$SC%:\>$BJ(HV=$Y-[9IF;$E*$Z4DW<HW(?Z-@
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M<DBN9_:(@A<)0RREED+ZYQK9C;(^Z(T+(O;F=NDKZ4QJS%R7/@LY[,AT+
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MBS-M=N)Z4_5.\*7*=W?:SXD\:.)3=U='8W/X[N:5W._W737.^I?TN-P[:P
M                              'QY#'F"7,#Y%)6QL\GBTG9W./26-2%
ML1/3!(6!Z1'MKRQOC,Y$*6YV9W9N4F)U*90682>29MIOKMKMG&0@Q\4[TLO_
M ):? #]S?CK^KD!)>E^-_'CC>S+HYQWH6EZ%CSFHU5N3%2]70>K69P5:[&[Z
MJ5S7!V)B0JU&NQ^^<;F:;;8SOMYOFY ;H
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M=;+M.,UI)&98JR0G\^)_3C E4.QFA.#E9;<@W.[F"RL;!W,
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MU='-S5.#Y(GYS4;>$5.+BJ5+E6_9DTW?., -[
M                                                 A!=_3AX8\CN
M35&\QKFIORRY'\;?.'\2UB_C#M6/>1GDS)U\S8__ &1BLY8X)(O$I(YGJ?\
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MX**+TU"3X
M
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MMB-?5=S#7M=]=17>1P:K9U-74U=;5B)M[.I9V&_1U7W
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MM\Z>+!94*?7=2T,R@E:B4UXIV-QDO;3.AY?=VSGO8P0V&"0
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MJ8_14G(4EXVP6I)*/+QOC&-L:'::F:XVQC.<8V[NWF^;GS0']@
M                          $1[9]]OQ!];O)7VL0 !+@            !
MKZS(@MF\<;69 J2I#T5@5-+S#5GA?!;HZ^M2&SUQ2Z>!+-W\96H(T:23VXQI
MX8S7O9UU[=L!L$                       &NFR&KD-M3:P3%27=MD]=U?
M#4B+3POCR=;!9+;[VX*E':7@C"5818J;0GN[[;]\@WO8UQW<[#9;%
M                  07YK^F/@U\.BM/T5W8")3H!(              ->.<
M-6+K8A5@Z*TVC?&*\L^&JD.^#?'%*R=R2HGM"K(VQIDG"9$172C0[&VV-L[J
M"^[C.,;=@;#                          &"VC%%<\K.Q8.@4IT2Z9P67
M11$L5X,RD2*Y%'W!H3*56"==SLIR#EF-]^YKG;NXSV8SD!F"%/LD0HTNVV-M
MDR5.GVVU[>[ML23H7G;7M\WLSG7S 'M
M        (CVS[[?B#ZW>2OM8@ "7
M                                 ""_-?TQ\&OAT5I^BN[01*= )
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MH,5IB5.2]<GE)U9J5$:J(+-SG&AFQ).V^N,9SIKG/=P2_N
M                     "(]L^^WX@^MWDK[6(  EP           #Y+\B<G
M)C>&]G>3HX[KFM>C:Y G1(7(]C<%*4TE&[DMSF4>W+S6Y1OJ=J2HTW)-SIW=
M\9USG "NOD0R<K*>@+%+F+F+(7-:YW5QPK0]*[4E2FR0MHNCD)6-/ORXG".,
M)3?/)J99R>J1YVVV*PJ)+\)IN7WM-B-5*"#59>$<E36\R[E#)[$CJ/Q[SQAS
ME5U31Q&[X4-JQ*D\*\QF--[XCRWKSRE6O@3M?";$8TW[2]ML9&JD4"0
M                                          $%^:_ICX-?#HK3]%=V
M B4Z 2                                          ")G/GWBO-/X)
MG(W]#TQ!$ZS?58>YK7GK&B7W@;P2SD
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M2?J0O;E99NF-]-=\:[X[<8SY@A*P@$@
M             B9SY]XKS3^"9R-_0],01.LWU6'N:UYZQHE]X&\$LY
M                               1'MGWV_$'UN\E?:Q  $N
M    $/><GN*Q'X6' [^W!QZ$P)A"
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M\5YI_!,Y&_H>F((G6;ZK#W-:\]8T2^\#>"6<@
M             (CVS[[?B#ZW>2OM8@ "7             "'O.3W%8C\+#@=
M_;@X]"8$PA
M(+\U_3'P:^'16GZ*[L!$IT D
M      $3.?/O%>:?P3.1OZ'IB")UF^JP]S6O/6-$OO W@EG(
M                        "(]L^^WX@^MWDK[6(  EP             A[
MSD]Q6(_"PX'?VX./0F!,(0
M           ""_-?TQ\&OAT5I^BN[ 1*= )
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M-G&FW7V'L/LNTSSOIC<8R\SM%S%5Q7=Q3WNF:=2N*YFVVJJWBQ9K+'QY,]5
M                         !$>V??;\0?6[R5]K$  2X             0
M]YR>XK$?A8<#O[<''H3 F$(
M      5_<R^5G)VEG>/USQ)X$6MS+M:3L.9)ERUGL H?CW!VC#FH:=O+J\+$
M6F$;RK4Q/LI)C[.U.;B>EUQN9LEU-(W,"%D:YE];6NG,AWY%=)*N;&K7)QQK
M^MX>\O(#)+3B30FP6:<X(:RM_$(366MW*SOJ2@;7A$J.WU[-=>WNXV"[2)R$
MN6Q6-2LEID# 3)X^S2$IBEC.JCLJ92WIN3.6C3)8^NUU6L4@;M5."5J,[&#4
MJG3<O?'>UR R   07YK^F/@U\.BM/T5W8")3H!(
M            HJZTOV3C=]1;_P!=6 LC[OO%SMMX7RA7/V^\;-.UB?)U&(L>
MKL" $@(  $C3W(?W +R_,]9GM+>QA-)/^NX_[E?_ %5;,Z.?]AP'WVX^MI;"
MBGI7C?H S_>Y,,E@\ENNCIWH8[&97>])5SI??'9=<$!\W^$2   "!?=T8?2W
M?WHY7OVA+16?W@,KS7T=_P ZZ63]@F29SZ2XWKU=J*\+!
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M7J;L4H.QLH2)^XF(,4&8V6*B4FINQ96-MM4Y&Q^-SM\_2E%:[;[=FNN<@/8
M $%^:_ICX-?#HK3]%=V B4Z 2                                 **
MNM+]DXW?46_]=6 LC[OO%SO_ .KY0KG[?>-FG:Q/DZC+YO\ R"QZNSQ_B  #
M_H^;YP#S_P!'S9_P@/'S=@#3W(?W +R_,]9GM+>QA-)/^NYP^Y7_ -54S.CG
M_8<!]\N/K:6PXIZ5XWZ ,_\ ?_[/3>8,EA,ENNCIYL,=B\KO>DJYTOO#LNN
M   \@/ @7W=&'TMW]Z.5[]H2T5G]X#*\V='?\ZZ63]@F29SZ2XYMXNU%>%@@
M               $,.;7-N'\&8#$["F=*\F[O0RZ8:PU+'^+E,NEUR]I5[,K
MH]^?$A8&IQ;3FJ-X):MB,K-M]M?&C2B^SMWQG <[7/\ ZG#)U!XSQ6H&E^#?
M4PBLJ3=0'A59;E(K?X93B#0)EB->WA'7B4.;U)B'%\U;"4+;G)NQAI.I&A>F
MVQAFFNN<@.O0       $1[9]]OQ!];O)7VL0 !+@    !X[<8\S.<8S_ '<
M'>U_RL?RX!%L'>U_RL?RX M@[VO^5C^7 %L'>U_RL?RX M@[VO\ E8_EP!;"
M'G.3;7%*1'Z;'OL.!W\./^_!QZ$EL)A][7_*Q_+@06P=[7_*Q_+@"V#O:_Y6
M/Y< 6P=[7_*Q_+@"V#O:_P"5C^7 %L'>U_RL?RX MAY^?\X$@
M                       J5ZX]S6'0'3,Y VI65XK..C\P.%1(W:UF M =
M/F2"R*Y8#'+$1502YZ[(S[8>X.ZKTD>+SDK<QQ-+U+/2&9T5D!41TFK_ .+-
M@<U:TCU8]7+JY\K)JX1NP5*&B.6T0L%JI=]*305Z5N*N4.#U4D78]'2,(R]U
MJ#_M'7&Z].7@OPF<XUV#KA   !!?FOZ8^#7PZ*T_17=H(E.@$@
M                      "BKK2_9.-WU%O_ %U8"R/N^\7.VWA?*%<_;[QL
MT[6)\G48BQZNP( 2 @  2-/<AO< O+\SUF>TMZ&$TD_Z[C_N5_\ 55,SHY_V
M' ??;CZVEL**>E>-^@#/][DPR6$R6ZZ.GFPQV,RN]Z2KG2^^.RZX(  $@ "!
M?=T8?2W?WHY7OVA+16?W@,KS9T=_SKI9/V"9)G/I+CFWJ[45X6"
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MN0=\O.S.Z>5DK]4D@_WTY?\ 4IP']O3W,;D$WEY.S.Z\>5DK]4L@_P!]./\
MM(=XI[F-R#OMYV9W7GRME?JDD'^^G+_J58#^WI[F-R";R\G9G==#?3$7KG+C
M4<H<%JM<HQ8,K+\,L4G*C<::HV+.FGA3]S-^YKWLYQCM[,=H\ZTHIBC.=D19
M_P 4?&W',DS."B9U^%.^L6& 9<                                 4
M:]<6XZSSQMD_%Z?2^V^.3O8Y=1V77_,DGA[<')>@*8F-67I$K!:S94\UA'I
MAB\\2[5[G='ATRC3I-5I"TPPQ.6?I@-5],.U.55TW'$92_\ 76X5]0>GT4?D
M)LLH^D:)I*!V<Y*5$?7)F)U=U$/ERN:PLQD>=R%ZA,H:TWARB\Z;::%[XR Z
M'@   07YK^F/@U\.BM/T5W8")3H!(
M  HJZTOV3C=]1;_UU8"R/N^\7.VWA?*%<_;[KYIVL3Y.HQ%CU=@0 D  0 D:
M>Y#^X!>7YGK,]I;V,)I)_P!=Q_W*_P#JJV9T<_[#@/OMQ];2V%%/2O&_0!G^
M]R89+!Y+=='3O0QV,RN]Z2KG2^^.SL.N!\(  ;8  @7V]&'TMW]Z.5[]H2T5
MG]X#*\U]'?\ .NEDO8)DF<^DN-Z]7;"O"P8               "$G/R^H'1G
M'V5Z67";@E,,M-CF-5O+[5G'>P.2[3 ")3"9"GS*[6K^MF:12/%;EXQDA6;E
M$<F--.+3&9U\/KD!SF]-R>\FG0OCM1U+_*/.%%NUS4"BMJ^(X[/?$^LZ]OQ\
MJR!*F9DTK'$>L:31ZZ$#QF(-^K(2Y*VLYS*-[AJC<Y5C??<.PT!3QU&J+J@N
M_.GQR%WAC6KN<_GKQWK9+/G#=:X/+/!LQ^WGI9&H]JL5G(8ZWNKF26<OP@)3
M;N&Y!&5.QW@">Y/P.,]GX4$^3$VK>%TU\H4J.W7J.DWM;=A*5]70=T7(DT]M
M2(6IPLX[UCQE1ULRJ3-'F8:'6>PN;"W:MNA_@GY(J)QC0[&XE'9?&N"3QRO>
M._R@"E[TD\>*Y'VU&M]*JA[XZMY5@6HW6EP#IVF>.J&N6I2;JZRT]XY#L3VS
M-&C=H?DB08-TUQH=G/:WB=E_>YI=!:XH;KWU%R,D$9.Y#V@7&5,2CCPL0Z3&
MXX_8/3\XWT]1J>M&11G1XFOCMZQJ0,B$MM)/SK("U!>N,';;=H[+#;"DS' >
M&_73H2[)/'T?+"SYF<GKR'O[PW_C$LM]MOA9QOK?C,ZP%C4J#7N3$N=S1Y8W
M-)B L_!+LVJN[G3<HW;46ZDQ*ZM\8K);>7?"%3)Y>V+& BD[K95D2\F-]7TF
M?(HG7F7^3J9MY0G%+T"\KL)U;\-A>2S-,G>,[XW\'KQ<HM6& D   !S2=2CW
MV4S] (1[5VX>F:)^B/ZDM,SYET\F$"QLC#@    #2'(/TA,OYY..W]H"LQC\
MYY/3TU'.=G"91&U.\W>,ALSMR^%?'G;D!Q     '1?TN?>RG?G$EOVFP#S'2
MSTM/0Q\;<\QY#'*G?60#768                                 %7G6
M5Y(VKQ0Z>-SW+1UF1^F;;;Y10\1A%K3**M,N@4"76/R!J^ ND@L-"_I5S(U0
M-/')&MT=7500HRU)#-U1!"E440G-#EZNR2\ZJ'Y>5Q8)?5!Z5%TWSIQHY0<D
M&F[8?PBXWK9A%$-'U\7(IK$[5LZ&8*GE?U7;T4<G% AD>KSG5P6(CB,H=3=2
MC,!VA\1KF=^1O%'C%R%D$?)B;_?''JEKF>XJGPJPGC+O:%;QJ;N4?(PMW,6X
M)9EKYNFU\-ML;W2\=_.=NW(".ES=1.!5AR_X]\-8[7\]L*<6]:*>NK%G#>QO
M;/5=%[N])69=<00R:>K60^/2*R)RQUR::VQAO/V5Z-7C#@L.2%EI"E\V(MU;
M&N[?Y[\AD/**T^-/%WB76]_'4LS5.784NL/EVS<==R;"MMB>YDTUW&(RYTO8
MZB5+VN")6QT5*"5>F=='D@OP..[W]R+9MLAM[F(<O4N' I0ZH2FQS/YM50<X
MMI"S#B2WKS:CNC=8A)<,)TN%Y211ML7J=@HO!N->]W->WLQ"4]@2
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MEE%Z:X\S&NFFN,8Q_!C V&FF*:8IIU*8BR&O55355-54VU3-LOZCD@^;_"(
M2  (%]W1A]+5_>CE>_:$M%9_> RO-G1W_.NED_8)DF<^DN.;>+M17A8(
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M!9Z6P9.MAI3NV0N2N+S*D"A2F='!HW<2"S<X*W)UWVT$.78MUUMX)
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M?LO&WZBW_KJP%D?=]XN=MO"^4*Y^WWC9IVL3Y.HQ%CU=@0 D  0 D
M"  ! OMZ,/I;O[T<KW[0EHK/[P&5YKZ._P"==+)>P3),Y])<;UZNV%>%@P
M             $.N<$GON+THZ&4=Q<:>821\U=XM;=)?CG2T?.'RK)%''AMD
M*JLY,[,RZ//,N(V.++PU+'!BRJ3G&;)W I2646:'&\DX1=(F0..8-$ODL'6,
M46MWL)-&Z:N7(.NJ;RYY,+)R7OR"?^;9D)T:<''Z?Z]X')7@^^9V8U+VS@.N
MWIF<;VSBEP]KRG&?C1%>'[:V.TXD"3CQ$;SFO)!%794MF#Q(=$3I<4\[7:52
M9PU7X5N>$VQK8B6'F)D1QZ8DL\P)\@     "(]L^^WX@^MWDK[6(  EP
M YI.I1[[*9^@$(]J[</3-$_1']26F9\RZ>3"!8V1AP    !I#D'Z0F7\\G';
M^T!68Q^<\GIZ:CG.SA,HC:G>;O&0V9VY?"OCSMR X@    #HOZ7'O93_ .*Q
M);_?_P!28!YCI9Z6GHH^-NF8\ACE3OK(!KK+@
M         "+?,WEM6_![CM.>1]I-$XE$?B"B+,C5!ZQCADPLNQ)Q/I8RP. 5
M]7\7+4),O<LF,QD2)"E*V.)*TV.R8:865IOOJ$!>/76OH[D7SHE/"^,4S=[&
MSH[4NN@*^Y)/S*TZ4Y9_(/C?"FZP[NI]H-2N1[VRR2(PY6>X$;+"==%Z5$=M
MC!6>YKN%R#BF.5IRRB-TA>^BYK4[;+46R\G)*)S2+%.FA&JI'DM6:G(WU3G=
M_.$Q^=#LZ&XT\'N'O  ""_-?TQ\&OAT5I^BN[ 1*= )
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MW5Q:'+!R3)Z?1E?VY2C,<-E'@M Z%@       1'MGWV_$'UN\E?:Q  $N
M  '-'U*/?9S3T A'M7;AZ7HIZ+LV.'+3,^9=/)A P;*PX     TAR#](3+^>
M3CM_: K,8_.>3T]-1SG9PF41M3O-WC(;,[<OA7QYVY <0    !T7]+CWLI_\
M5B2W'_H3!D>8Z6>EIZ*/C;IF/(8Y4[ZR :ZRX
M          HMZTUI;R&MS^'SUP,ZC7):*6?'X79B*\N!T5C:QYI>PZ[LU++(
M"X,TO?G0K5@LB*2J#H'8K39$I(,1G::&8VT-WT 5M=)&E8+%>4W$V._L ]8B
MIRJ&BO)601VVN:,:AC=4*N^KV2R)WMSD1:KE'''!KG=4\B"C,)9U!28HA.T'
M:IS=3S]]E0#KW   !!?FOZ8^#7PZ*T_17=@(E.@$@
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M$     =%_2Y][*?_ !6)+?M)@R/,=+/2T]%'QMSS'D,<J=]9 -=9@
M                          5L=71BY-23@!>;3Q++LA5:IOD"H=6FE7O2
M-WC(*@0V/$UMZQRDG\S;7SJMA]I\AZ2LAA>?&]E9FNB3_6]R '/1T:M>1"WF
M12\/H>@^I3Q^XL4S;//MVO0KF/'YK!*TD5$7 DV<^,\)7)+%>7A\L7DM$K,;
M&U2XJ]35)C*U^-%ZJ#"UAV=@[/@   07YK^F/@U\.BM/T5W8")3H!(
M                           HJZTOV3C=]1;_ -=6 LC[OO%SO_ZOE"N?
MM]XV:=K$^3J,OF^;S!8]79X$ ) 1J!\WT?HB0^;YO, /F_Z?^@0'S?-Y@D
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MUL1Y\$3IS5N&$I6_BY6NYFIF0Z3P   07YK^F/@U\.BM/T5W:")3H!(
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M]O1A]+5_>CE>_:$M%9O> RO-G1W_ #KI9/V"9)G/I+CFWB[85X6"
M        :_MG6-;U79>DS2O"Z'[U_,M96BCVJ_=_61K:..6'U*QZ-1A3IL\*
M&O)NB;";;51D[.O@\XW[,@.33@S$^K85R!J]7T_DG.&L^FV7+F4ZP&'K1RR
MO[PJK@AZ;]W9HXZP9*QOO*^)I3(IHH\F]G=Z3M6?"D>,]N,Y\7#L+
M!$>V??;\0?6[R5]K$  2X     <T?4H]]E-/0"$>U=N'IFBGHFW9[Y+3,^9=
M/)A P;(PX    $Q;%@#C%,1K35\Z?THL!RB+)MC72      #HOZ7/O93_P".
MQ);V_P!"8!YCI9Z6GH8^-N>8\ACE3OK(!KK,
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M:7[)QN_\W;_UU8"R/N^\7.VWA?*%<_;[QLT[6)\G48BQZNP( 2    'S9_\
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M_O?ZDP#S'2STM/11\;<\QY#'*G?60C768
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MX5UT4_((*_N"E6Q^$1N3DT'.B0G?.A1I.NV^F839K? M\!R
M !!BP/\ Q+>)7P&.H?\ I]Z7X(V4YP2                HJZTOV3C=]1;_
M -=6 LC[OO%SMMX7RA7/V^\;-.UB?)U&(L?LJ[             @!(  "^WH
MP^EN_O1RO?M"6BLWO 97FSH[_G72R?L$R3.?27&]>KMA7A8(
M   !CLOEL:@,3E$[F;RACD/A4=>Y;*Y"YF^ ;6&-1QM4O#Z\N!W9MX%"UM:,
MT\W;LSW2],Y 4D5A\H?X%7+-8##JVAG,F3)[/ET:B4(G)'$:VDE>/69<^(V)
M@DN)2X-:0A%$5AB\I1LN4%E8)29R8;KIW=M<!>R       "(]L^^WX@^MWDK
M[6(  EP     YH^I1[[.:>@$(]J[</2]%?1?P<.6F9\R[_QA P;*PX
M        .B[I<>]E/_.)+.S^A, \QTL]+3T4?&W3,>0QRIWUD(UUEP
M                          !2GUI[JXSK^+MY<7K%Y<5[Q/N%%6M.<I&:
MRI]4LKMY)4D*A/+JEH?'+A3Q9D:3DCBY%6XX-;$V>#4Y6(75R(6;D;I2#<@*
M^.EAU"Y]?O,>N*KD'7AX\\[$#M'9XI4<>8%P(=*(ETT-9(2\N9;TFL@V/-:%
MFUBYR3#HH)UR7JK+3[$ZZ_3XU =68   (+\U_3'P:^'16GZ*[L!$IT D
M          $&+ _\2WB5\!CJ'_I]Z7X(V4YP2                HJZTOV3
MC=]1;_UU8"R/N^\7.VWA?*%<_;[QLT[6)\G48_-\X6.5V  2'S?.$!\WS@U
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MLIWYQ);]IL \QTL]+3T,?&W3,>0QRIWUD UUEP
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M)@'F.EGI:>ACXVZ9CR&.5.^L@&NLN
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M<?!]0    !15UI?LG&[ZBW_KJP%D?=]XN=MO"^4*Y^WW7S3M8GR=1B+'J[
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MXDM[?Z$P?]0\QTL]+3T,?&W3,>0QRIWUD UUEP
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M*#])7$(=.OTA=]#>\ZZ=BG):^DHWKQ(@=QUP       '8O6?N;U]ZR(I]X4
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M'=<1!TBYM:/#*Z3/CG,$LX=ED\KXQ*R+2D&$Y.^Y2!N6D&M^=DV4^V0ZT0
M     1'MGWV_$'UN\E?:Q  $N     '-'U*/?933T A'M7;AZ9HIJ9JL^7+3
M,^9=/)A P;(PX              .B[I<>]E/_CL26_:3!@>8Z6>EIZ*/C;GF
M/(8Y4[ZR$:ZS              B-$??X\@_@C<//TR<Y@1LI<@D
M        4#<ZJ"ZD49ZG5>\Z>#-!<>[^94? R1\297';UMDVMT[8XR>_$5L+
MG=K)1MRY:N,*;(VD28SGL)W*7'Z[>;KV9#!^BE3W5TX8U;QOX2<E>-/&./\
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MN     '-'U*/?933T A'M7;AZ9HIZ)^'ODM,SYET\F$#!LC#@
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M8\SO:XV[,^9MC&<8SCMQ]'&,^:/)=6*IIG7AZQ3/"IBJ-:7] 2
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M(  EP     YH^I1[[.:>@$(]J[:/2]%?1<<N=]IF?,N_\80,&RL.
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MAF^F8<NQV5OX)     '(!=ONSV[^<^?>VMV'KV"R*YZ*GFPT#$Y3><NK?EK
M=I\                 !V+UG[F]?>LB*?>% /'L3E-YRZM^7H-Q_!HY,;S-
MQ\'U     %%76E^R<;O_ #=O_75>+(^[[Q<[;>%\H5S]OO&S3M8GR=1B+'*[
M  )D       $ )     !?=T8?2W?WHY7OVA+16;W@,KS7T=_SKI9/V"9)G/I
M+C>O5VHKPL$                          "(]L^^WX@^MWDK[6(  EP
M   YH^I1[[*:>@$(]J[</3-%-7--O\R6F9\RZ>3"!@V1AP
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M.EG/T;B.@O.;+NYL])8?I[OG0[=R/GX^H_S2A^=T\:=J-^I^@T?XW(>T#D
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M>2OM8@ "7     #FCZE'OLIIZ 0CVKMP]+T4U<U6_+EIF?,NGDP@8-E8<
M           '1?TN/>RG_G$EO9_0F#_K'F.EGI:>BCXVZ9CR&.5.^L@&NLN
M   UY;GN5V7^;^8^U]>,EF;TQ@_O=S]92Q>?/0N,^ZWOU=3BAW_G;?W1^AG[
M57+JYTOS^_9IY%'-A^0             !D40]-D7]<3)]\DPZ6<_1N(Z"\YL
MN[FSTEA^GN^=#MW(^?CZC_-*'YW3QIVHWZGZ#1_C<A[0.0
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MN\E?:Q  $N     '-)U*/?93/T A'M7;AZ9HGZ(_J2TS/F73R80+&R,.
M          #HOZ7'O93_ ,XDM[/Z$P?]8\QTL]+3T4?&W3,>0QRIWUD UUEP
M   &O+<]RNR_S?S'VOKQDLS>F,'][N?K*6+SYZ%QGW6]^KJ<4._\[;^Z/T,_
M:JY=7.E^?W[-/(HYL/R              ,BB'ILB_KB9/ODF'2SGZ-Q'07G-
MEW<V>DL/T]WSH=NY'S\?4?YI0_.Z>-.U&_4_0:/\;D/:!R
M!!?FOZ8^#7PZ*T_17=@(3H!(     Y +M]V>W?SGS[VUNP]>P617/14\V&@8
MG*;SEU;\M8#M/@          :@   &H   [%ZS]S>OO61%/O"@'CV)RF\Y=6
M_+T&X_@T<F-YFX^#Z@    "BKK2_9.-WU%O_ %U8"R/N^\7.^WA?*%<_;[KY
MIVL3Y.HQ%CU=C_$( 2 !_>^;S1 "0$  "0$  "0 ! OMZ,/I:O[T<KW[0EHK
M/[P&5YLZ._YUTLG[!,DSGTEQS;Q=L*\+!
MB/;/OM^(/K=Y*^UB  )<     .:3J4>^RF?H!"/:NW#TS1/T1_4EIF?,NGDP
M@6-D8<              '1?TN?>RG?G$EOVFP#S'2STM/0Q\;=,QY#'*G?60
M#767    :[MWW*K,_-_,O:^O&2S-Z8P?WNY^MI8O/GH7&?=;WZNIQ1;_ ,[(
M_0V>-5RJM^7Y_P ZU/(IYL/R(0             ,BB'ILB_KB9/ODF'2SGZ-
MQ'07G-EW<V>DL/T]WSH=NY'S\?4?YI0_.Z>-.U&_4_0:/\;D/:!R
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MNYL])8?I[OG0[=R/GX^H_P TH?G=/&G:C?J?H-'^-R'M Y
M @OS7],?!KX=%:?HKNT$2G0"0    !R 7;[L]N_G/GWMK=AZ]@LBN>BIYL-
MQ.47G+JWY:P':?                  =B]9^YO7WK(BGWA0#Q[$Y3><NK?E
MZ#<?P:.3&\S<?!]0    !15UI?LG&[ZBW_KJP%D?=]UL[;>%\H5S]OO&S3M8
MGR=1B+':BNP "=0  0 G4  $ &H  &H  )U  7V]&'TMW]Z.5[]H2T5F]X#*
M\U]'?\ZZ63]@F29SZ2XWKU=L*\+!                           B/;/O
MM^(/K=Y*^UB  )<     .:3J4>^RF?H!"/:NW#TS1/T1_4EIF?,NGDP@6-D8
M<              '1?TN/>RG_P =B2W/_H3!@>8Z6>EIZ*/C;IF/(8Y4[ZR
M:ZRX   #7=N^Y39GYOIE[7EXR69O3&#^]W'UM+%Y\]"XS[K>_5U.*+?^=D?H
M;/&JY56_+\_YUJ>13S8?D0@             9%$/39%_7$R??),.EG/T;B.@
MO.;+NYL])8?I[OG0[=R/GX^H_P TH?G=/&G:C?J?H-'^-R'M Y
M   "K:^^IL14,_OQHA/&BV;TJ?ATCCR_F;=D&D-=,S+193S#T-GO*%GA\PDC
M+,;@>J_J%U12E_31].=XHW+22"-U3CDQ$5-CC-7^C9W+QZ:9(JX!R)@<4;PQ
M/_-6I'IE=F\\M2@=&ETJ"YUS:XH5)6=BE"-:C/T-*WUSG7?3;&<>9D0E/L$@
M    #D NWW9[=_.?/O;6[#U[!9'<]%3S8:!B<IO.75ORU@.T^
M       [%ZS]S>OO61%/O"@'CV)RF\Y=6_+T&X_@T<F-YFX^#Z@    "BKK2
M_9.-WU%O_75@+(^[[Q<[;>%\H5S]ONOFG:Q/DZC+YOX__L%CU=C_ !?XOG /
M !_T //T?F_@R ?P@/'S?-]$0 D   ^;_"( 2'S=@ (%]O1A]+=_>CE>_:$M
M%9_> RO-G1W_ #KI9/V"9)G/I+CFWJ[85X6"
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M^GO-U,9NP,__ !TOM./1;XGJ;.A\I;W2Z6RMF:"V,PRVJ_VA^2JW::3:2O\
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M7UE;$^G;Z:]X5H]4Z54TRFEZZ;T[48AV4;[J-%IIVANA>F"=M=]MRQJMZ D
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M8MJU[)L13X'\@)]<7-3@]R$Y,OL<W>;4Z5O(Z!P*U,MJ6$PNY)- >8]=X?+
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M[>NQP2G[?Z0]N,LZ;NFJ/;;LSA'H5KC7777&NJ4TQ9,VZ]D?&Z'1#F
M                          B)97 WB1;]O(;VL:EF"368D/B2I8['NLH1
M,DJ60!9E? E]AP9K?4,#LUP@RW.#651(FQT.:M]=,I=BNYIV3:6)=B
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M(;&W)Y>8[$G25E(]7YPC#"[R-P5HD!JC=*E4KU!I1>NYYFVQ++0
M           &AKQXL<9>3B>.).1_'FDK[30Y<<YQ,BY*MA-E%QE>J\!A6I8=
M9BR/&&DQ=JE+U4> [F#]"]=3.]KC& 1,1.N]RWN-/'7D#!F>L;VH>G;DKB/+
MVUTC\"M"MH?.X>PN3,A4-C2O98Y)F=R:&I8VM:LU*08G)+W*3&[E:YP7OMKD
M61.NVK'8['X@P,<4B;&SQB+1EH;8_&XU'FQ$RL$?869&2W-#(R,[:0F;FIH:
MF].60F3$%EDD$EZZ::ZZZXQ@E75Q'Z5O$_C#&&(YYIZB[>O!FG5D3?;D9(:$
MK]NM-8;,.1<RY%0Y)F1+"9-(R%%7/LB0)VM7ASV-T.9$BLK"?<LDH@B*8C;3
M5>:%HR1L$EBLAI>IWZ+S.=(;1F$;>:ZA[HP2RS&MS8WILL62LZYG/;GV=-SS
M&&U60[JBS7 E2WIC=#<;D%;:"R&5M,!@K#+)=/6*%1)EG-@$1M+/9HTQQG;I
M9-TT.2+D$03RZ1HT9+Q)"(JA<U)+;HM..U0E*#="<::F;8R2RT
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MET-5G+CU!AAKE'FJ(3(]K;6XS.4Z! E1D%8U+2E:X6EB>0A(
M
M
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MVE'G<F\H-H\G<U2]R(8\NWAO%-%!YQ^J?N8,WWVQG;(9
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M.3_*"NB'^4UTJ0/4_P"63;YUV*T34INJIJ4.,/94_FLB=":VK4V_FJE:S'F
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MR%2]EGRFTO/>*N,JDTT>GHU2[>-HG1K)RY+#MS"#"\Z%:!:&
M                                      (S<Q^)]7\Y.--J\4[H42I+
M6%PM+2S2U1"79&Q2DM&S29DEB/+0[+VI[1HSLNC 1C?;=*=C8K.VN,8SG&V
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MSO"V^0DHC<JN_D+R:L,BT+QLY3"(_P"2L":Y/+$,?BC6<QP5@,.3-:<AN(\
M6I-QMMOWL=T-D<1N&U1\*XM;,0IY3,%+5<W(.UN2TOVF3RA>U9=BW&XH7.6D
M,YR%G9M$4;+4MY?B:;?0XTG7MQL<9V]N C-R!Z0W%/DH^\Y)#8CC;)"_J"U[
M159WOB.2]F;$Z2.<>%B%= =X"6JB;CM'G(XYO+\\#5.R_11KVXTT*[>W ;!G
MO32XZV+>4SY!R!;9&D\G?3XD732>R6^3-:9@TXZR>7K)LY+4+>;'%"DBR-7E
M=O@ISV4;I=2>S7*/;..]D/DPGI<<:H#).G!*6)=9V[GTMJ]MFM.-&J^4M*A*
MOCMS52S4[+][.*+C)&\I<BHDQ$;(S4FS9H2LSL9MH9KG!> C,V=!'AK':NX,
MU=#K!Y1P4KIV?M-*^,<[A5O-<;L:-O\ RGD1DMF\G?)&WP@M._.D:DF2U+,1
MLE*;-BRO%7-(YHC5"8X-A0WHJ\0(;4E%526]WC)3Z0Y\P_J8*K4F%A-K];MU
M\NX<:Z[E6%><K-B9*&6DOY+I@EQ3($+3@XI*1@O8G.N^Q@8^\]#;B!(_VSV2
M0S;DB[5=S?MY[Y%V%2NUJ-K97%;\DY#+HI.7+D+2)K##6F?PBUMY'#$.^BM2
M^N:,M+J8CU2X1&[I\AD$1Z,?&IJ@?*R-V5:_*'D=8O,FGMN/UR\CN0%I,$RO
MK\3!3>J0MU=PI^98#%83#8ZUG+3%FI:1@QNK7YU/6;*MRR\Z!9E4E:1VEZIK
M*G8?NY&Q*IZ]A=:1<QY4E+7<R.P2-ML69-W580F1D*W+=L:BLGFZ$E:&&][;
M&FN,]W ;"
M
G                                                !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>tm2115679d1-bc_fluency4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-bc_fluency4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!C@.0 P$1  (1 0,1 ?_$ 0P  0 " @(# 0$
M       ("08'!0H! P0""P$!  $% 0$!              $"! 4&!P,("1
M  8" 0$# PD0"0X&#@H#  ,$!08' 0(("1$2$R$4%? Q0946%U<8.%%A<8&1
MH2*V-W?7N-@967FQP2-SM#5UMPK1X?$RTM,DE-15=I:7F$(S)5AX.7*"1+75
M)C;&UB='AZ<H4K)C@\,T5$7G:(@:.A$!  $" P0"" \+" 8(!04   $" Q$$
M!2$Q$@9!85%Q@2(R$Q8'D;'!T8*2LM(S4Y,4%355H4)28G(CLS1T-A?APD-S
M5)2T"/#3)'4F&*)C@\.$)58WHT1DI&;4Y*7E=O_:  P# 0 "$0,1 #\ [_
M
M
M                              .%DDC8H?'7Z6REV0L,9BS*Z2.1/CF?
MHE;65B9$)[F[NS@J,S@M,A;F]*8<:9MY-"],YSY, /Y%<AY*<JY'S+EW])":
M&!X/IZ+]3>+0=MP9@_#F<R%19?(6:I5YI'FJ?5C0<;V!MB:Y3X^F-MW,DO;<
MK<XO.X?UPH%-XQ9L&A=DPEU3OL,L&)QV;Q%[2;8W2O,8EC.C?F!U3;XSG&R=
MQ:EY1VF<9\NN^ &6
M                                K ZUO_5']1K_ *(%X?:2Z .A#THN
MDUT'^5/"*N[NYS]3#;C;R-D#]8J*7U)IS)X=U#NQ-,<F[XRQ1;K7]N5M))\W
M[/L:0IE>-U"HS17D[Q2-=2M]-<!<+_19I1;4-YX=1;BO2%[V)R@Z7M-M;F74
M-M2@YS<X>GLA#8L?;*^*A2M3IZ#9UDUKM;(CW0MHU2HG?#,E78(U+RG[ [S
M
M       .N'_2F>:^>(O2CM&&QUWU;[,Y=NR/C1%"R%6NB\J(2I$M=KE=?,]=
M]%)[296#0O9#C=,XU3JWY+G;M[V--PZTD2Z0O](>6=*[XA;/4/$_'%"<(T-W
M'Q)P>HZGO@^3N+^U6ZWK%#T;X;LWV D5H$C5YMCN=U&3Z/,[Q>3.^'8B_HG?
M-$SDYTO&"EI4Z&*K1X4S!QHI]1KS-?3.:W6>-*J<<U*7Q=S$S6ACZU7&$>-]
M"=NR+&8SKG.N3-P[.H
M                                 *P.M;_U1_4:_P"B!>'VDN@#H_='
M.E/Z,7,^!582#J6O-2(^7:J2685/$\LO_E# GO5D2S]_3P7*F,UE9$=AZ,O:
M'EH\E[ITA9AQ?9N;G8S;;;(2NZ#D]KRO>OSR*XW]*BR;.L'I7NM6R.7RQFDS
MG*GJ"M3LSP>%EE36/9E)"%QPJ070LQ'VIW6IRW)P95!A6YBPG4M5N']!(
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MU[P9R
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MU173;KJIBY5CA$S$3.&_"-\X=.#[!YO0
M
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M%@R#0]<J-;TC4W,:+P=3CEF^GG0=X8
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MK48^*F:*Z*HI\;75=PG@FB9JCPHB.&G&)XMMGPXZZ\
M
M                                                "G#D)5SXQ]6+
MIUVJ\V]9DM(F+MRMCD9K%R<FMLJNLXZS\87)4I+C448&ILR]2:0/OBK%SX]G
MN;GX>Q:1,8F1E8(S/0CIQ0#:61O<N*^_/IS:2"N;I/5S?(L19>^BO6=^YYMZ
MDR[B6UTCYSL?E;M6Y_'%&2V8CW\6]W;"W!&%/8>"GHQG?CZKC*_1^%QBX>\\
MRF0G7FK:G6"1P.R+.P4MQ.'Z&6/U$;%XQV+3#L?E1E5M74*H9)LSH6(WO-S,
M7'TZK0G50FR=D1NQZ<?57I/[K82CG)4C6]0R-M=?H*4Y"F1"8H9RK=I%)%9S
MQQIW=$SS"#(6UI(N2WJS#BR32WERRIT+UWSH5G?.FD*TS %>O.#F>_<938Q%
MH;$4+U*Y6V*'HI[D>5F8VU(4CAHCRGU0(#4:IY<%&=#._IJJ382ZY+WSXGB=
MW&PZ)HMO4XJNWJYIM43AA&&,SAV9W1W)QV[L&)U+4:LEPT6Z8FY5&.,[H]?T
M8P96TF]0%W:FUV(=N)A1#HWHW$DI4SVX4I**6IBE)9:@K"K;!9^FAN,;Z]N>
MS;&<=H\J_)^BN:)C-XQ,QOM]#TI^E:HBJ)L83'8J<AYGU!_\]<1/:NW?\H%/
M%R]^#F_1MIPU7LV/0J/-.H/_ )XXAY^BV6_^TH#BY>_!SGHVS#5>SE_0K1 O
MGA!RWY#S9LGTUG5$M;TSLB%B;B8JNLAN;TJ= O7N1*H@EQ8WA0G7[J7#;.^Y
M9NFN>YIGNXVQG.<OD-<TG3[$Y>Q;OS1-4S/%P3.V(CHF-FQC\UIN?S=V+MRJ
MU%41ALXNWV)2_+2]0<O333TEP_W[FNNN-C$-RYWV[N,8[=]L*L9SMGL[<Y]G
M(Q&/+V.[.>C;9##5HZ<O_P!-[/#ZA&/^ZN&^_P#V2.Z\?_56",>7NQG/1MF&
MK=G+_P#3.SJ%8_X7#3?_ .[NXO\ _$-#_A[_ .M_^$G_ ,U_^G_Z:*%[\SN4
M_'N0LD-E"'C%+IH^&H=2(C $]M.+RC3N>QI:!:Y&/BQB:49*Q07@LLOSK91M
MDS7;!7AYSOC8M#Y:TG79KFW?N9:Q13,\=^JBFB<)B)IIFFFN9JVX[HC")VX[
M)P6M:]G]%HIJFQ.9NU5Q3P6*9JKC&)GBF*JJ(BG9AOF<9C9AMCZD_++J$XVU
M\ZX=:F:]N.]J1'98GVSCV>S;>4*\:_4R+ZOD[EVGP=8R,]J]'JVX8ZCF[5ZO
M"TG4*8Z[/K7)9DW<O>96F-<.O!N4J]O^%E"YO#;KGZ&#V-WSK]7(L;G*>DT_
M!ZKDI_[6B?3JI7MOF?.U>'IV=CMVJ_4B6R67EO=YQ7?DG".Z6O;7'V6K&N2/
M_;CV<ZZK6:.F9SV>QC&?HC$7]"R=J<*,_EJH_*I_FU5,M9U>_>C&<K?IGKIJ
MCW5,-62KJDP>$/:^-RJC;A87]KV*T<69U(C3<YH]CTY*LC"A$M>4YY?CI3]#
M-.W'9L7OKMCMQG&1EM/Y+M9^B*XU#+6Z:MTU4W)I]&BFN-_:8O/\T9K(S,1I
M]^],=%%=N)]"NJB?0Q9E".H+M92$QQ@'&2]9@C(SC"@V/%PISRESMMMKKJK*
M32?<Y+G;;3.,8,UU[>SR#(WO-[DLM/#?UW2J)G\*J['IVV(M\^9^]&-K0M5J
MCJIM3_WC./C=V#[/##D[]*/QC/\ YQ#Q\A=+_P#4&C^WN>\>GEOJGV!J_M+?
MOSXWD^QZ_#'E#]*-QK;_ ,XP\A=,_P#4&C?*7/\ 5GEQJ?V!K'M+?OWCXW\Z
MQ_;<,N4W_:Q2.;?L20/(33?_ %!HORES_5GEQJ73H.L?)V_]8?'#F6/[?AIR
MNQ_V$)8#/V)-@/(/(=&OZ)\M7_JSRZS_ $Z#K7R5'^L>,\RI*7CM.X<\N=,>
MSG6NV,S_ ,Z]0\@,I/@Z_H7R]?\ JSR\S4;]"USY"C_6/GWYNJ2/*JXD<PRL
M8]?N56RF]GU)GIVBN/-W15X&N:#/_B:X_P"Z43YP:Z?#T378_P##T3_WKY?C
M[Q\K/8MXS\PF_P";LHI=,;KC_$9<KV[/I"O^&6:J^#UC0:NUFYCT[4*?XDY:
MGX32-=H[>5B?2N2^TKGW5W9VKZPY(,WS?2=)2;7N_-QME'NLQY!YU>;'6?Z+
M.:3<_)S=OU<%=/G*T?\ I,GJMO\ *RESU,7J/ZB_&9OSC#ZYV#&L=O9MO(*L
MG3>67^^&99C--,8^?D33YJ>;[OZM1E;WY&9LU8]KOT5>=/E*U^L5YJU'X^7O
M4X=OO&1-O4"X>NFNF2;NCR;;?&,^&Y-DF;-M>WV-]ES(05KG_MA:WO-?SY9G
MOM.NS'XM5NKTJYE=6O.;R->CO=0M1/XU-RGTZ(?7$.=W%N<3U=7C%:+3AU1I
MS%!#NZZ&LL4=LDZ%F'IVF2.FJ5M5*2M3/)KG;3Q.[MX>=^S(\\_YM><].TRG
M5<SDJ_$53A--.%=RG'=-5NG&J(GLX3ALQP5Y'SC<G:CJ56EY;.4>.IC&*JN]
MMU8;XIN584S,=S';ABE>VNC8\HRG!H<4+J@/QG)*YM5IUR,[&/7R4I2F&DF8
MQ\[;(TF]9O9>Y-J_151=C?%43$QW)PENEJ]9OT1=L54UVYW33,3$]V-C[AYO
M0
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M#:="YHT+F2U-W2,Q1<JI\*CP;E'Y5$X51V,<,)Z)END:^SX
M                                                        ^!4Z
MM:)6VMZUR0)%[R>H3,Z)4L3IU;LI2(SW%4G;4QIFARX],WI33S-"M=]M"2]M
M\XQKKG.)BFJ8F8B<(W]2)F(F(G?(Y.K6SIM5CNY(&I)LJ1(M53DL3H4VRUR5
MDH&])J>J,**RJ7KE)9))?;WS33-=-<9VVQC**:JIPIB9DF8C;.R'WB$@
M                               (V37Y5O'S[SW);[8>.8"28
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M=L.EVKMN];IO6:J:[5<1--43$Q,3MB8F-DQ,;8F-[ZQ0K
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MLT56[5-%7A1&W;,_=G;Z+: \7H
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M&K6.2^7,MS!5S/9R\1J]6,\7%5A%54<-5448\,551,Q,X=,SOF92+&J-I
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M=*JN_.;%,U=_3PQ71%44S71,3.-,3-/A13/?1,1OPED-(;J
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M<SE[/Z1EXM9J_&%4\556%,SQ333%4S%-,SA,Q&&Z.B(PD.-5;0
M                           *_.G-]S3D7^L#Z@?XVMJB94T[N[*P,0J
M       8Y$XDP0=B2QJ,(<MK*C4NBM,CRJ6+<EJ'EV7/;EOYPO4*E6_G#FXG
M&=FV^<:=_NZXQKC77 9&                                 QTR*,)L
MM1SDQ#G:4((ZY11*Y>=+,8+879R:G=>A\RP?A!OD]P94QGB[%9.U\/NZ[8UV
MVQD,B                   !&R:_*MX^?>>Y+?;#QS 23
M        '&/3.VR%G=6!Y2%KVA[;EK2Z(C>]@I6WN*8Q(L3&9TVUWQH<G-VU
MSG&<9QV^3.,BJBNJW7%RB<*Z9B8GKA353%=,T5;:9C"41>%SLYLD1F] R8\X
M^4\=IHOA/G"G;;<]S@SL8H?:\>_+C&"DRYC.W)3EX_M$Z73M[.WLQF-:HIKO
M4:A:^"S-$5=JJ-E<=R=L]<K#3JIIMU96OP[-6';IG;3/H)FC"LB
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MF'3Z_%7X_"^+NQV:;M,8X],Q,[IA+,:0W4
M           5^=.;[FG(O]8'U _QM;5$RIIW=V5@8A4
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M3=IF8F)V3$Q.$Q,=F)=)MW*+MNF[:F*K=41,3&Z8F,8F.J8?4*%8
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MR;J-7%G]*N1315.^YEJ^^L5QVJ>\F(V4Q%,3.*<HYPZ(
M             *]F'FK,Y#U#L\-3*%E\-K5-QYN&VDEWSW9*Q9L.6539E(P5
MS:JWB>%ISRHK]N2VSWS']Q(2$NBK775NU-3DFGF$8[<.A$[BAU83.0!,^LB1
MS'A@UU7"H)?MNJJNK^\WZ9\LVZIZ?D$D;VV4O=:[QI!&==UK,T(E;J6G<3,-
M1KFG3FYU.WUTS."(GT'Z<^J=;E%0$BR>6M$06*M=I\,[#YCT!%ZKL!]D4D4G
MUX=5!#AQOL=7(HHU-Y%FK=[SC&$[XW:99S33'#3)&FB(LY6P,<-[,IGU%+RX
M\YNRM^1]+5DOY!Q.L^/=DTG&Z9L"4+(!:RODW>^W&&$U\[R*8PU [11XA=X+
MFI&].6B1:0I9W8EP3)M-RSD>A.*4W'CDI8SW87(&B^3K#6$#M3CXQUM8;G*J
MZE#RKJR8U%;#9*3HW-DF\V0-#Y$53'(Z_D+0Z)%IB@K7+86L+4>$JP21!CT2
MPWII.C8]U'?KNS.*%W:7+GUS]6MSHV*TZ]N<$:CEC:AJ=6A6I3#4RM*>7MC;
M0PO;;3;7/;C.<"913N[LK$A"H              &H[OIF+7W7[E6TT5R F-.
MQI9SDB89$^QTEZT3DJ-2F>29C[DTK'Z**3SM=US4:?JD<="\$J-=R=M]-O?+
M9BO*W8O6\...S$3AUQCCA/8G?'0\KUFF_;FW7CPSV)F/1PWQV8Z6J*2XA0:D
M.._Q=(Y*;!)C*R/H6IS<62;R^/K&UR,C[4UREQK8S$A<W2JV^4O2%2[[-[4M
MU(1+W)3NGVT[_;CWS.?N9G-?.ZZ:./'IB)QVS,<6S"K"-F,QMB(Q>5G*46<O
M\WIFKAP[,QT;<-O>X[\(G?,OEXI<-*VXCHYFCKI:]Z)YK+IQ)E[1H\20N*%%
M2>?R:7L.A<4=9&_M>DCBD=?4L=R\DX(5N;6T(_.L;&%]HG/:A>S\TS=PQIIB
M,<(QV4Q$[8B-DS$U8;HF9P1E<I;RL3%O';,STX;9F8V8SMB)PQZ8B,4O18+L
M                                         4$V)P;XD7?U.X)6]=T+
M5<-2\8FJ/<V^5=@Q6+MB.;SNV;.F4L0\9ZH6R(@WSY T.[Y!I9-Y5IC30]=J
MU,B?._FBY7H9..Q1A$U-",]=NO&J]V3FM?7'SA;?40O[J4.L!B=[P"PI-8/)
M> '7YR<=:9XW/[8\'Q5-6QK-52$^/,+W&V]9NM;/-5JHM6:JT,;=74;MNS>N
M@?9%-UO.FJ(\ZUV8R0EGI/D&=&+"VE;&XES!4K=^-)SBCTBR3'IMARU*3C2<
MF*L]T_P>]IY-L"%::(                       .,>V=!(69W8'4GSAK?&
MQ>SN2?MSKXZ!S2FHEA/>QY=?%3G[:]OL=HJHKJMUQ<HV54S$QVXVJ:J8KIFB
MKP9C#T41^#;HM25 Y52]F>))*)GLRJQVWSXF-E*=H>E2YD7::F:ZYU2GM3@6
M63G'DV+)QMCUQE]<IIG.1FZ/@[]NFN.[&$QZ,;5AIE4QEYL5>':KFF>Y.S[B
M98PS(@                " O*?7:E;=IGED@U+)9&E<53MU]G>TP?7,S<2M
M620*-M-M-,ZPV0F['9[_ 'L[X.TU[<8U\O3N2YCF'0M0Y(NXSF*Z9S64ZK]J
MF>.B/ZVB,-F["9Z7-><HG0-;R'.MK",O15&5S?78NU1P5S_55S,[=^,1T)\Z
M[:[ZZ[:[8VUVQC;7;7.,Z[:YQVXVUSCMQG&<9\F1S&8F)PG>Z5$X[8W-!\H.
M1]>\1Z+G'(6U"9$H@5?>YGT\3$VU*[O^_NKF$?A#7Y@W+'%J3*.Z\R5/DWO*
M"^X1C?;'>SKC7.<Y;Y?S_-.M6=!TR;<9Z_Q\/',TT]Y;JN3C,15,=[1.&R=N
M$+W3LA?U3.49'+</CJ\<.*<([VF:IQG">B)Z%1'_ /L?=/C_ #-R(_V;QC\(
M8ZI_R_\ /?X>0^5K_P!4VCR"USLV/;S[UFU?_P!( X*V3(2XS'6F^='(Q(J6
MZ[.-?QU,F\%)KKL;VFE3Q3OW\XWQV8[OE%QEO\NW/^;NQ9M5Z?QS$[[U?1_V
M3F7G;US)>9;D^OG?G"*ZM&HS%JS,9>(N7..[,Q3A35-N,-DXSQ;.Q+>OYWGB
ME_F^VO\ 5!F_]+!DO^6'SD?AZ9\O<_U+Y6_YW?,U\5K7]VM?_J6^^.O.RD^3
MTV=(#6Z6<$/C1%ELO5[R5A;VM!EI0.S(RGZE*$CXY&;J\K'\C.NF2\:YTQMG
MO8SC&,Z7SUYG.;?-[I-O6M>JR<Y.[F:;$>*N55U<=5%RY&,3;HCAX;=6,X[\
M-FW9TGS7?YBN0/.YK][EOE6C4*=1L9.O,U3?LT6Z/%T7+5J<*J;MR9JXKU&$
M81&&,X[,)F<.4N\                     "'$MX\S5_P"=-7<FT+S&D<$A
M/$;D%03HWG'KS9EM,K8M;CS.8X\-C28QJ(\LCC<TU,XZ+-U"XL_52<FTT3'%
M[FF$A"I1P:Y3<@%5*U[RT/XULE7\>(/R#BK38G'Y3(TEAW.ONVC+!XUE*W*L
M'"KH9 J)C9-=V6N>W5F:7:1I5,H1M_FV2$:3'B3VE.$SO:TEG3/Y/\H*W::Y
MY63"D(H;27"*S>)U%S&G'J=R];+K)L-=3*O'(VQ&*50R!D0HEI^+W']RHB@5
MONOB.;IILZ[::)=]AA,[^PSFQ^!?*KE NNFZ+W=J$JSD&JJ[C#!./3!5$KL*
MR:MCDFXO<CTW+=!-9_(9;7M>20U'95PL;.WJ6U"U';L\=;MLZJ5JI3M@H83.
MU+*@..5HNME\F+WY<QJEC)9R*A]74YM3M>O+[:]:L%*U0WSDQ(QR23V! :\.
MG;O-91:<@5N)1D=1H2$)J9'C"C)9IYL)P[+'^F)'8_$:7O.+Q-B9HQ&8_P \
M^?+0PQV/-B)E8F1J0<K[33H6QH:&TA,WMK>C3Z:Z%$DEZ%EZ8QC7&,8$RBG=
MW96."%0       " G'SC30LYJY!+9C540DLG?99:"YY?7EN\^<W)7M:,R+R>
ML5GF;FG&8++UUQG.?)KKC&/)C (PANGXGO%_X#J]]HRO[H#".P?$]XO_  '5
M[[1E?W0&$=@^)[Q?^ ZO?:,K^Z PCL'Q/>+_ ,!U>^T97]T!A'8/B>\7_@.K
MWVC*_N@,([!\3WB_\!U>^T97]T!A'8/B>\7_ (#J]]HRO[H#".P?$]XO_ =7
MOM&5_= 81V#XGO%_X#J]]HRO[H#".P?$]XO_  '5[[1E?W0&$=@^)[Q?^ ZO
M?:,K^Z PCL'Q/>+_ ,!U>^T97]T!A'8<#QKB4<@<VY3P^'M"6/19ENR*X9V%
MNQN4V-FKCQTHUU7Z($NV^Q:4M6YK3E!FNF,:['&[[YQWMLYR2E@
M                         -41&CZN@EHV]=$5BVC79M\8K_2UY1EW?UYT
MJ*JV/JXO B/1KDZK&5C31YD7GE:%-J9&6<8>8<=@P[?8S)&$;V@6/IY\2XY;
M*6Y6FNY"3)&ZS)%=3-$U%O7.XTG';EENR\V2VS%^.SC8*NA8S8[PL=E:LUX0
M1Q.M](K%*W4S58I//,8F$8XMA37Y5O'S[SW);[8>.8)23
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MWE;&2MYS1LY>BQ8C"U:BO/Y"K@HCL4X]B(F<9B*8V1V(Q\-/U
M       $/.856<O[CC45@_%+D]$^)!2]P<S;0ML^FVRZK13LA)*+T,Q5.PRY
M[;:Z8G!W/W5:N#J[I'4Q&3J5E(F\;;)I84T61PTY <,YW0>$O7EY[H[BY+W
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M2Z'*=]-<;'FZ)4Y9>-MLYS@LO77UM<8P'O
M           1LFORK>/GWGN2WVP\<P$DP                        $*>
M3.F\)N3BG<J;[ M)9IM/2/.#=B]3&2V&U0VHCE>.SP]D34Z(_'SG;/V)N=.S
MYN,WIGY_)YO)3OFUXR.W;G&?1C8QN=_-YBQF(_#X)[56S[DIK#",D
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MAK-<F]@)T<.F$M@VVS*ZO<G4QS"E:[1O51CQT^^NJ<S.G9W\8R!&,K/P2
M                                                  (V37Y5O'S[
MSW);[8>.8"28                        "*_-6(GR[C19^$&?">(FTD6&
MRJ]>]XR)? ER:4&GILZ=N<*#&QM4$Z_OOTQE=%O19U.UQ>!7/!,=F*XX?3F%
MCJ-N;F3KP\*F.*/8[6^:^E1,Z@<*FR?4O0B7Q..R8HLK;.Y96KZT)'/!6FV<
MYSG!7G7=\N>WR>7RBPS%J;&8KL3OHKFGT)P75JY%VU3<C=53$^C&++QXO0
M               1)YM0!WFM"OK[%-MB9[4#JT77 5!9>332I)7!ICUL443J
M688H/6LN%A!)6O9WSS"\9SV=N,[QYO-3L:?S-;RV=VZ9GZ*LI>C='B[\<&V>
MB(KX9F>BF):3YP=,OZARW<S.2V:ED:Z<W9G?/C+$\>$1TS-'%$1TS,(%=7^P
M&JUNC-=ED,N2_1TUC''J0E$EFX.\R-<+_ITY8VFF8QKVJ6M;DQ,;C.,9U-*V
MQG&,X&V^;'2[^B^>+*Z3F,?&Y>]FZ)F8PQBG+7XBKM51A5'5,.E>;34[.LY[
M3M5R_P %F+-5<1CCA-5FN9IGKIG&F>N)=-9WX>SFD:'J#EK>#&VGU1<_G^:D
MB;8_Z'O<X=$&RHQ,7+<MF^IL2B&Z5'LK4[EGY<U)&=$Q.J8T[=4C^KK7-F3U
MG6\WRMHM=4:IE,/'UU4X4VZ9PQ\7CX=S&>&,8X(G&J9JB(IK[E;U2QF\Y=TW
M*U3\YLX<<S&RF)[&.^>CL1OG'#"9<],NH+<Y'O?+^X-U#>9%:ZH9E03I_4&M
MZ$J.(#K A<S9VJ-Q1!A+KZ.:X+3SSA"@0DD(DQ:$E+IX.#"M0U+F#1^4M=T'
M3JJ:YS69SU=-FB,9\9<KL7;$37<G'":KV9M<==4S5WU5<XX2^6_\ZV@U\P>8
M'4]$RE=-NNFNUFZZJL9X<ODKE.8S5S\>NFU35531C%5RK9CC.,20E$H(<B$T
M?CZ4YHAK2=N<VMAN^FZUP6[%X)/D,A/*QKHN?5Q>OL?N*0K/@D8U+QG.W:=.
MT^O+UU9W.U1=U2[&%=<>#33CC%NU$^#;I]M7/?US-6[\"M7U>WF[=&FZ;158
MT*S5,V[<S$U5UX83>O3&RN]7'L;=/YNW$4Q.-FG1N^4Y.OO#R?\ G!J\?/W^
M:C_V^R?^^;7^&S;ZU_R*?^[FH_\ ^<S'^-T]V5Q\"/U>
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M,;&M<BCBYR:%Y>,Y\NQ1V^ &:  "-DU^5;Q\^\]R6^V'CF DF
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M9       !7YTYON:<B_U@?4#_&UM43*FG=W96!B%0       "O/I5?(2IO\
MER\/Q@;4!$;EA@)
M !PLD?"(S'7Z2*D3LY)H\RNCXH;F%M4O+ZO(:4)Z\U$RLZ+0Q8ZNRHM/DM,F
M*UR:>=MKIKC.VV '1/LCJ>]-GG-R,Y4K^;7,_J4OG%QEL9GBU-\-:RK^]*BH
M*<5OK6T"<WLFX6>DJU9K6D9RZ<[.)/F4D>D:HO3&3]"LD&IM]0["W1FX;T54
M5::<RJ%HB9<+6;F[1M#267\)%C^\OD*J640Q+,-TTK0G21J9'Q5+I@P2I-HN
M5FH6["I,D3F[)M#MS<Y"[0  1LFORK>/GWGN2WVP\<P$DP
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M-_RY=_XP-J B-RPP$@
M    U_;$6EDYJRRX3 K!<*EG4PK^91:%VJTLK;)'6LI9((XY-,<L%LCKSMHS
MOSA#'A62Y$HE><)E1B;!1N<:;; .HI><[D%.\V[7HB?==>^NG'-Y"NK4O#K<
M/3PHRN:3Y&2=CIJMXS(KAB')9ZTU@DWU?W%M[5JA^=6]0WK?%;D^FZ1$7M@.
MV/QY9WU@HNI&:3W3\8Z0-U?QA,[7WZ.CK3BX%FK4GR;8>C;$E"N+HRY5V^=Z
MZ-YIB3&IN/"VSIV9 ;D  $;)K\JWCY]Y[DM]L/',!),
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M7+P_&!M0$1N6& D
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MEU-(/+U-*,US_P#1W+WQG'T1AIB:9FF=\,A$Q,8QN>\0D
M   $#.-7_JEY#<DN.1^^Q+(O=&_D%5J<W0[7)D;GN=44X1HO$VV+U;8_+R2B
M"]=,Y[QAINV>S.<XQTOF[_SSE;2.;*8QS%-%62S$QA\)9VV9G\:NU,S./1$0
MYORG_P"2\T:MRK5LR]5=.=R\3C\'>V7HC\6B[$1&'3,RGF.:.D
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MW*P,0J        5Y]*KY"5-_RY>'XP-J B-RPP$@
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M>3:L9O9FQ&8R\?\ 7Y>>*::8PG;<HV3U4X.;<[S]"ZMI7.%.$6<M?G+YB?\
MJ,Q'#%54XQLMUX3$=FK%/;&<9QC.,]N,^7&<>7&<9]G YFZ2
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MNV,AD:\U1<KJJIPV3$8;:HCU5UD]6N9K,TV*J*8BK';MZ(F?46TC4F=
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MK\X+]S=$7FI3NXJW,D@IQ5'JC&)A#8DU^5;Q\^\]R6^V'CF"4DP
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M+S%]3WO8^[I9'2?K"W[+W,NSN.8MS
M          &K[N@#Y;%+V]5D8L245#);*J^?P"/6Q"#CDTTK!\F44=HZTV)$
M%"=8W'IY1"E[B6Y-^^B@C?16F+S@S3.,;8#HKV/T+NH-PCEU.6E'.-E"=3+:
MH^:]!<N9QRFB4JGC5U![!A=)SM%,)164LBG(.R9?"'%OF;8@+()1P]:>K4*B
M=-E)"G.=LY#O24?:!EUT_6]M'5Y9%2GV'#V25J*PN&.:Q"TX"I=T9:E3$K B
M^JQPPP2QC/VV3K4OCF>"=IMKWL]@#:@  C9-?E6\?/O/<EOMAXY@))@
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M[/E@U-^]S_\ FTF(PO,7U/>]A[NED=)^L+?LO<R[.XYBW,
M                                 !&R:_*MX^?>>Y+?;#QS 23
M                      !398]+VM0_+Z-\II!*FZ15[)KD:8SE06M<3I&Q
ML-@(W%@T0.K:I;M&Q*RLB<_*,O<I5OKY2-M=-,[;8+W++9W*9_2*M*MT33F*
M;,U=&$S1A.,3CCC.&.V.RUZ]EK^5U",]75$V9N1'7$5;.UA&[?V%R8TUL(
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M]7U $V>G9Y.853?O4^^M6<Q&%YB^I[WL?=TLCI/UA;]E[F79W',6Y@
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MM,R6R&R6VM:=J%M1$%-R!ORL>$9:]40<<I7&'!VXP       5^=.;[FG(O\
M6!]0/\;6U1,J:=T]N5@8A4 *;.KS_$='?RK.OX'&1N7*/AW^U3_.:]KVZUVY
M]12!_4_9_LC=NTUU^_5ZP*7X\O[/J^N)5/UC^O\ 7SY1"F48>''R=(+_ "C8
M7\YDQ%EIWZG1[+W4KG-?K$]STH2=^;]#L_9^N+U;OUGZ (?G'L?3R"93:Z=G
MRP:F_>Y__-I,1A>8OJ>][#W=+(Z3]86_9>YEV=QS%N8
M                              "-DU^5;Q\^\]R6^V'CF DF
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MU>M]40)L].SR<P:F_>I]_-I,1A>8OJ>][#W=+(Z3]86_9>YEV=QS%N8
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M9BYCJG_"/.=K78[W0]6X<OF-T4V\Q'P%V=VRJ,:*IQPCOJIVX+"!RUTX
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M;73K^6#4W[W/OYM)B,+S%]3WO8>[I9'2?K"W[+W,NSN.8MS
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M !]2M)B,+S#]3WO8>[I9'2?U^W[+W,NSN.8MS
M                      %8M<=,",5)9<YLRON7O-F.JK/NERO:QXNGL>J3
MXQ.IB[.J5>M0RC=72)\J=8UAL0$,Y"4QT\1&R)RD:8THLHONSBIX<.F64,73
M.HUBG<>?M)Q=KE5,+O9YY-0/BV[S-A5\=81>SW)G:=G3V/Q[2'$3[.C78S\M
MDC6R+)(KC;.^J/.T+<GW*(P4Q.&&_P":_*MX^?>>Y+?;#QS$*DDP
M                     !!U'MM2G,M>@,,RG@O*>/9=4.#-=L)45NP-&20L
M2DFXT\(G,AC6-CML;[=XY7G7&N?6U&<G#.Z-%7]/E:L)Z[=4^I5]QC8_V;4)
MC^COQC[*GUX^ZG$,&R0                     @SRG@4L@\FCW+FG&HUSL
M"M&PYGLB'H^]I[Z50GG:GO#4=H7G'C/<5SC*]#OV;;Y\+LSJ;L404.C\EZGD
M=1R=WD;7ZXHTO.5Q78NS_P#+YJ(PIJCL47/ KC=M^]XJI<[YRTW.Z=F[7.^A
M437J>4HFF_:C_P"8RTSC53/9KM^'1._9TS%,)7UQ8<3MB#QRPX.ZDO$8E#?H
MX-BTKMQMC'?W(5(U16?LTS@W+23$Z@G;&-R3RM]-L=N,C2=6TK/:)J-W2M1H
MFWG+-?#5$^C$Q/335$Q53,;)B8F&Z:5JF2UK3[6J:=7%S)WJ>*F8]"8F.BJF
M<::HG;$Q,2S<8YD               5Q=6B#<6I5T^^4$KY>T,P\B:EI>FK2
MN3: NB8@M\U?H?7$LT1N<"E&4YSC7DZRA<E*1#(4.2UC3YWN=IMC&-L9#KX\
M.^/UB]/Z]^ -]<C.G[T>V"K.6EI5Y1%.2CAY!Y?CE%QNL:XZVDKU5CRLGUCZ
MKF2U$*QD93VZ5NS0JROT.5FKD9QJ'!FIP=RL       %?G3F^YIR+_6!]0/\
M;6U1,J:=W=E8&(5 "FSJ\_Q'1W\JSK^!QD;ERCX=_M4_SFO:]NM=NKU%(/8-
MVQ:YB\_V/6]7K AX[/G?2#%.)C^OZW];U@'GL^=] ,3%X_L?U@'GU_5V?UP0
M\=G9]+M_LAO3O39Z=?RP:F_>Y_\ 7K28^L,+S%]3WO8>[I9'2?K"W[+W,NSP
M.8MS                                                1LFORK>/
MGWGN2WVP\<P$DP                             !&[E15CO9]6*#(>9N
MFLNNW=NLVKUQ&A.Z@J:Q#8Q<WH2\'8P7MAY)\1)C7?."O%-TWW[<:=@R6E9J
MC*YK"]MRUR)HKC\6K9,]S>L\]8JO6/S?PU$\5/;CU]S.:.M9INNK8C8K5C0G
M9\;2\/#;KWL;LLC1_P""R!E-U,SDW79M="C"]<[]FVY>-=_6VP/#/92O)9JO
M+5_>SLGLQ.Z>[#URU^G,V*;U/3&V.Q/3'HH9T]CF[\;F7XLG+G[QVJN59U\7
M+%[D\L9A2[,&Q%O!QY[LXX.U2^<=S_"-=/$\Z[-LX[<SG/H3Z(H^;8?/L*>S
MQ8[.+BZ,-^'1V&.R_P!)?/ZO'8_-MO8PPZ,/].VLD&MLP
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MS.N^V---M\ZEZYW,VQKC.W=TTU[=M]\]GDQCRYR ZWM(\KN2E*MCE;W,A?U
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M509,+"<LZF9QIG5-L65V?8=N9Q0N]$)
M       1LFORK>/GWGN2WVP\<P$DP
M0!<3<\1[[.>SM]DW'?D0^]CP9]EANK&YE>V-M'51OMG!+?')QIG?!VW]H6HU
M[VV2RR=<&9^F/I?(>+C;J.7IV=FNWV.N:?2ZY8J9^89KBG]4O3M_%K[/:J3\
MUVUWUUWTVUWTWUQMKMKG&VNVNV.W7;7;';C.N<9[<9P, RK]
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M!!FAQ!Y!VF#"CB32\[%FE&E[8VUVUSG&V,]N/(,!,3$X3LF&5B8F,8W/:(
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M2M"LT*.WUP87MC;&-L_- 6!@       K\Z<WW-.1?ZP/J!_C:VJ)E33N[LK
MQ"H 4V=7G^(Z._E:<_P.,C<N4?#O]JG^<U[7MUKMU>HI"]?^Q\_UQNS7-QY,
M>K'L@@[?H>KV 3@=F/5^P",3.?5Z_L>OY ,#L]7[?SP#R8^O\S^J!M/7^9ZO
M8!.Y-GIV?+"J;][GW\VDQ&%YB^I[WL?=TLCI/Z_;]E[F79W',6Y@
M"O7B)\J_JG_]*JD_Q">)8F184(
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M)MS;NQ%NN;<VIKB8GCCAG#&*)B(XHC"<9C;-,I\CF3I0
M     K\Z<WW-.1?ZP/J!_C:VJ)E33NGMRL#$*@!39U>?XCH[^59U_ XR-RY1
M\._VJ?5:]KVZUVZO44@=N>WU>R-V:[@_7U/)]'Z'T@4OSVY];Z7L=@*MC]=O
M;\SRY^?] $/&>WU>KYH&P[?K8_9^E\X#!Y\OSOJ?-_8 V/&,^KZ &";73L^6
M#4W[W/\ ^;28^S[.!A>8OJ>][#W=+(Z3]86_9>YEV=QS%N8         KUXB
M_*OZI_\ TJJ3_$)XEB9%A0@                                    1
MLFORK>/GWGN2WVP\<P$DP                                    &)R
M.!0:8:8+EL+B<ITQGMQI(XXSO>F,]G=[<:N:-5C&>[Y/H#UMYB_9^!KKH[4S
M'I2HKM6KGPE--7;B)]-756O3%KJ+6=)I;.7I%8,)6^E?<U!%#$:T$MVSFKP>
M08YKDCMG"C+,E[Q).I!9.IFV<&9[G=\/.QYGF?,W<K39L4S;OQAC5CCCA'1C
M'3OVX^JQ%G1;-%^JY=F*[<XX4X8;^[T)"'\"N)"G.<F4TTZ]O_Z>0S1+CZ6$
MLE)QCZ0QT:]J\;KT^A3[U=3I>0G^CCT9]=\&>GWQ'QC]RJDY/GV,IK!L\CL^
MAKI-,:?6%7E!J_3=Q]A1[U'T5D.BC#V57KO1MT_.+GKE0V1IOG$638F,8^AX
MLG-SY!/E!JGX=,^PH]ZCZ*R7X-7MJO7:VB'%3@]83M(&*"R!?)7B*GX3R!N8
M;@ERY4V;Y,V)[QQ9;\9G<C!^FQ>3=.^7@W7.F=N]C.!<WM5US+T4W+],4T5[
MIFW3&/W'E;R.F7JIIM3Q54[\*YV?=; ST^>.7L()]K_V-ES']MTR+?R@U'LV
M_:4^L]?HK)]BOVT^N\?F^N.^/6(L37Z%F2[]MPR'E!J/_5^TI]8^BLI^/[:?
M7<<[\ J*2M+HI:45BKG1.W+3VU#O:,K)+6KRDQIB-)N;LX8P5HI4:ZZ9VSG&
M-<;=HJHU_/37$5S:BB9C&>"G=V=R*M*RT4S-/'-6'X4M1=-N17[HCGE<V7$'
MUG@D+,VVC2Z2-*]K7M4@<GI>L=HP0M="M5\B(_PDQ1L888>8B[NFFV_<.*UQ
M><R6]/QMYC+5TU7Z_"BF8F)B(B(JV;(['1CM[$K?1Z\UA79O4S%JG=C&Z9G;
M&W?ZBTL:LS8                               "OSIS?<TY%_K ^H'^-
MK:HF5-.[NRL#$*@!39U>?XCH[^5IS_ XR-RY1\._VJ?YS7M>W6NW5ZBD+Z6?
MZOE]D;LUP^F"#ZOJ];ZH).SZ7J]7D /K]N00=GJS[()Q/I^7Z0(.SZ/]0$IL
M].SY8-3?O<^_FTF/E&%YA^I[WL/=TLCI/UA;]E[F79W',6Y@  T1R1O5LXXU
M.]6L[L"Z3(69>R(#&AM5IT*L_9[=$S669HH5%FDZZD;J<;[8SCMSC'9@;+RE
MRW>YLUNWHEB[39N7*:ZN*J)F(X*9JW1A.W#!KG-?,=GE71;FM7[55ZW;JHCA
MIF(F>.J*=\[-F.*M?\\Q7OP)S/\ UG9/\A'6_P" .J?:.7^3K]\Y/_'G2_L_
M,?*4>L?GF*]^!.9_ZSLG^0A_ '5/M'+_ "=?OC^/.E_9^8^4H]8_/,5[\"<S
M_P!9V3_(0_@#JGVCE_DZ_?'\>=+^S\Q\I1ZQ^>8KWX$YG_K.R?Y"'\ =4^T;
M'R=?OC^/.E_9^8^4H]9"KC5U9(+&N1G4,D1U0RQ4387(BJ)$D3%2)G+,;26K
MAWQOAVZ91OLCSJ<8<HC>Y^-M<8QC0W&OKXSD8_*>9+4<YF\UE*<_8IJRMVFW
M,^+J[[BM6[N,;=F$7(CMQ,K_ #?GJT[*97*YJK(WYIS5JJN(XZ>]BF[<M83L
MVXS;F>U,)J_GF*]^!.9_ZSLG^0C(?P!U3[1R_P G7[Y8?QYTO[/S'RE'K'YY
MBO?@3F?^L[)_D(?P!U3[1R_R=?OC^/.E_9^8^4H]8_/,5[\"<S_UG9/\A#^
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M&(:O>\:Y\[4QR/R&12U[:&HS;_BR%3FM.TQ_;&[ EEP
M C9-?E6\?/O/<EOMAXY@))@
M    #U'DEJ2#DYV,[%'E&$FZXVVUSL6;IG3?&-M<XVUSG7;/EQG&<"8G"<8W
MDQC&"%_&_A'!^-L_E\_CTJD<@62-J5Q]N0.I2(A.RL:YT;WA2F--38R8ZK<J
MVHC&I^V"<:EZYQX>=ML[#,ZEK=_4LO1E[E%-,4SC,QCMF(F.Y&V=C'9/3;63
MNU7:*JIF8PV]$8X]W<FJ,*R(
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M !&RF/NP\N/ONP/\7BG1K.B_7.K_ +9:_P 'EVQZS]4:3^R7?\7F$DQLS7
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M-*E_4QMODCFH<D;:G4[:;Z3BC#:W7-?E6\?/O/<EOMAXYB$I)@
M
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M(" $B-E,?=AY<??=@?XO%.C6=%^N=8_;+7^#R[8]9^J-)_9+O^+S"28V9K@
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M[.WN]_;7M[.T![M=M=M<;:YQMKMC&VNVN<9UVUSCMQG&<>3.,X >0
M      !ZS3BB-,F'FEDEXVTUR8;OJ7IC8S?4LO7.^^<:XV,,WQKKCV=LXQCR
MY >P  ?.0L2*=U!:94G4&)#O-U99!Y1NZ4_N:[^ HU+VVV(.[F^,]W;LV[,X
MSV "=8D5^-YHJ3JO-SS$RCS<\H[P%)79@U.=X>VWA'EYS]EIMV;8]G #Z
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MVCXAYK_>C4OV_,?IJWZ8<B?N/HW^ZLI_A[;8 P#:P
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M0$Y_T/DW_>5:,OR_]?9']LL_I*6O<V_NIJ?^[\S^AK43#[F?F*
M"\FION5UI][^&_:XVCXAYK_>C4OV_,?IJWZ8<B?N/HW^ZLI_A[;8 P#:P
M                       :ZL*IJ_M0V 'SU@]/&U=8K#;,%V]*O37Z#L",
MHG=N8W_NLSDW:N?F2-^5Z>:K,*$1OB]IA.^VNF=0CY=7 3BOR"F3[.[/@,B7
M/DS8&>)68DBEMW'6L3N>(Q_<[9FB5[0.M9_$H/>47;R5)J;1!+&]X2Y0'G(M
MM,HSSB#",(E):75W Y[ )%54SB$=DM:RV*.4%DL%=VE&KBSU#7AK-9'.,KV4
MPKS$YE6-!^Z;=/W/#\'/=QC& 2T'4'";CI1C;9+? 8M+]U-N1EGA$]D\YN*Y
M;5G[M!8TUO3+$X*BLBT)_,)]'87#FZ1N&K.UMKDC1-9JY0>F+*4'FF[D81#>
M=75G!J6K.O*=K%@)BE;53!XI6]?QA,K<5Y$=A4(8D$:B[&4O=UC@[+M&ID;"
M",'JE!ZDWN=\TS??.VV2=VQG8               (\G\4>/2Q%R0;'.L&5\:
M>73OA\Y%LTB6/<C9+-<M:XBU28,<65]='!K9T_O?0IL093MA*%/G*7"C.GG6
MYIVY&$.%HCAS0/'&0R*95K'9>KG4IC['#W>P;4MVX+XL/,(C)RE3'8&VSV\9
MW8DN9(*S*U9AY+.B6)V["G?)^Q.QV<F 1$0XN_\ @YQGY.R1/+K@@[^Z2'$-
M.K5\<8?:=M55M/JP/=C7XVK;63U3.84DMNL<O*E0IUCTF+=6@LQ8K[B?7"Q5
M@X3$2^"Y^!7%R^GM#(I[ Y @=D]>IJA=#ZPM>WJ1(FM/(U2Q:CJ&S$%,SN!-
M]H56C/<EG@1^0E.34GT7K"RB-"UBK4X3$2E7'H\PQ)@8XI%F9KCD8C+.V1Z.
M1YC0)FME86%E1$-K0S,[8B*)1MS6UMZ8LA.03IH425IKIKKC7&, ES
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M=XO?;7/;C.<"FO-YJY3-%RY<JHGHFJ9CT)E-.7L43Q444Q5V8C!GOYO?B_\
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MWK7,"X9=%:T+.>Z:@,<CLFLEAWE!:F-H;LY%Z>DC8*[E1Z>%19W56.G89J=
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M:\IS<-9995EV6IV6$I]4NFR5PLR72]P;2/!TQVDIC22=MOLLZ9VSG();<
M
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M;#!83ZHY'W:CRX)=?/6:S8C5]9.*)Q)WW*QJL6EXWQC??4$;=F/9=KT0K
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MRK*X93F)]2N3<@7MZUWY)2.Q5Q6QNA>JQL-;S-=?)C.71*=\Q+LB"%8
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M[5I=#-JB<8P@V>5<J4KW!Q6;D;(STR3)I*D.X.
M                       U-=]*0+D+7+A5=F(E[A#W20P&3JTK:Y*6A7L[
M5I8$7LV*&Z+D>VI^A2:60]":;IC/=.*TV+V^QWR VR                 U
M*92<!-O9)R-W0K\VBBJ5QI-.Y8<U6&S6 NDQ:YVK0[,_>\RV7[2%G(,PISCQ
M=2\9TQGNYR VT               #4UD4K [6DU+RV8HEZMZH*S3[<K@Y&Y*
M4!*":J:YG]5FJW%.1M@MU19A]ENI6$YO:7@XW0WL[Q>H&#;(
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MY-S#,9WV"X0
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MQ/DO920G/[=MM3"B]]-M<!,4
M
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MHT048<5E&YEMWF^BC?9#J7J'8(
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MR)[GCPL/K*OI$Q'JT1F8XVE^9($#@E\,XY1LL+3A>0
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MYWWXS_O7>YGW4>_KYN1Z<]][T+_RM[M_->YV^DOW;P^WN>3O )+@
M                                                       T)57Q
M7O?,OWWD?>#]^/W61KXTGO5>]Y[YGNY]S9?N/]_WW(_^-/NL]R'<]&^Z+_#/
M1O9X'[CV -]@    /6=X7A&^/X?@>'OXWC=WPO"[N?$\7O\ V'A]SM[W;Y.S
MUP$&.(/YLSW2VO\ $'^(I[L/2FOOY?%!]X#W2^FO/UW<]]?WF/\ E3TIZ4\Y
=[/3'[KYQXO\ P^\ G6                 __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>tm2115679d1-bc_micro4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-bc_micro4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!N@.0 P$1  (1 0,1 ?_$ .L  0 " P$! 0$! 0
M       '" 8)"@4$ P(+ 0$!  $$ P$               ,!! 8' @4("1
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M;V\^)"XNG+YY4'99PX]2:9YBWS';-Q7]H=7])N>,DRM[T[12X3W9-5EF['V
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M-A=3/_Q^D_X9E?\ T*&KNO\ _P#N];_Q?.?VBXAT9*Q$
M           !N([*N?\ -5Q+;2Q<C^$Z:'L=*/;D9EGP7ADS)9V[<O9!AF7'
M/!92EHR/+SR_^[CGSR/-?Y@-'_F#4>KNBQ&->9NYZBGX\V*-R8Y8KW9CEAZV
M_+#KO\L:5UJZP35NV\I8T^Y7/>_Y=.9K\I$S[D3;WHF=DMIS%!$6N?K4J5MY
M3$97HOW0V!-2I?R&HXXUH8LPQAH/[O')N"!,CDA>2?#GGO,LBLLN.[GQGR-
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M*R6I]>NMU>;BY-66X=3=HW+MVWTZ;$8;T6ZZ(N4[;=S>MU?[U,L>K;5:D7*
MN-6V535,0F;)]8W6QRFLFSYG--ER)2F;,%A,^DA[6U,D'C$>/-/+-*:N<C><
M,\\"LL,BN^PYO=;X@=:K.L4:_H>IZGFM*JUZC+37.5LV=,FU-6[.7M1777?N
MW(B)B;N$8Q$U1,583%AU=X8=3,QH5SJSUBTC1\EK-/5NO-Q1&<S&8U>+T4;T
M9F]-%%O+6;4S,3%C&K"9BF:9IQB>?H>PW@\
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M46OKQF=9LZQ'573/(TY.W8KM31N4X3<F[.]%6_C$X=S=P]UZ6RM50*Q-H>U
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MQ55,1C$]ZF*:>[WE&!M=I,                  &R7LTOUKVR_W&[W_ $E
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M^SVK^C7/%.I)MY\-]Q=!GSR4.U/AQZ[TSS]OG.QGBO[/:OZ-<\5??0'6+8>
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M::8FJ9GN1$3+L!'S<?64
M
M
M
M                   !B*V3YI)Y&X9PCPS*?HC-I/FOY.YQS39Q%YK]J+1X
MI_!\XFX+L9MEGEGSGCR7RGXXXXR[_GG&2*,;4W-E41^F*I_H<)JPKBC;$S^C
M#G9<(W,
M
M                                    10\?QRKO[*+F_>^AA/3]VK^/
M1X*T4_MJ?BU>&E*X@2@
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MPG)S2X%*#,%&.1!:=0'<X
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MUT2>\L4?4VG6_FI/9YGPRLSO+64EQ;WW%CD"#EZ0Y'MY>)^// ;!0
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MIFU.5JW(JB?*4=^8GW*_^&$$17%^G?F)C<J[T8>[3RRL*+5.
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M$XU8X[U,?]K#O3/N(:M^FY3.].[-4]SN8?!F=F/N;4WBV3
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M,EZI41X7(W$HX_-$'^F6
M     BAX_CE7?V47-^]]#">G[M7\>CP5HI_;4_%J\-*5Q E
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MSZ$5SX='QOU:DKB!*
M                             BAX_CE7?V47-^]]#">G[M7\>CP5HI_;
M4_%J\-*5Q E
M            &M#M3=<*=NK6V2V=>EY[=T97&JT/L^_Y4[Z>V\\51.7N,0B!
MND@E"!S^9T*P^7%I6)C.-0M_/)7?+.YW,N.<@'-9H%K<?/MMM,[C>])>W>4P
M^/6)'+8K&UMPMPX3:E)0;%WB[ERQ6)+("XL6;VG3J(\]\EYX)<TZTOA5R7SG
MQQW_ !R'<$          (HL3];Z&^U=X_N-N83VOV=WXD?/H17/AT?&_5J2N
M($H
M              "*'C^.5=_91<W[WT,)Z?NU?QZ/!6BG]M3\6KPTI7$"4
M                                                          5G
MW2YDV.G.V64+<T[+,>-9[WYB;RKB.%@)6F3<5;*N6)S4P,Q ZES9.@=/!&YM
M&253PY8X<I^2C.#.\Y#C\[(.1:KM5JZ,0MFW*_Q'!5H-2&NV++72\G^=(=(F
MZ6MT-P2N]?R2+X5F5%T-,LZ\@\EO2<.O@24Q*;'PV7./Y0[FP         !%
M%B?K?0WVKO']QMS">U^SN_$CY]"*Y\.CXWZM25Q E
M                                                     10\?QRK
MO[*+F_>^AA/3]VK^/1X*T4_MJ?BU>&E*X@2@
M                                    "BG: ZSZV7U23U-]BX-:<O2:
MYQN>W%#EE$V)9-:76Q.4>B2US=O5@^UC.Z]=UDL>&YIX3HT*I=P@5JO!8'8]
M[^=P'*I1?:ZO%'6+0\KJW/\ Q*EC:[V5DX2MHIS:W12@]HT-WP)ACBV1/ZRG
M]@E=H1F],FF-Q<G-W4.B5YE&!"(@Q0JP/*XXYP#LVU^O:M-GJ1JO8:FW[SFJ
MZY(/'[ A#SFF-0J5+%(D!2Y,2XMRCC%4U/"#(S).M2'<<')%91A)G'&>&7'
M3          BBQ/UOH;[5WC^XVYA/:_9W?B1\^A%<^'1\;]6I*X@2@
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M_91<W[WT,)Z?NU?QZ/!6BG]M3\6KPTI7$"4
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MX='N8X_]""NN)N44]W'?GW)P^#5[N&"PHM4X
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MS T@\@W#@PHXDTOG(LTHTO+C+'+'GGC+CGN\"UF)B<)[DPGB8F,8[S]114
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M&C<W]ZN_65>&6ULO]WM_$I\$,U%NF
M      'FO+RT1UH=9!('5M8F!B;5SR]O;RN2MC0S-#8E-6N3JZN2TTA$W-K<
MB(S.//.SP*)*PRSSRXQXYY :L*B[1'L@W39BM:,I2X=<2-D]AH"BL:NT<'@)
MC(Y6'$9$B6/37SZR&^%((MR_2%N0F*TK(N=RGI:1WII23/#/#+(-L(
M    BBQ/UOH;[5WC^XVYA/:_9W?B1\^A%<^'1\;]6I*X@2@
M      -35L]J)ZKK,G==>HWY\\RI0[QOYX]9GS9\Y_-2LQ+X[\W^KYP\3\/X
M/OO!^'-[WN]SON?Z1F>2ZH_;,I;S7VC=\I1%6'D\<,8[V._&/Z(8QFNL?V;,
M5Y?R.]N53&._ACAR;LH\_P",!_\ +Q][7_ED+K^2/_M?^7_[B#^:O_ _K_\
M</\ C ?_ "\?>U_Y9!_)'_VO_+_]P_FK_P #^O\ ]Q@=C=J.58<?;F ZB3&O
M!OGE63GA25:.*K(TVL+.B%E$-W)6=<$<8EO!\2Q29F=]SR3@?R9QCGSCQAD_
MDC_[7_E_^X?S5_X']?\ [C//^,!_\O'WM?\ ED'\D?\ VO\ R_\ W#^:O_ _
MK_\ </\ C ?_ "\?>U_Y9!_)'_VO_+_]P_FK_P #^O\ ]P_XP'_R\?>U_P"6
M0?R1_P#:_P#+_P#</YJ_\#^O_P!Q<?4/<SK5N,Y;_5OYA^9:)B6>&\\/.CYR
M^>SW0CP?@_-:.^)^+?-O=[O?&]_W_<[F/<_+T6MZ%_!J;=7E?*>4F8^#NX88
M?\56/?=MI>K?Q*JN/)[FY$?[V.../)&Q>$8^[@
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MV*BWZ#0#1N;^]7?K*O#+:V7^[V_B4^"&:BW3
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M "ZPO[:H[^XUC#+NIGXI<_=ZOGT,=ZS?<*/KH^;6Y[1LQ@H
M .QNMOX=0']BHM^@T T;F_O5WZRKPRVME_N]OXE/@AFHMTP
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M\DG%M6E8R5GCIU#4?.SD:%-/YA)2"5!LIF+BIR5<8^-Y8J/ \F^ +**P"U
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M9G>+E9<ED]_WF//./' LZIIFJ9IC"F9[D=_"-F*YIB8IB*IQG#O[7K#BJ
M     H_N_O[3&@<5@\ON>*7A*FRP) XQME3TA4$JM]U2+VQNQ=%!SXVQ4DY0
MSM^:?+O2SS>.,##/S>/R@-%-T=JO7F^^XG955QJ]!=SXJ9#MZ&6;6XLG^OUL
M5%#5%:XU-9K$<FD+VX)B6ES;_.%W0Y9)5?/)/?8\&<\=W#@!U;    \T]F9U
M3HW/BEJ;5#VT)7)"TO!Z%*<Z-B)XR09NZ-N<#"LE:)*ZYM:7E267GC@?RF*Y
MSXR\'AW ](    !%%B?K?0WVKO']QMS">U^SN_$CY]"*Y\.CXWZM25Q E
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M&ZV_AU ?V*BWZ#0#1N;^]7?K*O#+:V7^[V_B4^"&:BW3
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M)%K%E[*5S?M>M#_5]5+;5-C!3'24SELE=WAKP2+&<@XJ-MRCAK3N!>:9V<_
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M/4N&Z@W7&G%]97=UK!YLR!PIOP;G1"_,V+GDS*LEJS+$LM3QQP5WW/&8;=
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MKYUFXHVM+ZP:OJ&<TZ<EF*IMWKU==$U4TQNSNU3,8Q[D^XZ7!X;?1D
M !">RKI;['KE?[UKVTHWZ_6BD[5=*/8G#!,8WO5OM\%?E=:-*XM;E@C,1N,T
M*1$FXF\\%<X9\\9<\8]T!Q;]FKNENC*]T:GI2N;_ .TKO:<.FS=-2C9^#[=U
M#(TD2B%+2/7' K;Q+-\9.PL47US9ZAO<@PB#L[!R3BK7&$)^<EOAL.5 =V@
M         BBQ/UOH;[5WC^XVYA/:_9W?B1\^A%<^'1\;]6I*X@2@
M           .33;+^9F]?M/EWZ64#<^B_A.7^II\#66I_B-[ZRKPJ]#LU@
M    #<=V0WZQWE_J2"?UZ4#!NNW[++_&K\%++.JWP[WO4_K-X0U\S      :
M%^W/_537/]H;(_1L.'KG\J'XAK?U.6^=>>'/SK_A?5_]XS?S,NYU1[1?/X
M     !WXQ+]5(S^SS+^C4P^0.H_B%_ZZOYTONKI7X7EOW>W\R&0BS7X
M        UD=HYHQ?NX:O6F8:R[E]2"X=:;(E=@QNUT6N\+V!>7 J70=P@CK%
MRVR92Z(HF^/N34ZG?.*,[)<WNO'!/"E+GDF3F%!3C4CLJ>THUUVPD.S%B]LT
M9?3?;<L@SYLM E_9YT3!G2[X[7$=<HW"X*19".QI(^53%XTC=5!B%''$J1 E
M4JUA^";QA:J.-#?\     BAX_CE7?V47-^]]#">G[M7\>CP5HI_;4_%J\-*5
MQ E    :P>UC_EUA?VU1W]QK&&7=3/Q2Y^[U?/H8[UF^X4?71\VMSVC9C!0
M             =C=;?PZ@/[%1;]!H!HW-_>KOUE7AEM;+_=[?Q*?!#-1;I@
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MRKPRVME_N]OXE/@AFHMTP          .&_;7^:K9G_>"N;^\>2#ZL\._\O\
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MF5W/:X=E:Q UV!"Y3"')<W<D\.")OE;&N85BM#RI*/3\+$R=?EF5X3#/#O\
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MF_O'D@^K/#O_ "_T+_!LE_9K3XL<5/\ ,_K)_CVH?VN\KZ,Q8$
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M_O'D@^K/#O\ R_T+_!LE_9K3XL<5/\S^LG^/:A_:[ROHS%@0
M VC=C]_.<R?9]//Z@E&A/S)?Y8W?WS+_ #I>E_RF?YOV?W#,_-AUF#YX/J:
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MO3AA[M,Q,X]^N3(6\W157.8G&F9G]./?PPC''W)QB/\ AAM0'2.S
M<FFV7\S-Z_:?+OTLH&Y]%_"<O]33X&LM3_$;WUE7A5Z'9K       &X[LAOU
MCO+_ %)!/Z]*!@W7;]EE_C5^"EEG5;X=[WJ?UF\(:^9@     -"_;G_JIKG^
MT-D?HV'#US^5#\0UOZG+?.O/#GYU_P +ZO\ [QF_F9=SJCVB^?P       #O
MQB7ZJ1G]GF7]&IA\@=1_$+_UU?SI?=72OPO+?N]OYD,A%FOP
M        !%#Q_'*N_LHN;][Z&$]/W:OX]'@K13^VI^+5X:4KB!*    U@]K'
M_+K"_MJCO[C6,,NZF?BES]WJ^?0QWK-]PH^NCYM;GM&S&"@
M [&ZV_AU ?V*BWZ#0#1N;^]7?K*O#+:V7^[V_B4^"&:BW3           X;]
MM?YJMF?]X*YO[QY(/JSP[_R_T+_!LE_9K3XL<5/\S^LG^/:A_:[ROHS%@0
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MFZX^T2V_^_1?^S@?ZDN)OTF3\Q3SG^DSA!]#G_2:O%/^";KC[1+;_P"_1?\
MLX'^I+B;])D_,4\Y_I,X0?0Y_P!)J\4_X)NN/M$MO_OT7_LX'^I+B;])D_,4
M\Y_I,X0?0Y_TFKQ3_@FZX^T2V_\ OT7_ +.!_J2XF_29/S%/.?Z3.$'T.?\
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MC2Q*W2-WI&V(':[9'W!<4<>B0O:^!O[\E:EBPE.9F44?F7F9CAESCQSQCSW
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MF3QU<J8W=<P/:9&]LBM<VJE#.^M:E$JPP-RR3JTYI)G&)A>>/ 90
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MS6-.%@1MJ4\)>4[F_P -2.9TC9V]1PM)[PY0F++S\-AW.>>^Q[H2(
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MI^>'QX,?'(Z5LKRTJ>2&LA,F1@-X@
M     #F?B%7[AV]=';(U[0U$Z#3^N)WO+(85)+!VMGEHD36-/LBT,TO:GA*V
MU3#=>IXPSB&M+"N1K$Y1\P8SEJX]41G@E+PP4GAZRQFFL%LF4Z-3'M,;,TTK
MWLYNSEU#75-,8^LIR,/MWO+?%+'B$XVIMM1;,*FBJPX'#'*IFYM<(NB48-/C
M)RGE>9F<K2<EA1QY[2#<C+&E-R;GN>Q(Q4D1UGT,N"\*[U<L+6?!503M8T(B
MD^N4C9G3*\V6*VU;\;V";I1X>/+H/*CG6/-AY!"! :Y(5'CH6%OAPL6\]@]<
MELPV1LZL6JI?\11<%)Q3""%TY'FQ+%^.S\L:9QC-R4RRK9.:X2)E4LKFPH%!
MIW/)S5,W<H_!0M^:%;4'N13M*KGU*H#6S;V^YB[6#1=N5CVA52.43(B[(W)N
MMI2%U739>L")M.BD:3'$.UTUE7$EA!27'DHM<[)6CGN9J3#,\PJM:^RW:B1N
M;WQ5,[V96PVQM%]?-;)*^SWC:75'66%NUB3^@8S<EHWG;-7VOKE9"RZ:GXN1
M_=H@C;VQQ:&1.TQ;-$7ABYGF*^ Z[Z>D4FF%25;+9JF844RE%<PB12U'%EYC
MK&$DF>XRV.;\FCCH;@4:Y,)#JI-Q1J,L<<CD_&&?/''//< 2,
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M-ZD@3F\+UTA@K@SLG@T: EXP=UK,C9VG@.G(
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MM>M;5''$Q[08$9\+B\,^5)/!?/?Y8\8\@)H
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M4YR5OF<]:V8N>&$NK/@5F64N5\XGIN,.>.,L.. %@@
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ML]\J@K R/N==QO=HC3G.$O4]/9#MA$>T\M8..)LWF)GOAFPR7)4_+&8DSY-
M?1%-G=],9=%MAW[:I&[U0Z=M'='9\EZPET74Z&&JJ 0;;VYKW%WMWL=.RXVU
MS;D1)CJ52E<D;NE:%2)&2G6M:E5FJ<#PKCJ,Y;QQ=?7.N$/WB?F'/9WM4.V%
MA<]M?FAJ.=YO&T>O=I7[*G%\@S1(XH^PHAZLN?1#QM02XMZYM9D#FH2(4^!9
M"/DD)Z5[=[O(:AE^^N6VC&9&:[[0YQU!.T)44S4Y3))(+%=TTNFJJ+O\T*8/
M7RU[5SAEPYG*#Q%X+8B<W!*EX8<T67A> V+]CU_)"5_O?]I?_P#]*MMP&S\
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MD):N$3ZO-3,49;>%?)2@[DL!N3
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M">N:D->:L29OL;9C'#A:T>-&%*"O!9AU8@
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MD:0.2)0286:0J2X9\<_D[G(9\
M
M
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M23(3E*>/G)WMM.*?%",S(E60SF%J<L',Y*;ASB9B1SGEAEQSQEQQSP R(
M !XY\A8$RY4UJ7QG3N2%K,?%K<>YHBER-E)SX+->%20P_%0G:RC.>]R49X\%
M8\_DYR[H#[&]Q;W9$G<FI<C<V]87P<D7MZDE8B5%<\\\<&IU2;,P@\OGGCGC
MOL<N>/R /L
M
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MSG#/C$)Y
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M\]WD!OP
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MIUQ5;I%M?4'9V:H5/*H9N+UD[4WHDLGE[Y*K>(=+*1QGF;V'35=SE]3MUIW
M\QXYZ6,B!5*(\W,3FSH/$"3##BR,0VPZ*3NH;,TOU6FM!2*12RF'B@JK+K60
M3'#$J9.$4:8<TLK9S,RL.<BR9DF+;O NV&&66&#B6=CCEEQQQSR%K0
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M1ZP*Z;UL+M;31"LFIMC5 V1"0N+Y(_G2851+'AX_]KD>(8N3>[J$_!"7O_"
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M4Y:KG+OL2"NYW %[0
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ME-ID=@:V()MPTJ%3-E,(57R%CCCADA,S19'LW/)'/)7><\AL7
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MTFL!F9)7XXV-A:!X<"R",U6/&9F(7Q
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MU5$I$M:"5**0KHO!I2Q.B]L*3J5[ _,C4^,*L[-$K(YR*X.-"VX
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M+'+'GGC+'+CGN\<\?DYX ?T
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MBKE# 7"5LL;E;K&ZTL95+HCCXVBQS;TS.C3\YY8>!RS#=L
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M$DREUS1_7.[M9(XHELJ<F:7.#!%SZLO1U:C$K:VFMS;B4E4I&WDU/D4H"/\
M7+LUXG!-8Y34]BJ%D&L.T=G[)W&EKYKE9T]CV-8W#.)XKD$7:*DL-2@BDK7Q
M>KZ^2M$/3\N#8D1/30W&%GM*9$IY;20D1I[,K6)CC\O9FGBV&]UG,?8&Z16
MCM^<);14RR.7S.=FT5L$6&G="I0DM ^\+$<GL]>6HQ3&XYX(?%N&W#A'R%E:
M!U[@.N,2>XK!E,N>5,NF3S8L\F=@RQWG$\G\^D"9L;W662V2O)QAZUR-:F1"
MB*+)P3HTB)$0G3DE%%88<!.0                       /!DT5C$U95L:F
M,<89;'7+$O!Q8),SM[\RK\"C,#BL5K4ZIU2%5B6<7CGCQF7EQQECQSQ^7@ 0
M16,-2!B:VN.,+:V1?$O"--R!G;T:".X%)C$16+$D3IRT[3B6C.S*QX3XE\<%
M9\X\?F\\\ /20-S>U)<436A1MJ/ Q0=@D0)B4:7 U6H-5JC<4Z? LK$Q2K/S
M-,RXX[N9F>67/=YYYY ?"DC<=;S$9R!@941K?DY9H#4C6A3&(<WDTL]WR1YD
MD89)LG4XK'-3SASCR?ECQSGWW/'  X1N.NRGE8Z,#*Y*^4I*'E4X-:%8IY1)
MW!.[$(^3U!!AO*4AU2%*<"^[WF*@K SCCC/'CG@/06H43FC4M[DC2N"!828G
M6(5J<I6C5)S<><32%*8_ PD\DS'GN98Y8\X\\?T\ /HPPP+PQ++QQPPPQQPP
MPPQXQPPPQXXQQQQQQXXXQQQXX[G'''Y.. ']
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M'*24.:SC#QC)&2H4&&8E<Y=YCGGEEQQW>>>>0^P
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M:5Y/.%"E,\OK^?RJP/FV9'=Q-PPYP)X_-[O///*J(C##W8(Q]U, XJ@
M @%RDEOO%H36'0QQK9K9(I'H,[%FR>,2AX=52F5Y2@M1AFH:IDR)."$V4=XY
MPXX(XR[AGY>>>X.6%.&,XJ=W'"'J>([%^E-*] 9U[R0Z/*=+D/$=B_2FE>@,
MZ]Y(='E.ER,*L>0;%P&"2N:?/U*K_-IE6N_B7F+.BO&?%"^_\#X3UD_F=_\
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MGEE1+U[5,2$E9O\ ;IY^:TE-D4S%XP:,+%'^>^ RX.*\7YXX/YX+ 3^
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MJM8#=_\ 6AF/_P#K K7_ -5MK@-GX"%:7_\ BQ]M4[_]U"L^Y[RD?TIJ%%0
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M2@JNL#69TL.*TSI_==322P7ZIU2#P2?A9/;C<;-G;*9AR7D>Q*F/$PODQ+@
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M+7M[L\JVA5U\T[DRW7>4U*TIXU"]GJ-U[I56SV^9LC2LL9X?0;"TU#56U"^
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MI,.QX28D,)%]-B9"P'49:91+XSFFF0QXQ+++<D1AF>7*?GN8X88G<Y99<_\
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M88/S-GGG#)1CAABZ(<LLLLF-=QCCCCP?SSEEESSW.../Z0B)Q4GO/9K7^'4
M_8J*_H) $]\CO,U%%0! =Z,[0_JZ39WUK;GII6W0VX+6MW0IG)N5X85_8IV&
M"I$L*.3*,<#B\<^.,\>>.,L>.?Z>.!RI]WWG&?<]]EOJ1I?V15AT!BGU2*;U
M6V5=VG9!ZD:7]D58= 8I]4AO5;9-VG9!ZD:7]D58= 8I]4AO5;9-VG9"'J@I
M^I%OK0\=JVNE?BEP39"D\:A$94>*HD_S9X!&G\*V9^!2D]_SWA>/<PQ[O/<X
MX[HY355W.[/>4B(V)A]2-+^R*L.@,4^J1QWJMLJ[M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO
M[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>JVR;M.R#U(TO[(JPZ Q3ZI#>
MJVR;M.R&&TBP,4;E6QC5'65I8&M+=#+@F;65M1M2!/@9K[1:PS A&A)(3E8F
M+%AQN7&./'')AN>7/YV67/-:IF8C'9_3*D=S'W_Z%@1Q<@      5H2P&"RZ
M^[<.ED*B4G.2PNG_ !8V0QQG>C4_ASK(P.\ 8Y(U.1/AL4Q?&7>\\=]P7CW?
M^CQW.>,Q3&'*XX1-7=V)(]2-+^R*L.@,4^J1QWJMLJ[M.R#U(TO[(JPZ Q3Z
MI#>JVR;M.R$/; 4_4C;2EG+VZK:Z;UR2'NYZ1:BA$92JTQV!'/.!R=20V%G$
MFX<_T98Y<<\#E35.]'=E28C">Y"8?4C2_LBK#H#%/JD<=ZK;*N[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJM
MLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R*L.@,4^J0WJMLF[3L@]2-+^R
M*L.@,4^J0WJMLF[3LAAUATQ3R6 3E2FJ>M4ZA/#Y,>G4$06+E'$'%,JTPHXD
MTMJQ,*-*,QXRQRQYXYQYX[O K%56/?E28C#O0DNM?X=0#]BHK^@D I/?5CO,
MU%%0!"MO?^.45]M2#^[JR!RI]WWE)[\>^FH<56NA!-YIGVMLKK?.7RC.NTW9
MT5]-T\"R?W;*%D31;LO9C"LEY,6Y5\L94H5L: A$:X8D<*S$A)9.1G)>&./
M;%P$*TO_ /%C[:IW_P"ZA6?<]Y2/Z4U"BH             TT;O[/2&N=QH/
M3+MN=,-1*S<=9W"SBED(I6OK9=9?.BK2XBN29<;,Z@MA2TMZ%@_/QQ)+289F
M<]WG++G\@"J'76VL?)90\/N"Z-JZ#XD6O=MV"<JUK[.&?; SZSB(KM1-JKJ&
MUK!J!MUCV/G-!)[9HAF8Y4:S.2-HP;7%Y,0Y<^%(Y)Q"PRW=:\Z8VCJ=#*9K
M(K-TQ;M1J1F>P$RM>F<J0N^"26^;BN:$Q#8Z<0E?!ZQ>X'$8BOK]I9)G'U[
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M,""*M$FF/BA9DA<F.-MI12=CC^;IF9BWI<N33R4>)6)YQYW!AQ@2(
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M-[4U!-M*YC)EL1UZNC4]]I$VD;#LVHZJIFZ\*<L!GG,9?\[":#E5CQLN'3-
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M-@:@*G1[,UZDT%09M^4326CM:\,2^*O*!*GP*C*J#3A0EP38E1PU:&W$
M                   &%65_#J?_ +%2K]!+Q6.^I/>*U_AU /V*BOZ"0!/?
M([S-114 0K;W_CE%?;4@_NZL@<J?=]Y2>_'OIJ'%5S2MV\%PG=O))J41Z07/
ME;ANH\%JA=X_(8V@IM!3#5LK/YBMVMQN#A.JX757G#G]*E3(BF;EZ/F>1D>\
M7Q.)-58ATM (5I?_ .+'VU3O_P!U"L^Y[RD?TIJ%%0            !#_J4B
MOK]ZQGSA(//?U/\ J4^:_&F[S5\U?/3SZ^</$?FKYW\X/G?_ "?A?'O%O%OS
M? =__E $(7?IXYVO=+'?D#VJV0UEL)IJ]14"]32#7JX_M4GAI\KXF99#XV;(
MZS[!E)W!&]\=\6>VY-^7)?/>&<9\ /<B&H<2;)%)Y?:%A6)L9*)]KVRZT60Z
M70VT[XE8E<,LSM288>=41JFI:L@F;HYX6XX-2W!&UHVU2U)DV&23QCQE2I".
MZQ[.JDJGU/KW3F-RJW%]85KL/$]EF%_D\M9Y#8ZV<PW=Q!OJUM<AE2^+9%/D
M;46^W%MRO(Y+R[J8[SF5FO\ G'+ES 9=<^HJV?6KE>U/["W#JY<+K!6>L)W*
M:I;ZFE;+9T"C#O(G^%M4Y@=V5K:,-5/4 >9@[GL;TA2('9)BZ*DQQZE";DE
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MZJL5*U_%-^-QYY2M#P>*UI"J.LB-Z)GPA3 (+#T\(AD7?Y1 M)8#<ZY/'6=
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M&6///'/<[O'Y!2>^Y1WF3"@
M            (]LNVZII>.X3"XK-KVIXD:Y)F8N467-(W!(Z8[K2E)Z-JP>Y
M2Y-39FY*R$9V91'!OA3,"L^<<>>,<NX'I0*PH#:L3:I[5\XA]D05^\>^8YI
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MS;+RR,G%/QGDWFJ.,>3R^[W._P >Z$[@
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M+EF8>E+PQX4E<\\\>$P[H2L
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M3Q(36^MI9@UV[9;TPN6$27M[<<_M\\?),0>AQ5FO*];FI//#X[+IJQ<M-(Y
M$-:$N,TA-M459S]6,<N*378LFL?J;;6O[NGC.TVS?^$'?YY+K(@\37YEXRD]
M$4<[./B*I=RGXR6Y!#ZFKK:?M<;62IZ/F30MENWM;[:,%(."FNB'OU90S:VI
M+5FM<X\$3<ZO"+*M1@K%]D/S2H=4[=FOE1:9R6IU)B[DD(!DU';&)%K_ '-6
MM.[*0.WIRMVB?-:6B&V)237#Z*D=J3.O'YF0;*P-=)SFDR'VW,H*EFLA*:E\
MA39)/&DK@WX/Q:+$\-[X
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MEW.<E*=B7Y!M)
M               &/R?_ ,(S_5__ ,09/UG_ /"/_&V[_I__ ,P__(__ *[P
M(#(
M                    &/F?K4B_5_\ 5]S_ .T_6K_Q%I__ (+_ /M__P#,
2_P#ZGP #(            ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>tm2115679d1-lc_gene4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_gene4c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"<@)@ P$1  (1 0,1 ?_$ 0P  0 !!0 # 0
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M\X__ ",_>'S$^=8__:6T_+B_P;3T#B^DNZ@\Y3^)$_T1G[P^8GSK)#]I;/\
M+J_P;3T#B^DNZ@\Y/Q(G^B,_>?\ \$^=8_\ VEL_RXO\&T]!(OI+NH/.4'UC
MS?165_:'S%'SK)#]I;/\N. ^E&4]!(OI+NH/.4CUCS_16=<^8GSK)']I;/\
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MB)1$HB41*(E$2B)1$HB41*(E$2B)1%^%Z]39)'54$-"E$0#4 Z U&I )*@N
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M*E-:)4H-0%+DJ5&2VVVI_JC>G]Q08^SV\G]:N X[_56WZ3_$U>F^K@GM[O\
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M8N-<%K]WX#U[$V\<7.)5)V2G%"-?6Y+Y+$)R I@^$HN4U4[G $BI ( 8OF=
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MLL#:.8ED+?D;CE&'9OQ62!0&X(% J@F*7JJWJ5C+\P,EO.Y]LUI-#0X#$T(
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M,F92?9-GBD(T6L69CXPBBCB=31YUBH&(4!%0#Z !JW4E[,+IK#:D71(!=1I
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ME$1+B?ELPXMBX)H]5C7<U)9 M-C$M9%!4Z"S!Q).I=)FD\362,4R1C@<IBB
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M! O-1 /L*O\ 8SU4%;<N/V0/V?1/Z[M?TR%;30OYQ;?MV^-:KB'^0W7[!_\
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MF8Y?>G$A1.7R&$-0J*8U4U-*;%4/0/D&I0+Q@DD4_.5-,IS>^.4A0,;I'B8
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M5?9[2PC2F?LI6O>S7C W 1XB&I?.TX!KS:<--?.TXCU:=5,:\R4&W *K77F
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M8"5^/0*>ZNHX:B8U\]X[$Q,%/[U<N\MN]X-LQ5E;%\NVA!I=A#6MA]K;D2@
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M[HP!R/0%TL#3I .77]#_ #O]".O'4*VXQS6A.!7%/OB0$5=HP_\ ^5YG41$
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M!A$ #4=:\WXBXF9=,=96)/8'!S\J\PVT*]6X6X1?9N;J&H@?.!BUE:[M=IV
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M5_\ "%/3?5?B[?JO^44?AYHWQMUUH_DE/KN^?Q9$_>K_ .$*>F^J_%VW>?\
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M76C^24>N[Y_%L3]Z/_P^GIOJWQ=MU7_**?P\T;XVZZT?R2CUW?'XMBOO1_\
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MV*Z>IJ^ >KJ%^:H/&^J_%V]/T7_*)^'FBC.6ZZS/DU>$-"WO-*)IG0;MBG$
M$S=JN!N/5JJX5#3AX*MOXSUB0%K1"WG#75\+R/ KD? 6A1&KG3O'(7-IX& ^
M%;48WPTN95%Y*=HJH!R:<^@:"&@ZE#ET#I\=:*[U*_OS6ZD<[FR'>%%T=CI&
MF::*6<36<^9[YKX%N="PR,2T2122*0"%#@74#!IX1XZU@$[-JV5 <2O?U2JD
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(OSN&Y'"0I'#4! 0X^,!#K\52#101
M7%8PFL9Q<JJ)U$!-S=(AV>G3KU\:J%%00:JWAPI":B(-]!Z-!%+W. A4'=*
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M8/;1^M3R$H4^12%^Y@]M(?I -1Y"4*?(I"C_ .;^UV?U0"GD)Y7(H^1.%_\
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MT^G1%/,7^>#K'I#JTU]K6B+\SEP@V06=K+$2;M455UECGT2221(91910W,!
M*F0@B(CT:4\:5[RUXM7=/@_(^+\@9;QAD*V\CV=C1.X1NF0LZ683H-'EKQRD
MG*1BAXM9T5-\F@3W@^?XJN]D]KQ&11Q5KM8S&7@U Y%Z'9WNTQUO3PQ"9TQ>
MVE6MISDC.1C1&:0.U?$<0$W(PCXQTUT&ZQ2BYCCZ (:"72HFA? _<=FIAG;<
M1B1N1]I;7:AX0\'2'3X*MJXHYB_SQ?#TAT>&B)S%'H,7B.G2'3X/+1%(" ]
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MMV^V3@#'MTO[(C;[W&*W<Y>9 GX--!])'A&EDIR1F2:C23:BD50#(B10IA6
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MG[FG^L2?*I]@>M/[]M_JL7R2?-P[X7^46QA_%YQE^]K3[:]7/W-/]8D^53[
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M*(E$2B)1$HB41*(E$2B)1$HB41*(J!3*8=1U$0XAQX .FFH> =*5PIL12!
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MZYA[NO(CK;/N;@I]?%T7,+Q(M#D%=_9:AI0J;B:MH[M1!&1@52&46,BF=(%
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MT*^=@F]6WM^>!VV<[:LJ3L:->3DQ"$@Y682FW1%(:4>Q:J_IB$;%)B"HLA4
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M3![QCT[K6Y[:46[V--F&UG#YDCX\PA9$$H@D=%%99DYGEDR'4%4W*M<;N75
MW..H&UY@ZATKE[WB77M1J+RZE>":Y[O^$!=?8<*\.Z60;&SA80* TWCWW$E;
M+I-V[=)-N@BD@@D0J:2**94DDR%T I")D I"%+IP  T"M(22:G$E;\ -
M"\H% .@/J_3J*!2@% -- Z T#IZ*(IHB41*(J!'B/'P< #CU#X]0THBYN=[#
MN R?MFV49,R[B"=2MV^[?6CB1,JHQ;R)$ <)O1/S-71#HJ 84 Z0ZJR+2-LL
MX8\5:5BWLCX;<R1FCPO+W3^?<G;F-C.'LQY?G$[DO^Z?C,$W+ILVT<1WZMN&
M18-3$9M2$13 &[<A?- /".M+IC8YRQF#5-F]\MNU[S5V./0NC@'$1* =>NO#
M4-?*&@!6/3E64O+10E$2B+2+O#MI4CO=VLWOMXB[V98\>W:_M]XG=,A"+W$U
M8A"R:3\R:D4WDXA5<7()\@""Y.41UX]%7H)A!*)"*@*Q<0&XB,0-"5F/#>'6
MN.MN^/,!7*Z:WA&VCBF Q?///1%8]C<K&-MI"W)0XLO27"S-K*($4 2=L<Q"
MG]^-422;TAD&&-?;JKD<>Y&(L' "GM+ADIW1^]';#=-])=WEO.>8LQ/DJ84E
MY7']X6I;MS+P<FY%45W\?*O4VC<P$;E*D4J;8AC (\YCB4O+G?.X96@7#*N
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M3,F827L9JY=3KF^%+@ET8DMT.)$RK9O#W++H+H*(H$/V+8J9Q/S&,,R7,<L
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MC7CPX"&HB("'1QUZ:$ YJ:XU0$@ 1XCQ,)O((](AXQ\-00"H!H@HE'7B/$
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M2+_M+OJ)_K=/] G?9^9W_&53Z&_^QT_][^1/2+_M+OJ?E3_6Z?Z!.^S\SO\
MC*GH;_['3_WOY$](O^TN^I^5/];I_H$[[/S._P",JCT-_P#8Z?\ O?R)Z1?]
MI=]1/];I_H$[[/S._P",JGT-_P#8Z?\ O?R)Z1?]I=]1/];I_H$[[/S._P",
MJ>AO_L=/_>_D3TB_[2[ZB?ZW3_0)WV?F=_QE4>AO_L-/_>_D3TB_[2[ZB?ZW
M3_0)WV?F=_QE3T-_]AI_[W\B>D7_ &EWU$_UNG^@3OL_,[_C*GH;_P"PT_\
M>_D3TB_[2[ZB?ZW3_0)WV?F=_P 95/H;_P"QT_\ >_D3TB_[2[ZGY4_UNO\
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M[-4 ,FY9KIN$#E'B!BJ)&.40$*\^?&^-VY("UPV'!>EQR1RL$D1#F':#5?O
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MY_NB1D"SWH',!1<FK2RGWAG=.7NUBLAQ-US&(#2"\:I$2\J-U8UG6QS@=)Q
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MQ85O%+$VPT>LHIT#=%I"L00CFK=J](LJBF5,I$C+& @ %42O,MB)'XO#J*]
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M\U-1L44A!$0[0QG[EN4$]2CQ$>JLB*VN)_U+'O/^RTGQ JQ-=6UN*SR,8/\
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M'E>[#JBH/*OHHM6T+:LB"CK9M*&80$!$M46<=%1J!6S1L@@0J:8$(3WQ@(4
MYC:F'0-1KQRXN9[J5T]PXOE<:DG$U*]TMK6WM(6V]LQK(&"@ %  %< )@ @.
MHZ@.OM](>2K"OC!>2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(M5
M]YO^;_=/ZYVO^Z&/KN?5U_5<'Z$G\-RX#UG?T?<?IQ?Q&K:?P>4?I#7#+OU-
M$2B)1$HB41*(E$2B)1$HB41*(E$5!BB/DX?3X^Y[-%-:+UDG#QTRP<Q<O',9
M2->)F2=,)%NB\:+IF 0$BJ#@JB:A1 >@P#5;)'Q2"2(EKQD1@? K;XXY8S'*
MT.:<P<0>X5S-SEW0&RW-CI[,!8+S'-SR!RJ.I^P9V:C0,H ASG);SJ2>6HD*
M@!YW*Q*(B(B/$=:[C2_6+Q/I@$9E$T R;(T'N;P =X5Y_K'JOX2U9QE$!@N'
M9NC<X=W=J6"NVC17:N7N3O\ 9_[TAGBTI@G.!%$D>06C"[4C-9\P\RG.!9:&
M1AV! TY/?<!$*[JQ];EK*WL]5M*5VLQ;LV.WCRKSK4?4I=1/[71;S 9!^#]M
M?*:&C'#/#!:^.]A?>_X?<G&S;MR3*Q;3L4VBEN9E+)MU"$4!JW[.W3W&^*4J
M9"%\P4-2D#00T"MPWBSU=:DP&YC@;(:UWH:<Y\K=!QZ<UI7<%^M'2WGYK+</
MBP'D3UYO>[Q& _V:T7D&3[\ZTAY6Z&?G G'EU;XUA;G+JJ JCIS63)Z!]BZ_
M>\ X:Z#2&>JN?;:"G+(YN6'PPI<_UQVV7STD\D37_P#^,JDVY3OX8L0B"V]N
M2.5803!4NT>W7Y-1'L>,D.%%RIAYO3V@>$?#5?V+ZJ9/\TOL:C_NW#GR[;'O
M*C[>]<\1[#<OR#M^9,/_ ,A;X=\<ZI6F^_-RN06TBUW QR?,"0^EXOB,:B("
M<J7_ #AK8]MJ!H)P$1 W  UZ J.S]5ECBTV;CS2&3_[N57:>N+4!1WSUN.V)
ML7>/9M7NK=[I'O'\XN%39PR9(VRP?'U56OS)3V_$SH*B*YNVAXZXWR[,A#+&
M#L!3()=.!0JU-ZPN"]+%-+@;(]H_W<89CEF6BN6>/.5<@]6?'NL?SBX=&UQ.
M,DIDJ"?@AQIGE04V46^F"^X-PA:3MC,9NO:X<GO6QBBO;D2[6MRSW8%.FH J
MJ1R49=0&**?* %>E*)3#J CH(<GJOK:U2X:8M+B9;M/YQ&\_PDLY_>KM-&]2
M^CVKQ-K$TER\'W@\F.E:[ 'FE/A5VE=G,58 PSA&,0B<48TM&QFR"78BO#1+
M<DLX)IRB#V=< XFY 1( !JX<*#I7FE_J^IZH_?U">25W^T<!T-P:.X O5].T
M72=(9V>F6\<+:?FC$]+C5Q[I*S F0"!H :!PT#41$.'0(ZCKI6N.*V>Q5T1*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41:K[S?\W^Z?USM?]T,
M?7<^KK^JX/T)/X;EP'K._H^X_3B_B-6TW@_WP_\ E5PR[\JJB)1$HB41*(E$
M2B)1$HB41*(E$2B)1$HB41*(J#<?;Z@U\7'QT2B<O'CUAIPX<.L>'CHF2HTT
M#0"F -?+QX%*(<> :5**L-?Z+_\ 2T'Q<-!JE% Z]0"(@&H=0&$!Z!X]-31*
MT]F/L[J\E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(
ME$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$H
MBU7WF_YO]T_KG:_[H8^NY]77]5P?H2?PW+@/6=_1]Q^G%_$:MIP^J/TQKAEW
MYS4T1*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E
M$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB
M41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(M5]YW^;_=/ZY6O^Z&
M/KN/5U_54'Z$O\-RX#UF_P!'W'Z<7\1JVHKAUWZ41*(E$2B)1$HB41*(E$2B
M)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$0?HX:
MT11KX= ]GB/TJ)XU-15$J42B)1$HB41*(E$2B+5C>;_F_P!U?KE;&GE^,$?T
M^*NX]77]5P#_ &)/X;EY_P"LXTX.N#_MQ?Q&K:4!XZ:@/N?7KAUZ!S[%51$H
MB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2
MB)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(H$= UH44 (\
M.C3A[H!]6B*JB)1$HB41*(E$2B)1%^5=XW;$$ZJA2@'$=1TT#701'Q5-%!(&
M:PO>F=[2M0QVB)SS$F4!U:,A\Q(>/+VSDX W#PB!3&, =(5T6E\,W^I 2T[.
MW/YSMO0,_!3G7+ZOQ;IFE$Q5[6Y'YK=G2[WO<J3S+ $IN;N]P<WJF.CHM/7S
M 5 'PZ=7,!TT0UTZ:Z^#@G3F?KWOD/-Y/ME<+<^L'5)/^FC9$.?RO& O3?.0
MR7]TP_Y)2^V5E>AVB_!DZY]Q87IUQ!\./J#W4^<ADO[IA_R2E]LIZ':+\&3K
MGW$].N(*5WXNH/=5([C\F=3J'_)2?VRGH;HOP9.N?<50X[X@'YT1_N#W4#<A
MDT.ES#C_ (*3^V4]#=%^#)US[B@\><0;'1=0>ZJOG(9+^Z8?\DI?;*>AVB?!
MDZY]Q1Z=\0_#BZ@]U0.Y')8?^<Q'Y)2^V4]#M%^#)US[B>G7$'PXNH/=4_.0
MR7]TP_Y)2^V4]#M%^#)US[B>G7$'PX^H/=4?.0R7]TP_Y)2^V4]#M%^#)US[
MB>G7$'PX^H/=3YR&2_NF'_)27VRGH=HOP9.N?<3TZX@SWX^H/=6(\Y9HO:\<
M<2T#,K1RC!T[B%%"MX]-%43MI-LX1T.!Q'0%4PU#K#A6^X:X<TS3M7CN[8/$
MS6NI5U1BT@K0<3\4ZOJFC265XYAMWEM:- .#@1C7E[ZRT&XW)8:#Z7$!X-8E
M,>&H:>=S\:T/H?HAR;)3])=">.M?'YT5?T![JK^<ADO[IA_R2E]LIZ':+\&3
MKGW%3Z=<0?#CZ@]U/G(9+^Z8?\E)?;*>AVB?!DZY]Q/3OB$?GQ=0>ZGSD<E_
M=$/^2DOME/0W1/@R=<^XGIWQ#\*+J#W52;<ADS3_ )S#A_@I(/\ ]Y3T.T7X
M,G7/N*1QWQ!M=%U![JI^<ADP./I<..G5ZK2^V5'H=HOP9.N?<4^G7$'PH_W8
M]U>3YR.2_NB'_)*7VRI]#=$^#)US[BI].^(?A1=0>ZGSD<E_=$/^24OME/0W
M1/@R=<^XGIWQ#\*+J#W4^<CDO[HA_P DI?;*>ANB?!DZY]Q/3OB'X474'NJD
M=R&3!Z',.'^"DOME/0W1/@R=<J1QWQ!M?%U![JCYQ^3?NJ(_)2?VRGH;HOP9
M.N5/IWK_ ,./]V/=3YQ^3?NJ'_)2?VRGH;HOP9.N?<3T[U_X<?[L>ZJ_G(9+
M^Z8?\DI?;*>AVB_!DZY]Q4^G7$'PX^H/=3YR&2_NF'_)*7VRGH=HOP9.N?<3
MT[X@^'%U![JI'<ADT1X.8</\%)_T]/0W1?@R=<^XI''G$&UT74'NH&X_)FO%
MU#^Q%)_5/3T-T7X,G7/N(>/-?/YT74'NJKYR&2_NF'_)*7VRGH=HOP9.N?<4
M>G7$'PXNH/=3YR&3/NB&_)27VRGH=HGP9.N?<4GCOB$?G1=0>ZGSD,F?=$/^
M2DOME/0[1/@R=?\ (GIWQ#\*+J#W4^<ADO[IA_8BDOME/0[1?@R=<^XH/'7$
M'PXNH/=5([D,F=3F'_)27VRGH;HOP9.N?<4CCOB ?GQ=0>ZH^<?DW[JA_P E
M)_T]1Z&Z+\&3KGW%/IYK_P *+J#W5'SC\F_=4/\ DM/^GJ?0W1?@R=<^XH].
M]?\ A1=0>ZO)\Y')?W1#_DE+[93T-T3X,G7/N*/3OB'X474'NJD=R&3=>#F'
M_)2?]/3T-T7X,G7/N*H<><0?"BZ@]U2&Y#)@=+F''_!27VRGH;HOP9.N?<4'
MCSB#8Z+J#W4'<ADP0X.8</\ !27VRGH;HOP9.N?<0<><0;71=0>ZJ?G(9-#_
M ,YA^D/[U)_T]1Z&Z+\&3KGW%/IYQ!\*+J#W57\Y')?W1#_DE+[94^ANB?!D
MZY]Q4^G?$/PHNH/=3YR.2_NB'_)*7VRGH;HGP9.N?<3T[XA^%%U![J?.1R7]
MT0_Y)2^V4]#M$^#)US[B>G?$/PHNH/=3YR&3/NB&_)27VRGH=HGP9.N?<4^G
M?$/PHNH/=4#N0R9I_P YAP_P2E]LIZ&Z+\&3KGW%'IWQ!\*+J#W53\X_)OW5
M#_DI/[93T-T7X,G7/N*KT[U_X<?[L>ZGSC\F_=4/^2D_Z>H]#=%^#)US[B>G
MFO\ PHOW8]U5!N0R9IQ<P_Y*2^V5/H;HOP9.N?<4'CSB#X474'NJ?G(Y+^Z(
M?\DI?;*>ANB?!DZY]Q1Z=\0_"BZ@]U/G(Y+^Z(?\DI?;*>ANB?!DZY]Q/3OB
M'X474'NI\Y')GW3#_DE+[93T-T3X,G7/N)Z=\0_"BZ@]U4?./R;]U0_Y*3^V
M4]#=%^#)US[BJ].]?^''^['NJH-R&3-/^<PX_P""DOME/0W1?@R=<^XJ?3OB
M#X474'NJ?G(9+^Z8?\DI?;*>AVB_!DZY]Q/3OB#X<74'NI\Y#)?W3#_DE+[9
M3T.T7X,G7/N)Z=\0?#BZ@]U/G(Y+^Z8?\DI?;*>ANB?!DZY]Q/3OB'X<74'N
MI\Y#)?W3#_DE+[93T.T7X,G7/N)Z=<0?#CZ@]U4#N.R;]U0_Y*3^V4]#M$^#
M)URJO3O7Q^?%U![JJ#<ADO3BZB/R4E]LIZ':+\&3KGW%2>.^(/AQ]0>ZH'<A
MDSJ<P_Y*3^V4]#=%^#)US[BD<=\0#\^+J#W4#<ADW7BYA_R4G]LIZ&Z+\&3K
MGW%)X\X@^%%U![JJ^<CDO[HA_P DI?;*>ANB?!DZY]Q4^G?$/PHNH/=3YR&2
M_NF'_)27VRGH=HOP9.N?<3TZX@^'%U![J?.0R7]TP_Y)2^V4]#M%^#)US[B>
MG7$'PX^H/=3YR&2_NF'_ "2E]LIZ':+\&3KGW$].^(/AQ=0>ZH'<?DLW#TF&
M#CKQB$C>X*E/0[11^;)US[BD<=\0?"BZ@]U;BXHN&3NRPX*XIDZ*DC(^M/23
M() @E_:DS(LDN1,HB ?86Q=?'7G>O6<%AJLMG; B%F[2IJ<6-<?"2O5.'+^X
MU/1H;VZH9W[]:"@\E[FC#H 61JTZW:41*(E$2B)1$HB]/+RZ,4@=942ARD$X
MZCIH =8^(-*J:!F<E2:Y!:793R\]7,XAX=8$A4$4UUTS"*B9><>8"#KRD$P!
MIQ >'CXUV?"VA-OI/GMUC;,. Y2/'1<%QCQ&_3F?,+/"ZD;4GD!\1.SV%:S*
M'.J<RJIC**',)C',81,)A'SA-S:F$1\M>GM:&BC0 T9="\@>YSR7/)+SB>E4
M=-5*C$I10E%*41*(@]>G@HBBB*K3QU"F@Y52(>#I\-2HZ<E/\RB;%Z^6BVLP
MQ48/ ,9!0R1S 0W*;F1.50G'0W#G*%78)GV\HEC]\/;5N>&.XB[*3WIIX,O"
MO8< \TH"!0UTU'F$0Y@TUX!IPJTKE$HH2BDXI1"HHB@1X#T^T-$&:D>@?)1!
MFIHH2B)1$HB41**>9*(E$YDHB412%0I!Y5&NNH>[1378FFG7K4JDYI10E%*4
M4)1$HB41*(H'ZH?3HI">'R_4"B('0'DHAS4TVJ$#KHJAM2BI44131$HB41*(
ME$2BE**$HB41*(E$4C4!5.45*I2B)1$HB?S:*=J44)1$#Z/;HI"Z28#_ ,DM
MJ?X=_=+,UXUQ7_/Y_P"Y_#8O>>#/Z:MO^)_%>LPUSRZA*(E$2B)1$HB\*ZI4
M4E%#" <A#"'L!K0*#DM-,XY&48)JM$%AYS$TT*(B(B)C@4@\/T1JO,8Y[Q&S
M%Q- .E6GO;&QTDF#&@DGF"U,$ZJFBBQQ44-[XXCJ(CXZ]UL;..QM66L?O6M
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M%_TU;?\ $_BO68JYU=2E$2B)1$HB416-?PZ03S^YEQ]HO\VJFJAV7LYUR R
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M'30H]%7(H9)Y!%$-Z0[%;FFBMXS+,X-C&96#?GH;7].;Y7X#3I_YC/\ N_\
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M6T1>*D;V]ATGR>2M.7F5LWEWFEKV-DF^,>3&+I50UHOY6*9RC"YTW)YN5CP
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MNH=6.&9Y>8!0,\(EYJ6H<.8>K6NSX;;'\WD+*=O7'PTZ!R]"X;BA\AN8FO\
M^G PZ<*])IDK)<89V;9BQM&1^%K_ %+)RRF2/*1ED21;H)R"QR!Z>@Z,P9&
MAA7*)43@(\I! 1*(\*N"ZU>TN";MF_;&OO0K;K/1[RW#+*3L[O >5GW.<+H+
MCG&5V8/VB7]:.9)!C?$/&1KMTU2MF:41.M#.%T=&#:5=QSPC8B(E3 @]@J&G
M56CN+B*]U-DMH"QQ.T;>6E>FJW]O;2V&D20WE'Q@&FZ?S3^;B-F%#CA56YL
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M*#E>+M2XYMO/M),6$<M*NF[>7+#P!@>(QC950" W.4Y2"/, Z .VM-6;//\
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MI3&M:T;KVTR%*@U'-LPV]Q:!;@'$N.RK:&D91;U.9"ZM1$5"I^GIW)<J1"*
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M,(UJ2\_5P)G,9@=K_P!3I2J: "=27]",AV?/JH#7LBAY@%"M_P -&Y$#M_\
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M=T5S[E>XM)JS+UM[&;YS73[H(I04&\0 :8'&N[TFBV(W[  [S<2\1\Z3L#@
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M_P X^I^R[,.@ JAX9Z0,W,S%CTX^U15QND]%W[]:";R>BC<.BM5W #0>40T
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MWV+0&3)FSY^U]#:MVH*]GV?:@W1(CVG9\ZG)S@37EYC::Z:C6H)KCL*W J
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MZY:WM]&E<Z4S/BA!KND9C.@=7'JCEYEF;NSH!%UN5O*<MM%VI:,%%SC5J\6
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MN'&.2+UE8*2M@\%823A"UFD=!MXB5CGZJE[(&N0)A5@V434 C(&G8G*)%NU
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M9*0Z^/2&@] \/%J \OL:5"FNPY50>.H]8AT] B/68>'G"/CUIS9"JFNP8J-
MZ^/AZ@]@"Z 41\(  U/C5-0JM1$=1'CH("/#SN(:"(:<NH!J'1QUXU33O*JM
M2:K#,'M]P[;=_OLHPME,V%^R2CU5[<))*;5774D>7TPQFCB35CB=OR!KRHAI
MIPTK+?>W3X1;N>3"*4&&S+958<=A:1SFY8RDYK4U.W/:LR:Z_HN(].F@ /C
MH>:7V "L6E>E9E:8A!X@/CUUX &O#3CH !J'AZ:G+)16N>1300$/ /3P#K]C
M3C49"@4UKGF5',  )0$NH")1 VA.41XD\X= #FU]G2F?<3(UV%2'L:#J(!H
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MT9V=LQK8SG3;TG/PK(>@#KP'P![X- TT !_GM"\-1U'V:L +(+CMS4]6G$
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MW<>0KVO#/V^R*N>Y92<CK8W 9#B;=9R*W;H1$8UO65;-630OF=FW11(4H%\
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MXMPNG^L@[NW4-0^3>=-^C'B-DS.NHB/CU$*JN:_:UH1GN'Q%4V9'V)>?I_\
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M?,0XOD>]PP3;3^P+5=V]>./Y.=NF'<1#12.GYE1*XC'D91L*?9.W8F0)]D,
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MVF;BU<)S>4Y52>O6$F8-K=$$XEG14U95XSCI2)E4"#(/BG>&!4#F(JL8"\I
M(4NBFTJ<73KFRE[-SS4@BN)S[^:Z2WUFV=9LL]1@[5D;: @T-!ED0>99/VO[
M"W6(\JS>X+-63I;-^;Y6*)"1UT2&C&.M^/$SA242B(EHVCF:0/C.$P ITC]@
M4@]GR=HISWK+3#!.;J=YDN#A78.7!6+[5VW-N+*UC$5J#O%NTG8:]Q=' T$
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MHB416I=S4SN)<(E#4QDU TUTUU(8*J!HJ:57+[*./)<\X9ZR*JDN@IVZ"A2
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MAV>Q _\ "JH.6U&Y[%/YJJI5?>3\U53WT[R?FJJ>^G>5(]/_ '55/?5!SV*
MZ_\ )3['U:@]U.\I#I_[JJCOH,]BD.D?\E75Y?9J=GYRJV[%3^:JH5'>3\U5
M$[R@?_"CV:D=U2$#_P */8H>ZA57YJJA0,]BJ_-54*YWD_-51.\GYJJ)WD_-
M54CNIWD_-50]U.\H#I'_ "55"I&>Q4#T!_DHZ_)[%5;=J;%4/_A509;5!SV*
M0_\ "JA[JEN6Q!Z/^ZJH'=4G+8J?S545'>3\U5$[RK_-54]]5C+8GYJJ@]U3
MWD_-50=U.\GYJJ=].\GYJJA.\GYJJA.\GYJJD=U.\GYJJG9M4'N*#='_ '4^
MST4'=0]Q4EZ_\E/5T4/=0=Q5_FJJ%/>7C'I'_)1TU4.ZJ547H_[J>GJH>ZI'
M<57YJJ=]3WD_-53OJ#EL3\U54H,MBI_-54J@Y[%(='_=509;56,MBG\U5#W5
M/>3\U50%![B?FJJ>^I[R_:R_J@?Y,^DO_-_?=/TZ;-J=Y9#BO>!^QSI'_F71
MT!T?T52<MN2I&>Q7JA[T/ZE[W_WOH]\;H\54*X<U^BB)1$HB41*(E$2B)1%_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>tm2115679d1-fc_compou4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-fc_compou4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!B -2 P$1  (1 0,1 ?_$ 04  0 !! ,! 0$
M       ! @<("04&"@0#"P$! 0$  @,! 0            $"!@<%" D#!!
M  4# @("!PX-# D*$@4- 0(#! 4 !@<1""$),1)!41/55Y<987&1(A34%I;6
M%QA860J!L=$R%;8W=[?7F#D:\*'!0I(CTY15E79X4M)3DR14M#4X\6*",W6%
M-B=(F>&RPD,EM<4F5F:F1X?'*&A).D3DQJ>X>7)C@S1D=*1%9:6(*A$!  (
M P4&! ,$!0D'!0    $1(3$"\$%180-Q@9$2! 6AL2(RP08'T>'Q$T+2%'07
M4G*R(Z,5538(8H*2-646-U.#=28G_]H # ,!  (1 Q$ /P#W\4"@4"@Z5<E^
M6Y:R@-9!VJZE5@ZS6"B4%I2;=%$/2F3CF@**I)__ *13N:?;,%,9+AU4TIE6
MYBG+#PT38;!4I@2D;A/]FYXH"&J:R,.R42C6RHEX=559P4->)1Z*8&.>Y2UQ
M6]=J>J+OR%?ESJ'#T[9O/O+1BP'3B ,+)5MU)5,>/I5NZ:]G6EDQ%;;?-]A<
M(8F$1,[L.!E3F$1.M.MU+@64$?[HO-JR"J@=H#&'3L4Q*A^9\"X-4,)E,,8H
M5-T==7'=HG/IYICPYC#Z-"%'O X)\">)/%S9W>6AXGO X)\"F)/%S9W>6AXG
MO X)\"F)?%Q9H_3A:'Q/>!P3X%,2^+BS0^E"T/@>\#@GP*8D\7%G#].%H?$]
MX'!/@4Q(/GXXLW]B%H6>\#@GP)XD\7%G=Y:'B>\#@GP)XD\7%G=Y:![P."?
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MX'!/@3Q('G8XLWO+0/>!P3X%,2^+BS>\M"^1[P."? GB3Q<V=WEH>)[P."?
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MR4BA@(4Q4$W'=#")AX: -4J,UUDQXCH(<0*(]O41-Q\X:6/UH% H% H% H%
MH% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
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M':3F*N&780L9%!ZE:'="V*<YC&3$=!I4W:7&6.W[N#OY.4BS,(Z;^.9"' .
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MP5CK,6U?'L)95\PLH:^+A;;G<+8(N_JRTPR4!&)-8URYC*N)B%$[I% R0@'
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MF(4Q"F(4Q#73IIB(U >@0]&F(FKB(U#MAZ- U#L" _1^IJ-!&OF:>C^R4 H
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M-9E8:=\^B/Z1ELP !$"J<OG*A#E 1 #D'*TV(E,&NABB(!P'M5=S/])Z!RE
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M!/8WQG>%QY!Q#M[N.\CR6'<77I=GV4/-3EKP0M4W>HGG'@MD5EE$F@.! @:
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MJA]$.S^KITHMJ13*;01U'01$.ST^> T1^2@D1*(\"ET$QQ$IC &@=4#&T =
M#7B(\  .P%(B">+SJR]S-<Z_.3K:C[ 7:S$=L[V#*6YF*49K$=M+=O?*>0)J
MY;?M!\JW,<K6;/;3QN\% ^AP34 1T'4 MX89,_TGHO(;7AP$  .C77_H]%1I
M^E!HE^<*?Z&.%OZ^6S_\(IJ1FSJR;R(;_,\5_N:Q_P E2HTY*@4$#T4,FA2U
M0_\ ^C?)/_Y,>UA['9S;KVO,JY0-D/,/X;&MU(=CWD[Y#S=/L.M7*OR-_P X
M>V_WSI_Z4/*>RX^Z='_._"7\P0 *4H:B >E >/#Z8!KI7T<O#%W%&N(T1<Q$
M4R@MJW[<PG;4/DG(T(QN+(-PH$D\7XMFBF,S9QHEZT=DR_F!1ZYH$SM,!C8M
M<4CRPD$Y@]3:G-Q7U7J/4^]^IU^W>W:]73]OZ<^7K=;3G,_TNETI_P JOOUQ
M?DNHGS81_)KUZNMKC1HJ--]G?^SY3+8]L)F+FR!A;-\U,.Y&[+SNK<#8QEG!
MR'=R\Q*N[+E$V[9!)$@"  )01;H)E(BBF $3*4A-"ST?2]+[9^8OY73C3T?0
M='V['=ITZ8US,S,SEQF9QF;F;F7HQ_UN^GU=3VS\M>EZ&C5K]1K]=ZS3HTQ]
M6K5JGI>BBM,1C,S.&&$3G,9L_)%PSQ2V<04%(,Y/(SUJ=M<MQ,%"N6MDI*E$
MCRUX!TD!VRLV3TR;MZB<Y$R^E3-QUKR70T=7\P:X]5ZO1JT>S:-5]/IZKB>M
M.[J]2)Q\F_3HF(F<]4/1KU/4Z7Y9Z>KT?HNIHZGONO375ZNFM6GT\9:NCTIB
MXGJYZ=?4B9C3E$K+E*F'=3%Z@G.!Q5,)BBJH<W74$RYQZQU1,8PFU'K"8>GC
MK7)IO"/Z,>'=P^#B.F(N9BO-JG'*YG/'?-9[[G<]:NRO_1/V_P"O3[V-L]K_
M !(O:U#T*^=?ZJ__ "+[Q_?=?X/J'^C4W^EGL4_^GZ/G+)LQQ =.'G\> =&N
MHZ%$0[6NM=?NS85@.H (_J\WZ-$E28PAJ =@0] >(C_^;YM!3UQX_6]CMZ '
MFCYE#'N.N;3H =0U*/0 B/UI1$>C7HJ9+%3EDK(;K%U[ ZZ#IIJ'8$->P/8J
MHJH*3#IT=(AP\T>&@<= _7H;T@(CKKI]#]73030*!04F'0->'FB(Z %  1UT
MX?0\X*F/<?-55"@4&$_,E_-][U?ZKV;OP?3U6,TWNB<I#\V3L6_JQXD^U./#
M]BDK&7?+8G4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"@4"
M@MWEX-<3Y/\ O=WJ'HVW)5)R'#_BCJBG!GW.V_\ 2_)_X3[PI.:0N]12@4%D
M]P6 L1[G\2WI@[.%FQM^XTOR,/%7';LH ]R61ZQ5$7+9=(2N&#YHX(51%9,Q
M5"'#ITU"EU4KR:%;(VY<\#EYF-B':9?>WS>SM*AUC,L46ONI?W5"YOQ/:A!
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M3\F8ZWIV?$77:#61W(YRPGDZU7+U%X9M$P^-XFQ8^392XD 3F?.EK97,WZG
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M]IX"/FAI78OFTW]VF^W3^U\WOKK'3KKGIU9;LHSXQ5*1*J ?_LSSZ+-UTZ<
MU[CIIYO&EZ?\K3XQ^TQPK3KG'_)U=VYZT=EO6#:A@ !(<HAC&V0$IRB0X#ZB
M*.AB& #%'CV=*^=OZJ5_B)[Q4X?VW7^#Z@?HS<?I9['$Q4_V#I_BR9[D!C=8
M1X#QTT#@.NO2&G1V*Z_=FI[D7ZH:>8(!]$-:"!2 1#TPZ!P .CLZCQ*)1_5V
M:"!1X: 8>QIJ #Q#I'AIQ'S-*%@H%$.KKZ700$- '7K:ZZZAH/3^N--]B>X%
MT$->G74=-1]-]=TB(CKPZ=0#32AOO>GN)=--1^CJ8/,T 1X5(BEF;P0"(!T"
M/9TU\W7S=1 !&JAW(.WQX#J(:ZB!>KKV]1"@GN0:!Q[6HZ!Z;0-/3:ZB/TZE
M"GN/^NZ# ;H[1M0+T]%42*.I1+UN EZNG5 2Z  @&I> #J \>V':H=J02*!>
MJ'1T=G7H[(ZZCQH*!0 0$!-TE$G$H#H4>D $=1XCV]0HL37:D$=!UZP='5'T
MO27B(%Z?K0$YN':'3L42<50) !@-KT=KAKVM>/8&@_6@PGYDOYOO>K_5?S;^
M#Z=JQFF]T3E'_FR-BO\ 5DQ*/HVG'C22&Q.HI0*!0*!0*!0*!0*!0*!0*!0*
M!0*!0*!0*!0*!0*!0*!0*!0*!06[R\&N)\G_ 'N[V#T;;DOJ5)R'#_BCJBG!
MGW.V_P#3#*'X4+QJZL^](7>J*4"@T-\S_P#./<E37TP?"2R6.@\0^YP[^E52
M<X;XP#0-*BIH*1U =0#7SJ#0)BVT(+/O/RW*7GDR/:7.[V:;8,60. V<HW1=
M,[ FLM2,ZI?-W022J9O4=QS4.GZ@4<E$%/4XZ (" "%R3"9K;%OVX)% -3&X
M!J83:#PT 3&TTXFZ> <1UZ*FY=_-B'OCWCXVV+[<KTW%9+;2\G#6R>-B8>W8
M)+N\Y=-U7 Z"/MZW(Q(ZB9 =2;XP%U,)0*4!$1I&)-1]6^'E!Q+BS,6\;?OD
M''_-^W&;B=J^=\ZXIM3+VPJS\![DKHPI9F.8*2>33=?'=L1T8?V.S^8K51"/
M=2";HCM5RN*A=%.NDF6U6&]G/5<Y9[<6U7"^]/=_L"S-CK93S02HYLL7,%ZA
MC?:EO@LZ':C)91,^(U0B;(SO8S!3U2UR"U06$CZ78LR-'!5$U%P.<RRM2HFY
M6YB?+.6VWCR=VY6-N1&!M_?-*VL8W:)6]A2W+^QSEZRK&8ID1A+-F<B0'6N=
MG;[0A2ECH^1>H>J#HD]**IA-TC5DB*F8;]JBE!!AZH:]CL^8';H*>N&FHAI^
MQV]>P&E!4 \=-!_7^CV X4$T$:]OSZ".MT^8.@Z#YFM#YHZ_F#]#C]#SZ!U_
M,X::B/'@&@CVO,H'7[8=O@'$>'#70..E"%= H% H% H% H% H($-?^CVM0'M
M]/"@\^^?/_F,=E?'77E\Y3_"O._2J[DG[GH(#H#S@^E45-!HF^<)_P"ACA7^
MOEL__",:K#.O)O'A>,/%?[G,OUFR05&G)4"@@PZ (]H*#04J\0LGYQ@T=7"J
MFP;YEY<CFV;#574*D$S-6)E)*?N%@VZXAW5RSBERK"0NINJ(<!JW;-Q=-]*O
M<5TSMW"154E2&(JDJ1-5(Q!$2"0Y3@8JB9M-.(#KV=*1JG3,3IPE^D7$W&<,
M>]R#L<=X.R5>]EP%O(73;-L.I*".K:L?,%*^350(F4T:5L(N@,4X@!>/;'HK
MSOL.G^W>[^G])ZO7U)]-U.I$:OKG3AVW@\C[9?J?7]+H=;5JGHZM=3]4Q\=S
M!*'W$9,L>9QL]R-9T9/P-Z6)CV;GH]6PX2./:JMZ7?;$"XN@\E;4*<Q&<6RE
M5EA;JFZR:&G7 #$$U<RZOL?M_K.CU]/H.KJT=;I=;JZ=,_S-4^?R:->J-%:]
M6>J8B+C.<L)<@U^W>G]1HZL>GUZM/4T=37$3&N9\WDTZIJM4\8C'CC$N6BM\
M=RR#%Z_A-N;"/!G:]BR<BA(E=1+I20NTEM V?,V98@KR3MLCVXG3,!!/NS5Q
M'+@KH!@T_/7^4^CT=<:.I[AJGS=3J1'EFXK1Y[B9\U1KK3&KA,:HI_/U_P L
M^DZNO3I]5UXZE:]<:;B-51IG5A<SAJF-,3SC5IF,'/Q.\^\[B3EVT7A: 83=
MH0,M,7!'S/V5:IW)['W1$9P+ <J1)$'81S0JBIDUC <P  !TZU^?4_+72Z$Z
M=74];U=72ZNO3ITSIF)\OFCZ?YD>:XN:BX?S:_RM[7TZU:YT3HUZHC3Y=&B]
M-Y>?MY,VL(7DVRWCJ$R(O;<9$,+I(:0M]J#,4W!X)02 Q</4'"95&SM58BG6
M3$/2@ <>-<2]WZ/7]L]=K]#IZVO5KZ<UJGS3]V^IO&,L7@O7^V>B])ZG5Z;3
MHT:IT8:KTZ<]]89<%ZR))ID*FF0B:9"@4B9"@0A2@ @!2E+H4I0 >QI7AIU:
MM4^;5,SJXR_"-.G3'ETQ$:8W0_2LM% H% H% H% H% H% H% H%! CH CV@$
M>'3PH-?O-1O. LGEP;VKAN1^VBXM+;=E6+%R[6312-(3UK2$!$M"F..@K/9>
M110('[8YP *1C)JK3C;ZN5M;TU9_+HV46Q<3%2-FH;;=BAA)L5_WM9J\2M..
M!5NH0P (*)F'00JRD9,^:BE H% H% H% H% H% H% H% H% H% H% H% H%
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M*4.D1&HU@^F@4"@@0U 0[8"'HT'Y%2 /1 =>SJ'9Z T$:=IB_73S1_6^I0-
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M:!IKV^!2E 0'3IT+IYPTW4/WH% H% H% H% H% H% H% H% H% H% H% H%
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M]EE0Q ;?.)^R]Y9(?[#-7K*F"WJ/4WSB;_'>62/F"3-?K.F"7JG,]3?.)O\
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M[70*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!0*!06[R_\
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MY2<?ZQIAQ+G@?"_YT_R7^*/RDV'K&E1Q2YX'PO\ G3_)?XG_ "DV'K&F"W/
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M#KVRZ=41\W36BW*GN)-! -0UZ.@=!#30P%$!+J70-.&@:<*)VXH!NF :>F$
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M]/$0\W34..FOFT^9@ B4H  "8 #S>QJ(Z=' O$= #@4!T#0*$8)[D7J]7CH
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MSFD90N]44H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H% H%
MH% H%!;[+7W*LF?>^O/[7)*@T]?-Y_S<L;_6%W*?A8GJ;TTY-XU%4G^M-T]
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MUN_R[#?SHP]<41\SF\;3:(*N'=S6^U;HD,HLNXFHQ!)%,I1,91915R4J1"E
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M=L:5S!W8_9C.NI"3,U=')W("B CW(:91?/\ :F<U&,Q^[#;F]1K=--%!%%(
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M_P"M9O&__$+?%6<TTY>/S;ZJBE H% H% H% H% H% H% H% H% H% H% H%
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M@/9[ U,VLE5$N"A<%"X*%P4+@HI0*)<%"X*+<% H% H% H% H% H% H% H%
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MT?M^UY]$MU.!2^P.7KYCQ'1&\HR#NYJ40]*=W',D+9D0 >!1%-O%MS" = F
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MP8;,*4$)5B&+:1$13%$!#0' K"'9IACP3FO%O5W8YPVRWYMAQGB?*V+X^"W
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MD8\HVV[*6(F)VV_?X-E5 H% H% H% H% H% H% H% H% H% H% H% H% H%
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D;(,VK<@)H-6J*:#=!,-=")(I%(FF0->@  *@^B@4"@4"@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>tm2115679d1-ph_fluen4clr.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-ph_fluen4clr.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!,@.2 P$1  (1 0,1 ?_$ 1,  0 !! ,! 0
M       ' 04&" ($"0,* 0$  P$! 0$! 0           0(#! 4&!P@)$
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M$5KF)F*K\>XEIR4C8:*9@0SR3EGS:.CVA%52()F</'BJ#9$JBZA2%$Q@Y.8
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MI1Z!DB/'+-N)$U5@$W*@"!>X!SZ/PIX9S/%W.8<DP)V[>3<C.0,R1%H1,B[
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MD(&4(*1S HRE&1?.HG+R!B<#W"&6_5$B"(R#AP10]18J+MJ=F[*S<_O(2,2
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M..V50M)-D:%T!J.A33;8VP=N+16VKQ Q<[/2FP+"YLDY<W)VWVGNBR,6+!E
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MI)25@DH:\*.E]IOG\BP(T@M;Q"R(2C"0.HZ2&.>75\8(QH8XD$P%<F((G0$
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M"X5"TQE?B89EKZ@>(3*Q?HPL 0%02"\6.0"G]K#&!EV+6/>;'RR7N7)$F(B
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M;NFR"3M^T8RZ*!@ #!YM0WKCGD9G.<?DMJ.7D796K<YQ@)1$B\IGU1ZH)J6
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M(B6CIV+CYJ(=I/XN59-I"/>H"(HNF;M$J[==,3 4W@52. AR "'/;G"KKOG
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MNA973L+%<T;TDZ4?N6:RJZ44<3* 8/T-#/1CFV,_(R.9\]G*[E7&&V( E(D
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M6U<D19&$1(IIC8-VZ+DL2!D(C?-N <!Z])(%-25KD9=VX(#(D^R&R/5$.P<
M.W7H*<&7C)4_D..KG04XXZWODC>HRA].VS;P=6P/](3<G?;;I/;-6?MB2#II
M(J[#JZ;R->6F=!1XV;.(EJUCDER)I+(>; X8PN1F*.SD5!!H6-" =1Q"MDXE
M[#O&U>VBXP-)1D&E$2%8DQT(T-*@U7H'T/\ R\%9N&STNCGY2'64KT(=:\&8
M(=:(V"3W.T[M>4:KI1IG^M+TY64C4QF7/C6:M5UA073 ?1G3CCC)=ZC192$H
MG9)@?2/3HO5;JLWCMS64+3G&F:8XN"=@2L3V9M3"I6#8<? %CX8CRG1?VN5)
MPWE9-384\J2.0<(*"FS 174_0PYRHN1,^ZKN9]"WIT?JU5=PW;/UF?S=NGD5
ME41 =2UC4UQ9IV^5BIE:1SMY>:"QJZJK66/:XR.,I"*2QI=Q(,7^O'*2Q&;M
M _@>K*B*R8%* 9;*M6KN-'W>=V&:T@2XV5H#M9R10BH KJ].O'RS8MSM2M69
MQG*!$I1)E'822(EP ).TW!< ,W'$'O3EM5;:%TV7";U>45U:T*TS385JL,)1
MNV;59G.,V[ITVM9I6*?RMA"50]TEA;$.9-@@1(Q \1L8]O'CC#WN,KF?$-&8
MD8Q&FXF ?<[:$L'ZDCF7X0NV;>R./>(,HF(.A)&TD/%G/U2*:NN73/J#J&U$
M$RWV#?*Y=(V<D*^NO'_;!>+ LUD$8UP2YV^.FK:DL_CU+9+G263@$R!&QI$^
M$5>3FYH>\,H[2-O%_P!"BV<46K@O1F;Q V$$,#QW U(/54-Q6Z1QX*(]W'E]
M;RYI\RYEJC;>K"EMK#(4G6#&1W)<X46HVEC1W$>YA:&U=O7L>E*7:;5<%+&L
M0=QKA,2-4GKCQH'+YKQ=@[8XQ.\W9UWNL4 DR$93-!0",:DG0$D :D@56EJQ
M?RK@L8L1*_+0&48OKQDP?HZ>#J,.D.]M=W36S]CVBCC#7R4-1SR N&\NJ-;K
MR362E:AKJ8-+04(S1O-(7?NSRA&1720'=IB9P)A\!.S(GC>[6+V)(1N[)0N1
M#B3@_6)<O&<9!M&(,6HYYXC;.49 :OY=8*W*V-4SW[7-\HR<FXA5+I2K14TY
MAJ7Q.HD]C@GT.23;E Q1,X8&>>=('(<F(';GFK1><DSJG>^I2U;<<G!Z><0'
M2+IV<0BB1KJS/MC;=BH2LOGEC;N9HL,Q85!LZ:-"G8LS-Y(5)(3&4.1,Q3#>
M5V[.&R<I&.YV)>I !->D !^@=B@  O1U>7VYMZW6=U_7"SO3["$VK1V6U]92
MTG)V-*P4=V@S:.21MJH+UN"=O9$-)$*W>)O8XRBJ:Y132,1,QN>[ SVF$I1D
M).\?F/2#IHN[!SIX9N-"$X7;4H$2?27$$$$$%CK5F+AUU-([VDJ5K>TWM&LU
ME'7D!MU_#;45*\&-L;V\3=CCV-\N= JT/&N63RGGF9<KZ/;G6-(2[8%%TO$*
MJ)#^IS'F%SF-R%RZ!$6[4;89R=L P<FI/HHO/M6Q;!$>)?SG^7^=>ASDE1V;
M5I**6.C/5N9;*1DHV26>-?/H+))G79.!1.U?-3*(*AXB")#B0W;V#GEVKUN]
M'=:D) %O/T+NR\#+P;@M9EN5N<HB0?C$NQ!T(H:CK46K]+&A56\6T2UM7VS.
M)A/M5;,VS=5-L%.,<BZM.%(%1(%97=I)K':<>:,HF B'/.=6)>E@][W# WHD
M2>O34/IJ=&U*KE9=_-A:MY!>%F+1H!2FK ;C05+FBQK9.OM:Z;T/M(*WJ4MN
MA!AUIB5HS122D7UI79F:%9("Y=.7<@",21ND9 $CAZ(BV $ *)"AF4(F4A;@
M"2: =9T \ZYB6#KS-A6%:U3%3FQ*I&ZZHEBTW?JK4T:CJZT;!G4=J(VF:@)>
M45IL=L&1J\-(;-G&DX,/Z4]"32(\053!UX *(?48][(Y-R^_CY.)<,KS;C)A
M':WJ.0\@QEN8&!)V@OH.>48WIB49BFG3U_1QXKV TUM^O[KIY+?7F<S$':S,
MM6+)6;$FP1L-1M4 Z]$G*U/I1;^4C"2T6X,4JI6[EP0OB !,!@, ?+KH&CJ7
M<(F$3")A$PB81,(F$3"+\B/^M*<>F]&'^#;RX_M]7Y_4O\-NG-^W'_Y9?H'@
MI^YOM_3A_9FOR3Y_4B^\3(1991:-;=EV^OT*B0$C9[?:I)M$0,'%HBN\?OG2
MA4R$*'()HH)^+Q*K*&(DBF G.8I0$P<>?GXG+,2>=FW(V\6W$RE(F@ _3T#4
MF@6&1?A8MFY,M$!>P_2EU"!T$=1>HM*],5S@KCLC8&T=:4OJ9W$2,:SM1DV$
MI:HV*EM-ZS9RJ2K56M5U=XJ=W94DTGDD] /1#D:I%,O^1^)N13\;\@RN=>([
M4[.!8QKL\2P^V<2(DB_=(+[Y@!K1<0C]8;C3Y_.QCS+&E=S(_L@"8AR"*&I9
MJZL*@/5R6CZ)]16T[YMS;-KL-_G%)J0BI>8K407T=NT91,%$R[Y%E&L&;1)-
M)!(H>(ZAN#'55,)SB(B(Y^D>"O#W*/#?AW'PN3VA:L7+<+LZDRG<G")E*4I$
MDG@!H &"_P 3O'OB;GGBOQ1D\PY[?-[(M7+EF%(QC"U"Y,1A&,=!J2:F4BY*
MB: KT[;)N,K-7B'T]8IIR#2*AHU+SKQZN)#*&*F41*5--%(AE%5#B5-),HF,
M( &?19F;B<NQ9YV?<A9PK47G.1:,1I7K)8 "I) "^7PL',YGF6^7<MM3O\QO
M2VV[< \I%GH[:!Y2D2(QB"3HMMZ]NMWTB/U:_I&4@YK9?Z AM'9*K<D[67BR
M7B76U_38]R!6KB#@G0E3=2OA*N[>I*"B8$/"(_G.;X7M_>/9&7XJMW;7(JG%
MQG[N[$&@R+TA47+@<PM.8P@1O&]V_4N7^,+WW5Y)PO!URQ>\1AAFY;=Y9D:R
M.+CQDT3:M2:-R^PE.X);/44!;>W-L3>MQ7O.RILLS.J-4(]N#=DVCHZ.CFWB
M%!C',&I"I-T"G.8QA'Q'.H8QC&$1YS[#PWX8Y+X2Y8.4\CM=UB"1D7D92E(Z
MRE(U)X= # +XCQ7XNY_XTYL>=>(;_?9NP1#1$(1@-(PC&@&IK4DN5ZT_([_I
M6]O\*I/[DF.<_G7^)?\ [H[+_P \%_3_ /"9KSSMQO[-Q>VV?RJO[*3")A%9
M++_%RP?O)*_N!?)&J+&M4?>SH7\TX+^#T,@HI PB81,(HPTQ]ZRB_P WFGT3
MX4]*D_"A,(F$3")A%\%UDD"^-7L 1  X*)A$>!\@ /DYPH==?W19>0__ '%3
M\YDL5+A4]/8_FA_Y%3UO]QZV-I4;@GN@Q[/;C[7N_0E.SLX_,>H.&1QJJ^Z+
M(?[,?^24\G;^8PR.%7W2:?JAO^25_.88HX3W1:#_ -L-_P DI^23&TIN">Z+
M0/\ MAA_^+4_()C:4W!/=)I^J&_Y)7\YABCA/=)G^J&_Y)7\YABCA4]TF?ZH
M;_DE?SF&*.%7W29_JAO^25_.88HX3W29_JAO^25_.88HXZ4]T6GZJ/\ :'_)
M+ABFX)[HM [U1'_XLX_0)ABFX*GNDS_5#?\ )*_G,,4<+D60:'$"E4$1'N_0
MU Y[.>SVGJ!ABCAUW $! !#N$ $/8R%*KA%\U%")%$QQ$ #D>P!$>P.1[  ?
M)A%T_=%EW^,?7_0E/9_,>MDL5#A4!^Q[P-Y./TI3N_M,,CA/3V ?V7=V_I2G
MEY_W'KX92ZK[H,0_LA[N/TE3N_M,,5&X*GI[ ! ?%VAV!^A*=G'(?F/7R6DH
MW1'% ?L0[C#V!Q^DJ=P\?[CULC:5.X*OI[(>/;CV=WZ$?\DF&*;@$].8]G)N
M>.T/T%0>.P0_,>H.&*.%3W08=OM^_O\ T)3V.WVF-I1PGNBQ'^S[^?\ M2GE
M[_[##%'"K[H,0_L_+S^DJ=X]OYC#%''!4&18^53UOTI0/5_W'KXVE-P7+W29
M_JAO^25_.88HX5?=)G^J&_Y)7\YABCA4]TF?ZH;_ )-3\YAD<*ONDS[/T4>T
M> ]HI^=PQ1PZ[I1 P (<\#ZH" _.'NR%*KA$PB81,(F$3")A$PB81,(F$4>;
M=^]1LW_)]<O\79'"*U?Z)\(LDH'\6D/WPF_X9?9)0ZK'-R:TKNTJ8_KUKAI&
MUPB:#QXYH[6=7@8VZJI,7)6M=GE47+--U%O7!R\I+*E0\X!#*<E*(94E@ZG6
MBUGZ+:7KFJP4D@SJUBJ6VJ_&153MM9O]UL>P;G2J<+AW.4VHL;);%EYI:B-D
MY%95D7QJ$\^98#J**$$V=&1:C9F(PN0N P$GBY )J8EP"\=#KU%4B7'K ACY
M=7S+>TI@$H=OD\OK?,#.=79<LE0L"V9)4:-I4[\)#E@WIL@Q7AYHDAYXR;YO
M+)'8C&MT6A%'[E\_!84T4VQ3.#J& $P\?& Y(B-262C.5YZV"1T+U"]1=.H]
M@U/3M@15?2BX^&<OW%E]WI.NTUJXM<%;)Z#,FSJUVU-!7,YFC9M*J/B)30G5
M*@"HB!^O)P,S#)CE6IP8L7%'(< D.'(KM?<W *D;D)_5(/EZ?/T\5N7>.FK1
MNQYN$L=RUO 3$S!L%H=F_(+R-.Z@7"B"RU:FR13MDE9:N=9LFH$7(%=, .0H
M@B'E\S&Q,?#MFWC1$(&1);I/E3HX,P6A))<U4Z BFFF5(J9"(ID!,J92E*F"
M90 "D(F!0(4I2]@!P !QZF="*)=J[3C-40T>HVJ%LO<]+2+6-@:'KR*;25FE
MC+N$DWKUNT=/(R/:Q4*W,9R]<*KID103,/MC"!1Z\;!R,JU=OV]HLV8;I&1V
MCH$1TREI&(#DT5)S$6!J2?+T<5K@\W+T_2E?E^HX^CK9+3].MBM.KSHVHB#M
M"UW_ ,^>K.H:D,7"2<O*OV3I)9B,B<R39)%)<Y''HY3J#Y\9W.^G9G;N0V-6
M082W1$O5JY !X@5T?5>A?Q+=G#L9D<BQ<G?$B;<"3<M;)&#71M B9-NB 3ZI
M!+.RS.MCHWJFEG<]/ZO=*6_5SUU2+.VN40:.E:O+/&T/.R-"G56#X\?9F?HS
MAD\4:F4?QP'.D?@%@[-]H[O>X=]./:O-WDWNZVRV[7W49WTZ7^1N*VM9-&D>
MU09,D$&;%FW2:-6K5(C9JV:MR$1;MVS=$I$D$4$B F0A2E*0I0     ,J*%:
MG11YL75M!V:,(KL**86&-JK\\_",)@J9XZ%L2;1VR;6IL!B%\Q.QD>]<)-UQ
M-^@%6.8O!AY#NP^8Y.""<0B-TMZS>LP_5!+L#Q:IT=EG.$9_6T4/;7WW\"3C
M7]$J5 L^VI!]6)RRRCB/LE;CB576M&BR*2]TG)NRRC \TNH84D6[9F5P\=+*
M&,(%*4QQY+DS=G*[)MTB26H')>@%!V:*XCM BU %"W59TG=$GRH6D*O0-^46
M(O,)LFKQ%[UK9462L1LFF%DX,DQ"VBJ6]DV&4JD@@Q?E,9%18&SCGS:J*H<E
MS$78=YW+^N [=2Z#BWQBC-,#[M*>P2X&3$L.)8 Z+P@=-?E7OD S)I5MK;/E
M.ODO8ARX41C#J&>]4'3;54E?:1Y5US'=V&M1S O"0I@[CDBH@408 )2FO5<_
MS+W9Z8/E6.B#J_T0XW_I+;[2?K,*E&&O-3<1S]#96M'T@NBS687BB)(N)R)"
M)<./[Z=)D6CTTB'5*N9,HFRERYW<=Q!-0*:UIHNC&QI95TVXRA!HF1E(M$
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MK#55?U5!.HB%<24H^F)9S8;39YUP1]9+=9'B+5LYG[#(E21%[)'9,4&X&\(
M1!$A #@N<79JM'Z=%$O5?LK8.LJ)6Y"@QY2)6"]PE6NMW58JRJ&J*/*-))67
MV,YATC$&43@UFJ!!2,8J?B<>(P]G PQ/:CU=:W:3UK?^J^+UCNK>FT[LZJE7
M-:F<#K"I1-AU-K/<L2Y428PNQ-HT&:=.K#*@_:MS.&48Z5*U0!83>$X&R=/.
MJMN ?0?*MN;1TQ:&N:E<<6;6=9E'=0. UA\=LHV?0+7T55BK#QC]DNV>-*^Z
M:*B1:.*?T)8O '2-X2^'*W9MV23;#&1KJ?Y@N[*S\K-$(Y$@1;#18 ?, Y+
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ME067$WMUE%# 5(@#P!A$,^-\:_>_X<\+<NAD<MG:YCS"[/;&W;FT8@:RG)G
MX  5/0ON_ 'W'^*_&7-IXG-;=_E7++-O=.[=MO*1-(PM1=B>,B2T1H]%&G5A
MTQ3'2WL%C4'M@1M4-/1 3E<FRM!8/%FQ%1;.VDDR**J2+MFX3_+)G,0Z9BF[
M#<E#W/N[\>8WC_DT^96K)Q\JS<V7(/N .H,94)$@>(!!<:,5X'WG_=OE_=IS
MV'*K^0,K$O6N\M7-NV1B"THSB' E$C4$@Q;0N%Z,?([?I6]P_P#"Z7^Y9?/Q
M/^)?7E']6_\ /!?OG\)@KSW^MC?V;B]M\_E9?V4F$3"*R6;^+=@_>25_<#C
MU18UJC[V="_FG!?P>ACBBD#")A$PBC'3'WK:+ZU?:?1/]+"GK4G84)A$PB81
M,(K#8/V*D'JKE_X"GT\O%5ET^6JP[P\CV#Y>W)V]"SW-JN?KY9E#IP(^7!05
MJN/A'R"(9&WH-$?I%5Q#O .[MS/BM2O-?Y3=T1#7^B6CZ?J%>@Y+>J;2><[!
MVC?-/T1PT#6E^<-$+-<]<L9"PHHED4DE&[;S1D%W1"^,0$I1SKQGW2(!?;P
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MZH-'-X?1]@O^K;#%A0]=P%7]R$ 8/HMTLY9R)V"3<AP7,)$HDVQ&,7.V+.
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M324@*$-0%NG05X]"T]JGRBG5A9]6;VM;FLZ9K$_2E:H^CE+&48^/UV>;N;B
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MC(BP3\' NY1DXM8>!%)0'3DBA@)VB(CW0YCD2P1A0G_S(G=M85)JY+.7#<>
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MJL2'^M5-68NK+,_)=IM(W_RL4SV5L2AFYF!BKE>MT@ULHL*S8Y0$IDRB?Q<
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M>OM/HG^GA2I.PH3")A$PB816*?\ V*E_QY?^ IEHJLEAO(\\>OQEA(DLJ;0
MZ^F6*J&)J@?D\8=2RH/?A5.JX\!W]P_/RNT>=6W%?)=HU=D\T[;-G27B!3S3
MINBZ2 Y>XWFUR*$\7:/;QY<DA 251%JV;% C9JDV(41\)&R23<A0$?$8"%1*
MF"93&'D0+P'(Y%%+E< 81X+)N2Q[ KE$.$7(,FH.42@ @4J3@$?/)%*41  *
M8. ') "J9%<2QD:4ZZA8Y@51T4Q'*I634JKDAS <Y'"A4@.N0QR@(@81 1 !
M\F20@+E?5LR9,2G*R9LV953>)0K1HW:E5. #[<Y6Z213'[>\>W(5EV>.WV>_
M\7J=F&"AR[+CSZP^4.SV1[NW'I4.50#B(\=GSLJ"258T#A<\NJ@DH. DM5V&
M8<.T?]\<?^YCE9:%7CT*0$_TM/\ WA?^"&9K1<\(K=)_L1?_ (A;_F5,M'51
M+ZJP7\7TLN-%D53#]:J-57O]CNR5/S*O&0Y4L%\1_+@/ <AR4#<!XP*(\B '
MX\90$0 1 !X'@.>X,J274]B^0L60E<$,S:"5X83O"BU;^%X<P@(F=E\WX71N
M0#M4\7<'J!EFXH"=#JOIYA#]11Y%(J'/FD^?1R  %;\^'](* =A/RH>0,,%7
M<5\$8V.;E,1M'L&Q##R8K9DU0*;U/$5)$@#X0#@.?)D%G5@25]BM6Q$P23;-
MR) F9($2((D2!%01,HB"92 0$5#"(F+QX1$1[.W)8,@)6/62GURUUJ:J,W'>
M*OS\6[A95E'.'$*JM&ODP1<MVTA$*,WS$5$@X\:*A#@'EQN8OQ4$;AM.BN,#
M!0U8A(BMUR+8P=?@(QC"PD-&($;1\5$QC<C./CF2!  J35FT2(F0/4+D@DU)
M<J"(@-$,%=LE55> R'5@$ H!W?DY4!E9..>_M#CCCR" \<@(=P@(=GL9*"BX
M\>'GCU [Q$?*/JCW9"D:LI(1_2B>Q^2.4.JT7UR$3")A$PB81,(F$3")A$PB
M811YMW[U&SO\GUS_ ,7)+"*U?Z)\(LCH7/VL(\=H^Z$T/_YY??CY)3BM"NI[
M0^X^H-\>>AJ]1;=5TJC<-=0>IMK3]MI%?BK!+S\49#<LG*UB/FY=67@4(3Q1
M@QZ*#YLFH"B"Q3G-QC:E=.XWH[1NH.+#B>%=::+NS;>%;[J.%<E</=@W)$,-
MY8M %BT="3J7:E3$>V#P^FH6"H%MU]+;."H:,L&V>KV:FKVM)AL+3]1A9MG8
MHE&,MLV:?VW*S;^%6508N6Z;<K-'S+A=+TD$E._ YA.SCWK4[4'N Q]8 F)T
MW1+$UB2*-J[. 5Y@$IF,ZQG$\#UTK3BS$K8>I=.NJ-SQ[.>G]?OVM-DZ?76U
M6*_L-CB;BVH$VUB[*WUH9Y 2Q6GP7J('12=0X.3(JKIG(L4Y (.>/9YISOF6
M9>CS+'QL?$LR$+7=_6N18$W)[0(O(T;4;=!Q]J[A\MQN4V;\;ER?-+TY2(!B
M;<;8]41D_KB[N$I<8F$HEW<#;^K:ZJ]';(-:G%)Q3:.B$(*&CTW#HT=#P[3Q
M*,X>+9F5.@PCVZIQ\)$RAX2B  /A*4H=$+(MF4H$F4NDD@=E:!^A<]_,EDQM
M6[L8"W;#/&$8R.@)) &Z3 5/SDDZY;$Z89JU1NT[54-@V;6^ZMA-H9TVL%8M
M-D9TA"<IS3T>H%FJB50(V7B#^ $I0#MS+O&JAB&,;PD ,+>-NLW(9<;<C=)W
M #U31@#1SIJ7/#1=/-LS&R;EJU@&_P"Y6+>R NRW2#DRD6<QB"2?5BT>)#DK
M[5S4%ZJC7;=VDZ_3[9M7;S2J1$E%Q<P_:TB-2BZZG7'*R1YYBDX80HK*+/7;
M=LV,JZ4,/M#'-X@]7,L\EGC8^+@XT("U"6\F$092E)W8.&% * T#N5XT.]C*
M4IEW--:#R_D6GS3I\V;K*JZX>6C3>AH./Z?;W.W6<7I+UXXB^H5G-5A_78Y
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MRWNSU^ET^%D+':K1+,X.OP,4W.ZD)65D%B-VC-J@F F,=110.1'@I"\F,(%
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M>'_>Y?GF^GARI8*ON2P_4"_/,'Y.3N*C: J>Y+#]0#^V-]/(W%3M"Y%BV1#
M<J(%,'<("/(=G'////=C<69!$ NN^4/" %#N  #M];(4JN$7S42(J42*%\11
M 0$!YX$! 0$!]80'#HSKI>Y3#]KE^>;Z>6W%5VA/<IA^UR_/'Z>-Q38$]R6'
M[7+\P3!^3C<4VA/<EA^H!_;&^GD;BI8*GN3'_M<OSQ^GATVA5]RF'Z@7YYOI
MX<J-H3W)8?M<OSS?3R=Q3:$]R6'Z@']L;Z>-Q3:%3W)8?M</[8WT\C<4VA5]
MR6'=Z.7Y@F#\G)W%!$!4")CP[FY?GF^GC<4V@JON4P_:Y?GC]/&XIL"I[DQ_
M[7+\\?IY#J65?<EA^H!_;&^GD[BFT)[DL/U OS!,'Y.-Q4;0%3W)8?J!?FB8
M>[_LN[(<HU75P*4"E H=P=W;SD*RY81,(F$3")A$PB81,(F$3")A%'FW?O4;
M-_R?7/\ Q=D<(K5_HGPBR6@?Q:0_?";_ (9?9)0ZJR;CV?#Z9UQ9MFV%H^>P
M-2:)24RE&I*.'R46#I!%^]0:HI+N'7N<U5,N=-,AE#)IF\(<Y24HQ#R+!P/.
M=%>%NY=)C;B9$ FG0*D]@&JTXF=K='/47:75AM%.9WYAJ^.A7M"VJ-5F92%N
MT5=V#E2QP-'FH=KZ1<:_'"V(C88D?2F &$GI2 ^'VNEC'S+\;]Z-H^ZV0'FX
M(+@DT=PVE0TGIQ6]^UAV\3'O6\B,\NZ9[[6V0-K:0(/,C;+O 21M+Q:NH6T=
MIZ@M(:VK5'FY^\0$57KRX9Q5%48%4>(30"R4=D"*:1;=PH$='1C4ZRZO@*@U
M02,8YBE+E RYB6[%,,5+Q<['1\O#2#24BI5FWD8V18+INF3YB[2*NU=M7*)C
MI+H.$3@8ABB(&*/(9*A=\P@ =OXOQL(M$^I3K-;=/.W=<4>3H5FGZC.5V6MN
MPK9$QSEVE3JDWD$81.T-4V1':T@SKLRND><34(@#*,7!V50_FS)YD+T._./7
MO1#=IJ'(UZCJ.#OTKNGR_(CR^'-!M.).\;5"-PF(B3&.K&)<&H+$%J+9/7FW
M]<[7BHMU6IV.?.I-DM)%@'*R*<\S1CGB3=PL^AEO"]; U>'3X4,F!>3D,41Y
M*(Z^72N$N*$$'0N&[1]/G4J$3(F(^$A"^,QCG\)2E\1S![8Q@ /;";CO'M'"
M+H2<3%R94BR<:PD")+HN$2OF;=T"3A WG$%D@<)J^!=(Y>2&#@2CV@(#D[I;
M=H)8HP/45';EMK31]4N-O79,*U76;^P7RS/FT>*JONA+*^D2[Y%NR05=+/)!
M8Q2$21(914Y@(4!,8 &=\MNP$[>C@C5W+(-=7J.V53H6[Q,;/1,7/I+NF#&T
M0TC7)]-HDZ7:HJR,%+-VLE%K.00\X"*Z9%"D.'(9S6+HO1,F8B4AJ_U215M.
MS@H!EK(&)Z.K@:=.O8NML[9=:U54GUMLH2CIJW,1LRB*_%NYRQ3THL151I"U
M^%8$4>RLL\! _FT4BB80(8P\ 41#TL+"R,^_W&/MW[2292$8@#4F4B /.=2%
M$IQMQW2T]/R*&%^KO3E;HE/MM_MD'4IRXQ"+]A1@DDI2S#**H>D*5<K%L!%?
MMC:'-YA=NH"8I.2G(8?:";,KV+D8]WW>_"<;_")!<OH1T@\"'?@IC*,ANB08
M_-_-Q4B[,U92-]TJ*@+Q'RON0>1@[:U:H/%(>592; @N&/G7+)50R2[;TH2J
M%*8Q0-V@;D"FS(.*%3K59NSMU12*PCFT]'JF&;6IC5,KL'"A['%-'*SN",H!
ME##*M&T>J95,P^,H)B(YE"[;NOW<@6D06X$:CM"Z,C%R,4P&1"4#<MQG%PSP
MD'C(=1%05E9^TH\=XAV=X?C]X=N:%8#K6JMUZAM)Z#L]C97-@%,<V99S8VC^
M$K+Z5EMD.H*.;#>)M**K,2ZEY0U$BC,O=-XH50$6JA#&,"9!XWE:N>[QR#.$
MK1.T %Y1;^D. /#72K46ES&Q\:,3 MDW'E..U@!3:=SG<9!R0P(;K6SL?*1\
MLQ924:[1>L)%JW>L';<WG$';1TD5=LN@H7D#IK(F Q?6',%DO,#Y7WY.+\)W
MT?3W3_%WE#75[B+1";,U?:I!FL]@6=_J2;X\$A9&K43/!@7JCP4W"B)%%4BC
MXRIJ"7PB1W"\K&E,_P!:[8-&K578?R?\@=DV1:&D7;=Z#I^*"1$CO7 (QB28
M.'AD_.* 4A2@8>P [@EPH:?#;\OT+@>)_P!:K2<F9FV+\G:1X5L#T[4_IA')
M&8K>8!V= S'SI6HK@)/."7P^,..><@F+.:!3&%Z9V1 ,CH Y)]$5CK%/_6E;
M+)NXI"[_ ">KY[!.045(O%R)@CGJ7FQ3$YCQIA9/135!1(IO =1$?&7DHYQV
M,^WD9%S'%K)@8:2G:G"$PY!-N<J3 (8F)/!==[ R;%KOI3QY &((C<$I#='<
M'B ^FO $,:K,/M5_UKH2_P =_D^.T._S$CSVA_@'?G:X7$T_]'Y?LJ3NA#Y-
M#Y068Z^!^4D^5 VSI^9VUK[5HZ9T_KK1#%P6O(5QU[L.)*;L4BY;,2)JG<3Z
MP(IE%PJ<W(G%,A4P-'S*6.I;=U?S!>E>@.KR\;5W]8=<SD#!,8!9M<EXJL,X
M6X1^RM<?:+9RU=TZVH>78HU@D;:EC>*)59KF.Y!,QB%.D!S%49*NWE\ZV[MV
MC]77N[578]HJC:6MU+.Q5@I(SN0;%!2&>/).""38M7:#"<2KTM(KO(\CU-PF
MR=K&62*14?%C12[U&JF+R>KV?/PBMTO(M(:,?R[X3D91;-S(.SIIG64(U9HJ
M.7)DTDRG55,5)(1 I0$1$.S*R.V)DQ+#A4H9$#B5Y_:CZP-66_:$!3];O:/"
M:OM3RQM6R#]K+5V\*;16CW%Z<,S0)VH0[.*LE96-,)/%E4U5S*"D*?GQ$N,?
M%Q,;$E<LFW: FY@S'UZF714EB-7*[\WF/,^<Y,+V?<NY&5W<+<3,F4]EN(A"
M%7)$(1  X1##1>@C%BV9$6]%3 @.G*SU4"B82F<.3><74 #F$"BHI[8>..3"
M(]XY$+<8/L&I?SE87LB[D;>^+[(" _JQH!3HT7?RZYTPB81,(F$3")A$PB81
M,(OR(_ZTI^S>C#_!MX_\[J[Z>?U+_#;IS?MQ_P#EE^@>"O[J_P#ZR']F:\:_
MDP/DT+1\HSL:VP@7A/6>N=>Q*$A<+@E$$L$P+V14\U#P<)#*OXUNLZ>B!U%%
ME5B)HI)&'@YN"C^L?>1]XMCP#A6K@L^\<POR:$#+;$ ?6E*3$TH  *DZA>[S
MOF\>5VQ( RN$T HYUU8L&U+'@&K2<.O+I]3^2+L+?1NLY1W=]H[EH\I97/4O
M,0C*N3M4UW*2DI5#:^U7$LI>9<5B<>MXYP,Y.@NF[70>D;-2I$(<Y_$\$\\G
M]ZMD\XYG$6>5XEZ,/=(R,HW+H GWEZ1$=\0X[NVQB#$RD26"\WEM\\\N"_=)
MV1)]5ZAF/0SDD>AS5@/$PQO$(F$3"81$3"81,(B(\F,)C"(B8QA'GGO[_+G[
M+$,&% OKH0$ T0!$+UV^1OZ#K/UG]3$786UN;4>D=/<Y2]G6J7&."8E)5]&6
M!&2KU6B(XSMBB4\T[B#E<.E%/"T;@8X)JG\*9ORG[W/&V-X3\/2Q96C>S,^%
MRU"+[1$&+2G(L?J@T %31P*KP/$7,H\OQ:@RG.@'IU-:>;5M-1[]]5^NU>C.
MUO8>G2;Z5O>X4K59E=L+M&D7(U.IR<RY;.J51VR#IXO$3#PK@0D9@#D<';*E
M10 GB..<?W><ZC]Y_+H9/,K<;?*.6FU:&()&<;UZ, 1?OD@"<(M^SLMM$@9S
M<@+_ "5^\_P_+[HN:SP^4W9W>><VC?NG.,8PG8L3F1+'Q@#(V[DA)KN1]<Q,
M86]H)(\X@  #@.?*/(F$PB(F$PF,(B(B8PCR(B(B)AY'M[<_;E^   !AIY>3
MZOVDJN$3"+VZ^1W_ $K>W^%TK]R2^?RK_$OKRCLO_/!?V-_";KSS^MC?V9KV
MVS^5E_9*81,(K)9?XN6#]Y)7]P+X&J+&M4?>SH7\TX+^#T,<44@81,(J#W#[
M&$&JC/3/WK:-^\#3Z*F$4FX1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A%'FW?O4;-_R?7/\ Q=D<(K5_HGPBR6@?Q:0_?";_ (9?
M9)0ZKK[(HB&R*A*U-6Q6JHJ2*0E:VBD32]>MD$XX$I7\%,MP,JP?$(8Q0. #
MP!A[,SG",VW:Q+CM6]G)O8XF+)87(&$J O$ZBH/0X.H-0HS-T_P<)2Z!4*3:
M[;3G6M@<'KMI;O4)F=<&D43H3JMA4G$';:>7FP4,JX5<%$YG @KX@, <]5K(
MNV@8@O:E*)E$OMD(EP)-5NP@]!7,8 Z4+,&X.O/ZD0M*WCM(*&79&]==,FB5
M[0T<T-%U2OPFR-/1K>!K6XRHM$F4B>6A)2US*Q$'#Y%H[*@*"[<  !$=,[,E
MFY$LJ<8QN29Q%VI1ZDU40ALB(AV\NA>JFOJ%7-7T>HZ\I[0T?5*-7(>K5R/,
MJ=<S.&@F",;'-Q76,=54R31 I1,81$PAR.<BNM:^K7JU1Z8X"'?M];V"_2DW
M,%B6J2+Y"NU]NN,6\DTF[N>79RK@\C)>B@V9((LU4UG:I$UEFP&\>(BY,RV0
MD8Q#F3>J'H'/6?)UMW=N-J-Z[. B9L8@^NPJ9,S -H217J<JPRG3[L#J%CS6
M'<&QK/KI20@;=5659TO-2572?T*Y))G;H75Z_26DW-@09'(19NF8&S9TB8Z1
MS H(9C8.2THY# ;J %PPXUXGC\ZZ>81Y7OMRY9WG]UZTI@"6XZQHXVQX$,[N
M0M8VW2COKICMC:PZ$1@]E6.S>CU^S[JM2#:6W59VP.FCV#A]HGDW\!6_@[A'
M?GR.'L4"LLDS!($FQS%$!QP\*&%"Y&!W=Y=E,]3\!P    9AU!=W/^>WN?W[
M%Z_"-LX^+;L1$6J( O*18$RG(RE)R36A7KVW\[YI/T@" N*9!5!,3"F"GA#S
M@$,8 .9,%!'@1#GC.Q>$HOW'N"FZ4J#FWW1^#%IRJSB4C>>)[M6!1NJ>&K39
MR1%9)*5L3XA&C,A^//.52D+R8P%$X&JD=3^8.O.361IKK[MDD?>E$CXG6E$C
M&P.Z='3.SX0\R.PZ\#Q75^V*](-(*O2]LUD_21<J+M5W2*+DZ1B BL!RAI"&
M"(3O782EGD",) ^K&+O)P]2>%-*K<9>4,;W 2'N1N=X8L'W ,""S@-J 6/%>
MGNOJ/%:XI==I$$O(KQ%:CDHR.6EY![+29FB F\R5Y)R*[E\]6(F(%\XJ<QS
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M=_(+KJJJ'.HJJH(B/   =?A+PCRCP9RO_"N41EW1F9SE(O.<R -TC3@  !0
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MU#MIBQ.YJ9(W;2#U6(AE451*1- IUW"Y4BJ%$W(:=Y=-ON7/<@F0'#<S$]I
M )Z%7:'<-N_1Y:=:FQB+WT-I[H^C>GBW1]-]#!0&GI(IAY[T8%A,L"'G>?#X
MA$W'?E%*^S@RI$CF1*4ZH%$4R'-X"G-P/A*8X$4$@"/>/A'@/(/=A2%YN1NV
M[Q;;\VU'UAZ)KL+7;+L.4A=564[<TK7YZ1]RGR\3#%_OR0;HOG,4D]\#M19
M7J!#)G:HF.!3>K8E[E@'F%C(,<V<^Z[N-9&!^M*71%Z:=;\%2$#?NFW( 0C
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M /A^)[5SZ5R9/B[(RL:YC2LQ$;D)1)W&@D"'^5;]I_) :F(FFG\+&QA!-,A
M'T.M\B!2@4!'^\._LS8?Q)^(!_W;A>U=^TOXIG_"IX9G.4SS7F#R)/U;/$O_
M $5S'Y(+4P_^M?8O_0ZW]0X_,GX@'_=N%[5W[2I^5'PQ_P"*\Q]FS]E ^2"U
M,'_K7V-_T.M_4&2?XE/$!_[MPO:N_:3\J/AC_P 5YA[-G[*K^"#U-\:^Q?\
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MOG51#Q&X  Y'L#/R>9$I&0  )T&@7RA+E]%V<JH3")A$PBLEF_BW8/WDEOW
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MV=6XS8J[$7J=65>>*0$#,EI%JS.) %)*5?L&YUFS4X^?<)E$2%'LY"S<E'>
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MN9Q#NFQW;5LVD(UTFFH4BK8RJ0&3$OB 0XSB)>LM2JFAZNE3R4P<  >0 #Z
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MTO+-=8U&KR.KYZXT1G K2Z%\L^II"85K5F<2SZ=\[%3"D/.KL53D25(")4_
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MD2&&YB"1%]P (]8!RR]/(MBRC(UC&QK=%G'Q[5!DQ:-R%2;MFC5,J#=!!,@
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MR+NM2DQ%-7KZ'6%9!T(LW"R9E")^EM4E@((B0%DB' /$0H@12"!2AQP !P'
M>L'J!A%CEMIU5OD$\K%TKT1::[( F#Z$G6#>2C'8)*%52](9NDU4%?-JD Q>
M2\E, "':&$5VC(N.A8]G$Q#%I&1<<W2:,(]BW2:LV;5 H$1;MFZ)2)(HID
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M]@2]>M6DHET!I^2D'U-AI="ZLB$@JHV(W:041YACXS&33(9VJ3VZQE..0N9
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MT>W*\75@I'0_2B>Q^2.4.JU7UR$3")A$PB81,(F$3")A$PB811YMW[U&S?\
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M81,(F$3")A$PB81,(F$3")A%'FW?O4;-_P GUR_Q=D<(K5_HGPBN^L0 :>U
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MH'H7"$Z^-%, IU3V'9G43M:6U;4-G6^JURA[&LD?48.T5=Y9B3DU+0M=FXR
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MCD*)2',48.1>/ZWR 'SM4^=1'$L Z4&@<D!]6'#S+L:\Z%>FW5ERHNP:=2[
ME<-9-K!':_FIW9NT;>K4H&R1!X*4K$(WM]SG&C"K*19O-IQY$P;)"4IRD Y2
MF!+(NS!B3ZIUH _R:]:F&+9MD2 .Z(I4T!X=G4MPR@(%* ]X '/L^4?FYBMU
MRPB81,(H]O>I]7;13CT=EZZI&P$HA1PK%)W2K0EF2C%'2::;I1@299/"M#N$
MTB@<2 43@4 'GC"+R"^4NT)I/7@="$YKG3NLJ78E/E$.G=@67J-$K%>F#-7C
M.\BNS+(Q,8T=@W< F '(!_"< #D!R7^=5(IYOH7R^33T+I38DKU_S>Q-/ZRN
MTZG\H=U&,_=>W46LV&5*V2D(?S+87TM&NG0()%'VI/%X2\]@8>J!B&Z&^8+V
M!HNIM7ZN)(I:TUU1]?I2ZB"LJE3*K"5E.25:D.FV4?DAF3,KL[<BA@()^1*!
MAXR%8="D,.X,(L(V73PV'KF^T$9!>)"[TRSU$95J'B<QH6.%>PXOT"^(OB59
M@\\X4.0Y$O&3&6V0ET$*LANB8](7D!K[I?ZN4W_R?.OK?JC5T%2>B"<>0\WL
M:$O31\\OT&UU!/Z]A+)3:P+$DA LI)4[966:/E"NA=*AYHJJ29E<[Y7[ %V4
M3(RNC0\/6!J>/:O/MV<C]E"<8[;3U?7U3$,.&JQ&&^3PZ@$-(]'FN@2K,*\C
MZ5(Z*ZO&A9Y)P21THXV"QV,V:P+IH )3#U!Y&NV $*(F!M.N.!#PX]YM=Y.5
M35X]K-Y=BD8UW9;B&T:78[T^;SKG?_D]=GM;SU$PT?JL-T5'J&V),WAA9I+J
M@VYJ6AU-A:6;%A+5?9NI:-;X$MPCX8C(!;'C$E%'S<P(+&1\V4PHY,2(2,ML
MH19MH)+=!(43Q;@E, ;H3+_6( ?@0-5L)7NCC8\=6OE ZZ[H^J;$SZA;]6Y7
M75<V&\F)>E6JJP% J-<]SKD>&?A:XD@NX5<B"OI"CQLH";@!,8.1S-^)E:+R
M&T5;45.BV[B;70T3O-'T-&JM37WR?G5ALBK;5K;IQ.ZZUD]::AG]>Z+VOOU]
MMM^;8VK=BEN3]A$[HK;$=C4G5<_7TPC6R2TO)R;=V/IA2-Q(4IMO>;,""*S#
M@D!J$-H:$\?D<KG]UR+D9 ^K#U6B9&500:'4 BFI;4 <=W^D'IRMM)W!<]QW
M'2GP4O'^OXG7D4M:NH[:?41LF6;I6!]8)5%Q,6>ZV"FP=(:O#IGCFR")I(SA
M5PJLHD50$LY[UR,K0A&6X._U0!]/D.M=-BU(7#<G';ZK5D9'RTTZ%@O4!T_]
M3+&;ZT8C3>M*1M2M]:.N"1!K%;+VQJCK5]K;:R?ZU/'S,4[8+KV*HJ,BHO6/
MH1A61?+JE5(5,PK%M:NV6MFX3$VSP#O5_2JWK=Y[G=QC(7!Q+,=K>C]*O^K^
MD;:$5-=1Z5H;PL-'[=Z0M*:)K\\E)-9-RWLU4UW<ZK9@>M6XBZ(PC9*>243.
M ^!P B).[G(G?AMAMJ8W)%NTCZ%,,>8G/<S2MQB_6-S_ #K5FU=-O4_9M=ZU
MB-RT>I:EUST^]'W4II6Y7J!NY+W-/%+'J6.JS'859K,%'FDU8,D?$KN",A T
MJ*Q?-B@'M!4V%VR)2V$F<[D2 S<79U@+5[;$78B-N%J427?@ X'FTU70T;L6
MT]3'45TM5=%"G5.'HO2?NJL?"#I78D/:;*@PLD%0*U$WJ!43AETM?,G2R('C
M&4RV"3*]34!5H4B B>;D8VK4S4DS%"*<2QZ>MJ*;4I7;L'8#NS4%RU _5U#5
MUNK*]'^Q*YM#IKEX+9.RMS5W7-AWY/6ZV;MN%<F+G$$V)HN<U]78B$4@ZO5&
MSJ%"?=(F%(&YE$?/*J&.)>P.<7XF$@0(DLS"E"Y70;$A<@8DR W.2>D,O/='
MY,;J257T;>$FE>A=F]-7330VVJW!KDW=UIQO:D;,6M#FK6V#0*JPGZI9ZDLX
MCQ>N4U2QZKSTAOYM9$IAZ!E6ANC4PG,O2NTCAUCR=<DL.\3"8;?"%*TW.]>H
MBC\-=64JWOHEWQ9=B[NO,UI'X0%NJ1"F6*:8$ZLMG:OJFK;*GK2MT6U4S8%4
MU]:Z^SV/2&3F%55;.XXKA^NT6!L)2E*!PK&_:$8Q$F$'_5!>KNY#CY%:>/>E
M.4C%Q<'])@*,S<137^1>UFO*NE2*)4:>@V9LT:S7HJ$3:QRLDLP;DCFB34J+
M):8>R,JHU3!/@@N%UEA+QXCF'D<X9'=(RZ2O1B-L1'H"S+*JRA/J1TVWZA]!
M[>T6[GW=5;;:U]:*"O9F+%"3>0"=EB7,8,LVCG*S=N^68BN"A4CJ$*H)>!,
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MG.M/0FA92ATH87;T3K^OT20FY#9TBVCF$]$V_:@6I0D*%>&.81X^C"1!8QE
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M4CMH:XL%IE*-"7NHRUT@DA6F*G'6"*>V*,2Y*4RCV);.SOVI4S&#Q"8@>$1
M!XYP8R $B#M/%D$X&1@"#,<'^=1'JGJJUA?],U?=-BE8O5=<MDO/PT<A?;#
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M).4C6SY[69A['N(IS)P;ARDH>,?+QCM5N=5'PJ&24,41X$<=B#K65)IB3U.
M#@H!ZG/9W  =@!V< &$^=?;"*(-PZ)U7ON!9UG;--C;C#QDHC-Q)'3B2C)"%
MET$E$4Y2$FX-Y&S</(%14,3SS9PDH)#" CP.7A<G;.Z!8LJ7+=NZ-MP @*/(
M'HPZ8*N@+6NZ7IT,U-=JSLA1O'I2""2]]I[59E7K<Y(#T2N+ Q;KF SD_B4<
M&'Q+BH;@0L;]XZR)HWFZ%2./8B/5@ 7?S@,_:LWB^G?34(XK+N)U]!,G%-O5
MNV=6%D?3?'#WV]A,!;[*U,H[/XG\^%@> MYSQI "YO 0O <5-RX7<Z@ ]@5Q
M;@&8"A)\YU7UA.GW3]<A-7UR$H<+'0FEW2[W5T<AZ9Z/3'3J)DX)PM$^<='4
M\:T1,ND!%4ROM%A\O @-VX2227EJ@MVPP #1TZEA2W1WTW+A12'U+6B%UI7;
M-4:09LM+M#PE4N;>0:VFM>-M))'DH*:3E7 JM'@N$/.* H4H*%*8+"_>#^L:
MZ]HT*J<>R2#M#QT[#KZ>A6:U]#?2M=XRD0]DTO5WD?KNL-*34DF[J>BEH^EL
M1,9M3G;V'EH][.U4!.;Q1T@HZ:*>,_C3-XS<S&_>B21(O(N>WI[566+CR B8
MC;$,.P<.Q=V^]%?3#LQ]7I*XZ;JCYY6(5C5XHT::6K+<U4CE%E655EF57D85
MG8:NU4<*"G'2*;IF7SI_T/@P@,1OWH/MD:_/TJ9X]B9!E$4#>;H[.K12Y=-0
MZZV'2VVNKE4(6;H[-[6'[6L+(G;Q31U2YB,L%46:H,CM?1_<*8AFJZ!""4@&
M1* @)>2C2,I1.Z):1_3JM)0A,;9!X4IV:>C@HQM_1WTU7[9+?;EQT]49^_HN
MHM\M-/4GWHTK(P7'N#*V*OHO$JW9I:!$A!8NY!HZ<LS)D%$Y!(02WC>NQAW8
MD=BSECV)S[R409]/9\_G4M5+6-'HDM=IVHUJ.@I?8UB+;+L\9>>!2Q6,L>TB
MPEGP*J*$!S[GLDTN$P3)X2 /AYY'*&<B ": ,%I&$($F(:4BYZRP'S >A:][
MKZ!NDCJ*NP;(W/I2NWB\A#LJ^-D=RMKBWYX6.5<+,8]0(&?BT%46JCI02>,A
MC!XA#GC-;>5D6H[+<B(NL+N'C7Y[[T!*;:U67ZXZ0^G74@ZY/KO5T'6E=2C=
MAUVX0>SCYS5?A&*4EV"/<2TH_74+82%X6!8RH%#]+\ =F5G?NW'W2)W,_6VB
MO;Q[-H 6X@"+MU/JKU>^F71NS)BY3UYUO 6"7V'KD^IKR]<#(-U+3KT\HWF2
M5F9*P>-$W;5M)-BJH*F+Z2W$3%34(0ZA3Q&]=@ (DABXZBIE8LS),X@[H[3U
MCH4=:;Z"ND3I^L#NUZBT33:C9GD6ZA%+ 4\U.3*$4_)YN081\C9)68=139\G
M[58K8Z7GBE*!_$   7N9.1=&VY(F*SM8F-8EOM0 D>/%8M2/DU>AS7-R8; I
M_3E18VVQ4J:;BI-RI8)I*+EQ=>G%E(Z)G9F3AF,@B\_1$54FY3H&_2Q*'9DR
MR\F<=DIG:RK#!Q(3[R%N(FNH[^3(Z&7UYD-E.>GRMJ7B6MSV^R<^6?O"*[VX
M24LI./YYPV1LZ;!5XZEE3+GY1$@F'CCP]F2,O)$-@F1%FX:*3@X9N=X;8WN[
MUUZ=5NK8BE2K$Z0H !$X&3*4 [@*2/7  #D>>  ,YN*ZEC^JRF)K6A%,' _:
ME #QZQXUN</[D<<46?81,(F$49:;*)=84DA@X,2";IF#U#)G5*8/F#CBBDW"
M)A$PBH8.0XR0B\WM]VGJRN/5BST)T][BHFGH6(Z?(7;4R_M>LFNPW,U*3.Q;
M;4!:(BXD& QR#1I!(G+X1,!S'-SY,_7O#&#X%Y?X#EXI\5<OR>89,^;3Q8BW
MD&P(1ACVKKEHRW$RG(=C+\E\1\P\;9_CX>%_#/,,; PX<HAE2-S&%^4YSR+M
MH@$SAM C =+DE=(-*?*=AV?UWM-?_<RQ8]XCY1L0<Y;_ #']S?\ PUG_ .\9
M_86O^7_O9X^(L#_=P_?KE\"ORG?/']=_3?/J?U9(G^D./\Q_<W_PUG_[QG]A
M1_E_[VO^(L#_ '=']^J? K\IU_[[VF^SM_\ 9EBOZ1>7'^8_N;_X:S_]XS^P
MI_R_][/_ !%@?[N'[]!TM\IT <_UWM-<?_TRQ79SZO%A''^8_N;_ .&L_P#W
MC/["?Y?^]GCXBP/]W#]^GP*_*=_^^]IO_P"YEBOH_;%VX_S']S?_  UG_P"\
M9_83_+_WL_\ $6!_NX?OU@&UJC\IKJ[6E^V0XZS=.RR%$J%@MBL4GTV138\D
M2!C',F9B1P:?4\P9R5N) /X1\///&>MR'.^YSGG.\3DT?#V?;EE9%NUN/,)G
M;OD([FV59W9>+XCQ/O:Y#R#-YW_C^!<.)BW;VS_#XC=W<#)G[\L[,]5Z1Z:M
M$I>-1ZMNLV* S-OUU2K/+>BI^9:^Z<]7(V5?>CH@(@DAZ4Z/X"_V)> S\@\1
M85CEOB#.Y;BO[MCYEZW!ZG;"Y*,7/$L Y7ZQX>S;_,N08/,<IO>;^)9N3:@W
M3MQE)AP#DJ2L\=>NF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBCW;9#*:JV6F4.3'H%
MQ(4/5,>O2)2A\T1PBMG@-ZG_ *JO!_V7J81?;6A3-/MTAU"G*>,N\V<A#@ <
M-90491J8GJIJ$<B(9*BJD_(4K%IFYUJOSM7K4O+-V,Y=%Y-M5X]8BXJR[B&9
M!(R::!TTCHIBT9#YPWG#$ 0[N1PE.*R@.T/4];"*N$3")A$PB81,(F$3")A$
MPB81,(F$3")A%YT[_P!%0>X>MSIIDKWK4E\US5M*]0Z$HO-PRDI3XZQ3,SJ@
ML0VF"+)'BE7KYFR<BV27 _()',0.0$<ZK=TPQYB):9E'MXKENVA/)@91W0$9
M=E=NORKSZT'TP6"@:MZ ;7!Z;G*GMJ&ZDME,]@6,M7DD[?!T"2A=QQL2E;WC
MA-631I*0!$$0;N#>A$2(V(D4  @!T7[PE.[ E[>P,'U--.O5<UJQLA;D(D71
M<->('K:GHT[ OIH+4,VQ5Z*J96]$; I75CJ3<9+!U9[9E:?,PK20IZ*5@#8S
MZ9W ]2)6]KQNV7#MN5@RCW\FKXC$461:@@42KMR)%R4I V3'U1UT:G!NL*MF
MV1W41$B_&7KR;A5Z\034#Z%"+OI]W0UB^G*:V5"WR#TK"ZGV]5_<5'I_9]0#
MBH[=F=X6Z<6?SNK)2!L4K%FO=&7C6T?,(QZI41:J)J*-TUA.I?O+;S$6[S<*
MOMH!T]1X*G=7-MO>"(")'U=U3(G3K'%2O7]%.=?R>G9OJ/T5NW=V@&_35LZD
M4BGS](:VZQT_;%HVG-6*"CY?6>N59!K1U+%KYTA%PSWS148!#S;9RZ:&(<X5
M-S<)"S*,;F\$U:@'2=:ZCCT*XML8F]&4[>P@4T)+Z<'&AX=*E=BTOFC]AS=@
ML_3]M^*8[6^3]JVH:/5:@RLFZ5XC9M8M&TI -9V:WLG,\M&RQH>SQYDY*7=)
M1YQ4.07?*0@%#MF THG;=)+TH6JWZ!Z%<[[<R\)>M9 #>M4;J$^<:TZU!4IT
M_P#4M.Z;BJ_1J7>H*VC\EQTST252&+,PDWDA7-R6^=V5K)JM,G9QYKDYIJJB
M9H]=9(S@%P1,8I%^<T[RR+A,B".^D?DH>QU25N\8 0!![D?/4=K+L5_IS<6B
MC]1):Y7^I*QTN;TY6JM8XZ@:)H72SZ?+Q]^AYXC.&H,W!5-;9=PHD<S7<O04
M9KQ<O%F5BDUG9G()8-QC%S#<)<29<&UX \.(U06B8SI/:8<(B/%].)'H:A=V
M6Y'R:M>N=7ON[F0Z^C$]9/HFDN8G<Z&D+#TUS-ZMK168;/JY.:CFD8&-5?UB
M%.V\[-1<)',W1E 3\2QB>/,,HQE&)?UW-'W,.EQT]#K?$C*,I!O4I7;M<U<-
MU=(^=>OF<2[DPBQJUVZO4B&<6&TR:$/"M7,<T7D')5CI)N9:0:Q4>D)6Z2R@
MG=2#U)(O!>PQP$> Y'"+)"B!@ Q1Y P (#ZH"'(#\["*N$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PBP?9,B,70K:[* BK[A2#9N0O:<[I\
M@=DU(F']D<ZRX  =XC@:H5=ZE'FB:O6XLX@)XR B(\XAV )F<>V;F'@>![TL
M(LAPB81,(HQU.<J-87A1.;SU=G[%#*(J!X5FZ+:9>'8)J%#L#QL%4SAZI3 .
M$&BD[")A$PB81:(H_P#^3":[O_8@I8?_ &Z;&X\H>7/T^7_HU:__ &6]_P#9
M8Z_,(_\ K+=__6K/_P![D*%9/??4.[ZBM@UJEVV:L$?3]]UJ@):H+HU^K2D]
M;+5>@35NM$MN]&&0C8R7A&5A?ORI*2AE?.H)(>C*><*4WU./X5\'0\'XF5S+
M'MV<C(Y5<R#E>^@7O>!=OPM6H81F3*,Y6X6W%L!I2EN#.OE;_BCQM/QGF8W*
M\BY>P\;FUG'&)[B>Y]WE:QYWKLLX1:,K<;MRZ 9%Y1C:8NPBBA]6?4DN_DEY
M*TV&73=:IVGL-9E=]/U*C5V(85QI()UB7UQ/Q\@21V"W+84T&KA!1-50K4X+
M+ D!B"?W^;> ?!D(0MV,:S;,<_%Q]UG,NW[DY7)1[R&1;,=N.3;W3B01ZPVQ
M=B!\[R'[P/&EZ[*>5EWKV_E^5D;+N#;QK<(VQ+NY8]S=NR6N;82#2]4[I;7!
M,@T[;/5',:Z(\D-D;*A;'<[1IRM0=CV-T_Z\J$; ENTT0DV_J[6.6>MK0868
M"F!7I>$2*%. >(0X\KF/(/ N/SDVK6#AW,/&L9ER=O'YAD7I7.XAZD;I+&U6
MKP-2"-%ZG+>?>/LCD8O7>994<[*OX5JW<O\ +;-B-KO[@%R5L.1>H6:7U:'4
MJ3!W]N76\_(42WV&!V:_HMLN+*6LT77FL*YM\4PZ>+%MF(BI".C!&/AK#&3[
M!)-SZ(1,JC3S0B4#'-SX?^4O#?.L2/->76;N#9RK%F4+<KAF+,I<PMXLY1E+
MUIVYVY$QWNTG8L OH8^+/$W)<J7*>9W[.?D8E^\)W86Q;[Z,>7W,N$91B3&W
M.%P 2V,\-I-9%7NMR_4C*,&:,IU*ZE/);4UY(6VI$KM1@U9>HRD7[G2"AJ/'
MO#.VMUJ23 RJ+M:3!5=%4Y3%.'(%#ES+'@NQ>E*SR7F'<8&9&U=[R[<$;T9;
MHCOI18V;NYI0%IHD @CBNC"O>.,BP(W^>\N]XYAB2NV1;L0,K$X[9'N(DD9%
MK;NC(W?6!8@\!B#27VS:_D]=R7K;>QDMA35TTGL&89G;U*!J3>":$K<RQ/'(
MMX)NW(]*=9MYSSBPF.'B$ 'C/1O8_(.7_>[R[E/A_".'CXO,[$)/=N73</>0
MD)$W"=M"S"G%>5;R?$7,ON9YESCQ%G#-R<OE%^Y%K-NR+8-B;P A]:M7-:LM
MRNFO_P!G70G^1?5X_/I,)GYKXQ_\W<U__(Y/^VFOU'P?_P"4N5__ (_'_P!C
M!39GSB^B3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB811_L\_CHT^Q\0%/-((P"1>.3*&
MG7:$3YLH<#R*A'1@]8.W 0Z*_P#N,7U _B][C=X_E?4[N["+&#\5_8Z2IN08
MWJ'*U,<PCX$K!6156;$+V\ >2B)!;R=HLP#R]I%)&$6G'5:Y7J=AZ>ML&BYF
M2@M<[0=&N"L%#R=@?156M-7EH1[)EAX9H^EGY$'HMP,5!)0X%,(\<81=P.N#
M0(!^RMG_ .8C=O'L_P 0 PBY?UX- ?MS9W^8G=G] ,(G]>#0/[;V?_F(W8/T
M* .20R)_7@T!^V]G_P"8?=W^C_(4.J?UX- _MK:'^8?=O] ,*4_KP: _;>SP
M]G0^[0#_ ! PR*O]>#0'[<V>/L:(W:/_ * 9+(J?UX- #_W[L\/6^ C=@?1U
M_D(J_P!>#0'[<V?_ )B-V_D:_P *'3^O!H#]N;/_ ,P^[O\ 1_A'"?UX- ?M
MO9_^8?=W^C_".J?UX- _MK:'^8?=OY- PI0>N#0/A$0=[/YX$?O$;M]3UZ
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M,(F$3")A%:)N985^,>2\DJ*3-BB*RO@(*BJ@_E4T$$B^W7<.%! B:8>V.<P
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MPB81,(F$3")A$PB814$>,(NC(2;"+:+OY%VBR9-B><7<N5"(HIEYX 3'.(
MF,/ !WB/9A%'\<V>WF18V&6;J,ZM&N/3JU#.DS(NY%Z0#)-K!+H&#VB*:9SG
M9-S<\>,%3@"A2 0W0GS*3\(F$3"*@ASQSY!YPBP*=I8KR(6"LO\ [7+'QPY=
M(H>=CITA""5-O8H]-1N#\B7/Z&L!BN$N1\)^/:BH$U#+H_;^M  1M>X9S J
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ME5W!459YVV[0+YQ)- !$1!,1X$#HQ"DDA"D*!" !2E "E*   %  X*
M4.X/)A-5SPB81,(F$3")A%Q,4#<<_0 >?G@.$4?2].=(21[!3GQ(.95X/(,5
M$SGKUB,'''NPR0,0Z;W@OA*[1#SP!^6!0H>')X=2<5U@V.C#"FTO,4[JKP3
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MMR0'1V1A39&5?(S-Z?-Y9=J(*1U<9IG^UF*< )O \\PZ+YR7E4"&$A'2Q">
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MZA7\;^]^S"/U)\'?W;;"[.[_ *T*<_/]%YPZ4\OYT^#O[M]A]_//VT*<_/\
M1@'C%$=M!Y>E/@Z#^6^Q/FVA4?HM^_'6GF0== /_ )[[#]\ZG;[/][=O=CT*
M/2J!KDH#R%VV$ ^J%G4Y\O9^Q>[MPZE^A<O@[^[?8GOH5#Z#;%$[53X._NWV
M)[Z5?J;#A*=?EYU7X._NWV)[Z%?J?">;R]*I\'?W;[$]]*OU-APE.OR\ZK\'
M?W;[#]]*OU-BB.WE_*GP=_=QL3WT*_4V%!3X._NXV)[Z%?J?")\'?W;[$]]*
MH_1;8HI[/+Y4^#O[N-B>^A3\AOA$^#L/Y<;$]]"OU/A1YD^#O[N-B>^A7ZGP
MGF\O2J?!W]V^Q/?2K]383T^7G5?@[^[C8GOH4^I\*063X._NWV)[YU/J;(1^
MI/@\'^6^P_?0K]2Y-%+^7D4^#O[M]B>^A7ZF##J/+RJGP=A_+C8GOH5^I\*/
M,J?!W]V^Q/?2K]38HIIY?SJOP=_=QL3WT*?4V$=4^#O[M]A^^E7ZFPX2GE_.
MJ_!W]V^Q/?0H/T6V*(_0J?!W]V^Q/?2K]38HGEY55?@[^[?8?OH5^IL44OU)
M\'8?RXV)[Z%?J?"KYD^#O[M]A^^A7ZF'%%(/4GP=_=QL3WSJ?4V$=/@\^[?8
M?OH4^IL44OU(.N_NWV)[Z%0_\6PH=^"I\'1!_+W38:@?F?ML=I_-\2":*G]U
MD.$Z^"["6LJ:*B:TC&KV%9(/T-2TRLM: ((]HB1"=>OVR0\_F2!QY,(LV;,V
MC-$C=FU;M4$P I$6R*:"1  .  B:12D* !W<!A%V   [@PBKA$PB81,(F$3"
M)A$PBIP ]H@'XO\ ;PB^:B**Q#)*I)JI'*)#IJ% Z9B"' E,0P"42B ]H<<8
M186[UO2G*PNDH-&)>&Y$SZO.7M:>&,/>8[J <1RRA@\@F$1#%472'7*)>01N
M.PD"\\@0+=(+\!Y \X\])6-QZHF$1\HXT0U3X._NXV)[Z%/J;".W!4^#O[M]
MB>^E7ZFR4IY?SJOP=_=QL3WT*_4^$3X._NWV)[Z%0^@VQ1.U4^#O[M]B>^E7
MZFPX2G7Y>=5^#O[N-B>^A7ZGPH3X._NWV)[Z% _\6PI=/@[^[?8?OI5^I<44
MOY>15/@[^[?8?OI5^IL444\OYT^#O[M]B>^E7ZFQ1*>7\ZK\'?W;[$]]"OU,
M.$!ZD^#O[M]A^^A3ZF#"/U*GP=_=OL3WTJ_4V'2GE_.J_!W]V^P_?0K]38='
M\O(I\'?W;[#]]"GU-D44OU)\'@_RWV'[Z%?J7)HCI\'?W;[#]]*OU-APH<>7
M\Z?!X/\ +?8?OH5^I<44NGP=_=OL3YEH5^I@PH)ZD^#O[M]B>^A7ZGR$?J3X
M//NWV'[Z%?J;%%+]2?!W]W&Q/?0I]3X4._!/@[^[C8GOH4^I\E!1/@[^[?8?
MOH5#_P 6PZ/U*GP=_=OL3WTJ_4V'"4\OYU7X._NWV)[Z% _\6R$?J5/@[^[?
M8GOI5^ILEPE.OR\Z?!W]V^Q/?2K]38<)3K\O.J_!W]V^Q/?0K]38='ZD^#S[
MM]A^^A3ZFQ12_4GP=_=OL/WT*?4PY%$?J5/@[^[?8?OI5^ILFBBGE_.J_!X/
M\M]A^^A7ZEQ12_EY%/@[^[?8?OH5^I@Q103U)\'?W;[$]]*OU,.$\O*JI\'?
MW;[$]]*OU-APE.OR\Z?!W]V^Q/?2K]38HE/+^=5^#O[N-B>^=3ZFR$<I\'?W
M<;$]]"OU/DH[\$^#O[M]A^^A7ZF'%$=4^#O[M]B>^E7ZFQ1*>7\ZK\'?W;[$
M]]"H?^+9"/U(&N_NWV)[Z%1_\6R4=N"?!TD/8K<]A*E_,C;'B7J 8!,V(@I[
M8.SL-V9"/5=E#6E,(J1P]B!G7) #P.+/(25I5)X1 P&3&P.Y$J1@,'("0 $/
M)ARG8LW1;MVR946Z"2")  ")(IE22( =@ 5,@%(4 #R '&$7V  #NPB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+QC^42T]9HFZ:5O%7Z
MC^IRCGV_U':QU=8JU2-Q3U?J4?6K$=^C*%@X-H0&\6\5*U((*%Y$#"/JYW8M
MP;91,(%H$U )=>=F6I;HSC.X-TP*&C'J6,V7Y1G7?2/8;AT]5QW/;C0Z<U%$
M=LV[=V\:[';1L;^68?;6,'KDMJ<@_P!ARD#&/ *<' L$!,*;1N90_;DC%G?:
M[+U=^C L.#GH?SJLLR&/(V8^ML9S*0<\: Z^D=3U4IS'RHT,XW8PUG0]9^[<
M*>,UI+F&V7VIZYV3>8?9T3&S49,Z@H-R>Q9+Q'PC&5*#T@OFZYW2"Z")#*IC
MXJC"(M[YFKG0. W D:&GS+0Y[WN[A$-34@$N 7B/U@ :L1H14T4T=*>X-[W[
M=?6E ;+B8G[0=7;H+5]>NXV>;2$FQ9(T*F3!*Z,*WC6JI47#:3]/](465,9T
M[40#L3YS*]"W&W P^N8N:=?EY%;6;ER=RX)CU(R85ZA1F\[UUZE&^H?E(V>T
MML6JH'URQA:=6I&_1TLNKLFH_"S2B:[;RKJ2FMB:=?/6%FAX&73A3BT59"_.
M4%T!5*4JAC$O/%,(B3U+<*%^@Z.L[>9WEPP #!WJ-P;B8Z@'AKP*RC6?7-L&
M^5L^S)/I@V#7-.6S7UXV-JV^A-UZ6]*AJ/$2$H=MLR(9/C.:"]MB3#SD2)1?
M$,0X%5%-0!#(GCQ@=HF#<! ([>CI93#*G*.^5N0MF)(/8'KT/PJ?,H:GOE2)
MBGZWU5;[SIR!H$_U%LDK+HV!N&W:K%1)Z$A7XJ7FK9LFRK$*SK"C%>80;I1[
M0CYVN*P"!0 IQRXPWF8PD2(?68'5VH./G99G.(A&4XB,K@]4&0 9G]8\-= Y
MZ.+?%Y\K]JEYK>JRU9AZ]\)MANMZUZ_@;;L>L5W6U>FM;,X23L\N?:)EG458
MJT^CK-&GBE(Y%==X+XH&22,DL!)&#/>07V,#058]7 T0Y]ONP1MW$D5D!&C?
MK<16A'3I0ME=.^4T/M]IJ:(T?IIU?]A;+N6X]:/H<]YK[&I52\:;JD7<9EV>
M[I>E1EAI$E"3+99I(L 5,J+DB8I%6\9"TEB;-QNR:  .FH--.FFA]*N,TW!$
M68[IR)&H8&/76G00MPNGOJ2CMV:8E-K35;DM>/Z;-[#J.R*K)NV<J:K6C5TU
M)0EN;MI6-44:349XXLSEHY3 OGFZI.2E/XBAA=M=W/8XDX!'8=/G6]B]WMOO
M&VL2#U&)8^9PM8:_\H!=IMG1=A+=/4Q&Z(W?-R5-T)?W%Q@5IZRV[W.L+FEI
M72GM3KO:E"[)>UE="+<%4=*(F<-A<II@J(DWEC1<QWCO(AR&]+'JXZ+&.7(Q
M$]G[*1:)<.]6<<'T%3UMHK7,?*DZYB:'1MFFHT^M49/14ON[8JJ;^,3>ZZ*6
MT(:\J5)?>E+H,E;%:MC^D1B8J*HH( S66.?PIB&2,*9D8DUW,.OB_H4'.B("
M9#1V.>K@W:]%@]5^5CK<A5=V/9JCUZ6N.I=02N\F<)JK9U=V' V*G15@A:^^
MA'5D8$;HUV[QSVP-@.T<I@BY*8RK=0Q4S@698<@8@$[3+:Y!'D%2/,([92(B
M91CN:,A+S/P+_P ^JEYOUX6BCJ[):]1&F@U4]JW3_,=2-10A[G&W-*TTR*GT
M:^O *N6J#)%I=&K^9BDU6Z?G4C*ON"''@>:''$V-J3@RVZ-U^C5OF6ARIPW"
M_':T-U"[C1NW1Q45U4.2?RA59TP?<-QO=8O4=<I&T]/U)9T.Z;3B"T6-V-LW
M5$A>C5^%>S)VT+KV KL;#/C2KD14!TLU\293G4(&7]V,Q&,"#'UBX%6!;SJA
MRHVC(S!$O5#$T<A^+-UE9AI_Y46F;'G*Q6)&J1K.4':5>U;?I^J7B'NE!@E[
MS4+?9Z)9H*U1P$0F(67>TY:.=IJD;.F3Q1,ITS <#9$\.409.=' (8T(!'R]
M=%:WF"Y(18'UF)!<!PX+]%&X%UFVI/E$H#<)=<LZYKR=:V;8O4K=](1M>D7C
M9-TE3*; SMT^%XRJ(JD/7)FBLX^2;)<>,4I-'G*SQC;,@9#:(@^<D!NT&BFW
ME]X(M$B1F8A^@.=W80'':%Z6![' ?B^=V?CYRKLX=:Y81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$6L/5)I3X8Z6D8NU-SZM6I;2PV!L[TWL"3H+V97"(4!-I/.(SV\FQ;
MJ(%.DF?@$SB)@'MS6S<[N7U8R=M0ZQOVN]C]:42*T++Q]T/U'L.CWIDZ;=UW
M_;NZ-U;CZN:HO#P-;WAO "ZNAI"KN5)2PVMW)6E4C&I,HYHY:IK';)N7:Y5B
MIIIF[1+W7+1OWIVXB,;=LZB->SK7G6;PQL>W=G*4KEV(^M*@+.:G3Y3U+8)Q
M\KS2G.J4+7#T6/)<$MLJZ;LCJ<O\"TTE69YO6OMK2LC_ '"P&0BS5&PQQ12B
ME00*X7>>)%0B1BF',A@SW[2?5VOH7-69NGI6W^(0[O< 'W,23Z@H_P!>H;HZ
MZ*2'G57OF[;9Z#OM*I$)7:/NF0VVCL^)<[!JDZV>I4Z,8$"3KD]6 GXZR03%
MJHI*1ZC=PW5> <B2I$S@(!06;48W-Q>46:AX]K55^_O2G:V@"$G>O1T$.XXC
M19'U4_*#?U>-V0.CXC6[*=GGE(:["6E+YL6L:DK]OCGDJ_BDJ;JF?MZJ,+<-
MB(*QQCN&:Z[-!L5PV ZHBN'ABQB][;-PFCM0.W66T'7\BMD9G<W1:VN6>I$7
MZHO0RZG J'*R*T]:=]/>[#5M1=--ZVK&ZHK&N[7O%=G8ZE%6*L%V+$FG6%,I
M5><2RY;W?8>!_OQVV2<-V8E#S*3@ZIR#D#'AM$IS ,B0->'$] \M%:61/<8V
M[<I"(!E4<:L!Q(%2'%#JK!;^OF6J-OZA%WVG7S73'2Y!0]AW!L>3M,8PG$4K
M+KQ&\P%?K%).7TV2LRR[E)BLDNNV;I+.$^5> .)0QA*,?6_:3- W06J?YU$L
MHPE/U?V5L5+]3L!5SZ!IUM$NO/E<M8/F>PW>T(6NU\M2U3:=S1GP;['JVTRN
M:Q4O<Y.0K-A/$N&:==O:KJ7;%;H*&%@Y\Z;PN2BDKQI+"G00>I:H(U_0LXY]
MLB4I[6$2?5D)4'3T'JTZUT:O\K56I"O;:=S%'K3ZST/3-YWI6X36NTZWL5E,
MUBC(L%9:KV>5B@2+4KNF$BD)$SD59NP$_F5CBD<N2<&3Q )8R$:@BIZ.D*!S
M".V4B(O&!EZL@: /5M#Y.ZVFT;U:W;86WH_46U-+O=3R]YU.CO'5KHEO@[>V
MG*$F_BHR3C[)[EBD>O6^)>3#<3H@"S=1-7E-;Q$,4,+EF$8;X2W %CPK^D+H
MM7YSN=W<CM)CN%7I05Z"_ /3CT: ]:-RMCOKNE: [F>NB6HL9T[4NRQ=/Z-;
M$X8J1=CDKA9&+^;M[#W=A$"HR#1JDDBH!E#"9(P<=@9U8X QW_9">]O7'5P7
M)E2/O(![TPV.T.WC^A9ZKM^S=.5HTW,-Y[J)G:)7>CCJ)W1-Z]WS:UW>R9J6
MA;%#3K%E?16?2+7[8(5N]5:-!.LL5HV$J93<!V5V"Z)#U-V^(>.GF5Q<-DQ+
MS([N18FO35;+;!^4*IFK2ZUEKK3YEM5[MTLW7J@EY9B[9.G->AJ<SJC@]:29
M*JMRR$I)N;2DW1/YQ-+S@ )C  B(8PQC-Q$U$Q'T\5M/+C;8S!VF!EV,!\_F
M6O=1^5ZJ$J:^,9^CP1;%&Z?V'N>A0] V?6=E(RT1KF%).3=.NLA!""--N8,#
ME61\158]P4%"$<>=3 A]98)]4@EMP!)!&O$=(6$.81+N X@9!I T&H+:'JJ.
ML\)M@?E I2"7E%M[:/L.J8A[TY3'4]05X^SP%TD)RAUE.!^V.O3C&*60) WE
MHM8V8HM_&JV6(J)16*<ABCF<8'^[D)'?M/"O2.D>3+:.40?VL#$;-PJY8-0]
M!#@,Y'6NW.=:&ZJ!K&][)VKTJV6IQ]1@:QL9JM'7. LL.ZUC-2S=K.G?RK$P
M%87VE1"OIK^+\!D%$0$4%S^$<"Q;E(1A,$FFG'AYBH.3=A SG;( #ZO3MX$:
MMIUE;#:.ZBT]Y[!WG78"L.&M,T[9H*F,;RL\24;7.Q/(%":L;:-9I@)D6]95
M=I-53F,(BMR !P&97+?=PC)ZR#MT!_TK:W=[R<X@>K$L[ZEJ^A:@*]9<IKVT
M7&LTG6VPMI6^[];UTZ>(6#M&S8X\:PL#'6KJZ)RD"ZEB$;U/7K<D,(>YQ .H
MW*90Y"F,8"YM[N)Q!D1&(M[M.MO375<_O)@2(Q,I&\8Z_P"B[]0'I^97ES\H
M)=4H2HPC?IUF9+>,SU&V/I?L6MV=TKQ8:"OT)0IF_DL;:XJJ TD**XBH]%<[
MCS)'22*I@%+QD I@QH.?7_9B D"W!V9NGSJ?>IL!L/>&9B0]' ?7H;CKU<%F
MU2ZYGLE;];ZNN&II.H;.L.^I_0.Q8'[8HF7B:988G5C_ &JPL$1-LQ$MEKEC
MKY&QFIP3163!P)54RF((9!QPQG&3Q$1('I#LW4Q5QDEXPE%IF>TUT.TR<'B"
M!_,M:MP=<F\;!NOI_IFE:HRBH@.M"[]/^S&4S8XUH:XQ=7H,=9&@M%%(Q^JQ
M8ODY1PN;P&26*JP(D81!7LUACVHVY2N&O=B0II5EC/)NRO0C;%.],2Y9VB_6
MO:<.X/8#N'D.[R#Y<X%Z"KA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+77J#Z>H[J )J8DC97U;#
M5.XJ;M]H+&/;2 S3RGG=G2@G8.E4O16;\'8@=4@F.3P]A1YS6U=-K=1Q*)'I
M65ZS&]M<MMD)>A:X7_H"<RVRMG[!U+O&<TP3>+^-F-KQ3.@TV\/W$_'1;:$"
MS:WLMH2,_P!;65[%-2).7*2;Y)0Q"*D125+XS:QR6C&-R(EMTJ13H(&H6,L7
MUYSMS,-^K &M X<4/\ZL'4)\G$/4*UF*7:M^6N3TY:D85*?H=[IM5V;98%6*
MC(J)>26G]I6@!M&I):P-X=)9VX:%=G(^,=TW\PNH<QIM99MD3$1W@XBGI&A;
MYJ*M[#%X2@9GNI!B"W90ZC]!J*K9#3_30MIG9.XK57MB2K^C[>>0,^YH4E#M
M3R%?M\/5H"F.9UG?"O!FI!K(P-::AZ(NB/F7 **@J;Q^$N5R[WD!$CUAQ?K)
MT\ZWMVN[G*0/JRJW6P&OF6N[KY.5I:=MU+86T]R2>T(/7UDF;%2F%AU]4D]I
M-D9=I,L I]GWP@8;K;:"P93RZ)(M5)$JZ!4DW"BQ2<#I[SM@8PB 2 [$M3CM
MT?K6)Q!*<97)&0B20X#UI]9G9J-QXKZ4GY.YY5F$54I?J3VC:-84"E;!H^G-
M?*LHR%94Z.V%!2D"Z=7*0BG"9]J.ZTRE#IQ'N@B@1JF  8%5/T7$LK<=VR(F
M2"3KIT=#\6U2&'M8;YF$8D :4-*LSMP?1NE93;>@N,EZ%TZPU3V=)5#9'313
MTZ/2MD.Z=7;@SG*ZO$Q$;.P]QHLZ;W)EHF=5@6CA1-)PV7151+YI8H<^*L<@
MB<B0#"9<C1NP]2M+%B80$9$3A%@:5'%QI7BK9)] T@Z@:)*M-]V=;=U$E[M)
MLMJ6NE52X0#J/V$$=]LE)+JA[Z'6(G7R)H9D:.C6*S8[!1J0Y5SG,J921D5+
MQ&PM1SPXOJ_TJ/=2P(F>\!-6''4,S-IZ/.LYH/1H:H732>P9[<=TOMIU');:
MFGCN?81;9C9'^VJ\SKKQC%0\=YB/HM4K#-D3W,BF!#H)<#XC&.<ZAHE?W1E$
M1 C)O,WSOQ*M#'VRC,R)E'=T5W4^3@I.TITXP6G:%L/7QYIW;X?8^R=J["F/
M=-H@Q%,FUYU[,RM>*FT.<%6,>1\9 BHB!UB]I@+SP%+MTW9B;,P ]  6EFR+
M,# $D&4C7_2)DWF=:ZZ^Z %Z9,:J@);>ULN.@-#71:_:;TE)5B$9#7)]%.;"
MMI6._-7)YFXPE'4L+@8AHJV;"W*5 %5%O,@)M)Y&_<=H%R08GT/30.RQMXNP
MQ&^1M0+B/I:NI8G]*[T?\G'I]K6NIJI.)B?<0O4=86,RDDD#5NKJMA#31[G7
MZ_1A,5PW3C8+8K]_.-RJIB3TEZ=,Q#$Y\0Y5QX%@\1Z>WS44C$M[9Q<M,^CH
M;SU[5:W'07;;5K_;U&V=U(V"UDV=K@^L&/VM:XJ6NJO68@\M%RREF<TN!<N(
M^T[ 7/$)(J2CE=,"H"H1%%$JI@Q[P 8RC  B3ZDN>W@.KY5$L4SC*,YR.Z+:
M -U]I4E=1G1-2.I%YH5Y9K-.0?P)V>+E'R4,@@!-D5-B,4^>:^M0G43-]K<I
M8J[&2"A2B?A=B4/"(&$0K:ORM;F .X>@]/;J/.K7\:-_8Y(VGAQ'0>HEB1U!
M81LKY/JK[$L^T;L&QIVOVR[[,UOMNG2K2NUZ31UO<]:TZ9HT>LVB9E-[%VF*
MEZ]8GS=VU>I%(9)R8""4Q2'+:.3*,1%@8@$=KEU$L6,I&;D2)!#-1OYU;K5T
M 2>Q=';/U3L;J'NL[9=CR-9F8^[P%6KU*AM9RU0?)OH1[K;74,LI"P*AE$Q%
MX<[E9=Z<PF.J >$"S')$)B<8  #1W=^D\5$\7O+<H2F=TFJP#-HP63ZCZ!*#
MI_J,BM_0-JFW;>OZ)JVF*[KEVT:EK,))5N*KU86V6S5*J98+?,TNL,X=8P$*
M4K),2 (@;@L3R93L]T0'WDOQ+\.SBIMXHMY'?B4B-@CMX!N/::#HHM]LYEU)
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB816B=BBS<1*PZBQD$I6,?QBBR8 *B)'[55J95,
M# )#&3*KR #V"(9(HFH9>?#[Y.RO? MTUZX@=HSD)?.E=O)HZTVJO5:[/>DI
MSR7F+'&VJB2WGH*:K\^BD@#EH"R*G][)B1<@@(CT^]'O)S,1MGJ*_(5R>Z1%
MJW;C(B5H4-.AJC2JO*O17L8FO$:\TZJ[XI=S6^7MDM.35,JDSJZ<:3D4A$NZ
M&_T0<6M1^#QBFW!>/8 Y%=D\\2X.#F.H!Z]] R<P&UFU+]K]/3T]"D8\P/[R
M6[<^@KU-3Z58-8_)TP6GT=*O*'M!_"V/5.U;WLZ7=-J176E4M)-III-K_58.
MAQJ[""UU#/FB!",/<WQ>@& 3B58YC"-YY1GN$HN#$#6H;2O%1#$%O;MD08R)
M.E7UIP6==3O1K.]1,I(*);J>P%1L]7:U.Z:PO&NJCNS6KUNR6D5&MFI]3O9O
M<ZAW\B,JLD>5;E7*N4J JMU!0)E+5\6OU7(+@@L>QQJ%:]CFZ_K-$Q8@@$>@
M]*C(/DW4ZHQ5K.F.HK:6IZ+;=8T#4NWX)HVB['/[ K6O(16K14Q$WB04:SM"
MN[NJ+#&KR;(%0]& HIHIJE(J2_O6X[KD(RF)$CH#UTZ'JRR&$(#9;G.,#$1(
MXEJ.^KD4)[.U2\CT.:Z6@^J"HSLY.S].ZG8JG0DU#O#%!]5F%*UQ%:\B58R<
M55<OI*533AT9 KMT!E =E 3 ;@1-GW\A*$@/6A\M76WNT#&Y&1)C<^2@'Z%@
MD+T#OI:KWVD[JWQ9-J5.X:YE=9-(&(I%3U<Q91<J9LJ6TSZ57!P2W[#B5V:1
MV4FN""3;@WA; )SF-8Y $A*W 1(+ZD_S#I5?=C*)C=F9 AM //0:JW*= UOL
M=$VE1-C]3%EM$=?]43^HHI*NZXINO8>&BIXC<BMLLT!7U3M;_?6Y&I2)OW*C
M9%(AU0203%4YAD9$8SC*,!ZLGU)TX=042Q93A*$[DCN@8Z :\>WR9;%QO37&
MQN[=9;J+:Y)5_K31$GHIK 'CVH,I>.DY>N2YK"[>E5](;ODCUXI 0(4R0@L8
M>>S@<N]/=FVVLG^?Z5MW0[T77+B.UO./H5QBNGN.B^IRU]2Y;*_6E;5J6M:G
M6JAV+8L:T95JPS%@2F4Y$%!=JNW:DL*9DC$ A2D 0$1'L@W";7=,&W.I%MKW
M?/ZVUEB>[.DFK;UOZ5SM-CEVC ^D]F:0DJY&H-TR/H39IXXTC,)2IS&<LI*,
M!@'F"E3,0QC<F'LX&UN]*W%@*[@?0JW;$;DG)+;2/2M7H_Y,-&=>PZ>ZNH.X
M[@J]>T%>.FV%K#FG5BI)--<VPT&,>Y/(PZB[E>WP?VOMA-("4".E$DS@BCX1
M*;4Y1#]W$1D9"3N]1^@K#W,287)RE$0,= *']*RUIT VR2J=\IFPNINUVZ$L
MNJ;;J:O,H37=+U\QC(ZW1H12]JN["L"1MLNYQ;,OFVCET#-L@0QQ(W*<YCY
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M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7 Y
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*")A$PB81,(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>tm2115679d1-lc_erbb24c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d1-lc_erbb24c.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!$ .0 P$1  (1 0,1 ?_$ 1(  0 !! ,! 0$
M       ! @8'" 0%"0,*"P$! 0$! 0 # 0            $" P0%!@<($
M!@$" @0'!0H0$Q$-!@<! @,$!08' !$A"#%!$@E187$3%!47@9$B%E?PH;'!
MU)755I88T3(CTR0E-28V1K8W=Y<9"N%"4M(S-%1TE+3$155UM<5V1QKQ8G*R
MDZ.SPT2D985FAB<H.(*20U-C<X-DA*6'6"FBPF=(V#EYF:9HMZA)$0 ! P(#
M! 4*! (&!P,)"0 ! !$"(0,Q$@1!46$%<8&1$P;PH;'1(C*2%!4'P>%24T(C
M\6)R,Y,7HK+"TD,T58)SH^)C=*34918W"+,DE"5%=2969O_:  P# 0 "$0,1
M #\ _?QHB:(K5M-QA*B@W4E%5U7;]3T>*AXYLM(S<PZX?D:+BVI3NG:@=H.V
M8 !)(H]I0Q" )@(*JU$39/M)S*J>KL;0ZG;32;BW;6:['2$H"F[,Y,X4J<(X
MW$?Q S>7*   B<!$2A%6#H7$%:=*F<V64M]T=*$%-8;1;)I>+5 >(B-5BW,5
M34CB81'M)QQ! ![("!0  J+['PGAY4H%<8LQVZ*&P_DNF5YV.X ( /:<QZIM
MPW'WQ\.B.OF&#,)AT8>Q;^U_4_L3HCE/89A/I]CV+?VOZG]B=$<J P7A,!W]
MC^+O=Q_4OL1HCE3[#,)_(]BW]K^I_8G1'.\I[#,)_(]B[[@*I]B=$<[RH]AF
M$_D>Q;[N/ZF/]Z=1@CG:Z>PO"?7A[%ON8^J8?WIT9'4^PS"GR/8L_:^J7V)T
M8(Y5AW6N\I>.18!D"O<NU']: N,;\<(C&U:&0!J*8.?0?7#=F+KT?SQ.WYOM
M=CMAOMN&M1A*7N@GH"S*Y&'OR Z2ND<_>6,Z[$V]XCRP-*G/.GK*#M#I/%C>
MO3+N-64;R+6*FEBDCI%PP<(G36(BH<R1R"4P (#J]W-VRE^A3O8 9C(93@75
MT*4GE<0JGQ\7IV!$J0#1.0^.*E?Q\2K P54(BD]&P':!$@T454*4JGG>P)AV
MWWU,LLV5CFW;53..7._L[U\JG4.5>_,G4G1JI@"Y1K)4$'C^J06.["R:+=CS
MGFG+F):.T4%/-_"[)C .W'HTE"4?>!!XI&X)!XR!' KK:E%<GU\D5XFD17+;
M<91JF=9S&U=CC*P/VZ29NPHJNRBD7;A),AQ !,8H  CMJFW.(>42.I!=C,M"
M0/05#Z(Y0(V[M,:OXCEP99$D"$584-W'XS:W%XDJ43I':UI5N697*J7B3LHC
MV@Z-],DS', <N]J*=[ 2R&0S[GJKVE,/X%A8Q_,2F*,3LHV+9.I&1?.:'4TF
M[-@R;J.GCMPH,3L1%NW2,<PCP H;ZR!5ABMYFJ31=)1Z)RSY)I]8R!1,>X;M
M-+N<#&6>K62(HU2=1<Y S+1)]&2K!P$0 +,WK18JA#;!N4VK*)A(QD&D"S*0
MG&<1.!>)#@OB"N36\<<MMR9.9*J8_P )62.92TS .G\!4J-*LV\W7I-S#3T0
MNY81ZZ*4G#2S-5LZ0,(*(+IF(< ,40"&)CB&+)&8D'B7#[]V*N'V%X3^2#%W
M[7]2^Q&BI)6-I>*Y2*_>F&,INJ8+BK])TV<R&QJLA4J8UEG%'K+QG'V"TD16
MB2$"&AWD@B1PL8P%3%0-^&XZT+<S'/$>R[/QW+!NP$^[) FSMM88GH"O*OXK
MY>;5"1-DK>-<-3]>GXUC,0<Y#TRE2<3,1,DU3>1\G%R+.,5:/6#YJL51%9(Y
MB*)F Q1$! =9,6+$56A,2&8%XD4JNX]A>$OD>Q;^U_4_L3HJY4^PS"0!^L]B
MW]K^I_1]4Z,$<J/89A/Y'\7?<!4_L3J)F*PODB4Y*,16N@T;)$/@6HW#*,JG
M#8_K4M3ZH29M#]1VSCP"/8HPJRQ6A9"0;MS.503;$7723,H!U"%'I&U<G$R@
M'C'$[ESG?MVY1A<DTI%@-ZMJ+R-W?DU<+K0HQ]RRN+7CJ?AZI=HH8>AH?%ZU
M3\J$%$UAX^<1J,:>QNIP09^@)+*.DW1BI'(4YBE&FS=$1(Q+2J*;-ZD=39E(
MPC,9HEC7 [EL87!N$Q !]CV+>(=5 J@_WIUSHNN8[RK<+COEJ4MBM$+0<(C<
MT8(+2I4RU2BC925HS\(LM@/"^KQD2PII(?1P<BGYD5O@=KM<-7*6S-[._8IF
M#Y7]O%GJRN,N#<(F #!B#%IBB " A0*D(" ] @(1.P@.HJY4^PS"?5A[%ONX
M_J8_WIT9'*GV&X3^1_%?[7U2^Q.HP1SQ5/L*PG\C^+OVOZE]B-5@CE/87A+Y
M(,7?<!4OL1J,$<JV+KC_ ):L<U&S7R[X\P[6*=3H*3LMHL4O1JBUBX.!AFBS
MZ4E7[DT0)4&C%F@=10P[[%*.M1B9R$8AY$TZ5F4Q;B9S+0 <G<!M77URI\K%
MM=L(^M4W!4Y(2=2@K\RCHZKT5S)N*3:!7+7;62-3C_3BP$T9JJ5LZ,F"*QTS
M%*81*( ,) .11VZT$P2P-6=GV;U>XX,PD "(X?Q:4 #<1&@5,   Z1$1B=@#
M4HM.5;DSCKELKCZNQD]0,)0TA;Y8T#5&4M4Z.P=V2;)&OI@\1!MG,<DI*R18
MJ,<N100 Z@((*'V[)1$*(D@D!P,>"R9B) D6)-.*N0,&X3$ WP]BT/)C^IAY
M/ZT[]&LT6G.]/89A/Y'\6_M?U,?HQ(ZJ.=Z>PO"?R/XN_:_J?THG;1'.]!P7
MA,?\3^+OVOZG].('1'*>PO"?R/XN'_X?U/Z41HCE/89A/Y'L6^[C^IC_ 'IU
M&".4]A>$OD>Q;^U_4_L3JHY3V%X3#_$_BT?+CZIC[WY4AMHP1RGL+PG\CV+O
MN JGV)T1RGL+PG\C^+A_Y@5/[$Z(Y3V%X2^1[%O[7]4^Q.B.4]A>$_D?Q=Y/
M9_4_L3HR9BI]AF$_D>Q=]P%4^Q.B.=Y4>PO"?R/XM#R8^J>_O^J1U&".4]A>
M$_D?Q=]P%3^Q.JCE/87A/KP]BSW,?5,!]T?5/'1@CE/87A/Y'L6_M?5,/?\
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M"R$DW>D43%N:VI:?YJ$(VR/Y@#OC5JAL7K1AL9<[\=7'0W;L[@+V26$68LY
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M"IO-=;UVU.T8G+*9-#&.5M[X=C+CI[%V%X2&>-H N)2S.:,P<MTN.@KTBO>
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MD)E $H=K;<W#IU4]"K,Q>EWW9NB]E CDVZ"H;-U#%(FN/P>"*AS@!3?A1$0
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M-9N<BR9C)'*8>L9PG$3@08G:%Q-N<)&$P8S!J%90M7(-RO/1UP:&4!('0I*
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M$1+ESO!BB8.R.W>;<_G$/!_VB=5,Q4AW1/+* "4,N=X-V3" B'[IMS^["(=
M_P#:)T3,54'=&\M %$H9=[P?LB  (?NFW/YQ .@-_OB=P]S49'*J'ND.6H0
M!R_W@X@40,'_ -3;G\X"7H'_ +1'5HRN93^Y(\M?RP=X1_\ S-N?S_\ 41HP
M3,>"H'NC.6<=A'+O>#CL;M!_]3;G\X&\(?\ 6(U5'*K_ ')'EJ^5_O!__P"9
MMS^__J)U&5S*#=T?RTG 0-E_O!Q 0V$/W3;G\Z-]^D>8C?I#1E,Q7S#NB^68
M-]LN]X.&X[C_ /4VY_>)N/$?^L3T\=5,Q7T_<D.6H.'M?[P?@   ?NFW/YP
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MB!C24,43[[]LQ?-" GWZQXZ?-Z;]R/:GR&JP[F78$-W7O>$F[8&Y*N8(P*&
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MJ=.!)YQ#SD<=CKK?TFJ,H&-N9:W 8;0*CJ6IO[F%WB ;?]3#F&X__AU+\/*
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M+MV2*8UES$+V>!=BF2$.&@U>F_<CVI\AK#0VI]@]:C]R\[PG@/WE/,$&Q_.
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MQYKL]H!#IVT^<TW[D7Z4^0U;-W,VZ @]UWWA0^< W)7S &!7;SH#C>4$%=@
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M, [#L.W'8>@0';K =$7FSS=&'[^7NIB[AL.9^9T1#L_"$2\GV6P 0/\ PI0
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MK[#_  O;"&2W\(!K^B_MY['VYU-K][ZV?\/E5O\ WBOYG^Y,!<^Y>GU!_P"
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MYSJ!@GTC&R[V%B7DM#>D^J)1U',W$C%>F)E1>>K7JJ)W+'TM(H%4\T8OG"@
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M5^$'4/XK[VBI_!>I&BB:(FB+&V9?UH,J_L;7G]3$IHJ,5Q,%_K)X>_8MQ_\
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M1V^+4EOT\;,]^IM,O$)E"GV=XY^UN1]RRO?J4=,JC#CY=2@,=8XX_G<D]_\
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M%^9:2TVS:K(NI!I$^91,5<43%(M2>Z^I.&JSDW(3_&>:.ZHR9)/\>,B2<5R
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M5O\ 2ZHQ4*UWW$0';AMU=(ZZABN9#*DP[\.''Q]'5L/@'5915>,=@#AT]/\
M TQ12'E ?& ]>C(J1XCV>H?%UAQ\.A 944*L;($ID.+@1/C&FUJZVE9XFV0C
M[A>G&/:TS;"W<K*R,I8(ZGWR7!,JJ*:!$6L6Y5.JN4QA32*=0MC&+M,D#@'/
M8X]*S,S >V 9[B6': 3YE9W+IFAES"8<I>76%=D:HC:VTH"U?DG[&64C9&#G
M)*N2J+:7C=F,Q%FDHE4S-VF5,'34Q%1(03=@N[D#;F8$N0L6;O?6A< 9]G11
M9L^;Y^WSM<R NB<?%]'\#4/!%0/#LCX-]M KCTJ2FWWW#;;;<=7T**H>C;Q:
MB+MIG^3Q_P#:6+_I8FH/Q574<=QV$.D.K?J#QAJ@E13T;CMT]0:NU%0)N/1\
M_?P#X-#O5&+*K\,''K\?^9J8H:+%N9\IQ>&,=RE\E(F4L2B$M4:M7ZO!F:$F
MK;=\@V^#HE'JL8L_608-%Y^V61H@=PN<J+1 RBZFY$A =PMYY9<,>P!SYESN
MW!:AG+FH  VDE@.LK&[K/4MBFNO9[FCK%8Q0DK.P]>J+K&UNMF=F]]G)\DFN
MQI]4K4)C"LY8F[\U:Q"RZ\<QK#Q$[1,[A!PJFBY\SONA,M9)E1RX$6XN20W7
MBN??2@'U $2[#*3)^ &4%Z8 =9JW22W/7RK0U=J%H=Y26<1U];W9:I1\-CO+
M%CMTJXQL^8QN0(8] KM#E;Y%V:EO) @2<4]C6TDR3(JHJ@5-%4Y T]YR ,&>
MH:N%268[#@AU5@ '-B[4)-,: .XVAG%=RY%8YXN52Z,KS*5C+T?*1./,8RV:
M+%,#5<@1L.YQ17TA4L=_ILM,5&/CLDUBM+ 5O).:XK*DCWBA&[CS:YRIB.GO
M @&+$EMF.[AUL@U6GE$R$AE$<VWW1B12H&UG;IHN7"\Z?+%8*Y?+;'Y4;-X#
M&C*ORMM=SU-R/572<+;Y#U139ZMPUIIT+.WR!NDS^089[ MI-K+/C%;M3JK'
M(0PZ>Z"(Y:G"H.&+[FVO@@U-D@EZ19Z$8X,X<N:!G<X+O:?S4X&OB-;/6KNY
M4<VK);C#<;!3E'R)3K6SR<UJ#R_JU"STVYU*OVRER!Z6Q-)(J3#)BV<-#IG2
M5."R7;ALW(OF& ?$$,[.XQK2BL=1:DS&IEE8@@NSLQ#BE:[%;UNYUN66C)Q:
MEER2X;J3EBRY4H*.BL>94M4[/6;!%G0IV68.!KE3H\Y8)F0I\ZOLJ5LU5*NT
M26>(&59H++DHL7I Y1L!Q&!PV[5#J;$6>6)(%"7,2Q  #ECZ\%8W,ASXX.P;
MAV;R#&76$M=BD\&V/->+8B.AKQ9:_:8!I"N7=4G;-/4RORK&BTFT38(L$928
M<1C99RKYE-45BB0-6M/<G<RL1[0!PZ\<2%B]J[5NT9@@G(9#%B&HY + X E;
M-+V6XO<<Q%GJ-3B+';YVO5V685R7M)ZC7TW4['L'C@TE9 @[+(,XJ*([,<XH
M1SYXH0FR:)SCPY"($F):+[G]7I7H,I&#Q ,FVEAVL?0597+MFEWF^HVV4F*D
M6E6K'66,C85N\,RL*=MKI[EC&8+"SDC3;2$5 .9^J/ECE%NLZC8UZFH55!PU
M261.4=7;8MR %08@BC4-:_T]!7.Q=-Z!D0THR,35PX+%CM[ =X!6>M^ #X1V
MW]_\#7/ +N<5 AQWZ^KQ^'CU:F"NQ5<=O'X]595(& 1#PC_!U%5R60_DMJ'@
M=MN/AW<$U3MWH,5]98.U*2 ;]#YWQZ>EPK^!J(<5PP#8-NK5X(J=_"(>+APW
M]_JTH2BJ^8?!K*B>/Q 'O;_@ZVX9$X[^X'T_%X]91 X@ Z;44;AT!Q'P?-XM
M,%52<?@'[.QC  [ 83 43;?! PE*<Q2B;@(@4=@ZAZ-5-JTTBL[\P#?F!A,%
M6W"^(G*TMBC(&6W4MC/.]NM#RLP-9DF%:IC>U1URP-CJ/BELG7.0/&QQR/5^
MP#!\N8#)M#B/8V[7==Y&4J2 K$#B6:1P'X+R"]?[X69PC[I+B9+-0.# ,Y=J
M[#N5VX6SW;;YD_*^',@X[KU1N6+(6B6=W+8_R(OE&@R$1D,+#ZIA5;$^I&/9
M.)O4.%;44D(U6.,D5LY;KHN%4U0VD[48PC<B28R<5#&C<33KZJ+=J].=R5JY
M$1G$ T)D*OM85I4-M%:K'DASBNVV>UL0H8Z8.(UGF:!P<\05O@M\T.9>>IL7
M>"97@</EJ:[22P#&1,L!75A4L#99,6;LQ6IA1*FKKN!W><EB8OA3%F=_>X,=
MBR=3(7N[$?9S-C[6#N(M[HVEQ4&BRQE_FSY?L"6%E4<KWX]9LLA45[\SA6=+
MR';GQZ,PEEX29N"Z='J5F!E6ZX];G/*O5Q2;Q;4/279D4!!0<PLW+@S1#AVQ
M&.[U;UTN7[5J66X6DQ+,308F@P&W=M5L-.:1BOS9(\M*E:;EAYK&4)=*;DYI
M9$7K"S6>:9O["VHS>$3BRID6?4J*>RK%VF^7!TA'N \T0"%,9W7\GO7J"Q'X
M]JR+X-_N6]G*X+[=S=%<=^"^V"N9UKG'*^>Z#$5!6*K6(9*#95B\GFB/T,E,
MU[#?Z-8IEC%DCD"0\;$WW&DNQ:G!T[!\W0*XW3[8)Z7+7=PC(GVI8C=0'S@C
MH5M7N]G. 'LQP+XX@^<'I6UH?.UR&_8NR   'BTP11MN.X"'#W?IZFVBKT4;
M[[@'#8?P=]%%5MUAMY>G3;5%2!MPZM^OP!X/?UI@BD!'Q#Y/ICK)H55(CMT^
MX'AT?>BR#CD1]9O]P_W$3KW#@OT='3QUF> 9:BLPZYK2:(FB)HB:(FB)HB:(
MFB+R![U;F)O7+[%X^=($SK'XEO->NU(MUMPQ@B)YAV]9R!9KKANM8U>VRA*X
M^O\ +F*V9STV[8&%%*,>+LC,%O./'<>02'KZO+R[%;_=HSB$IE/(J"6<N8/*
MQDJ"U5-&9@[MV4Y*86-[5A8E%]$W>1PABL+A*;CYL\4#ER)$C"OYKX';"E05
MK7K#?@%W?-CSD<QN+<F9^L>+"8O-A?DUB<!2>9J9<J]-O;WE@,QS"[RSDHUN
MC;,QCJ3\2J*X9.([TF,D E)4RR"OF4B%4$$)8/L65><'F)YA:_F'$7+ORQ.<
M85R\W?".?^8V<N>7J]8+/72U3!2N-H>/H<;#5^?K;AM)7VVY38INY15R?U5&
M-7"B39RN8@)P!4GT/V-ZUI&'>D\P60*B[YD,9U?&->P+A3&_)C?LWXZN$;9)
M3(]^+S5%K\K:VF/K<PF(Z%JOLOJ5E0<QHN8^2&>D4E6JP,B"572B5"VRFL]\
MW=$YSF>!%I;$.;8"]XPS5E<:=0,<VFJ6SEYI]8$[7"<U?+A)W^PPMR#*=F15
M@BM3-(9P[?-7+AD MF;H".A4,]<%T?=]<W><L@1F3ZSSFC8:;S%8[Q?CS+5P
MP*ZY=)'&\_4JK8H2;/+3M!=UK)V9FF<*F]M<#(Q3)>.5;RR+N-%!TP07<(IF
M*;5@NT<\&&.:GO >[)K.,:_S!P\E6,H<RD_)*Y@Y7^87 \*LQ6Y3,KQH)14]
MF3&M(AIV6(X=E-Z&R77=%1[:HI@F0QPE%J(+$D'#\0O>C564T1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1-$31$T1>.6=^<^_P?/SB#',7$2]<Y=L2W5:
MGYRR4$TBC79JZ9*PG=+G7:K*Q2I4A69T^)@ E5E2&6,@80,<"=I(%/W;PYX!
MY9J?MKKN:WKEN]XJUNG%W1Z?(3.%JQJ[5J=R,MANRGW8%!+ /5OP#Q-]P^;:
M?[I\OY/8M7+/A#0WS:UNISQ%N5[4:.]>MVY1-2+4+?>$A\K@EJ/G.N357RQW
MA-,R#6)%A:JC'\AT9;:18&9A<QZK'+>7) &\Q$J&* I#-PE/(43[%4%(O9$.
MD-?7-7IM9R7[8:CENLA*SK9>))6KL#20EIM-%XRWY97<*AZA?9])J]!SS[J:
M?F.BE"_HX>&8W;-P5B8ZK52:<3_7A9'%L5D#N^G0'Y<O5(;[5/-G,U30*;^$
M+6>8K)\6DF'$?@D10* ='#7QOW.@1XJ[\_\ 'Y?H+O\ B:'3R_%?)?:NY&7A
M+N8/EL<RYC:_PM?J8'T+=K7Y\OT9-$7AQFIJ+J[=XC/ /:*SYIN[=B , "/F
MPK4C@>;4#?P$-8Q'W=?T1R"?=\N\+:;;+D_/9?XD=9#_ &%_-G/89^;>+=6_
MLQYYX?AT=T=%,_\ VB]QPU_.Z_I/H31$T1-$31$T1-$31%Y:=UN)!;=X2!>W
MN7O2><0%.U^%[?K6GF#L?YWS8E]W45*]2]51-$31%C;,OZT&5?V-KS^IB4T5
M&*XF"_UDL/?L6X__ %*1.H,$.*OBS?F!+_SBO_I=:&*R<%KUKKL7-4#T[^#Y
M_7[^G%:&Y5:+*#\WB]_4501 =@Z=_I=?#ATZHP46MO-12L[9%Q0^H^ ;-1:A
M/V:491-QF+JYMD:<V-W"3CXW0]1FZ<SD96M6NQM@*P3E"HG6CVKE=9L9%Z1J
MNCULRMQN9K@) W-CL=]@\N/'41O3MY;)B)'%WPV@-@3@^RK55]X1KEHIN,*E
M4+;7L9U.1J\8E ,ZYB$]@4Q]#P$3^0:^P@36AHQG *A$HI J"R?\F[6PF =]
M9N2$I&0<@[3BMVHRC 1F "!A'#J65Q\F_P!#RZQBMH'S;:B)JLB@1V\?X.BK
M*1\'AZ/+QU7HHNXFOY)'@/1ZFB_GM2!MK(573[\=OFX[_@:H44Z,B@ X &JS
ME$^;Z6IL187Y@,3*9HQF[IT?.%K%EC+5C[(U%L:S#ULQA<AXGO-?R/1WLS#^
M?:FF*XI8JT@A)M"+(+N(]98J*R*WFU2=+4Q">;$,0>@ACZ:+E>M][;R.Q!!'
M3$@A]X<5&Y:^6G%W.#>$<>7Z<L_+/%99PWD8]UH-6AJ]E)WC":9RV/[QCFTM
MKA9I&6"YLY.1B;N9Q'*QK "QJS,$U?32+G,3H)V8O$9S"08EP^((;LVFO!ES
ME;U,A&9-OO(R<!BV!!<X[7%*-MJN)AWE/N]&S#&9NMUNI\K:[(IS(6O*4=68
MR9C8!&]YY-AIHR:X_;2BCQ\G4ZW!8E20<*R#@SYZY6,XV)YT44K.]&4.[B#E
M]EN@/CVI;L2A<%TD&1S/TG+AP:/25AO+G*3D*#Y:H"+C'L3:I["_=@<S'*NK
M!5N+F)"9O%^OM,Q<,&\J,>+4BKF/7=XQ<(@U5[#E==Z@!2#N?;I:O1[[,:1E
M>C)]P!+^E<+VEGW&6+&4=-.# 5)(BS?#YUW<_P HG,%E:P(YAR-?<.Q&8*##
MX9C<)QU,JUW#&ZB&(LCHY69N<N1<_,.+$LZLLJ'H2S6*<@$.D J-UW"FX#D7
MK4(]W$2,"[NSU#4:E..*V;%Z<N]G*/> #*P+4+UVU.P8<5W4]RN<Q-CD6^<G
MMOPDWYEV.<Z/EUG M(F]EP2,-1<5V7#C&H/9%553(KN0>5RX/Y!:7!-/\G>8
M0!H#=$3*07K0&0"7=&)&QZD2?=L9OQ5E8O2(N$Q[X2$MN6@,6W[27ZF5PX2Y
M3\DX]R%BR_W2XT2<DJ?+\\]@M*=7B[!&-)"6YN<K5C)$1\6FDLH^781]:3BG
M+5TFY<JJF*<G845^&89<O0E"4 "'R,_]6+>=6SIYVY1E(BG>/3]<A+S8+"SK
MD1SS!8@?XOQ[DC$")\E<HK7E;R])7.$O,FG'>H4;RC!VK&B<,\CB]EXVO3EN
MZ;2:8)I'(DY+Y[L&;*;[^V9]Y,2I/,&;A0]FQ8EI+HM&W&4?:MY9.#N-17CM
M6].4JGG(>7U6C8#ME'J.8T:C6:I!W6YLY=W7($63&.BIR=8-H]A(.QF4&*"R
MD49PU<-TW8I'<(JD*9(W"V;?>9KH)MN[#;Y;5Z;D;O<F-D@7&9S4#RV<=A7S
MY7\>WW%.)8?'M_B\:1CRLO'+>*-C*8ND^TFF3WL2TM:KA.7R.C9V9R+;+=(2
M,E,O3$,#YVY,X,85%% !>G&<S*+D'>WF:C =F"FGMSMVQ"65QN?I<O5R:D[2
M25L/N'7MM\[?P:XKNR@ X[AL/B#YO!HG!5 ._1JNC)U]6P?P0U<%%]V8?DUG
M_/;8?)^+I[^_J<505R)7\TY'^?WGO>D*:FQ1< /!MP^;W]:%.A4[U [B&_1P
MWVZ>K64"GHZ V#Z?NZJB@?#U[@'N#MP^?ITXJJ?'Y ][?\'3BHH'B ^#CH50
MH+ML/E^D&HAQHI'@&X>$.CR_3U0.Q%K1C_#5JJ]NYD\K3TM5IO*N:YI*-K#I
MPRF9"I5#%>/H%W X7H4A'F<1,J\8-'\I)S=A2:N$"O)2<=E05*0J)R]93!C"
M #0CVDG$^@#@ N$+4H2G=)!N3[ ![H\Y/22M>L'\K>:L-369LDU)ERKXMNE\
MIM8K%9Q)B*IY'AN7-:PUZ;<OW>4[_ DE(";?WN3AWRD:52+29BFU22*X6=]D
M!)UN7H7!&$L\H@XDC-T#AY47&U8NVS*Y'NXSD &B#E<;2*$G91J"KKJYWDLR
M5,\Q2V6%[3C!0#9UA\P1.;31EO3YFZE2XEE',C<MU;?$=C31PVXCF:\:9LNH
M9FHPD'"JL<I(&%X:QOQ%K( ?=9J92?U;WV]6+469:6<K_>$Q?,#F_C8?P[LN
MSH.!-5L+DG MBN^6\BY$83D$QCKER77OEC8L7B#\S]C:+7=WEI;6)VHBB= :
MXW:.2HK$(8SDRI>!1  '7*-P1@(-43$NIF7>Y:,KDI@AC;,>LG%:Y6_DARC)
M5U\]I63ZO3LM5F@<K3'#E\+'3#UO3LDX%K-MI5HG9-F+<BKV M]/N\HP12+N
MJ";L3*E 2AOTC?@)>T"8$R<;P6;K!"Y'37,C1D!= BQ; AW/6"5LK@WEQC\$
M6^27K#QN>BIX*P/A^O1ZOI"E@!UB)SDI68L,^Z,B1HZ=6<]U2<'5(8RJKL%U
M%  3@(\YW3,5][,3VMZEVM61:E[/NY(@;_9?'I=;2?-OXM_IZX+LG\#5=$'Z
M8:O%5-PWV\.HB='DT=NA3%-_=Z1X:<54T*B@ Z/%M_!]_3:BR'CD0]92 !_,
MA/G*@&LS6XK,&N:TFB)HB:(FB)HB:(FB)HB\<.]HQK@RSQ^%+C?N:S+W*MF"
M$G)6M8<=X.@H;(F0\M-'UIQCD:XXX@L.RE!R,]O\D=[BJ&>-%(]@FXC7")17
M448+.FKDBZ/NL\C\QF7L@YMMMPR%S=7K!=1>6/$L4MS>?>H5*Y)Y<I=EBD[$
M$=BKEYP90['6V[.-652.XFYY;MB($"/*?\53+16X^=N[]PIS"Y21R==IW*,:
ME)(XZ;9+QO4;IZ@QAFYOB*TO[EC%++=<)&.7M@)3Y^35.GZ(\C_3F_8:OO2F
MJ22)"SQVKK,N]WMC7-,; EMF7.8QC<:S.9L6A,JUG*(0F2V6/N8.44?9+P>6
M?3@EVBF'WK%)@PCX\[0SV(;0\>HR>(/&J;K1,5T=F[K[E>L-LH\ZS;Y!IU5J
M,%A>M3>(*5=WT)B/*D-RYRJ,Y@EIE.J"@[<63V92[9)9F9!VR,]*BFA("\;)
MD1+748#!=SCCD"@<79GS'FFO<R7-*ZD<[66TVO(-0FKK0']6=R]AKZ57A_5D
MB3%[;(47&XYA&K=&LLTYWT2(!N7L)F[2OG(JK_Y?^3BEX%OEWRTYR3F?-^7K
M]6JK19?)^=;C&6JSL,>TEW,259HE=:URN4ZK0-?92]A?/EQ;QQ7LB]<F6>N'
M!RIB0BPCS=;_ '\?=3<3=GVT\S6X<>QV@Y/<O]D1_A>UL([=>V_CU"M1P/1^
M(7I3JK*:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O&8G*?4.=
MF"Y\,>VZQV>G-''.T:8KEOJ*S5.8BYS'N,:%6BK(@\17;NVBB#AZT72-V=R*
MF[)BB :_>SXUUOV^U/AOFFAM6;\QX>RW+5P'+*%_47IL6((+B$@:X5!7\]R\
M#:'[E:7Q/RCF-V_IK9\1Y[5ZR0)QG8TUB#AW!!>Y"0I0EB"K.[J"@9BQ_F7F
M@QIF.?B+*]Y8*OAWE@I4M#LB-&Z] @QN61ZL4RA&S4SM4D+>&XG,J45R]L$S
MF/V ./N^]7,^0\SY#R?F_(;5RS;YQ>U7,+T9%R+T^ZL7-I;V[,J"FT .R^,^
MQ'*O$7*?$'/.1^(KMJ]/DEG1\MLSA$![%L7=1:JP?^7?@[AP:$EG.[_((;T2
MB9_KINSYVK\ZG-O'G[(_PLWF2Q79IN7<>R/H%K2X<-PX]>OSO[E SYCRS5;+
MW(.6R^#2PM'SVROTS[72C#E?--&,;'B+FD3_ -O67+X\UT!;UZ_.E^EIHB\3
M;ZGZ;C_O+[& ]H?OX<%-2J  ; G2(OE.;B4!ZP1424#Q" Z_H/EA[OF?A'2?
M_P"=UA_Q9<Q/G!"_F_F@S<L\9:Q\?$^A'^%#E<?,0?.O;$H[E 0VX@ \.C7\
M^+^D,:J=$31$T1-$31$T1-$7ECW6H[M^\-\7>F<X?]T*4/T]$7J=HB:(FB+&
MV9?UH,J_L;7G]3$IHJ,5Q,%_K)X?_8NH'ZE(G1#B5>UH5;H5Z95=.6[1NG'N
M3+.7:H(MD$P3'M*+*B ]A,H=([#JC%0X+6SUY5MAWN52^O*?O?R$-=,PXKDX
MWJGUY51X?'&I<?\ AE/Z2(Z.$Z2%(3E6#A\<JCPX?FT3\9TS#BZ)Z\JV_P"C
M*I=']FB?C.F8<4HGKRK#^G*I>'\VB=0[_P#B=''%'&]3Z\JWVY5+?^W)/QG3
M,'VHXWJ/7=7ZKE4?KR3A_K&CCBCA/7E6 -OCE4>'_#1/QC5$AA5"5(3E6^W*
MH@']N2?C(:9AL1PH&;JP[;7*I"'7^7)-P'J$-D1U!(<4<;2I"<JP]%RJ7UY+
M^,:9@K3>H]>58 X7*I; ']F2?C.@(Q4<+N9J9KA%8_SUJK* GA(E1,JTL5,5
M$3M2BDX3 41[;=8GPB&X;EZM!(*EAM"Z?UY5OMRJ7UZ)^,AIF'%1PH&;JO1\
M<JEQZAF2?C.F8(X0)RK]=RJ/B_+HG1_J&F8(\4]>5;< ^.52#IX>N2"/^PAJ
M.CQWIZ[JX?IRJ.W3^;1/GAYC5S!F1QO4^O:M]N51'_CHGXQIFV!*;U'KRK?;
ME4?KT3H_U#0D(XVE/7E7Z0N51^O1/QC1PA(V$.@3E6^W*H_7H@_[3IFVU2B!
M.58 V&Y5(.'#\NB;^[^(ZF8#>E-Z>O:M]N51^O1/QG6LT>*43UY5_MRJ/UZ)
M^,ZF8<4<*0G*L/Z<JC]>2?C&AD$IM*>O*OQ_/E4OKR3Y_P"(Z.CC>GKRK?;E
M4?KT3\9U<T<$<;U 3=6#<?CE4@W_ .&B</\ 60X:SF"KC>%/KRK!T7*I?7DG
MTD1U<P4<;U 3E6'C\<JE[DR3\9#5S!"1O7W9S-9,]9%)<:HH8SUJ5-,DP03G
M.+A,"ID+YGX1SF$  .L1VZ]3,,-JT#M<+DRLU6BRLF12VU9%0D@](HDM+D(J
MDH1RJ4Z:I/,CV%"&W P;\!#1]ZA(VE=<,W5A']&52]R:)^,:.'=!(#<JO7E5
MZKG4OKR3\9T<>7]"CA/7E7#].-1^O1/QC02CN*4WA/7E7^W*H_7HGXQH9#%'
M&]/7E6^W*I?7DOXQIF!5]G>$]>5;;]&51^O)/QG3,%'&] G*M]N=2^O)/QD-
M,W!'&]/7=6W_ $8U'?\ MR3?_8=,P1QO5(S=7$/T95'W9HOXQIF WHXWA2$Y
M5MMOCE4>'_#1/QC3-':Z.%(3=6^W*H^'\VB#TC_YC02"4WA1Z[JP<0N52'?_
M (9)]) =5QM5<,U$]>U8/TXU/CX)HGXQJ.%*':$]>5;[<JB/_'1/QG1PVUT<
M;"H";J_1\<JGT_V9(&_^LCHX5)&PA3Z\J^_Z,:E]>2</+^(Z.% V\*?7E6Z?
MCE4?KT3;_8-42"$C>H]>5;I&Y5+Z\D^=^(ZF8<4<(,Y5A#]&52V\(S)?QC;1
MXMM5! .(4!-U8.'QRJ(_\=$_&-,PP4)&*J]>5;[<JE]>2?C.F8<4<;T]>5?I
M^.52^O1/%_Y'3-6B.-ZR/C.0AW<K(DCIV%E52L2'.C&/RNU4T_/%#SBA0(3L
M)]H=M_#J3+A:B0]"%FK7-;31$T1-$31$T1-$31$T18.SAB#E]S'",(#F I&-
M+M$,W2\C7D\AQL$[<P$N+<6QYVH2LH4LI5[$U16#S4C&+-7S8PE,FJ0P .B8
MK /*=RA8PY7KID-U@S..5)_&M^5E[1,X0NV3D\Q5V#R+8)EG(36286YW(+#F
M%"3F46PM7#5]8'L:8# <B*:A0-HJ7VK>_11-$31$T1-$7FQS="'W\'=4%[8
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MR&XA>>G>VJ,,BX.Q 1P<SAG"TG*G,HR3Z#*RF)\7(RT*[4V'< 1/:3\ Z#G
M>KC^G_9(7N4^(M<8 "Y<U&GT!_LZG4&,QU]V.H+\I^_%O3\Y\+Z*5\DV-/I=
M3S( 8F6DTPE ]7>EN)&Y<7GS:!D"_9WF&A1_.YW;$%?FI"E$XI^=STYN10)V
M>(F,E0P#J'X.X:W]MI'EG+>7:>?_ !?%D[)ZM&+7IO+E]SC]3YES2_"AL>#H
M:@;6?62N^BQZ%<E(%&;[I[F"R8T!06V77?-%GF..N'964AKAF"[6RN+JDX^;
M5&MHM#;;CV=@XZ\W, =/]Z^5\HN-FT,>7Z.389[6EM6YCH[PR7HT,HZC[#\W
MYU8S&WKSS/70)Q-N]J[]ZU_X61>S$6J"T9'+%XE68M%0'P@HW3. _/U^"7HY
M;TX[I$>=?T19EFLPEOB/0N?KFNB:(FB)HB:(FB)HB\M>ZX4*=KW@Y2E !2[T
MCG$(<P?PYAE:>IVO#P*H >YJ!4_@O4K5431$T18VS+^M!E7]C:\_J8E-%1BN
M)@O]9/#W[%M _4I$Z(<5V>5OUM[M_@[(_P"P#H,5B?NE>8(_AA_T/T!'\'6L
M5Q0=@'?KZ-O=\&H'13T\?G?@]>^E#THGSO+J-5$\ ;]>PB'D$?'J]."+!V?+
M=6*53&TU8[)0:<Y+-(-JW;\EX]F,CU.O3:[%\F9T[B8.1@W4<Z<Q1G+9%T9^
MT()E_-"*GG!14[68RD6B)'> 6)"Y7I",7) .PD. ?+RWXYY&6B\;RO8SBEX5
MW!DBRVM@R]+0<,"SL>A<9[T&WQL4\81;N$A;BW.$DQ8J-TS,VCE-'B! ,;6K
MK>D<</0*=6!6-)2Q$,V/I->O$<%MMN/'8-P#;;CXN/'CKST7H0HAQVZ>O3T(
MJ0^$'$>@?%^!JX(JAWZ/I</=Z>G4V<$4ZF.**];R/Y,KG'@-'J'N?E2CPX:T
M0J?P"LGW1X>3R^#?643M>(?+T![^JHHZMP^$(=&_S_!OIM1./9WX@/@ /'QX
M<=3AL1:S<X$;)RF!IU!E%/YZ%9W#$LWD*OQ;-Q(R4_B2OY6IDYE>&:Q;0#.9
MDCRA1SX'#%,ISOV@*MRD.*O8-Z=,0+H)+28L=TLI8]K57FU8D;) K%XN-\1(
M&0XT>FW!8%RUF?$%A"ERV-KO+4W&TUD2 JN>LWXB@)>J.XNGHT7(TK3:XMDN
M-KR,I 1I;JR8M7CEB8CF*(\30%=H#HV_:W:N!XS#SRDQB=[ARSUIOQ9USN7;
M9:42T#("4@-C%J[*]CLL<8\4RCE>YTNBO,UY]C\0ND^:1:BWN$L\A4;YDC'=
M3E<2(8UGK7;312$VZ>,Y68ER1TH4C*2E(UJDHJHNDX<BYW/);B9B,.\]EPS@
M$YG '8XP!Z W(=[.0@93[II,78D!F<XT<L:$BM=MNA<,TT[$K.ZN,PY?L,[E
M7NT,]9MM"UFEBN$*?F*@5K&[ZH3] CV,5%L,>RK5"Z2"9VC)-$C\S=)=P15T
MD+@;EM2N9!&($;\8AMH)+OOP%?Z%S,[T+6?-+-+3RET2 BW1B:;=HHOB\RS<
MV2MR/B;-&<+[AI2 P:XS+DZQ^N)^XXDG[)DLD7E$] -*5AFI6'['':IG$G&L
MH]5I7@_)+=JW.':"]V"W>1B+CR88 TH]:UP)+E:SS!/=RF;;1<XD5JVZF(:F
MP*\8K+DC4)"K6>&S!DZW<L-9YIZS#JY4NLS:K&=W2)W!MG)9XJ?MSYF2P73&
M$-EA[&$;/Y '9$))4Z(N#IM4BHX-O,"#&(OFW@&QS!F& +/3=TK1N&!!C*1T
MXN"IW93MVAVKO7QHLYD3-]IQ5!JY=SG5*7<[AWATH^D*I8IVFSTI5:?F:IM\
M-QSB1DX\\Q7HZ#KDB48DJ(,WB+(HMTSE;J.$5+,0M1)RP,@+>+&IB7\XKL>J
MELW+I ,IB)-SA02:(X4-,#YPL(Y@R5?+YR_/FV6<EY8K$G9>1E65QU"TAM(,
M6V9,L2S.WP5Z9W.%BJT^CK+)@P;1P*1CHJ31HT>KO4TDE"E<H=+<(1O/;$2!
M=J^P49B_GQV+G<G.=@BX95LT VEB[TQPIQ)7J99K!6JI@BOSEL?5F%CX^KT,
M6LU=*;*WJKP$V6/BS1,S.UV)78R)V<8^(!Q<%<L_13@4XN$MM]>&(,KA$7))
M- 6+;@5\C,B-IRV J0]5B;D:677QWE1SYAF\92G,?F*QQ=YA8:0K-0R@TMTK
M'VES>*-5I4AGU;J?K26<13= R[X%U8Q5R#MR#CSIMZOWX_V &Q(:C$[3MZP*
M,N6C?)+=WDB#@).7<#<Y;BSN76Z?1U; '@W'I^CKR8U7L3?AU;[='3O_  !U
M0HG2''@/S?.'48!% B8.H/(&X[:M'1=G!_FY!AQW]<1/D#\GM^'EWUIG*G#:
MNPMOZ*[1_A'._P!U'>H>*NU6YPW#CT=/5[_C'412&X!MU@'N#X-M1JHFP; .
MW1QV#Z&M;*HH*'0/1PVV]W?4/!%5P\6^I5T4<1$! 0V\'1^#OJOVHH'<>CH^
M</AW\&WS],*E%&W$O'KZN@/  >#?5"%>?=GAI[+EDYK<F5F&4[6&\.Y@Y=>7
M=".;*M'TGDV?HYY/+5SC.P+4QWKFT(0M78.$S%,0T0\[!]E=]>P&-L6[9/O2
M$I= -!V.3TA?'SC*[*Y=&,(2C'I(>1[6 Z"K3Y;,VUZH,&[-G>"V?!6/N7BH
M3%HD4<._%-WAV]HS%?KK3%;9*H5I@_F5U63QXX>L'2,E+,G#3SRSD2KCOJ]:
M,BY#793/\3YA4O4[\-E<%-/>$ P)[F-L'# TIANQ&(5P72\8=R%S:4.@A,4B
MFN<&9%0NTH\5C2QMTR1FFQT]W 0M4@#DBTSNX:.KMC(M,R2BAA>."MF*9A!!
M<2R$+EO3F1!.>+#<(OCVX#\EN<K=W4QA09)/Q,B&;L-3T#>N]YAV]^G\RW"$
M@\IY<H%<I_)5=,J1L;C:R*5MC)Y.K^1GC6N.Y54D<\.]59MB@*C%(Z19)N4$
M'A7#3M(FS9$!;$I1C*1N@5K1O+HQ%4O=X;IC&4A$6R:;P:>6W;1:]6JZV6DY
M-6YOG->EIV4H>&^6ASDV(@HEP:3LE RE5K2QN\3$,$$NTH\B+Z,#*^;+_*Z3
M)4!  '7:,8RA\L" #*3<""&\SA<C*49_,D%Q&+L*D$5 Z"Q6PW*G0[!2LMY8
M?7-#:_Y"Q/A+)62W:1#BT-D.[6O-T[88=FL)>P9C4DGC:':$W,9-@P;@/A'C
M?G&=N.7W(RD!T #TXKMIX2C<D9>\8Q)Z29/V8="WT#K#J#H^;Q:\19>T*=]'
M9%2/'CXMN(#Q\7'PZT'9"JM^ >/PZR"R* $=^(>';W/#Y=$0>([=76/S]M6F
M.U%/#H\ :AWJJ='8446S?*V/Y[+%U;UU,1\H2+?;R;;ZI=EN!J5O%J+JFB)H
MB:(FB)HB:(FB)HB\V.\IS='<NN*(S)<SG7+^(F,A+Q>,&D9BFH4FTK3$ODRY
M4F"3N#L]LPKF(6,IC2&].?LTC(HL7Q5%FZJ:ZYVHI$*PIR"9$A;#S+Y'@J#S
M$\Q/-+59##R-NNF2,J89Q/BNIPEY2N<7"0%=,_I?+%@VR6BZ2->],<$,XDI%
MNV8-SE,@0YDE-$&&UU<?-3R49_RUDO.$/C2P8RC,'\X,3A"+SY.6QQ81R3CO
MV,2BR$BIC&"C8I> M 9!I:+-@GZP>LO4SY%1V .B*@@FVH:AEVF>>7+G%NN0
M,=\PV-4N7^.S-0J?S2\MY*?;)R]K8]?8&SA<:6^HN1O7L? GG$\FU!ABV#?R
MD*9H:.D3NGK-%\W[*+HQ&=N#^7F6MH=U3F6C5<_+UC&^8\D>7O,...4.@Y[M
M=S1L;?*E9#E23K\:]?8QB(MNYKDN;*=;KC9JEZ>Y9FKSSSCL!? 8J!"NU]JR
MR[Y4.;'-W-+G"X<S])P?)XGN.,\P\O>%;C2LMW-W:,(X2OL(XC5GL!BF9Q:U
M@7&7,E/!24M$ZI/CV6;9HQ9))-FZP.R,&5X\IO)3FJKWM&W<T#W%DC'XZY/:
MSR(XZ@,6N[8NA=L70\PVD;9D^^.IUM%N*]9+^2$BR(P;$SI.#(BX )!V98IT
MWI669:\VOD.Y3.4;O!>[%L?+OA]ACB?M>3N9F#GY-G9;I-GD(9MRFY3D",%$
M;/9)MLD0'R*:H'3(10!)MVMA$!%6( <</Q"]Z=$31$T1-$31$T1-$31$T1-$
M31$T1-$31$T1-$31$T1-$7&>*>9:.51X DW74$?] F8WTM;@,TP-Y"S,Y8&6
MX%:,]VDD/WF6)WQA$33CO(EB,(@ ;FG\FW&6';;I#\EZ_1/NS+_^>ZVW^W&Q
M#X-/:C^"_./M' 1\ :*Y'W;LK]S_ !-1=G_M+>_7YPOTE89YC8 EJY?,ZUA0
MAU26+#F3H,Z:8B4ZA9:E3; 2$,'$#F!?8!ZAU\_X5U)T7BCENL!8VM?IY_#=
MA+\%]>\7:2.O\*<ST,P3&]R_4P(&/MV9QH>M>-6:7SG+>!,#@L8'#E_W2_-3
M;W %*4!.^>8WPK"]K8.!1\\[5#AT#K]XY!;AR3Q+S+)2,?&W+K0Z!?U<_P
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M=$N!=G<.E'YW""*1UU-TPNQN*F$WX>=_Z%Q^['CY.FV++&!N7V7M=NY6,<X
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M&=]/)DI@SM5MS^1:CLGR]O/G+XNSTS;V_-GJSU61;5@VDW&Z6B^S*E@+.V[
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M&<^<4)Z*I-1 !&R&Z90/VT?@_"VZ0USF "T2\=_Y+I"1E$&0:6Y7"&X#Q$.
M='EZ-0E:"GYNG4=%\]A$1V';KVW'?W]N.J$51M@#HXCOMMU:E43JZ.'1PX[!
M],-1D5[7GB\KO7^<>H\1Z0VB4OP=:(5<;-RLH.D?FX]._P _4Z5%(] ]7#4=
M%!>CB/SQZ.K5]")U[<>'AZ^'5X=M'[$5C9+R# XMI$Y>[&F_<Q\,$:V;QD2W
M*\FYZ=GI>/KM8K$$T.J@DZG+-8Y=HP:$.HFD*[@HJ'(F!CEW;MFY++';O\YZ
MJK%VY&U SEAZ2: =)-%CV(S>:)K]@L.=Z6MRXQ\"O&$]9WZ[4:6K$JC,&738
MIQEJKDN[CSS1%VQDUXXY2N"'$HI^=(;MATE:<B-DYR=P/H9<HWB(F5^/=MO(
M;M"[B3YB<!PE;@[C,9HQC&U2S1TA+5RQO+G!HP\_'1+ILQE74.]%WYJ1+&/7
MB:3@J7;.@<VQRE[)MLBQ>),!&68'!BMF_9$1,RCE(H77.B,[X2L!K@2 RYC>
M=''\'\9KQZFN$))A5*X#59\:=FQ9.UBLXA)J@8QW B*2>W9,8#<-#9NAGC(.
M:4Q*"]9D2!*)8.:B@40V=<)V*(MUAK^7L;S4#03 6\3<?<H)U$5,#%,9-6>D
M$WOHL<@OV!!)4Y@36$! AC"&VH;-T$"49 G"AJ@O6I RC*)C'&N"YE;S'B:Y
MQL!,5')-*LT7:;&ZIU<?P=BCI)O,VUE&NIEY6&"C9<_;GVT0R5=*-1 JQ6Y!
M.)>R("*5J[$G-$@@/4;-Z1O6I 99 @EL=N+=E5U]BS[@^H1X2ELR[CNMQIG]
MLBDWTY:HJ-;JR=#FVM:NL8@=VX2](D:K8'J31\BGVE$%S@!B](A19NSI&,B:
M8#?4=HP4-^S /*40*[1LH>PT.Y6GG3F8Q;@_&\Y>)>ZT5>5]GMHOE K#^Z0\
M,ODE*OP2\VT:5IVH=T+MO+B1)%)RBDN03KD @'.8I1U9L7+LQ  LX!+.STKT
M*7M1;LVS,D.Q(#XM6B[C)N9#XYQ$QRB2I/;0[E#XX8QU1834=$.'<ODF?KE;
MBF7KR633CF:#61L:8JKJE*7S9##L CJ0MY[F1V >K/0 G\%;M[N[?>,22U'W
MEOQ60*/,6^<@$Y&\T);&]@.Z=I*U9>S0EO41:)*=ED_+.5_\K%TY!'8Y2%^$
MGT&X\=8F(Q+0.:.]F6[<I2B\QEEN<'T*ZA$=^ B'1XMO>Z-M9HMJL -X=_=$
M-_I[_2U5$ 0VWX"/DV'R:R:JIQ[0>#;?;08(NTA $)R$'J]<Q7O^L&_'6MJ@
M<!<VVCM:K.(\0^,D[_=1WH:JKH/F\>LBO0B#]$!V_ \>K7%%&X!MT_"\?D\>
MLU13_ ^CJ\45/X;HX=?A\/5T=6G2BJ#P>]QW$0\.IB44#\[RB Z;47S45303
M566/YM%),RJBAM]B))E$ZB@[;CV2$ 1'Q:T$)9:IT[FC5N$U6HDF)[1#(Y8Q
M]=,C<NLK)V6JG89GAZ6QC999DH+-VY7QU+3D#/QTFR2EB[&CW8G.)%4%40],
MM.(Q)S#V9 2H?9)]-013;TKR1U1G( 1/M1)A4>T W9B#78NZQ?GBW7;*]JQ'
M<L,2^-)ZIT.!ODA(*7ZGWN+*UM$R^B8.'<*U?BPEI!.&>.DTU.(MF_:';MDW
MS<LPA;%R,A(&38$88X]*U9OSN796IP,91 .(.+MAT'L7#O.?[]0LATVGRF Y
M9W7,@Y-C,:U&Z1V4*.LO*JOV;V5=6$*4*9+ WBX6%BW;UV4Q^VD@W'<=Q*&K
M"Q;G S$QFC%R&/IPJ64GJ+ENX(&!RRDP+CT< YZEE>\YGQ%C!ZUCLC9/H=$?
MOVC>18LK;9HN =OX]U(GB&[YHA(N$%7#4TF0R)CD 03,4PG[)2B8.4+5R8]B
M,B. ==IW;5NDY1!Z59J',!!J<QKOES6K\JWE2XZ97Z+N8O&*E<FEG+@/.U5H
M@F;TXDRC$]I^0P[IKMD51)MYHPZWW)[GOG#.S;>G<L"]'O\ N6.#OL/#>ZJQ
M?G^ RKDO,^.8."F&A<.24/%JVAXLS4A[BL^>62$EUX!% PNTFM>M=1DHM8RW
M\E7:',3X.ERS*W",R1[6S=ACT@A+=X7+DH %H[=AQPZP5GO?H$.O\ >O7GP7
M=4B(\ WXB(#Y Z-O'J\44\=^/1XNL?I;^]H[U15>'YNH-1V[$4"(@(<.GKU<
M:HIZ-_'O\P;Z>A%.HBC@'B^=OY=4.Z+9[E;'>U6/^T"6WA$ D$@$0\71JG!:
MA[RW@UE=DT1-$31$T1-$31$T1-$6DW/A<:S'8#OU,-G'&V$,CS55=WBA2>2+
MZCC^%E1Q79*G9I5I.S"+MO-L:')N3,H>P/F9%%6<=+B8 $YTRF)UK47D6YD;
M9S?\TEHRS/7CEOK3.B8!<8Z;8.P/S30_,=*V%Y-Y KT\[RS<$ZRP@Z_6XBO'
MA_5<*/HBK]8LLY\^HD D1$H) X$%=9SA\U',9CJ]<UMWQODV(I],Y+H?EBD1
MQ/*U&K3$/G%7,,\Y<WM.V3\I'FN<, UERWC:SZAD8SS,TV65=^G)F!L2JF@=
M9HYO<U9T3Y@<,\NF&LF-\))V[EPYFN8ZPY"5J%8MTNZD,&.\00M0H96=U8RU
M>95>8ELHG=6$R;3UJK'L?-,7;!4YG 11Z@<#YF]:T C>\CYI,CXLM7,]#6:M
MX^@,$XLY!;U/X-3I<3)1&97_ #3!597)[23L$V9[=H4K*'LIF5.)"OF H2[?
MM2 R:)A;E*]BWXF,]YIQ#S+\\\#9+VZRCC[%')O0^:/&]&>52JP(U*8EK/S)
M1TI36$S7(J/G[#&.H[$\:7SLDY=N06.H8AB ;L!<0ZR_M-L;UK'7*'S.<QC[
M)E4I.5;@;/:68>[VH///#,86HTRHS-)O4].M(FQX>IZ\$G7HJ0Q].#86A:L:
M?4=3*)V#KTZ7>%-VT15B7['6(;1S,96SCW@'=DPV0.3'F!Y9F$-E+F2E&%FS
M%)X@>Q5B>GY2\LLSU^'2QQDB[R9)$B"XN3&<H((>:1,'G!4[)1RMBC]'XA>]
M&JLIHB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+06X%,Z[R_!Y!.)
MR1/)YGMZ"6_!(\IE;"S+SFW'BX(R$-__ ">OTK0D0^TO,:5GSS1A_P"SI]4?
M-F\Z_,=? S^\'+)/2WR#7?Z>IT7^X5OUK\U7Z<FB)HB:(FB)HBT=D"BGWDU2
M.' '?(_D0!\8L,\XNVW_ -"$B/OZ_1+1?[3WQ^GQ%8_TM'J/]U?FEXD?>+3C
M^&7AK4?Z.MTO^\MXM?G:_2TT1-$31$T1-$31%Y9=UKMZ/WA@  @(=Z7SA 81
M'<##ZRIG$. ;;!L7;CT;]>B+U-T1-$31%C;,OZT&5?V-KS^IB4T5&*XN#/UD
M\/?L6X__ %)Q.B'%=EE;];>ZAX:[)!_K!M-KK)P*\Q!Z1\H_1T=<%1T;\?'Q
MZM_=ZMM79Q1/+L [#Q#P!]+CJ>A%3N/0''Q[^_T]6M4V*=*J#;;;<!\G#K\6
MA)5I@L,9RK;VS5-@Q9X0Q?GX&L^UD5J/E2=C:]%-Q;L9!!M/PTC,46_QB4['
MK.O-AYUHD?T5=;S:P'^ ?K9D(ES*4*8BOXBGXKC?@9P80C.N!I^!JN)R[X]M
MF+L3PE3NLHRD)].6M<RJSB)29FX"J,++9Y:?B:'6Y:P%2F)"N4>,D$8QDJNF
MB)D&Q>RFF3LD+;TXSN&411AY@SGB<4L6Y6[8C/&N^CEV?<, LX]6X<>OW>GP
M_.UQVU755!T!K+[%4Z.C_,U0-J%4]7$!$?'L(^/;CI4%%(" AP\FG!%>M[ 0
M>5P=_P!(U0][U0B.WO:JIQZE9(;& 1'HWZ]NGR\-1C@HIV#80VX?-[N@WHHV
M$/&/T?%T].GH15<!#<0]_P#@Z< BPMG['$UE+&SJ JTA&1MPA+5CS(]*<3GI
M@UU:X8KOE>R'7HNS>KR*/R5V=?5T&+Q5 BJ[=!R99)-11,I#=K%P6YC,/9((
M/0006XU7&_;E=MY8EI @CI!!#\*5X+"=V@^9>_N<:9 ?8AQ%%2V'LG-+I$8E
M?9@E)YQ<&[NA7ZCSC_VD!C-G7JK-1*MO;.X0!A7@[-G +KI&73 G6!L0S0S2
M(E%G;"H.#UPK7T+A..IGEGEAFA)P'-:$&K!C6E-^^EM8GY:+K Y9A<J7>%H2
M S#_ )E[I/U*$D?7T3CNQYI<XO;0-=J3R1KT4:9(2&I+L\O)I-F(+R3]R8B0
MI+;C;EZ,K9A$G"(<[<KN]>-!N92&GF+@N2:N8D#89,S4X5-*O18NOG+?=:9R
M^0B*%>K0.L9]V7S+8$ML?7 %\\E,@6VK8ZD8J/A8R.C$7-DBWTI3I0YC% AS
MNW!1!,5'!A#K"_"5_$M*_"0?<"<2],0N-W33C8< /'33B6Q<B.%*X'S+MI_E
MSSMDJ5'),G3,0T*;I=8P/7Z=BJ*NTI-T;*;?$62FV3'PW28+0H4:I#2J9/0X
M1FI&2:T0L *+]LH;#D7[4!D!F03(DLQ#AJ!Z[S4.MRL7[DL[0$@(L :'*7K0
M-N%"V/!77)88SQ(V!#/"-"QS&Y$;<PM/RT&$FF35PB']8K.'YS#[U*1RN7'J
M+(V1)A.Q*R)W7J11GZ*S:-#&.8@GU!<L@=T\N[R$.W]82P?#9B^)6I6;YEWH
M$>\$P6>C")CBV-=S8!<K$O+ADF'O>*+GDB$H"BE7LG/):[$RB)=2Q,XB3YDL
MF5VWTQ*LK2\&Q=O@:PC=\U>.C)M52%'82 "QB%ER];E"48/40&Y\L2"_FHEG
M3W(SC*>4L;AWMFD"&IL#O^:PY)\I6?(O$$CCVOUC$]PDLB<GT=RY65Q;KL_C
MV>-)VNKVQ9E)U]NC39DMKKTHWLI.RV25C#(R+-!4YO,E$Q>HU%DW!.1D&NY@
MPQ=L:T-.*YRTMX6C;B(DRM9:DT9\*5%>&"WYNU4E'F&X^I&QAC[,;UG#TYA*
M8XR)+LXZGSX0B48#THRTE4KE&^GQ[MB5PQ,YC#H'62*)A2'LG+XX2 N9LQCC
M48^D>E>RY RM91&,S2AP/F/3@K=Y:L:W'&]8NI+<R@*M\<\DS-VK6*ZA.R-D
MIN&ZL_@JW#,<?UJ6?QL(BNW%[!N)=V1BP81:4C*N"-$"I !CZOW(SD,KEHL2
M<27-3CT8DL LZ:U*W$YF#R< .1$,*!VW.:"I.S'8L0* ".WTQX^77!>E1P$
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MF]S1T3P[=0^_P#I\FA#(FW#YNG^#H&Q1!X;> >'S>+54Z%L[RM@'QKL8]&T
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M_P WAJL&GL=1U)B:VUC%9B!JJL9C&0"7Q<RL]&@Y..IEX;8NF ],K1)I@_+
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M(;!UVBL_9;CHQ&Q3*>"%P_>]A 6,3Q_Y45C?B']M]""^%%<O0@X=O/\ ,,4
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MVX#O\9ZSPVZ_S7V'48C>HQX*/8_>]P'T")V .'YYZSU_\;:C$45R\0@8@O8
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MNCIA@BJ\'C^=PU33!14&-MU>'IV_@ZA595;^_P!.P]/N^#3%&4;[AN''112
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MWK,.N:TFB)HB:(FB)HB:(FB)HBPAF?EIY>^8UK ,<_X1Q1FIC57CV0K#/*=
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M7."+Y(1\>Q OH;%DS%-L@R)Z*T;MQ(R;'5.V9D\RFF)&C91<YDTPV(03F$H
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M'^]>^HZI,O)D]LN0PZ9IGQ_Y.UP/[T#J]".?+^A3[9<A=4PQV#K^+M<$??\
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M!.%R!@10B0(/07JOL>8B$R'44E8XB:93'.<[YL4A"%#M&.<QE0*4I0#<1'@
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M@[B%J^WY .2MN<#ARS8C<[ )03D*JSE&X )1(&S61]*; *91^ /8W(( )=A
M!#[C/[F_<"88\WUP_LW#$]L6/GKM7TR'VM^W4)9AR;EY/&U&0W82<>9?4W()
MR5F+V1Y8,,  ]/9H\.01WZ0$2(%$0'K#61]R_'XK]8YA_C3]:T?M?]NB&/).
M6M_W%O\ W5\%.[]Y*5%#J?>S8D1 XB(-VE6:LF26X[B#:/9B@P:%W'<"I)D
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MKEKOM?)8']@F92_PLZSC\D+V*TV1>T3MB+84(D&:4L_?N#IB<K0"%:B"12@
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M$+<G8Y!&?SY&<Q3PA)5NV[%PCZU7:BY@B'1CBJ&I$W 5M%!\P.)SN"J* *P
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M)!%F[,BB9TU*FJ9)(QQ3*1;$:(FB(/#CHBQ<#GXSY.3;ID!6(QU'*.%EA#X
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M*@ 'ICM-(?.I0L04P.'R_0DW(.VYS$(8GI7)J%:;U:$;QI%SOGAU%WTQ++%
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MLGI3B+<',:\>*.Y;^KCVK.=^YHLQX4YDLO8SJF7,;+V')=Y[N3 T[SCSU)K
MLJM'Y9H6>IN1RI9H:*F&5$D'TO(TQI7*RV4%"*1FIYKYT%R#YH\5(5R4CF^Y
MTLOY>QGRK5+F3QHU?DYD^<; ECYG:SB."L*64*I@?#N),EUZTUFI.YM2G1.0
M*U8LA.JS.BU5=PHR4.\$$"*?D="@;5DR8LO7+D3S-<\_<JN*LG9$5BG=\D&U
MJK%QDX-GZLAYVS8XO-GQM-62.B@7=%AVMFD*DI(%9%55*S])\R!S@0##%K@<
M5MSHB:(FB)HB:(FB)HB:(FB)HB:(FB(([ (^#CHBLRQW5C!NFT,T:NYZT2)
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ML-C_ (T:']U,-])WJJ,=R>W'#?RHT/[J(?ZKT1CN3VY8;^5"B?=1#_5>B,5
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5*93'\VBGLFD4B92E BNC1$T1?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>tm2115679d2_ex10-5img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  [ 54# 2(  A$! Q$!_\0
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M/4?B1P?R]1GVS2%$;=$P.UB"#@_GCT/Z_7JK;,;VZ+_D?3![]CU]OSB_;_\
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M7G<HV4>5\WXQX69'PUQ%Q)+AC.HRD^((N2LTDN57=URNZMV:M9MGYW#]K?\
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M=Y?#[%U["5KIIJ]G9;/[ROK"[(_2S8/4_I_A1L'J?T_PK^9/X?\ [9O[<_\
MP5=^-'Q5\,_L7?$?1OV2?V6_@]JD%A=_&"?P%!XU\>^._P#A(9-;MM"FV^(V
M@C*^(8='_P"$G;PQX2/A"Z\'0(+;QKXUNKJ6"VFS-?\ VS?VX_\ @EM^U1\*
M/A3^W3\8='_::_9B^-<K1^'?C*W@G0?!7BCPJL>O:)H>N:U_Q(5?:/"DFOZ#
M=^,O#/B=_%TL7A;6X?\ A"_&V^"XLZ7]G]/=YK7Y;N^U^]K_ #)^OK^];O\
MTC^G_8/4_I_A1L'J?T_PK\)_^"MOBK_@IA\'-'\0_M*_LG?M$_#7X8?LZ?"_
MX1^';_Q[X&UOPUX4\1>-O$'CD^,_$UOX@UO1%\2?!GQG'+:MX=UKP3LMQXS\
M))&NBZ],\0=XYF_,GX8_\%$_^"KO[2?[#/C7Q_\ !?7+:YUSX QZKKWQT^.E
M[X#\(-XV\=ZCJ>OQMH?PS^%'@30?APWA*-O!WP^GB\4^-/%0\'JX'EA/DA4>
M+A9?=73CO;=JSO:SO;7RWV#Z^NTOZ^1_7?KMGJ%]I&IV6DW_ /9>JW6EW]II
MNIFV#_8-0F@EBCU';R,),Z2 =3C<N[//\U'_  2 _P""?/\ P4"_97_:M^,O
MQ*_:3OKC3_ NO>#O%6C:K?-\5=)^(</QE\>ZQK?AQ]%\<G33K5YX@5[=-%UV
M=/$_B^'PIXTDDULQ^6W_  EGC?;%^Q/\=_\ @K+^W9^P1>:U\)?C+X%\!?'#
MPO\ M'-8Z?\ &KXI^!-*TW2?'?P<3P1KCZWH&T?!CQ7X3UKQ!X7^(>JZ*B>*
MO"_@V.!O^$?D@=T\]HYL[_@CY^W;^VY^T+^W+\;/V>OVI?C;IOQ.T'X7_"+X
MH7O]EZ-X#^'/AK1_^$Z\!?%_X5> !K.FZOX:^'?@SQ+<VXCU_7XT@N6:V29X
MI0GG1Q$=/U?&87"YM%.%EI46KDOY;6VN^CVMHCF>(PF)Q65/5MWE#LM-OP_X
M/;^HJ1"WY=NH/T[]:(T*_EWZD_3MTK^9'_@L3\=_^"IW[&'B37OC]\+?VF?A
M[X3_ &7?&/Q%\%?#?X6?#32_ ?PW\2_$S0M3E^&SZUKMUKL_CGX*M;1Z%<>(
MO!'CE[?9XS\5SK!XA\-K##;HDL$74>!_VI_^"H7[=W[._P *X?V(IO ?A:YT
M'X<^ [?XY_M7?%G3="\-OXV^.O\ 8&@ZSX\\%?"GP.OAGQ?X;<^%GFN_#/CC
MQ:?!Y\'-XTNY8O 1\'+X2(;!49N"]Y<KU].MKW_IW.CZ['G^K=?PVW/Z2BP7
M&<\T!@V<9X]:_EK_ ."6'_!1_P#;&UG]MCQC^PA^W+J8\6>,;D>.='T?5=1\
M/>#=)\2^%_'/@+1!KVM:'O\ A[X?A\+:]X?\5^&M"UOQ1;S"16A<(58QAXW^
MOO\ @L+_ ,%+_B)^Q)9?"_X4? ;0=%U+X\_&<:A<:/K_ (ET^WU+2O WAM=7
MBT:*=-"5I+C7/$'B7Q!)Y5F+KR?#$<>ASFY$OF0R4?V=B_KBP2LY/:S5FK7O
M?73K?5:JU[B^OX7ZI]<YGR_COZ'[J%E0 '_/USCJ:^,=$_X* _L9>)OB\GP$
M\/?M(_#+7?C!<:K)X;L_"&C:TVJ"\\3HGF?\(_#K5M"WAV3Q"7#(GAR/Q*]Z
M0518F=@R_D'^U[^RW_P5.^''['OQ;^+&H?\ !27Q#XY\6Z+\)?%'B/XO?#?_
M (5;X(\%>&;OP-#H(NO&FC>"/&FB;&T'Q#X3\/1Z\T7BJV\(>%6\8NL<FWP6
M#*T'EO\ P21_9F_8M_;:\'_L\?M/1?"35_A3\8?V*=9\,?#O5O"?@G5&T_X:
M_$KQ1X(8>// _P 9/$/]N>'%\3:_KZ^(-<D\2Q/_ ,);B6318897\6^!4\&2
M76JPW^R/%\S:4DFE]EVO[U^CT2:37?RR^LKZW]3\K^J\O0_J?HHHKB/2,6^L
MHKNUN;2<;X9[*2WF'W2P9"N 3Z[B.<]OI7\1_P 1?!FI_#OQ]XV\!ZE%.][X
M/\1:GX;NFN3D.FB:SN5E/0JP(8'H0<U_<+( /F/0C:WT/&._4>U?SQ_\%8OV
M9;O1?%-M^T9X0TL3:'XD73M&^)HMK=2VD>((2F@:%KT8;9)+_P )3#-:>&IW
M6,10OI45OYCR>+' _?OH\<783(^*,QR7'M*AQ)1AAXMRLHUZ<FZ:U:2]K"4H
M+JYPC%?$D_Y^^D'PUB\VX;RS.<%K/AZHZK77DE%*_P#VZX_)>A^,%?MS_P $
M?9$32_VI0V<OHWPS52.Q_LOXHC'XD@?3-?B-7[S_  '_ &GO^">/[.7A[QK:
M?##4?B!IVI^.-(TNQ\0OJNC:UJK_ -H:)I&O-HH&] 8R?[8U8DAFW,@)"E5:
MOZ&\;H8[,.#:>0Y%D_&>?RXAK4*RJ.DZE.*P]>G5E&=I)QE./-&FVFE*\FUR
M:_S[X,O!8/C!YWC\WX-X?7#T91Y5)1;YHN*:ONHNSEU:TZGX[_L^ 'X^?!$'
MH?B_\,0?H?&F@@U]W?\ !7<8_:FT8< #X/>%P,9QC^V_'^,9]N_?K7YY?";Q
M'I7A#XJ_"_Q3KD]Q;:/X7^)'@/Q-K'V09_XE>A:UH&O:[QGGMGVSWK]2OVQ_
MCI^P;^T)I_B+QYIUWXVU+XS6_@.?P[X-OO[)UW3+(3Z3)+/H?]JH$*>7YNOY
M+.Y9@Q^4;<MIQ1+%X#Q*X-S[^P^-.),D?!W%]&].BZE5>TJ6NVI1Y*$'^\K2
M=U"*YW&25FN&E@\9X<<89)_;/!O#N=_ZX<'R;<E&'NI-*S5W.6JA9;W3:NC\
M=:^I_P!B;P%/\0_VIO@KHT$<TL.E^.=,\8ZHTI 3[%X)(\<0*<D9WS:,B =6
M9@HR6 KY8K^B/_@E1^S+<_#SP;JGQW\<61M_$WQ+T^&U\$6MXC->V'@3S/[9
M35W8<%_%<[Q"'+)M\*>'O#$\;.VO7,0]+QAXOP7"? &<XA24:G%$9TJ2;2;E
M*G)2DE=2:IPDZDG'X4HW:<HW\[PLX2Q?%?&.3X27P\-VE)VT233UZ:M6U[OL
M[?L[117,^)'UJ'PWX@F\+1VL_B--(U)O#D%T0+&35UTYVTI'XP(6E$0DQA65
MI%)"FO\ .4_T5/YA_P#@YW_Y)C^R9_V4#XG?^F#PW7[O_P#!/[_DQ?\ 8L_[
M-*_9T_\ 5.^"*_G,_;D_8_\ ^"V'[?NB> ?#7QN^#W[.&F6/P[U?5M>\.+\.
MO'&E^'2^I:PENK-JZZ]\1?%YD15TBW4>4&7+$ %@^/T[_P"">FE?\%9/AIK7
MP7^"7[2OPP_9[T#]F/X9_"K1_A]:>(_!>L-J/Q(>'P-X13P_X$#2CXB2(Q==
M(T;_ (2Q6\'GSF:18&"-*Z]]>WU5+FBVE*ZOKJ^B_,\RA_O7]=D?DU_P<2:;
M8:Q^VU^Q_I.J0"YL-3^'&EV5_9@Y^VZ<?B=KS,O!XP3DCW]*_K ^+D$%I\&_
MB?:V\$4$$/PY\;0VEO;@!1L\(ZR=@4  $J&^4<Y!W$DFOY5/VUOV#?\ @K_^
MV=\;?!OQ9\>_";X#6-Q\*G;1_ 4?A/QWHFDZ?J7AS1O&C>)-%.NQ>(?$?BQ_
M,<LTC@KO+$N_S$U^Q7Q-U3_@JYXB_8K\'V.A_#3]GF7]K#Q3XF\4^&?C5X>O
M-4>#P)IWPPUJ+Q]I&B:OX)8?$6-6\0[9/!4Q2;QB[;VN""?+D6-XAQ>%RA*4
M6XWYDFFXWLU=7TT3WM]P8=?[5F^G\MG;>UUI_P "Y^87_!L+X>T0>$_VL_%P
MLMNO7?B3X7>&S>=SIB:5XWUM$Z<!FE!)'.54=":\_P#^#H08\5?L;?\ 8M?'
M?]=9^$5>T_\ !)C]C+_@J%^PG\2SX1\1?#;X-6OP ^)?BZPUCXP:W>>,-)\1
M^---TS0-)U^/15\%-X?\2HC%9=8VO&?"6XE2#@$FO._^"G7["7_!5;]O3XPR
M76J_"SX+K\,/A)XR^,&C? S4O#WCG2_#_B?7/AGXB\7QMH&K^,TUWQ)*C>(C
MX:T70"4M#X2C\PNV6D:5SU<\?[8^N\T;7NG==K=_7^M#FY?^$GZI9WY>7\;]
MOT/ZK/%O_(I^*/\ L :W_P"FN>OY.?\ @U^T32GUW]M;Q'/8VIUC3-)^ VAV
M.J]-2L-.\0-\7-:UC16.<[#)HN@(0%8[M#0\!>?T\U+Q1_P6HU+]G"[$_P (
M_P!EP_M&:A\87TF?P\VJ[_ J_ M_ Q5M;29OB,Q'BC_A/F91&LH<6Q)\ORE!
M7\_O^"4W[#?_  5)_8.^+=S9R_#3X.V_P:^,OBKX9#X[:GJWC#1O$/BO0/"_
M@=?$#8\$1Z+XEB\MR?&FN8$W_"6[67DIR:Y,.U'!YK%RBI-PLG))RM:_*MWZ
M+YG3B$_K>4]K2^6V_;8YS_@Z*^]^PW]/VFO_ $7\ Z_J.^&FA:5X0^'/@#PG
MX>L;?3?#OASP-X8T'0].M=HL=-TW1="TG2-)TE&Q]R."-(XAC($6T[MHW?S*
M?\%6?V&_^"I/[>/Q;MK.+X:?!VX^#7P:\5?$T? G4])\8:-X>\5Z_P"%_'"^
M'VQXWCUKQ++YC@^"]#R(?^$2W,W!?@U^G_@_Q!_P5MLOV.?%MWKOPT_9W@_;
M%TGXGZ1H_@+PG:7>[X8WOP?71/ QFUO6BOQ&+'Q*VN_\)F'3_A,CB-(MJ?-R
MJ[B\'E45*+DI3<DFFX\VJYDM5YWMUMW'AT_K>;.VEH_.R>Q^2?\ P;L 1?M7
M?M\#_ITTH\\<#XG^/3^?^0*I_P#!Q3>V^G?M2?L(WM[/;6UC9VNIWFH7MY<[
M-.L].'Q)\.?.W R2NT9Z8 4<*!53]B#]A_\ X+'_ +%WQ8\?_$;P#\(_@#>#
MXQWFCVWQ(7QCXXTCQ%_9VF#7_P"W]7?0UT3XB^$,.LNL:VT7&X.J,H!V$_H/
M_P %N_\ @G#\4OVX/"'PH\=? "WTW7?BE\'9O%EA-X+U36]'T'_A./#&OC0I
MUBTK7-?SX9@U_P +^(-$+6?_  E8,'V?7?$<>^-WMTEZ^>']KJ?-'D_FNN7U
M<KV2VUO;5=SEL_['M9WMMU^X_<C7];TCPOH6K^(M;OK?3-&T/2-1UW6=1N2%
ML+#2M(A?5=9U5P"Q"1Q[Y9#DL-FY0=AW?R6?\&OHSXI_;0'KX:^ W3_L,_%Z
MOJK]F7]FC_@K;^TWX9T/X1_\%"/'T'PZ_9AT2XV^/_"^BW/P^?XW?M >']*6
MW30?AKKWB#X=QR)H_P .418;?QQ=J/"GC#Q/%#):B3Q;'XEF\7I\R?\ !.?]
MA'_@KI^P/\0]8N?!7PL^!%WX1^+6L>!+;XIS^+_'>C>(]5L?"_AO7=;8R:"N
M@^(_")?Q!%H&O:N=Z@J'9,') KFBXQPF;81N-Y<J3NK2Y6W[NMGO?2^CZK4Z
M)Q<L5E6*[J2?ES*VO;_@?=Z?_P '._\ R3']DS_LH'Q._P#3!X;K^C7]G_1]
M*\+_  -^#GAK1;&WTC1]#^%G@'2M)TZUM]EE8:;I?A+1H88450JK'%&JQHQ9
M2W#8+[V/\VG_  4U_8V_X*U?MX^-KSPQ>_"OX&)\&?AA\5?B?>?!75/#_B_2
MM \5:_X$UO5/[)T+5O&::]XED,OB)?#.CZ(^RU_X1)-S2;=S[J_3[X1WG_!5
M3PW^Q3\1+7Q+\,?V?X/VNO"&K^!O#GP(\+V6K>9\-=?^'^B'P'HNNZOXY8_$
M61X]>?0D\=2QQKXRA5I8?#13+!D95[?54KQNKMI.[U;6WYW6GS*H?[UZ_P"2
M/QX_X(YG'_!;#_@H'G_H ?M:C_S;#X35\T?ME67Q+U__ (.!+[0?#GQ4MO@K
MXVU3XH?!K1/AQ\3?$7@_2/'&F>%-3UWX*^ 1X%_L3P1XC/\ PC?B+/B+J7.Y
MO&OB#YLG)KZ#_9T_89_X+._LO_M+_%W]JOX=_!W]GJ\^)7QFM/'5IXNM?$_C
MG3-4\-)_PGWC+1/'>MR:'H\/Q&\)>0&\0:%HX64L@(+ -R0?T<_X*M?\$GO%
MO[8M[X&_:3^ 7B.Q\ _M7>!M,\-V&J6=QJ\FB>'?'FFZ%<'6M# UF%)'\.^/
MO"/B5E;P3XK.4ME)21HHXP1TO$83Z[)W7+*-EI>SLTV^C3OKZ6ZW.;ZOB_J=
MNO\ 3_K^D>G:S^QG_P %7_$.D:IH>K?\%8_#FIZ3K6E:OI&IVA_8D^ H%YIV
MMQ/"Q!"[%_=.ZKGY6#';DC(^-?#G_!-KQ7_P3C_X)[_\%.M,T_X\P?&2?XF_
M 4L--T+P>? P\(#P5H7Q"77=D9\2>+F,OBKP[XT57#*A2/1N-VYPO7^"OCG_
M ,'#DOA:Q^&NK_LH_ FV\7^4NDM\=/%GB7P-MT^#YE_M[7=#\/?&G_A'=?UL
MM\S-X4\)^5E3GP0$W _H_P#L/_L)V'[.7P-^)/A+XUZ_;?'7XL_M%Z]XE\:?
MM+^.M8LBNG>/-:\9:2VB:SI.R14(\.QZ3JFLHL?!9]>\0MN=)MJ\OMWAE9N-
MN:+T2U<6I)[NVWKKKT.K_>ON].G]=KG\\'_!$/X.?MF?$KX#?%O4/V7/VWM(
M_9FTC3?B]-IWB[P7<_L\?#GXN7^M:FW@GPZVB^-9M>\> ^(X!M3_ (1<>')]
MBH/#[J)%WE7_ $"_:G_X(_\ [9O[7NC>%;7]I_\ X*2>%_B!I'P[N]4OO#8O
M/V5/AQX*DT :^=$.M[];\!>)/",JACH&C[6<;?D(R,H&^:M%_P""=O\ P4J_
MX)>_M!^-OB+_ ,$];3PA^T%\&/B')]FN?A_XOU[1-)U,^&8-7:71-'\;:-KW
MBCP>^N^(/"*ZQ<IX-\2^&/&$;216]X'B\(6WBR7P8?JG6/@5_P %2/\ @I)?
M^'OAO^VKX-^'/[(O[).E^)-*\1_$;X>?#KQ%/K/Q+^,QT%HM7303KWASXC>-
M/L_AH>)-F\'_ (0Q0BSW+KXR2+PK*O5B<2WC'C8RBKN][)M.R6J;5W9;NVFC
MV.;#8:V#^I-/[_U['V!_P4Y\-7G@S_@DM\>?">IZP/$.I>%_@;X(\,WVO_9Q
M8-K>I:1KG@;1CKF!GR_/>+SMO/WBN05P/(?^#?.RM++_ ()Q^#KJVM+6VEU3
MXG_$^]U"XM\>7>ZHFOKH7F 8RK-#HVE*Q)VMM0'A,U;_ ."I7PG_ ."BWQJ\
M/ZO^S5^R?\./@IK'[,OCKX1>&-"\8:OXKUNQ\.>--#\5:1XQUN>71]$$OB/R
M4\.'0M'\$1HH\)SQH/\ A(8EF#LL">&?\$M?@3_P59_9!NOA?^SW\1OAG\#-
M-_92TKQ%XXUOQSXCL_$>E>(OB19'7])U[6XET5_#WB58Y-WB?^PT,9\)!BCG
M[J2$GE5OJC5U>]TKZV2[;W]?OVMU?\QGS_4_HM[+]'_D:_CI_P""'G_*7K]M
MC_LFW[1W_K3'PFK^DC]M+5?VR_#_ ,+O#]]^PWX7^%WC#XMOXZTR#Q!I'Q;N
MDL?#0\ OHOB0ZSJT3KXA\*9U^/Q!_P (A]GB2=B8I;E1&T>2/YL?V7_V"?\
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6S5DD][:7^Y?J9_5UO=!1116!U'__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>tm2115679d2_ex10-5img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H "L# 2(  A$! Q$!_\0
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H3)%E\IKB93D/.<X/L.E%%;RQ5:2LY'/#!8>$N:,5<Z*BBBN<ZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>tm2115679d2_ex10-5img003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H "L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^N?U[Q?I
M^A2>0X>>ZQGRD_A]-Q[?K5SQ#J@T?0[F[! D"[8O=SP/\?PKQ95N+^\"C?-<
M3/@9.2S&N_!X55;SGLCS<?C94;0I_$SK)?B1JS2DQ6]HB9X4JS'\3FMG2?B-
M;3LL6IVYMW/'FQ_,GXCJ/UKF[&2/0K.\TW5=&9[V[3]P7521G('7ISZ5B7^E
M7VF&,7MM)!YF=F\=<=?YBN[ZM0G[O+;L[[^AYOUO$T[3YK]U;;R>A[LK*Z*Z
M,&5AD$'@BEK@OASK$DR7&ES2,WEKYD.><+T(_4?F:[VO'KTG2FX,][#UU7IJ
MHCC?B0CMX?MV4$JMR"V.WRM7EZNR.'1BK Y!!P0:]UU?3DU72KFRDP!*A )_
MA;J#^!Q7BTMDVF:J+;5(9%6-QYJ+]XK_ +)Z=.E>KEU5.FX=4>+FM&2JJIT9
MT/B-BVK^'F8DL;*W))/).XU1\:RR/XKO49V949=JDY"_*O2FZUK5I?ZII\]K
M#,D%I#'%MDQN(5B>WM4?B74]/U?4/MME#<1RR9,WFD8/  QCZ&MJ4)1<+KH_
MEK<YZ]2,HSM+JOGI8N^ 4E?Q7"T9.Q(W,G^[C'\R*]<KCO 6@3:9:2WMW'LG
MN  BGJJ=>?3)_D*[&O+QU13K/EZ:'LY=2E3H+FW>H5G:KH6G:R@6]ME=E&%<
M<,OT(HHKDC)Q=XNS.V48S7+)71RL_P ,[5I@8-1ECC[J\8<_F"/Y5LZ7X*T?
H3)%E\IKB93D/.<X/L.E%%;RQ5:2LY'/#!8>$N:,5<Z*BBBN<ZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>tm2115679d2_ex10-5img004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H "L# 2(  A$! Q$!_\0
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H3)%E\IKB93D/.<X/L.E%%;RQ5:2LY'/#!8>$N:,5<Z*BBBN<ZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>tm2115679d2_ex10-5img005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H "L# 2(  A$! Q$!_\0
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H3)%E\IKB93D/.<X/L.E%%;RQ5:2LY'/#!8>$N:,5<Z*BBBN<ZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>tm2115679d2_ex10-5img007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H "L# 2(  A$! Q$!_\0
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H3)%E\IKB93D/.<X/L.E%%;RQ5:2LY'/#!8>$N:,5<Z*BBBN<ZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>tm2115679d2_ex10-5img008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  H "L# 2(  A$! Q$!_\0
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H3)%E\IKB93D/.<X/L.E%%;RQ5:2LY'/#!8>$N:,5<Z*BBBN<ZC__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>tm2115679d2img_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2img_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D "0# 2(  A$! Q$!_\0
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;-);W]6SHZ***\0^B"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>tm2115679d2img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D "0# 2(  A$! Q$!_\0
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;-);W]6SHZ***\0^B"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>tm2115679d2img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D "0# 2(  A$! Q$!_\0
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;-);W]6SHZ***\0^B"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>tm2115679d2img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D "0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^JU[J%GI
MT0EO+F*!#P"[8S]/6C4+V/3M.N+R4$I"A<@=\=J\7O+K4O$>IO*4FN)FR5CC
M4ML7T '0"NO"X7VUVW9(X<9C/J]HQ5Y,]7B\6Z#-($34X03_ '\J/S(Q6R"&
M4$$$'D$=Z\4NK*"ZMX/[*L;UI8(L7I9"P5_7CH.#Z=/K70^ ?$,T5\ND7#L\
M,H/DECGRV SCZ'^=;5L"E!SIO;HS"AF,I5%"JEKLU>W]=/4]+HHHKSCU3%\6
MQ/-X5U%$&2(MWX @G]!7D>CG&MV&/^?B/_T(5[J0&4@@$'@@]Z\\U?P9J6FW
MSWWAZ1MKD_NT;:\8/8'N/UKTL#7C&,J<G:YY.8X:<YQJQ5[;VWWN8F<:1XEQ
M_P _4/\ Z')5;PC"\WBK3U0'*R;S[  DU9L]"\5K)-';V]U%]H/[TEM@?KU)
M//4_G7>>%?"L?A^%Y9766\E #.!P@_NC_'O736KPI4Y*Z;?;TL<>'PU2M4@[
;-);W]6SHZ***\0^B"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>tm2115679d2img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D "0# 2(  A$! Q$!_\0
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;-);W]6SHZ***\0^B"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>tm2115679d2img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D "0# 2(  A$! Q$!_\0
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;-);W]6SHZ***\0^B"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>tm2115679d2_ex10-5img03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_ex10-5img03.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !% 4T# 2(  A$! Q$!_\0
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M GQ]<*-H,TN0.,_N6/\ .NG\&ZUJ]MX4GMKCPU>PR:7:CR5D5U-T<'A04X/
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>tm2115679d2_img4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_img4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ 4X# 2(  A$! Q$!_\0
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5'EQ _P"X"?Y\]Z[7H,"BBE<=C__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>tm2115679d2_img5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2115679d2_img5.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  D "0# 2(  A$! Q$!_\0
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MNHPIJ[N_Q=SL?A_:O;>& SJ5\^9I1GTP #_X[173QQI%&L<:A40!5 Z "BO
MJS]I-S[GU%&G[*G&'9#J9)%',FR6-74_PL,BBBLS0JQZ/ID4F^/3K1'_ +RP
7*#_*KH&!@444W)O=B45'9!1112&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !" 4P# 2(  A$! Q$!_\0
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MEU?3?HQ*-1^\I)P7Q::V>UFM-[%FBBBJ*"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *"0.3110  YZ4F1G'/3/0D=<=0,9]LY[XQ2FJDMU'%,D
M)+^8R,ZJJ.XV(I9F;;D*H(V[FVY=E099D!+2>D;-ZOY+=[K;^NA,I*"O)V5[
M?-[%N@$'..QQ^-0PS),N] X!_OHZ$$!21L8 @C< < X8,K892*EQ_//'?CO_
M )ZXI;:-J_W=D]+OJQI\VJV_KS%HHHIC"BC/^<'Z_P"?RZT4 %%%% 'X _\
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ME?1)\UK.STOI>Q_4+]HCW!3O#,"0"A!R!DKS_%CG;U(Y IBWD+N40N2N[?\
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MM)E_XH0^*;N2U@T)U2]TNY-_813S1:A%)$OZN_!_]M#XD_M5_P#!/*+]K/\
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M'F3H*#5UOS*^KV:M;:V^E];>_B9"64$DKC( .<D9  /4_P!>#3!<1D$_,&!
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M*E:<,.VYWH-4HIPLK22O=IMRO96E+EU^SN?U!0D-!&RKL#1A]F01'N7<4R,
MA22H &!@8  &)AT_%OYFJ]L$%N"GW7,LN[#+O,SO(TFUR63S"Y<H<!"VT*H
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MIJRDK/ETT_&W3[C\'_!A_P""\GPP\+Z9\/&^'W[%?Q?.@:?;:'HOQ/\ $'Q
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  J DT# 2(  A$! Q$!_\0
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MV/X%_P#AL_"W_P @5],0ZEIK1PE+ZRPY,48%U;G,B85XE*R%6D0_*Z*25/!
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MR!U=D*1[][[EC=EV@[E1R,A20!<^8?\ AA[]CW_HV/X%_P#AL_"W_P @4?\
M##W['O\ T;'\"_\ PV?A;_Y KZHHH ^5_P#AA[]CW_HV/X%_^&S\+?\ R!1_
MPP]^Q[_T;'\"_P#PV?A;_P"0*^J** /E?_AA[]CW_HV/X%_^&S\+?_(%'_##
MW['O_1L?P+_\-GX6_P#D"OJBB@#Y7_X8>_8]_P"C8_@7_P"&S\+?_(%'_##W
M['O_ $;'\"__  V?A;_Y KZHHH ^5_\ AA[]CW_HV/X%_P#AL_"W_P @4?\
M##W['O\ T;'\"_\ PV?A;_Y KZHHH ^5_P#AA[]CW_HV/X%_^&S\+?\ R!1_
MPP]^Q[_T;'\"_P#PV?A;_P"0*^J** /E?_AA[]CS_HV/X%_^&S\+?_(%'_##
MW['G_1L?P+_\-GX6_P#D"OJ"Y8K&<,H8AMH?B-B$8X<]E&,GD=*^?;[]I#X-
MV.D_$/5SXH>\LOA?X@T[POXUCT/3-1UR^M_$&L&Q;3=)MM*TFTO=1U"YO9]4
MMH(+:QMIIY990@1@>0#!_P"&'OV//^C9/@5_X;/PM_\ ('L?RI/^&'_V._\
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M;O3?%4FHQZ7=64A;$KRWFE7]KL&&S",9WK0!Y+_PP]^Q[_T;'\"__#9^%O\
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MT-#$X"NBLH! !5< $;2,8Z%<@^Q-#KM[INVUV]/Q_JP>Q?E^%]-NA^1'P/\
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MDMAX8\<70MO#\WPZ74HM/D\&6W@FRT34'U=-+C?5O#97Q%Y5Q+JT\5[AR_\
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M^*-1MO\ A8WAWP?H5UXCU?P=?>&[+5H=*UR'Q1IEM>Z3:W5W9:@MI?7=E=0
MR1(U?;GBC0]%'PLOH!H^EB&;PI:V,T(T^T$4MDUG;0M9R1B'9):M"3$;=@83
M%^[*;>*]0L]-TYK2R9K"R9H+6)(6:U@+0H;9(RD1,>8U,8$>U"!L 7&WBG[1
M)WY%;56M'M9O5=4R73]U/F>K\_\ /RWW/PT^$?QUU'7OV^]<\>^,OBMXDL?
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MPJ5*>=)$TFTJ2I7=@J2,8.*N$E%MM*2::L[=>NJ9G43<59VU7Z^:/YZ/"_\
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->^WI==RY11161T'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>56
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  F "H# 2(  A$! Q$!_\0
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#Y__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
